Tumor or cancer of the human MAMMARY GLAND.
| Excerpt | Reference |
|---|
| "Breast cancer is the result of a multistage carcinogenic process." | ( Brennan, MJ, 1975) |
| "Since metastasizing breast cancer is hormone-related, hormonal therapy is based on control of tumor growth by elimination of the hormonal influence, hormone ablatives, or administration of steroid hormones to change the hormonal milieu of thehost organism." | ( Maass, H, 1976) |
| "Breast cancer is often hormone responsive, since growth or regression of tumors can often be modulated by appropriate endocrine manipulations." | ( Horwitz, KB; McGuire, WL; Pearson, OH; Segaloff, A, 1977) |
| "Development of breast cancer is often preceded by the occurrence of preneoplastic mammary lesions, which may be the result of long-term exposure to estrogens and prolactin." | ( Vorherr, H, 1979) |
| "Management of breast cancer is biologically, immunologically, and histologically heterogeneous in character and requires multidisciplinary treatment: surgery, radiotherapy, hormone, chemotherapy, and immunotherapy." | ( Chandra, AB, 1979) |
| "A case of male breast carcinoma is discussed with reference to the effect of steroids on the hormonal receptors at the malignant cell." | ( Weber, J, 1977) |
| "Non-invasive breast cancer is comprised of two distinct entities: lobular carcinoma in-situ (LCIS) and ductal carcinoma in-situ (DCIS)." | ( Posner, MC; Wolmark, N, 1992) |
| "Breast cancer is the commonest killing malignant disease of women in the European Community." | ( O'Higgins, N, 1992) |
| "The prognosis for breast cancer is improved in women receiving hormone replacement therapy." | ( Gambrell, RD, 1992) |
| "Female breast cancer is a major medical problem with significant public health ramifications." | ( Crowell, EB; Jubelirer, SJ, 1992) |
| "Breast cancer is the most common cancer in women and is a major killer." | ( Fentiman, IS, 1992) |
| "Local recurrence of breast cancer is a relatively common entity." | ( Bines, S; Bradley, C; Faber, LP; Kluiber, R; Witt, TR, 1991) |
| "Breast cancer is the leading cause of cancer death in women in the industrialized world, and the rates of breast cancer incidence are rising." | ( Anderson, LE; Davis, S; Stevens, RG; Thomas, DB; Wilson, BW, 1992) |
| "Breast cancer is a common cause of suffering and death in Australia." | ( Ingram, D, 1991) |
| "As breast cancer is responsive to hormonal therapy, AG has been used in the treatment of metastatic breast cancer." | ( Bellora, MG; Bergamino, T; Ciancio, A; Ferrero, A; Sismondi, P; Zola, P, 1991) |
| "Breast cancer is the most common cancer in women in the United Kingdom and despite advances in treatment, metastatic disease remains incurable and many women die from the disease." | ( Jones, AL; Powles, TJ, 1991) |
| "Breast cancer is the most common malignancy in women." | ( Chittoor, SR; Swain, SM, 1991) |
| "Breast tumors are a complex mix of epithelial, stromal, and vascular elements." | ( Cullen, KJ; Hill, S; Lippman, ME; Rosen, N; Smith, HS, 1991) |
| "Breast cancer is by far the most common type of cancer in women accounting for 20% of all new cases." | ( Baum, M; Colletta, A; Ziv, Y, 1991) |
| "Hormonal therapy of breast cancer is widely used and effective." | ( Canetta, R; Kelley, S; Nicaise, C; Rozencweig, M; Schacter, LP; Smaldone, L, 1990) |
| "Breast carcinoma is the most common internal malignant primary tumor in women." | ( Atienza, NL; Gutierrez, GT; Medina-Lavadia, AT; Tianco, EA; Villalon, AH, 1990) |
| "Breast cancer is a leading cause of cancer death among women." | ( Berger, MS; Chianese, DA; Greene, MI; Hellman, ME; Kelsten, ML; Maguire, HC; Weiner, DB, 1990) |
| "Breast cancer is now the leading cancer in women in Bombay, while cancer of the cervix uteri predominates in the rest of the country." | ( Jayant, K; Jussawalla, DJ; Yeole, BB, 1990) |
| "Argyrophilia in breast carcinomas is of uncertain significance." | ( Azzopardi, JG; Bussolati, G; Ghiringhello, B; Gugliotta, P; Papotti, M; Sapino, A, 1987) |
| "If breast tumors are mishandled, the relatively labile ER protein may lose its steroid-binding capacity (become inactivated) and not be measurable by the routine steroid-binding assay." | ( Dhirani, N; McBlain, WA; Molnar, LA; Tran, K, 1989) |
| "Breast cancer is characterized by hormonal regulation." | ( Dickson, RB; Lippman, ME; Thompson, EW, 1989) |
| "Breast cancer is difficult to detect in pregnancy, even by mammography." | ( DiSaia, PJ; Wile, AG, 1989) |
| "Breast cancer is the most common cancer in the United States comprising 30% of all cancers." | ( Henderson, BE, 1989) |
| "Three to 5% of breast carcinomas are argyrophilic, including some which are mucinous and thus "composite", whereas there are no argyrophilic cells in normal breast nor in benign breast pathology." | ( Aillet, G; Auger, JJ; Barbin, JG; Fiks, M; Gaillard, F; Guillard, Y; Le Bodic, MF, 1987) |
| "Treatment for breast cancer is subdivided into two categories; one is for primary breast cancer which is curable by surgery and the other is for advanced or recurrent breast cancer." | ( Izuo, M; Yokoe, T, 1986) |
| "Breast cancer is a protean disease and deserves a multidisciplinary approach to evaluation and treatment." | ( Edland, RW, 1988) |
| "Breast cancer is more common among women in upper rather than lower social classes, among women who never have been married, among women living in urban areas, among women living in the northern US than in the southern US, and among whites than blacks, at least among those over age 50." | ( Berkowitz, GS; Kelsey, JL, 1988) |
| "Adjuvant therapy of breast cancer is accepted as a useful method for reducing mortality in patients with histologically axillary involved lymph nodes." | ( Jonat, W; Maass, H, 1987) |
| "Breast cancer is a heterogeneous disease whose biologic behavior is reflected by a variety of prognostic variables." | ( Suhrland, LG, 1987) |
| "Optimum control of breast cancer is achieved through early detection (most important) and aggressive primary therapy that aims to achieve total local control, plus the use of the best available systemic therapy for patients with high risk of occult systemic disease." | ( Urban, JA, 1986) |
| "The incidence of breast cancer is discussed with regard to dietary habits, geographic location, and economic status." | ( Smith, RE, 1987) |
| "Breast cancer is either hormone independent or hormone dependent." | ( Allegra, JC, 1987) |
| "Breast cancer is one of the types of malignant tumor which have hormonal dependency and anti-tumor treatments utilizing this characteristic are widely performed." | ( Tominaga, T, 1986) |
| "Breast carcinoma is known to metastatize to all organs." | ( Lee, YT, 1985) |
| "The epidemiology of breast cancer is reviewed with particular emphasis on its etiology." | ( Morgan, RW; Vakil, DV, 1973) |
| "suggests that breast cancer is more frequent in young women on oral contraceptives for more than 8 years and who did not bear children up to term before the age of 25." | ( Gorins, A, 1984) |
| "Breast cancer is the most common cancer among American women, whereas in Japan it ranks third behind gastric and uterine cancers." | ( Yonemoto, RH, 1980) |
| "Breast tumors are known to be heterogeneous with respect to estrogen receptor status, and the low complete remission rate may be related to this biochemical heterogeneity." | ( Allegra, JC; Bland, KI; Richman, SP; Wittliff, JL; Woodcock, TM, 1982) |
| "Breast tumors are known to be heterogeneous with respect to estrogen receptor (ER) status, and the low complete remission rate may be secondary to this biochemical heterogeneity." | ( Allegra, JC, 1983) |
| "Breast carcinoma is the most prevalent type of cancer in American women." | ( Moore, CT; Moore, DH, 1983) |
| "Hereditary breast cancer is heterogeneous." | ( Albano, WA; Danes, BS; Heieck, JJ; Layton, MA; Lynch, HT; Lynch, JF; Mulcahy, GM, 1984) |
| "Hereditary breast cancer is heterogeneous." | ( Albano, WA; Danes, BS; Heieck, JJ; Layton, MA; Lynch, HT; Lynch, JF; Mulcahy, GM, 1984) |
| "The incidence of breast cancer is moderately increased in women given DES, but the possibility cannot be excluded that some unrecognized concomitant of DES exposure accounts for this increase." | ( Barnes, AB; Barrett, JA; Burnside, S; Colton, T; Greenberg, ER; Lanza, LL; Neff, RK; Resseguie, L; Stevens, M; Young, RH, 1984) |
| "Cancer of the breast is the leading type of cancer in women in the United States (28 percent), and the leading cause of death from cancer in women (20 percent)." | ( Davidson, AT, 1981) |
| "The incidence of breast cancer is significantly lower in both estrogen and estrogen-progestogen users than in postmenopausal women never using these hormones." | ( Gambrell, RD, 1981) |
| "Breast cancer is the most common cancer in women in the United States." | ( Lombard, LF, 1982) |
| "The incidence of breast cancer is slightly higher for whites, but it has increased in blacks by 25%." | ( Marchant, DJ, 1982) |
| "Breast cancer is the most common cause of cancer death in women." | ( Braunsteiner, H; Frommhold, H; Gattringer, C; Grünewald, K; Huber, H; Margreiter, R; Mikuz, G; Senn, HJ, 1981) |
| "Breast cancer is one of the most responsive of the common solid tumors when systemic therapy is indicated in the treatment of locally advanced or disseminated cancer." | ( Bisel, HF, 1980) |
| "Breast cancer is the most common cause of cancer death in women in this country." | ( Knight, WA; McGuire, WL; Osborne, CK; Yochmowitz, MG, 1980) |
| "Breast cancer is a frequent disease especially in the Western world with an incidence that increases by 1% each year." | ( Ferrero, JM; Namer, M; Serin, D, 1995) |
| "Breast cancer is the most common malignancy occurring in Western women, and is one of the leading causes of cancer mortality." | ( Jordan, VC; Wolf, DM, 1993) |
| "Breast cancer is a major health problem in the United States." | ( Kemeny, MM, 1994) |
| "Carcinogen-induced mammary cancer is suppressed by fenretinide, both at early and late stages of carcinogenesis, in young and mature rats." | ( Cobleigh, MA, 1994) |
| "Breast cancer is a worldwide problem but its frequency varied from place to place." | ( Ali, S; Hussain, MA; Reza, H; Tyagi, SP, 1994) |
| "Human breast cancer is characterised by its high frequency of metastasis and its oestrogen responsiveness, allowing specific anti-oestrogen therapy." | ( Rochefort, H, 1994) |
| "Hormonal therapy of breast cancer is the oldest treatment in advanced disease." | ( Espie, M, 1994) |
| "Breast cancer is the commonest form of cancer in Australian women." | ( Bolton, A; Dale, BM; Kotasek, D; Norman, JE; Sage, RE, 1994) |
| "Breast cancer is a solid tumor moderately responsive to chemotherapy and/or endocrine therapy." | ( Ikeda, T, 1994) |
| "Breast cancer is a leading cause of death among women in industrialized societies." | ( Stevens, RG, 1993) |
| "Metastatic breast cancer is incurable." | ( Muss, HB, 1994) |
| "The risk of breast cancer is high mainly when estrogens are used in high dose and for long periods in women with a past or present history of benign breast disease." | ( Bricaire, C, 1993) |
| "Breast cancer is the most common malignancy in women and hormone resistance is a challenging problem in its treatment." | ( Baylin, SB; Davidson, NE; Issa, JP; Ottaviano, YL; Parl, FF; Smith, HS, 1994) |
| "Male breast cancer is a rare tumor consisting only 1% of all breast cancers." | ( Bounds, WE; Burton, GV; Schwalke, MA, 1993) |
| "A third of breast cancers are estrogen dependent and respond to endocrine therapy." | ( Milgrom, E; Pichon, MF, 1993) |
| "Breast cancer is the most common cancer among women in both Europe and the U." | ( Englisbe, BH; Harper, GR, 1993) |
| "The incidence of breast cancer is 25-30% of all malignant female tumors and represents the highest rate of mortality." | ( Langhi, M; Luque, EH; Muñoz de Toro de Luque, M; Romero Acuña, J; Romero Acuña, L, 1993) |
| "Many breast tumors are hormone dependent, and there is evidence that hydrolysis of estrone sulfate (E1S) to estrone, by estrone sulfatase, is an important source of the estrogen which is found in tumors." | ( Duncan, L; Howarth, NM; Potter, BV; Purohit, A; Reed, MJ, 1993) |
| "Male breast cancer is a rare tumour in all parts of the world." | ( Lowenfels, AB; Pasker-de Jong, P; Sasco, AJ, 1993) |
| "Breast cancer is the most common malignancy affecting women, and its incidence has been increasing in many countries." | ( Skegg, DC, 1995) |
| "Breast cancer is the most common cause of death in women aged 35-55 years." | ( Bhakta, P; Donnelly, P; Mayberry, J, 1995) |
| "Presence of PR in breast tumors is an important indicator of likely responsiveness to endocrine agents." | ( Balleine, RL; Bilous, AM; Clarke, CL; Graham, JD; Harvey, SS; Milliken, JS; Yeates, C, 1996) |
| "Although breast cancer is perceived to be relatively chemosensitive, cytotoxic drug therapy only leads to cure in the adjuvant setting." | ( Bowman, A; Cameron, DA; Gregory, WM; Leonard, RC, 1996) |
| "Breast cancer is the most commonly occurring cancer among women in Singapore, a country which has experienced significant changes in lifestyle over the past three decades." | ( Duffy, SW; Lee, HP; Lee, J; McGee, MA; Seow, A, 1996) |
| "Breast cancer is a disease of modern life." | ( Davis, S; Stevens, RG, 1996) |
| "Breast cancer is a common and lethal disease in the US, and evidence suggests that gonadal steroids play a role in the development of breast cancer." | ( Kaunitz, AM, 1996) |
| "The issues with breast cancer are more complex, mainly because of a variety of unresolved effects." | ( Brinton, LA; Hulka, BS, 1995) |
| "Breast carcinoma is frequently associated with nonrandom chromosomal aberrations, but their identification by standard cytogenetics (SC) is often limited by technical difficulties." | ( Ho, JP; Quan, DE; Simpson, JF; Slovak, ML, 1996) |
| "One third of breast cancers are hormone dependent and regress on blockade of estrogen biosynthesis or receptor-mediated action." | ( Santen, RJ; Yue, W, 1996) |
| "Node-negative breast cancers are considered to comprise a subgroup which is amenable to cure with local-regional therapy alone." | ( Bonadonna, G; Valagussa, P; Zambetti, M, 1996) |
| "Breast cancer is no longer seen as an absolute contraindication to either pregnancy or the use of hormone replacement therapy (HRT); however, oncologists are uncertain about the appropriate use of HRT, either alone or with tamoxifen." | ( Maher, EJ, 1995) |
| "Breast cancer is thought to start in the lining of the milk duct or lobule." | ( Barsky, SH; Love, SM, 1996) |
| "Metastatic breast cancer is a major and increasing public health problem." | ( Piccart, M, 1996) |
| "Although metastatic breast cancer is an incurable disease, chemotherapy has had an impact on survival since the use of anthracycline drugs has become widespread." | ( Trudeau, ME, 1996) |
| "Human breast carcinomas are frequently infiltrated by inflammatory cells secreting several cytokines which may regulate the activity of both immune cells and neoplastic cells." | ( Blais, Y; Gingras, S; Haagensen, DE; Labrie, F; Simard, J, 1996) |
| "Chemotherapy for breast cancer is given on the basis of empirical information from clinical trials, an approach which falls to take into account the known heterogeneity of chemosensitivity between patients." | ( Andreotti, PE; Bruckner, HW; Cree, IA; Dewar, JA; Hunter, EM; James, EA; Kurbacher, CM; Preece, PE; Subedi, AM; Sutherland, LA; Untch, M, 1996) |
| "Breast cancer is a devastating disease." | ( Elstner, E; Heber, D; Koeffler, HP, 1996) |
| "Breast cancer is the most common cancer among women worldwide." | ( Alberg, AJ; Daudt, A; Helzlsouer, KJ, 1996) |
| "Breast cancer is the second most common cancer among women in Madras and southern India after cervix cancer." | ( Black, RJ; Gajalakshmi, CK; Sankaranarayanan, R; Shanta, V; Swaminathan, R, 1997) |
| "Metastatic breast cancer is a major cause of cancer death in Australian women." | ( Davison, JD; Francis, PA; Ganju, V; Michael, M; Millward, MJ; Rischin, D; Shapiro, JD; Toner, GC, 1997) |
| "More than 50% of breast cancers are diagnosed in women aged 65 years or older, a quickly growing segment of the population." | ( Kimmick, G; Muss, HB, 1997) |
| "Breast cancer is a major health problem in America, accounting for almost one-third of cancer-related deaths in women." | ( Bell, RA; Bostick, RM; Kimmick, GG, 1997) |
| "The risk of breast cancer is increased after ORT of 5 years or longer (RR: 1." | ( Burger, CW; Kenemans, P; Koomen, I; Peters, NA; van Leeuwen, FE, 1997) |
| "Receptor-positive breast cancer is somewhat less common in premenopausal patients." | ( Valavaara, R, 1997) |
| "Although breast carcinomas are considered to originate from glandular epithelial cells, some exhibit 'squamoid features', comprising stratification with a gradient in the nuclear-cytoplasmic ratio within individual cancer cell nests on microscopy." | ( Fukutomi, T; Hirohashi, S; Sakamaki, C; Tsuda, H, 1997) |
| "Breast cancer is the most common malignancy among Egyptian women." | ( Helal, T; Khalifa, A; Nassiri, M, 1997) |
| "Breast cancer is a genetic disease arising from a series of germ-line and/or somatic DNA changes in a variety of genes, including BRCA1 and BRCA2." | ( Ainsworth, PJ; Archer, TK; Mancini, DN; O'Malley, FP; Rodenhiser, DI; Singh, SM; Xing, W, 1998) |
| "Aging, sleep, and breast cancer are important concerns of postmenopausal women." | ( Brzezinski, A, 1998) |
| "Moreover, human breast carcinomas are often infiltrated by stromal/immune cells secreting a wide spectra of cytokines." | ( Blais, Y; Carrière, MC; Gingras, S; Labrie, F; Simard, J; Turgeon, C, 1998) |
| "Breast cancer is one of the most common forms of cancer observed in women, and endogenous estrogen is thought to play a major role in its development." | ( Ardies, CM; Dees, C, 1998) |
| "Locally advanced breast carcinoma is associated with a poor prognosis." | ( Bengtsson, NO; Bergh, JC; Fornander, TG; Hatschek, T; Jansson, TE; Karlsson, YA; Malmström, PO; Sjöberg, SM; Söderberg, M, 1998) |
| "Metastatic breast cancer is still an incurable disease." | ( Bontenbal, M; de Wit, R; Klijn, JG; Seynaeve, C, 1998) |
| "Breast carcinoma is a leading cause of cancer death in women in the US." | ( Shen, F; Weber, G, 1998) |
| "Metastatic breast cancer is commonly thought to be incurable." | ( Coniglio, D; Elkordy, M; Fishman, R; Gilbert, C; Hussein, A; Matters, L; Peters, WP; Petros, W; Ross, M; Rubin, P; Vredenburgh, J, 1998) |
| "Breast cancer is a disease that commonly metastasizes to bone, increasing morbidity, mortality, and health service costs." | ( Cook, GJ; Fogelman, I, 1999) |
| "Since breast cancer is now being detected at an earlier stage than previously and since adjuvant chemotherapy may cause ovarian failure, an increasing number of women are becoming postmenopausal at a younger age after breast cancer treatment." | ( , 1999) |
| "Since breast cancer is now being detected at an earlier stage than previously and since adjuvant chemotherapy may cause ovarian failure, an increasing number of women are becoming postmenopausal at a younger age after breast cancer treatment." | ( , 1999) |
| "Worldwide, breast cancer is the most common malignancy accounting for 20-32% of all female cancers." | ( Brainard, GC; Kavet, R; Kheifets, LI, 1999) |
| "Since breast cancer is now being detected at an earlier stage than previously and since adjuvant chemotherapy may cause ovarian failure, an increasing number of women are becoming postmenopausal at a younger age after breast cancer treatment." | ( , 1999) |
| "Breast cancer is the most common cancer among American women, whereas Asian women, who consume a traditional diet high in soy products, have a relatively low incidence." | ( Bhuiyan, M; Li, Y; Sarkar, FH; Upadhyay, S, 1999) |
| "The induction of breast cancer is a long process, containing a series of biological events that drive a normal mammary cell towards malignant growth." | ( Clarke, R; Hilakivi-Clarke, L; Lippman, M, 1999) |
| "Since breast cancer is now being detected at an earlier stage than previously and since adjuvant chemotherapy may cause ovarian failure, an increasing number of women are becoming postmenopausal at a younger age after breast cancer treatment." | ( , 1999) |
| "Metaplastic breast cancer is a rare disease with little information available to guide therapy." | ( Adjei, AA; Ingle, JN; Rayson, D; Suman, VJ; Wold, LE, 1999) |
| "The fear of breast cancer is the most important concern for women who have to decide whether to take hormone replacement therapy (HRT) for the treatment and prevention of postmenopausal disturbances." | ( Chiechi, LM; Secreto, G, 1999) |
| "Most women with breast cancer are treated systemically with either chemotherapy or tamoxifen, or both, and mortality is substantially reduced." | ( Kotwall, CA, 1999) |
| "Since breast cancer is frequently associated with bone metastasis, bone scintigraphies have been performed to determine pre-operative staging and to survey postoperative bone metastasis." | ( Fukunaga, M; Mimura, H; Miyoshi, H; Nagai, K; Otsuka, N; Sone, T; Tamada, T; Tomomitsu, T; Yanagimoto, S, 1999) |
| "The risk of breast cancer is decreased in association with an increased level of polyunsaturated fatty acids in the erythrocyte membranes." | ( Alagöl, H; Bugdayci, G; Camlibel, M; Erdem, E; Sancak, B; Turkmen, G, 1999) |
| "Human breast tumors are usually composed of heterogeneous cell populations that exhibit different sensitivities to therapeutic agents." | ( Candas, B; Couillard, S; Gutman, M; Labrie, C; Labrie, F, 1999) |
| "Breast cancer is an important cause of morbidity and mortality in Brazil." | ( Andrada-Serpa, MJ; Barreto, HH; Carmo, PA; Eluf-Neto, J; Inomata, ON; Kussumi, TA; Mendonça, GA, 1999) |
| "Women with breast cancer are the most frequent recipients of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (autotransplants) in North America." | ( Antman, KH; Armitage, JO; Bitran, JD; Fay, JW; Fields, KK; Freytes, CO; Gale, RP; Herzig, RH; Horowitz, MM; Kennedy, MJ; Klein, JP; Lazarus, HM; McCarthy, PL; Pecora, AL; Pelz, CJ; Reed, E; Rowlings, PA; Sobocinski, KA; Spitzer, G; Stadtmauer, EA; Vaughan, WP; Williams, SF; Wolff, SN, 1999) |
| "Breast cancer is associated with endogenous hormone levels, but the exact relation and underlying mechanisms remain unclear." | ( Byers, TE; Innes, KE, 1999) |
| "Every day that breast cancer is delayed is a day that it is prevented." | ( Osborne, MP, 1999) |
| "Human breast cancer is the predominant malignancy and the leading cause of cancer death in women from Western societies." | ( Chen, N; Chen, WY; Ramamoorthy, P; Sticca, R; Wagner, TE, 1999) |
| "Recurrent cutaneous breast cancer is difficult to manage, with surgery, radiotherapy and systemic therapy all having their limitations." | ( Clive, S; Gardiner, J; Leonard, RC, 1999) |
| "Because breast cancer is the most common cancer and second leading cause of cancer-related deaths in women in the United States, we investigated whether flavopiridol could be an effective agent against a series of isogenic breast- cancer cell lines having different levels of erbB-2 expression and differential invasion and metastatic characteristics." | ( Alhasan, S; Bhuiyan, M; Li, Y; Sarkar, FH; Senderowicz, AM, 2000) |
| "Breast cancer is relatively sensitive to chemotherapy." | ( Ohsumi, S; Saeki, T; Takashima, S, 2000) |
| "The growth of breast carcinoma is promoted by autocrine growth factors such as the bombesin (BN)-like peptides and epidermal growth factor (EGF)." | ( Arencibia, JM; Cai, RZ; Groot, K; Halmos, G; Kahán, Z; Schally, AV; Sun, B, 2000) |
| "Adjuvant CMF in breast cancer is cost-effective in Norway." | ( Norum, J, 2000) |
| "A hallmark of breast carcinoma is the deposition of fibrinogen (FBG) without subsequent conversion to fibrin in the tumor stroma." | ( Rybarczyk, BJ; Simpson-Haidaris, PJ, 2000) |
| "Prevention of breast cancer is still under clinical investigation with only one drug, tamoxifen, showing benefit in high risk patients." | ( Carolin, KA; Pass, HA, 2000) |
| "Breast cancer is the commonest form of cancer in women in Western countries and second most common in women of developing countries like India." | ( Devi, R; Kumar, R; Singh, MM; Walia, I, 1999) |
| "Some breast tumors are classified as primary neuroendocrine carcinomas because of argyrophilia and positivity for neuroendocrine markers (chromogranins A and B and neuron-specific enolase), regardless of their cellular rest and cord structures." | ( D'Eredità, G; Rubini, G, 2000) |
| "Breast cancer is the most common cancer in women." | ( Lamartiniere, CA, 2000) |
| "Over 30% of breast cancers are diagnosed after age 70." | ( Hillen, HF; Hupperets, PS, 2000) |
| "Breast cancer is the most relevant form of cancer among women in Latin America." | ( Cho, S; Peña-Rosas, JP; Rickard, S, 1999) |
| "Breast cancer is the most common malignant disease in Western women." | ( Bozan, B; Erden Inal, M; Koşan, M; Ozkaya, O; Portakal, O; Sayek, I, 2000) |
| "Breast cancer is probably the result of a series of genetic events, each with its own histopathologic correlate in the hyperplasia to carcinoma sequence." | ( Dawson, PJ; Strickland, LB, 2000) |
| "The risk of breast cancer is much higher in industrial countries than in developing countries, where women are characterized by lower energy intake and higher energy expenditure." | ( Ellison, PT; Jasieńska, G; Thune, I, 2000) |
| "Breast cancer is an ideal model to test the efficacy of combined modalities given its known sensitivity to both radiotherapy and chemotherapy." | ( Brechbiel, MW; Clarke, K; Lee, FT; Old, LJ; Scott, AM; Smyth, FE, 2000) |
| "Breast cancer is the second most prevalent cancer affecting Indian women." | ( Feng, J; Kannan, K; Krishnamurthy, J; Nakajima, T; Shanmugam, G; Tsuchida, N, 2000) |
| "Breast cancer is the most common cancer in women worldwide." | ( Jin Lim, E; Lai, LC; Nesaretnam, K; Reimann, K, 2000) |
| "Early detection of breast cancer is crucial for efficient and effective treatment." | ( Aznar, M; Gagnon, JH; Lisbona, R; Loutfi, A; Murthy, K; Thompson, CJ, 2000) |
| "Breast cancer is nowadays one of the most frequent cancers in female subjects." | ( Braendle, W, 2000) |
| "Metastatic breast cancer is a devastating problem, clinical application of I3C as a potent chemopreventive agent may be helpful in limiting breast cancer invasion and metastasis." | ( Fan, S; Goldberg, ID; Meng, Q; Rosen, EM, 2000) |
| "Breast cancer is the most commonly diagnosed cancer in American women." | ( Albanese, C; Amanatullah, DF; Hulit, J; Lisanti, MP; Pestell, RG; Reutens, A; Rosen, E; Sparano, JA; Wang, C; Zafonte, BT, 2000) |
| "Chemoprevention of breast cancer is a rapidly growing field." | ( Osborne, MP; Rosenbaum Smith, SM, 2000) |
| "Pregnancy after breast cancer is a realistic consideration for some breast cancer survivors and is not clearly detrimental to either the mother or her offspring." | ( Moore, HC, 2000) |
| "Magnetic heating of breast tumors is a promising technique for future interventional radiologic treatments." | ( Andrä, W; Hergt, R; Hiergeist, R; Hilger, I; Kaiser, WA; Schubert, H, 2001) |
| "Breast cancer is one of the most common forms of cancer observed in women." | ( Gustafsson, JA; Warner, M, 2000) |
| "Breast cancer is among the most common of the cancers that occur in women living in western societies." | ( Clarke , R; Hilakivi-Clarke, L; Trock, B, 2001) |
| "Breast cancer is characterized by elevated glucose consumption resulting in increased uptake of 18F-FDG." | ( Avril, N; Dose, J; Jänicke, F; Menzel, M; Nathrath, W; Schelling, M; Schwaiger, M; Weber, W, 2001) |
| "Breast carcinoma is thought to arise because of multiple successive changes in the genome of the normal epithelial cells." | ( Baldetorp, B; Isola, J; Kytölä, S; Rennstam, K; Tanner, M, 2001) |
| "Node-positive breast carcinoma is an aggressive disease." | ( Blanco-Sequeiros, G; Pääkko, P; Talvensaari-Mattila, A; Turpeenniemi-Hujanen, T, 2001) |
| "Risk factors for breast cancer are related to endogenous hormones and reproductive events." | ( Feigelson, HS; Henderson, BE, 2000) |
| "Many human breast tumors are driven by high intratumor concentrations of 17beta-estradiol that appear to be locally synthesized." | ( Ahluwalia, BS; Ampy, F; Clarke, R; James, MR; Lee, RY; MacPherson, A; Skaar, TC; Zwiebel, JA, 2001) |
| "Breast cancer is sensitive to several cytotoxic drugs." | ( Hortobagyi, GN, 2001) |
| "Breast cancer is the leading type of cancer in women." | ( Muthuswamy, S; Raste, AS, 2000) |
| "Breast cancer is a classic hormone-dependent malignant disease that is influenced by estrogen." | ( Fuqua, SA; Russo, J; Shackney, SE; Stearns, ME, 2001) |
| "Metastatic breast cancer is a partially chemotherapy-sensitive neoplasm." | ( Crown, JP, 2001) |
| "Breast cancer is a common problem in older women." | ( Kimmick, GG; Muss, HB, 2001) |
| "As far as breast cancer is concerned, most epidemiological studies suggest no difference in risk between therapy with estrogens alone or estrogens combined with progestogens, but recent data do indicate an increased risk with combined therapy." | ( Skouby, SO, 2000) |
| "Breast cancer is the most common cancer among women in the United States." | ( Moore, S, 2001) |
| "Menopause and breast cancer are common independent health events, and coincide in some women." | ( Ganz, PA, 2001) |
| "Breast cancer is the most common malignancy among women." | ( Geng, Y; Sicinski, P; Yu, Q, 2001) |
| "Because breast carcinomas are overwhelmingly ductal in origin, this review focuses on stromal influences guiding postnatal ductal development and there is only the briefest account of the role of embryonic stroma (mesenchyme)." | ( Silberstein, GB, 2001) |
| "Obesity and breast cancer are common conditions that often coexist." | ( Bjarnason, GA; Franssen, E; Madarnas, Y; Sawka, CA, 2001) |
| "The risk of breast cancer is higher in patients suffering from gross cystic disease." | ( Bicikova, M; Simickova, M; Tallova, J; Tomandl, J, 2001) |
| "Breast cancer is the leading cancer site in women, both in the developed and the developing world." | ( Sasco, AJ, 2001) |
| "Breast cancer is the second most common cancer among women in India, after cancer of the cervix uteri." | ( Chopra, R, 2001) |
| "Breast carcinoma is the most frequent cancer in women and is the second leading cause of death." | ( Buyukberber, S; Camci, C; Kutlu, R; Sari, R; Sevinc, A; Totan, Y, 2001) |
| "Breast cancer is among the commonest malignancies in women and tamoxifen has been widely used for more than two decades for treatment of breast cancer." | ( Chiyabutra, T; Kleabkaew, P; Sinawat, S, 2001) |
| "Breast cancer is a disease with long natural history." | ( Somani, N, 2001) |
| "(18)FDG uptake in breast cancer is a function of microvasculature for delivering nutrients, Glut-1 for transportation of (18)FDG into the cell, HK for entering (18)FDG into glycolysis, number of tumor cells/volume, proliferation rate (also reflected in necrosis), number of lymphocytes (not macrophages), and HIF-1alpha for upregulating Glut-1." | ( Bos, R; Comans, EF; Hoekstra, OS; Joshi, U; Lammertsma, AA; Molthoff, CF; Semenza, GL; van Der Groep, P; van Der Hoeven, JJ; van Der Wall, E; van Diest, PJ, 2002) |
| "Prevention of breast cancer is a pertinent question and major publications are presented." | ( Lucchi-Angellier, E, 2001) |
| "Breast cancer is a common disease in the United States and Europe and is therefore a major target for prevention strategies." | ( Dickler, MN; Norton, L, 2001) |
| "Chemoprevention for breast cancer is both old and new." | ( Pritchard, KI, 2001) |
| "The risk of breast cancer is increased by early parity and is decreased by breast feeding, by oophorectomy, and by cigarette smoking." | ( Narod, SA, 2001) |
| "Metastatic breast cancer is a common clinical entity, and its treatment is still a major clinical problem in modern oncology." | ( Altinova, AE; Coşkun, U; Gunel, N; Yamac, D, 2001) |
| "Breast cancer is a major cause of cancer death in women, and the genetic abnormalities leading to the common sporadic forms of the disease are still under active investigation." | ( Cardiff, RD; Landesman-Bollag, E; Romieu-Mourez, R; Seldin, DC; Sonenshein, GE; Song, DH; Sussman, DJ, 2001) |
| "Breast cancer is one of the most common cancer forms affecting many women." | ( Landberg, G, 2002) |
| "Breast cancer is one of the major causes of mortality among women in the United States." | ( Bohr, VA; Evans, MK; Mambo, E; Nyaga, SG, 2002) |
| "Acinic cell-like breast carcinoma is a newly recognized entity, and few acinic cell-like breast carcinoma cases have been reported." | ( Hirokawa, M; Kudo, H; Monobe, Y; Sai, T; Sano, N; Sano, T; Sugihara, K, 2002) |
| "The etiology of breast cancer is closely linked to the female hormone estrogen, with high life-time exposure being suggested to increase breast cancer risk [Nature 303 (1983) 767]." | ( Bouker, KB; Cabanes, A; Clarke, R; Hilakivi-Clarke, L; Kerr, L; Olivo, S, 2002) |
| "Breast cancer is one of the most frequent neoplasms in women." | ( Bourlon-Cuellar, R; Candelaria, M; Noel-Ettiene, LM; Sánchez-Sánchez, JM; Zubieta, JL, 2002) |
| "Breast cancer is the most common cancer among women and the leading cause of death in women, 40 to 55 years of age." | ( Benshushan, A; Brzezinski, A, 2002) |
| "Metastatic breast cancer is a chemotherapy-responsive disease, and significant palliation of cancer-related symptoms can be achieved with effective treatment." | ( Conte, P; Gennari, A; O'Shaughnessy, JA, 2002) |
| "Drug resistance in breast cancer is a major obstacle to successful chemotherapy." | ( Assersohn, L; Dowsett, M; Feldman, AL; Gadisetti, C; Jazaeri, AA; Libutti, SK; Liu, ET; Powles, TJ; Sotiriou, C, 2002) |
| "Breast cancer is one of the most common cancers worldwide." | ( Tripathy, D, 2002) |
| "Breast cancer is the most common malignancy among American women." | ( Cianfrocca, M; Goldstein, LJ, 2001) |
| "Breast cancer is the leading cause of death among women and the contribution of circulating oestrogens to the growth of some mammary tumours has been recognized." | ( Lombardi, P, 2002) |
| "Breast cancer is hormone related, as are cancers of the endometrium, ovary, and prostate." | ( Hamajima, N; Hirose, K; Inoue, M; Iwata, H; Matsuo, K; Saito, T; Tajima, K; Takezaki, T; Yang, C, 2002) |
| "Their uses in breast cancer are continually evolving as new clinical trial results become available." | ( Cummings, FJ, 2002) |
| "Breast cancer is a leading cause of cancer-related mortality among postmenopausal women in the US, and the economic burden of breast cancer care comprises a large percentage of the healthcare budget." | ( Ibrahim, D; Newman, L; Simon, MS; Stano, M, 2002) |
| "Although metastatic breast cancer is responsive to radioimmunotherapy (RIT), a systemic targeted radiation modality, complete and permanent remissions are not typical with single-modality treatment." | ( Burke, PA; DeNardo, GL; DeNardo, SJ; Lamborn, KR; Matzku, S; Miers, LA, 2002) |
| "As prevalence of breast cancer is greatest in industrialized regions, exposure to light at night has been proposed as a potential risk factor." | ( Brainard, GC; Glickman, G; Levin, R, 2002) |
| "In Nigeria, breast cancer is rare, while deaths due to pregnancy and childbirth are common, indicating that OC use can prevent many female deaths." | ( Ibekwe, J, 1993) |
| "Invasive breast carcinomas are composed of invasive and noninvasive components in varying proportions and sometimes the two components show different histopathological responses to chemotherapy, however there has been no study as yet comparing the pathological response to chemotherapy of invasive and noninvasive components." | ( Akashi-Tanaka, S; Fukutomi, T; Hasegawa, T; Matsuo, K; Tsuda, H; Watanabe, T, 2002) |
| "Breast cancer is the most common malignancy in women and constitutes 18% of all cancers in women." | ( Haimov-Kochman, R; Hochner-Celinkier, D; Lavy, Y, 2002) |
| "30-40% of breast cancers are hormone dependent or sensitive." | ( Petit, JC, 1972) |
| "The risk of breast cancer is increased by an early menarche, late age at 1st birth, and by a late menopause which implicates ovarian steroids in the initiation or promotion of breast cancer, as some breast cancers are estrogen dependent." | ( Chandran, R, 1992) |
| "Prevention of breast cancer is a high priority for women at risk for the disease." | ( Sakorafas, GH, 2002) |
| "Development of breast tumors is often accompanied by angiogenesis--the formation of new blood vessels." | ( Bloomquist, AK; Jeunehomme, F; Muller, S; Rick, A; Rico, D; Skarpathiotakis, M; Yaffe, MJ, 2002) |
| "Breast cancer is the second most common cause of brain metastases, and 10-15% of patients develop clinically overt central nervous system disease." | ( Fenner, MH; Possinger, K, 2002) |
| "Prostate and breast carcinomas are sex hormone-related carcinomas, which are known to be associated with an over-expression of the proto-oncogene Bcl-2." | ( Blaukat, A; Bu, S; Fu, X; Heldin, NE; Landström, M, 2002) |
| "Breast cancer is a serious illness affecting approximately one in nine women in the United States." | ( Go, V; Kasat, K; Pogo, BG, 2002) |
| "Breast cancer is the most frequent cancer occurring in women." | ( Amsler, E; Aractingi, S; Marinho, E; Sigal-Zafrani, B, 2002) |
| "Breast cancer is the most common malignancy amongst women in the United States and decreased mortality over the past decade has been attributed to a combination of screening and adjuvant therapies." | ( Benson, JR; Pitsinis, V, 2003) |
| "Breast cancer is the most common malignancy detected in American women." | ( Cersosimo, RJ, 2003) |
| "Breast cancer is a great problem of public health all over the world." | ( Migliani, R; Rabarijaona, LP; Raharisolo Vololonantenaina, CR; Rajemiarimoelisoa, C; Rasendramino, M, 2002) |
| "Breast cancer is the first cause of this dissemination." | ( Chabert, P; Dieny, A; Grimonpont, A; Hadjseyd, M; Mechin-Cretinon, I; Mohseni, H; Truong, P, 2003) |
| "Sporadic breast carcinoma is polygenically inherited." | ( Comings, DE; Cone, LA; Gade-Andavolu, R; MacMurray, JP; Muhleman, D, 2003) |
| "Breast cancer is sensitive to chemotherapy and endocrine therapy, but the prognosis of advanced or relapsed breast cancer is unsatisfactory." | ( Hatake, K; Sugimoto, Y; Takahashi, S, 2003) |
| "Breast cancer is one of the major cancers around the world but its etiology is still not well understood." | ( Ahsan, H; Chen, SY; Faraglia, B; Gammon, MD; Garbowski, GC; Hibshoosh, H; Kadlubar, FF; Lin, D; Neugut, AI; Santella, RM; Teitelbaum, SL; Zhang, Y, 2003) |
| "Breast cancer is the most frequent female malignant disease in developed countries." | ( Kahán, Z; Thurzó, L, 2003) |
| "Breast cancer is the most common cancer and the second greatest cause of cancer-related death among women in the United States." | ( O'Shaughnessy, JA, 2003) |
| "Breast cancer is the most common malignancy in women in the United States." | ( Gradishar, WJ; Kaklamani, VG, 2003) |
| "Breast cancer is the most common cancer among Malaysian women." | ( Hisham, AN; Yip, CH, 2003) |
| "Breast cancer is the second most frequent cancer of Thai women." | ( Arpornwirat, W; Cheirsilpa, A; Kalalak, A; Sangrajrang, S; Sornprom, A; Soussi, T; Thisuphakorn, P, 2003) |
| "Breast cancer is certainly not preventable at the same degree as lung cancer is by avoiding cigarette smoking or bladder cancer by avoiding exposure to some specific professional carcinogens." | ( Orazi, G; Vinatier, D, 2003) |
| "Breast cancer is the most common cancer in women and the leading cause of cancer death among women 35-54 years of age." | ( Brody, JG; Rudel, RA, 2003) |
| "Lung and breast cancer are associated with high plasma levels of MMP-9 and TIMP-1." | ( Atkins, HL; Hurewitz, AN; Hymowitz, MH; Lau, YH; Meek, AG; Susskind, H; Valentine, ES; Zucker, S, 2003) |
| "Advanced breast cancer is largely incurable and current treatment modalities are aimed towards restricting tumour growth, prolonging survival, palliating symptoms and maintaining quality of life (QoL)." | ( Parker, LM; Piccart, M; Pritchard, KI, 2003) |
| "The majority of breast cancers are oestrogen dependent and although current treatment strategies have improved, approximately 50% of the patients will develop metastasis." | ( Dabrosin, C; Gauldie, J; Palmer, K, 2003) |
| "Modern treatment of cancer of the breast is based on established prognostic factors (patient age, receptor status, tumor size, lymph node involvement, tumor grading), and thus takes the patient's individual risk profile into account." | ( Höffken, K; Sayer, HG, 2003) |
| "Metastatic breast cancer is a partially chemotherapy-sensitive neoplasm." | ( Crown, J; Pegram, M, 2003) |
| "Breast cancer is responsible for considerable morbidity and the majority of female deaths in industrialized countries." | ( Starek, A, 2003) |
| "Human breast cancer is extensively infiltrated by mast cells that contain powerful anticoagulants such as heparin, tryptase and chymase." | ( Corwin, MA; Samoszuk, M, 2003) |
| "Breast cancer is the most frequent type of tumor in women." | ( Chen, XP; Huang, P; Huang, SL; Ouyang, DS; Wang, LS; Zhou, HH; Zhu, B, 2003) |
| "Breast cancer is the most common malignant disease of women." | ( Gong, C; Hamar, P; Hu, X; Jia, W; Song, E; Su, F, 2003) |
| "Breast cancer is a prototype for exploring variations in pathological diagnosis and etiology." | ( Bhan, CM; Goel, A; Srivastava, KN, 2003) |
| "Risk factors of breast cancer are listed and evaluated individually." | ( Eckhardt, S, 2003) |
| "Breast cancer is one of the most common cancers of women in the Western world." | ( Goss, PE; Strassmer-Weippl, K, 2003) |
| "Breast cancer is a disease that is in need of novel treatment strategies and the use of the catechins epigallocatechin gallate (EGCG), epigallocatechin (EGC) and epicatechin gallate (ECG) is currently being investigated as a potential therapy." | ( Rosengren, RJ, 2003) |
| "Breast cancer is the most prevalent cancer in women in Western societies." | ( Borne, BV; Duijts, SF; Zeegers, MP, 2003) |
| "Breast cancer is significantly less prevalent among Asian women, whose diets contain high intake of soy products and tea." | ( Blackburn, GL; Mai, Z; Yu, L; Zhou, JR, 2004) |
| "Many breast cancers are driven to grow by estrogen, and tamoxifen exploits this by blocking estrogen action at the estrogen receptor." | ( Tonetti, DA, 2004) |
| "The incidence of breast cancer is on the rise but as yet there is no guaranteed beneficial treatment for many of the sufferers." | ( Bhatia, K; Lord, R; Roberts, K; Stanton, P, 2004) |
| "Their presence in breast tumors is used to predict functional estrogen receptors (ERs) and, therefore, also to predict the likelihood of response to endocrine therapies and disease prognosis." | ( Allred, DC; Cui, Y; Fuqua, SA; Hilsenbeck, SG; Hopp, TA; Horwitz, KB; Weiss, HL, 2004) |
| "Breast carcinoma is the most common neoplasm found among women in the Western world." | ( Buscombe, JR; Schillaci, O, 2004) |
| "Breast cancer is associated with increased glucose consumption and can therefore be visualised with the glucose analogue [(18)F]2-deoxy-2-fluoro-D-glucose (FDG) and positron emission tomography (PET)." | ( Buck, AK; Mattfeldt, T; Reske, SN; Schirrmeister, H, 2004) |
| "Breast cancer is the most common cancer among Malaysian women." | ( Hisham, AN; Yip, CH, 2004) |
| "The death rate from breast cancer is falling rapidly in most developed countries due, at least in part, to the use of adjuvant endocrine therapy in women with endocrine responsive disease." | ( Clemons, M; Coleman, RE; Verma, S, 2004) |
| "Primary breast carcinoma are frequently infiltrated by dendritic cells (DC)." | ( Bachelot, T; Bendriss-Vermare, N; Biota, C; Blay, JY; Caux, C; Goddard, S; Massacrier, C; Menetrier-Caux, C; Thomachot, MC; Treilleux, I, 2004) |
| "Human breast cancer is the leading cause of cancer death in women from Western societies, and a large study of the epidemiology demonstrated strong associations between human prolactin and risk of breast cancer." | ( Goodhew, KL; Holly, JM; Keith, AJ; Perks, CM; Savage, PB; Winters, ZE, 2004) |
| "If detected early, breast cancer is eminently curable." | ( Argani, P; Blum, MA; Fackler, MJ; Garrett, E; Lange, J; Lapides, A; McVeigh, M; Mehrotra, J; Sukumar, S, 2004) |
| "Breast cancer is the only other cancer demonstrating endogenous functional NIS expression." | ( Adelman, D; Carrasco, N; Dohan, O; Goris, M; Nowels, K; Wapnir, IL; Yudd, A, 2004) |
| "Women with breast cancer are at risk for elevated depression, anxiety, and decreased natural killer (NK) cell number." | ( Burman, I; Diego, M; Field, T; Fletcher, MA; Hernandez-Reif, M; Hurley, J; Ironson, G; Katz, G; Kuhn, C; Schanberg, S; Weiss, S, 2004) |
| "Breast cancer is one of the most common malignancies in the United States." | ( Kumar, R; Santen, RJ; Song, RX; Zhang, Z, 2004) |
| "Breast cancer is the most common cancer in women worldwide." | ( García Rodríguez, LA; González-Pérez, A; Ronquist, G, 2004) |
| "Breast cancer is a major cause of mortality in Western countries and there is an urgent requirement for novel treatment strategies." | ( Chander, SK; Ireson, CR; Parish, DC; Potter, BV; Purohit, A; Reed, MJ; Woo, LW, 2004) |
| "ER-negative breast cancers are a distinct group of tumors with several common morphological features." | ( El-Rehim, DM; Ellis, IO; Lee, AH; Paish, CE; Pinder, SE; Putti, TC; Rakha, EA, 2005) |
| "Breast cancer is the most frequent malignancy among women in the European Union and better therapies are needed, especially for metastatic tumors." | ( Llagostera, E; Montaner, B; Perez-Tomas, R; Scheffer, GL; Soto-Cerrato, V, 2004) |
| "Breast cancer is one of the main life-threatening diseases that a woman may have to face during her lifetime." | ( Angelopoulos, N; Barbounis, V; Kaltsas, D; Livadas, S; Tolis, G, 2004) |
| "Breast cancer is still one of the most important tumors among women in industrialized countries." | ( Báñez-Coronel, M; Gutiérrez, R; Lacal, JC; Megías, D; Olmeda, D; Ramírez de Molina, A; Rodríguez-González, A, 2004) |
| "Breast cancer is regarded as a systemic disease even when tumors are completely resected." | ( Chehal, A; Khalil, M; Shamseddine, A; Taher, A, 2004) |
| "Breast cancer is the most commonly diagnosed cancer in women." | ( Brown, P; Kramer, R, 2004) |
| "Breast cancer is a significant cause of morbidity and mortality." | ( Hussain, SA; Rea, DW; Stevens, A; Williams, S, 2004) |
| "About 75% of breast tumors are positive for the estrogen receptor (ER) or progesterone receptor (PgR) or both, and estrogen is the main stimulant in the development and growth of these tumors." | ( Altundag, K; Altundag, O; Arun, B; Gunduz, M, 2004) |
| "The risk of breast cancer is also not increased in women with polycystic ovary syndrome who have chronic estrogen exposure and androgen excess." | ( Davis, SR; Somboonporn, W, 2004) |
| "Breast cancer is one of the commonest cancers among women in Malaysia." | ( Chong, FB; Hejar, AR; Rosnan, H; Zailina, H, 2004) |
| "Advanced breast cancer is often associated with metastatic bone disease, causing a number of serious complications for the patients such as hypercalceamia, pain, nerve compression and fractures." | ( Coleman, RE; Cross, NA; Eaton, CL; Evans, CA; Holen, I; Neville-Webbe, HL; Nyambo, R, 2004) |
| "Breast cancer is a major cause of female morbidity and mortality worldwide." | ( Clamp, A; Clemons, M; Danson, S, 2003) |
| "Breast cancer is a hormone-dependent cancer, and the presence of estrogen receptor alpha (ER-alpha) in tumors is used clinically to predict the likelihood of response to hormonal therapies." | ( Cui, Y; Fuqua, SA; Hopp, TA; Osborne, CK; Parra, IS; Weiss, HL, 2004) |
| "Currently, breast cancer is the leading cause of cancer-related death in women." | ( Muhammad, TS; Najimuddin, N; Samian, MR; Sulaiman, SF; Tan, ML, 2005) |
| "Most breast cancers are hormone responsive, but eventually develop resistance to individual endocrine agents." | ( Lynn, J, 2004) |
| "Breast cancer is the most common cancer among women worldwide." | ( Chacko, P; Joseph, T; Mathew, BS; Pillai, MR; Rajan, B, 2004) |
| "Breast cancer is the most common cancer found in women in the United States." | ( Harwood, KV, 2004) |
| "Early diagnosis of breast cancer is crucial for effective treatment, and the need exists for greater detection ability and specificity than possible by screening x-ray mammography (currently the primary imaging technique for the detection of breast lesions)." | ( Lui, BJ; Reznik, A; Rowlands, JA, 2005) |
| "Breast cancer is the most common cause of cancer death in women worldwide." | ( Muti, P, 2004) |
| "Metastases in breast cancer are a vital concern in treatment, with epidermal growth factor receptor and ErbB2 strongly implicated in mediating tumor invasion and spreading." | ( Iozzo, RV; Kay, P; Kirby, S; McQuillan, DJ; Owens, RT; Reed, CC; Waterhouse, A, 2005) |
| "Breast cancer is composed of phenotypically diverse populations of cancer cells." | ( Abraham, BK; Athelogou, M; Brauch, H; Fritz, P; Hauptvogel, P; McClellan, M, 2005) |
| "For patients whose breast cancers are not responsive to endocrine therapy, there are a large number of cytotoxic drugs that will induce a response." | ( Colbern, GT; Gabizon, AA; Henderson, IC; Moore, MR; Overmoyer, BA; Park, JW; Robert, NJ; Shapiro, CL; Silverman, P; Sparano, JA; Vogel, CL; Winer, EP, 2004) |
| "Breast cancer is the second most frequent tumor in Mexico 30-50% are diagnosed in locally advanced stages requiring neoadjuvant chemotherapy." | ( Candelaria, M; Cantu-de Leon, D; Cervantes-Vazquez, G; Leonor-Ortíz, J; Mora-Tizcareño, A; Muñoz-Gonzalez, D; Perez-Sanchez, M; Ramirez-Ugalde, MT; Zeichner-Gancz, I, 2005) |
| "Although breast cancer is most often treated with conventional cytotoxic agents it has proved difficult to induce apoptosis in breast cancer cells, but improved clinical responses may be obtained by identifying therapies that are particularly effective in activating apoptosis." | ( Aiello, S; Aránega, A; Campos, J; Espinosa, A; Gallo, MA; Marchal, JA, 2005) |
| "Breast cancer is the leading type of cancer among women, and bone metastases are common in patients with breast cancer, affecting more than half of all patients with advanced disease." | ( Coleman, RE, 2005) |
| "Breast cancer is a complex genetic disease characterized by the accumulation of multiple molecular alterations." | ( Chan, MM; Iglehart, JD; Lu, X; Merchant, FM; Miron, PL, 2005) |
| "Breast cancer is the most common cancer disease in women in the western world." | ( Christensen, IJ; Fog, CK; Lykkesfeldt, AE, 2005) |
| "Breast cancer is a very heterogeneous disease considering a number of biomarkers which are under investigation." | ( Todorović-Raković, N, 2005) |
| "Invasive breast cancer is a heterogeneous disease sustained by intercorrelated and complex growth pathways." | ( Gasparini, G; Longo, R; Morabito, A; Torino, F, 2005) |
| "Breast cancer is the second most frequent cancer affecting women." | ( Boivin, RP; Luu-The, V; Poirier, D; Tremblay, MR, 2005) |
| "Breast cancer is the most common cancer diagnosis among women in the United States." | ( Johansen, AM, 2005) |
| "Breast cancer is a hormone-sensitive cancer and in most post-menopausal women hormone receptor positive." | ( Bauerschlag, D; Jonat, W; Maass, N; Schem, C, 2005) |
| "Breast cancer is a heterogeneous disease." | ( Hillner, BE; Jeffrey, SS; Lønning, PE, 2005) |
| "Many breast cancers are dependent for proliferation on estrogens synthesized from androgens (i." | ( Boulay, A; Chen, S; Evans, DB; Lane, HA; O'Reilly, T; Rudloff, J; Ye, J; Zumstein-Mecker, S, 2005) |
| "Breast cancer is the most common cancer in women in the United States, and it is second among cancer deaths in women." | ( Dumitrescu, RG; Shields, PG, 2005) |
| "Breast cancer is a complex disease involving numerous genetic aberrations." | ( Calaf, GM; Hei, TK; Roy, D, 2005) |
| "Breast cancer is the 2nd most common tumors in Thai women." | ( Kongdan, Y; Pasutharnchat, K; Sundarathiti, P; Suranutkarin, PE, 2005) |
| "Most patients with breast cancer are likely to benefit from local treatment (surgery and/or radiotherapy)." | ( Rai, S; Stotter, A, 2005) |
| "Breast cancer is a major health problem in developed countries." | ( Pritchard, KI; Wong, NS, 2005) |
| "Breast cancers are visible during lactation owing to their lower signal intensity and more intense initial contrast enhancement with early washout compared with normal breast tissue." | ( Daniel, BL; Espinosa, LA; Herfkens, RJ; Ikeda, DM; Vidarsson, L; Zakhour, M, 2005) |
| "Breast cancer is often an estrogen-dependent disease." | ( Avenin, D; Beerblock, K; Do Huyen, N; Emile, G; Estéso, A; Gligorov, J; Lotz, JP; Ségura, C; Selle, F, 2005) |
| "Breast cancer is a heterogenous disease in terms of both clinical behavior and molecular characteristics." | ( Kim, CY; Kim, WS; Paik, S; Song, YK, 2005) |
| "Breast cancer is the commonest cancer for females in Malaysia, with a prevalence of 86." | ( Imran, AK; Naing, I; Norsa'adah, B; Rusli, BN; Winn, T, 2005) |
| "Breast cancer is a neoplasm which is considered well-responsive to chemotherapy, radiation therapy and endocrine therapy." | ( Amano, S; Enomoto, K; Negishi, N; Sakurai, K, 2005) |
| "Breast cancer is the most common newly diagnosed cancer in women." | ( Baber, R; Hickey, M; Kwik, M, 2005) |
| "Breast tumors are usually classified according to their response to estrogens as hormone-dependent or -independent." | ( Cafferata, EG; Coló, GP; Costas, MA; Kordon, EC; Nahmod, VE; Nojek, IM; Quaglino, A; Rubio, MF; Werbajh, S, 2006) |
| "Breast cancer is the most common female malignancy in the UK, with an overall lifetime risk of 1 in 9." | ( Kwan, K; Marsden, J; Ward, C, 2005) |
| "A majority of breast cancers are hormone (estrogen) receptor-positive and amenable to endocrine therapy, and for those women five years of the selective estrogen receptor modulator tamoxifen is standard therapy." | ( Chowdhury, S; Ellis, P, 2005) |
| "Breast cancer is often hormone responsive with growth or regression of tumors modulated by endocrine manipulations." | ( Calaf, GM, 2006) |
| "Breast cancer is an increasingly common malignancy." | ( Kim, HW; Kim, KN; Kim, MK; Park, JH; Park, YH; Pie, JE, 2006) |
| "Breast cancer is the most common cancer in women and a significant cause of death." | ( Bernard-Gallon, DJ; Bignon, YJ; Caëtano, B; Chalabi, N; Delort, L; Le Corre, L, 2006) |
| "Costs of breast cancer care (letrozole therapy, surveillance, recurrences, terminal care) and treatment of osteoporosis and utilities were derived from literature." | ( Brandman, J; Delea, T; Goss, PE; Johnston, SR; Karnon, J; Smith, R; Sung, J, 2006) |
| "Most breast cancers are "lipogenic", defined by high fatty acid synthase (FAS) content and dependence on fatty acid synthesis for growth and survival." | ( Cole, BF; Gibson, JJ; Kinlaw, WB; Morganelli, PM; Schwartz, GN; Wells, WA, 2006) |
| "HER2/neu positive breast tumors are difficult to treat." | ( Lanza-Jacoby, S; McGuire, KP; Neavyn, M; Ngoubilly, N, 2006) |
| "Breast cancer is the most frequent cancer among women, and the number is increasing worldwide." | ( Hansen, J, 2006) |
| "Breast cancer is the second most common cause of mortality after lung cancer." | ( Ajarim, D; Al-Omair, A; Al-Qudaihi, G; Al-Tweigeri, T; Alshabanah, M; Bin Amer, S; Dermime, S; Elkum, N; Ghebeh, H; Lehe, C; Mohammed, S; Qattan, A; Tulbah, A, 2006) |
| "Breast cancer is one of the most common cancers in women of developed and developing countries." | ( Sachdanandam, P; Shanthi, P; Veena, K, 2006) |
| "Metaplastic breast carcinoma is very rare, and metaplastic carcinoma with chondroid differentiation is even rarer." | ( Jung, WH; Kim, YJ; Lee, H; Shim, HS, 2006) |
| "The risk of breast cancer is inversely related to parity." | ( Böcker, W; Schneider, HP, 2006) |
| "Breast cancer is the most frequently diagnosed and the second cause of cancer death in women, thus making breast cancer a most feared disease." | ( Labrie, F, 2006) |
| "Breast cancer is one of the leading causes of cancer-related mortality, and a cure is desperately needed." | ( Dang, C; Hudis, C, 2006) |
| "Breast cancer is one of the most common malignancies among Japanese women." | ( Fujiuchi, N; Okubo, K; Saeki, T; Takeuchi, H, 2006) |
| "In women, breast cancer is the second most common form of cancer and the leading cause of death caused by malignancy." | ( Jensen, BV, 2006) |
| "Metastatic breast cancer is still defined as an incurable disease, with the lungs being the most common metastatic sites in breast cancer patients." | ( Bang, SI; Choi, YJ; Kim, DK; Kim, JH; Kim, MH; Nam, DH; Nam, SJ; Son, MJ; Song, HS; Yang, JH, 2006) |
| "Breast cancer is the most frequent malignant disease in women." | ( Beldoménico, HR; Beldoménico, PM; Durando, M; García, SR; Kass, L; Luque, EH; Muñoz-de-Toro, M, 2006) |
| "Breast cancer is a malignancy whose dependence on estrogen exposure has long been recognized even though the mechanisms whereby estrogens cause cancer are not clearly understood." | ( Fernandez, SV; Fernbaugh, R; Garber, J; Lareef, HM; Russo, IH; Russo, J; Russo, PA; Sheriff, FS, 2006) |
| "Women with breast cancer are not typically offered embryo or oocyte cryopreservation to preserve their fertility before chemotherapy because of the potential risks associated with high estrogen levels arising from ovarian stimulation." | ( Bang, H; Cil, A; Hourvitz, A; Oktay, K; Oktem, O; Safro, B; Sahin, G, 2006) |
| "HER-2/neu in breast cancer is associated with tamoxifen resistance, but little data exist on its interaction with estrogen deprivation or fulvestrant." | ( Hilsenbeck, S; Jiang, S; Massarweh, S; Mohsin, SK; Osborne, CK; Rimawi, M; Schiff, R; Wakeling, AE, 2006) |
| "Mammary cancer is one of the solid malignancies, which easily metastasizes to bone." | ( Fujiuchi, N; Ookubo, K; Saeki, T; Takeuchi, H, 2006) |
| "Breast carcinoma is one of the leading causes of malignancy in females." | ( Hemrajani, DK; Joshi, N; Meena, SP, 2006) |
| "Breast cancer is a hormone responsive disease, and its proliferation and progression correlate with estrogen." | ( Iwashige, A; Kagami, S; Tsukada, J; Uramoto, H, 2006) |
| "Breast cancer is a sex steroid hormone-dependent malignant neoplasia." | ( Borja-Cacho, E; Damián-Matsumura, P; García-Becerra, R; González, L; Larrea, F; Lemus, AE; Pérez-Palacios, G; Santillán, R, 2006) |
| "Breast cancer is the most common cancer in women, with a general upward trend in incidence." | ( Bay, BH; Huang, J; Jin, R; Tan, PH, 2006) |
| "Breast cancer is a hormone-based disease with numerous factors contributing to the lifetime risk of developing the disease." | ( Gupta, PB; Kuperwasser, C, 2006) |
| "Breast cancer is a heterogeneous disease, so therapeutic predictive biological markers need to be identified." | ( Aragona, F; Barresi, E; Cabibi, D; Calascibetta, A; Martorana, A; Rausa, L; Sanguedolce, R, 2006) |
| "Breast cancer is the most common nonskin malignancy affecting women." | ( Gentleman, R; Harris, LN; Hwang, J; Iglehart, JD; Li, X; Lu, X; Miron, A; Shi, Q, 2006) |
| "Breast cancer is a heterogeneous disease and it is of importance to select patients with regard to different prognosis and treatment sensitivity to individualize treatment regimes." | ( Fernö, M; Johnsson, A; Malmström, J; Marko-Varga, G; Niméus, E, 2007) |
| "Hypoxia in breast cancer is associated with poor prognosis and down-regulation of the estrogen receptor." | ( Brennan, DJ; Duffy, MJ; Gallagher, WM; Jirstrom, K; Kronblad, A; Landberg, G; Millikan, RC; O'Brien, SL; Rydén, L, 2006) |
| "Breast cancer is the most common malignancy and the second most common cause of cancer-related death in women." | ( Abrial, C; Chollet, P; Curé, H; Durando, X; Leheurteur, M; Mouret-Reynier, MA; Tacca, O, 2006) |
| "Breast cancer is the most common cancer among women and about 80% of breast cancers express hormone receptors." | ( Andreetta, C; Smith, I, 2007) |
| "The majority of breast cancers are oestrogen dependent and in postmenopausal women the supply of oestrogens in breast tissue is derived from the peripheral conversion of circulating androgens." | ( Rice, S; Whitehead, SA, 2006) |
| "Breast cancer is frequently characterised by increased 2-fluoro-2-deoxy-D-glucose uptake and many studies have shown encouraging results in detecting axillary lymph node metastases." | ( Berrettini, A; De Cicco, C; Fernandez, JR; Galimberti, VE; Intra, M; Luini, A; Paganelli, G; Rotmensz, N; Spano, G; Veronesi, P; Veronesi, U; Viale, G, 2007) |
| "Breast cancer is the second leading cause of cancer deaths in women in the United States." | ( Dizdaroglu, M; Evans, MK; Jaruga, P; Lohani, A; Nyaga, SG; Trzeciak, AR, 2006) |
| "Breast cancer is the commonest female cancer in Singapore." | ( Emmanuel, SC; Heng, R; Leong, HS, 2007) |
| "Breast cancer is the second most common cause of cancer-related death in women in the US and the UK, accounting for 15-17% of all female cancer deaths." | ( Marsh, S; McLeod, HL, 2007) |
| "Breast cancer is the most frequent type of cancer in women and is the second leading cause of cancer death in Canadian women." | ( Hollett, PD; Mathews, M; Sloka, JS, 2007) |
| "Breast cancer is the leading cause of cancer-related deaths in Asia, and in recent years is emerging as the commonest female malignancy in the developing Asian countries, overtaking cancer of the uterine cervix." | ( Agarwal, G; Aggarwal, V; Cheung, PS; Pradeep, PV; Yip, CH, 2007) |
| "Breast cancer is one of the most extensively studied cancers and its genetic basis is well established." | ( Bansal, A; Bhatnagar, D; Khandelwal, R; Mittal, A; Saijanani, S; Saxena, S; Tuteja, A, 2007) |
| "Breast cancer is the most common cause of cancer death in women worldwide." | ( Cavalieri, E; Muti, P; Rogan, E, 2006) |
| "The incidence of breast cancer is rising throughout the world." | ( Jordan, VC; Patel, RR; Sharma, CG, 2007) |
| "The development of breast cancer is believed to be a multi-step process, sequentially progressing from normal to hyperplastic, to in situ, and to invasive stages." | ( Man, YG, 2007) |
| "Furthermore, breast cancer is the most common cancer diagnosed and second most common cause of cancer-related deaths in women." | ( Engel, RH; Kaklamani, VG, 2007) |
| "Breast cancer is the most frequently encountered carcinoma in women worldwide." | ( Kumar, S; Saxena, AK, 2007) |
| "The incidence of breast cancer is increasing among Japanese women." | ( Fujiwara, Y; Ono, M, 2007) |
| "Breast cancer is a leading cause of cancer deaths in women." | ( Dizdaroglu, M; Evans, MK; Jaruga, P; Lohani, A; Nyaga, SG, 2007) |
| "Breast cancer is a leading threat to women's health." | ( Ding, H; Field, TS, 2007) |
| "Breast cancer is the prevalent cancer worldwide." | ( Abedtash, H; Namazi, S; Rouhani Fard, SA, 2008) |
| "Breast carcinoma is one of the most common malignancies in women, and its carcinogenesis is still unknown." | ( Bourne, P; Khilko, N, 2007) |
| "Breast cancer is a very heterogeneous disease, and markers for disease subtypes and therapy response remain poorly defined." | ( Bataille, R; Campion, L; Campone, M; Charbonnel, C; Genève, J; Gouraud, W; Jézéquel, P; Magrangeas, F; Martin, AL; Minvielle, S; Roché, H, 2008) |
| "Breast cancer is the most common female malignancy in Western countries." | ( Adler, LP; Avril, N, 2007) |
| "Breast cancer is the commonest cancer in women and represents a significant problem from the clinical and public health perspectives." | ( Faridah, Y; Ng, KH; Ranganathan, S, 2007) |
| "Loss of ER-alpha in breast cancer is correlated with poor prognosis, increased recurrence after treatment, and an elevated incidence of metastasis." | ( Dhasarathy, A; Kajita, M; Wade, PA, 2007) |
| "Breast cancer is one of the leading causes of cancer death in women." | ( Dai, J; Dong, X; Guo, D; Ji, Ch; Ma, D; Ma, R; Qu, X; Ye, J; Zang, S, 2007) |
| "Women with early breast cancer are exposed to an ongoing risk of relapse, even after successful surgical resection of the primary tumor and, where given, radiotherapy." | ( Cufer, T, 2007) |
| "Breast cancer is characterized by malignant transformation of epithelial cells, but stromal cells also play an important role in tumorigenesis." | ( Czerwenka, K; Fink-Retter, A; Gschwantler-Kaulich, D; Haas, C; Hudelist, G; Kubista, E; Singer, CF, 2008) |
| "(1) Worldwide, breast cancer is the most common type of cancer in women, and the second most frequently diagnosed cancer overall." | ( Paridaens, R; Poole, R, 2007) |
| "Metastatic breast cancer is an incurable disease, often characterized by poor response to standard chemotherapy, which is mainly based on anthracyclines and taxanes." | ( Gabano, E; Gariboldi, MB; Molteni, R; Monti, E; Osella, D; Ravizza, R, 2007) |
| "Breast cancer is the commonest solid tumor observed during pregnancy." | ( Berveiller, P; Goffinet, F; Goldwasser, F; Mir, O; Pons, G; Ropert, S; Treluyer, JM, 2008) |
| "Breast cancer is the most frequent cancer in reproductive age women." | ( Atabekoglu, C; Sonmezer, M, 2007) |
| "Breast cancer is the leading cause of cancer deaths among women worldwide." | ( Foster, PA; Ho, YT; Kasprzyk, PG; Leese, MP; Newman, SP; Potter, BV; Purohit, A; Reed, MJ, 2008) |
| "Breast cancer is one of the most common malignancies in Western society." | ( Auricchio, F; Bilancio, A; Castoria, G; Ciociola, A; D'Amato, L; de Falco, A; Di Domenico, M; Di Stasio, R; Lombardi, M; Migliaccio, A, 2008) |
| "The development of breast cancer is promoted by diverse factors that impact on intracellular signaling to promote proliferation and cell survival." | ( Caiazza, F; Harvey, BJ; Thomas, W, 2008) |
| "When primary breast tumors are locally advanced, it may be worthwhile to rule out brain metastases even if pCR is obtained after NAC." | ( Akashi-Tanaka, S; Kinoshita, T; Shien, T; Terada, K; Tsukamoto, S, 2007) |
| "BRCA1-mutant breast tumors are typically estrogen receptor alpha (ER alpha) negative, whereas most sporadic tumors express wild-type BRCA1 and are ER alpha positive." | ( Chung, WY; Couch, FJ; Daly, PA; Dervan, PA; Farragher, SM; Gorski, JJ; Harkin, DP; Hosey, AM; James, CR; Johnston, PG; Kay, E; McCann, A; Mullan, PB; Mulligan, JM; Murray, MM; Quinn, JE; Scott, AN; Stewart, GE, 2007) |
| "Breast cancer is a leading cause of cancer death among women worldwide." | ( Dodwell, D; Williamson, D, 2008) |
| "Breast cancer is the most common malignancy of women in Western societies." | ( Emons, G; Girgert, R; Gründker, C; Hanf, V, 2008) |
| "Breast cancer is the most common neoplasm in women and is the leading cause of cancer-related death for women." | ( Banerjee, S; Rabi, T, 2008) |
| "Treatment of breast cancer is usually associated with significant psychological stress." | ( Bauer, ME; Braga Filho, AP; da Silva Hoffmann, F; Luz, C; Muller, MC; Nunes, DF; Rodriguez, AL, 2007) |
| "Breast cancer is a rare disease in men representing nearly 1% of the total breast cancer cases worldwide." | ( Dutta, U; Pant, K, 2008) |
| "Male breast cancer is rare and has been the focus of limited research." | ( Arendt, LM; Schuler, LA, 2008) |
| "Breast cancer is the second leading cause of cancer death among women in the United States." | ( Hansch, C; Verma, RP, 2008) |
| "Breast carcinoma is the most common malignancy in women." | ( El Sharkawy, SL; Farrag, AR, 2008) |
| "Breast cancer is a devastating illness that affects tens of thousands of American women each year." | ( Reeder, JG; Vogel, VG, 2007) |
| "Further studies in breast cancer are warranted." | ( Adams, BJ; Baum, CM; Bello, CL; Burstein, HJ; Cobleigh, MA; DePrimo, SE; Eisenberg, PD; Elias, AD; Lehman, M; Miller, KD; Rugo, HS; Wolff, AC, 2008) |
| "The majority of breast cancers are estrogen-dependent, and estrogen has been shown to regulate VEGF in normal breast tissue and experimental breast cancer." | ( Dabrosin, C; Garvin, S, 2008) |
| "ER-negative breast cancers are highly invasive and metastastic and are typically more advanced than their ER-positive counterparts." | ( Der, CJ; Hanker, AB; Morita, S; Repasky, GA; Ross, DT; Seitz, RS, 2008) |
| "In Asia, breast cancer is characterised by an early age of onset: In Malaysia, approximately 50% of cases occur in women under the age of 50 years." | ( Kang, P; Lee, DS; Lee, SS; Lee, SY; Mohd Taib, NA; Selamat, S; Teo, SH; Toh, GT; Yip, CH; Yoon, SY, 2008) |
| "Breast cancer is a clinically heterogeneous disease that can affect individuals with seemingly identical clinicopathologic parameters differently." | ( Pusztai, L, 2008) |
| "Early detection of breast cancer is one of the most important factors in determining prognosis for women with malignant tumors." | ( Causer, P; Leung, T; Levman, J; Martel, AL; Plewes, D, 2008) |
| "Breast cancers are not responsive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), although 30% of breast cancers overexpress EGFR." | ( Boerner, JL; Ethier, SP; Hunter, LA; Mueller, KL, 2008) |
| "Breast cancer is a major health problem in women of developed Western countries." | ( Body, JJ; Journé, F; Laurent, G; Leclercq, G, 2008) |
| "Breast cancer is the leading cause of cancer deaths among non-smoking women worldwide." | ( Andersson, H; Franke, HR; Komen, J; van den Berg, A; Vermes, I; Wolbers, F, 2008) |
| "Breast cancer is the leading cause of cancer-related mortality and morbidity among women worldwide and IDC (infiltrating ductal carcinoma) is the most common type of invasive breast cancer." | ( Gam, LH; Majid, MI; Othman, MI; Seng, L; Singh, M; Subathra, S, 2009) |
| "Breast cancer is a heterogeneous disease with distinct molecular subtypes characterized by differential response to targeted and chemotherapeutic agents." | ( Amler, LC; Cavet, G; Haydu, L; Hu, X; Lackner, MR; Modrusan, Z; Mohan, S; O'Brien, C; Pandita, A; Rivers, CS; Toy, K, 2008) |
| "Breast cancer is one of the most prevalent woman cancers." | ( Husnu Can Baser, K; Khan, IA; Khan, SI; Kirimer, N; Ma, G; Pasco, DS; Tabanca, N, 2009) |
| "Breast cancer is the most common cancer among women." | ( Aboghe, DH; Bolduc, C; St-Amand, J; Yoshioka, M, 2008) |
| "The majority of breast cancers are estrogen receptor (ER) positive and depend on estrogen for growth." | ( Jordan, VC; Sengupta, S, 2008) |
| "The development of breast cancer is dependant in part on oestrogen." | ( Powles, TJ, 2008) |
| "Breast cancer is the most common female cancer and the second cause of cancer death in women." | ( Baracat, EC; Bugano, DD; Conforti-Froes, N; Yamaguchi, NH, 2008) |
| "Breast cancer is the second leading cause of cancer death in women." | ( Halterman, PA, 2008) |
| "Breast cancer is one of the leading causes of mortality among women." | ( Etminan, M; Regueira-Méndez, C; Takkouche, B, 2008) |
| "Breast cancer is the most common cancer diagnosed in Europe, with an estimated 429,900 new cases diagnosed in 2006." | ( Harbeck, N, 2008) |
| "Breast cancer is a major cause of death worldwide." | ( Androutsopoulos, V; Arroo, RR; Potter, GA; Wilsher, N, 2009) |
| "Since breast cancer is the second leading cause of death in American women behind lung cancer, there is a strong impetus to identify potential new drug treatments for breast cancer." | ( Cooperwood, JS; Khan, MO; Musa, MA, 2008) |
| "BRCA2 hereditary breast cancers are usually ER(+), differing from BRCA1 hereditary cancers, which are usually ER(-)." | ( Anderson, S; Holt, JT; Lieberman, R; Malone, JL; Nelson, AC, 2009) |
| "The majority of breast cancers are sporadic, and risk factors are primarily related to estrogen exposure." | ( Kolesar, JM; Thomsen, A, 2008) |
| "Breast cancer is the most common female malignancy, for which HRT is one of many modifiable risk factors, often attracting disproportionate attention." | ( Marsden, J; Sturdee, D, 2009) |
| "Breast cancer is the most commonly diagnosed cancer in women in the United States." | ( Liu, RH; Sun, J, 2008) |
| "However, breast cancer is a heterogeneous disease and it has been suggested that it may be possible to identify additional susceptibility alleles by restricting analyses to particular subtypes." | ( Dunning, AM; Easton, DF; Mavaddat, N; Pharoah, PD; Ponder, BA, 2009) |
| "Breast cancer is the most common female cancer in Western Europe and North America, and becoming an increasing problem in developing countries such as India and China." | ( Lof, M; Weiderpass, E, 2009) |
| "Breast cancer is one of the most common neoplasms in women and is a leading cause of cancer related deaths worldwide." | ( Amarante, MK; Aoki, MN; da Silva do Amaral Herrera, AC; do Val Carneiro, JL; Ehara Watanabe, MA; Fabris, BA; Mantovani, MS; Nixdorf, SL; Pelegrinelli Fungaro, MH, 2009) |
| "Breast cancer is the leading cause of death among women between 40 and 55 years of age and is the second overall cause of death among women." | ( Izevbigie, E; Tchounwou, P; Yedjou, C, 2008) |
| "Breast cancer is the most frequent cancer in women." | ( Bruzzone, A; Giulianelli, S; Lanari, C; Lüthy, IA; Soldati, R; Vanzulli, SI, 2009) |
| "Breast cancer is the most common cancer in most part of the world and it is the most common cancer among Malaysian women." | ( Nor Aina, E, 2008) |
| "Breast cancer is among the leading causes of cancer morbidity worldwide and accounts for a significant proportion of overall healthcare costs." | ( Leighl, N; Lwin, Z, 2009) |
| "One third of all breast cancers are estrogen receptor alpha (ERalpha) negative, carry a poor overall prognosis, and do not respond well to currently available endocrine therapies." | ( Andersson, T; Ekström, EJ; Ford, CE, 2009) |
| "The progression of breast cancer is associated with oxidative stress." | ( Busby, B; Covington, J; Gu, JW; Johnson, JW; Young, E, 2009) |
| "Prostate and breast cancer are hormone-dependent malignancies of the aging male and female and require the local production of androgens and estrogens to stimulate cell proliferation." | ( Byrns, MC; Penning, TM, 2009) |
| "Breast cancer is the most frequent form of cancer in women, with the highest incidence of metastasis to the bone." | ( Abdoune, R; Boudot, C; Brazier, M; Kamel, S; Mentaverri, R; Petit, L; Saidak, Z, 2009) |
| "Breast cancer is one of the principal oncological challenges in the Western world." | ( Jyrkkiö, S; Lapela, M; Lehikoinen, P; Lindholm, P; Minn, H; Någren, K, 2009) |
| "Breast cancer is the most frequent cancer and the second leading cause of cancer deaths in women today." | ( Bakare, O; Berhe, S; Beyene, D; Copeland, RL; Das, JR; Enwerem, NM; Kanaan, YM; Williams, V; Zhou, Y, 2009) |
| "Breast cancer is a global public health burden with more than one million new diagnoses worldwide each year." | ( McArthur, H, 2009) |
| "Breast cancer is a daunting disease and constitutes a continuing medical health problem through the ages for millions of women worldwide." | ( Ekmektzoglou, KA; German, V; Xanthos, T; Zografos, GC, 2009) |
| "Inflammatory breast cancer is an aggressive and biologically distinct form with a higher frequency of HER2 overexpression than other breast cancers." | ( Awada, A; Bachelot, T; Blackwell, K; DeSilvio, M; Johnston, S; Kaufman, B; Salazar, V; Spector, N; Trudeau, M; Westlund, R; Zaks, T, 2009) |
| "Worldwide, breast cancer is the most frequent malignancy among females." | ( Elzawawy, A, 2009) |
| "Older women with breast cancer are underrepresented in clinical trials, and data on the effects of adjuvant chemotherapy in such patients are scant." | ( Becker, HP; Berry, DA; Burstein, HJ; Cirrincione, CT; Cohen, HJ; Dressler, LG; Gralow, JR; Grenier, D; Hart, RD; Hudis, CA; Kartcheske, PA; Kornblith, AB; Magrinat, G; Mahmood, AA; Mauer, AM; Muss, HB; Norton, L; Parker, BA; Partridge, AH; Perez, EA; Theodoulou, M; Wheeler, JD; Winer, EP; Wolff, AC, 2009) |
| "Breast cancer is the most common neoplasia in women." | ( Abad, M; Esparís-Ogando, A; Montero, JC; Ocaña, A; Ortiz-Ruiz, MJ; Pandiella, A, 2009) |
| "Breast cancer is the female malignant neoplasia with the highest incidence in the industrialized world." | ( Macciò, A; Madeddu, C; Mantovani, G, 2009) |
| "Breast cancer is the most common female cancer, with annually more than one million new patients diagnosed worldwide." | ( Fodor, J; Kásler, M; Polgár, C, 2009) |
| "Breast cancer is often associated with inappropriate activation of transcription factors involved in normal mammary development." | ( Chaudhury, M; Frank, DA; Nelson, EA; Richardson, A; Signoretti, S; Walker, SR; Zou, L, 2009) |
| "Breast cancer is a frequent indication for ovarian cortex cryopreservation due to its high incidence." | ( Camarasa, N; Novella-Maestre, E; Pellicer, A; Roselló-Sastre, E; Sánchez-Serrano, M; Teruel, J, 2009) |
| "Breast cancer is known to be a hormone-dependent disease, and estrogens through an interaction with estrogen receptor (ER) enhance the proliferative and metastatic activity of breast tumor cells." | ( Akiyama, M; Daigo, Y; Katagiri, T; Kim, JW; Lin, ML; Nakamura, Y; Nishidate, T; Park, JH; Shimo, A; Tsunoda, T; Ueki, T, 2009) |
| "Breast cancer is the most common type of malignancy diagnosed in women." | ( Miele, E; Spinelli, GP; Tomao, F; Tomao, S, 2009) |
| "Breast cancer is the most common malignancy diagnosed among women." | ( Cetinkalp, S; Karaca, B; Uslu, R; Yurekli, BS, 2009) |
| "Her-2/nue positive breast cancer is an aggressive disease with a higher potential of invasion and metastasis." | ( Azim, HA, 2007) |
| "Breast cancer is the commonest cancer of women the world over, and its incidence is rising, especially in developing countries, where the disease poses a major health care challenge." | ( Agarwal, G; Basurto, CS; Chaparro, JM; Forgach, ER; Margaritoni, M; Ramakant, P; Rendón, JC, 2009) |
| "Breast cancer is the second leading cause of cancer deaths in US women." | ( Badisa, RB; Cooperwood, JS; Darling-Reed, SF; Goodman, CB; Joseph, P; Latinwo, LM, 2009) |
| "Breast cancer is the most common cancer worldwide and the leading cause of cancer mortality in women." | ( Fentiman, IS; Tran, P, 2009) |
| "Breast cancer is the most frequently diagnosed cancer in women." | ( Liu, RH; Yang, J, 2009) |
| "The majority of breast cancers are estrogen responsive, but upon progression of disease other growth promoting pathways are activated, e." | ( Benjaminsen, RV; Christiansen, IJ; Emdal, KB; Frogne, T; Kirkegaard, T; Lykkesfeldt, AE; Norrie, IC; Sonne-Hansen, K, 2010) |
| "Cervix and Breast cancers are the most common cancers among women worldwide and extract a large toll in developing countries." | ( Aranke, S; Badwe, R; Daniel, EE; Ganesh, B; Gupta, S; Kerkar, R; Miller, AB; Mishra, GA; Mittra, I; Notani, P; Ramani, S; Shastri, SS; Singh, S; Thakur, MH; Uplap, P, 2010) |
| "Treatment of breast cancer is becoming more individualized with the recognition of tumor subgroups that respond differently to available therapies." | ( Cornelissen-Steijger, P; Drost, R; Evers, B; Jonkers, J; Joosse, SA; Liu, X; Nederlof, P; Pietersen, AM; Puppe, J; van Lohuizen, M; Yu, Q, 2009) |
| "Breast cancer is one of the most common malignancies in women and is highly resistant to chemotherapy." | ( Liu, XH; Wang, YL; Zheng, XF, 2009) |
| "Breast cancer is a major health burden worldwide." | ( Bertollo, CM; Correa, CR; Goes, AM, 2009) |
| "In conclusion, breast cancer is associated with lipid alterations and enhanced oxidative stress linked to high leptin levels in overweight." | ( Ahmed, FZ; Badid, N; Belbraouet, S; Benhabib, R; Hamzaoui, D; Merzouk, H; Merzouk, SA; Mokhtari, N; Narce, M, 2010) |
| "Triple negative breast cancer is a recently defined subgroup of tumors which do not express receptors for estrogen or progesterone and which do not show any overexpression of HER2 receptors." | ( Dietl, J; Engel, JB; Häusler, S; Honig, A; Krockenberger, M, 2009) |
| "Meningiomas and breast cancers are common tumors among women in the fifth to seventh decade." | ( Ho, JT; Lee, TC; Lin, CH; Lin, JW; Lin, YJ; Su, FW; Wang, HC, 2009) |
| "Triple negative breast cancers are defined by the absence of oestrogen, progesterone and HER2 expression." | ( Caldas, C; Dawson, SJ; Provenzano, E, 2009) |
| "Breast cancer is the second leading cause of cancer related deaths among females worldwide." | ( Duan, H; Liu, K; Liu, Q; Lu, Z; Luan, J; Wang, F; Wang, S; Wu, E; Yagasaki, K; Yu, P; Zhang, G; Zhang, Y, 2009) |
| "Data on cost of breast cancer care were obtained from the Second Xiangya Hospital of Central South University, Changsha, PR China." | ( Chongqing, T; Gannong, C; Jianhe, L; Junhua, C; Karnon, J; Liubao, P; Wei, C; Xia, L; Xiaomin, W, 2009) |
| "Breast cancer is the second leading cause of cancer deaths among women in the United States." | ( Carper, SW; Elegbede, JA; Hall, C; Yeruva, L, 2010) |
| "Many breast tumors are hormone-dependent, and estrogens, especially estradiol (E2), have a pivotal role in their growth and development." | ( Alho-Richmond, S; Huhtinen, K; Johansson, N; Karkola, S; Koskimies, P; Lilienkampf, A; Vihko, K; Wähälä, K, 2009) |
| "Breast cancer is a highly heterogeneous disease with distinct histologic subtypes." | ( Gao, L; Huang, X; Lee, CK; Liu, B; Ordentlich, P; Wang, S, 2009) |
| "Drug resistance of breast cancer is a complicated process involving the expression of many upregulated or downregulated genes." | ( Peng, H; Song, LW; Yang, HW; Zhou, Z, 2009) |
| "Breast cancer is the main cause of cancer-related death among women in Western countries." | ( Redondo, M; Roldan, MJ; Tellez, T, 2009) |
| "Menopausal breast cancer is associated with high plasma estradiol concentrations, while premenopausal breast benign were associated high plasma prolactin concentrations which indicate that high plasma estradiol in menopause is arisk factor for breast cancer development while high prolactin in premenopausal is arisk factor for breast benign." | ( Al-Hourani, H; Almuhrib, T; Atoum, M; Nimer, N; Raheem, SN; Rasheed, M, 2010) |
| "Breast cancer is the most common malignancy affecting females worldwide but conventional risk factors are able to explain only a small proportion of these cases." | ( Gangane, N; Joshi, D; Joshi, R; Quadri, M, 2009) |
| "The growth of many breast tumors is stimulated by estradiol (E2), which activates a classic mechanism of regulation of gene expression and signal transduction pathways inducing cell proliferation." | ( Andò, S; Casaburi, I; Chimento, A; De Luca, A; Iacopetta, D; Maggiolini, M; Onofrio, A; Pezzi, V; Puoci, F; Rizza, P; Sirianni, R, 2010) |
| "The biology of breast cancer is closely releted to sex steroid hormones." | ( Kuźmicki, M; Leśniewska, M; Miltyk, W; Pałka, J; Swiatecka, J; Tomaszewska, M; Wołczyński, S, 2009) |
| "Breast cancer is the most common malignancy among females in Malaysia." | ( Cheong, SK; Ibrahim, N; Leong, PP; Muhammad, R; Seow, HF, 2011) |
| "Triple-negative breast cancer is extremely aggressive and more likely to metastasize than other subtypes of breast cancer." | ( Hama, Y; Nakagawa, K, 2013) |
| "Breast cancer is the most common cancer among women and the second leading cause of death in women after lung cancer." | ( Al Huda, FA; Al Mohannadi, S; Al Shammary, I; Javed, A; Khan, HA; Usmani, S, 2008) |
| "Breast cancer is a major cause of death worldwide." | ( Han, EH; Hwang, YP; Jeong, HG; Kim, HG; Song, GY, 2010) |
| "The majority of breast cancers are due to low penetrance genes, which can act with environmental factors, particularly nutrition." | ( Bernard-Gallon, DJ; Bignon, YJ; Delort, L; Kwiatkowski, F; Satih, S, 2010) |
| "Breast cancers are either estrogen receptor-positive (ER) or negative (ER)." | ( Chiu, GN; Wong, MY, 2010) |
| "Patterns of breast cancer care continue to be amended because of the more frequent use of anthracyclines and taxanes in earlier lines of therapy (particularly in the adjuvant setting) and the emergence of multidrug resistance." | ( Stein, A, 2010) |
| "Breast cancer is a public health problem in the Western countries." | ( Bernard-Gallon, DJ; Bignon, YJ; Bosviel, R; Chalabi, N; Fontana, L; Rabiau, N; Satih, S, 2010) |
| "Breast cancer is the most common type of cancer among women in northern America and northern Europe; dietary prevention is a cost-efficient strategy to reduce the risk of this disease." | ( Lin, D; Rathore, K; Siriwardhana, N; Song, X; Wang, HC, 2010) |
| "Breast cancer is the most common cancer among women, and it is the second leading cause of cancer deaths in women today." | ( Arbneshi, T; Arumugam, SR; Khan, SA; Lu, W; Ray, PC; Senapati, D; Singh, AK; Yu, H, 2010) |
| "Chemotherapy for breast cancer is given on the basis of empirical information from clinical trials, an approach which falls to take into account the known heterogeneity of chemosensitivity between patients." | ( Min, HY; Ning, YL; Qi, CJ; Qian, KQ; Ye, H; Zhu, YL, 2009) |
| "Breast cancer is the most frequently occurring cancer in women of developed countries, and as a result of new developments in breast cancer treatment, more women are cured after being diagnosed with this disease." | ( Iatrakis, G; Navrozoglou, I; Zervoudis, S, 2010) |
| "Breast cancer is the most common malignancy among women, with an age-specific incidence profile." | ( Galli, F; Pierpaoli, E; Pilolli, F; Piroddi, M; Provinciali, M; Viola, V, 2010) |
| "Breast cancer is the most common carcinoma in the world and the second most prevalent in Indian females." | ( Gupta, SK, 2009) |
| "Breast cancer is the most common cancer diagnosed in women." | ( Donnon, T; Paterson, AH; Railton, C; Trotter, T; Webster, M, 2010) |
| "Breast cancer is the second cause of cancer mortality worldwide and there is an unmet need for novel anticancer agents." | ( Chow, LW; Ong, EY; Tse, LA; Yip, AY, 2010) |
| "Breast cancer is the most common cancer and the second most common cause of cancer death in women." | ( Hooks, MA, 2010) |
| "Breast cancer is the most frequent cancer in women and consists of a heterogeneous collection of diseases with distinct histopathological, genetic and epigenetic characteristics." | ( Aas, T; Bukholm, I; Børresen-Dale, AL; Dejeux, E; Geisler, S; Gut, IG; Kristensen, VN; Lønning, PE; Rønneberg, JA; Solvang, H; Tost, J, 2010) |
| "Breast cancer is the second most common cause of CNS metastasis, following lung cancer." | ( Altundag, K; Arslan, C; Dizdar, O, 2010) |
| "Breast cancer is the most commonly diagnosed cancer among United States (US) women." | ( Sahmoun, AE; Singh, BB, 2010) |
| "Breast carcinoma is the most common malignancy in women." | ( He, S; Jiang, Y; Liu, F; Liu, S; Xie, Z; Zu, X, 2010) |
| "Breast cancer is increasingly considered a heterogeneous disease." | ( Antonini, N; Linn, SC; Loo, CE; Oldenburg, HS; Rodenhuis, S; Russell, NS; Rutgers, EJ; Straver, ME; Vrancken Peeters, MT; Wesseling, J, 2010) |
| "Breast cancer is the most common malignancy in women." | ( Beland, FA; Chekhun, VF; Kovalchuk, O; Pogribny, IP; Shpyleva, SI; Starlard-Davenport, A; Tryndyak, VP, 2011) |
| "Breast cancer is the leading nonhematologic cause of meningeal carcinomatosis (MC)." | ( Bidard, FC; Cottu, PH; Diéras, V; Gauthier, H; Girre, V; Guilhaume, MN; Laurence, V; Livartowski, A; Mignot, L; Pierga, JY, 2010) |
| "Breast cancer is the commonest cancer affecting women world wide." | ( Biswas, M; Hashim, H; Islam, R; Kamil, M; Khalid, I; Yusuf, N, 2010) |
| "Breast cancer is the most common cause of cancer-related death among women in the USA, and additional effective and well-tolerated chemotherapeutic agents are urgently needed." | ( Cigler, T; Vahdat, LT, 2010) |
| "Breast cancer is one of the most common tumors in women of Western countries." | ( de Lumen, BO; Hernández-Ledesma, B; Hsieh, CC, 2010) |
| "Breast cancer is the second most common cause of cancer death in women among the United States." | ( Patel, TA; Perez, EA; Saurel, CA, 2010) |
| "Breast cancer is one of the most common cancers to cause death in the world, and the accurate diagnosis is of great importance to determine the stage of the disease and then to design the suitable therapy." | ( Fan, Q; Li, G; Li, T; Liu, T; Zhao, J; Zhu, X, 2010) |
| "Breast cancer is the second cause of death in women in Europe and North America." | ( Al-Nahhas, A; Bonciarelli, G; Crepaldi, G; Facci, E; Fornasiero, A; Grassetto, G; Mandoliti, G; Marzola, MC; Minicozzi, AM; Nashimben, O; Otello, D; Pasini, F; Rossi, E; Rubello, D, 2011) |
| "Breast cancer is the leading cancer in women of reproductive age; more than a quarter of women diagnosed with breast cancer in the US are premenopausal." | ( Wang, M; Zhang, JJ, 2010) |
| "Breast cancer is a leading cause of mortality and morbidity in women, mostly due to high metastatic capacity of mammary carcinoma cells." | ( Balic, M; Cindric, M; Cipak, A; Ciz, M; Goshev, I; Jaganjac, M; Lojek, A; Margaritoni, M; Mihaylova, B; Mrakovcic, L; Sitic, S; Waeg, G; Zarkovic, N, 2010) |
| "Breast cancer is the leading cause of death among women, and morphine is used to relieve the pain of patients with cancer." | ( Altaner, S; Berkarda, S; Durmus-Altun, G; Tuncbilek, N; Ustun, F; Uzal, C, 2011) |
| "Breast cancer is associated with inflammatory processes based on an up-regulation of cyclooxygenase-2 (COX-2) expression." | ( Becker, S; Diedrich, K; Dittmer, C; Fischer, D; Friedrich, M; Hoellen, F; Kelling, K; Landt, S; Salehin, D; Thill, M, 2010) |
| "Breast cancer is the most common type of cancer diagnosed in women." | ( Roy, V; Vishnu, P, 2010) |
| "Molecular apocrine breast cancer is an estrogen receptor negative subtype characterized by the over-expression of steroid response genes." | ( Liu, J; Naderi, A, 2010) |
| "Breast cancer is one of the most commonly diagnosed cancers and the leading cause of death in women." | ( Gu, T; Ma, C; Tang, Q; Wang, T; Yang, D, 2010) |
| "Breast cancer is one the highest causes of female cancer death worldwide." | ( Done, SJ; Harrington, LA; Nguyen, J; Rashid-Kolvear, F; Taboski, MA; Wang, DY, 2010) |
| "A majority of breast cancers are estrogen receptor (ER) positive and have a luminal epithelial phenotype." | ( Dye, WW; Elias, A; Finlayson, C; Haughian, JM; Horwitz, KB; Kabos, P; Sartorius, CA; Wang, X, 2011) |
| "Acute DIC in breast cancer is a rare condition and is not well studied." | ( Chang, DY; Cheng, AL; Huang, CS; Lin, CH; Lin, PH; Lu, YS; Yeh, KH, 2010) |
| "Breast cancer is the most frequently occurring malignancy among women in India, however, the recorded stage distribution at presentation in India is less favorable than in Europe." | ( Grunfeld, EA; Kohli, N, 2010) |
| "Breast carcinoma is related to the increase of lipid peroxidation in plasma with concomitant decrease of antioxidant (AO) defense capacity in blood cells, which becomes more pronounced during aging of the patients." | ( Kasapović, J; Pajović, SB; Pejić, S; Radošević-Jelić, L; Saičić, ZS; Stojiljković, V; Todorović, A, 2010) |
| "Basal-like breast cancers are triple-negative (estrogen receptor negative, progesterone receptor negative, erythroblastic leukemia viral oncogene homolog 2 (ERBB2) negative) tumors with an aggressive clinical behavior that lacks effective molecular targets for therapy." | ( Inoue, J; Ishida, T; Ito, T; Semba, K; Shimizu, T; Watanabe, S; Yamaguchi, N; Yamamoto, M, 2010) |
| "Breast cancer is the commonest malignancy of women in Nigeria." | ( Nsonwu, A; Omabbe, MC; Usoro, CA; Usoro, NI, 2010) |
| "Breast cancer is the most common cause of cancer-related death worldwide, thus remaining a crucial health problem among women despite advances in conventional therapy." | ( Chen, N; Donat, U; Gentschev, I; Hess, M; Krewer, B; Seubert, CM; Stritzker, J; Sturm, JB; Szalay, AA; Tietze, LF; von Hof, JM, 2011) |
| "Triple-negative breast cancer is defined by the lack of expression of estrogen-receptor, progesterone-receptor, and HER-2/neu." | ( Maegawa, RO; Tang, SC, 2010) |
| "Progression of breast cancer is associated with remodeling of the extracellular matrix, often involving a switch from estrogen dependence to a dependence on EGF receptor (EGFR)/HER-2 and is accompanied by increased expression of the main binding protein for insulin-like growth factors (IGFBP-3)." | ( Dennison, G; Foulstone, EJ; Frankow, A; Holly, JM; Jarrett, C; McIntosh, J; Perks, CM; Winters, ZE, 2010) |
| "Breast cancer is one of the most common cancers in women worldwide and accounts for one-sixth of cancer deaths in the United States." | ( Arlinghaus, RB; Leng, X; Wu, Y, 2011) |
| "Breast cancer is the most common solid tumor diagnosed in women." | ( Rosen, M; Weinstein, S, 2010) |
| "Breast cancer is primarily a hormone-dependent tumor that can be regulated by status of steroid hormones including estrogen and progesterone." | ( Fujimura, T; Horie-Inoue, K; Ijichi, N; Ikeda, K; Inoue, S; Osaki, A; Saeki, T; Shigekawa, T; Tsuda, H, 2011) |
| "Invasive malignant breast cancers are typically branchy and benign breast tumors are typically smooth." | ( Shih, WH; Shih, WY; Yegingil, H, 2010) |
| "Metastatic breast cancers are hard to treat and almost always fatal." | ( Deng, XQ; Jiang, PD; Li, ZG; Mao, YQ; Shi, W; Tang, QQ; Wei, YQ; Yang, SY; Zhao, YL; Zheng, YZ, 2010) |
| "Breast cancer is one of the most frequent of human malignancies, and it is therefore fundamental to identify the underlying molecular mechanisms leading to cancer transformation." | ( De Laurenzi, V; De Luca, A; Di Ilio, C; Favaloro, B; Grossi, M; Rossi, C; Ruggiero, C; Sacchetta, P; Sallese, M; Sanna, F, 2010) |
| "ERα-negative breast cancer is clinically aggressive and has a poor prognosis because of the lack of hormone target-directed therapies." | ( Li, Y; Meeran, SM; Tollefsbol, TO; Yuan, YY, 2010) |
| "Breast cancer is the most common cancer in women." | ( Adrian, CA; Alonso-Burgos, A; Garcia-Tutor, E; Marre, D, 2011) |
| "Breast cancer is one of the leading causes of cancer-related deaths in the world." | ( Altundag, K; Arslan, C; Tonyali, O, 2010) |
| "Breast cancer is a disease of ageing." | ( Abadie, S; Blot, E; Bourbouloux, E; Brain, EG; Debled, M; Fourme, E; Genève, J; Girre, V; Kirscher, S; Laguerre, B; Luneau, S; Mertens, C; Mourey, L; Rousseau, F; Uwer, L; Van Praagh-Doreau, I, 2011) |
| "Breast cancer is the most common cancer among Malaysian women and early detection can play an important role in reducing cancer morbidity and mortality." | ( Kandiah, M; Parsa, P, 2010) |
| "Breast cancer is the leading cancer in women today and the major challenge is late presentation then later contributes to poor outcome and high fatality rate." | ( Rosmawati, NH, 2010) |
| "Metastatic breast cancer is a disease which is not curable." | ( Bravencová, Z, 2010) |
| "Seventy percent of breast tumors are estrogen receptor (ER) positive." | ( Bentires-Alj, M; Meyer, DS, 2010) |
| "Breast cancer is the most prevalent malignancy in women." | ( Pogribny, IP, 2010) |
| "Breast cancer is the leading cause of female mortality, and the high mortality is mainly attributable to metastasis." | ( Chen, CC; Chen, PH; Pai, HC; Peng, CY; Teng, CM; Yang, CR, 2011) |
| "Breast cancer is a heterogeneous disease and existing clinicopathological classifications do not fully capture the diversity in clinical disease course." | ( Kok, M; Linn, SC, 2010) |
| "Breast cancer is the most prevalent women's cancer, with an age-adjusted incidence of 122." | ( Chen, JJ; Gallagher, CM; Kovach, JS, 2010) |
| "Breast cancer is frequently a hormonally dependent cancer, and associations of circulating estrogens and androgens with subsequent breast cancer risk are well established in postmenopausal women." | ( Brinton, LA; Dorgan, JF; Kahle, LL; Stanczyk, FZ, 2010) |
| "Breast cancer is the most commonly diagnosed invasive malignancy and the second leading cause of cancer death in women." | ( Friedenreich, CM; Lynch, BM; Neilson, HK, 2011) |
| "Breast cancer is a heterogeneous disease and each patient should be offered an adapted treatment in an effort to reduce the risk of relapse and death, with the minimal toxicities." | ( Campone, M; Frénel, JS, 2010) |
| "Breast cancer is a leading cause of female deaths worldwide." | ( Gam, LH; Liang, S; Singh, M, 2010) |
| "Breast cancer is a leading cause of mortality in women." | ( Dharmaraj, S; Gam, LH; Liang, S; Singh, M, 2010) |
| "Breast cancer is a disease characterised by both genetic and epigenetic alterations." | ( Alberio, R; Allegrucci, C; Dixon, JE; Johnson, AD; Kumari, R; Rushton, MD; Shah, M; Sottile, V; Watson, S, 2011) |
| "Breast cancer is the most commonly diagnosed invasive malignancy and the second leading cause of cancer death in women globally." | ( Friedenreich, CM, 2011) |
| "Breast cancer is the most widely spread cancer in the world, attracting much research and individualized tumour response testing (ITRT) methods are now used to individualize patient chemotherapeutic administrations." | ( Bessette, B; Fermeaux, V; Giraud, S; Lautrette, C; Loum, E, 2011) |
| "Breast cancer is the most common tumor among women with inherited mutations in the p53 gene (Li-Fraumeni syndrome)." | ( Bigelow, C; Dunphy, KA; Jerry, DJ; Roberts, AL; Tao, L; Yan, H, 2011) |
| "Measures to prevent breast cancer are receiving particular attention by women at high risk from either clinico-pathologic findings or genetic susceptibility." | ( Axelrod, D; Kleinberg, D; Singh, B; Smith, J, 2011) |
| "BRCA2-associated breast tumors are less likely than non-BRCA1/BRCA2 familial breast cancers to exhibit EMSY amplification." | ( Andrulis, IL; Bane, AL; Mulligan, AM; O'Malley, FP; Pinnaduwage, D, 2011) |
| "Breast cancer is the most frequently diagnosed cancer in Malaysian women, irrespective of age group and ethnicity." | ( Rosmawati, NH, 2010) |
| "Breast cancer is one of the most common cancers in women and it is highly treatable by radiotherapy and/or radiochemotherapy." | ( Jeong, HK; Jung, S; Lee, MS; Shin, J, 2011) |
| "Breast cancer is the second most frequent cause of death by cancer." | ( Ardelean, A; Pallag, A; Pop, O; Roşca, E; Suciu, R, 2011) |
| "Breast cancer is the most common cancer among women." | ( Shields, GC, 2009) |
| "Breast cancer is a heterogenous disease and hormonal factors are involved." | ( Lyytinen, H; Ylikorkala, O, 2011) |
| "Because breast cancer is the most common malignancy and the second most common cause of cancer death among women, many nuclear medicine imaging techniques are essential in the evaluation and therapy of patients with this disease." | ( Moadel, RM, 2011) |
| "Breast cancer is a heterogeneous disease comprised of at least five major tumor subtypes that coalesce as the second leading cause of cancer death in women in the United States." | ( Parvani, JG; Schiemann, WP; Taylor, MA, 2011) |
| "Breast cancer is a disease that has plagued many women globally." | ( Bay, BH; Lai, Y; Yip, GW, 2011) |
| "Breast cancer is a genetically heterogenous disease with subtypes differing in prognosis and chemosensitivity." | ( Bebek, G; Budd, GT; De, S; Downs-Kelly, E; Eng, C; Orloff, MS; Stark, GR; Tan, MH; Wesolowski, R, 2012) |
| "Breast cancer is the leading cause of cancer mortality among women in Malaysia." | ( Biswal, BM; Naing, NN; Norsa'adah, B; Rahmah, MA; Rampal, KG, 2011) |
| "Breast cancer is a collection of diseases in which molecular phenotypes can act as both indicators and mediators of therapeutic strategy." | ( Altenburg, JD; Bieberich, AA; Harvey, KA; Jo Davisson, V; Siddiqui, RA; Terry, C; Vanhorn, JF; Xu, Z, 2011) |
| "Metastasis of breast cancer is a major contributor to mortality." | ( Ball, GR; Caldas, C; Ellis, IO; Green, AR; Martin, SG; Mohammed, RA; Parr, T; Spiteri, I; Storr, SJ; Woolston, CM, 2011) |
| "Early-onset breast cancer is one of the most common malignancies and causes of death among young women, and its incidence is increasing." | ( Aboussekhra, A; Al-Moghrabi, N; Al-Qasem, AJ, 2011) |
| "Breast cancer is one of the most common forms of cancer observed in women and endogenous estrogens are thought to play a major role in its development." | ( Abedtash, H; Ardeshir-Rouhani-Fard, S; Namazi, S, 2011) |
| "Breast cancer is one of the most common cancers in the world among women and its effective control depends upon sufficient knowledge about its epidemiology at the regional as well as global levels." | ( Chabra, S; Chauhan, A; Menezes, RG; Shetty, BS; Subba, SH; Thakur, V; Warrier, R, 2011) |
| "Basal-like breast cancers are commonly negative for expression of estrogen and progesterone receptors and HER-2 (triple-negative breast cancer), which makes this subtype of breast cancers more aggressive and less responsive to standard treatment." | ( Dolai, S; Liu, F; Molloy, MP; Xu, Q, 2011) |
| "Breast cancer is the most common cancer and the second leading cause of cancer death in industrialized countries." | ( Bachmeier, B; Efferth, T; Fichtner, I; Killian, PH; Kronski, E; Pfeffer, U, 2011) |
| "Metastatic breast cancer is a deadly disease which requires new therapeutic strategies." | ( Chen, F; Cryns, VL; Koblinski, J; Malin, D; Schiller, C, 2011) |
| "Breast cancer is the second most frequently diagnosed tumor in women." | ( Amala, K; Bhujanga Rao, AK; Gondi, CS; Gorantla, B; Jogi, KV; Junnarkar, A; Myneni, PC; Naidu, MU; Rao, JS; Venkat Ramana, G, 2011) |
| "Fifteen∼20% of all breast cancers are HER2 positive and have a poor prognosis." | ( Okamura, T; Saito, Y; Suzuki, Y; Tokuda, Y, 2011) |
| "Breast cancer is a major challenge for pharmacologists to develop new drugs to improve the survival of cancer patients." | ( Adrian, TE; Ahmed Al Sultan, M; Al Marzouqi, N; Arafat, K; Attoub, S; Collin, P; Iratni, R; Mester, J; Nemmar, A; Yasin, J, 2011) |
| "From these analyses, breast tumors are predicted to be sensitive to VPA." | ( Bild, AH; Chang, JT; Cohen, AL; Gustafson, AM; Jeffrey, SS; Johnson, E; Soldi, R; Spira, A; Welm, BE; Wilcox, R; Zhang, H, 2011) |
| "ErbB2-positive breast cancer is tend to be more aggressive than other types of breast cancer and therefore further investigation on the signaling pathways of erbB2 is needed for the therapeutic target for breast cancer treatment." | ( Adachi, R; Hasegawa, T; Horiuchi, S; Sakamaki, T; Sakurazawa, Y; Sato, K, 2011) |
| "Breast cancer is the most common cancer in women living in the Western world, even though it occurs worldwide." | ( Demir, G; Emekli-Alturfan, E; Kaşikci, E; Oztürk, LK; Yarat, A, 2011) |
| "Breast cancer is the commonest female malignancy in the Western world and the most reliable predictor for survival is axillary lymph node metastases." | ( Hand, F; Kell, MR; Robertson, IJ, 2011) |
| "The risk of breast cancer is greater for formulations that contain both estrogen and progesterone, compared with estrogen alone." | ( Narod, SA, 2011) |
| "Breast cancer is the most common malignant disease in women, and it is not the primary tumor but its metastasis kills most patients with breast cancer." | ( Ji, Y; Kong, H; Li, X; Meng, J; Wu, X; Xu, H; Zhang, W, 2011) |
| "Advanced breast cancer is common in less affluent parts of Asia." | ( Hartman, M; Pathy, NB; Taib, NA; Verkooijen, HM; Yip, CH, 2011) |
| "The etiology of breast cancer is still unknown and adequate primary prevention strategies or interventions are still not possible." | ( Al-Naggar, DH; Al-Naggar, RA; Assabri, A; Bobryshev, YV; Chen, R, 2011) |
| "Sporadic breast cancers are mainly attributable to long-term exposure to environmental factors, via a multi-year, multi-step, and multi-path process of tumorigenesis involving cumulative genetic and epigenetic alterations in the chronic carcinogenesis of breast cells from a non-cancerous stage to precancerous and cancerous stages." | ( Rathore, K; Wang, HC, 2012) |
| "Breast cancer is an estrogen-driven disease." | ( Dairkee, SH; Goodson, WH; Jaffee, IM; Luciani, MG; Moore, DH; Sayeed, SA, 2011) |
| "Basal-like breast cancer is an aggressive disease with limited therapeutic options because these tumors frequently express the 'triple-negative' phenotype." | ( Ambs, S; Cheng, RY; Glynn, SA; Ridnour, LA; Switzer, CH; Vitek, MP; Wink, DA, 2011) |
| "Breast cancer is primarily a hormone-dependent tumor that can be regulated by the status of steroid hormones, including estrogen and progesterone." | ( Aogi, K; Horie-Inoue, K; Ijichi, N; Ikeda, K; Inoue, S; Osaki, A; Saeki, T; Saji, S; Shigekawa, T; Shimizu, C; Tsuda, H, 2011) |
| "Breast cancer is the most common cancer affecting women in the UK." | ( Boland, A; Dickson, R; Dundar, Y; Fernández Santander, A; Fleeman, N; Howell, S; Martin Saborido, C; Newman, W; Oyee, J; Payne, K; Walley, T, 2011) |
| "Breast cancer is the leading cause of death for women between the ages of 35 to 65." | ( Bertucci, F; Birnbaum, D; Castellano, R; Charaffe-Jaufret, E; Finetti, P; Houvenaeghel, G; Mamessier, E; Moretta, A; Olive, D; Sylvain, A, 2011) |
| "Breast cancer is no exception and indeed, many studies have revealed considerable complexity and heterogeneity in the population of primary breast tumors and substantial changes in a recurrent breast tumor that has acquired metastatic properties and drug resistance." | ( Andrechek, ER; Cardiff, RD; Leung, JY; Nevins, JR, 2012) |
| "Breast cancer is the leading cause of cancer-related deaths in women." | ( Cotrim, Z; Domingues, MR; Domingues, P; Dória, ML; Helguero, L; Macedo, B; Simões, C, 2012) |
| "Breast cancer is the number one neoplastic disease of women, with the HER2-high carcinomas presenting a considerable challenge for efficient treatment." | ( Akporiaye, E; Dong, LF; Grant, G; Massa, H; Neuzil, J; Zobalova, R, 2012) |
| "Breast cancer is the malignant neoplasia with the highest incidence in women worldwide." | ( Barbosa, DS; Campos, FC; Cecchini, AL; Cecchini, R; De Rossi, T; Freitas, LF; Herrera, AC; Panis, C; Pinge-Filho, P; Simão, AN; Victorino, VJ, 2012) |
| "Prognosis of breast cancer is believed to be a multifactorial process best achieved by complex factors including host and tumor-derived biomarkers together with traditional clinicopathological parameters and tumor histologic markers." | ( Abdel-Aty, A; Demian, SR; Ghoneim, HM; Kazem, A; Maher, S; Saad, A, 2009) |
| "Breast cancer is the fourth most frequent cause of death, and it is currently the most frequent cause of death among Japanese women." | ( Chino, A; Hirasaki, Y; Namiki, T; Ogawa, K; Okamoto, H; Ueda, K, 2011) |
| "Breast cancer is the most frequent cancer and the leading cause of cancer-related deaths in women worldwide." | ( Brandt, B; Hilvo, M; Iljin, K; Issa, R; Kallioniemi, O; Lehtinen, L; Oresic, M; Pantel, K; Pollari, S; Reemts, J; Vainio, P; Wikman, H, 2012) |
| "Breast cancer is conventionally treated by surgery and radiotherapy, with adjuvant chemotherapy and hormonotherapy as supplementary treatments." | ( Chan, JY; Fong, WP; Fung, KP; Hoi, SW; Law, BK; Tse, GM; Wong, HM; Yue, GG, 2012) |
| "Breast cancers are sensitive to hormones such as estrogen, which binds to and activates estrogen receptors (ER) leading to significant changes in gene expression." | ( Aydogdu, E; Edvardsson, K; Katchy, A; Williams, C, 2012) |
| "Breast cancer is the second leading cause of cancer-related deaths in western countries." | ( Barbetti, V; Dello Sbarba, P; Morandi, A; Riverso, M; Rovida, E, 2011) |
| "Breast cancer is the most common cancer among Malaysian women." | ( Aina, EN; Fuad, I; Hanie, SS; Nurismah, MI; Razif, SM; Rohaizak, M; Sharifah, NA; Sulaiman, S, 2011) |
| "Breast cancer is the female malignant neoplasia with the highest incidence in the industrialized world." | ( Macciò, A; Madeddu, C, 2011) |
| "Breast cancer is the most common cancer in Malaysian females." | ( Bulgiba, AM; Dahlui, M; Ramli, S, 2011) |
| "Treatment of breast cancer is complex and challenging due to the heterogeneity of the disease." | ( Baxter, RC; Christopherson, RI; Leong, S; McKay, MJ, 2012) |
| "Breast cancer is the most commonly diagnosed cancer among women." | ( Asatiani, MD; Mahajna, J; Nevo, E; Reznick, AZ; Ruimi, N; Wasser, SP, 2011) |
| "Breast cancer is the uncontrolled, abnormal growth of malignant breast tissue affecting predominantly women." | ( Armstrong, A; Bagust, A; Blundell, M; Boland, A; Davis, H; Dickson, R; Dundar, Y; Fleeman, N; Moonan, M; Oyee, J; Thorp, N, 2011) |
| "Breast cancer is the most common cancer diagnosed in women and the second most common cause of female cancer-related deaths, with more than one million new cases diagnosed per year throughout the world." | ( Dwivedi, A; Saxena, R, 2012) |
| "Breast cancer is the most common malignant tumor in women these days accounting for approximately 24% of all cancer." | ( Dang, TT; Dao, TT; Le, TV; Nguyen, QT; Oh, WK; Pham, TH; Thuong, PT, 2012) |
| "Breast cancer is the most frequent cancer among women with about 1." | ( Buchholz, S; Moegele, M; Ortmann, O; Seitz, S, 2012) |
| "Breast cancer is the most frequent tumor and a major cause of death among women." | ( Andò, S; Barone, I; Bonofiglio, D; Catalano, S; Gelsomino, L; Giordano, C; Gu, G; Menichini, F; Statti, G, 2012) |
| "Prevention of breast cancer is difficult, as most risk factors are difficult to control." | ( Peeters, PH; van Diest, PJ; Verkooijen, HM, 2012) |
| "Breast cancer is the most common cancer and the second leading cause of cancer-related mortality worldwide." | ( Bowles, H; Burchiel, SW; Lauer, FT; León-Buitimea, A; Rodríguez-Fragoso, L; Thompson, TA, 2012) |
| "Breast cancer is the most common malignancy in women, and many breast cancer patients fail conventional treatment strategies of chemotherapy, radiation, and antiestrogen therapy." | ( Gao, JX; Liu, CM; Wang, XY; Wang, YX; Zhang, L, 2012) |
| "Breast cancer is commonly treated by various combinations of surgery, radiation therapy, chemotherapy and hormone therapy." | ( Choromańska, A; Chwilkowska, A; Drag-Zalesinska, M; Dumanska, M; Kulbacka, J; Kuzma-Richeret, A; Marcinkowska, A; Mosiadz, D; Pola, A; Saczko, J; Wysocka, T, 2011) |
| "Breast cancer is one of several tumors, including prostate, thyroid and kidney, which display a remarkable predilection for metastasis to bone." | ( Benayahu, D; Glait-Santar, C, 2012) |
| "Breast cancer is the most frequently occurring cancer in women globally and early detection increases the survival rate of patients." | ( Kanaga, KC; Nithiya, J; Shatirah, MF, 2011) |
| "Breast cancer is the most common cancer in females worldwide, and the second leading cause of cancer deaths in women." | ( Bankwar, VV; Bhagat, VK; Lodha, KM; Lodha, RS; Nandeshwar, S; Pal, DK; Saxena, DM; Shrivastav, A, 2011) |
| "However, breast cancer is a diverse disease and little is known about the relationships between miRNA expression, clinical outcome and tumour subtype." | ( Ali, HR; Bardwell, H; Blows, F; Caldas, C; Dawson, SJ; Jones, J; Pharoah, P; Quesne, JL; Warren, J, 2012) |
| "Breast cancer is increasingly regarded as a heterogeneous disease which can be classified into distinct molecular subtypes with prognostic significance." | ( Jin, F; Li, B; Li, Y; Lv, M; Mao, X; Yao, F, 2011) |
| "More than 85% of breast cancers are sporadic and attributable to long-term exposure to environmental carcinogens, such as those in the diet, through a multistep disease process progressing from non-cancerous to premalignant and malignant stages." | ( Choudhary, S; Donnell, RL; Sood, S; Wang, HC, 2012) |
| "Breast cancer is the leading cause of cancer-related deaths in women worldwide." | ( Chen, DR; Chien, SY; Kuo, SJ; Su, CC; Yan, MY, 2012) |
| "Metastatic breast cancer is considered an incurable disease, with complete remission rarely achieved after treatment." | ( O'Shaughnessy, JA; Perez, EA; Rugo, HS, 2011) |
| "Metastatic breast cancer is considered an incurable disease, with complete remission rarely achieved after treatment." | ( O'Shaughnessy, JA; Perez, EA; Rugo, HS, 2011) |
| "Although breast cancer is rare among young women and the elevated risk of breast cancer associated with DMPA appears to dissipate after discontinuation of use, our findings emphasize the importance of identifying the potential risks associated with specific forms of contraceptives given the number of available alternatives." | ( Beaber, EF; Daling, JR; Li, CI; Malone, KE; Porter, PL; Tang, MT, 2012) |
| "The risk of breast cancer is generally increased by MHT, particularly in lean women with no previous MHT who start estrogen-progestin therapy near the menopause and continue for several years, but there is no increased risk 5 years after stopping MHT." | ( Davey, DA, 2012) |
| "RCG for breast carcinoma is validated." | ( Dhar, M; Nandini, NM; Rekha, TS, 2011) |
| "Breast cancers are highly heterogeneous but can be grouped into subtypes based on several criteria, including level of expression of certain markers." | ( Dong, C; Evers, BM; Rychahou, PG; Wang, Y; Wu, Y; Yao, J; Yu, Y; Zhou, BP, 2012) |
| "Breast cancer is a heterogeneous disease with a variable prognosis." | ( Bathen, TF; Buydens, LM; Fjøsne, HE; Giskeødegård, GF; Gribbestad, IS; Lundgren, S; Postma, G; Sitter, B, 2012) |
| "Breast cancer is the most prevalent cancer in women." | ( Boisbrun, M; Chapleur, Y; Colin, C; Flament, S; Grillier-Vuissoz, I; Kuntz, S; Martin, H; Mazerbourg, S; Richert, L; Salamone, S, 2012) |
| "Luminal breast cancer is the most frequently encountered type of human breast cancer and accounts for half of all breast cancer deaths due to metastatic disease." | ( Banach-Petrosky, W; Ganapathy, V; Kareddula, A; Miles, G; Nienhuis, H; Reiss, M; Xie, W, 2012) |
| "Breast cancer is a disease in which cancer cells form in the tissues of the breast." | ( Duo, J; Wang, GW; Ying, GG; Zhang, L, 2012) |
| "Breast cancer is the most common cancer in women, and it can metastasize very rapidly." | ( Abdul Majid, AM; Abdul Majid, AS; Aisha, AF; Al Suede, FS; Nassar, ZD, 2012) |
| "Most of breast cancers are resistant to mammalian target of rapamycin complex 1 (mTORC1) inhibitors rapamycin and rapalogs." | ( Bai, X; Jia, C; Li, H; Lin, J; Liu, A; Wang, L; Wang, X; Yang, C; Yao, G; Zheng, H, 2012) |
| "Breast cancer is primarily a hormone-dependent tumor that can be regulated by the status of the steroid hormones estrogen and progesterone." | ( Aogi, K; Horie-Inoue, K; Ijichi, N; Ikeda, K; Inoue, S; Osaki, A; Saeki, T; Saji, S; Shigekawa, T; Shimizu, C; Tsuda, H, 2012) |
| "Prostate and breast cancer are major causes of death worldwide, mainly due to patient relapse upon disease recurrence through formation of metastases." | ( Biondi, G; De Martino, D; Di Dato, V; Garrone, B; Guglielmotti, A; Liguori, L; Mangano, G; Marino, N; Navas, L; Spano, D; Vastolo, V; Zollo, M, 2012) |
| "Breast cancer is the most aggressive form of all cancers, with high incidence and mortality rates." | ( Cho, BW; Darvin, P; Do Park, K; Hong, DY; Hwang, TS; Joung, YH; Kim, SY; Lee, HK; Lim, EJ; Moon, ES; Na, YM; Park, JH; Park, T; Yang, YM; Ye, SK, 2012) |
| "Breast cancer is one of the most common cancers in humans." | ( Gotoh, N; Hinohara, K; Inoue, J; Kanauchi, H; Kobayashi, S; Mori, M; Nishioka, K; Ogawa, T; Shimizu, S; Tada, K; Tojo, A; Tsuji, E; Umezawa, K, 2012) |
| "Breast cancer is a common cancer with a leading cause of cancer mortality in women." | ( Chen, Y; He, L; Liu, C; Smith, WW; Wang, N; Zhan, Y; Zhang, J; Zhang, Y; Zheng, L, 2012) |
| "Breast cancer is one of the most common types of cancer in women, and is the second leading cause of cancer-related deaths in the United States." | ( Huang, Y; Liu, MM; Wang, J, 2012) |
| "Breast cancer is a molecularly heterogeneous disease, and predicting response to chemotherapy remains a major clinical challenge." | ( Baxter, RC; Christopherson, RI; Crossett, B; Leong, S; Lin, MZ; Nunez, AC, 2012) |
| "Breast cancer is the second leading cause of death due to cancer in women." | ( Wang, J; Wu, J, 2012) |
| "Breast cancer is the most common cancer and the leading cause of cancer death in women." | ( Li, Y; Meeran, SM; Patel, SN; Shukla, S; Tollefsbol, TO, 2012) |
| "Luminal breast cancer is a highly endocrine responsive disease." | ( Alba, E; Albanell, J; Arcusa Lanza, A; Bermejo, B; Calvo, L; Carrasco, E; Chacon, JI; De la Haba, JR; Lluch, A; Lopez Garcia-Asenjo, JA; Plazaola, A; Sanchez-Rovira, P, 2012) |
| "Breast cancer is one of the most common cancers amongst women in North America." | ( Collins, J; Hudlicky, T; Ma, D; Pandey, S, 2012) |
| "Breast cancer is the most frequent cancer in women." | ( Gu, Y; Shi, W; Song, N; Yu, K; Zhang, H; Zhou, L, 2012) |
| "Breast cancer is a frequently reported cancer in women all over the world." | ( Kalyan, CS; Naresh, B; Pawar, SC; Priyamvada Devi, A; Setti, A; Venugopal Rao, V, 2012) |
| "Breast cancer is the leading cause of neoplasia-related deaths among women, but no data are available in the literature on the safe use of oncological treatments in glucose 6-phosphate dehydrogenase (G6PD)-deficient patients." | ( Bramati, A; Farina, G; Girelli, S; La Verde, N; Mihali, D; Moretti, A; Piva, S; Sburlati, P, 2012) |
| "Breast cancer is the most prevalent cancer in women worldwide and is classified into ductal and lobular carcinoma." | ( Choi, KC; Choi, KJ; Kim, SU; Yi, BR, 2012) |
| "Breast cancer is the most common cancer in women in developed countries, and the contribution of genetic susceptibility to breast cancer development has been well-recognized." | ( Jukkola-Vuorinen, A; Kallioniemi, A; Otsukka, M; Pylkäs, K; Vuorela, M; Winqvist, R, 2012) |
| "HER-2-positive breast cancer is a breast cancer subtype with an increasing body of knowledge regarding potential targeted drug combinations that are significantly improving outcomes through a biologically tailored therapy approach; neratinib emerges as a promising tool in this context." | ( Jerez, Y; López-Tarruella, S; Márquez-Rodas, I; Martín, M, 2012) |
| "Breast cancer is still the leading cause of cancer deaths among women worldwide, and new therapies to treat this dangerous disease are desperately needed." | ( Ahmad, A; Biersack, B; Sarkar, FH; Schobert, R, 2012) |
| "Metastatic breast cancer is incurable." | ( Barnhart, TE; Cai, W; Chen, X; Engle, JW; Hong, H; Leigh, BR; Nickles, RJ; Niu, G; Severin, GW; Yang, Y; Zhang, Y, 2012) |
| "Breast cancer is the second most common cancer in women in India and the disease burden is increasing annually." | ( Gadgil, A; Muwonge, R; Roy, N; Sankaranarayanan, R; Sauvaget, C, 2012) |
| "Breast cancer is the most common cancer among women in Malaysia." | ( Abdul Manaf, MR; Al-Dubai, SA; Alabsi, AM; Ganasegeran, K; Ijaz, S; Kassim, S, 2012) |
| "Breast cancer is one of the most common cancers among women in India and around the world." | ( Dasari, S; Kumar, D; Kumar, S; Kundu, GC; Patil, HS; Puranik, VG; Sharma, P; Thulasiram, HV, 2012) |
| "Breast cancer is one of the most common cancers in women worldwide." | ( Abitew, AM; Askari, M; Nikbakht, M; Sharma, SC; Singh, N; Sobti, RC, 2012) |
| "Metastatic breast cancer is a heterogeneous disease, commonly affecting the liver." | ( Bagni, O; Cianni, R; Cortesi, E; Filippi, L; Notarianni, E; Pelle, G; Rabuffi, P; Saltarelli, A, 2013) |
| "Breast cancer is the most commonly occurring type of cancer in the world." | ( Danilo, C; Frank, PG, 2012) |
| "Worldwide, breast cancer is the commonest cause of cancer death in women." | ( Aina, EN; Al-Sadat, N; Dahlui, M; Ibrahim, NI, 2012) |
| "Breast cancer is the most common of all malignant diseases in women." | ( Kaplan, DL; Seib, FP, 2012) |
| "Breast cancer is the most commonly diagnosed cancer among women in the United States." | ( Thomson, CA, 2012) |
| "Breast cancer is the most commonly diagnosed cancer in women worldwide and characterized its by molecular and clinical heterogeneity." | ( Altundag, K; Arik, Z; Babacan, T; Kertmen, N; Keskin, O; Ozisik, Y; Petekkaya, I; Sarici, F; Solak, M; Turkoz, FP, 2013) |
| "Breast cancer is usually present for many years (as long as 5-10 years) before it can be clinically diagnosed (theory of the 'dormant malignant cell')." | ( Arora, MK; Chauhan, A; Seth, S; Trehan, AS, 2012) |
| "Nodal staging in breast cancer is a key predictor of prognosis." | ( Tong, F; Wang, S; Xie, F; Yang, D; Yang, H; Zhang, J; Zhou, B, 2012) |
| "Worldwide, breast cancer is the most commonly diagnosed cancer among women and is the leading cause of female cancer deaths." | ( Alam, S; Kelleher, SL, 2012) |
| "Breast cancer is a common diagnosis and the majority of women treated will be cured." | ( Choksi, P; Taxel, P; Van Poznak, C, 2012) |
| "Breast cancer is the most common cancer and the second leading cause of cancer death and morbidity among women in the western world." | ( Martins-Green, M; Penichet, M; Rocha, A; Wang, L, 2012) |
| "More than 85% breast cancers are sporadic and attributable to long-term exposure to environmental carcinogens through a multistep and multiyear disease process." | ( Choudhary, S; Sood, S; Wang, HC, 2014) |
| "Triple-negative breast cancer is characterized by aggressive tumours whose cells lack oestrogen and progesterone receptors and do not over-express HER2." | ( Adams, C; Cazzanelli, G; Coombes, C; Hu, Y; Masrour, N; Papoutsoglou, P; Patel, N; Raguz, S; Rasul, S; Yagüe, E; Zhou, Y, 2013) |
| "Breast cancer is still the leading cause of cancer deaths among women worldwide and new therapies and drugs are continuously being conceived and explored to better control or even cure this disease." | ( Biersack, B; Schobert, R, 2012) |
| "Breast cancers are composed of molecularly distinct subtypes with different clinical outcomes and responses to therapy." | ( Barillot, E; Cruzalegui, F; De Koning, L; Decaudin, D; Depil, S; Dubois, T; Dumont, A; Gentien, D; Gravier, E; Lang, G; Maire, V; Marangoni, E; Marty-Prouvost, B; Némati, F; Pierré, A; Richardson, M; Rigaill, G; Roman-Roman, S; Tesson, B; Tucker, GC; Vincent-Salomon, A, 2013) |
| "The metastasis of breast cancer is the leading cause of cancer death in women, and the lung is a common location of a secondary tumor that has metastasized from the primary source tumor." | ( Li, Y; Shen, J; Sun, H; Wang, S; Xu, P; Yin, Q; Yu, H; Zhang, Z, 2013) |
| "Breast cancer is the most common cancer and the leading cause of cancer death among women in Malaysia." | ( Beshir, SA; Hanipah, MA, 2012) |
| "Breast cancer is a heterogeneous disease at both the clinical and molecular levels." | ( Becker, N; Haag, D; Heck, S; Hovestadt, V; Lichter, P; Mannherz, O; Riazalhosseini, Y; Sahin, Ö; Schneeweiss, A; Shahmoradgoli, M; Sinn, HP, 2013) |
| "Breast cancer is a common disease which threatens the life of women." | ( Jiang, Y; Leung, AW; Xia, X; Xiang, J; Xu, C, 2012) |
| "Breast cancer is the most common cause of cancer deaths among women worldwide." | ( Abdel-kader, MH; Ali, SE; El-Tayeb, TA; Gomaa, I, 2012) |
| "Breast cancer is a heterogeneous disease with a diversity of clinical behaviors." | ( Hayashida, T; Hirose, S; Ikeda, T; Jinno, H; Kitagawa, Y; Matsuda, S; Takahashi, M, 2012) |
| "Breast cancer is a heterogeneous and complex disease." | ( Ball, GR; Ellis, IO; Gritzapis, AD; Hughes, DC; Laversin, SA; Li, G; McArdle, SE; Miles, AK; Missitzis, I; Phatak, VM; Powe, DG; Rees, RC, 2013) |
| "Treatment delays in breast cancer are generally thought to affect prognosis but the impact on survival remains unclear." | ( Dahlui, M; Mujar, M; Taib, NA; Yip, CH, 2013) |
| "Breast cancer is the world's leading cause of death among women." | ( Câmara, DA; Damião, MC; de Azevedo, RA; de Souza, DM; de-Sá-Júnior, PL; Ferreira, AK; Parise Filho, R; Pasqualoto, KF; Pereira, A; Tavares, MT, 2013) |
| "Breast cancer is one of the most common cancers of women in India with high fatality rate." | ( Chakraborty, D; Das, S; Mondal, PK; Mukherjee, A; Sen, S, 2012) |
| "Breast cancer is the second most common cancer with a high incidence rate worldwide." | ( Chan, YS; Fang, EF; Ng, TB; Pan, WL; Wong, JH; Ye, XJ, 2013) |
| "Breast cancer is a major cause of cancer death in women in the world." | ( Chiosi, E; D'Auria, R; Di Gesto, D; Di Maiolo, F; Esposito, A; Naviglio, S; Sorvillo, L; Spina, A, 2013) |
| "Breast cancer is the most common cancer among women." | ( Anandi, NM; Chow, VT; Ignacimuthu, S; Li, F; Rajendran, P; Samy, RP; Sethi, G; Stiles, BG, 2012) |
| "Breast cancer is the most commonly diagnosed cancer in women in the world and is one of the leading causes of death due to cancer." | ( Abulkhair, O; Dilshad, A; Nemenqani, D; Tamimi, W, 2012) |
| "However, breast cancer is the leading tumor metastasizing from extragenital organs to the uterus." | ( Bayoglu, IV; Can, A; Demir, L; Dirican, A; Erten, C; Kucukzeybek, Y; Somali, I; Tarhan, MO; Unay, FC; Yetimalar, MH; Yigit, SC, 2012) |
| "Breast cancer is a heterogenetic tumor at the cellular level with multiple factors and components." | ( Cameron, AG; Gao, X; Ke, S; Li, M; Lin, J; Qiu, X; Wang, W; Yallampalli, S; Yu, D; Yustein, JT; Zhang, F; Zhang, S; Zou, C, 2013) |
| "Breast cancer is one of the most lethal diseases in women; however, the precise etiological factors are still not clear." | ( Chen, H; Hardy, TM; Li, Y; Tollefsbol, TO, 2013) |
| "Breast cancer is the leading cause of cancer death among females, and novel chemotherapeutic drugs for treating breast cancer are needed urgently." | ( Bai, LL; Fu, DY; Han, WL; Li, Y; Liu, JS; Shi, JM; Ye, WC; Yin, ZQ; Yiu, A; Zhang, DM, 2013) |
| "Breast cancers are the most common source of metastases to bone, of which cancer-induced bone pain is a frequent pathological feature." | ( Seidlitz, EP; Singh, G; Ungard, RG, 2013) |
| "Breast cancer is the most common malignancy among females; nevertheless, so far no data is available in the literature on the safety of oncological treatments in patients with sickle cell disease (SCD)." | ( Al Zaman, AS, 2013) |
| "Breast cancer is the most common malignancy among women and has an age-specific incidence profile." | ( Chen, CS; Ho, CT; Ho, YS; Huang, CS; Lee, CH; Lee, WJ; Tam, KW; Tu, SH; Wu, CH, 2013) |
| "Breast cancer is the most common malignancy affecting women and there remains a need for effective adjuvant therapies for this disease, for which plant sterols may play a distinctive role." | ( Grattan, BJ, 2013) |
| "Breast cancer is currently the most lethal gynecologic malignancy in many countries, and paclitaxel is a cornerstone in the treatment of this malignancy." | ( Fan, S; Li, L; Mao, J; Shi, Y; Song, B; Tang, J; Wang, B; Yu, X, 2013) |
| "The recurrence of breast cancer is associated with drug-resistance of cancer stem cells (CSCs), while overexpression of cell membrane ATP-binding cassette (ABC) transporters and resistance of mitochondrial apoptosis-related proteins are responsible for the drug-resistance of CSCs." | ( Ju, RJ; Li, N; Li, XY; Lu, WL; Ma, X; Mu, LM; Shi, JF; Sun, MG; Yan, Y; Zhang, CX; Zhao, WY; Zhou, J, 2013) |
| "Breast cancer is an increasing health problem in India." | ( Fotedar, V; Gupta, M; Gupta, MK; Seam, RK; Vats, S; Verma, S, 2013) |
| "Breast cancer is the leading cause of cancer-related death among women in Malaysia." | ( Ahmad, Z; Keng, SL; Yusuf, A, 2013) |
| "Breast cancer is the most common cancer and the second principal cause of cancer deaths among women worldwide, including Malaysia." | ( Akhtari-Zavare, M; Ismail, IZ; Juni, MH; Said, SM, 2013) |
| "However, most breast tumors are eventually resistant to TAM therapy." | ( Wang, ZY; Zhang, X, 2013) |
| "Breast cancer is estimated as one of the most common causes of cancer death among women." | ( Kim, SY; Lee, IS; Moon, A, 2013) |
| "Breast cancer is a large global health burden and the most frequently diagnosed malignancy in women worldwide." | ( Askeland, RW; Fisher, RA; Maity, B; O'Malley, Y; Stewart, A; Sugg, SL, 2013) |
| "Growth of breast cancers is often dependent on ovarian steroid hormones making the tumors responsive to antagonists of hormone receptors." | ( Bagó, JR; Ballaré, C; Beato, M; Blanco, J; Castellano, G; Reyes, D; Soronellas, D, 2014) |
| "Breast cancer is a leading cause of cancer death among women, and the failure of normal apoptosis has been proved in the development of breast cancer." | ( Bei, CY; Chen, J; Duan, YX; Tian, J, 2013) |
| "Breast cancer is the leading cause of cancer and mortality in women worldwide." | ( Hayasaka, T; Hosokawa, Y; Ide, Y; Koizumi, K; Matsunuma, R; Morita, Y; Nishio, T; Ogura, H; Sasaki, T; Setou, M; Shiiya, N; Tanaka, H; Waki, M, 2013) |
| "Breast cancer is a leading cause of morbidity and mortality in women worldwide." | ( Pandey, S, 2013) |
| "Breast cancer is the second leading cause of death in women and thus has received a great deal of attention by researchers." | ( Clark, BJ; Delamere, NA; Distler, AA; Khundmiri, SJ; Lederer, ED; Olberding, JR; Salyer, SA, 2013) |
| "Breast cancer is a heterogeneous group of neoplasms predominantly originating in the terminal duct lobular units." | ( Aznar, MÁ; Blanco-Prieto, MJ; Estella-Hermoso de Mendoza, A; Lasa-Saracíbar, B, 2013) |
| "Metastatic breast cancer is currently incurable and the goals of therapy focus on prolonging survival and maintaining quality of life by controlling symptoms and minimizing toxicity." | ( Saji, S, 2013) |
| "Breast cancer is the most common cancer in women." | ( Li, JH; Zeng, ZJ; Zhang, YJ; Zhao, ST, 2013) |
| "Breast cancer is a complex and heterogeneous disease that affects about one out of every eight women." | ( Das, P; Postovit, LM; Siegers, GM, 2013) |
| "Basal-like breast cancer is an aggressive disease for which targeted therapies are lacking." | ( Ellis, MJ; Guo, Z; Li, S; Luo, J; Ma, CX; Xu, S, 2013) |
| "Breast cancer is a heterogeneous disease affecting thousands of people every year." | ( Aziz, K; Georgakilas, AG; Nowsheen, S; Yang, G, 2013) |
| "Breast cancer is one of the most frequently diagnosed cancers and the leading cause of cancer death among women." | ( Asakura, S; Hirata, K; Kutomi, G; Minatoya, M; Mori, M; Nagata, Y; Otokozawa, S; Sugiyama, Y, 2013) |
| "Breast cancer is the most universal cancer in women, but the medications for breast cancer usually cause serious side effects and offer no effective treatment for triple-negative breast cancer." | ( Chen, LH; Chen, YJ; Huang, C; Huang, HC; Lee, SY; Lin, CL; Tu, TH, 2013) |
| "Triple negative breast cancer is prevalent in eastern India." | ( Das, S; Gayen, R; Jha, A; Mahata, M; Maitra, S; Sen, S, 2012) |
| "Breast cancer is the most commonly malignancies in women." | ( Gao, J; Guo, J; Li, L; Liu, M; Tang, H; Wu, M; Xie, X, 2013) |
| "Breast cancers are now the commonest cancer of females of West Bengal in contrast to rest of India except Mumbai." | ( Gangopadhyay, S; Maiti, PK, 2012) |
| "Breast cancer is the second commonest malignancy affecting half a million women worldwide each year." | ( Asegaonkar, S; Bardapurkar, JS; Chaudhari, SC, 2012) |
| "Breast cancer is the most common malignancy in women." | ( Kim, H; Kim, JH; Lee, JE; Park, GS, 2013) |
| "Breast cancer is one of the most frequent diseases in women today." | ( Karimi, N; Roshan, VD, 2013) |
| "Breast cancers are considered to be primarily regulated by estrogen signaling pathways because estrogen-dependent proliferation is observed in the majority of breast cancer cases." | ( Horie-Inoue, K; Ijichi, N; Ikeda, K; Inoue, S, 2013) |
| "One-third of all breast cancers are present as clinically nonpalpable lesions." | ( Ahmed, M; de Rosales, RT; Douek, M, 2013) |
| "Breast cancer is one of the hormone-dependent cancers that may be adversely affected by elevated oestrogen or progesterone concentrations, particularly the endocrine active (hormone receptor positive) breast cancers." | ( Child, T; Fatum, M; McVeigh, E, 2013) |
| "The aetiology of breast cancer is multifactorial." | ( Barr, L; Darbre, P; Exley, C; House, E; Metaxas, G; Polwart, A, 2013) |
| "Breast cancer is the most common and leading cause of cancer mortality among Malaysian women." | ( Ab Hadi, IS; Ahmad, Z; Keng, SL; Mahamood, Z; Yusuf, A, 2013) |
| "Breast cancer is a major public health problem and the low effectiveness of conventional therapies to achieve long-term survival results in increased mortality associated with advanced breast cancers." | ( Damle, AA; Narkar, AA; Pawar, YP, 2013) |
| "Breast cancer is increasingly treated with neoadjuvant chemotherapy to improve surgical resectability and evaluate tumor response, which is assessed histopathologically." | ( Abi-Raad, R; Brachtel, EF; Corben, AD; Koerner, FC; Macklin, EA; Popa, I; Taghian, AG; Teo, CH, 2013) |
| "Breast cancer is the most frequently diagnosed cancer in women." | ( Song, GQ; Zhao, Y, 2013) |
| "Breast carcinoma is becoming a spread disease that needs a specif teraphy." | ( Bortolotti, M; Fontanella, B; Pasini, GF; Racheli, M; Zanini, G, 2013) |
| "Breast cancer is a highly malignant carcinoma and most deaths of breast cancer are caused by metastasis." | ( Chang, LS; Chiu, CC; Chu, CL; Lin, SR; Tsai, PC, 2013) |
| "Breast cancer is second most common cancer in Indian women." | ( Bandyopadhyay, A; Barui, G; Chakrabarti, S; Karmakar, R; Maity, PK; Roy, A, 2012) |
| "More than 85% of breast cancers are sporadic and attributable to long-term exposure to environmental carcinogens and co-carcinogens." | ( Choudhary, S; Sood, S; Wang, HC, 2013) |
| "Breast cancer is defined as a cancer originating in tissues of the breast, frequently in ducts and lobules." | ( Gomes, AM; Pavão, MS; Stelling, MP, 2013) |
| "Breast cancer is becoming more prominent in women today." | ( Abu, N; Akhtar, MN; Alitheen, NB; Ho, WY; Yeap, SK, 2013) |
| "Most relapses in breast cancer are in the early category." | ( Baum, M; De Kock, M; Demicheli, R; Forget, P; Gukas, I; Hrushesky, WJ; Retsky, M; Rogers, RA; Sukhatme, V; Vaidya, JS, 2013) |
| "Breast cancer is the most common cause of cancer death among women worldwide, and diet plays an important role in its prevention and progression." | ( Ghavami, L; Goliaei, B; Nikoofar, A; Taghizadeh, B, 2015) |
| "Chemoresistance of breast cancer is a worldwide problem for breast cancer and the resistance to chemotherapeutic agents frequently led to the subsequent recurrence and metastasis." | ( Kong, X; Li, X; Wang, Y; Yan, S; Yang, Q, 2013) |
| "Breast cancer is the most occurring type of cancer among women." | ( Bialešová, L; Brtko, J; Lenko, V; Macejová, D, 2013) |
| "Breast cancer is the leading cause of cancer-related deaths in women age 40 and younger in developed countries, and although generally improving, survival rates for young women with breast cancer remain lower than for older women." | ( Freedman, RA; Partridge, AH, 2013) |
| "Breast cancer is the most common cancer among Malaysian women." | ( Abdullah, NA; Ali, ZM; Ibrahim Tamim, NS; Ibrahim, L; Kamaluddin, MA; Muhammad, NA; Mustafa, AN; Wan Mahiyuddin, WR, 2013) |
| "Breast cancer is the most frequently diagnosed tumor type and the primary leading cause of cancer deaths in women worldwide and multidrug resistance is the major obstacle for breast cancer treatment improvement." | ( He, Z; Qu, C; Yin, J; Zhang, W; Zhang, Z; Zheng, G, 2014) |
| "Breast cancer is the most common hormone-dependent malignancy in women." | ( Cheng, JC; Huang, HF; Leung, PC; Zhang, Y, 2013) |
| "Breast cancer is the leading malignant disease among western women with incidence increasing over time." | ( Hellmann, SS; Lynge, E; Njor, SH; Schwartz, W; Vejborg, I, 2013) |
| "The treatment of breast cancer is one of the best examples to underline the outstanding effectiveness of the individualized approach." | ( Dank, M; Tõkés, T, 2013) |
| "Breast cancer is primarily a hormone-dependent tumor that is regulated by the status of the estrogen and progesterone receptors." | ( Aogi, K; Horie-Inoue, K; Ijichi, N; Ikeda, K; Inoue, S; Miyazaki, T; Osaki, A; Saeki, T; Saji, S; Shigekawa, T; Shimizu, C; Tsuda, H, 2013) |
| "Breast cancer is the most frequently diagnosed cancer in women." | ( Andrade, WP; Baiocchi, G; Bitencourt, AG; Damascena, AS; do Socorro Maciel, M; Fanelli, MF; Lima, EN; Osório, CA; Soares, FA, 2013) |
| "Breast cancer is the most common malignancy for females worldwide." | ( Gu, Y; Han, L; Jiang, L; Shi, H; Tan, H; Wu, P; Xiu, Y; Zhang, H, 2014) |
| "Breast cancer is an important health threat to women worldwide, and is associated with a 9-14% incidence of thrombophilia." | ( Alger, PW; Ley, ML; Matika, RW; Nielsen, VG; Steinbrenner, EB; Waer, AL, 2013) |
| "Breast Cancer is the most common malignancy among women." | ( Danza, K; De Summa, S; Lacalamita, R; Lambo, R; Paradiso, A; Pilato, B; Sambiasi, D; Tommasi, S, 2014) |
| "Breast cancer is the second most common source of brain metastases (BM)." | ( Bartolotti, M; Brandes, AA; Franceschi, E, 2013) |
| "Breast cancer is the leading cause of cancer death in women living in the western hemisphere." | ( Bilban, M; Giessrigl, B; Gollinger, M; Jäger, W; Jeitler, M; Kalipciyan, M; Krieger, S; Krupitza, G; Mader, RM; Schmidt, WM, 2013) |
| "Breast cancer is the most frequent cancer in women globally and represents the second leading cause of cancer death among women (after lung cancer)." | ( Babu, GR; Lakshmi, SB; Thiyagarajan, JA, 2013) |
| "Breast cancer is currently the leading cause of cancer-related deaths among women globally." | ( Hsu, A; Tan, BK; Wong, FC; Woo, CC, 2013) |
| "Breast cancer is the most common type of cancer occurring among women in the United States." | ( Huang, SL; Kim, H; Lee, SY; McPherson, DD; Rim, Y, 2014) |
| "Breast cancer is the second leading cause of cancer mortality in women, estimated at nearly 40,000 deaths and more than 230,000 new cases diagnosed in the U." | ( Breitwieser, GE; Cross, BM; Rao, R; Reinhardt, TA, 2014) |
| "Breast cancer is a common malignant tumor which affects health of women and multidrug resistance (MDR) is one of the main factors leading to failure of chemotherapy." | ( Cai, JX; Chen, SY; Dong, Q; Dong, YL; He, HR; Hu, SS; Lu, J; Sun, JY; Wang, TT; Xie, J; Xing, JF; Zhang, WP, 2013) |
| "Breast cancer is the most common invasive cancer in women of reproductive age." | ( Bozza, C; Del Mastro, L; Lambertini, M; Manno, M; Osa, EO; Puglisi, F, 2014) |
| "Breast cancer is a major health problem that threatens the lives of millions of women worldwide each year." | ( Aboussekhra, A; Al-Sharif, I; Remmal, A, 2013) |
| "Breast cancer is the most commonly diagnosed invasive malignancy and first leading cause of cancer-related deaths in Iranian women." | ( Ahmadi Ashtiani, H; Anjarani, S; Bokaee, S; Javadi, L; Khaki, A; Rastegar, H, 2013) |
| "Breast cancer is the most common female neoplasm that drives the transformation of normal mammary epithelial cells into highly malignant derivatives." | ( Jahan, P; Latha, KP; Maruthi, G; Murthy, TS; Nalini, S; Ramachander, VR, 2014) |
| "Breast cancer is one of the most common malignant tumor forms among women and many women succumb to their disease." | ( Fiuza, SM; Marques, MP; Oredsson, S; Persson, L; Silva, TM, 2014) |
| "Breast cancer is the most common malignancy in women of developed countries." | ( Blanquer-Rossello, MM; Nadal-Serrano, M; Oliver, J; Pons, DG; Roca, P; Sastre-Serra, J, 2014) |
| "At the same time, breast cancer is the most frequent malignant tumor in women." | ( Ferrari, CK; Franca, EL; Franca, JL; Franca-Botelho, Ado C; Honorio-Franca, AC, 2013) |
| "Breast cancer is a leading cause of death in women." | ( Amid, A; Fouz, N; Hashim, YZ, 2014) |
| "Breast cancer is a major health problem worldwide." | ( Al-Olayan, ES; Daghestani, MH; Elamin, MH; Elobeid, MA; Hassan, ZK; Omer, SA; Virk, P, 2014) |
| "Breast cancer is the commonest type of cancer among women, and in Malaysia 50-60% of the new cases are being detected at late stages." | ( Ahmad, N; Masri, AM; Oranye, NO; Subramanian, P; Taib, NA, 2013) |
| "Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females owing." | ( Cao, DY; Dun, JN; Fang, Y; Wang, J; Xiang, B; Xue, GQ; Zhang, L, 2013) |
| "Breast cancer is a leading cause of cancer-associated death worldwide." | ( Elortza, F; Falcon-Perez, JM; Gil, D; Gonzalez, E; Piva, M; Rodriguez-Suarez, E; Royo, F; Vivanco, Md, 2014) |
| "Breast carcinoma is the most common female cancer with considerable metastatic potential." | ( Li, D; Liu, L; Song, X; Wang, N; Wei, Y; Xia, Y; Xiong, Y; Yan, Y; Ye, T; Yu, L; Zeng, J; Zhang, L; Zhu, Y, 2014) |
| "Breast cancer is the most prevalent type of cancer in women and responsible for significant female cancer-related mortality worldwide." | ( Lintermans, A; Neven, P; Paridaens, R; Van Asten, K; Wildiers, H, 2014) |
| "Primary accessory breast cancer is extremely rare, and the diagnostic efficacy of Tc-MIBI breast-specific γ imaging (BSGI) has not been reported elsewhere." | ( Kim, BS; Moon, BI; Sung, SH; Yoon, HJ, 2014) |
| "Breast cancer is one of the most prevalent types of cancer among women." | ( Goliaei, B; Khodagholi, F; Nikoofar, A; Rouhani, M, 2014) |
| "Breast cancer is the most common cancer in women in Israel and throughout the world." | ( Riskin-Mashiah, S, 2013) |
| "Breast cancer is the most common cancer among women globally." | ( Daliana, NF; Fatihah, MA; Maznah, D; Norlaili, AA, 2013) |
| "ErbB2(+) breast cancer is an aggressive breast cancer subtype generally associated with lower estrogen receptor alpha (ERα) expression and more aggressive tumor behavior compared to ERα(+)/ErbB2(-) breast cancer." | ( Brandt, B; Grabinski, N; Jücker, M; Milde-Langosch, K; Möllmann, K; Müller, V; Pantel, K; Schumacher, U, 2014) |
| "HLA-II in breast carcinoma is associated with increased IFN-γ levels, reduced expression of the estrogen receptor (ER) and reduced age at diagnosis." | ( Codner, D; Drover, S; Hirasawa, K; Komatsu, Y; Mostafa, AA; Steimle, V; Young, MN, 2014) |
| "HER2(+) breast cancer is currently treated with chemotherapy plus anti-HER2 inhibitors." | ( Al-Awar, R; Aman, A; Chung, PE; Deng, T; Egan, SE; Jiang, Z; Joseph, B; Ketela, T; Liu, JC; Moffat, J; Rottapel, R; Schachter, NF; Uehling, D; Zacksenhaus, E, 2014) |
| "Some cases of breast cancer are composed of clones of hormonal-independent growing cells, which do not respond to therapy." | ( Azzam, N; Fares, B; Fares, F; Larsen, S; Lindkaer-Jensen, S, 2014) |
| "Breast cancer is the most common malignancy and the second leading cause of cancer-related death among women in the developed countries." | ( Basaran, G; Cabuk, D; Dane, F; Korkmaz, T; Seber, S; Telli, F; Teomete, M; Turhal, S; Yumuk, PF, 2014) |
| "Breast cancer is a heterogeneous disease with intrinsic molecular subtypes." | ( Bae, MS; Kim, KG; Moon, WK; Park, IA; Seo, M, 2015) |
| "Breast cancer is the second most lethal cancer in women." | ( Cao, Q; Chen, W; Dilsizian, V; Goloubeva, O; Hersl, J; Jenkins, J; Jones, L; La, H; Smith, M; Tkaczuk, K, 2014) |
| "Breast cancer is a leading cause of morbidity and mortality in women worldwide." | ( Alavi, HA; Attarian, H; Azargashb, E; Ebrahimi, A; Ghaderian, SM; Ghadyani, M; Kamalian, N; Mirfakhraie, R; Rafat, J; Rakhsha, A; Rezvani, H; Tabarestani, S, 2014) |
| "Breast cancer is one of the common tumors occurring in woman and despite treatment, the prognostic is poor." | ( Beira, FT; Braganhol, E; Campos, VF; Collares, T; da Silva, FA; Del Pino, FA; Gamaro, GD; Monte, LG; Pinto, LS; Prietsch, RF; Spanevello, RM, 2014) |
| "Most breast cancers are estrogen receptor-positive and treated with antiestrogens, but aberrant signaling networks can induce drug resistance." | ( Pasquale, EB; Riedl, SJ; Wallez, Y, 2014) |
| "Breast cancer is the second leading cause of cancer-related deaths in women." | ( Branson, OE; Chaney, SB; Cheney, CM; Freitas, MA; Harshman, SW; Hoover, ME; Huang, C; Huebner, K; Rosol, TJ; Shapiro, CL; Wysocki, VH, 2014) |
| "Breast cancer is among the most common malignancies that metastasize to the brain, with 15% to 20% of patients with metastatic breast cancer eventually developing brain metastases." | ( Allen, JE; Dicker, DT; El-Deiry, WS; Glantz, MJ; Patel, AS; Prabhu, VV; Sheehan, JM, 2014) |
| "Breast cancer is increasingly being detected at earlier stages, and partial breast irradiation for patients with low-risk-group tumor has come to be applied in the US and Europe as an alternative to whole-breast irradiation." | ( Akamatsu, H; Isobe, Y; Karasawa, K; Koba, Y; Ogata, R; Omatsu, T, 2014) |
| "Breast cancer is the most common type of cancer in women in many areas and is increasing found in developing countries, where the majority of cases are diagnosed in late stages." | ( Bae, KH; Cho, K; Choi, JS; Han, BS; Kamal, AH; Kim, SY; Kim, WK; Lee, SC, 2014) |
| "Breast cancer is a disease of cell cycle, and the dysfunction of cell cycle checkpoints plays a vital role in the occurrence and development of breast cancer." | ( Bai, J; Cheng, T; Hao, X; Hu, L; Hu, Y; Lee, MH; Li, C; Yuan, W; Zetterberg, A; Zhang, J; Zhang, S; Zhang, X, 2014) |
| "Breast cancer is the most common female malignant disease, and the second leading cause of cancer-related death in the United States." | ( Cai, Y; Chen, C; Chen, S; Huang, J; Lu, X; Wang, Z; Wu, Q; Yang, Q; Zhu, L, 2014) |
| "Multicentric breast cancer is often considered a contra-indication for sentinel lymph node (SLN) biopsy due to concerns with sensitivity and false negative rate." | ( Barneveld, PC; Bavelaar-Croon, CD; Bosscha, K; Contant, CM; de Roos, WK; van la Parra, RF, 2014) |
| "Breast cancer is a heterogeneous disease defined by both germline and somatic abnormalities." | ( Blum, JL; Byrski, T; Campone, M; Cullell-Young, M; Delaloge, S; Gonçalves, A; Kahatt, C; Lardelli, P; Lubinski, J; Nieto, A; Wolp-Diniz, R, 2014) |
| "Breast cancer is one of the most common tumors in females." | ( Cheng, TL; Ho, WY; Huang, PJ; Hung, JH; Lee, KH; Wang, CC; Wu, SJ, 2014) |
| "Breast cancer is increasingly reported in young premenopausal women in Asia." | ( Ng, CH; Rozita, AM; Taib, NA; Tiong, V; Yip, CH, 2014) |
| "In India, breast cancer is the leading malignancy among women in a majority of the cancer registries." | ( Kamalamma, L; Kurian, B; Quereshi, MA; Sreedevi, A, 2014) |
| "Breast cancer is one of the most prevalent cancers amongst women in the world." | ( Ahmed, A; Ahmed, SM; Bhatnagar, S; Gupta, R; Mishra, S; Rana, SP; Satija, A; Singh, SP, 2014) |
| "Breast cancer is the most common malignancy in women and the appearance of distant metastases produces the death in 98% of cases." | ( Flamini, MI; Gauna, GV; Nadin, BS; Sanchez, AM; Sottile, ML; Vargas-Roig, LM, 2014) |
| "Breast cancer is a major health problem worldwide." | ( Hu, C; Jiang, F; Li, Y; Li, Z; Mu, J; Ning, S; Si, L; Wang, X; Ye, X, 2015) |
| "Breast cancer is the most frequent cancer affecting women." | ( Beck, RC; Begnini, KR; Campos, VF; Collares, T; Dellagostin, OA; Guterres, SS; Leon, PM; Oliveira, CP; Pohlmann, AR; Schultze, E; Seixas, FK; Thurow, HS; Yurgel, VC, 2014) |
| "HER2-positive breast tumors are predominantly positive for CD24, suggesting that the expression of the two molecules is related." | ( Arima, Y; Hosonaga, M; Kohno, N; Saya, H; Sugihara, E, 2014) |
| "Breast cancer is a major health problem for women worldwide." | ( Ellenbogen, RG; Erickson, AE; Kievit, FM; Tsao, CT; Wang, K; Zhang, M, 2014) |
| "Breast cancer is the most common cancer in women." | ( Deng, F; Geng, S; Huang, C; Li, X; Liang, Z; Wu, J; Wu, R; Xie, C; Xie, W; Zhong, C; Zhu, J; Zhu, M; Zhu, W, 2014) |
| "Breast cancer is the second most common cause of cancer-related deaths in women." | ( Ong, JL; Roy, SS; Satsangi, A; Satsangi, RK; Vadlamudi, RK, 2014) |
| "The summary RR for breast cancer is 1." | ( Deng, Q; Fan, WY; Wang, WY; Wang, X; Yang, WS, 2014) |
| "Breast cancer is the most common cancer type." | ( Alizadeh, S; Babaknejad, N; Bahrami, S; Delpesheh, A; Hemati, F; Rahimifar, P; Sayehmiri, F; Sayehmiri, K, 2014) |
| "Breast cancer is the most common malignant cancer among women, both in Poland and worldwide." | ( Terlikowska, K; Terlikowski, S; Witkowska, A, 2014) |
| "Breast cancer is the most prevalent cancer among women." | ( Alavi, SE; Ebrahimi Shahmabadi, H; Koohi Moftakhari Esfahani, M; Movahedi, F, 2014) |
| "Its activity in breast cancer is currently being evaluated." | ( Harbeck, N; Hurvitz, SA; Shatsky, R, 2014) |
| "Breast cancer is the most common in women worldwide, with some 5-10% of all cases due to inherited mutations of BRCA1 and BRCA2 genes." | ( Ali, A; Aslam, B; Javed, I; Khaliq, T; Majeed, W; Muhammad, F; Raza, A, 2014) |
| "Since over 60% of breast cancers are estrogen receptor positive (ER+), many therapies have targeted the ER." | ( Hatkevich, T; Patel, YM; Ramos, J; Santos-Sanchez, I, 2014) |
| "Patients with breast cancer are classified as having cells that over-express the human epidermal growth factor receptor 2 (known as HER2-positive) or not (HER2-negative)." | ( Balduzzi, S; D'Amico, R; Guarneri, V; Mantarro, S; Moja, L; Pistotti, V; Tagliabue, L, 2014) |
| "Breast cancer is one of the most deadly diseases in women." | ( Chan, FL; Chen, S; Leung, LK; Li, F; Lin, SM; Wong, TY, 2014) |
| "Breast cancer is a neoplasm with the highest incidence and mortality rate among young women worldwide." | ( Camacho-Zavala, E; García-Castillo, V; González, GF; Jacobo-Herrera, NJ; Pérez-Plasencia, C; Urrutia, EL; Zentella-Dehesa, A, 2014) |
| "The breast cancer is globally one of the most important causes of cancer-related mortality for women." | ( Alacam, H; Bedir, A; Okuyucu, A; Ozdemir, T; Salis, O, 2014) |
| "Breast cancer is characterized by great molecular heterogeneity demonstrated, e." | ( Alsner, J; Kyndi, M; Myhre, S; Nord, S; Overgaard, J; Sørensen, FB; Sørlie, T; Tramm, T, 2014) |
| "Although breast cancer is one of the leading causes of death in women worldwide, there is an overall improvement in the survival of this patient population." | ( Goyal, V; Jassal, DS; Premecz, S; Saeed, MF; Singal, PK, 2014) |
| "Breast cancer is a devastating disease that results in approximately 40,000 deaths each year in the USA." | ( Chisholm, C; Deng, C; Huang, R; Lahusen, TJ; Li, C; Sakamuru, S; Thomas, CJ; Vazquez-Ortiz, G; Xia, M; Xu, X, 2014) |
| "Breast cancer is the most frequently diagnosed cancer in women in the United States." | ( Arumugam, A; Lakshmanaswamy, R; Lissner, EA, 2014) |
| "Breast cancer is the one of most common cancer in worldwide which accounts for high mortality rate." | ( Wang, C; Wang, H; Wu, N; Yu, J; Zhang, J, 2014) |
| "Breast cancer is the most common malignant diseases in women." | ( Chen, Q; He, H; Tao, S; Yue, W, 2014) |
| "Breast cancer is the most common malignancy that is believed to be largely under genetic control." | ( Ding, P; Ding, S; Sun, B; Yang, Y, 2015) |
| "Breast cancer is the most common female malignancy in the world." | ( Esfahani, A; Farrin, N; Jafarabadi, MA; Movassaghpourakbari, A; Ostadrahimi, A; Ziaei, JE, 2014) |
| "Lymph node-positive breast tumors are more likely to express COX2 than node-negative tumors." | ( Barron, TI; Bennett, K; Flahavan, EM; Sharp, L; Visvanathan, K, 2014) |
| "Breast cancer is a global public health problem and the most frequent cause of cancer death among women." | ( Andrade, Fde O; Conti, Ad; Dagli, ML; de Miranda, JX; Moreno, FS; Ong, TP, 2014) |
| "Breast cancer is the most common malignancy tumor amongst Malagasy women registered at the pathology unit of the "Institut Pasteur de Madagascar"." | ( Hasiniatsy, NR; Rabarikoto, HF; Rafaramino, F; Rakotoson, JL; Ranoharison, HD; Razafimanjato, N; Samison, LH; Vololonantenaina, CR, 2014) |
| "Breast cancer is the largest detected cancer amongst women in the US." | ( Chekmareva, MA; Chen, W; Desai, JP; Foran, DJ; Pandya, HJ; Roy, R, 2015) |
| "Breast cancer is the most common malignancy in women worldwide and remains a major cause of mortality, thus necessitating further therapeutic advancements." | ( Benveniste, EN; Gibson, SA; Gray, GK; McFarland, BC; Rowse, AL, 2014) |
| "Tamoxifen‑resistant breast cancer is a major clinical problem and new treatment strategies are highly warranted." | ( Lykkesfeldt, AE; Pedersen, AM; Thrane, S; Yde, CW, 2014) |
| "Breast cancer is the most common cause of deaths and the most frequently diagnosed cancer among women worldwide." | ( Al-Sadat, N; Aziz, NA; Dahlui, M; Farid, ND; Jamaludin, M, 2014) |
| "Breast cancer is a common cause of cancer mortality among women." | ( Abubakar, MB; Gan, SH; Wei, K, 2014) |
| "Endocrine-resistant breast cancer is a major clinical obstacle." | ( Gherezghiher, T; Jordan, VC; Maximov, PY; Michalsen, BT; Molloy, ME; Patel, H; Thatcher, GR; Tonetti, DA; White, BE; Xiong, R; Zhao, H, 2014) |
| "Breast cancer is the most common cancer among women in Malaysia, about one in 19 women being at risk." | ( Che, CC; Coomarasamy, JD; Suppayah, B, 2014) |
| "Breast cancer is a leading cause of death for women in the world." | ( Al-Kassas, R; Lasham, A; Madani, AU; Shelling, AN; Tharkar, P, 2015) |
| "Breast cancer is classified into three groups according to its expression of hormone/growth factor receptors: (i) estrogen receptor (ER) and progesterone receptor (PR)-positive; (ii) human epidermal growth factor receptor 2 (HER2)-positive; and (iii) ER, PR, and HER2-negative (triple-negative)." | ( Hirsch-Weil, D; Hong, S; Jaiswal, AS; Narayan, S; Proulx, ER, 2014) |
| "MHA associated with breast cancer is very rare, and is regarded as a disease with a poor prognosis." | ( Fujiyama, J; Fukuda, K; Kiuchi, J; Konishi, T; Masuyama, M; Morita, M; Nakashima, S; Umehara, S, 2014) |
| "Breast cancer is the most common malignancy in women worldwide." | ( Bai, W; Chen, L; Han, G; Hu, X; Li, Z; Luo, J; Sun, J; Wang, Y; Yang, X; Zhang, Y; Zhou, Y, 2014) |
| "Breast cancer is genetically heterogeneous, and recent studies have underlined a prominent contribution of epigenetics to the development of this disease." | ( Berg, T; Bock, C; Boidol, B; Colinge, J; Dürnberger, G; Kerzendorfer, C; Kralovics, R; Kubicek, S; Licciardello, MP; Müllner, MK; Nijman, SM; Penz, T; Schuster, M; Sdelci, S; Superti-Furga, G; Trefzer, C, 2015) |
| "Brain metastasis of breast cancer is an important clinical problem, with few therapeutic options and a poor prognosis." | ( Dewhurst, S; Feng, C; Gelbard, HA; Granger, M; Polesskaya, O; Rhoo, KH; Sur, J, 2014) |
| "Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer-related mortality in females worldwide." | ( Hu, W; Jiang, YH; Ma, N; Sui, CG; Zheng, RR, 2014) |
| "Breast cancer is the second leading cause of cancer deaths in women in the United States." | ( McCaskill, ML; Rogan, E; Thomas, RD, 2014) |
| "Breast cancer is still one of the leading diagnosed cancers in women today." | ( Abdullah, MP; Abu, N; Akhtar, MN; Alitheen, NB; Ho, WY; Lim, KL; Omar, AR; Sulaiman, MR; Yeap, SK; Zulfadli, AJ, 2014) |
| "Breast cancer is the most common malignancy in women worldwide and the second most common cancer in females in India." | ( Ghosh, S; Kotne, S; Rao, PB; Sarkar, S; Simhareddy, S; Turlapati, SP, 2014) |
| "Osteoporosis and breast cancer are common diseases in postmenopausal women." | ( Trémollieres, FA, 2014) |
| "Breast cancer is the leading cause of death in female cancer patients due to the lack of effective treatment for metastasis." | ( Fan, D; Hu, J; Iwanowycz, S; Jia, X; Saaoud, F; Wang, J; Wang, Q; Wang, Y; Yu, F, 2014) |
| "Breast cancer is a significant cause of death in women." | ( Ahn, S; Jung, D; Kim, S; Lee, D; Lee, H; Park, KH; Park, S; Wang, HY, 2014) |
| "About 70% of all breast cancers are estrogen receptor alpha positive (ER+) and are treated with antiestrogens." | ( Clarke, R; Cook, KL; Demas, DM; Eltayeb, AE; Facey, CO; Hilakivi-Clarke, LA; Schwartz-Roberts, JL; Shajahan-Haq, AN; Warri, AM, 2014) |
| "Breast cancer is the most common form of cancer in women and the leading cause of cancer death in American women, with over 207,090 new cases of invasive breast cancer in women and about 39,840 deaths from breast cancer in 2010." | ( Fancellu, G; Nicolin, V; Valentini, R, 2014) |
| "Breast cancer is the second leading cause of cancer‑related mortality in females worldwide." | ( Lu, J; Ma, R; Sun, D; Tang, J; Wang, L; Wu, J, 2015) |
| "Breast cancer is of particular interest given that increased inflammation within the subcutaneous mammary adipose tissue depot can alter the local tissue inflammatory microenvironment such that it resembles that of obese visceral adipose tissue." | ( De Boer, AA; Liddle, DM; Ma, DW; Monk, JM; Power, KA; Robinson, LE; Turk, HF, 2014) |
| "Breast cancer is one of the most known cancer types caused to the women around the world." | ( Chitrala, KN; Yeguvapalli, S, 2014) |
| "Breast cancer is the most common type of cancer affecting women in North America and Europe." | ( Pluchino, LA; Wang, HC, 2014) |
| "Breast cancer is one of the most common types of cancer worldwide." | ( Dai, K; Fan, Q; Li, H; Liu, G; Liu, X; Ouyang, Z; Qin, A; Qu, X; Tang, T; Yan, W; Zhai, Z, 2015) |
| "Breast cancer is the most frequent malignancy in women." | ( Bruzzone, A; Copsel, S; Davio, C; Galés, C; Gargiulo, L; Lüthy, IA; Rivero, EM; Sénard, JM, 2014) |
| "Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women, worldwide." | ( Arunakaran, J; Arunkamar, R; Balakrishnan, S; Bhat, FA; Brindha Mercy, A; Elumalai, P; Raja Singh, P; Sharmila, G, 2014) |
| "Breast cancer is the most frequently diagnosed cancer among women." | ( Abehsera, D; de Santiago, J; Panal, M; Revello, R; Sánchez-Mendez, JI; Zapardiel, I, 2015) |
| "Breast cancer is the most common type of malignancy among females." | ( Chen, BS; Feng, QZ; Huang, ZJ; Jiang, L; Luo, Q; Luo, WY; Wu, BL; You, J, 2015) |
| "Breast cancer is the leading cause of cancer-related death in women." | ( Song, GQ; Zhao, Y, 2015) |
| "Breast cancer is the most diagnosed cancer in women worldwide." | ( Hoek, JB; Zakhari, S, 2015) |
| "Breast cancer is a prominent cause of mortality in women worldwide, with about 2/3(rd) cases linked to hormone mediated malignancy itself." | ( Sharma, AK; Sharma, R; Zghair, AN, 2014) |
| "Breast cancer is a burden for western societies, and an increasing one in emerging economies, because of its high incidence and enormous psychological, social, sanitary and economic costs." | ( Aguirre, E; Alés-Martínez, JE; Andrés, R; Barnadas, A; Chacón, JI; Córdoba, O; Florián, J; Frau, A; González, S; Jara, C; Lluch Hernández, A; Plazaola, A; Ramos, M; Ruiz, A; Sánchez Rovira, P, 2015) |
| "Breast cancer is one of the most common malignancies, often with complicated etiology and poor clinical outcome." | ( Li, J; Liu, J; Liu, P; Ren, Y, 2015) |
| "Breast cancer is the leading cause of cancer related death in women." | ( Altomare, D; Carson, J; Creek, K; Davis, J; Enos, R; Fayad, R; McClellan, J; Murphy, E; Nagarkatti, M; Nagarkatti, P; Steiner, J, 2014) |
| "Breast cancer is the most common cancer in women worldwide." | ( Cuzick, J; Sestak, I, 2015) |
| "Basal-like breast cancer is an aggressive tumor subtype with a poor response to conventional therapies." | ( Callari, M; Cargnelutti, M; Carollo, R; Cimino, D; Cordova, A; Daidone, MG; Giammona, A; Giordano, S; Iovino, F; Mangiapane, LR; Montemurro, F; Petrelli, A; Stassi, G; Taverna, D; Todaro, M, 2015) |
| "Breast cancer is the most common type of female cancer." | ( Ardestani, SK; Asadipour, A; Dadgar, A; Firoozpour, L; Foroumadi, A; Moshafi, MH; Pordeli, M; Rodaki, A; Safavi, M; Vosooghi, M, 2014) |
| "Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer-related death among women worldwide." | ( Elsayed, GH; Yahya, SM, 2015) |
| "Breast cancer is the most common cancer affecting women in China and the world." | ( Chen, WL; Ji, YJ; Jiang, K; Li, Q; Lu, Q; Xue, XH, 2015) |
| "Breast cancer is the most common female malignancies in the world which seriously impacts the female health." | ( Chen, Q; He, HF; Tao, SF, 2015) |
| "Breast cancer is the second leading cause of malignant death among women." | ( Ackerman, WE; Blackstone, BN; Ghadiali, SN; Kniss, DA; Li, R; Powell, HM, 2015) |
| "Breast cancer is the cause of considerable morbidity and mortality in women." | ( Camargo, MS; Cuesta-Rubio, O; Espanha, LG; Nogueira, CH; Oliveira, MT; Oliveira-Höhne, AP; Resende, FA; Santoni, MM; Varanda, EA; Vilegas, W, 2015) |
| "Breast cancer is the most common female cancer in Kerala, South India, with the incidence increasing in the past two decades, also in young women." | ( Manjula, VD; Poothiode, U; Varughese, AA, 2015) |
| "Breast cancer is the most frequent oncological disease among women." | ( Čereškevičius, D; Jankauskaitė, R; Juozaitytė, E; Savukaitytė, A; Šepetauskienė, E; Ugenskienė, R, 2015) |
| "Chemoresistance of breast cancer is a growing problem and still a major clinical obstacle to successful treatment in clinical patients." | ( Dai, L; Fu, Z; Ji, C; Lv, J; Lv, M; Pan, B; Shi, M; Xia, K; Xie, H; Xu, P, 2015) |
| "Breast cancer is one of the most common cancers and the second leading cause of cancer death among women worldwide." | ( Bidmeshki Pour, A; Darakhshan, S; Ghanbari, A; Gholami Rad, F, 2015) |
| "Breast cancer is the most vicious killer for women's health, while metastasis is the main culprit, which leads to failure of treatment by increasing relapse rate." | ( Chen, L; Chen, Y; Gu, W; Huang, Y; Li, Y; Meng, Q; Su, J; Sun, H; Tang, S; Xu, M; Yin, Q; Yu, H; Zhang, Z, 2015) |
| "Breast cancer is a major form of cancer, with a high mortality rate in women." | ( Afraidooni, L; Akbarzadeh, A; Darabi, M; Daraee, H; Eatemadi, A; Eskandari, L; Mellatyar, H; Zarghami, N, 2016) |
| "Breast cancer is the most common cause of cancer death among women (522,000 deaths in 2012)." | ( ElMarzouky, MS; Marzouk, SA; Nassar, YH; Omar, HS; Shaker, OG, 2015) |
| "Breast cancer is a prevalent malignancy among women, especially in developing countries." | ( Baradaran, B; Hosseini, BA; Karami, H; Kazemi, T; Orangi, M; Pasdaran, A; Shanehbandi, D, 2015) |
| "The metastasis of breast cancer is the leading cause of cancer death in women." | ( Chen, X; Li, M; Li, Q; Lv, S; Tang, Z; Zhang, Y, 2015) |
| "Breast carcinoma is the leading cause of cancer-associated mortality in female individuals worldwide." | ( Du, YY; Pan, YY; Shen, YY; Yuan, Y, 2015) |
| "Breast cancer is associated with high levels of incidence, morbidity and mortality; therefore, the identification of effective chemopreventive strategies is crucial." | ( Du, Y; Pan, Y; Shen, Y; Zhang, Y, 2015) |
| "Breast cancer is one of the most common causes of the death among women worldwide." | ( Daglia, M; Habtemariam, S; Nabavi, SF; Nabavi, SM, 2015) |
| "Breast cancer is one of the most common and lethal cancers in women." | ( Bao, JL; Pan, YH; Shan, M; Wang, C; Xu, M; Zhao, LM, 2015) |
| "Breast cancer is the most common cancer and the second principal cause of cancer deaths among women worldwide, including Malaysia." | ( Akhtari-Zavare, M; Ghanbari-Baghestan, A; Khaniki, H; Latiff, LA, 2015) |
| "Breast cancer is a common cancer leading to many deaths among females." | ( Chou, WY; Chuang, KH; Kao, PH; Lee, YH; Lin, YY; Sun, D; Wang, HW; Wu, YL, 2015) |
| "Breast cancer is one of the most prevalent types of malignant tumor." | ( Cai, J; Chen, S; Dong, W; Dong, Y; Hu, S; Lu, J; Xing, J; Zhang, W; Zheng, X, 2015) |
| "Hormone-dependent breast cancer is the first example of cancer treated by targeted therapy for more than 30 years." | ( Bachelot, T; Cohen, P; Heudel, PE; Maudelonde, T; Tredan, O; Treilleux, I; Vilquin, P, 2015) |
| "Breast carcinoma is the most common female cancer with considerable metastatic potential." | ( Hu, M; Jie, H; Lei, Q; Li, Y; Liu, C; Shen, G; Song, X; Wang, D; Wei, Y; Xia, Y; Xie, Y; Xiong, Y; Yang, F; Ye, T; Yu, L; Zeng, A; Zhu, Y; Zuo, Z, 2015) |
| "Breast cancer is the most common type of cancer in women and represents a major issue in public health." | ( Español, AJ; Rojo, D; Salem, A; Sales, ME, 2015) |
| "Breast cancer is the most frequently occurring cancer among women throughout the world." | ( Akbarzadeh, A; Badrzadeh, F; Darabi, M; Mirakabad, FS; Rahmati-Yamchi, M; Salehi, R; Taheri-Anganeh, M; Zarghami, N; Zeighamian, V, 2016) |
| "The development of breast cancer is linked to the loss of estrogen receptor (ER) during the course of tumor progression, resulting in loss of responsiveness to hormonal treatment." | ( Hedges, RA; Kadlubar, SA; Kieber-Emmons, T; Monzavi-Karbassi, B; Rogers, LJ; Yao-Borengasser, A, 2015) |
| "Breast cancer is the most common malignancy in females." | ( Greenspan, D; Lebron, L; Pandit-Taskar, N, 2015) |
| "Breast cancer is one of the major causes of cancer-related deaths in the world today." | ( Abdullah, MP; Abu, N; Akhtar, MN; Alitheen, NB; Kee, BB; Lim, KL; Mohamed, NE; Omar, AR; Yeap, SK; Zulfadli, AJ, 2015) |
| "Metastasis of breast cancer is promoted by epithelial-mesenchymal transition (EMT)." | ( Cui, YH; Kim, IG; Kim, RK; Kim, YH; Lee, SJ; Suh, Y; Uddin, N; Yoo, KC, 2015) |
| "Chemoprevention of breast cancer is feasible with the use of non-toxic phytochemicals from edible and medicinal plants." | ( Sehrawat, A; Singh, SV, 2016) |
| "Breast cancer is the major cause of cancer death in women worldwide." | ( Chung, WY; Kim, HJ; Kim, KR; Lee, SK; Ma, GT; Park, KK, 2015) |
| "Breast cancer is the most common type of malignant tumor in women." | ( Cai, S; Chen, J; Chen, M; Chen, Q; Li, G; Wu, D; Xia, Y; Zhang, J; Zhang, X, 2015) |
| "Breast cancer is the second leading cause of cancer-related mortality in women." | ( Connor, MK; Riddell, MC; Shpilberg, Y, 2015) |
| "Human breast cancer is a major cause of global morbidity and mortality in women and it is a process that involves numerous molecular and cellular alterations attributed to environmental substances and agents such as hormones." | ( Calaf, GM; Ponce-Cusi, R, 2015) |
| "Breast cancer is considered the most common cancer for women worldwide and it is now the second leading cause of cancer-related deaths among females in the world." | ( Arra, C; Barbieri, A; Bimonte, S; D'Aiuto, M; Izzo, F; Luciano, A; Palma, G; Rea, D, 2015) |
| "Breast cancer is the second leading cause of cancer-related death in women." | ( Devulapally, R; Paulmurugan, R; Sekar, TV, 2015) |
| "Breast cancer is the most frequent primary site of metastasis to the uterine corpus, with invasive lobular carcinoma more likely to spread to gynecologic organs than invasive ductal carcinoma." | ( Akagi, K; Hayasaka, A; Igeta, S; Ishigaki, N; Iwahashi, H; Kudo, T; Makino, H; Matsuura, R; Sakurada, J; Shima, T; Suzuki, H; Toyoshima, M; Yoshinaga, K, 2015) |
| "Luminal B breast cancers are associated with early relapse following endocrine therapy and often exhibit a poor prognosis that is similar to that of the aggressive basal-like breast cancers." | ( Maggi, LB; Weber, JD, 2015) |
| "Breast cancer is the most common cancer in women worldwide." | ( Koyakutty, M; Menon, D; Mony, U; Narayanan, S; Paul-Prasanth, B; Vijaykumar, DK, 2015) |
| "Among women, breast cancer is most prevalent and the state occupies fifth position globally." | ( Ghatak, S; Lallawmzuali, D; Lalrohlui, F; Pautu, JL; Senthil Kumar, N; Thapa, S; Zohmingthanga, J, 2016) |
| "Though breast cancer is the most common cancer among women in Kerala, India, epidemiological data on breast cancer in the state is largely lacking." | ( Chirukandath, R; Culas, TB; Kuttappan, SV; Rajan, G; Vettuparambil, A; Vijayan, SM, 2015) |
| "Breast cancer is one of the most common cancers affecting women globally." | ( Dai, XL; Feng, YZ; Han, ZB; Liu, YF; Qiu, J; Yang, YT, 2015) |
| "Breast cancer is one of the most significant causes of female cancer death worldwide." | ( Chen, G; Li, L; Shi, Y; Sun, L; Wei, W; Zheng, D, 2015) |
| "Worldwide, breast cancer is the most common malignant neoplasm and the second most common cause of cancer death in women." | ( Alipour, S; Eskandari, A; Jafari-Adli, S, 2015) |
| "Breast cancer is a common cancer affecting women in Malaysia and the use of complementary/ alternative medicine (CAM) has been associated with delays in getting treatment." | ( Hashim, H; Hwa, YS; Knight, A, 2015) |
| "Breast cancer is the leading cause of cancer deaths among women." | ( Goins, B; Ong, JL; Roy, SS; Satsangi, A; Satsangi, RK; Tolcher, AW; Vadlamudi, RK, 2015) |
| "Breast cancer is the most common cancer in women." | ( Gunaratna, MJ; Hua, DH; Li, J; Madiyar, F; Nguyen, TA; Prior, AM; Shishido, S; Swisher, LZ, 2015) |
| "Breast cancer is the second most common cancer worldwide, and the leading cause of cancer death in women." | ( Martinel Lamas, DJ; Medina, VA; Rivera, ES, 2015) |
| "Breast cancer is the leading cause of cancer deaths in women world-wide." | ( Fadzli, F; Jamaris, S; Rahmat, K; See, MH; Taib, NA; Tan, GH; Teh, YC; Westerhout, CJ; Yip, CH, 2015) |
| "Breast cancer is the most frequently occurring cancer in women and the most common cause of cancer death worldwide." | ( Akhtari-Zavare, M; Ismail, IZ; Juni, MH; Latiff, LA; Said, SM, 2015) |
| "Breast cancer is one of the most feared diseases among women and it could induce the development of psychological disorders like anxiety and depression." | ( Baharom, N; Ghazi, HF; Hassan, MR; Mohd Mujar, NM; Samsuri, MF; Shah, SA, 2015) |
| "Breast cancer is a leading cause of death in women and with an increasing worldwide incidence." | ( Li, C; Song, Z; Wang, X; Wang, Y; Zhang, D, 2015) |
| "Breast cancer is one of the most common cancers affecting women worldwide." | ( Chen, K; Duan, WM; Gong, FR; Gui, Q; Li, DM; Li, W; Lian, L; Liu, L; Shen, M; Tao, M; Wang, WJ; Wu, MY; Xu, MD; Zhu, J, 2015) |
| "Breast cancer is the leading cause of cancer death among women worldwide especially in a developing country like India." | ( Mahanta, LB; Nath, DC; Rajbongshi, N; Sarma, JD, 2015) |
| "Breast cancer is a menacing cancer, primarily affecting women." | ( Dubey, AK; Gupta, U; Jain, S, 2015) |
| "Although breast cancer is a heterogeneous disease, this is the first study assessing pre-diagnostic levels of free triiodothyronine (fT3), free thyroxine (fT4), thyroid-stimulating hormone (TSH), and thyroid peroxidase antibodies (TPO-Ab) in relation to breast cancer subgroups and aggressiveness." | ( Borgquist, S; Brandt, J; Manjer, J, 2015) |
| "Breast cancer is a disease characterised by both oxidative reactions and inflammation." | ( Carioca, AA; Damasceno, NR; Ellery, TH; Latorre, MR; Luzia, LA; Rondó, PH; Verde, SM, 2015) |
| "Breast cancer is the leading cause of death among women worldwide." | ( Bal de Kier Joffé, ED; Berardi, DE; Campodónico, PB; Diaz Bessone, MI; Farias, EF; Flumian, C; Motter, AN; Todaro, LB; Urtreger, AJ, 2015) |
| "Breast cancer is one of the most common malignancies and a major cause of cancer-related mortality all over the world." | ( Liu, D; Long, J; Ou, C; Xia, H; Zhu, Y, 2015) |
| "Increased risk of breast cancer is a critical side effect associated with the use of a menopausal hormone therapy (MHT)." | ( Arnal, JF; Communal, L; Foidart, JM; Gérard, C; Gompel, A; Lenfant, F; Mestdagt, M; Noel, A; Péqueux, C; Silva, E; Tskitishvili, E, 2015) |
| "Basal phenotype breast cancer is one of the most aggressive breast cancers that frequently metastasize to brain." | ( Chen, Q; Chen, X; Gainey, LO; Hou, A; Nanes, MS; Xiao, J; Xie, M; You, S; Zhou, L, 2015) |
| "Breast cancer is the leading cause of death in women worldwide." | ( Bañuelos-García, JI; Carranza-Rosales, P; Carranza-Torres, IE; Coronado-Martínez, C; Guzmán-Delgado, NE; Morán-Martínez, J; Viveros-Valdez, E, 2015) |
| "Breast cancer is the most prevalent cancer type worldwide." | ( Hodgins, SJ; Kiely, M; Kiely, PA; Merrigan, BA; O'Connor, EM; Tormey, S, 2015) |
| "Breast cancer is the leading cause of death among women, with approximately 1 million diagnoses annually." | ( Cheng, A; Kou, X; Li, J; Xue, Z; Yu, W; Zhang, Z; Zhou, F, 2015) |
| "Breast cancer is the most common form of cancer and the second leading cause of cancer deaths among women in the USA." | ( Sardesai, SD; Storniolo, AM, 2015) |
| "Breast cancer is the second leading cause of cancer death in women worldwide and the third most common cancer in India." | ( Chaudhary, A; Deshpande, R; Kaul-Ghanekar, R; Ketkar, M; Mansara, P; Shinde, K, 2015) |
| "Breast cancer is the most common cancer among females." | ( Beer, B; Egeter, J; Fuchs, D; Gamper, E; Geisler, S; Hubalek, M; Hüfner, K; Kohl, C; Meraner, V; Oberguggenberger, A; Sperner-Unterweger, B, 2015) |
| "Nearly 25% of all breast cancer is characterized by overexpression of HER2 (human epidermal growth factor receptor 2) which leads to overactivation of prosurvival signal transduction pathways, especially through Akt-mTOR-S6K kinases, and results in enhanced proliferation, migration, induction of angiogenesis, and apoptosis inhibition." | ( Herman-Antosiewicz, A; Kaczyńska, A; Świerczyńska, J, 2015) |
| "Breast cancer is the most common cancer for women and is a major cause of mortality in women." | ( Choi, HS; Hong, SH; Kim, SR; Ko, SG; Ku, JM; Seo, HS; Shin, YC, 2015) |
| "Breast cancer is a heterogeneous disease, characterized by various molecular phenotypes that correlate with different prognosis and response to treatments." | ( De Iuliis, F; Salerno, G; Scarpa, S; Taglieri, L, 2015) |
| "Breast cancer is the most common cancer in female population." | ( Sun, X; Wang, C; Wang, H; Wang, K; Wang, Y; Yang, F, 2016) |
| "Breast cancer is a heterogeneous disease and new clinical markers are needed to individualise disease management and therapy further." | ( Dutta, C; Emin, S; Fornander, T; Karlsson, E; Nordenskjöld, B; Pérez-Tenorio, G; Stål, O; Veenstra, C, 2015) |
| "Breast cancer is the leading cause of cancer-related death among women worldwide." | ( Kim, JY; Kim, KH; Kwak, JH; Pyo, S, 2015) |
| "Breast cancer is the most common cancer and the leading cause of cancer mortality among women of all ethnic and age groups in Malaysia." | ( Khan, AH; Khan, TM; Leong, JP; Ming, LC, 2015) |
| "Breast cancer is a leading cause of death for women." | ( Nadal-Serrano, M; Oliver, J; Pons, DG; Roca, P; Sastre-Serra, J; Torrens-Mas, M, 2015) |
| "Breast cancer is the most common female cancer worldwide including India, where advanced stages at diagnosis, and rising incidence and mortality rates, make it essential to understand cancer literacy in women." | ( Dhillon, PK; Gupta, A; Shridhar, K, 2015) |
| "Breast cancer is a leading killer of women worldwide." | ( Burgess, C; Duan, W; He, ZX; Pan, ST; Qiu, JX; Shumyak, SP; Yang, TX; Yin, JJ; Zhang, XJ; Zhou, SF; Zhou, ZW, 2015) |
| "Breast cancer is a hormone-dependent cancer and usually treated with endocrine therapy using aromatase inhibitors or anti-estrogens such as tamoxifen." | ( Berezikov, E; Horie-Inoue, K; Ikeda, K; Inoue, S; Mano, H; Osaki, A; Saeki, T; Sato, W; Shigekawa, T; Suzuki, T; Ueno, T, 2015) |
| "Breast cancer is highly metastatic to bone and drives bone turnover that further promotes cancer engraftment and expansion, the so-called vicious cycle." | ( Vikulina, T; Weitzmann, MN; Yamaguchi, M, 2015) |
| "Breast cancer is the most common cause of death among women." | ( Li, X; Li, Y; Qu, X; Wang, C; Wang, W; Wei, Z; Xiang, F; Zhao, J; Zhou, X, 2015) |
| "Breast cancer is the most common type of cancer among women worldwide." | ( Bazargani, YT; de Boer, A; Leufkens, HG; Mantel-Teeuwisse, AK; Schellens, JH, 2015) |
| "Breast cancer is a heterogeneous disease that can be subdivided into clinical, histopathological and molecular subtypes (luminal A-like, luminal B-like/HER2-negative, luminal B-like/HER2-positive, HER2-positive, and triple-negative)." | ( Berdasco, M; Blanco-Luquin, I; Coca, V; Cordoba, A; De La Cruz, S; Escors, D; Guerrero-Setas, D; Ibañez, B; Illarramendi, JJ; Jauregui, I; Kochan, G; Lera, JM; Liechtenstein, T; Perez-Janices, N; Torrea, N; Vicente-Garcia, F, 2015) |
| "Breast cancer is the second most common cancer worldwide and the leading cause of cancer death in women, with incidence rates that continue to rise." | ( McCabe, CJ; Poole, VL, 2015) |
| "Breast cancer is the most common type of tumor in female and chemoresistance has been a major clinical obstacle to the treatment in clinical patients." | ( Fu, Z; Huang, L; Li, W; Lu, C; Lv, M; Lv, S; Ma, J; Wang, L; Wu, X; Xu, P; Yin, H; Zhou, Q, 2015) |
| "Breast cancer is the most frequent neoplasia in women and is responsible for approximately 13." | ( Bañales, JM; Becerril, JL; Benítez, JG; Juárez, JJ; Navarro, MD; Zerón, HM, 2015) |
| "Breast cancer is increasing among young women in Tunisia." | ( Choura, M; Daoud, J; Frikha, M; Hadiji-Abbes, N; Khabir, A; Mokdad-Gargouri, R; Sellami-Boudawara, T; Trifa, F, 2015) |
| "Breast cancer is a leading malignancy affecting the female population worldwide." | ( Bellahcène, A; Bianchi, E; Blomme, A; Castronovo, V; Costanza, B; Cusumano, PG; Delvenne, P; Di Valentin, E; Drion, P; Gofflot, S; Jerusalem, G; Lifrange, E; Maris, P; Maweja, S; Palacios, AP; Trombino, GE; Turtoi, A, 2015) |
| "Breast cancer is the leading cause of cancer deaths among women of all ages worldwide." | ( Chakraborty, S; Chakravarty, R; Dash, A, 2015) |
| "Breast cancer is a major health problem in both developing and developed countries." | ( Al Sheeha, M; Omran, OM, 2015) |
| "Breast cancer is one of the most common cancers and is the second leading cause of cancer mortality in women worldwide." | ( He, W; Jiang, B; Lau, HT; Li, X; Liang, Y; Ma, X; Nie, F; Xun, H, 2016) |
| "Sporadic breast cancer is frequently associated with aberrant DNA methylation patterns that are reversible and responsive to environmental factors, including diet." | ( Cebula-Obrzut, B; Fabianowska-Majewska, K; Kaufman-Szymczyk, A; Lubecka-Pietruszewska, K; Smolewski, P; Stefanska, B, 2015) |
| "Breast cancer is the major cause of cancer death for women worldwide." | ( Shim, Y; Song, JM, 2015) |
| "Breast cancer is characterized by molecular heterogeneity, and four major breast cancer subtypes have been identified, each characterized by significant differences in survival, prognosis, and response to therapy." | ( De Iuliis, F; Giantulli, S; Giuffrida, A; Milana, B; Rubinacci, G; Salerno, G; Scarpa, S; Silvestri, I; Taglieri, L; Terella, F, 2016) |
| "About 50-70% of breast cancers are estrogen receptor α (ERα) positive and most of them are sensitive to endocrine therapy including tamoxifen." | ( Chu, J; Gong, C; Hu, P; Liu, B; Liu, Q; Liu, Y; Lv, X; Song, E; Su, F; Sun, L; Wu, Y; Zhu, Y, 2015) |
| "Breast cancer is a disease with an increasing incidence, and it originates from several factors." | ( Habánová, M; Predná, L; Sláviková, E; Wyka, J, 2015) |
| "In Malaysia, breast cancer is the first cancer among females regardness of race." | ( Akhtari-Zavare, M; Ismail, IZ; Juni, MH; Latiff, LA; Said, SM, 2015) |
| "Breast cancer is the most common type of cancer among women and the survival of patients affected by it is increasing, mainly due to several new approaches in early diagnosis and more effective treatments." | ( da Cunha Bianchi, PK; Gebrim, LH; Kfoury, JR; Salvadori, ML; Silva, RS, 2015) |
| "Breast cancer is the most common malignancy in women, and was the second highest cause of mortality in women in 2013." | ( Liu, C; Liu, Y; Meng, C; Wu, F, 2015) |
| "Breast cancer is the most common cause of female cancer-associated mortality." | ( Hu, S; Huang, L; Meng, L; Sun, H; Xu, Y; Zhang, W, 2015) |
| "Because breast cancer is an angiogenesis-dependent type of malignancy, we evaluated the clinical acceptability of breast tissue images produced using our first prototype photoacoustic mammography (PAM) system in patients with known cancer." | ( Asao, Y; Fakhrejahani, E; Haga, H; Hashizume, Y; Kanao, S; Kataoka, M; Kitai, T; Mikami, Y; Shiina, T; Sugie, T; Takada, M; Togashi, K; Toi, M; Torii, M; Yamaga, I, 2015) |
| "Although breast cancer is the most prevalent cancer in India, there is no organised national breast cancer screening programme." | ( Gangane, N; Ng, N; Sebastian, MS, 2015) |
| "Around 60-80% of all breast tumors are estrogen receptor-positive." | ( Amaral, C; Correia-da-Silva, G; da Silva, ET; Lopes, A; Roleira, FM; Teixeira, N; Varela, CL, 2015) |
| "Breast cancer is the leading cause of cancer-related deaths among women." | ( Alayev, A; Berger, SM; Cuesta, R; Holz, MK; Salamon, RS; Schwartz, NS; Snyder, RB, 2016) |
| "Breast cancer is the most fatal malignant cancer among women, the conventional therapeutic modalities of it are limited." | ( Dong, L; Gao, L; Li, H; Liu, C; Sun, Z; Wang, Q; Wang, X, 2015) |
| "Breast cancer is the most common type of female cancer." | ( Bae, HS; Joo, J; Jun, SY; Jung, SY; Kim, SI; Lee, ES; Lee, Y; Lim, MC; Son, Y; Yun, S, 2015) |
| "Breast cancer is the commonest form of cancer in women, but successful treatment is confounded by the heterogeneous nature of breast tumours: Effective treatments exist for hormone-sensitive tumours, but triple-negative breast cancer results in poor survival." | ( Alasmael, N; Meira, LB; Mohan, R; Plant, NJ; Swales, KE, 2016) |
| "Breast cancer is the most common cancer among women worldwide, including Malaysia." | ( Akhtari-Zavare, M; Ismail, IZ; Juni, MH; Lattif, LA; Md Said, S, 2015) |
| "Breast cancer is believed to result from the interplay of genetic and non-genetic risk factors, and individual genetic variation may influence the efficacy of chemotherapy." | ( Fan, T; Fan, Z; Li, J; Lin, B; Ouyang, T; Wang, T; Wu, L; Xie, Y; Yao, L; Yin, CC; Zhang, H, 2016) |
| "A majority of breast cancers are driven by estrogen via estrogen receptor-α (ERα)." | ( AlTahan, A; Baban, D; Bridges, E; Buffa, FM; Davidoff, AM; Harris, AL; Interiano, RB; Jones, DT; Li, JL; Nicholson, R; Qu, C; Ragoussis, J; Vogt, N; Yang, J, 2015) |
| "Breast cancer is a major cause of cancer death among women." | ( Bao, M; Cao, Z; Du, L; He, J; Qian, H; Zhang, B; Zhou, Q, 2016) |
| "Breast cancer is one of the most common cancers among women with high mortality and morbidity." | ( Chu, P; Guo, C; Han, G; Hang, H; Li, X; Lin, Y; Liu, S; Peng, J; Sun, B; Sun, Z; Tang, Z; Wang, S; Wu, J; Yang, C; Yang, N; Zhao, L, 2016) |
| "Breast cancer is a leading cause of death among females worldwide." | ( Dong, T; Dong, Y; Guo, M; Herman, JG; van Engeland, M; Zhang, M; Zhong, G, 2015) |
| "Breast cancer is the most common cancer in women globally." | ( Byun, HJ; Darvin, P; Joung, YH; Kang, DY; Sp, N; Yang, YM; Yoo, YB, 2016) |
| "Women with breast cancer are at increased risk of developing skin cancer." | ( Andersson, M; Frederiksen, K; Kjaer, SK; Mellemkjaer, L; Praestegaard, C; Steding-Jensen, M, 2016) |
| "Breast cancer is a heterogeneous disease comprising different biological subtypes." | ( Bartsch, R; Gnant, M; Steger, GG, 2016) |
| "Almost 70% of breast cancers are estrogen receptor α (ERα) positive." | ( Carlson, K; Delgado-Rivera, L; Gutgesell, LM; Katzenellenbogen, JA; Martin, T; Moore, TW; Patel, HK; Pham, TND; Thatcher, GRJ; Tonetti, DA; Xiong, R; Zhao, H; Zhao, J, 2016) |
| "Breast cancer is the leading site of new, non-skin, cancers in females in the United States, and possible factors that may modulate breast cancer risk need to be identified." | ( Adams, SA; Bennett, CL; Hebert, JR; Orekoya, O; Porter, N; Samson, M; Steck, SE, 2016) |
| "Breast cancer is the second most cause of death (1." | ( Paul, S; Shahi, UP; Solanki, PP; Srikrishna, S, 2015) |
| "Globally, breast cancer is the most frequently diagnosed cancer among women." | ( Bishayee, A; Biswas, J; Sarkar, N; Sinha, D, 2016) |
| "Breast cancer is a highly malignant carcinoma and most deaths of breast cancer are caused by metastasis." | ( Chang, LS; Fu, YS; Lin, SR; Tsai, PC, 2016) |
| "Breast cancer is the most common gynecologic tumor globally that threatens women's health." | ( Gong, Y; Hao, XY; Li, BJ; Ren, GH, 2015) |
| "Breast cancer is one of the most common cancers in women worldwide." | ( Hsieh, CC; Huang, YS, 2016) |
| "Breast cancer is the most commonly occurring cancer among women." | ( Choghaei, E; Falahati, M; Hasanpour, M; Hashemi, ZS; Khamisipour, G; Mossahebi-Mohammadi, M; Naeimi, B; Shamsian, S; Tahmasebi, R, 2016) |
| "Breast cancer is the second leading cause of cancer death among women and the median survival of metastatic breast cancer (MBC) has remained, for many decades, at two to three years after diagnosis." | ( Aseyev, O; Cardoso, F; Ribeiro, JM, 2016) |
| "Drug resistance in breast cancer is the major obstacle to effective treatment with chemotherapy." | ( Bartlett, JM; Boutros, PC; Braunstein, M; Kalatskaya, I; Krzyzanowski, PM; Liao, L; Lobo, N; Lyttle, N; Marcellus, R; Spears, M; Stein, LD; Taylor, KJ; Twelves, CJ; Yao, CQ, 2016) |
| "Advanced breast cancer is incurable for most patients with limited therapeutic options." | ( Cortés, J; López-Miranda, E, 2016) |
| "Breast cancer is one of the most common types of malignancies in females worldwide." | ( Elkhoely, AA; Kabel, AM, 2016) |
| "However, most breast tumors are eventually resistant to tamoxifen therapy." | ( Wang, ZY; Yin, L, 2016) |
| "Breast cancer is the most frequently diagnosed cancer in women, and one of the leading causes of cancer-related deaths worldwide." | ( Azad, N; Iyer, AK; Muni, T; Venkatadri, R; Yakisich, JS, 2016) |
| "Breast cancer is the most common malignancy among women worldwide." | ( Crisóstomo, J; Gomes, AL; Gomes, M; Letra, L; Matafome, P; Patrício, M; Santos, L; Santos-Silva, D; Sarmento-Ribeiro, AB; Seiça, R, 2016) |
| "HER2-positive breast cancer is heterogeneous." | ( Baselga, J; de Haas, SL; Guardino, AE; Huober, J; Lewis Phillips, GD; Olsen, S; Pegram, MD; Ro, J; Samant, MK; Verma, S, 2016) |
| "Breast cancer is the most common type of cancer affecting Malaysian women." | ( Chong, ET; Chua, KH; Chuah, JA; Goh, LP; Lee, PC; See, EU, 2016) |
| "Breast cancer is the most common nondermatologic malignancy among women in the United States, among which endocrine receptor-positive breast cancer accounts for up to 80%." | ( Gius, D; O'Brien, J; Santa-Maria, CA; Zhu, Y; Zou, X, 2016) |
| "Breast cancer is a hormone-dependent disease in which estrogen signaling targeting drugs fail in about 10 % due to resistance." | ( Alami, M; Chabbert-Buffet, N; Cherbonnier, C; Esber, N; Fagart, J; Hamze, A; Lombès, M; Loosfelt, H; Resche-Rigon, M, 2016) |
| "Breast cancer is the most common cancer among women in worldwide, especially in developing countries." | ( Baghbani, E; Baradaran, B; Goldar, S; Khaze, V; Mansoori, B; Mohammadi, A; Mohammadnejad, L; Shanehbandi, D, 2016) |
| "Breast cancer is the leading cause of cancer death in women." | ( Azami, S; Dehghankelishadi, P; Dorkoosh, FA; Gholami, M; Mahdavi, M; Ravar, F; Saadat, E, 2016) |
| "Breast cancer is a public health concern worldwide." | ( Abdalla, F; Bhat, HK; Bhat, NK; Chatterjee, A; Dandawate, P; Padhye, S; Ronghe, A; Singh, B, 2016) |
| "Breast cancer is rare in male patients." | ( Beckers, A; Bours, V; Corman, V; Daly, AF; Dassy, S; Manto, F; Potorac, I; Segers, K; Thiry, A, 2016) |
| "Breast cancer is the most common and deadly cancer among women worldwide." | ( Christoforou, N; Lee, S; Rizk, N, 2016) |
| "Breast cancer is the most common type of cancer with high incidence in women." | ( Fan, L; Ming, J; Zhao, F; Zhou, Y, 2016) |
| "Breast cancer is the most frequent malignancy in women." | ( Arana, MR; Catania, VA; Rigalli, JP; Ruiz, ML; Theile, D; Tocchetti, GN; Villanueva, SS; Weiss, J, 2016) |
| "Worldwide, breast cancer is the most common cancer among women and is a leading cause of cancer death." | ( Ahmad, I; Jain, S; Javid, J; Kaza, R; Khurana, N; Masroor, M; Mir, R; Nandi, K; Ray, PC; Saxena, A; Yadav, P; Zuberi, M, 2016) |
| "This type of breast cancer is more aggressive and tends to reoccur more often than HER2-negative breast cancer." | ( Adams, DJ; Bansal, V; Kulhari, H; Kuncha, M; Naidu, VGM; Pooja, D; Shrivastava, S; Sistla, R, 2016) |
| "Breast cancer is a major cause of global mortality in women." | ( Calaf, GM; Gallardo, M, 2016) |
| "Breast cancer is considered as an increasing major life-threatening concern among the malignancies encountered globally in females." | ( Banerjee, M; Bera, R; Chakraborty, B; Chattopadhyay, S; Choudhuri, T; Kumar, S; Mukherjee, SK, 2016) |
| "Basal-like breast cancers are highly aggressive malignancies associated with very poor prognosis." | ( Blancafort, P; Evans, CW; Ho, D; Iyer, KS; Ormonde, CF; Rashwan, R; Singh, R; Sorolla, A; Wang, E, 2016) |
| "Breast cancer is the major cause of cancer-related death in women." | ( Flamini, MI; Neira, FJ; Sanchez, AM; Shortrede, JE; Uzair, ID, 2016) |
| "Breast cancer is the most commonly diagnosed cancer among women worldwide and the most common cause of cancer death in women." | ( Hong, AS; Jaeger, BM; Letter, H; Odell, MC, 2016) |
| "Breast cancer is the most frequently occurring disease among women worldwide." | ( Abdullah Al-Dhabi, N; Agastian, P; Baaru, R; Balamurugan, K; Choi, KC; Ilavenil, S; Kim, YO; Srigopalram, S; Valan Arasu, M, 2016) |
| "Breast cancers are routinely assessed for estrogen receptor status using immunohistochemical assays to assist in patient prognosis and clinical management." | ( Guggisberg, N; Klimowicz, AC; Kornaga, EN; Magliocco, AM; Morris, DG; Ogilvie, T; Webster, M, 2016) |
| "Breast cancer is the most common malignancy in women, with metastases being the cause of death in 98%." | ( Flamini, MI; Sanchez, AM; Shortrede, JE; Vargas-Roig, LM, 2016) |
| "Breast cancer is the most frequently diagnosed cancer and the second leading cause of cancer related deaths among women worldwide." | ( Machado, VA; Peixoto, D; Queiroz, MJ; Soares, R, 2016) |
| "Breast cancer is the second most common cancer and a leading cause of cancer death in women." | ( Kala, R; Tollefsbol, TO, 2016) |
| "Breast cancer is the most common malignancy and also the second leading cause of cancer death among women and also in women that have a high mortality." | ( Alizadeh-Navaei, R; Ghasemzadeh Kolagar, H; Jafari, M; Jangholi, E; Javidi, MA; Khazaei Jalil, S; Mirmalek, SA; Parsa, T; Parsa, Y; Salimi-Tabatabaee, SA; Yadollah-Damavandi, S, 2016) |
| "The incidence of breast cancer is alarmingly increasing worldwide and also among Saudi women." | ( Abuzenadah, AM; Al-Qahtani, MH; Al-Thubaity, F; Buhmeida, A; Chaudhary, AG; Dallol, A; Gari, MA; Jayapal, M; Karim, S; Merdad, A; Mirza, Z; Schulten, HJ, 2016) |
| "Breast cancer is the most common cancer in women worldwide, and is a leading cause of cancer death among women." | ( Accurso, A; Amato, B; Catanuto, G; Iannone, L; Moja, L; Nava, MB; Rispoli, C; Rocco, N; Spano, A; Testa, S, 2016) |
| "Basal-like breast cancer is an aggressive tumor subtype with poor prognosis." | ( Cheong, SK; Choo, HL; Chung, FF; Hii, LW; Khor, NT; Leong, CO; Rosli, R; See, SJ; Tan, BS; Tan, SH; Tan, YF; Tiong, KH; Wong, SF, 2016) |
| "Breast cancer is the second leading cause of cancer deaths among women." | ( Ahirwar, D; Elbaz, M; Ganju, RK; Nasser, MW; Ravi, J, 2017) |
| "Breast cancer is the commonest female cancer worldwide and its propensity to metastasize negatively impacts on therapeutic outcome." | ( Bhatt, ML; Goel, MM; Kumar, R; Kumar, V; Mishra, DP; Singh, R; Singh, SP, 2016) |
| "Breast cancer is the most prevalent malignancy among women with wide differences in clinical profile from region to region." | ( Advani, S; Asegaonkar, SB; Kulkarni, U; Saraf, M; Takalkar1, UV, 2016) |
| "Breast cancers are heterogeneous, making it essential to recognise several biomarkers for cancer outcome predictions." | ( Chae, SW; Choi, SH; Do, SI; Kim, DH; Kim, K; Kwon, MJ; Lee, HJ; Min, KW; Moon, KM; Oh, S; Park, CH; Park, YL; Pyo, JS; Sohn, JH, 2016) |
| "HER2-positive breast tumors are known to harbor cancer stem-like cell populations and are associated with an aggressive tumor phenotype and poor clinical outcomes." | ( An, H; Cho, TM; Cho, Y; Kim, JY; Lee, N; Oh, E; Seo, JH; Sung, D, 2016) |
| "Breast cancer is a major global health problem with high incidence and case fatality rates." | ( Chen, K; Lin, W; Liu, J; Tong, J; Ye, H; Zhang, C; Zhao, J; Zhu, W, 2016) |
| "Breast cancer is the second leading cause of cancer death worldwide." | ( Benech, JC; Cabral, P; Cerecetto, H; Fernández, M; Lecot, N; Oddone, N; Rodriguez-Haralambides, A, 2016) |
| "Triple-negative breast cancers are highly aggressive, and patients with these types of tumors have poor long-term survival." | ( Cichewicz, RH; Du, L; Mooberry, SL; Robles, AJ, 2016) |
| "Breast cancer is the most common type of cancer in women." | ( Davoodzadeh, H; Ebadi, A; Rahmani, H; Shahriary, A; Sheikhi, MA, 2017) |
| "Breast cancer is among the most common malignant tumors." | ( Cui, R; Ding, X; Lin, J; Wang, Y; Yu, J, 2016) |
| "Breast cancer is one of the most prevalent cancers in women, and nearly half of breast cancer patients develop distant metastatic disease after therapy." | ( Heo, JY; Kim, S; Kweon, GR; Lim, K; Park, JI; Shin, S; Song, KS; Wu, T; Yun, EJ, 2016) |
| "Breast cancer is a leading cause of cancer-related mortality among women." | ( Cheng, L; Feng, X; Jia, L; Song, X; Zhao, L; Zhao, Y; Zhou, H, 2016) |
| "Breast cancer is one of the most lethal types of cancer in women worldwide due to the late stage detection and resistance to traditional chemotherapy." | ( Bao, J; Li, J; Wang, H; Wu, C, 2016) |
| "Breast cancer is one of the deadliest cancers worldwide due to its strong metastasis to other organs." | ( Gao, Q; Hao, A; Hao, C; Hao, J; Ji, S; Sun, J; Zhang, H; Zhang, W; Zhang, X, 2016) |
| "Breast cancer is the second most common cancer worldwide after lung cancer with the vast majority of early stage breast cancers being hormone-dependent." | ( Bright, SA; Fayne, D; Kelly, PM; Meegan, MJ; Pollock, JK; Williams, DC; Zisterer, DM, 2016) |
| "Luminal A breast cancer is the most common breast cancer subtype which is usually treated with selective estrogen receptor modulators (SERMS) like tamoxifen." | ( Bräuchle, C; Hermawan, A; Knyazev, P; Ljepoja, B; Mickler, FM; Roidl, A; Sommer, AK; Ullrich, A; Wagner, E, 2016) |
| "Breast cancer is a hormone-related carcinoma and the most commonly diagnosed malignancy in women." | ( Chen, MC; Huang, CC; Huang, PH; Lee, YT; Lin, H; Wang, HY; Yue, CH, 2016) |
| "Breast cancer is a major disease with high morbidity and mortality in women." | ( Chen, Y; Liu, H; Song, F; Tian, M; Wu, S; Zhang, H, 2016) |
| "Breast cancer is one of the commonest malignant tumors threatening to women." | ( Leung, AW; Tang, QJ; Wu, J; Xiao, Q; Xu, C; Xue, C; Zhang, H; Zhang, N, 2016) |
| "Breast cancer is the second leading cause of cancer-related deaths among women in the United States." | ( Ambs, S; Basudhar, D; Cheng, RY; de Oliveira, GA; Glynn, SA; Heinecke, JL; Kesarwala, A; Ridnour, LA; Somasundaram, V; Wink, DA, 2017) |
| "Breast cancer is the most frequently diagnosed cancer and the highest cause of cancer mortality in females worldwide." | ( Augereau, P; Bourien, H; Campone, M; Frenel, JS; Gourmelon, C; Patsouris, A, 2016) |
| "Breast cancer is the most common cancer and the second principal cause of cancer deaths in women worldwide as well as in Malaysia." | ( Akhtari-Zavare, M; Ataollahi Eshkoor, S; Ismail, IZ; Juni, MH; Latiff, LA; Said, SM, 2016) |
| "Breast cancer is the most common malignant disease amongst Western women." | ( Aitken, AS; Arulanandam, R; Bell, JC; Bourgeois-Daigneault, MC; Diallo, JS; Falls, T; Garcia, V; Pelin, A; Roy, DG; St-Germain, LE, 2016) |
| "Considering that breast cancer is a very heterogeneous disease and patients respond differently to treatment, the molecular analysis of TAM's biological activity could provide the necessary framework to understand the complex effects of this drug in target cells." | ( Rangel, N; Rondón-Lagos, M; Sánchez, MC; Villegas, VE; Zaphiropoulos, PG, 2016) |
| "Breast cancer is the most common type of cancer affecting women." | ( Castro, L; Côrte-Real, M; Gerós, H; Gonçalves, M; Guedes, JP; Loureiro, L; Pereira, CS; Rodrigues, LR, 2016) |
| "Breast cancer is believed as the second most common cause of cancer-related deaths in women for which tamoxifen is frequently prescribed." | ( Chitkara, D; Kumar, P; Kumar, R; Raza, K; Singh, B; Thakur, CK; Thotakura, N, 2016) |
| "The majority of breast cancers are estrogen receptor positive (ER+)." | ( Andreucci, E; Chiarugi, P; Fearns, A; Francica, P; Isacke, CM; Martin, LA; Morandi, A, 2016) |
| "Breast cancer is one of the most aggressive and pervasive cancers identified in females." | ( Duan, ML; Ji, NN; Tong, JH; Wang, SH; Xia, M; Xu, JG; Zhang, YM, 2016) |
| "Breast cancer is the primary reason for cancer-related death in women worldwide and the development of new formulations to treat breast cancer patients is crucial." | ( Liu, Q; Wang, J; Wang, S; Wang, Y; Yang, L; Yu, C; Zhu, R, 2016) |
| "Breast cancer is one of the leading causes of death for women worldwide." | ( Liu, P; Xu, B; Zhang, C, 2016) |
| "Breast cancer is one of the most frequent cancer types within female populations." | ( Akbarzadeh, A; Amiri, B; Chiani, M; Ebrahimi-Far, M; Saffari, Z; Soleimani, E, 2016) |
| "Breast cancer is by far the most frequent cancer of women (23% of all cancers), ranking second overall when both sexes are considered together." | ( Bhandari, M; Jeyaraj, P; Kamal, VK; Kulshrestha, R; Prasad, N; Rath, G; Roy, S; Sachdev, J; Shankar, A, 2016) |
| "Breast cancer is one of the most common malignancies in women." | ( Arpino, G; De Placido, G; De Placido, S; De Rosa, P; Locci, M; Nazzaro, G; Pagano, T; Schettini, F; Vallone, R, 2016) |
| "Breast cancer is the most diagnosed cancer in women and ranked second female disease killer." | ( Ebrahim, HY; El Sayed, KA; Hailat, MM; Mohyeldin, MM, 2016) |
| "Breast cancer is the most common cancer in women, and mastectomy is commonly performed as part of the management." | ( Babar, M; Davies, G; Harada, A; Hards, M; Harwell, S; Neville, I; Ravalia, A, 2016) |
| "Breast cancer is heterogeneous at different levels: biologic subtypes, intratumoral areas, and sites of metastases." | ( Niraula, S; Ocana, A, 2016) |
| "Breast cancer is a common cancer among women." | ( Basu, S; Caldefie-Chézet, F; Harris, H; Larsson, A; Rossary, A; Vasson, MP; Wolk, A, 2016) |
| "Breast cancer is an umbrella term used to describe a collection of different diseases with broad inter- and intratumor heterogeneity." | ( Angerer, TB; Fletcher, JS; Landberg, G; Magnusson, Y, 2016) |
| "Estrogen-dependent breast cancer is often treated with the aromatase inhibitors or estrogen receptor (ER) antagonists." | ( He, J; Kou, X; Nie, P; Song, Z; Wang, S; Wu, B; Zhu, J; Zou, Z, 2016) |
| "Breast cancer is the most frequent cancer in women." | ( Alamolhodaei, NS; Behravan, J; Karimi, G; Mosaffa, F, 2016) |
| "Breast cancer is the second most common type of cancer in the world, and is by far the most prevalent form of cancer in women." | ( Chu, P; Fang, D; Luo, R; Tang, Z; Wu, H; Zhang, Z, 2016) |
| "Breast tumors are characterized into subtypes based on their surface marker expression, which affects their prognosis and treatment." | ( Bao, X; Bhute, VJ; Ma, Y; Palecek, SP, 2016) |
| "HER2 breast cancers are aggressive and are associated with poor prognosis." | ( Bal, A; Bhusari, P; Dhawan, DK; Mittal, BR; Parmar, M; Shukla, J; Singh, G; Vatsa, R, 2017) |
| "In women breast cancer is still the most commonly diagnosed cancer." | ( Depping, R; Dunst, J; Jelkmann, W; Kosyna, FK; Wolff, M, 2017) |
| "Indian women with breast cancer are usually diagnosed in advanced stages leading to poor survival." | ( Bantwal, K; Chakrabarty, A; Gadgil, A; Haldar, I; Kantharia, S; Muwonge, R; Roy, N; Sankaranarayanan, R; Sauvaget, C, 2017) |
| "Breast cancer is the most common malignant disease occurring in women and represents a substantial proportion of the global cancer burden." | ( Cho, JH; Choi, HG; Kim, CY; Kim, D; Kim, HK; Kim, ND; Ko, E; Lee, C; Lee, SH; Nan, HY; Park, JS; Son, JB; Yoon, S, 2016) |
| "Breast cancer is a common malignancy in women." | ( Han, X; Li, A; Liu, Y; Pan, B; Shao, L; Shi, X; Si, X; Sun, L; Sun, Y; Yang, N; Zang, R; Zhang, E; Zhang, Z, 2016) |
| "Breast cancer is the most frequently detected malignancy and a major cause of cancer death among women around the world." | ( Binu, VS; Chakrabarty, J; Chillakunnel Hussain Rawther, S; Devi, ES; Fernandes, DJ; George, A; Mathew, S; Nayak, BS; Pai, MS, 2017) |
| "Breast cancer is the second cause of cancer-related death among Women." | ( Anwar, F; Kamal, MA; Kumar, V; Liu, Y; Mushtaq, G; Wang, C; Wang, J; Xiao, F; Yuan, C; Yuan, D, 2016) |
| "Breast cancer is associated with risk factors such as advancing age and obesity." | ( Coleman, WB, 2016) |
| "Breast cancer is one of the most common primary malignant tumors of among women, the long-term survival of which has stagnated in the past decades." | ( Dong, JL; Sun, ZL; Wu, J, 2017) |
| "Breast cancer is one of the leading causes of cancer death in women." | ( Banerji, S; Cai, N; Davie, JR; Huang, S; Jia, G; Murphy, L; Pitz, M; Xu, W, 2017) |
| "Breast cancer is one of the most common malignancies among women in the world, investigating the characteristics and special transduction pathways is important for better understanding breast development and tumorigenesis." | ( Feng, X; Han, H; Zhou, J; Zhou, W; Zou, D, 2017) |
| "Breast cancer is a leading cause of morbidity and mortality in women." | ( Ke, ZJ; Luo, J; Wang, Y; Xu, M, 2017) |
| "Breast cancer is a complex disease with at least five different molecular subtypes identified." | ( Huynh, FC; Jones, FE; Nguyen, D, 2017) |
| "Breast cancer is the most common female cancer, affecting approximately one in eight women during their lifetime in North America and Europe." | ( Dubeau, L; Fourkala, EO; Fraser, L; Jacobs, IJ; Jaeger, B; Janni, W; Jones, A; Keshtgar, M; Kiechl, S; Mayr, A; Menon, U; Penninger, JM; Philpott, S; Rack, B; Rosenthal, A; Roylance, R; Schett, G; Scholz, C; Schramek, D; Teschendorff, A; Weger, S; Widschwendter, M; Willeit, J; Zaikin, A, 2017) |
| "Breast cancer is a systemic disease which has challenged physicians worldwide as it is the most predominant cancer in women often leading to fatality." | ( Bhar, S; Gadre, G; Lokhande, R; Mehta, A; Ramana, M; Ranade, P, 2017) |
| "Breast cancer is the most common cancer in women worldwide." | ( Dehghan Manshadi, HR; Faraji, A; Houshmand, M; Mobaraki, M; Zare, M, 2016) |
| "Breast cancer is the leading cause of cancer-related deaths in women and earlier detection can substantially reduce deaths from breast cancer." | ( Du, J; Li, F; Li, H; Liu, X; Wan, C; Xu, L; Yang, H, 2017) |
| "Claudin-low breast cancer is a molecular type of breast cancer originally identified by gene expression profiling and reportedly associated with poor survival." | ( Bane, AL; Dias, K; Dvorkin-Gheva, A; Hallett, RM; Hassell, J; Levine, M; Pond, GR; Whelan, T; Wu, Y, 2017) |
| "Breast cancer is one of the most frequently diagnosed forms of cancer and different treatments are used to block its progression." | ( Capone, F; Ciliberto, G; Colonna, G; Costantini, S; Guerriero, E; Sorice, A; Storti, G, 2017) |
| "Chemoresistance in breast cancer is a major obstacle, especially in p53 mutation types." | ( Azadbakht, M; Jahani, M; Mansouri, K; Norooznezhad, F, 2017) |
| "Breast cancer is one of the most common type of female cancer worldwide and represents 14% of cancer-related deaths in women." | ( Hu, H; Lu, HY; Shan, XH; Wang, P; Xiong, F, 2017) |
| "Breast cancer is a complex and multifactorial disease." | ( Cominetti, MR; Fuzer, AM; Lee, SY; Mott, JD, 2017) |
| "Breast cancer is a major threat to human health, it is not the primary breast tumor that is ultimately responsible for the majority of deaths, but the tumor metastasis, which frequently follows a specific pattern of dissemination." | ( Li, H; Oupicky, D; Ping, Q; Sun, M; Wang, K; Yang, X; Zhou, Y, 2017) |
| "Breast cancer is the most prevalent type of cancer in women and the leading cause of cancer deaths due to its high metastasis to the lymph nodes, lungs bones and brain." | ( Cominetti, MR; Popolin, CP, 2017) |
| "Breast cancer is the most common cancer in women in India." | ( Sharma, D; Singh, G, 2016) |
| "Breast cancer is the leading cause of cancer death among women." | ( Chen, S; Dong, Y; Meng, T; Ojima, I; Wang, C; Xing, Y; You, H; Zheng, X, 2017) |
| "Global burden of breast cancer is expected to increase to >2 million new cases every year by 2030 and 10% of these are likely to have hereditary breast and ovarian cancer syndrome." | ( Annapurna, S; Darooei, M; Hasan, Q; Iyer, GR; Maddali, S; Poornima, S; Pujar, AN; Salma, BU; Shah, A, 2017) |
| "Breast cancer is the most commonly diagnosed cancer type worldwide among women and more than 90% of patients die from tumor metastasis." | ( He, P; Huang, A; Lan, L; Xing, Y; Yi, Z; Ying, X, 2017) |
| "Breast cancer is the second leading cause of cancer deaths among women." | ( Chesca, DL; Eloy, JO; Lee, RJ; Marchetti, JM; Petrilli, R; Saggioro, FP, 2017) |
| "Breast cancer is a one of the leading tumor types significantly affecting women health worldwide." | ( Liang, Z; Xi, Y, 2016) |
| "Breast cancer is a hormone-dependent malignancy and is the most prevalent cause of cancer-related mortality among females." | ( Hu, Z; Ma, W; Wang, Y; Yan, Y; Zhang, K; Zhao, P, 2017) |
| "Breast cancer is associated with a high mortality rate around the world due to its aggressiveness and high resistance to conventional therapies." | ( Almeida, IV; Biazi, BI; Fernandes, LM; Vicentini, VEP, 2017) |
| "Breast cancer is the most common malignancy and remains a leading cause of cancer-related deaths in female." | ( Cheng, L; Li, XT; Liu, S; Song, XL; Wang, X; Wang, XM; Wang, YH; Xiao, Y, 2017) |
| "The breast cancer is reported as one of the most common tumors among women worldwide." | ( Han, NN; Huang, Q; Liu, KJ; Zhou, Q, 2017) |
| "Breast cancer is reported as the most frequent tumor with limited treatments among the female worldwide." | ( Song, W; Yan, CY; Zhen, LL; Zhou, QQ, 2017) |
| "Breast cancer is the main cause of mortality among women." | ( Baptista, MS; Bruni-Cardoso, A; Dos Santos, AF; Gomes, VM; Labriola, L; Meotti, FC; Mineiro, MF; Oliveira, TC; Terra, LF; Wailemann, RA, 2017) |
| "Breast cancer is the most common cause of cancer mortality among women worldwide; therefore, a strategy to defeat breast cancer is an extremely important medical issue." | ( Alamolhodaei, NS; Hayes, AW; Karimi, G; Ramezani, M; Tsatsakis, AM, 2017) |
| "Breast cancer is chosen as a tumor model and the Au nanoclusters and photosensitizer co-loaded liposomal nanocomposites are studied to improve the effect of PDT both in vitro and in vivo, and its corresponding mechanism is investigated." | ( Cai, P; Gao, F; Gao, L; Gao, X; Liu, R; Wang, Y; Yuan, Q; Zhao, Y; Zheng, W, 2017) |
| "Its role in early breast cancer is uncertain due to conflicting data from randomised controlled trials (RCTs)." | ( Amir, E; Cescon, DW; Ethier, JL; Natori, A, 2017) |
| "Breast cancer is the most diagnosed and the major cause of cancer death in women worldwide." | ( Bruzzone, A; Entschladen, F; Gargiulo, L; Lüthy, IA; Piñero, CP; Rivero, EM; Zänker, K, 2017) |
| "Breast cancer is one of the most frequent cancers in the population, especially in older women." | ( Correia-Branco, A; Martel, F; Nunes, C; Silva, C, 2017) |
| "Breast cancer is one of the most common cancers diagnosed in women." | ( Lakshmanaswamy, R; Nandy, SB; Pedroza, DA; Subramani, R, 2017) |
| "Breast cancer is the second leading cause of cancer-related mortality in women." | ( Auguste, DT; Kim, B; Li, M; Tao, Y, 2017) |
| "Basal-like breast cancer is characterized by being triple negative and aggressive." | ( Augereau, P; Campone, M; Frenel, JS; Gourmelon, C; Patsouris, A; Robert, M, 2017) |
| "Breast cancer is one of the most lethal malignancies for women." | ( Aranda, A; Bernardo, AR; Cosgaya, JM; Jiménez-Lara, AM, 2017) |
| "Breast cancer is a leading cause of cancer-related deaths." | ( Chan, KK; Coulter, JA; Davidson, MA; El-Tanani, M; Hengst, L; Irwin, GW; Jaekel, H; Lappin, TR; Matchett, KB; Maxwell, P; McCrudden, CM; Mills, KI; Platt-Higgins, A; Rudland, PS; Rülicke, T; Schober, S; Yuen, HF; Zhang, SD, 2017) |
| "Breast cancer is among the most important causes of cancer related death in women." | ( Avan, A; Ferns, GA; Hasanzadeh, M; Hassanian, SM; Khazaei, M; Khedri, M; Rezaee, M; ShahidSales, S; Tajbakhsh, A, 2018) |
| "Both ovarian/breast cancers are the most prevalent hormone-associated gynecological-cancers, where uncontrolled cellular proliferations/genetic-errors are noticed." | ( Ghosh, TK; Maiti, S; Mandal, K; Nazmeen, A; Roy, SK; Sinha, NK, 2017) |
| "Breast cancer is the most common cancer in women for which doxorubicin is still the mainstay treatment." | ( Mahalingaiah, PKS; Ponnusamy, L; Singh, KP, 2017) |
| "Breast cancer is one of the most common malignant diseases in females worldwide, and the major cause of mortality is metastasis that is primarily attributed to angiogenesis." | ( Chen, J; Li, Y; Li, Z; Liu, Y; Mu, J; Ning, S; Shen, Z; Zhu, D, 2017) |
| "Breast cancer is one of the most frequently diagnosed cancer in woman." | ( Badana, AK; Kumari, S; Malla, R; Mohan, GM; Shailender Naik, G, 2017) |
| "The progression of breast cancer is closely related to the levels of estrogens within the body." | ( Gong, Y; Guo, D; Guo, M; Min, M; Wang, J; Wang, X; Xu, C; Yin, J; Yin, X; Zhang, B; Zhao, Y; Zheng, J; Zheng, Z; Zhou, X, 2017) |
| "Breast cancer is the most common cancer type and cause of cancer-related mortality among women worldwide." | ( Acun, T; Doberstein, N; Gemoll, T; Habermann, JK; Oztas, E; Ried, T; Thorns, C, 2017) |
| "Lobular breast cancer is the second most common type of invasive breast cancer." | ( de Vries, E; Glaudemans, A; Hospers, G; Poppema, B; Schröder, C; Venema, C, 2017) |
| "Breast cancer is a leading cause of cancer fatalities among women worldwide." | ( Al-Ajmi, RA; Al-Olayan, EM; Alkhuriji, AF; Daghestani, MH; Elamin, MH; Elkhadragy, MF; Elmahi, AB; Hamed, SS, 2019) |
| "Breast cancer is the most common type of cancer and the second leading cause of cancer death in American women." | ( Chen, L; He, K; Li, J; Pan, Y; Shao, D; Tan, Y; Zhang, F; Zhao, Y; Zheng, X, 2017) |
| "Globally, breast cancer is the most common life-threatening malignant disease among women." | ( Abrahamse, H; Aniogo, EC; George, BPA, 2017) |
| "Breast cancer is the most common invasive type of cancer among women." | ( Han, Y; Jia, Z; Wang, X; Xu, S; Yang, Z; Zhao, C, 2017) |
| "Breast cancer is one of the most common malignancies in women and metastasis is the cause of morbidity and mortality in patients." | ( Avcı, ÇB; Balcı, T; Gündüz, C; Kayabaşı, Ç; Kırmızıbayrak, PB; Süslüer, SY; Yelken, BÖ, 2017) |
| "Breast cancer is the most common carcinoma among Chinese women." | ( Chen, YC; Li, HJ; Li, JC; Li, SJ; Li, Y; Liu, CS; Su, TQ; Yu, DH; Zhou, L, 2017) |
| "Breast cancer is the most frequently diagnosed cancer and cause of cancer death in women worldwide." | ( Chen, XX; Feng, F; Lao, LX; Leung, GP; Mak, JC; Sze, SC; Wang, Y; Xiao, JB; Zhang, KY; Zhang, ZJ, 2017) |
| "Breast cancer is one of the most common cancers in females." | ( Jeong, H; Kim, JG; Lee, S; Seong, M, 2017) |
| "Breast cancer is the most vicious killer for women, and tumor metastasis is one of the leading causes of breast cancer therapy failure." | ( Dong, XY; Lang, TQ; Li, YP; Yin, Q; Zhang, PC, 2017) |
| "Worldwide breast cancer is the most common cancer in women." | ( Adhikary, AK; Banik, U; Othman, NH; Parasuraman, S, 2017) |
| "Breast cancer is a heterogeneous disease due to its clinico-pathological features and response to therapy." | ( Bernard-Gallon, D; Bignon, YJ; Dagdemir, A; Judes, G; Karsli-Ceppioglu, S; Lebert, A; Penault-Llorca, F, 2017) |
| "Breast cancer is one of the most lethal malignancies in the world." | ( Cai, Y; Li, H; Li, M; Tan, Z; Wu, J; Zhang, Y, 2017) |
| "Breast cancer is the most prevalent cancer among women worldwide." | ( Bordoloi, D; Kunnumakkara, AB; Thakur, KK, 2018) |
| "Breast cancer is the most common malignancy in women in terms of incidence and mortality." | ( Carin, AJ; Heitz, D; Lodi, M; Mathelin, C; Neuberger, K; Reix, N; Scheer, L; Thiébaut, N; Tomasetto, C, 2017) |
| "Breast cancer is the most common neoplasm in women and has the highest associated mortality rate." | ( Bayo, J; Castaño, MA; Navarro, F; Rivera, F, 2018) |
| "Breast cancer is the second most common cancer worldwide, accounting for 25% of all female cancers." | ( Hiscox, S; Jones, S; Kandil, S; Prencipe, F; Westwell, AD, 2018) |
| "Breast cancer is one of the most frightful causes of death among females worldwide." | ( Chen, J; Gao, J; Guan, X; Jia, L; Liu, P; Peng, C; Peng, F; Shen, J; Tang, H; Xie, X; Xiong, L, 2017) |
| "Breast cancer is the most common malignancy among women in Mexico." | ( Ali, AA; Chavarri-Guerra, Y; de Lima Lopes, G; Diaby, V; Ezendu, K; Soto-Perez-de-Celis, E; Williams, KJ, 2017) |
| "Breast cancer is one of the commonest sources of ocular metastasis." | ( Lamichhane, S; Shah, RK, 2017) |
| "Breast cancer is the most common malignant disease in women worldwide, but the current drug therapy is far from optimal as indicated by the high death rate of breast cancer patients." | ( Si, M; Wong, HL; Wu, D; Xue, HY, 2017) |
| "Breast cancer is the common cancer in China." | ( Chang, H; Chen, J; Mi, M; Peng, X; Yu, X; Zhang, Q, 2017) |
| "The cause of breast cancer is multifactorial and includes hormonal, genetic and environmental cues." | ( Brown, KA; Gérard, C, 2018) |
| "Breast cancer is the most common malignant disease that occurs in women." | ( Gurunathan, S; Peng, QL; Yuan, YG, 2017) |
| "O-GlcNAcylation in breast cancer is clinically relevant, as we show that O-GlcNAc levels are higher in breast cancer as compared to matched normal tissues, and PR-positive breast cancers have higher levels of OGT." | ( Chalise, P; D'Santos, CS; Goodman, ML; Hagan, CR; Madan, R; Papachristou, EK; Slawson, C; Trinca, GM, 2018) |
| "Breast cancer is the second largest cause of cancer death among U." | ( Boone, C; Costanzo, M; Lange, CA; Myers, CL; Wang, W; Xu, ZZ, 2017) |
| "BACKGROUND Breast cancer is among the deadliest cancers across the world and is responsible for countless deaths." | ( Chen, X; Liu, Y; Wang, Y; Zhao, L; Zhao, W, 2017) |
| "Breast cancer is one of the most frequent diseases among women, but the effective treatments is still a challenge." | ( da Silva, FH; de Marchi, PGF; de Melo Cotrim, AC; de Sousa Pereira, C; Deluque, AL; Fagundes, DLG; Franca, EL; Honorio-Franca, AC; Ribeiro, AAL, 2018) |
| "Triple-negative breast cancer is a unique subtype that lacks specific targets, and its treatment primarily includes chemotherapy." | ( Apuri, S, 2017) |
| "The metastasis of breast cancer is the leading cause of death, while lung metastasis is a major clinical phenomenon in patients with invasive breast cancer." | ( Ju, RJ; Liu, L; Lu, WL; Mu, LM; Xie, HJ; Zeng, F, 2018) |
| "Breast cancer is the most frequently diagnosed cancer in women." | ( Astuti, M; Mubarika Haryana, S; Murdiati, A; Zuhrotun Nisa, F, 2017) |
| "Breast cancer is considered as the most common malignant disease in women." | ( Liu, H; Song, Z; Wang, M; Wang, X; Yang, L; Yang, W, 2017) |
| "Breast cancer is a common cause of cancer‑related deaths in women." | ( Chen, T; He, M; Ji, F; Jiang, Y; Jin, Q; Liu, Y; Wang, N; Yang, J; Ye, X; Zhang, Z; Zhong, C, 2017) |
| "Breast cancer is one of the most common cancers in female patients who have type 2 diabetes mellitus and obesity." | ( Hamaguchi, Y; Horikawa, T; Iwasaki, A; Iwaya, C; Kawanami, T; Komatsu, S; Nabeshima, K; Nomiyama, T; Tanabe, M; Tanaka, T; Terawaki, Y; Tsutsumi, Y; Yamashita, S; Yanase, T; Yoshinaga, Y, 2017) |
| "Neuroendocrine breast cancer is a rare entity that was defined in 2003 by the World Health Organization as a separate breast cancer subtype." | ( Abbas, J; Abou Dalle, I; Assi, HI; Boulos, F; Salem, Z, 2017) |
| "Women with breast cancer are at risk of psychosocial distress and may suffer from aberrant diurnal cortisol rhythms." | ( Fong, TCT; Ho, RTH; Yip, PSF, 2018) |
| "Patients with breast cancer are typically at risk of skeletal complications throughout their disease course." | ( Lüftner, D; Niepel, D; Steger, GG, 2018) |
| "Triple-negative breast tumors are very aggressive and contain relatively high proportion of cancer stem cells, and are resistant to chemotherapeutic drugs including cisplatin." | ( Aboussekhra, A; Al-Mazrou, A; Al-Sharif, I; Islam, SS; Remmal, A; Sultan, A, 2018) |
| "Clinically, breast cancer is generally classified into estrogen receptor-positive (ER+) or estrogen receptor-negative (ER-) subtypes." | ( Chen, J; Huang, Y; Li, R; Lu, H; Ren, Q; Tian, J; Wang, Y; Zhang, X, 2017) |
| "Breast cancer is one of the most common cancers in the world." | ( Krishnegowda, N; Ramasamy, K; Samayoa, C; Tekmal, RR, 2017) |
| "Breast cancer is a common cancer in women of worldwide." | ( Chai, H; Jing, W; Liang, C; Tu, J; Yu, M; Yu, Y; Zhu, M; Zuo, J, 2018) |
| "Breast cancer is one of the most frequently occurring malignant tumors affecting women's health." | ( Han, X; Liu, M; Ren, Y; Shi, J; Yu, K; Zhang, J; Zhang, X; Zhen, L, 2018) |
| "Breast cancer is one of the most serious diseases, posing threats to women's physical and mental health." | ( Cui, L; Jia, G; Li, Y; Liu, W; Luo, J; Shen, P; Tang, Y; Wang, Y; Xie, Q; Zhang, W; Zhao, S; Zheng, R, 2018) |
| "Breast cancer is the second-leading cause of death in women worldwide owing to aggressive metastasis, lack of early diagnosis and poor access to treatment amenities." | ( Lather, V; Pandita, D; Poonia, N, 2018) |
| "Breast cancer is a prevalent cancer in female." | ( Li, J; Li, Y; Wang, R; Yin, L; Zhao, Y, 2018) |
| "Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among women worldwide." | ( Baura, VA; Biembengut, IV; Chequin, A; Costa, FF; de O Pedrosa, F; de Souza, EM; Klassen, G; Klassen, LMB; Manica, GCM; Ramos, EAS; Toledo, MB, 2018) |
| "Breast cancer is the most frequent cancer in women." | ( Augereau, P; Berton Rigaud, D; Bourbouloux, E; Campone, M; Frenel, JS; Gourmelon, C; Patsouris, A; Robert, M, 2017) |
| "Pathogenesis of breast cancer is paralleled by distinct alterations in the expression profile of several microRNAs (miRNAs)." | ( Generali, D; Majeed, M; Norouzi, S; Pirro, M; Sahebkar, A, 2018) |
| "Breast cancer is a disease of high mortality, characterized by the progressive accumulation of mutations that contribute to the uncontrolled development of breast tissue cells." | ( Bezerra, DLC; de Oliveira Santos, R; de Sousa Melo, SR; do Nascimento Marreiro, D; Dos Santos, LR; Mendes, PMV; Morais, JBS; Severo, JS; Vieira, SC, 2018) |
| "Breast cancer is one of the most common types of carcinoma in humans." | ( Lai, XX; Li, G; Lin, B; Yang, H, 2018) |
| "Breast cancer is one of the major causes of death in the USA." | ( Hussain, F; Khan, ZS; Munir, MT; Rahman, SM; Santos, JM; Tarafdar, K, 2018) |
| "Metaplastic breast carcinomas are ductal carcinomas that undergo metaplasia into non-glandular growth patterns." | ( Shruti, S; Siraj, F, 2017) |
| "Breast cancer is a global public health problem." | ( Begnini, KR; Buss, J; Collares, T; da Silva, LP; de Pereira, CMP; Mastelari, R; Pacheco, B; Saueressig, S; Segatto, NV; Seixas, FK; Tessmann, J, 2018) |
| "Breast cancer is the most prevalent female malignancy throughout the world." | ( Du, J; Yu, Y; Zhan, J; Zhang, H, 2017) |
| "Breast cancer is the most common cancer in females." | ( Patel, S, 2018) |
| "Breast cancer is the most common cancer and the leading cause of cancer death among women." | ( Colori, B; Di Bella, G; Toscano, R, 2017) |
| "Advanced breast cancer is resistant to chemotherapy and its underlying mechanisms are not fully explored." | ( Chai, F; Li, Z; Liu, L; Qu, M; Sun, Y; Wan, H; Zhang, P, 2018) |
| "Breast cancer is one of the most commonly diagnosed invasive cancers among women around the world." | ( Gorain, M; Haldar, S; Kumar, D; Kumar, S; Kundu, GC; Miele, L; Mulani, FA; Thulasiram, HV; Yadav, AS, 2018) |
| "The development of breast cancer is influenced by the adipose tissue through the proteins leptin and adiponectin." | ( Dozal-Domínguez, DS; Flores-Merino, MV; García Vázquez, FJ; Hernández-Navarro, MD; Mociño-Rodríguez, MD; Sandoval-Cabrera, A; Santillán-Benítez, JG, 2017) |
| "Breast cancer is the most common cancer in women worldwide." | ( Jongrungruangchok, S; Kangsamaksin, T; Kasorn, A; Loison, F; Ponglikitmongkol, M, 2018) |
| "Breast cancer is an alarming global public health problem and a main cause of cancer-related death in women." | ( Cheng, L; Ju, RJ; Li, CQ; Li, XT; Liu, S; Peng, XM; Qiu, X; Song, XL; Wang, T, 2018) |
| "Management of breast cancer is a rapidly evolving field, and, although evidence-based guidelines are available for clinicians to provide direction on critical issues in patient care, clinicians often left to address these issues in the context of community practice situations with their patients." | ( Abraham, J; Caldera, H; Coleman, R; Elias, A; Goetz, MP; Kittaneh, M; Lower, E; Mahtani, R; Pegram, M; Rugo, H; Schwartzberg, L; Terry Mamounas, E; Traina, T; Vogel, C, 2018) |
| "Chemotherapy for breast cancer is significantly restricted by the tumor's physio-pathological complexity." | ( Chen, L; Huang, Y; Peng, J; Qian, Z; Tan, L; Wang, Y; Zhao, H, 2016) |
| "Breast cancer is one of the common causes of mortality for women in Iran and other parts of the world." | ( Ahangari, G; Bakhtou, H; Deezagi, A; Olfatbakhsh, A, 2019) |
| "Background Breast cancer is highly prevalent among women worldwide." | ( Amaral, MEA; Campos, MM; de Azevedo Junior, WF; Leite, CE; Nery, LR, 2018) |
| "Background: Breast cancer is the most common cancer among women worldwide." | ( Basaveswara Rao, MV; Prasad, K; Thota, K, 2018) |
| "Breast cancer is the most common cancer in women characterized by a high variable clinical outcome among individuals treated with targeted therapies." | ( Hoidy, WH; Jabir, FA, 2018) |
| "Breast cancer is the second most common cause of mortality in women in the United States." | ( Abd-Rabou, AA; Bharali, DJ; Mousa, SA, 2018) |
| "Breast cancer is the most common cancer affecting females worldwide and its lifetime risk increases with age." | ( De Sanctis, R; Ferraro, E; Losurdo, A; Masci, G; Santoro, A; Torrisi, R; Zuradelli, M, 2018) |
| "Breast cancer is a common cause of cancer mortality throughout the world." | ( Chen, E; Cheng, X; Cui, Y; Li, W; Liu, T; Peng, K; Qin, X; Tang, C; Wang, Z; Xu, X, 2018) |
| "Breast cancer is a heterogeneous and multifactorial disease with variable disease progression risk, and treatment response." | ( Akhavan-Niaki, H; Asouri, M; Fattahi, S; Ghadami, E; Motevalizadeh Ardekanid, A, 2018) |
| "Breast cancer is the most common cancer among women worldwide and metastasis is the leading cause of death among patients with breast cancer." | ( Cao, XC; Chi, JR; Ding, Y; Ge, J; Li, YR; Luo, W; Wang, X; Yang, ZJ; Yu, Y, 2018) |
| "Breast cancer is the most common cause of cancer among women in most countries (WHO)." | ( Li, XH; Ran, B; Tian, JM; Yan, DM; Zhang, CL, 2018) |
| "Breast cancer is the most common malignancy in women of the Western world." | ( Awasthi, S; Beneš, H; Boerma, M; Bose, C; Hauer-Jensen, M; Sharma, R; Singh, SP, 2018) |
| "Breast cancer is a malignant disease with high mortality rate among women in the world." | ( Abedi, SM; Ahmadpour, S; Hosseinimehr, SJ; Noaparast, Z, 2018) |
| "Breast cancer is one of the major malignancies with a mounting mortality rate in the world." | ( Li, W; Sun, Y; Wang, Y; Yu, W; Zhang, Y; Zhu, M, 2019) |
| "Breast cancer is the most common cancer in women worldwide." | ( Chen, W; Lee, MH; Li, H; Liu, X; Wang, M; Wang, W; Xu, Y; Zhang, H, 2018) |
| "Breast cancer is the most common malignancy in women worldwide and is still associated with high mortality rates, despite improved treatment strategies." | ( Cha, YJ; Kim, ES; Koo, JS, 2018) |
| "Breast cancer is the most common cancer among women." | ( Bai, F; Chen, J; Chen, T; Ge, M; Liu, Y; Lu, Y; Wu, K; Xie, F; Yin, Y; Zhang, J, 2018) |
| "Breast cancer is a serious health problem worldwide." | ( Cao, J; Chen, Y; Fu, Z; Li, Q; Liu, Y; Wu, J; Xie, M, 2018) |
| "Breast cancer is one of the most prevalent malignancies and the leading cause of cancer‑associated mortality in women worldwide and in China." | ( Chen, W; Du, L; Li, X; Mu, L; Song, A; Zhang, Y; Zhen, L, 2018) |
| "Breast cancer is a tremendous threat to humans in many countries, and thus we need to find safe and effective drugs for treatment." | ( Deng, J; Dong, Y; Duan, Z; Fan, D; Fu, R; Mi, Y; Qu, L; Wei, B; Zhu, C, 2018) |
| "Breast cancer is a highly heterogeneous disease influenced by the hormonal microenvironment and the most common malignancy in women worldwide." | ( Martínez-Romero, E; Montes-Grajales, D; Olivero-Verbel, J, 2018) |
| "Breast cancer is one of the most common malignancies in females, and 17β-estradiol (E2)/estrogen receptor α (ERα) signaling plays an important role in the initiation and progression of breast cancer." | ( Cao, R; Chen, Y; Ding, W; Li, Z; Liu, J; Liu, K; Shen, Y; Wen, G; Xu, T; Zeng, T; Zhao, J; Zhong, J; Zu, X, 2018) |
| "Most breast cancers are hormone dependent." | ( Tang, C; Yang, H; Yin, C, 2018) |
| "Breast cancer is the commonest cancer disease and the main cause of cancer death in women worldwide." | ( Chu, YK; Pang, BB; Yang, H, 2018) |
| "Breast cancer is a major public health problem throughout the world." | ( Ho, CT; Hung, CH; Hung, CM; Kuo, SC; Lin, YC; Liu, BL; Liu, CW; Way, TD, 2018) |
| "Breast cancer is one of the most lethal tumors in the world, among which 15% are triple-negative breast cancers (TNBCs) with higher metastasis and lower survival rate." | ( Guo, Q; He, Z; Li, Z; Tan, R; Wei, L; Yang, L; Yao, J; Zhu, Y, 2018) |
| "Breast cancer is the most common cancer of women." | ( Khazaei, M; Khazaei, MR; Mirzapur, P; Moradi, MT, 2018) |
| "Globally, breast cancer is the most common cancer and the second leading cause of cancer-related death among women." | ( Jaman, MS; Sayeed, MA, 2018) |
| "Breast cancer is one of the most commonly diagnosed cancers in women." | ( Choudhury, M; Gollahon, LS; Munir, MT; Ponce, C; Powell, CA; Rahman, SM; Tarafdar, K; Yanagita, T, 2018) |
| "Breast cancer is the most common cancer in women and affects 1." | ( Chang, DC; Chang, GH; Cheng, YC; Hsu, CM; Kuan, FC; Lee, IY; Lee, KD; Lin, CL; Lin, YS; Lin, YY; Liu, HT; Lu, CN; Shu, LH; Tsai, MS; Wu, CY; Yang, PR; Yang, YH; Yeh, RA, 2018) |
| "Breast cancer is the most common female malignant tumors in the world." | ( Che, Y; Duan, X; Gao, H; Guo, W; Huang, J; Huang, T; Jin, Y; Lei, L; Li, Y; Ma, H; Ren, W; Xia, X; Zhai, T, 2018) |
| "Breast cancer is the most common cancer of occurrence in women and has the highest mortality incidence rate therein." | ( Arya, M; Kaithwas, G; Kanoujia, J; Parashar, P; Saraf, SA; Singh, M; Tripathi, CB, 2018) |
| "Breast cancer is one of the major challenges for women's health." | ( Deng, S; Gao, Y; Hou, L; Hu, J; Jiang, J; Li, G; Xie, S; Xiong, B; Zhao, X, 2018) |
| "Breast cancer is the second leading cause of cancer-related death among women." | ( Cánovas, B; Gomis, RR; González-Suárez, E; Igea, A; Isoda, M; Nebreda, AR; Paull, TT; Pérez-Montoyo, H; Sartori, AA; Serra, V; Stracker, TH, 2018) |
| "Breast cancer is one of the most prevalent forms of cancer in the United States and worldwide." | ( Johnson, TA; Singla, DK, 2018) |
| "Breast cancer is the second leading cause of cancer‑associated mortalities in women." | ( Cheng, L; Hu, P; Jiang, H; Liu, R, 2018) |
| "Breast cancer is the main risk associated with menopause hormone therapy (MHT)." | ( Gompel, A; Plu-Bureau, G, 2018) |
| "Breast cancer is the most common cancer among women worldwide." | ( Cao, W; Geng, S; Huang, C; Jiang, Y; Li, X; Liang, Z; Ma, X; Wang, S; Wu, J; Wu, R; Xie, C; Yang, X; Zhong, C; Zhu, J; Zhu, M; Zhu, W, 2018) |
| "Breast cancer is one of the leading causes of cancers among the variety of cancers in woman all over the world." | ( Adhikari, N; Amin, SA; Das, K; Gaikwad, R; Gayen, S; Ghorai, S; Jha, T; Patel, T, 2018) |
| "Renal metastasis of breast cancer is rare in clinical practice." | ( Liu, C; Wang, H; Wang, R; Xia, D; Xu, J, 2018) |
| "Breast cancer is most frequently diagnosed cancer and fifth leading cause of death in women." | ( Asif, M; Bhadauria, S; Chourasia, MK; Khanna, A; Shrivastava, R; Singh, PK; Trivedi, S, 2018) |
| "Breast cancer is the most common cancer disease of women in industrialized countries." | ( Bauerschlag, D; Kratzenstein, S; Maass, N; Mundhenke, C; Röcken, C; Schmidt, T; Vollmers, PL, 2018) |
| "Breast cancer is the second leading cause of cancer death in women." | ( Dilger, JP; Li, R; Lin, J; Liu, H, 2018) |
| "Background and aims Breast cancer is the most prevalent adult cancer worldwide." | ( Arving, C; Fjällskog, ML; Hellerstedt-Börjesson, S; Nordin, K; Peterson, M; Rissanen, R, 2018) |
| "Breast cancer is a leading cause of mortality among women with cancer worldwide." | ( Cao, L; Li, C; Li, J; Liang, T; Lin, B; Yang, Y; Ye, Z; Zeng, J; Zhou, K, 2018) |
| "Breast cancer is the most common cancer in women in the western world." | ( Braziewicz, J; Hołody, Ł; Kunikowska, J, 2018) |
| "Breast cancer is the second most common fatal cancer in women." | ( Abdelrahman, M; Al Sannat, S; Lewis, B; Matbouly, M; Mohamed, S; Mostafa, E; Mostafa, RM; Muhammad, B; Shafei, A, 2018) |
| "Breast cancer is one of the most common causes of mortality in women." | ( Buszman, E; Iriti, M; Kabała-Dzik, A; Kubina, R; Rzepecka-Stojko, A; Stojko, J; Wojtyczka, RD, 2018) |
| "Breast cancer is the most common malignancy in women worldwide." | ( Beijnen, JH; de Vries Schultink, AHM; Hövels, AM; Rosing, H; Schellens, JHM; Ten Ham, RMT; van Nuland, M; Vreman, RA, 2018) |
| "Human breast cancer is a malignant type of cancer with high prevalence." | ( Cao, X; He, Y; Huo, Y; Liu, J; Liu, M; Wang, S; Yang, Z, 2018) |
| "The breast cancer is the most common type of cancer in women." | ( Beyramabadi, SA; Gharib, A; Homayouni-Tabrizi, M; Khashi, M; Morsali, A; Neamati, A; Yadamani, S, 2018) |
| "MHA due to breast cancer is rare and is associated with poor prognosis; however, rapid initiation of chemotherapy may be effective." | ( Aoki, R; Asai, H; Kamei, Y; Komatsu, S; Kusakabe, E; Mizuno, Y; Murakami, A; Nishiyama, K; Sugimori, W; Taguchi, K; Takada, Y; Yamasawa, H; Yamashita, M, 2018) |
| "Breast cancer is the second most common cancer and the second leading cause of death from cancer among women in the United States (US)." | ( Gao, Y; Tollefsbol, TO, 2018) |
| "Breast cancer is the second leading cause of cancer-related deaths in US, which necessitates constant research for medications with minimal adverse effects." | ( Bokoskie, T; Chandra, S; Hunke, M; Kashyap, A; Martinez, W; Pattabiraman, M, 2018) |
| "Breast cancer is one of the major health issues confronting women; however, treatment with conventional chemotherapeutic drugs is limited." | ( Calaf, GM; Carrión, F; Ponce-Cusi, R, 2018) |
| "Breast cancer is the leading cause of cancer related deaths in women worldwide and is classified into subtypes based on the cancer's receptor status." | ( Carr, A; Coté, D; Cremona, M; Crown, J; Eustace, A; Fay, J; Furney, S; Hennessy, B; Kay, E; Kennedy, S; Madden, S; Milewska, M; Toomey, S, 2018) |
| "Breast cancer is one of the leading causes of cancer-related death among women." | ( Harrelson, J; Heers, H; Lee, MW; Stanislaw, J, 2018) |
| "About 75% of breast cancers are estrogen receptor alpha (ER-α) positive, and women typically initially respond well to antihormonal therapies such as tamoxifen and aromatase inhibitors, but resistance often emerges." | ( Aparicio, A; Bonnefous, C; Brigham, D; Darimont, B; Douglas, K; Govek, S; Hager, JH; Heyman, R; Joseph, JD; Kahraman, M; Kaufman, J; Lai, A; Lee, K; Lu, N; Maheu, K; Nagasawa, J; Prudente, R; Qian, J; Rix, PJ; Sensintaffar, J; Shao, G; Smith, ND, 2018) |
| "Breast cancer is the most common malignancy in women worldwide." | ( Carpenter, E; Farfus, A; Filkowski, J; Kovalchuk, O; Li, D; Lykkesfeldt, AE; Malach, M; Rodriguez-Juarez, R; Storozynsky, Q; Wang, B, 2018) |
| "Breast cancer is a major cause of death among women worldwide." | ( Boechat, FCS; Branco, JR; Chipoline, IC; da Silva, FC; de Souza, MCBV; Esteves, AM; Ferreira, VF; Lima, MFO; Oliveira, VG; Sola-Penna, M; Zancan, P, 2018) |
| "Breast cancer is the most diagnosed diseases and the second-leading cause of death in females, among which the estrogen receptor positive (ER+) patients are more common of all cases." | ( Huang, B; Liu, J; Luo, N; Pan, X; Wang, X; Wu, X; Xu, Z; Zheng, X, 2018) |
| "Breast cancer is the most common cancer in women worldwide." | ( Bhardwaj, A; Jacquier, M; Kuriakose, S; Portet, S; Shrivastav, A; Varma Shrivastav, S; Zhang, Y, 2018) |
| "Breast cancer is one of the most common diseases among women worldwide and it is characterized by a high ratio of malignancy and metastasis and low rate of survival of patients." | ( Aras, S; Cansaran-Duman, D; Kılıç, N, 2018) |
| "Breast cancer is the most frequently diagnosed tumor in women worldwide, with a significant impact on morbidity and mortality." | ( Jorge, AJL; Leite, AM; Macedo, AVS; Martins, WA, 2018) |
| "Globally, breast cancer is reported as a primary cause of death in women." | ( Almutairi, AF; Cho, M; Islam, MT; Mahmud, MZ; Misran, N, 2018) |
| "Breast cancer is the most common cancer among Egyptian women." | ( Kassem, H; Kassem, N; Talima, S, 2019) |
| "Breast cancer is the most common cancer worldwide that costs lives of millions of people every year." | ( Amutha, T; Panikar, S; Rajananthini, AU; Rautray, S, 2018) |
| "Breast cancer is a common type of cancer among female cancer patients and the main cause of cancer-related deaths." | ( Bi, Y; Chen, X; Cui, D; Shu, J; Xiong, X; Zhao, Y, 2018) |
| "Breast carcinomas are known to express somatostatin receptors and this is the first report of Ga-68-DOTA-NOC uptake in a breast tumor." | ( Barroso, S; Borges Faria, D; Francisco, E; Pereira de Oliveira, J; Sampaio Vieira, T; Souto Moura, C, 2018) |
| "Treatment of breast cancer is strongly influenced by prior treatment of HL." | ( Baxstrom, K; Blaes, A; Lee, C; Peterson, B; Turcotte, L; Vogel, R; Watson, AP, 2018) |
| "Breast cancer is the most frequently diagnosed cancer and has become the main cause of cancer-related death among women worldwide." | ( Fan, D; Liu, Y, 2018) |
| "Breast cancer is reported a very complex disease along with heterogeneous morphological characteristics and unrelated clinical behavior, and is a leading cancer among female." | ( Li, XY; Wang, KY; Wang, XN; Yang, C; Zhang, XS, 2018) |
| "Breast cancer is the major cause of death from cancer among women around the world." | ( Abbasi Gamasaee, N; Aryan, H; Ghiasvand, S; Jangholi, E; Javidi, MA; Radmansouri, M; Shahriari, F; Zare Marzouni, H, 2018) |
| "Breast cancer is a severe threat to the health and lives of women due to its difficult early diagnosis and the unsatisfactory therapeutic efficacy of breast cancer treatments." | ( Ao, M; Chen, YL; Guo, Y; Liu, FQ; Ran, HT; Tan, MX; Wang, XY; Wang, ZX; Yu, JH, 2018) |
| "Breast cancer is the most frequent cause of cancer in women." | ( Chakraborty, T; Roy, S; Sil, A, 2019) |
| "Breast cancer is one of the leading causes of cancer-related morbidity and mortality among women worldwide." | ( Basu, P; Maier, C, 2018) |
| "Breast cancer is the most common neoplastic disorder diagnosed in women." | ( El-Sokkary, GH; Ismail, IA; Saber, SH, 2019) |
| "Mortality from breast cancer is usually attributable to metastasis." | ( Buggy, DJ; Crowley, PD; Foley, AG; Freeman, J; Gallagher, HC; Iwasaki, M; Ma, D, 2018) |
| "Breast cancer is the most common type of diagnosed cancers in women, difficult to treat, and has received international attention because of its aggressive nature and inherent drug resistance mechanisms." | ( Gopi, M; Gopimohan, R; Maya, V; Pillai, LS; Ramaswami, K; Ravindran, S; Regidi, S; Varghese, J; Varghese, SD, 2018) |
| "Breast cancer is a leading lethal gynecological cancer." | ( Lim, W; Park, S; Song, G, 2018) |
| "Breast cancer is one of the most common malignant tumors among females." | ( Bao, Y; Chai, J; Chen, X; Gao, H; Liu, H; Shi, S; Yu, K; Zou, L, 2019) |
| "Lung and breast cancer are the leading causes of mortality in women worldwide." | ( Hung, CS; Lee, TH; Lin, RK; Wang, SC; Wen, WC; Yen, YT, 2018) |
| "Breast cancer is the most diagnosed cancer among South African women and a major cause of cancer-related deaths worldwide." | ( Abrahamse, H; Houreld, NN; Mfouo-Tynga, I, 2018) |
| "Breast cancer is the second cause of cancer mortality in women globally." | ( Chen, JX; Chen, Y; Duan, WJ; Li, MM; Li, MX; Pan, WL; Pang, JX; Zhai, LY; Zheng, L, 2018) |
| "Breast cancer is a major cause of death globally, and particularly in developed countries." | ( Avan, A; Farjami, Z; Ferns, GA; Ghayour-Mobarhan, M; Heydari-Majd, M; Hosseinnia, M; Mehramiz, M; Miri, M; Mohammadpour, A; Rezayi, M; Samadi, S; Tabadkani, M, 2019) |
| "Breast cancer is the leading cause of cancer death among women." | ( Ma, R; Zhai, X; Zhang, L; Zhu, X, 2019) |
| "Breast cancer is the most relevant type of cancer and the second cause of cancer- related deaths among women in general." | ( Caetano, W; César, GB; Consolaro, MEL; Damke, E; Damke, GMZF; Gonçalves, RS; Hioka, N; Kimura, E; Montanha, MC; Souza, RP, 2020) |
| "Breast cancer is the most common malignancy in women." | ( Mantzoros, CS; Panagiotou, G; Papakonstantinou, E; Polyzos, SA; Vagionas, A, 2019) |
| "BACKGROUND Breast cancer is the most prevalent cancer and the leading cause of cancer death among women." | ( Jin, X; Xiong, H; You, C, 2018) |
| "Breast cancer is the most common malignancy of women all over the world." | ( Altıparmak, B; Gümüş Demirbilek, S; Korkmaz Toker, M; Turan, M; Uysal, Aİ, 2019) |
| "Breast cancer is the most frequent malignancy among females worldwide." | ( Azam, F; Eid, EEM; Halim, MA; Hassan, M; Taban, IM, 2018) |
| "Breast cancer is one of the leading types of cancer in women worldwide." | ( Toropov, AA; Toropova, AP, 2018) |
| "Breast cancer is the most frequently diagnosed cancer in women worldwide." | ( Ren, G; Shi, Z; Teng, C; Yao, Y, 2018) |
| "Breast cancer is a complex disease driven by multiple factors including both genetic and epigenetic alterations." | ( Dakeng, S; Dittharot, K; Patmasiriwat, P; Promkan, M; Suebsakwong, P; Suksamrarn, A, 2019) |
| "Breast cancer is the second leading cause of death in women worldwide." | ( Hasan, MA; Sarker, SR; Shakil, MS, 2019) |
| "Breast cancer is the second leading cause of death among women in the US." | ( Abdul-Karim, F; Aguila, B; Bedogni, B; Bonk, KW; Keri, RA; Savadelis, A; Thakur, V; Welford, SM; Zhang, K; Zmina, P, 2019) |
| "Breast cancer is a major global health problem, and most of the chemotherapeutic agents are highly toxic with long-term side effects." | ( Abdullah, ML; Al-Hoshani, A; Al-Shabanah, O; Hafez, MM, 2018) |
| "Breast cancer is a disease where cells in the tissue of the breast, grow and divide without normal control." | ( Jaitak, V; Sharma, R, 2020) |
| "Breast cancer is currently the most common cancer in women worldwide." | ( Khazaei, M; Pazhouhi, M, 2019) |
| "Normally, 35% of breast cancer is Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2)-positive that predisposes to poor prognosis and relapse, while ethanol drinking leads to invasion of their ERBB2 positive cells triggering the phosphorylation status of mitogen-activated protein kinase." | ( Balzano, A; Biancolella, M; Campagna, P; Floris, A; Frank, J; Luo, J; Orlandi, A; Orrù, S; Pucci, S; Ramani, K; Tomasi, ML; Zhou, J, 2019) |
| "Breast cancer is the most common malignancy in the world with the highest rate of morbidity and mortality." | ( Alivand, MR; Bayat, S; Mansoori Derakhshan, N; Mansoori Derakhshan, S; Shekari Khaniani, M, 2019) |
| "Breast cancer is a heterogeneous disease, and the complexity of breast carcinogenesis is associated with epigenetic modification." | ( Dowhan, DH; Muscat, GEO; Wang, SM, 2019) |
| "Breast cancer is a common malignancy with poor prognosis." | ( Du, M; Gu, HF; Mao, XY, 2020) |
| "Breast cancer is one of the most common malignancies and the major cause of cancer-related death in women." | ( Bai, R; Huang, X; Jiang, X; Li, M; Li, X; Lin, D; Liu, Z; Mai, D; Pan, L; Su, J; Tan, L; Tan, W; Yang, J; Ye, Y; Zhang, B; Zhang, J; Zhao, Q; Zheng, J; Zheng, Y; Zuo, Z, 2019) |
| "Breast cancer is one of the leading causes of cancer deaths in female worldwide." | ( Dai, K; Guo, Y; Jin, X; Wei, Y; Xu, Q; Zhou, J, 2019) |
| "Breast cancer is the most prevalent cancer diagnosis in women, with triple-negative and human epidermal growth factor 2 (HER2)-enriched advanced breast cancers having the poorest prognoses." | ( Fernando, W; Greenshields, AL; Hoskin, DW, 2019) |
| "Breast cancer is the second leading cause of cancer death among US women; hence, identifying potential drug targets is an ever increasing need." | ( Bittner, M; Datta, A; Hua, J; Lopes, R; Sima, C; Vundavilli, H, 2019) |
| "Breast cancer is the leading cause of death among women worldwide." | ( Arif, JM; Bhatt, MLB; Dhasmana, A; Lohani, M; Raza, S, 2019) |
| "Breast cancer is the second leading cause of cancer death in women with increasing incidence." | ( Asadi, M; Boroumand, N; Davoodian, M; Hashemy, SI; Jafarian, AH; Mehrabi Bahar, M, 2019) |
| "Breast cancer is the most common malignancy and also the second leading cause of cancer mortality in women globally." | ( Chen, Z; Hu, H; Lao, YH; Leong, KW; Li, M; Mintz, RL; Shao, D; Tao, Y; Wang, HX, 2019) |
| "Breast cancer is one of the leading fatal diseases for women worldwide who cannot have surgery typically have to rely on systemic chemotherapy to extend their survival." | ( Ding, F; Jin, X; Liu, Y; Lu, X; Wang, J; Wei, Y; Yang, S, 2019) |
| "Breast cancer is the most common malignancy among young women of reproductive age." | ( Amant, F; Huitema, ADR; Lok, CAR; Passier, JLM; Schuurman, TN; van der Wall, E; Witteveen, PO, 2019) |
| "Breast cancer is a devastating disease, with different types of breast cancer recurring locally or distant as metastatic/advanced disease following initial treatment." | ( Brutkiewicz, RR; Liu, J; Seki, T; Tsuji, M, 2019) |
| "Breast cancer is a leading cause of mortality in women across the globe." | ( Arfuso, F; Dharmarajan, A; Mandal, S; Sethi, G; Warrier, S, 2019) |
| "Breast cancer is the most common cancer in women." | ( Gulmez, A, 2019) |
| "Breast cancer is the most common type of carcinoma in women worldwide, but the mechanisms underlying tumour development and progression remain unclear." | ( Chen, Y; Chen, Z; Feng, H; Jiang, X; Luo, Y; Shi, F; Yu, J; Zhang, C; Zhao, L; Zheng, K, 2019) |
| "Breast cancer is the most prevalent cancer in women worldwide, which remains incurable once metastatic." | ( Chen, Y; Guo, C; Jin, L; Pan, Y; Shen, Y; Shi, W; Tang, T; Wang, Y; Wu, Y; Xia, T; Xing, Y; Yin, X; Zhang, Y, 2019) |
| "Breast cancer is a group of multigenic diseases." | ( Aristizábal, F; Ariza Márquez, YV; Briceño, I; Niño, LF; Yosa Reyes, J, 2019) |
| "Breast cancer is a prominent cause of death among women worldwide." | ( Cao, Y; Feng, YH; Gao, LW; Jin, F; Jin, QX; Li, XY; Lu, SL; Wang, YY; Wei, MJ; Xu, YY, 2019) |
| "Breast cancer is the most common cancer among women worldwide, and approximately 70% of breast cancers are hormone receptor-positive and express estrogen receptor-α (ERα) or/and progesterone receptor." | ( Cao, XC; Chen, AX; Chi, JR; Ge, J; Liu, BW; Yu, Y; Yu, ZH, 2019) |
| "Breast cancer is the second most common cause of cancer-related death among women." | ( Garcia-Estevez, L; Moreno-Bueno, G, 2019) |
| "Breast cancer is one of the most aggressive and pervasive cancers identified in females." | ( Liu, T; Wang, X; Yao, Y; Zhang, D, 2019) |
| "Breast cancer is the most frequent diagnosed cancer among women with a mortality rate of 15% of all cancer related deaths in women." | ( Jain, S; Kumar, S; Paul, A; Raj, A; Roy, R; Singhai, A; Sonkar, AA, 2018) |
| "Breast cancer is a severe threat to the health of women, and the metastasis of tumor cells leads to high mortality in female patients." | ( Chen, Q; Chen, Y; Han, X; He, W; Lu, E; Sha, X; Sun, Y, 2019) |
| "Breast cancer is the most common invasive cancer in women, and the second main cause of deaths in women, after lung cancer." | ( Bhatia, R; Rawal, RK, 2019) |
| "Brain metastatic breast cancer is challenging to treat due to the presence of the blood-brain barrier (BBB) and a lack of ability to target precisely." | ( Chaudhary, P; Kumar, P; Ranjan, AP; Treuren, TV; Vishwanatha, JK, 2019) |
| "Breast cancer is the most common malignant disease among women worldwide and the novel therapeutic agents are urgently needed." | ( Chen, M; Deng, W; Lee, K; Li, Y; Long, Q; Qin, G; Qiu, H; Shi, D; Tang, Y; Wang, S; Wang, X; Xu, X; Zhai, Q; Zhang, C; Zhang, K, 2019) |
| "Breast cancer is characterized by cellular and molecular heterogeneity." | ( Morales-Montor, J; Segovia-Mendoza, M, 2019) |
| "Metastatic breast cancer is regarded as an incurable entity." | ( Aguirre, LE; Mahtani, R; Ramdial, JL; Torres, A; Vogel, CL, 2019) |
| "Breast cancer is one of the leading causes of cancer-related morbidity and mortality among women worldwide." | ( Azevedo, A; Faria, J; Martel, F; Negalha, G, 2019) |
| "Human breast cancer is a malignant form of tumor with a relatively high mortality rate." | ( Chao, C; Chen, JY; Ren, GP; Tang, GJ; Tang, GY; Yin, L; Zhang, W; Zhou, R, 2019) |
| "Breast cancer is associated with high mortality due to tumor metastasis." | ( Du, Y; He, Z; Kan, Q; Li, N; Liu, R; Lu, Q; Song, H; Sun, J; Wang, H; Wang, K; Wang, M; Wang, Y; Yang, W; Ye, H; Yu, B; Zhang, H; Zhang, W; Zhong, L, 2019) |
| "Breast cancer is a global public health problem where it is the second most prevalent cancer." | ( El-Sayed, Y; Menshawy, S; Sadek, KM; Taha, NM; Zeweil, MM, 2019) |
| "Breast cancer is the most diagnosed malignancy among women in the United States." | ( Colacino, JA; Gonzalez, TL; Rae, JM, 2019) |
| "Breast cancer is the most common malignancy in women of developed countries." | ( Alorda-Clara, M; Gaya-Bover, A; Oliver, J; Pons, DG; Roca, P; Sastre-Serra, J; Vilanova-Llompart, J, 2019) |
| "However, breast cancer is the most common form of cancer and second leading cause of death among women." | ( Agarwal, T; Jaiswal, M; Khandewal, R; Khanna, M; Pant, H; Priyadarshni, R; Qadri, SK; Saxena, R; Sejwal, P, 2019) |
| "Breast cancer is worldwide commonly found malignancy in women and effective treatment is regarded as a huge clinical challenge even in the presence of several options." | ( Ahmed, S; Fathi, N; Fratantonio, D; Hasan, MM; Khan, H; Rastrelli, L; Sharifi, S; Ullah, H, 2019) |
| "Breast cancer is the most frequent cancer in women." | ( Barbrel, B; Beaudoux, V; Blin, G; Kantor, G; Zacharatou, C, 2019) |
| "Breast cancer is the most common female-specific malignancy in Taiwan and developed countries worldwide, and its incidence continues to grow." | ( Hou, MF; Lee, YC; Wang, CH; Wang, YY; Yang, YF; Yuan, SF, 2019) |
| "Nearly 75% of breast cancers are hormone receptor-positive (HR+) and human epidermal growth factor receptor type 2-negative (HER2-), making endocrine therapy the mainstay of treatment for HR+ and HER2- combination." | ( Li, J; Shao, Z; Wang, Z, 2019) |
| "Breast cancer is a leading cause of cancer mortality in developed countries." | ( Chhabra, M; Clark, C; Gudi, SK; Manzari, N; Mousavi, SM; Naik, G; Rahmani, J; Thompson, J; Varkaneh, HK; Zhang, Y, 2020) |
| "Breast cancer is a highly aggressive disease contributing to high mortality rate among females across the globe owing to wide geographical variations, change in lifestyle along with rapid tumor growth, drug resistance, and high metastasis rate." | ( Agrawal, U; Bondhopadhyay, B; Hussain, S; Khan, A; Kumar, R; Mehrotra, R; Nazir, SU; Rasool, I; Singh, A; Singh, N; Tanwar, P; Tripathi, R, 2019) |
| "Breast cancer is a neoplastic disease with high morbidity and mortality in women worldwide." | ( Castro-Vázquez, SS; De La Fuente-Granada, M; González-Arenas, A; Guerrero-Rodríguez, SL; Mondragon-Peralta, A; Pérez-Tapia, SM; Vásquez-Bochm, LX; Velasco-Velázquez, MA; Velázquez-Paniagua, M, 2019) |
| "Breast cancer is the most prevalent cancer and one of the most important causes of death in women throughout the world." | ( Amin, N; Asemi, Z; Reiter, RJ; Shafabakhsh, R, 2019) |
| "However, because breast cancer is a highly heterogeneous disease, the responses of different patients to everolimus may vary." | ( Guan, X; Li, C; Li, L; Liu, B; Ma, F; Qian, H; Xu, B; Yi, Z, 2019) |
| "1." | ( Jiang, G; Li, Z; Liu, S; Shan, C; Wang, X; Zhou, X, 2020) |
| "Breast cancer is one of the common types of malignancy worldwide and in Pakistan." | ( Akram, B; Alvi, M; Azmi, MB; Effendi, MUN; Ghani, F; Jafri, L; Jahan, M; Khan, S; Lateef, T; Mudassir, HA; Qureshi, SA; Raheem, A; Rais, S; Udani, SK, 2019) |
| "Breast cancer is one of the main diagnosis cancers annually worldwide." | ( Gu, X; Liang, X; Liu, J; Peng, Y; Tang, Y; Zhao, Y, 2019) |
| "Breast cancer is the leading cause of death in women." | ( Chen, M; Mu, X; Singh, S; Xiao, B; Yang, B; Zhang, B, 2019) |
| "Breast cancer is one of the major malignancies threatening women's health worldwide, and chemotherapy tolerance has become a severe limitation of clinical treatment." | ( Chen, Y; Jiang, H; Ren, F; Zhang, W, 2019) |
| "Breast Cancer is common in women, but its etiology is not yet fully understood." | ( Abreu, LC; Baracat, EC; Baracat, MCP; Barros, EPM; Cipolla-Neto, J; Simões, R; Soares Junior, JM; Sorpreso, ICE; Valenti, VE; Veiga, ECA, 2019) |
| "Breast cancer is the most prevalent malignancy and second leading cause of death in women worldwide, with hormone receptor-positive luminal breast cancers being the most widespread subtype." | ( Chumakova, A; Esakov, EL; Gullapalli, K; Hale, J; Jensen, J; Lathia, J; Reizes, O; Richards, EG; Torre-Healy, L; Trivedi, D; Wessely, O, 2019) |
| "The breast cancer is the leading cause of death in women." | ( Dang, C; Kang, L; Li, K; Wang, H; Zhang, Y; Zhu, K, 2019) |
| "While breast cancer is associated with a higher risk of incident stroke, bleeding events remained similar." | ( Belarte Tornero, LC; Contreras Mármol, H; Cruz-Utrilla, A; de Lara Delgado, G; Guedes Ramallo, P; Huertas Nieto, S; Martínez-Cámara, A; Pardo Sanz, A; Portero-Portaz, JJ; Rincón, LM; Salido Tahoces, L; Tamayo Obregon, A; Zamorano Gómez, JL, 2019) |
| "BACKGROUND Breast cancer is one of the most malignant tumors worldwide." | ( He, H; Li, M; Li, S; Liu, C; Ren, H; Sheng, Y; Wang, C; Wang, T; Zhou, Q, 2019) |
| "Breast cancer is the most incident cancer among women worldwide and in the United States." | ( Hussain, F; Santos, JM, 2019) |
| "Breast cancer is the second most common primary cancer associated with MPE, but the efficacy and safety of intrapericardial carboplatin (CBDCA) have never been evaluated in breast cancer." | ( Fujisawa, T; Imai, H; Kaira, K; Kotake, M; Minato, K; Yanagita, Y, 2019) |
| "Breast cancer is the second leading cause of cancer-related mortality in women." | ( Gupta, N; Srivastava, SK, 2019) |
| "Breast cancer is also highly heterogeneous, which hinders the identification of individual cells with the capacity to survive anticancer treatment." | ( Ochiya, T; Prieto-Vila, M; Sasaki, H; Shimomura, I; Takahashi, RU; Usuba, W; Yamamoto, Y, 2019) |
| "Breast carcinoma is a multifaceted-etiology malignancy." | ( Bal, A; Goyal, R; Gupta, T; Sahni, D; Singh, G, 2020) |
| "Breast cancer is the most common cancer among women globally." | ( Arora, D; Bagadi, SAR; Bhatnagar, A; Chintamani, C; Malvia, S; Pradhan, D; Sarin, R; Saxena, S, 2019) |
| "Breast cancer is the most common type of malignancies in women worldwide, and genotoxic chemotherapeutic drugs are effective by causing DNA damage in cancer cells." | ( Boonnoy, P; Khongkow, M; Kongsema, M; Lam, EW; Vongsangnak, W; Wong-Ekkabut, J; Wongkhieo, S, 2019) |
| "Breast cancer is a multifactorial disease and its etiology is linked to multiple risk factors." | ( Abolhassani, M; Akbari, H; Asadikaram, G; Fallah, H; Heidari, MR; Khazaeli, P; Moazed, V; Paydar, P; Zeynali Nejad, H, 2019) |
| "TAM-R breast cancer is characterized by Del-1 overexpression and tumor progression can be inhibited by Del-1 depletion, which restores TAM sensitivity." | ( Chae, YS; Jeong, JH; Jung, JH; Kang, SH; Kim, EA; Kim, WW; Lee, J; Lee, SJ; Park, HY; Park, JH; Park, JY, 2019) |
| "Breast cancer is one of the most prevalent cancers in women." | ( Dai, J; Dong, L; Qin, S; Wang, Y; Zhang, B; Zhang, Y; Zheng, P, 2019) |
| "Breast cancer is one of the most serious cancers worldwide, and chemotherapy resistance frequently drives cancer progression." | ( Feng, X; Gao, C; He, Y; Hou, S; Shan, M; Yang, Y; Zhang, G; Zhang, L; Zhang, R, 2019) |
| "Breast cancer is the major cause of tumor-associated mortality in women worldwide, with prognosis depending on the early discovery of the disease and on the type of breast cancer diagnosed." | ( Bujak, IT; Cipak Gasparovic, A; Milkovic, L; Rodrigues, C; Soveral, G; Tomljanovic, M, 2019) |
| "Its safety for breast cancer is the same as for only estrogen therapy and better than for estrogen-gestagen therapy." | ( Fait, T, 2019) |
| "However, breast cancer is heterogenous and associations with heavy metals vary by subtype." | ( Argos, M; Chen, HY; Erdal, S; Gann, PH; Kresovich, JK; Rauscher, GH, 2019) |
| "Breast cancer is a leading cancer in women and is considered to be the second-most common metastatic cancer following lung cancer." | ( Goli, M; Mechref, Y; Mirzaei, P; Peng, W, 2019) |
| "Breast cancer is one of the leading causes of death worldwide and is the result of dysregulation of various signaling pathways in mammary epithelial cells." | ( Avelino-Cruz, JE; Felix, R; Flores, A; González-González, L; González-Ramírez, R; Monjaraz, E, 2019) |
| "Breast cancer is the most commonly occurring neoplasm in females, comprising 16% of all female cancers worldwide." | ( Aaseth, J; Akbari, A; Bjørklund, G; Chartrand, MS; Chirumbolo, S; Jouybari, L; Kiani, F; Sanagoo, A; Sayehmiri, F; Sayehmiri, K, 2019) |
| "Breast cancer is second most leading cause of death in all over the world and not only limited to the females." | ( Kohli, K; Mangla, B; Neupane, YR; Singh, A, 2019) |
| "Breast cancer is the leading cause of cancer-related death in women worldwide." | ( Chen, H; Fang, J; Jiang, S; Ruan, Q; Sun, J; Yang, X; Zhang, M; Zhang, Y; Zhou, F; Zhou, W; Zhu, T, 2019) |
| "Breast cancer is the most common nonskin cancer among women in the United States and the second leading cause of cancer death." | ( Barry, MJ; Cabana, M; Caughey, AB; Davidson, KW; Doubeni, CA; Epling, JW; Krist, AH; Kubik, M; Landefeld, CS; Mangione, CM; Owens, DK; Pbert, L; Silverstein, M; Tseng, CW; Wong, JB, 2019) |
| "Breast cancer is the most common malignancy in women, and neoadjuvant chemotherapy has been recommended to the patients with locally advanced breast cancer as the initial treatments." | ( Bayarmaa, B; Lu, J; Peng, J; Wang, Y; Wu, Z; Xu, S; Yan, T; Yin, W; Zhou, L, 2019) |
| "Breast cancer is the most frequent carcinoma in females, which could be classified to 4 subtypes and the current treatment is still far from satisfactory." | ( Du, Y; Wang, J; Wang, P, 2019) |
| "Breast cancer is the most prevalent cancer in women worldwide, which remains incurable once metastatic." | ( Chen, X; Deng, S; Jin, L; Li, X; Ni, L; Pan, Y; Tang, T; Wang, Y; Xia, T; Zen, K; Zhang, Y; Zhu, G; Zhu, Q, 2019) |
| "Breast cancer is the most commonly diagnosed malignancy in females, the etiology being multifactorial and includes the role of lifestyle exposure to DNA-damaging chemicals such as dietary carcinogens benzo (a) pyrene (BaP) and 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP)." | ( David, RM; Gooderham, NJ; Malik, DE, 2019) |
| "Breast cancer is the most common neoplasm, comprising 16% of all women's cancers worldwide." | ( Bjørklund, G; Chirumbolo, S; Doşa, MD; Hosnedlova, B; Islami, F; Jouybari, L; Kiani, F; Kizek, R; Sanagoo, A; Sayehmiri, F, 2020) |
| "Breast cancer is a worldwide commonly found malignancy in women and effective treatment is regarded as a huge clinical challenge even in the presence of several treatment options." | ( Chatgilialoglu, C; Di Bella, G; Ferreri, C; Hanikoglu, A; Hanikoglu, F; Kucuksayan, E; Menounou, G; Ozben, T; Sansone, A, 2020) |
| "HER2-positive breast tumors are found in 25-30% of patients with breast cancer and are characterized by aggressive course and reduced sensitivity to both chemotherapy and hormone therapy." | ( Alexandrov, VA; Baranenko, DA; Bespalov, VG; Filatova, LV; Osipov, MA; Panchenko, AV; Semenov, AL; Semiglazova, TY; Stukov, AN; Tyndyk, ML; Yurova, MN, 2019) |
| "Breast cancer is one of the most lethal types of cancer in women worldwide." | ( Abu-Irmaileh, B; AbuThiab, T; AlBayyari, S; Hameduh, T; Mubarak, MS; Zalloum, H; Zalloum, W; Zihlif, M, 2020) |
| "Breast cancer is the most frequent cancer affecting women worldwide." | ( Hirano, Y; Komatsu, Y; Okumura, S, 2020) |
| "Breast cancer is the second in mortality rate malignancy among women." | ( Constantinou, AI; Gregoriou, G; Mesaritis, A; Neophytou, CM, 2019) |
| "Breast cancer is the most common malignancy in women worldwide, accounting for 25% of cases of all cancers and is responsible for approximately 500,000 deaths per year." | ( Auletta, L; Basso, L; Fatone, G; Fiordelisi, MF; Greco, A; Mancini, M; Meomartino, L; Salvatore, M, 2019) |
| "Breast cancer is a global problem, and a large number of new cases are diagnosed every year." | ( Cai, R; Chen, S; Fan, Y; Guan, X; Li, Q; Lin, S; Luo, Y; Ma, F; Wang, J; Xu, B; Yuan, P; Yue, J; Zhang, P, 2019) |
| "Breast cancer is one of the most common causes of mortality in women." | ( Seo, KI; Won, YS, 2020) |
| "Breast cancer is a leading cause of cancer-related death in women; however, chemotherapy of breast cancer is often hindered by dose-limiting toxicities, demonstrating the need for less toxic approaches to treatment." | ( Fernando, W; Greenshields, AL; Holbein, BE; Hoskin, DW; Power Coombs, MR, 2019) |
| "Breast cancer is the second cause of death in the world." | ( Aghamiri, S; Jafarpour, A; Shoja, M, 2019) |
| "Breast cancer is one of the most common cancers diagnosed among women worldwide." | ( Hayashi, T; Hou, XW; Li, LZ; Shang, XY; Song, SJ; Wang, W; Yao, GD; Zhang, Y; Zhang, YY, 2019) |
| "Breast cancer is one of the main causes of malignancies in females." | ( Hemida, AS; Holah, NS, 2020) |
| "Breast cancer is the most frequently occurring cancer among women worldwide." | ( Chattipakorn, N; Chattipakorn, SC; Leemasawat, K; Phrommintikul, A, 2020) |
| "Breast cancer is the most common cause of deaths in women." | ( Al-Sheddi, ES, 2019) |
| "Most of breast cancers are hormonedependent." | ( Gompel, A, 2019) |
| "Breast cancer is one of the most frequent and malignant types of cancer in women, with an increasing morbidity and mortality rate; in particular, treatment of triple negative breast cancer remains a challenge, since the efforts made with targeted therapies were ineffective." | ( Adorno, G; Catani, MV; Gasperi, V; Savini, I; Vangapandu, C; Ventimiglia, G, 2019) |
| "Breast cancer is one of the biggest global dilemmas and its current therapy is to target the hormone receptors by the use of partial agonists/antagonists." | ( Acharya, R; Bose, P; Chacko, S; Lapenna, A; Pattanayak, SP, 2019) |
| "Breast cancer is one of the leading causes for cancer related deaths in women, and early detection is extremely important to improve survival rates." | ( Nyayapathi, N; Xia, J, 2019) |
| "Breast cancer is the most common cancer among women." | ( Omidi, M; Ramshini, S; Rouhani, M, 2019) |
| "Breast cancer is one of the most frequent malignancies in the female population." | ( Bao, H; Chen, H; Chen, J; Cong, D; Jia, J; Li, Q; Li, Y; Liu, Z; Luan, X; Lv, Z; Meng, Q; Pei, J; Ren, Z; Sun, F; Tang, H; Wang, L; Yang, Y; Zhao, W; Zhou, X, 2020) |
| "Breast cancer is a frequent female malignant tumor with high mortality and poor prognosis." | ( Jiao, Y; Li, Y; Liu, Y; Luo, Z, 2019) |
| "Breast cancer is the most common cancer in women and several perioperative factors may account for tumor recurrence and metastasis." | ( Huang, YH; Lai, HC; Lee, MS; Lou, YS; Lu, CH; Wong, CS; Wu, ZF; Yu, JC, 2019) |
| "Breast cancer is the most frequently diagnosed malignancy and the second common cause of death in women worldwide." | ( Bai, R; Liang, Z; Shim, H; Wu, R; Xie, Y; Yao, C; Yoon, Y; Yu, W, 2020) |
| "Breast cancer is the second most commonly diagnosed cancer in women worldwide." | ( Wei, HC, 2019) |
| "Breast cancer is the most prevalent cancer among women worldwide." | ( Chen, H; Chen, T; Cui, R; He, Y; Huang, X; Liang, G; Tao, Z; Wang, C; Wang, L; Wu, W; Yang, L; Yu, Y; Zhao, L; Zheng, B; Zhu, Z, 2019) |
| "Breast cancer is the leading cause of death in women among all cancer types." | ( Al-Jawadi, A; Alhaj, S; Dharmawardhane, S; Gollahon, L; Moussa, H; Moustaid-Moussa, N; Ramalingam, L; Rasha, F, 2020) |
| "Breast cancer is a leading cause of cancer death among women worldwide." | ( Peilong, C; Wei, T; Xiaojun, X, 2020) |
| "Breast cancer is the most prevalent malignancy among women." | ( Gu, Y; Ji, H; Li, D; Niu, X; Wang, J; Wang, Y; Yin, L; Zhang, H; Zhang, Q; Zhou, X, 2020) |
| "Breast cancer is the commonest cancer in women worldwide." | ( Bhandarkar, P; Deepa, KV; Gadgil, A; Löfgren, J; Mehare, S; Roy, N, 2020) |
| "Breast cancer is the most common cancer of women." | ( Chadha, P; Goswami, M; Kumar, D; Mehta, A; Panaych, A; Panigrahi, M; Suryavanshi, M; Vishwakarma, G, 2019) |
| "Breast cancer is the most common cancer in women, with more than 1." | ( Baker, JR; McCluskey, A; Sakoff, JA, 2020) |
| "Breast cancer is the current leading cause of cancer death in females worldwide." | ( Abdelhasib, M; Abdelsayed, R; Alhashim, A; Elmarakby, AA; Katary, MA, 2019) |
| "Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in women." | ( Lim, W; Park, S; Park, W; Song, G, 2019) |
| "Breast cancer is the most common type of cancer among women." | ( Abiri, A; Afzalipour Khoshkbejari, M; Amanollahi, S; Cho, CH; Jabbarzadeh Kaboli, P; Li, M; Mohammadi, M; Mokhtarian, R; Shen, J; Vazifemand, R; Wu, X; Xiao, Z; Yazdi Sani, S; Zhao, Y, 2020) |
| "Breast cancer is the most common type of invasive cancer and one of the leading causes of cancer death in women worldwide." | ( Dong, J; Liu, S; Tian, C; Wang, H; Xu, R; Zhang, C, 2020) |
| "Breast cancer is one of the most common malignant tumors worldwide." | ( Gao, Y; He, YQ; Hu, PC; Li, K; Pan, WT; Tian, YH; Wang, Y; Wei, L; Xu, XL; Zhang, JW, 2019) |
| "Breast cancer is the second most common cause of cancer-related mortality among women around the world." | ( Avan, A; Cho, WC; Hasanian, SM; Khazaei, M; Soleimanpour, S; Yaghoubi, A, 2019) |
| "Breast cancer is the most frequently diagnosed malignancy in women, and comorbidities like hypertension and obesity diminish their quality of life and negatively affect their response to chemotherapy." | ( Becerril-Alarcón, Y; Benítez-Arciniega, AD; Campos-Gómez, KA; Campos-Gómez, S; Reyes-Barretero, DY; Soto-Piña, AE; Valdés-Ramos, R; Valdez-Andrade, JJ, 2019) |
| "BACKGROUND Breast cancer is a common malignant tumor worldwide." | ( Sun, Y; Tong, Y; Wang, W, 2019) |
| "Breast cancer is one of the leading causes of mortality specifically for the women." | ( De, A; Jawahar, N; Jubee, S; Reddy, ES, 2020) |
| "Breast cancer is the most incident and mortal cancer type in women, with an estimated 2 million new cases expected by 2020 worldwide, with 600,000 deaths." | ( Alves, RJ; Gomes, ER; Oliveira, MC; Ottoni, FM; Pádua, RM; Silva, IT, 2020) |
| "Breast cancer is the second leading cause of deaths in women globally." | ( Chanda, D; Dudi, RK; Fatima, K; Iqbal, H; Khan, F; Kumar, Y; Luqman, S; Mondhe, DM; Negi, AS; Shanker, K; Tabassum, M; Verma, AK, 2020) |
| "Breast cancer is one of the most prevalent and reoccurring cancers and the second most common reason of death in women." | ( Al-Suhaimi, EA; Almatroudi, A; Alomary, MN; Alzohairy, MA; Ansari, MA; Chung, IM; Farooqui, Z; Rajakumar, G; Sajid Jamal, QM; Thiruvengadam, M, 2021) |
| "Breast cancer is one of the most common malignancies in women worldwide and is associated with a variety of risk factors." | ( Ahamada, H; Bai, Z; Chen, X; Wang, C; Zhang, T, 2019) |
| "Breast cancer is an important and common tumour among women worldwide." | ( Jiao, K; Li, Z; Shen, Z; Teng, M, 2020) |
| "Breast cancer is the most common cancer among American women and a major cause of mortality." | ( Curtis, C; Ducker, GS; Graves, EE; Li, AM; Li, Y; Liu, L; Massagué, J; Melemenidis, S; Rabinowitz, JD; Rankin, EB; Seoane, JA; Thompson, CB; Vanharanta, S; Xiao, Y; Ye, J; Zhou, Y, 2020) |
| "Breast cancer is the fifth most prevalent cause of death among women worldwide." | ( Al-Mansoub, MA; Al-Wajeeh, AS; Harvey, TM; Ismail, MN; Khalid, IA; Latiff, A; Salhimi, SM, 2020) |
| "Breast cancer is the most common malignant tumor in women." | ( Jiang, YH; Li, XX; Meng, FD; Sui, CG; Sun, SL; Wang, DQ; Zheng, J, 2020) |
| "Breast cancer is the leading cause of death in women worldwide, with resistance to current therapeutic strategies, including tamoxifen, causing major clinical challenges and leading to more aggressive and metastatic disease." | ( Hanif, R; Jansson, PJ; Kovacevic, Z; Lim, SC; Maqbool, SN; Park, KC; Richardson, DR, 2020) |
| "Breast carcinoma is the foremost death causing disease in female population worldwide." | ( Ahmad, Z; Ahmed, F; Farooq, N; Husnain, T; Ijaz, B; Sarwar, MB, 2020) |
| "In India breast cancer is the number one cancer among females with an incidence rate of 25." | ( Chaluvarayaswamy, R; Malila, N; Nandagudi Srinivasa, M; Somanna, SN, 2020) |
| "Breast cancer is the most common cancer among women in Malaysia, and the incidence of 31." | ( Dahlui, M; Donnelly, M; Htay, MNN; Ibrahim Tamin, NSB; Loh, SY; Schliemann, D; Somasundaram, S; Su, TT, 2020) |
| "Breast cancer is the second most common cancer in the world." | ( Farhat, D; Gadot, N; Ghayad, SE; Hussein, N; Icard, P; Le Romancer, M; Léon, S; Lincet, H, 2020) |
| "Advanced stages of breast cancer are frequently complicated by bone metastases which cause substantial cancer-related morbidity and mortality." | ( Göbel, A; Hofbauer, LC; Jaschke, N; Kleymann, A; Rachner, TD, 2020) |
| "Breast cancer is the most common female tumour type and accounts for the leading cancer mortality in women worldwide." | ( Bascialla, L; De Giorgi, A; Gallerani, E; Giaquinto, A; Grigioni, E; Gueli, R; Marrazzo, C; Nigro, O; Pinotti, G; Vallini, I, 2020) |
| "Breast cancer is one of the most common cancers and leading causes of death in the women worldwide." | ( Akbarzadeh, M; Heidari, M; Isazadeh, A; Maroufi, NF; Mohammadian, M; Nouri, M; Pouremamali, F; Rashidi, M; Taefehshokr, S; Vahedian, V; Zahedi, M, 2020) |
| "Breast cancer is the most frequently occurring cancer in women." | ( Abed, A; Amouheidari, A; Ghasemi, A; Haghjooy Javanmard, S; Laher, I; Naji Esfahani, H; Shariati, L; Vaseghi, G, 2020) |
| "Breast cancer is the most common cause of death in women worldwide." | ( Ali, SS; Hashmi, HF; Hassan, FU; Heng, W; Junaid, M; Khan, A; Khan, AA; Rehman, Z; Sayaf, AM; Wei, DQ, 2020) |
| "Breast cancer is the most common cancer spread among women worldwide." | ( Abdul Rahman, H; Ismail, S; Noman, S; Shahar, HK, 2020) |
| "Breast cancer is the leading cause of cancer-related disease in women." | ( Cheng, HG; de Los Campos, G; Gonzalez-Reymundez, A; Li, I; Pathak, A; Pathak, DR; Vazquez, AI, 2020) |
| "Breast cancer is the most frequent cancer among women." | ( Bard, JM; Nazih, H, 2020) |
| "Breast cancer is the most prevalent cancer in females and disease recurrence remains a significant problem." | ( Chan, CWH; Chan, JYW; Choi, KC; McCarthy, A; Miaskowski, C; So, WKW; Tsui, SKW; Waye, MMY; Yeo, W, 2020) |
| "The majority of breast cancers are oestrogen-receptor-positive (ER+) and are subject to endocrine therapy; however, an unpredictable subgroup of patients will develop resistance to endocrine therapy." | ( Alfarsi, LH; Craze, ML; El-Ansari, R; Ellis, IO; Green, AR; Masisi, BK; Mohammed, OJ; Rakha, EA, 2020) |
| "Breast cancer is one of the well-known malignant tumors among women." | ( Ezzati, M; Safa, A; Velaei, K; Yousefi, B, 2020) |
| "However, most breast tumors are immuno-suppressive and only modestly respond to immunotherapy." | ( Fernando, V; Furuta, S; Letson, J; Sharma, V; Walia, Y; Zheng, X, 2020) |
| "Breast cancer is the leading cause of death among women worldwide." | ( Ang, SC; Chai, XY; Chin, X; Gandhi, A; Lo, CH; Mat Sikin, S; Saania, P; Tan, LT; Ting, SSW; Tuan Mat, TNA, 2020) |
| "Breast cancer is the most common type of cancer in women." | ( Bao, Y; Chen, AT; Chen, J; Chen, Z; Deng, G; Ma, J; Xu, W; Yao, G; Yu, ZQ; Zhang, S; Zhou, J, 2020) |
| "Breast cancer is the most common invasive cancer and the second leading cause of cancer death in women after lung cancer." | ( Diao, QP; Guo, H, 2020) |
| "Breast cancer is a heterogeneous disease, and it lacks special tumor markers." | ( An, Y; He, P; Li, R; Zhang, F, 2020) |
| "Breast cancer is the leading cause of cancer death in women." | ( Chen, J; Cong, D; Han, B; Li, Q; Li, Y; Liu, Z; Luan, X; Meng, Q; Pei, J; Ren, Z; Sun, F; Sun, Y; Tang, H; Wang, Z; Yang, Y; Zhang, Z; Zhou, X, 2020) |
| "Breast cancer is a common cancer that occurs due to different epigenetic alterations and genetic mutations." | ( Anwar, H; Badgeley, A; Lakshmikuttyamma, A; Lawrence, K; Murphy, P; Selvakumar, P; Sharma, U, 2020) |
| "Breast cancer is a disease of aging, and the incidence of breast cancer is projected to increase dramatically as the global population ages." | ( Gutierrez, E; Hill, A; Kimmick, G; Liu, J; Sammons, S; Sedrak, MS, 2020) |
| "Breast cancer is the most commonly diagnosed cancer in women, and more than half of breast surgery patients experience severe acute postoperative pain." | ( Cui, Y; Dong, S; Kang, W; Liu, K; Liu, S; Pan, Z; Sun, Q; Wu, H, 2020) |
| "Luminal breast cancer is the most common subtype of breast cancer, representing more than 60% of all breast cancers." | ( Jiang, YZ; Liu, XY; Shao, ZM; Wang, H, 2020) |
| "Breast cancer is the most common type of cancer among women and ranks the second among cancer-related deaths after lung cancer." | ( Ağca, CA; Ahmed, BM; Aybek, H; Çiftci, M; Temel, Y, 2020) |
| "Breast cancer is the commonest cancer among women." | ( Gupta, SD; Haresh, KP; Kazi, M; Mathur, S; Parshad, R; Seenu, V; Suhani, S; Verma, E, 2020) |
| "Breast cancer is the second leading cause of cancer-related deaths among women, largely due to the progression of a significant fraction of primary tumours to the metastatic stage." | ( Agostini, M; Amelio, I; Anemona, L; Butera, A; Candi, E; Cassandri, M; Knight, RA; Lena, AM; Mauriello, A; Melino, G; Montanaro, M, 2020) |
| "Breast cancer is the second leading cause of cancer-related deaths in women." | ( Fu, Q; Guo, L; Huang, M; Peng, Y; Pu, Y; Wu, Y; Zheng, Y, 2020) |
| "Breast cancer is the most common cancer among women in India." | ( Ginsburg, O; Kumar, S; Nair, TS; Singh, R; Sood, B; Srivastava, A; Srivastava, AK; Srivastava, V; Usmanova, G, 2020) |
| "Breast cancer is the most frequently diagnosed malignancy among women and the second leading cause of cancer death worldwide." | ( Chen, M; Cui, L; Li, H; Niu, J; Shi, D; Sun, L; Zhao, P, 2020) |
| "Breast cancer is the most common cancer types among women." | ( Cansaran-Duman, D; Değerli, E; Torun, V, 2020) |
| "Breast cancer is the most common cancer type in women." | ( He, Z; Huang, D; Ling, L; Liu, T; Luo, L; Tang, H; Wang, X; Zhai, D; Zhang, J; Zhang, Q; Zhang, Z; Zheng, G, 2020) |
| "Breast cancer is one of the most common types of cancer among women worldwide." | ( Guven, M; Mete, M; Mutlu, T; Ozoran, E; Talu, CK; Tekin, B; Trabulus, DC, 2020) |
| "Breast cancer is becoming the most common cancer among women of Indian origin." | ( Clark, J; Daniel, S; Gnanapragasam, S; Johnson, MJ; Venkateswaran, C, 2022) |
| "Breast cancer is one of the most life-threatening malignancies with high mortality among women." | ( Adibkia, K; Aghanejad, A; Barar, J; Barzegar-Jalali, M; Dolatkhah, M; Hashemzadeh, N; Omidi, Y, 2020) |
| "Breast cancer is the most common malignancy for women and one of the most common worldwide." | ( Amini, P; Aryafar, T; Ashrafizadeh, M; Eftekhari, SM; Farhood, B; Khalafi, L; Mahdavi, SR; Musa, AE; Najafi, M; Nodooshan, SJ, 2021) |
| "Breast cancer is the most ubiquitous type of neoplasms among women worldwide." | ( Manoharan, R; Natarajan, SR; Ponnusamy, L; Thangaraj, K, 2020) |
| "Breast cancer is a malignancy and one of the most frequent causes of cancer death among women worldwide." | ( Li, M; Liu, Y; Piao, H; Sun, T; Yu, H, 2020) |
| "Breast cancer is a malignant tumor that occurs in the epithelial tissue of the breast gland, the morbidity, and mortality of which continue to increase." | ( Gu, J; Huang, L; Zhang, Y, 2020) |
| "Breast cancer is a heterogeneous cancer with diverse clinical symptoms and an ambiguous molecular spectrum." | ( Bisht, R; Bohra, JS; Chandra, P; Karki, K; Khanna, HD; Shahi, KS, 2019) |
| "Breast cancer is the most prevalent type of cancer among women worldwide." | ( Kuran, D; Pogorzelska, A; Wiktorska, K, 2020) |
| "Breast cancer is a widespread disease that affects women globally." | ( Jothi, EA; Lv, P; Xiao, Z; Yang, J; Zhang, H, 2020) |
| "Breast cancer is one of the leading causes of mortality in women, worldwide." | ( Alvi, SB; Jogdand, A; Rajalakshmi, PS; Rengan, AK, 2020) |
| "Breast cancer is one of the most commonly diagnosed cancer among women globally." | ( Al-Abbasi, FA; Al-Abd, AM; Anwar, F; Bawadood, AS; El-Halawany, AM, 2020) |
| "Breast cancer is the second leading cause of cancer deaths in women worldwide and represents a highly aggressive nature with limited therapeutic options; thus, investigating novel therapeutic agents for breast cancer is much needed." | ( Chang, CF; Chen, YC; Chiu, CC; Chiu, CF; Hung, SW; Lin, YQ; Park, JM, 2020) |
| "Breast cancer is one of the most prevalent cancers in women worldwide." | ( Bi, M; Chen, L; Chen, M; Jin, VX; Li, L; Liu, Z; Tang, D; Tao, H; Wang, H; Xu, X; Yu, W; Zhang, W; Zhang, Z; Zheng, Y; Zhou, Y, 2020) |
| "Breast cancer is the most frequent cancer diagnosed in women and the second most common cancer-causing death worldwide." | ( Gnanapragassam, VS; Horstkorte, R; Nagasundaram, M, 2020) |
| "Breast cancer is a heterogeneous disease typically prevalent among women and is the second-largest cause of death worldwide." | ( Hossen, MS; Khandker, SS; Shakil, MS, 2020) |
| "Breast cancer is the most common invasive cancer in women worldwide." | ( Ingle, JN; Qin, S; Wang, L; Yu, J; Zayas, J, 2020) |
| "Breast cancer is the most frequent cancer amongst women worldwide including in Asia where the incidence rate is rapidly increasing." | ( Chiu, JW; Dawood, S; Huang, CS; Md Yusof, M; Nag, S; Sookprasert, A; Yap, YS, 2020) |
| "Early detection of breast cancer is important in diagnosis and treatment, and so in enhancing patient survival and reducing death rates." | ( Belal, A; Darwish, H; Omran, M; Rashed, R; Zahran, F, 2020) |
| "Her2-dependent breast cancer is treated with pharmacological drugs (eg, Herceptin, lapatinib) that target Her2 signaling." | ( Crawford, DR; Ilic, Z; Saxena, AR; Sripada, V, 2020) |
| "Breast cancer is one of the most prevalent malignancies and leading causes of females' mortality worldwide." | ( Feizollahzadeh, S; Karimi Douna, B; Mahmoudi, R; Mohammadian, M; Rezapour-Firouzi, S; Toofani Milani, A, 2020) |
| "Breast cancer is one of the most frequent cancers among women worldwide." | ( Ding, H; Liu, Y; Lu, H; Qin, X; Ren, T; Wang, S; Wu, Q; Zhang, Y; Zhao, Q, 2020) |
| "Breast cancer is the most common cause of death related to cancer in women, and several studies proved that flavonoids could induce apoptosis in this cancer through different pathways." | ( Arefian, E; Attari, F; Delphi, L; Gholipour, H; Moradi, M; Moridi Farimani, M; Sepehri, H, 2020) |
| "Breast cancer is the common malignancy with high morbidity and mortality in women." | ( Liu, Y; Wu, X; Xu, G; Yan, J; Zhou, Z, 2020) |
| "Breast cancer is the most common cancer among women." | ( Chiu, HH; Hsieh, CC; Kuo, CH; Wang, CH, 2020) |
| "Breast cancer is a complex disease and encompassing different types of tumor." | ( Caixeta, ES; de Oliveira, JC; Dos Santos, MH; Ferreira-Silva, GÁ; Horvath, RO; Ionta, M; Lamartine-Hanemann, SDS; Machado-Santelli, GM; Miyazawa, M; Niero, EL; Rocha-Sales, B; Soncini, R, 2020) |
| "Breast carcinoma is a malignant disease that represents the most common non-skin malignancy and a chief reason of cancer death in women." | ( Amini, E; Behzad, SB; Eisvand, F; Nabiuni, M; Sahebkar, A; Seyfi, D; Shakeri, A, 2020) |
| "Breast cancer is the most common cancer in women and is the second most common cause of death in women." | ( Cumhur Cure, M; Cure, E; Kadiyoran, C; Vatansev, H, 2020) |
| "Breast cancer is the most common cancer in women worldwide, and advanced breast cancer is the leading cause of cancer death in women." | ( Huang, G; Li, M; Li, N; Qiao, J; Xu, L; Yu, J, 2020) |
| "Breast cancer is the most common malignant tumor and usually occurs in women." | ( Li, Q; Li, Y; Liu, X; Xiong, H; Yao, W, 2020) |
| "Breast cancer is the most common malignancy in women worldwide." | ( Ghorbani-Abdi-Saedabad, A; Hanafi-Bojd, MY; Hoshyar, R; Mollaei, H; Parsamanesh, N; Tayarani-Najaran, Z, 2020) |
| "Breast cancer is the leading cause of cancer‑-associated deaths in women." | ( Hao, X; Li, W; Sang, M; Shan, B; Wu, Y, 2020) |
| "Breast cancer is the most common reason of cancer death in women." | ( Li, X; Ma, W; Wang, B; Xu, S; Ye, X; Yu, M; Zhang, J; Zhang, Y, 2020) |
| "Breast cancer is the most deadly type of cancer among females, with 55." | ( Basu, T; Chaudhuri, D; Mandal, N; Shendge, AK, 2021) |
| "Breast cancer is the 2nd leading cause of cancer-related death among women." | ( Ghanbari, F; Mader, S; Philip, A, 2020) |
| "Breast cancer is the most commonly diagnosed noncutaneous malignancy and remains the second leading cause of cancer deaths in women." | ( Cornett, WR; Lucas, C; McKinley, BP; Rinkliff, JM; Tingen, JS, 2020) |
| "Breast cancer is the leading cause of cancer mortality in women worldwide." | ( Alves Passos, CL; Ferreira, C; Fialho, E; Schmidt, B; Silva, JL, 2020) |
| "Breast cancer is frequently characterized by calcifications in mammography." | ( Fushimi, A; Manome, Y; Tachibana, T; Takeyama, H, 2020) |
| "Breast cancer is the second leading cause of death among women globally." | ( Ashfaq Khan, M; Badran, A; Baydoun, E; Choudhary, MI; Imad, R; Mohammad, N; Tul-Wahab, A; Zafar, H, 2020) |
| "HER2-positive breast cancer is an aggressive subtype that typically responds poorly to standard chemotherapy." | ( Brabec, V; Kasparkova, J; Kostrhunova, H; Markova, L; Zajac, J, 2020) |
| "Breast cancer is the second greatest cause of cancer-related death in women." | ( Brindisi, M; Cappello, AR; Fiorillo, M; Frattaruolo, L; Lisanti, MP; Sotgia, F, 2020) |
| "Breast cancer is the most common type of cancer in women and the second leading cause of death worldwide after lung cancer in both men and women." | ( Divakar, S; Rymbai, E; Saravanan, J; Sugumar, D, 2020) |
| "Breast cancer is the most common kind of cancer among women in the world." | ( Farzaneh, S; Noori, S; Nourbakhsh, M; Zarghi, A, 2020) |
| "Breast cancer is making up one-quarter of all new female cancer cases diagnosed worldwide." | ( Alewood, PF; Gruber, CW; Liu, H; Möller, A; Muttenthaler, M, 2020) |
| "Breast cancer is one of the most prevalent diseases threatening women's health today." | ( Feng, X; Han, H; Sun, T; Xu, J; Zhou, W, 2021) |
| "Breast carcinoma is one of the most common malignancies in women." | ( Cai, Z; Ding, W; Feng, Z; Lim, D; Liu, G; Wang, Z; Zhang, F, 2020) |
| "Breast cancer is a malignant disease and a great cause of morbidity and mortality in women." | ( Huang, L; Liu, A; Liu, Q; Yang, F; Zhang, J; Zhang, L, 2020) |
| "Breast cancer is a heterogeneous disease that includes different molecular subtypes." | ( Chen, J; Fan, M; Gao, J; Ge, H; Jiang, C; Li, W; Li, X; Shen, Y; Sun, Y; Wang, Y; Wu, X; Xu, Q; Xue, W; Zhou, L, 2020) |
| "Breast tumors are also surrounded by adipose tissue, which is a major bodily source of ATX." | ( Benesch, MGK; Brindley, DN; Meng, G; Tang, X, 2020) |
| "Breast cancer is a heterogeneous disease with different biological outcome and ability to acquire resistance to therapy." | ( Aničić, J; Avirović, M; Babarović, E; Ban, J; Demaria, M; Georgev, P; Mustać, E; Rajković-Molek, K, 2020) |
| "Breast cancer is one of the most common types among women." | ( Batista, AA; Colina-Vegas, L; Corrêa, RS; de Araujo-Neto, JH; Leite, CM; Martínez-Otero, D; Martins, PR; Silva, CG, 2021) |
| "Breast cancer is the most common cause of cancer-related deaths among women worldwide." | ( Heo, KS; Huynh, DTN; Jeon, H; Jin, Y; Nguyen, TLL, 2020) |
| "Breast cancer is the most common cancer in women and the second leading cause of cancer death." | ( Beidokhti, D; Cho, HM; Ding, H; Molloi, S, 2021) |
| "The prevalence of breast cancer is remarkably increasing worldwide." | ( El-Sherbiny, M; Elsherbiny, NM; Zaitone, SA, 2020) |
| "Invasive breast cancer is highly regulated by tumor-derived cytokines in tumor microenvironment." | ( Dai, J; Dong, G; Fang, R; Fu, J; Guo, X; Li, C; Li, Z; Ma, Q; Ning, Z; Shi, H; Si, C; Xiong, H; Yan, F; Zhang, H; Zhang, J; Zhao, L, 2020) |
| "Lung metastasis of breast cancer is a leading cause of cancer-related death in women." | ( Canup, BSB; Dai, F; Gou, S; Huang, Y; Ke, B; She, Z; Song, H; Xiao, B; Zhang, X, 2020) |
| "Breast cancer is the most common malignancy in women and metastasis is the leading cause of breast cancer-related deaths." | ( Huang, X; Lin, Y; Wang, N; Wang, S; Wang, X; Wang, Z; Yang, B; Zhang, J; Zheng, Y, 2020) |
| "Breast cancer is the second most common malignancy among women." | ( Bastos, FF; Bastos, VLFDC; Bastos-Neto, JDC; Calixto, MRP; Davis, RAH; de Lima, JR; Dos Santos, VL; Fagundes, TR; Madeira, TB; Nixdorf, SL; Panis, C; Rech, D; Victorino, VJ; Zanandrea, AC, 2021) |
| "Breast cancer is the commonest form of cancer among women globally, including in India." | ( Daniel, S; Hutchinson, A; Johnson, MJ; Venkateswaran, C, 2021) |
| "Triple-negative breast cancer is the most aggressive form of breast cancer with limited intervention options." | ( Bhakta-Guha, D; Guha, G; Mahalakshmi, R; Nirekshana, K; Priyanga, J; Sharan Kumar, B; Sridharan, V; Vinoth, P, 2020) |
| "Breast cancer is the leading cause of death among women with malignant tumors worldwide." | ( Huang, C; Huang, H; Jiang, W; Jiao, B; Rixiati, Y; Shi, Y, 2020) |
| "Breast cancer is reported to be the most common cancer among women in India with a high mortality to incidence ratio." | ( Kathrikolly, TR; Nair, S; Shetty, RS, 2020) |
| "Breast cancer is the most common cancer among women and its metastasis which generally observed at the last stage is the major cause of breast cancer-related death." | ( Akbarzadeh, M; Amirzadeh-Iranaq, MT; Ashoori, Z; Ashouri, N; Bizzarri, M; Faridvand, Y; Fattahi, A; Kazemzadeh, H; Maroufi, NF; Mortezania, Z; Nejabati, HR; Nouri, M; Rashidi, MR; Vahedian, V, 2020) |
| "Breast cancer is the most frequently diagnosed cancer in women and the first cause of cancer death in France." | ( Cavadias, I; Héquet, D; Lerebours, F; Rouzier, R, 2020) |
| "Breast cancer is the most commonly diagnosed cancer and is the second leading cause of death in women." | ( Shi, J; Sun, Z; Xu, X; Yang, B; Zhu, D, 2020) |
| "Breast cancer is the leading cause of cancer mortality in women worldwide." | ( Chen, Z; Feng, Z; Li, F; Qiu, J; Sun, J; Xia, L; Xu, Z, 2020) |
| "Breast cancer is the most common cancer type among female worldwide." | ( Dongmin, C; Fei, L; Huimei, H, 2020) |
| "Breast cancer is a type of cancer that begins in the breast tissue." | ( Ma, W; Yang, X, 2020) |
| "ERα-positive breast cancers are successfully treated with tamoxifen; however, a significant number of patients develop tamoxifen-resistant disease." | ( Barkovskaya, A; Itkonen, HM; Mills, IG; Moestue, SA; Prasmickaite, L; Seip, K, 2020) |
| "Breast cancer is one of the most common types of cancer in the world and a major cause of mortality." | ( Bringmann, G; Fayez, S; Kumar, S; Kushwaha, PP; Prajapati, KS; Shuaib, M; Singh, AK, 2020) |
| "Breast cancer is one of the most common female malignant cancers." | ( Dai, H; Hu, L; Huang, P; Jiang, S; Li, Q; Lu, J; Nie, H; Peng, J; Wu, Z; Xu, Y; Yin, W; Zhang, S; Zhang, X; Zhang, Z, 2020) |
| "Breast cancer is surrounded by adipose tissue and has been associated with obesity." | ( Cani, PD; Corbet, C; Delzenne, N; Feron, O; Gallez, B; Gourgue, F; Jordan, BF; Joudiou, N; Mignion, L; Muccioli, GG; Terrasi, R; Van Hul, M; Yelek, C, 2020) |
| "Breast cancer is currently among the most common causes of mortality in women." | ( Barreto, GE; González, J; Keikha, M; Sahebkar, A, 2021) |
| "Breast cancer is the most common cancer in women and the leading cause of cancer mortality in women over 40 it's the year." | ( Avci, CB; Demir, B; Gunduz, C; Lerminoglu, F; Ozates, NP; Shademan, B; Soğutlu, F, 2021) |
| "Breast cancer is one of the most frequent cancers in women and the globally leading cause of cancer-related deaths." | ( Chen, G; Dai, M; Gong, J; Wang, L; Xiong, X; Xu, W; Yuan, L, 2021) |
| "Nowadays, breast cancer is still the leading cause of malignancy-related deaths in women, and incidence and mortality rates of it are expected to increase significantly the next years." | ( Hao, J; Liu, T; Song, S; Wang, X, 2021) |
| "Breast cancer is the major type among the women population globally." | ( Al-Ramadan, SY; Al-Saeedi, FJ; Ben Ammar, R; Elsayed Mohamed, M; Islam, M; Rajendran, P, 2020) |
| "Breast cancer is also known to be responsive to the treatment with steroid hormones, which promotes cancer development and progression; however, the nature of these associations remains unclear." | ( Fujita, T; Ishii, Y; Kambe, J; Nagaoka, K; Sovijit, W; Watanabe, G; Yamaguchi, H, 2021) |
| "Breast cancer is the leading form of cancer in women, which is also hormone- dependent." | ( Malayil, AS; Narayanankutty, A; Poothaadammal, AK, 2021) |
| "Breast cancer is one of the most common malignancies and the second leading cause of death in women." | ( Ambrosio, J; García-Becerra, R; Gómez de León, CT; Morales-Montor, J; Nava-Castro, KE; Segovia-Mendoza, M, 2020) |
| "Breast cancer is one of the most common cancers in women and is associated with a high mortality rate." | ( Ahn, KS; Kim, M; Kim, S; Lee, C; Oh, SR; Park, J; Ryu, HW, 2020) |
| "breast cancer is the most common malignancy in females worldwide and a major cause of cancer-related deaths in both developing and developed countries." | ( Aduayi, OS; Akute, OO; Ige, JT; Olaogun, JG; Omonisi, AE; Omotayo, JA, 2020) |
| "Breast cancer is the most prevalent cancer among females in the world." | ( Asadolahi, M; Darbankhales, S; Darbeheshti, S; Ganjkhanlou, Z; Ghahremani, H; Mirfakhraie, R; Safakish, L; Saket-Kisomi, K; Salami, S; Sirati-Sabet, M, 2020) |
| "Breast cancer is the most commonly diagnosed cancer and is the leading cause of cancer death in women worldwide." | ( Qi, X; Ren, L; Wang, J; Yuan, L; Zhang, Y, 2020) |
| "Basal-like breast cancer is an incurable disease with limited therapeutic options, mainly due to the frequent development of anti-cancer drug resistance." | ( Alcaraz-Sanabria, A; Burgos, M; Corrales-Sanchez, V; Galan-Moya, EM; Martinez-Canales, S; Montero, JC; Nieto-Jimenez, C; Nuncia-Cantarero, M; Ocaña, A; Pandiella, A, 2020) |
| "Breast cancer is the second most commonly identified cancer in women in the United States after skin cancer." | ( Kar, S; Konar, D; Kumar, K; Maru, S, 2022) |
| "Triple negative breast cancer is an aggressive disorder which accounts for at least 15% of breast cancer diagnosis and a high percentage of breast cancer morbidity, hence intensive research efforts are focused on the development of effective therapies to overcome the disease." | ( Alwattar, JK; Chouaib, R; Gali-Muhtasib, H; Mehanna, MM; Sarieddine, R, 2020) |
| "Breast cancer is the most common cancer among women." | ( Fischbach, C; Kalish, M; Pabst, L; Petit, T; Pflumio, C; Pivot, X; Velten, M, 2020) |
| "Breast cancer is known as the most devastating cancer in the global female community and is considered as one of the severe health care burdens in both developed and developing countries." | ( Alhumaydhi, FA; Ali, I; Bourguet-Kondracki, ML; Hussain, A; Hussain, F; Hussain, H; Hussain, J; Hussain, R; Ibrahim, M; Khalid, M; Khalil, AA; Khan, M; Rauf, A; Rengasamy, KRR, 2022) |
| "Breast cancer is the most frequent cancer in women." | ( Martel, F; Romano, A, 2021) |
| "Breast cancer is the most common cancer occurring in women and causing the highest number of deaths among them." | ( Boszkiewicz, K; Piwowar, A; Sawicka, E, 2020) |
| "Breast cancer is a heterogeneous disease where the tumor microenvironment, including extracellular components, plays a crucial role in tumor progression, potentially modulating treatment response." | ( Bogestål, Y; Garre, E; Gustafsson, A; Håkansson, J; Landberg, G; Leiva, MC; Ståhlberg, A; Svanström, A, 2021) |
| "The treatment of breast cancer is often ineffective due to the protection of the tumor microenvironment and the low immunogenicity of tumor cells, leading to a poor therapeutic effect." | ( Dong, Q; Du, C; Du, J; Li, F; Wan, C; Xu, L; Yang, H; Zheng, D, 2020) |
| "Breast cancer is the most common malignant disease in women." | ( Lu, Q; Wang, L; Wang, W; Zeng, S; Zheng, H, 2020) |
| "Breast cancer is the most common cause of cancer death in women, according to Global Cancer Observatory." | ( Cárdenas-García, M; Carrasco-Carballo, A; Guadalupe Hernández-Linares, M; Sandoval-Ramírez, J, 2021) |
| "Breast cancer is the most frequent cancer among women and the most important cause of death." | ( Onsori, H; Rahmati, M; Safi, M, 2022) |
| "Breast cancer is the most common type of cancer." | ( Choi, YJ; Heo, K; Jin, Y; Park, SJ, 2021) |
| "Breast cancer is one of the leading causes of brain metastasis." | ( Al Moustafa, AE; Alam, K; Augustine, R; Hasan, A; Mraiche, F; Zahid, AA, 2021) |
| "Breast cancer is the most frequently diagnosed malignancy and leading cause of cancer-related deaths among women worldwide." | ( Hao, M; Zhang, T; Zhang, W, 2021) |
| "Breast cancer is a common malignant tumor in women, and the anti-cancer effect of selenium (Se) is recognized." | ( Pan, D; Sun, G; Wang, N; Wang, S; Zhu, X, 2021) |
| "Breast cancer is the most prevalent malignancy amongst women worldwide while ovarian cancer represents the leading cause of death among gynecological malignancies." | ( Bleich, S; Hass, R; Hillemanns, P; Kahl, KG; Melzer, C; Stapel, B; von der Ohe, J, 2021) |
| "Breast cancer is the most commonly diagnosed cancer among women and its metastases results in poor survival rates in patients." | ( Othman, AH; Pratap, J; Tandon, M; Winogradzki, M, 2021) |
| "Hormone-dependent breast cancer is the most abundant molecular subtype of the disease." | ( Alhusban, A; Alkhalifa, AE; Ayoub, NM; Ibrahim, DR, 2021) |
| "Breast cancer is the leading cause of cancer death in women." | ( Gu, Y; Ji, H; Li, J; Niu, X; Wang, J; Wang, Y; Yang, Y; Yin, L; Zhang, H; Zhang, Q; Zhou, X, 2021) |
| "Metastatic breast cancer is a significant contributor to mortality among women, but its complex regulation represents a barrier to precision targeting." | ( Gu, Z; Hua, C; Tu, Y; Wei, P; Wei, T; Xiao, M; Yan, L; Zhang, J; Zhou, R, 2021) |
| "Breast cancer is the most diagnosed cancer in women." | ( Feng, ZP; Liu, CG; Xin, HW; Xin, HY; Yang, Z; You, H; Zhang, ZW, 2021) |
| "Up to 80% of breast cancers are grouped as ER-positive, which implies a crucial role for estrogen in breast cancer development." | ( Chan, YS; Chen, FW; Chen, PS; Cheng, TL; Feng, SY; Hsu, HP; Hung, JH; Jiang, JZ; Lai, MD; Lin, FP; Liu, YW; Omar, HA; Phan, NN; Sun, Z; Wang, CY; Yeh, PH; Yen, MC, 2021) |
| "Breast cancer is the most frequently diagnosed malignancy among women." | ( C Marques, MM; D C Vieira, RA; Evangelista, AF; O Silva, VA; Oliveira, RJ; Reis, RM, 2021) |
| "Breast cancer is the most frequently diagnosed cancer in women and the second most common form of cancer, causing death after lung cancer, all across the globe at an alarming rate." | ( Banjare, L; Jain, AK; Thareja, S, 2021) |
| "Metastatic breast cancer is a leading cause of cancer-related death in women worldwide." | ( Brownlie, D; Doughty-Shenton, D; Kitamura, T; M Carlin, L; Nixon, C; O Carragher, N; Yh Soong, D, 2021) |
| "Breast cancer is the most common cancer in females and mostly metastasizes to liver, brain, bones, and lungs." | ( Ahmad, U; Ahmad, W; Hassan, A, 2020) |
| "Breast cancer is a prominent type of malignancy among women with a high rate of mortality." | ( Ahn, KS; Alahmadi, TA; Alharbi, SA; Chinnathambi, A; Jung, YY; Liew, YY; Lin, ZX; Mohan, CD; Preetham, HD; Rangappa, KS; Rangappa, S, 2021) |
| "Breast cancer is currently the most common cancer and the leading cause of cancer death among women worldwide." | ( Li, Q; Peng, X; Song, W; Zhao, R; Zhu, X, 2021) |
| "Breast cancer is one of the leading causes of death worldwide." | ( Ashrafizadeh, M; Bejandi, AK; Farahani, MV; Ghahremaniyeh, Z; Hashemi, F; Hushmandi, K; Khan, H; Saleki, H; Sharifzadeh, SO; Zabolian, A; Zarrabi, A, 2021) |
| "Breast cancer is the leading cause of cancer-related death in women worldwide." | ( Alexandrova, EM; Eyermann, CE; Haley, JD, 2021) |
| "Breast cancer is not associated with increased expression of inflammatory cytokines in PBMCs." | ( Ahmadzadeh, A; Ahmmadpour, F; Mohammadzadeh, G; Rashidi, M; Salmasi, A; Zare Moayedi, M, 2021) |
| "Breast cancer is the most common malignant disease in women all over the world and its chemotherapy outcome is restricted by multidrug resistance." | ( Chen, K; Chen, S; Du, Y; Duan, J; Li, J; Li, X; Lu, W; Luo, Q; Xie, Y; Xu, J; Zhang, Z, 2021) |
| "Breast cancer is the first leading cause of women cancer-related deaths worldwide." | ( Abdin, SM; Mdkhana, B; Omar, HA; Zaher, DM, 2021) |
| "Breast cancer is the most frequently diagnosed cancer among women in both transitioned and transitioning countries and has become a major women's health problem." | ( Basu, P; Mehrotra, R; Ray, K; Srivastava, A; Tripathi, R, 2021) |
| "Premenopausal breast cancer is usually estrogen receptor positive, and hence, prolonged ovarian suppression by medical or surgical means to prevent recurrence has become standard of management to improve disease-free survival." | ( Castracane, VD; Kauffman, RP; Young, C, 2021) |
| "Breast cancer is one of the most lethal types of cancer in women." | ( Afzali, E; Ansari, M; Eslaminejad, T; Shahrokhi-Farjah, M; Yazdi Rouholamini, SE, 2021) |
| "Breast cancer is more likely attributed to a combination of genetic variations and lifestyle factors." | ( Cao, S; Dong, Y; Li, W; Qian, Y; Wei, P; Wu, M; Zhou, J; Zhu, Z, 2021) |
| "Breast cancer is the most common and fatal malignant tumor in women, which causes great social burden throughout the world." | ( , 2021) |
| "Breast cancer is the most common malignancy in women caused by genetic and epigenetic changes." | ( Agarwal, P; Deshpande, P; Gupta, V, 2021) |
| "Breast cancer is the most common type of cancer affecting women worldwide." | ( Bay, BH; Chandrika, M; Chua, PJ; Huang, RYJ; Muniasamy, U; Ng, CT; Tan, PH; Thike, AA; Yip, GW, 2021) |
| "Breast cancer is the leading cause of cancer-related deaths in the United States." | ( Abdollahzadeh, E; Glackin, C; Guo, J; Lam, B; Liu, J; Lolarga, J; Nafie, E; Rodriguez, S, 2021) |
| "Breast cancer is the most common female cancer worldwide." | ( Chen, L; Ghauri, MA; Liu, F; Sarwar, A; Su, Q; Ullah, A; Wang, J; Wu, Q; Zhang, Y, 2021) |
| "Low risk of breast cancer is observed among females consuming a moderate quantity of soy throughout their life." | ( Chauhan, SS; Kumar, V, 2021) |
| "Breast cancer is the most common cancer in women and occurs mostly with poor outcomes." | ( Ahmed, R; Daniyal, M; Jiang, S; Li, B; Liu, B; Liu, Y; Long, Y; Wang, W; Wang, Z; Xie, Q, 2021) |
| "Breast cancer is a major disease for women worldwide, where mortality is associated with tumour cell dissemination to distant organs." | ( Abélanet, S; Fayad, R; Fontaine-Vive, F; Franco, M; Luton, F; Macia, E; Mehiri, M; Mus-Veteau, I; Robiolo, A; Vazquez-Rojas, M, 2021) |
| "Breast cancer is a common malignant tumor in women with limited treatment options and multiple side effects." | ( Ajami, A; Amani, D; Jalalpourroodsari, M; Khalizadeh, M; Rashidi, M; Shiran, MR, 2021) |
| "Breast cancer is the most frequent cancer among females and the second most common cause of cancer deaths worldwide." | ( Cao, X; Liu, C; Lv, M; Lv, Z; Mao, Y; Nie, G; Wang, H; Wang, Y, 2021) |
| "Breast cancer is a complex disease." | ( Chen, S; Han, F; Huang, W; Li, A; Li, Y; Wang, L; Wang, W, 2021) |
| "Majority of the breast cancers are hormone receptor-positive and commonly treated by hormone therapy." | ( Wang, X; Yang, D, 2021) |
| "Breast cancer is the leading cause of cancer-related death in women worldwide." | ( Calaf, GM, 2021) |
| "The metastasis of breast cancer is an important cause of tumor recurrence." | ( Fan, R; Li, J; Pei, W; Wang, H; Wang, X; Wang, Y; Zeng, X; Zhang, Y, 2021) |
| "Breast cancer is one of the leading causes of cancer death in women." | ( Brunton, VG; Faulds, K; Findlay Paterson, KA; Graham, D; Kapara, A; Zagnoni, M, 2021) |
| "Breast cancer is the most common cancer and the second leading cause of cancer-related death amongst American women." | ( Bi, Y; Cai, W; Jiang, H; Liu, G; Liu, H; Wang, H, 2021) |
| "Breast cancer is the prevalent type of tumor in women and is the leading cause of death among female cancers." | ( Gurer-Orhan, H; Panieri, E; Saso, L; Stepanić, V; Tascioglu Aliyev, A, 2021) |
| "Luminal breast cancer is resistant to chemotherapy and is more likely to not respond to chemotherapy before surgery." | ( Choi, JH; Jeon, CW; Jung, M; Jung, SU, 2021) |
| "Globally, breast cancer is a serious concern that exhibits a persistent rise in its incidence and related mortality even after significant advancement in the field of cancer research." | ( Bandyopadhyay, A; Banerjee, PP; Bhattacharya, S; Chattopadhyay, A; Garai, S, 2021) |
| "Breast cancer is the most common tumor type observed in women in the United States." | ( Isaacs, C; O'Regan, R; O'Shaughnessy, JA, 2020) |
| "Breast cancer is the most common neoplasm among women but thanks to innovative therapies, patients' prognosis has considerably improved." | ( Cabral, ÁS; Calmon, MF; Candido, NM; de Melo, MT; Leonel, ECR; Piva, HL; Rahal, P; Taboga, SR; Tedesco, AC, 2021) |
| "Among females, breast cancer is the most common type of cancer." | ( Erdal, GS; Gulturk, I; Ozmen, A; Tacar, SY; Tural, D; Yilmaz, M, 2021) |
| "On a global scale, breast cancer is the most common type of cancer in women, and it is still a growing problem." | ( Grodecka-Gazdecka, S; Hołysz, H; Paszel-Jaworska, A; Romaniuk-Drapała, A; Rubiś, B, 2021) |
| "T1 breast cancer is expected to have a good prognosis." | ( Adachi, Y; Endo, Y; Hattori, M; Horisawa, N; Iwata, H; Kataoka, A; Kotani, H; Nozawa, K; Ozaki, Y; Oze, I; Sawaki, M; Sugino, K; Takatsuka, D; Yoshimura, A, 2021) |
| "The majority of breast cancers are estrogen receptor (ERα) positive making endocrine therapy a mainstay for these patients." | ( Alers, V; Balinda, HU; Brenner, AJ; deGraffenried, L; Garcia, M; Gruslova, A; Huang, T; McClellan, B; Sareddy, GR; Vadlamudi, RK; Viswanadhapalli, S, 2021) |
| "Breast cancer is one of the most frequent malignancies." | ( Alegre Del Rey, EJ; Aranzana, MC; Díaz, MDCM; Fénix-Caballero, S; Hoces, AM; Olry de Labry Lima, A; Sierra-Sánchez, JF; Špacírová, Z; Vegas, AS, 2021) |
| "Breast cancer is a fatal disease and is a leading cause of death in women worldwide." | ( Munien, C; Viriri, S, 2021) |
| "Breast cancer is the most common cancer of women, and fifth leading cause of mortality worldwide." | ( Bazzolo, B; Camarillo, IG; Conconi, MT; Filippini, R; Mittal, L; Piovan, A; Sieni, E; Sundararajan, R, 2021) |
| "Breast cancer is one of the most common malignant tumors among women population on a global scale, with a huge number of new cases and deaths each year." | ( Chen, H; Meng, D; Zhang, Y; Zheng, J; Zheng, X, 2021) |
| "Metastatic breast cancer is a prevalent life-threatening disease." | ( Gelat, B; Johar, K; Pandya, HA; Rathaur, P; Rawal, R; Soni, MN, 2021) |
| "Breast cancer is the second most leading cause of death among women." | ( Arya, GC; Jaitak, V; Kaur, K, 2021) |
| "Breast cancer is believed to be driven by epigenetic regulation of genes implicated in cell proliferation, survival, and differentiation." | ( Fang, R; Shi, H; Ye, L, 2021) |
| "Breast cancer is at the forefront of female malignancy and the leading cause of cancer death among women." | ( Antonijević, B; Anđelković, M; Bulat, Z; Čolaković, N; Djordjevic, AB; Granić, M; Javorac, D; Kotur-Stevuljević, J; Miljaković, EA; Oprić, S; Petričević, S, 2021) |
| "Breast cancer is the most familiar solid tumor analyzed in women." | ( Afridi, HI; Baig, JA; Chanihoon, GQ; Kazi, TG; Talpur, FN, 2022) |
| "Breast cancer is a complex heterogeneous disease with multiple underlying causes." | ( Akinyele, O; Wallace, HM, 2021) |
| "Breast cancer is the most common malignancy in women with high mortality." | ( Kostecká, Z; Očenáš, P; Salayová, A; Valko-Rokytovská, M, 2021) |
| "Breast cancer is the leading cause of cancer-related deaths among women." | ( Granja, A; Pinheiro, M; Reis, S; Sousa, CT, 2021) |
| "However, 20-30% of breast cancer is resistant to tamoxifen treatment." | ( Kim, H; Kim, S; Ko, Y; Lee, JE; Shin, I; Son, S, 2021) |
| "Breast cancer is the most common malignancy in women worldwide." | ( Burade, V; Goswami, S; Pateliya, B, 2021) |
| "Breast cancer is one of the most common malignant tumours among women." | ( Deng, W; Jiang, CW; Liu, F; Zhou, Q, 2021) |
| "Breast cancer is one of the malignant tumours which mainly affect the female population." | ( Byran, G; Gomathi, S; Rajagopal, K; Sri, VB, 2022) |
| "Breast cancer is the highest global spread of invasive cancer in women." | ( Nandgude, T; Pagar, R, 2021) |
| "Breast cancer is the second leading cause of cancer deaths in women with significant morbidity and mortality." | ( Chanda, D; Das, S; Dwivedi, A; Gautam, Y; Iqbal, H; Khan, F; Khan, H; Khan, S; Konwar, R; Negi, AS; Pathak, N; Raghuvanshi, DS; Shanker, K; Sirohi, VK; Yadav, P, 2021) |
| "Breast cancer is the most frequently diagnosed cancer in women worldwide." | ( Besiroglu, M; Gucin, Z; Seker, M; Shbair, AT; Simsek, M; Sucuoglu, Z; Topcu, A; Turk, HM; Yasin, AI; Yurtsever, I, 2022) |
| "Breast cancer is the leading cause of cancer among Malaysian women." | ( Dahlui, M; Donnelly, M; Htay, MNN; Ibrahim Tamin, NSB; Loh, SY; Schliemann, D; Somasundaram, S; Su, TT, 2021) |
| "Breast cancer is an uncontrolled growth of epithelial cells." | ( George, M; Ghosh, A; Mitra, B; Rakshit, S; Roy, AG; Sarkar, K; Sinha, K, 2021) |
| "Breast cancer is one of the most common type of tumor and the leading cause of death in the world's female population." | ( Abbasi, A; Hassan, ZM; Pakravan, N, 2021) |
| "Breast cancer is one of the most common malignant tumors in women." | ( Jiang, Q; Sun, Q; Xuan, Z; Yang, Y; Yin, D; Zhang, M, 2021) |
| "Melanoma and breast cancers are two common cancers worldwide." | ( Alipanah, H; Farjam, M; Osanloo, M; Roozitalab, G; Zarenezhad, E, 2021) |
| "Breast cancer is the most common cause of malignancy and cancer-related morbidity and death worldwide that requests effective and safe chemotherapy." | ( Liang, W; Shi, J; Wei, X; Xia, H, 2021) |
| "Breast cancer is the most prevalent type of cancer among women, affecting about 2." | ( Andrzejevski, VMS; Brusamarello, T; Everton, SS; Pirolli, AV, 2022) |
| "Breast cancer is a complex and multifactorial disease which stems significantly from both environmental and genetic factors." | ( Hu, CY; Tong, ZT; Wei, W; Wu, BJ; Wu, Y; Zhong, F, 2021) |
| "Breast cancer is the most common cancer worldwide." | ( Chen, HW; Gao, YH; Li, XY; Liu, C; Liu, YS; Su, X; Xing, YW; Xiong, XJ; Yang, F; Yuan, C; Zhang, YJ, 2021) |
| "Breast cancer is the most common malignancy in women, and its incidence increases annually." | ( Chen, P; Cui, G; Lin, J; Liu, W; Wu, J; Yao, G; Yu, M; Zhou, D, 2021) |
| "Breast cancer is the leading cause of cancer-related death for women." | ( Hung, E; Liang, YH; Teng, JW; Wang, HS; Wu, JM, 2021) |
| "Breast cancer is among the leading causes of death due to cancers around the globe." | ( Ebrahimi, M; Pooladi, M; Teimouri, M, 2021) |
| "Breast cancer is the most prevalent malignancy among women worldwide." | ( Fan, W; Jin, Z; Teng, C; Wang, F; Zhang, J; Zhu, L, 2021) |
| "Breast cancer is the most common cancer among females and the leading cause of cancer-related deaths." | ( Mishra, A; Mishra, AK; Pateriya, A; Shrivastava, A; Srivastava, A; Tomar, MS, 2021) |
| "Breast cancer is one of the most common cancers among females and is associated with high mortality and morbidity rates." | ( Liu, C; Shu, Y; Tang, L; Wang, L; Yao, C, 2021) |
| "Breast cancer is the most common malignancy in women worldwide, and environmental factors, especially diet, have a role in the etiology of this disease." | ( Costa, I; Escrich, E; Garcia-Guasch, M; Moral, R; Navarro, L; Rivero, V, 2022) |
| "HER2-amplified breast cancer is a clinically defined subtype of breast cancer for which there are multiple viable targeted therapies." | ( Babcock, D; Boddapati, S; Chin, K; Devlin, K; Esch, A; Garay, JP; Gray, JW; Heiser, L; Hollern, DP; Korkola, JE; Kwon, S; Liby, T; Liu, M; Smith, R; Thompson, W; Watson, SS; Zheng, T, 2021) |
| "More than 80% of breast cancer are discovered when the woman feels a lump being present and about 90% of the cases, the cancer is noticed by the woman herself." | ( da Cunha, EFF; Gonçalves, MA; Pereira, BTL; Ramalho, TC; Santos, TMR; Tavares, CA, 2022) |
| "Breast cancer is the most frequent type of cancer and the major cause of mortality in women." | ( Albert, R; Alcon, C; Gómez Tejeda Zañudo, J; Letai, A; Montero, J; Samitier, J; Scaltriti, M; Wagle, N, 2021) |
| "Breast cancer is a common cancer and is the leading cause of cancer-related deaths among women worldwide." | ( Aburmaileh, B; Ahram, M; Al-Ameer, HJ; Kebsa, W; Lahouel, M; Mansour Al Shhab, MA; Mustafa, E; Rouibah, H; Zihlif, M, 2021) |
| "Breast cancer is becoming the most common cancer among women in India." | ( Daniel, S; Hutchinson, A; Johnson, MJ; Singh, C; Venkateswaran, C, 2022) |
| "Women with breast cancer are more likely to develop osteoporosis than women without breast cancer due to certain factors that can affect both diseases simultaneously." | ( Cai, SQ; Chen, QQ; Huang, SF; Li, YZ; Lin, S; Lin, ST; Sun, XQ, 2021) |
| "Breast cancer is the most common cancer in women and the leading cause of cancer-associated mortality." | ( Hellig, J; Stevens, Z, 2022) |
| "Breast cancer is the leading cause of cancer-related deaths among women worldwide." | ( Alves, CG; Correia, IJ; de Melo-Diogo, D; Granja, A; Lima-Sousa, R; Pinheiro, M; Reis, S; Sousa, CT, 2021) |
| "Breast cancer is the most common cancer in American women, except for skin cancers." | ( Asadian, F; Dastgheib, SA; Farbod, M; Karimi-Zarchi, M; Neamatzadeh, H; Sadeghizadeh-Yazdi, J; Salari, S; Sayad, S; Shaker, SH, 2021) |
| "Breast cancer is the most common female malignancy and the second leading cause of cancer related deaths." | ( Budziszewska, B; Starek, A; Starek-Świechowicz, B, 2021) |
| "Breast cancer is the leading cause of cancer death in women." | ( Liu, X; Xiao, C; Yao, X; Zeng, W; Zheng, F; Zhu, Y, 2022) |
| "Breast cancer is the most commonly diagnosed cancer among women worldwide." | ( Kanno, Y; Kizu, R; Ozawa, M; Sanada, N; Taga, C; Yamashita, N, 2022) |
| "Breast cancer is the most prevailing cancer type among women causing the highest number of cancer-related mortality." | ( Das, AK; Jaiswal, P; Kataria, S; Lukashevich, V; Nayak, A; Parmar, HS; Tripathi, V, 2021) |
| "Breast cancer is more common in female patients with schizophrenia than in the general population." | ( Correll, CU; Lähteenvuo, M; Solmi, M; Taipale, H; Tanskanen, A; Tiihonen, J, 2021) |
| "Breast cancer is the leading cause of cancer death among women worldwide." | ( Amigo, NL; Bareño, LA; Bechis, A; Cammarata, A; Delbart, DI; Giri, GF; Pan, MD; Spanevello, RÁ; Suarez, AG; Todaro, LB; Urtreger, AJ; Villaverde, MS, 2022) |
| "Breast cancer is one of the most common cancers worldwide among women, and angiogenesis has an important effect on its growth and metastasis." | ( Cao, J; Li, J; Liu, X; Mao, G; Qi, C; Wang, L; Zhang, Q; Zheng, L; Zheng, S; Zhou, Q, 2022) |
| "Breast cancer is rapidly emerging as the leading cause of cancer in Indian women." | ( Agnihotri, M; Agrawal, N; Kothari, K; Shah, V; Sood, P; Tummidi, S, 2021) |
| "Breast cancer is now the leading cause of cancer morbidity and mortality among women worldwide." | ( Dai, H; Fu, C; Han, X; Liu, Y; Pan, Y; Wang, H; Wang, HQ; Yang, W, 2021) |
| "Breast cancer is the leading cause of cancer-related death in women worldwide, and despite multiple chemotherapeutic approaches, effective treatment strategies for advanced metastatic breast cancer are still lacking." | ( Ge, XM; Huang, FH; Li, S; Li, X; Pang, JL; Wu, Y; Zhang, YH, 2021) |
| "Breast cancer is the most common cancer among women worldwide and is one of the leading causes of cancer-related mortalities." | ( Eugenio, KPY; Jimeno, CA; Lusica, PMM; Sacdalan, DBL, 2021) |
| "Breast cancer is one of the main cancers that effect of the women's health." | ( Bi, D; Chen, D; Liu, Y; Ma, Y; Youssefi, N, 2022) |
| "Breast cancer is the most frequent cancer in women worldwide and late diagnosis often adversely affects the prognosis of the disease." | ( Aversa, I; Bond, HM; Chiarella, E; Fernandes Guerreiro, J; Garcia-Calderón, D; Genard, G; Hanley, R; Marafioti, MG; Mesuraca, M; Nisticò, C; Pagliari, F; Seco, JC; Spadea, MF; Tirinato, L, 2021) |
| "Breast cancer is the most common malignancy in women." | ( Jang, JH; Kim, JA; Lee, SY, 2021) |
| "Breast cancer is the fastest-growing cancer among females and the second leading cause of female death." | ( Hu, Y; Li, Y; Li, Z; Lu, Y; Shen, Y; Song, W; Xia, Y, 2021) |
| "HER2+ breast cancer is highly aggressive and proliferative even after multiple chemotherapy regimens." | ( Gan, N; Li, H; Peng, X; Sun, Q; Suo, Z; Zhang, S; Zhao, G; Zhao, L, 2021) |
| "Breast cancer is caused by abnormal growth of the cells and progressed due to the over-expression of estrogen (ER) and progesterone (PR)." | ( Ahmad, B; Anwar, F; Bashir, M; Hira, S; Imtiaz, MT; Ismail, T; Mehmood, Y; Najm, S; Saleem, U, 2021) |
| "Breast cancer is the most commonly diagnosed malignant tumor and the leading cause of cancer-related death in women worldwide." | ( Li, J; Ouyang, Q; Shui, Z, 2021) |
| "Breast cancer is one of the leading causes of cancer mortality worldwide." | ( Khedri, A; Mawalizadeh, F; Mohammadzadeh, G; Rashidi, M, 2021) |
| "Breast cancer is the most common cancer of women-it affects more than 2 million women worldwide." | ( Drzeżdżon, J; Górska-Ponikowska, M; Jacewicz, D; Jamrozik, M; Kostrzewa, T; Kołaczkowski, M; Kuban-Jankowska, A; Siemińska, J; Wołosewicz, K; Łaźny, R, 2021) |
| "Breast cancer is the most commonly diagnosed malignant tumor among females." | ( Long, G; Luo, Y; Tang, J; Zhou, L, 2021) |
| "Breast cancer is the cancer with the highest incidence all over the world." | ( Chen, Y; Deng, M; Jia, Y; Ling, Y; Liu, X; Lu, M; Qiu, T; Xiang, R; Yang, C; Yang, Y; Zhou, Y, 2021) |
| "Breast cancer is the most common cancer in the world." | ( Feng, T; Gu, R; Guo, Y; Li, K; Li, Q; Li, S; Lin, P; Ou, D; Yuan, H; Zhang, J; Zhao, G, 2021) |
| "Breast cancer is one of the most reported cancers that can lead to death." | ( Ahmad, MF; Halin, DSC; Mazlan, NS; Mohamed, R; Osman, NH; Ramli, MM; Reshak, AH; Rosman, AS, 2021) |
| "Breast cancer is one of the cancers with the highest incidence among women." | ( Huang, Y; Lai, B; Zheng, S, 2021) |
| "Breast cancer is the second leading cause of cancer death in women after lung cancer." | ( Albustanji, S; Alhusban, AA; Hamadneh, LA; Shallan, AI, 2022) |
| "Breast cancer is the most common type of cancer among women worldwide and in Japan." | ( Iwata, H; Kosaka, N; Masuda, N; Toi, M, 2021) |
| "Breast cancer is the most prevalent cancer among women." | ( Chen, S; Cui, C; Wang, Y; Yang, X; Zhang, S, 2021) |
| "Breast cancer is the most common cause of cancer mortality in India, yet breast cancer literacy remains poor." | ( Agrawal, T; Johnson, AR; Maggi, RM, 2022) |
| "Breast cancer is the most frequently diagnosed cancer, and no effective treatment solution has yet been found." | ( Cansaran-Duman, D; Çolak, B; Yangın, S, 2021) |
| "Breast cancer is a highly heterogeneous disease with multiple drivers and complex regulatory networks." | ( Abou-Hamad, J; Al-Zahrani, KN; Cook, DP; Labrèche, C; Pascoal, J; Pryce, BR; Sabourin, LA, 2021) |
| "Breast cancer is the most common cancer diagnosed in women, however traditional therapies have several side effects." | ( Cechowska-Pasko, M; Jabłońska-Trypuć, A; Krętowski, R, 2021) |
| "Breast cancer is now globally the most frequent cancer and leading cause of women's death." | ( Ala-Hongisto, H; Bertula, K; Elo, LL; Euro, L; Heikkilä, P; Hollmann, B; Hukkinen, K; Ikkala, O; Joensuu, H; Junttila, MR; Kivento, M; Klefström, J; Kovanen, P; Leidenius, M; Martikainen, L; Mattson, J; Meretoja, T; Metcalfe, C; Monni, O; Munne, PM; Mutka, M; Nevalaita, L; Patrikainen, L; Peura, A; Pokki, J; Pouwels, J; Räty, I; Ruuska, J; Sahu, B; Salmela, M; Suomi, T; Väänänen, J; Yavuz, K, 2021) |
| "Breast cancer is the leading cause of cancer death among women and almost all of the breast cancer-caused mortality is related to metastasis." | ( Feng, G; Guo, Q; Hao, YN; Liu, H; Liu, J; Liu, Y; Sun, X; Yang, L; Zhang, CG; Zhao, CC, 2022) |
| "Breast cancer is the most common cause of cancer-related death among women, and prognosis is especially poor for patients with triple-negative breast cancer (TNBC); therefore, there is an urgent need for new effective therapies." | ( Chen, M; Jiang, D; Liao, WZ; Peng, HJ; Xu, LQ; Yao, LJ; Zhou, LJ; Zou, WH, 2021) |
| "Breast cancer is considered one of the utmost neoplastic diseases globally, with a high death rate of patients." | ( Aghaabbasi, K; Aghaei Afshar, A; Azedi, F; Dadashzadeh, A; Dehshahri, A; Fatemi, I; Kesharwani, P; Madamsetty, VS; Moghassemi, S; Mohammadinejad, R; Pardakhty, A; Schneible, JD; Shirvani, A; Tavakol, S; Zarrabi, A, 2022) |
| "Breast cancer is one of the commonest malignancies in women with first occurrence and fifth mortality in the world." | ( Gu, Y; Guo, G; Li, L; Wang, N; Xiong, Y; Zhu, M, 2022) |
| "Breast cancer is the most common malignancy in women worldwide." | ( Helmy, MW; Houssen, ME; Omran, GA; Salahuddin, MM, 2021) |
| "Breast cancer is one of the most common cancers in the world with tumor heterogeneity." | ( Gao, Y; Guan, YQ; He, J; Jiang, S; Wang, X; Yin, L; You, R; Zhang, LK, 2022) |
| "Breast cancer is the most common cancer among women around the world." | ( Adhikari, R; Khatri, A; Lamichhane, S; Rai, RP; Shrestha, BG; Shrestha, SK, 2023) |
| "Breast cancer is one of the most severe problems, and it is the primary cause of cancer-related death in females worldwide." | ( Aziz, BK; Ghafour, DD; Kivrak, A; Rasul, HO, 2021) |
| "Breast cancer is the most common case of cancers." | ( Avila, F; Guslianto, BW; Khayrani, AC; Lischer, K; Sahlan, M; Sitorus, SRA, 2021) |
| "Metastatic breast cancer is the second most common cause of brain metastasis (BM), and this problem is particularly marked for the amplified HER2 subtype (HER2+), with a cumulative incidence reaching up to 49 % in the ER-/HER2+ subgroup." | ( Bachelot, T; Bailleux, C; Darlix, A; Jacot, W, 2021) |
| "Breast cancer is one of the main challenging areas in cancer treatment." | ( Ghasemi, F; Sahebkar, A; Ziasarabi, P, 2021) |
| "Breast cancer is one of the leading causes of morbidity and mortality in women worldwide." | ( Xu, Y; Yu, E; Yu, Q; Zheng, Z, 2022) |
| "Breast cancer is the most common malignancy among women globally." | ( Amritha, S; Gopal, G; Rajkumar, T; Sabitha, K; Shirley, S; Sridevi, V; Swaminathan, R, 2022) |
| "Breast cancer is the most prevalent cancer type reported in women equally affecting both the high-income and low-income countries." | ( Ali, I; Iqbal, S, 2022) |
| "Breast cancer is the most common malignancy in women worldwide." | ( Chen, X; Gao, P; Guo, X; Liang, Y; Liu, H; Ma, R; Sun, Y; Wang, M; Wang, Y; Zhao, R; Zhu, W, 2022) |
| "Breast cancer is the most frequent female cancer and second cause of cancer-related deaths among women around the world." | ( Acar Çevik, U; Ahmad, I; Celik, I; Işık, A; Kaplancıklı, ZA; Özkay, Y; Patel, H, 2023) |
| "Breast cancer is the most common cancer in women." | ( Acar, A; Acikalin, T; Gursoy, P, 2022) |
| "Breast cancer is the most common cause of cancer death in women; therefore, its early detection and treatment are crucial." | ( Naghib, SM; Shahbazi, N; Zare-Dorabei, R, 2022) |
| "Breast cancer is a high-burden malignancy for society, whose impact boosts a continuous search for novel diagnostic and therapeutic tools." | ( Ascensão, L; Carvalho, L; Coelho, JMP; Ferreira, D; Ferreira, HA; Ferreira-Gonçalves, T; Gaspar, MM; Marques, V; Reis, CP; Rodrigues, CMP; Viana, AS, 2022) |
| "Breast Cancer is one of the most commonly diagnosed cancers worldwide and a major cause of death among women." | ( Abou Najem, S; Fakhoury, R; Hodroj, MH; Idriss, M; Rizk, S; Younes, M, 2022) |
| "Breast cancer is the most common type of cancer in women." | ( Agossou, C; Atchadé, MN; Djibril, AM; Kurisheva, SV, 2022) |
| "Management of breast cancer is multidisciplinary requiring critical analysis of emerging evidence especially with its appropriateness to local practice." | ( Chakraborty, S; Chatterjee, S, 2021) |
| "Breast cancer is the primary cause of cancer-related deaths in women." | ( Deng, H; Feng, N; Hu, J; Huang, T; Jiang, Y; Lu, C; Xu, M; Zhao, X, 2022) |
| "Breast cancer is characterized by a hypoxic microenvironment inside the tumor mass, contributing to cell metastatic behavior." | ( Altei, WF; Baptista, MP; Casali, BC; Gozzer, LT; Selistre-de-Araújo, HS, 2022) |
| "Breast cancer is the most common malignancy in women, and is both pathologically and genetically heterogeneous, making early detection and treatment difficult." | ( Chennathukuzhi, VM; Cloud, AS; Ganeshkumar, S; Gunewardena, S; Jensen, RA; Kumaraswamy, E; Shimak, RM; Vargheese, AM, 2022) |
| "Female breast cancer is the world's most prevalent cancer in 2020." | ( Farghadani, R; Naidu, R, 2022) |
| "Breast cancer is quite common in women, and surgery is the most effective treatment in most cases." | ( Bilgin, S; Dost, B; Genc, C; Kaya, C; Koksal, E; Ustun, YB, 2022) |
| "Breast cancer is the most common and deadliest type of cancer in women." | ( Fresco, P; Gonçalves, J; Quintas, C; Silva, D, 2022) |
| "Triple-negative breast cancer is highly dependent on glycolysis and is typically treated with a combination of surgery, radiation therapy, and chemotherapy." | ( De la Mora-De la Mora, I; de Vos, P; Enríquez-Flores, S; Fernández-Lainez, C; Flores-López, LA; García-Torres, I; Gracia-Mora, I; Gutiérrez-Castrellón, P; López-Velázquez, G; Martínez-Pérez, Y; Olaya-Vargas, A, 2022) |
| "Breast cancer is currently the leading cause of worldwide cancer incidence exceeding lung cancer." | ( Abdelhaleem, EF; El-Nassan, HB; Kassab, AE; Khalil, OM, 2022) |
| "Breast cancer is the most prevalent cancer and the leading cause of cancer-related death among women worldwide." | ( Cejuela, M; Martin-Castillo, B; Menendez, JA; Pernas, S, 2022) |
| "Breast cancer is one of the most common cancers globally." | ( Haam, S; Huh, YM; Ki, J; Kim, E; Kim, J; Park, J; Rho, HW; Son, HY, 2022) |
| "Breast cancer is the foremost cause for mortality among women." | ( Barathe, PC; Dhyani, VS; Haridas, HT; Krishnan, JB; Kudiya, KK; Pundir, P; Rajendran, A; Sirur, AJN; Soni, P, 2022) |
| "Breast cancer is heterogeneous in nature and contributed extensively to the increased mortality rate." | ( Chaudhari, R; Kumar, A; Meghani, N; Nasra, S, 2022) |
| "Breast cancer is one of the most common types of malignancies in the world." | ( Aliasgharzadeh, A; Amini, P; Aryafar, T; Ashrafizadeh, M; Farhood, B; Musa, AE; Najafi, M; Nodooshan, SJ; Taeb, S; Tavakoli, S; Vakili, Z, 2022) |
| "Breast cancer is the leading cause of cancer death among women in worldwide and France." | ( Brabencova, E; Foulon, A; Jonckheere, N; Ouadid-Ahidouch, H; Rodat-Despoix, L; Rybarczyk, P; Sevestre, H, 2022) |
| "Breast cancer is considered as one of the most important health problems due to its poor prognosis and high rate of mortality and new diagnosed cases." | ( Asemi, Z; Dana, PM; Heidar, Z; Mirzaei, H; Mirzamoradi, M; Mohammadi, S; Sadoughi, F; Shafabakhash, R; Targhazeh, N, 2022) |
| "Breast cancer is one of the most significant causes of female cancer death worldwide." | ( Dadashpour, M; Hashemi, M; Khoshravan, L; Zarghami, N, 2022) |
| "Breast cancer is prevalent and diverse with significantly high incidence and mortality rates." | ( Huang, H; Ji, P; Mou, Y; Ren, Z; Wang, X; Yin, J, 2022) |
| "Breast cancer is the second most cause of mortality among women worldwide due to the uncontrolled proliferation of tumor cells in the mammary epithelial tissues." | ( Ang, KP; Chen, J; Hao, X; Qiu, G; Ren, G; Tamrin, MIM; Yan, S, 2022) |
| "Breast cancer is the most common cancer in women worldwide." | ( Cai, Y; Cao, Q; Ding, Y; Fan, R; Huang, Q; Li, X; Li, Z; Liu, B; Niu, Z; Tan, X; Wang, B; Wu, L; Xia, Y; Yang, H; Yang, X; Zhang, C; Zhou, Z; Zhuang, T, 2022) |
| "Breast cancer is the most commonly diagnosed invasive non-skin malignancy in women worldwide, and it is the leading cause of cancer-related deaths in them." | ( Al-Dowish, N; Al-Jubran, KM; Alam, MA; Alsaffar, F; Alwosaibai, K; Baig, WA; Chaudhry, TM, 2022) |
| "Breast cancer is the most commonly diagnosed invasive non-skin malignancy in women worldwide, and it is the leading cause of cancer-related deaths in them." | ( Al-Dowish, N; Al-Jubran, KM; Alam, MA; Alsaffar, F; Alwosaibai, K; Baig, WA; Chaudhry, TM, 2022) |
| "Breast cancer is one of the most commonly diagnosed cancers." | ( Dammann, J; Lai, P; Sun, S; Tian, C, 2022) |
| "Breast cancer is the most prevalent cancer and the second-leading cause of cancer-related death for women in the USA." | ( Arora, R; Chakravarty, S; Hix, J; Kenyon, E; Kiupel, M; Powell, K; Sempere, LF; Shapiro, EM; Volk, M; Westerhuis, JJ; Zaluzec, EK, 2022) |
| "Breast cancer is primarily classified into ductal and lobular types, as well as into noninvasive and invasive cancer." | ( Hama, K; Hayashi, Y; Inoue, K; Karasawa, K; Kijima, Y; Kiriya, M; Morimoto-Kamata, R; Nakamura, Y; Natsugoe, S; Nojiri, H; Shinden, Y; Sumimoto, T; Suzuki, K; Tanigawa, K; Yokoyama, K; Yui, S, 2022) |
| "Breast cancer is one of the most prevalent malignant diseases, and one of the main causes of mortality among women across the world." | ( Cheng, S; Shi, Y; Wang, J; Wu, X; Xia, S, 2022) |
| "Breast cancer is characterized by high morbidity and mortality." | ( Chen, H; Cheng, M; Gao, P; Li, G; Li, H; Qin, L; Wang, L; Zhang, X, 2022) |
| "Breast cancer is one of the most common malignant neoplasms, and despite the dynamic development of anticancer therapies, 5-year survival in the metastatic stage is still less than 30%." | ( Baczyńska, D; Kasperkiewicz-Wasilewska, P; Kulbacka, J; Rembiałkowska, N; Saczko, J; Sauer, N; Szewczyk, A; Szlasa, W; Wala, K, 2022) |
| "The incidence of breast cancer is rising in Japan, particularly in postmenopausal women." | ( Atkinson, C; Hart, K; Milligan, G; Mitra, D; Mycock, K; Taylor-Stokes, G; Zhan, L, 2022) |
| "Breast cancer is the most common cancer in women." | ( Chen, B; He, Q; Li, H; Li, X; Liu, X; Song, Y; Wang, Y; Yu, X; Zeng, H; Zhang, H; Zhou, D; Zhou, W, 2022) |
| "Breast cancer is the most common malignancy in women and is rated among one of the three common malignancies worldwide in combination with colon and lung cancer." | ( Das, S; Roy, P; Sur, S; Wui, WT, 2022) |
| "Breast cancer is one of the greatest global dilemmas, and the current treatment option is to target hormone receptors with partial agonists/antagonists." | ( Elancheran, R; Maruthanila, VL; Mirunalini, S, 2022) |
| "Breast cancer is the most invasive and life-threatening cancer in women." | ( El-Sherbiny, IM; Ibrahim, A; Khalil, IA, 2022) |
| "Breast cancer is the most frequent cancer diagnosed in women worldwide." | ( Groheux, D, 2022) |
| "Breast cancer is the most common cancer affecting women's health, and its incidence rate is continuously increasing." | ( Feng, H; Li, W; Ma, K; Ma, Y; Wang, T, 2022) |
| "Breast cancer is a common malignancy that severely threatens women's mental health and lives." | ( Cao, X; Chen, T; Wang, X; Wu, Y, 2023) |
| "Triple-negative breast cancer is often aggressive and resistant to various cancer therapies, especially corresponding targeted drugs." | ( Gong, T; Li, Y; Lin, Q; Lin, Y; Sun, X; Wang, H; Xie, Z; Xu, Y; Yang, L; Zhang, L; Zhang, Y; Zhang, Z, 2022) |
| "Breast cancer is the most common cancer type among women worldwide." | ( Horie, K; Iino, K; Ikeda, K; Inoue, S; Kawabata, H; Mitobe, Y; Sato, W; Suzuki, T; Takeiwa, T, 2022) |
| "Breast cancer is the leading cause of cancer death among women in the world, and its morbidity and mortality are increasing year by year." | ( Jia, A; Jiang, H; Luo, H; Sun, B; Wang, Z; Zhang, P, 2022) |
| "Breast cancers are heterogeneous with variable clinical courses and treatment responses." | ( Chan, CW; Chan, GHJ; Chen, SJ; Chong, WQ; Choo, JRE; Goh, BC; Hartman, M; Jan, YH; Lee, MX; Lee, SC; Lim, JSJ; Lim, SE; Ngoi, N; Ow, SGW; Tan, HL; Tan, KT; Tang, SW; Wong, A; Yadav, K; Yvonne, ALE, 2022) |
| "Breast cancer is a leading cause of death in premenopausal women." | ( Barrett, JE; Bartlett, TE; Boggavarapu, NR; Clarke, RB; Dubeau, L; Evans, DG; Evans, I; Gemzell-Danielsson, K; Ghezelayagh, TS; Haran, S; Herzog, C; Howell, SJ; Jones, A; Jones, L; Lalitkumar, PG; Papaikonomou, K; Pashayan, N; Ponandai-Srinivasan, S; Rådestad, AF; Reisel, D; Risques, RA; Simões, BM; Widschwendter, M, 2022) |
| "Breast cancer is the leading cause of cancer-related mortality amongst women." | ( Kastora, SL; Mamas, MA; Myint, PK; Pana, TA; Sarwar, Y, 2022) |
| "Breast cancer is a serious worldwide public health problem and is currently the most common cancer overall." | ( Banani, A; Benbrahim, Z; Boubbou, M; Bouchikhi, C; Bouhafa, T; Boukansa, S; El Fatemi, H; Fdili Alaoui, F; Gamrani, S; Melhouf, MA; Mellas, N, 2022) |
| "Breast cancer is amongst the most prevalent diseases in women due to overactivity of human epidermal growth factor receptor 2 (HER2)." | ( Amirzada, MI; Asad, MHHB; Bashir, H; Javed, MA; Khan, MT; Rajoka, MSR; Shah, N; Shaikh, AJ; Uddin, Z, 2022) |
| "Breast cancer is one of the most common types of cancer in women worldwide." | ( AmeliMojarad, M; Pourmahdian, A, 2022) |
| "Breast cancer is the most common cancer in women ın the world." | ( Baygar, T; Cavusoglu, T; Elbe, H; Ozturk, F; Yigitturk, G, 2022) |
| "Breast cancer is the most common malignancy among women." | ( Aziz, BK; Ghafour, DD; Kivrak, A; Rasul, HO, 2023) |
| "Breast cancer is the most common cancer affecting women." | ( Bard, JM; Bobin-Dubigeon, C; Croyal, M; Nazih, H, 2022) |
| "Locally advanced breast cancer is a heterogeneous disease with respect to response to neoadjuvant chemotherapy (NACT) and survival." | ( Bathen, TF; Cao, MD; Eikesdal, HP; Fleischer, T; Giskeødegård, GF; Knappskog, S; Kristensen, VN; Lønning, PE; Pedersen, CA; Rye, MB; Tessem, MB; Tost, J, 2022) |
| "Breast cancer is still the leading cause of cancer-related deaths among women aged 20-59 and metastatic breast cancer remains an incurable disease." | ( Annovazzi, A; Barberi, V; Cognetti, F; Ferretti, G; Renna, D; Russillo, M, 2022) |
| "Breast cancer is a complex multifactorial disease and polymorphisms in nucleotide excision repair pathway are associated with the potential risk of breast cancer." | ( Pongsavee, M, 2022) |
| "Breast cancer is a heterogeneous disease consisting of atypical cell populations that share stem cell-like characteristics associated with therapeutic resistance, disease relapse, and poor clinical outcome." | ( Gupta, S; Kumar, S; Prajapati, KS; Shuaib, M, 2022) |
| "Breast cancer is the most common cancer among women worldwide." | ( Chuang, YS; Hsieh, HM; Lee, CY; Lin, PC; Pan, CH; Wu, CF; Wu, MT, 2022) |
| "Breast cancer is one of the most common cancers among women that is associated with high mortality." | ( Alamdari, SG; Amini, M; Baradaran, B; Jalilzadeh, N; Mohammadzadeh, R; Mokhtarzadeh, A; Oroojalian, F, 2022) |
| "Its role in breast cancer is poorly understood." | ( Gong, J; Lai, G; Liu, T; Wu, X; Yang, Y, 2023) |
| "Breast cancer is the most common cancer in women worldwide." | ( Basu, N; Das, BC; Guptasarma, ML; Narad, P; Tandon, C; Tandon, S, 2022) |
| "Breast cancer is the most frequent cancer among women." | ( Abdelbasset, WK; Abdullaev, B; Al-Awsi, GRL; Al-Gazally, ME; Al-Mualm, M; Alsaikhan, F; Ansari, MJ; Jalil, AT; Maashi, MS; Mustafa, YF; Opulencia, MJC; Shalaby, MN, 2022) |
| "Nowadays, diet and breast cancer are studied at different levels, particularly in tumor prevention and progression." | ( Blanckaert, V; Chénais, B; Fodil, M; Mimouni, V; Ulmann, L, 2022) |
| "Breast cancer is the most diagnosed cancer in humans." | ( Abdelwahed, M; Chavarria, H; Hacking, SM; Nasim, M; Wu, D, 2022) |
| "Breast cancer is one of the most common types of cancer diagnosed and the second leading cause of death among women." | ( Butnariu, M; Calina, D; Cho, WC; Hossain, R; Islam, MS; Islam, MT; Khalipha, ABR; Khan, RA; Martorell, M; Ray, P; Sarkar, C; Sharifi-Rad, J; Umbetova, A, 2022) |
| "Breast cancer is a leading cause of tumor-related death among women around the world, but its pathogenesis is still unclear." | ( Li, H; Liu, J; Sun, M; Sun, Y, 2022) |
| "Breast cancer is the most common malignancy among women worldwide." | ( Aliberti, SM; Barbieri, A; Bisogno, I; Capunzo, M; Caraglia, M; Cianciola, E; D'Arena, G; Giudice, A; Pentangelo, P, 2022) |
| "Breast cancer is the most prevalent malignancy and the first leading cause of cancer-related mortality among the female population worldwide." | ( Chan, HF; Chen, K; Lai, W; Li, M; Tao, Y; Wang, H; Wen, X; Wu, T; Zhou, H, 2022) |
| "Breast cancer is the most common cancer among women." | ( Aginčić, A; Bećiragić, E; Cerić, T; Delić, U; Greene, F; Hadžikadić-Gušić, L; Iljazović, E; Koprić, D; Marijanović, I; Mekić-Abazović, A; Mustedanagić-Mujanović, J; Šišić, I; Tanović, M; Zorlak, A, 2023) |
| "Breast cancer is one of the most diffuse cancers in the world and despite the availability of the different drugs employed against it, the need for new and particularly more specific molecules is ever growing." | ( Calcabrini, A; Cecchetti, S; Colone, M; Dupuis, ML; Gori, A; Serra, S; Spadaro, F; Stringaro, A; Vitali, A, 2022) |
| "Breast cancer is the most frequently diagnosed cancer and is the leading cause of cancer-associated mortality in women worldwide." | ( Feng, Z; Huang, L; Kong, L; Li, M; Liu, F; Wang, D; Wei, Y; Xiao, F; Xiong, Y; Zhang, H; Zhang, W; Zhou, Y, 2022) |
| "Breast cancer is the most common cancer in women worldwide." | ( Bachok, N; Hashim Isa Merican, SR; Md Hashim, MN; Mohamad, IS; Ramely, R; Soh, JY; Wan Mokhter, WM; Wan Zain, WZ; Wong, MP; Yahya, MM; Zakaria, AD; Zakaria, Z, 2022) |
| "Breast cancer is a common malignancy in women and is a diverse disease." | ( Shahab, M; Wadood, A; Zheng, G, 2022) |
| "Breast cancer is the most common type of neoplasm and the second cause of cancer-related death in women." | ( Bahadori, MH; Evazi Bakhshi, S; Habibi Roudkenar, M; Mohammadi Roushandeh, A; Shekarchi, S, 2022) |
| "Breast cancer is the most commonly diagnosed type of cancer and ranks second among cancer that leads to death." | ( Gupta, P; Kohli, K; Neupane, YR; Parvez, S; Sultana, Y, 2023) |
| "Breast cancer is the most commonly diagnosed and major cause of cancer-related deaths in women worldwide." | ( Deshpande N, S; Malkaje, S; Navada, S; Srinivasa, MG, 2023) |
| "Breast cancer is the second major cause of death worldwide among women." | ( Azedi, F; Bayandori, M; Hamblin, MR; Hasanzadeh, A; Heidari, E; Karimi, M; Mohammad Gholinia Sarpoli, L; Zare-Karizi, S, 2022) |
| "Breast cancer is a fatal cancer with the highest mortality in female." | ( Du, J; Li, B; Li, L; Li, Y; Lin, J; Liu, J; Song, D; Wang, F, 2022) |
| "Breast carcinoma is one of the most common malignant tumors in women." | ( Bucan, V; Koop, F; Mett, TR; Schlottmann, F; Strauß, S; Vogt, PM, 2022) |
| "Breast cancer is one of the most diagnosed forms of cancer among women worldwide." | ( Bevacqua, MT; Crocco, L; Di Meo, S; Isernia, T; Matrone, G; Pasian, M, 2022) |
| "Breast cancer is one of the most prevalent cancers and a significant cause of fatalities in women." | ( Rahaie, M; Sadeghi, S, 2022) |
| "Breast cancer is a common malignancy and a leading cause of cancer-related deaths in women worldwide." | ( Aguirre, JJ; Garcia-Zapirain, B; Hameed, Z; Isaza-Ruget, MA, 2022) |
| "Even though breast cancer is the most diagnosed cancer among women, treatments are not always successful in preventing its progression." | ( Danen, EHJ; Dekker, Y; Le Dévédec, SE; Liu, Q, 2022) |
| "Human breast cancer is among one major health concerns with high prevalence and mortality among women worldwide." | ( Ahmed, A; Hashim, Z; Ilyas, A; Syed, B; Syed, N; Zarina, S, 2023) |
| "Breast cancer is a heterogeneous disease and there are only limited known relations of plasma metabolomic signatures with the tumour characteristics in early BC and knowing them would be of great advantage in noninvasive diagnostics." | ( Baranovicova, E; Dankova, Z; Dvorska, D; Halasova, E; Kudelova, E; Racay, P; Smolar, M; Zubor, P, 2022) |
| "Breast cancer is the most common malignancy in women and may become worse when a high concentration of hydrazine is absorbed from the environment or drug metabolite." | ( Jin, Y; Liu, B; Tang, C; Tian, E; Tong, H; Wang, F; Wang, X, 2022) |
| "Breast cancer is the commonest malignancy of women and with its incidence on the rise, the need to identify new targets for treatment is imperative." | ( Das, M; Giannoudis, A; Sharma, V, 2022) |
| "Mortality from breast cancer is almost exclusively a result of tumor metastasis and resistance to therapy and therefore understanding the underlying mechanisms is an urgent challenge." | ( Avivi, C; Barshack, I; Ben-Yosef, S; Doron, H; Erez, N; Ershaid, N; Monteran, L; Scharff, Y; Sonnenblick, A; Zait, Y, 2022) |
| "Breast cancer is a type of cancer with the highest incidence worldwide in 2021, with early diagnosis and rapid treatment intervention being the reasons for the decreasing mortality rate associated with the disease." | ( Batista de Carvalho, ALM; Batista de Carvalho, LAE; Figueiredo, P; Mamede, AP; Marques, MPM; Santos, IP; Silva, MC, 2022) |
| "Breast cancer is the most aggressive malignant tumor with high morbidity and mortality." | ( Hu, H; Tian, S; Wei, Y; Zhao, H, 2022) |
| "Breast cancer is the most common cancer diagnosed among women worldwide and more than half are diagnosed above the age of 60 years." | ( Abdel-Razeq, H; Abdel-Razeq, N; Abu Rous, F; Abuhijla, F; Edaily, S, 2022) |
| "Breast tumors are characterized by metabolic heterogeneity and significant metabolic plasticity, which can be targeted by combining anti-metabolic treatments and new therapies." | ( Petővári, G, 2022) |
| "Breast cancer is a common cancer, accounting for approximately 30% of all new cases of cancer diagnosed in women." | ( Li, J; Tan, X; Wei, Z; Zhang, X, 2022) |
| "Breast cancer is the most common malignancy and the second leading cause of cancer-related mortality in Spanish women." | ( Alvarez Lopez, IM; Anton Torres, A; Barnadas Molins, A; Bellet Ezquerra, M; Cantos Sanchez de Ibargüen, B; Ciruelos Gil, EM; de Casa, S; De la Cruz Merino, L; De la Haba-Rodriguez, J; de Toro Salas, R; Delgado Mingorance, JI; Diaz Fernandez, N; Galve Calvo, E; Gavila Gregori, J; Gimeno, A; Gonzalez-Santiago, S; Hernando Melia, C; Jiménez-Rodriguez, B; Martin, M; Martínez Jañez, N; Moreno Anton, F; Quiroga Garcia, V; Rodriguez Sanchez, CA; Salvador Bofill, J; Vicente Rubio, E; Vidal, M; Villanueva Vazquez, R, 2022) |
| "Since breast cancer is less common in men than in women, data on the use of new therapeutic agents, including cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors, are limited in patients with metastatic hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) male breast cancer." | ( Acar, Ö; Aksoy, S; Aykan, MB; Çelebi, A; Chalabiyev, E; Doğan, A; Dursun, B; Erdoğan, AP; Günenç, D; Güven, DC; Hacıbekiroğlu, İ; İnanç, M; Kahraman, S; Kaman, Ö; Keskinkılıç, M; Kılıçkap, S; Melisa Celayir, Ö; Mutlu, E; Ön, S; Özen, M; Vedat Bayoğlu, İ; Yalçın, Ş; Yavuzşen, T; Yıldırım, HÇ, 2022) |
| "Breast cancer is a serious public problem in modern society." | ( Aebisher, D; Bartusik-Aebisher, D; Gustalik, J, 2022) |
| "Breast cancer is a major cause of cancer-related morbidity and mortality in women." | ( Cao, J; Chen, Z; Tang, J; Wang, S; Wang, X, 2023) |
| "Breast cancer is the most prevalent type of cancer among women worldwide." | ( Kong, X; Liang, Y; Wang, Y; Yang, Q; Ye, F; Zhang, Y, 2022) |
| "HER2-positive breast cancer is an aggressive subtype of breast cancer with five-year survival rates of 30% for the advanced stage." | ( Anderson, J; Antonios, B; Deol, J; Gaikazian, S; Ghimire, B; Gupta, R; Gupta, S; Huben, M; Jaiyesimi, I; Jindal, V; Stender, M, 2022) |
| "Most breast cancer is estrogen receptor (ER) positive but responds less to neoadjuvant or adjuvant chemotherapy than ER-negative breast cancer." | ( Fan, Z; Jin, C; Jin, Y; Li, L; Li, S; Liu, C; Miao, QR; Zhang, X; Zhao, B, 2023) |
| "Breast cancer is a common form of cancer that affects both men and women." | ( Choudhary, SS; Gujaran, TV; Kumar, BH; Manandhar, S; Mehta, CH; Nayak, UY; Pai, KSR; Priya, K, 2023) |
| "Breast cancer is the most commonly diagnosed cancer and registers the highest number of deaths for women." | ( Anniciello, AM; Botti, G; Brancati, N; De Pietro, G; Di Bonito, M; Feroce, F; Foncubierta, A; Frucci, M; Gabrani, M; Jaume, G; Pati, P; Riccio, D; Scognamiglio, G, 2022) |
| "TF expression in breast cancer is associated with higher tumor grade, metastasis and poor survival." | ( Blok, EJ; Bogdanov, VY; Kocatürk, B; Krijgsman, D; Kuppen, PJK; Lewis, CS; Noordhoek, I; Rondon, AMR; Ruf, W; Swier, N; Ünlü, B; van den Akker, RFP; Versteeg, HH, 2022) |
| "Breast carcinoma is the most commonly occurring cancer in women." | ( Fukuyama, M; Hiroshima, Y; Imai, K; Ishiyama, K; Kudo, C; Minamiya, Y; Morishita, A; Nanjo, H; Nomura, K; Sato, Y; Takahashi, E; Takashima, S; Terata, K; Wakita, A; Yatsuyanagi, M, 2022) |
| "Breast cancer is a heterogeneous disease." | ( Chan, SY; Chan, WL; Khoo, US; Leung, MH; Man, EPS; Tsang, WC; Tsoi, H; You, CP, 2022) |
| "HR+ breast cancers are defined by the prominence of signaling pathways dependent on the estrogen receptor." | ( Bailleux, C; Grellety, T; Hajjaji, N; Petit, T, 2023) |
| "Breast cancer is one of the main causes of death in women worldwide." | ( Budziszewska, B; Starek, A; Starek-Świechowicz, B, 2023) |
| "Breast cancer is the frequent cause of disease burden related to cancer among women." | ( Feng, W; He, R; Jiang, B; Li, Y; Qi, X; Wan, Z; Xie, L; Zhu, H, 2022) |
| "Breast cancers are known to be driven by the transcription factor estrogen receptor and its ligand estrogen." | ( Ak, C; Chitsazan, AD; Doe, AR; Handu, M; Haverlack, S; Mohammed, H; Mulqueen, RM; Naldiga, S; Ors, A; Saldivar, JC; Wen, Y, 2022) |
| "Breast cancer is the most common malignancy in developed countries and the main cause of deaths in women worldwide." | ( Cortes-Reynosa, P; de la Garza, M; Rodriguez-Ochoa, N; Rodriguez-Rojas, K; Salazar, EP, 2023) |
| "Breast cancer is the most common cancer in women worldwide." | ( Chen, S; Fang, Y; Jin, F; Liu, Q; Wu, D; Yao, F, 2023) |
| "Breast cancer is one of the most commonly diagnosed cancers in woman which accounts for more than 1 in 10 new cancers in the entire world." | ( Kumar, SA; Mohaideen, NSMH; S, H, 2023) |
| "Mitotic count in breast cancer is an important prognostic marker." | ( Ibrahim, A; Makhlouf, S; Miligy, IM; Minhas, F; Rakha, EA; Toss, MS, 2023) |
| "Breast carcinomas are composed of cancer cells surrounded by various types of non-cancer cells such as fibroblasts." | ( Aboussekhra, A; Al-Ansari, MM; Al-Nasrallah, HK, 2022) |
| "Breast cancer is a heterogeneous disease, and the survival rate of patients with breast cancer strongly depends on their stage and clinicopathological features." | ( Chang, YJ; Chen, YR; Chong, KH; Hsu, WH; Lee, MC; Tsai, KW; Tu, YT, 2022) |
| "Breast cancer is the most diagnosed cancer among women, and its incidence and mortality are rapidly growing worldwide." | ( Angeletti, M; Bonfili, L; Cecarini, V; Cortese, M; Cuccioloni, M; Eleuteri, AM; Gong, C; Kilani, S; Selmi, S; Zheng, Y, 2022) |
| "Breast cancer is recognized globally as one of the leading causes of malignant morbidity." | ( Camps, I; Mishra, A; Pathak, Y; Tripathi, V, 2023) |
| "Breast cancer is a heterogeneous disease involving complex mechanisms." | ( Fang, CM; Loh, HS; Ngai, SC; Wong, SHM, 2023) |
| "Breast cancer is a heterogeneous disease involving complex mechanisms." | ( Fang, CM; Loh, HS; Ngai, SC; Wong, SHM, 2023) |
| "Breast cancer is a heterogeneous disease involving complex mechanisms." | ( Fang, CM; Loh, HS; Ngai, SC; Wong, SHM, 2023) |
| "Breast cancer is the most prevalent cancer, and it is accompanied by high heterogeneity." | ( Chen, T; Li, C; Li, W; Li, Z; Wang, X; Yang, Q; Zhou, X, 2023) |
| "Breast cancer is the most prevalent cancer, and it is accompanied by high heterogeneity." | ( Chen, T; Li, C; Li, W; Li, Z; Wang, X; Yang, Q; Zhou, X, 2023) |
| "Breast cancer is the most prevalent cancer, and it is accompanied by high heterogeneity." | ( Chen, T; Li, C; Li, W; Li, Z; Wang, X; Yang, Q; Zhou, X, 2023) |
| "Breast cancer is the most common malignancy in women in the United States, with surgical options including lumpectomy and mastectomy followed by breast reconstruction." | ( Aghayev, A; Ahmad, S; Azene, EM; Ferencik, M; Hedgire, SS; Kirsch, DS; Lee, YJ; Nagpal, P; Pass, HA; Pillai, AK; Ripley, B; Singh, N; Steigner, ML; Tannenbaum, A; Thomas, R, 2022) |
| "Breast cancer is the most common malignancy in women in the United States, with surgical options including lumpectomy and mastectomy followed by breast reconstruction." | ( Aghayev, A; Ahmad, S; Azene, EM; Ferencik, M; Hedgire, SS; Kirsch, DS; Lee, YJ; Nagpal, P; Pass, HA; Pillai, AK; Ripley, B; Singh, N; Steigner, ML; Tannenbaum, A; Thomas, R, 2022) |
| "Breast cancer is the most common malignancy in women in the United States, with surgical options including lumpectomy and mastectomy followed by breast reconstruction." | ( Aghayev, A; Ahmad, S; Azene, EM; Ferencik, M; Hedgire, SS; Kirsch, DS; Lee, YJ; Nagpal, P; Pass, HA; Pillai, AK; Ripley, B; Singh, N; Steigner, ML; Tannenbaum, A; Thomas, R, 2022) |
| "Breast cancer is now the most prevalent cancer in females, therefore, it is essential to identify factors affecting its initiation and progression." | ( Bidmeshkipour, A; Hajmomeni, P; Sisakhtnezhad, S, 2023) |
| "Breast cancer is now the most prevalent cancer in females, therefore, it is essential to identify factors affecting its initiation and progression." | ( Bidmeshkipour, A; Hajmomeni, P; Sisakhtnezhad, S, 2023) |
| "The development of breast cancer is usually related to multiple pathways." | ( Bai, M; Guo, S; Huang, M; Liang, J; Qu, Y; Song, Y; Zhao, Y, 2023) |
| "The development of breast cancer is usually related to multiple pathways." | ( Bai, M; Guo, S; Huang, M; Liang, J; Qu, Y; Song, Y; Zhao, Y, 2023) |
| "Breast cancer is the most common malignant tumor in women worldwide, and environmental pollutants are considered to be risk factors." | ( Lao, QF; Li, SL; Liu, L; Martin, FL; Pang, WY; Qiao, ZP; Zhang, QQ, 2023) |
| "Breast cancer is the most common malignant tumor in women worldwide, and environmental pollutants are considered to be risk factors." | ( Lao, QF; Li, SL; Liu, L; Martin, FL; Pang, WY; Qiao, ZP; Zhang, QQ, 2023) |
| "Breast cancer is a worldwide health concern, and surgical removal has remained the preferred therapeutic option in most patients." | ( Dehghanpisheh, L; Karami, A; Karami, MY; Mojarad, N; Niazkar, HR; Panah, A; Sabzloun, Z; Tahmasebi, S; Talei, A, 2022) |
| "Breast cancer is a worldwide health concern, and surgical removal has remained the preferred therapeutic option in most patients." | ( Dehghanpisheh, L; Karami, A; Karami, MY; Mojarad, N; Niazkar, HR; Panah, A; Sabzloun, Z; Tahmasebi, S; Talei, A, 2022) |
| "Breast cancer is very common among women." | ( Acun, A; Burlage, LC; Cetrulo, CL; Lantieri, LA; Lellouch, AG; Lupon, E; Oganesyan, RV; Randolph, MA; Taveau, CB; Uygun, BE, 2023) |
| "Breast cancer is very common among women." | ( Acun, A; Burlage, LC; Cetrulo, CL; Lantieri, LA; Lellouch, AG; Lupon, E; Oganesyan, RV; Randolph, MA; Taveau, CB; Uygun, BE, 2023) |
| "Breast cancer is currently become a major public health problem in both developed and developing regions, it is one of the most common surgical problems in Ethiopia." | ( Fasil, A; Kebede, T; Melak, T; Sina, AA, 2022) |
| "Breast cancer is currently become a major public health problem in both developed and developing regions, it is one of the most common surgical problems in Ethiopia." | ( Fasil, A; Kebede, T; Melak, T; Sina, AA, 2022) |
| "Breast cancer is the most common type of cancer in women, with chemotherapy being the main strategy." | ( Lara, P; Melguizo, C; Mesas, C; Prados, J; Quiñonero, F; Rama, AR; Vélez, C, 2022) |
| "Breast cancer is the most common type of cancer in women, with chemotherapy being the main strategy." | ( Lara, P; Melguizo, C; Mesas, C; Prados, J; Quiñonero, F; Rama, AR; Vélez, C, 2022) |
| "Breast cancer is the most common type of malignancy among women." | ( Feng, W; He, R; Jiang, B; Li, Y; Ouyang, Y; Qi, X; Tan, Y; Wan, Z; Xie, L; Zhu, H, 2022) |
| "Breast cancer is the most common type of malignancy among women." | ( Feng, W; He, R; Jiang, B; Li, Y; Ouyang, Y; Qi, X; Tan, Y; Wan, Z; Xie, L; Zhu, H, 2022) |
| "Breast cancer is the most common malignant neoplasm in women worldwide." | ( Barros, AV; Bezerra, TS; Fachin, LP; Ferro, CC; Folha Filho, EAC; Fraga, CAC; Leite, ALDS; Oliveira, MJC; Rocha, FTR; Sales-Marques, C; Santos, DC; Santos, SMLD; Silva, AMRD; Silvestre, DWA, 2022) |
| "Breast cancer is the most common malignant neoplasm in women worldwide." | ( Barros, AV; Bezerra, TS; Fachin, LP; Ferro, CC; Folha Filho, EAC; Fraga, CAC; Leite, ALDS; Oliveira, MJC; Rocha, FTR; Sales-Marques, C; Santos, DC; Santos, SMLD; Silva, AMRD; Silvestre, DWA, 2022) |
| "Breast cancer is the most common cancer to spread to the choroid and orbit." | ( Grossniklaus, HE; Stålhammar, G, 2023) |
| "Breast cancer is the most common cancer to spread to the choroid and orbit." | ( Grossniklaus, HE; Stålhammar, G, 2023) |
| "Breast cancer is among the most prevalent mortal cancers in women worldwide." | ( Ahmadi, S; Akbarzadeh, I; Bazzazan, S; Chiani, M; Hosseini, S; Mostafavi, E; Saffar, S; Seraj, M, 2022) |
| "Breast cancer is a heterogeneous disease with distinct clinical and molecular characteristics." | ( Abdelhay, E; Binato, R; Crocamo, S; de Paula, B; Dos Santos, EC, 2022) |
| "Breast cancer is the most common malignant cancer and is the second most common cause of cancer-related deaths among females worldwide." | ( Cheng, Y; Jiang, T; Lan, H; Li, Y; Sun, X; Wan, X, 2023) |
| "Breast cancer is still the leading cause of cancer death in women." | ( Jafari-Gharabaghlou, D; Mohammadinejad, S; Zarghami, N, 2022) |
| "Prostate cancer and breast cancer are sex-steroid-dependent diseases that are driven in major part by gonadal sex steroids." | ( Brown, K; Michael, P; Roversi, G; Sharifi, N, 2023) |
| "Breast cancer is the most commonly diagnosed cancer and a leading cause of cancer-related death among women worldwide." | ( Kumar, U; Oliveira, HA; Somvanshi, RK, 2023) |
| "Breast cancer is the most common malignant tumor in women, and the liver is the main target organ for breast cancer metastasis." | ( Fang, C; Feng, J; Gong, T; Li, J; Tan, Y; Wu, Q; Xiang, L; Zhou, X, 2023) |
| "Breast cancer is known as the most common type of invasive cancer in women." | ( Bilgin, S; Erden Tayhan, S; Koç, E; Yıldırım, A, 2023) |
| "Breast cancer is the second most common cancer globally." | ( Aghaee-Bakhtiari, SH; Arefinia, R; Hatamluyi, B; Pasdar, A; Ranjbari, S; Rezayi, M, 2023) |
| "Exosomal miRNAs of breast cancer are known to enter the bone and degrade it, which facilitates cancer cells invasion into the bone interior and ensures its successful colonization." | ( Friedman, A; Siewe, N, 2023) |
| "Surgery for breast cancer is common, and intravenous opioids are often used to control postoperative pain." | ( Ahlberg, H; Hultin, M; Johansson, J; Myrberg, T; Wallgren, D, 2023) |
| "Breast cancer is the most frequent malignancy in women, with a 70% chance of patients being cured; however, metastatic disease is not considered curable using currently available chemotherapeutic options." | ( Cólus, IMS; da Rocha, CQ; Okuyama, NCM; Pereira, ÉR; Ribeiro, DL; Serpeloni, JM, 2023) |
| "Breast cancer is the most common tumor and the leading cause of cancer death in women." | ( Kong, F; Pan, Y; Zhang, H; Zhang, Q, 2023) |
| "Breast cancer is the fifth leading cause of death, worldwide affecting both genders." | ( Akbarizadeh, AR; Fatehi, R; Firouzabadi, N; Rashedinia, M; Zamani, M, 2023) |
| "Breast cancer is one of the most commonly diagnosed cancer types among women worldwide." | ( Bharat Lokhande, K; Goja, A; Nagar, S; Pandey, K; Saha, A; Swamy, KV, 2023) |
| "Breast cancer is one of the most common cancers worldwide and the discovery of new cytotoxic agents is needed." | ( Atmaca, H; Ilhan, S; Korkmaz, E; Yilmaz, ES; Zora, M, 2023) |
| "Breast cancer is the most commonly diagnosed cancer worldwide." | ( Chen, J; Li, Y; Miao, H; Tian, J; Wei, W, 2022) |
| "Worldwide, breast cancer is the most common cancer in women and is the main cause of death among all neoplasia in this group." | ( Cabañas-Cortés, MA; Cano-Sánchez, J; de Jesús-Aguilar, J; Elizondo, G; Murillo-González, FE; Tirado-Garibay, AC, 2023) |
| "Breast cancer is one of the most common cancers diagnosed worldwide and the second leading cause of death among women." | ( Bostan, H; Ghazisaeedi, M; Masoorian, H; Saeedi, S; Sajjadi, H; Yazdipour, AB, 2023) |
| "Breast cancer is the frequently diagnosed cancer and the leading cancer death among women." | ( Antony, GR; Littleflower, AB; Parambil, ST; Subhadradevi, L, 2023) |
| "Weight gain after breast cancer is common." | ( Boyages, J; Cave, A; Ee, C; Naidoo, D; Vaddiparthi, V, 2023) |
| "Globally, breast cancer is one of the leading causes of cancer death in women." | ( Liu, L; Luo, D; Wang, C; Xue, L; Zhang, S; Zhu, W, 2023) |
| "Some Breast cancers are human epidermal growth factor receptor 2 (HER2) positive." | ( Ajayi, TM; Hammed, SO; Odunitan, TT; Oladipo, OO; Olugbodi, SA; Oluwafemi, AT; Omoboyowa, DA; Saibu, OA; Singh, G, 2023) |
| "Women's breast cancer is one of the most significant healthcare issues for the human race that demands a proactive strategy for a cure." | ( Ajouaoi, S; Ben Mrid, R; Bouargalne, Y; Bouchmaa, N; Cacciola, F; El Fatimy, R; Nhiri, M; Zyad, A, 2023) |
| "Breast cancer is one of the most common cancers in women." | ( Cechowska-Pasko, M; Jabłońska-Trypuć, A; Krętowski, R, 2023) |
| "Breast cancer is the second leading cause of cancer-related death in women in the world, and its management includes a combination of surgery, radiation therapy, chemotherapy, and immunotherapy, whose effectiveness depends largely, but not exclusively, on the molecular subtype (Luminal A, Luminal B, HER2+ and Triple Negative)." | ( Colombo, I; Corsetto, PA; Rizzo, AM; Zava, S, 2023) |
| "Breast cancer is the first leading tumor in women in terms of incidence worldwide." | ( Acconcia, F; Battocchio, C; Ciccone, L; Cracco, P; Fiocchetti, M; Iucci, G; Marino, M; Montalesi, E; Moreno, S; Muzzi, M; Nencetti, S; Orlandini, E; Venditti, I, 2023) |
| "Breast cancer is one of the most prevalent malignancies and the leading cause of cancer-associated mortality in China." | ( Che, HL; Ge, YJ; Jin, YY; Wang, J; Wang, YX; Wu, GS; Xiong, H; Xue, KW; Zhao, ZC, 2023) |
| "The incidence of breast cancer is often associated with geographic variation which indicates that a person's surrounding environment can be an important etiological factor in cancer development." | ( du Plessis, M; Engelbrecht, AM; Fourie, C; Stone, W, 2023) |
| "Breast cancer is the most prevalent cancer in women and represents a serious disease that is harmful to life and health." | ( Liang, Z; Liu, L; Liu, W; Lu, Y; Zhou, Y, 2023) |
| "Women with breast cancer are keen to know their predicted survival." | ( Ab Hadi, IS; Mamat Azlan, MH; Mohd Hairon, S; Mohd Isa, SA; Musa, KI; Nik Ab Kadir, MN; Yaacob, NM; Yahya, MM; Yusof, SN, 2023) |
| "Breast cancer is the most commonly diagnosed cancer among Chinese American women." | ( Assoumou, B; Chang, E; Chen, LS; Han, T; Hsiao, HY; Hsiao, SC; Wang, H; Wang, JH, 2023) |
| "Breast cancer is the most common and high-incidence cancer in women." | ( Fang, P; Gong, W; Leng, M; Shi, Y, 2023) |
| "Breast cancer is a persistent threat to women worldwide." | ( Bhattacharya, K; Hany, D; Nowak-Sliwinska, P; Picard, D; Zoetemelk, M, 2023) |
| "Breast cancer is responsible for the highest mortality all over the world." | ( Chen, Y; Tian, Z; Xu, F; Yang, H, 2023) |
| "Breast cancer is the most common malignancy affecting women's health, with an increasing incidence worldwide." | ( Abdul Wadood Al-Shammaree, S; Ali Khadem, Z, 2022) |
| "Oligometastatic breast cancer is usually defined as advanced breast cancer with less or equal than 5 metastatic lesions." | ( André Di Ricco, B; Martins Medeiros, E; Miyasaki Piovesana, M; Peron, V; Teixeira Liutti, V, 2023) |
| "Breast cancer is the leading cause of cancer-related mortality in women worldwide." | ( Li, H; Shen, S; Yan, D; Yuan, J; Zhu, W, 2023) |
| "Breast cancer is the most frequently diagnosed malignancy and the leading cause of cancer-related deaths in women worldwide." | ( Feng, T; Gong, D; Kou, Q; Li, K; Li, Q; Li, S; Lin, P; Wang, G; Wang, Q; Yuan, H; Zhang, J; Zhao, G, 2023) |
| "Breast cancer is the most frequently diagnosed cancer among women worldwide." | ( Dalan, AB; Mohammed, EE; Sahin, F; Türkel, N; Yigit, UM, 2023) |
| "The risk of breast cancer is higher in CF patients compared to the general population." | ( Brancikova, D; Brat, K; Homola, L; Os, A; Stastna, N, 2023) |
| "Breast cancer is one of the leading causes of death in women worldwide." | ( Al-Shehri, M; Kaushik, AC; Mehmood, A; Wang, L; Wang, Z; Wei, DQ; Yao, J; Zhang, H, 2023) |
| "Breast cancer is one of the common malignancies with poor prognosis worldwide." | ( Chen, X; Lian, B; Shen, K, 2023) |
| "Breast cancer is the third most common cancer in Ireland and alcohol use remains high." | ( Doyle, A; Galvin, B; Millar, SR; Mongan, D; O'Dwyer, C, 2023) |
| "As breast cancer is a prevalent disease among women in Ireland, it is essential that the public, in particular women who drink, are made aware of this association." | ( Doyle, A; Galvin, B; Millar, SR; Mongan, D; O'Dwyer, C, 2023) |
| "Breast cancer is one of the most frequently observed malignancies worldwide and represents a heterogeneous group of cancers." | ( Bednarczyk-Cwynar, B; Dzikowska, P; Kaczmarek, M; Lisiak, N; Rubis, B; Wisniewska, U; Zaprutko, L, 2023) |
| "breast cancer is the cancer with the highest incidence in women in Brazil, representing 29." | ( Castelo Filho, A; Lopes, GM; Nicolau, SM; Vizzotto, AO, 2023) |
| "Breast cancer is characterized by uncontrolled cell growth in the breast tissue and is a leading cause of death globally." | ( Abbasi, SW; Akbar, A; Jahangir, M; Mehnaz, S; Raza, RZ; Riasat, A; Shahid, I; Shoaib, M, 2023) |
| "On the other hand, breast cancer is one of the major causes of cancer-related morbidity and mortality worldwide, where the human epidermal growth factor receptor-positive (HER2-positive) subtype is one of the most aggressive ones with a high rate of lymph node metastasis." | ( Bashraheel, SS; Khalaf, S; Kheraldine, H; Moustafa, AA, 2023) |
| "Breast cancer is the most common cancer type in women worldwide." | ( Cools, P; Denys, H; Fiers, T; Van de Vijver, K; Veldeman, L; Vergauwen, G; Verstraelen, H, 2023) |
| "Breast cancer is the most common cancer and the deadliest among women worldwide." | ( Clusan, L; Ferrière, F; Flouriot, G; Pakdel, F, 2023) |
| "Breast cancer is among the most recurrent malignancies, and its prevalence is rising." | ( Alsrhani, A; Althobiti, MM; Alzahrani, B; Alzerwi, NAN; Elderdery, AY; Elkhalifa, AME; Idrees, B; Mok, PL; Rayzah, M; Subbiah, SK, 2023) |
| "Breast cancer is a worldwide health problem." | ( Asghar, MS; Asgher, MZ; Aslam, J; Wahab, A; Zafarullah, S, 2023) |
| "Breast cancer is the most prevalent cancer in females, and approximately 70 % of all patients have evidence of metastatic bone disease, which substantially affects the quality of life and survival rate of breast cancer patients." | ( Chen, H; Jiang, G; Lin, Z; Yang, Y; Zeng, X; Zheng, T, 2023) |
| "Breast cancer is the second most common malignancy worldwide and 70% of all breast cancer cases are estrogen receptor-positive (ER+)." | ( Kaur, M; Palma, GBH, 2023) |
| "Breast cancer is the most prevalent cancer worldwide, with high morbidity and mortality." | ( Chen, M; Hao, X; Pan, C; Qiu, J; Song, H; Tang, Y; Yang, J; Zhao, P, 2023) |
| "Breast cancer is the most frequently diagnosed cancer in women worldwide." | ( Coskun, HS; Goksu, SS; Ilhan, RG; Ilhan, Y; Tatli, AM, 2023) |
| "Globally, breast cancer is the leading malignancy in females." | ( Bhattacharyya, S; Dey, S; Gupta, A; Majumder, S; Mukhopadhyay, A; Nath, S; Roy, S; Saha, S, 2023) |
| "Breast cancer is the most frequent malignancy in women with more than one in ten new cancer diagnoses each year." | ( Kumar, J; Kusanur, R; Niranjan, V; Philip, S; R, V; Uttarkar, A, 2023) |
| "Breast cancer is one of the most lethal cancers, especially in women." | ( Abolhassani, H; Ashrafnia Menarbazari, A; Bidaki, A; Farmani, AR; Hosseini, F; Mirzaei Chegeni, M; Moeinzadeh, A; Nabipoorashrafi, SA; Seyedi, SA; Tavakkoli Yaraki, M; Zaer, M, 2023) |
| "Breast cancer is a leading cause of cancer-related death worldwide, and chemoresistance often leads to poor patient outcomes." | ( Bow, YD; Chen, SY; Chen, YC; Chiu, CC; Hsu, SK; Hung, CT; Li, WJ; Lin, IL; Pan, WH; Wen, ZH; Wu, CY, 2023) |
| "Breast cancer is the most common cancer among women worldwide." | ( Mishra, V; Mishra, Y; Ranjan, A; Srivastava, N; Tambuwala, MM, 2023) |
| "Breast cancer is one of the most threatening cancers that poses a great risk to women's health." | ( He, F; Xie, C; Xu, X, 2023) |
| "Breast cancer is one of the main global diseases with a high mortality rate that mainly affects the female population." | ( Avilés-Gaxiola, S; Criollo-Mendoza, MS; Garcia-Carrasco, M; Gutiérrez-Grijalva, EP; Heredia, JB; Vazquez-Olivo, G, 2023) |
| "Breast cancer is one of the most malignant cancers." | ( Feng, E; Han, Q; Kong, Z; Wan, L; Zhu, B, 2023) |
| "While breast cancer is the most common cancer in women, cutaneous metastases are rare in breast cancer." | ( Abdulraheem, AM; Al Heyasat, AN; Alhasan, M; Almasri, NM; Naji, D; Odeh, R, 2023) |
| "Breast cancer is the one with low level of inflammation and low risk of malnutrition." | ( Ge, YZ; Hu, CL; Ruan, GT; Shi, HP; Song, MM; Xie, HL; Zhang, XW, 2023) |
| "Breast cancer is one of the leading causes of cancer deaths in women worldwide." | ( Abdolmaleki, P; Allahverdi, A; Kianamiri, S; Ramazi, S; Salimian, M, 2023) |
| "Breast cancer is the most common cancer among Japanese women and often yields a better prognosis than other cancers." | ( Hiroi, S; Iwasaki, K; Miyashita, M; Morioka, Y; Saeki, T; Shimizu, E; Yoshida, M, 2023) |
| "Neuroendocrine breast cancers are rare tumors that were recognized as a distinct entity by WHO classification in 2003." | ( Al Tamimi, NS; Belbaraka, R; Bennouna, Y; El Fadli, M, 2023) |
| "Breast cancer is the third most common cancer in women after skin and lung cancer." | ( Fenwick Antony, ER; Minu Jenifer, M; Sakthivel, M; Sasikala, S; Sivasamy, R; Velavan, K, 2023) |
| "Breast cancer is the most common cancer in urban Indian women and the second most common cancer in all Indian women." | ( Bhardwaj, PV; Dulala, R; Loke, C; Rajappa, S, 2024) |
| "Breast cancer is the second most diagnosed malignancy in American women with a lifetime occurrence of 1 in 8 women in the United States." | ( Desai, D; Khosla, A; Potdar, R; Sawhney, A; Singhal, S, 2023) |
| "Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer-related death." | ( Kizawa, M; Koda, D; Komura, Y; Kurita, T; Nakajima, T; Niwa, N; Takahashi, M; Takizawa, Y, 2023) |
| "Breast carcinoma is a molecularly diverse illness, and it is among the most prominent and often reported malignancies in female across the globe." | ( Annadurai, S; Gupta, N; Kesharwani, P; Molugulu, N; Sonam Dongsar, T; Tsering Dongsar, T; Wahab, S, 2023) |
| "Breast cancer is the most common malignancy in women, and it is linked to several risk factors including genetic alterations, obesity, estrogen signaling, insulin levels, and glucose metabolism deregulation." | ( Manzella, L; Martorana, F; Massimino, M; Parrinello, NL; Stella, S; Vigneri, P; Vitale, SR, 2023) |
| "Results in early breast cancer are discordant, with sustained improvement in invasive disease-free survival demonstrated for abemaciclib but not other CDK4/6 inhibitors to date." | ( Barrios, C; Cameron, D; Emde, A; Gnant, M; Janni, W; Johnston, S; Martin, M; Neven, P; Srock, S, 2023) |
| "Breast cancer is the most frequently diagnosed cancer, and more than half a million people die from it each year worldwide." | ( Alksnė, M; Baltriukienė, D; Jasmontaitė, D; Liudvinaitis, M; Rinkūnaitė, I; Šimoliūnas, E; Skinderskis, A, 2023) |
| "Breast cancer is the most common cancer among females, and surgery plays a central role in its treatment." | ( Fernandes, A; G, C; Jain, S; Jaiswal, R; Joseph, L; Kr, A; Kumar, R; Reddy, L; Reddy, T; S, V; Shekhar, N; Yashas, N, 2023) |
| "Breast cancer is the most common cancer in women." | ( Arnal, JF; Buscato, M; Dalenc, F; Davezac, M; Fontaine, C; Lenfant, F; Meneur, C; Zahreddine, R, 2023) |
| "Breast cancer is one of the most diagnosed cancers worldwide, with an incidence of 47." | ( Burgos, V; Maria, DA; Marín, V; Pardi, P; Paz, C; Pérez, R, 2023) |
| "Breast cancer is the most frequent cancer in women; however, it is curable in most cases (up to 80 %) when detected and treated at an early non-metastatic stage." | ( Al Aboody, MS; Alhoqail, WA; Alothaim, AS; Arulselvan, P; Eraqi, MM; Mickymaray, S; Suresh, K, 2023) |
| "Breast cancer is the most common cancer in women." | ( Cacciatore, C; Crichi, B; Farge, D; Frere, C; Moati, E, 2023) |
| "Breast cancer is currently the most prevalent malignancy among women." | ( Aizpurua-Perez, I; Arregi, A; Gonzalez, D; Labaka, A; Macia, P; Perez-Tejada, J; Ugartemendia, G; Zabalza, N, 2024) |
| "Breast cancer is one of the most common cancers with a high mortality rate among women worldwide." | ( Jalalpour Choupanan, M; Reiisi, S; Shahbazi, S, 2023) |
| "Breast cancer is resistant to conventional treatments due to the specific tumour microenvironment, the associated acidic pH and the overexpression of receptors that enhance cells tumorigenicity." | ( Alves, NM; Bastos, FR; Costa, RR; Pashkuleva, I; Reis, RL; Soares da Costa, D, 2023) |
| "Breast cancer is one of the most serious and deadly cancers in women worldwide, with distant metastases being the leading cause of death." | ( Chen, S; Chen, X; Dong, X; Li, R; Liu, J; Ru, X; Tan, J; Wen, T, 2023) |
| "Breast cancer is composed of metabolically coupled cellular compartments with upregulation of TP53 Induced Glycolysis and Apoptosis Regulator (TIGAR) in carcinoma cells and loss of caveolin 1 (CAV1) with upregulation of monocarboxylate transporter 4 (MCT4) in fibroblasts." | ( Bartrons, R; Birbe, RC; Caro, J; Domingo-Vidal, M; Győrffy, B; Ko, YH; Lin, Z; Martinez-Outschoorn, U; Philp, NJ; Roche, ME; Tuluc, M; Whitaker-Menezes, D, 2023) |
| "Breast cancer is the most prevalent cancer type in women worldwide." | ( Amler, E; Bober, P; Filová, E; Géci, I; Sabo, J, 2023) |
| "Breast cancer is not highly thrombogenic but is highly prevalent, resulting in increased VTE cases." | ( Bucciol, R; Othman, M, 2023) |
| "Breast cancer is a malignancy that affects mostly females and is among the most lethal types of cancer." | ( Mazandarani, A; Mohammadnejad, J; Taravati, A; Yazdian, F, 2023) |
| "Breast cancer is a leading cause of cancer death in women worldwide, and early detection is crucial for effective treatment." | ( Hekım, MG; Ozcan, M; Ozcan, S; Yıldırım, N; Yur, M, 2023) |
| "Breast cancer is the first most common cancer worldwide, and radiation therapy has a major role to play in locoregional adjuvant treatment." | ( Camps Maléa, A; Hennequin, C; Rivera, S, 2023) |
| "Breast cancer is a common cancer in women and a leading cause of mortality." | ( Chen, H; Deng, Y; Zhang, M, 2023) |
| "Breast cancer is a leading cause of cancer-related deaths in women." | ( Brant, TS; Goodrich, JA; Kugel, JF; Miller, GM, 2023) |
| "Breast cancer is the leading cause of cancer deaths for women worldwide." | ( Alzahrani, FM; Fasseas, K; Giannopoulou, E; Kalofonos, HP; Karamouzis, MV; Manou, D; Raftopoulou, S; Sarantis, P; Siatis, KE; Theocharis, AD, 2023) |
| "Breast cancer is a complex and diverse condition that disrupts multiple signaling pathways essential for cell proliferation, survival, and differentiation." | ( Afzal, O; Almalki, WH; Altamimi, ASA; Alzarea, SI; Bhat, AA; Dua, K; Gupta, G; Kazmi, I; Singh, SK; Subramaniyan, V; Thangavelu, L; Thapa, R, 2023) |
| "Breast cancer is an abnormal division of breast cells." | ( Anees, M; Ishtiaq, A; Khan, JS; Malik, S; Murtaza, I; Nasrullah, MA; Sultan, A; Tareen, U, 2023) |
| "Breast cancer is the second most common type of cancer worldwide and the leading cause of cancer death in women." | ( da Silva, JL; Dos Santos, NAN; Ferreira, C; Fialho, E; Lima, DGV; Passos, CLA; Polinati, RM, 2023) |
| "Breast cancer is a malignancy that occurs in cells in the breast tissue where cells in the breast divide and grow out of control, invade surrounding tissues, or spread (metastasize) to distant areas of the body." | ( Ahmad, M; Usman, AN, 2023) |
| "Breast cancer is the most commonly diagnosed cancer in women and hormonal therapy is an established treatment for estrogen receptor (ER) positive breast cancers." | ( Karak, PK; Phillips, EF, 2023) |
| "Breast cancer is the highest incidence of all types of cancer in women, and the cancer metastasis process accounts for a majority of cancer deaths." | ( Panichayupakaranant, P; Sukketsiri, W; Suttithumsatid, W, 2023) |
| "Breast cancer is the most fatal type of cancer in women worldwide." | ( Auda, IG; Hassan, ZH; Mahdi, LH, 2023) |
| "Breast cancer is the most common cancer in women worldwide." | ( Esfandbod, M; Etesam, F; Taleghani, SY, 2023) |
| "Breast cancer is the leading cause of cancer death among women worldwide." | ( Aissa, AF; Barreiro, EJ; Caixeta, ES; Fonseca, R; Hanemann, JAC; Ionta, M; Melo, ML; Miyazawa, M; Nacif, JLM; Pauli, F; Zavan, B, 2023) |
| "Breast cancer is a leading cause of cancer-related morbidity and mortality worldwide, with the highest incidence among women." | ( Alraih, AM; Alzain, AA; Ibraheem, W; Yousif, FA, 2023) |
| "Breast cancer is one of the most prevalent and deadly cancers among women worldwide." | ( Aghamohammadi, V; Alipanah-Moghadam, R; Clark, CCT; Jeddi, F; Nemati, A; Rezaie, H, 2023) |
| "Breast cancer is the most common cancer and the leading cause of cancer death among females worldwide." | ( Chen, H; Chen, S; Fong, DYT; Liu, Y; Wan, C; Zhou, J, 2023) |
| "Breast cancer is the most prevalent and leading cause of mortality worldwide among women." | ( Ali, Q; Ibrahim, S; Khan, MU; Khan, Z; Khawar, A; Khurram, I; Mubeen, M; Saleem, A, 2023) |
| "Breast cancer is the commonest cancer among women in India, yet the uptake of early detection programs is poor." | ( Bhandarkar, P; Gadgil, A; Nathani, P; Patil, P; Roy, N; Sawhney, R; Veetil, DK; Venghateri, JB, 2023) |
| "Breast cancer is a significant health issue for women, and human epidermal growth factor receptor-2 (HER2) plays a crucial role as a vital prognostic and predictive factor." | ( Chen, K; Hao, L; Liu, Y; Wang, J; Zhu, X, 2023) |
| "Globally, breast cancer is among the most frequently diagnosed and common cause of death among women." | ( Arnachellen, D; Augustine, TN; Pillay, K; Xulu, KR, 2023) |
| "Filipino women with breast cancer are an understudied group and are often combined with other Asian groups." | ( Cil, TD; Giannakeas, V; Li, WW; Lim, DW; Narod, SA, 2023) |
| "Breast cancer is a prevalent malignant tumor, posing a significant threat to women's health globally due to its increasing incidence and tendency to affect younger patients." | ( Qiao, S; Wang, H; Wang, T, 2023) |
| "Breast cancer is one of the world's most prevalent cancer and the most common type of cancer in Malaysia." | ( Andrew Tong, JW; Hee, MQ, 2023) |
| "Breast cancer is the most common malignancy in women, and medicinal plants can prevent and play an inhibitory role for cancer." | ( Akhtari, J; Davoodi, A; Falahianshafiei, S; Pasha, H, 2023) |
| "Triple-negative breast cancer is a subtype of breast cancer with a poor response to chemotherapy." | ( Hatami, M; Kheirollah, A; Khorsandi, L; Kouchak, M; Rashidi, M, 2023) |
| "Breast cancer is a significant global concern, with tamoxifen, the standard treatment, raising long-term safety issues due to side effects." | ( Budiman, YP; Destiarani, W; Hardianto, A; Kurnia, D; Mardetia, SS; Mayanti, T, 2023) |
| "Breast cancer is the second leading cause of death for women worldwide." | ( Madvar, RR; Taher, MA, 2024) |
| "Breast cancer is a major cause of death among human females across the globe." | ( Asrani, RK; Bhardwaj, P; Choudhary, S; Gupta, VK; Kumar, R; Patial, V; Sharma, D; Singh, R; Soni, M; Tripathi, BN; Virmani, N, 2024) |
| "Breast cancer is the most dangerous type in women and its fatality rate has increased over the past decade." | ( Abirami, A; Antony Joseph Velanganni, A; Devan, U; Grzegorz Małecki, J; Ramesh, R, 2023) |
| "Breast cancer is currently the most prevalent form of cancer worldwide." | ( Jiang, X; Lu, Z; Xia, Y; Xiang, Z; Xie, J; Yuan, Y, 2023) |
| "Breast cancer is the most common malignancy globally, and is considered a major cause of cancer-related death." | ( Anbar, HS; El-Gamal, MI; El-Gamal, R; El-Nablaway, M; Elfarrash, S; Salem, AA; Shoma, A; Zaraei, SO, 2023) |
| "Most of the breast cancers are estrogen receptor-positive recurring with a steady rate of up to 20 years dysregulating the normal cell cycle." | ( Ahmed, A; Ishaq, M; Islam, M; Saeed, H; Sultan, R; Wei, L, 2023) |
| "Breast cancer is the most common malignancy diagnosed during pregnancy." | ( Bakhuis, CFJ; Moelans, CB; Suelmann, BBM; van der Wall, E; van Diest, PJ; van Dooijeweert, C, 2023) |
| "Breast cancer is characterized by insidious onset, rapid progression, easy recurrence, and metastasis." | ( Chen, L; Chen, Y; Dai, J; Fan, Y; Fu, S; Li, J; Lu, Y; Wen, Q; Wu, Z; Zeng, F; Zhou, P, 2023) |
| "Breast cancer is the predominant cancer among women worldwide, and chemotherapeutic agents, such as doxorubicin (DOX), have the potential to significantly prolong survival, albeit at the cost of inducing severe cardiovascular toxicity." | ( Chen, J; Liu, A; Meng, T; Su, G; Tian, P; Zhang, D; Zhang, Y; Zheng, Y, 2023) |
| "Breast cancer is the most progressive cancer among women worldwide." | ( Alghamdi, AA; Alrokayan, SH; Khan, HA; Prasad, NR, 2023) |
| "Breast cancer is one of the most common malignant tumors in women all over the world." | ( Cheng, YY; Hu, X; Jin, W; Li, W; Liu, W; Liu, Y; Lu, Y; Nie, Y; Pan, B; Shu, Y; Song, K; Su, Y; Zhang, J, 2024) |
| "Breast cancer is a complex and heterogeneous disease with a high mortality rate due to non-specific cytotoxicity, low intratumoral accumulation and drug resistance associated with the ineffectiveness of chemotherapy." | ( de la Fuente Freire, M; Elena Martín, M; García-Fernández, J; González, VM; Pinto-Díez, C; Rivadulla Costa, L, 2023) |
| "Breast cancer is the most common cancer among women, and melanoma is the most dreadful type of skin cancer." | ( Alipanah, H; Alipanah, M; Ghanbariasad, A; Osanloo, M; Pishamad, S; Zarenezhad, E, 2023) |
| "Breast cancer is one of the most common type of cancers worldwide and remains a critical health issue." | ( Feng, X; Gao, S; Gao, X; Ge, TT; Pan, XJ; Shi, XG; Sun, P; Wang, TS; Wang, YK; Zuo, XM, 2023) |
| Excerpt | Reference |
|---|
| "172 patients who had had mastectomy for breast cancer were treated by repeated adjuvant chemotherapy, either with phenylalanine mustard (P." | ( Ahmann, DL; Bisel, HF; Edmonson, JH; Frytak, S; Hahn, RG; Ingle, JN; O'Connell, MJ; O'Fallon, JR; Payne, WS; Rubin, J; Scanlon, PW, 1978) |
| "Our initial trial in advanced breast cancer with A--C produced an overall objective response rate of 78% in 51 patients with advanced breast cancer without prior chemotherapy." | ( Jones, SE; Salmon, SE, 1979) |
| "Ninety-eight patients with metastatic breast cancer, heavily pretreated with other agents, were entered in a phase II trial of hexamethylmelamine (HEX)." | ( Balcerzak, S; Fabian, CJ; Haut, A; Rasmussen, S; Smith, F; Stephens, R; Tranum, B, 1979) |
| "4 patients with breast cancer, treated with Calusterone, a 17-alkylated, orally active androgenic steroid, were studied to determine the effect of this drug on testosterone metabolism." | ( Bradlow, HL; Hellman, L; Levin, J; Zumoff, B, 1977) |
| "Not all women with receptor containing mammary cancer will respond favorably to endocrine therapy, but those patients whose tumors lack a critical amount of estrophilin have little chance of benefit from either endocrine ablation or hormone administration." | ( Block, GE; Jensen, EV; Polley, TZ, 1975) |
| "As a new step in the strategy of breast cancer therapy based on receptor determinations a combined therapy with hormones and cytotoxic chemotherapeutics has to be checked in clinical trials in uture." | ( Heuson, JC; Leclercq, G, 1975) |
| "Since metastasizing breast cancer is hormone-related, hormonal therapy is based on control of tumor growth by elimination of the hormonal influence, hormone ablatives, or administration of steroid hormones to change the hormonal milieu of thehost organism." | ( Maass, H, 1976) |
| "A group of patients with metastatic breast cancer treated by a distinct drug regimen is analyzed with special respect to clinical and psychological problems." | ( Fernholz, HJ; Frik, W; Nüvemann, M, 1976) |
| "ER assays of breast cancer tissue proved to be a useful but imperfect tool in predicting clinical progress following hormonal maneuvers but some readings may be spuriously low due to imperfect techniques of measurement, prior exogenous hormonal administration or hormonal ablation, and previous irradiation of the tumor." | ( Brooks, SC; Cortez, A; Singhakowinta, A; Walt, AJ, 1976) |
| "However, since most patients with breast cancer present with local or regional disease but go on to die of disseminated cancer, major improvements in survival are most likely to occur by treating this neoplasm as a systemic disease through cobmining effective local therapy with systemic treatments." | ( Band, P; Bauer, M; Carbone, PP; Tormey, D, 1977) |
| "Three patients with metastatic breast cancer responded to diethylstilbestrol (DES) therapy, but later they developed endometrial carcinoma." | ( Khandekar, JD; Mukhopadhyaya, P; Victor, TA, 1978) |
| "Three patients with metastatic breast carcinoma who had untreated locally advanced primary tumors were treated initially with combination chemotherapy followed by hygienic mastectomy." | ( Aisner, J; Elias, EG; Morris, D; Wiernik, PH, 1978) |
| "There was a lower incidence of breast cancer in the treated group." | ( Beckman, EM; Nachtigall, LE; Nachtigall, RD; Nachtigall, RH, 1979) |
| "Eighteen patients with advanced breast cancer refractory to combination chemotherapy with 5-FU, Adriamycin, Cytoxan (FAC) were treated with methotrexate 30 to 40 mg/m2 iv and vincristing 1." | ( Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Tashima, CK; Wiseman, CL; Yap, HY, 1979) |
| "Thirteen consecutive stage II breast cancer patients were treated with long-term adjuvant chemotherapy using chlorambucil." | ( Lerner, HJ, 1978) |
| "The patients had inoperable/metastatic breast cancer that had been well-controlled with chemotherapy for many years (7 years and 4 months, 7 years and 1 month, 6 years and 3 months, and 4 years and 7 months, respectively)." | ( Falkson, G; Falkson, HC; Portugal, MA; Stevens, K, 1979) |
| "175 patients with metastatic breast cancer, treated with chemotherapy, were analyzed retrospectively to identify the characteristics of prognostic importance in predicting response to chemotherapy and survival from onset of the chemotherapy." | ( Bettelheim, P; Breyer, S; Francesconi, M; Graninger, W; Jakesz, R; Kolb, R; Micksche, M; Mörz, R; Moser, K; Rainer, H; Reiner, G; Schemper, M, 1979) |
| "Fifty patients with metastatic breast cancer were treated with 8-day courses of vincristine (1 mg iv, Day 1), adriamycin (50 mg/m2 iv, Day 1), cyclophosphamide (100 mg/m2 orally, Days 1-8), methotrexate (200 mg iv by 3-hour infusion, Day 8), and citrovorum factor rescue (15 mg in 12, 18, and 24 hours after methotrexate, Day 8) at 3-4-week intervals." | ( Arwidi, A; Lindholm, CE; Mattsson, W; von Eyben, F, 1977) |
| "In contrast, breast cancer patients show little difference between treatments." | ( Ansfield, F; Cornell, G; Davis, H; Hill, G; Klotz, J; Minton, J; Nealon, T; Ramirez, G; Wilson, W, 1977) |
| "Ninety-two women with advanced breast cancer were allocated at random to receive either cytotoxic or endocrine treatment." | ( Baum, M; Forbes, J; Jones, V; Priestman, T, 1977) |
| "In patients with metastatic breast carcinoma, who have undergone adrenalectomy in the past, a therapeutic trial with Nafoxidine may be worthwhile particularly in patients who have demonstrable estrogen receptor in the tumor of those who have in the past shown regression of tumor after endocrine therapy." | ( Jain, J; Samal, B; Singhakowinta, A; Vaitkevicius, VK, 1977) |
| "Thirty-four patients with metastatic breast cancer and no prior chemotherapy were treated with an induction regimen of four courses of adriamycin-cyclophosphamide followed by a fixed sequence of three courses of methotrexate-5-fluorouracil alternating with each course of adriamycin-cyclophosphamide." | ( Abeloff, MD; Ettinger, DS, 1977) |
| "Six out of eight patients with breast cancer metastases, one out of 13 with bronchial cancer metastases, and three out of nine with other types of cancer metastases also benefitted from the treatment." | ( Gautier, H; Huguenin, P; Lheritier, J; Mathé, G; Morin, P; Palangie, T; Parrot, R; Poisson, M; Pouillart, P, 1977) |
| "Two hundred and nine patients with breast cancer in an advanced stage were treated according to a chemotherapeutic regimen associating doxorubicin, vincristine and methotrexate, administered in courses of 5 days every three weeks." | ( Berlie, J; Brulé, G; Carton, M; Chauvergne, J; Clavel, B; Gary-Bobo, J; Guerrin, J; Klein, T; Pommatau, E, 1977) |
| "Sixty-nine patients with advanced breast cancer treated with cytotoxic chemotherapy were randomized to receive concomitantly either norethisterone acetate (progestogen group) or a placebo (placebo group)." | ( Begent, RH; Hayward, JL; Knight, RK; Rubens, RD; Sexton, SA, 1978) |
| "50 patients with primary breast cancer were studied to determine the CEA and HCG contents in their tumor cells before any treatment was initiated." | ( Eneroth, P; Lidbrink, E; Wahren, B; Wallgren, A; Zajicek, J, 1978) |
| "Seventy-eight advanced breast cancer patients with hormone-resistant disease or visceral metastases were randomized to receive either of two low dose regimens consisting of cyclophosphamide (C), methotrexate (M), 5-fluorouracil (F), and Adriamycin (A) as their initial chemotherapy." | ( Catalano, RB; Creech, RH; Engstrom, PF; Grotzinger, PJ; Harris, DT, 1979) |
| "Thirteen patients with neglected mammary cancer were treated with karminomycin in combination with hexamethylmelamine." | ( Assekritova, IV; Gorbunova, VA; Lichinitser, MR, 1977) |
| "Patients with breast cancer may show an increased requirement for thiamin particularly when treated with 5-fluorouracil, and a number of metabolic disturbances in which ascorbic acid may play a central role." | ( Dickerson, JW, 1979) |
| "We investigated its usefulness in breast cancer patients after conventional endocrine therapy and combination chemotherapy had failed." | ( Benjamin, RS; Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Legha, SS; Wiseman, C, 1979) |
| "Eighty-nine breast cancer patients were studied for the end result of therapy." | ( Alsabti, E, 1979) |
| "91 women with metastatic breast cancer, who received prior CTX-5FU or CTX-5FU-PRD, were treated in 3 consecutive clinical trials with either CTX-5FU-PRD-MTX-VCR, MTX-VCR, or MTX-VCR-PRD in order to elucidate whether the effectiveness of 5 drugs was due only to the newly added drugs (MTX-VCR +/- PRD) or whether the previously used drugs (CTX-5FU) were necessary as potentiating agents." | ( Nemoto, T; Rosner, D; Snyderman, M, 1979) |
| "One hundred women with primary breast cancer with 4 or more metastatic axillary nodes were treated for 9 months postoperatively with vincristine, prednisone, cyclophosphamide, methotrexate, and fluorouracil (VPCMF)." | ( Cooper, RG; Glidewell, O; Holland, JF, 1979) |
| "In 36 patients with advanced breast cancer, most of whom had been subjected to major endocrine ablation therapy such as bilateral adrenalectomy, correlation between the presence or absence of estrogen receptor (ER) in tumors and response to chemotherapy was investigated." | ( Kondo, H; Nomura, Y; Yamagata, J, 1979) |
| "Treatment of breast cancer by combination therapy induced luteal insufficiency, anovulatory cycles and sometimes hypergonadotropic amenorrhea in premenopausal women with previously normal mentrual cycles and ovarian function." | ( Geiger, W; Künzig, HJ; Schmidt-Rhode, P; Schulz, KD; Weymar, P, 1979) |
| "Seventy-eight advanced breast cancer patients, most of whom had had prior treatment, were treated with the synthetic antiestogen tamoxifen." | ( Green, L; Hoth, D; Macdonald, JS; Schein, PS; Smythe, T; Wiggans, RG; Woolley, PV, 1979) |
| "A patient with advanced breast cancer who had undergone a total bilateral adrenalectomy in the past refused adrenal steroid replacement therapy with the idea that this would be the easiest and quickest way to end her life." | ( Arnstein, AR; Jain, J; Singhakowinta, A; Vaitkevicius, VK, 1977) |
| "Patients with breast cancer were studied with regard to changes in the levels of serum thyroxine (T4) and serum triidothyronine (T3) after intramuscular administration of TSH for three days to investigate the thyroid reserve in these patients." | ( Abe, R; Kimura, M; Saito, S; Sakurada, T; Yoshida, K, 1977) |
| "Fifty patients with breast cancer refractory to endocrine manipulation and/or combination chemotherapy were treated with mitomycin-C 20 mg/m2 I." | ( Blumenschein, GR; Bodey, GP; Buzdar, AU; Hortobagyi, GN; Krutchik, AN; Livingston, RB; Tashima, CK; Yap, HY, 1978) |
| "Fifty patients with metastatic breast cancer were treated with a combination of vincristine, Adriamycin and prednisolone (VAP) at four weekly intervals." | ( Baker, JW; Dady, PJ; Ford, HT; Gazet, JC; McKinna, JA; Nash, AG; Powles, TJ; Russell, JA, 1978) |
| "Patients with advanced breast cancer who had not previously received chemotherapy were treated on a three-arm prospective study: adriamycin day 1 plus 5-FU on day 1 and 8 (AF), adriamycin day 1, plus 5-FU day 1 and 8, and cyclophosphamide day 1 (AFC), and adriamycin day 1 plus 5-FU day 1 and 8, cyclophosphamide day 1 and methotrexate day 1 (AFCM)." | ( Costanzi, J; Hoogstraten, B; Kennedy, A; Maloney, TR; Palmer, RL; Rivkin, S; Samal, B; Smith, F; Thigpen, T; Tranum, B; Tucker, WG; Vaughn, CB; Wilson, H, 1978) |
| "Ninety-one patients with advanced breast cancer failing adriamycin (ADR)-containing combination chemotherapy were treated with a combination of mitomycin C (MMC) and megestrol acetate." | ( Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Krutchik, AN; Legha, SS; Luna, MA; Tashima, CK; Yap, HY, 1978) |
| "Thirty-two patients with advanced breast cancer were treated with a combination of vincristine (1 mg/m2, not exceeding 2 mg, administered intravenously on day 1), adriamycin (40 mg/m2 administered intravenously on day 1), and cyclophosphamide (200 mg/m2 administered orally for 4 days on days 3-6)." | ( Jones, SE; Rainey, JM; Salmon, SE, 1979) |
| "Forty-five patients with disseminated breast cancer were given a trial of combination chemotherapy consisting of fluorouracil, adriamycin, and cyclophosphamide (FAC) and immunotherapy with BCG given by scarification." | ( Blumenschein, GR; Burgess, MA; Cardenas, JO; Freireich, EJ; Gottlieb, JA; Gutterman, JU; Hersh, EM; Hortobagyi, G; Livingston, RB; Mavligit, GM, 1976) |
| "One hundred patients with localized breast carcinoma have been treated by radiation alone from July 1, 1968, until June 30, 1973, at the Joint Center for Radiation Therapy." | ( Hellman, S; Weber, E, 1975) |
| "Management of breast cancer by surgery combined with irradiation can only affect disease within the treated area." | ( Montague, ED; Romsdahl, MM, 1976) |
| "Patients with advanced breast cancer and estradiol receptors in their tissue may show a favorable clinical response to hormonal therapy in 40-60% of cases." | ( Mickal, A; Schneider, GT, 1977) |
| "Forty-three patients with metastatic breast cancer who had not received prior chemotherapy were divided into two groups on the basis of whether or not a bone marrow examination revealed tumor." | ( Bull, JM; Ingle, JN; Simon, RM; Tormey, DC, 1977) |
| "The cell proliferation pattern in human breast cancer has been studied in eight patients in vivo using intravenously administered 3HTdR as a pulse and as a continous label." | ( Hoffman, J; Post, J; Sklarew, RJ, 1977) |
| "For the metastasized breast cancer the indication for the ablative and additive hormonal treatment and/or for the combination chemotherapy is clearly outlined." | ( Ehrhart, H; Hartenstein, R; Pape, W, 1977) |
| "The human breast cancer (Br-10) serially transplanted to nude mice (BALB/c-nu/nu) grew well in female mice but very slowly or not at all in untreated male mice and female mice treated with 1 mg of testosterone i." | ( Hirohashi, S; Kameya, T; Nagai, K; Shimosato, Y; Tsunematsu, R, 1977) |
| "Forty-four patients with metastatic breast cancer were treated with monthly courses of cyclophosphamide, methotrexate and 5-fluorouracil." | ( Biran, S; Brufman, G; Hochman, A; Krasnokuki, D, 1977) |
| "The end results of therapy of 1,358 breast cancer patients were studied." | ( Fried, IA, 1977) |
| "Patients with proven metastatic breast cancer have patterns reflecting their clinical status: those who respond to treatment have glycoprotein electropherograms similar to the group of patients with benign breast lesions, while those who do not have increased amounts of alpha2- beta-glycoprotein." | ( Dermer, GB; Silverman, LM; Tökes, ZA, 1977) |
| "Interviews were administered to breast cancer patients admitted to five hospitals in the Baltimore metropolitan area." | ( Chang, L; Levin, ML; Lilienfeld, AM; Thomas, DB, 1976) |
| "Seventy-two women with metastatic breast cancer were treated with multiple-agent chemotherapy." | ( Dao, TL; Nemoto, T; Rosner, D, 1976) |
| "Eighty-four patients with disseminated breast carcinoma were treated with the combination of hormonal therapy and combination chemotherapy from the time of diagnosis." | ( Dalcq, JM; Derriks, R; Laurent, C; Mannes, P; Moens, R, 1976) |
| "6 patients with breast cancer were treated for 4 weeks with the antiestrogen Tamoxifen, and for another 4 weeks with a combination of Tamoxifen and levodopa." | ( Costa, M; Di Benedetto, G; Gallamini, A; Indiveri, F; Nizzo, MC, 1976) |
| "Patients whose breast carcinomas possess only low concentrations of a receptor molecule that binds estrogens with high affinity are unlikely to respond to hormonal manipulative therapy when the disease recurs." | ( Johnson, IE; Mobbs, BG, 1976) |
| "About 40% of human breast cancers respond to endocrine therapy while in Sprague-Dawley rats induced mammary tumors are 80% hormone responsive." | ( Kolodny, D; Sherman, L; Smithline, F, 1975) |
| "Two cases of advanced breast cancer treated with a water-salt extract from BCG are presented, showing a positive response -- marked and durable regression of the breast tumor and of the axillar metastases, parallel in the second case with a disappearance of lung metastases." | ( Hadziev, S; Kavaklieva-Dimtrova, J; Mandulova, P, 1975) |
| "Using breast carcinoma in women as an example, it is shown that a carcinogenic effect cannot be demonstrated for two of the supposed carcinogenic factors, namely repeated diagnostic radiographic measures and administration of Rauwolfia-alkaloid containing drugs." | ( Fuchs, G; Oeser, H, 1975) |
| "78 women with breast cancer metastases were divided into 5 groups as to type of therapy and observed." | ( Arutiunian, DE; Barkhudarian, LKh; Gazarian, ES; Movsesian, MA; Ovsepian, LKh, 1975) |
| "Although breast cancer presents as localized disease and is treated with local modalities, i." | ( Carbone, PP, 1975) |
| "Recurrent cervical, ovarian, and breast cancers have been treated with immunochemotherapy." | ( Pattillo, RA, 1976) |
| "Forty patients with metastatic breast cancer who had received no previous cytotoxic therapy were treated with a combination chemotherapy program CMF (P), which included methotrexate, 60 mg/m2, and 5-fluorouracil, 700 mg/m2 intravenously on the first and eighth days, in addition to cyclophosphamide, 100 mg/m2, and prednisone, 40 mg/m2, by mouth daily from the first to the fourteenth day of a 28-day cycle." | ( Canellos, GP; Chabner, BA; DeVita, VT; Gold, GL; Schein, PS; Young, RC, 1976) |
| "Estrogen receptor (ER) analysis in breast cancer has been used in three clinical situations: to select patients with advanced breast cancer for hormonal therapy, as a prognostic parameter, and for selection of women with early breast cancer to adjuvant hormonal treatment." | ( Andersen, J, 1992) |
| "If confirmed in a larger series of human breast tumors, these in vitro results would indicate a promising role for ELS in clinical treatment, mainly of ER+ breast cancer patients." | ( Catania, S; De Marco, C; Sanfilippo, O; Silvestrini, R; Zaffaroni, N, 1992) |
| "In patients with stage III breast cancer who had responded to preoperative treatment and had had a low PRAL, two-year locoregional recurrence rate was only 13% as compared to 68% in a similar group of patients with high PRAL (P < 0." | ( Gabuniia, RI; Godin, VP; Letiagin, VP; Portnoĭ, SM, 1992) |
| "Tamoxifen, which is effective in breast cancer therapy, provides endocrine control of estrogen-regulated breast tumor growth." | ( Bernstein, L; Henderson, BE; Ross, RK, 1992) |
| "To review the incidence of breast cancer in a continuous 22-year study of conjugated estrogen-medroxyprogesterone acetate hormone replacement therapy." | ( Nachtigall, LE; Nachtigall, MJ; Nachtigall, RD; Nachtigall, RH; Smilen, SW, 1992) |
| "The method was used in 26 breast cancer patients before neoadjuvant chemotherapy." | ( Agrinskaia, IA; Alipchenko, LA; Biakhov, MIu; Chkhikvadze, VD; Gorb, AI; Krivenko, EV; Voznyĭ, EK, 1992) |
| "In Ireland, breast cancer is treated primarily by general surgeons." | ( O'Higgins, N, 1992) |
| "Sixty women with breast cancer (mean age: 61 years; range 36-78 years) were treated with Epirubicin (4'epi-Doxorubicin), 60 mg m-2, as single drug therapy." | ( Bengtsson, NO; Eksborg, S; Elfsson, B; Hardell, L; Sjödin, M, 1992) |
| "A total of 21 elderly patients with breast carcinoma without evidence of systemic dissemination received tamoxifen (20 mg daily) as primary treatment." | ( Asís, M; Caprarulo, L; Cassanello, G; Elena, H; Jimenez, R, 1992) |
| "Sixty-eight patients with advanced breast cancer were treated with mitoxantrone and clinical responses assessed." | ( Cairns, J; Cantwell, BJ; Cattan, AR; Hall, AG; Harris, AL; Horne, CH; Wright, C, 1992) |
| "Sixteen patients with metastatic breast cancer were treated with four cycles of doxorubicin, 5-fluorouracil, and methotrexate (AFM induction)." | ( Anderson, KC; Ayash, L; Elias, AD; Hunt, M; Lynch, C; Mazanet, R; Pap, S; Schwartz, G; Tepler, I; Wheeler, C, 1992) |
| "Progress in the treatment of breast cancer developed along multiple directions of research during the last decade." | ( Hortobagyi, GN, 1992) |
| "We treated this locally advanced breast cancer by intra-arterial infusion chemotherapy." | ( Akiyama, H; Nakazawa, H; Suzuki, N, 1992) |
| "From 1983-1989, 106 patients with breast cancer were treated in our pain management unit on 6767 treatment days." | ( Grond, S; Jung, H; Radbruch, L; Zech, D, 1992) |
| "Three patients with breast cancer with poor prognosis were treated with high-dose chemotherapy (HD-CT) and peripheral blood stem cell transplantation (PBSCT) as adjuvant treatment." | ( Ezaki, K; Maeda, H; Maruyama, F; Matsui, T; Miyazaki, H; Nomura, T; Okamoto, M; Sobue, R; Tsuzuki, M; Wakita, M, 1992) |
| "We reported a case of locally advanced breast cancer who was cannulated into the right internal thoracic artery through the right femoral artery by Seldinger's method for intra-arterial chemotherapy and obtained good results." | ( Miura, T; Murata, M; Seki, M; Shinohara, K; Takagi, S; Tezuka, T, 1992) |
| "5'-DFUR is a promising drug for breast cancer treatment, and its tablet form makes chemotherapy easier for the patient." | ( Inaji, H; Miura, S; Morimoto, K; Ohta, J; Taguchi, T; Ueda, N; Yayoi, K, 1992) |
| "Outpatients with advanced and recurrent breast cancer were treated by a combination therapy of the following drugs: doxifluridine (5'-DFUR) orally administered at a dose of 1200 mg/day; cyclophosphamide (CPA) orally given at dose of 100 mg/day; and tamoxifen (TAM) orally given at dose of 20 mg daily." | ( Irie, K; Kawahara, T; Okumura, T; Ota, J; Sakai, K; Shimoyama, T; Taguchi, T; Terasawa, T; Yamamoto, M; Yasutake, K, 1992) |
| "Twenty-six patients of breast cancer with pleural effusion have been treated with this therapy since 1983." | ( Harada, T; Hori, T; Kan, N; Kodama, H; Mise, K; Ohgaki, K; Okino, T; Satoh, K; Teramura, Y; Yamasaki, S, 1992) |
| "In the mammary cancer cell line T-47D, cells treated with danazol had increased progesterone receptor concentrations of 558." | ( Barker, S; Gledhill, JM; Goode, AW; Hinson, JP; Panahy, C; Puddefoot, JR; Vinson, GP; Wanless, C, 1992) |
| "In conclusion, ifosfamide's efficacy in breast cancer has been confirmed and the drug is highly recommended in combination chemotherapy as a first-line treatment." | ( Gad-el-Mawla, N, 1992) |
| "Therapy for metastatic breast cancer can palliate disease and prolong life, but cannot cure." | ( Sledge, GW, 1992) |
| "Postoperative radiotherapy for breast carcinoma had thus no effect on either trace element or nutritional status." | ( Antila, HM; Kirvelä, O; Näntö, V; Nikkanen, V; Salo, MS, 1992) |
| "Although the risk of breast cancer is a matter of controversy, it does not seem to increase with estrogen therapy; the addition of progestogen may decrease the risk for some women." | ( Gambrell, RD, 1992) |
| "A 66-year-old woman with left breast cancer (medullary carcinoma; T1cN1M0; Stage II A) was treated with breast conserving therapy combined with lumpectomy, radiotherapy, chemotherapy and endocrine therapy beginning in March, 1990." | ( Hamada, N; Inomata, T; Nishioka, A; Ogawa, Y; Ogoshi, S; Sawada, A; Tanaka, Y; Terashima, M, 1992) |
| "MCF-7 human breast cancer cells propagated in vitro were treated with adenosine derivatives added to the culture medium." | ( Eigenbrodt, E; Hugo, F; Mazurek, S; Zander, U, 1992) |
| "Thirty-four women with metastatic breast cancer were treated at the National Cancer Institute of the National Institutes of Health, with a regimen of leucovorin (L), 500 mg/m2 i." | ( Allegra, CJ; Denicoff, AM; Gupta-Burt, S; Pai, LH; Poirier, MC; Reed, E; Swain, SM; Venzon, DJ, 1992) |
| "The FM 2 breast carcinoma, finally, was the only xenograft whose growth was not influenced by treosulfan at doses up to that which was lethal to 50% of the treated mice (LD50 value)." | ( Köpf-Maier, P; Sass, G, 1992) |
| "Treatment of T-47D and MCF-7 human breast cancer cells with 10 nM of the synthetic progestin ORG 2058 for 24 hr resulted in an increase in all four PRLR mRNA transcripts detected." | ( Clarke, CL; Graham, J; Kelly, PA; Ormandy, CJ; Sutherland, RL, 1992) |
| "The response of breast cancer to endocrine therapy depends on depriving the tumor cells of estrogen stimulation of cell division." | ( Powles, TJ, 1992) |
| "147 stage II pre- and perimenopausal breast cancer patients were treated with cyclophosphamide-methotrexate-5-fluorouracil (CMF)- based adjuvant regimens." | ( Addamo, GF; Coialbu, T; Costantini, M; Giacchero, A; Guido, T; Repetto, L; Rosso, R; Toma, S, 1992) |
| "Thirty nine patients with metastatic breast cancer, all previously treated with chemotherapy including anthracycline, were given Elliptinium acetate (80 mg/m2/day) and a continuous infusion of Vinblastine (2 mg/m2/day) for 3 consecutive days every 4 weeks." | ( Kayitalire, L; Le Chevalier, T; Spielmann, M; Thomas, F; Toussaint, C; Tursz, T, 1992) |
| "Forty-six patients with metastatic breast cancer who had not received previous chemotherapy for advanced disease entered a phase II trial of weekly chemotherapy with cyclophosphamide (250 mg/m2) + epirubicin (25 mg/m2) for 16 weeks." | ( Alba, E; Alonso, L; Aranda, E; Belon, J; Blanco, E; Breton, JJ; Garcia, A; Lasso, R; Sanchez-Chaparro, MA, 1992) |
| "Fifty-five women with metastatic breast cancer were treated with carboplatin (CBDCA), 55 mg/m2 i." | ( Gonzalez, FG; Herranz, P; Hidalgo, OF; Rebollo, J; Tangco, E; Vieitez, JM, 1992) |
| "A 69-year-old female with advanced breast cancer was daily administered 20 mg of tamoxifen." | ( Furusawa, A; Momono, S; Nakagawa, K; Sasaki, Y; Sato, T; Shibata, C, 1992) |
| "Therefore, in advanced male breast cancer with a high estrogen receptor status, operation in conjunction with hormone therapy may lead to a favorable result in some cases." | ( Minamisono, Y; Nagasaki, S; Sugimachi, K; Tateishi, M; Toda, T, 1992) |
| "In 8 out of 12 premenopausal breast cancer patients there was a reduction in plasma IGF-I during treatment with goserelin (mean levels before treatment 23." | ( Aakvaag, A; Johannessen, DC; Lien, EA; Lønning, PE, 1992) |
| "A new approach for the treatment of breast cancer could be the use of progesterone antagonists." | ( McGuire, WL; Michna, H; Neef, G; Nishino, Y; Schneider, MR, 1992) |
| "Fifteen women with metastatic breast cancer undergoing autologous bone marrow transplantation were treated with an intensive induction regimen including cyclophosphamide and mitoxantrone in a phase I-II study." | ( Hooker, JL; Lewkow, LM; Movahed, A, 1992) |
| "Subsequently 52 patients with stage T4 breast cancer were randomised in a phase III trial to receive either radiotherapy alone (RT) or this chemotherapy and radiotherapy (CHOP + RT)." | ( Chetty, U; Hardman, PD; Jack, WJ; Kerr, GR; Leonard, RC; Rodger, A, 1992) |
| "A 68-year-old woman with metastatic breast carcinoma manifested bilateral tamoxifen-induced retinopathy after 9 years of low-dose therapy." | ( Chang, T; Gonder, JR; Ventresca, MR, 1992) |
| "43 postmenopausal breast cancer patients were treated orally with the aromatase inhibitor formestane (4-hydroxyandrostenedione) at daily doses of 62." | ( Coombes, RC; Dowsett, M; King, N; Mehta, A; Powles, TJ; Smith, IE; Stein, RC, 1992) |
| "The frontline chemotherapy for advanced breast cancer has been either CMF or CAF and the combinations can obtain an overall response rate exceeding 50%, including complete responses of 10-15% and median survival times of 12-18 months." | ( Ogawa, M, 1992) |
| "The Early Breast Cancer Trialists' Collaborative Group (EBC TCG) has recently reported the effectiveness of endocrine therapy, oophorectomy for premenopausal patients, and tamoxifen for pre- and post-menopausal patients in the adjuvant treatment for operable breast cancer patients." | ( Nomura, Y, 1992) |
| "Many breast tumors appear to follow a predictable clinical pattern, being initially responsive to endocrine therapy and to cytotoxic chemotherapy but ultimately exhibiting a phenotype resistant to both modalities." | ( Boulay, V; Brünner, N; Clarke, R; Leonessa, F; Thompson, EW; Wright, A, 1992) |
| "Patients (n = 174) with metastatic breast cancer previously untreated with anthracycline cytotoxic agents were randomized into two groups: Group 1 received FEC (5-fluorouracil 500 mg/m2, epirubicin 60 mg/m2 and cyclophosphamide 500 mg/m2) once every fourth week and group 2 received the treatment once weekly in the same monthly dosage." | ( Blomqvist, C; Elomaa, I; Helle, L; Hietanen, P; Nevasaari, K; Rissanen, P, 1992) |
| "The rate of bilateral breast cancer was reduced in tamoxifen-treated patients whereas the rate of new primary malignancies other than breast cancer was somewhat higher in tamoxifen-treated patients." | ( Aspegren, K; Bergljung, L; Fernö, M; Killander, D; Landberg, T; Möller, T; Rydén, S, 1992) |
| "Twenty-six patients with advanced breast cancer were treated with a new anti-estrogen, Droloxifene (3-hydroxy-tamoxifen)." | ( Gundersen, S; Haarstad, H; Kvinnsland, S; Mella, O; Raabe, N; Wist, E, 1992) |
| "Using MCF-7 human breast cancer cells, assay of the rate of PRLR gene transcription by the nuclear run-on technique indicated that 3 mM NaB reduced PRLR gene transcription by 50% after 3 h of treatment and that this effect was maintained for at least 24 h." | ( de Fazio, A; Kelly, PA; Ormandy, CJ; Sutherland, RL, 1992) |
| "The DNA damage induced in a human breast cancer cell line treated with 1,5 (10)-estradiene-3,4,17-trione (3,4-estrone-o-quinone; 3,4-EQ) has been measured qualitatively and quantitatively." | ( Abul-Hajj, YJ; Ngo, EO; Nutter, LM, 1991) |
| "A 24-year-old patient who developed breast cancer 16 years after chemotherapy for osteosarcoma is presented." | ( Hishinuma, S; Ikeda, T; Inada, T; Kotake, K; Koyama, Y; Ogata, Y; Ozawa, I; Sekiguchi, C; Shimamura, K; Shimizu, H, 1991) |
| "In MCF-7 human breast cancer cells treated with 10(-6) mol/l (molar) tamoxifen, the fraction of nuclei showing replication patterns decreased from 42% to 8% within 8 days, but PCNA and Ki-67 antigens remained detectable in most cells during this interval, indicating a relatively slow decrease of antigen expression in cells that have entered a quiescent state." | ( Cornelisse, CJ; Keijzer, R; van de Velde, CJ; van Dierendonck, JH; Wijsman, JH, 1991) |
| "In the human breast cancer cell line T47D, stimulation of HERV-K genome expression was observed following female steroids treatment." | ( Ono, M, 1990) |
| "A 49-year-old patient with breast cancer had a leiomyoma that rapidly enlarged shortly after she started therapy with tamoxifen." | ( Chang, AE; Cody, RL; Dilts, PV; Hopkins, MP, 1992) |
| "Adjuvant therapy for breast cancer with tamoxifen is suggested to be of benefit to both women with negative and women with positive axillary nodes, and treatment lasting several years is currently being investigated." | ( Love, RR; Surawicz, TS; Williams, EC, 1992) |
| "Investigations of the effect on breast cancer of the addition of progestins to postmenopausal replacement therapy have also produced inconsistent results." | ( Jones, JK; Miller, V; Newschaffer, CJ; Staffa, JA, 1992) |
| "Fifty-two consecutive patients with breast cancer and liver metastases have been treated with epirubicin." | ( Richards, MA; Rubens, RD; Smith, P; Twelves, CJ, 1991) |
| "Forty-nine women with breast cancer were enrolled in a prospective, longitudinal study of the genetic damage caused by treatment." | ( Albertini, RJ; Branda, RF; O'Neill, JP; Sullivan, LM, 1991) |
| "In this study, patients with operable breast cancer T2 or T3, treated by mastectomy + axillary dissection and with invaded axillary nodes (N+), were randomized to receive either: 1) postoperative locoregional and pelvic radiotherapy (RX) and Poly(A)." | ( Berlie, J; De Gislain, C; Delozier, T; Denis, V; Julien, JP; Lacour, J; Laplanche, A; Mourali, N; Namer, M; Petit, JC, 1991) |
| "Fourteen patients with advanced breast cancer were treated with the ribonucleotide reductase inhibitor didox 6 g m-2 given by intravenous infusion over 36 h every 3 weeks." | ( Brampton, MH; Harris, AL; Kaye, SB; Rubens, RD; Soukop, M; Williams, CJ, 1991) |
| "Primary chemotherapy in localised breast cancer may prevent tumour spread during surgical treatment and reduce proliferation of micrometastases." | ( Asselain, B; Dorval, T; Durand, JC; Garcia Giralt, E; Jouve, M; Palangie, T; Pouillart, P; Scholl, SM; Vilcoq, J, 1991) |
| "14 patients with advanced breast cancer were treated parenterally with Iscador, an extract of Viscum album (mistletoe)." | ( Hajto, T; Hostanska, K; Kovacs, E, 1991) |
| "Twenty patients with early breast cancer were treated with external irradiation, delivered with two tangential beams (6 MV X-rays) using a half-beam block (HBB) and 3-D compensating filters." | ( Canesi, P; Ciocca, M; Italia, C; Landoni, L; Montanaro, P; Valdagni, R, 1991) |
| "In addition, urine of breast cancer patients under adjuvant chemotherapy was screened for CB immunoreactivity with a sandwich type enzyme immunoassay which revealed significant interindividual differences in concentrations with some urines containing immunoreactivity comparable to healthy controls." | ( Dengler, R; Emmerich, B; Fritz, H; Gabrijelcic, D; Lah, T; Turk, V, 1991) |
| "Twenty-eight patients with advanced breast cancer refractory to prior hormone and/or first-line chemotherapy (with or without anthracycline drugs) were treated with the investigational agent amonafide at a dose of 800 mg/m2 intravenously over 3 hours repeated every 4 weeks." | ( Depisch, D; Dittrich, C; Gisslinger, H; Haider, K; Kornek, G; Linkesch, W; Scheithauer, W, 1991) |
| "Thirteen pretreated advanced breast cancer patients received a combination of alpha interferon 5 million IU every 2 days, subcutaneously, plus tamoxifen 10 mg 3 times daily, until disease progression." | ( Amoroso, D; Campora, E; Gardin, G; Giudici, S; Merlini, L; Miglietta, L; Naso, C; Pronzato, P; Queirolo, P; Repetto, L, 1991) |
| "The overall relative risk of breast cancer associated with this therapy was 1." | ( Dupont, WD; Page, DL, 1991) |
| "An advanced breast cancer patient refractory to CAF (Cyclophosphamide, Adriamycin, 5-fluorouracil), 5-FU-Methotrexate sequential therapy and Tamoxifen was treated with the combination 5' DFUR, MMC, Etoposide and MPA." | ( Ohtagaki, S; Toge, T; Toi, M; Yagi, M; Yoshinaka, K, 1991) |
| "Sixty patients with locally advanced breast cancer, but with no evidence of distant metastases were randomised to receive primary endocrine therapy or chemotherapy after assessment and 'Trucut' biopsy of the primary tumour." | ( Coombes, RC; Ford, HT; Gazet, JC, 1991) |
| "97 female breast cancer patients who received their first two FEC courses (epirubicin 50-75 mg/m2, 5-fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2) entered this randomised crossover study (76 had previously received an adjuvant treatment); tetracosactrin was administered intramuscularly and methylprednisolone intravenously immediately before chemotherapy administration." | ( Bastit, P; Bonneterre, J; Cappelaere, P; Chevrier, A; Fargeot, P; Geyer, G; Kerbrat, P; Metz, R; Roche, H; Tubiana-Hulin, M, 1991) |
| "The hormone sensitivity of ER positive breast cancer was also influenced by the rate of tumour cell proliferation, with tumours expressing high levels of Ki67 immunostaining rarely responding to therapy." | ( Blamey, RW; Bouzubar, N; Dixon, AR; Ellis, IO; McClelland, R; Nicholson, RI; Robertson, JF; Walker, KJ, 1991) |
| "IL-6-treated dividing breast carcinoma cells are characterized by an increased probability of separation from neighbors and the substratum." | ( Cardinale, I; Murphy, JS; Tamm, I, 1991) |
| "Fifty-two women with advanced breast cancer were treated with 6 cycles of epirubicin." | ( Beer, M; Fountzilas, G; Giannakakis, T; Kalogera-Fountzila, A; Kosmidis, P; Makrantonakis, P; Pavlidis, NA; Skarlos, D; Tsavaris, N, 1991) |
| "A case of recurrent breast carcinoma was successfully treated with MST-16 in an early phase II study." | ( Arimura, T; Fukuda, M; Katayama, K; Watanabe, H, 1991) |
| "Using the CAMA-1 breast cancer cell line, treatment with multiple immunotoxins was compared with chemoimmunoseparation with 4-HC, a panel of five unconjugated monoclonal antibodies and magnetic microspheres." | ( Bast, RC; Houston, LL; O'Briant, KC; Peters, WP; Shpall, EJ, 1991) |
| "Thirty patients with advanced breast cancer, not pretreated with chemotherapy for advanced disease, received a polychemotherapy regimen containing 5-fluorouracil (500 mg/m2 iv), epirubicin (50 mg/m2 iv) and cyclophosphamide (500 mg/m2 iv) every four weeks." | ( Baroni, M; Ercolino, L; Martoni, A; Pannuti, F; Tanneberger, S; Zamagni, C, 1991) |
| "(3) In hepatic metastasis of breast cancer, arterial infusion therapy was more effective, and the survival period was prolonged significantly." | ( Aogi, K; Jinushi, K; Sawamura, A; Toge, T, 1991) |
| "Adjuvant breast cancer therapy with tamoxifen is associated with greater disease-free survival and possibly overall survival." | ( Cameron, L; Connell, BL; Leventhal, H; Love, RR, 1991) |
| "Improvements in treatment of breast cancer by local surgery and adjuvant therapy can be expected to be modest at best." | ( Baum, M; Colletta, AA; Ziv, Y, 1991) |
| "Twenty-seven women with metastatic breast cancer were treated with doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH) every other week, alternating with 5-fluorouracil (5FU) and high-dose calcium leucovorin, for a 12-week induction regimen, followed by weekly doxorubicin and oral daily cyclophosphamide." | ( Coltman, CA; Ellis, GK; Green, S; Hynes, HE; Livingston, RB; Rivkin, S; Schulman, S, 1991) |
| "Chemotherapy for metastatic breast cancer is palliative, and the optimal duration of therapy is unknown." | ( Capizzi, RL; Case, LD; Cooper, MR; Cruz, JM; Muss, HB; Powell, BL; Richards, F; Spurr, CL; White, DR, 1991) |
| "We treated 250 women with metastatic breast cancer with six courses of cyclophosphamide, doxorubicin, and fluorouracil given every three weeks." | ( Capizzi, RL; Case, LD; Cooper, MR; Cruz, JM; Muss, HB; Powell, BL; Richards, F; Spurr, CL; White, DR, 1991) |
| "In patients with breast cancer who received induction chemotherapy for 18 weeks, subsequent continuous chemotherapy was associated with a significant prolongation of the time before progression as compared with those receiving no further therapy; overall survival, however, was not significantly different in the two groups." | ( Capizzi, RL; Case, LD; Cooper, MR; Cruz, JM; Muss, HB; Powell, BL; Richards, F; Spurr, CL; White, DR, 1991) |
| "In 48 postmenopausal breast cancer patients receiving an adjuvant therapy with 30 mg tamoxifen for 22 months on an average the effect of hormonal therapy on different immunologic parameters was examined and compared with an age-matched control group of breast cancer patients without hormonal therapy." | ( Krebs, D; Mallmann, P, 1991) |
| "In 61 breast cancer patients the effect of an combined adjuvant chemo-/immunotherapy with thymopentin (Timunox, Cilag) on different parameters of cell-mediated immunity (Leucocyte Migration Inhibition Test, serum level of tumor necrosis factor alpha, IL 2, Interferon alpha and distribution of lymphocyte subsets in the peripheral blood) and the clinical course of disease was evaluated and compared to patients receiving only chemotherapy." | ( Krebs, D; Mallmann, P, 1991) |
| "Thirty-one patients with advanced breast cancer were treated with CI941, an anthrapyrazole structurally related to mitoxantrone." | ( Ashley, SE; Calvert, AH; Judson, I; Mansi, JL; Smith, IE; Talbot, DC, 1991) |
| "Thirty-five patients with breast cancer were examined for estrogen receptor (ER) by biochemically and immunohistochemically, and sensitivity to antiestrogen agents was investigated experimentally in order to obtain strict indications for antiestrogen therapy." | ( Imamura, H, 1991) |
| "Recently during therapy of breast cancer with the new antiestrogen droloxifene, spikes of CA 125 and CA 15-3 were also found in about one-third of patients responding to therapy." | ( Kreienberg, R, 1991) |
| "Monocytes from untreated breast cancer patients released significantly less hydrogen peroxide than controls (Breast = 75 +/- 17." | ( Baughman, RP; Lower, EE, 1990) |
| "132 patients with advanced recurrent breast cancer were treated with four courses of mitozantrone 14 mg/m2 intravenously every 3 weeks (9 weeks)." | ( Cantwell, BM; Carmichael, J; Dawes, P; Evans, RG; Farndon, J; Ghani, S; Harris, AL; Wilson, R, 1990) |
| "For primary breast cancer, most physicians would offer the choice of local excision followed by radiation therapy or modified radical mastectomy." | ( Belanger, D; Moore, M; Tannock, I, 1991) |
| "Forty-nine patients with advanced breast cancer who had failed from first-line cyclophosphamide, methotrexate, and 5-fluorouracil (CMF regimen) chemotherapy, were randomized to treatment with either epirubicin (Epi) or doxorubicin (Dox) at a dose of 20 mg/m2 given intravenously (i." | ( Dal Fior, S; Favretto, S; Gasparini, G; Panizzoni, GA; Pozza, F, 1991) |
| "A total of 40 patients with metastatic breast cancer were treated with 120 mg/m2 i." | ( Carmo-Pereira, J; Costa, FO; Henriques, E; Miles, DW; Richards, MA; Rubens, RD, 1991) |
| "In 58 breast cancer patients with meningeal carcinomatosis (MC) pretreatment characteristics, clinical course, and response to treatment were evaluated." | ( Boogerd, W; Engelsman, E; Hart, AA; van der Sande, JJ, 1991) |
| "A total of 60 patients with advanced breast cancer were treated with a combination of prednimustine (P: 110 mg/m2, days 1-5), mitoxantrone (M: 12 mg/m2, day 1) and 5-fluorouracil (F: 500 mg/m2, day 1) (PMF)." | ( Dusleag, J; Kasparek, AK; Lechner, P; Pfeiffer, K; Samonigg, H; Schmid, M; Smola, M; Steindorfer, P; Stöger, H, 1991) |
| "We present the results of 186 breast cancer patients treated initially for locoregional disease by radiotherapy alone, combining cobalt therapy with external electron beam or interstitial iridium implants." | ( Dubois, JB; Gary-Bobo, J; Pourquier, H; Pujol, H; Salomon, A, 1991) |
| "Forty-six women with breast cancer treated with adjuvant FAC (fluorouracil, doxorubicin and cyclophosphamide) entered a multicenter, randomized, double-blind, cross-over trial in which thiethylperazine (T) (6." | ( Barriga, JJ; Diaz-Rubio, E; Gonzalez-Larriba, JL; Martin, M; Rosell, R; Valerdi, JJ, 1991) |
| "A total of 101 patients with advanced breast cancer were treated during the years 1976 to 1978 with doxorubicin, vincristine and cyclophosphamide, and randomized to receive either levamisole or placebo in a double-blind fashion." | ( Klefström, P; Nuortio, L, 1991) |
| "No leukemia was observed among 1132 breast cancer patients treated with adjuvant CMF (cyclophosphamide/methotrexate/5-fluorouracil) after a median follow-up of 7." | ( Petru, E; Schmähl, D, 1991) |
| "Large systematic trials in metastatic breast cancer have established tamoxifen as the recommended hormonal therapy for postmenopausal women with ER-positive tumors." | ( Osborne, CK; Sunderland, MC, 1991) |
| "A case of inflammatory breast cancer, for which an intra-arterial infusion chemotherapy was reported that it was effective." | ( Kawai, K; Kawasaki, S; Komatsubara, S; Misumi, T; Morokoshi, Y; Murakami, M; Ono, M; Teramoto, S; Usuki, H; Yamamoto, M, 1991) |
| "Treatment of MCF-7 cells, a human mammary carcinoma cell line, with phorbol ester [12-O-tetradecanoylphorbol-13-acetate (TPA)] or calcium ionophore (A23187) was associated with striking effects on levels of estrogen receptor (ER) mRNA, specific binding of 17 beta-[3H]estradiol [( 3H]E2), and immunoreactive ER." | ( Eikvar, L; Eskild, W; Hansson, V; Lahooti, H; Landmark, BF; Ree, AH; Walaas, SI, 1991) |
| "For adjuvant treatment of early breast cancer, however, the improvement of both recurrence-free survival and overall survival probably outweighs the increased frequency of uterine tumors." | ( Fornander, T; Rutqvist, LE; Wilking, N, 1991) |
| "to 20 patients with recurrent breast cancer at the time of first relapse who had been treated with the adjuvant therapy including TAM 10 mg b." | ( Abe, O; Izuo, M; Koyama, H; Nomura, Y; Tashiro, H; Tominaga, T, 1991) |
| "56 female patients with breast carcinoma and treated with polychemotherapy: adriamycin, vindesine, ciclophosphamide and 5-fluorouracil were studied, divided in three groups with different antiemetic schedule: group A 40 mg/iv of metoclopramide; group B 40 mg iv of metoclopramide and 125 mg/iv of methylprednisolone before beginning chemotherapy; and group C 2 mg/oral of lorazepam, 125 mg/iv methyl-prednisolone and 1 mg/kg/oral of metoclopramide previously to begin chemotherapy; at two and four hours of the first dose, metoclopramide was repeated the same doses (really) three doses each two hours." | ( Guillén Lloveria, G; Mayordomo Cámara, JJ; Sáenz Cusi, A; Sáez Martínez, MJ; Tres Sánchez, A, 1990) |
| "Three human breast carcinoma xenografts, MCF-7, R-27 and T-61 serially transplanted into nude mice were treated with mitomycin C (MMC) alone, KM2210 (estra-1, 3, 5(10)-triene-3, 17 beta-diol, 3 benzoate 17-[4-(4-bis(2-chloroethyl)amino)phenyl)-1-oxobutoxy)acetate) alone and KM2210 followed by MMC." | ( Arisawa, Y; Fujita, S; Inoue, S; Ishibiki, K; Josui, K; Kubota, T; Kuzuoka, M; Oka, S; Suto, A; Yamamoto, T, 1990) |
| "Thirty-two patients with metastatic breast cancer had previously been treated with chemotherapy (including anthracyclines)." | ( Milla, A; Sanchiz, F, 1990) |
| "Most patients with breast cancer should be given the option of breast-preserving treatment." | ( Auclerc, G; Baillet, F; Borel, C; de Maublanc, MA; Forget, G; Housset, M; Jacquillat, C; Soubrane, C; Thill, L; Weil, M, 1990) |
| "Thirty-two patients with advanced breast cancer were treated with mitomycin-C 10 mg/m2 IV and vinblastine 6 mg/m2 IV every 21 days in combination with lonidamine 450 mg/day P." | ( Arcangeli, G; Marini, G; Marpicati, P; Meriggi, F; Montini, E; Simoncini, E; Zaniboni, A, 1990) |
| "The immune status of breast cancer patients was followed during antiestrogen treatment for at least 1 year or until progression of the disease." | ( Toivanen, A; Tuominen, J; Valavaara, R, 1990) |
| "The growth of MCF-7, a human mammary carcinoma, in athymic nude mice was inhibited by intraperitoneal administration of erbstatin for 14 days in combination with an iron chelator, foroxymithine, which inhibits the decomposition of erbstatin." | ( Hirabayashi, N; Hori, T; Mukaida, H; Toge, T; Toi, M; Umezawa, K; Wada, T, 1990) |
| "40 patients with metastatic breast cancer, under treatment with epirubicin (greater than 50 mg/m2) and cyclophosphamide (greater than 500 mg/m2), had an antiemetic therapy with Ondansetron 3 x 8 mg day, for a maximum of 10 cycles." | ( Adler, M; Albrecht, U; Jaenicke, F; Marschner, NW; Nagel, GA, 1990) |
| "Hormonal therapy of breast cancer is widely used and effective." | ( Canetta, R; Kelley, S; Nicaise, C; Rozencweig, M; Schacter, LP; Smaldone, L, 1990) |
| "Eighteen women with metastatic breast cancer previously untreated with chemotherapy were entered on a phase II trial of intravenous menogaril, a new anthracycline derivative." | ( Abeloff, MD; Donehower, RC; Ettinger, DS; Fetting, JH; Grochow, LB; Kennedy, MJ, 1990) |
| "Apocrine differentiation in breast cancer may be a marker for oestrogen receptor positive tumours that do not respond to hormonal therapy." | ( Bundred, NJ; Forrest, AP; Miller, WR; Shaw, DA; Stewart, HJ, 1990) |
| "Chemotherapy for liver metastasis of breast cancer has rarely been found effective." | ( Ando, K; Funahashi, H; Imai, T; Kato, M; Kato, N; Narita, T; Odaka, K; Oike, E; Ono, M; Sato, Y, 1990) |
| "Thirty-two cases of infiltrating ductal breast carcinoma were stained with a monoclonal anti-OR antibody (H222), using a standard streptavidin-biotin method, following pretreatment with pronase." | ( Leong, AS; Raymond, WA, 1990) |
| "Treatment of ZR-75-1 human breast cancer cells with oestrogen has no direct effect on the expression of a transfected MMTV-LTR but enhances its inducibility in response to glucocorticoid treatment." | ( Bansal, GS; Latchman, DS, 1990) |
| "Twenty-four patients with metastatic breast cancer, all but 1 pretreated with one or more chemotherapeutic regimens, were entered in a pilot study to assess toxicity and efficacy of the combination mitoxantrone and vinblastine." | ( Cruciani, G; Fiorentini, G; Leoni, M; Marangolo, M; Rosti, G; Salerno, V; Tienghi, A; Turci, D, 1990) |
| "Thirty-four patients with metastatic breast cancer were treated in a multicenter phase II study with pirarubicin (THP) using a dosage of 75 mg/m2/every 3 weeks." | ( Beyer, JH; Edler, L; Essers, U; Fiebig, HH; Greifenberg, B; Kleeberg, UR; Reichel, L; Salewski, E; Wander, HE, 1990) |
| "Thirty patients with advanced breast cancer, previously treated with anthracycline and 5 fluorouracil in bolus administration, were evaluated with a chemotherapy regimen generally used in head and neck cancer." | ( Bastit, P; Bugat, R; Cappelaere, P; Chauvergne, J; Fumoleau, P; Horner, D; Metz, R, 1990) |
| "Characterization of breast cancer cells by histology, flow cytometry, and steroid receptors was performed on 197 Stage II breast node positive cancer patients given adjuvant chemotherapy, plus tamoxifen for patients with positive hormone receptors." | ( Booher, K; Buss, D; Case, LD; Cooper, MR; Galleshaw, J; Gregory, B; Kute, TE; Muss, HB; Stanley, V, 1990) |
| "Its use as an adjuvant in breast cancer management has been successful, with a proportion of women benefiting from long periods of tamoxifen treatment." | ( Gibson, DF; Jordan, VC, 1990) |
| "Hormone treatment of breast cancer has been common practice for many years." | ( Saez, S, 1990) |
| "Twenty five patients of advanced breast cancer (Stage IIIb and IV) were studied and the histological changes following chemotherapy were looked." | ( Khanna, AK; Khanna, S; Kumar, A; Saxena, SK, 1990) |
| "Data on usual diet prior to the breast cancer diagnosis were collected by self-administered questionnaires of the semi-quantitative food frequency type." | ( Ewertz, M; Gill, C, 1990) |
| "The T-47D human breast cancer cell line was treated with the synthetic progestin, ORG 2058, and the resultant changes in ER mRNA and ER levels determined by Northern analysis and radioligand binding, respectively." | ( Alexander, IE; Shine, J; Sutherland, RL, 1990) |
| "34 patients with metastatic breast cancer previously not treated with chemotherapy for metastatic disease entered this phase II trial, which tested the efficacy and toxicity of the chemotherapy combination epirubicin 120 mg/m2 and cyclophosphamide 600 mg/m2 (HD-EC regimen) i." | ( Adler, M; Ammon, A; Beyer, JH; Marschner, N; Nagel, GA, 1990) |
| "A Case of local recurrent breast cancer in a 45-year-old female with complete response to Combination of chemotherapy and topical administration of Adriamycin is reported." | ( Deguchi, S; Hokama, A; Kurihara, K; Muto, Y; Nomura, K; Toda, T, 1990) |
| "Adjuvant systemic therapy of breast cancer has been shown to reduce relapses and prolong survival in the women treated." | ( Castiglione, M; Cavalli, F; Goldhirsch, A; Neuenschwander, H; Senn, HJ, 1990) |
| "Our earlier study in breast cancer showed that second-line CAP (cyclophosphamide, adriamycin, cis-platinum) treatment was not cross-resistant to the CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) regimen and produced a 51% response rate." | ( Kolarić, K; Tomek, R, 1990) |
| "When postmenopausal breast cancer patients were administered either daily oral or parenteral weekly treatment with 4-OHA at doses that did not affect their gonadotropin levels, plasma estrogen concentrations were significantly reduced." | ( Banks, PK; Brodie, AM; Coombes, RC; Dowsett, M; Inkster, SE, 1990) |
| "A 34-year-old female patient with breast cancer metastasizing to bone had a remission after a course of treatment with medroxyprogesterone acetate (MPA) 1,200 mg/day, but again had a metastasis to the lungs." | ( Harada, N; Kanda, K; Kida, H; Narita, K; Uchimura, M; Waki, S, 1990) |
| "We treated 27 patients with metastatic breast cancer who had been heavily pretreated with regimens including ADM." | ( Descorps-Declere, A; Ecstein, E; Gil-Delgado, MA; Jasmin, C; Marino, JP; Misset, JL, 1990) |
| "Fifty-seven breast cancer patients under follow-up between 1987 and 1988 at the Radiotherapy Department, Lagos University Teaching Hospital following mastectomy and radiotherapy were given combination chemotherapy as adjuvant therapy or as a result of recurrent disease." | ( Ajekigbe, AT; Ketiku, KK, 1990) |
| "59 women with metastatic breast cancer in menopause were treated with 1 g/day aminoglutethimide and 3 mg/d dexamethasone." | ( Gürtler, R; Müller, U; Schmidt, UM; Stier, G; Tanneberger, S, 1990) |
| "Widespread local recurrence of breast cancer, untreatable by surgery or radiation therapy, can present a serious therapeutic problem predominantly in patients refractory to systemic therapy." | ( Eibl, H; Hilgard, P; Nagel, G; Peukert, M; Sindermann, H; Unger, C, 1990) |
| "Fifteen patients with breast cancer treated with mitoxantrone preoperatively from December 1986 to June 1983 were evaluated as to treatment validity and histological response." | ( Meng, ZX, 1990) |
| "When postmenopausal breast cancer patients were administered either by daily oral or parenteral weekly treatment with 4-OHA, plasma estrogen concentrations were significantly reduced." | ( Banks, PK; Brodie, AM; Inkster, SE; Koos, RD; Son, C, 1990) |
| "Fifty to sixty percent of ER-positive breast cancer responds to endocrine treatment, while only about 10% of ER-negative cancer do." | ( Nomura, Y, 1990) |
| "Fifty-three women with breast cancer were treated with a new 16-week dose-intense, chemotherapy regimen." | ( Abeloff, MD; Beveridge, RA; Damron, DJ; Davidson, NE; Donehower, RC; Fetting, JH; Gordon, GG; Waterfield, WC, 1990) |
| "Thirty-three patients with metastatic breast cancer received 135 cycles of chemotherapy consisting of mitoxantrone, methotrexate and chlorambucil." | ( Burghouts, JT, 1990) |
| "Thirty-five patients with metastatic breast cancer who had received one or two prior chemotherapeutic regimens were treated with elliptinium acetate at a dose of 80 mg/m2 for 3 days every 3 weeks." | ( Buzdar, AU; Esparza, LT; Fraschini, G; Holmes, FA; Hortobagyi, GN; Lichtiger, B; Ro, JS, 1990) |
| "Fourteen patients with metastatic breast cancer previously treated with one chemotherapy regimen received Pirarubicin at a dose of 70 mg/m2 at 3-week intervals." | ( Gärtner, S; Geyer, J; Giesske, H; Lenk, H; Rotte, KH; Tanneberger, S; Wiener, N, 1990) |
| "A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide." | ( Paridaens, R; Piccart, M; Richard, V; Sculier, JP, 1990) |
| "We have treated 28 women with advanced breast cancer of whom 26 had received prior endocrine therapy." | ( Coombes, RC; Cunningham, DC; Davenport, J; Dowsett, M; Ford, HT; Gazet, JC; Stein, RC; von Angerer, E, 1990) |
| "Treatment of MCF-7 human breast cancer cells with 17 beta-[3H]estradiol resulted in a rapid accumulation of occupied nuclear estrogen receptor complex in which levels were maximized within 1 h and decreased after 3 h." | ( Harris, M; Safe, S; Zacharewski, T, 1990) |
| "Patients with metastatic breast cancer entered the study after hormone therapy had failed; prior treatment with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) was also allowed." | ( Hossfeld, DK; Jonat, W; Langenbuch, T; Mross, K, 1990) |
| "Patients with early breast cancer (T1-2 N0-1) can be treated by lumpectomy and irradiation with a local control and survival equal to more radical surgery." | ( Mansfield, CM, 1990) |
| "In patients with metastatic breast cancer, a combination of cytotoxic and endocrine therapy generally leads to a higher rate of remission than in patients treated with either modality alone." | ( Rose, C, 1990) |
| "Fifty patients with advanced breast cancer (21 undergoing first and second stage palliative treatment: group 1, and 29 undergoing stage three or more: group 2), were included in a phase II trial with administration of a combination relay chemotherapy consisting of cisplatin (100 mg/m2/day) and fluorouracil (1,000 mg/m2/day), in continuous perfusion during 4 days, in cycles of five days repeated every three weeks (mean duration: 12 weeks)." | ( Bécouarn, Y; Chauvergne, J; David, M; Durand, M; Mauriac, L; Ravaud, A, 1990) |
| "Treatment of T-47D human breast cancer cells with retinoic acid for 48 h resulted in a marked concentration-dependent decrease in the level of PR mRNA and immunoreactive protein which was similar to the known effect of progestins on these parameters." | ( Clarke, CL; Graham, J; Koga, M; Roman, SD; Sutherland, RL, 1990) |
| "Local radiotherapy as treatment for mammary cancer induced unstable chromosome aberrations in peripheral blood lymphocytes." | ( Doloy, MT; Duranton, I; Guedeney, G; Leroy, A; Magdelenat, H; Rigaud, O, 1990) |
| "In 165 women with breast cancer who were candidates for mastectomy because the largest diameter of the tumor was 3 cm or more, we administered primary chemotherapy in the attempt to substitute conservative for mutilating surgery." | ( Bartoli, C; Bonadonna, G; Brambilla, C; Coopmans de Yoldi, G; Ferrari, L; Greco, M; Luini, A; Rilke, F; Veronesi, U; Zucali, R, 1990) |
| "Twenty-three patients with metastatic breast carcinoma were induced with a complex systemic therapy regimen in an attempt to ascertain if a complete remission rate greater than 50% could be obtained with intensive drug exposure." | ( Carbone, PP; Davis, TE; Kline, JC; Love, RR; Palta, M; Tormey, DC, 1985) |
| "Fourteen women with locally recurrent breast carcinoma on the chest wall following mastectomy were given 30 courses of photodynamic therapy (PDT)." | ( Dao, TL; Dougherty, TJ; Nseyo, UO; Potter, WR; Schuh, M, 1987) |
| "Treatment of human breast cancer cytosol with tamoxifen (Tam) or 4-monohydroxytamoxifen (MHT) enhances the immunoreactivity of the estrogen receptor toward monoclonal antibody H222 but not monoclonal antibodies D547 or D75." | ( Berthois, Y; Jensen, EV; Martin, PM, 1988) |
| "Colcemid-treated T-47D human breast cancer cells were permeabilised, stained with ethidium bromide, and analysed by flow cytometry." | ( Epstein, RJ; Smith, PJ; Watson, JV, 1988) |
| "Controversial questions in recurrent breast cancer include the magnitude of the survival benefit of combination chemotherapy and the best choice of first line chemotherapy." | ( Brincker, H, 1988) |
| "Our results suggest that breast cancer PR exhibit a marked molecular heterogeneity which may partially explain the differences in response to hormonal therapy, particularly for tumors with high receptor levels which nonetheless fail to respond to treatment." | ( Goussard, J; Lechevrel, C; Roussel, G, 1989) |
| "From 1976 to 1984, 135 recurrent breast cancer patients were treated with chemotherapy and/or additive endocrine therapy and their initial therapies and survival time were analyzed." | ( Iwanaga, T; Koyama, H; Nishizawa, Y; Noguchi, S; Shiba, E; Terasawa, T, 1989) |
| "A 51-year-old female with advanced breast cancer involving multiple bone metastases was daily administered 400 mg of UFT and 20 mg of tamoxifen." | ( Endo, F; Ishii, T; Kito, T, 1989) |
| "Forty-two patients with metastatic breast cancer refractory to first-line therapies were treated with combination chemotherapy with mitomycin-C and vinblastine." | ( Balañá, C; Bellmunt, J; Colomer, R; del Campo, JM; Jolis, L; Navarro, M, 1989) |
| "Monolayer cultures of MCF-7 human breast cancer cell line were treated with arachidonic acid (AA) and 15-L-(s)-hydroperoxyeicosatetraenoic acid (15-L-(s)-HPETE) in a concentration range of 10(-5)-10(-11) M and their relative cytotoxic potential was determined." | ( Beneytout, JL; Najid, A; Tixier, M, 1989) |
| "Thirty postoperative patients with breast cancer (stage I, II) were studied to clarify the changes of peripheral lymphocyte subsets by administration of anticancer drugs (UFT, cyclophosphamide (CPM]." | ( Kimura, M; Koida, T, 1989) |
| "Eight lines of human breast tumors implanted in nude mice were treated with various antitumor agents at two different doses, maximum tolerated doses (MTD) and rational doses (RD) that were pharmacokinetically equivalent to the clinical doses; the response rates to both doses were compared." | ( Inaba, M; Kobayashi, T; Maruo, K; Nomura, T; Ohnishi, Y; Sakurai, Y; Tashiro, T; Ueyama, Y, 1989) |
| "Twenty-five patients with metastatic breast cancer in progression after prior chemotherapy +/- hormonotherapy were treated with etoposide 50 mg/m2 i." | ( Cellerino, R; Menichetti, ET; Miseria, S; Silva, RR; Torresi, U; Tummarello, D, 1989) |
| "Human breast cancer cells (MCF-7) showed increased responses to methotrexate and vincristine after a 48-hr pre-treatment with medroxyprogesterone acetate." | ( Braunsberg, H; Ghilchik, MW; Owen, AM; Shaikh, N, 1989) |
| "Exposure of cultured human breast cancer cells (MCF-7) to medroxyprogesterone acetate (MPA) prior to treatment with adriamycin (ADR) enhanced the effect of the cytotoxic drug on cell yield after further growth of viable cells." | ( Braunsberg, H; Ghilchik, MW; Owen, AM; Shaikh, NA, 1989) |
| "Thirty-eight premenopausal breast cancer patients were treated for periods up to 12 months with a sustained-release formulation of the luteinizing hormone-releasing hormone agonist goserelin [Zoladex, (D-Ser(But)6Azgly10-LH-RH); 3." | ( Blamey, RW; Griffiths, K; Nicholson, RI; Robertson, JF; Turkes, A; Walker, KJ; Walker, RF, 1989) |
| "A postmenopausal patient with breast cancer with a left infrahilar lung mass was treated with tamoxifen." | ( Aisner, J; Belani, CP; Pearl, P; Whitley, NO, 1989) |
| "Twenty-eight patients with a metastatic breast cancer who have achieved a complete remission from a combination chemotherapy that included doxorubicin have been analyzed to ascertain the factors which affect the duration of the response and the survival time." | ( Fukutani, H; Hirano, A; Horikoshi, N; Inoue, K; Mizunuma, N; Mukaiyama, T; Ogawa, M; Shinagawa, K; Tabata, M, 1989) |
| "A patient with breast cancer was treated with adoptive immunotherapy of CTL because she had severe side effect from antineoplastics ." | ( Kitsukawa, K, 1989) |
| "To examine the risk of breast cancer after noncontraceptive treatment with estrogen, we conducted a prospective study of 23,244 women 35 years of age or older who had had estrogen prescriptions filled in the Uppsala region of Sweden." | ( Adami, HO; Bergkvist, L; Hoover, R; Persson, I; Schairer, C, 1989) |
| "Between 1980 and 1987, 14 patients with breast cancer who refused mastectomy were treated at the V." | ( Meenakshi, ML; Nagarajan, V; Savithri, S, 1989) |
| "An effective immunotherapy for breast cancer has yet to be established." | ( Fujimori, M; Iida, F; Kobayashi, S; Komatsu, M; Masuda, H; Shimizu, T; Sugenoya, A; Takahashi, S; Tsuchiya, S, 1989) |
| "Two cases of advanced breast cancer are reported that have had no recurrence for more than five years after multidisciplinary treatment including intra-arterial infusion chemotherapy." | ( Aogi, K; Doihara, H; Kurita, A; Murakami, M; Saeki, H; Soga, H; Takashima, S; Takiyama, W; Tanada, M; Yokoyama, N, 1989) |
| "Eighty-one patients with operable breast cancers received the short-term and intensive preoperative chemotherapy, followed by radical mastectomy are presented." | ( Zhang, B, 1989) |
| "Case report of a 45-year-old woman with breast cancer who underwent mastectomy with axillary lymphonodectomy and radiation therapy." | ( Blaschke, U; Gerber, B; Kasch, R, 1989) |
| "It is concluded that in breast cancer: (1) Estrogen sulfates can play an important role in the biological response of estrogens; (2) Anti-estrogens and progesterone significantly decrease the uptake and estradiol levels in hormone-dependent mammary cancer cell lines; (3) The control of the sulfatase and 17 beta-hydroxysteroid dehydrogenase activities, which are key steps in the formation of estradiol in the breast, can open new possibilities in the treatment of hormone-dependent mammary cancer." | ( Gelly, C; Nguyen, BL; Pasqualini, JR; Vella, C, 1989) |
| "Its role in the treatment of metastatic breast cancer should be tested in patients with less advanced disease." | ( Bartholomew, M; Boucher, AE; Demers, LM; Harvey, HA; Lipton, A; Manni, A; Simmonds, MA, 1989) |
| "Sixty patients with stage IIIA and IIIB breast cancer have been treated with a combined modality approach including induction chemotherapy, surgery and adjuvant chemotherapy: 74." | ( Amoroso, D; Battistini, G; Bertelli, G; Canavese, G; Caroti, C; Catturich, A; Conte, PF; Gardin, G; Pronzato, P; Tomao, S, 1989) |
| "The modern treatment of breast cancer has evolved over the past 100 years based on clinical observations." | ( Badwe, R; Desai, PB; Koppikar, A; Rao, DN; Sampat, MB; Sarkar, S; Shinde, SR; Tiwari, J; Vyas, JJ, 1989) |
| "Using electron microscopy, in the human breast cancer cell line T47D, the synthetic progestin R5020, and 5 alpha-dihydrotestosterone were shown to increase significantly the number of lipid droplets per cell section compared to control cells or estradiol- and dexamethasone-treated cells." | ( Chalbos, D; Chambon, M; Rochefort, H; Vial, HJ, 1989) |
| "Thirty-six consecutive patients with breast cancer and liver metastases with abnormal liver biochemistry were treated with epirubicin 25 mg m-2 i." | ( Coleman, RE; O'Reilly, SM; Richards, MA; Rubens, RD; Twelves, CJ, 1989) |
| "The question of which breast cancer patients to treat has been addressed by reviewing posters presented at the International Symposium on Endocrine Therapy." | ( Stewart, HJ, 1989) |
| "A patient with metastatic breast cancer treated with epirubicin (Pharmorubicin) developed a severe urticarial reaction which progressed to ulceration following possible sensitisation to the drug by preceding extravasation." | ( Cassidy, J; Rankin, EM, 1989) |
| "Estrogen receptor (ER) positive MCF-7 breast cancer cells implanted into the axillary mammary fat do not grow into palpable tumors unless sustained release preparations of estrogen are administered." | ( Friedl, A; Gottardis, MM; Jordan, VC; Robinson, SP, 1989) |
| "Only in breast cancer patients with multiple bone metastases was circulating BGP higher after the onset of antiblastic treatment and through the entire course of therapy, accompanied by bone pain remission and regression of bone lesions (BGP = 6." | ( Bartalucci, S; Cecchettin, M; Gemelli, MT; Giorgi, F; Neri, B; Pacini, P, 1989) |
| "Endocrine polychemotherapy of advanced breast cancer of women was monitored by vaginal hormone receptor cytological examinations and hormone receptor assay." | ( Iglódi, F, 1989) |
| "Thirty-nine patients with metastatic breast cancer who had not received prior chemotherapy for metastatic disease were treated in a phase II trial with a combination of mitoxantrone (10 mg/m2), methotrexate (40 mg/m2) and 5-fluorouracil (600 mg/m2) i." | ( Bleeker, PA; Meeuwissen, OJ; Neijt, JP; Nortier, JW; Schornagel, JH; Splinter, T; van der Vegt, S; van Groenestijn, A; van Kessel, D, 1989) |
| "The polypeptide patterns of MCF-7 human breast cancer cells (MCF-7gpt) and a stably v-H-ras-transfected subclone (MCF-7ras) have been analyzed following estradiol treatment." | ( Bronzert, D; Dickson, RB; Hampton, L; Lippman, ME; Thorgeirsson, SS; Wirth, PJ; Worland, PJ, 1989) |
| "Thirty-one patients with metastatic breast carcinoma refractory to standard hormonal and chemotherapy were treated with cisplatin 100 mg/m2 per course and etoposide 300 mg/m2 per course divided over 5 days." | ( Burton, GV; Cox, EB; Olsen, GA; Vugrin, D, 1989) |
| "Although the role of radiotherapy in breast cancer is controversial, there are clearly defined indications for its use." | ( Berg, D; Morgan, G, 1989) |
| "Two patients with breast cancer who had multiple distant metastases and 2 pediatric patients are now alive with NED after 5 years of the treatment and seem to have been cured." | ( Fujimoto, T; Kubota, M; Nakasaki, H; Norihisa, Y; Noto, T; Ohta, M; Okumura, A; Tajima, T; Tokuda, Y; Yokoyama, S, 1989) |
| "399 patients with early breast cancer were randomly allocated to treatment by either modified radical mastectomy or lumpectomy and radiotherapy." | ( Chaudary, MA; Doran, Z; Fentiman, IS; Habibollahi, F; Hayward, JL; Rubens, RD; Tong, D; Winter, PJ, 1989) |
| "Systemic treatment for breast cancer was left to the discretion of the physician." | ( Bijvoet, OL; Cleton, FJ; van Holten-Verzantvoort, AT, 1989) |
| "Cisplatin's role in metastatic breast cancer was initially confined to heavily pretreated patients." | ( Roth, BJ; Sledge, GW, 1989) |
| "Ninety-four patients with metastatic breast cancer were entered in a prospective randomised trial comparing 2 schedules of the same combination chemotherapy." | ( Belli, L; Beuzeboc, P; Dorval, T; Garcia-Giralt, E; Jouve, M; Livartowski, A; Mosseri, V; Palangie, T; Scholl, S; Vedrenne, J, 1989) |
| "Women with breast cancer whose blood and urinary androgens are at the lower end of the normal range have an early age at diagnosis, a rapid recurrence rate after mastectomy and tumours that are unresponsive to endocrine therapy." | ( Bulbrook, RD; Thomas, BS, 1989) |
| "Fifty-five breast cancer patients treated with mitoxantrone, methotrexate and 5-fluorouracil gave a response rate of 52." | ( , 1989) |
| "Twenty-eight patients with advanced breast cancer were treated by WLD-dox (12 mg/m2 week)." | ( François, E; Frenay, M; Khater, R; Milano, G; Namer, M; Pons, D; Renee, N; Thyss, A, 1989) |
| "Hormonotherapy of metastatic breast cancer was begun in 1896." | ( Namer, M, 1989) |
| "Chemotherapy of metastatic breast cancer induces temporary tumor responses, without any incidence on vital prognosis." | ( Cappelaere, P, 1989) |
| "Some problems concerning treatment for breast cancer were reviewed including primary operative procedures, adjuvant treatment or systemic treatment for advanced breast cancer." | ( Nomura, Y, 1989) |
| "In contrast, patients with secondary breast cancer, particularly those receiving antiestrogen therapy, had a melatonin peak similar to controls." | ( Bartsch, C; Bartsch, H; Bellmann, O; Fuchs, U; Gupta, D; Lippert, TH, 1989) |
| "A total of 35 patients with advanced breast cancer were treated with mitoxantrone, 14 mg/m2 I." | ( Chantarakul, N; Jirapanuwat, S; Rojananin, S; Skulchan, V; Suphaphongs, N; Tepmongkol, P; Thansakul, A, 1989) |
| "Seventy-five patients with stage 4 breast cancer were treated with a first-line chemotherapy regimen consisting of cyclophosphamide 600 mg/m2, mitoxantrone 12 mg/m2, and vincristine 1." | ( Bezwoda, WR; Dansey, R; Seymour, L, 1989) |
| "The association between survival in breast cancer and menopausal hormone treatment prior to diagnosis was analyzed by comparing 261 women who developed the disease in a population-based cohort of estrogen-treated women with 6,617 breast cancer patients without any recorded estrogen treatment drawn from the same population." | ( Adami, HO; Bergkvist, L; Bergström, R; Krusemo, UB; Persson, I, 1989) |
| "Although patients with recurrent breast cancer are not curable with presently available treatments, the duration of survival after the development of metastases has increased to about three years." | ( Mackintosh, JF, 1989) |
| "An audit of 43 breast cancer patients, considered to be of high operative risk and treated only with Tamoxifen was performed." | ( Falk, GL; Gray, JG; Gwynne-Jones, D, 1989) |
| "The groups comprised (1) early breast cancer (T1-2a, N0M0; n = 64); (2) untreated advanced fungating cancer (n = 27) and (3) advanced cancer relapsing after endocrine therapy (n = 29)." | ( Anderson, E; Gilmore, OJ; Plowman, PN; Puddefoot, JR; Stebbings, WS; Vinson, GP, 1989) |
| "The MCF-7 human breast cancer cell line responds to estradiol stimulation in vitro by increased proliferation only if prolonged subcultures in dextran-coated charcoal-treated fetal calf serum have been made previously." | ( Habrioux, G; Najid, A; Nicolas, A; Tixier, M, 1989) |
| "Then, four patients with advanced breast cancer were treated with combination of I." | ( Abe, M; Akimoto, M; Harada, Y; Hirakawa, H; Matano, S; Mori, S; Ouchi, N, 1989) |
| "In 34 patients with primary advanced breast cancer, intra-arterial administration of ADR (50 mg X 3, total dose 150 mg, 10 cases), 4' epi ADR (50 mg X 3, 150 mg, 8 cases; 70 mg X 3, 210 mg, 10 cases) and THP-ADR (50 mg X 3, 150 mg, 6 cases) was performed, and its effects and side effect were analyzed." | ( Asaishi, K; Hayasaka, H; Mikami, T; Narimatsu, E; Okazaki, A; Okazaki, M; Okazaki, Y; Sato, H; Toda, K; Watanabe, Y, 1989) |
| "Sixty women with metastatic breast cancer refractory to at least one chemotherapeutic regimen were treated with fluorouracil (FUra) and high-dose continuous infusion folinic acid (leucovorin calcium)." | ( Akman, S; Bertrand, M; Carr, B; Doroshow, JH; Flanagan, B; Goldberg, D; Leong, L; Margolin, K; Newman, E; Odujinrin, O, 1989) |
| "Forty patients with metastatic breast cancer were treated with a new combination regimen consisting of cyclophosphamide, epirubicin, high-dose folinic acid and 5-fluorouracil (super-FEC)." | ( Boari, L; Ferragni, A; Ferrari, V; Marini, G; Marpicati, P; Montini, E; Simoncini, E; Zaniboni, A, 1989) |
| "Forty-eight patients with advanced breast cancer were treated in a disease-specific phase I trial of doxorubicin and iproplatin combination chemotherapy." | ( Casper, ES; Curley, T; Hakes, TB, 1989) |
| "Thirty-six patients with metastatic breast cancer, 23 with documented progression of the disease after first-line chemotherapy (CAF or CMF) and 13 without prior chemotherapy, were treated with a simultaneous 120-h infusion of cisplatin (CDDP) and 5-fluorouracil (5-FU)." | ( Barrajón, E; Campbell, W; Fernández Hidalgo, O; Gil, A; González, F; Lacave, AJ, 1989) |
| "Ten patients with metastatic breast cancer refractory to multiple chemotherapeutic regimens as well as hormonal therapy were treated with continuous intravenous infusion of 5-fluorouracil (5-FU) at 200-300 mg/m2/24 h through a Broviac catheter using a Cormed pump." | ( Chang, AY; Most, C; Pandya, KJ, 1989) |
| "Twenty-five patients with breast cancer were treated by short infusion of adriamycin at a dose of 12 mg m-2 week-1 (41 courses)." | ( Frenay, M; Iliadis, A; Launay, MC; Milano, G; Namer, N, 1989) |
| "One hundred ninety-seven patients with breast cancer treated by modified radical mastectomy between the years 1978 and 1981 were studied." | ( Evans, DM; Wright, DJ, 1987) |
| "A 54-year-old woman with metastatic breast cancer developed veno-occlusive disease of the liver following chemotherapy with mitomycin C and doxorubicin." | ( Craft, PS; Pembrey, RG, 1987) |
| "In two breast cancers treated with radiation therapy, resulting in a decrease of tumor volume of more than 50%, a similar change in the tumor P-31 spectrum was observed: An intense PCr signal developed (PCr/ATP = 1." | ( Bakker, CJ; Luyten, PR; Moerland, MA; Sijens, PE; Vermeulen, JW; Wijrdeman, HK, 1988) |
| "In the human breast cancer cell line T47D, stimulation of HERV-K genome expression by progesterone was observed after estradiol treatment." | ( Kawakami, M; Ono, M; Ushikubo, H, 1987) |
| "When the breast cancer patients' macrophages were pretreated with these neuropeptides, enhancement in cytotoxicity was observed at 10(-10) M of [met]-enkephalin, and [leu]-enkephalin and at 10(-8) M and 10(-12) M of alpha-endorphin." | ( Cameron, DJ, 1987) |
| "One hundred women with advanced breast cancer were treated with endocrine therapy alone and the clinical response was correlated with the estrogen receptor status of the tumor as determined by a fluorescent histochemical assay designed to estimate the percentage of cancer cells with high cytoplasmic estrogen binding activity." | ( Chen, PZ; Mei, Z; Meng, XG; Yao, XY, 1989) |
| "A total of 14 females with advanced breast cancer were treated with epirubicin at a median cumulative dose of 827 mg/m2 (range, 550-1244)." | ( Brynjolf, I; Dombernowsky, P; Godtfredsen, J; Havsteen, H; Munck, O; Svahn, T, 1989) |
| "Seventeen patients with advanced breast cancer were imaged with a specially collimated gamma camera to study tumor uptake of 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) before and during therapy." | ( Minn, H; Soini, I, 1989) |
| "Out of 23 cases with breast cancer who completed the treatment, CR was observed in 2 and PR in 6, the response rate being 34." | ( Hayashi, K; Kitamura, M; Kosaki, G; Takahashi, I; Tominaga, T, 1985) |
| "In 23 cases of primary advanced breast cancer, intra-arterial infusion chemotherapy of Adriamycin (ADR) and Mitomycin C (MMC), which were injected jointly or individually, was performed and its effects and side effects were studied." | ( Asaishi, K; Ebata, T; Hayasaka, H; Narimatsu, E; Okazaki, A; Okazaki, M; Okazaki, Y; Sato, N; Toda, K; Totsuka, M, 1985) |
| "Overall, our breast cancer patients treated with MAP at high doses (300 patients) showed a 65% incidence of pain relief." | ( De Sanctis, R; Fruet, F; Martoni, A; Murari, G; Pannuti, F; Strocchi, E, 1985) |
| "As for the treatment of recurrent breast cancer, it is important to consider hormone receptor, lesion and age and to choose the effective mode of treatment for the first (recurrence of the) disease." | ( Hirai, T; Iino, Y; Ishida, T; Izuo, M; Kawai, T; Ogawa, T; Suzuki, H; Yokoe, T, 1985) |
| "Sixty-eight women with metastatic breast cancer occurring less than five years positives after the treatment of the primary tumour, with estrogens and/or progesterone receptors (EPR), were randomized." | ( Bonichon, F; Chauvergne, J; Durand, M; Mauriac, L, 1986) |
| "Thirty-seven patients with advanced breast cancer were treated with megestrol acetate 160 mg daily." | ( Blackledge, GR; Latief, T; Morrison, M; Mould, JJ; Spooner, D, 1986) |
| "Recent changes in hormonal therapy for breast cancer were reviewed and discussed." | ( Izuo, M, 1987) |
| "Normocalcaemic breast cancer patients with progressive osteolytic bone metastases were treated with clodronate 1." | ( Blomqvist, C; Borgström, GH; Elomaa, I; Lamberg-Allardt, C; Porkka, L, 1987) |
| "Of 97 patients with operable breast cancer, 24 were preoperatively treated with tamoxifen (20 mg twice daily) for 3 days (TAM 3-day), 22 were treated for 7 days (TAM 7-day), 21 for 14 days (TAM 14-day), and 30 received no treatment (control group)." | ( Koyama, H; Miyauchi, K; Nishizawa, Y; Noguchi, S, 1988) |
| "Forty-six patients with advanced breast cancer were treated orally with high-dose medroxyprogesterone acetate (MPA), and a 28% (2 CRs, 11 PRs) response rate was obtained." | ( Hisamatsu, K; Nomura, Y; Tashiro, H; Toi, M, 1988) |
| "A total of 32 patients with metastatic breast cancer responding with at least disease stabilization to treatment with two commercially available preparations of medroxyprogesterone acetate (MPA) or one preparation of megestrol acetate (MA) were followed for their plasma concentrations." | ( Becher, R; Miller, AA; Schmidt, CG, 1988) |
| "About one third of patients with breast cancer show objective improvement with aminoglutethimide, and it may also be of use in the treatment of adrenal carcinoma." | ( Nicholls, PJ; Shaw, MA; Smith, HJ, 1988) |
| "A total of 25 patients with metastatic breast cancer who had failed one prior chemotherapy regimen and had not received prior treatment with doxorubicin were treated with menogaril (200 mg/m2 i." | ( Edmonson, JH; Ingle, JN; Long, HJ; Loprinzi, CL; Schaid, DJ; Schutt, AJ, 1988) |
| "Estrogen receptor (ER) concentration of breast cancer tissue is important in predicting the response of each patient to hormonal, especially antiestrogen treatment." | ( Kangas, L; Valavaara, R, 1988) |
| "Thirty-three patients with metastatic breast cancer were treated with various dosages of MA under a phase-II study." | ( Blossey, HC; Emrich, D; Nagel, GA; Wander, HE, 1985) |
| "However, comparing 9 breast cancer patients, when having had both short-term and non-short-term CMF treatment, the effects on steroid excretion patterns appear to arise at an early stage." | ( Carruba, G; Castagnetta, L; Ciaccio, M; Di Carlo, A; Polito, L; Traina, A, 1985) |
| "We treated 17 patients with metastatic breast cancer with the four-drug combination of vincristine (0." | ( Heringer, R; Lefebvre, B; Maroun, JA; Stewart, DJ, 1986) |
| "Seventy-two women with advanced breast cancer were treated with aminoglutethimide and hydrocortisone (AG)." | ( Blomqvist, C; Elomaa, I; Rissanen, P, 1986) |
| "Patients with breast cancer who had been vaccinated either before or after the onset of disease, but before the initiation of chemotherapy, were shown to have developed significant anti-TBE antibody titers which persisted throughout the course of adjuvant treatment and could be boostered by revaccination during the course of CMF administration." | ( Dorner, F; Eibl, MM; Müller, C; Pötzi, P; Stuller, I; Zielinski, CC, 1986) |
| "Thirty-three patients with advanced breast cancer were treated with combination chemotherapy and hormonal synchronization in an attempt to increase the overall response rate generally obtained with traditional modalities of treatment." | ( Cervi, GC; Gorni, F; Marini, G; Marpicati, P; Simoncini, E; Zaniboni, A, 1986) |
| "The relationship between DNA content of mammary cancer and subsequent response to endocrine therapy was studied in 136 patients with advanced disease." | ( Baildam, AD; Barnes, DM; Howell, A; Moore, M; Sellwood, RA; Swindell, R; Turnbull, L; Zaloudik, J, 1987) |
| "Hormone-dependent metastasized breast cancer of post-menopausal women can be treated with four equivalent drugs: tamoxifen, megestrol, medroxyprogesterone, and--combined with steroid suppletion therapy--aminoglutethimide." | ( Harmsen, HJ; Porsius, AJ, 1988) |
| "Following mastectomy for node-positive breast cancer, 261 postmenopausal women were randomized to observation or adjuvant treatment with cyclophosphamide, fluorouracil, prednisone (CFP) alone or combined with tamoxifen (T)." | ( Cullinan, SA; Everson, LK; Ingle, JN; Krook, JE; Martin, JK; Paulsen, JK; Twito, DI; Votava, HJ; Wieand, HS; Wold, LE, 1988) |
| "Endocrine therapy of breast cancer was reviewed historically, and growth or regression of the tumor in relation to estrogen level in pheripheral blood was elucidated." | ( Tominaga, T, 1988) |
| "The successful treatment of advanced breast cancer has reached a plateau in recent years." | ( DeGregorio, MW; Holleran, WM; Maghsoodnia, M, 1988) |
| "All pre- and postmenopausal high-risk breast cancer patients in the protocols DBCG 77 of the Danish Breast Cancer Cooperative Group received postmastectomy irradiation before randomization to either adjuvant systemic therapy or no such treatment." | ( Brincker, H; Christensen, JJ; Frederiksen, PL; Johansen, H; Laursen, F; Nybo-Rasmussen, A; Overgaard, M; Panduro, J; Sørensen, NE; van der Kooy, P, 1988) |
| "In the Danish Breast Cancer Cooperative Group's (DBCG) protocol 77B, 1,028 premenopausal patients were randomized after mastectomy to radiotherapy (RT) alone (control), RT + 12 cycles of cyclophosphamide (C) or to RT + 12 cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)." | ( Jørgensen, J; Løber, J; Mouridsen, HT; Søgaard, J, 1988) |
| "Metastatic breast cancer continues to take thousands of lives each year despite the advances in screening and adjuvant therapy." | ( Eyre, HJ; Ward, JH, 1988) |
| "In the group of breast cancer patients (P T0-2N0-1M0) who received adjuvant polychemotherapy (TMF, CMF schemes) the survival rates are higher by 12." | ( Barash, NJ; Bavli, JL; Kostetskaya, TV; Kremen, BV; Migmanova, NS; Moiseyenko, VM; Popova, RT; Rzhankov, SV; Seleznyov, IK; Semiglazov, VF, 1986) |
| "Treatment of metastatic breast cancer with GnRH analogs has been associated with remarkable absence of significant toxicity." | ( Harvey, H; Lipton, A; Manni, A; Max, D; Santen, R, 1986) |
| "Fifty-seven patients with advanced breast cancer were treated with a combination of 5-fluorouracil and mitomycin C (FuMi)." | ( Aspegren, K; Landberg, T, 1986) |
| "Fifty-seven patients with postoperative breast cancer received MMF (mitomycin, methotrexate, futraful therapy with SNMC and 60 were given MMF alone." | ( Akimoto, M; Iwasaki, H; Kasai, M; Kimura, M; Matano, S; Nakajima, Y; Sawano, A, 1986) |
| "In cultures of the human mammary carcinoma-derived cell line MDA-MB-231, plasminogen activator (PA) activity was reduced substantially following treatment with the glucocorticoid dexamethasone." | ( Belin, D; Busso, N; Failly-Crépin, C; Vassalli, JD, 1987) |
| "H466-B and T47-D breast carcinoma cell lines were treated with recombinant gamma interferon (r gamma IFN) to study major histocompatibility complex (MHC) class I and class II antigen responses." | ( Abita, JP; Calvo, F; de Cremoux, P; Faille, A; Gauville, C; Jabrane, N; Lagier, G; Lechat, P, 1987) |
| "A 51-year-old woman with breast cancer metastatic to the pleura was treated with intrapleural instillation of adriamycin after thoracentesis, and systemic administration of FEMP, with complete response for more than 11 months." | ( Adachi, Y; Bada, K; Denno, R; Kohno, Y; Nishizawa, F; Ogasahara, K; Ohbayashi, M; Takahashi, J; Takeda, R; Yoshimura, T, 1987) |
| "Forty-three postmenopausal breast cancer patients with axillary lymph node metastasis were randomized to receive postoperative radiotherapy (45 Gy) or the combination of radiotherapy and 6 months of chemotherapy." | ( Hrafnkelsson, J; Nilsson, K; Söderberg, M, 1987) |
| "Twenty-eight patients with inflammatory breast cancer were treated with combined modality therapy consisting of (1) intraarterial infusion chemotherapy (IA chemotherapy) through the internal thoracic artery and subclavian artery, (2) surgical ablation, (3) extended radical mastectomy, and (4) adjuvant chemotherapy in that order." | ( Koyama, H; Miyauchi, K; Nishizawa, Y; Noguchi, S; Terasawa, T, 1988) |
| "Of these, 44 patients had bilateral breast cancer prior to initiation of adjuvant therapy (prechemotherapy) and 17 patients developed primary breast cancer on the contralateral side during or after completion of adjuvant therapy (postchemotherapy)." | ( Berté, E; Buzdar, AU; Hortobagyi, GN; Smith, TL, 1988) |
| "Four human breast carcinoma strains serially transplanted into nude mice were used for the experimental chemotherapy and combination chemoendocrine therapy." | ( Koh, J, 1988) |
| "Twenty-six patients with metastatic breast cancer where treated, after failure of a first line chemotherapy including an anthracycline, with a second line combination of vindesine, methotrexate and thiotepa." | ( Bastit, P; Chevallier, B; Comoz, M, 1988) |
| "Ten men with advanced breast cancer were evaluated for response to treatment with the luteinizing hormone-releasing hormone (LH-RH) analogue, buserelin, alone or in combination with the antiandrogen, flutamide." | ( Doberauer, C; Niederle, N; Schmidt, CG, 1988) |
| "Twenty-nine patients with metastatic breast cancer were treated with a combination chemotherapy consisting of Epirubicin 50 mg/m2 IV on day 1, Cyclophosphamide 500 mg/m2 IV on day 1 and Ftorafur 800 mg/day PO every day (ECF therapy)." | ( Fukutani, H; Hirano, A; Horikoshi, N; Inoue, K; Mizunuma, N; Mukaiyama, T; Ogawa, M; Shinagawa, K; Tabata, M, 1988) |
| "We treated 21 patients with advanced breast cancer with buserelin, aminoglutethimide and cortisone acetate in an attempt to obtain a complete estrogen blockade both in premenopausal and postmenopausal patients." | ( Ferrari, V; Marini, G; Marpicati, E; Montini, E; Moretti, R; Simoncini, E; Zaniboni, A, 1988) |
| "Postmenopausal patients with metastatic breast cancer were treated with aminoglutethimide (AG) and high-dose medroxyprogesterone acetate (MPA)." | ( Blijham, GH; Mellink, WA; Meulenberg, PM; Van Deijk, WA, 1985) |
| "Postmenopausal patients with primary breast cancer were treated with tamoxifen, ethynyloestradiol or prednisolone for up to 12 days before mastectomy and the effects of pretreatments with these drugs on the activities of phosphofructokinase (PFK), 6-phosphogluconate dehydrogenase (6PGDH) and alpha-glycerolphosphate dehydrogenase (alpha-GPDH) in the carcinomas were compared with age, stage and menopausal status matched untreated controls." | ( Boi, A; Deshpande, N; Di Martino, L; Maltinti, M; Mitchell, I, 1985) |
| "Patients with advanced breast cancer or advanced prostate cancer have been treated with an LH-RH-agonist ICI 118630." | ( Nicholson, RI; Walker, KJ, 1985) |
| "Above all, some CR cases in breast cancer indicated remarkable superiority of this drug for monotherapy." | ( Fujita, M; Nakano, Y; Ohota, J; Taguchi, T, 1985) |
| "Sixty-two women with advanced breast cancer were admitted to a pilot study in which a modified CMF regimen was administered." | ( Brandi, M; De Lena, M; Logroscino, A; Lorusso, V; Maiello, E; Paradiso, A, 1988) |
| "Twenty-five patients with advanced breast cancer were treated with 4-demethoxydaunorubicin (4-DMDR), a new antitumor analogue of daunorubicin, at the dose of 15-20 mg/m2/day x 3 days by oral route every 3-4 weeks." | ( Bozzi, D; Brandi, M; Calabrese, P; De Lena, M; Romito, S, 1988) |
| "Seventeen patients with metastatic breast cancer who had failed prior chemotherapy were treated with intravenous AZQ at a dose of 15-20 mg/m2 weekly for four consecutive weeks followed by a two-week rest period." | ( Haas, C; Martino, S; Ratanatharathorn, V; Samal, BA; Singhakowinta, A, 1988) |
| "Fourteen patients with advanced breast cancer were treated with a combination of vincristine, mitozantrone and prednisolone." | ( Cassidy, J; Leonard, RC; Merrick, MV; Smyth, JF, 1988) |
| "A 61-year-old woman with left advanced breast cancer (T3a, N2, M0, Stage IIIa) underwent preoperative chemotherapy." | ( Fujii, T; Kurihara, T; Owada, S; Teshigawara, O, 1988) |
| "Treatment of breast cancer cytosol with RNase A did not alter ER elution from either the hydrophobic or size-exclusion (TSK 3000 SW) columns." | ( Hyder, SM; Wittliff, JL, 1988) |
| "Cyclophosphamide was administered to 12 breast cancer patients in combination with methotrexate and fluorouracil." | ( De Bruijn, EA; Lameijer, DW; Roozendaal, KJ; Slee, PH; Tjaden, UR; Van Oosterom, AT, 1988) |
| "No other systemic therapy for breast cancer was prescribed." | ( Coleman, RE; Miles, M; Rubens, RD; Scrivener, W; Woll, PJ, 1988) |
| "Thirty patients with advanced breast cancer, not pretreated with chemotherapy, received a polychemotherapy regimen containing mitoxantrone, fluorouracil and cyclophosphamide at the dose of 10 mg/m2, 500 mg/m2 and 500 mg/m2 i." | ( Canova, N; Ercolino, L; Martoni, A; Pannuti, F; Rani, P, 1988) |
| "Twenty-nine advanced breast cancer patients, considered unable to tolerate conventional cytotoxic chemotherapy, were treated with a weekly schedule of epirubicin (15 mg/m2 i." | ( Algeri, R; Bastreghi, G; Guarnieri, A; Pepi, F; Pirtoli, L; Sapio, L; Tucci, E, 1988) |
| "We treated 34 patients with breast carcinoma metastatic to the liver and refractory to prior chemotherapy with sequential hepatic arterial infusion of cisplatin and vinblastine in an attempt to enhance their antitumor activity." | ( Buzdar, AU; Carrasco, CH; Charnsangavej, C; Fraschini, G; Hortobagyi, GN; Jabboury, KW, 1988) |
| "Twenty-seven women with metastatic breast cancer were treated with mitoxantrone as a single agent, with the use of an intensive dose-escalating schedule." | ( Bhardwaj, S; Holland, JF; Jones, RB; Paciucci, PA; Shpall, EJ; Strashun, A; Wilfinger, CL, 1988) |
| "Fifteen patients with advanced breast cancer who had achieved either a good partial or a complete response to conventional chemotherapy were selected to receive intensification treatment with high-dose melphalan 140-200 mg/m2 (HDM)." | ( Coombes, RC; McElwain, TJ; Powles, TJ; Vincent, MD, 1988) |
| "Sixty-eight breast cancer patients for outpatient adjuvant chemotherapy (CT) with cyclophosphamide, methotrexate, and fluorouracil (CMF) on a 1-day schedule entered a randomized trial comparing the antiemetic-efficacy of different doses of methylprednisolone (MPN)." | ( Bruzzi, P; Campora, E; Chiara, S; Lionetto, R; Rosso, R, 1987) |
| "One hundred-twenty-seven advanced breast cancer patients who had been -for most of them- heavily pretreated with chemo- and/or hormone therapy received 500 mg aminoglutethimide and 30 mg hydrocortisone/day." | ( Bonneterre, J; Demaille, A; Pion, JM, 1987) |
| "Forty-eight patients with advanced breast carcinoma who had not received prior chemotherapy (minimum follow up 21 months) were randomised to receive either adriamycin 70 mg m-2 i." | ( Cantinho-Lopes, MG; Carmo-Pereira, J; Costa, FO; Godinho, F; Henriques, E; Rubens, RD; Sales-Luis, A, 1987) |
| "Adjuvant therapy of breast cancer is accepted as a useful method for reducing mortality in patients with histologically axillary involved lymph nodes." | ( Jonat, W; Maass, H, 1987) |
| "Yet, of all solid tumors, breast cancer remains one of the most responsive tumors to hormonal therapy, radiotherapy, and chemotherapy." | ( Suhrland, LG, 1987) |
| "A 42-year-old woman with metastatic breast cancer developed bilateral optic disc swelling, retinal hemorrhages, and visual impairment three weeks after starting treatment with low doses of tamoxifen." | ( Ashford, AR; Donev, I; Garrett, TJ; Tiwari, RP, 1988) |
| "Two patients developed breast cancer after treatment of Hodgkin's disease." | ( Anderson, T; Cox, JD; Gillin, M; Greenberg, M; Janjan, NA; Schewe, K; Wilson, JF, 1988) |
| "The risk of breast cancer was not associated with the duration of use, years since first use, or years since last use of exogenous oestrogen therapy." | ( McMichael, AJ; Rohan, TE, 1988) |
| "Sequential hormone therapy for advanced breast cancer can offer significant and prolonged disease control with minimal morbidity." | ( Anderson, KM; Bonomi, PD; Economou, SG; Gale, M; Von Roenn, JH; Wolter, JM, 1988) |
| "Fourteen evaluable advanced breast cancer patients, extensively pretreated by chemotherapy, received a combination of cisplatin (DDP) and etoposide (VP 16)." | ( Calciati, A; Donadio, M; Ferrati, P; Giaccone, G, 1988) |
| "For the treatment of recurrent breast cancer, surgical treatment of the local lesion is only of limited significance, leaving a major role for systemic treatment such as chemotherapy and endocrine therapy." | ( Asaishi, K; Hayasaka, H; Okazaki, M, 1988) |
| "Forty-four evaluable patients with breast carcinoma previously treated with combination chemotherapy consisting of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) were treated with a combination chemotherapy regimen consisting of doxorubicin (A) (20 mg/m2 on days 1, 8, 15, and 22, repeated every 28 days) and mitomycin (MIT) (10 mg/m2 on day 1, repeated every 28 days)." | ( Colozza, M; Davis, S; Grignani, F; Tonato, M, 1988) |
| "Patients with operable breast cancer were treated at the University of Kansas Medical Center with lumpectomy, peri-operative interstitial Iridium, and external beam radiotherapy, and concomitant adjuvant chemotherapy in a majority of node positive cases." | ( Gerald, K; Jewell, WR; Krishnan, EC; Krishnan, L; Mansfield, CM; Reddy, EK; Thomas, JH, 1988) |
| "A patient with stage IV advanced breast cancer with multiple metastasis (bones of the whole body, lungs) were treated by ovariectomy, administration of an non-steroidal antiestrogen (tamoxifen) and mild chemotherapeutic drugs, with favorable results." | ( Komaki, K; Konishi, Y; Mituyama, N; Monden, Y; Morimoto, T; Oomine, Y; Tanaka, T; Yamakawa, T, 1988) |
| "Oestrogen pre-treatment of T-47D human breast cancer cells improves the therapeutic index of VP-16 without the need for cell synchronisation or highly precise drug scheduling." | ( Bleehen, NM; Epstein, RJ; Smith, PJ; Watson, JV, 1988) |
| "In 23 cases of breast cancer treated conservatively using external beam and interstitial radiotherapy, lithium fluoride thermoluminescent dosimetry has been used to measure the radiation dose received by the breast tissue at depth." | ( Aird, EG; Crawshaw, IP; Dawes, PJ, 1988) |
| "Treatment of CG5 human breast cancer cells with recombinant interferon-alpha 2b (rIFN-alpha 2b) can increase the synthesis and release, in culture medium, of the 90K." | ( Baiocchi, G; Iacobelli, S; Mancuso, S; Natoli, C; Panici, PB; Perrone, L; Scambia, G, 1988) |
| "Forty-three patients with advanced breast cancer were treated with adriamycin, vincristine and mitomycin C at 6 week intervals." | ( Calman, KC; Harding, M; Kaye, SB; Milsted, RA; Sangster, G, 1988) |
| "Fourteen patients with disseminated breast cancer with primary or secondary resistance to tamoxifen were treated with LY156758." | ( Buzdar, AU; Holmes, F; Hortobagyi, G; Hug, V; Marcus, C, 1988) |
| "For local treatment of inflammatory breast cancer and recurrent breast cancers with liver metastasis, we applied intraarterial infusion chemoembolization therapy utilizing albumin microspheres containing adriamycin (ADM-ms), which was developed by Morimoto." | ( Asaishi, K; Hayasaka, H; Mikami, T; Morimoto, Y; Narimatsu, E; Okazaki, A; Okazaki, M; Okazaki, Y; Toda, K; Watanabe, Y, 1988) |
| "58 patients with clinically localised breast carcinoma, treated by either mastectomy alone or lumpectomy plus local radiotherapy, have now been followed for up to 51 months (median 12 months)." | ( Auger, MJ; Galloway, MJ; Leinster, SJ; Mackie, MJ; McVerry, BA, 1987) |
| "All three patients had been treated for breast carcinoma; in two the disease had been bilateral, and in two the gastric tumour was the first manifestation of relapse of that patient's breast carcinoma." | ( Bilous, M; Langlands, AO; Tiver, KW; Walker, Q, 1986) |
| "Twenty-nine patients with metastatic breast cancer were treated orally with idarubicin (15 mg/m2 X 3 days every 3-4 weeks)." | ( Amoroso, D; Conte, PF; Lionetto, R; Pronzato, P; Rosso, R; Sertoli, MR, 1986) |
| "Forty-eight patients with metastatic breast cancer previously treated with cytostatics (except anthracyclines) underwent peroral treatment with 4-demethoxydaunorubicin (4-DMDR), a new daunorubicin analogue." | ( Kolarić, K; Mechl, Z; Potrebica, V; Sopkova, B, 1987) |
| "Thirty-eight patients with advanced breast cancer were treated with oral 4-demethoxydaunorubicin in a continuous weekly schedule at a dose of 15 mg/m2/week." | ( Howell, A; Smith, DB, 1987) |
| "Twenty-five patients with metastatic breast cancer received greater than 80 endocrine cycles and greater than 300 courses of chemotherapy by this protocol; two-thirds of these patients had previously failed other endocrine or chemotherapy regimens." | ( Benz, C; DeGregorio, M; Drakes, T; Gandara, D; Miller, B; Monroe, S; Wilbur, B, 1987) |
| "When T 47D human breast cancer cells were treated with 10 nM of the potent antiestrogen, 4-hydroxyclomiphene, growth rate was reduced to about 50% of control." | ( Koga, M; Sutherland, RL, 1987) |
| "A popular misconception infers that all breast cancers are systemic from their inception, that variations of primary therapy will not affect prognosis, and that an effective systemic therapy is already available." | ( Urban, JA, 1986) |
| "Ninety patients with breast cancer refractory to cyclophosphamide/fluorouracil/methotrexate (CMF) have been randomized in their treatment, receiving either doxorubicin or mitoxantrone." | ( Gochnour, D; Hoth, D; Neidhart, JA; Roach, R; Young, D, 1986) |
| "From 1973 to 1980, 701 patients with breast cancer measuring less than 2 cm in pathological diameter and with no palpable axillary lymph nodes were randomized to Halsted mastectomy (349) or to "quadrantectomy" with axillary dissection and radiotherapy to the ipsilateral breast tissue (QUART) (352)." | ( Luini, A; Veronesi, U; Zucali, R, 1986) |
| "One-third of the cases of breast cancer in postmenopausal women are hormone-dependent and the lesions regress upon treatment with antiestrogens or inhibition of estrogen biosynthesis." | ( Feil, PD; Leszczynski, D; Manni, A; Santen, RJ; Santner, SJ; Tilson-Mallet, N; Wright, C, 1986) |
| "In a trial, 1,000 cases of breast cancer were divided into two groups by the envelope method, and cyclophosphamide, 150 mg/day, was orally administered to one of the groups for 34 days (total dose, 5,100 mg) to investigate the utility of the chemotherapy in comparison with the control group not given adjuvant therapy." | ( Yoshida, M, 1986) |
| "Adjuvant treatment of breast cancer with AVCF gave significantly longer disease-free survival than CMF in the group of patients taken as a whole, in the subgroup with lymph node involvement and in the premenopausal subgroup." | ( Belpomme, D; Delgado, M; Fumoleau, P; Guerrin, J; Le Mevel, B; Mathé, G; Metz, R; Misset, JL; Plagne, R; Reizenstein, P, 1986) |
| "Seventeen patients with metastatic breast cancer were treated with a high-dose combination chemotherapy regimen and autologous bone marrow support." | ( Andersen, J; Antman, K; Come, S; Eder, JP; Elias, A; Henner, WD; Peters, W; Schnipper, L; Schryber, S; Shea, T, 1986) |
| "Its use in adjuvant therapy of breast cancer represents a major departure from the conventional management and, therefore, if the cooperation of practitioners and cooperative groups is to be secured, its rationale and safety must be well-defined." | ( Ragaz, J, 1986) |
| "In chemotherapy of advanced breast cancer, the dose intensities of regimens containing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) and cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) correlate with remission rate." | ( Hryniuk, WM; Levin, L; Levine, MN, 1986) |
| "Among 422 patients with advanced breast cancer treated in a randomized trial we observed 60 complete responses (CR)." | ( Brunner, KW; Cavalli, F; Goldhirsch, A; Mermillod, B; Pedrazzini, A, 1987) |
| "As women with stages I and II operable breast cancer have recurrences of their tumors after exposure to antiestrogen therapy, it is practical to consider treatment with megestrol acetate, whose mechanism of action of killing tumor cells may be different from that of tamoxifen." | ( Allegra, JC, 1987) |
| "Forty patients with advanced breast cancer who were not eligible for treatment with other conventional hormones or chemotherapy were entered into the study." | ( Aisner, J; Moody, M; Tait, N; Tchekmedyian, NS, 1987) |
| "Twenty-nine patients with stage IV breast carcinoma were treated with fluoxymesterone (20 or 30 mg/d)." | ( Ammirata, S; Davis, SR; Dilley, WG; Haagensen, DE; Leight, GS; Lokich, JJ; Silva, JS; Wells, SA; Zamcheck, N, 1986) |
| "Patients with metastatic breast carcinoma and similar presentations should be considered for prophylactic therapy with allopurinol and hydration before chemotherapy." | ( Coonley, CJ; Dyer, MC; Stark, ME, 1987) |
| "AG is active in postmenopausal breast cancer following failure of first-line hormonal therapy, toxicity limiting its use earlier in the disease." | ( Gilmore, OJ; Plowman, PN; Rowell, NP, 1987) |
| "A total of 79 metastatic breast cancer patients were treated with a combination of vincristine, doxorubicin and cyclophosphamide (VDC)." | ( Balázs, M; Tüske, M, 1986) |
| "Forty-six outpatients with breast cancer who had experienced severe emesis as a result of chemotherapy were evaluated for the antiemetic efficacy of high-dose metoclopramide (HD-MCP) and dexamethasone (DXM)." | ( Ben-Baruch, N; Ben-Yosef, R; Biran, S; Brufman, G; Gez, E; Uziely, B; Warner-Efraty, E; Yitzhaki, N, 1987) |
| "Twenty-three patients with advanced breast cancer were treated with the combination of mitoxantrone and doxorubicin." | ( Lefebvre, BM; Maroun, JA; Perrault, DJ; Stewart, DJ, 1987) |
| "It was concluded that the GF of breast carcinomas showed a great variability, which seemed to be independent of host factors such as age, menopausal status, parity history, or smoking habits; a second conclusion was that breast tumors' GF was not stimulated by steroid hormone treatment in vitro, and its response did not correlate with their hormone receptor status." | ( Jones, B; Russo, J, 1987) |
| "Two cases of recurrent breast carcinoma were treated with KM2210 in an early phase II study conducted at our institute and complete response (CR) was obtained." | ( Kawamura, E; Kubota, T; Kurokawa, T; Miyagawa, T; Toyoda, H; Yamada, Y, 1987) |
| "A total of 39 women with metastatic breast cancer entered a pilot phase II study of the vindesine-mitoxantrone-mitomycin (VMMc) combination chemotherapy." | ( Belpomme, D; Cour, V; George, C; Gisselbrecht, C; Heritier, F; Le Rol, A; Maral, J; Marty, M; Michaud, G, 1987) |
| "These results indicate that breast cancer cells can be recruited in vivo with DES and that chemotherapy following estrogenic stimulation is effective and feasible with acceptable toxicity." | ( Alama, A; Bertelli, G; Canavese, G; Carnino, F; Catturich, A; Conte, PF; Di Marco, E; Gardin, G; Jacomuzzi, A; Monzeglio, C, 1987) |
| "Twenty-two patients with inflammatory breast carcinoma received preoperative chemotherapy consisting of weekly administration of cyclophosphamide, doxorubicin hydrochloride, fluorouracil, and vincristine sulfate for six weeks." | ( Burton, GV; Cox, EB; Hart, LL; Iglehart, JD; Leight, GS; Olsen, GA; Prosnitz, LR; Seigler, HF, 1987) |
| "Since chemotherapy for metastatic breast cancer is not curative, consideration of the quality of life is important in selecting a treatment regimen." | ( Bishop, JF; Byrne, M; Coates, A; Gebski, V; Gill, G; Harvey, V; Jeal, PN; Snyder, R; Tattersall, MH; Woods, RL, 1987) |
| "Treatment of MCF7 human mammary carcinoma cells with the nonsteroidal antioestrogens, tamoxifen and clomiphene, leads to a concentration-dependent decrease in cellular proliferation rate which can be resolved into oestrogen-reversible and oestrogen-irreversible components." | ( Hall, RE; Ruenitz, PC; Sutherland, RL; Watts, CK, 1987) |
| "Thirty cases of fungating breast cancer (stages III and IV) were treated preoperatively by combination chemotherapy using cyclophosphamide (Endoxan), methotrexate, 5-fluorouracil, and prednisone." | ( Khanna, NN; Khanna, S; Kumar, A; Shah, LL, 1987) |
| "Thirty-seven patients with disseminated breast cancer refractory to previous therapy were treated with a combination of mitomycin, doxorubicin, and vinblastine (MAV)." | ( Borovik, R; Cohen, Y; Epelbaum, R; Robinson, E, 1986) |
| "In order to mimic postmenopausal breast cancer, we ovariectomized rats after N-methyl-N-nitrosourea administration." | ( Coombes, RC; Easton, D; Goss, PE; Singh, D; Wilkinson, JR; Williams, JC, 1986) |
| "The incidence of breast cancer has continued to decrease each year at Wilford Hall United States Air Force Medical Center with the ever-increasing use of combined progestogen-oestrogen replacement therapy over the past 12 yr." | ( Gambrell, RD, 1986) |
| "ER-positive breast cancer responds well to ablative surgery or administration of anti-estrogenic compounds." | ( Tominaga, T, 1986) |
| "Fifty patients with Stage IV breast cancer were entered into a prospective Phase II trial of combination chemotherapy that consisted of mitoxantrone (10 mg/m2), methotrexate (40 mg/m2), and 5-fluorouracil (600 mg/m2) given in a 3-weekly schedule." | ( Bezwoda, WR; Hesdorffer, CS, 1986) |
| "Twenty-six patients with breast carcinoma who experienced severe emesis due to chemotherapy were evaluated for the antiemetic efficacy of high-dose metoclopramide (HD-MCP) and dexamethasone (DXM)." | ( Gerra, C; Gez, E; Goodman, S; Isacson, R; Sulkes, A, 1986) |
| "Three cases of advanced breast cancer treated with preoperative systemic chemotherapy (FAC) were reported." | ( Akashi, Y; Ishikawa, H; Jimi, M; Mawatari, Y; Miyoshi, A; Mizumoto, K; Ohyabu, H; Ryu, S, 1986) |
| "Thirty-two patients with metastatic breast cancer who had not received prior chemotherapy for metastatic disease were entered into a trial of mitoxantrone 12 mg/m2 plus cyclophosphamide 600 mg/m2 given at three weekly intervals." | ( Bezwoda, WR; Hesdorffer, C, 1986) |
| "The Ludwig Breast Cancer Study Group conducted four concomitant trials involving adjuvant chemotherapy and endocrine therapy." | ( Gelber, R; Goldhirsch, A, 1986) |
| "Treatment of MCF 7 human breast cancer cells with three high affinity hydroxylated antiestrogens (Kd for the estrogen receptor = 0." | ( Ruenitz, PC; Sutherland, RL; Watts, CK, 1986) |
| "Five men with advanced breast cancer were treated with aminoglutethimide (AG) plus replacement dose hydrocortisone." | ( Dowsett, M; Harris, AL; Smith, IE; Stuart-Harris, R, 1986) |
| "The treatment schedule for disseminated breast carcinoma has been developed." | ( Aplevich, NN; Gritsaĭ, AA; Kondrat'eva, AP; Lichinitser, MR; Vyshinskaia, GV, 1986) |
| "Only 13% of postmenopausal advanced breast cancer patients responded to endocrine treatment with aminoglutethimide plus danazol whilst 33% responded to aminoglutethimide alone, despite a similar suppression of serum oestradiol levels in the two groups." | ( Dowsett, M; Jeffcoate, SL; Murray, RM; Pitt, P, 1986) |
| "Twenty-six women with metastatic breast cancer were treated with intensive Adriamycin (Adria Laboratories, Columbus, OH) as a single agent administered for three successive days once a month." | ( Bhardwaj, S; Holland, JF; Jones, RB; Norton, L; Strashun, A; Wilfinger, C, 1987) |
| "Among breast cancer patients the increased risk of leukaemia associated with chemotherapy was confined to women who had been under 50 years of age at the time of diagnosis of the breast cancer (for whom the relative risk was 13." | ( Day, NE; Haas, JF; Kaldor, JM; Kittelmann, B; Mehnert, WH; Möhner, M; Staneczek, W, 1987) |
| "We treated 31 patients with breast cancer metastatic to the liver and refractory to prior chemotherapy with percutaneous hepatic arterial infusion of cisplatin (DDP) (120 mg/m2) at 4-week intervals." | ( Carrasco, CH; Charnsangavej, C; Fleishman, G; Fraschini, G; Hortobagyi, GN; Patt, YZ; Yap, HY, 1987) |
| "Analyses were performed on 11 breast cancer patients, 3 at stage 1 and 8 at stage 2, the latter being subjected to cyclophosphamide, methotrexate, 5-Fluorouracil (CMF) adjuvant chemotherapy." | ( Aquino, A; Ballatore, P; Bonmassar, E; D'Atri, S; De Vecchis, L; Fuggetta, MP; Nunziata, C; Roselli, M; Tentori, L, 1987) |
| "Tamoxifen-induced exacerbation of breast cancer ("tamoxifen flare") is reported to occur in 4-20% or more of treated patients." | ( Fletcher, WS; Hartley, JW; Wong, J, 1987) |
| "14 patient with breast cancer of loco regional diffusion (M0), 4 of whom had negative axillary lymph nodes, were administered precautional chemotherapy with CMF, on the basis of anatomo-clinical prognostic elements (size of the neoplasia, grading (tumoral limits, neoplastic embolisation etc." | ( Cherchi, PL; Dessole, S; Fadda, G; Piras, G; Sardu, GM, 1985) |
| "Between 1977 and 1980, 118 breast cancer patients with locally advanced disease, T3B-4, any N, M0 or T1-3, tumor positive axillary apex biopsy, were randomized to one of three arms: I: radiotherapy (RT) to the breast and adjacent lymph node areas; II: RT followed by 12 cycles of cyclophosphamide, methotrexate, 5 fluorouracil (CMF) and tamoxifen during the chemotherapy period; III: 2 cycles of adriamycin and vincristine (AV), alternated with 2 cycles of CMF, then RT, followed by another 4 cycles of AV, alternated with 4 CMF; tamoxifen during the entire treatment period." | ( Engelsman, E; Hart, G; Schaake-Koning, C; van der Linden, EH, 1985) |
| "Treatment strategies for metastatic breast cancer are determined by various prognostic factors." | ( Wascher, H, 1985) |
| "Patients with advanced breast cancer may develop acute, severe hypercalcemia when treated with estrogens or antiestrogens." | ( Eilon, G; Mundy, GR; Saez, S; Valentin-Opran, A, 1985) |
| "Fifty-four patients with advanced breast cancer who had failed prior non-anthracycline combination chemotherapy were randomized to treatment with either epirubicin 85 mg/m2 or doxorubicin 60 mg/m2 intravenously every three weeks." | ( Casper, ES; Cassidy, C; Currie, V; Geller, NL; Hakes, TB; Jain, KK; Kaufman, RJ; Petroni, GR; Schwartz, W; Young, CW, 1985) |
| "The risk of breast cancer after estrogen therapy has been studied in both retrospective and prospective investigations." | ( Persson, I, 1985) |
| "Twenty-eight patients with advanced breast cancer, all previously treated with hormonotherapy and/or chemotherapy, entered this study." | ( Cervi, GC; Gorni, F; Marini, G; Marpicati, P; Simoncini, E; Zaniboni, A, 1985) |
| "Only one third of breast cancer responds to the endocrine therapy, and suitable patients should be selected the treatment." | ( Nomura, Y; Tashiro, H, 1985) |
| "After treatment of early breast carcinoma (stage I, II, and some III), the recurrent lesion can be classified as local, regional, distant, or combinations thereof." | ( Lee, YT, 1985) |
| "Patients with measurable, recurrent breast cancer with limited prior chemotherapy with or without radiotherapy for metastatic disease, and who had not been exposed to prior doxorubicin, were randomized to receive either mitoxantrone or doxorubicin every three weeks with cross-over on progression." | ( Allegra, JC; Bryan, S; Dukart, G; Henderson, IC; Reisman, A; Woodcock, T; Woolf, S, 1985) |
| "Sixty-four patients with disseminated breast cancer were treated with an aggressive chemotherapy program of prednisone, methotrexate, 5-fluorouracil, Adriamycin (doxorubicin) and cyclophosphamide (PM-FAC)." | ( Flournoy, N; Livingston, RB; Mortimer, J; Stephens, RL, 1985) |
| "Thirty-eight patients with advanced breast cancer were treated with the 'VEMFAH' multiple-drug combination chemotherapy, consisting of vincristine (V), cyclophosphamide (Endoxan; E), methotrexate (M), 5-fluorouracil (F), adriamycin (A), and prednisolone (H)." | ( Hoshino, A; Ito, Y; Kamiya, O; Kinoshita, T; Kojima, T; Nagata, K; Ohara, K; Sato, H; Sugiura, I; Yamada, M, 1985) |
| "The values of ER contents in human breast cancer and untreated rat uteri obtained by this procedure were correlated well with those by [3H] estradiol binding assay." | ( Kishimoto, S; Koga, M; Matsumoto, K; Nakao, M; Noma, K; Sato, B, 1985) |
| "Treatment results are available (Ludwig Breast Cancer Study Group, Lancet i (1984) 1256-1260)." | ( Goldhirsch, A, 1985) |
| "This review of endocrine therapy in breast carcinoma has been prepared principally with the aim of listing many persisting controversies in this area, even if significant advances have been made after the hormone receptor determination became available." | ( Cocconi, G, 1985) |
| "In 16 patients with breast cancer who were administered UFT or FT-207 (UFT: 9 cases, FT-207: 7 cases) for a were prior to surgery, we studied the concentrations of 5-FU in the blood and tumor tissues, and in normal and metastatic lymph nodes sampled during surgery." | ( Kimura, M; Koida, T, 1985) |
| "Eight previously irradiated breast cancer patients with local recurrences were treated with intra-arterial infusions of 8 mg/m2 mitomycin C given at 3-week intervals." | ( Fodstad, O; Gundersen, S; Hager, B; Kvalheim, G, 1985) |
| "The responsiveness of the human mammary carcinoma cell line MCF-7 to estradiol and tamoxifen treatment has been studied in different culture conditions." | ( Bayard, F; David, JF; Faye, JC; Jozan, S; Tauber, JP; Tournier, JF, 1985) |
| "Twenty-two patients with advanced breast cancer have been treated with sequential chemo-hormonotherapy consisting of tamoxifen 20 mg/day orally for 14 consecutive days, followed by no therapy for ten days, then estrogen 0." | ( Cruciani, G; Fiorentini, GM; Marangolo, M; Rosti, G; Tienghi, A; Turci, D, 1986) |
| "A series of 301 cases of male breast carcinoma has been analysed; of these, 292 have been treated at The Christie Hospital, Manchester and followed-up for a maximum of 15 years." | ( Ribeiro, G, 1985) |
| "Twenty patients with metastatic breast carcinoma received megestrol acetate following additive or ablative therapy." | ( Carpenter, JT; Peterson, L, 1985) |
| "Forty-three advanced breast cancer patients, whose tumors had been assayed for ER and PR were treated with megestrol acetate as initial hormonal therapy." | ( Anderson, K; Bonomi, P; Bunting, N; Economou, S; Johnson, P; Roseman, D; Shorey, W; Strauss, A; Wolter, J, 1985) |
| "Since the treatment of postmenopausal breast cancer patients with aminoglutethimide caused hypothyroidism with an unexpectedly high frequency previous treatment was suspected to contribute to hypofunction of the thyroid." | ( Bonfrèr, J; Bruning, P; Burgers, M; De Jong-Bakker, M; Nooyen, W, 1985) |
| "A group of 74 patients with advanced breast cancer received elliptinium as second- or third-line treatment (100 mg/m2/week)." | ( Amiel, JL; Caille, P; De Jager, R; Le Chevalier, T; May-Levin, F; Mondesir, JM; Rouësse, JG; Sancho-Garnier, H; Spielmann, M, 1985) |
| "Only patient C (breast cancer) had received chemotherapy." | ( Boulet, L; Dufour, M; Panasci, LC; St Germain, J, 1985) |
| "Sixty-three patients with Stage IV breast carcinoma refractory to standard combination chemotherapy agents such as 5-fluorouracil (5-FU) were entered into a study to determine the efficacy of a multiple dose schedule of N-(phosphonacetyl)-L-aspartic acid (PALA) and whether the addition of PALA improves the therapeutic efficacy of 5-FU." | ( Buzdar, AU; Hortobagyi, GN; Mann, GB; Valdivieso, M; Yap, HY, 1985) |
| "Eleven patients with advanced breast cancer and four with astrocytoma were treated with plasma perfused over columns containing staphylococcal Protein A (SPA)." | ( Apuzzo, ML; Bertram, JH; Boquiren, D; Grunberg, SM; Hengst, JC; Kunkel, L; Nelson, J; Plotkin, D; Shulman, I; Waugh, WJ, 1985) |
| "Twenty-two patients with metastatic breast cancer refractory to conventional chemotherapeutic agents were treated with 1-beta-D-arabinofuranosylcytosine (Ara-C) at a dose of 2 g/m2 over 2 h every 12 h for 3 doses at 21-day intervals." | ( Blumenschein, GR; Buzdar, AU; Feldman, LD, 1985) |
| "Postmenopausal women with metastatic breast cancer were treated with trilostane, initially 240 mg daily increasing after 3 days to 480 mg daily and after a further three days to 960 mg daily." | ( Beardwell, CG; Bu'lock, D; Hindley, AC; St John, J; Wilkinson, PM, 1985) |
| "Described is a patient with early breast carcinoma who developed clinical radiation pneumonitis during primary radiation therapy and concomitant chemotherapy that included prednisone." | ( Catane, R; Gez, E; Isacson, R; Sulkes, A; Weshler, Z, 1985) |
| "Since data from animal breast tumors and preliminary evidence from human breast tumors indicates an excellent correlation between the presence of abundant tumor EBP and endocrine-induced breast cancer regressions, precise quantitation of EBP in all human primary tumors may prove to be an excellent prognosticator of endocrine therapy in metastatic breast cancer." | ( McGuire, WL, 1973) |
| "Seventeen patients with metastatic breast carcinoma were treated with a combination of 5-fluorouracil, methotrexate, vincristine, cyclophosphamide and prednisone." | ( Blom, J; Stutz, FH; Tormey, DC, 1973) |
| "Early diagnosis of breast cancer metastases to the bones using scintigraphy of the skeleton in the preoperative period gives an opportunity to reveal tumor dissemination and to provide adequate treatment without imposing on patients inappropriate therapeutic measures." | ( Denisov, LE; Ermolaeva, EV; Iarygin, LM; Zhuravleva, LI, 1984) |
| "Postmenopausal patients with metastatic breast cancer were treated with medroxyprogesterone acetate (MPA) (Clinovir) in dosages between 500 and 1500 mg orally per day." | ( Blossey, HC; Koebberling, J; Nagel, GA; Wander, HE, 1984) |
| "A total of 202 patients with advanced breast cancer were entered into two prospectively randomized Phase II trials conducted by the Eastern Cooperative Oncology Group, in an effort to identify promising agents and combinations for previously treated cases." | ( Colsky, J; Cummings, FJ; Gelman, R; Israel, L; Kuperminc, M; Skeel, RT; Tormey, D, 1981) |
| "Forty breast cancer patients with meningeal carcinomatosis were treated with a combined program of whole brain irradiation therapy with intrathecal and intraventricular methotrexate and citrovorum factor rescue." | ( Blumenschein, GR; Hortobagyi, GN; Levens, ME; Rasmussen, S; Yap, BS; Yap, HY, 1982) |
| "Sixty-five patients with advanced breast cancer, progressive despite prior endocrine therapy in all cases and prior chemotherapy in most cases, were treated with aminoglutethimide, 250 mg four times a day." | ( Coates, AS; Fox, RM; Kaye, SB; Tattersall, MH; Woods, RL, 1982) |
| "Thirty-eight metastatic breast cancer patients were treated with aminoglutethimide." | ( Blumenschein, GR; Buzdar, AU; Legha, SS; Powell, KC, 1982) |
| "MCF-7 human breast cancer cells that were treated for one hour prior to X irradiation with the cyclic AMP-inducing agent 1-methyl-3-isobutylxanthine displayed a slight but significant increase in surviving fraction over untreated controls at each radiation dose level." | ( Gifford, L; Griem, K; Little, JB; Umans, RS; Weichselbaum, RR, 1983) |
| "After labeling KCl-treated human breast cancer cytosols with 125I, double immunodiffusion, immunoelectrophoresis, and autoradiography revealed that radiolabeled AFP codiffused and comigrated with alpha 1 electrophoretic mobility in a manner identical to that of added carrier cord serum AFP." | ( Delluomo, DS; Jacobson, H; Mizejewski, G; Sarcione, EJ; Zloty, M, 1983) |
| "Twelve patients with recurrent breast cancer were treated with Peplomycin monotherapy." | ( Fukuda, T; Kimura, M; Koida, T, 1983) |
| "Adjuvant chemotherapy of early breast cancer in premenopausal women has nearly reached the point where it can be said with confidence that the relapse-free survival rate, as well as overall survival rate, is being lengthened, especially when drug combinations are used." | ( Mitchell, MS, 1983) |
| "Advanced breast cancer which has temporarily responded to a course of tamoxifen (Nolvadex) therapy may show a response a second or third time when rechallenged by the same agent subsequently." | ( Stoll, BA, 1983) |
| "Fifty-seven patients with metastatic breast carcinoma have been treated with mitomycin C (10 mg/m2 IV 6-weekly), melphalan (6 mg/m2 PO X 3 days, 3-weekly), and methotrexate (35 mg/m2 IV 3-weekly) to assess the efficacy and toxicity of this regimen." | ( Coombes, RC; Ford, HT; Gazet, JC; Perez, DJ; Powles, TJ, 1984) |
| "48 patients with metastatic breast cancer and extensive bone involvement were treated with salm-calcitonin and polychemo-therapy or hormonal treatment." | ( Beaufort, F; Gölles, M, 1984) |
| "Samples from 11 patients with breast cancer treated with 5-FU-containing chemotherapy regimens were assayed." | ( Ardalan, B; Cooney, D; Lippman, M; Macdonald, J; Schein, P, 1981) |
| "In the therapy of metastatic breast cancer MAP was used with different dosages and different forms of administration." | ( Blossey, HC; Kleeberg, U; Köbberling, J; Nagel, GA; Wander, HE, 1982) |
| "In 114 patients with metastatic breast cancer resistant to chemo- and hormonal therapy another attempt was made to treat these patients with the hormone combination of aminoglutethimide (AG) 1000 mg daily and medroxyprogesteroneacetate (MAP) 1500 mg daily for 6 weeks, than 500 mg MAP daily." | ( Blossey, HC; Nagel, GA; Wander, HE, 1982) |
| "In the breast cancer patients analyses were performed before and after 1, 2, 4, 8 and 12 weeks of treatment with tamoxifen." | ( Carlström, K; Sköldefors, H; Theve, NO; Wallgren, A; Wilking, N, 1982) |
| "Induction of mammary cancer in rats by administration of the chemical carcinogen 7,12-dimethylbenz(a)anthracene reveals that the same factors influencing human breast cancer risk also affect the susceptibility of the rat mammary gland to the chemical carcinogen." | ( Russo, IH; Russo, J; Tay, LK, 1982) |
| "11 patients (age 36-60 years) with breast cancer and CT-scan documented brain metastases (BM) were treated with hormonochemotherapy: 5-fluorouracil 500 mg/m2 i." | ( Bleichner, F; Mende, S; Meuret, G; Stoeter, P, 1983) |
| "38 patients with metastasizing breast cancer who were stratified according to prognostic criteria were treated with high-dose medroxyprogesterone acetate (MPA)." | ( Beaufort, F; Fereberger, W, 1983) |
| "Seventy-six patients with metastatic breast cancer were treated with fluorouracil, adriamycin (doxorubicin) and cyclophosphamide (FAC) plus high-dose medroxyprogesterone acetate (HD-MPA)." | ( Barduagni, A; Barduagni, M; Di Lauro, L; Lopez, M; Papaldo, P; Perno, CF, 1983) |
| "Prediction of response of metastatic breast cancer to progestins largely follows the conventional rules established for the selection of additive hormonal therapy." | ( Blumenschein, GR, 1983) |
| "We treated 105 patients with advanced breast cancer, using the progestational agent medroxyprogesterone acetate (MPA), 200 mg orally tds in a non-randomised trial." | ( Coates, A; Dalgleish, A; Fox, R; Hedley, D; Raghavan, D; Tattersall, MH, 1984) |
| "In 57 patients with metastasized breast carcinoma, serum CEA levels (CEA-Ria-Kit, Abbot) were correlated with the clinical course under endocrine or cytostatic therapy." | ( Garbrecht, M; Kleeberg, UR; Müllerleile, U; Pompecki, R; Treidler, J, 1984) |
| "Twenty-six patients with metastatic breast cancer were treated with high dose medroxyprogesterone acetate (MAP) p." | ( Carli, A; D'Aniello, C; De Stefano, A; Guarnieri, A; Mariani, L; Nardi, P; Tucci, E, 1984) |
| "In the therapy of metastatic breast cancer with high dose MAP the cortisol like effect could be shown even in long term treatment." | ( Blossey, HC; Kleeberg, U; Köbberling, J; Nagel, GA; Wander, HE, 1982) |
| "Out of 3718 breast cancer patients treated at Petrov Research Institute of Oncology 262 patients [7%] proved to have minimal (less than 1 cm in diameter) form of breast cancer." | ( Orlov, AA; Pavlov, KA; Semiglazov, VF, 1983) |
| "In 41 cases of primary breast cancer preoperative treatment was performed using 2 methods consisting CPA + FT-207 (5-FUDS) (for Group I) and CPA + FT-207 (5-FUDS) + MMC (for Group II) to determine clinical and histological efficacies." | ( Andoh, H; Fujii, Y; Gotoh, M; Hagiwara, H; Hara, Y; Kataoka, J; Kobayashi, T; Komuro, K; Nagasaki, Y; Nagayama, A; Nakamura, K; Nakamura, R, 1983) |
| "Patients with advanced, evaluable breast cancer were biopsied before the start of endocrine treatment, and ER and cAR measurements were performed." | ( Døskeland, SO; Ekanger, R; Kvinnsland, S; Thorsen, T, 1983) |
| "In patients with breast cancer, measurements of hormone receptor activity are valuable (1) in predicting which patients with advanced disease will respond to endocrine therapy, (2) as an additional independent guide to the patients' prognosis." | ( Forrest, AP; Hawkins, RA, 1983) |
| "The results of treatment of 959 breast cancer patients by AG and glucocorticoids in several studies are reviewed." | ( Cikes, M, 1983) |
| "Thirty-five patients with advanced breast cancer refractory to initial chemotherapy were randomized to receive two-drug doxorubicin-CCNU or three-drug doxorubicin-CCNU-vincristine (VCR) treatment." | ( Bateman, JR; Block, JB; Chlebowski, RT; Pugh, R; Weiner, JM, 1983) |
| "Twelve patients with breast carcinoma were treated with high-dose combination chemotherapy supported by autologous bone marrow transplantation (ABMT)." | ( Kubota, M; Mitomi, T; Nakasaki, H; Sonoda, H; Sugita, T; Tajima, T; Tokuda, Y; Yokoyama, S, 1983) |
| "Estrogen-responsive human breast cancer cells (MCF-7) displayed a higher frequency of intercalator-induced protein-associated DNA scission after treatment with 17 beta-estradiol (E2) than did cells that had not received estrogen treatment." | ( Kerrigan, D; Lippman, ME; Zwelling, LA, 1983) |
| "A middle-aged woman was treated for breast carcinoma with postoperative adjuvant chest wall irradiation, followed four and seven years later with therapy to spinal ports for palliation of metastatic disease." | ( Albain, KS; Ultmann, JE, 1983) |
| "The treatment of operable breast cancer by primary radiation therapy instead of mastectomy is undergoing evaluation in the United States and Europe." | ( Beadle, GF; Harris, JR; Hellman, S, 1984) |
| "Women with breast carcinoma and four or more involved ipsilateral axillary lymph nodes were randomly assigned to receive an induction course and 2 yr of maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF, 150 patients), CMF plus vincristine and prednisone (CMFVP, 166 patients), or chemoimmunotherapy with CMF plus the methanol extraction residue of BCG (CMF-MER, 85 patients)." | ( Falkson, G; Falkson, HC; Glidewell, OJ; Henry, PH; Holland, JF; Leone, LA; Perloff, M; Tormey, DC; Weinberg, VE; Weiss, RB, 1983) |
| "Chemotherapy results in metastatic breast cancer reached a plateau: Remission rate and duration are nearly equivalent for several regimens but not equitoxic." | ( Hartlapp, JH; Illiger, HJ; Peiss, J; Vaupel, HA, 1983) |
| "Adjuvant therapy trials in breast cancer have grown steadily more complex since 1971, when the first long-term adjuvant trial in the United States was initiated." | ( Carbone, PP, 1983) |
| "Fifty cases of advanced breast cancer (stages III and IV) were treated by combination chemotherapy." | ( Khanna, NN; Khanna, S; Kumar, A; Pant, GC, 1984) |
| "Additive endocrine therapy of breast cancer was first initiated by androgen treatment through intramuscular administration which proved to be effective in about 25% of trial cases." | ( Miura, S; Yoshida, M, 1984) |
| "Half of our patients presenting with breast cancer will eventually require cytotoxic chemotherapy." | ( Andrews, J; Cheng, ZM; Collins, J; Leyden, M; Russell, I; Sullivan, J, 1984) |
| "For patients with breast cancer who had received extensive prior therapy, 3 mg/m2/day for 5 days repeated every 6-8 weeks were well-tolerated doses; and for patients with gastrointestinal cancer, the maximum-tolerated dose was 4 mg/m2/day." | ( Bedikian, A; Blumenschein, G; Hortobagyi, G; Valdivieso, M; Yap, HY, 1983) |
| "43 patients with advanced breast cancer, resistant to conventional therapies, were treated with mitomycin C at a dose of 20 mg/m2 i." | ( Barduagni, A; Barduagni, M; Di Lauro, L; Lopez, M; Papaldo, P; Perno, CF, 1983) |
| "Twenty-five patients with metastatic breast cancer who had failed with combination chemotherapies including adriamycin were treated with a combination of mitomycin C, methotrexate, and vincristine (MMV)." | ( Hamada, Y; Kanda, K; Nomura, Y; Saeki, K; Tashiro, H, 1983) |
| "21 patients with metastatic breast cancer, refractory to conventional agents, were treated with a combination of BCNU, vincristine, mitomycin-C and prednisone given every 4 weeks." | ( Anderson, P; DiBella, NJ; Fink, K; Garfield, D; Murphy, J; Speer, J, 1984) |
| "It was shown that after the breast cancer became refractory to tamoxifen, the major endocrine ablation therapy was effective particularly in ER (+) cancers, irrespective of the response to the antiestrogen." | ( Nomura, Y, 1984) |
| "Thirty-six (36) women with metastatic breast cancer refractory to conventional therapies were treated with cis-diamminedichloroplatinum II." | ( Jain, J; Mackenzie, M; Martino, S; Samal, BA; Singhakowinta, A; Vaitkevicius, VK; Yoshida, S, 1984) |
| "Twenty-six patients with advanced breast cancer, (12 previously treated with adriamycin-containing regimens, 14 not exposed to adriamycin because of poor cardiac performance), were treated with combination chemotherapy including mitomycin C plus 5-fluorouracil." | ( Ardizzoni, A; Conte, PF; Pronzato, P; Rosso, R, 1984) |
| "A total of 134 patients with advanced breast cancer and no prior chemotherapy for advanced disease were treated with mitoxantrone, 14 mg/m2 intravenously every 3 weeks." | ( Coleman, RE; Cornbleet, MA; McDonald, M; Mouridsen, HT; Rainer, H; Rubens, RD; Smith, IE; Smyth, JF; Stuart-Harris, RC; van Oosterom, AT, 1984) |
| "Preliminary results of other phase II breast cancer trials indicate a similar spectrum of toxicity but suggest more significant antitumor activity even in patients previously treated with doxorubicin." | ( Forastiere, AA; Hughes, AK; Perry, MC; Wood, WC, 1984) |
| "A 67-year-old patient with breast carcinoma on treatment with aminoglutethimide (AG) developed profound leukopenia and sepsis." | ( Gez, E; Sulkes, A, 1984) |
| "Preliminary favorable results in breast cancer stimulated a phase II study at our institution to define the activity of VM 26 in patients with advanced, homogeneously pretreated breast cancer." | ( Crivellari, D; Franchin, G; Galligioni, E; Grigoletto, E; Talamini, R; Tirelli, U; Trovó, MG; Tumolo, S; Veronesi, A, 1984) |
| "Seventy patients with advanced breast carcinoma were treated with a loading dose regimen of 160 mg Tamoxifen on day 1 followed by a maintenance dose of 20 mg daily from day 2 onwards." | ( Ribeiro, GG; Wilkinson, PM, 1984) |
| "Twenty-eight patients with advanced breast cancer who had no prior chemotherapy received 14 mg/m2 of mitoxantrone iv on Day 1 and 600 mg/m2 of cyclophosphamide on Day 2, repeated every 4 weeks." | ( Ehninger, G; Heidemann, EG; Waller, HD; Weible, KH, 1984) |
| "Thirty-four patients with advanced breast cancer, who had not received previous chemotherapy for metastatic disease, were treated with mitoxantrone 14 mg/m2 i." | ( Coleman, RE; Knight, RK; Maisey, MN; Rubens, RD, 1984) |
| "When T-47D human breast cancer cells were grown in medium supplemented with foetal calf serum (FCS) which had been depleted of endogenous oestradiol (E2) by dextran-charcoal treatment (CS-FCS) tamoxifen and E2 had biphasic effects on cellular proliferation." | ( Reddel, RR; Sutherland, RL, 1984) |
| "Twenty-two patients who had metastatic breast cancer previously treated with combination chemotherapy, cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) or CMF with vincristine and prednisone, were treated with Carminomycin (carubicin) 20 mg/m2 body surface area by intravenous bolus injection once every 3 weeks." | ( Aboud, A; Blumenschein, GR; Bodey, GP; Esparza, L; Hortobagyi, G; Issell, B; Yap, HY, 1984) |
| "The dose of adjuvant chemotherapy for breast cancer may be an important factor in the success of the treatment program." | ( Coleman, CN; Cox, RS; Levine, JF; Martinez, A; Ray, GR; Rogoway, WM; Stockdale, FE, 1984) |
| "Nevertheless, because breast cancer is one of the most responsive of the solid tumors to cytotoxic drugs, appropriately chosen chemotherapy can relieve symptoms and prolong survival." | ( Loeb, V; Lyss, AP, 1984) |
| "Forty-one women with advanced breast cancer were treated with cyclophosphamide, methotrexate, 5-FU, and prednisone." | ( Cadman, EC; Cross, J; Glick, JH; Horton, J; Taylor, SG, 1984) |
| "Although no breast cancer patient can be cured after metastases have been found, the fact that survival is prolonged and the symptoms and signs of advanced disease can be relieved, often impressively, by the administration of cytostatic chemotherapy justifies their implementation." | ( Lenzhofer, R; Rainer, H, 1984) |
| "Two cases of primary advanced breast cancer and 4 cases of recurrent breast cancer were treated with cyclophosphamide, Adriamycin and FT-207 combined with hormone therapy." | ( Kagaya, H; Matsuoka, S; Miyata, S; Sato, Y; Uchino, J; Une, Y; Yakura, Y, 1984) |
| "Twenty-nine patients with metastatic breast cancer were treated with fluorouracil, adriamycin, cyclophosphamide (FAC), and methotrexate (MTX), with or without leukovorin rescue." | ( Aboud, A; Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Yap, HY, 1984) |
| "A total of 241 patients with early breast cancer had serial bone scans and chest radiographs during the first two years of follow-up after primary treatment." | ( Chaudary, MA; Hayward, JL; Maisey, MN; Rubens, RD; Shaw, PJ, 1983) |
| "In metastatic breast cancer cyclophosphamide seems to have a shallow dose response curve and high intermittent dosage seems to have no advantage over chronic daily administration." | ( Anderson, H; Bramwell, VH; Howell, A; Rankin, EM, 1983) |
| "In 37 cases of locally advanced breast cancer, arterial administration of adriamycin (ADR), given a total dose of 150 mg in a single dose of 30 mg or 50 mg, was attempted as means of preoperative chemotherapy, and its tumor contraction action in the primary breast cancer and side effects were studied." | ( Inoue, K; Koyama, H; Kurokawa, Y; Sakai, K; Takatsuka, Y; Terasawa, T; Tominaga, T; Watanabe, H; Yayoi, E; Yoshida, K, 1983) |
| "The risk of breast cancer and endometrial cancer in 1483 menopausal and postmenopausal women who had received estrogen therapy for other than contraceptive use was examined." | ( Halliday, M; Morgan, RW; Vakil, DV, 1983) |
| "Forty-three patients with metastatic breast cancer were treated with a total of 385 cycles of combination chemotherapy consisting of adriamycin, cyclophosphamide, 5-fluorouracil, methotrexate and vincristine sulphate given over 24 hr and followed by a leucovorin 'rescue'." | ( Hill, BT; Howell, A; Marks, P; Monypenny, I; Morrison, JM; Price, LA, 1983) |
| "When MCF 7 human mammary carcinoma cells in exponential growth phase were treated with tamoxifen a dose-dependent inhibition of cell growth was observed." | ( Green, MD; Hall, RE; Reddel, RR; Sutherland, RL; Taylor, IW, 1983) |
| "Estrogen receptor (ER) analysis of breast cancer tissue has been shown to be very useful in predicting which patients will respond to hormone therapy and have a better prognosis." | ( Barrows, G; Kute, TE; Linville, C, 1983) |
| "This latter subset of advanced breast cancer patients should probably be spared too intensive cytotoxic treatment." | ( Alberto, P; Brunner, KW; Cavalli, F; Goldhirsch, A; Jungi, WF; Martz, G; Mermillod, B; Pedrazzini, A, 1983) |
| "Included in this study were 43 breast cancer patients treated with adjuvant chemotherapy who presented metastasis only in bone." | ( Blumenschein, GR; Buzdar, AU; DeMartini, AL, 1983) |
| "In advanced breast cancer it has been hypothesized that the presence of progesterone receptor (PR) might be a more sensitive marker for predicting response to endocrine therapy (2, 3)." | ( Clark, GM; McGuire, WL, 1983) |
| "Sixty-five patients with advanced breast carcinoma were treated with mitoxantrone, an anthracenedione with structural similarities to adriamycin." | ( Bozek, T; Pavlidis, NA; Smith, IE; Stuart-Harris, RC, 1984) |
| "The primary management of breast cancer by irradiation does not induce substantial changes in the ability of patients to tolerate adjuvant chemotherapy." | ( d'Angelo, T; DeMoss, EV; Edwards, BK; Gorrell, CR; Lichter, AS; Lippman, ME, 1984) |
| "Of 29 evaluable patients with breast cancer (six of whom had received prior chemotherapy), one achieved a complete response and five achieved a partial response (total response rate, 21%)." | ( Calman, KC; Crossling, F; Ferguson, C; George, WD; Habeshaw, T; Hutcheon, A; Kaye, SB; McArdle, C; Sangster, G; Smith, D, 1984) |
| "In human breast cancer, about 90% of unresponsive tumors and 60-80% of tumors responsive to endocrine therapy can be predicted by receptor measurement." | ( Kuroda, H; Matsumoto, K; Takeyama, M, 1984) |
| "Patients with advanced and recurrent breast cancer who had showed either complete response or partial response to the previous CAF therapy (cyclophosphamide 100 mg/body/day p." | ( Akai, S; Fujii, G; Hattori, T; Hayasaka, H; Inoue, G; Izuo, M; Kubo, K; Nomura, Y; Ogawa, N; Okamoto, T; Ota, K; Sakai, K; Taguchi, T; Tazima, S; Tominaga, T; Yoshida, M, 1982) |
| "To treat advanced breast cancer that proved refractory to endocrine therapy or other forms of chemotherapy, we administered intravenous administration of adriamycin every 3--4 weeks, in principle, at a dose of 100 mg per 50 kg body weight (total dose, 300--400 mg)." | ( Hayashi, K; Itoh, I; Kaneko, H; Kitamura, M; Onodera, T; Takahashi, I; Tominaga, T, 1980) |
| "Eleven patients with metastatic breast cancer refractory to conventional therapy were treated with a combination of hexamethylmelamine 250 mg/m2 p." | ( Lawson, D; Moore, M; Smalley, R, 1980) |
| "Thirty-two patients with inflammatory breast cancer were treated with a combined modality approach consisting of combination chemotherapy with fluorouracil, doxorubicin hydrochloride, and cyclophosphamide, followed by radiation therapy." | ( Barker, JL; Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Montague, ED, 1981) |
| "Altogether 117 patients with advanced breast cancer were treated with either tamoxifen 10 mg by mouth twice daily or aminoglutethimide 250 mg by mouth four times daily with hydrocortisone 20 mg twice daily in a randomised cross-over trial in which patients who failed to respond to the first treatment or relapsed while receiving it were switched to the other." | ( Ford, HT; Gazet, JC; Harmer, CL; Harris, AL; McKinna, JA; Morgan, M; Parsons, CA; Smith, IE; Villardo, A; Walsh, G; White, H, 1981) |
| "Seventeen women with breast cancer were treated with tamoxifen (20 mg, twice a day)." | ( Carlström, K; Damber, MG; Helgason, S; von Schoultz, B; Wilking, N, 1982) |
| "In twenty-nine cases of primary breast cancer preoperative treatment using CPA and FT-207 (or 5-FUDS) was performed to determine their efficacy." | ( Amano, R; Ando, H; Fujii, Y; Hara, Y; Hashiguchi, F; Komuro, K; Kurata, T; Nakamura, K; Nakamura, R; Sakamoto, R; Shimada, A; Yamazaki, M, 1982) |
| "Fifteen patients with metastatic breast cancer previously treated with chemotherapy were treated with a regimen consisting of vincristine, Adriamycin, and mitomycin." | ( Oster, MW; Park, Y, 1983) |
| "Forty-one men with metastatic breast cancer were treated with 70 trials of hormone therapy." | ( Blumenschein, G; Buzdar, A; Hortobagyi, G; Kantarjian, H; Yap, HY, 1983) |
| "Forty-four patients with metastatic breast cancer who had previously received extensive conventional systemic therapy, including combination chemotherapy with doxorubicin, were treated with Bisantrene, a new anthracene derivative." | ( Barnes, BC; Blumenschein, GR; Bodey, GP; Schell, FC; Yap, BS; Yap, HY, 1983) |
| "Thirty-three patients with metastatic breast cancer who have failed prior combination chemotherapy including adriamycin, cyclophosphamide, 5-fluorouracil and methotrexate, were treated with AZQ given on a 5-day I." | ( Bedikian, AY; Blumenschein, GR; Bodey, GP; Schell, FC; Yap, HY, 1983) |
| "Twenty patients with Stage I or II breast cancer, all of whom had undergone radiation therapy planning, were examined with internal mammary lymphoscintigraphy (IMLS) and computed tomography (CT)." | ( Collier, BD; Cox, JD; Greenberg, M; Komaki, R; Lawlor, PM; Lawson, TL; Palmer, DW; Wilson, JF, 1983) |
| "Recurrent breast cancer can now be treated more effectively with endocrine therapy, combined with chemotherapy." | ( Hamada, T; Hori, S; Nagao, K; Nakagaki, S; Yoshikawa, N, 1983) |
| "Forty-two cases of human breast carcinomas were submitted to tamoxifen treatment between first diagnosis and surgery (4 to 30 days)." | ( Jacrot, M; Louis, J; Mermet, MA; Mouriquand, C; Mouriquand, J; Saez, S; Sage, JC, 1983) |
| "This regimen is effective in advanced breast cancer resistant to other chemotherapy regimens." | ( Cirera, L; Doncel, F; Estapé, J; Millá, A, 1983) |
| "A woman with metastatic breast carcinoma developed acute haemolytic anaemia on two occasions following treatment with methotrexate (MTX) and 5-fluorouracil (5-FU)." | ( Bonnem, EM; Priego, VM; Sacher, RA; Schanfield, MS; Woolley, PV, 1983) |
| "Forty-seven patients with advanced breast cancer were treated with a combination of prednimustine (P), methotrexate (M), 5-fluorouracil (F), and tamoxifen (TAM)." | ( Boesen, E; Mouridsen, HT, 1983) |
| "Thirty patients with resectable breast cancer were treated with transarterial one shot infusion of 20 mg of adriamycin as a preoperative adjuvant chemotherapy." | ( Fukuda, K; Kato, G; Sawai, K; Takahashi, T; Tokuda, H, 1983) |
| "Twenty-six patients with advanced breast cancer and progressive disease were treated by norethisterone." | ( Clavel, B; Milgrom, E; Pallud, C; Pichon, MF, 1982) |
| "Stage II or III breast carcinoma patients were assigned to one of three adjuvant chemotherapy groups after mastectomy." | ( Caprini, JA; Cohen, E; Cunningham, MP; Khandekar, JD; Oviedo, MA; Scanlon, EF; Trueheart, RS, 1980) |
| "Extracts of estradiol-treated human mammary carcinoma and human malignant melanoma cells yielded concentrated protease activities." | ( Hakim, AA, 1980) |
| "Thirty-eight patients with advanced breast cancer, resistant to prior endocrine therapy and in most cases prior chemotherapy, were treated with aminoglutethimide, 250 mg qds." | ( Fox, RM; Kaye, SB; Tattersall, MH; Woods, RL, 1981) |
| "This product, of acceptable efficacy in breast cancer treatment, will probably occupy an original place in anti-cancer chemotherapy because of its lack of myelotoxicity." | ( Amiel, JL; Brulé, G; Huertas, D; Le Chevalier, T; Mondésir, JM; Rouëssé, J; Sancho-Garnier, H; Tursz, T, 1981) |
| "The visceral carcinomas (2 breast cancers, 1 carcinoma respectively of the pancreas, the rectum, the liver, the kidneys, the renal pelvis, and the urinary bladder, and one seminoma) were treated by generally accepted surgical principles as far as treatment of the patients was possible." | ( Binswanger, U; Briner, J; Largiadèr, F; Uhlschmid, G; Vollenweider, A, 1982) |
| "The risk of breast cancer has not been shown to be increased with estrogen therapy, and progestogens may provide additional protection for this tumor." | ( Gambrell, RD, 1982) |
| "Thirty-seven patients with metastatic breast carcinoma were treated in randomized study with cisplatin 60 mg/m2 or 120 mg/m2 I." | ( Forastiere, AA; Hakes, TB; Wittes, JT; Wittes, RE, 1982) |
| "Opinions regarding the best possible treatment of cancer of the breast are more controversial than ever." | ( Becher, R, 1982) |
| "Since in the treatment of advanced breast cancer chemotherapy and the various hormonal manipulations seem recently to have reached a plateau of effectiveness when used alone, it is widely assumed that the combination of both treatment modalities could improve therapeutic results." | ( Alberto, P; Beer, M; Brunner, KW; Cavalli, F; Jungi, WF; Martz, G; Mermillod, B; Obrecht, JP, 1982) |
| "Patients with advanced breast carcinoma and no prior chemotherapy were prospectively evaluated to assess the induction capabilities of cyclophosphamide, methotrexate and 5-fluorouracil (CMF), Adriamycin and vincristine (AV), and CMF plus prednisone (CMFP)." | ( Band, PR; DeWys, W; Gelman, R; Perlia, C; Rice, MA; Rosenthal, SN; Sears, M; Tormey, DC, 1982) |
| "Patients with metastatic breast cancer previously treated with non-Adriamycin containing chemotherapy were treated with Adriamycin at a dose of 60 mg/m2 administered as a continuous infusion through a central venous catheter." | ( Benjamin, RS; Blumenschein, GR; Ewer, M; Freireich, EJ; Legha, SS; Mackay, B; Wallace, S; Yap, HY, 1982) |
| "Forty patients with advanced breast cancer have been treated by endocrine therapy." | ( Forrest, AP; Hawkins, RA; Miller, WR, 1982) |
| "In vitro cultures of breast cancer tissue demonstrate that some tumours are hormone-sensitive and others hormone-insensitive, but it cannot be predicted whether cell proliferation is stimulated or inhibited by hormone treatment." | ( Andersen, J; Bichel, P; Poulsen, HS, 1982) |
| "The development of mammary cancer in men on stilbestrol therapy for prostatic cancer has recently been challenged." | ( Greenblatt, RB; Nezhat, C; Samaras, C; Vasquez, JM, 1982) |
| "There may also be some protection from breast cancer in progestin-treated postmenopausal women." | ( Gambrell, RD, 1982) |
| "A group of 47 patients with advanced breast cancer were treated with a combination of prednimustine, methotrexate, 5-FU, and tamoxifen." | ( Boesen, E; Mouridsen, HT, 1982) |
| "Twenty-seven early localized breast cancer cases in elderly patients, 21 stage I and six stage II, were treated with Tamoxifen only." | ( Helleberg, A; Lundgren, B; Norin, T; Sander, S, 1982) |
| "Thirty-three patients with advanced breast cancer were treated with PALA at a schedule of 1500 mg/m2/day for 5 days every 3 weeks." | ( Davis, TE; Falkson, G; Keller, AM; Taylor, SG, 1982) |
| "Forty patients with metastatic breast cancer were treated with a combination of continuous 5-day infusion vinblastine and peptichemio." | ( Blumenschein, GR; Bodey, GP; Buzdar, AU; Hortobagyi, GN; Schell, FC; Yap, HY, 1982) |
| "Seventeen patients with advanced breast cancer were treated with cis-diamminedichloroplatinum (DDP) 100 mg per m2 every 21--28 days." | ( Aisner, J; Bachur, N; Egorin, M; Ostrow, S; Wiernik, PH, 1980) |
| "Twenty patients with primary breast cancer were treated with tamoxifen (10 mg p." | ( Imura, H; Kato, Y; Kurata, M; Waseda, N, 1981) |
| "Seventy-three women with metastatic breast cancer were treated with aminoglutethimide and dexamethasone." | ( Asbury, RF; Bakemeier, RF; Bennett, JM; Fölsch, E; McCune, CS; Savlov, E, 1981) |
| "A 57-year-old woman with metastatic breast carcinoma treated by surgery and high-dosage tamoxifen chemotherapy developed tamoxifen retinopathy characterized by white superficial refractile retinal lesions primarily in the paramacular area." | ( Kaiser-Kupfer, MI; Kupfer, C; Rodrigues, MM, 1981) |
| "Sixty-two patients with breast cancer treated with Adriamycin-containing adjuvant chemotherapy developed recurrent disease." | ( Barnes, BC; Blumenschein, GR; Buzdar, AU; Campos, LT; Distefano, A; Hortobagyi, GN; Legha, SS; Schell, FC; Wiseman, CL; Yap, HY, 1981) |
| "Among 470 patients with metastatic breast cancer treated with tamoxifen, ten patients (2." | ( Blumenschein, GR; Buzdar, AU; Legha, SS; Powell, K, 1981) |
| "An 80-year-old woman with metastatic breast cancer to the lungs and bones was treated with tamoxifen, 10 mg twice daily, with arrest of disease of six month's duration." | ( Arafah, BM; Manni, A, 1981) |
| "58 women with metastatic breast cancer, non-responsive to hormone therapy, were treated with a modified CMF regimen." | ( Denz, H; Huber, H; Kratzer, H; Michlmayr, G, 1981) |
| "Fifty-one patients with metastatic breast carcinoma were randomized to treatment with weekly 5-fluorouracil (5-FU) either by mouth or intravenously." | ( Bateman, JR; Chlebowski, RT; Pugh, RP; Weiner, JM, 1981) |
| "Thirty-six patients with advanced breast cancer were treated with the regimen of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)." | ( Chang, JC; Wergowske, G, 1981) |
| "Thirty-one patients who had metastatic breast cancer extensively pretreated with combination chemotherapy, including doxorubicin, were tested with dihydroxyanthracenedione, 3 to 4 mg/m2 body surface area daily for 5 consecutive days every 4 weeks." | ( Blumenschein, GR; Bodey, GP; Buzdar, AU; Schell, FC; Valdivieso, M; Yap, HY, 1981) |
| "Results of treatment for advanced breast cancer have plateaued indicating the need for new treatment approaches." | ( Osborne, CK, 1981) |
| "Estrogen receptor (ER) status in breast cancer is useful in predicting the response to the hormonal treatments." | ( Cox, CE; Harvey, HA; Lawrence, BV; Lipton, A; Santen, RJ; Smart, EK; Wells, SA; White, DS, 1980) |
| "A choroidal metastasis from a primary breast carcinoma in a 32-year-old woman underwent clinically complete regression during a course of five-drug combined chemotherapy for widespread metastases." | ( Brinkley, JR, 1980) |
| "In 25 cases of postmenopausal breast cancer, estradiol receptor (ER) and progesterone receptor (PR) were measured in cutaneous metastatic nodules before and after administration of 30 mg of tamoxifen per day for 1 week." | ( Baulieu, EE; Lalanne, C; Namer, M, 1980) |
| "Sixty breast cancer patients with hormone-resistant metastatic disease who had progressed after chemotherapy with low-dose cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) or with L-phenylalanine mustard underwent treatment with a low-dose Adriamycin regimen,i." | ( Catalano, RB; Creech, RH; Shah, MK, 1980) |
| "Polychemotherapy of breast cancer was tried years ago, but remained for Cooper to arouse professional interest in multiple-drug therapy." | ( Bisel, HF, 1980) |
| "Twenty patients with generalized breast cancer metastasizing in bones were subjected to treatment by a combination of adriablastine with cyclophosphane or adriablastine with cyclophosphane, 5-fluoruracil, vincristine using repeat 8-day cycles with 3-week intervals between them." | ( Borisov, AI; Dobroskok, LB; Korman, DB; Maslova, IA, 1980) |
| "Thirty-four patients with metastatic breast carcinoma were treated with the following combination: methotrexate 60 mg/m2 i." | ( Hancock, B; Todd, ID; Wilkinson, PM, 1980) |
| "Nineteen patients with advanced breast cancer were treated with 1 g medroxyprogesterone acetate (MPA) i." | ( Castiglione, M; Cavalli, F, 1980) |
| "Clinical research pertinent to breast cancer treatment attempting to manipulate this therapeutic index is not restricted to studies in patients." | ( Hellman, S, 1980) |
| "Samples from 11 patients with breast cancer treated with 5-FU-containing chemotherapy regimens were assayed." | ( Ardalan, B; Cooney, D; Lippman, M; Macdonald, J; Schein, P, 1980) |
| "Although most breast cancer tissues contain cytosol estrophilin, essentially only patients whose cancers have moderate to high levels of estrophilin, designated estrophilin-rich, are found to respond to endocrine therapy." | ( DeSombre, ER; Jensen, EV, 1980) |
| "Eighty-eight patients with advanced breast cancer were retrospectively reviewed to compare estrogen receptor (ER) data with response to cytotoxic chemotherapy." | ( Cohen, JL; Marsland, TA; Raam, S; Rosenbaum, C; Stolbach, LL, 1980) |
| "30 patients with advanced breast carcinoma, and 20 patients with advanced endometrial carcinoma were treated with high doses, 500 mg." | ( Aspesi, G; Bernardo-Strada, MR; Imparato, E; Pavesi, L; Robustelli Della Cuna, G, 1980) |
| "1 g a week, in the treatment of breast cancer whenever auxillary ganglia have already been invaded by the neoplasm; this treatment supersedes chemotherapy treatment which has several uncomfortable side effects; and 3) hormonotherapy with high dose of medroxyprogesterone acetate, i." | ( Bonte, J, 1980) |
| "The authors evaluated 492 patients with breast cancer treated with (n = 32) and without (n = 456) axillary lymph node dissection." | ( Graybill, JC; Griem, KL; Hartsell, WF; Kuznetsova, M; Zusag, TW, 1995) |
| "Patients with metastatic breast cancer who received up to one prior adjuvant chemotherapy regimen were eligible for both studies." | ( Gelmon, KA, 1995) |
| "45 patients with metastatic breast cancer were treated with EPI 120 mg/m2 by intravenous (i." | ( Carpano, S; Conti, F; Di Lauro, L; Giannarelli, D; Gionfra, T; Lopez, M; Paoletti, G; Pignatti, F; Vici, P, 1995) |
| "We describe two patients with breast cancer in remission after treatment with mitomycin in combination with 5-fluorouracil." | ( Hagen, T; Jakobsen, E; Ottestad, L; Schjølseth, SA, 1995) |
| "Radioimmunotherapy (RIT) in breast cancer patients using I-131-chimeric L6 (ChL6) and in human breast cancer xenografts in nude mice using Y-90-1,4,7,10-tetraazacylododecant N,N',N",N"'-tetraacetic acid-peptide ChL6 (Y-90-ChL6) has shown promise." | ( Chi, SG; DeNardo, GL; DeNardo, SJ; deVere White, RW; Gumerlock, PH; Lamborn, KR; Mack, PC; Miers, LA; Shen, S; Winthrop, MD, 1995) |
| "Most menopausal patients with breast cancer receive tamoxifen therapy." | ( Achiron, R; Goldenberg, M; Lipitz, S; Mashiach, S; Sivan, E, 1995) |
| "With the role of tamoxifen in breast cancer being well documented, recent interest has concentrated on its now proven efficacy in adjuvant treatment of patients with the disease in its early stages, and on its prophylactic role in women at high risk of developing the disease." | ( Plowman, PN, 1993) |
| "For patients with stage IV breast cancer, the median progression-free survival after high-dose chemotherapy was 9 months; the median overall survival had been reached at 22 months." | ( Ahn, C; Akman, SA; Doroshow, JH; Forman, SJ; Leong, LA; Margolin, KA; Morgan, RJ; Nagasawa, S; Raschko, JW; Somlo, G, 1994) |
| "In advanced breast cancer high-dose consolidation chemotherapy with haematological rescue has resulted in prolonged disease free and overall survival in a small percentage of patients." | ( Baumann, I; de Wynter, EA; Dexter, TM; Lange, C; Luft, T; Morgenstern, GR; Ranson, M; Testa, NG; Van Hoef, ME; Yvers, A, 1994) |
| "We present a patient with metastatic breast cancer treated with high-dose chemotherapy and bone marrow transplantation." | ( Ciaccia, D; Corey, GR; Peters, W; Thel, MC; Vredenburgh, JJ, 1994) |
| "32 consecutive early breast cancer patients were treated to evaluate the feasibility of an accelerated CEF regimen (cyclophosphamide 600 mg/m2, epirubicin 60 mg/m2 and 5-fluorouracil 600 mg/m2) given intravenously every 2 weeks for six cycles together with granulocyte colony stimulating factor, 5 micrograms/kg/day subcutaneously from day 4 to day 11." | ( Canavese, G; Catturich, A; Del Mastro, L; Garrone, O; Guenzi, M; Rosso, R; Sertoli, MR; Venturini, M, 1994) |
| "50 women with advanced breast cancer were treated with an intensified regimen which consisted of high-dose epirubicin (110 mg/m2) every 2 weeks and filgrastim (5 micrograms/kg) subcutaneously for 13 days, starting 24 h after chemotherapy." | ( Athanasiades, A; Bafaloukos, D; Bamia, C; Fountzilas, G; Giannakakis, T; Kalogera-Fountzila, A; Kosmidis, P; Pavlidis, N; Skarlos, D, 1994) |
| "Patients with metastatic breast cancer will receive 4-5 cycles of induction chemotherapy on one of the ongoing Medicine Branch protocols." | ( Chiang, Y; Cowan, KH; Dunbar, CE; Goldspiel, B; Kohler, D; McDonagh, KT; Nienhuis, AW; O'Shaughnessy, JA; Sorrentino, BP; Wilson, W, 1994) |
| "Ovarian ablation has been used for breast cancer treatment for nearly 100 years." | ( Davidson, NE, 1994) |
| "Estrogen-dependent ZR-75-1 human breast cancer cells were treated with 5-azacytidine, an inhibitor of DNA methylation, and cultured in the absence of estradiol or in the presence of antiestrogens." | ( Dekker, A; Dorssers, LC; Foekens, JA; van Agthoven, T; van Agthoven, TL, 1994) |
| "Approximately one third of breast cancers grow independently of estrogen, lack detectable estrogen receptor (ER) protein, and rarely respond to hormonal treatment." | ( Baylin, SB; Davidson, NE; Ferguson, AT; Lapidus, RG, 1995) |
| "Endocrine treatments of breast cancer patients play an important role in the management of this common tumor of women." | ( Sauter, C, 1995) |
| "A total of 49 stage IV breast cancer patients, 11 pretreated with hormones, 26 with chemotherapy, and 12 with both, received 30 mg TAM and two dose levels of IFN-beta and retinyl palmitate." | ( de Filippis, S; Discepoli, S; Frati, L; Rea, S; Recchia, F; Sica, G; Torchio, P, 1995) |
| "Proliferation of MCF-7 human breast cancer cells, which also respond to EGF and estrogens, was stimulated by LiCl (1-5 mM) within the concentration range that is encountered during human therapy with lithium." | ( Curran, EM; Engler, KS; Grady, LH; Taylor, JA; Welshons, WV, 1995) |
| "Human MDA-MB-435 breast cancer cells were treated in vitro for 6 days with batimastat at concentrations ranging from 0." | ( Bone, EA; Fife, R; Goulet, R; Qulali, M; Sledge, GW, 1995) |
| "We concluded that optimal treatment of breast cancer in the elderly should include surgery." | ( de Vries, JE; van Dalsen, AD, 1995) |
| "Sixteen patients with advanced breast cancer were treated with neoadjuvant intraarterial chemotherapy with high dose epirubicin." | ( Fukuda, K; Kikkawa, N; Kobayashi, K; Mishima, H; Shin, E; Takatsuka, Y; Tono, T; Yagyuu, T, 1995) |
| "In a responding patient with advanced breast cancer, pre-treatment total TS protein was 130 fmol/mg and the TS activity was 3." | ( Aiba, K; Horikoshi, N; Ito, Y; Kasumi, F; Mihara, H; Ohta, H; Shibata, H; Takahashi, S; Takahashi, T, 1995) |
| "125 stage III breast cancer patients, including 51 cases of inflammatory carcinoma, were treated with the following combined modality approach: three courses of primary 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) chemotherapy followed by locoregional treatment and subsequent adjuvant chemotherapy consisting of three courses of FAC alternating with three courses of cyclophosphamide, methotrexate, 5-fluorouracil (CMF)." | ( Campora, E; Canavese, G; Catturich, A; Corvò, R; Gardin, G; Guenzi, M; Naso, C; Pronzato, P; Repetto, L; Rosso, R, 1995) |
| "Forty-one patients with advanced breast cancer were given carboplatin and vinorelbine as second-line therapy." | ( Anastasio, E; Bucci, L; De Sena, G; Facchini, G; Finizio, A; Gesue, G; Iaffaioli, RV; Santangelo, M; Scaramellino, G; Tortoriello, A, 1995) |
| "Ninety-three patients with advanced breast cancer were treated with five cycles of FLAC chemotherapy and either IL-3 alone, GM-CSF alone, sequential IL-3 and GM-CSF administered by schedule A (5 days of IL-3 followed by 10 days of GM-CSF) or schedule B (9 days of IL-3 followed by 6 days of GM-CSF), or concurrent administration of IL-3 and GM-CSF for 15 days." | ( Chow, C; Cowan, KH; Danforth, D; Denicoff, A; Goldspiel, B; Gossard, M; Jacobson, J; Keegan, P; Miller, L; Noone, MH; O'Shaughnessy, JA; Tolcher, A; Venzon, DJ, 1995) |
| "44 patients with advanced breast cancer were treated with high-dose epirubicin (130 mg/sqm), because of its steep dose-response curve." | ( Bucci, L; Caponigro, F; Di Martino, N; Facchini, G; Fei, L; Iaffaioli, RV; Mantovani, G; Santangelo, M; Tortoriello, A, 1995) |
| "One patient with primary breast carcinoma had a false-negative scan and another had a false-positive scan in the presence of fibrosis following lumpectomy and radiation therapy." | ( Hreshchyshyn, MM; Nabi, H; Ortman-Nabi, J; Rosner, D; Wild, L, 1995) |
| "A 32-year-old woman with metastatic breast cancer received local radiation therapy to the lumbosacral area." | ( Campbell, DL; Perez, EA; Ryu, JK, 1995) |
| "Thirty patients with advanced breast cancer were treated with an intensified FEC regimen, planned at 21-day intervals, sequenced with granulocyte-macrophage (GM)-CSF (15 patients) or granulocyte (G)-CSF (15 patients)." | ( Ascari, E; Cazzola, M; Danova, M; De Renzis, MR; Locatelli, F; Mazzini, G; Riccardi, A; Rosti, V, 1995) |
| "Thirty-five women with metastatic breast cancer (dominant visceral metastases in 56%, and involvement of > or = three sites in 67%) who never received chemotherapy of any type were studied." | ( Capri, G; Caraceni, A; Fulfaro, F; Gianni, L; Laffranchi, A; Martini, C; Munzone, E; Spreafico, C; Tarenzi, E; Villani, F, 1995) |
| "To determine the risk of breast cancer in relation to the use of combined estrogen and progestin hormone replacement therapy (HRT)." | ( Daling, JR; Habel, LA; Rossing, MA; Stanford, JL; Voigt, LF; Weiss, NS, 1995) |
| "Treatment of human breast cancer cells with 2." | ( Brueggemeier, RW; Chang, CJ; Gilbert, NE; Lin, YC; O'Reilly, JE, 1995) |
| "Many patients with node-negative breast cancer will be cured by local therapy alone." | ( Hall, PD; Hall, RK; Lesher, BA, 1995) |
| "Long term treatment of breast cancer patients with 10 mg/day has continued in 17 patients without an escape of estradiol suppression." | ( Demers, L; Dowsett, M; Dyroff, M; Plourde, PV; Webster, A; Yates, R, 1995) |
| "Treatment planning for breast cancer is a challenge for bridge separations greater than 24 cm." | ( Klein, EE; Michalet-Lorenz, M; Taylor, ME, 1995) |
| "Three gastric, three colon and three breast cancer patients were administered 300 mg/m2 FUra continuously for 10 h per day from 2100 h to 0700 h for more than 20 consecutive days." | ( Furuya, Y; Kohno, N; Saitoh, Y; Yamamoto, K; Yamamoto, M, 1995) |
| "Data encompassing initial breast cancer diagnosis, metastatic presentation, and response to induction treatment were examined for correlations with improved PFS." | ( Antman, K; Ayash, LJ; Elias, A; Fairclough, D; Frei, E; Reich, E; Schnipper, L; Schwartz, G; Warren, D; Wheeler, C, 1995) |
| "Patients with metastatic breast cancer who may have received up to one prior chemotherapy regimen in the adjuvant setting were eligible." | ( Gelmon, KA; Tolcher, AW, 1995) |
| "Breast conservation surgery for early breast cancer requires post-operative radiotherapy to give local control rates equivalent to mastectomy." | ( Gilmore, OJ; Gray, R; Lee, KS; Plowman, PN, 1995) |
| "Fifty-one patients with metastatic breast cancer who had all relapsed or whose disease had progressed within 12 months from completion of an anthracycline-containing chemotherapy protocol (six receiving adjuvant therapy, 19 receiving neoadjuvant therapy, and 26 receiving treatment for metastatic disease) were enrolled in this phase II trial from June 1992 to May 1994." | ( Capri, G; Caraceni, A; Fulfaro, F; Gianni, L; Laffranchi, A; Martini, C; Munzone, E; Spreafico, C; Tarenzi, E; Villani, F, 1995) |
| "Chemotherapy in patients with advanced breast cancer remains palliative." | ( Catimel, G; Clavel, M, 1993) |
| "Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity." | ( Beex, LV; Bijvoet, OL; Blijham, G; Cleton, FJ; Hermans, J; Kroon, HM; Neijt, JP; Papapoulos, SE; Sleeboom, HP; van Holten-Verzantvoort, AT, 1993) |
| "Eighteen patients with advanced breast cancer were commenced on treatment with high dose doxorubicin (100 mg m-2) or doxorubicin (100 mg m-2) and cyclophosphamide (500 mg m-2) at 2 weekly intervals." | ( Dodwell, DJ; Ferguson, JE; Howell, A; Richards, MA; Seymour, AM, 1993) |
| "Seventeen patients with metastatic breast cancer were treated with two courses of cyclophosphamide (CPA; 3." | ( Crown, J; Gilewski, T; Hamilton, N; Harrison, M; Hudis, C; Kritz, A; Moore, M; Reich, L; Schneider, J; Vahdat, L, 1993) |
| "A total of 44 women with advanced breast cancer who had failed first- and second-line chemotherapy were given combination chemotherapy consisting of folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC)." | ( Aquino, A; Francini, G; Gonnelli, S; Petrioli, R, 1993) |
| "Metastatic breast cancer remains an incurable disease; therefore, both the efficacy and the toxicity of palliative chemotherapy are important considerations." | ( Hainsworth, JD, 1993) |
| "We treated 22 women with metastatic breast cancer with high-dose cyclophosphamide and thiotepa and, following the infusion of 4-hydroperoxycyclophosphamide-purged marrow, administered G-CSF, 16 micrograms/kg daily, from day 0 to engraftment." | ( Davidson, NE; Davis, J; Huelskamp, AM; Kennedy, MJ; Noga, SJ; Ohly, K; Passos-Coelho, J, 1993) |
| "The goal of all new strategies of breast cancer treatment is to improve the likelihood of cure and to lessen the physical and psychological sequelae of mastectomy." | ( van de Velde, CJ, 1993) |
| "A total of 259 chemotherapy-naive breast cancer patients treated with a 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) or 5-fluorouracil, epirubicin, cyclophosphamide (FEC) regimen were randomly assigned to ondansetron (OND) 8 mg tablet or alizapride (ALI) 150 mg intravenous (i." | ( Bonneterre, J; Clavel, M; d'Allens, H; Paillarse, JM, 1995) |
| "The prognosis of stage III breast cancer remains grim despite modern adjuvant therapy." | ( Blomqvist, C; Elomaa, I; Gröhn, P; Rissanen, P; Saarto, T; Tiusanen, K, 1995) |
| "54 patients (pts) with metastatic breast cancer were treated with aminoglutethimide 250 mg p." | ( Czech, I; Dziewulska-Bokiniec, A; Wojtacki, J, 1994) |
| "In cases of recurrent progressive breast cancer, ADM, CPM, 5-FU, MTX, MMC and vinca alkaloids have proven to be effective, but CMF and CAF have been considered the standard chemotherapy regimen." | ( Taguchi, T, 1994) |
| "Most of breast cancer patients are treated with CMF, which is a combination of three anticancer agents, cyclophosphamide, methotrexate and 5-fluorouracil." | ( Shyamala Devi, CS; Subramaniam, S, 1994) |
| "Sera from 300 metastatic breast cancer patients with ER-positive (ER+), ER status unknown, or ER-/progesterone receptor-positive (PR+) randomized to receive second-line hormone therapy with either megestrol acetate or fadrozole were evaluated." | ( Chinchilli, VM; Demers, L; Grossberg, H; Harvey, H; Konrad, K; Leitzel, K; Lipton, A; Teramoto, Y; Volas, G, 1995) |
| "Patients with ER+/c-erbB-2+ metastatic breast cancer are less likely to respond to hormone treatment than ER+/c-erbB-2- patients." | ( Chinchilli, VM; Demers, L; Grossberg, H; Harvey, H; Konrad, K; Leitzel, K; Lipton, A; Teramoto, Y; Volas, G, 1995) |
| "As reported by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) in Lancet (1992), the 10-year relapse-free survival or overall survival was significantly better in the tamoxifen (TAM) treatment group than in the control group in both node-positive and -negative groups." | ( Iino, Y; Morishita, Y; Takei, H, 1995) |
| "Therapy for advanced breast cancer has not improved significantly in recent years, remaining strictly palliative in nature and intent." | ( Azli, N; Bayssas, M; Chevallier, B; Dieras, V; Fumoleau, P; Kerbrat, P; Van Glabbeke, M, 1995) |
| "Thirty patients with metastatic breast cancer either previously treated with adjuvant tamoxifen for at least 24 months or treated with tamoxifen for metastatic disease and showing an objective response or stability of disease, were given MA (single daily dose of 160 mg per os) and alpha 2a IFN (3 million units-MU-three times per week intramuscularly-i." | ( Amoroso, D; Balestrero, M; Boccardo, F; Brema, F; Cellerino, R; Farris, A; Folco, U; Iacobelli, S; Mesiti, M; Miglietta, L, 1995) |
| "One hundred patients with metastatic breast cancer were randomly selected to receive combined chemotherapy treatment with adriamycin (50 mg/m2) or mitoxantrone (12 mg/m2) associated with 5-fluorouracil (600 mg/m2) and cyclophosphamide (600 mg/m2) administered intravenously every 21 days with a maximum of ten cycles." | ( Alonso, MC; Climent, MA; Llanos, M; López, JJ; Ojeda, B; Seguí, MA; Solà, C; Tabernero, JM, 1995) |
| "A 42-year-old woman with metastatic breast carcinoma treated with only DuP-941 developed, and died of, heart failure for which no other explanation was apparent." | ( Chandra, L; Higginson, LA; Huan, SD; Veinot, JP; Walley, VM; Walsh, SM, 1995) |
| "Women with metastatic breast cancer who had measurable disease, required laboratory tests, had received no prior chemotherapy for metastases, had a Cancer and Leukemia Group B (CALGB) performance status < or = 2, and provided informed consent were eligible." | ( Abrams, J; Aisner, J; Budman, D; Cirrincione, C; Citron, M; Holland, J; Muss, H; Panasci, L; Perloff, M; Perry, M, 1995) |
| "Sixteen patients with breast cancer (11 with locally advanced tumors, three with recurrent disease in the contralateral breast, two of them with distant and regional metastases, and two with distant metastases) underwent a baseline and two follow-up PET scans after the first and third/fourth polychemotherapy course." | ( Ahlström, H; Bergh, J; Jansson, T; Långström, B; Lilja, A; Westlin, JE, 1995) |
| "In advanced breast cancer patients, indirect evidence was obtained that chemotherapy as well as endocrine therapy may prolong the survival of patients: changes in the survival of a defined cohort in decades, a comparison of the survival time of all patients randomized to a regimen with a higher response rate and that of patients with a lower response rate, and a comparison of the survival of responders and non-responders." | ( Nomura, Y, 1995) |
| "The five products of breast carcinoma cells were measured in 184 patients with node-negative breast carcinoma who were enrolled in the Kumamoto Adjuvant Chemo-Endocrine Therapy for Breast Cancer prospective randomized trial, and the predictive values of these factors for relapse-free and overall survival were evaluated." | ( Ogawa, M; Sakai, K; Yamashita, J, 1995) |
| "It is shown that breast cancer can be considered as a paradigm of comprehensive cancer biology and treatment based on analysis of each individual tumor." | ( Martin, PM; Saez, S, 1995) |
| "We treated 19 patients with advanced breast cancer resistant to tamoxifen with a new specific antioestrogen (ICI 182780) which, in animal studies, has no agonist activity." | ( Blamey, R; DeFriend, D; Howell, A; Robertson, J; Walton, P, 1995) |
| "Patients who developed breast cancer during hormone replacement therapy had fewer locally advanced cancers (large tumors and extensive lymph node involvement) and more well-differentiated cancers (infiltrating lobular cancers and grade 1 cancer)." | ( Bonnier, P; Giacalone, PL; Laffargue, F; Martin, PM; Piana, L; Romain, S, 1995) |
| "Treatment is ad infinitum." | ( Carlstedt, SC; Desai, PR; Scanlon, EF; Springer, GF; Tegtmeyer, H, 1994) |
| "Fourteen patients with recurrent breast cancer were treated with a combination of mitoxantrone (10 mg/m2 iv, day 1), vincristine (1 mg/m2 iv, day 1) and prednisolone (30 mg/day day 1-7)." | ( Fukunaga, M; Iba, T; Kidokoro, A; Momose, F; Yagi, Y, 1995) |
| "The Early Breast Cancer Trialists' Collaborative Group metaanalysis provides compelling evidence of the benefits associated with the use of tamoxifen and chemotherapy as separate adjuvant modalities in women with stages I and II breast cancer." | ( Tolcher, AW, 1994) |
| "In 1978 the International (Ludwig) Breast Cancer Study Group (IBCSG) initiated four complementary randomized controlled clinical trials to evaluate the roles of chemo-endocrine combinations or endocrine therapy alone in specific populations defined by risk (for pre- and perimenopausal patients) or by age (for postmenopausal patients)." | ( Castiglione-Gertsch, M; Collins, J; Cortes-Funes, H; Forbes, J; Gelber, RD; Goldhirsch, A; Hacking, A; Johnsen, C; Lindtner, J; Rudenstam, CM, 1994) |
| "With current adjuvant chemotherapy for breast cancer, in which a combination of cyclophosphamide and an anthracycline is often used, there is no place for scalp hypothermia." | ( Liefers, GJ; Repelaer van Driel, OJ; Tollenaar, RA; van de Velde, CJ, 1994) |
| "Human breast cancer is characterised by its high frequency of metastasis and its oestrogen responsiveness, allowing specific anti-oestrogen therapy." | ( Rochefort, H, 1994) |
| "One hundred and thirty eight breast cancer patients at high risk of locoregional, as well as systemic relapse, who were referred to three centers in Australia and New Zealand were treated with postoperative radiation therapy and chemotherapy simultaneously." | ( Ackland, SP; Bonaventura, A; Christie, D; Dady, P; Denham, JW; Hamilton, CS; Lamb, DS; O'Brien, M; Spry, NA; Stewart, JF, 1995) |
| "Most of the breast cancer patients are treated with CMF which is a combination of three anticancer agents namely cyclophosphamide, methotrexate and 5-fluorouracil." | ( Devi, CS; Jagadeesan, M; Subramaniam, S, 1994) |
| "Fifty patients with large operable breast cancer, median tumor diameter 6 cm (range, 3 to 12), were treated with 5FU 200 mg/m2/d via a Hickman line using an ambulatory pump for 6 months with epirubicin 50 mg/m2 intravenously (IV) and cisplatin 60 mg/m2 IV every 3 weeks for eight courses." | ( Ebbs, S; Gusterson, B; Johnston, S; Jones, A; Prendiville, J; Ramage, F; Robertshaw, H; Sacks, N; Smith, IE; Walsh, G, 1995) |
| "Twenty females with disseminated breast cancer received courses of polychemotherapy with 21-day intervals." | ( Bagdasarov, IuB; Min'kov, ED; Niu-Tian-de, GB; Odzharova, AA; Shkhvatsabaia, LV; Zaĭtseva, TI, 1994) |
| "Several phase II trials involving breast cancer patients with limited prior therapy have yielded overall response rates (complete response and partial response) of 44% to 62% among women receiving paclitaxel." | ( Seidman, AD, 1994) |
| "Until a few years ago, every treated breast cancer was an absolute contraindication to hormonal replacement therapy (HRT)." | ( Birkhäuser, M, 1994) |
| "Twenty-five women with advanced breast carcinoma refractory to first-line chemotherapy entered a phase II trial to evaluate the efficacy of ifosfamide and carboplatin." | ( Herman, RL; Kelley, AS; Muggia, FM; Russell, CA; Spicer, DV; Turrill, M, 1995) |
| "A patient with recurrent breast cancer, who was diagnosed with eyelid metastasis as a part of systemic metastases and in whom systemic chemotherapy was markedly effective, is reported." | ( Abe, K; Adachi, I; Kaneko, A; Narabayashi, M; Tokue, Y; Tsuda, H; Watanabe, T; Yin, DF; Zhang, GJ, 1995) |
| "Overexpression of the EGF receptor in breast cancer correlates with poor prognosis and failure on endocrine therapy for both ER-/EGFR+ and ER+/EGFR+ tumors, suggesting a role for EGFR in the progression to hormone independence." | ( Chrysogelos, SA; Lauber, AH; Murphy, JM; Yarden, RI, 1994) |
| "The expression of MDR in breast tumors is related to their origination from a tissue that constitutively expresses Pgp as well as to the development of resistance during successive courses of chemotherapy." | ( Glazer, RI; Rohlff, C, 1994) |
| "A total of 16 patients with advanced breast cancer who had failed a first-line treatment without any vinca alkaloid were entered in the study." | ( Adenis, A; Bonneterre, J; Fumoleau, P; Giroux, B; Marty, M; Pion, JM; Pouillart, P, 1995) |
| "In recent years, tamoxifen therapy for breast carcinoma has been associated with endometrial carcinoma with increasing frequency." | ( Dallenbach-Hellweg, G; Hahn, U, 1995) |
| "Chemotherapy for systemic therapy in breast cancer has been widely used, and has been supported by many varied compounds with different origins and different compositions." | ( Calzada, L; Salazar Esquivel, EL; Tellez, MC, 1995) |
| "We have studied a group of 16 advanced breast cancer patients who received cyclical cytotoxic chemotherapy (CMF-cyclophosphamide, methotrexate and 5-fluorouracil) and have documented the progressive differential effects of chemotherapy on endogenous immune cells as judged by changes in immunophenotype and absolute numbers of lymphocyte subsets, together with analysis of natural-killer-cell function." | ( Blamey, RW; Chan, S; Galvin, A; Halbert, CF; Robins, RA; Sewell, HF, 1993) |
| "We have recently treated 66 women with breast cancer with escalating doses of ifosfamide, carboplatin, and etoposide (ICE) followed by autologous stem cell rescue (ASCR)." | ( Elfenbein, GJ; Fields, KK; Hiemenz, JW; Janssen, WE; Kronish, LE; Machak, MC; Perkins, JP; Zorsky, PE, 1993) |
| "One hundred and five breast cancer patients with stage T3/4, N+/-, Mo were treated at random either with a pre- and postoperative chemotherapy (A) (5-drug-combination + tamoxifen) or with a pre- and postoperative radiotherapy (B)." | ( Dobianer, K; Helmer, H; Hruza, C; Locker, G; Rainer, H; Spona, J; Stühlinger, M, 1994) |
| "106 previously untreated breast cancer patients have been immunohistochemically analysed for EGF-R, ER, Ki67, and c-erbB-2 product." | ( Blamey, RW; Cannon, P; Ellis, IO; Gee, JM; Manning, DL; McClelland, RA; Nicholson, RI; Robertson, JF, 1994) |
| "In this study 26 women with metastatic breast cancer responding to lower dose combination chemotherapy were treated with 18 g/m2 of hydroxyurea added to the widely used combination of cyclophosphamide (CY) 6 g/m2 and thiotepa 600 mg/m2." | ( Edwards, B; Kessinger, A; Reed, EC; Vaughan, WP, 1994) |
| "The MCF-7 human mammary carcinoma cell line undergoes morphological differentiation in vitro when treated with 17-beta-estradiol." | ( DePasquale, JA; Gierthy, JF; Samsonoff, WA, 1994) |
| "In the breast cancer study, 22 patients have been enrolled to date and eight patients have completed treatment." | ( Gelmon, KA, 1994) |
| "for locally advanced breast cancer with remote metastases on the grounds that the effect of this treatment is "semi-local and semisystemic," I." | ( Kikkawa, N; Kobayashi, K; Mishima, H; Nakagawa, H; Shin, E; Takatsuka, Y; Tamaki, Y; Tono, T; Yagyu, T, 1994) |
| "We reported 2 cases of breast cancer with lymph node metastasis treated with CAF (cyclophosphamide, adriamycin, 5-fluorouracil) and medroxyprogesterone acetate (MPA)." | ( Hagiwara, S; Hirose, K; Iwai, K; Kimura, M; Shimokawa, Y; Uemura, K, 1994) |
| "Two human breast carcinoma cell lines (MCF-7, MCF-7 Adr) and a rat esophageal cancer cell line (RE-B2T) were used to evaluate the antiproliferative potential of gossypol (GP)-containing milk (GP-Milk), which was collected from Brown Swiss dairy cows treated daily with federally allowable 450 ppm of GP for 6 days." | ( Brueggemeier, RW; Chang, CJ; Hu, YF; Lin, YC, 1994) |
| "Adjuvant tamoxifen therapy for breast cancer patients has been found to be associated with various endometrial pathologic conditions, including endometrial cancer." | ( Altaras, M; Beyth, Y; Cohen, I; Cordoba, M; Dror, Y; Rosen, DJ; Shapira, J; Tepper, R, 1994) |
| "We treated breast cancer patients with Ps node involvement using an extended surgery (Ps+Sc, n = 17, group A) combined with targeting chemotherapy and compared the survival rate by this method with that by the dissection of the Ps node alone (n = 23, group B) to assess the prognosis of advanced breast cancer by extended surgery." | ( Asaga, T; Masuzuma, C; Yoshida, A, 1994) |
| "Hormonal therapy of breast cancer is the oldest treatment in advanced disease." | ( Espie, M, 1994) |
| "To evaluate a treatment for breast cancer and to demonstrate the safe use of iridium-192 high-dose-rate (HDR) implantations." | ( Hammer, J; Labeck, W; Seewald, DH; Track, C; Zoidl, JP, 1994) |
| "MCF-7 human breast cancer cells grown as solid tumors in athymic mice chronically treated with TAM reproducibly develop a TAM stimulated phenotype (Osborne et al." | ( Jordan, VC; Wolf, DM, 1994) |
| "A total of 18 patients with metastatic breast cancer were accured; 14 had adjuvant chemotherapy and 8 had chemotherapy for advanced disease." | ( Heath, R; Hoen, H; Jackson, DV; McCulloch, J; McFarland, J; Muss, HB; Pavy, M; Ramseur, W; Thomas, GW, 1994) |
| "Two pre-menopausal breast cancer patients who were treated with tamoxifen developed both permanent supraphysiological oestrogen concentration and ovarian cysts." | ( Altaras, MM; Ben-Nun, I; Beyth, Y; Cohen, I; Maymon, R; Shulman, A; Tepper, R, 1994) |
| "Since ER positivity in breast cancer is highest in the early stage of its natural history, hormonal treatment should be given as the initial treatment after both surgery and recurrence." | ( Inaji, H; Koyama, H; Motomura, K; Noguchi, S, 1994) |
| "A 35-year-old female with inflammatory breast cancer was treated with preoperative intra-arterial infusion chemotherapy." | ( Matsuno, S; Migita, T; Saito, Y; Shibata, C; Shiiba, K, 1994) |
| "The current breast cancer treatment paradigm, based primarily on Gompertzian kinetics and animal models, advocates short-course, intensive chemotherapy subsequent to tumor debulking, citing drug resistance and host toxicity as the primary reasons for treatment failure." | ( Bame, PD; Retsky, MW; Swartzendruber, DE; Wardwell, RH, 1994) |
| "In 20% of premenopausal breast cancer women on Tamoxifen (TAM) treatment there is an ovarian enlargement: in literature one case of acutely cystic ovaries is described." | ( Bellino, R; Lanza, A; Lauricella, A; Leo, L; Re, A; Tessarolo, M; Wierdis, T, 1994) |
| "Peritoneal metastasis of breast cancer was one of the worst reactions with any therapy." | ( Arima, M; Ebihara, Y; Kimura, K; Koyanagi, Y; Kusama, M; Matsunaga, T; Murata, A; Nakamura, Y; Shimizu, T, 1994) |
| "In contrast to female breast cancer patients, who have a 4% attrition rate to adjuvant tamoxifen treatment, MBC patients have a 20." | ( Anelli, A; Anelli, TF; Borgen, PI; Lebwohl, DE; Tran, KN, 1994) |
| "To date, 2,972 Stage I breast cancer patients have been randomized to evaluate the efficacy of a 5-year administration of 4-HPR to prevent new contralateral primary breast cancers." | ( Costa, A; Decensi, A; Formelli, F; Torrisi, R, 1993) |
| "Moreover, in breast cancer patients with liver metastasis, bone metastasis appears to be a prognostic factor associated with good response to this immunotherapy." | ( Ichinose, Y; Imamura, M; Kan, N; Kodama, H; Li, L; Moriguchi, Y; Okino, T; Sugie, T; Yamasaki, S, 1993) |
| "In women with metastatic breast cancer with bone marrow involvement, durable responses after high-dose chemotherapy are possible utilizing peripheral blood progenitor support rather than marrow purging." | ( Mick, R; Myers, SE; Williams, SF, 1994) |
| "Four cases of recurrent breast cancer effectively treated by CPT-11 were reported." | ( Doihara, H; Takashima, S; Yokoyama, N, 1994) |
| "A 72-year-old female with right breast cancer having multiple lung metastases was treated by combined administration of 5'-DFUR at 800 mg/day, and tamoxifen, at 20 mg/day, after standard radical mastectomy." | ( Akashi, Y; Hachiya, Y; Miyoshi, A; Noshiro, H; Tohma, H, 1994) |
| "Because locally advanced infiltrating breast carcinomas are frequently diagnosed by fine-needle aspiration, histologic grade can be determined in the mastectomy specimens only after chemotherapy." | ( Fechner, RE; Frierson, HF, 1994) |
| "Fifty patients with advanced breast cancer refractory to prior tamoxifen therapy were assigned to investigational treatment with high-dose toremifene administered 120 mg orally twice a day." | ( Hajba, A; Pyrhönen, S; Valavaara, R; Vuorinen, J, 1994) |
| "The study included 8 premenopausal breast cancer patients undergoing adjuvant chemotherapy." | ( Barni, S; Cazzaniga, M; Lissoni, P; Mainini, E; Rovelli, F; Tancini, G, 1994) |
| "Treatment of human MCF-7 breast cancer cells with chemosensitizers (CS), such as verapamil, trifluoperazine or BSO, for 72 hr resulted in an enhanced sensitization of cells to Adriamycin, trifluoperazine being the most potent compound in the reversion of chemoresistance." | ( Hénichart, JP; Hornez, L; Mestdagh, N; Vandewalle, B, 1994) |
| "The doses of chemotherapy used to treat breast cancer, especially early breast cancer, should not be reduced if the maximal benefit is to be achieved." | ( Budman, DR; Cooper, MR; Ellerton, JA; Ferree, CR; Hart, RD; Korzun, AH; Moore, A; Norton, L; Wood, WC; Younger, J, 1994) |
| "Forty-eight patients with inflammatory breast cancer were treated by an induction regimen with cyclophosphamide (1200 mg/m2), and epirubicin (75 mg/m2)." | ( Bourstyn, E; Culine, S; De Rocquancourt, A; Dieras, V; Espie, M; Extra, JM; Giacchetti, S; Marty, M; Maylin, C; Morvan, F, 1993) |
| "Thirty-one patients with metastatic breast cancer treated on three successive high-dose chemotherapy and autologous bone marrow transplantation trials between January 1987 and March 1992 who achieved a complete response were evaluated." | ( Halpern, H; Heimann, R; Mundt, AJ; Rubin, SJ; Sibley, GS; Weichselbaum, RR; Williams, S, 1994) |
| "In 29 patients (9 breast carcinomas, 8 soft tissue sarcomas, 8 lymph node metastases of head and neck cancers and 4 different other tumors) the oxygenation status was examined before, during and after radio- and partially thermoradiotherapy." | ( Feldmann, HJ; Füller, J; Molls, M; Sack, H, 1994) |
| "Amplification of mdr-1 occurs in breast cancer patients receiving endocrine treatment." | ( Lönn, S; Lönn, U; Stenkvist, B, 1993) |
| "The patients included 27 with localised breast cancer, 19 who had been treated for breast cancer but were now disease-free, 17 with liver metastases, 8 with bone metastases, and 7 with disseminated breast cancer but with neither metastases to the liver or bone." | ( Bent, DJ; Bodger, WA; Buamah, PK; Skillen, AW, 1993) |
| "We have analysed breast cancer biopsy specimens for genetic alterations at and around topoisomerase loci in order to obtain molecular insight into factors which may determine how tumours respond to chemotherapy." | ( Brown, R; Douglas, F; George, WD; Kaye, SB; Keith, WN; McCallum, HM; Wishart, GC, 1993) |
| "Thirty-six women with advanced breast cancer were treated with CSA 2." | ( Altomonte, V; Davidson, NE; Farmer, ER; Hess, AD; Huelskamp, AM; Jones, RJ; Kennedy, MJ; Vogelsang, GB, 1994) |
| "Survival among women with breast cancer improved significantly in a geographically defined population during the period when adjuvant systemic therapy became widely used." | ( Bajdik, CD; Coppin, CM; Gelmon, KA; Jackson, SM; Olivotto, IA; Plenderleith, IH; Ragaz, J; Wilson, KS; Worth, A, 1994) |
| "No other systemic therapy for breast cancer was allowed after their inclusion in the study." | ( Bajetta, E; Bochicchio, AM; Colleoni, M; Nolè, F, 1993) |
| "Tamoxifen treatment for breast cancer should continue." | ( Costantino, JP; Cronin, WM; Fisher, B; Fisher, ER; Redmond, CK; Wickerham, DL, 1994) |
| "Most breast tumors show estrogen-dependent growth and are thus susceptible to antiestrogenic therapy." | ( Balaguer, P; Demirpence, E; Gagne, D; Nicolas, JC; Pons, M; Trousse, F, 1994) |
| "A total of 23 women with stage II breast cancer receiving adjuvant cyclophosphamide, methotrexate and 5-fluorouracil had detailed pharmacokinetic monitoring performed on the first and third courses of therapy." | ( Bunting, PS; Erlichman, C; Hardy, R; Kerr, I; Moore, MJ; Soldin, S; Thiessen, JJ, 1994) |
| "This regimen has activity in metastatic breast cancer comparable to conventional and/or standard chemotherapy regimens for advanced disease." | ( Honig, SF; Swain, SM, 1994) |
| "Patients with breast cancer and a high number of involved axillary lymph nodes have a poor prognosis, despite adjuvant chemotherapy." | ( de Graaf, H; de Vries, EG; Dolsma, WV; Mulder, NH; Mulder, PO; Sleijfer, DT; Smit Sibinga, CT; van der Graaf, WT; van der Ploeg, E; Willemse, PH, 1994) |
| "Poor prognosis of Stage IV breast cancer patients have at best a 10% 3-year survival rate with conventional chemotherapy." | ( Buzdar, AU; Dicke, KA; Dunphy, FR; Fornoff, JE; Hortobagyi, GN; Huan, SD; Spitzer, G; Yau, JC, 1994) |
| "In the breast conserving management of mammary cancer a high-dose-rate (HDR)-Iridium-192 source is used for interstitial boosting of the primary tumor site after external radiotherapy." | ( Hammer, J; Seewald, DH; Track, C; Zoidl, JP, 1994) |
| "Nineteen patients with metastatic breast cancer who had failed prior first line FEC chemotherapy (fluorouracil 500 mg/m2, epirubicin 50 mg/m2 cyclophosphamide 500 mg/m2, every 4 weeks) were treated with a combination of fluorouracil 500 mg/m2, doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 every 4 weeks (FAC)." | ( Biron, P; Catimel, G; Chauvin, F; Clável, M; Guastalla, JP; Rebattu, P, 1994) |
| "A total of 25 patients with advanced breast cancer were treated weekly with i." | ( Bauernhofer, T; Derstvenscheg, E; Kasparek, AK; Kuss, I; Moser, R; Ploner, F; Schmid, M; Steindorfer, P; Stöger, H; Wilders-Truschnig, M, 1994) |
| "Patients with metastatic breast carcinoma resistant to first line chemotherapy may require further treatment." | ( Agostara, B; Callari, AM; Cusimano, MP; Gebbia, N; Gebbia, V; Testa, A, 1994) |
| "13 (39%) in the untreated breast cancer patients (p < 0." | ( Dziewulska-Bokiniec, A; Kortas, B; Skokowski, J; Wojtacki, J, 1994) |
| "Postmenopausal women with advanced breast cancer, who could not benefit from loco regional therapy, with positive or unknown estrogen or progesterone receptors were entered in this study." | ( Chevallier, B; Krams, M; Marty, M; Mertens, H; Mignot, L; Pouillart, P; Pujade Lauraine, E; Serin, D; Spielmann, M; Tubiana Hulin, M, 1993) |
| "Treatment of extracts from human breast cancer (MCF7) cells with either alkali or ethanol increased immunoreactivity of PP2Ac subunit severalfold on Western blots with Ab299/309, but did not apparently change molecular weight or isoelectric point of the protein." | ( Favre, B; Hemmings, BA; Turowski, P; Zolnierowicz, S, 1994) |
| "Patients with metastatic breast cancer refractory to all standard dose therapy were treated with escalating doses of mitoxantrone (45 to 105 mg/m2) and thiotepa (900 to 1,350 mg/m2) followed by autologous stem cell rescue." | ( Ballester, OF; Elfenbein, GJ; Fields, KK; Foody, MC; Hiemenz, JW; Janssen, WE; Kronish, LE; Perkins, JB; Zorsky, PE, 1993) |
| "At least half of all advanced breast cancers are positive for estrogen receptor (ER) and progesterone receptor (PR), but many nevertheless fail to respond to endocrine therapy." | ( Horwitz, KB, 1993) |
| "Quantitative FDG PET scans of primary breast cancers showed a rapid and significant decrease in tumor glucose metabolism after effective treatment was initiated, with the reduction in metabolism antedating any decrement in tumor size." | ( Cody, R; Helvie, M; Hutchins, GD; Wahl, RL; Weber, B; Zasadny, K, 1993) |
| "A third of breast cancers are estrogen dependent and respond to endocrine therapy." | ( Milgrom, E; Pichon, MF, 1993) |
| "Fifty patients with advanced breast cancer were treated by high dose cisplatin (DDP) combination chemotherapy during the period of August 1984 to June 1991." | ( Zhou, JC, 1993) |
| "One hundred six women with metastatic breast cancer were given dibromodulcitol (mitolactol), doxorubicin, vincristine, tamoxifen, and fluoxymesterone (DAVTH) for 6 months of induction treatment, then randomized to receive one of two chemotherapy regimens if they had obtained an induction partial response (PR) or no change (NC), or to receive observation versus chemotherapy if they had obtained an induction complete response (CR)." | ( Falkson, CI; Falkson, G; Gelman, R; Glick, J; Harris, J, 1994) |
| "By studying iron metabolism in breast cancer, we may be able to selectively inhibit tumor growth without toxic effects, and with other tumor biologic data be better able to select the stage I patient for adjuvant therapy." | ( Elliott, MC; Elliott, RL; Head, JF; Wang, F, 1993) |
| "119 patients with metastatic breast cancer and no prior endocrine therapy were randomized to receive either tamoxifen (TAM) 20 mg/day orally (64 patients), or medroxyprogesterone acetate (MAP) 1g/day i." | ( Brunner, K; Castiglione-Gertsch, M; Cavalli, F; Goldhirsch, A; Metzger, U; Pampallona, S; Senn, HJ; Varini, M, 1993) |
| "27 patients with advanced breast cancer, 22 of them pretreated, received intravenous (iv) mitoxantrone, 14 mg/m2, day 1, iv leucovorin, 300 mg, days 1 and 15, and 5-FU, 4 g, 48-h infusion, days 1 and 2, 15 and 16, once every 28 days (MLF regimen)." | ( Wils, JA, 1993) |
| "A 67-year-old advanced breast cancer patient with multiple bone metastases showed a remarkable response to the combination therapy of mitoxantrone (MIT) and medroxyprogesteron acetate (MPA) after failure of anthracycline therapy." | ( Andoh, T; Iijima, T; Iino, Y; Inoue, T; Izumi, M; Kobayashi, I; Morishita, Y; Yamada, T; Yokoe, T; Yokota, T, 1994) |
| "Sixty-seven breast cancer patients with cytologically-confirmed malignant pleural effusion, who required intrapleural treatment, were analyzed retrospectively." | ( Hori, T; Kan, N; Kato, H; Kodama, H; Kudo, T; Mukaihara, S; Ogawa, H; Ohsumi, K; Takenaka, A; Yasumura, T, 1993) |
| "However, only about 30% of breast cancers are estrogen-dependent and can be treated by hormonal manipulation." | ( Groot, K; Halmos, G; Pinski, J; Radulovic, S; Schally, AV; Szepeshazi, K; Yano, T, 1994) |
| "At least 50% of all breast cancer patients worldwide would survive longer, however, if public awareness about and early detection of the condition were increased and greater use were made of efficient treatment of proven value." | ( Koroltchouk, V; Love, RR, 1993) |
| "These data suggest that some breast cancer patients who acquire resistance to tamoxifen may not develop cross-resistance to treatment with steroidal antiestrogens." | ( Bei, M; Brünner, N; Clarke, R; Frandsen, TL; Holst-Hansen, C; Lippman, ME; Thompson, EW; Wakeling, AE, 1993) |
| "Twenty patients with metastatic breast cancer were treated every 3 weeks with TFP 5 mg by mouth every 6 hours on days 0-5 and doxorubicin 60 mg/m2/96 hr on days 1-4 by continuous intravenous infusion." | ( Bauer, L; Budd, GT; Bukowski, RM; Ganapathi, R; Lichtin, A; Van Kirk, P, 1993) |
| "An oral combination chemotherapy for breast cancer may be of advantage for many patients, if its activity is equivalent to that of i." | ( Alberto, P, 1993) |
| "All patients had advanced breast cancer presumably sensitive to endocrine therapy (estrogen receptor-positive [ER+] and/or progesterone receptor-positive [PgR+] status) with measurable lesions; none had received prior systemic antineoplastic therapy for metastatic disease; prior adjuvant hormonal therapy (HT) or CT (without anthracyclines) was allowed if interval since completion was longer than 1 year." | ( Heuson, JC; Julien, JP; Klijn, JG; Mignolet, F; Paridaens, R; Sylvester, R; Van Zyl, J; Veyret, C, 1993) |
| "Seventy one women with breast cancer in clinical stage IIIa were treated by chemotherapy and radical operation on the basis five features, namely: survivals, relapses, metastases, quality of life, and post-therapy complications." | ( Czub, M; Markowska, J; Markowski, M; Tomczak, P; Wiese, E, 1993) |
| "Sixteen patients with breast cancer were administered epi-adriamycin (Epi-ADM) singly or in a combination of 5-FU and mitomycin C through both subclavicular artery and internal thoracic artery." | ( Kikkawa, N; Takatsuka, Y; Tamaki, Y, 1993) |
| "Two patients developed breast cancer 14 and 8 years after treatment of Hodgkin's disease." | ( Cascinu, S; Catalano, G; Fedeli, A, 1993) |
| "The effect of estradiol treatment of the human mammary carcinoma cell MCF-7 on the adenylyl cyclase system was examined." | ( Kimura, N; Nagata, N; Shimada, N; Yasutomo, Y, 1993) |
| "An increasing number of patients with breast cancer is being treated with preoperative chemotherapy." | ( Broussard, WF; Hortobagyi, GN; Kim, EE; Nieweg, OE; Singletary, SE; Tilbury, RS; Wong, WH, 1993) |
| "Treatment of the breast cancer cells with the antiestrogen tamoxifen (10(-6) mol/l) led to an increase of 32P incorporation into phosphoinositides and a decrease of 32P incorporation into phosphatidylcholine." | ( Barinov, VV; Bassalyk, LS; Krasil'nikov, MA; Kuzmina, ZV; Letyagin, VP; Shatskaya, VA, 1993) |
| "No change of breast cancer mortality has been reported previously after long-term hormone replacement therapy." | ( Adami, HO; Bergkvist, L; Hoover, R; Persson, I; Schairer, C; Yuen, J, 1993) |
| "84 patients with large operable breast cancer have been treated with primary medical chemotherapy rather than mastectomy in three sequential studies." | ( Baum, M; Jones, AL; McKinna, JA; O'Brien, ME; Sacks, N; Smith, IE, 1993) |
| "In 289 patients of early breast cancer treated with conservative surgery and radical irradiation, multivariate analysis suggests that higher dose per fraction with teletherapy and higher brachytherapy boost dose adversely affect cosmesis and contribute to the late complications." | ( Deore, SM; Dinshaw, KA; Sarin, R; Sharma, V; Shrivastava, SK, 1993) |
| "T47D breast cancer cells showed a similar effect with mibolerone, while hAR expression in normal skin fibroblasts did not respond to androgen treatment." | ( Blaschke, D; Hermeking, H; Herzinger, T; Hörz, W; Wolf, DA, 1993) |
| "The chemotherapy dose intensity for breast cancer has been recently considered to be an important factor in determining clinical outcome." | ( Bertelli, G; Guenzi, M; Miglietta, L; Pronzato, P; Queirolo, P; Rosso, R; Rubagotti, A; Sertoli, MR; Vitale, V, 1993) |
| "For hormone therapy for breast carcinoma, tamoxifen acts as an antiestrogen on the breast but often acts as an estrogen agonist on the endometrium; tamoxifen therapy may be associated with endometrial hyperplasia, polyps, adenomyosis, adenomatous hyperplasia, and adenocarcinoma." | ( Deligdisch, L, 1993) |
| "Tamoxifen therapy for breast cancer is linked with endometrial hyperplasia, polyps, adenomyosis, adenomatous hyperplasia, and adenocarcinoma." | ( Deligdisch, L, 1993) |
| "A total of 18 women with advanced breast cancer were treated with sulofenur [LY186641; N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)-urea], a diarylsulfonylurea that has broad-spectrum activity against a number of murine mammary tumour xenografts." | ( Button, D; Nicolson, MC; Powles, TJ; Smith, IE; Talbot, DC; Walling, J, 1993) |
| "Forty-six patients with metastatic breast cancer were treated with the combination of carboplatin and etoposide." | ( Crown, J; Currie, V; Gilewski, T; Hakes, T; Hudis, C; Lebwohl, D; Reichman, B; Seidman, A; Surbone, A; Yao, TJ, 1993) |
| "A group of primary breast cancer patients was randomised to receive either tamoxifen (n = 59) or placebo (n = 44) treatment in the interval between clinic and surgery (median 21 days)." | ( Anderson, E; Clarke, RB; Howell, A; Jones, LJ; Laidlaw, IJ, 1993) |
| "Women with breast cancer should be informed of treatment options and the advantages and disadvantages of each choice as it applies to their individual circumstance." | ( Guinee, VF; Shallenberger, R; Singletary, SE, 1993) |
| "Fifty-one women with advanced breast cancer responding to therapy were treated with escalating doses of CSA (1." | ( Altomonte, V; Beveridge, RA; Davidson, NE; Farmer, ER; Huelskamp, AM; Kennedy, MJ; Vogelsang, GB, 1993) |
| "Case records of 449 patients with breast carcinoma treated during 1983-1984 were reviewed." | ( Amma, NS; Cherian, T; Nair, KS; Nair, MK; Padmakumari, G; Sankaranarayanan, R; Varghese, C, 1993) |
| "Early detection of breast cancer by breast self-examination and physician breast examination should be encouraged in developing countries to improve treatment results in breast cancer." | ( Amma, NS; Cherian, T; Nair, KS; Nair, MK; Padmakumari, G; Sankaranarayanan, R; Varghese, C, 1993) |
| "A total of 165 women with breast cancer from 14 Canadian centers who were about to receive this chemotherapy for the first time were randomly assigned to receive either ondansetron (n = 85) or dexamethasone plus metoclopramide (n = 80), a widely used, standard antiemetic regimen." | ( Latreille, J; Levitt, M; Lofters, WS; Perrault, DJ; Potvin, M; Rayner, HL; Warner, E; Warr, D; Wilson, KS; Yelle, L, 1993) |
| "For women with breast cancer who are being treated with cyclophosphamide, methotrexate, and fluorouracil, the efficacy of dexamethasone and metoclopramide in controlling nausea and vomiting equaled or exceeded that of ondansetron." | ( Latreille, J; Levitt, M; Lofters, WS; Perrault, DJ; Potvin, M; Rayner, HL; Warner, E; Warr, D; Wilson, KS; Yelle, L, 1993) |
| "Tamoxifen is widely used to treat breast carcinoma in postmenopausal women." | ( Hall, DA; Hulka, CA, 1993) |
| "In premenopausal early-stage breast cancer, chemotherapy adds substantial clinical benefit at a modest cost." | ( Hillner, BE; Smith, TJ, 1993) |
| "A series of 105 patients with operable breast cancer previously entered in the WMOA adjuvant therapy trials were reviewed in order to assess methods of treatment on relapse and subsequent patterns of relapse and survival, related to previous adjuvant therapy." | ( de Takats, PG; Dunn, JA; Kerr, DJ; Morrison, JM, 1993) |
| "51 patients with stage IIIB and IV breast cancer entered a prospective phase II study of combination chemotherapy that consisted of mitoxantrone (8 mg/m2) day 1, methotrexate (25 mg/m2) day 1, vincristine (1 mg/m2) day 2 and carboplatin (250 mg/m2) day 2 (MIMOC) given in a 3-weekly schedule." | ( Bacoyiannis, C; Bafaloukos, D; Daliani, D; Karabelis, A; Karvounis, N; Klinaki, A; Kosmidis, P; Milonakis, N; Samonis, G, 1993) |
| "TAM-stimulated growth of MCF-7 human breast tumors has been observed in athymic mice after prolonged treatment with TAM." | ( Jordan, VC; Langan-Fahey, SM; McCague, R; Parker, CJ; Wolf, DM, 1993) |
| "Fifty-three patients with metastatic breast cancer, pretreated and/or with a low performance status, were treated with 25 mg/m2/week of the drug." | ( Archili, C; Barni, S; Crispino, S; Lissoni, P; Paolorossi, F; Tancini, G, 1993) |
| "Clinical trials in patients with breast cancer have yielded conflicting results as to its efficacy in the treatment of this malignancy." | ( Alvarez, X; Goodrich, KH; Holcombe, RF, 1993) |
| "153 women with advanced breast cancer were randomly allocated for treatment with SMF [prednimustine (Sterecyt) + methotrexate + 5-fluorouracil, 83 patients] or CMF (cyclophosphamide+methotrexate+5-fluorouracil, 70 patients)." | ( Bunting, JS; Hope-Stone, H; Keen, CW; Nilsson, B; Parmar, H; Roberts, JT; Slater, A; Termander, B; Yosef, H, 1993) |
| "The observed activity of cisplatin in breast cancer and its unattractive toxicity profile in palliative treatment warranted further study of platinum analogues in this disease." | ( Clavel, M; Dodion, P; Gundersen, S; Kaye, SB; Renard, J; Smyth, JF; Vermorken, JB, 1993) |
| "The current status of breast cancer chemotherapy in Japan was examined and compared with internationally accepted standard therapy, by reviewing the previous treatment of patients with advanced or metastatic breast cancer who had been referred to the National Cancer Center Hospital East." | ( Abe, K; Fujii, H; Igarashi, T; Imoto, S; Itoh, K; Ohtsu, T; Sasaki, Y; Wakita, H, 1995) |
| "In menopausal patients with breast cancer who receive tamoxifen therapy, transvaginal sonography may show an abnormal endometrium." | ( Achiron, R; Frenkel, Y; Goldenberg, M; Horovitz, A; Lipitz, S; Mashiach, S; Sivan, E, 1995) |
| "Two female breast cancer patients who received combined tamoxifen and tegafur as postsurgical adjuvant therapy developed severe hepatotoxicity after being treated for three and eight months, respectively." | ( Abe, J; Hirayama, C; Maruyama, S; Matsui, K; Tanaka, J, 1995) |
| "The aim of the breast cancer study is prevention of a contralateral primary lesion in women already treated for breast cancer; the aim of the basal cell carcinoma study is prevention of recurrences or new occurrence after surgical resection; and the aim of the oral leukoplakia study is prevention of recurrences and new occurrence after CO2 laser resection." | ( Boracchi, P; Camerini, T; Chiesa, F; Costa, A; De Palo, G; Del Vecchio, M; Formelli, F; Marubini, E; Nava, M; Veronesi, U, 1995) |
| "28 patients with recurrent advanced breast cancer were treated with a salvage regimen consisting of vincristine, epirubicin and ifosfamide/mesna (VIE)." | ( Gurney, H; Harnett, P; Kefford, R; Stuart-Harris, R, 1995) |
| "Fifteen patients with breast cancer and skeletal metastases who had bone pain refractory to opioid analgesics and who were not eligible for or had not responded to local field radiotherapy, were treated with strontium-89." | ( Alonso, C; Berna, L; Carrio, I; Estorch, M; Ferré, J; Torres, G, 1995) |
| "Discodermolide-treated breast carcinoma cells displayed spectacular rearrangement of the microtubule cytoskeleton, including extensive microtubule bundling." | ( Day, BW; Gunasekera, SP; Hamel, E; Kowalski, RJ; Lin, CM; Longley, RE; Rosenkranz, HS; ter Haar, E, 1996) |
| "Fifty-five patients with metastatic breast cancer who had been previously treated with a median of two prior chemotherapy regimens were entered onto the study." | ( Barnes, CS; Cowan, KH; Denicoff, AM; Goldspiel, BR; Gossard, MR; Kohler, DR; McCabe, M; Noone, MH; O'Shaughnessy, JA; Tolcher, AW; Zujewski, J, 1996) |
| "The promoter effect of oestradiol in breast cancer, the higher risk of breast cancer in infertile nulliparous women and the increased use of treatments to include ovulation would suggest that the risk of cancer after this type of treatment might be affected." | ( Avril, A; Bussières, E; Gaillard, F; Jourdain, O; Mauriac, L; Stockle, E, 1995) |
| "Combination chemotherapy for metastatic breast cancer will palliate symptoms in the majority of patients but only a small percentage will have prolonged survival." | ( Beith, JM; Bell, D; Levi, JA; Snyder, RD; Tattersall, MH; Wheeler, H, 1995) |
| "Patients with metastatic breast cancer commenced chemotherapy with a starting dose of epirubicin of 120 milligram per metre squared (mg/m2) and cyclophosphamide 600 mg/m2." | ( Beith, JM; Bell, D; Levi, JA; Snyder, RD; Tattersall, MH; Wheeler, H, 1995) |
| "Patients with early breast cancer (T1/T2) had a complete clinical resolution in 41% (16/39) of cases after MMM and in 20% (7/35) of cases following endocrine therapy compared with 14% (2/14) advanced tumours (T3/T4) following MMM and (0/12) following endocrine therapy." | ( Coombes, RC; Corbishley, C; Ford, HT; Gazet, JC; Griffin, M; Lowndes, S; Makinde, V; Quilliam, J; Sutcliffe, R, 1996) |
| "Patients with early-stage breast cancer who are at substantial risk for systemic metastases are increasingly treated with breast-conserving therapy and adjuvant chemotherapy." | ( Come, SE; Gelman, RS; Harris, JR; Hayes, DF; Henderson, IC; Recht, A; Shulman, LN; Silver, B, 1996) |
| "Older women with metastatic breast cancer are good candidates for endocrine therapy." | ( Muss, HB, 1996) |
| "When considering the natural history of breast cancer from screening, evaluation of suspicious lesions, primary therapy, staging, adjuvant therapy, monitoring, metastatic disease, and palliative care, it is striking that most cost-effectiveness studies have been related to screening or the use of adjuvant drug therapies." | ( Hillner, BE, 1996) |
| "A total of 2,795 women with early breast cancer, stage I to IIIA, were randomized onto a trial (European Organization for Research and Treatment of Cancer [EORTC] 10854) to compare surgery followed by one course of perioperative chemotherapy versus surgery alone." | ( Clahsen, PC; Delozier, T; Floiras, JL; Julien, JP; Mignolet, FY; Sahmoud, TM; van de Velde, CJ, 1996) |
| "Thirty-seven women with metastatic breast cancer were treated." | ( Bowling, K; Chen, TL; Donehower, RC; Kennedy, MJ; Noe, DA; Rowinsky, EK; Sartorius, S; Zahurak, ML, 1996) |
| "Forty-nine patients with poor-prognosis breast cancer, non-Hodgkin's lymphoma (NHL), or ovarian cancer were treated with escalating doses of paclitaxel infused over 24 hours, followed by CPA (5,625 mg/m2 intravenously over 1 hour in three divided doses) and cDDP (165 mg/m2 intravenously as a continuous infusion over 72 hours) and AHPCS." | ( Arron, J; Bearman, SI; Cagnoni, PJ; Day, T; Dufton, C; Hami, L; Jones, RB; Martinez, C; Matthes, S; Purdy, MH; Shpall, EJ; Stemmer, SM; Taffs, S, 1996) |
| "Forty-six patients with metastatic breast cancer received the following regimen as first- or second-line treatment: paclitaxel 135 mg/m2 by 1-hour intravenous (i." | ( Blum, JL; Greco, FA; Hainsworth, JD; Jones, SE; Mennel, RG, 1996) |
| "Adjuvant therapy for early breast cancer is effective but may be toxic." | ( Bernhard, J; Castiglione-Gertsch, M; Coates, AS; Crivellari, D; Forbes, JF; Gelber, RD; Goldhirsch, A; Hürny, C; Peterson, HF; Rudenstam, CM; Senn, HJ; Simoncini, E, 1996) |
| "International Breast Cancer Study Group trial VI assessed adjuvant chemotherapy in 1475 premenopausal and perimenopausal patients, and trial VII assessed adjuvant tamoxifen or chemoendocrine therapy in 1212 postmenopausal patients with node-positive breast cancer." | ( Bernhard, J; Castiglione-Gertsch, M; Coates, AS; Crivellari, D; Forbes, JF; Gelber, RD; Goldhirsch, A; Hürny, C; Peterson, HF; Rudenstam, CM; Senn, HJ; Simoncini, E, 1996) |
| "Here we demonstrate that treatment of breast carcinoma MCF-7 cells with PGA2 leads to G1 arrest associated with a dramatic decrease in the levels of cyclin D1 and cyclin-dependent kinase 4 (cdk4) and accompanied by an increase in the expression of p21." | ( Chrest, FJ; Gorospe, M; Holbrook, NJ; Liu, Y; Xu, Q, 1996) |
| "Nineteen patients with metastatic breast cancer and six patients with refractory non-Hodgkin's lymphoma were initially treated with etoposide (VP-16) (2 gm/m2) and granulocyte-colony stimulating factor (G-CSF)." | ( Blume, KG; Chao, NJ; Hoyle, CF; Kusnierz-Glaz, CR; Long, GD; Negrin, RS; Schriber, JR, 1995) |
| "Nine patients with advanced breast cancer were referred for visual symptoms after high-dose chemotherapy with cisplatin, cyclophosphamide, and carmustine and autologous bone marrow transplantation without total body irradiation or local head irradiation." | ( Jaffe, GJ; Khawly, JA; Peters, WP; Petros, W; Rubin, P, 1996) |
| "We describe a patient with metastatic breast cancer and liver dysfunction who had severe mucocutaneous toxicity after administration of a standard dose of paclitaxel." | ( Buzdar, A; Cohen, PR; Dhingra, K; Gagel, R; Holmes, F; Payne, JY, 1996) |
| "Patients with metastatic breast cancer were randomly assigned to receive as second-line chemotherapy either MMM (mitomycin 8 mg/m2 day 1; mitoxantrone 8 mg/m2 days 1 and 22; methotrexate 35 mg/m2 days 1 and 22) alone or in combination with filgrastim (5 micrograms/kg s." | ( Blomqvist, C; Jantunen, I; Kellokumpu-Lehtinen, P; Maiche, A; Muhonen, T; Pertovaara, H; Pyrhönen, S; Voutilainen, L, 1996) |
| "Women with stage IV breast cancer who had achieved a CR or PR during conventional chemotherapy were enrolled in a phase II trial of high-dose cyclophosphamide 7500 mg/m2 and thiotepa 675 mg/m2 (C+T) followed within 180 days by high-dose melphalan (M) 140 mg/m2." | ( Bitran, JD; Hanauer, S; Harris, E; Johnson, L; Kempler, J; Klein, L; Martinec, J; Samuels, B; White, W, 1996) |
| "Women treated with tamoxifen for breast cancer are at increased risk of endometrial cancer." | ( Arredondo, MA; Cuenca, RE; Edge, SB; Giachino, J; Hempling, R, 1996) |
| "The results of tamoxifen treatment in breast carcinoma override the risk of developing endometrial carcinoma." | ( Bar-Am, A; Daniel, Y; Inbar, M; Lessing, JB; Peyser, MR, 1996) |
| "Although breast cancer is perceived to be relatively chemosensitive, cytotoxic drug therapy only leads to cure in the adjuvant setting." | ( Bowman, A; Cameron, DA; Gregory, WM; Leonard, RC, 1996) |
| "Two hundred forty-nine patients with N+ breast cancer, recruited from eight French cancer centers, were randomized to receive 12 monthly cycles of adjuvant chemotherapy, either CMF (n = 112) or doxorubicin, vincristine, cyclophosphamide, and fluorouracil (AVCF) (n = 136)." | ( Belpomme, D; Chollet, P; Delgado, M; di Palma, M; Fargeot, P; Fumoleau, P; Guerrin, J; Hill, C; Ithzaki, M; Le Mevel, B; Mathé, G; Metz, R; Misset, JL; Plagne, R, 1996) |
| "Paclitaxel in breast cancer needs further evaluation in large trials that use combination chemotherapy and involve earlier disease stages." | ( Bonneterre, J; Bontenbal, M; Catimel, G; Conte, P; Fumoleau, P; Gelmon, K; Klaassen, U; Nabholtz, JM; Namer, M; Spielmann, M; Winograd, B, 1996) |
| "Thirty-five postmenopausal women with breast carcinoma receiving tamoxifen therapy underwent pelvic MR imaging." | ( Ascher, SM; Bae, CJ; Barnes, WA; Johnson, JC; Patt, RH; Zeman, RK, 1996) |
| "Five patients with ductal breast cancer were studied using simultaneous administration of 99Tcm-labelled BW250/183 and 131I-labelled B72." | ( Jekunen, AP; Kairemo, KJ; Korppi-Tommola, ET; Niskanen, EO; Savolainen, SE, 1996) |
| "33 women with advanced breast cancer resistant to anthracyclines were treated with paclitaxel 175 mg/m2 in a 3 h infusion every 3 weeks." | ( Athanassiades, A; Bafaloukos, D; Dombros, N; Fountzilas, G; Giannakakis, T; Karakousis, K; Kosmidis, P; Skarlos, D, 1996) |
| "Twenty seven Patients with advanced breast cancer were treated with CAC (carboplatin, adriamycin, cyclophosphamide) regimen." | ( Feng, F; Zhang, P; Zhou, J, 1995) |
| "A 70-year-old female with advanced breast cancer was admitted to our department for treatment of hypercalcemia." | ( Akazawa, K; Inoue, T; Shiba, E; Takai, S, 1996) |
| "In hormone-sensitive breast cancer, anti-tumor activity is maximized by treatment with a combination of RU-486 and estrogen antagonists such as tamoxifen or luteinizing hormone releasing hormone analogues." | ( Figg, WD; Sartor, O, 1996) |
| "The T61 breast cancer xenograft described here provides an experimental model of the effects of estrogen treatment at a molecular level." | ( Brunner, N; Cullen, K; Spang-Thomsen, M, 1996) |
| "A total of 1696 patients with early breast cancer, 1286 of whom were treated with either CMF-based adjuvant chemotherapy (n = 410), tamoxifen (n = 656) or with a combination of the two (n = 220) were considered for the present analysis." | ( Boccardo, F; Casella, C; Perrotta, A; Rubagotti, A, 1996) |
| "Our study of 15 patients treated for breast carcinoma with tamoxifen found that papillary serous carcinoma was the most common tumor in this group of patients." | ( Malpica, A; Mitchell, MF; Silva, EG; Tornos, C, 1995) |
| "A 55-year-old woman with recurrent breast cancer treated with sequential mastectomies, chemo-and hormonal therapy of UFT, CPM and TAM, achieved remission." | ( Kimura, M; Koida, T; Sekihara, M, 1996) |
| "Among patients with breast cancer, tumors that contain estrogen receptors (ER) are associated with improved survival and better response to hormone therapy than those not expressing these receptors." | ( August, DA; Rock, CL; Ruffin, MT; Saxe, GA; Schottenfeld, D, 1996) |
| "Treatment of Hs578T breast cancer cells with long chain saturated fatty acids (0." | ( Hardy, RW; Jo, H; McDonald, JM; Wickramasinghe, NS, 1996) |
| "Metastatic breast cancer in elderly patients is less often treated with chemotherapy than in younger patients because of concerns related to toxic effects and tolerance." | ( Buzdar, AU; Frye, DK; Hortobagyi, GN; Ibrahim, NK; Walters, RS, 1996) |
| "Patients with metastatic breast carcinoma who are older than 65 years tolerate the acute side effects of doxorubicin-based combination chemotherapy as well as the younger age group." | ( Buzdar, AU; Frye, DK; Hortobagyi, GN; Ibrahim, NK; Walters, RS, 1996) |
| "A 49-year-old female with breast cancer after mastectomy and chemotherapy was found suffering from diabetes insipidus and panhypopituitarism syndrome." | ( Castillo Pallarés, FJ; Chesa-Jiménez, J; de Avila, CR; Ruiz Hernández, G; San Martín Ciges, E, 1996) |
| "Because of the increased risk of breast cancer for infertile nulliparous women, the suspected promoter role of estradiol in mammary carcinogenesis and the high frequency of ovulation inducer treatments, it was interesting to focus on the risk of breast cancer after such a treatment." | ( Avril, A; Bussieres, E; Dallay, D; Jourdain, O; Lajus, C; Mauriac, L; Quenel, N; Roux, D, 1996) |
| "Treatment of SKBr3 human breast carcinoma cells with the benzoquinoid ansamycin, geldanamycin, rapidly depletes p185c-erbB-2 protein-tyrosine kinase." | ( Chavany, C; Mimnaugh, EG; Neckers, L, 1996) |
| "To determine whether, when primary breast cancer is treated by local excision supported by systemic therapy appropriate to the oestrogen receptor status (ER) of the tumour, local radiotherapy can be avoided." | ( Everington, D; Forrest, AP; George, WD; Harnett, AN; McArdle, CS; Prescott, RJ; Smith, DC; Stewart, HJ, 1996) |
| "After local excision of a primary breast cancer, we conclude that radiotherapy to the residual breast tissue is advisable even when selective adjuvant systemic therapy is given." | ( Everington, D; Forrest, AP; George, WD; Harnett, AN; McArdle, CS; Prescott, RJ; Smith, DC; Stewart, HJ, 1996) |
| "Treatment of MCF-7 human breast cancer cells with 10 nM 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) did not decrease prolactin receptor (PRLR) binding." | ( Lu, YF; Safe, S; Sun, G; Wang, X, 1996) |
| "It has been reported that breast tumors that overexpress c-erbB-2/neu are less responsive to certain adjuvant chemotherapy regimens than those that express a normal amount of the gene product." | ( Hung, MC; Li, J; Liu, B; Tan, M; Wang, SS; Yu, D, 1996) |
| "Sixty chemotherapy-naive breast cancer patients of 30 to 71 years in age, P." | ( Ionta, MT; Massidda, B, 1996) |
| "However, as the S-phase fraction in breast cancer is generally low, the variation between the different measurements is too large; therefore, the S-phase fraction is not a suitable indicator of response to treatment." | ( Breedijk, AJ; Bruning, PF; Maas, RA; Peterse, JL, 1996) |
| "The incurability of metastatic breast cancer with conventional chemotherapy has prompted many units to investigate the role of high dose chemotherapy and autologous stem cell rescue in patients with advanced or poor risk primary disease." | ( Bass, G; Flower, CD; Hood, IM; Lee, MA; Mahendra, P; Marcus, RE; Mewar, D; Wilson, CB, 1996) |
| "However, many survivors of breast cancer experience debilitating symptoms as a consequence of oestrogen deficiency and over the long term are at an increased risk of dying prematurely from cardiovascular disease or a hip fractures because they are denied hormone replacement therapy." | ( Sands, R; Studd, J, 1996) |
| "In 50 consecutive node-positive breast cancer patients, serial coagulation studies (fibrinogen method of Clauss, antithrombin III, protein C amidolytic methods, D dimer enzyme-linked immunoadsorbent assay [ELISA] techniques, and plasminogen activator inhibitor [PAI] activity u-PA inhibition test) and impedance plethysmography (IPG) for screening of deep vein thrombosis (DVT) were performed preoperatively and postoperatively, before each of six cycles of adjuvant chemotherapy (60 mg/m2 epirubicin and 600 mg/m2 cyclophosphamide) and 3 months thereafter." | ( Dietrich, M; Heilmann, L; Hommel, G; von Tempelhoff, GF, 1996) |
| "In patients with advanced breast cancer responsive to cytotoxic chemotherapy, tumor-cell contamination is not increased in PBPC collected after 5 or 7 days priming with G-CSF and appears similar to that seen when PBPC are primed with cyclophosphamide followed by GM-CSF." | ( Davidson, NE; Davis, JM; Huelskamp, AM; Kahn, DJ; Kennedy, MJ; Moss, TJ; Noga, SJ; Passos-Coelho, JL; Ross, AA, 1996) |
| "Of patients with stage IV breast carcinoma who had not received prior chemotherapy for advanced disease, objective responses occurred in nine of 20 (45%), and the median response duration was 5 months." | ( Lazarus, H; Malik, U; Robert, N; Sarta, C; Silverman, P; Sparano, JA; Venkatraj, U, 1996) |
| "Primary breast cancer samples and matched asynchronous recurrences were studied from 50 patients who had not received any adjuvant therapy." | ( Helin, H; Holli, K; Isola, J; Kononen, J; Kuukasjärvi, T, 1996) |
| "Loss of ER expression in recurrent breast cancer should be considered as a cause for poor response to endocrine therapy in primarily ER-positive patients." | ( Helin, H; Holli, K; Isola, J; Kononen, J; Kuukasjärvi, T, 1996) |
| "We report that butyrate treatment of breast cancer MCF-7 cells causes a nonreversible growth inhibition by inducing apoptosis in a time- and dose-dependent manner." | ( Kumar, R; Mandal, M, 1996) |
| "Node-negative breast cancers are considered to comprise a subgroup which is amenable to cure with local-regional therapy alone." | ( Bonadonna, G; Valagussa, P; Zambetti, M, 1996) |
| "Forty-eight postmenopausal breast cancer patients receiving 20 mg/day tamoxifen for 6-84 months (mean 29) and 38 control breast cancer patients without any hormonal treatment were examined by transvaginal ultrasonography and endometrial biopsy." | ( Arvas, M; Beşe, N; Beşe, T; Demirkiran, F; Kösebay, D; Mandel, N, 1996) |
| "This is a retrospective analysis of breast cancer patients given adjuvant 'CMF' cytotoxic chemotherapy." | ( Rees, GJ, 1995) |
| "As the conservative management of breast cancer is now widely adopted, oncologists and physicians should be aware of such rare side effects due to radiation therapy." | ( Amanti, C; Di Paola, M; Folliero, G; Tombolini, V; Zurlo, A, 1995) |
| "Seventeen patients with advanced breast cancer were treated with neoadjuvant intraarterial chemotherapy with high dose epirubicin." | ( Kikkawa, N; Shin, E; Takatsuka, Y, 1996) |
| "We treated patients with advanced breast cancer with moderately high-dose doxorubicin and cylophosphamide and GM-CSF." | ( Boven, E; Hoekman, K; Honkoop, AH; Pinedo, HM; van Groeningen, CJ; Vermorken, JB; Wagstaff, J, 1996) |
| "A rare case of breast carcinoma metastasizing to the endometrial and endocervical mucosa during tamoxifen treatment is presented." | ( Bukovsky, I; Czernobilsky, B; David, A; Lifschitz-Mercer, B; Maymon, R; Schneider, D, 1996) |
| "Although metastatic breast cancer is an incurable disease, chemotherapy has had an impact on survival since the use of anthracycline drugs has become widespread." | ( Trudeau, ME, 1996) |
| "Twenty-one advanced breast cancer patients, with or without previous adjuvant CMF chemotherapy, were included." | ( Bosnjak, SM; Mitrović, LB; Nesković-Konstantinović, ZB; Radulović, SS, 1996) |
| "110 patients with advanced breast cancer previously untreated by chemotherapy were randomized to receive cyclophosphamide and vincristine, together with either doxorubicin 50 mg/m2 i." | ( Campbell, IR; Green, JA; Kelly, V; Slater, AJ, 1996) |
| "It has been demonstrated, both in breast cancer cell lines and in metastatic breast cancer patients with cutaneous lesions that could be biopsied, that treatment with interferon beta (IFN-B) can increase expression of both estrogen (ER) and progesterone receptors (PgR)." | ( Campora, E; Conte, PF; Giannessi, PG; Naso, C; Pronzato, P; Repetto, L; Rosso, R; Spinelli, I; Vigani, A, 1996) |
| "Ten patients with metastatic breast cancer received paclitaxel 125 mg/m2 over 24 hours either immediately before or after doxorubicin 48 mg/m2 over 48 hours as the initial chemotherapy treatment." | ( Booser, DJ; Buzdar, AU; Fraschini, G; Holmes, FA; Hortobagyi, GN; Madden, T; Newman, RA; Theriault, RL; Valero, V; Walters, RS; Willey, J, 1996) |
| "Adjuvant chemotherapy for breast cancer has been the routine practice in the past decade." | ( Buzdar, AU; Diamandidou, E; Frye, D; Hortobagyi, GN; Smith, TL; Witjaksono, M, 1996) |
| "A group of 90 breast cancer patients undergoing chemotherapy were assessed prospectively to estimate the prevalence of acute (post-treatment) and anticipatory emesis in the 1990s." | ( Casado, A; Diaz-Rubio, E; Fernández-Marcos, A; López Martin, JA; Martín, M; Rodriguez-Lescure, A; Sanchez, JJ, 1996) |
| "The influence of Ukrain on breast cancer was studied in ten women and monitored in each patient by clinical examination, mammography, ultrasonography, histopathology and immunofluorescence in the tissue material obtained after radical mastectomy performed ten days after discontinuation of the treatment." | ( Brzosko, WJ; Fomin, KA; Nowicky, JW; Uglyanica, KN, 1996) |
| "A recurrent breast cancer with lung metastases was treated with the new anticancer drug Ukrain." | ( Kadan, P; Korsh, OB; Melnyk, A, 1996) |
| "Thirty women with advanced breast cancer who had undergone at most one prior adjuvant chemotherapy regimen, were treated at three different dose levels with doxorubicin (50, 60 and 60 mg/m2) followed 30 minutes later by paclitaxel (155, 175 and 200 mg/m2, respectively) every 3 weeks." | ( Boesgaard, M; Dombernowsky, P; Gehl, J; Paaske, T; Vittrup Jensen, B, 1996) |
| "The patients with node-positive breast cancer who have a higher likelihood of gaining benefit from adjuvant therapy are those with tumours with cyclin D1 nuclear expression, small size and less than 3 metastatic nodes." | ( Barbareschi, M; Barbazza, R; Bevilacqua, P; Bonoldi, E; Boracchi, P; Buttitta, F; Caffo, O; Dalla Palma, P; Gasparini, G; Marchetti, A; Pelosio, P; Verderio, P, 1996) |
| "Forty-six patients with metastatic breast carcinoma were treated with tamoxifen, 10 mg orally, twice a day for 28 days; etoposide, 100 mg/m2, on Days 1-3; mitoxantrone, 10 mg/m2, on Day 1; and cisplatin, 30 mg/m2, on Days 1 and 2." | ( Arvizu, C; Conzen, SD; Kaufman, PA; LeMarbre, P; Maurer, LH; Mills, LE; Mott, LA, 1996) |
| "Adequate radiotherapy for breast cancer can be safely administered after high-dose CTC with autologous PBSC support." | ( Baars, JW; Beijnen, JH; Borger, JH; Richel, DJ; Rodenhuis, S; Rutgers, EJ; Schaake-Koning, CC; Schornagel, JH; van der Wall, E; van Zandwijk, N, 1996) |
| "In patients with node-positive breast cancer adjuvant chemotherapy with cyclophosphamide+ methotrexate+fluorouracil has been reported to improve survival in comparison with patients who are not given this treatment." | ( Becagli, P; Messori, A; Tendi, E; Trippoli, S, 1996) |
| "Chemotherapy for breast cancer is given on the basis of empirical information from clinical trials, an approach which falls to take into account the known heterogeneity of chemosensitivity between patients." | ( Andreotti, PE; Bruckner, HW; Cree, IA; Dewar, JA; Hunter, EM; James, EA; Kurbacher, CM; Preece, PE; Subedi, AM; Sutherland, LA; Untch, M, 1996) |
| "Ten patients with metastatic breast cancer and no prior hormonal therapy exposure received octreotide at 150 micrograms subcutaneously thrice daily." | ( Hatfield, AK; Ingle, JN; Kardinal, CG; Krook, JE; Suman, VJ, 1996) |
| "Three women with breast carcinoma were treated with combination chemotherapy, including cyclophosphamide, 5-fluorouracil, and methotrexate, after mastectomy." | ( Kramer, N; Leitner, SP; Michaelson, RA; Rosenstein, ED, 1996) |
| "Treatment of MCF-7 human breast cancer cells with 10 nM 17 beta-estradiol (E2) resulted in a 2-fold induction of heat shock protein (Hsp) 27 mRNA levels, and this response persisted for up to 24 h." | ( Duan, R; Porter, W; Safe, S; Wang, F; Wang, W, 1996) |
| "Operable breast cancer patients with positive or negative axillary lymph nodes, will have a 20% decrease in their annual odds of death at 10 years with appropriate systemic therapy." | ( Piccart, MJ; Roy, JA, 1996) |
| "Adjuvant chemotherapy for breast cancer, although generally safe and of proven benefit, can have severe complications." | ( Anderson, CM; Hortobagyi, GN; Walters, RS, 1996) |
| "Treating breast cancer cells with 400 microM mimosine for 24 h inhibited cyclin E- and cyclin A-associated kinase activity by 85% or more, although immunoblots using anti-cyclin A, cyclin E, cdc2, and cdk2 antibodies showed that these key subunits were still present in the cells at pretreatment levels." | ( Green, SL; Kulp, KS; Vulliet, PR, 1996) |
| "One hundred sixty-two advanced breast cancer patients were randomized to receive epirubicin-based chemotherapy with or without dexrazoxane." | ( Bellina, RC; Bruzzi, P; Carnino, F; Conte, PF; Cyrus, P; Del Mastro, L; Gallo, L; Garrone, O; Guelfi, M; Lionetto, R; Michelotti, A; Molea, N; Pronzato, P; Rosso, R; Testore, F; Tibaldi, C; Venturini, M; Vinke, J, 1996) |
| "When human breast cancer T47D cells were treated with all-trans-retinoic acid (RA), the RA 4- and 18-hydroxylase activities were induced in microsomes in a time-dependent manner, indicating that these cells readily metabolized RA into more polar compounds, such as all-trans-4-hydroxy-RA and all-trans-18-hydroxy-RA." | ( Choi, JH; Han, IS, 1996) |
| "Women with stage IV breast cancer who were receiving cytotoxic chemotherapy and had at least one lytic bone lesion were given either placebo or pamidronate (90 mg) as a two-hour intravenous infusion monthly for 12 cycles." | ( Blayney, D; Hortobagyi, GN; Knight, RD; Lipton, A; Porter, L; Seaman, J; Simeone, JF; Sinoff, C; Theriault, RL; Wheeler, H, 1996) |
| "AcF is highly active in breast cancer with acceptable toxicities and can be used before alkylating agent-based high-dose therapy." | ( Cameron, DA; Gabra, H; Lee, LE; Leonard, RC; Mackay, J, 1996) |
| "Current treatments for metastatic breast cancer are not associated with significant survival benefits despite response rates of over 50%." | ( Anderson, E; Anderson, T; Cameron, DA; Chetty, U; Craig, J; Dixon, M; Gabra, H; Hawkins, A; Jack, W; Kunkler, I; Lee, L; Leonard, R; Leonard, RC; MacKay, J; Matheson, L; Miller, W; Parker, AC, 1996) |
| "A total of 14 pts with advanced breast cancer pretreated with P were entered into the study." | ( Dittrich, C; Fazeny, B; Grisold, W; Huber, H; Meryn, S; Zifko, U, 1996) |
| "Postmenopausal breast cancer patients treated with tamoxifen have been found to have a high incidence of ovarian tumors." | ( Altaras, MM; Beyth, Y; Cohen, I; Shapira, J; Tepper, R; Yigael, D; Zalel, Y, 1997) |
| "Thirty-two patients with advanced breast cancer have been treated with epirubicin 90 mg/m2, immediately followed by paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) infused over 3 hours, every 21 days." | ( Baldini, E; Conte, PF; Da Prato, M; Gennari, A; Gentile, A; Giannessi, PG; Michelotti, A; Salvadori, B; Tibaldi, C, 1996) |
| "Despite its intensive use in adjuvant breast cancer therapy for more than 30 years, the exact mechanisms of action of tamoxifen have not yet been fully characterized." | ( Bracke, M; Bruyneel, E; Castronovo, V; Charlier, C; Lechanteur, C; Mareel, M, 1996) |
| "In 42 patients with locally advanced breast cancer treated with neoadjuvant chemotherapy followed by surgery and radiation therapy, the effects of chemotherapy on tumor architecture, morphometric nuclear and nucleolar characteristics, DNA ploidy, proliferation index measured by mitotic activity index, expression of differentiation antigens, and microvessel density were studied." | ( De Jong, JS; Hoekman, K; Honkoop, AH; Linn, SC; Pinedo, HM; van Diest, PJ; Verheul, HM; Wagstaff, J, 1997) |
| "Sixteen patients with advanced breast cancer were treated with 4 cycles of dose escalating FAC chemotherapy (5-fluorouracil, adriamycin, cyclophosphamide) each followed by 10 micrograms/kg/d G-CSF for 13 days." | ( Baumann, I; de Wynter, E; Dexter, TM; Howell, A; Lange, C; Luft, T; Swindell, R; Testa, NG; Van Hoeff, ME, 1996) |
| "152 of 211 breast cancer patients received post-operatively a combination chemotherapy including the anthracycline analog mitoxantrone, while 59 patients were treated with conventional CMF therapy." | ( Fehm, T; Jäger, W; Katalinic, A; Maimonis, P; Teramoto, Y; Weitz, S, 1997) |
| "In women with breast cancer, adjuvant therapy with tamoxifen reduces relapse and improves overall survival." | ( Isaksson, E; von Schoultz, E; Wilking, N, 1997) |
| "A series of 35 breast cancer patients receiving adjuvant chemotherapy were consecutively assigned either to a scalp cooling regimen (19 patients) or to an ambient temperature regimen (16 patients)." | ( Chaitchik, S; Inbar, M; Kalmus, Y; Kalmus, Z; Ron, IG, 1997) |
| "Radiotherapy for locally advanced breast carcinoma, following mastectomy, axillary dissection, and adjuvant systemic therapy, results in fewer locoregional but more distant recurrences at first relapse." | ( Falkson, G; Gilchrist, KW; Neuberg, D; Olson, JE; Pandya, KJ; Richter, MP; Solin, LJ; Tormey, DC; Veeder, M, 1997) |
| "All patients had advanced metastatic breast cancer and have been extensively pretreated with chemotherapy (28 patients), radiotherapy (13 patients), and hormonotherapy (24 patients)." | ( Panagos, GE, 1997) |
| "Patients with progressive metastatic breast cancer who had previously received other chemotherapy were treated with docetaxel 75 mg/m2 or 100 mg/m2 given as a one hour infusion every three weeks." | ( Davison, JD; Francis, PA; Ganju, V; Michael, M; Millward, MJ; Rischin, D; Shapiro, JD; Toner, GC, 1997) |
| "Twenty-eight patients with metastatic breast cancer were treated with doxorubicin (90 mg/m2) and cyclophosphamide (1000 mg/m2) at 3-week intervals." | ( Boven, E; Giaccone, G; Hoekman, K; Honkoop, AH; Pinedo, HM; van Groeningen, CJ; Vermorken, JB; Wagstaff, J, 1996) |
| "In metastatic breast cancer patients who have had prior exposure to anthracyclines, single agents induce less than 15% and combination chemotherapy less than 20%-30% of objective responses." | ( Achterrath, W; Becher, R; Eberhardt, W; Harstrick, A; Hayungs, J; Klaassen, U; Losch, M; Seeber, S; Stahl, M; Vanhoefer, U; Wilke, H, 1996) |
| "Forty-three patients with advanced breast cancer pretreated with 1-5 (median 2) different chemotherapy regimens were entered into this phase I/II trial." | ( Achterrath, W; Becher, R; Eberhardt, W; Harstrick, A; Hayungs, J; Klaassen, U; Losch, M; Seeber, S; Stahl, M; Vanhoefer, U; Wilke, H, 1996) |
| "MDA-MB-435 human breast cancer cells treated with 10 micrograms/ml of RRR-alpha-tocopheryl succinate (vitamin E succinate, VES) for one, two, three, and four days exhibit 9%, 19%, 51%, and 73% apoptotic cells, respectively." | ( Heim, K; Kline, K; Qian, M; Sanders, BG; Simmons-Menchaca, M; Yu, W, 1997) |
| "Postmenopausal breast cancer patients who were treated with tamoxifen and progestogens showed a uniform decidual reaction of the endometrium." | ( Altaras, MM; Bernheim, J; Beyth, Y; Cohen, I; Cordoba, M; Figer, A; Shapira, J; Tepper, R; Yigal, D, 1997) |
| "Up to 50% of these anaplastic breast cancer xenografts were cured by combined modality therapy." | ( DeNardo, DG; DeNardo, GL; DeNardo, SJ; Kroger, LA; Kukis, DL; Lamborn, KR; Meares, CF; Miers, LA; O'Donnell, RT, 1997) |
| "Thirteen patients with advanced breast cancer treated with oral megestrol acetate, 160 mg/d." | ( Goker, H; Kanji, A; Subramanian, S; Sweeney, H, 1997) |
| "A small increase in the risk of breast cancer has been reported after long term use of combined estrogen-progestagen treatment." | ( Dabrosin, C; Hammar, M; Ollinger, K; Ungerstedt, U, 1997) |
| "Multiple mechanisms may render breast cancer cells resistant to treatment with the antiestrogen tamoxifen." | ( Lykkesfeldt, AE, 1996) |
| "Endocrine therapy of breast cancer consists of a variety of both medical and surgical ablative treatment modalities, but ablative therapy is increasingly replaced by medical treatment." | ( Bontenbal, M; Foekens, J; Klijn, JG; Setyono-Han, B; Seynaeve, C, 1996) |
| "Twelve patients with early breast cancer were examined before and a year after radiotherapy." | ( Carlens, P; Fornander, T; Glas, U; Gyenes, G; Rutqvist, LE, 1997) |
| "Optimal treatment of early stage breast cancer remains an active area of study." | ( Blum, JL; Fay, JW; Jones, SE; Mennel, RG; Senzer, N, 1997) |
| "The results of advanced breast cancer therapy with tamoxifen have been evaluated." | ( Pawlicki, M; Pernal, J; Rolski, J; Zemełka, T, 1996) |
| "On day 0, 15 normocalcemic breast cancer patients with bone metastases were treated with 3 mg of ibandronate injected intravenously over 60-120 s." | ( Body, JJ; Buck, S; Huss, HJ; Ludwig, H; Pecherstorfer, M; Schlosser, K, 1996) |
| "Sixteen patients with metastatic breast carcinoma who had relapsed after prior doxorubicin-containing adjuvant chemotherapy were treated with paclitaxel (90 mg/m2) by intravenous (i." | ( Glick, JH; Goldstein, LJ; Neuberg, D; Robert, NJ; Sledge, GW; Sparano, JA; Wood, W, 1997) |
| "Human breast cancer MCF-7 wild-type (WT) and resistant (TH) cell lines were cultured in whole human plasma to study anthracycline retention after treatment with different combinations of PTX, Cremophor EL (CEL) (PEG35 castor oil; BASF, Parsippany, NJ), and DOX." | ( Bonadonna, G; Capri, G; Giani, A; Gianni, L; Locatelli, A; Tarenzi, E; Viganò, L, 1997) |
| "Treatment of T47-D human breast carcinoma cells with recombinant prolactin (rhPRL) induced a concentration- and time-dependent increase in the phosphotyrosine content of JAK2." | ( Canbay, E; Goffin, V; Kilic, E; Norman, M; Zachary, I, 1997) |
| "Whether hormonal breast cancer treatment affects the suppression of HAE by danazol remains unknown." | ( Boyages, J; Christie, DR; Clarke, CL; Kirk, JA, 1997) |
| "Thirty cases (breast cancer-20 cases, malignant lymphoma-4 cases, different malignancies-6 cases) of histologically/cytologically verified malignant pleural effusion (MPE) in 29 patients were treated with intrapleurally instilled mitoxantrone (30 mg)." | ( Aasebø, U; Norum, J; Sager, G; Slørdal, L, 1997) |
| "In this study 194 women with breast cancer received adjuvant CNF combination therapy (cyclophosphamide, mitoxantrone and 5-fluorouracil)." | ( Hirvikoski, PP; Johansson, RT; Kumpulainen, EJ, 1997) |
| "In the majority of premenopausal breast cancer patients, an adjuvant chemotherapy-induced early menopause occurs, which is known to be a strong predictor of osteoporosis." | ( Blomqvist, C; Elomaa, I; Mäkelä, P; Saarto, T; Sarna, S; Välimäki, M, 1997) |
| "adipose layer of 10 breast cancer patients (8 females and 2 males) scheduled to receive neoadjuvant chemotherapy due to locally advanced breast cancer." | ( Blochl-Daum, B; Eichler, HG; Gnant, M; Helbich, T; Jakesz, R; Jansen, B; Mader, RM; Müller, M; Steger, GG; Steiner, B, 1997) |
| "The value of multihormonal therapy in breast carcinoma is not established, and the addition of progestogens to tamoxifen may not reduce of developing endometrial lesions, including carcinoma." | ( Berezowsky, J; Chalvardjian, A; Murray, D, 1994) |
| "The incidence of contralateral primary breast cancer in the treated group was 1." | ( Huang, X; Wang, Y; Xing, B, 1996) |
| "Sixty-two early-stage breast cancer patients undergoing accelerated adjuvant chemotherapy were randomized to receive EPO 150 U/kg three times a week or no additional treatment." | ( Bertelli, G; Canavese, G; Costantini, M; Del Mastro, L; Garrone, O; Lionetto, R; Melioli, G; Pasquetti, W; Rosso, R; Sertoli, MR; Venturini, M, 1997) |
| "A total of 17 patients with metastatic breast cancer were enrolled in the study, and 14 completed at least one cycle of therapy and were evaluable for response." | ( Petros, WP; Sutton, LM; Warmuth, MA; Winer, EP, 1997) |
| "One hundred ten had a history of breast cancer; 43 of these had been treated with tamoxifen while at the JHHA (Group I), and 66 had not (Group II)." | ( Breuer, B; Giambanco, V; Marchello, V; Subramaniam, G, 1997) |
| "Sixty-seven symptomatic breast cancer patients who had been on tamoxifen treatment, including 34 premenopausal and 33 postmenopausal patients, and another group of 48 patients who had not been on tamoxifen, including 25 premenopausal and 23 postmenopausal patients, were recruited." | ( Cheng, WF; Huang, SC; Lin, HH; Torng, PL, 1997) |
| "PCT was administered to 29 women with breast cancer." | ( Adami, F; Banzi, C; Criscuolo, M; Frassoldati, A; Piccinini, L; Silingardi, V, 1997) |
| "Liver function tests from 194 breast cancer patients who received adjuvant chemotherapy with or without tamoxifen (TAM) were reviewed." | ( Hirvikoski, PP; Johansson, RT; Kumpulainen, EJ, 1997) |
| "The recognition that early breast cancer is a systemic disease has led to the development of multimodal treatments incorporating adjuvant hormonal and chemotherapies." | ( Di Leo, A; Piccart, MJ, 1997) |
| "The main therapy for primary breast cancer is not surgery, but a systemic therapy involving administration of cytotoxic chemotherapy or the use of ablative or additive endocrine therapy to control disseminated micrometastasis." | ( Inaji, H; Koyama, H; Motomura, K; Noguchi, S, 1997) |
| "Two cases of recurrent breast cancer, for which combined therapy using toremifene and oral chemotherapeutic agents were effective, are reported." | ( Asanuma, F; Miyagawa, T; Toyoda, H; Uesato, K; Yamada, Y, 1997) |
| "Among women with breast cancer whose disease is progressing after at least six months of treatment with TAM, there is no advantage to maintaining TAM when MPA is to be given." | ( Byrne, MJ; Coates, AS; Dewar, J; Flower, C; Forbes, J; Gebski, V; Gill, PG; Lunn, M; Simes, RJ; Stewart, J; Tattersall, MH, 1997) |
| "In postmenopausal breast cancer (BC) patients, tamoxifen (TAM) is frequently used in first-line therapy, and for those relapsing under TAM, aromatase inhibitors would be the drug of choice." | ( Amichetti, M; Attili, A; Bajetta, E; Barni, S; Bichisao, E; Bolelli, GF; Bombardieri, E; Buzzoni, R; Comella, G; D'Aprile, M; Ferrari, L; Jirillo, A; Martinetti, A; Noberasco, C; Schieppati, G; Zilembo, N, 1997) |
| "Eighty women with metastatic breast cancer received a total of 352 fully evaluable courses of therapy." | ( Cavalli, F; Cerny, T; de Jong, J; Goldhirsch, A; Martinelli, G; Pagani, O; Sessa, C; Zimatore, M, 1997) |
| "A 2-h treatment of MCF-7 breast cancer cells with 0." | ( Busch, H; Perlaky, L; Valdez, BC, 1997) |
| "Patients with Stage II-III breast cancer, who had pretreatment platelet counts > or = 150 x 10(9) per L and patients who underwent < or = 1 prior chemotherapy regimen had improved CD34+ cell yields." | ( Beeker, T; Birch, R; Buckner, CD; Foster, J; Geier, L; Greco, FA; Hainsworth, J; Hazelton, B; Price, H; Rhinehart, S; Schwartzberg, LS; Weaver, CH; West, J, 1997) |
| "A 60-year-old woman with advanced breast cancer received palliative chemotherapy with 22." | ( Faivre, S; Goldwasser, F; Misset, JL; Soulié, P, 1997) |
| "Clinical chemotherapy of breast carcinomas must be considered insufficient, mainly due to the appearance of drug resistance." | ( Fichtner, I; Lemm, M; Naundorf, H; Stein, U; Walther, W, 1997) |
| "Fifty-five women with metastatic breast cancer were treated with a regimen consisting of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 administered intravenously over 3 hours on day 1 only plus leucovorin given intravenously over 30 to 60 minutes followed by 5-fluorouracil 350 mg/m2 via intravenous push on days 1 to 3 every 28 days for six cycles." | ( Garrett, M; Hande, KR; Johnson, DH; Nicholson, B; Paul, D; Shyr, Y, 1997) |
| "The records of 36 women with breast cancer who were more than 70 years old and were treated only with tamoxifen and local excision from January 1985 to July 1996 were retrospectively reviewed." | ( O'Connell, TX; Tan, LR; Yeh, S, 1997) |
| "Among breast cancer patients who received anthracycline-containing chemotherapy, response to treatment correlated with histological grade." | ( Blomqvist, C; Franssila, K; Hietanen, P; Niskanen, E; Wasenius, VM, 1997) |
| "Cardiac function was evaluated in 86 breast cancer patients after standard chemotherapy, followed by ablative chemotherapy and chest irradiation." | ( de Graaf, H; de Vries, EG; Dolsma, WV; Mulder, NH; Sleijfer, DT; van der Graaf, WT; Willemse, PH, 1997) |
| "Women with newly diagnosed early breast cancer were interviewed by means of questionnaires, and a 72 h urine collection and blood sample were taken before any treatment started." | ( Ingram, D; Kolybaba, M; Lopez, D; Sanders, K, 1997) |
| "Most previously described patients with breast cancer and PCP received treatment with corticosteroids, a known risk factor for PCP." | ( Kulke, MH; Vance, EA, 1997) |
| "Seventy-one patients with stage IV breast cancer were treated with Caelyx at doses of 45 to 60 mg/m2 every 3 to 4 weeks for a maximum of six cycles." | ( Carmichael, J; Howell, A; O'Byrne, K; Ranson, MR; Smith, D; Stewart, S, 1997) |
| "Eighteen women treated for ovarian or breast cancer were examined with autonomic cardiovascular function tests, once before the treatment and once after the second course of paclitaxel." | ( Antila, K; Ekholm, E; Rantanen, V; Salminen, E, 1997) |
| "Eleven patients with T4 breast cancer received induction intraarterial chemotherapy (IACT) as the first step in multidisciplinary therapy." | ( Chang, HT; Mok, KT; Tzeng, WS, 1997) |
| "Therapy for metastatic breast cancer has not improved significantly in recent years." | ( Klaassen, U; Seeber, S, 1997) |
| "Twenty-four patients with metastatic breast cancer that had progressed after high-dose chemotherapy with peripheral blood progenitor cell (PBPC) support were given intramuscular methotrexate in combination with oral UFT (tegafur and uracil) and oral leucovorin (the MUL regimen)." | ( Ayala, F; Casado, A; Diaz-Rubio, E; López-Martin, JA; Martin, M; Nieto, Y; Rodriguez-Lescure, A, 1997) |
| "Optimal management of locally advanced breast cancer (stage III) generally includes a combination of primary chemotherapy followed by surgery (if feasible), and local radiotherapy and adjuvant chemotherapy with or without hormonal therapy." | ( Gradishar, WJ, 1997) |
| "Locally advanced breast cancers may form large, infected skin ulcers, which were traditionally treated with radiation therapy." | ( Braverman, AS; Dauphin, S; el Tamer, M; Katz, S; Sohn, C; Wait, R, 1997) |
| "Until now breast cancer treatment and research has been impeded by the limited means of evaluating the breast cancer in vivo: primarily clinical palpation and mammography of the breast tumor." | ( Davis, PL; McCarty, KS, 1997) |
| "Of 104 operable breast cancer patients who were treated with either regimen, 78 were evaluable for response to preoperative chemotherapy and had undergone local therapy." | ( Ames, F; Asmar, L; Buzdar, AU; Hortobagyi, GN; McNeese, M; Rahman, Z; Singletary, S; Theriault, RL, 1997) |
| "Forty-six patients with metastatic breast cancer received the following regimen as first- or second-line treatment: paclitaxel 135 mg/m2 by 1-hour intravenous infusion on day 1; mitoxantrone 10 mg/m2 by intravenous bolus on day 1; 5-fluorouracil 350 mg/m2 by intravenous bolus on days 1, 2, and 3; and leucovorin 300 mg intravenous over 30 to 60 minutes, immediately preceding 5-fluorouracil on days 1, 2, and 3." | ( Greco, FA; Hainsworth, JD, 1997) |
| "Patients with untreated metastatic breast cancer received two cycles of doxorubicin 60 mg/m2 and paclitaxel 200 mg/m2." | ( Champlin, R; Frye, D; Hortobagyi, G; Mehra, R; Rahman, Z; Rondon, G; Valero, V, 1997) |
| "This suggested that the therapy for a breast cancer patient with distant metastasis must be considered according to the region of recurrence." | ( Ayabe, H; Hara, S; Hashizume, S; Itoyanagi, N; Oka, T; Shinguu, H; Tagawa, Y; Tooyama, H; Tou, K; Tsuji, H; Yamamoto, S; Yamazumi, K, 1997) |
| "Sixty-one women with stage II-IV breast cancer were treated." | ( Areman, EM; Cahill, R; Foelber, R; Frankel, S; Gehan, EA; Lippman, ME; Mazumder, A; Meehan, KR; Rajagopal, C; Sacher, RA; Verma, UN, 1997) |
| "This regimen proved active in advanced breast cancer following anthracycline-containing chemotherapy, and the 3-day schedule could be offered to such patients with acceptable toxicity." | ( Acito, L; Bascioni, R; De Signoribus, G; Giorgi, F; Giuliodori, L; Giustini, L; Silva, RR; Testa, E, 1997) |
| "For previously treated advanced breast cancer, there is no standard second-line therapy." | ( Chen, PM; Chiou, TJ; Hsieh, RK; Liu, JH; Tung, SL; Wang, WS; Yen, CC, 1997) |
| "Previously untreated, locally advanced breast cancer patients were eligible: only patients who presented with T3/T4 tumors that could not be resected with primary wound closure were eligible, while inflammatory breast cancer patients were excluded." | ( Danenberg, K; Danenberg, P; Denk, M; Dunnington, G; Florentine, B; Formenti, SC; Groshen, S; Keren-Rosenberg, S; Leichman, G; Lenz, H; Muggia, F; Press, M; Silberman, H; Spicer, D; Uzieli, B; Watkins, K, 1997) |
| "The treatment of breast cancer by retinoic acid (RA) may be mediated by lipid peroxidation." | ( Chan, HM; Hurnanen, D; Kubow, S, 1997) |
| "We have treated two human breast cancer cell lines that differ in p53 status with epirubicin in order to study if there are differences in cell cycle kinetic response." | ( Baldetorp, B; Borg, A; Hedenfalk, IA; Oredsson, SM, 1997) |
| "Forty-three patients are alive and breast cancer-free at a median of 947 days (range 661-1730 days) after the start of therapy, including one patient who developed myelodysplastic syndrome 809 days after the start of HDCT." | ( Barón, AE; Bearman, SI; Bolwell, BJ; Cagnoni, PJ; Jones, RB; Mechling, BE; Overmoyer, BA; Purdy, MH; Ronk, B; Ross, M; Shpall, EJ; Taylor, CW, 1997) |
| "Resistance to antihormone treatments in breast cancer is a dominant feature in the evolution of this malignancy." | ( Actis, AM; Caruso, SP; de Levin, RW; Levin, E, 1997) |
| "Hormonotherapy in metastatic breast cancer is actually performed using 3 therapeutic classes: antiestrogen as tamoxifen (TAM), progestins, megestrol acetate (MA) and medroxyprogesterone acetate (MPA), aromatase-inhibitors as aminoglutethimide (AG)." | ( Bonneterre, J; Leriche, N, 1997) |
| "Small invasive breast cancers up to 10 mm in size have an excellent prognosis and are being detected in increasing numbers by mammographic screening, yet optimal treatment remains controversial." | ( Cawson, JN; Henderson, MA; Kitchen, PR; Winch, KL, 1998) |
| "We found that small invasive breast cancers are commonly treated by breast conservation, which usually includes axillary dissection." | ( Cawson, JN; Henderson, MA; Kitchen, PR; Winch, KL, 1998) |
| "Twenty-two breast cancer patients treated with multiagent chemotherapy were sequentially studied with PET." | ( Baker, LH; Fisher, SJ; Kison, PV; Sugawara, Y; Wahl, RL; Zasadny, KR, 1998) |
| "Patients with large primary breast cancers are being treated with neo-adjuvant chemotherapy." | ( Ah-See, AK; Dewar, J; Eremin, O; Heys, SD; Hutcheon, AW; Miller, I; Ogston, K; Sarker, TK; Walker, LG, 1998) |
| "Treatment of cultured human MCF7 breast cancer cells with I3C reversibly suppresses the incorporation of [3H]thymidine without affecting cell viability or estrogen receptor (ER) responsiveness." | ( Bjeldanes, LF; Cover, CM; Firestone, GL; Hallden, G; Hsieh, SJ; Kim, GS; Tran, SH, 1998) |
| "T-47D, Hs-578T (human breast carcinoma cell lines), and MDCK (normal dog kidney) cells were maintained in MCDB 153 supplemented with 1% fetal bovine serum (FBS), or in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% FBS and treated with melatonin (10(-9) M or 10(-10) M) for 2 and 5 days, with or without 10(-8) M estradiol." | ( Machado-Santelli, GM; Matsui, DH, 1997) |
| "37 patients with advanced breast cancer resistant to anthracyclines were treated with paclitaxel 200 mg/m2 by 3-h infusion and carboplatin at an area under the curve of 7 mg." | ( Aravantinos, G; Athanassiadis, A; Bafaloukos, D; Briasoulis, E; Dombros, N; Fountzilas, G; Ioannidis, I; Kalogera-Fountzila, A; Kosmidis, P; Pavlidis, N; Skarlos, D, 1997) |
| "To assist patients with node-negative breast cancer and their physicians in arriving at optimal decisions regarding treatment." | ( , 1998) |
| "In the treatment of breast cancer, anthracycline-containing combinations are frequently used as adjuvant therapy or to treat patients with metastatic disease." | ( Asmar, L; Buzdar, AU; Hortobagyi, GN, 1997) |
| "For patients with primary breast cancer for whom chemotherapy would be appropriate, anthracyclines are often incorporated in adjuvant regimens." | ( Ravdin, PM, 1997) |
| "Twenty-one patients with metastatic breast carcinoma received epirubicin 90 mg/m2 in combination with paclitaxel 200 mg/m2 given as a 3-hour infusion, and granulocyte-colony stimulating factor (G-CSF) starting 24 hours after chemotherapy to mobilize PBPCs." | ( Bengala, C; Conte, PF; Favre, C; Greco, F; Macchia, P; Mazzoni, A; Menconi, MC; Pazzagli, I; Tibaldi, C; Vanacore, R, 1998) |
| "One hundred women with metastatic breast cancer (MBC) underwent high-dose chemotherapy with autologous stem cell rescue at our institution beginning in 1986." | ( Bitran, JD; Grad, G; Grinblatt, DL; Laport, GF; Williams, SF, 1998) |
| "Sixty metastatic and recurrent breast cancer patients who had been given cyclophosphamide, methotrexate and fluorouracil (CMF) therapy previously and were treated at the Oncology Departments of Cukurova and Ege University Medical Schools between March 1992-94, were randomized into 2 groups for the chemotherapy program." | ( Bilkay, BC; Burgut, R; Erkisi, M; Hazar, B; Seyrek, E, 1997) |
| "Fifty-three metastatic breast cancer patients were treated with a four-drug program of high-dose chemotherapy including cyclophosphamide (6 g/m2), thiotepa (500 mg/m2), carboplatin (800-1,600 mg/m2) and mitoxantrone (20-60 mg/m2) with autologous peripheral blood progenitor cell support followed by filgrastim." | ( Alonso, JL; Ayala, F; Casado, A; Díaz-Rubio, E; Llorente, L; López Martín, JA; Martín, M; Nieto, Y; Pérez Calvo, J; Pérez López, C; Rodríguez Lescure, A; Villegas, A, 1997) |
| "The outcome of metastatic breast cancer patients in complete remission after induction chemotherapy or NED status seems to be good with our high-dose chemotherapy including four drug and PSCR." | ( Alonso, JL; Ayala, F; Casado, A; Díaz-Rubio, E; Llorente, L; López Martín, JA; Martín, M; Nieto, Y; Pérez Calvo, J; Pérez López, C; Rodríguez Lescure, A; Villegas, A, 1997) |
| "In this study, 164 asymptomatic breast cancer patients (110 on treatment with tamoxifen, 20 mg/day, and 54 controls) were examined with pelvic ultrasound and endometrial biopsy." | ( Bertelli, G; Cosso, M; Cusimano, E; Del Mastro, L; Garrone, O; Guido, T; Gustavino, C; Nicolò, G; Rosso, R; Venturini, M, 1998) |
| "Female patients (n=371) with metastatic breast cancer were treated with endocrine or chemoendocrine therapy as the first-line treatment." | ( Nomura, Y, 1998) |
| "MCF-7, an estrogen receptor-positive breast cancer cell line, MCF-10F, an immortal estrogen receptor-negative breast epithelial cell line, and MDA-MB-231, a malignant estrogen receptor-negative breast epithelial cell line, were treated with 5, 10, 20 or 40 microg/ml resveratrol, and their proliferative activities were determined with the WST-1 colorimetric assay after periods of time ranging from 24 to 144 h of treatment." | ( Mgbonyebi, OP; Russo, IH; Russo, J, 1998) |
| "Eight patients with advanced breast cancer were entered into a prospective, longitudinal trial that included examination by MR imaging and proton MR spectroscopy before chemotherapy and through 12 months after treatment with carmustine, cyclophosphamide, and cisplatin, combined with autologous hematopoietic progenitor cell support (AHPCS)." | ( Brown, MS; Cagnoni, PJ; Jones, RB; Sheeder, JL; Simon, JH; Stears, JC; Stemmer, SM, 1998) |
| "Asymptomatic women (n = 44) with breast cancer on postoperative tamoxifen treatment were referred to our gynecological ultrasound unit." | ( Goldstein, SR; Horan, C; Nachtigall, LE; Porges, RF; Schwartz, LB; Snyder, J, 1998) |
| "Thirty-three metastatic breast cancer patients with prior chemotherapy (adjuvant alone, 9 patients; chemotherapy for metastatic disease alone, 13 patients; chemotherapy for both, 11 patients) received paclitaxel (Taxol) 135 mg/m2 over 1 h followed by vinorelbine (Navelbine) 30 mg/m2 over 10 minutes on day 1 every 3 weeks." | ( Casado, A; Diaz-Rubio, E; Garcia Carbonero, I; Martin, M; Perez Segura, P, 1998) |
| "Treatment options for hormone-dependent breast cancer focus on interfering with the endocrine system in an attempt to modify the effects of estrogen." | ( alKhouri, N; Higa, GM, 1998) |
| "A significant proportion of breast cancer patients and unaffected individuals from familial breast cancer (FBC) families exhibited premature separation of centromeres (PSC) and aneuploidy in the untreated cultures." | ( Ghosh, SN; Pai, SA; Rao, NM; Shinde, SR, 1998) |
| "Adjuvant therapy for breast cancer is an area in constant evolution." | ( Taguchi, T, 1998) |
| "Twenty-one women with primary, operable breast carcinomas were treated with tamoxifen 20 mg daily." | ( Allred, DC; Ashley, S; Dowsett, M; Makris, A; Ormerod, MG; Powles, TJ; Titley, JC, 1998) |
| "A significant proportion of breast cancer patients receiving tamoxifen therapy relapse during treatment following acquisition of tamoxifen-resistant or oestrogen-independent phenotypes." | ( Boylan, M; Lynch, M; van den Berg, HW, 1998) |
| "Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined." | ( Bonadona, V; Chauvin, F; Cutuli, B; D'Anjou, J; de Gislain, C; de Lafontan, B; Fondrinier, E; Giard, S; Granon, C; Hill, C; Kerr, C; Lasry, S; Lasset, C; Lefeuvre, C; Lesur, A; Luporsi, E; Mauriac, L; Mignotte, H; Parache, RM; Rodier, JF, 1998) |
| "Women with primary breast cancer who receive systemic therapy may experience ovarian failure or early menopause, leading to a loss of bone mineral density (BMD)." | ( Ashley, S; Kanis, J; McCloskey, E; Nevantaus, A; Paterson, AH; Powles, TJ; Rosenqvist, K; Tidy, VA, 1998) |
| "Human breast cancer tumors (HBT 3477) in mice were treated with 90Y-DOTA-peptide-ChL6 to examine the effects of increasing dose on the therapeutic efficacy and toxicity of this new agent." | ( DeNardo, GL; DeNardo, SJ; Gumerlock, PH; Kroger, LA; Kukis, DL; Lamborn, KR; Meares, CF; Miers, LA; Salako, Q; Shen, S; Winthrop, MD, 1998) |
| "Oxygenation of human breast cancers can safely be measured in patients prior to surgical therapy." | ( Felgner, C; Haensch, W; Hohenberger, P; Schlag, PM, 1998) |
| "A group of twenty postmenopausal breast cancer patients treated with tamoxifen was used for examination of the endometrial morphology, role of transvaginal sonography, and consequences of insufficient collaboration between gynaecologist and oncologist." | ( Resl, M; Reslová, T; Tosner, J; Vávrová, I, 1997) |
| "Treatment of human breast cancer cells with either H2O2 or hyperoxia increased the activity of spermidine/spermine N1-acetyltransferase (SSAT)." | ( Chopra, S; Wallace, HM, 1998) |
| "The International Breast Cancer Study Group (IBCSG) prospectively explored the efficacy of retreatment for patients upon relapse using the same therapy administered during the adjuvant programme." | ( Castiglione-Gertsch, M; Coates, A; Collins, J; Gelber, RD; Goldhirsch, A; Gudgeon, A; Hacking, A; Isley, M; Lindtner, J; Rudenstam, CM; Senn, HJ; Tattersall, M, 1997) |
| "In estrogen-receptor-negative breast cancer, and for patients who have failed hormonal therapy or have liver metastases, chemotherapy should be initiated." | ( Reichardt, P, 1998) |
| "Between 1984 and 1990, 277 stage I breast cancer patients with tumours negative for both oestrogen and progesterone receptors were randomised to receive either low-dose short-term chemotherapy or no chemotherapy." | ( Fridrik, M; Gnant, M; Hausmaninger, H; Jakesz, R; Kolb, R; Kubista, E; Samonigg, H; Sevelda, P; Steger, G; Steindorfer, P; Stierer, M; Tschurtschenthaler, B, 1998) |
| "was instituted in 30 breast cancer patients treated with high-dose chemotherapy (a 4-day intravenous continuous infusion of cyclophosphamide 1500 mg/m2 per day, thio-TEPA 125 mg/m2 per day and carboplatin 200 mg/m2 per day)." | ( Aznar, E; Climent, MA; Guillem, V; Olmos, T; Palau, J; Ruiz, A; Soriano, V, 1998) |
| "We now report that treatment of ER+ breast cancer cells with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (5-aza-2'-dC) leads to accumulation of RII transcript and protein in three different cell lines." | ( Ammanamanchi, S; Brattain, MG; Kim, SJ; Sun, LZ, 1998) |
| "Seven benign lesions and three breast cancer recurrences showed less than 185% signal increase at 90 seconds after contrast administration." | ( Dyess, DL; Harpen, MD; Kreisberg, CN; Snow, RD; Tucker, JA, 1998) |
| "Patients (age-matched) with breast cancer, confirmed by fine-needle aspiration, were either treated with 20 mg ml(-1) oral tamoxifen per day or received no medication in the 3-week interval between assessment and surgery." | ( Brotherick, I; Browell, DA; Cunliffe, WJ; Egan, M; Higgs, MJ; Lunt, LG; Shenton, BK; Webb, LA; Young, JR, 1998) |
| "Forty chemotherapy naive breast cancer patients treated with epirubicin at a dose of 110 mg/m2 on an outpatient basis were enrolled in the study." | ( Athanassiadis, A; Damigos, D; Fountzilas, G; Giannakakis, T; Nicolaides, C; Pavlidis, N; Skarlos, D, 1998) |
| "Prospective evaluation of PET during breast cancer chemohormonotherapy demonstrated a decline in FDG uptake in patients responsive to treatment, while no significant decline in FDG uptake is seen in the non-responding patients examined post initiation of treatment." | ( Wahl, RL, 1998) |
| "About 20 patients with primary breast cancer were enrolled in the study: 10 were not given any treatment before surgery and served as control subjects and 10 received OCs." | ( Diamandis, EP; Katsaros, D; Melegos, DN, 1998) |
| "The EORTC Breast Cancer Cooperative Group carried out a randomized trial to compare doxorubicin with epirubicin as second-line chemotherapy in patients with metastatic breast cancer." | ( Andersson, M; Bontenbal, M; Cocconi, G; Jassem, J; Klijn, JG; Mouridsen, HT; Paridaens, R; Rotmensz, N; Sylvester, R; van Oosterom, AT; Wildiers, J, 1998) |
| "Fifty-five patients with advanced breast cancer were treated with a single cytotoxic drug, Topo II-inhibitor, epirubicin (30 mg m(-2) weekly up to 1000 mg m(-2)), as first line cytotoxic chemotherapy." | ( Holli, K; Isola, JJ; Järvinen, TA; Kuukasjärvi, T, 1998) |
| "Infusional 5-fluorouracil in advanced breast cancer has been associated with improved clinical response rates when compared with conventional bolus therapy." | ( Asselain, B; Beuzeboc, P; Diéras, V; Dorval, T; Garcia-Giralt, E; Jouve, M; Livartowski, A; Palangié, T; Pierga, JY; Pouillart, P; Scholl, S, 1998) |
| "Treatment of well established BT-474 breast cancer xenografts overexpressing HER2 in athymic mice with rhuMAb HER2 resulted in a dose-dependent antitumor activity." | ( Albanell, J; Baselga, J; Kim, YM; Mendelsohn, J; Norton, L, 1998) |
| "Local control rate for inflammatory breast cancer (IBC) is < 50% with standard chemotherapy-radiotherapy regimen." | ( Boyages, J; Gurney, H; Harnett, P; Kefford, R, 1998) |
| "Up to recently women with a history of breast cancer were not allowed relief of menopausal symptoms with hormonal replacement therapy (HRT)." | ( Birkhäuser, M; Castiglione, M; Rageth, JC, 1998) |
| "Many cases of early breast cancer appear to be restricted to the breast and perhaps the axillary lymph nodes, but may relapse if given local treatment only." | ( Fey, MF, 1998) |
| "Chemotherapy for metastatic breast carcinoma may cause striking morphologic changes in the liver that resemble cirrhosis." | ( Gorman, B; Schreiner, SA; Stephens, DH, 1998) |
| "Accordingly, we transfected MCF-7 breast cancer cells with estrogen-responsive reporters followed by treatment with one of four phytoestrogens (genistein, daidzein, formononetin, and equol) or a combination of these in the absence of estradiol." | ( Frawley, LS; Willard, ST, 1998) |
| "Fifty patients with untreated breast cancer had clinical examination of their axilla performed (graded as positive or negative), followed by PET of the axilla and midthorax." | ( Ah-See, AK; Eremin, O; Heys, SD; Jibril, JA; Miller, ID; Norton, M; Ogston, KN; Sharp, P; Smith, FW; Smith, IC; Whitford, P, 1998) |
| "Primary systemic treatment of breast cancer with cytotoxics yields a high response rate and allows conservative surgical procedures in bulky tumours." | ( Colleoni, M; Goldhirsch, A; Luini, A; Minchella, I; Noberasco, C; Nole, F; Orecchia, A; Orecchia, R; Veronesi, P; Viale, G; Zurrida, S, 1998) |
| "However 40% of ER+ breast cancer patients do not respond to anti-hormone therapy." | ( Averboukh, L; Biswas, DK; Ewaniuk, DS; Jawde, TF; Martin, K; Pardee, AB; Sheng, S; Wang, F, 1998) |
| "It is predicted that the latter type of breast cancers will not respond to antihormone therapy." | ( Averboukh, L; Biswas, DK; Ewaniuk, DS; Jawde, TF; Martin, K; Pardee, AB; Sheng, S; Wang, F, 1998) |
| "The choice of systemic treatment for breast cancer depends on the tumour characteristics and stage of disease, and the patient's age, general state of health, menopausal status and oestrogen receptor (ER) status." | ( Buzdar, A, 1998) |
| "Prognosis is poor in hypercalcaemic breast cancer patients with WHO performance 3-4 and advanced metastatic disease when effective systemic treatment can no longer be offered." | ( Ejlertsen, B; Kristensen, B; Loft, H; Mouridsen, HT, 1998) |
| "There are 106 women treated for breast cancer T1c-3a, N0-1, M0 in the study." | ( Bauer, J; Bustová, I; Dorazilová, V; Fischer, J; Hacklová, M; Honová, H; Kohoutek, M; Kůta, M; Kyselá, T; Machácek, J; Miller, V; Petruzelka, L; Pribylová, O; Siffnerová, H; Suk, J; Tajblová, J; Vodvárka, P, 1998) |
| "For high-risk, node-negative breast cancer patients, a prospective randomized trial of surgical adjuvant chemotherapy comparing 6 cycles of CMF with 2 years of daily uracil/tegafur (UFT) started in October 1996." | ( Watanabe, T, 1998) |
| "We have analyzed 35 biopsies from breast cancer patients treated with induction chemotherapy." | ( Aznar, JC; Ciocca, DR; Gago, FE; Tello, O; Vargas-Roig, LM, 1998) |
| "With the rise in the incidence of breast carcinoma it is important that the attention of both ophthalmologists and oncologists should be drawn to the potential ocular toxicity of systemic 5-fluorouracil chemotherapy, which may lead to lacrimal canalicular fibrosis with permanent epiphora." | ( Bentley, CR; Lee, V; Olver, JM, 1998) |
| "Postmenopausal women with breast cancer in remission (N = 140) who were participating in a randomized clinical trial of tamoxifen chemoprevention therapy completed measures of trait anxiety, symptoms, cancer worry, and breast self-examinations (BSEs) during the first 6 months of the trial." | ( Cameron, LD; Leventhal, H; Love, RR, 1998) |
| "Thirty patients with metastatic breast cancer received sustained weekly paclitaxel therapy at an initial dose of 100 mg/m2 until disease progression." | ( Albanel, J; Albanell, J; Baselga, J; Currie, V; Gollub, M; Hudis, CA; Moynahan, ME; Norton, L; Seidman, AD; Tepler, I; Theodoulou, M; Tong, W, 1998) |
| "A retrospective study of anemia in breast cancer patients treated with four cycles of cyclophosphamide and doxorubicin with fluorouracil (CAF) or without fluorouracil (CA) was conducted." | ( Gilbert, CJ; Hayward, SL; Maravich-May, D; Meadowcroft, AM, 1998) |
| "In this study, human breast cancer cells were treated with cis-diamminedichloroplatinum to cross-link protein to nuclear DNA in situ, and proteins bound to DNA were isolated." | ( Coutts, AS; Davie, JR; Murphy, LC; Samuel, SK; Spencer, VA, 1998) |
| "A total of 54 breast cancer patients receiving high-dose cyclophosphamide, cisplatin and carmustine were treated prospectively in four sequential cohorts." | ( Berry, D; Cavanaugh, C; Fehdrau, R; Gilbert, CJ; Hussein, A; McKinstry, C; Peters, WP; Petros, WP; Ross, M; Rubin, P; Vredenburgh, J, 1998) |
| "Peripheral blood progenitor harvests of breast cancer patients are contaminated with tumor cells, suggesting a potential role for these cells in the relapse after high-dose chemotherapy." | ( Arnold, W; Dörken, B; Körner, IJ; Mapara, MY; Schumacher, A; Wolff, G, 1998) |
| "Currently, radiological evaluation of breast cancer is important not only for early detection of this disease, but also for staging, assessing certain prognostic factors, and monitoring response to treatment." | ( Dehdashti, F; Flanagan, FL; Siegel, BA, 1998) |
| "The role of tamoxifen in controlling breast cancer includes adjuvant treatment for early stage breast cancer and palliative treatment of advanced disease." | ( McCorkle, R; Pasacreta, JV, 1998) |
| "We now show that progestin treatment of breast cancer cells regulates Stat5a and 5b, Stat3, and Stat1 protein levels in a PR-dependent manner." | ( Horwitz, KB; Lange, CA; Manning, NG; Owen, G; Powell, R; Richer, JK, 1998) |
| "Twenty-one patients with metastatic breast cancer and no previous chemotherapy for metastatic disease were treated with high-dose cyclophosphamide (Cy; 5000 mg/m2), followed by granulocyte colony-stimulating factor." | ( Ball, E; Bloom, E; deMagalhaes-Silverman, M; Lembersky, B; Lister, J; Pincus, S; Rybka, W; Voloshin, M; Wilson, J, 1997) |
| "Women with primary breast cancer associated with extensive axillary node involvement or large primary tumors have a very poor prognosis despite treatment with standard-dose adjuvant chemotherapy." | ( Basser, RL; Begley, CG; Cebon, J; Collins, JP; Juttner, CA; Maher, DW; Olver, I; Russell, I; Szer, J; To, LB, 1995) |
| "Two hundred ninety-nine breast cancer patients were prospectively randomized to receive either five cycles (CA5) or 10 cycles (CA10) of adjuvant treatment with cyclophosphamide (500 mg/ m2) and doxorubicin (45 mg/m2) administered by intravenous bolus every 21 days." | ( Blanks, D; Gelman, R; Hardenbergh, PH; Harris, J; Hauptman, P; Hayes, DF; Henderson, IC; Recht, A; Shapiro, CL, 1998) |
| "As monochemotherapy in metastatic breast cancer, gemcitabine yielded response rates up to 46% as first- and second-line treatment." | ( Akrivakis, C; Flath, B; Grunewald, R; Lüftner, D; Mergenthaler, HG; Possinger, K, 1998) |
| "A case of locally advanced breast cancer was treated with intra-arterial infusion chemotherapy using high-dose epirubicin." | ( Fukunaga, M; Hasegawa, S; Hirao, T; Kan, K; Kim, Y; Kondou, M; Takatsuka, Y, 1998) |
| "Treatment for breast cancer can impact the onset of menopause and precipitate symptoms such as hot flashes." | ( Barton, DL; Finck, G; Loprinzi, CL; Quella, SK; Sloan, JA, 1998) |
| "We previously established a breast cancer cell line, KPL-1, derived from a patient with recurrent disease which appeared under tamoxifenadministration." | ( Akinaga, S; Kurebayashi, J; Kurosumi, M; Nakata, T; Otsuki, T; Sonoo, H; Yamamoto, S, 1998) |
| "Twenty-three breast cancer patients with bone metastases treated by combined chemotherapy of cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) were monitored using bone scans; a bone resorption marker, pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen (ICTP); a bone formation marker, bone-specific alkaline phosphatase (BAI-p); and a tumor-specific marker (CA15-3)." | ( Koizumi, M; Matsumoto, S; Ogata, E; Takahashi, S; Yamashita, T, 1999) |
| "In locally advanced breast cancer (LABG), we examined whether chemotherapy induced modifications in [3H]-dt-LI, and bcl-2 expression and their relationship with tumour regression and prognosis." | ( Baldini, E; Bevilacqua, G; Collecchi, P; Conte, PF; Evangelista, G; Gardin, G; Giannessi, P; Naccarato, AG; Passoni, A; Roncella, M, 1998) |
| "In patients with metastatic breast carcinoma, doxorubicin-containing chemotherapy had a response rate of 65% and a CR rate of 16." | ( Asmar, L; Buzdar, AU; Frye, DK; Hortobagyi, GN; Rahman, ZU; Smith, TL; Theriault, RL, 1999) |
| "Nowadays, the majority of breast cancer patients receive conservative surgery followed by radiotherapy; when adjuvant taxanes are used, radiotherapy should be delayed because of their radiosensitization effect, with potential detrimental effects." | ( Conte, PF; Del Mastro, L, 1998) |
| "In the breast cancer adjuvant therapy setting, the critical issue to consider in treatment decision-making is the tradeoff between quality and quantity of life." | ( Bonetti, M; Cole, BF; Gelber, RD; Gelber, S; Goldhirsch, A, 1998) |
| "Six metastatic breast cancer patients, including one brain metastasis, one lung metastasis, three local recurrences and one bone metastasis, underwent multidrug chemotherapy with CBDCA, Etoposide (ETP) and Epirubicin (EPI)." | ( Idezuki, Y; Ishizuka, N; Kobayashi, M; Murata, N; Suwata, J; Takada, S, 1999) |
| "Human breast tumors that are initially responsive to tamoxifen (TAM) eventually relapse during treatment." | ( Benz, CC; Dowsett, M; Johnston, SR; Kushner, PJ; Lu, B; Scott, GK; Smith, IE, 1999) |
| "Tamoxifen, which is used for treating breast cancer, exhibits estrogenic and antiestrogenic characteristics, depending on the tissue." | ( Biber, E; Resch, A; Resch, H; Seifert, M, 1998) |
| "In stade II and III breast cancer, neoadjuvant chemotherapy with FEC-HD obtains an important histological response with an acceptable toxicity." | ( Arnoud, L; Belichard, C; Coudert, B; Darut-Jouve, A; Guerrin, J; Jolimoy, G, 1999) |
| "Three hundred seventy-two women with breast cancer who had at least one lytic bone lesion and who were receiving hormonal therapy were randomized to receive 90 mg of pamidronate or placebo as a 2-hour intravenous infusion given in double-blind fashion every 4 weeks for 24 cycles." | ( Costello, S; Glück, S; Heffernan, M; Hortobagyi, GN; Kennedy, I; Knight, RD; Leff, R; Lipton, A; Mellars, K; Reitsma, DJ; Seaman, JJ; Simeone, J; Stewart, JF; Theriault, RL, 1999) |
| "We studied 10 patients with breast cancer without primary chemotherapy and 3 patients with primary chemotherapy before surgery." | ( Azpeitia, D; Benito, E; Escobedo, A; Martín-Comín, J; Muñoz, A; Recaj, M; Ricart, Y, 1999) |
| "PYY inhibits growth of breast cancer in vitro and in vivo and may be of benefit in the treatment of this malignancy." | ( Grisé, KR; Laird, EC; McFadden, DW; Rongione, AJ, 1999) |
| "Thirty-nine breast carcinoma patients who had been treated with adjuvant CMF (6 courses) followed (n = 20) by 3 years of tamoxifen 20 mg daily or not (n = 19) were examined with neuropsychologic tests and interviews." | ( Boogerd, W; Bruning, PF; Lindeboom, J; Muller, MJ; Schagen, SB; van Dam, FS, 1999) |
| "For the treatment of metastatic breast cancer in which the goal of treatment is palliation, epirubicin (at doses equivalent to doxorubicin) has been shown to be equally efficacious and less toxic than doxorubicin." | ( Findlay, BP; Walker-Dilks, C, 1998) |
| "Fifty-two patients with metastatic breast cancer who had disease relapse or progression after completion of an anthracycline-based front-line regimen were treated with gemcitabine 900 mg/m2 on day 1 and day 8 and docetaxel 100 mg/m2 on day 8." | ( Agelaki, S; Alexopoulos, A; Apostolaki, F; Georgoulias, V; Giannakakis, T; Kakolyris, S; Kalbakis, K; Kosmas, C; Kourousis, C; Malamos, N; Mavroudis, D; Potamianou, A; Rigatos, G; Samonis, G; Sarra, E; Vlachonicolis, J, 1999) |
| "The current options for treating breast cancer are limited to excision surgery, general chemotherapy, radiation therapy, and, in a minority of breast cancers that rely on estrogen for their growth, antiestrogen therapy." | ( Bjeldanes, LF; Cover, CM; Cram, EJ; Firestone, GL; Hong, C; Hsieh, SJ; Riby, JE, 1999) |
| "Skin deposits from breast cancer can present serious therapeutic problems, especially when resistant to conventional therapy." | ( Beijnen, JH; Mandjes, IA; Sindermann, H; ten Bokkel Huinink, WW; Terwogt, JM, 1999) |
| "Because treatment for breast cancer may adversely affect skeletal metabolism, we investigated vertebral fracture risk in women with non-metastatic breast cancer." | ( Ashley, S; Kanis, JA; McCloskey, EV; Paterson, AH; Powles, T; Spector, T, 1999) |
| "For patients with metastatic breast cancer (MBC) who undergo high-dose therapy with autologous peripheral blood progenitor cell (PBPC) transplantation, an important prerequisite is a mobilization regimen that efficiently mobilizes PBPCs while producing an effective anti-tumor effect." | ( Brettell, M; Briggs, P; Chapple, P; Francis, P; Gardyn, J; Gates, P; Januszewicz, EH; Juneja, S; Millward, MJ; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Toner, GC; Wolf, M, 1999) |
| "In patients with breast cancer and skin metastases, topically applied miltefosine solution yields at least partial regression of the lesions in approximately a quarter of patients when used as an adjunct to standard treatment (surgery, radiotherapy, systemic chemotherapy or hormone therapy) or when standard treatments are contraindicated." | ( , 1998) |
| "Endocrine treatments for human breast cancer have been based largely upon the removal of estrogenic stimuli." | ( A'Hern, R; Barnes, DM; Detre, S; Dowsett, M; Gillett, C; Hills, M; Johnston, SR; Riddler, S; Salter, J, 1999) |
| "Treatment of metastatic breast cancer remains in flux." | ( Miller, KD; Sledge, GW, 1999) |
| "We treated human breast cancer cell lines with RGD-containing peptides, which can disrupt integrin attachment, and investigated alterations in FAK phosphorylation, cell detachment and death." | ( Holly, JM; Newcomb, PV; Norman, MR; Perks, CM, 1999) |
| "Sixty patients with metastatic breast cancer who had finished any adjuvant therapy at least 6 months previously and who had not received treatment for advanced disease were entered onto the study." | ( Biville, F; Closon, MH; Delgado, FM; Fernandez, R; Gruia, G; Llombart, A; Lluch, A; Turpin, F, 1999) |
| "The adjuvant therapy of early breast cancer currently succeeds in eradicating micrometastatic disease in a proportion of women at risk of relapse." | ( Gradishar, WJ, 1999) |
| "Thirty patients with advanced breast cancer who had metastatic bone pain were treated with 186Re-etidronate using different dosages in a noncomparative, open-label study." | ( Blijham, GH; de Klerk, JM; Han, SH; Quirijnen, JM; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonneberg, BA, 1999) |
| "198 chemonaive patients with breast cancer, treated with a moderately emetogenic chemotherapy, were randomly assigned to receive either oral granisetron 1 mg twice a day on day 1, followed by metoclopramide, 60 mg on day 2 and 3, or ondansetron, 8 mg IV on day 1, followed by ondansetron 8 mg tablet twice a day on day 2 and 3." | ( Granisétron, PK; Mabro, M, 1999) |
| "In the present study, cells from four breast carcinomas, seven ovarian carcinomas of various stages of differentiation, and ascites from a diffuse metastatic tumor were treated by PDT in vitro." | ( Cattaneo, R; Haller, U; Jentsch, B; Koechli, OR; Schlosser, V; Walt, H, 1999) |
| "Thirty-one patients with untreated breast cancer were studied prospectively." | ( Bom, HS; Jaegal, YJ; Lee, JH; Song, HC; Yoon, JH, 1999) |
| "25 women aged 20 to 40 years with breast cancer stage I-II were divided into two groups: control group underwent conservative treatment without correction and the study group was given the extract of Ural licorice for 14 days." | ( Khasina, MA; Klimkina, TN; Luchaninova, VN; Palagina, MV; Shvets, OV, 1999) |
| "Older patients with metastatic breast cancer and no significant comorbidity can be treated with doxorubicin-based chemotherapy with no added risk of developing congestive heart failure beyond that in the younger age group." | ( Ali, MK; Asmar, L; Buzdar, AU; Ewer, M; Fraschini, G; Frye, DK; Hortobagyi, GN; Ibrahim, NK; Theriault, RL, 1999) |
| "Fifty-two breast cancer patients with bidimensionally measurable metastatic disease and no prior chemotherapy for metastatic disease received a 135 mg/m2 intravenous (i." | ( Azarnia, N; Ervin, T; Hayes, DF; Keating, J; Shapiro, CL; Welles, L, 1999) |
| "In ZR-75-1 human breast cancer cells, cotreatment of LE135 and LE540 with all-trans-RA inhibited all-trans-RA-induced apoptosis of the cells, further demonstrating that RARbeta plays a role in RA-induced apoptosis of breast cancer cells." | ( Agadir, A; Hashimoto, Y; Kagechika, H; Li, Y; Zhang, Xk, 1999) |
| "In the survival analysis of early breast cancer patients, we have to estimate the contribution of second cancers to properly evaluate the effect of treatment." | ( Murakami, S; Nomura, Y; Takenaka, Y; Tsutsui, S, 1999) |
| "Advanced breast cancer has a poor prognosis (median duration of survival about 2 years); thus, treatment options are largely palliative." | ( Lamb, HM; Wiseman, LR, 1998) |
| "Fifty patients with stage IIIB and IV breast cancer entered a prospective study receiving combination chemotherapy consisting of mitoxantrone (8 mg/m2) on day 1, methotrexate (30 mg/m2) on day 1, vincristine (1 mg/m2) on day 2, and carboplatine (250 mg/m2) on day 2 (MIMOC), plus cyclical hormonotherapy with tamoxifen (20 mg daily, days 1-10) and megestrol acetate (160 mg daily, days 11-21)." | ( Agelaki, S; Chalkiadakis, G; Georgoulias, V; Kakolyris, S; Kalbakis, K; Koukourakis, M; Samonis, G; Sanidas, E; Tsiftsis, D; Vlachonicolis, J, 1999) |
| "Twenty-three patients with metastatic breast cancer and prior chemotherapy were entered in a phase II study between June 1993 and December 1994." | ( Dabaja, B; Dandashi, A; El Saghir, NS; Salem, Z; Shamseddine, AI; Taher, A, 1999) |
| "The adjuvant endocrine therapy of breast cancer with non-steroidal antiestrogens of the triphenylethylene-type such as tamoxifen is clinically well established, and pure steroidal antiestrogens are being introduced in clinical trials to circumvent the probable occurrence of tamoxifen resistance." | ( Ehlers, EM; Schubert, C, 1999) |
| "Metaplastic breast cancer is a rare disease with little information available to guide therapy." | ( Adjei, AA; Ingle, JN; Rayson, D; Suman, VJ; Wold, LE, 1999) |
| "Estrogen receptor (ER)-negative breast carcinomas are often difficult to treat as they do not respond to hormone therapy." | ( Katzenellenbogen, BS; Lazennec, G, 1999) |
| "Patients with breast cancer scheduled to receive FAC chemotherapy (5-fluorouracil, adriamycin and cyclophosphamide) were eligible for the study." | ( Griffin, T; Hidalgo, M; Medina, G; Rinaldi, D; Turner, J; Von Hoff, DD, 1999) |
| "Animal models for breast cancer metastasis are valuable tools for studying mechanisms of metastasis and for preclinical testing of anti-metastatic therapy regimens." | ( Engebraaten, O; Fodstad, O, 1999) |
| "Eleven breast cancer patients received chemotherapy with 1." | ( de Vries, EG; Hofstra, LS; Mulder, NH; Sluiter, WJ; Spijkervet, FK; Timens, W; Timmer-Bosscha, H; van Buuren, AH; van der Graaf, WT; Wymenga, AN, 1999) |
| "Two cases of metastatic breast cancer are reported in which endocrine chemotherapy with Toremifene + 5'-DFUR proved markedly effective." | ( Kuroda, T; Mizutani, H; Nakamura, Y; Tadaoka, N; Takahashi, N, 1999) |
| "Combined chemotherapy for early breast cancer with cyclophosphamide, methotrexate, and fluorouracil has low associated mortality, but related deaths were seen among women aged 65 years or older in International Breast Cancer Study Group trials." | ( Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Gelber, RD; Goldhirsch, A; Price, KN, 1999) |
| "Doxorubicin-resistant human breast carcinoma cells (MCF-7-AdrR) were treated with either doxorubicin, tamoxifen, cyclosporine A, or the cyclosporine A analog SDZ PSC 833 (PSC 833) or with combinations thereof, and ceramide and glucosylceramide metabolisms were measured by cell radiolabeling." | ( Cabot, MC; Giuliano, AE; Han, TY; Liu, YY; Lucci, A, 1999) |
| "Patients with earlier stage breast cancer and operable tumors may also benefit from treatment with neoadjuvant chemotherapy." | ( Blohmer, JU; Costa, SD; Dresel, V; Eidtmann, H; Gademann, G; Hilfrich, J; Jackisch, C; Kaufmann, M; Merkle, E; Raab, G; von Minckwitz, G, 1999) |
| "In women with inoperable primary breast cancer or large T2 tumors, preoperative chemotherapy may induce tumor shrinkage, facilitate surgery and possibly improve survival." | ( Billgren, AM; Fornander, T; Rutqvist, LE; Skoog, L; Tani, E; Wilking, N, 1999) |
| "MR imaging depicted a primary breast cancer in 19 patients (86%; identified at excisional biopsy or mastectomy in 17, resolved on follow-up MR images during treatment in two)." | ( Fraker, DL; Orel, SG; Reynolds, CA; Schnall, MD; Schuchter, LM; Solin, LJ; Weinstein, SP, 1999) |
| "Patients with metastatic breast cancer who achieved a complete or partial remission after standard chemotherapy were eligible for the study." | ( Abati, A; Carter, C; Chang, YN; Chiang, Y; Chow, C; Cowan, KH; Cusack, G; Dunbar, C; Goldspiel, B; Gottesman, MM; Hines, K; Huang, H; Leitman, SF; McDonagh, K; Moscow, JA; Nienhuis, A; Noone, M; O'Shaughnessy, J; Pastan, I; Read, EJ; Schneider, E; Sorrentino, B; Steinberg, S; Wilson, W; Zujewski, JA, 1999) |
| "Administration of Ram to breast cancer patients on CMF or CEF therapy is thus concluded to be useful in the inhibition of nausea and vomiting." | ( Hojo, S; Noguchi, S; Shiba, E; Taguchi, T; Takamura, Y; Tsukamoto, F; Watanabe, T; Yoneda, K, 1999) |
| "A 60-year-old woman with her right breast cancer showing simultaneous and multiple liver metastases was initially treated with CEFT [cyclophosphamide (CPA), epirubicin (epi-ADM), 5-fluorouracil (5-FU), tamoxifen (TAM)]." | ( Fujitake, S; Kataoka, S; Maeda, Y; Nozaki, H; Shimizu, M; Tohyama, M, 1999) |
| "Xeloda is active in breast cancer and is administered orally." | ( Blum, JL, 1999) |
| "Early determination that breast cancer is bilateral and multifocal can change therapy strategy and, subsequently, mortality and morbidity rates." | ( Alakavuklar, M; Alanyali, H; Balci, P; Canda, T; Capa, G; Degirmenci, B; Derebek, E; Durak, H; Gorken, IB; Kocdor, MA, 1999) |
| "SLP induction in breast carcinoma cells treated with retinoids in vitro or in vivo was found to correlate with permanent growth inhibition under the conditions of minimal cytotoxicity, suggesting that this response may be particularly important for the antiproliferative effect of differentiating agents." | ( Broude, EV; Chang, BD; Christov, K; Dokmanovic, M; Kandel, ES; Lausch, E; Roninson, IB; Ruth, A; Xuan, Y; Zhu, H, 1999) |
| "We treated MCF-7 breast cancer cells three times with cytotoxic concentrations of BG + BCNU to isolate a population of MCF-7 cells possessing BG + BCNU resistance (BBR)." | ( Gerson, SL; Phillips, WP, 1999) |
| "Women with early breast cancer should be offered hormone replacement therapy after a full explanation of the benefits, risks, and controversies." | ( Gambrell, RD; Natrajan, PK; Soumakis, K, 1999) |
| "Patients with resected breast cancer involving four or more ipsilateral axillary lymph nodes were treated with nine cycles of chemotherapy, using 14-day intertreatment intervals." | ( Baselga, J; Crown, JP; Fennelly, D; Gilewski, T; Hudis, C; Lebwohl, D; Moynahan, M; Norton, L; Raptis, G; Riedel, E; Seidman, A; Sklarin, N; Surbone, A; Uhlenhopp, M; Yao, TJ, 1999) |
| "The fear of breast cancer is the most important concern for women who have to decide whether to take hormone replacement therapy (HRT) for the treatment and prevention of postmenopausal disturbances." | ( Chiechi, LM; Secreto, G, 1999) |
| "Most women with breast cancer are treated systemically with either chemotherapy or tamoxifen, or both, and mortality is substantially reduced." | ( Kotwall, CA, 1999) |
| "Metastatic breast cancer remains incurable with conventional chemotherapy." | ( Cottu, PH; Espie, M; Extra, JM; Marty, M; Mignot, L; Morvan, F; Zelek, L, 1999) |
| "Women with metastatic breast cancer were treated every 14 days for 6 courses with 75 mg/m2 epirubicin and 1200 mg/m2 cyclophosphamide, followed by conventionally-delivered (q 3-4 weeks) chemotherapy." | ( Cottu, PH; Espie, M; Extra, JM; Marty, M; Mignot, L; Morvan, F; Zelek, L, 1999) |
| "(1) Forty-six breast cancer patients were randomly assigned to a group in which oral 5'-DFUR (1200 mg/day) was administered for more than 5 days before operation (24 patients) and a control group who received no preoperative chemotherapy (22 patients)." | ( Kazui, T; Kimura, T; Kobayashi, T; Sugimura, H; Suzuki, K; Uno, T; Yoshida, M; Yoshida, T, 1999) |
| "Patients with progressive advanced breast cancer previously untreated with anthracylines and progestins were given epirubicin (30 mg/m2) and ifosfamide (2 g/m2) on days 1 and 8 at 3-weekly intervals." | ( Becher, R; Bechtel, C; Berke, A; Borquez, D; Donsbach, GM; Hartwich, G; Hawig, I; Heckmann, M; Hirche, H; Huhn, R; Klaassen, U; Kloke, O; Oberhoff, C; Rudolph, R; Schindler, AE; Schnepper, U; Seeber, S; Stephan, L; Szanto, J; Wolf, E, 1999) |
| "Because the prostate and breast cancer lines usually present autocrine stimulatory loops involving EGFR, we also examined transgenic adenocarcinoma mouse prostate C1 and MDA-468 treated with the EGFR-specific kinase inhibitor PD153035 to determine whether invasiveness is dependent on EGFR signaling." | ( Greenberg, NM; Kassis, J; Kim, HG; Lo, H; Moellinger, J; Wells, A, 1999) |
| "There is concern that breast cancer patients treated with left-sided radiation therapy (XRT) and doxorubicin (DOX) may have an increased risk of cardiac toxicity." | ( Come, SE; Gelman, RS; Gollamudi, S; Hardenbergh, PH; Harris, JR; Hayes, DF; O'Neill, A; Recht, A; Shulman, LN; Silver, B, 1999) |
| "Treatment of MCF-7 breast cancer cells with the marine toxin maitotoxin (MTX) induces cell death." | ( Malaguti, C; Paolo Rossini, G; Yasumoto, T, 1999) |
| "Advanced breast cancer patients' quality of life was high, showing the efficacy of endocrine therapy, but women with primary disease reported better physical, social, and functional well-being and fewer breast cancer concerns." | ( Benson, S; Cella, D; Fallowfield, LJ; Howell, A; Leaity, SK, 1999) |
| "Twenty-six patients with breast cancer who had relapsed after previously receiving high-dose chemotherapy and autologous hematopoietic cell support received a second course of high-dose cytoreductive therapy and autologous hematopoietic cell support as salvage therapy." | ( Bearman, S; Cagnoni, P; Jones, R; Nieto, Y; Peters, W; Ross, M; Shpall, E; Vredenburgh, J, 1999) |
| "Patients with metastatic breast cancer received induction therapy with doxorubicin, fluorouracil, and methotrexate (AFM)." | ( Affronti, ML; Berry, D; Broadwater, G; Chao, NJ; Coniglio, D; Elkordy, M; Gilbert, C; Hussein, A; Jones, R; Long, GD; Peters, WP; Petros, WP; Rizzieri, DA; Ross, M; Rubin, P; Shpall, EJ; Vredenburgh, JJ, 1999) |
| "Patients with high risk primary breast cancer were treated with high-dose cyclophosphamide and thiotepa and stem-cell transplant following surgery and conventional-dose adjuvant chemotherapy." | ( Buzby, GP; Fox, KR; Glatstein, E; Loh, E; Luger, SM; Mangan, PA; Mick, R; Moore, HC; Porter, DL; Schuchter, LM; Schuster, S; Sickles, C; Silberstein, LE; Solin, LJ; Stadtmauer, EA, 1999) |
| "Treatment of the human breast cancer cell lines MDA-MB-453, ZR-75-1 and T47-D with high dose (100 nM) MPA resulted in 26-30% inhibition of cell growth, which was partially reversed by co-treatment with a 10-fold excess of the synthetic antiandrogen, anandron." | ( Bentel, JM; Birrell, SN; Holds, DJ; Horsfall, DJ; Pickering, MA; Tilley, WD, 1999) |
| "We reviewed the mammograms of 102 breast cancer patients treated with tamoxifen (20 mg per day); these patients were subgrouped into tamoxifen-only patients and patients treated with tamoxifen in combination with another therapy (chemotherapy, radiotherapy, or both)." | ( Oh, KK; Son, HJ, 1999) |
| "On follow-up mammography of breast cancer patients, breast parenchyma was shown to be decreased after tamoxifen therapy." | ( Oh, KK; Son, HJ, 1999) |
| "Tamoxifen is effective in treating breast cancer, reduces breast cancer incidence among high-risk women, and is associated with increased endometrial cancer risk." | ( Bernstein, L; Cerhan, JR; Deapen, D; Ford, L; Liff, J; McGann-Maloney, E; Perlman, JA; Schwartz, SM, 1999) |
| "We obtained information on breast cancer treatment and endometrial cancer risk factors through interviews and reviews of medical records." | ( Bernstein, L; Cerhan, JR; Deapen, D; Ford, L; Liff, J; McGann-Maloney, E; Perlman, JA; Schwartz, SM, 1999) |
| "Patients with poor-prognosis stage IV breast cancer were treated with this "neo-FAC" as front-line therapy." | ( Ellis, GK; Green, S; Kraut, MJ; Livingston, RB; Martino, S; Paradelo, JC; Pierce, HI; Taylor, SA, 1999) |
| "Conditioned medium from irradiated breast cancer cells, but not from nonirradiated cells, inhibited the growth of untreated MDA-MB-231 cells." | ( Arnold, SF; Bluman, EM; McGrath, BE; Tims, E, 1999) |
| "Women with breast cancer are the most frequent recipients of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (autotransplants) in North America." | ( Antman, KH; Armitage, JO; Bitran, JD; Fay, JW; Fields, KK; Freytes, CO; Gale, RP; Herzig, RH; Horowitz, MM; Kennedy, MJ; Klein, JP; Lazarus, HM; McCarthy, PL; Pecora, AL; Pelz, CJ; Reed, E; Rowlings, PA; Sobocinski, KA; Spitzer, G; Stadtmauer, EA; Vaughan, WP; Williams, SF; Wolff, SN, 1999) |
| "Adjuvant treatment of breast cancer with tamoxifen may be associated with reduced risk of cardiovascular disease." | ( Anker, G; Lien, EA; Love, RR; Lønning, PE; Refsum, H; Ueland, PM; Yang, Y, 1999) |
| "Cultured breast cancer MCF-7 and MDA-MB-231 cells that express high levels of heat shock protein 70 and 27 kDa are resistant to treatment with certain anticancer drugs." | ( Gist, ID; Kiang, JG; Tsokos, GC, 1999) |
| "In response to findings from the Breast Cancer Prevention Trial that tamoxifen treatment produced a 49% reduction in the risk of invasive breast cancer in a population of women at elevated risk, the National Cancer Institute sponsored a workshop on July 7 and 8, 1998, to develop information to assist in counseling and in weighing the risks and benefits of tamoxifen." | ( Bryant, J; Costantino, JP; Croyle, R; Freedman, L; Gail, MH; Helzlsouer, K; Vogel, V, 1999) |
| "Fenretinide treatment of women with breast cancer for 5 years appears to have no statistically significant effect on the incidence of second breast malignancies overall, although a possible benefit was detected in premenopausal women." | ( Boni, C; Camerini, T; Campa, T; Costa, A; D'Aiuto, G; De Palo, G; Decensi, A; Del Turco, MR; Del Vecchio, M; Di Mauro, MG; Formelli, F; Magni, A; Malone, WF; Mariani, L; Marubini, E; Miceli, R; Muraca, MG; Perloff, M; Pinto, C; Sporn, MB; Veronesi, U, 1999) |
| "Patients with metastatic breast cancer, especially those with progression after several prior chemotherapy treatments, need efficient chemotherapy." | ( Bergman, M; Ekholm, E; Huhtala, S; Salminen, E, 1999) |
| "In endocrine therapy trials in advanced breast cancer, patients with response (complete response/partial response [CR/PR]) and patients with stable disease for at least 6 months (SD(6m)) have shown similar survival and therefore are often defined as a population with clinical benefit (patients with CR/PR or SD(6m))." | ( Bernhard, J; Bonnefoi, H; Castiglione-Gertsch, M; Cavalli, F; Fey, MF; Goldhirsch, A; Hürny, C; Morant, R; Schmitz, SF; Thürlimann, B, 1999) |
| "A total of 487 women with breast cancer, 357 treated with tamoxifen and 130 controls, were screened with TV USS, and endometrial thickness was measured." | ( Dillon, P; Dixon, JM; Leonard, RC; Love, CD; Muir, BB; Scrimgeour, JB, 1999) |
| "Twelve breast cancer patients received transcriptionally targeted gene therapy in a phase I clinical trial using direct intratumoral injection of plasmid construct combined with systemic administration of prodrug." | ( Hurst, HC; Lemoine, NR; Martin, LA; Pandha, HS; Rigg, A; Sikora, K; Stamp, GW, 1999) |
| "Premenopausal women with breast cancer often enter a premature menopause during initial treatment of their malignancy, with resulting loss of childbearing capacity, onset of menopausal symptoms, and subsequent prolonged exposure to long-term risks of menopause." | ( Ennis, M; Goodwin, PJ; Hood, N; Pritchard, KI; Trudeau, M, 1999) |
| "Although this preinvasive form of breast cancer is not life-threatening, treatment options may include mastectomy, breast-conserving surgery, radiotherapy, or tamoxifen." | ( Esserman, LJ; Hwang, ES, 1999) |
| "Sixty-three breast cancer patients with advanced disease (24 locally advanced and 39 metastatic), who had not received prior chemotherapy (except adjuvant), received weekly cisplatin (CDDP) doses of 30 mg/m2 together with escalating doses of paclitaxel (PTX) and epirubicin (EPI) for a minimum of six cycles." | ( Apicella, A; Bianchi, U; Biglietto, M; Capasso, I; Cartenì, G; Comella, G; Comella, P; D'Aiuto, G; D'Aniello, R; De Lucia, L; Di Bonito, M; Frasci, G; Lapenta, L; Maiorino, L; Piccolo, S; Thomas, R, 1999) |
| "It is not been established whether breast cancer patients who have a primary tumor 5 cm or larger but no axillary nodal or distant metastases at the time of the diagnosis (pT3N0M0) benefit from post-operative radiation therapy after mastectomy." | ( Blomqvist, C; Heikkilä, P; Helintö, M; Joensuu, H, 1999) |
| "We identified 81 patients with T3N0M0 breast cancer out of the total of 4190 breast cancer patients treated in one university radiotherapy department from 1987 to 1994 from the department patient registry, and examined the clinical records and histopathological slides." | ( Blomqvist, C; Heikkilä, P; Helintö, M; Joensuu, H, 1999) |
| "In two patients with breast carcinoma, radioactive technetium was administered intravenously and a gamma probe was used preoperatively and intraoperatively to identify the site of cranial bone involvement." | ( Albert, GD; Alex, JC; Krag, DN; Weinberg, DA, 1999) |
| "She had a history of breast carcinoma 6 years ago, which was treated by breast amputation and radiation." | ( Morresi-Hauf, A; Welsch, U; Wöckel, W, 1999) |
| "Twenty-five patients with metastatic breast cancer were treated with ICE after failure of previous chemotherapy." | ( Asbury, R; Boros, L; Chang, AY; Garrow, G; Hui, L; Rubins, J, 1999) |
| "Recurrent cutaneous breast cancer is difficult to manage, with surgery, radiotherapy and systemic therapy all having their limitations." | ( Clive, S; Gardiner, J; Leonard, RC, 1999) |
| "In 1984, the German Breast Cancer Study Group started a multicenter randomized trial to compare six versus three cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) starting perioperatively and to investigate the additional effect of tamoxifen as adjuvant treatment in node-positive breast cancer patients treated with mastectomy." | ( Bastert, G; Beyerle, C; Bojar, H; Neumann, RL; Sauerbrei, W; Schmoor, C; Schumacher, M, 2000) |
| "In human breast cancer, lack of response to endocrine therapy is often associated with decreased expression of the estrogen receptor and increased expression of epidermal growth factor receptor (EGFR) and/or HER-2/neu (ErbB-2)." | ( Egeblad, M; Jäättelä, M; Larsen, SS; Lykkesfeldt, AE, 1999) |
| "Treatment of breast cancer with the antiestrogen tamoxifen is effective in approximately one half of the patients with estrogen receptor-positive disease, but tumors recur frequently because of the development of metastases that are resistant to tamoxifen." | ( Brinkman, A; Dorssers, LC; Kok, EM; van der Flier, S, 2000) |
| "Patients with primary breast tumors expressing a high level of Bcar1/p130Cas protein appear to experience more rapid disease recurrence and have a greater risk of (intrinsic) resistance to tamoxifen therapy." | ( Brinkman, A; Dorssers, LC; Foekens, JA; Klijn, JG; Kok, EM; Look, MP; Meijer-van Gelder, ME; van der Flier, S, 2000) |
| "In human MCF-7 breast cancer cell tumors raised in nude mice in the presence of estrogen, the growth and expression of pS2 marker gene could not be maintained after estrogen withdrawal by treatment with FC1271a." | ( Cockcroft, N; Dahllund, J; Härkönen, P; Hemminki, K; Kangas, L; Koskinen, M; Laine, A; Peng, Z; Qu, Q; Väänänen, K; Zheng, H, 2000) |
| "(3) The results for the mouse breast cancer (EMT6) studies of the sequence of AAs again indicated that M employed first markedly reduced responsiveness to subsequent treatment, particularly with AAs." | ( Ara, G; Bunnell, C; Elias, A; Frei, E; Richardson, P; Teicher, B; Tew, K; Wheeler, C, 2000) |
| "Women with BRCA1- or BRCA2-associated breast cancer are at increased risk for contralateral breast cancer and ovarian cancer and therefore may consider secondary cancer prevention strategies, such as prophylactic surgery and tamoxifen therapy." | ( Garber, JE; Kuntz, KM; Schrag, D; Weeks, JC, 2000) |
| "To this end, we transfected T47-D breast cancer cells with an estrogen-responsive reporter and then treated the cells (for 4-48 h) with varying concentrations of TGF-alpha, E2, the antiestrogen 4-hydroxy-tamoxifen (HOT), and/or one of three phytoestrogens." | ( Frawley, LS; Willard, ST, 1999) |
| "Estrogenic recruitment of breast cancer cells before FAC chemotherapy did not influence the efficacy of adjuvant chemotherapy in stage II/IIIA breast cancer patients after a follow-up of 6." | ( Baggen, MG; Beudeker, M; Bontenbal, M; Braun, JJ; Burghouts, JT; Foekens, JA; Helle, P; Janssen, JT; Klijn, JG; Leisink, M; Ras, GJ; Stiegelis, WF; van der Linden, GH; van der Velden, PC; van Geel, AN; van Putten, WL, 2000) |
| "Patients with metastatic breast cancer in complete remission are the ones most likely to have an improved outcome with subsequent high-dose chemotherapy and autologous peripheral blood stem cell transplantation (HDC-PBSCT)." | ( Bilgrami, S; Bona, RD; Clive, J; Edwards, RL; Feingold, JM; Kazierad, D; Khan, AM; Khan, IA; Rodriguez-Pinero, F; Tutschka, PJ, 2000) |
| "Fifteen patients with breast cancer received taxol 170 mg/m2 (continuous infusion, day 1) and rhG-CSF (8 microg/kg/day, from day 2 until the end of apheresis) (T-G group), while seven breast cancer patients were additionally treated with CY (4 g/m2) on day 2, followed by rhG-CSF starting at similar doses on day 3 (T-CY-G group)." | ( Ayala, F; de Arriba, F; Gómez-Espuch, J; Lozano, ML; Moraleda, JM; Ortuño, F; Vallejo, C; Vicente, V, 2000) |
| "The theoretical prediction that breast cancer is a systemic disease, and that patients may benefit from addition of systemic therapy to local treatment, has now been confirmed by three decades of clinical investigations." | ( Cufer, T, 1999) |
| "The long term outcome of women with breast carcinoma and isolated SCN metastases whose disease is sensitive to CT appears to be favorable; whether this result is superior to that achieved with standard therapy alone remains to be confirmed in prospective, randomized trials." | ( Abraham, R; Crump, M; Goss, PE; Nagy, T, 2000) |
| "In this small group of breast carcinoma patients, the NI was found to be the most powerful predictor of neutropenia after CMF-based chemotherapy." | ( Allen, BJ; Aslani, A; Levi, JA; Pavlakis, N; Smith, RC, 2000) |
| "Twelve women with metastatic breast cancer were treated with continuous infusion high dose leucovorin, 5-fluorouracil and cisplatin." | ( Booser, DJ; Holmes, FA; Hortobagyi, GN; Walters, RS, 2000) |
| "Women, with non-metastatic breast cancer, eligible for non-intensified adjuvant chemotherapy attending our hospital were proposed two administrations of chemotherapy and radiotherapy: a sequential and a concomitant one." | ( Alzieu, C; Bertucci, F; Camerlo, J; Cowen, D; Genre, D; Gravis, G; Maraninchi, D; Moatti, JP; Protière, C; Resbeut, M; Viens, P, 2000) |
| "In p53 wild-type MCF-7 breast carcinoma cells, the cyclin-dependent kinase inhibitor protein p21/WAF1 was markedly induced after the treatment with MMC alone, although this response was significantly delayed from the time of MMC treatment." | ( Akinaga, S; Akiyama, T; Eastman, A; Shimizu, M; Sugiyama, K; Takahashi, R; Tamaoki, T; Yamaguchi, K, 2000) |
| "Sixty-five women with breast cancer, on tamoxifen oral therapy (20 mg/day), and a totally normal eye examination, were prospectively followed up." | ( Bashshur, Z; Khalil, A; Noureddin, BN; Salem, Z; Seoud, M; Shamseddin, A, 1999) |
| "A new paradigm governed surgery for breast cancer, and lumpectomy followed by radiation therapy became accepted practice." | ( Fisher, B, 1999) |
| "Patients with breast cancer who develop subsequent hepatic metastases have higher relative hepatic arterial perfusion during triple-phase CT; however, after correction for chemotherapy interval, this difference was not statistically significant." | ( DeLong, DM; Foti, AM; Killius, JS; Nelson, RC; Paulson, EK; Sheafor, DH, 2000) |
| "Their role in the treatment of advanced breast cancer is well established and their use in adjuvant therapy is currently being explored." | ( Goss, PE, 1999) |
| "Treatment of human breast cancer cell lines in culture with these analogues has been shown to decrease cell proliferation and induce programmed cell death." | ( Casero, RA; Davidson, NE; Hahm, HA; McCloskey, DE; Woster, PM, 1999) |
| "The choice of treatment for elderly breast cancer patients needs particular care because the presence of physiological functional impairments can modify the drug bioavailability in an unpredictable manner." | ( Bajetta, E; Bichisao, E; Pozzi, P; Toffolatti, L; Zilembo, N, 2000) |
| "Of the 40 recurrent breast cancer patients, 26 were pretreated with anthracycline." | ( Naito, Y; Oura, S; Sakurai, T; Suzuma, T; Tanino, H; Yamamiti, N; Yoshimasu, T, 2000) |
| "Currently the relative risk increase of breast cancer during long-term hormone replacement therapy cannot be exactly measured." | ( Tóth, KS, 2000) |
| "Of the 156 advanced breast cancer patients, 83 had had MTT assay before chemotherapy." | ( Song, S; Tang, Z; Xu, J, 1997) |
| "Forty-three breast cancer patients were treated by TNCF (THP-doxorubicin, vinorelbine, cyclophosphamide, fluorouracil, D1 to D4) with CSF support: 11 patients received GM-CSF (D5 to D14); 16 patients G-CSF (D5 to D14) and 16 patients GM-CSF (D5-D14) plus G-CSF (D10-D14)." | ( Bay, JO; Bétail, G; Charrier, S; Chassagne, J; Chollet, P; Communal, Y; Curé, H; Kwiatkowski, F; Plagne, R; Portefaix, G, 2000) |
| "Adhesion of metastatic human mammary carcinoma MDA-MB-435 cells to the basement membrane protein collagen type IV can be activated by treatment with arachidonic acid." | ( Akiyama, SK; Olden, K; Paine, E; Palmantier, R; Roberts, JD, 2000) |
| "Endocrine therapy for breast cancer is now well established and with the identification of a second oestrogen receptor, ERbeta, 3 years ago it is timely to review the possible significance of this receptor in breast cancer management." | ( Kerin, MJ; Speirs, V, 2000) |
| "These data suggest that pretreatment of breast cancer with 1,25(OH)2D3 or ATRA lowers the threshold for cell killing by chemotherapy agents and may provide a novel treatment option for this disease." | ( Christakos, S; Uytingco, MS; Wang, Q; Wieder, R; Yang, W, 2000) |
| "Twenty-four breast cancer patients on adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) were studied along with 16 healthy pre-menopausal women." | ( Kajdaniuk, D; Marek, B, 2000) |
| "For high-risk patients with breast cancer with more than three positive axillary lymph nodes, this series adopted a modified sequential regimen of ACMF first with Adriamycin (A) as a single agent in 3-weekly administration for three courses, and then a combination of cyclophosphamide, methotrexate, fluorouracil (CMF) every 3 to 4 weeks for six courses given in an outpatient setting concurrent with radiation therapy as an adjuvant treatment." | ( Chen, CM; Cheng, SH; Hsieh, CI; Huang, AT; Liu, MC; Liu, TW; Tsou, MH, 2000) |
| "We studied, in primary breast tumors through direct cDNA sequencing of exons 2-11, whether TP53 gene mutations can predict response in patients with advanced disease to either first-line tamoxifen therapy (202 patients, of whom 55% responded) or up-front (poly)chemotherapy (41 patients, of whom 46% responded)." | ( Bakker, B; Berns, EM; Claassen, CJ; Cornelisse, C; Devilee, P; Foekens, JA; Henzen-Logmans, SC; Inganäs, M; Klijn, JG; Look, MP; Meijer-van Gelder, ME; Portengen, H; van Putten, WL; van Staveren, IL; Vossen, R, 2000) |
| "From a retrospective analysis of 735 breast cancers treated in our institute, we found 61 lymphedema of the arm." | ( Betel, E; Dembele, B; Deme, A; Dieng, M; Diop, M; Diop, PS; Drabo, B; Fall, MG; Kasse, AA; Ndaw, D; Timbely, G; Toure, P, 1999) |
| "She was receiving tamoxifen therapy for breast cancer and had bilateral ovarian Brenner tumors." | ( Brief, DK; Danikas, D; Goudas, VT; Rao, CV, 2000) |
| "Advanced breast cancer patients aged between 18 and 70 with ECOG PS 0-2 who had not responded to, or had relapsed after, first-line anthracycline-based chemotherapy, were randomized to receive either gemcitabine 1000 mg/m2 or vinorelbine 25 mg/m2 in combination with escalating doses of docetaxel (starting from 30 mg/m2), all on days 1 and 8 every three weeks." | ( Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; De Rosa, V; Elmo, M; Frasci, G; Lapenta, L; Petrillo, A; Thomas, R; Vallone, P, 2000) |
| "Thirty-nine consecutive stage II breast cancer patients were treated." | ( Angiolini, C; Bertelli, G; Del Mastro, L; Esposito, M; Lunardi, G; Numico, G; Pastrone, I; Rosso, R; Straneo, M; Tolino, G; Vannozzi, MO; Venturini, M; Viale, M, 2000) |
| "We retrospectively evaluated 443 breast cancer patients treated with high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) with autologous stem cell support to characterize the cardiac toxicity of this regimen." | ( Bearman, SI; Cagnoni, PJ; Jones, RB; Matthes, S; Nieto, Y; Shpall, EJ, 2000) |
| "There is substantial evidence that breast cancer risk is associated with prolonged exposure to female hormones, since early onset of menarche, late menopause, hormone replacement therapy and postmenopausal obesity are associated with greater cancer incidence." | ( Russo, IH; Russo, J, 1998) |
| "194 postmenopausal women with breast cancer who were receiving adjuvant tamoxifen therapy." | ( Dragalin, V; Flynn, PJ; Hynes, HE; Kirshner, JJ; Morrow, GR; Pandya, KJ; Pierce, HI; Raubertas, RF; Rosenbluth, RJ, 2000) |
| "Forty-five patients with metastatic breast cancer without clinically evident disease were treated with thiotepa 750 mg/m2, mitoxantrone 40 mg/m2 and carboplatin 1000 mg/m2 followed by stem cell transplantation to determine the safety and efficacy of CD34+ selection of peripheral blood stem cells." | ( Ahmed, T; Ali, MF; Bar, M; Chun, HG; Durrani, H; Farley, T; Goldberg, R; Kancherla, R; Lake, D; Lipshutz, M; Mannancheril, A; Mittelman, A; Preti, R; Puccio, C; Qureshi, Z; Seiter, K, 2000) |
| "Nineteen breast cancer patients pretreated with one or two anthracycline-containing regimens for visceral metastases received i." | ( Brodowicz, T; Herscovici, V; Koestler, WJ; Steger, GG; Tomek, S; Vaclavik, I; Wiltschke, C; Zielinski, CC, 2000) |
| "We report a case of far advanced breast cancer showing an excellent response to chemo-endocrine therapy." | ( Hayashi, K; Kasuga, Y; Kondo, R; Munakata, Y; Nishimura, H; Takasuna, K, 2000) |
| "Twenty patients (pts) with metastatic breast cancer with disease progression, previously treated with chemotherapy and tamoxifen, were administered oral letrozole (2." | ( Cappellini, GC; Casali, A; Casali, M; Giuntini, T; Sega, FM; Terzoli, E, 2000) |
| "The assessment of angiogenesis in breast cancer is of importance as a key indicator of survival and response to therapy." | ( Adams, J; Allgar, V; Banks, RE; Bicknell, R; Cairnduff, F; Carder, PJ; Downey, S; Forbes, MA; Hallam, S; Kaufman, S; Lansdown, M; MacLennan, K; Perren, TJ; Selby, PJ; Walker, JJ, 2000) |
| "We treated 36 patients with advanced breast cancer in a multicentre phase I/II study." | ( Blijham, GH; Erdkamp, FL; Hillen, HF; Lalisang, RI; Nortier, JW; Schouten, HC; Voest, EE; Wals, J; Wils, JA, 2000) |
| "Between 1978 and 1993 the International Breast Cancer Study Group (IBCSG) treated 3700 premenopausal and perimenopausal patients with various timing and duration of adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF with or without low-dose prednisone and oophorectomy)." | ( Aebi, S; Castiglione-Gertsch, M; Coates, AS; Collins, J; Cortes-Funes, H; Crivellari, D; Gelber, RD; Gelber, S; Goldhirsch, A; Lindtner, J; Rudenstam, CM; Simoncini, E; Thürlimann, B; Werner, ID, 2000) |
| "Young premenopausal breast cancer patients treated with adjuvant CMF chemotherapy had higher risk of relapse and death than older premenopausal patients, especially if their tumours expressed oestrogen receptors." | ( Aebi, S; Castiglione-Gertsch, M; Coates, AS; Collins, J; Cortes-Funes, H; Crivellari, D; Gelber, RD; Gelber, S; Goldhirsch, A; Lindtner, J; Rudenstam, CM; Simoncini, E; Thürlimann, B; Werner, ID, 2000) |
| "A retrospective review of advanced breast cancer patients treated with CI-5FU between October 1992 and October 1996 was performed." | ( Karapetis, CS; Kotasek, D; Patterson, WK; Pittman, KB; Sage, RE, 1999) |
| "Twenty-four patients with metastatic breast cancer were treated with CI-5FU." | ( Karapetis, CS; Kotasek, D; Patterson, WK; Pittman, KB; Sage, RE, 1999) |
| "Patients with metastatic breast carcinoma who were previously treated with chemotherapy were administered increasing doses of a 96-hour paclitaxel i." | ( Bella, MA; Beretta, MD; Cocconi, G; Ferrozzi, F; Mambrini, A; Quarta, M; Vasini, G, 2000) |
| "Of the 42 women with metastatic breast cancer (age 33 to 74 years; mean age, 55 years), 13 were chemotherapy-naive and 29 had received adjuvant chemotherapy." | ( Alba, E; García-Conde, J; Khayat, D; Lluch, A; Moreno-Nogueira, JA; Palomero, M; Pérez-Manga, G; Rivelles, N, 2000) |
| "The incidence of PTS in breast cancer patients treated with a BCNU-containing HDC regimen can be remarkably high." | ( Blume, KG; Cao, TM; Hu, WW; Johnston, LJ; Negrin, RS; Rizk, NW; Shizuru, JA; Stockerl-Goldstein, KE; Taylor, TL; Wong, RM, 2000) |
| "Despite the critical importance to breast cancer treatment, little is known about the loss of estrogen responsiveness and the development of antiestrogen resistance." | ( Haslam, SZ; Lu, H; Woodward, TL, 2000) |
| "Thirty two cases with stage III and IV breast cancer were treated with epirubicin (EPI) 90-110 mg/m2, cyclophosphamide (CTX) 600 mg/m2 and 5-fluorouracil (5-Fu) 900 mg/m2 every 21 days." | ( Dai, A; Feng, J; Zheng, X, 1998) |
| "T47D human breast cancer cells express a functional estrogen receptor alpha (ERalpha) and AhR, and treatment of these cells with 17beta-estradiol (E2) or TCDD resulted in a rapid proteasome-dependent decrease in immunoreactive ERalpha and AhR proteins (>60-80%), respectively." | ( Safe, S; Saville, B; Stoner, M; Wormke, M, 2000) |
| "Two cases of recurrent breast cancer are reported in which chemotherapy with mitoxantrone proved remarkably effective." | ( Katagata, N; Matsuoka, T; Nomizu, T; Takenoshita, S; Tsuchiya, A; Watanabe, F; Yabuta, T; Yamaki, Y, 2000) |
| "Treatment of quiescent MCF-7 human breast cancer cells with either the polypeptide growth factors insulin-like growth factor-I (IGF-I) or epidermal growth factor (EGF), the steroid hormone estradiol (E2) or the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) results in increased steady-state levels of cyclin D1 mRNA and protein." | ( Dufourny, B; Hamelers, IH; Steenbergh, PH; Sussenbach, JS, 2000) |
| "Treatment of MCF-7 human breast cancer cells with the DNA damaging drugs adriamycin, campthothecin, or etoposide causes a coordinated up-regulation of both isoforms." | ( Jeng, J; Wang, TT, 2000) |
| "Antiestrogens are widely used for breast cancer treatment, where they act primarily by inhibiting the mitogenic action of estrogens on tumor cells." | ( Addeo, R; Altucci, L; Belsito Petrizzi, V; Boccia, V; Bresciani, F; Cancemi, M; Cicatiello, L; Germano, D; Pacilio, C; Salzano, S; Weisz, A, 2000) |
| "In women aged 55 years or more with breast cancer, capecitabine showed at least comparable efficacy to CMF combination therapy." | ( Maeda, Y; Sasaki, T, 2000) |
| "Patients with advanced breast cancer, performance status 0-2, measurable disease, and a normal left ventricular ejection fraction, who may have received adjuvant chemotherapy were treated with epirubicin 75 mg m(-2) followed by a 3-h infusion of paclitaxel 175 mg m(-2) repeated every 3 weeks." | ( Boyer, M; Gurney, H; Lewis, C; McKendrick, J; Millward, M; Richardson, G; Rischin, D; Smith, J; Toner, G, 2000) |
| "Seventy postmenopausal patients with breast cancer treated with anti-estrogens for at least 6 months were entered." | ( Buchmann, J; Koelbl, H; Methfessel, G; Strauss, HG; Wolters, M, 2000) |
| "Tamoxifen-treated breast carcinoma survivors are at elevated risk of endometrial carcinoma." | ( Althuis, MD; Bush, TL; Khoo, L; Langenberg, P; Magaziner, J; Sexton, M; Tkaczuk, K, 2000) |
| "Oestrogen receptor positive breast cancers are associated with a better prognosis than oestrogen-receptor negative breast cancers since they are more responsive to hormonal treatment." | ( Lai, LC; Nesaretnam, K; Ng, JH; Reimann, K, 2000) |
| "Raloxifene reduces the risk of breast cancer by 76% after treatment for four years and builds an atrophic endometrium without any bleedings." | ( Eriksen, EF, 2000) |
| "Another report, from the International Breast Cancer Study Group, raised the controversial question of whether there really is much added benefit from the addition of chemotherapy to tamoxifen in postmenopausal women with negative lymph nodes if their tumors have ERs (Abstract 281)." | ( Kuter, I, 2000) |
| "One hundred and ninety-one breast cancer patients (99 stage II/IIIA; 27 stage IIIB; 65 stage IV responsive to conventional-dose chemotherapy) were treated with high-dose chemotherapy (CTM) delivered over 4 days (cyclophosphamide (6 g/m2), thiotepa (600 mg/m2), and mitoxantrone (24-60 mg/m2)) followed by autologous hematopoietic stem cell rescue." | ( Cassidy, M; Cecchi, G; Cohen, N; Damon, LE; Gold, E; Irwin, D; Linker, CA; Ries, CA; Rugo, HS; Tracy, M; Wolf, JL; Zander, AR, 2000) |
| "We report three cases of women with breast cancer who developed renal impairment following treatment with high-dose ifosfamide." | ( Hill, PA; Power, DA; Prince, HM, 2000) |
| "Treatment of advanced or recurrent breast cancer with medroxyprogesterone acetate (MPA) shows high response rates and the accessory effects of appetite stimulation, improvement in performance status (PS) and bone marrow protection." | ( Baba, K; Fukuda, M; Hamamoto, R; Matsuda, M; Matsuoka, Y; Miyayama, H; Mizumoto, T; Nagao, K; Nishimura, R; Yamashita, H, 2000) |
| "Fifteen stage II breast cancer patients on adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) were studied along with 15 healthy premenopausal women." | ( Ciesielska-Kopacz, N; Glogowska-Szelag, J; Kajdaniuk, D; Kos-Kudla, B; Marek, B; Ostrowska, Z; Swietochowska, E; Wielkoszyski, T, 2000) |
| "Fourteen of them, 7 of whom had breast cancer, were treated a third time 28 (range 5-79) days after the second course (median dose of pamidronate 1." | ( Body, JJ; Dumon, JC; Louviaux, I, 2000) |
| "Some patients with locally advanced breast cancer receive preoperative (neoadjuvant) chemotherapy, which may alter lymphatic drainage and lymph node structure." | ( Breslin, TM; Cohen, LF; Hunt, KK; Kuerer, HM; Ross, MI; Sahin, AA, 2000) |
| "Choroidal metastases from breast cancer represent an unusual metastatic presentation that has been traditionally treated with radiation therapy." | ( Antonopoulos, M; Kosmas, C; Malamos, NA; Tsavaris, N, 2000) |
| "Early detection and prompt treatment of breast cancer are the main tools to decrease mortality rates." | ( Fuster, D; Martin, F; Mateos, JJ; Muñoz, M; Ortega, M; Pons, F; Vidal, S, 2000) |
| "In conclusion, in a group of metastatic breast cancer patients, treated routinely by systemic therapies it was found, that the use of higher cut-off point for EGF-R positivity can improve the prediction of endocrine sensitivity." | ( Branković-Magić, MV; Mitrovic, LB; Nesković-Konstantinović, ZB; Nikolić-Vukosavljević, DB; Spuzić, I, 2000) |
| "We apply STEPP to a breast cancer clinical trial data set to evaluate the treatment effect as a function of the oestrogen receptor content of the primary tumour." | ( Bonetti, M; Gelber, RD, 2000) |
| "Moreover, increased incidence of breast cancer diagnosis after prolonged hormone replacement therapy (HRT) use seems to be associated with clinically less advanced disease." | ( Atsma, WJ; Burger, CW; Coelingh-Bennink, HJ; Eden, JA; Hammar, M; Kenemans, P; Marsden, J; Purdie, DW; Verheul, HA, 2000) |
| "We now show that treatment of MCF-7 breast cancer cells with the pure estrogen antagonist ICI 182780 results in inhibition of cyclin E-Cdk2 activity prior to a decrease in the G(1) to S phase transition." | ( Carroll, JS; Musgrove, EA; Prall, OW; Sutherland, RL, 2000) |
| "In conclusion, breast cancer patients with metastatic bone pain can benefit from therapy with 89Sr." | ( Conill, C; Fuster, D; Herranz, D; Martín, F; Mateos, JJ; Muñoz, M; Pons, F; Vidal-Sicart, S, 2000) |
| "Three populations of breast cancer were studied: 43 before the beginning of tamoxifen; 78 after 5-72 months of tamoxifen, and 34 before tamoxifen and after 12-24 months of tamoxifen treatment (PAIRED GROUP)." | ( Andía, D; Lafuente, P; Matorras, R; Usandizaga, JM, 2000) |
| "A total of 65 patients with invasive breast cancer treated with axillary lymph node dissection were preoperatively evaluated by MRI." | ( Fjøsne, HE; Haraldseth, O; Kvistad, KA; Lundgren, S; Rydland, J; Smethurst, HB, 2000) |
| "Human breast carcinoma MCF-7 cells growing on microscope slides were treated with the DNA topoisomerase I inhibitor, camptothecin (CPT)." | ( Bedner, E; Darzynkiewicz, Z; Kunicki, J; Li, X, 2000) |
| "Fifty-eight postmenopausal women with breast cancer who were treated with tamoxifen." | ( Azaria, R; Beyth, Y; Cohen, I; Figer, A; Flex, D; Tepper, R, 2000) |
| "The prevalence of breast cancer (a hormonally driven neoplasm) in the United States, the potential health benefits of estrogen replacement therapy for postmenopausal women, and the burgeoning research focusing on selective estrogen receptor modulators (SERMs) have resulted in additional complexity in managing breast cancer." | ( Morrow, M; Newman, LA; Sellin, RV; Singletary, SE; Vogel, C; Wood, WC, 2000) |
| "Forty-five patients (31 with breast cancer, 14 with ovarian cancer) were treated at seven different dose levels." | ( Barbarisi, A; Benassai, G; Carbone, I; Ciccarelli, PD; Crovella, F; De Rosa, P; Frattolillo, A; Iaffaioli, RV; Libutti, M; Santangelo, M; Tortoriello, A; Turitto, G, 2000) |
| "Information on potential breast cancer risk factors, such as demographic characteristics, smoking and drinking habits, diet, exercise, menstrual and reproductive factors, was obtained by self-administered health questionnaire including a validated semiquantitative food frequency questionnaire." | ( Hayashi, M; Nagata, C; Shimizu, H; Takami, R; Takeda, N; Yasuda, K, 2000) |
| "Under a diagnosis of locally advanced breast cancer (T4bN2M1, stage IV) with liver metastases, we attempted sequential neoadjuvant chemotherapy." | ( Fukuda, H; Fukuda, K; Kim, YH; Kitano, H; Kokufu, I; Taniguchi, H; Yamada, K; Yamamoto, M; Yano, T, 2000) |
| "Sixty-eight breast cancer patients with advanced disease, who had not received prior chemotherapy (except adjuvant), received weekly cisplatin 30 mg/sqm, paclitaxel 120 mg/sqm and epirubicin 50 mg/sqm plus G-CSF (day 3-5), for a maximum of 12 cycles." | ( Capasso, I; Carteni, G; Comella, G; Comella, P; D'Aiuto, G; D'Aniello, R; De Lucia, L; Di Bonito, M; Frasci, G; Frezza, P; Lapenta, L; Maiorino, L; Rivellini, F; Thomas, R, 2000) |
| "A patient with metastatic breast carcinoma developed an acute onset of branch retinal artery occlusion, bilateral blindness, and a myelopathy involving the lower extremities after high-dose chemotherapy and bone marrow transplant." | ( Arnold, AC; Glasgow, BJ; Vinters, HV; Wang, MY, 2000) |
| "Two hundred and sixteen T2 breast cancer patients were treated consecutively with surgery followed by 5'DFUR (600 mg/body/day) + tamoxifen (20 mg/body/day) for 2 years." | ( Akasaka, Y; Hata, Y; Nakanishi, Y; Ogita, M; Sasaki, F; Sawada, Y; Takahashi, H; Uchino, J; Yoshimoto, M, 2000) |
| "Patients with stage II or III breast cancer who had undergone doxorubicin-based neoadjuvant chemotherapy before breast surgery were eligible." | ( Ames, FC; Breslin, TM; Buzdar, AU; Cohen, L; Delpassand, ES; Feig, BW; Fleming, JB; Hortobagyi, GN; House, R; Hunt, KK; Kuerer, HM; Newman, LA; Ross, MI; Sahin, A; Singletary, SE, 2000) |
| "122 cases with lung metastases from breast cancer were treated by chemotherapy or chemotherapy plus endocrine therapy." | ( Xu, B; Zhou, A; Zhou, J, 1997) |
| "The Bedford Breast Cancer Registry, which contains prospective diagnostic, treatment and follow-up data on all breast cancers treated in North Bedfordshire, was analysed to compare breast cancer outcome between 1990-1992 and 1993-1996, that is before and after the advent of surgical subspecialization." | ( Callam, MJ; Golledge, J; Wiggins, JE, 2000) |
| "The majority of elderly breast cancer patients have oestrogen-dependent tumors, thus, tamoxifen is widely administered." | ( Audisio, RA; Castiglione, F; Comandini, D; Granetto, C; Repetto, L; Ross, R; Venturino, A, 2000) |
| "We enrolled 52 breast cancer patients who were treated with breast-conservation treatment and administered oral toremifene for 3-5 years as adjuvant endocrine therapy." | ( Hamada, N; Inomata, T; Kariya, S; Murata, Y; Nishioka, A; Ogawa, Y; Saibara, T; Terashima, M; Yoshida, S, 2000) |
| "Early detection of breast cancer is crucial for efficient and effective treatment." | ( Aznar, M; Gagnon, JH; Lisbona, R; Loutfi, A; Murthy, K; Thompson, CJ, 2000) |
| "The estrogen dependency of human breast cancer has been successfully exploited in the treatment of early and advanced diseases and provides a unique opportunity for chemoprevention of this common malignancy." | ( Anchim, T; Dabrowska, M; Dziecioł, J; Swiatecka, J; Wołczyński, S, 2000) |
| "In 77 patients with 84 breast tumors scheduled for surgical tumor removal, color-coded duplex sonography was performed before and after administration of Levovist." | ( Aronius, R; Schietzel, M; Stuhrmann, M, 2000) |
| "Adjuvant chemotherapy in breast cancer patients has had limited success, which is possibly because of lack of effect on non-proliferating cells accompanied by the emergence of drug-resistant cell clones." | ( Engebraaten, O; Fodstad, O; Juell, S; Sivam, G, 2000) |
| "The increase in the risk of breast cancer may be larger with estrogen-progestogen therapy than with estrogen alone." | ( Clavel-Chapelon, F; Hill, C, 2000) |
| "The observed increase in the risk of breast cancer is open to biases, particularly to a screening bias if women receiving hormonal replacement therapy have a more intensive surveillance than other women." | ( Clavel-Chapelon, F; Hill, C, 2000) |
| "Estrogen receptor (ER)-positive breast cancers initially respond well to estrogen ablation treatment but finally acquire refractoriness, the phenomenon that is a major clinical problem." | ( Fujita, T; Kaiho, S; Kuwabara, K; Ogata, E; Oizumi, I; Okazaki, T; Tanaka, Y, 2000) |
| "Potential targets for selective breast cancer therapy are herein reviewed." | ( Albanese, C; Amanatullah, DF; Hulit, J; Lisanti, MP; Pestell, RG; Reutens, A; Rosen, E; Sparano, JA; Wang, C; Zafonte, BT, 2000) |
| "Adriamycin-resistant human breast cancer MCF-7/DOX cells, presenting a comparable GSH concentration, but a 14-fold increase of the GST P1-1 activity relative to the sensitive MCF-7 cells, have been treated with adriamycin in the presence of verapamil, an inhibitor of the 170 P-glycoprotein (P-gp) drug transport protein, and scrutinized for any production of GSH-adriamycin conjugates." | ( Gaudiano, G; Koch, TH; Lo Bello, M; Nuccetelli, M; Ravagnan, G; Serafino, A; Sinibaldi-Vallebona, P, 2000) |
| "Fourteen consecutive patients with breast cancer were treated with high dose chemotherapy consisting of the CTCb regimen followed by stem cell transplantation." | ( Britt, GW; Garner, GD; Harkness, K; Jillella, AP; Kallab, AM; Litaker, MS, 2000) |
| "Some patients with breast cancer currently undergo bone marrow biopsy to make clinical decisions regarding therapy; however, lobular carcinoma can be difficult to detect in routine histologic sections." | ( Arber, DA; Carter, NH; Ikle, D; Lyda, MH; Tetef, M; Weiss, LM, 2000) |
| "Normal mammary epithelial cells and mammary cancer cells were initially treated with staurosporine at a cytostatic (i." | ( Chen, X; Danes, C; Hall, MJ; Herliczek, T; Keyomarsi, K; Lawrence, DA; Lowe, M, 2000) |
| "Human breast cancer cell lines, MCF7, MDA-MB-231, and MDA-MB-435, as well as normal cells, including the normal breast epithelial cell line MCF-10A, and fibroblasts, were treated with SAHA." | ( Huang, L; Pardee, AB, 2000) |
| "Treatment of human breast cancer cell line MCF7 cells with SAHA induced p21 mRNA as a consequence of an immediate-early gene activation." | ( Huang, L; Pardee, AB; Sakai, T; Sowa, Y, 2000) |
| "Twenty-one patients with metastatic breast cancer were treated with pegylated liposomal doxorubicin (20 mg/m2, day 1) and paclitaxel (100 mg/m2, days 1 and 8) for six cycles every 2 weeks." | ( Kurbacher, CM; Mallmann, P; Schwonzen, M, 2000) |
| "In patients with metastatic breast cancer, second-line therapy with aromatase inhibitors can improve survival in comparison with megestrol." | ( Cattel, F; Messori, A; Trippoli, S; Vaiani, M, 2000) |
| "Twenty breast cancer patients with progression of skin metastases were treated with a 6% solution of miltefosine, which was topically administered once daily during the first week and twice daily thereafter." | ( Bontenbal, M; Planting, AS; Seynaeve, C; Sindermann, H; Smorenburg, CH; Verweij, J, 2000) |
| "From 1/1985 through 12/1993, 1,155 breast cancer patients received postoperative radiotherapy with curative intent in our department." | ( Bormann, G; Dunst, J; Fach, A; Furch, S; Marsch, W; Steil, B, 2000) |
| "Patients with metastatic breast carcinoma were eligible for the study if they had disease progression after at least 2 prior chemotherapy regimens." | ( Booser, D; Buzdar, AU; Dhingra, K; Fraschini, G; Frye, D; Holmes, FA; Hortobagyi, GN; Rivera, E; Theriault, RL; Valero, V; Walters, R, 2000) |
| "This data indicates that in high-risk breast cancer patients the immunohistochemical evaluation of p53 and bcl-2 may be of clinical value in distinguishing different responses to adjuvant anthracycline-based chemotherapy." | ( Benevolo, M; Botti, C; Buglioni, S; Del Monte, G; Di Filippo, F; Mottolese, M; Nisticò, C; Papaldo, P; Vasselli, S; Vici, P, 2000) |
| "Eleven women with breast cancer received paclitaxel (every 2 weeks for 4 cycles) as neoadjuvant treatment." | ( Demaria, S; Formenti, SC; Kim, AY; Klein, P; McMullen, H; Muggia, F; Oratz, R; Perkins, AB; Shapiro, RL; Symmans, WF; Volm, MD; Yee, HT, 2000) |
| "Magnetic heating of breast tumors is a promising technique for future interventional radiologic treatments." | ( Andrä, W; Hergt, R; Hiergeist, R; Hilger, I; Kaiser, WA; Schubert, H, 2001) |
| "In patients who experienced breast cancer and who have chemotherapy-induced menopause, risedronate preserves bone." | ( Crandall, C, 2001) |
| "In treating advanced or recurrent breast cancer, anthracycline-containing chemotherapy is used for palliation and to maintain quality of life." | ( Akao, S; Hiraide, H; Ishikawa, H; Maruyama, M; Matsumoto, F; Mochizuki, H; Okamura, H; Sato , K; Tabei, T; Tamakuma, S; Touma, M; Yagi, Y, 2001) |
| "Treatment of MCF-7 human breast cancer cells with 17beta-estradiol (E(2)) results in increased DNA synthesis and cell proliferation and enhanced enzyme activities associated with purine/pyrimidine biosynthesis." | ( Barhoumi, R; Burghardt, R; Chen, I; Kladde, M; Safe, S; Samudio, I; Stoner, M; Vyhlidal, C; Wang, F, 2001) |
| "Preoperatively, 23 breast cancer patients were divided into a group treated with 5-FU at 200 mg/day for 2 weeks (Group A) and a non-treatment group (Group B), and breast cancer tissues were taken postoperatively." | ( Asaga, T; Inaba, M; Nagano, A; Yanoma, S, 2001) |
| "Thirty-four patients with metastatic breast cancer (MBC) who had progression of disease after high-dose chemotherapy (HDCT) with peripheral blood progenitor cell support (PBPC) had methotrexate, uracil and tegafur (UFT), and leucovorin (MUL) therapy administered: methotrexate administered intramuscularly in combination with UFT given orally and leucovorin given orally." | ( Casado, A; Diaz-Rubio, E; Garcia-Carbonero, I; Garcia-Saenz, JA; Macias, JA; Manrique, I; Martín, M; Oruezabal, M, 2000) |
| "Women treated with tamoxifen for breast cancer are at increased risk of endometrial cancer." | ( Kimura, M; Koyama, H; Matsuyama, Y; Mitsuyama, S; Miura, S; Nomura, Y; Ohashi, Y; Sano, M; Takashima, S; Tominaga, T; Ueo, H, 2000) |
| "For early stage breast cancer patients treated with adjuvant tamoxifen, overexpression of erbB2 is an independent marker of poor prognosis." | ( Borg, A; Fernö, M; Källström, AC; Malmström, P; Nordenskjöld, B; Stål, O, 2000) |
| "Node-positive breast carcinoma patients were randomly assigned to receive either no further treatment after radical mastectomy (179 women) or 12 monthly cycles of adjuvant CMF chemotherapy (207 women)." | ( Biganzoli, E; Bonadonna, G; Boracchi, P; Casalini, P; Cascinelli, N; Colnaghi, MI; Gianni, L; Marubini, E; Ménard, S; Pilotti, S; Tomasic, G; Valagussa, P, 2001) |
| "Xenograft tumors from a human breast carcinoma line (MDA-MB-435) were particularly susceptible to these treatments." | ( Ruoslahti, E; Yi, M, 2001) |
| "New treatment strategies for advanced breast cancer have focused on both the development of new molecular targets in breast cancer cells, as well as improving the therapeutic index of presently available therapy." | ( Gradishar, WJ, 2001) |
| "Seventeen patients with breast cancer were treated with 210 mg / m(2) of paclitaxel infused over 3 h as a single agent in a phase II study." | ( Minami, H; Ogawa, M; Sasaki, Y; Watanabe, T, 2001) |
| "It is well known that breast carcinomas without estrogen receptor (ER) have a poor prognosis and do not respond to antiestrogenic therapy." | ( del Senno, L; Lambertini, E; Nastruzzi, C; Penolazzi, L; Piva, R, 2000) |
| "Most breast cancer patients treated with anti-oestrogens will eventually develop resistance towards treatment." | ( Heiberg, I; Larsen, SS; Lykkesfeldt, AE, 2001) |
| "In patients with metastatic breast cancer (MBC), early dose intensification with multiple cycles of peripheral blood stem cell-supported high-dose chemotherapy (HDCT) seems superior to a late dose-intensification strategy." | ( Bastert, G; Egerer, G; Goerner, R; Grischke, EM; Haas, R; Hensel, M; Ho, AD; Hohaus, S; Khbeis, T; Schneeweiss, A; Solomayer, E, 2001) |
| "Twenty patients with left-sided breast cancer underwent cardiac perfusion imaging using single photon emission computed tomography (SPECT) prechemotherapy, pre-RT, and 6 months post-RT." | ( Bentel, GC; Borges-Neto, S; Hardenbergh, PH; Hollis, D; Kedem, R; Marks, LB; Munley, MT; Prosnitz, LR, 2001) |
| "A 55-year-old woman with metastatic breast carcinoma to the liver and hyperbilirubinemia was treated with sequential, empiric chemotherapy agents with the goal of preventing severe toxicity through dose reduction, avoidance of combination therapy, divided doses (weekly therapy), and selection of drugs less dependent on hepatic clearance." | ( Akerley, W; Gurevich, I, 2001) |
| "Fifty-seven patients with breast carcinomas of 3 cm diameter or more received neoadjuvant chemotherapy with four cycles of AT (doxorubicin and docetaxel)." | ( Akashi-Tanaka, S; Fukutomi, T; Katsumata, N; Matsuo, K; Miyakawa, K; Nanasawa, T; Tsuda, H; Watanabe, T, 2001) |
| "Two cases of advanced and metastatic breast cancers were treated by docetaxel (TXT) in combination with intra-arterial infusion of adriamycin (ADM)." | ( Doihara, H; Hino, M; Ishibe, Y; Nagahiro, I; Ogasawara, Y; Sano, Y; Shimizu, N; Teramoto, A; Yoshitomi, S, 2001) |
| "Treatment of MCF-7 breast cancer cells with 1,25(OH)2D3 (10-100 nM for 24-48 h) brought about a maximal increase of 41+/-13% (mean +/- SE) in the oxidized/reduced glutathione ratio without affecting total glutathione levels." | ( Hadari-Naor, I; Koren, R; Liberman, UA; Ravid, A; Rotem, C; Zuck, E, 2001) |
| "Elucidation of these pathways in breast cancer may ultimately lead to novel and more effective treatments for this disease." | ( Donovan, J; Slingerland, J, 2000) |
| "Immunodetection of p27 in breast tumors could be useful in the assessment of prognosis, especially in those cases in which the commonly used parameters are insufficient, and might ultimately influence the therapy of this disease." | ( Chiarle, R; Inghirami, G; Pagano, M, 2001) |
| "A total of 267 women with metastatic breast cancer were randomized to receive either AT (doxorubicin 50 mg/m(2) followed 24 hours later by paclitaxel 220 mg/m(2)) or FAC (5-fluorouracil 500 mg/m(2), doxorubicin 50 mg/m(2), cyclophosphamide 500 mg/m(2)), each administered every 3 weeks for up to eight cycles." | ( Berzins, J; Gorbunova, V; Jassem, J; Jelic, S; Mrsic-Krmpotic, Z; Munier, S; Nagykalnai, T; Pieńkowski, T; Płuzańska, A; Renard, J; Weil, C; Wigler, N, 2001) |
| "Many active cytotoxic agents exist for breast cancer therapy, and numerous combination chemotherapy regimens are derived from them." | ( Seidman, AD, 2001) |
| "Treatment of early breast cancer has been revolutionized during the past 30 years and new data continue to refine our knowledge of systemic treatments for this stage of disease." | ( Bonadonna, G; Capri, G; Gianni, L; Moliterni, A; Valagussa, P; Zambetti, M, 2001) |
| "Sexual dysfunction persists after breast cancer treatment, despite recovery in other domains." | ( Ganz, PA; Greendale, GA; Petersen, L; Zibecchi, L, 2001) |
| "Surgery of breast cancer was done at 16 hours after the administration of 74 MBq of 99mTc labeled nanocolloid." | ( Kasumi, F; Koizumi, M; Makita, M; Nomura, E; Ogata, E; Saito, M; Sekine, N; Tada, T; Takahashi, K; Takahashi, T; Takiguchi, T; Uchida, K; Yamada, Y; Yoshimoto, M, 2001) |
| "Breast conservation therapy for early breast cancer is an established but grossly under-utilized treatment option in India for various reasons." | ( Chawla, S; Deo, SS; Julka, PK; Mohanti, BK; Raina, V; Rath, GK; Shukla, NK, 2001) |
| "When patients with metastatic breast cancer become pregnant, management is complicated by the potential harms of drug treatment to the fetus and by the potential effects of the pregnancy on the cancer." | ( Clark, K; Hunter, W; Isaacs, RJ, 2001) |
| "A cohort of 630 women diagnosed with breast cancer from 1987 to 1994 was selected from a population-based registry; 440 patients were treated with tamoxifen and 190 patients without it." | ( Bebar, S; Djurisic, A; Fras, PA; Kovacic, J; Robic, V; Ursic Vrscaj, M, 2001) |
| "Treatment of ER+ human breast cancer cells (MCF-7 and ZR75." | ( Frey, RS; Singletary, KW; Yan, W, 2001) |
| "In this report, the Early Breast Cancer Trialists' Collaborative Group present their third 5-yearly systematic overview (meta-analysis) of treatment with tamoxifen." | ( , 2001) |
| "Array analysis of MDA-MB-231 breast carcinoma cells treated with 5-Aza-CdR confirmed the elevation of nm23-H1 mRNA, whereas relatively few other genes exhibited altered expression." | ( Clare, SE; Clark, G; Elkahloun, AG; Hartsough, MT; Mair, M; Osborne, CK; Sgroi, D; Steeg, PS, 2001) |
| "A total of 221 women with stage I or II breast cancer and no prior chemotherapy who were scheduled to receive adjuvant chemotherapy with intravenous cyclophosphamide, fluorouracil and methotrexate or cyclophosphamide, epirubicin, and fluorouracil given every 3 weeks were included in a double-blind parallel trial." | ( Dombernowsky, P; Handberg, J; Herrstedt, J; Kjaer, M; Sigsgaard, T, 2001) |
| "In patients with recurrent breast cancer, triple-modality therapy is feasible with acceptable toxicity." | ( Feyerabend, T; Jäger, B; Mahlmann, B; Richter, E; Vesely, H; Wiedemann, GJ, 2001) |
| "We studied 774 women treated for breast cancer where plasma levels of oestradiol had been measured 1-2 days pre-operatively." | ( Adami, HO; Degerman, M; Holmberg, L; Lindgren, A; Nordén, T; Wide, L, 2001) |
| "Metastatic breast cancer (MBC) is still in most cases an uncurable disease and the main goal of treatment is a good quality of life for these patients." | ( Cervek, J; Cufer, T; Jagodic, M; Zakotnik, B, 2001) |
| "Improvements in breast cancer treatment will arrive with better understanding of its biology and through biologically oriented therapeutic interventions as well as better identification of patient populations susceptible to benefit from classical therapies (endocrine and chemotherapy)." | ( Nabholtz, JM; Slamon, D, 2001) |
| "Metastatic breast cancer is a partially chemotherapy-sensitive neoplasm." | ( Crown, JP, 2001) |
| "The urine samples from all of the breast cancer patients were collected before any chemotherapy or radiotherapy." | ( Dai, Q; Dunning, LA; Gao, YT; Holtzman, JL; Jin, F; Shu, XO; Wen, WQ; Zheng, W, 2001) |
| "Stage IV breast cancer patients were randomized to receive as first-line chemotherapy either standard CEF (cyclophosphamide 600 mg/m(2), epirubicin 60 mg/m(2), and fluorouracil 600 mg/m(2)) administered every 21 days (CEF21) or accelerated-intensified CEF (cyclophosphamide 1,000 mg/m(2), epirubicin 80 mg/m(2), and fluorouracil 600 mg/m(2)) administered every 14 days (HD-CEF14) with the support of G-CSF." | ( Bergaglio, M; Carnino, F; Comis, S; Contu, A; Del Mastro, L; Gallo, L; Guarneri, D; Lionetto, R; Pronzato, P; Rosso, R; Venturini, M; Vesentini, L, 2001) |
| "The data from 484 breast cancer patients who were treated with breast-conserving surgery and radiation were analyzed." | ( Buchholz, TA; Buzdar, AU; Cristofanilli, M; Erwin, J; Esteva, FJ; Hortobagyi, GN; Hunt, KK; Mathur, D; McNeese, MD; Newman, L; Singletary, SE; Strom, EA; Tucker, SL, 2001) |
| "Therefore, breast cancer therapy should be aimed at inhibition of growth factor-dependent breast cancerous cell proliferation." | ( Bernardini, R; Bianchi, A; Cantarella, G; Chiarenza, A; Lazarovici, P; Lempereur, L, 2001) |
| "61 postmenopausal women with operable breast cancer were treated with the adjuvant antioestrogen tamoxifen 20 mg or toremifene 60 mg daily for 3 years." | ( Blomqvist, C; Elomaa, I; Mäkelä, P; Saarto, T; Välimäki, M; Vehmanen, L, 2001) |
| "A 50-year-old woman treated for breast cancer with mitomycin C developed severe hypertension, followed by deep coma 3 days later." | ( Katayama, Y; Kitamura, H; Komaba, Y; Nishiyama, Y, 2001) |
| "Treatment of human breast carcinoma MCF7 cells with doxorubicin, one of the most active antineoplastic agents used in clinical oncology, induces apoptosis and leads to increases in sphingosine levels." | ( Cuvillier, O; Edsall, LC; Levade, T; Milstien, S; Murthy, SK; Nava, VE; Spiegel, S, 2001) |
| "Twenty patients with high risk primary breast cancer underwent a high dose chemotherapy program at Ramathibodi Hospital, Bangkok." | ( Chiernsilp, A; Jootar, S; Ratanatharathorn, V; Ungkanont, A, 2000) |
| "Twenty-nine women with breast carcinoma were treated." | ( Bláha, M; Filip, S; Maricka, P; Medková, V; Stránský, P; Vanásek, J; Vavrová, J, 2001) |
| "The International Breast Cancer Study Group (IBCSG) conducted a dose-finding phase I trial of epirubicin (E) and docetaxel (D) as first-line therapy in advanced breast cancer patients." | ( Bauer, J; Borner, M; Crivellari, D; Goldhirsch, A; Graffeo, R; Hess, D; Lombardi, D; Martinelli, G; Nolè, F; Pagani, O; Sessa, C; Thürlimann, B; Veronesi, A, 2001) |
| "From 1992 to 1997, 247 stage I-II breast cancer patients, treated with conserving surgery, were treated at the National Cancer Institute of Genoa in a randomized study comparing the same CEF regimen delivered every two weeks (CEF14) or three weeks (CEF21)." | ( Canavese, G; Cavallari, M; Del Mastro, L; Guenzi, M; Ricci, P; Sanguineti, G; Stevani, I; Venturini, M, 2001) |
| "The study included 20 metastatic breast cancer patients, who were treated with taxotere (100 mg/mq I." | ( Ardizzoia, A; Conti, A; Fumagalli, E; Gardani, G; Lissoni, P; Maestroni, GJ; Tancini, G; Vaghi, M, 2001) |
| "A 50-year-old female patient with breast cancer (stage IV) was treated with Ukrain because of the impossibility of radiotherapy and chemotherapy." | ( Prokopchuk, OL; Susak, YM; Zemskov, SV, 2000) |
| "When used first-line in metastatic breast cancer, both cisplatin and carboplatin are active agents and hence candidates for combination therapy." | ( Crown, J, 2001) |
| "With PBPC mobilization in patients with breast cancer used as a model for chemotherapy-induced PBPC recruitment, the kinetics of progenitor cells mobilized either with cyclophosphamide (CY) or epirubicin/paclitaxel (EPI-TAX) followed by the administration of G-CSF was compared." | ( Dettke, M; Greinix, HT; Höcker, P; Kalhs, P; Kührer, I; Worel, N, 2001) |
| "Patients diagnosed with breast cancer who had completed their primary treatment were randomly assigned to black cohosh or placebo, stratified on tamoxifen use." | ( Evans, J; Grann, VR; Jacobson, JS; Kaufman, EL; Kinne, D; Klaus, L; Lo, KM; Moore, A; Neugut, AI; Rosenman, PJ; Troxel, AB; Vahdat, L, 2001) |
| "Twelve patients with metastatic breast cancer received a total of 86 cycles of therapy." | ( Adamson, PC; Caruso, R; Chow, C; Cowan, KH; Kaiser, M; Kleiner, D; Lawrence, JA; Merino, M; Murphy, RF; Noone, M; O'Shaughnessy, J; Shovlin, M; Venzon, DJ; Zujewski, J, 2001) |
| "We analyzed several urine samples from breast cancer patients undergoing tamoxifen treatment." | ( Carter, S; Dovichi, NJ; Kovarik, P; Li, XF; Sakuma, T; Zhao, JY, 2001) |
| "As far as breast cancer is concerned, most epidemiological studies suggest no difference in risk between therapy with estrogens alone or estrogens combined with progestogens, but recent data do indicate an increased risk with combined therapy." | ( Skouby, SO, 2000) |
| "From a cohort of 1481 breast carcinomas treated with BCT in the period 1980-1994, a total of 68 pT1-3 N0-1 patients developed LR as first event." | ( Elkhuizen, PH; Hermans, J; Leer, JW; van dE Vijver, MJ, 2001) |
| "Women with stage I or II breast cancer with primary treatment of simple or modified mastectomy or breast-conserving surgery with radiotherapy scheduled to receive adjuvant chemotherapy." | ( Knobf, MT; McInnes, JA, 2001) |
| "From a randomized study in high-risk breast cancer patients on the efficacy of high-dose versus standard-dose adjuvant chemotherapy, late effects on cognitive functioning were analyzed by neuropsychological tests." | ( Boogerd, W; Hamburger, HL; Muller, MJ; Schagen, SB; van Dam, FS, 2001) |
| "An underinvestigated area of breast cancer survivorship involves the possible impairment of cognitive function following adjuvant chemohormonal therapy." | ( Olin, JJ, 2001) |
| "Among 36 metastatic breast cancer patients treated with this new combination, the overall response rate was 92%, including 31% with a complete response." | ( Bengala, C; Conte, P; Donati, S; Gennari, A; Guarneri, V; Landucci, E; Orlandini, C; Salvadori, B, 2001) |
| "Stage III and IV breast cancer patients received induction chemotherapy with three cycles of CEF (cyclophosphamide 600 mg/m2, epirubicin 100 mg/m2, 5-fluorouracil 600 mg/m2) followed by three cycles of HDC consisting of escalating doses of cyclophosphamide (dose range 1200 3000 mg/m2) and carboplatin (dose range 600-1000 mg/m2), supported by DMSO-free PBPC reinfusion." | ( Bergaglio, M; Bertelli, G; Bertoglio, S; Bighin, C; Del Mastro, L; Lambiase, A; Melioli, G; Pietra, G; Rosso, R; Semino, C; Sertoli, MR; Signorini, A; Venturini, M; Viscoli, C, 2001) |
| "Node-positive breast cancer patients who were aged 70 years or younger were randomly allocated to one of the following treatments: CMF for six cycles (oral cyclophosphamide); EC for eight cycles (epirubicin 60 mg/m(2), cyclophosphamide 500 mg/m(2); day 1 every 3 weeks); and HEC for eight cycles (epirubicin 100 mg/m(2), cyclophosphamide 830 mg/m(2); day 1 every 3 weeks)." | ( Bartholomeus, S; Beauduin, M; Beauvois, S; Closon-Dejardin, MT; Di Leo, A; Dolci, S; Dufrane, JP; Finet, C; Focan, C; Gobert, P; Kerger, J; Liebens, F; Lobelle, JP; Michel, J; Nogaret, JM; Paesmans, M; Piccart, MJ; Ries, F; Tagnon, A; Vindevoghel, A, 2001) |
| "Raloxifene therapy reduces breast cancer risk in postmenopausal osteoporotic women regardless of lifetime estrogen exposure, but the reduction is greater in those with higher lifetime exposure to estrogen." | ( Cauley, JA; Cummings, SR; Eckert, S; Jamal, S; Krueger, KA; Lippman, ME; Sashegyi, A; Walls, EL, 2001) |
| "We reviewed the medical records of six breast cancer patients who developed leukoencephalopathy after chemotherapy which included 5-FU and also evaluated thorough neurological examinations including mini-mental status examination, cerebrospinal fluid studies, brain images and brain biopsies." | ( Cho, KH; Choi, SM; Kim, BC; Kim, MK; Lee, SH; Yang, YS, 2001) |
| "Most patients with lymph node-negative breast cancer are cured by locoregional treatment; however, about 30% relapse." | ( Graeff, H; Harbeck, N; Jänicke, F; Meisner, C; Prechtl, A; Schmitt, M; Selbmann, HK; Sweep, CG; Thomssen, C; Untch, M, 2001) |
| "In selected patients with early-stage breast cancer, treatment of the lumpectomy cavity alone with outpatient HDR brachytherapy is both technically feasible and well tolerated." | ( Baglan, KL; Chen, PY; Edmundson, G; Frazier, RC; Jaffray, D; Kestin, LL; Kini, VR; Martinez, AA; Mele, E; Vicini, FA, 2001) |
| "Treatment of metastatic breast cancer (MBC) with paclitaxel (T) and doxorubicin has yielded high response rates but the regimen is associated with significant cardiac toxicity." | ( Fountzilas, G; Razis, ED, 2001) |
| "Two hundred ten patients with primary breast cancer (T1-T4, N0, N1-2) were randomised to receive treatment with neoadjuvant chemoendocrine therapy or conventional post-operative chemoendocrine therapy." | ( Coombes, RC; Ford, HT; Gazet, JC; Gray, R; Lowndes, S; Makinde, V; McConkey, C; Quilliam, J; Sutcliffe, R, 2001) |
| "MCF7/ADR cells and MCF7/WT, an MCF7 breast cancer cell line sensitive to ADR, were treated with NOM as the acetate ester." | ( Chen, Y; Guo, WJ; He, KL; Li, J; Xia, P; Xu, LZ; Zheng, YH, 2001) |
| "Women with invasive breast cancer receiving systemic therapy at our institution between 1980 and 1998 were identified and their recorded height and weight were used to calculate BSA and body mass index (BMI)." | ( Bjarnason, GA; Franssen, E; Madarnas, Y; Sawka, CA, 2001) |
| "A patient with skin metastases of breast carcinoma was treated with intravenous infusion of PLD (Caelyx) in combination with ultrasound hyperthermia." | ( Dvorák, J; Hrncírová, I; Jandík, P; Melichar, B; Mergancová, J; Petera, J; Urminská, H; Zoul, Z, 2001) |
| "Women with breast cancer who develop chemotherapy-induced ovarian failure should have their bone density monitored and treatments to attenuate bone loss should be evaluated." | ( Leboff, M; Manola, J; Shapiro, CL, 2001) |
| "Patients had advanced or metastatic breast cancer with evidence of disease progression while receiving continuous adjuvant antiestrogen therapy, had experienced relapse within 12 months of stopping adjuvant antiestrogen therapy given for at least 6 months, or had experienced disease progression while receiving antiestrogen therapy for advanced disease." | ( Brady, C; Buzdar, A; Davidson, N; Douma, J; Elledge, R; Morgan, M; Nabholtz, J; Porter, L; Smith, R; Xiang, X, 2001) |
| "240 patients with unresectable breast cancer were treated with curative radio- and chemo- or hormonotherapy from 1990-1995." | ( Coupek, P; Filip, S; Petera, J; Slampa, P; Soumarová, R; Zatloukal, P, 2001) |
| "To describe the physicians with whom breast cancer patients discuss treatment options and assess whether discussing surgical options with a medical oncologist is associated with type of surgery and satisfaction." | ( Borbas, C; Guadagnoli, E; Keating, NL; Landrum, MB; Weeks, JC, 2001) |
| "Women in Massachusetts discussed breast cancer treatments with more physicians than women in Minnesota (mean 3." | ( Borbas, C; Guadagnoli, E; Keating, NL; Landrum, MB; Weeks, JC, 2001) |
| "69 patients with advanced breast cancer previously untreated with anthracyclines or paclitaxel entered a phase II multicentre study in which FEC was followed by paclitaxel." | ( Bernardo, G; Brugnatelli, S; Danova, M; Fava, S; Giardina, G; Giordano, M; Grasso, D; Montanari, G; Pedrotti, C; Poli, MA; Pugliese, P; Riccardi, A; Rinaldi, E; Tinelli, C; Trotti, G, 2001) |
| "Twenty women with advanced breast cancer were treated with Docetaxel." | ( Pawlicki, M; Rolski, J; Rysz, B; Utych, G; Wiczyńska, B; Zemełka, T, 2001) |
| "Endocrine therapy for breast cancer, which began with ovariectomy, has a history of more than 100 years." | ( Tominaga, T, 2001) |
| "The presence of ER or PgR in primary breast tumors is the best-established marker for response to endocrine therapy." | ( Kurebayashi, J; Sonoo, H, 2001) |
| "Forty-one patients with advanced breast cancer who were either over the age of 65 or considered to be poor candidates for combination chemotherapy received docetaxel 36 mg/m2 weekly for 6 consecutive weeks, followed by 2 weeks without treatment." | ( Baker, M; Bradof, JE; Burris, HA; Erland, JB; Greco, FA; Grimaldi, M; Hainsworth, JD; Kalman, LA; Sullivan, T; Yardley, DA, 2001) |
| "Twenty-four breast cancer patients on CMF chemotherapy were studied along with a control group of 16 healthy pre-menopausal women." | ( Kajdaniuk, D; Kos-Kudla, B; Marek, B, 2001) |
| "One hundred forty-four patients with breast cancer and osteolytic bone metastases were randomized to receive either oral clodronate 1,600 mg/d (73 patients) or placebo (71 patients), in addition to either chemotherapy or hormonal therapy, for up to 12 months." | ( Assadourian, S; Barbet, N; Bessa, E; Beuzeboc, P; Frenay, M; Mauriac, L; Misset, JL; Monnier, A; Pion, JM; Switsers, O; Tubiana-Hulin, M, 2001) |
| "In the meta-analysis of the Early Breast Cancer Trialists' Collaborative Group, the proportional reduction in recurrence and mortality for 5 years of tamoxifen therapy was 50% and 28% respectively for patients with ER(+) tumors." | ( Muss, HB, 2001) |
| "Recent advances in chemotherapy for breast cancer include important studies on the role of dose-intensity, modifications of available agents to reduce side effects, and the availability of oral chemotherapeutics." | ( Bunnell, CA; Burstein, HJ; Winer, EP, 2001) |
| "Adjuvant chemotherapy in breast cancer has clearly been shown to reduce mortality." | ( Swain, SM; Tan, AR, 2001) |
| "A total of 20 patients with breast cancer were treated with letrozole, 2." | ( Bairaktari, ET; Elisaf, MS; Kakaidi, B; Katsaraki, A; Nicolaides, C; Pavlidis, NA; Tzallas, CS, 2001) |
| "In this cohort of breast cancer patients treated with chemotherapy, summed EDR scores were significantly associated with time to tumor progression and overall survival." | ( Bornstein, R; Fruehauf, JP; Li, KT; McLaren, CE; Mehta, RS; Nguyen, KP; Parker, RJ; Yu, IR, 2001) |
| "Thirty-two patients with advanced breast cancer previously exposed to multiple endocrine treatment regimens (median 4, range 2-10) were enrolled." | ( Anker, G; Howell, A; Iddon, J; Jørgensen, LM; Lønning, PE; Mella, O; Taylor, PD; Wie, L, 2001) |
| "Improvement in breast cancer treatment outcome in Madagascar is the result of earlier diagnosis of the disease." | ( Pignon, T; Rafaramino, F; Rakotobe, P, 2001) |
| "Patients with abnormal HER2 in their breast cancer cells (generally 2 or 3+ with the HercepTest, overexpression by other immunohistochemical assays or amplification by fluorescence in situ hybridization [FISH] assay) have demonstrated the greatest response to trastuzumab treatment." | ( Thor, A, 2001) |
| "Three human breast cancer cell lines (MCF-7, T47D; MDA-MB-486) and one human colon cancer cell line [Colo 320 HSR (+)] were treated for 24-h with each of four polyphenols [quercetin; (+)-catechin, trans-resveratrol; caffeic acid] at concentrations ranging from 10(-7) M to 10(-4) M, after which, p53 concentrations were measured in cell lysates by a time-resolved fluorescence immunoassay." | ( Diamandis, EP; Goldberg, DM; Grass, L; Levesque, M; Soleas, GJ, 2001) |
| "Should a woman with a history of breast cancer be given hormone replacement therapy is one of the most controversial issues in the oncology field." | ( Rostom, AY, 2001) |
| "However, a portion of ER-positive breast cancers and most endometrial cancers do not respond to anti-oestrogens and continued treatment results in hormone resistance, mostly without loss of the ER." | ( Beckmann, MW; Brumm, C; Djahansouzi, S; Flötotto, T; Gläser, M; Hanstein, B; Niederacher, D, 2001) |
| "Additional studies in metastatic breast cancer patients, for whom prolonged administration with an anthracycline is of potential clinical benefit, are underway." | ( Pagani, O; Trudeau, M, 2001) |
| "A neoadjuvant study for primary breast cancer that randomized treatment between letrozole and tamoxifen provided a context within which these issues could be addressed prospectively." | ( Borgs, M; Brady, C; Coop, A; Dugan, M; Ellis, MJ; Evans, DB; Jänicke, F; Llombert-Cussac, A; Mauriac, L; Miller, WR; Quebe-Fehling, E; Singh, B, 2001) |
| "Locally advanced breast cancer constitutes more than 50% to 70% of patients presenting for treatment." | ( Chopra, R, 2001) |
| "A cohort of 2,339 breast cancer patients undergoing surgical intervention and radio-, chemo- or hormonal therapy were studied in 216 centres." | ( Beuth, J; Bock, PR; Hanisch, J; Ost, B; Pakdaman, A; Rethfeldt, E; Schneider, B, 2001) |
| "Complementary treatment of breast cancer patients with OE improves the quality of life by reducing signs and symptoms of the disease and the side effects of adjuvant antineoplastic therapies." | ( Beuth, J; Bock, PR; Hanisch, J; Ost, B; Pakdaman, A; Rethfeldt, E; Schneider, B, 2001) |
| "Estrogen-induced growth of MCF-7 breast cancer cells in vitro was blocked by treatment with the antibody to estrogen receptor and correlated closely with acute hormonal activation of mitogen-activated protein kinase and Akt kinase signaling." | ( Márquez, DC; Pietras, RJ, 2001) |
| "Neoadjuvant chemotherapy for breast cancer creates new possibilities for the analysis of biological factors in the tumor and/or host, which may play a role in the response to treatment." | ( Demaria, S; Formenti, SC; Muggia, F; Oratz, R; Shapiro, RL; Symmans, WF; Volm, MD; Yee, HT, 2001) |
| "Seventy-eight patients with primary breast cancer over 3 cm in diameter in stages II A, II B, III A and III B according to the UICC classification received neoadjuvant chemotherapy from August 1, 1998 to June 30, 2000 at the Breast Division of the National Cancer Center Hospital." | ( Akashi-Tanaka, S; Fukutomi, T; Hasegawa, T; Katsumata, N; Miyakawa, K; Takahashi, T; Tsuda, H; Watanabe, T, 2001) |
| "Women with breast cancer in a distinct stage of disease can benefit from high-dose therapy (HDT) with autologous stem cell support; however, a significant number of these patients relapse despite this intensive treatment." | ( Badbaran, A; Gieseking, F; Gutensohn, K; Hornung, R; Jänicke, F; Jung, R; Kröger, N; Krüger, WH; Renges, H; Tögel, F; Zander, AR, 2001) |
| "Sixteen women with unilateral breast cancer who underwent standard external-beam radiation therapy to the breast and axilla >3 years before enrollment and ten healthy women were studied." | ( Beckman, JA; Creager, MA; Harris, JR; Kalinowski, BH; Thakore, A, 2001) |
| "Susceptibility to the breast cancer-enhancing effect of alcohol may also be affected by other dietary factors (such as low folate intake), lifestyle habits (such as use of hormone replacement therapy), or biological characteristics (such as tumor hormone receptor status)." | ( Gapstur, SM; Singletary, KW, 2001) |
| "In metastatic breast cancer, HER2-positive, ER-positive patients can show responses to endocrine treatment, but experience shorter time to progression and survival than HER2-negative patients." | ( Di Leo, A; Larsimont, D; Lohrisch, C; Piccart, M, 2001) |
| "A total of 6 breast cancer patients, 5 with local recurrent tumors on their anterior chest wall and 1 with far advanced primary breast tumor, underwent multimodal therapy in which cryosurgery was performed in combination with local injection of the non-specific immunopotentiator OK-432." | ( Honda, S; Kawaguchi, Y; Kimura, A; Kunieda, K; Matsui, K; Miya, K; Saji, S; Sugiyama, Y; Takao, H, 2001) |
| "Three hundred eighty postmenopausal breast cancer patients receiving adjuvant tamoxifen treatment for 3 years were randomized to either continue tamoxifen for 2 more years or to switch to low-dose aminoglutethimide (250 mg daily) for 2 years." | ( Amoroso, D; Boccardo, F; Caroti, C; Cruciani, G; Farris, A; Mesiti, M; Mustacchi, G; Romeo, D; Rubagotti, A; Schieppati, G; Villa, E, 2001) |
| "Six hundred ninety-eight breast cancer patients (T1c, T2, T3, T4b, N0 to 1, and M0) were enrolled onto a randomized phase III trial that compared four cycles of fluorouracil, epirubicin, and cyclophosphamide administered preoperatively versus the same regimen administered postoperatively (the first cycle administered within 36 hours after surgery)." | ( Duchateau, L; Julien, JP; Tubiana-Hulin, M; van de Velde, CJ; van der Hage, JA; Vandervelden, C, 2001) |
| "The German Adjuvant Breast Cancer Study Group (GABG) conducts trials of preoperative chemotherapy in patients with primary breast cancer using a combination of doxorubicin and docetaxel (ADoc)." | ( Blohmer, JU; Caputo, A; Costa, SD; du Bois, A; Eidtmann, H; Gademann, G; Gerber, B; Graf, E; Hilfrich, J; Jackisch, C; Kaufmann, M; Lampe, D; Merkle, E; Raab, G; Schütte, M; Sinn, HP; Tulusan, AH; von Minckwitz, G, 2001) |
| "Twenty seven breast cancer patients with receptor-positive tumors stage IIb-IIIa (TNM) were treated with an aromatase inhibitor--letrozole, 2." | ( Bershteĭn, LM; Gamaiunova, VB; Ivanov, VG; Kovalenko, IG; Semiglazov, VF; Tsyrlina, EV; Zhil'tsova, EK, 2001) |
| "human breast cancer MCF-7 cells were treated with tamoxifen and cisplatin." | ( Netzker, R; Otto, AM; Schubert, S, 2001) |
| "Women with locally advanced breast cancer were treated with doxorubicin (60 mg/m2 i." | ( Araújo, F; Fernandes, A; Figueira, A; Lobato, R; Morais, J; Moreira, A; Oliveira, J; Passos-Coelho, JL; Ribeiro, J; Silva, S; Sousa, C; Vale, D, 2001) |
| "A 65-year-old woman with primary breast carcinoma (T 3 N 0 M 0) received neoadjuvant chemotherapy consisting of 4 cycles of 50 mg." | ( Hiraga, K; Honda, O; Matsuo, K, 2001) |
| "Twenty-five patients with advanced breast cancer were treated with an intravenous push-injection of DOX that was immediately followed by a 1-h infusion of DOC." | ( Aiba, K; Hashimoto, D; Horikoshi, N; Irie, T; Ito, Y; Mizunuma, N; Nakane, M; Saotome, T; Sugiyama, K; Takahashi, S; Tanigawara, Y; Yoshida, N, 2001) |
| "Further study of breast cancers revealed 83% of tumors with high pS70-Bcl-2 expression responded to paclitaxel or docetaxel treatment, whereas 57% of those with low expression not respond." | ( Matsuo, Y; Shibasaki, F; Shibata, M; Shitashige, M; Toi, M; Yano, T, 2001) |
| "Human breast cancer cell lines without detectable ERs such as MDA-MB-435 and MDA-MB-231 were treated in estrogen-depleted medium followed by a brief treatment with estrogen." | ( Hung, MC; Lee, JN; Tsai, EM; Wang, SC, 2001) |
| "Forty-one patients with breast cancer were treated with RT and adjuvant CT, including paclitaxel." | ( Assaad, SI; Kuter, I; Niemierko, A; Powell, SN; Roche, M; Schoenthaler, R; Taghian, AG; Younger, J, 2001) |
| "Stage IV hormone-sensitive breast cancer is often treated with aromatase inhibitors (anastrozole, letrozole, exemestane), which block the conversion of dehydroepiandrosterone (DHEA) to estrone and estradiol." | ( Fletcher, WS; Morris, KT; Pommier, RF; Schmidt, J; Toth-Fejel, S, 2001) |
| "In vitro, human breast cancer cell lines T-47D (estrogen-receptor and progesterone-receptor positive) and HCC 1937 (estrogen-receptor and progesterone-receptor negative) were treated with DHEA-S." | ( Fletcher, WS; Morris, KT; Pommier, RF; Schmidt, J; Toth-Fejel, S, 2001) |
| "Treatment of all breast cancer cell lines (except MDA-453) with 1 microM ZD1839 almost completely eliminated HER2 phosphorylation." | ( Arteaga, CL; Bianco, R; Moulder, SL; Muthuswamy, SK; Simpson, JF; Yakes, FM, 2001) |
| "Forty-two patients with resected breast carcinoma involving one or more ipsilateral axillary lymph nodes, were randomized to receive two different schedules of adjuvant chemotherapy using 14-day dosing intervals: either (a) three cycles of doxorubicin 80 mg/m(2) as i." | ( Currie, V; D'Andrea, G; Fornier, MN; Gilewski, T; Hudis, C; Moasser, M; Moynahan, ME; Norton, L; Panageas, KS; Salvaggio, R; Seidman, AD; Sklarin, N; Theodoulou, M, 2001) |
| "Nine untreated primary breast carcinoma patients underwent whole-body planar and tomographic (SPECT) imaging 30 min and 4-5 h after injection of 185 MBq (123)I-TX." | ( Cocquyt, V; De Vos, F; Dhaene, K; Dierckx, RA; Slegers, G; Van Belle, S; Van de Wiele, C; VandenBroecke, R, 2001) |
| "Thirty-five patients with metastatic breast cancer received docetaxel, 35 mg/m2 weekly for six weeks, followed by two weeks without treatment." | ( Bischoff, J; Forstpointner, R; Geuenich, S; Gutschow, K; Heinemann, V; Hiddemann, W; Kentenich, CH; Malekmohammadi, M; Sommer, H; Stemmler, HJ, 2001) |
| "Data sources were the Breast Cancer Prevention Trial, the Surveillance, Epidemiology, and End-Results program, time trade-off preference ratings, the Group Health Cooperative of Puget Sound, and the United States Health Care Financing Administration." | ( Grann, VR; Heitjan, DF; Hershman, D; Jacobson, JS; Neugut, AI; Sundararajan, V, 2002) |
| "Advanced breast cancer patients without response, with stable disease, or with recurrence within 6 months of prior treatment were given GEM 1,000 mg/m(2) and VRL 25 mg/m(2), once every 2 weeks for at least six cycles." | ( Athanasiadis, I; Malamos, NA; Pergantas, N; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG; Tsavdarides, D, 2002) |
| "Twenty patients with locally advanced breast tumors and 18 patients with locally recurrent tumors underwent tumor biopsy before chemotherapy, and CYP3A4 mRNA expression levels in tumor tissues were assayed by real-time quantitative polymerase chain reaction." | ( Ando, A; Miyoshi, Y; Noguchi, S; Taguchi, T; Takamura, Y; Tamaki, Y, 2002) |
| "Human breast cancer cell lines were treated in vitro with genistein." | ( Shao, Z; Shen, Z, 1999) |
| "Fifty women with breast cancer metastatic to bone or bone marrow involvement on light microscopy at the time of initial evaluation were treated with high-dose chemotherapy (HDC) and peripheral blood progenitor cell (PBPC) transplantation with CD34(+) cell selection using the Isolex 300i system." | ( Abella, E; Baynes, RD; Cassells, L; Dansey, RD; Hamm, C; Karanes, C; Klein, JL; Peters, WP, 2001) |
| "Eighty postoperative patients of breast cancer were selected and divided into two groups, the treated group (40 cases) was given intravenous Shenmai injection for 7 days and compared with the control group (40 cases) in wound healing time, postoperative drainage volume, complication and blood picture, and the NK cell, T-lymphocyte subsets (CD3, CD4, CD8), were compared before and after treatment." | ( Cao, Y; Liu, P; Qiao, X, 2000) |
| "Adjuvant treatment of early breast cancer has experienced major changes in the last 25 years." | ( Glück, S, 2001) |
| "Treatment of BT-20 breast cancer cells, which express EGFR, with EGF resulted in rapid (5 minutes) accumulation of EGFR and Raf-1 into plasma membrane-associated endocytotic vesicles." | ( Bewick, M; Lafrenie, RM; Zhang, L, 2002) |
| "Metastatic breast cancer is a common clinical entity, and its treatment is still a major clinical problem in modern oncology." | ( Altinova, AE; Coşkun, U; Gunel, N; Yamac, D, 2001) |
| "Fifty-three patients with metastatic breast cancer were treated." | ( Bonadonna, G; Brambilla, C; Demicheli, R; Gianni, L; Marchianò, A; Mariani, G; Tagliabue, P; Valagussa, P; Villa, E; Zucchinelli, P, 2001) |
| "Metastatic breast cancer patients aged < or = 75 years, with ECOG performance status 0-2, were eligible, provided that they had received previous anthracycline- and taxane-based chemotherapy for the advanced disease." | ( Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; Di Bonito, M; Frasci, G; Rubulotta, R; Thomas, R; Vallone, P, 2002) |
| "For ER-positive breast cancer patients, the adjuvant endocrine therapy gives results superior or equal to multi-drug chemotherapy after radical mastectomy." | ( Jiang, Z; Liu, X; Song, S, 2001) |
| "Forty-three breast cancer patients were given the NF neo-adjuvant chemotherapy (Navelbine 25 mg/m2 and 5-Fu 500 mg/m2) for 3 cycles before the operation." | ( Fang, G; Sheng, Y; Shi, J, 2001) |
| "Newly diagnosed breast cancer cases were recruited before any treatment and matched with controls randomly selected from the electoral roll." | ( Beilby, J; Ching, S; Hahnel, R; Ingram, D; Rossi, E, 2002) |
| "(1) For the treatment of metastatic breast cancer, the reference first-line cytotoxic chemotherapy is an anthracycline-based combination such as doxorubicin + cyclophosphamide." | ( , 2001) |
| "Thus, CK2 may promote breast cancer through dysregulation of key pathways of transcriptional control in the mammary epithelium, and inhibition of CK2 has a potential role in the treatment of breast and other cancers." | ( Cardiff, RD; Landesman-Bollag, E; Romieu-Mourez, R; Seldin, DC; Sonenshein, GE; Song, DH; Sussman, DJ, 2001) |
| "For women with metastatic breast cancer, complete remission is uncommon, and stable disease is a reasonable goal of successful therapy." | ( Hara, Y; Hikosaka, Y; Iwase, H; Kobayashi, S; Toyama, T; Yamashita, H, 2001) |
| "We enrolled 1217 primary breast cancer patients and randomly assigned them into two treatment groups; one received six-month postoperative 5'-DFUR treatment by consecutive or intermittent administration, and the other surgery alone." | ( Abe, O; Abe, R; Asaishi, K; Enomoto, K; Hattori, T; Hayasaka, H; Hirata, K; Izuo, M; Kimijima, I; Koyama, H; Miura, S; Monden, Y; Morimoto, T; Nakazato, H; Nomura, Y; Ohashi, Y; Ota, J; Senoo, T; Sonoo, H; Sugimachi, K; Taguchi, T; Toge, T; Toi, M; Tominaga, T; Uchino, J; Watanabe, H; Yamaguchi, S; Yoshida, M, 2002) |
| "In the breast cancer cell line L56Br-C1, treatment with 10 microm DENSPM induced SSAT activity 60 and 240-fold at 24 and 48 h after seeding, respectively, which resulted in polyamine depletion." | ( Hegardt, C; Johannsson, OT; Oredsson, SM, 2002) |
| "Women with hormone dependent breast cancer initially respond to hormone deprivation therapy with tamoxifen or oophorectomy for 12-18 months but later relapse." | ( Jeng, MH; Masamura, S; McPherson, R; Santen, R; Santner, S; Shim, WS; Song, R; Wang, JP; Yue, W, 2001) |
| "Tamoxifen is an effective treatment for breast cancer; however, as well as exerting antagonistic effects on the estrogen receptor (ER), tamoxifen acts as a partial agonists in estrogen-sensitive tissues, resulting in stimulation of the endometrium and tumor growth in some patients who become resistant to treatment." | ( Robertson, JF, 2001) |
| "Treatment of breast carcinoma cells with a combination of ZD1839 and TRA resulted in a synergistic inhibitory effect." | ( Campiglio, M; Ciardiello, F; De, LA; Gianni, L; Maiello, M; Menard, S; Normanno, N; Salomon, DS; Somenzi, G, 2002) |
| "We treated 12 patients with metastatic breast cancer with weekly paclitaxel therapy." | ( Fukuda, K; Kimura, F; Kokufu, I; Taniguchi, H; Yamada, K; Yamamoto, M; Yano, T, 2002) |
| "For each patient, pretreatment breast cancer biopsies were prospectively analyzed by immunohistochemistry (IHC) for estrogen and progesterone (ER/PR) hormonal receptors, HER2/neu and p53 overexpression." | ( Bettini, A; Cohen, D; Danenberg, K; Danenberg, P; Formenti, SC; Groshen, S; Naritoku, W; Press, M; Salonga, D; Skinner, K; Spicer, D; Tsao-Wei, D, 2002) |
| "However, in postmenopausal subjects of breast carcinoma (both without and with cardiovascular disease), serum TC, Apo-B, and Lp (a) were significantly decreased and serum TG, HDL and Apo A1 were significantly elevated, after 3 and 6 months of tamoxifen treatment, than the corresponding baseline values of postmenopausal subjects." | ( Bhatnagar, VB; Sharma, D; Sharma, U; Singh, VS, 2001) |
| "Fourteen patients with metastatic breast cancer who developed epiphora during weekly docetaxel therapy underwent an ophthalmologic examination, and probing and irrigation of the nasolacrimal ducts." | ( Ahmadi, MA; Arbuckle, R; Booser, D; Delpassand, E; Esmaeli, B; Esteva, F; Hortobagyi, G; Ibrahim, N; Valero, V, 2002) |
| "Similarly, in MCF-7 breast cancer cells that have natural expression of ER and EGFR, EGF promoted acute phosphorylation of serine and tyrosine residues in ER, and a direct interaction between ER and EGFR after treatment with EGF was found." | ( Lee, J; Lin, T; Márquez, DC; Pietras, RJ, 2001) |
| "Eighty-five women with primary breast cancer involving >or=10 lymph nodes received four cycles of standard-dose chemotherapy followed by a high-dose regimen consisting of: cyclophosphamide (1875 mg/m(2) once daily x 3), cisplatin (165 mg/m(2) given over 72 h), carmustine (600 mg/m(2)), and stem cell transplantation." | ( Berry, D; Broadwater, G; Colvin, OM; Gibbs, JP; Gilbert, CJ; Jones, RB; Peters, WP; Petros, WP; Vredenburgh, JJ, 2002) |
| "Many women with early-stage breast cancer treated in the past received a recommendation for shorter durations of tamoxifen therapy." | ( Gradishar, WJ; Hellmund, R, 2002) |
| "As many breast cancer patients receive adjuvant chemotherapy using anthracyclines or anthracenediones and taxanes, more therapeutic options are needed for subsequent lines of therapy." | ( Dodwell, DJ; duBois, A; Martin, M; Namer, M; Spielmann, M; Unger, C, 2001) |
| "The anti-idiotype monoclonal antibody breast cancer vaccine 11D10 (TriAb) was administered before and after autologous stem cell transplantation (ASCT) in 45 patients with metastatic breast cancer whose disease was responsive to conventional chemotherapy." | ( Adkins, D; Battacharya-Chatterjee, M; Broun, ER; Connaghan, DG; Dipersio, JF; Foon, KA; Hale, GA; Holland, HK; Howard, DS; Klingemann, HG; Munn, RK; Phillips, GL; Raptis, A; Reece, DE, 2001) |
| "Thirteen patients with metastatic breast cancer who were referred for treatment protocols with gemcitabine/epirubicin/paclitaxel or epirubicin/paclitaxel chemotherapy regimens were included in this study." | ( Conte, PF; Dani, D; Donati, S; Gennari, A; Giorgetti, A; Landucci, E; Mariani, G; Pisani, P; Poli, M; Puccini, G; Salvadori, B; Salvadori, PA; Sorace, O, 2000) |
| "A 45-year-old woman with breast cancer underwent chemotherapy and radiotherapy as well as autologous peripheral blood stem cell transplantation." | ( Arpaci, F; Beyzadeoglu, M; Celasun, B; Erdogan, E, 2002) |
| "79 patients with primary breast cancer and 26 patients with epithelial ovarian carcinoma underwent cytostatic treatment, and the associated myelosuppression was evaluated by the determination of cytopenia and the need for supportive therapy." | ( Bergauer, F; Dimpfl, T; Janni, W; Kaestner, R; Linka, F; Rack, B; Rjosk, D; Schindlbeck, C; Sommer, H; Strobl, B, 2001) |
| "In postmenopausal Greek women with breast cancer, the levels of Lp(a) and triglycerides and the ApoAI/ApoB ratio respond more favorably to tamoxifen treatment in ApoE4-negative than in ApoE4-positive patients." | ( Bairaktari, E; Elisaf, M; Karabina, SA; Liberopoulos, E; Nicolaides, C; Pavlidis, N; Tselepis, A, 2002) |
| "We treated 11 patients with stage IV breast cancer of whom two had never received chemotherapy for their metastatic disease." | ( Booser, DJ; Cristofanilli, M; Esteva, FJ; Hortobagyi, GN; Rahman, Z; Rivera, E; Syrewicz, L; Valero, V, 2002) |
| "Interest in translational studies on breast cancer is presently devoted to identifying biological predictors of disease prognosis and response to treatment." | ( Abdel Salam, I; Abdel Wahab, N; Gaballah, HE; Mansour, OM, 2001) |
| "Thirty women with metastatic breast cancer were treated with weekly docetaxel and trastuzumab as first- or second-line therapy." | ( Arun, B; Booser, D; Cristofanilli, M; Esmaeli, B; Esteva, FJ; Fritsche, HA; Guerra, LT; Hortobagyi, GN; Murray, JL; Pusztai, L; Smith, TL; Sneige, N; Valero, V, 2002) |
| "It is useful in metastatic breast cancer, adjuvant therapy, preoperative treatment, ductal carcinoma-in-situ and chemoprevention." | ( Goss, PE; Strasser, K, 2002) |
| "A cohort of 85 Chinese breast cancer patients who received adjuvant chemotherapy with doxorubicin and cyclophosphamide was found to have a significantly higher incidence of grade 3 (n=44, 52%) and grade 4 (n=21, 25%) neutropenia when compared with an historic Western cohort." | ( Ho, WM; Hui, P; Johnson, PJ; Ma, B; Yeo, W, 2002) |
| "Locally advanced breast cancer (LABC) is commonly treated with neoadjuvant chemotherapy followed by definitive surgery." | ( Charlop, A; Dunnwald, LK; Ellis, GK; Gralow, JR; Lawton, TJ; Livingston, RB; Mankoff, DA; Schubert, EK; Tseng, J, 2002) |
| "Twenty patients with untreated breast cancer had (99m)Tc-sestamibi imaging 20 and 120 min after tracer injection before and after a 3-d course of toremifene (780 mg/d)." | ( Chaudhary, KS; Glass, DM; Harrington, KJ; Lalani, el-N; Mubashar, M; Peters, AM; Sinnett, D; Stamp, GW, 2002) |
| "Forty-five patients affected by primary breast cancer underwent clinical examination, mammography, sonography, 99mTc-sestamibi scintimammography, and biopsy for histopathological diagnosis before neoadjuvant chemotherapy." | ( Cachin, F; Cayre, A; Chevillard, S; Feillel, V; Ferrière, JP; Finat-Duclos, F; Kwiaktowski, F; Maublant, J; Mestas, D; Penault-Llorca, F; Verrelle, P, 2002) |
| "Eighteen patients with breast cancer were treated either for adjuvant purposes or for metastatic disease." | ( Baraza, R; Nyabola, LO; Nyong'o, AO; Othieno-Abinya, NA, 2001) |
| "Tamoxifen is used to treat breast cancer and may reduce the risk of breast cancer." | ( Boone, K; Chang, L; Chlebowski, R; Cooray, D; Ernst, T; Jovicich, J; Salvador, C; Walot, I, 2002) |
| "MCF-7 breast cancer cells were treated with mitomycin C or agonistic anti-CD95 antibody, and levels of TPS and CYFRA 21-1 in tissue culture supernatants were compared with the frequency of cells exhibiting the following markers of cell death: intracellular cytokeratin-18 cleavage, surface staining with annexin-V, propidium iodide uptake, DNA fragmentation." | ( Sheard, MA; Simickova, M; Valik, D; Vojtesek, B, 2002) |
| "In patients with operable breast cancer, adjuvant hormonal therapy and adjuvant chemotherapy result in significant and long-term reductions in the rates of disease recurrence and death." | ( Mamounas, EP, 2001) |
| "The management of node-negative breast cancer is problematic due to the lack of reliable prognostic para-meters that distinguish patients who benefit from adjuvant chemotherapy." | ( Jänicke, F, 2000) |
| "Twenty-two breast cancer patients who had recurrent and metastatic measurable foci were treated from Dec." | ( Duan, Y; Guan, Z; Liu, X; Song, S; Wu, S; Yang, L; Yu, J, 2002) |
| "One-hundred and seventeen breast cancer patients received paclitaxel (300 mg/m(2)) administered as a 24-h continuous intravenous infusion." | ( Areman, EM; Cairo, MS; Ebadi, M; Gehan, E; Herscowitz, HB; Lippman, ME; Meehan, KR; Slack, R, 2002) |
| "Women with early breast cancer in one physician's practice who had received either or both of these drugs were surveyed using a self-administered questionnaire." | ( Blau, R; Lower, EE; Rohatgi, N, 2002) |
| "Samples came from node-positive breast cancer patients randomly treated either with one of two anthracycline-based regimens [full-dose epirubicin-cyclophosphamide (HEC) and moderate-dose epirubicin-cyclophosphamide (EC)] or with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in the context of a Phase III adjuvant therapy trial." | ( Di Leo, A; Dolci, S; Gancberg, D; Isola, J; Jarvinen, T; Larsimont, D; Leroy, JY; Paesmans, M; Piccart, MJ; Rouas, G; Tanner, M, 2002) |
| "The study includes a surgically treated breast cancer patient and a matching group of women with no sign of estrogenic-dependent disease." | ( Garrido Frenich, A; Martínez Vidal, JL; Moreno Frías, M; Olea, N; Olea-Serrano, F, 2002) |
| "Patients with metastatic breast carcinoma were eligible if they had disease progression after anthracycline-based therapy and had never been exposed to taxanes." | ( Booser, DJ; Cristofanilli, M; Frye, DK; Hortobagyi, GN; Rivera, E; Rosales, MM; Valero, V, 2002) |
| "Endocrine adjuvant therapy for breast cancer in recent years has focussed primarily on the use of tamoxifen to inhibit the action of estrogen in the breast." | ( Dowsett, M; Simpson, ER, 2002) |
| "Metastatic breast cancer is a chemotherapy-responsive disease, and significant palliation of cancer-related symptoms can be achieved with effective treatment." | ( Conte, P; Gennari, A; O'Shaughnessy, JA, 2002) |
| "Two human breast cancer cell lines, the estrogen receptor(ER)-positive MCF-7 and the ER-negative MDA-MB231, were thus analyzed for the amount of beta-thymosin mRNAs by RNase protection assay and for the respective peptide levels by HPLC following different hormonal and drug treatments." | ( Hannappel, E; Huff, T; Müller, CS; Otto, AM, 2002) |
| "HER-2/neu-overexpressing breast cancer cell lines were resistant to apoptosis induced by UV treatment and hypoxia, which was suppressed in the presence of the phosphatidylinositol 3-kinase inhibitors LY294002 and wortmannin, indicating a link between AKT activation and stress resistance in HER-2/neu-overexpressing cells." | ( Altomare, DA; Bacus, SS; Chin, DM; Farrell, MP; Gudkov, A; Gurova, K; Lyass, L; Testa, JR, 2002) |
| "Tumor relapse occurring in high-risk breast cancer patients after high-dose chemotherapy (HDC) and autologous stem-cell transplantation may arise from cells resistant to chemotherapy, as well as from tumor cells reinfused with autologous stem cell grafts." | ( Behr, W; Brockmeyer, C; Ehnle, S; Hempel, P; Müller, P; Oruzio, D; Riethmüller, R; Schlimok, G; Wochner, M, 2000) |
| "To determine the risk of recurrence of breast cancer associated with the use of hormone replacement therapy (HRT) in the management of menopausal symptoms in women previously treated for breast cancer who were taking concurrent tamoxifen or who were estrogen receptor-positive." | ( Dew, JE; Eden, JA; Wren, BG, 2002) |
| "Drug resistance in breast cancer is a major obstacle to successful chemotherapy." | ( Assersohn, L; Dowsett, M; Feldman, AL; Gadisetti, C; Jazaeri, AA; Libutti, SK; Liu, ET; Powles, TJ; Sotiriou, C, 2002) |
| "PKC may be therefore a target for breast cancer treatment." | ( Dabrowska, M; Dziecioł, J; Jarzabek, K; Laudański, P; Wołczyński, S, 2002) |
| "Patients with histologically proven breast cancer having either metastatic disease, or high-risk locoregional disease that were entered into treatment protocols with first-line taxane (paclitaxel or docetaxel) plus anthracyclines or mitoxantrone combinations and developed LMC as the first evidence of progression after major response (CR or >80% PR) were analyzed in the present study (n = 155)." | ( Antonopoulos, MJ; Gregoriou, A; Kosmas, C; Malamos, NA; Rokana, S; Stamataki, M; Stefanou, S; Tsavaris, NB; Vartholomeou, M, 2002) |
| "For this purpose, MCF-7 breast cancer cells were treated with 10-20 microM curcumin, and the effects on cell proliferation and mitosis studied." | ( Holy, JM, 2002) |
| "Among these breast cancers those that are estrogen-responsive respond well to existing therapeutic regimens while estrogen non-responsive cancers metastasize widely, demonstrate a high relapse rate, and respond poorly to therapy." | ( Cakir, Y; Plummer, HK; Schuller, HM; Tithof, PK, 2002) |
| "Thus, some breast cancer cells may survive antiestrogen treatment by bypassing specific growth inhibitory signals induced by antagonist-occupied estrogen receptors." | ( Bouker, KB; Brünner, N; Clarke, R; Davis, N; Gu, Z; Lee, RY; Leonessa, F; Liu, A; Lu, J; Skaar, TC; Wang, Y; Welch, JN; Zhu, Y, 2002) |
| "We demonstrate that tumour growth of breast cancer MCF7 cells implanted in female athymic mice is reduced by treatment with antisense Efp oligonucleotide." | ( Fujita, M; Hosoi, T; Inoue, S; Muramatsu, M; Ouchi, Y; Saito, T; Tsukui, T; Urano, T, 2002) |
| "Among endocrine therapies used to treat breast cancer, fulvestrant is unique not only in its mechanism of action but also in its mode of administration." | ( Lynn, J, 2002) |
| "Thirty women with advanced breast cancer undergoing chemotherapy were randomly assigned into two groups treated with either single agent Paclitaxel or Docetaxel." | ( Boulamatsis, D; Kanelopoulos, P; Kosmas, C; Tsavaris, N; Vadiaka, M, 2002) |
| "The International Breast Cancer Study Group Trial VI randomly assigned 735 pre- and perimenopausal patients to receive 'classical' cyclophosphamide, methotrexate and fluorouracil for three consecutive cycles, or the same chemotherapy for six consecutive cycles." | ( Bastert, G; Beyerle, C; Bonetti, M; Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Collins, J; Crivellari, D; Gelber, RD; Goldhirsch, A; Holmberg, SB; Lindtner, J; Litman, HJ; Neumann, RL; Rudenstam, CM; Sauerbrei, W; Schmoor, C; Schumacher, M; Thürlimann, B, 2002) |
| "Seventeen patients with advanced breast cancer were treated with oxaliplatin, 5-fluorouracil, and folinic acid, and preliminary data were analyzed." | ( Agostara, B; Blasi, L; Laudani, A; Leonardi, V; Savio, G, 2002) |
| "Based on the data from 18 patients with breast cancer who were treated orally with 280 or 525 mg/m(2) of IST-622 once daily after breakfast for five consecutive days, we analyzed the relationship between the area under the plasma concentration versus time curve (AUC) and toxicities using a sigmoid E-max model and logistic regression." | ( Asai, G; Kimura, M; Nishiyama, K; Nomura, Y; Sekine, T; Shin, E; Takashima, S; Toi, M; Tominaga, T; Yamamoto, N, 2002) |
| "Two neuroblastoma and two breast carcinoma lines also demonstrated decreased survival following EX5 treatment whereas nontransformed human fibroblasts were not affected." | ( Pereira, P; Rozen, R; Sabbaghian, N; Schievella, AR; Sekhon, J, 2002) |
| "A significant proportion of breast cancers are estrogen-dependent and are therefore amenable to endocrine therapy." | ( Köberle, D; Thürlimann, B, 2001) |
| "In advanced breast cancer, aromatase inhibitors and inactivators are likely to become established as the primary choice over tamoxifen in postmenopausal female breast cancer patients when hormonal therapy is indicated in the first-line setting." | ( Dixon, JM, 2002) |
| "Eligible for the study were metastatic breast cancer patients who had received a maximum of one prior therapy for metastatic disease." | ( Awada, A; Beex, L; Biganzoli, L; Bruning, P; Coleman, R; de Valeriola, D; Hamilton, A; Hennebert, P; Mauriac, L; Nooij, M; Piccart, M; Van Hoorebeeck, I, 2002) |
| "According to the overview of Early Breast Cancer Trialists' Collaborative Group, anthracycline containing regimens are superior to cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) as adjuvant chemotherapy for breast carcinoma, but no comparative information is available in terms of primary chemotherapy." | ( Bella, M; Bisagni, G; Boni, C; Bruzzi, P; Camisa, R; Ceci, G; Cocconi, G; Di Blasio, B; Leonardi, F; Rondini, E; Savoldi, L, 2002) |
| "In human breast carcinomas, the presence of EGFR correlates with lack of response towards anti-estrogen therapy suggesting the concomitant inhibition of both the receptors for estrogen and EGF to improve breast cancer therapy." | ( Lichtner, RB; Schmidt, M, 2002) |
| "To compare the prognostic factor of breast cancer survival between breast cancer diagnosed in subjects receiving hormone replacement therapy (HRT) before diagnosis to those without such a therapy." | ( Estève, J; Jacquemier, J; Remontet, L; Séradour, B, 2002) |
| "In MCF-7 breast cancer cells Gab2 was markedly tyrosine phosphorylated in response to heregulin and also following EGF, insulin or bFGF administration, indicating that a variety of RTKs implicated in breast cancer development or progression couple to this docking protein." | ( Daly, RJ; Gu, H; Head, DR; Henshall, SM; Kairouz, R; Lyons, RJ; Malaney, S; Neel, BG; Parmar, J; Sutherland, RL, 2002) |
| "After the usefulness of ovariectomy in breast cancer patients was demonstrated, endocrine therapy has been one of the most effective treatments of breast cancer." | ( Asaga, S; Hohjou, T; Ikeda, T; Jinno, H; Kitajima, M; Matsui, A; Mitsui, Y; Muto, T; Tajima, G; Tokura, H, 2002) |
| "Treatment of MCF7 human breast cancer cells with taxol induces G2/M arrest followed by mitotic death." | ( Balkenende, A; Coco-Martin, J; Michalides, R; Tiemessen, M; Verschoor, T, 2002) |
| "Although metastatic breast cancer is responsive to radioimmunotherapy (RIT), a systemic targeted radiation modality, complete and permanent remissions are not typical with single-modality treatment." | ( Burke, PA; DeNardo, GL; DeNardo, SJ; Lamborn, KR; Matzku, S; Miers, LA, 2002) |
| "Clinical observations suggest that human breast tumors can adapt in response to endocrine therapy by developing hypersensitivity to estradiol." | ( Adam, L; Jeng, MH; Kumar, R; Masamura, S; Santen, RJ; Song, RX; Yue, W, 2002) |
| "For stages I and II breast cancer, detection of CK-19-positive cells in the peripheral blood before adjuvant therapy was associated with reduced disease-free interval (P =." | ( Apostolaki, S; Georgoulias, V; Kakolyris, S; Kotsakis, A; Kouroussis, Ch; Malamos, N; Mavroudis, D; Perraki, M; Reppa, D; Stathopoulou, A; Vlachonikolis, I; Xenidis, N, 2002) |
| "Patients with histologically proven breast cancer having either metastatic disease or high-risk locoregional disease that were entered into treatment protocols with first-line taxane (paclitaxel or docetaxel) plus anthracyclines or mitoxantrone combinations and developed LMC as the first evidence of progression after major response (CR or >80% PR) were analyzed in the present study (n = 155), and compared, as regards the incidence of LMC, to a matched-pair retrospective group of 155 patients treated with nontaxane regimens in our unit." | ( Antonopoulos, MJ; Gregoriou, A; Kosmas, C; Malamos, NA; Rokana, S; Stamataki, M; Tsavaris, NB; Vartholomeou, M, 2002) |
| "Women with metastatic breast cancer and at least a partial response (PR) to induction chemotherapy received three separate high-dose cycles of chemotherapy with peripheral blood progenitor support and G-CSF." | ( Antman, K; Balmaceda, C; Donovan, D; Frederick, D; Haythe, J; Hesdorffer, CS; Kaufman, E; Nichols, G; Papadopoulos, K; Savage, D; Sharpe, E; Tiersten, A; Troxel, A; Vahdat, LT, 2002) |
| "11 patients with breast cancer and 10 patients with lung cancer receiving systemic chemotherapy were studied." | ( Israel, VK; Liebman, HA; Presant, CA; Rochanda, L; Waisman, JR; Weitz, IC, 2002) |
| "However, breast cancer patients treated with conventional cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy showed a higher risk of cognitive impairment." | ( Boogerd, W; Muller, MJ; Rodenhuis, S; Rosenbrand, RM; Schagen, SB; van Dam, FS; van Rhijn, D, 2002) |
| "Invasive breast carcinomas are composed of invasive and noninvasive components in varying proportions and sometimes the two components show different histopathological responses to chemotherapy, however there has been no study as yet comparing the pathological response to chemotherapy of invasive and noninvasive components." | ( Akashi-Tanaka, S; Fukutomi, T; Hasegawa, T; Matsuo, K; Tsuda, H; Watanabe, T, 2002) |
| "Patients with resected breast cancer were treated if they were node-positive and estrogen receptor-negative, positive for overexpression of Her-2-neu, or had four or more involved nodes." | ( Ellis, GK; Gralow, JR; Green, SJ; Livingston, RB; Thompson, T, 2002) |
| "Combined chemotherapy of breast cancer using antracyclins proved to be superior over classical drug combinations." | ( Nagykálnai, T, 2002) |
| "Treatment of human breast cancer MCF-7 cells with resveratrol also suppressed the NF-kappaB activation and inhibited proliferation at S-G(2)-M phase." | ( Aggarwal, BB; Banerjee, S; Bueso-Ramos, C, 2002) |
| "Twenty-one postmenopausal breast cancer patients were given tamoxifen (20 mg/day) as the adjuvant treatment after the surgery." | ( Ikeda, N; Miyoshi, Y; Noguchi, S; Taguchi, T; Tamaki, Y; Tanji, Y; Yoneda, K, 2002) |
| "Initiation and progression of breast cancer results from mutations and the abnormal expression of many genes that control cellular proliferation, differentiation, invasion, metastasis and sensitivity to therapy (chemotherapy and radiation therapy)." | ( Elliott, RL; Head, JF; Yang, DC, 2002) |
| "In the phase 1/2 study, 75 breast cancer patients underwent a bone marrow harvest and myeloablative STAMP V chemotherapy and were randomized to receive placebo or one of three doses of PEG-rHuMGDF." | ( Abboud, CN; Beveridge, R; Cruickshank, S; Frei-Lahr, D; Holden, J; Macri, M; Menchaca, D; Schuster, MW; Waller, EK, 2002) |
| "Data on hormone replacement therapy and breast cancer risk come from a number of observational studies (mostly American studies)." | ( Abbà, C; Ambroggio, S; Biglia, N; Campagnoli, C; Ponzone, R, 2001) |
| "Treatment of human breast cancer cell lines with 2-deoxy-D-glucose results in cessation of cell growth in a dose dependent manner." | ( Aft, RL; Gius, D; Zhang, FW, 2002) |
| "Response of breast carcinomas to tamoxifen treatment depends, among others, on the estrogen receptor status." | ( Bejar, J; Boss, JH; Eldar, S; Lev, M; Misselevich, I; Sabo, E, 2002) |
| "In women with breast cancer, knowledge of the local/regional extent of the tumor is essential for staging, treatment planning, monitoring response to therapy, and follow-up." | ( Aloj, L; Bacharach, SL; Carrasquillo, JA; Chow, C; Danforth, DN; Galen, B; Merino, M; Neumann, RD; Whatley, M; Zujewski, J, 2002) |
| "In high-grade, advanced breast cancers, inactivation of the TP53 pathway could greatly improve the response to this chemotherapy regimen." | ( Bertheau, P; Beuzard, Y; de Roquancourt, A; de Thé, H; Espié, M; Janin, A; Lerebours, F; Marty, M; Plassa, F; Turpin, E, 2002) |
| "Modern treatment of premenopausal breast cancer is based on well-established prognostic and predictive factors for disease outcome such as nodal status, hormone receptor expression, tumour size, tumour grading and patient age." | ( Höffken, K; Kath, R; Kliche, KO; Sayer, HG, 2002) |
| "Again, the incidence of breast cancer was lower in estrogen-treated women (141/100,000) than untreated women (342/100,000)." | ( Gambrell, RD, 1984) |
| "ZR-75 breast cancer cells were grown under conditions of normoxia (21% O(2)) or hypoxia (1% O(2) or cobaltous chloride), and hypoxia significantly increased hypoxia-inducible factor 1alpha protein within 3 h after treatment, whereas ERalpha protein levels were dramatically decreased within 6-12 h, and this response was blocked by the proteasome inhibitor MG-132." | ( Burghardt, R; Dean, D; Safe, S; Saville, B; Stoner, M; Wormke, M, 2002) |
| "Two hundred and eighty-eight had early breast cancer, requiring surgery, eligible for consideration of adjuvant therapy." | ( Catcheside, A; Feldman, M; Stanford, R; Stotter, A, 2002) |
| "A patient with breast cancer developed severe asthenia, accompanied with progressively increasing transaminases, during adjuvant chemotherapy with CMF (cyclophosphamide, methotrexate and 5-fluorouracil)." | ( Bogers, J; Schrijvers, D; van den Brande, J; van Marck, E; van Outryve, S; Vermorken, JB; Wilmes, P, 2002) |
| "Hot flushes: Treatment for breast carcinoma, not receiving Tamoxifen." | ( Clover, A; Ratsey, D, 2002) |
| "Treatment of breast cancer cells with the combination of HCT and specific AMF inhibitors, erythrose 4-phosphate or D-mannose 6-phosphate, resulted in an additive inhibitory effect on both the growth rate and invasiveness of cells as compared with treatment with each agent alone." | ( Bagheri-Yarmand, R; Kumar, R; Ragoussis, J; Raz, A; Talukder, AH; Williams, RR, 2002) |
| "Despite modest activity in metastatic breast cancer, the toxicity observed with the combination of estramustine and docetaxel precludes the routine use of this combination in the treatment of breast cancer." | ( Ansari, R; Einhorn, LH; Fata, F; McClean, JW; Miller, KD; Porcu, P; Sledge, GW; Soule, SE; Zon, R, 2002) |
| "Three hundred seventy-one metastatic breast cancer patients with no prior systemic chemotherapy for advanced disease were randomized to receive either EPI alone (60 mg/m(2) on days 1 and 2 every 21 days), EPI and CDDP (30 mg/m(2) on days 1 and 2 every 21 days), EPI and LND (450 mg orally daily, given continuously), or EPI, CDDP, and LND." | ( Alquati, P; Berruti, A; Bitossi, R; Bonazzi, G; Bottini, A; Bruzzi, P; Bumma, C; Castiglione, F; Danese, S; De Lena, M; De Matteis, A; DeFabiani, E; Dogliotti, L; Farris, A; Giardina, G; Gorzegno, G; Lorusso, V; Moro, G; Nuzzo, F; Sarobba, MG, 2002) |
| "Among 155 patients with breast cancer treated by Seishu Hanaoka the exact death dates of only five patients including Kan Aiya, the first to have received a tumour excision under general anesthesia are known to us and the remaining 149 patients remain unclarified concerning their death dates." | ( Matsuki, A, 2002) |
| "The systemic treatment of breast cancer is a moving target, reflected by the continuous update of treatment guidelines." | ( Wolff, AC, 2002) |
| "As well as in breast cancer and lung cancer treatment, its association in a chemoradiation planned treatment becomes frequent and effective." | ( Benezery, K; Lagrange, JL; Magné, N; Namer, M; Otto, J, 2002) |
| "Global gene expression patterns in breast cancer cells after treatment with oxidants (hydrogen peroxide, menadione, and t-butyl hydroperoxide) were investigated in three replicate experiments." | ( Chandramouli, VR; Chen, Y; Chuang, YY; Coffin, D; Cook, JA; DeGraff, W; Liu, ET; Mitchell, JB; Russo, A; Tsai, MH; Yan, H; Zhao, S, 2002) |
| "The role of chemotherapy in breast cancer brain metastases is not clearly defined; the results of the 8 trials found in the literature are reported." | ( Fenner, MH; Possinger, K, 2002) |
| "Following these treatments, inoperable breast cancer often becomes fully resectable, and initially operable tumours requiring mastectomy may be successfully removed by breast-conserving surgery." | ( Anderson, TJ; Dixon, JM; Miller, WR, 2002) |
| "Among 371 breast cancer patients receiving hormonal therapy, the proportion of patients with an SRE was 47% for Pam vs." | ( Gleason, D; Gordon, D; Kowalski, MO; Lipton, A; Reitsma, D; Rosen, L; Saad, F; Seaman, J; Small, E; Smith, M, 2002) |
| "Transient transfection of ER-positive breast cancer cell lines T47D and MCF7 with G1/S cyclins could overcome the growth arrest induced by ICI 182780 treatment." | ( Balkenende, A; Bindels, EM; Lallemand, F; Michalides, R; Verwoerd, D, 2002) |
| "Sixty-three patients with metastatic breast cancer were treated with paclitaxel 200 mg/m2, 1 hr i." | ( Calvert, S; Greco, FA; Hainsworth, JD, 2002) |
| "Metastatic and locally advanced breast cancer remain a fertile field for investigation of new chemotherapeutic agents and chemotherapy combinations." | ( Durgam, S; Levin, M; Novetsky, A, 2002) |
| "Nineteen patients with lymphedema after breast cancer therapy were evaluated." | ( Rockson, SG; Sirsikar, SP; Strauss, W; Szuba, A, 2002) |
| "Treatment of breast cancer requires a fully integrated multidisciplinary management as well as an ongoing dialogue with laboratory scientists." | ( Cardoso, F; Di Leo, A; Piccart, MJ, 2002) |
| "Inhibitors of the breast cancer resistance protein (BCRP/ABCG2) multidrug transporter are of interest as chemosensitizers for clinical drug resistance, for improving the pharmacokinetics of substrate chemotherapeutic drugs, and in functional assays of BCRP activity for tailoring chemotherapy." | ( Allen, JD; Koomen, GJ; Lakhai, JM; Reid, G; Schellens, JH; Schinkel, AH; van der Valk, M; van Loevezijn, A; van Tellingen, O, 2002) |
| "We report on two female patients with breast cancer who on treatment with docetaxel developed acral erythrodysesthesia syndrome." | ( Eich, D; Eich, HT; Krieg, T; Scharffetter-Kochanek, K; Tantcheva-Poor, I, 2002) |
| "Human breast cancer cell lines, which express high levels of endogenous Neu receptor, were treated with the anti-Neu antibody, trastuzumab, together with flavopiridol and subject to MTT assay." | ( Albanese, C; D'Amico, M; Lee, RJ; Mani, S; Pestell, RG; Wang, C; Wu, K, 2002) |
| "We report a recurrent case of breast cancer successfully treated with intra-arterial infusion of doxorubicin hydrochloride (ADM) combined with systemic CAF therapy." | ( Hasegawa, S; Ishiwa, N; Matsumoto, A; Morinaga, S; Nishimura, J; Noguchi, Y; Okoshi, T; Yamamoto, Y; Yoshikawa, T, 2002) |
| "Sixty-seven patients with breast cancer treated with adjuvant tamoxifen were included." | ( Hayakawa, K; Morimoto, T; Mukaihara, S; Nakamura, Y; Nishino, M, 2003) |
| "Patients with hormone-sensitive breast cancer who have responded to tamoxifen may receive additional benefit from a second endocrine agent following progression or relapse after tamoxifen therapy." | ( Bross, PF; Cohen, MH; Pazdur, R; Williams, GA, 2002) |
| "In contrast, S1P treatment of breast cancer cells does not activate matriptase, and instead these cells constitutively activate the protease." | ( Benaud, CM; Dickson, RB; Lin, CY; Oberst, M, 2002) |
| "Thirty-one patients with advanced breast cancer either resistant to anthracycline-based regimens or relapsing after anthracycline-based adjuvant chemotherapy received a combination of a 3-h infusion of paclitaxel 135 mg/m2 on day 1 and a 4-h infusion of ifosfamide 1." | ( Blomqvist, C; Elomaa, L; Järvenpää, R; Kellokumpu-Lehtinen, P; Kokko, R; Lantto, A; Lehtinen, R, 2002) |
| "A total of 30 patients with operated breast cancer were treated with 500 mg/m2 oral ftorafur for 10 consecutive days plus 20 mg/m2 intramuscular (im) administered thiotepa on d 1 and 8 every 28 d adjuvant chemotherapy." | ( Galmarini, CM; Galmarini, D; Galmarini, FC; Garbovesky, C, 2002) |
| "In patients with pretreated advanced breast cancer, capecitabine is effective as monotherapy and also in combination with other agents." | ( Goa, KL; Ibbotson, T; Wagstaff, AJ, 2003) |
| "Forty-eight patients with stage II, III breast cancer as proved by cytology biopsy, were treated with either 5-Fu, epirubicin, cyclophosphamide (FEC) or epirubicin, paclitaxel (ET) regimens for 2 cycles every 3 - 4 weeks." | ( Cao, Y; Liu, H; Liu, P; Qiao, X; Tong, F; Yang, D; Zhang, J; Zhou, B, 2002) |
| "Despite modern chemotherapy, advanced breast cancer remains a significant cause of cancer morbidity and mortality in women." | ( Broadwater, G; Chao, NJ; Folz, RJ; Hussein, A; Long, GD; Marks, LB; Peters, WP; Rizzieri, D; Ross, M; Stuart, MJ; Vredenburgh, JJ, 2002) |
| "Mice inoculated with the ZR-75-1 breast cancer line and treated with a selective ET(A) receptor antagonist (ABT-627) had significantly fewer osteoblastic bone metastases and less tumor burden compared with untreated mice." | ( Guise, TA; Mohammad, KS; Yin, JJ, 2003) |
| "In these women with untreated breast cancers, FDG uptake (SUV-lean) and tumor blood flow are strongly correlated." | ( Tatsumi, M; Wahl, RL; Zasadny, KR, 2003) |
| "Because low or absent PR in primary breast cancer is associated with poor prognosis and response to hormone therapy, our results suggest that low PR status may serve as an indicator of activated growth factor signaling in breast tumor cells, and therefore of an aggressive tumor phenotype and resistance against hormonal therapy." | ( Cui, X; Deng, W; Lee, AV; Lu, Y; Mills, GB; Oesterreich, S; Zhang, P, 2003) |
| "Since many breast tumors and cancer cell lines overexpress IGF-IR, we tested IGF-I effects on chemotherapy-treated breast cancer cells." | ( Mamay, CL; Mingo-Sion, AM; Molina, MD; Van Den Berg, CL; Wolf, DM, 2003) |
| "For treatment of early breast cancer in older women, little evidence is available from randomised trials." | ( Berner, J; Christiaens, MR; de Keizer, G; Fentiman, IS; Legrand, C; Nagadowska, M; Paridaens, R; Rutgers, E; Therasse, P; Van Geel, A; Wildiers, J, 2003) |
| "To evaluate its efficacy in sensitizing breast cancer cells to chemotherapy, MPG has been overexpressed in the breast cancer cell line, MDA-MB231." | ( Fishel, ML; Kelley, MR; Seo, YR; Smith, ML, 2003) |
| "Indeed, long-term treatment of human breast cancer cells (HBCCs) with PEA downregulates the expression of the enzyme responsible for AEA degradation, the fatty acid amide hydrolase, thereby leading to an enhancement of AEA-induced, and cannabinoid CB1 receptor-mediated, cytostatic effect on HBCCs." | ( Bifulco, M; Bisogno, T; De Petrocellis, L; Di Marzo, V; Ligresti, A; Melck, D, 2002) |
| "Elderly patients with breast carcinoma who have no evidence of axillary lymph node involvement may be treated effectively with conservative surgery and tamoxifen." | ( Coradini, D; De Palo, G; Galante, E; Martelli, G; Marubini, E; Miceli, R; Salvadori, B; Zucali, R, 2003) |
| "During the last decade, except for breast cancer, few "solid" tumours have benefited from significant progress in systemic treatment able to reduce the progression of metastases in advanced disease or to eradicate possible micro-metastases in the adjuvant situation." | ( Cardoso, F; Dochy, E; Piccart, M, 2003) |
| "Fifty-one patients with locally advanced breast tumors (n = 43) or locally recurrent tumors (n = 8) underwent tumor biopsy and were treated with CE (cyclophosphamide (600 mg/m2) plus epirubicin (60 mg/m2), q3w)." | ( Egawa, C; Inaji, H; Koyama, H; Miyoshi, Y; Motomura, K; Noguchi, S; Taguchi, T; Takamura, Y; Tamaki, Y, 2003) |
| "ERalpha levels in the mouse uterus and breast cancer cells were significantly lower after cotreatment with E plus TCDD than after treatment with E or TCDD alone, and our results indicate that AhR-mediated inhibition of E-induced transactivation is mainly due to limiting levels of ERalpha in cells cotreated with E plus TCDD." | ( Abdelrahim, M; Burghardt, R; Safe, S; Saville, B; Stoner, M; Walker, K; Wormke, M, 2003) |
| "A conservative approach to treating breast cancer patients was adopted for those more than 70 years of age with T1-3 and small localized T4b N0-1 lesions." | ( Apffelstaedt, JP; Odendaal, Jde V, 2003) |
| "Two phase II trials in 50 breast cancer patients compared the STn-KLH vaccine with and without a single low-dose infusion of cyclophosphamide used as an immunomodulator prior to initiation of treatment." | ( Miles, D; Papazisis, K, 2003) |
| "In the case of treatment of breast cancer cells, decoy oligonucleotides mimicking CRE binding sites, promoter region of estrogen receptor alpha gene, NF-kB binding sites have been used with promising results." | ( Gambari, R; Piva, R, 2002) |
| "Concern exists that the reduction in breast cancer risk associated with the onset of the menopause will be negated with exposure to hormone replacement therapy (HRT)." | ( Marsden, J, 2002) |
| "Between 1982 and 1995, 727 Stage I-II breast cancer patients were treated with breast conservation therapy at Massachusetts General Hospital." | ( Assaad, SI; Coen, JJ; Kachnic, LA; Powell, SN; Taghian, AG, 2003) |
| "Treatment of MCF-7 human breast cancer and HT-29 human colon carcinoma cells with PX-12 and pleurotin prevented the hypoxia (1% oxygen)-induced increase in HIF-1alpha protein." | ( Birmingham, A; Kirkpatrick, DL; Newman, DJ; Powis, G; Welsh, SJ; Williams, RR, 2003) |
| "Tamoxifen is being used successfully in breast cancer patients as adjuvant hormonal therapy." | ( Akin, ML; Celenk, T; Erenoglu, C; Gulluoglu, BM; Karadag, A; Sakar, B; Uluutku, H, 2003) |
| "Tamoxifen, used in breast cancer treatment, may induce hepatic steatosis." | ( Cengiz, O; Coşkun, U; Elbeg, S; Günel, N; Ozkan, S; Sancak, B; Toruner, FB; Uner, A; Yilmaz, E, 2003) |
| "Currently, the therapy for breast cancer is determined by immunohistochemical staining of the primary tumour for oestrogen receptor alpha (ERalpha)." | ( Ali, S; Buluwela, L; Coombes, RC; Kothari, MS; Livni, N; Shousha, S; Sinnett, HD; Slade, MJ; Thorpe, P; Van Noorden, S; Vashisht, R, 2003) |
| "A woman treated for breast cancer with mastectomy and radiotherapy in 1965 presented with a pleural mass and high CA 15." | ( Annoni, G; Dal Lago, D; Miguoli, R; Vergani, C; Villa, G, 1998) |
| "Postmenopausal hormone-sensitive breast cancer is currently treated with either antioestrogens or aromatase inhibitors (AIs), due to the clinical efficacy and safety of these drugs." | ( Bajetta, E; Bombardieri, E; Buzzoni, R; Celio, L; Ferrari, L; Gattinoni, L; La Torre, I; Longarini, R; Martinetti, A; Seregni, E, 2003) |
| "In the treatment of breast cancer, combination chemotherapy is used to overcome drug resistance." | ( Appleyard, MV; Chamberlain, MP; Hupp, TR; Liem, AA; O'Neill, MA; Thompson, AM, 2003) |
| "Women with breast cancer on tamoxifen treatment need more attention and frequent evaluation of their reproductive organs, especially postmenopausal (either spontaneous or chemotherapy induced) women, although the American College of Obstetricians and Gynecologists (ACOG) comments that no more than annual pelvic exams with Pap smears are needed in asymptomatic women." | ( Chen, P; Chen, YJ; Wang, PH; Yang, CC, 2003) |
| "The finding that breast cancer cells that are resistant to conventional chemotherapeutic agents remain sensitive to 2-substituted oestrogen sulphamates offers considerable potential for the treatment of women with drug-resistant breast cancer." | ( Leese, MP; Newman, SP; Potter, BV; Purohit, A; Reed, MJ; Suzuki, RN, 2003) |
| "Thirty-three patients with metastatic breast cancer received paclitaxel 175 mg/m(2 )either as first- (15 patients) or as second-line (18 patients) treatment." | ( Bachhuber, A; Knapstein, PG; Lehr, HA; Mahlke, M; Pilch, H; Schmidt, M; Steiner, E; Victor, A; Weikel, W, 2003) |
| "Although its single-agent activity in breast cancer is modest, its potential role may be in concert with traditional chemotherapy." | ( Lahn, M; Roychowdhury, D, 2003) |
| "Strategies of gene therapy for breast cancer in ongoing clinical protocols can be divided into four: (1) suppression of oncogenes or transduction of tumor suppressors; (2) enhancement of immunological response to cancer cells; (3) transduction of suicide genes; and (4) protection of bone marrow using drug resistance genes." | ( Hatake, K; Sugimoto, Y; Takahashi, S, 2003) |
| "1007 cases of female breast cancer patients treated with breast conserving surgery and subsequently irradiation with a median dose of 66 (50-80) Gy including boost with tangential high voltage photon beams." | ( Puric, E; Schwegler, N, 2003) |
| "To estimate the risk of recurrence of breast cancer associated with the use of topical vaginal estrogen therapy in the management of vaginal atrophy in women previously treated for breast cancer." | ( Dew, JE; Eden, JA; Wren, BG, 2003) |
| "T-47D (ER+/PR+) and HCC1937 (ER-/PR-) breast cancer cells were pretreated with 100 microM anastrozole, with or without tamoxifen, and stimulated with 22." | ( Calhoun, K; Cheek, J; Fletcher, W; Pommier, R; Toth-Fejel, S, 2003) |
| "Of 332 postmenopausal women with breast cancer who were treated with tamoxifen, 32 (9." | ( Cohen, I; Potlog-Nahari, C; Shapira, J; Tepper, R; Yigael, D, 2003) |
| "In postmenopausal patients with breast carcinoma who were treated with tamoxifen, long-term follow-up US of simple ovarian cysts demonstrates a significant decrease in cyst size over time." | ( Cohen, I; Potlog-Nahari, C; Shapira, J; Tepper, R; Yigael, D, 2003) |
| "However, patients with breast cancer have been commonly treated with antifolate chemotherapies." | ( Alberts, SR; Cerhan, JR; Grabrick, DM; Kushi, LH; Olson, JE; Potter, JD; Sellers, TA; Vachon, CM; Vierkant, RA, 2002) |
| "However, one-third of breast cancers fail to respond to endocrine therapy and most endocrine-responsive breast cancers subsequently become resistant to endocrine therapy." | ( Kurebayashi, J, 2003) |
| "We describe a woman with metastatic breast cancer treated with multiple rounds of prior cytotoxic and endocrine therapies, who presented with ipsilateral diaphragmatic paralysis." | ( Okamura, Y; Sakurai, T; Shimizu, Y; Suzuma, T; Umemura, T; Yang, QF; Yoshimura, G, 2003) |
| "Treatment of MDA-MB-231 breast cancer cells with NS-398 (a COX-2 inhibitor) or ciglitazone (CGZ, a PPARgamma-ligand) significantly inhibited cell proliferation and markedly increased apoptotic rates." | ( Badawi, AF; Badr, MZ; Michael, MS, 2003) |
| "23 patients with 27 breast tumors (21 carcinomas and 6 fibroadenomas) were examined with dynamic MR imaging after administration of Clariscan, an iron oxide nanoparticle with large T1 relaxivity and a long plasma half life." | ( BjØrnerud, A; Haraldseth, O; Haugen, O; Kvistad, KA; Rydland, J; Torheim, G; Torres, C, 2003) |
| "Thirty-one patients with breast cancer underwent MRI before and after neoadjuvant treatment." | ( Delorme, S; Fink, C; Junkermann, H; Klein, SK; Lüdemann, HP; Sinn, HP; Wasser, K; Zuna, I, 2003) |
| "Fourteen women with proven breast cancer underwent MR imaging prior to and following neoadjuvant chemotherapy." | ( Delille, JP; Garrido, L; Halpern, EF; Kopans, DB; Slanetz, PJ; Yeh, ED, 2003) |
| "Our clinical data on 1,969 breast cancer patients (stage I-III) (tamoxifen--947; control--1,022) showed a double rise in endometrial carcinoma risk in cases receiving hormone therapy." | ( Berstein, LM; Bulgatova, EA; Chepik, OF; Maksimov, SIa; Meshkova, IE; Semiglazov, VF, 2003) |
| "Clinical observations suggest that human breast tumors can adapt to endocrine therapy by developing hypersensitivity to estradiol (E(2))." | ( Berstein, L; Jeng, MH; Kumar, R; Masamura, S; Santen, RJ; Song, RX; Yue, W; Zhang, Z, 2003) |
| "E2 treatment of breast cancer cells alters expression of nearly all of the IGF family members including IGF-I, IGF-II, IGF-binding proteins, IGF type I receptor (IGF-RI), and insulin receptor substrate 1." | ( Hamelers, IH; Steenbergh, PH, 2003) |
| "In five heavily pretreated women with breast cancer, one patient had a complete response, one patient had a partial response, and one patient had stable disease." | ( Shapiro, CL; Xu, Y, 2003) |
| "In women with metastatic breast cancer and where hormone receptors are present, a policy of treating first with endocrine therapy rather than chemotherapy is recommended except in the presence of rapidly progressive disease." | ( Ghersi, D; Hornbuckle, J; Wilcken, N, 2003) |
| "Women with breast cancer treated with tamoxifen should undergo annual gynaecological examination, but endometrial sampling should be obtained only in the event of endometrial bleeding." | ( Akrivis, Ch; Polyzos, D; Varras, M, 2003) |
| "Second, a common therapy for breast carcinoma (tamoxifen) may be associated with cardiac protection." | ( Christakis, NA; Lamont, EB; Lauderdale, DS, 2003) |
| "Many believe that breast cancer should be treated by specialists." | ( Deapen, D; Helsper, JT; Skinner, KA; Sposto, R; Ye, W, 2003) |
| "Preoperative chemotherapy for stage II breast cancer may reduce locoregional tumors and provides initial treatment for systemic micrometastases." | ( Altemus, R; Berman, A; Chaudhry, U; Chow, C; Cowan, K; Danforth, DN; Merino, M; Shriver, C; Steinberg, SM; Zujewski, J, 2003) |
| "Patients with clinical stage II breast cancer (T2N0, T1N1, and T2N1) were prospectively randomized to receive either preoperative or postoperative chemotherapy with five 21-day cycles of fluorouracil, leucovorin calcium, doxorubicin, and cyclophosphamide (FLAC)/granulocyte-colony-stimulating factor." | ( Altemus, R; Berman, A; Chaudhry, U; Chow, C; Cowan, K; Danforth, DN; Merino, M; Shriver, C; Steinberg, SM; Zujewski, J, 2003) |
| "When breast cancer cell lines were treated with all- trans -retinoic acid, OCT3 expression was repressed, associated with decreased cell proliferation." | ( Bali, M; Branch, DR; Goss, PE; Jin, T; Schultz, GA; Wang, P, 2003) |
| "In untreated breast cancer, (18)F-FDG SUV values changed approximately linearly after 27 min at a rate ranging from -0." | ( Beaulieu, S; Dunnwald, LK; Kinahan, P; Lewellen, B; Mankoff, DA; Pham, P; Schubert, EK; Tseng, J, 2003) |
| "In untreated breast cancer, the SUV at any time point approximately predicts the rate of change of SUV over time." | ( Beaulieu, S; Dunnwald, LK; Kinahan, P; Lewellen, B; Mankoff, DA; Pham, P; Schubert, EK; Tseng, J, 2003) |
| "The current treatment of breast carcinomas recognizes the importance of combination therapy in order to increase efficacy and decrease side effects of conventional chemotherapy." | ( Eiseman, J; Shamsuddin, AM; Tantivejkul, K; Vucenik, I, 2003) |
| "Anaemia is frequent in breast cancer patients but often remains undiagnosed and untreated." | ( Baumann, J; Denison, U; Krippl, P; Lang, A; Obermair, A; Peters-Engl, C; Samonigg, H; Sevelda, P; Wagner, H, 2003) |
| "Patients with advanced breast cancer refractory to at least one chemotherapy regimen (ER negative tumors) or two hormonal regimens (ER positive tumors) were treated with troglitazone at 800 mg p." | ( Burstein, HJ; Demetri, GD; Mueller, E; Sarraf, P; Spiegelman, BM; Winer, EP, 2003) |
| "ZR-75-1 anchorage-dependent breast cancer cell line, its derivative 9D3S suspension cells (9D3S-S), and 9D3S cells attached to fibronectin-coated plates (9D3S-A) were treated with TPT (1 microM) or CPT-11 (40 microM) for 48 h." | ( Nyormoi, O; Satoh, TH; Surmacz, TA; Whitacre, CM, 2003) |
| "Advanced breast cancer is largely incurable and current treatment modalities are aimed towards restricting tumour growth, prolonging survival, palliating symptoms and maintaining quality of life (QoL)." | ( Parker, LM; Piccart, M; Pritchard, KI, 2003) |
| "Co-treatment with EPA renders breast cancer cells that overexpress a constitutively active Akt more responsive to the growth inhibitory effects of tamoxifen by approximately 35%." | ( DeGraffenried, LA; Fernandes, G; Friedrichs, WE; Fulcher, L; Hidalgo, M; Peralba, JM; Silva, JM, 2003) |
| "NB1011 treatment of high-TS-expressing breast carcinoma cells (MCF7TDX) results in the induction of p53 and p21 protein levels, whereas no p53 or p21 induction is observed in the low-TS-expressing MCF7 tumor cells." | ( Dellinger, RW; Karjian, PL; Neuteboom, ST, 2003) |
| "Our results indicate that disseminated breast cancer cells in BM can survive first-line adjuvant chemotherapy." | ( Braun, S; Coith, C; Ebel, S; Hemsen, A; Jänicke, F; Kentenich, C; Oberhoff, C; Pantel, K; Riethdorf, S; Thurm, H; Wallwiener, D, 2003) |
| "Treatment of human breast cancer cell lines in culture with SL11144 decreased cell proliferation and induced programmed cell death in a time- and dose-dependent manner." | ( Casero, RA; Davidson, NE; Dunn, VR; Frydman, B; Hacker, A; Hager, ER; Huang, Y; Kink, JA; Marton, LJ; Phillips, DL; Reddy, VK; Valasinas, AL, 2003) |
| "Data from 83 patients with breast cancer treated with autologous blood stem cell transplantation were analyzed." | ( Auer, Y; Brown, C; Glück, S; Klassen, J; Luider, J; Morris, D; Rodriguez-Galvez, M; Russell, J; Stewart, D; Syme, R, 2003) |
| "The majority of breast cancers are oestrogen dependent and although current treatment strategies have improved, approximately 50% of the patients will develop metastasis." | ( Dabrosin, C; Gauldie, J; Palmer, K, 2003) |
| "Modern treatment of cancer of the breast is based on established prognostic factors (patient age, receptor status, tumor size, lymph node involvement, tumor grading), and thus takes the patient's individual risk profile into account." | ( Höffken, K; Sayer, HG, 2003) |
| "Metastatic breast cancer is a partially chemotherapy-sensitive neoplasm." | ( Crown, J; Pegram, M, 2003) |
| "Women with HER2-positive metastatic breast cancer were treated with epirubicin 75 mg/m(2) i." | ( Bighin, C; Del Mastro, L; Lunardi, G; Schettini, G; Stevani, I; Vannozzi, MO; Venturini, M, 2003) |
| "The Zoladex Early Breast Cancer Research Association (ZEBRA) trial compared the efficacy and tolerability of goserelin (Zoladex) with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy in pre-/perimenopausal women with node-positive early breast cancer." | ( Blamey, R; Cuzick, J; de Haes, JC; Fogelman, I; Jonat, W; Kaufmann, M; Namer, M; Sauerbrei, W; Schumacher, M, 2003) |
| "The patient who had recurrent breast cancer with multiple lung metastases was treated with a combination of docetaxel (TXT) 80 mg/body three cycles, two courses of 40 mg/body four times and medroxyprogesterone acetate (MPA) 600 mg p." | ( Mio, H, 2003) |
| "Interestingly, breast cancer cells that were VDR+ as well as estrogen receptor positive (ER+) showed cell cycle arrest and apoptosis, while VDR+ but ER- cells (UISO-BCA-4 breast cancer cells) showed enhanced expression of various differentiation markers with la(OH)D5 treatment." | ( Das Gupta, TK; Hussain, EA; Mehta, RG; Mehta, RR; Ray, R, 2003) |
| "Capecitabine is now licensed for use in breast cancer, both in combination with IV docetaxel after anthracycline failure, and as single-agent therapy after failure of anthracyclines and taxanes." | ( , 2003) |
| "Systemic chemotherapy for operable breast cancer substantially decreases the risk of death." | ( Allred, DC; Chamness, GC; Chang, JC; Elledge, R; Gutierrez, MC; Hilsenbeck, SG; Mohsin, S; O'Connell, P; Osborne, CK; Tsimelzon, A; Wooten, EC, 2003) |
| "Treatment of SKBr3 human breast cancer cells with CP-654577 reduces the levels of the activated form of mitogen-activated protein kinase, increases the levels of cyclin-dependent kinase inhibitor p27(kip1) and reduces expression of cyclins D and E." | ( Barbacci, EG; Boscoe, BP; Cox, ED; Emerson, E; Iwata, KK; Jani, JP; Kath, JC; Liu, Z; Miller, PE; Moyer, JD; Provoncha, K; Pustilnik, LR; Rossi, AM, 2003) |
| "Groups of breast cancer-bearing dark agouti (DA) rats were treated with 100, 150 or 200 mg/kg doses of irinotecan or vehicle control daily for two days, and killed at 6, 24, 72 or 96 h after treatment." | ( Bowen, JM; Cummins, AG; Gibson, RJ; Inglis, MR; Keefe, DM, 2003) |
| "The ER-positive and ER-negative breast cancer cells were pretreated with fulvestrant and stimulated with 900 microg/dL (22." | ( Calhoun, KE; Fletcher, WS; Muller, P; Pommier, RF; Toth-Fejel, S, 2003) |
| "The DNA content in breast cancer tissue might be useful in determining a suitable therapy for individual cases, based on the malignancy grade." | ( Abu-Bedair, FA; El-Aaser, AA; El-Gamal, BA; Ibrahim, NA, 2003) |
| "CEF chemotherapy for breast cancer carries a small increased risk of sAL compared with CMF." | ( Bramwell, V; Crump, M; Levine, M; Pritchard, K; Shepherd, L; Tu, D, 2003) |
| "It is suggested that breast cancer showing Erb B-2 overexpression is more sensitive to treatment with anthracyclines and less to CMF." | ( Dabrowska, M; Kłaniewski, T; Molenda, W; Swiatoniowski, G, 2003) |
| "All cases of breast cancer treated at UMMC from January 1999 to June 2001, except for stage IV disease, were included in the study." | ( Ong, TA; Yip, CH, 2003) |
| "The management of both breast cancer and concurrent and subsequent pregnancy in an attempt to update the treating physicians in making informed decisions in diagnosis and therapy are reviewed." | ( Rosner, D; Yeh, J, 2002) |
| "Most of the breast cancers initially respond to endocrine therapy that reduces the levels of estrogens or competes with estrogen for binding to its receptor." | ( Horie, K; Ikeda, K; Inoue, S; Urano, T, 2003) |
| "Pathologic response of breast cancer to chemotherapy has a great prognostic importance." | ( Gong, C; Hamar, P; Hu, X; Jia, W; Song, E; Su, F, 2003) |
| "We present a review of 105 cases of breast cancers diagnosed and treated at Dr Ram Manohar Lohia Hospital in a five years prospective study between 1997 and 2002." | ( Bhan, CM; Goel, A; Srivastava, KN, 2003) |
| "We recently found that breast cancer cell lines that are resistant to chemotherapy or to the recombinant TRAIL protein are susceptible to TRAIL gene therapy." | ( Davis, J; Fang, B; Gu, J; Ji, L; Lin, T; Nishizaki, M; Roth, JA; Xiong, M; Zhang, L, 2003) |
| "Two human breast carcinoma xenografts in nude mice, MCF-7 and Br-10, were treated with UCN-01, TAM or both agents together." | ( Hashimoto, M; Hosoda, Y; Kitajima, M; Koh, J; Koyama, T; Kubota, T; Migita, T, 2003) |
| "The rate of second non-breast cancer malignancy was increased among patients treated with >10 cycles of cyclophosphamide-containing chemotherapy." | ( Buchholz, TA; Buzdar, AU; Hortobagyi, GN; McNeese, MD; Outlaw, EL; Perkins, GH; Strom, EA; Woodward, WA, 2003) |
| "Among 94 patients with breast carcinoma who were treated with CMF, it was found that ErbB2 overexpression was associated significantly with poor DFS (P < 0." | ( Klos, KS; Shi, D; Smith, TL; Yang, W; Yang, Y; Yao, J; Yu, D; Zhou, X, 2003) |
| "A 61-year-old woman with breast cancer was scheduled for breast preserving therapy under general anesthesia." | ( Cho, S; Kajita, I; Kayo, R; Murakami, T; Saito, H, 2003) |
| "Twenty-two patients with metastatic breast cancer were treated by a combination of testosterone and N,N',N'', triethylenethiophosphoramide (Thio-TEPA)." | ( HILTON, JH; KUWAYTI, K, 1963) |
| "The pretreatment of breast cancer cells with chemotherapeutic drugs followed by TRAIL reversed their resistance by triggering caspase-3, -9, and -8 activation." | ( Asim, M; Chen, X; Shankar, S; Singh, TR; Srivastava, RK, 2003) |
| "A 62-year-old woman with a history of breast carcinoma being treated with tamoxifen presented with a rapidly enlarging pelvic mass." | ( Blank, SV; Flax, H; Gagner, JP; Levine, PH; Mittal, K; Wei, XJ, 2003) |
| "MDA-MB-435 and MDA-MB-231 human breast carcinoma cells were treated with dexamethasone or medroxyprogesterone acetate (MPA) in cultures containing either charcoal-stripped serum or FCS." | ( Halverson, D; Ouatas, T; Steeg, PS, 2003) |
| "To compare, in high-risk breast cancer patients, the effects on health-related quality of life (HRQoL) of two adjuvant treatments." | ( Bergh, J; Bolund, C; Brandberg, Y; Erikstein, B; Hietanen, P; Kaasa, S; Michelson, H; Nilsson, B; Nilsson, J; Wiklund, T; Wilking, N, 2003) |
| "From March 1994 to March 1998, 525 breast cancer patients (estimated relapse risk > 70% within 5 years with standard therapy) were included in the Scandinavian Breast Group 9401 study." | ( Bergh, J; Bolund, C; Brandberg, Y; Erikstein, B; Hietanen, P; Kaasa, S; Michelson, H; Nilsson, B; Nilsson, J; Wiklund, T; Wilking, N, 2003) |
| "In the MDA-MB-435 human mammary carcinoma xenograft model, in which the primary tumor is transplanted into the murine mammary fat pad, BAY 12-9566, administered daily at a dose of 100 mg/kg/day p." | ( Chien, DS; Nozaki, S; Sissons, S; Sledge, GW, 2003) |
| "Paclitaxel is used to treat breast cancers, but the mechanisms by which it induces apoptosis are poorly understood." | ( Brosens, JJ; Coffer, PJ; Coombes, RC; Fernández de Mattos, S; Lam, EW; Medema, RH; Saunders, CA; Stahl, M; Sunters, A; Zoumpoulidou, G, 2003) |
| "Twenty-two breast cancer patients treated with breast-conserving surgery and radiation were evaluated." | ( Canale Cama, G; Cella, L; d'Alesio, V; Durante, M; Gialanella, G; Grossi, G; Pacelli, R; Pugliese, M; Punzo, G; Salvatore, M; Sardi, I; Scampoli, P; Solla, R, 2003) |
| "The adjuvant chemotherapy of breast cancer changed in the past two decades." | ( Boér, K; Juhos, E; Láng, I; Pintér, T; Szántó, J, 2003) |
| "Treatment of breast cancer cells with MIS and interferon gamma (IFN-gamma) co-stimulated IRF-1 and CEACAM1 expression and synergistic induction of CEACAM1 by a combination of MIS and IFN-gamma was impaired by antisense IRF-1 expression." | ( Brachtel, E; Carey, JL; Donahoe, PK; Gupta, V; Hoshiya, Y; Kawakubo, H; Maheswaran, S; Sasur, L; Scott, A, 2003) |
| "Many estrogen receptor-positive breast cancer patients initially respond to treatment with antihormonal agents such as tamoxifen, but remissions are often followed by acquisition of resistance and ultimately disease relapse." | ( Barrow, D; Gee, JM; Hutcheson, I; Knowlden, J; Madden, TA; McClelland, R; Nicholson, RI, 2003) |
| "To evaluate the feasibility of treating breast neoplasms with use of magnetic resonance (MR) imaging-guided focused ultrasound (US) surgery." | ( Amara, M; Belblidia, A; Boulanger, Y; Gianfelice, D; Khiat, A, 2003) |
| "In hormone-dependent breast cancer, five years of postoperative tamoxifen therapy--but not tamoxifen therapy of longer duration--prolongs disease-free and overall survival." | ( Abrams, JS; Castiglione, M; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Norton, L; Palmer, MJ; Pater, JL; Perez, EA; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Therasse, P; Tu, D, 2003) |
| "Patients with hormone-sensitive breast cancer who have responded to tamoxifen (TAM) may receive additional benefit from a second endocrine agent after progression or relapse after TAM therapy." | ( Baird, A; Bross, PF; Chen, G; Jee, JM; Lostritto, RT; Morse, DE; Pazdur, R; Rahman, A; Rosario, LA; Williams, G; Williams, GM; Yang, P, 2003) |
| "Hormone responsive breast cancer cell lines MCF-7 and T47D, and the ER- cell line MDA-231, were treated with either 4-hydroxy tamoxifen (4OHT) or arzoxifene during weekly courses of treatment with 5-fluorouracil (5-FU) or methotrexate (MTX)." | ( Licun, W; Tannock, IF, 2003) |
| "Treatment was for advanced breast cancer that had progressed either during anti-oestrogen therapy or within 12 months of completing that therapy." | ( Ben Ayed, F; Burdette-Radoux, S; Caicedo, JJ; Chaudri-Ross, HA; Davidson, N; Gershanovich, M; Gervasio, H; Johnson, S; Lang, R; Manikhas, G; Pluzanska, A; Rose, C; Thomas, R; Vtoraya, O, 2003) |
| "treatment arm and the breast cancer trial included a 3 mg oral treatment arm." | ( Hainsworth, J; Janssens, J; Vergote, I, 2003) |
| "Novel approaches are needed for breast cancer patients in whom standard therapy is not effective." | ( Blaufox, MD; Dadachova, E; Lin, EY; Lu, P; Mani, J; Moadel, RM; Nguyen, AV; Pollard, JW, 2003) |
| "The study of breast cancer patients suggests that the tumor and normal organ dosimetry of 18F-FDG makes it suitable for therapy of this malignancy." | ( Blaufox, MD; Dadachova, E; Lin, EY; Lu, P; Mani, J; Moadel, RM; Nguyen, AV; Pollard, JW, 2003) |
| "Stage IV breast cancer therapy costs were collected by surveying UK oncologists, and utilities for associated health states were from published sources." | ( Bokemeyer, C; Gagnon, DD; Martin, SC; van Hout, B; Van Marwijk Kooy, M; Zhang, L, 2003) |
| "In this study of breast cancer patients, we examined the combined effect of topical As2O3 and radiation therapy on fungating and/or skin-infiltrating lesions of breast cancer." | ( Chang, HH; Chang, KH; Chen, HW; Chen, YJ; Chung, CH; Huang, MJ; Lai, YL; Lin, LH; Su, WH; Wang, WY, 2003) |
| "Long-term tamoxifen treatment of breast cancer can result in tamoxifen-stimulated breast cancer, in which estrogen inhibits tumor growth after tamoxifen withdrawal." | ( Chen, B; Gajdos, C; Jordan, VC; Liu, H; Osipo, C, 2003) |
| "Given the high prevalence of breast cancer, improved detection of liver metastases, encouraging survival achieved with currently available cytotoxic agents and the fact that a significant portion of patients with liver metastases alone have progression of their tumour in the liver again, a more aggressive multimodality treatment approach through prospective clinical trials seems worth exploring in this specific subset of women." | ( Atalay, G; Biganzoli, L; Calvert, AH; Coleman, R; Cufer, T; Gamucci, T; Minisini, A; Paridaens, R; Piccart, MJ; Renard, F; Therasse, P, 2003) |
| "Locally advanced breast cancer (LABC) is commonly treated with neoadjuvant chemotherapy followed by definitive surgery." | ( Dunnwald, LK; Ellis, GK; Gralow, JR; Lawton, TJ; Linden, HM; Livingston, RB; Mankoff, DA; Schubert, EK; Tseng, J, 2003) |
| "Current treatment of ER-positive breast tumors is directed towards interruption of estrogen activity." | ( Hung, H, 2004) |
| "Standard management of breast cancer metastatic to bone includes systemic chemotherapy and, if applicable, hormone therapy, as well as radiotherapy for control of pain or prevention of pathologic fractures." | ( Hortobagyi, GN, 2003) |
| "Since 1984, we have had 151 breast cancer patients with cytologically-confirmed malignant pleural effusions by local transfer of autologous effusion lymphocytes cultured with a conditioned medium containing T-cell growth factor after intrapleural preadministration of a streptococcal preparation, OK-432." | ( Kan, N, 2003) |
| "A total of 5 breast cancer patients, 2 with far advanced primary breast tumor and 3 with local recurrent tumors on their anterior chest wall, underwent multimodal therapy in which cryosurgery was performed in combination with local injection of the non-specific immunopotentiator OK-432." | ( Kawaguchi, Y; Saji, S; Sugiyama, Y, 2003) |
| "Among the 23 metastatic breast carcinoma patients treated in our institution from September 2001 to December 2002, 10 (43%) patients were immunohistochemically positive for the HER2 protein." | ( Iwamoto, M; Kobayashi, T; Lee, SW; Nohara, T; Sumiyoshi, K; Tanigawa, N, 2003) |
| "Patients with operable invasive breast cancer following completion of primary therapy, who were candidates to receive adjuvant endocrine therapy, were eligible for this study." | ( Buzdar, AU, 2003) |
| "A total of 94 patients with high-risk breast cancer were enrolled in a prospective single center study to evaluate the use of dose-intensified chemotherapy (doxorubicine 75 mg/m(2) and cyclophosphamide 3000 or 6000 mg/m(2) for four cycles) with repeated (x 2) stem cell reinfusion." | ( Arnoulet, C; Bardou, VJ; Bertucci, F; Braud, AC; Chabannon, C; Genre, D; Gonçalves, A; Gravis, G; Houvenaeghel, G; Jacquemier, J; Ladaique, P; Maraninchi, D; Sainty, D; Viens, P; Viret, F, 2003) |
| "We determined the risk of breast cancer and tumor characteristics among current postmenopausal hormone therapy users compared with nonusers, by duration of use." | ( Ballard-Barbash, R; Barlow, WE; Buist, DS; Carney, PA; Cutter, G; Geller, BM; Kerlikowske, K; Miglioretti, DL; Taplin, SH; Weaver, DL; Yankaskas, B, 2003) |
| "We calculated the relative risk (RR) of breast cancer (invasive or ductal carcinoma-in-situ) and type of breast cancer within 12 months of postmenopausal therapy use among current hormone users with a uterus (proxy for estrogen and progestin use) and without a uterus (proxy for estrogen use), compared with nonusers." | ( Ballard-Barbash, R; Barlow, WE; Buist, DS; Carney, PA; Cutter, G; Geller, BM; Kerlikowske, K; Miglioretti, DL; Taplin, SH; Weaver, DL; Yankaskas, B, 2003) |
| "Treatment of ZR-75 breast cancer cells with 17beta-estradiol (E2) induced a greater than fourfold increase of VEGF mRNA levels." | ( Abdelrahim, M; Qin, C; Safe, S; Samudio, I; Saville, B; Stoner, M; Wormke, M, 2004) |
| "These new data build on the idea that breast cancer can be controlled as a chronic disease and will permit patients to live long and productive lives during targeted maintenance treatment." | ( Cheng, D; Fox, JE; Jordan, VC; Liu, H; Osipo, C; Schafer, JM, 2003) |
| "Fifth Main Meeting of the Early Breast Cancer Trialist's Collaborative Group, Oxford, UK, September 2000) and following internationally accepted treatment guidelines (National Institutes of Health Consensus Development Panel." | ( Cardoso, F; Piccart, MJ, 2003) |
| "The goal of endocrine therapy in breast cancer is to block the action of estrogen on the tumor cells either by inhibiting estrogen from binding to the specific estrogen receptor or by inhibiting its synthesis." | ( Brodie, AH; Mouridsen, HT; Rose, C; Smith, IE, 2003) |
| "Patients with node-positive (1-3) breast cancer were assigned to open-label epirubicin/vinorelbine (EV), epirubicin/vino-relbine and sequential paclitaxel (EV/T), epirubicin/cyclophosphamide (EC) or epirubicin/cyclophosphamide plus sequential paclitaxel (EC/T) therapy." | ( Breitbach, P; Eggemann, H; Elling, D; Kohls, A; Krocker, J; Kümmel, S; Morack, G; Schlosser, H, 2003) |
| "In the treatment of advanced breast cancer, improvement of the antitumor efficacy by the addition of vinorelbine to epirubicin remains to be demonstrated in a randomized phase III trial." | ( Andersen, J; Ejlertsen, B; Hansen, S; Højris, I; Kjaer, M; Kristensen, B; Mouridsen, HT; Møholt, K; Rose, C, 2003) |
| "Estrogen/progestin use in breast cancer survivors should be considered only for women with severe vasomotor symptoms refractory to other approaches after extensive informed decision-making including review of current Food and Drug Administration labeling concerns with use limited to the lowest dose and shortest duration possible." | ( Chlebowski, RT; Col, NF; Kim, JA, 2003) |
| "36 females at the age 33-66, with breast cancer underwent primary surgical treatment with SLN Biopsy in Department of Gynaecology and Oncology Jagiellonian University between 2001-2002." | ( Basta, A; Basta, P; Opławski, M; Pityński, K; Tomaszewska, R, 2003) |
| "Many cases of breast cancer show loss of estrogen receptor (ER) alpha expression, which leads to unresponsiveness to antihormonal treatment even though there is no loss of the structurally and biochemically similar ER beta." | ( Bang, YJ; Jang, ER; Jeong, G; Kim, TY; Lee, ES; Lee, JS; Lim, SJ, 2004) |
| "In an International Breast Cancer Study Group (IBCSG) randomized clinical trial (Trial VIII) for pre- and perimenopausal women with lymph node-negative breast cancer, we compared sequential chemotherapy followed by the gonadotropin-releasing hormone agonist goserelin with each modality alone." | ( Bonetti, M; Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Gelber, RD; Goldhirsch, A; Nasi, ML; O'Neill, A; Price, KN, 2003) |
| "We report two cases of NM from breast carcinoma and a third with esophageal carcinoma, which responded to treatment with capecitabine, an oral prodrug for 5-flurouracil." | ( Giglio, P; Groves, MD; Tremont-Lukats, IW, 2003) |
| "Overall, 1130 patients with breast carcinoma who had all types of bone metastases (osteolytic, mixed, or osteoblastic by radiology) were randomized to receive treatment with either 4 mg of Zol or 8 mg of Zol as a 15-minute infusion or 90 mg of Pam as a 2-hour infusion every 3-4 weeks for 12 months." | ( Chen, BL; Coleman, RE; Dugan, W; Eisenberg, PD; Gordon, DH; Kaminski, M; Major, P; Provencher, L; Rosen, LS; Seaman, J; Simeone, J, 2004) |
| "As its role in human breast cancer progression and response to therapy is defined, Stat5a could become a new molecular target for breast cancer therapy." | ( Cotarla, I; Furth, PA; Gehan, E; Ren, S; Singh, B; Zhang, Y, 2004) |
| "A total of 40 patients with lung or breast cancer were randomized to receive Ptx (400 mg) or a placebo, 3 times daily, during the entire period of radiotherapy." | ( Atavci, S; Egehan, I; Kitapci, M; Ozturk, B, 2004) |
| "Ninety patients with breast cancer were included; 70 patients received single agent paclitaxel either weekly or every 3 weeks and 20 received FAC (5-FU, doxorubicin, cyclophosphamide) chemotherapy." | ( Arun, B; Booser, D; Bruera, E; Cleeland, CS; Fritsche, HA; Hortobagyi, GN; Ibrahim, N; Lara, J; Martinez, MM; Mendoza, TR; Pusztai, L; Reuben, JM; Rivera, E; Royce, M; Syed, A; Valero, V; Willey, JS, 2004) |
| "Current antiestrogen therapy for breast cancer is limited by the mixed estrogenic and antiestrogenic activity of selective estrogen receptor modulators." | ( Appella, E; Fan, YX; Farrar, WL; Howard, OM; Maynard, AT; Mihalic, K; Wang, LH; Xiao, W; Yang, XY; Zhang, X, 2004) |
| "In primary breast cancer, the expression levels of biological markers relevant to the progression of the disease may be altered by administration of anticancer drugs." | ( Bachleitner, T; Dubsky, P; Fitzal, F; Gnant, M; Jakesz, R; Kandioler, D; Mader, RM; Mittlböck, M; Roka, S; Rudas, M; Sporn, E; Steger, GG; Taucher, S; Wenzel, C, 2003) |
| "We evaluated data from 39 451 breast cancer patients diagnosed from 1980 through 2000 who were initially treated with tamoxifen and found that the overall risk of subsequent uterine corpus cancer was increased more than twofold (observed-to-expected ratio [O/E] = 2." | ( Curtis, RE; Fraumeni, JF; Freedman, DM; Sherman, ME, 2004) |
| "Until recently, endocrine therapy for breast cancer was relatively simple." | ( Ellis, MJ; Wong, ZW, 2004) |
| "Among patients with breast cancer who consulted the Department of Radiology, Kochi Medical School to undergo breast-conservation treatment, toremifene (TOR) alone was administered to 7 postmenopausal women as initial treatment for reasons such as the patient's desire, advanced age, and concomitant disease." | ( Hamada, N; Kariya, S; Nishioka, A; Ogawa, Y; Yoshida, S, 2004) |
| "119 patients with operable breast cancer were treated with six cycles of FEC (100 5-fluorouracil (5-FU) 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2)." | ( Borel, C; Eber, M; Ghnassia, JP; Haegelé, P; Millon, R; Mors, R; Petit, T; Rodier, JF; Velten, M; Wilt, M, 2004) |
| "In metastatic breast cancer, the estrogen receptor (ER) is a well-known prognostic factor predictive of response to hormonal treatment in most, but not all, patients." | ( Bennink, RJ; Janssen, AG; Noorduyn, AL; Rijks, LJ; Sloof, GW; van Tienhoven, G, 2004) |
| "The effects of raloxifene after treated breast cancer and sequential use of tamoxifene after raloxifene (or the contrary) are not known and should be tested in specific pre-clinical and clinical studies." | ( Guyot, B; This, P, 2004) |
| "Patients with metastatic breast cancer received 80 mg/m(2) paclitaxel administered weekly on days 1, 8 and 15 of a 28-day cycle." | ( Bontenbal, M; Kerkhofs, LG; Schothorst, KL; Seynaeve, C; Smorenburg, CH; Sparreboom, A; Stoter, G; ten Tije, AJ; van Reisen, LG; Verweij, J, 2004) |
| "Advances in breast cancer continue to focus on the development of novel agents as well as the development of novel combinations, with the major therapeutic goal of treatment strategies revolving around improving response rates, delaying the time to disease progression, palliating symptoms, and improving quality of life." | ( Yardley, DA, 2004) |
| "In HER2/neu-positive metastatic breast cancer, the combination of chemotherapy and trastuzumab has become a standard of care." | ( DeMichele, A; Domchek, S; Fox, K; Stein, S, 2004) |
| "Medical charts of 310 breast cancer patients who received chemotherapy at eight oncology practices during 1997 through 2001 were reviewed in this historical case series study." | ( Fridman, M; Hatch, M; Hennessy, DD; Kirshner, J; Tannous, RE, 2004) |
| "In the chemically induced rat breast cancer models, orally administered ZK-703 and ZK-253 caused a nearly complete (>80%) inhibition of tumor growth." | ( Bohlmann, R; Gieschen, H; Heinrich, N; Hoffmann, J; Hofmeister, H; Kroll, J; Künzer, H; Lichtner, RB; Nishino, Y; Parczyk, K; Sauer, G; Schneider, MR; Ulbrich, HF, 2004) |
| "Telomerase is elevated in >90% of breast carcinomas and therefore has received much attention as a target for breast cancer therapy and cancer diagnostic research." | ( Katiyar, SK; Mittal, A; Pate, MS; Tollefsbol, TO; Wylie, RC, 2004) |
| "In patients with advanced breast cancer, treatment with paclitaxel and doxorubicin has been shown to produce impressive overall response rates (up to 94%) and to prolong overall survival significantly over a combination of fluorouracil (5-FU), doxorubicin, and cyclophosphamide (Cytoxan, Neosar) in one prospective phase III clinical study." | ( Zielinski, CC, 2003) |
| "In women with hormone-dependent breast cancer, tamoxifen (TAM) frequently induces tumor regression, but regrowth occurs with continuation of antiestrogen therapy." | ( Berstein, LM; Conaway, M; Santen, RJ; Wang, JP; Yue, W; Zheng, H, 2004) |
| "We studied 19 breast cancer (BC) patients and 17 multiple myeloma (MM) patients entered in a high-dose chemotherapy (HDC) program of tandem autografting with CD34+ cell-selected PBPC." | ( Amodeo, R; Anghel, G; De Rosa, L; Majolino, I; Pandolfi, A; Riccardi, M, 2004) |
| "Diagnosis and treatment of breast cancer can be a stressful experience, putting women at risk of posttraumatic stress disorder (PTSD)." | ( Compas, BE; Dausch, B; Gulla, V; Hong, R; Luecken, LJ, 2004) |
| "In this pilot study, 22 women with breast cancer on tamoxifen therapy with at least two hot flashes a day took oral gabapentin at 300 mg three times a day for 4 weeks." | ( Griggs, JJ; Guttuso, TJ; Morrow, GR; Pandya, KJ; Roscoe, JA; Rosenblatt, JD; Sahasrabudhe, DM; Thummala, AR, 2004) |
| "YTX treatment of MCF-7 breast cancer cells causes the accumulation of a 100 kDa fragment of E-cadherin, which we have named ECRA(100)." | ( Callegari, F; Malaguti, C; Ronzitti, G; Rossini, GP, 2004) |
| "These proteins represent potential breast cancer biomarkers that could aid in diagnosis, therapy, or drug development." | ( Buchanan, NS; Hamler, RL; Kachman, MT; Kreunin, P; Lubman, DM; Miller, FR; Zhu, K, 2004) |
| "The incidence of breast cancer is on the rise but as yet there is no guaranteed beneficial treatment for many of the sufferers." | ( Bhatia, K; Lord, R; Roberts, K; Stanton, P, 2004) |
| "Patients with breast cancer (n=123) were randomized to receive doxorubicin and DOC either in combination (60 mg/m2 of each drug), or by alternated or sequential schedule (100 mg/m2 DOC and 75 mg/m2 doxorubicin) every 3 weeks for a maximum of eight cycles as first chemotherapy for stage IV disease." | ( Azli, N; Buzzi, F; Capri, G; Cresta, S; Cuna, GR; Frevola, L; Gianni, L; Grasselli, G; Jirillo, A; Lelli, G; Mansutti, M; Martoni, A; Murawsky, M; Sguotti, C; Tarenzi, E; Terzoli, E, 2004) |
| "We show that in the human breast carcinoma T47D cells, upon estrogen treatment, p130Cas rapidly and transiently associates with the estrogen receptor alpha in a multi-molecular complex containing the c-Src kinase and the p85 subunit of PI 3-kinase." | ( Baj, G; Cabodi, S; Defilippi, P; Di Stefano, P; Gippone, S; Moro, L; Silengo, L; Smeriglio, M; Surico, N; Tarone, G; Turco, E, 2004) |
| "The treatment of inflammatory breast cancer includes preoperative anthracycline-based chemotherapy, surgery, and radiation therapy." | ( Buzdar, AU; Cristofanilli, M; Frye, DK; Gonzalez-Angulo, AM; Hortobagyi, GN; Kau, SW, 2004) |
| "Less than half of breast cancer patients respond to second-line chemotherapy with paclitaxel after failing treatment with anthracyclines such as doxorubicin." | ( Blais, DE; Bonin, M; Guo, B; Hembruff, SL; Kirwan, AF; Parissenti, AM; Villeneuve, DJ, 2004) |
| "Patients with stage I (T1c)-IIIA breast cancer were eligible if planned adjuvant therapy consisted of either tamoxifen alone, doxorubicin + cyclophosphamide every 21 days for four cycles (AC), or AC followed by paclitaxel every 21 days for 4 cycles (AC>T)." | ( Chen, TT; Cobleigh, MA; Galbraith, S; Miller, KD; Rush-Taylor, A; Saphner, TJ; Sledge, GW; Sparano, JA; Waterhouse, DM; Wolff, AC, 2004) |
| "Complete pathologic response of breast carcinoma to neoadjuvant chemotherapy is a well defined outcome that correlates with prolonged survival." | ( Buzdar, AU; Fiterman, DJ; Frye, D; Gal-Gombos, E; Green, M; Hortobagyi, GN; Kuerer, H; Poniecka, A; Pusztai, L; Rajan, R; Rouzier, R; Smith, TL; Symmans, WF; Whitman, G; Yang, Y, 2004) |
| "The animal model of human breast cancer on severe combined immune deficiency (SCID) mice was set up to explore the suicide gene therapy by the regulation of Tet-On." | ( Chen, Q; Hu, WX; Luo, SQ; Zeng, ZJ, 2004) |
| "These agents are active against breast cancer in hormone-naïve postmenopausal women and in women who have experienced failure of tamoxifen or failure of tamoxifen plus other hormonal therapy." | ( Campos, SM, 2004) |
| "The presence of the ER in breast tumors predicts improved disease-free survival and response to selective ER modulators (SERMs), such as tamoxifen, or other forms of endocrine therapy." | ( Frasor, J; Katzenellenbogen, BS, 2004) |
| "Estrogen receptor (ER)-negative breast carcinomas are often difficult to treat with antiestrogens." | ( Barrón-González, A; Castro Romero, I, 2004) |
| "We aimed to monitor the HBV status of breast cancer patients undergoing chemotherapy with preemptive lamivudine over time." | ( Chao, TY; Dai, MS; Lu, JJ; Shyu, RY; Wu, PF, 2004) |
| "Sixteen women with metastatic breast cancer were treated with trastuzumab (2 mg/kg every week) and docetaxel (100 mg/m2) as first-line therapy." | ( Julka, PK; Mukhopadhyay, P; Rath, GK; Sharma, DN, 2004) |
| "For patients with clinical Stage II breast cancer, T3 primary disease, four or more positive lymph nodes after chemotherapy, and age < or =40 years old predicted for LRR." | ( Buchholz, TA; Buzdar, AU; Garg, AK; Hortobagyi, GN; Hunt, KK; Kuerer, HM; McNeese, MD; Perkins, GH; Sahin, A; Schechter, N; Singletary, SE; Strom, EA; Tucker, SL; Valero, V, 2004) |
| "Human breast cancer primary cultures are useful tools for the study of several aspects of cancer biology, including the effects of chemotherapy and acute gene expression in response to different hormonal/chemotherapy treatments." | ( Baldi, A; Garbovesky, C; Lüthy, IA; Mladovan, A; Vázquez, SM, 2004) |
| "The efficacy of tamoxifen in breast cancer treatment only lasts a few years and the tumor eventually recurs." | ( Badia, E; Duchesne, MJ; Oliva, J; Pons, M; Semlali, A, 2004) |
| "Lastly, tumors from breast cancer patients overexpressing the LMW forms of cyclin E are polyploid in nature and are resistant to endocrine therapy." | ( Akli, S; Chang, S; Keyomarsi, K; Multani, AS; Pathak, S; Tucker, SL; Wingate, HF; Zhang, N; Zheng, PJ, 2004) |
| "Cytotoxic chemotherapy of advanced breast cancer is frequently complicated by drug resistance." | ( Bastert, G; Gückel, B; Lindner, M; Meyer, A; Stumm, S; Wallwiener, D, 2004) |
| "Therefore, to estimate the response of breast cancers to DENSpm, we measured induction of SSAT in breast cancer explants treated in vitro with this polyamine analogue." | ( Casero, RA; Davidson, NE; Gabrielson, E; Hacker, A; Pegg, AE; Tully, E, 2004) |
| "A high proportion of breast cancers induced SSAT in response to DENSpm, supporting the continued consideration of this class of agents for treatment of breast cancer." | ( Casero, RA; Davidson, NE; Gabrielson, E; Hacker, A; Pegg, AE; Tully, E, 2004) |
| "The death rate from breast cancer is falling rapidly in most developed countries due, at least in part, to the use of adjuvant endocrine therapy in women with endocrine responsive disease." | ( Clemons, M; Coleman, RE; Verma, S, 2004) |
| "Studies show that high Akt activity in breast carcinoma is associated with endocrine therapy resistance." | ( Chandrasekar, B; deGraffenried, LA; Donzis, E; Freeman, JW; Friedrichs, WE; Hidalgo, M; Silva, J; Weiss, GR, 2004) |
| "In advanced breast cancer, letrozole was superior to tamoxifen as first-line treatment; time to disease progression was significantly longer (9." | ( Curran, MP; Perry, CM; Simpson, D, 2004) |
| "Forty-one patients with metastatic breast cancer were treated with paclitaxel between November 2000 and September 2002." | ( Hirono, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, N; Okubo, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y, 2004) |
| "Thirty-four patients with advanced breast cancer were treated with a combination of paclitaxel 175 mg/m2 and liposomal doxorubicin 30 mg/m2, every 3 weeks." | ( Chasen, MR; Eek, R; McMichael, G; Mohammed, C; Rapoport, BL; Slabber, C; Vorobiof, DA, 2004) |
| "pS2/TFF1 overexpression in breast carcinomas correlates with response to hormonotherapy." | ( Bellocq, JP; Chenard, MP; Rio, MC; Tomasetto, C, 2004) |
| "In poor prognosis breast carcinomas (PPBCs) treated by intensive preoperative CT, we compared the predictive value of S phase fraction (SPF), mitotic index (MI) and Ki67." | ( Al Ghuzlan, A; Beuzeboc, P; Campana, F; Fréneaux, P; Jouve, M; Klijanienko, J; Nos, C; Rosty, C; Rousseau, A; Sastre-Garau, X; Sigal-Zafrani, B; Vincent-Salomon, A, 2004) |
| "MCF-7 breast cancer cells, which express high levels of AIB1, and a tamoxifen-resistant derivative cell line engineered to overexpress HER2 (MCF-7/HER2-18) were treated with estrogen, tamoxifen, epidermal growth factor (EGF), or heregulin in the absence or presence of the EGF receptor (EGFR) tyrosine kinase inhibitor gefitinib." | ( Ali, S; Massarweh, S; Osborne, CK; Schiff, R; Shou, J; Wakeling, AE; Weiss, H, 2004) |
| "Because treatment regimens for breast cancer commonly include gemcitabine, we evaluated two promising combinations in preclinical studies: gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) with either ionizing radiation or docetaxel (Taxotere; Aventis Pharmaceuticals, Inc, Parsippany, NJ)." | ( Im, MM; Ostruszka, L; Robinson, BW; Shewach, DS, 2004) |
| "Fifty-three patients with metastatic breast cancer who had failed or relapsed after anthracycline-based chemotherapy entered the study and were evaluable." | ( Brandi, M; Colucci, G; Gebbia, N; Giotta, F; Lopez, M; Schittulli, F; Valerio, MR; Vici, P, 2004) |
| "Treatment advances in breast cancer continue to revolve around the development of novel agents and combinations, with the major therapeutic goal of these investigational treatment strategies revolving around the improvement of response rates, delaying the time to disease progression, palliation of symptoms, and improving quality of life." | ( Yardley, DA, 2004) |
| "One hundred and three women with breast cancer who had at least one osteolytic lesion received 180 mg of DP as a 2-h intravenous infusion given every 4 weeks for a life-time, following local radiotherapy." | ( Balafouta, M; Gennatas, C; Kokakis, J; Kouloulias, VE; Kouvaris, JR; Mystakidou, K; Pistevou-Gombaki, K; Varela, MN; Vlahos, LJ, 2004) |
| "The study was performed on six breast cancer patients with 26 cutaneous lesions in whom all standard treatment modalities were exhausted." | ( Cemazar, M; Cufer, T; Kranjc, S; Rebersek, M; Sersa, G, 2004) |
| "Human mammary cancer cells (MCF-7) were treated with various beta-ionone concentrations (25, 50, 100 and 200 mumol/L), with a negative control." | ( Chen, B; Li, B; Liu, J; Ma, R, 2004) |
| "We predict that the reduction in breast cancer mortality due to adjuvant therapy is 7% in women aged 55-74 years, while the reduction due to screening, which was first implemented in women aged 50-69 years in 1990-97, will be 28-30% in 2007." | ( de Koning, HJ; Draisma, G; Fracheboud, J; van de Poll-Franse, LV; Vervoort, MM, 2004) |
| "The 4th European Breast Cancer Conference, organized under the auspices of the European Organization for Research and Treatment of Cancer Breast Cancer Group, of the European Breast Cancer Coalition (Europa Donna) and of the European Society of Mastology (EUSOMA), was held in Hamburg, Germany on 16-20 March 2004." | ( Jassem, J; Senkus-Konefka, E, 2004) |
| "In patients with metastatic breast cancer participating in a trial on first-line chemotherapy, the association of serum HER-2/neu ECD with progression-free interval, survival, and response was studied." | ( Jänicke, F; Köhler, G; Löning, T; Lück, HJ; Möbus, V; Müller, V; Pantel, K; Sattler, D; Thomssen, C; von Minckwitz, G; Wilczak, W; Witzel, I, 2004) |
| "Treatment of MCF-7 breast cancer cells with TNF-alpha resulted in activation of p38 MAP kinase that persisted for at least 24h." | ( Koren, R; Liberman, UA; Ravid, A; Weitsman, GE, 2004) |
| "To determine if breast cancer risk in women with SLE is modified by a history of exposure to hormone replacement therapy (HRT) or oral contraceptives (OC), after adjusting for other risk factors." | ( Allen, A; Bernatsky, S; Boivin, JF; Clarke, A; Gordon, C; Joseph, L; Leung, MH; Moore, AD; Rajan, R; Ramsey-Goldman, R, 2004) |
| "In addition, breast cancer incidence in patients treated with HRT in our clinic seemed to be higher than the incidence in average Japanese women." | ( Koera, K; Nagata, H; Nakano, H; Nozaki, M, 2004) |
| "Looking for novel breast cancer antigen epitopes is helpful for its treatment, diagnosis, and prevention." | ( Cui, D; Estrada, GG; Gao, H; Gao, T; Jin, G; Sarai, A; Sun, T; Tian, F, 2004) |
| "Women with Stage 1 and 2 breast cancer may benefit from thrice-weekly massage therapy for reducing depressed mood, anxiety, and anger and for enhancing dopamine, serotonin, and NK cell number and lymphocytes." | ( Burman, I; Diego, M; Field, T; Fletcher, MA; Hernandez-Reif, M; Hurley, J; Ironson, G; Katz, G; Kuhn, C; Schanberg, S; Weiss, S, 2004) |
| "Using both IHC and FISH, advanced breast cancers show statistical evidence of decreasing incidence of Her2/neu expression after antiaromatase neoadjuvant treatment." | ( Chow, LW; Guan, XY; Loo, WT; Toi, M; Zhu, L, 2004) |
| "Tamoxifen therapy for patients with breast carcinoma is perceived as an independent risk factor for venous thromboembolic events (VTE), but the risk associated with other adjuvant therapies is less well recognized." | ( Deitcher, SR; Gomes, MP, 2004) |
| "All agents used for breast carcinoma chemoprevention and adjuvant therapy appear to increase the risk of VTE." | ( Deitcher, SR; Gomes, MP, 2004) |
| "In the majority of women with primary breast cancer, the benefits of treatment with FEC 100 in terms of disease-free and overall survival outweigh the risks, and cardiac risk factors should be carefully evaluated in patient selection." | ( Barats, JC; Bonneterre, J; Chapelle-Marcillac, I; Clavère, P; Datchary, J; Fargeot, P; Fumoleau, P; Goudier, MJ; Kerbrat, P; Monnier, A; Montcuquet, P; Roché, H; Van Praagh, I; Veyret, C, 2004) |
| "To test these hypotheses, 20 breast cancer survivors and 20 controls completed four 6-wk treatments in a randomized, crossover design: supplementation with soy protein (S) (26." | ( Adlercreutz, H; Greany, KA; Kurzer, MS; Nettleton, JA; Thomas, W; Wangen, KE, 2004) |
| "Since the prevalence of depression in breast cancer patients is nearly triple that of the general population, it is likely that a subgroup of breast cancer patients will receive long-term treatment with both an SSRI and tamoxifen." | ( Duggan, D; Lehmann, D; Nelsen, J; Newman, N; Ramanath, V; Smith, A, 2004) |
| "Our hypothesis is that breast cancer patients with COMT (L/L) genotype may be at increased risk of cataract formation after tamoxifen treatment." | ( Chi, CW; Lee, SM; Li, AF; Liu, HC; Liu, TY; Tseng, LM, 2004) |
| "Seventy percent of breast cancers are hormone-responsive due to the presence of estrogen receptors ERalpha and ERbeta, which are important diagnostic and therapeutic targets in cancer treatment." | ( Kumar, R; Santen, RJ; Song, RX; Zhang, Z, 2004) |
| "When capecitabine-treated breast cancer patients develop macrocytosis in the absence of anemia, investigations of other causes of macrocytosis are not warranted." | ( Hamilton, M; Karvellas, CJ; Mackey, JR; Sawyer, M, 2004) |
| "How women with early-stage breast cancer perceive the risks and benefits of tamoxifen therapy seems critical for sustaining adherence to adjuvant tamoxifen therapy." | ( Fink, AK; Guadagnoli, E; Gurwitz, J; Rakowski, W; Silliman, RA, 2004) |
| "These breast cancer subgroups may represent separate biological entities with potential differences in sensitivity to therapy, occurrence of metastasis, and overall prognosis." | ( Altomare, V; Apicella, A; Fazio, VM; Gallo, AP; Gravina, C; Liguoro, G; Nicol, T; Paradiso, A; Parrella, P; Poeta, ML; Prencipe, M; Rabitti, C; Rinaldi, M; Rossiello, R; Schittulli, F; Scintu, M; Seripa, D; Tommasi, S, 2004) |
| "Tamoxifen treatment inhibited breast cancer cell growth and increased BMD but caused uterine hypertrophy in this preclinical model of postmenopausal breast cancer." | ( Barrett, JC; Berrigan, D; Brodie, A; Hursting, SD; Jelovac, D; Macedo, L; Núñez, NP; Perkins, SN, 2004) |
| "We analysed 147 women with breast cancer treated with adjuvant RT, and who were included in the KFS 00539-9-1997/SKL 00778-2-1999 prospective study aimed at evaluating the predictive value of CD4 and CD8 T-lymphocyte apoptosis for the development of radiation-induced late effects." | ( Azria, D; Dubois, JB; Gourgou, S; Kramar, A; Lemanski, C; Mirimanoff, RO; Ozsahin, M; Pelegrin, A; Romieu, G; Sozzi, WJ; Zouhair, A, 2004) |
| "Forty-one patients with primary breast cancer and treated with neoadjuvant anthracycline-based chemotherapy (FAC or FEC) were included for the present study." | ( Albanell, J; Alonso, C; Bellet, M; Cardesa, A; Colomo, L; Fernandez, PL; Gascon, P; Martin-Richard, M; Muñoz, M; Rey, MJ; Tabernero, J, 2004) |
| "Estrogen receptor (ER)-negative breast cancers are a group of tumors with poor prognosis and fewer cancer prevention and treatment strategies compared to ER-positive tumors." | ( El-Rehim, DM; Ellis, IO; Lee, AH; Paish, CE; Pinder, SE; Putti, TC; Rakha, EA, 2005) |
| "All hopes for a cure for breast cancer turned to appropriate combinations of cytotoxic chemotherapy." | ( Jordan, VC; Liu, H; Meeke, K; Osipo, C, 2004) |
| "In anthracycline-pretreated metastatic breast cancer (MBC), adding capecitabine to docetaxel improves survival, time to progression (TTP) and response rates beyond docetaxel." | ( Holland, M; Reichardt, P; Sternberg, CN, 2004) |
| "Transfection of HER2/neu in MCF-7 breast cancer cells appeared to be associated with an increased resistance of the cells to hormonal therapy." | ( Kao, MC; Lee, HH; Lin, JK; Way, TD, 2004) |
| "The treatment of MCF-7 breast cancer cells with genistein induced a sustained increase in concentration of intracellular Ca2+ resulting from depletion of the endoplasmic reticulum Ca2+ stores." | ( Sergeev, IN, 2004) |
| "45 premenopausal women with early stage breast cancer were treated with adjuvant chemotherapy." | ( Blomqvist, C; Elomaa, I; Risteli, J; Risteli, L; Saarto, T; Vehmanen, L, 2004) |
| "We assessed whether breast cancer patients treated with tamoxifen were at increased risk of developing cataracts compared to women not prescribed tamoxifen." | ( Bradbury, BD; Jick, SS; Kaye, JA; Lash, TL, 2004) |
| "Acute abdominal pain in patients with breast carcinoma treated with taxane-based chemotherapy signaled a potentially fatal colitis, and warrants aggressive supportive care." | ( Buzdar, AU; Hortobagyi, GN; Ibrahim, NK; Li, Z; Mante Menchu, RP; Theriault, R; Valero, V; Wang, M; Wathen, JK, 2004) |
| "The estrogenic status of patients with breast cancer may influence the prognosis and the response to treatment and is currently assessed by immunological measurement of serum estradiol." | ( Balaguer, P; Dalenc, F; Faye, JC; Nicolas, JC; Roché, H; Séronie-Vivien, S, 2004) |
| "100 women with locally advanced breast cancer >3 cm were treated with three cycles of single-agent epirubicin at a dose of 120 mg/m2." | ( Ardizzoia, A; Barni, S; Biasioli, R; Freddi, E; Frontini, L; Grassi, MM; Lucani, L; Mandalà, M; Nosenzo, MA; Piazza, E; Pravettoni, A; Recalcati, A; Rezzani, C; Sala, R; Trabucchi, E; Villa, S; Visini, M, 2004) |
| "Human breast cancer MCF-7 cells were cultured and treated with botanical extracts (final concentration: 10 mg/L) and 17beta-E2 (final concentration: 0." | ( Chen, J; Liu, Z; Lu, C, 2004) |
| "However, approximately one-third of all breast cancer patients with ER-alpha-positive tumors progress on antiestrogen therapy." | ( Bickis, MG; Chibbar, R; Klassen, S; McFadden, A; Shoman, N; Torlakovic, E, 2005) |
| "The terms breast cancer or neoplasia, aromatase, aromatase inhibitors, third-generation, endocrine therapy, and antiestrogens were used to search MEDLINE for English-language studies published between 1966 and April 2004." | ( Abou-Jawde, RM; Alemany, CA; Budd, GT; Choueiri, TK, 2004) |
| "Women with breast cancer who were treated with tamoxifen had an 82% increased risk of ischemic stroke and a 29% increased risk of any stroke, but the absolute risk is small." | ( Bushnell, CD; Goldstein, LB, 2004) |
| "Patients with metastatic breast cancer (MBC) require chemotherapy that improves outcomes without compromising quality of life." | ( Leonard, R; Miles, D; Reichardt, P; Twelves, C, 2004) |
| "Success in breast cancer treatment depends greatly upon early detection, and in the employment of prognostic markers able to anticipate the evolution of the disease, allowing a more rational management of the patient." | ( Armanasco, E; Bal de Kier Joffé, E; Cresta, C; Giménez, L; Mauro, L; Peters, MG; Puricelli, L; Vidal, Mdel C, 2004) |
| "We obtained information on breast cancer treatment and stroke risk factors through medical record review and telephone interviews." | ( Bernstein, L; Chen, W; Fischberg, GM; Geiger, AM, 2004) |
| "Endocrine treatments of breast cancer patients antagonize estrogen and may lead to consequences of estrogen deprivation including menopausal symptoms." | ( Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I, 2004) |
| "The treated breast carcinoma cells were tubulin-positive but the proliferating histiocytes were tubulin-negative." | ( Garg, K; Lemos, LB; Papasozomenos, S; Qu, Z, 2004) |
| "For metastatic breast cancer patients who have hormone receptor-positive tumors, hormonal therapy aiming at optimal palliation and prolongation of life is the initial treatment of choice." | ( Fuchimoto, S; Inagaki, M; Miyoshi, K; Nakagawa, T; Ohsaki, T; Ohtsuka, S; Yumura, M, 2004) |
| "Human breast cancer cell line MCF-7, human gastric cancer cell line BGC-823, human prostate cancer cell line DU-145, and human colon cancer cell line HT-29 were treated with 5-Aza-CdR." | ( Chen, JX; Cui, XY; Fu, PF; Wang, T, 2004) |
| "Forty patients with locally advanced breast carcinoma underwent neoadjuvant chemotherapy." | ( Arbion, F; Body, G; Brunereau, L; Chapiron, C; Denis, F; Desbiez-Bourcier, AV, 2004) |
| "A total of 256 breast cancer patients were randomized to a 5-year or 2-year tamoxifen administration group." | ( Hatake, K; Ito, Y; Iwase, T; Kasumi, F; Makita, M; Nakagawa, K; Nishimura, S; Tada, K; Takahashi, K; Takahashi, S; Ueno, M; Yoshimoto, M, 2004) |
| "Postmenopausal primary breast cancer patients (n = 197) with node-negative, hormone receptor-positive who were treated at our department or in other related medical institutions from April 1997 through March 2001 were given adjuvant therapy." | ( Aoki, T; Kaise, H; Kusama, M; Misaka, T; Nakayama, S; Ota, D, 2004) |
| "Patients with breast cancer treated with sequential paclitaxel, FAC, and radiation therapy appeared to have a very low rate of clinically relevant radiation pneumonitis that was no different from that of patients treated with FAC alone." | ( Buchholz, TA; Buzdar, AU; Hortobagyi, GN; Kau, SW; McNeese, MD; Perkins, GH; Schechter, NR; Strom, EA; Thames, HD; Thomas, ES; Whitman, GJ; Yu, TK, 2004) |
| "In the treatment of advanced breast cancer, third-generation aromatase inhibitors (AIs) have shown superior efficacy and tolerability compared with tamoxifen and megestrol acetate, the previous standard endocrine therapies in the first- and second-line settings, respectively." | ( Tobias, JS, 2004) |
| "The International Breast Cancer Study Group (IBCSG) conducted two complementary randomized trials for peri- and postmenopausal patients with node-positive breast cancer to compare toremifene versus tamoxifen as the endocrine agent and simultaneously investigate a chemotherapy-oriented question." | ( Castiglione-Gertsch, M; Coates, AS; Gelber, R; Gelber, S; Goldhirsch, A; Pagani, O; Price, K; Simoncini, E; Zahrieh, D, 2004) |
| "Thirty-six patients with advanced breast cancer were stratified for the presence of bone and non-bone involvement and treated at four dose levels from capecitabine 800 mg/m2 orally days 1-14 and vinorelbine 20 mg/m2 intravenously days 1 and 8, to capecitabine 1250 mg/m2 orally days 1-14 and vinorelbine 25 mg/m2 intravenously days 1 and 8, for a maximum of six cycles." | ( Aebi, S; Ballabeni, P; Castiglione-Gertsch, M; Goldhirsch, A; Hess, D; Pagani, O; Rauch, D; Rufener, B; Thürlimann, B, 2004) |
| "To treat the clinically advanced breast cancer, combination therapy with trastuzumab (initially 4 mg/kg followed by two or more cycles of 2 mg/kg) and paclitaxel (80 mg/m2) were given intravenously every week for eight cycles and then every two weeks thereafter." | ( Aiba, K; Hagino, T; Hirano, A; Kawase, K; Kobayashi, M; Kobayashi, T; Okawa, Y; Shioya, H; Sugiyama, K; Uno, S; Usui, N; Yoshida, K, 2004) |
| "Two recurrent breast cancer patients, suffering from carcinomatous pleurisy and dyspnea due to pleural effusion, were treated with distilled water." | ( Fujishima, M; Fukunaga, M; Furukawa, H; Imamura, H; Kawasaki, T; Kishi, K; Kishimoto, T; Masutani, S; Nakayama, T; Shimizu, J; Takemoto, H; Tatsuta, M; Yamamoto, K, 2004) |
| "We report a case of local advanced breast cancer with multiple lung metastases (T4bN2M1) achieving a significant improvement of QOL by multimodal therapy with chemotherapy, antibody therapy, radiation therapy and surgery." | ( Enomoto, T; Handa, K; Hayashi, K; Kuranami, M; Sengoku, N; Watanabe, M, 2004) |
| "In postmenopausal women with advanced breast cancer progressing on prior endocrine therapy, fulvestrant is at least as effective as the third-generation aromatase inhibitor (AI) anastrozole." | ( Franco, S; Frankel, C; Perez, A; Tan-Chiu, E; Vogel, CL, 2004) |
| "The reduction in invasive breast cancer incidence continues beyond 4 years of raloxifene treatment in postmenopausal women with osteoporosis." | ( Barrett-Connor, E; Cauley, JA; Cummings, SR; Disch, D; Martino, S; Mershon, J; Powles, TJ; Secrest, RJ, 2004) |
| "Information about breast cancer treatment and prevention in African American women is scant, and recommendations for therapy from clinical trials for breast cancer are based primarily on data obtained from white women." | ( Bryant, J; Cronin, W; Garvey, L; James, J; Mamounas, E; McCaskill-Stevens, W; Wickerham, DL; Wilson, J, 2004) |
| "In asymptomatic postmenopausal breast cancer tamoxifen-treated patients, the use of wider ultrasonographic endometrial cutoff values could be associated not only with the performance of fewer endometrial samplings, but also with a higher possibility of endometrial pathologies, including endometrial cancers, being left undiagnosed." | ( Aviram, R; Cohen, I; Fishman, A; Markovitch, O; Shapira, J; Tepper, R, 2004) |
| "Sixty-eight patients with inflammatory breast carcinoma (IBC) received treatment in 2 prospective randomized trials of multimodality therapy for locally advanced breast cancer." | ( Baldini, E; Collecchi, P; Evagelista, G; Gardin, G; Lionetto, R; Prochilo, T, 2004) |
| "Patients with newly diagnosed breast cancers > or = 5 cm in size by palpation were treated with docetaxel/cisplatin, both at 70 mg/m2 intravenously every 21 days for 4 courses." | ( Doliny, P; Gomez-Fernandez, C; Hurley, J; Lee, YJ; Powell, J; Reis, I, 2004) |
| "Studies show that high Akt activity in breast carcinoma is associated with a poor pathophenotype, as well as hormone and chemotherapy resistance." | ( deGraffenried, LA; Donzis, EJ; Friedrichs, WE; Hidalgo, M; Middleton, AK; Roth, RA; Russell, DH; Silva, JM, 2004) |
| "Patients with metastatic breast cancer (n = 30) who failed a prior chemotherapy regimen for metastatic disease received 45 mg/m2 pegylated liposomal doxorubicin (PLD) every 4 weeks following prophylactic administration of metoclopramide (10 mg) and dexamethasone (8 mg)." | ( Hausmaninger, H; Mayer, P; Mlineritsch, B; Oberaigner, W; Rass, C; Reiter, E; Russ, G; Vesenmayer, G, 2004) |
| "Patients with measurable metastatic breast cancer after failure of prior chemotherapy (including anthracyclines and/or taxanes) were eligible." | ( Borquez, D; Harstrick, A; Kaufmann, M; Loibl, S; Oberhoff, C; Schleucher, R; Seeber, S; Vanhoefer, U; von Minckwitz, G; Welt, A, 2005) |
| "Cell cultures of breast cancer cells were treated with beta-adrenergic agonists and antagonists, and changes in gene expression were determined by both relative competitive and real time PCR." | ( Cakir, Y; Plummer, HK; Schuller, HM; Yu, Q, 2004) |
| "From 59 breast cancer patients treated with neoadjuvant chemotherapy and 33 without neoadjuvant therapy (control), core biopsy samples before the chemotherapy or surgery and surgical specimens were obtained for assay of ER, PR, and HER-2 expression." | ( Wang, J; Wang, YD; Wu, YL; Zhao, GR; Zhao, J, 2004) |
| "The treatment of breast cancer has progressed substantially over the past 15 years." | ( Palmieri, FM; Perez, EA; Tack, DK, 2004) |
| "Female breast cancer patients who receive treatments that reduce estrogen levels, such as aromatase inhibitors, may increase their risk of developing osteoporosis and their risk of fracture." | ( Ravdin, PM, 2004) |
| "In the 43 treated metastatic breast cancer patients, trastuzumab was combined with docetaxel (35 patients), paclitaxel (2 patients), or vinorelbine (6 patients)." | ( Casorzo, L; Montemurro, F; Redana, S; Risio, M, 2005) |
| "Many therapies used in the treatment of breast cancer reduce estrogen levels and have the potential to affect bone negatively by increasing the risk of osteoporosis and associated bone fractures." | ( Joy, AA; Mackey, JR, 2005) |
| "Early diagnosis of breast cancer is crucial for effective treatment, and the need exists for greater detection ability and specificity than possible by screening x-ray mammography (currently the primary imaging technique for the detection of breast lesions)." | ( Lui, BJ; Reznik, A; Rowlands, JA, 2005) |
| "For patients with high-risk breast cancer treated with modified radical mastectomy, treatment with radiation therapy (schedule of 16 fractions) and adjuvant chemotherapy leads to better survival outcomes than chemotherapy alone, and it is well tolerated, with acceptable long-term toxicity." | ( Coldman, AJ; Coppin, CM; Durand, R; Gelmon, K; Jackson, SM; Knowling, MA; Le, N; Manji, M; Olivotto, IA; Phillips, N; Ragaz, J; Spinelli, JJ; Weir, L; Wilson, KS, 2005) |
| "Liver metastases from breast cancer are associated with a poor prognosis, however, local control with microwave thermocoagulation therapy has been used in certain subgroups of these patients in the past decade." | ( Abe, H; Endo, Y; Hanasawa, K; Kurumi, Y; Morikawa, S; Naitoh, H; Naka, S; Shiomi, H; Tani, T; Umeda, T, 2005) |
| "The relationship between breast cancer-associated fatty acid synthase (FAS; oncogenic antigen-519) and chemotherapy-induced cell damage has not been studied." | ( Colomer, R; Lupu, R; Menendez, JA; Vellon, L, 2005) |
| "Ester 3 was active against human breast carcinoma in mice and the toxicity of the agent was not observed in mice during the treatment, implying that this agent is effective for treatment with low toxicity." | ( Cao, ZS; Dejesus, A; Giovanella, B; Mendoza, J, 2005) |
| "Treatment of a ZR-75-1 breast cancer cell line stably transfected with AND-34 plus 2 micromol/L LY294002 or 10 micromol/L NSC23766, a Rac-specific inhibitor, abrogated AND-34-induced resistance to ICI 182,780." | ( Castro, AF; Felekkis, KN; Lerner, A; Narsimhan, RP; Near, R; Quilliam, LA; Zheng, Y, 2005) |
| "Recurrent breast cancer patients who never have undergone anthracycline-containing regimens should be treated with anthracycline regimens." | ( Fujiuchi, N; Ohokubo, K; Saeki, T; Sasaki, Y, 2005) |
| "Patients included those with metastatic breast cancer without any prior anti-HER2 treatment, anthracycline therapy, or any other chemotherapy for metastatic disease." | ( Du Bois, A; Eidtmann, H; Emons, G; Harbeck, N; Himsl, I; Jackisch, C; Kahlert, S; Kreienberg, R; Kuhn, W; Langer, B; Lueck, HJ; Meerpohl, HG; Muscholl, M; Pauschinger, M; Schaller, G; Thomssen, C; Untch, M; Wallwiener, D; Wiese, W, 2004) |
| "Metastases in breast cancer are a vital concern in treatment, with epidermal growth factor receptor and ErbB2 strongly implicated in mediating tumor invasion and spreading." | ( Iozzo, RV; Kay, P; Kirby, S; McQuillan, DJ; Owens, RT; Reed, CC; Waterhouse, A, 2005) |
| "Patients with endocrine-responsive breast cancer represent a distinct population for which tailored adjuvant treatments are needed." | ( Castiglione-Gertsch, M; Dellapasqua, S, 2005) |
| "Neoadjuvant (preoperative) therapy for breast cancer may allow for the development of intermediate markers of treatment benefit, thereby circumventing the need for efficacy trials of adjuvant therapy, which require much larger patient numbers and longer follow-up." | ( Ashley, S; Boeddinghaus, I; Detre, S; Dixon, JM; Dowsett, M; Ebbs, SR; Francis, S; Griffith, C; Hills, M; Salter, J; Skene, A; Smith, IE; Walsh, G, 2005) |
| "The treatment of breast carcinoma with tamoxifen was found to reduce a woman's risk of acute MI or angina during the 5 years of recommended therapy." | ( Bradbury, BD; Jick, SS; Kaye, JA; Lash, TL, 2005) |
| "For patients whose breast cancers are not responsive to endocrine therapy, there are a large number of cytotoxic drugs that will induce a response." | ( Colbern, GT; Gabizon, AA; Henderson, IC; Moore, MR; Overmoyer, BA; Park, JW; Robert, NJ; Shapiro, CL; Silverman, P; Sparano, JA; Vogel, CL; Winer, EP, 2004) |
| "Chemotherapy for operable breast cancer decreases the risk of death." | ( Allred, DC; Chamness, GC; Chang, JC; Elledge, R; Gutierrez, MC; Hilsenbeck, SG; Kalidas, M; Lewis, MT; Mohsin, S; O'Connell, P; Osborne, CK; Tham, YL; Tsimelzon, A; Wong, H; Wooten, EC, 2005) |
| "In women with hormone-sensitive breast cancer, three of these agents, letrozole, anastrozole, and exemestane, provide an important alternative endocrine therapy to the antiestrogen tamoxifen, which blocks estrogen activation of the estrogen receptor." | ( Mouridsen, HT, 2004) |
| "Treatment of the breast cancer cell line, MDAMB468 with the DNA methylation inhibitor, 5-azacytidine (5-AzaC) results in growth arrest, whereas the growth of the normal breast epithelial line DU99 (telomerase immortalized) is relatively unaffected." | ( Guo, Y; Huper, G; Marks, JR; Murphy, SK; Olson, JA; Wang, W, 2005) |
| "Tamoxifen treatment of breast cancer is associated with an increased risk of endometrial cancer, but tamoxifen-related risks of endometrial cancer are unclear in premenopausal women, in long-term users of tamoxifen, and in women for whom several years have passed since ending treatment." | ( Jones, ME; Swerdlow, AJ, 2005) |
| "Fifty-three survivors of breast cancer (all between 2-5 years after diagnosis and initial surgical removal of cancerous tissue) and 19 healthy non-BCS comparison subjects were administered a comprehensive neurocognitive battery, and measures of mood, energy level, and self-reported cognitive functioning." | ( Abraham, L; Bower, JE; Castellon, SA; Ganz, PA; Greendale, GA; Petersen, L, 2004) |
| "The survival of breast cancer patients has significantly improved through the treatment with anthracyclines." | ( Králícková, P; Malír, F; Melichar, B; Roubal, T, 2004) |
| "About 50% of patients with breast cancer have no involvement of axillary lymph nodes at diagnosis and can be considered cured after primary locoregional treatment." | ( Benoy, IH; Dirix, LY; Elst, H; Salgado, R; Scharpé, S; Van Dam, P; Van Marck, E; Vermeulen, PB; Weyler, J, 2005) |
| "Pretreatment of human breast cancer cells with wortmannin or LY294002, selective inhibitors of phosphoinositide 3-kinase (PI3K), diminished Cch-mediated MAPK/ERK phosphorylation." | ( Jiménez, E; Montiel, M, 2005) |
| "BT474 and SK-BR-3 breast cancer cell lines were treated with Epidermal Growth Factor (EGF), Heregulin, and with Herceptin in different combinations." | ( Brockhoff, G; Diermeier, S; Hofstaedter, F; Horváth, G; Knuechel-Clarke, R; Szöllosi, J, 2005) |
| "Although breast cancer is most often treated with conventional cytotoxic agents it has proved difficult to induce apoptosis in breast cancer cells, but improved clinical responses may be obtained by identifying therapies that are particularly effective in activating apoptosis." | ( Aiello, S; Aránega, A; Campos, J; Espinosa, A; Gallo, MA; Marchal, JA, 2005) |
| "Three hundred and sixty-six breast cancer patients were enrolled in this study; 292 patients were treated with 20 mg/daily of TMX as adjuvant therapy and the remaining 74 did not receive therapy." | ( Hannuna, K; Iuele, T; Marziani, R; Melluso, J; Mossa, B; Napolitano, C, 2005) |
| "Forty-two consecutive breast cancer patients with scintigraphic and radiographic evidence of bone metastases were treated with a single infusion of 4 mg zoledronic acid before anticancer chemotherapy." | ( Battistoni, F; Dicuonzo, G; Gasparro, S; Gavasci, M; Grilli, C; La Cesa, A; Rocci, L; Santini, D; Tonini, G; Vincenzi, B; Virzì, V, 2005) |
| "Mortality from breast cancer has decreased in large part because of adjuvant chemotherapy." | ( Chehal, A; Fuleihan, Gel-H; Mahfoud, Z; Mourad, YA; Salamoun, M; Salem, Z; Shamseddine, A, 2005) |
| "In none of the hormone-dependent breast cancers, the combined treatment with E2 and P4 had any effect on GH secretion and cell proliferation." | ( Augustowska, K; Gregoraszczuk, EL; Krzysiek, J; Milewicz, T; Ryś, J; Sztefko, K, 2005) |
| "Among breast cancer patients treated with conservative surgery, there is no advantage to giving RT before adjuvant chemotherapy." | ( Bellon, JR; Come, SE; Gelman, RS; Harris, JR; Henderson, IC; Recht, A; Shulman, LN; Silver, BJ, 2005) |
| "It is well-known that breast cancer easily metastasizes to the bone, liver, pleura and lymph node, but rarely to the ovarium or peritoneum when chemotherapy is conducted." | ( Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Nonogaki, H; Tanaka, T; Tsubono, M; Yasumizu, R, 2005) |
| "We investigated relapse-free (RFS), breast cancer-corrected (BCCS) and overall survival (OS) related to TP53 status in node-positive breast cancer patients that had received polychemotherapy [cyclophosphamide, methotrexate, 5-fluorouracil (CMF)] and/or endocrine therapy (tamoxifen)." | ( Andersson, J; Bergh, J; Carlsson, G; Gustavsson, B; Holmberg, L; Inganäs, M; Klaar, S; Larsson, L; Nilsson, J; Ohd, J; Rudenstam, CM, 2005) |
| "Women diagnosed with breast cancer received massage therapy or practiced progressive muscle relaxation (PMR) for 30-min sessions 3 times a week for 5 weeks or received standard treatment." | ( Beutler, J; Field, T; Fletcher, MA; Fraser, M; Hernandez-Reif, M; Hurley, J; Ironson, G; Kuhn, C; Schanberg, S; Vera, Y, 2005) |
| "Subjects consisted of 23 breast cancer patients undergoing post-operative external radiotherapy for breast conserving therapy, 12 tongue and seven prostate cancer patients undergoing interstitial radiotherapy, 19 esophageal cancer patients undergoing external radiotherapy and chemotherapy, and 11 cervical cancer patients undergoing external radiotherapy and brachytherapy with or without chemotherapy." | ( Inoue, T; Koizumi, M; Nakamura, H; Shuo, X; Tanaka, E; Yamazaki, H; Yoshioka, Y, 2005) |
| "For the first-line therapy of advanced breast cancer in postmenopausal women, fulvestrant was shown to be active and well tolerated in a trial that compared fulvestrant 250 mg once monthly and tamoxifen 20 mg once daily." | ( Bundred, N, 2005) |
| "In all, 1,990 women with Stage 0-II breast cancer were treated with conservative surgery and whole-breast irradiation from 1970-1998." | ( Anderson, PR; Eisenberg, DF; Freedman, GM; Hanlon, AL; Nicolaou, N, 2005) |
| "In the International Breast Cancer Study Group (IBCSG) trial VII, 1212 postmenopausal patients with node-positive disease were randomized to receive tamoxifen for 5 years or tamoxifen plus three concurrent courses of cyclophosphamide, methotrexate and 5-fluorouracil ('classical' CMF) chemotherapy, either early, delayed or both." | ( Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Collins, J; Crivellari, D; Erzen, D; Forbes, J; Gelber, RD; Goldhirsch, A; Holmberg, S; Li, S; Lindtner, J; Murray, E; Pagani, O; Price, KN; Rudenstam, CM; Simoncini, E; Thürlimann, B; Veronesi, A, 2005) |
| "Many patients with breast cancer suffer from anaemia, as a consequence of the disease itself or its treatment." | ( Leonard, RC; Untch, M; Von Koch, F, 2005) |
| "Estrogen receptor (ER)-negative breast carcinomas do not respond to hormone therapy, making their effective treatment very difficult." | ( Antrobus, K; Kimber, I; Lim, FL; Moggs, JG; Moore, DJ; Murphy, TC; Orphanides, G; Stuckey, R, 2005) |
| "The knowledge that breast cancers in a great percent of patients have specific estrogen (ER) and progesterone (PgR) receptors, which made them hormonal dependent, induced the development of a large choice of hormonal drugs for the treatment." | ( Basić-Cabaravdić, H, 2005) |
| "Following treatment of breast cancer patients with oral gefitinib (Iressa) 250 mg/d for > or = 14 days, gefitinib concentrations (mean, 7." | ( Barnett, S; Bichat, F; Giles, PB; Guilbaud, N; Kemp, JV; Kendrew, J; McKillop, D; Partridge, EA; Patterson, AB; Spence, MP; Stephens, TC; Wood, PG, 2005) |
| "Treatment of breast carcinoma MCF-7 cells causes a concentration-dependent block of cell cycle progression exclusively at mitosis." | ( Andersen, RJ; Chan, Q; Karjala, G; Manzo, E; Roberge, M, 2005) |
| "Eligible breast cancer patients were naive to emetogenic chemotherapy and treated with cyclophosphamide +/- doxorubicin or epirubicin." | ( Bohidar, N; Eisenberg, PD; Gabriel, M; Gralla, RJ; Grunberg, SM; Herrstedt, J; Hesketh, PJ; Horgan, KJ; Hustad, CM; Klinger, G; Muss, HB; Raftopoulos, H; Rodgers, A; Skobieranda, F; Warr, DG, 2005) |
| "Human breast cancer cells were tested in vitro for cytotoxicity, colony formation inhibition, BrdU incorporation and gene expression profiling after treatment with tanshinone IIA." | ( Liu, G; Lu, Y; Wang, W; Wang, X; Wei, Y; Yuan, S; Zhang, J, 2005) |
| "As part of a population-based Breast Cancer Family Registry, questionnaires on initial breast cancer treatment and subsequent recurrence were mailed to Australian women diagnosed between 1991 and 1998." | ( Buys, S; Friedlander, ML; Giles, GG; Hopper, JL; McCredie, MR; Milne, RL; Phillips, KA; Ward, JH, 2005) |
| "We report three cases with advanced breast cancer were treated with a weekly dose of paclitaxel (TXL)." | ( Katsumine, Y; Noda, N; Osawa, I; Uehara, S; Yuasa, H, 2005) |
| "Targeted therapy for breast cancer is a reality at this time, and several new agents hold promise for expanding and refining the pool of patients likely to further benefit from this approach in the near future." | ( Hobday, TJ; Perez, EA, 2005) |
| "However, only a portion of all breast cancer patients respond to current estrogen based endocrine therapy, and with continued treatment nearly all will become unresponsive and experience relapse." | ( Cialacu, V; Lewis, MJ; Pawlak, KJ; Wiebe, JP; Zhang, G, 2005) |
| "224 patients with locally advanced breast cancer were randomly assigned to 75 mg/m(2) cyclophosphamide given orally on days 1-14, and 60 mg/m(2) epirubicin and 500 mg/m(2) fluorouracil both given intravenously on days 1 and 8, for six cycles every 28 days (6 months' treatment; standard treatment) and 224 patients to 830 mg/m(2) cyclophosphamide and 120 mg/m(2) epirubicin both given intravenously on day 1, and 5 microg/kg filgrastim per day given subcutaneously on days 2-13, for six cycles every 14 days (3 months' treatment; dose-intensive treatment)." | ( Bonnefoi, H; Bottomley, A; Coens, C; Cufer, T; Dyczka, J; Efficace, F; Gotay, C; Lichinitser, MR; Mauriac, L; Piccart, M; Schornagel, JH; Shepherd, L; Therasse, P; Welnicka-Jaskiewicz, M, 2005) |
| "In 115/122 breast cancer patients not hypersensitive to initial PTX treatment, 20 mg dexamethasone (DXM) doses were tapered by 2." | ( Adamson, B; Braverman, AS; McManus, M; Pierre, S; Rao, S; Salvatti, ME, 2005) |
| "We used data from a breast cancer pilot study carried out in Kerala, India in 1997, for which organochlorine levels were measured in three biological media, blood serum, breast adipose tissue, and gluteal adipose tissue, of 37 fasting breast cancer cases (pretreatment)." | ( Baris, D; Matthews, A; Pellizzari, E; Rusiecki, JA; Sinha, R; Sturgeon, S; Zheng, T, 2005) |
| "Human breast cancer cells MDA-MB-231 were repeatedly treated in culture with a given therapeutic agent with or without bexarotene for 3 months." | ( Lamph, WW; Yen, WC, 2005) |
| "The results suggest that inhibition of breast cancer growth in nude mice by dietary fish oil and inhibition of breast cancer cell growth in culture by treatment with DHA and EPA is mediated by activation of N-SMYase." | ( Harvey, KA; Jackson, K; Ruzmetov, N; Sech, L; Siddiqui, RA; Stillwell, W; Welch, ZR; Wu, M; Zaloga, GP, 2005) |
| "Patients with locally advanced breast cancer were treated with intravenously administration of weekly docetaxel (20 mg/m2) and concurrent radiation therapy (66-70 Gy)." | ( Araki, T; Kashiyama, S; Komiyama, T; Kuriyama, K; Marino, K; Ohnishi, H, 2005) |
| "Future studies of women with breast cancer using tamoxifen should be designed to determine the stroke etiologies that are most common in women using tamoxifen, the role of additional chemotherapy and existing stroke risk factors, and the potential mechanisms of venous and arterial thrombosis." | ( Bushnell, C, 2005) |
| "Biosynthesis of PC was increased in breast cancer cell lines upon treatment." | ( Akech, J; Das, SK; Sinha Roy, S, 2005) |
| "Five breast cancer patients received (111)In-2IT-BAD-m170 for imaging, and 3 of the 5 received high doses of (90)Y-2IT-BAD-m170 therapy followed by PBSC infusion." | ( DeNardo, GL; DeNardo, SJ; Kroger, LA; O'Donnell, RT; Richman, CM; Shen, S; Siantar, CH; Yuan, A, 2005) |
| "Retrospectively, patients with primary breast carcinoma (N = 882) with > or = 10 metastatic ALNs, treated between 1954 and 1998, were selected from 3 institutions: The University of Texas M." | ( Arriagada, R; Bermejo, B; Buzdar, AU; Delaloge, S; Dunant, A; Garcia-Conde, J; Hortobagyi, GN; Kau, SW; Le, M; Lluch, A; Montero, AJ; Rouzier, R; Sahin, AA; Singletary, SE; Spielmann, M; Theriault, RL; Valero, V, 2005) |
| "Thirty invasive breast cancer patients (31 breasts) who received NAC as BCT and needle biopsy before chemotherapy were included in this study." | ( Ito, S; Kariya, S; Moriki, T; Murata, Y; Nishioka, A; Ogawa, Y; Ohnishi, T; Yoshida, S, 2005) |
| "This study suggests that breast cancer cells that overexpress HER-2 may be resistant to low-doses of anthracycline-based chemotherapy." | ( Ito, S; Kariya, S; Moriki, T; Murata, Y; Nishioka, A; Ogawa, Y; Ohnishi, T; Yoshida, S, 2005) |
| "Cells of an oestrogen-dependent human breast cancer-derived line, MCF-7, were treated with a range, 0." | ( Busbee, D; Chowdhary, R; Hokanson, R; Mankame, T, 2004) |
| "We analyzed TS and DPD expression in breast carcinomas to evaluate the clinicopathological significance of these enzymes in patients with invasive breast cancer receiving 5-FU-based chemotherapy." | ( Sun, J; Yang, Q; Yu, Z; Zhang, Q; Zhen, J, 2005) |
| "Forty-eight patients with breast cancer with multi-bone metastases were randomly divided into three groups:15 patients received (188)Re-HEDP (group A), 15 patients received pamidronate (group B) and 18 patients were treated by (188)Re-HEDP plus pamidronate (group C)." | ( Chen, SX; DU, JQ; Jiang, NY; Liang, JG; Liu, XG; Lu, XP, 2005) |
| "Stage III breast cancer patients continue to suffer high relapse and death rates despite standard chemotherapy regimens." | ( Craighead, P; Mackey, J; Paterson, AH; Ruether, JD; Russell, J; Smylie, M; Stewart, DA, 2005) |
| "An effective treatment for operable breast cancer, NCT with epirubicin plus paclitaxel results in significant downstaging or eliminating of primary tumors in breast cancer, thus expanding the indication of breast conservation therapy." | ( Cao, YM; Liu, HJ; Liu, P; Qiao, XM; Tong, FZ; Yang, DQ; Zhou, B, 2005) |
| "Systematic undertreatment of breast cancer in overweight and obese women may contribute to the poorer prognosis in these women." | ( Griggs, JJ; Lyman, GH; Sorbero, ME, 2005) |
| "Overweight and obese women with breast cancer often receive intentionally reduced doses of adjuvant chemotherapy." | ( Griggs, JJ; Lyman, GH; Sorbero, ME, 2005) |
| "In parallel, research on the biology of breast cancer is establishing novel prognostic and predictive factors, which may allow better treatment tailoring." | ( Aglietta, M; Montemurro, F; Redana, S; Valabrega, G, 2005) |
| "Women treated for breast cancer and men receiving androgen ablation for prostate cancer experience hot flushes that are more frequent, severe and longer lasting than those experienced by the general menopausal population." | ( Adelson, KB; Hershman, DL; Loprinzi, CL, 2005) |
| "Since most breast cancer patients are postmenopausal and treated with hormone therapy, we developed a model to simulate this type of patient." | ( Brodie, A; Goloubeva, O; Jelovac, D; Long, B; Macedo, L; Sabnis, G, 2005) |
| "We prospectively evaluated low-stage breast cancers treated with neoadjuvant chemotherapy using whole-volume sonography and color Doppler imaging." | ( Bartz, B; Carson, PL; Fowlkes, JB; Gordon, SP; Johnson, TD; LeCarpentier, GL; Pai, D; Roubidoux, MA; Schott, AF, 2005) |
| "In older women with early breast cancer and no palpable axillary nodes, it may be safe to give no axillary treatment." | ( Boracchi, P; Daidone, MG; De Palo, G; De Palo, M; Martelli, G; Oriana, S; Pilotti, S; Zucali, R, 2005) |
| "Older patients with T1N0 breast cancer can be treated by conservative breast surgery and no axillary dissection without adversely affecting breast cancer mortality or overall survival." | ( Boracchi, P; Daidone, MG; De Palo, G; De Palo, M; Martelli, G; Oriana, S; Pilotti, S; Zucali, R, 2005) |
| "The outcome of breast cancer treatment can vary in different geographic and ethnic groups." | ( Badwe, R; Budrukkar, AN; Chinoy, RF; Dinshaw, KA; Hawaldar, R; Sarin, R; Shrivastava, SK, 2005) |
| "In human primary breast cancer, anthracycline treatment causes an early increase in apoptosis and a decrease in proliferation." | ( Allred, DC; Arpino, G; Ciocca, DR; Daguerre, P; Elledge, R; Gago, F; Leuzzi, M; Mohsin, SK; Vargas-Roig, L; Weiss, H, 2005) |
| "In this cohort of older patients with breast cancer, the risk for toxicity from adjuvant chemotherapy depended more on the type of regimen (anthracycline vs." | ( Brogan, K; Howard, J; Hudis, C; Hurria, A; Jakubowski, A; Norton, L; Panageas, KS; Pearce, C; Zauderer, M, 2005) |
| "Seventeen women with Stage III-IV breast carcinoma were included in the study who progressed (n = 13 women) or had stable disease (n = 4 women) on doxorubicin-containing or taxane-containing chemotherapy regimens." | ( Blumenschein, G; Boniface, G; Booser, D; Fleming, DR; Hortobagyi, GN; Ibrahim, N; Pusztai, L; Rivera, E; Rouzier, R; Symmans, FW; Theriault, R; Wagner, P; Wong, F, 2005) |
| "Forty-two women with metastatic breast cancer previously treated with anthracyclines (93%) and/or taxanes (36%) received mitomycin-vinblastine-cisplatin (MVP) (n=23), or cisplatin-etoposide (PE) (n=19), as first-, second- and third-line treatment at a tertiary referral centre between 1997 and 2002." | ( Decatris, MP; O'Byrne, KJ; Sundar, S, 2005) |
| "In patients with metastatic breast cancer, sequential 18F-FDG PET allowed prediction of response to treatment after the first cycle of chemotherapy." | ( Avril, N; Bader, M; Dose Schwarz, J; Hemminger, G; Jänicke, F; Jenicke, L, 2005) |
| "Selection criteria were (a) metastatic breast cancer, (b) endocrine therapy (any line of treatment), and (c) evaluation of HER-2 expression (any method)." | ( Arpino, G; Bianco, AR; Cancello, G; Caputo, F; Carlomagno, C; Ciardiello, F; D'Agostino, D; De Laurentiis, M; De Placido, S; Lauria, R; Malorni, L; Massarelli, E; Montagna, E; Ruggiero, A; Tortora, G; Zinno, L, 2005) |
| "HER-2-positive metastatic breast cancer is less responsive to any type of endocrine treatment." | ( Arpino, G; Bianco, AR; Cancello, G; Caputo, F; Carlomagno, C; Ciardiello, F; D'Agostino, D; De Laurentiis, M; De Placido, S; Lauria, R; Malorni, L; Massarelli, E; Montagna, E; Ruggiero, A; Tortora, G; Zinno, L, 2005) |
| "In metastatic breast cancer, several Phase II trials document the activity of gemcitabine in pretreated and unpretreated patients." | ( Heinemann, V, 2005) |
| "Women with metastatic breast cancer, Karnofsky performance status > or = 70, and previous treatment with > or = 3 regimens containing anthracyclines, taxanes, and capecitabine were eligible." | ( Blum, JL; Clark, RS; Liepa, AM; Melemed, AS; Mennel, RG; O'Shaughnessy, JA; Snyder, D; Yardley, DA; Ye, Z, 2005) |
| "Persistent high mortality rates in breast cancer patients, in spite of latest advances in diagnosis and therapy, affirm the necessity of new developments in tumor biology prognostic factors." | ( Aizen, B; Barrios, E; Berois, N; Estrugo, R; Lavigna, R; Musé, I; Osinaga, E; Pressa, C; Sóñora, C; Varangot, M, 2005) |
| "Patients with metastatic breast cancer were treated with gemcitabine (1000-1400 mg/m(2)) on days 1, 8 and 15 and mitoxantrone (10-14 mg/m(2)) on day 8." | ( Akrivakis, K; Flath, B; Heilmann, V; Kreienberg, R; Mergenthaler, HG; Possinger, K; Schmid, P; Sezer, O, 2005) |
| "Human breast carcinomas represent a heterogeneous group of tumors diverse in behavior, outcome, and response to therapy." | ( Alvarenga, M; Dufloth, R; Matos, I; Schmitt, F; Zeferino, LC, 2005) |
| "In pretreated metastatic breast cancer patients, the sustained weekly administration of docetaxel, even though it demonstrated an activity similar to a 3-weekly schedule could not be maintained for the planned 24 weeks due to the progressive emergence of nonhematological side effects that approached DLTs." | ( Barni, S; Bria, E; Carlini, P; Cognetti, F; Cuppone, F; Ferretti, G; Frontini, L; Garufi, C; Milella, M; Nisticò, C; Terzoli, E; Vanni, B, 2005) |
| "Current therapy for hypercalcemia in breast cancer patients relies on the inhibition of bone resorption by a class of drugs known as bisphophonates." | ( DeMauro, S; Wysolmerski, J, 2005) |
| "Forty-five breast cancer patients were randomized into three groups: Group I--chemotherapy, control, Group II--midazolam+chemotherapy, and Group III--propofol+chemotherapy." | ( Argun, G; Baran, O; Dikmen Mentes, S; Ertunc, FN; Unsal, D, 2005) |
| "Clinical benefit has been shown in breast cancer patients with HER-2 amplification or overexpression when trastuzumab is used alone or in combination with chemotherapy." | ( Gligorov, J; Nabholtz, JM, 2005) |
| "Patients with clinical stage I-IIIA breast cancer were randomly assigned to receive PST of paclitaxel doses administered either weekly (for a total of 12 doses of paclitaxel) or once every 3 weeks (four cycles), followed by four cycles of fluorouracil/doxorubicin/cyclophosphamide (FAC) in standard doses every 3 weeks." | ( Booser, DJ; Buzdar, AU; Carter, C; Cristofanilli, M; Frye, D; Green, MC; Hortobagyi, GN; Hunt, KK; Ibrahim, NK; Pusztai, L; Rivera, E; Rosales, MF; Sahin, AA; Sikov, W; Smith, T; Strom, EA; Symmans, WF; Theriault, RL; Valero, V, 2005) |
| "In the present study, human breast cancer MDA-MB-231 cells treated with pristimerin (1 and 3 micromol/L) showed rapid induction of apoptosis, as indicated by caspase activation, DNA fragmentation, and morphologic changes." | ( Chan, ML; Chang, FR; Chen, WY; Tsai, CY; Wu, CC; Wu, YC, 2005) |
| "Long-term endocrine therapy for breast cancer may have clinical implications as drugs that potentially alter the lipid profile may increase the risk of developing cardiovascular disease." | ( Bafaloukos, D; Chrissochou, M; Gogas, H; Markopoulos, C; Michailidou, A; Misitzis, J; Papadiamantis, J; Tzoracoleftherakis, E; Xepapadakis, G; Zobolas, V, 2005) |
| "Fear of breast cancer was not prominent, and participants were less inclined to take tamoxifen as preventive therapy after receiving information." | ( DeGregorio, M; Henderson, S; Kuppermann, M; Melnikow, J; Nease, R; Nuovo, J; Paterniti, DA, 2005) |
| "Aromatase inhibitors successfully treat breast cancer and endometriosis, whereas their roles in endometrial cancer, uterine fibroids, and aromatase excess syndrome are less clear." | ( Amin, S; Bulun, SE; Deb, S; Demura, M; Gurates, B; Imir, G; Langoi, D; Lin, Z; Martin, R; Tamura, M; Thung, S; Utsunomiya, H; Yilmaz, B, 2005) |
| "Primary breast cancer samples employed were obtained for (1) patients subsequently treated with tamoxifen for advanced disease where endocrine response and survival data were available and (2) ER+ elderly patients during tamoxifen response and relapse." | ( Ellis, IO; Gee, JM; Gutteridge, E; Nicholson, RI; Pinder, SE; Robertson, JF; Rubini, M, 2005) |
| "Fine needle aspirations of 82 breast cancers were obtained before starting preoperative paclitaxel followed by 5-fluorouracil, doxorubicin, and cyclophosphamide chemotherapy." | ( Anderson, K; Ayers, M; Cristofanilli, M; Fan, C; Hess, KR; Hortobagyi, GN; Ibrahim, N; Morandi, P; Perou, CM; Pusztai, L; Rabiul, I; Ross, JS; Rouzier, R; Stec, J; Symmans, WF; Wagner, P, 2005) |
| "The basal-like and erbB2+ subtypes of breast cancer are more sensitive to paclitaxel- and doxorubicin-containing preoperative chemotherapy than the luminal and normal-like cancers." | ( Anderson, K; Ayers, M; Cristofanilli, M; Fan, C; Hess, KR; Hortobagyi, GN; Ibrahim, N; Morandi, P; Perou, CM; Pusztai, L; Rabiul, I; Ross, JS; Rouzier, R; Stec, J; Symmans, WF; Wagner, P, 2005) |
| "Four breast cancer patients treated with radioimmunotherapy alone had grade 3 or 4 myelosuppression." | ( Chew, HK; DeNardo, GL; Denardo, SJ; Goldstein, DS; Kukis, DL; Lamborn, KR; Lara, PN; Meares, CF; Natarajan, A; O'Donnell, RT; Richman, CM; Shen, S; Tuscano, JM; Wun, T; Yuan, A, 2005) |
| "The study involved 30 breast cancer patients: 14 were treated with paclitaxel alone (group A) and 16 with paclitaxel and adriamycin (group B)." | ( Capri, G; Caraceni, A; Curzi, S; Luca, G; Martini, C; Scaioli, V, 2006) |
| "In conclusion, breast cancer patients showed suppressed neutrophil migratory response upon chemotherapy, accompanied by bacterial infection episodes." | ( Cunha, FQ; Mendonça, MA; Murta, EF; Tavares-Murta, BM, 2006) |
| "Twenty-five percent of all women with breast carcinoma are premenopausal and are at risk for chemotherapy-induced menopause with long-term side effects." | ( Fornier, MN; Hudis, C; Modi, S; Norton, L; Panageas, KS, 2005) |
| "Forty consecutive breast cancer patients suffering troublesome hot flushes have been treated for 8 weeks with venlafaxine XR 37." | ( Biglia, N; Cacciari, F; Kubatzki, F; Maggiorotto, F; Ponzone, R; Roagna, R; Sismondi, P; Torta, R, 2005) |
| "We hypothesized that ER+/PR- breast tumors are more likely than ER+/PR+ breast tumors to have an aggressive phenotype, to express HER-1 and overexpress HER-2, and are less likely to benefit from tamoxifen adjuvant therapy." | ( Arpino, G; De Placido, S; Elledge, RM; Lee, AV; Osborne, CK; Schiff, R; Weiss, H, 2005) |
| "20 patients had a history of breast cancer being treated with adjuvant tamoxifen therapy and developed subsequently endometrial cancer." | ( Freites, ON; Rieck, GC; Williams, S, 2005) |
| "The study includes the breast cancer female patients who had received chemotherapy (CMF, tamoxifen) and the newly diagnosed breast cancer patients, who had not received any chemotherapy." | ( Khanam, A; Mehreen, L, 2005) |
| "We prospectively recruited consecutive breast cancer patients receiving radiation therapy after breast surgery." | ( del Moral, R; Guerrero, R; López, E; Martín-Oliva, D; Martínez-Galán, J; Muñoz-Gámez, JA; Núñez, MI; Oliver, FJ; Ruiz de Almodóvar, JM; Valenzuela, MT; Villalobos, M, 2005) |
| "A study presented in this issue of Breast Cancer Research suggests that recently developed inhibitors of phosphoinositide-dependent protein kinase 1, a more proximal target of the PI3K pathway, may provide an alternative route to effective PI3K pathway inhibition for breast cancer treatment." | ( Crowder, RJ; Ellis, MJ, 2005) |
| "Combined treatment of breast cancer cell lines, namely hormone-sensitive MCF-7 and hormone-insensitive MDA-MB-231 cell lines, indicates that these compounds maintain agonistic activity so that the potential advantage in vehiculation of the cytotoxic moiety by means of the receptor system is counteracted by the proliferative effect of the estrogenic component of the entire molecule, especially at low concentrations." | ( Bonetti, S; Cassino, C; Colangelo, D; Gabano, E; Ghiglia, A; Osella, D; Prandi, C, 2005) |
| "An audit of surgical treatment of early breast cancer was introduced nationally in 1999." | ( Babidge, W; Boult, M; Cuncins-Hearn, A; Kollias, J; Maddern, G; Tyson, S, 2005) |
| "Most patients with breast cancer are likely to benefit from local treatment (surgery and/or radiotherapy)." | ( Rai, S; Stotter, A, 2005) |
| "Treatment of two breast cancer cell lines, SW-620 and MCF-7, and one colon cancer cell line, HT-29, by 1,25(OH)2D3 for 48 h profoundly stimulated CYP24A1 mRNA expression (EC50=0." | ( Anderson, MG; Kroeger, PE; Nakane, M; Ruan, X; Wu-Wong, JR, 2006) |
| "Current trends in surgery for breast cancer and the adjuvant treatments of chemotherapy and radiotherapy are also discussed." | ( Boyages, J; Brennan, M; French, J; Ung, O; Wilcken, N, 2005) |
| "Long-term endocrine therapy for breast cancer may have clinical implications as drugs that potentially alter the lipid profile may increase the risk of developing cardiovascular disease." | ( Gogas, H; Koukouras, D; Lappas, H; Markopoulos, C; Papadiamantis, J; Polychronis, A; Xepapadakis, G; Zobolas, V, 2005) |
| "Primary chemotherapy for breast cancer (BC) has drawn attention to control of local diseases and enable breast conservative surgery." | ( Saito, T; Takahashi, K; Tokunaga, Y, 2005) |
| "Sixteen patients with metastatic breast cancer previously treated with anthracycline and taxane were utilized in the study." | ( Chedid, S; Cristofanilli, M; Esteva, F; Frye, DK; Hortobagyi, G; Ibrahim, N; Mettinger, KL; Rivera, E; Valero, V, 2006) |
| "Thirty-three primary breast cancer patients with tumor diameter more than four centimeters were treated with wide local excision and axillary lymph node dissection." | ( Li, JF; Lin, BY; Ouyang, T; Wang, TF; Xie, YT, 2005) |
| "A cohort of 446 breast cancer patients received definite surgery and adjuvant chemotherapy with CMF at Chang Gung Memorial Hospital from 1990 to 1998." | ( Chang, HK; Chen, MF; Chen, SC; Hsueh, S; Hwang, TL; Lin, YC; Lo, YF; Tsai, CS, 2005) |
| "Treatment of breast cancer cells and osteosarcoma cells with estradiol, estren, substance A and substance B led to non-genomic activation of Akt (protein kinase B) and extracellular signal-regulated kinase 1/2 (ERK1/2) signaling cascades mediated by Src (Rous Sarcoma Virus, non-receptor tyrosine kinase) and phosphatidylinositol-3-kinase (PI3K) stimulation." | ( Fritzemeier, KH; Otto, C; Stangl, V; Wessler, S; Wilck, N, 2006) |
| "In MCF-7, the ER-positive human breast cancer cell line, treated with BaP, the formation of BaP-DNA adducts and DNA synthesis were inhibited in a concentration-responsive manner, but there was no change in MDA-MB-231, the ER-negative cell line." | ( Kang, SC; Lee, BM, 2005) |
| "To this end, CG5 breast cancer cells were treated in vitro with gemcitabine followed by epirubicin, doxorubicin, docetaxel or paclitaxel." | ( Biroccio, A; D'Angelo, C; Leonetti, C; Lopez, M; Paoletti, G; Scarsella, M; Zupi, G, 2005) |
| "Two COX-2 overexpressing human breast cancer cell lines (Her-18 and MDA-MB-436) were treated with celecoxib (20 micromol/L and 50 micromol/L) and Ad-mda7 (multiplicity of infection, 1000 and 2000 viral particles/cell)." | ( Chada, S; Hunt, KK; Liu, Y; Lucci, A; McKenzie, T; Suh, YJ; Swisher, SG, 2005) |
| "Fifty-seven patients with metastatic breast cancer have been treated with reduced dose capecitabine 1g/m2 twice daily for 14 days repeated every 3 weeks after failure of a number of chemotherapy regimens or hormonal treatment." | ( Coleman, RE; El-Helw, L, 2005) |
| "A 45-year-old woman with breast cancer overexpressing HER2 and metastasizing to choroidal plexus, lymph nodes and skin received a combination of trastuzumab and paclitaxel as first-line treatment." | ( Goldhirsch, A; Munzone, E; Nolè, F; Sanna, G, 2005) |
| "Our results suggest that the control of breast carcinoma (ER-) growth by tachykinin receptor antagonists may become a new form of targeted therapy for these human tumors." | ( Benzo, A; Bigioni, M; Goso, C; Irrissuto, C; Maggi, CA, 2005) |
| "Adjuvant chemotherapy (ACT) in breast cancer exposes patients to morbidity, but improves survival." | ( Holtmon, M; Norum, J, 2005) |
| "The increasing number of breast cancer patients who suffer from menopausal symptoms is mainly due to the extensive use of adjuvant treatments in the younger women." | ( Biglia, N; Jacomuzzi, ME; Maggiorotto, F; Mariani, L; Ponzone, R; Sismondi, P, 2005) |
| "Two patients with metastatic breast cancer developed oral aphthous ulcers after only two administrations of weekly docetaxel without any other toxicity." | ( G Oumlker, E; Rodenhuis, S, 2005) |
| "The primary goals of the treatment of breast carcinomas are multiple, depending on the situation in which the patients are treated." | ( Avenin, D; Beerblock, K; Do Huyen, N; Emile, G; Estéso, A; Gligorov, J; Lotz, JP; Ségura, C; Selle, F, 2005) |
| "In the field of estrogen therapy breast cancer risk is one of the most controversially discussed topic." | ( Mueck, AO; Seeger, H; Wallwiener, D, 2006) |
| "Subgroups of breast cancer that have an impaired response to endocrine treatment, despite hormone receptor positivity, are still poorly defined." | ( Anagnostaki, L; Chebil, G; Fernö, M; Jirström, K; Jönsson, PE; Landberg, G; Nordenskjöld, B; Rydén, L; Stål, O; Thorstenson, S, 2005) |
| "A meta-analysis by the 2005 Early Breast Cancer Trialists' Collaborative Group confirmed that about 6 months of anthracycline-based polychemotherapy in the adjuvant setting reduced the yearly death rate from breast cancer by about 38% for women younger than 50 years and by 20% for women aged 50-69 years." | ( Charbonneau, F; Gelmon, K; Laing, K; Latreille, J; Mackey, J; McLeod, D; Pritchard, K; Provencher, L; Trudeau, M; Verma, S, 2005) |
| "Data on patients with invasive breast cancer (Stages I to IIIA) seen between 1992 and the end of 2001 and who received adjuvant chemotherapy were analyzed." | ( Ajarim, DS; Ezzat, AA; Ibrahim, EM; Rahal, MM; Raja, MM, 2005) |
| "Decreased ICAM-1 expression by breast carcinoma cells that survive paclitaxel treatment may negatively impact on cytotoxic lymphocyte-mediated destruction of paclitaxel-resistant breast cancer cells in the context of chemo-immunotherapy or chemo-adoptive immunotherapy." | ( Fawcett, H; Giacomantonio, C; Hoskin, DW; Mader, JS; Robichaud, M, 2005) |
| "On the other hand, hormonal therapy for breast cancer has been progressing rapidly with the advent of drugs such as selective estrogen receptor (ER) modulators and aromatase inhibitors." | ( Hayashi, S; Yamaguchi, Y, 2005) |
| "The feature of breast cancer cells and tissues to accumulate copper can be used as a targeting method for anticancer therapy through treatment with novel compounds such as CQ and PDTC that become active proteasome inhibitors and breast cancer cell killers in the presence of copper." | ( Chen, D; Cui, QC; Daniel, KG; Dou, QP; Miller, FR; Orlu, S, 2005) |
| "Thirty-two patients with advanced breast cancer pretreated with chemotherapy were enrolled in a dose-finding trial to determine the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of paclitaxel given on days 1, 8 and 15 of each cycle combined with capecitabine given twice daily from day 1 through day 14, every 21 days." | ( Bilancia, D; Cognetti, F; Di Costanzo, F; Gasperoni, S; Landucci, E; Manzione, L; Mazzoni, F; Papaldo, P, 2006) |
| "In 50 consecutive patients with breast cancer stages II and III, physical examination, mammography and scintimammography were performed before and after the administration of neoadjuvant chemotherapy." | ( Baena-Cañada, JM; Benítez, E; García-Curiel, A; Palomo-González, MJ; Partida-Palma, F; Rueda-Ramos, A, 2005) |
| "Treatment of MCF-7 breast cancer cells with 50 microM Pb significantly decreased cell proliferation relative to control (p < 0." | ( Corbit, R; Ebbs, S; King, ML; Murphy, LL, 2006) |
| "Women with stage I to III breast cancer received dose-dense AC --> paclitaxel as neoadjuvant or adjuvant chemotherapy." | ( Bunnell, CA; Burstein, HJ; Come, SE; Doherty, J; Gelman, R; Haldoupis, M; Harris, LN; Keshaviah, A; Moy, B; Parker, LM; Partridge, AH; Ryan, PD; Schapira, L; Schumer, ST; Winer, EP; Younger, J, 2005) |
| "To model adjuvant treatment of human breast cancer, MCF-7 cells were injected s." | ( Tannock, IF; Wu, L, 2005) |
| "Patients with measurable metastatic breast cancer who had previously received an anthracycline and a taxane in either the adjuvant or metastatic setting were treated with gemcitabine 1250 mg/m2 (intravenous; days 1 and 8) and pemetrexed 500 mg/m2 (intravenous; day 8) every 21 days." | ( Adjei, AA; Fitch, TR; Hillman, DW; Ingle, JN; Kugler, JW; Ma, CX; Niedringhaus, RD; Perez, EA; Rowland, KM; Steen, P, 2006) |
| "This is the first report of breast carcinoma metastatic to the endometrium in a patient on adjuvant anastrozole therapy." | ( Bolat, F; Erkanli, S; Haberal, A; Kayaselcuk, F; Kuscu, E; Sakalli, H, 2006) |
| "We selected a group of breast cancer patients in high-dose chemotherapy (HDCT) protocols who were at risk for pulmonary injury." | ( Folz, RJ; Huang, YC; Macintyre, NR; O'brien, SR; Vredenburgh, J, 2006) |
| "Of 31,748 women with stage I to III breast cancer, 5,575 (18%) received chemotherapy." | ( Doyle, JJ; Grann, VR; Hershman, DL; Jacobson, JS; Neugut, AI, 2005) |
| "We report a case of advanced breast cancer with multiple lung and liver metastases (T4bN1M1) achieving a significant improvement of QOL by multi-disciplinary therapy." | ( Amano, S; Enomoto, K; Kashio, M; Kitajima, A; Matsuo, S; Negishi, N; Sakamoto, A; Sakurai, K; Suzuki, M; Tani, M, 2005) |
| "Their fate in primary breast cancer patients undergoing adjuvant therapy is of particular interest." | ( Becker, S; Becker-Pergola, G; Fehm, T; Solomayer, EF; Wallwiener, D, 2006) |
| "Moreover, breast cancer cells that were treated with GRN163L for only 1 week prior to plating in invasion chambers, and when bulk telomere are still long, exhibit significantly diminished invasive potential." | ( Dikmen, ZG; Gellert, GC; Gryaznov, S; Shay, JW; Wright, WE, 2006) |
| "Overexpression of cyclin E in breast tumors is associated with a poor response to tamoxifen therapy, greater genomic instability, more aggressive behavior, and a poor clinical prognosis." | ( Dandekar, S; Dhillon, NK; George, M; Glick, D; Gregg, JP; Libertini, SJ; Mudryj, M; Robinson, BS; Sawai, E, 2005) |
| "Choline kinase is overexpressed in breast cancer cells and activated by oncogenes and mitogenic signals, making it a potential target for cancer therapy." | ( Bhujwalla, ZM; Glunde, K; Mori, N; Raman, V, 2005) |
| "We studied 82 human breast cancer samples from patients treated with neoadjuvant doxorubicin-based chemotherapy and studied whether or not nuclear location of the transcription factor NF-kappaB was associated with expression of bcl-2 and bax and whether or not expression of these proteins correlated with chemotherapy response." | ( Aggarwal, BB; Buchholz, TA; Chakravarti, N; Cristofanilli, M; Esteva, FJ; Garg, AK; Hortobagyi, GN; Kuerer, HM; Pusztai, L; Sahin, AA; Singletary, SE, 2005) |
| "Sixty-three primary breast cancer patients were treated with docetaxel (60 mg/m(2), q3w) for four cycles in the neoadjuvant setting." | ( Kato, K; Kim, SJ; Miyoshi, Y; Nakamura, H; Noguchi, S; Taguchi, T; Tamaki, Y; Yodoi, J, 2005) |
| "Tamoxifen treatment for breast cancer increases proliferation of the endometrium, resulting in an enhanced prevalence of endometrial pathologies, including endometrial cancer." | ( Blok, LJ; Burger, CW; Ewing, PC; Gielen, SC; Kühne, LC, 2005) |
| "Given the importance of the ER in breast cancer growth and regulation, delineating the impact of these agents under conditions related to tumor treatment is of significant importance." | ( Boldison, J; Hess-Wilson, JK; Knudsen, KE; Weaver, KE, 2006) |
| "Survival of MDA-MB-231 breast carcinoma cells was determined by clonogenic assay following spheroid culture, doxorubicin exposure, and NO mimetic administration." | ( Adams, MA; Graham, CH; Muir, CP, 2006) |
| "Treatment of the invasive breast cancer cell lines, Hs578T and MDA-MB-231, with beta-aminopropionitrile (betaAPN), an irreversible inhibitor of LOX catalytic activity, leads to a significant decrease in cell motility/migration and adhesion formation." | ( Csiszar, K; Fogelgren, B; Fong, SF; Hendrix, MJ; Hess, AR; Kirschmann, DA; Payne, SL; Seftor, EA; Wiley, EL, 2005) |
| "Study participants from the Long Island Breast Cancer Study Project provided a spot urine specimen and completed a comprehensive interviewer-administered questionnaire." | ( Bradlow, HL; Britton, JA; Gammon, MD; Kabat, GC; Neugut, AI; O'Leary, ES; Sepkovic, DW; Teitelbaum, SL; Terry, MB, 2006) |
| "Seventy-three patients with advanced breast cancer positive for Her-2/neu as revealed by immunohistochemistry were divided into the study group (n=32) to receive treatment with the regimen of Herceptin plus TAX and control group (n=41) with the regimen of epirubicin(EPI) plus TAX." | ( Chen, B; Chen, JZ; Cui, F; Huang, YX; Luo, RC, 2005) |
| "Of 27 breast cancer tissues treated with paclitaxel, nine (33%) showed translocation of YB-1 from the cytoplasm to the nucleus together with increased expression of P-glycoprotein during the course of treatment." | ( Fujimori, M; Fujita, T; Hama, Y; Ito, K; Izumi, H; Kimura, M; Kohno, K; Maeno, K; Nakagomi, H; Sano, M; Shingu, K; Tsuchiya, S, 2005) |
| "Women who are diagnosed with early breast cancer remain at considerable risk of recurrence over the next several decades, even if their tumors were small and lymph nodes were negative, and despite receiving standard adjuvant therapy." | ( Chowdhury, S; Ellis, P, 2005) |
| "Consequently, even if a small number of breast cancer cells are EBV infected, the impact of EBV infection on the efficiency of anticancer treatment might be of importance." | ( Arbach, H; Bauchet, T; Boualaga, N; Bride, N; Guinebretière, JM; Joab, I; Lefeu, F; Mathieu, MC; Mourah, S; Peyrat, JP; Podgorniak, MP; Ramirez, V; Seignerin, JM; Takada, K; Viglasky, V, 2006) |
| "Adjuvant chemotherapy for breast cancer can be associated with a variety of side effects, one of which is the induction of premature menopause in premenopausal patient." | ( Davis, AL; Klitus, M; Mintzer, DM, 2005) |
| "Current chemotherapy regimens for breast cancer result in high incidences of anemia, which can be treated with erythropoietic agents." | ( Charu, V; Gabrail, N; Rossi, G; Schwartzberg, L; Senecal, FM; Tomita, D; Yee, L, 2005) |
| "Thirty-eight postmenopausal women with breast cancer and vasomotor symptoms were randomized to treatment with electro-acupuncture (n = 19) or applied relaxation (n = 19) during 12 weeks." | ( Hammar, M; Nedstrand, E; Wijma, K; Wyon, Y, 2005) |
| "Chemoprevention of breast cancer has been mostly aimed at reducing the rate of cell division through administration of anti-hormones." | ( Calaf, GM, 2006) |
| "Twelve patients with metastatic breast cancer were treated with bortezomib (VELCADE) at a dosage of 1." | ( Booser, DJ; Broglio, KR; Cristofanilli, M; Esseltine, D; Gonzalez-Angulo, AM; Hortobagyi, GN; Islam, R; Krishnamurthy, S; Pusztai, L; Reuben, JM; Stec, J; Yang, CH, 2006) |
| "In all, 23 patients with IHC 3+ primary breast cancer were treated with trastuzumab plus docetaxel." | ( Arnould, L; Benoit, L; Bertheau, P; Bonnetain, F; Cabaret, V; Coudert, B; Fermeaux, V; Garnier, J; Gelly, M; Jeannin, JF; Migeon, C; Penault-Llorca, F, 2006) |
| "We experienced a case of recurrent breast cancer resistant to prior medications, which was treated with oral S-1, a fluoropyrimidine-class anticancer drug, and exhibited the marked shrinkage of liver metastasis." | ( Mitsuyama, S; Nishihara, K, 2006) |
| "In addition, breast cancer cell lines with SFRP1 promoter hypermethylation reexpressed SFRP1 mRNA after treatment with 5-azaC, implying that DNA methylation is the predominant epigenetic mechanism for SFRP1 gene silencing." | ( Argani, P; D'Costa, A; Fackler, MJ; Garrett-Mayer, E; Lo, PK; Mehrotra, J; Sukumar, S, 2006) |
| "Ten patients with advanced breast cancer whose tumors overexpressed HER-2, but not ER or PgR, were treated with weekly trastuzumab at standard doses with or without chemotherapy." | ( Bonizzi, G; Curigliano, G; Goldhirsch, A; Munzone, E; Nolè, F; Renne, G; Rocca, A, 2006) |
| "Twenty-five breast cancer patients who had completed adjuvant chemotherapy were enrolled." | ( Choe, MA; Choi, S; Kim, KS; Kwon, SH; Lee, SW; Yi, MS, 2005) |
| "A total of 164 female breast cancer patients, previously treated with anthracyclines, received anthracycline-based chemotherapy either with (n = 85) or without (n = 79) dexrazoxane for a maximum of six cycles." | ( Espié, M; Llombart, A; Marty, M; Monnier, A; Rapoport, BL; Stahalova, V, 2006) |
| "The Cochrane Breast Cancer Group Specialised Register was searched on 21st August 2003 using the codes for "early breast cancer", "endocrine therapy", "psychosocial" or "surgery"." | ( Beverley, CB; Hind, D; Reed, MW; Wyld, L, 2006) |
| "Seventy-six patients with breast cancer underwent (99m)Tc-MIBI scintimammography before treatment, and static planar images were taken at 10 min and 180 min after scintimammography." | ( Cui, SD; Li, LF; Li, WL; Liu, H; Liu, ZZ; Yang, H, 2005) |
| "In estrogen sensitive breast cancer cell lines, tamoxifen treatment reduces IRS-1 expression and function; consequently, inhibiting IRS-1/PI-3K signaling." | ( Abrams, MT; Alexeev, V; Cesarone, G; Garofalo, C; Igoucheva, O; Surmacz, E; Wickstrom, E; Yoon, K, 2006) |
| "Efflux transporters, p-glycoprotein and breast cancer resistance protein (BCRP), located at barrier sites such as the blood-brain barrier may affect distribution of steroids used for treating chronic inflammatory conditions and thus the extent to which they may perturb the hypothalamic-pituitary-adrenal axis." | ( Barrand, MA; Cahn, AP; Cooray, HC; Hladky, SB; Shahi, S; van Veen, HW, 2006) |
| "Currently, a large population of breast cancer survivors is at increased risk of death from CVDs and second cancers, especially when treated with RT at a young age." | ( Aleman, BM; Hooning, MJ; Klijn, JG; Kuenen, MA; van Leeuwen, FE; van Rosmalen, AJ, 2006) |
| "In the current study, human breast cancer cells were continuously treated (24 hours) with 2-deoxy-D-glucose, and total glutathione content as well as the expression of the first enzyme in the glutathione synthetic pathway [glutamate cysteine ligase (GCL)] were found to be induced 2." | ( Andringa, KK; Aykin-Burns, N; Coleman, MC; Domann, FE; Hitchler, MJ; Spitz, DR; Walsh, SA, 2006) |
| "A common problem in breast cancer therapy is resistance to the antiestrogen tamoxifen." | ( Kilker, RL; Planas-Silva, MD; Waltz, PK, 2006) |
| "Postmenopausal women with primary breast cancer who were disease free after 2 to 3 years were randomly assigned to switch from tamoxifen to exemestane or continue with tamoxifen until 5 years of treatment were completed." | ( Bliss, JM; Coombes, RC; Fallowfield, LJ; Hall, E; Jones, SE; Porter, LS; Price, MH; Snowdon, CF, 2006) |
| "Histopathological blocks of primary breast cancer patients who had been randomized to receive 2-years tamoxifen or no adjuvant therapy in two mature randomised clinical trials were retrieved." | ( A'Hern, R; Baum, M; Dowsett, M; Farndon, J; Houghton, J; Iden, C; Sainsbury, R; Salter, J, 2006) |
| "Women undergoing treatment for breast cancer often have a number of pre-existing risk factors for bone loss, including existing or induced postmenopausal status." | ( Aapro, M, 2006) |
| "BT-474 human breast cancer cells in exponential growth phase were treated with Herceptin alone, adriamycin alone and their sequential administration (Herceptin before adriamycin and vice versa), respectively." | ( Fan, YX; Lü, CW; Luo, RC; Miao, JX; Tan, K; Yan, X, 2006) |
| "Mortality in breast cancer has declined in the past decade, owing to advances in diagnosis, surgery, radiotherapy, and systemic treatments." | ( Muss, HB; Perez, E, 2005) |
| "Antiestrogens used for breast cancer (BC) treatment differ among each other for the ability to affect estrogen receptor (ER) activity and thereby inhibit hormone-responsive cell functions and viability." | ( Altucci, L; Ambrosino, C; Ardovino, M; Biglia, N; Bontempo, P; Calogero, RA; Cicatiello, L; De Bortoli, M; Elkon, R; Facchiano, A; Medici, N; Menini, N; Molinari, AM; Nebbioso, A; Ponzone, R; Scafoglio, C; Sismondi, P; Weisz, A, 2006) |
| "Gene therapy for advanced breast cancer is anticipated to be a useful therapeutic approach." | ( Hatake, K; Ito, Y; Sugimoto, Y; Takahashi, S, 2006) |
| "Costs of breast cancer care (letrozole therapy, surveillance, recurrences, terminal care) and treatment of osteoporosis and utilities were derived from literature." | ( Brandman, J; Delea, T; Goss, PE; Johnston, SR; Karnon, J; Smith, R; Sung, J, 2006) |
| "Nude mice inoculated with human breast cancer MDA-MB-231 cells and treated with GTP and EGCG were effective in delaying the tumor incidence as well as reducing the tumor burden when compared to the water fed and similarly handled control." | ( Gaddipati, JP; Maheshwari, RK; Sharma, A; Singh, AK; Thangapazham, RL; Warren, J, 2007) |
| "Thus, in metastatic breast cancer patients pre-treated with anthracyclines, the weekly administration of paclitaxel, 5-FU and folinic acid with G-CSF support seems to be extremely tolerable and active." | ( Agostara, B; Barni, S; Bria, E; Colella, E; Cuppone, F; D'Ottavio, AM; Frontini, L; Izzo, F; Nistico, C; Sperduti, I; Terzoli, E; Valenza, R, 2006) |
| "Adjuvant chemotherapy for breast cancer patients has been derived from the results of various clinical studies and metaanalysis." | ( Ito, Y; Tokudome, N, 2006) |
| "Seventy-seven patients with primary breast cancer who had undergone neoadjuvant anthracycline-based chemotherapy were included in the present study." | ( Alberti, S; Angelucci, D; Cianchetti, E; Ficorella, C; Iacobelli, S; Lattanzio, R; Marchetti, P; Natoli, C; Piantelli, M; Ricevuto, E; Tinari, N, 2006) |
| "Patients with high-risk, operable breast cancer were treated with three cycles of paclitaxel 175 mg/m2 every 3 weeks, followed by twice-weekly paclitaxel 30 mg/m2 and concurrent radiation." | ( Beauchamp, RD; Billheimer, D; Chakravarthy, AB; Grau, AM; Johnson, DH; Jones, C; Kelley, MC; Mayer, IA; McLaren, B; Pietenpol, JA; Simpson, JF; Truica, CI, 2006) |
| "A premenopausal woman with early stage breast cancer became amenorrheic with adjuvant chemotherapy, and remained so during 5 years of daily tamoxifen." | ( Hargis, JB; Nakajima, ST, 2006) |
| "Postmenopausal women with early stage breast cancer that was known to be estrogen receptor (ER) positive were randomized to treatment with Tam (20 mg per day orally for 5 years) alone or combined with Flu (10 mg orally twice per day for 1 year)." | ( Donohue, JH; Goetz, MP; Ingle, JN; Krook, JE; Kugler, JW; Mailliard, JA; Michalak, JC; Perez, EA; Pisansky, TM; Suman, VJ; Wold, LE, 2006) |
| "The Danish Breast Cancer Cooperative Group (DBCG) trial 89-b randomized premenopausal patients with receptor-positive, primary breast cancer between nine cycles of CMF chemotherapy given every 3 weeks and ovarian ablation by oophorectomy." | ( Fayers, PM; Groenvold, M; Mouridsen, HT; Petersen, MA, 2006) |
| "Patients with metastatic breast cancer are frequently treated with anthracyclines and taxanes, which are among the most active agents in this disease." | ( Amadori, D; Frassineti, GL; Gianni, L; Maltoni, R; Massa, I; Milandri, C; Nanni, O; Passardi, A; Zoli, W; Zumaglini, F, 2006) |
| "HER2/neu positive breast tumors are difficult to treat." | ( Lanza-Jacoby, S; McGuire, KP; Neavyn, M; Ngoubilly, N, 2006) |
| "The MDA-MB-435eB1 human Her2/neu breast cancer cells were treated with varying concentrations of DIM and paclitaxel." | ( Lanza-Jacoby, S; McGuire, KP; Neavyn, M; Ngoubilly, N, 2006) |
| "Forty-nine patients with advanced-stage breast cancer were treated with escalating doses of oral capecitabine from 500 mg/m2 to 1375 mg/m2 twice daily on days 1-14 and escalating doses of vinorelbine from 12." | ( Adamoli, L; Ascione, G; Catania, C; Goldhirsch, A; Minchella, I; Munzone, E; Nolè, F; Rocca, A; Sanna, G; Verri, E; Zampino, MG, 2006) |
| "Patients with hormone receptor-positive breast cancer received anastrozole (n = 228) or tamoxifen (n = 223) with or without chemotherapy for 12 weeks before primary surgery." | ( Bines, J; Buzdar, AU; Cataliotti, L; de Oliveira, CT; Dube, P; Noguchi, S; Petrakova, K; Takatsuka, Y, 2006) |
| "Among all patients with advanced breast cancer who had been entered into five phase II/III trials using fulvestrant as first- to ninth-line endocrine therapy in our Unit since 1993, 54 patients who fulfilled the following criteria were studied for their subsequent endocrine response: (i) oestrogen receptor positive or unknown; (ii) having been on a subsequent endocrine therapy for > or =6 months unless the disease progressed before; and (iii) with disease assessable for response according to International Union Against Cancer criteria." | ( Cheung, KL; Owers, R; Robertson, JF, 2006) |
| "A total of 6644 node-positive breast cancer patients received adjuvant treatment." | ( Berry, DA; Budman, DR; Cirrincione, C; Citron, ML; Goldstein, LJ; Henderson, IC; Hudis, C; Martino, S; Muss, HB; Norton, L; Perez, EA; Winer, EP, 2006) |
| "Adjuvant therapy of breast cancer patients reduces the risk of recurrence and mortality, although, a substantial proportion of patients acquire resistance and relapse in the disease." | ( Askmalm, MS; Nordenskjöld, B; Rutqvist, LE; Stal, O; Wegman, P; Wingren, S, 2006) |
| "Using PCR and RFLP we genotyped 220 breast cancer patients randomized to radiotherapy versus chemotherapy and tamoxifen versus no tamoxifen." | ( Askmalm, MS; Nordenskjöld, B; Rutqvist, LE; Stal, O; Wegman, P; Wingren, S, 2006) |
| "R115777 is a promising treatment for breast cancer but the relation between effect and growth factor receptor and ras status has to be established." | ( Anderson, E; Bundred, NJ; Clarke, RB; Knox, F; Morris, J; Wärnberg, F; White, D, 2006) |
| "We did not observe any association of breast cancer risk with 8-oxodG levels, but when cases with radiation treatment were removed from the analysis, a significant inverse trend (P = 0." | ( Agrawal, M; Eng, SM; Gammon, MD; Gaudet, MM; Neugut, AI; Rossner, P; Santella, RM; Teitelbaum, SL; Terry, MB; Zhang, FF, 2006) |
| "Optimal management for metastatic breast cancer frequently involves cytotoxic chemotherapy." | ( Ershler, WB, 2006) |
| "About 30-40% of breast cancers lack steroid receptors (ER and/or PR) at diagnosis that worsen prognosis and limit the usage of hormone therapy." | ( Berstein, LM; Kovalenko, IG; Levina, VV; Poroshina, TE; Semiglazov, VF; Tsyrlina, EV; Vasilyev, DA, 2006) |
| "Despite recent advances in treatment, breast cancer remains a serious health threat for women." | ( Booker, AJ; Christensen, LA; Finch, RA; Vasquez, KM, 2006) |
| "In patients with advanced breast cancer, hypercalcemia develops within the first few weeks of initiation of tamoxifen therapy." | ( Arumugam, GP; Sachdanandam, P; Shanthi, P; Sundravel, S, 2006) |
| "We report 3 cases of women with breast cancer undergoing treatment with liposomal doxorubicin who developed palmar-plantar erythrodysesthesia and diffuse morbilliform eruptions." | ( Cady, FM; Kneuper-Hall, R; Metcalf, JS, 2006) |
| "Patients with breast cancer or sarcoma who presented with fever and neutropenia and were identified as low risk received empiric, oral, quinolone monotherapy (gatifloxacin at a dose of 400 mg once daily)." | ( Benjamin, RS; Elting, LS; Frisbee-Hume, SE; Manzullo, EF; McMahon, L; Patel, S; Rolston, KV; Theriault, RL, 2006) |
| "The diagnosis and treatment of breast cancer is an ordeal for women on a number of levels." | ( Boyages, J; Brennan, M; French, J; Houssami, N; Stuart, K, 2006) |
| "Advanced breast cancer patients were treated with ixabepilone (6 mg/m2) for 5 consecutive days every 3 weeks in a phase II clinical trial." | ( Berman, AW; Croarkin, E; Lee, JJ; Low, JA; Mannan, N; Parks, R; Steinberg, SM; Swain, SM, 2006) |
| "In MCF-7 breast cancer cells, we observed that phosphorylated histone H3 (phospho-H3) at Ser(10) but not Ser(28) increased with phorbol ester (12-O-tetradecanoylphorbol-13-acetate, TPA) treatment." | ( Davie, JR; Espino, PS; He, S; Li, L; Yu, J, 2006) |
| "One-hundred and forty-six menopausal breast cancer patients, candidate to receive tamoxifen underwent endometrial assessment by Transvaginal Ultrasonography (TU) before the start of therapy." | ( Centinaio, G; Garuti, G; Grossi, F; Luerti, M; Nalli, G; Sita, G, 2007) |
| "In menopausal breast cancer patients the incidence of endometrial abnormalities before the start of tamoxifen therapy is high and includes 2." | ( Centinaio, G; Garuti, G; Grossi, F; Luerti, M; Nalli, G; Sita, G, 2007) |
| "In vivo experiments were performed on breast cancer xenografts to examine whether the combination therapy with S-1, an oral dihydrouracil dehydrogenase (DPD) inhibitory fluoropyrimidine, plus docetaxel functions as an additive/synergistic modulator in tumor growth." | ( Fukushima, M; Ikeda, T; Kitajima, M; Kubota, T; Ohmiya, H; Suto, A; Takeshita, T, 2006) |
| "Therapy of ER+ human breast cancer cells with a replication-competent HSV-1 mutant is improved in the presence of estrogen, in contrast to more standard therapies, such as chemotherapy and radiation, which demonstrate decreased efficacy in similar conditions." | ( Adusumilli, PS; Bhargava, A; Chan, MK; Eisenberg, DP; Fong, Y; Gonen, M; Huq, R; Kim, TH; Stanziale, SF; Stiles, BM, 2006) |
| "Endocrine therapy for hormone-sensitive breast cancer is a well-established treatment option, both in adjuvant and palliative settings." | ( Langenegger, T; Schiesser, D; Thürlimann, B; Wahl, P, 2006) |
| "Apoptosis of human breast carcinoma cells (SKBR-3, MCF-7, and MDA-468) has been observed after treatment of these cells with anti-cancer drug cis-platin and glycosphingolipid biosynthesis inhibitor L- and D-PPMP, respectively." | ( Banerjee, S; Basu, S; Boyle, PJ; Ma, R; Tuteja, N, 2006) |
| "Patients with metastatic breast cancer receive multiple lines of cytotoxic chemotherapy, with taxane and anthracycline-based regimens being the most active." | ( Athanassiadis, A; Fountzilas, G; Pavlidis, N; Pentheroudakis, G; Razis, E, 2006) |
| "Since breast cancer metastasizes early and it is unlikely that improvements in the treatment of metastatic disease could permit a cure in most cases in the foreseeable future, it is clear that prevention is essential in order practically to eliminate deaths from breast cancer." | ( Labrie, F, 2006) |
| "In intermediate-risk breast cancer, complete hormonal blockade and chemotherapy provided similar outcomes." | ( Bonneterre, J; Chollet, P; Clavère, P; Fargeot, P; Fumoleau, P; Goudier, MJ; Guastalla, JP; Kerbrat, P; Monnier, A; Roché, H; Serin, D, 2006) |
| "At 10 years, the risks for breast cancer death in ER-positive, tamoxifen-treated patients were 2." | ( Alexander, C; Baker, J; Blick, NT; Capra, A; Fehrenbacher, L; Greenberg, D; Habel, LA; Hackett, J; Jacobs, MK; Langholz, B; Pho, M; Quesenberry, CP; Shak, S; Walker, M; Watson, D, 2006) |
| "AIs delivered as up-front therapy for breast cancer have no effects on unspecific endometrial thickening." | ( Cellani, F; Centinaio, G; Garuti, G; Luerti, M; Montanari, G; Nalli, G, 2006) |
| "Out of 64 women with metastatic breast cancer randomized to a multi-site clinical intervention trial of supportive-expressive group therapy (SET), a subsample of 29 met eligibility criteria for this study." | ( DiMiceli, S; Giese-Davis, J; Sephton, S; Spiegel, D, 2006) |
| "Patients with stage II or III breast cancer underwent three cycles of neoadjuvant chemotherapy with doxorubicin 50 mg/m2 and docetaxel 75 mg/m2 every 3 weeks followed by curative surgery." | ( Chang, ES; Han, S; Kang, SS; Kim, JR; Kim, SB; Lim, SH; Noh, WC; Paik, NS; Park, HS, 2006) |
| "S-1 could be a valuable agent for breast cancer treatments, since it showed clinical efficacy and mild toxicity, and can be given orally." | ( Aogi, K; Doihara, H; Nishimura, R; Ohsumi, S; Saeki, T; Taira, N; Takashima, S, 2006) |
| "In patients with metastatic breast cancer previously treated with anthracyclines the combination vinorelbine-docetaxel is very active and well tolerated representing a valid therapeutic option for the management of this patient population." | ( Agostara, B; Gebbia, V; Laudani, A; Leonardi, V; Pepe, A; Savio, G; Scianna, C, 2006) |
| "In primary breast cancer, taxane-based compared with anthracycline-based adjuvant chemotherapy significantly reduces the relative risk of recurrence (ranging from 17% to 36%) and sometimes improves overall survival." | ( Clavarezza, M; Del Mastro, L; Venturini, M, 2006) |
| "The treatment of refractory metastatic breast cancer is primarily palliative, without a significant impact on overall survival." | ( Capomolla, E; Carpano, S; Cauchi, C; Conti, F; Foggi, P; Giacinti, L; Giannarelli, D; Leonetti, C; Lopez, M; Paoletti, G; Vici, P, 2006) |
| "Patients with all stages of primary breast cancer are at continuing risk of relapse following 5 years of adjuvant tamoxifen therapy, even in the absence of lymph node involvement." | ( Dixon, JM, 2006) |
| "The primary use of ERalpha in breast cancer is for predicting likely response to hormone treatment." | ( Duffy, MJ, 2006) |
| "Thirty-two patients with metastatic breast cancer (n = 11) or LABC (n = 21) received AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2) administered intravenously on day 1 plus tipifarnib (100, 200, or 300 mg bid for 6 to 14 days) without (n = 2) or with (n = 30) granulocyte colony-stimulating factor (G-CSF) for up to four cycles." | ( Hershman, D; Hopkins, U; Hoschander, S; Kazi, A; Lee, D; Li, T; Malafa, M; Moulder, S; Munster, P; Pellegrino, C; Sebti, SM; Sparano, JA; Vahdat, L; Wright, JJ, 2006) |
| "The treatment of metastatic breast cancer aims to relieve symptoms by controlling disease and prolonging survival with better QOL." | ( Ito, Y; Tokudome, N, 2006) |
| "Patients with advanced or recurrent breast cancer within 1 regimen of prior chemotherapy and without prior use of both Docetaxel and 5'-DFUR were enrolled." | ( Ikeda, M; Ishiguro, K; Kataoka, T; Komaki, K; Kurebayashi, J; Morimoto, T; Sonoo, H; Tanaka, K; Tangoku, A; Yoshizawa, K, 2006) |
| "In the large international breast cancer studies, beneficial results were obtained for the post-surgical endocrine therapy of postmenopausal women with breast cancer, and the similar use of this drug has been approved in Japan." | ( Tsukagoshi, S, 2006) |
| "Patients with breast cancer primary tumours generally achieved the target efaproxiral exposure and therefore gained greater benefit from efaproxiral treatment than NSCLC patients." | ( Craig, M; Hackman, J; May, J; Pintér, T; Shaw, E; Stea, B; Steffen, RP; Suh, JH, 2006) |
| "The results suggest that, in early breast cancer, MUC1 immunotherapy is beneficial, and that a larger phase III study should be undertaken." | ( Alexis, MN; Apostolopoulos, V; Drakaki, H; Loveland, BE; McKenzie, IF; Piddlesden, SJ; Pietersz, GA; Plebanski, M; Pouniotis, DS; Tsibanis, A; Tsikkinis, A; Vassilaros, S, 2006) |
| "Selenium status in premenopausal breast cancer patients, as measured by serum selenium, GPx and SelP, was within the normal range before and following adjuvant chemotherapy, and was not affected by chemotherapy-induced ovarian failure." | ( Breedlove, HA; Burk, RF; Hill, KE; Shapiro, CL; Smith, AM, 2006) |
| "Based on phase II data in advanced breast cancer (BC), the fluorouracil, epirubicin, and vinorelbine (FEN) combination was assessed as perioperative chemotherapy, integrated in a multidisciplinary treatment for locally advanced BC." | ( Ardavanis, A; Arnogiannaki, N; Chrysochoou, M; Ioannidis, G; Karamouzis, M; Missitzis, I; Orphanos, G; Pissakas, G; Rigatos, G; Scorilas, A; Sotiropoulou, A; Tryfonopoulos, D, 2006) |
| "Systemic therapy for breast cancer is undergoing many interesting advances." | ( Perez, EA; Roy, V, 2006) |
| "Single-agent activity against breast cancer in untreated patients reached 31% and, depending on the type and degree of prior chemotherapy, response rates tended to decrease stepwise from 28% in lightly pretreated patients (ie, with only adjuvant chemotherapy or at maximum one chemotherapy treatment for metastatic disease) to 8% in heavily pretreated patients after exposure with anthracyclines, taxanes, and capecitabine." | ( Dittrich, C, 2006) |
| "Two patients with breast cancer received docetaxel-containing chemotherapy as adjuvant or neoadjuvant therapy during pregnancy." | ( Burton, GV; Lewis, D; Potluri, V, 2006) |
| "Cases with prostate plus breast cancer received estrogen treatment more often than controls with prostate cancer only (p = 0." | ( Grönberg, H; Karlsson, CT; Malmer, B; Wiklund, F, 2006) |
| "In endocrine therapy, TAM resistant breast cancer cells are likely to be generated by the activation of EGFR signaling pathway after long-term TAM treatment, and EGFR inhibitors might increase the therapeutic effects in breast cancer treatment." | ( Wang, XY; Wu, ZY; Zhen, LL; Zheng, W; Zhu, X, 2006) |
| "A 56-year-old female with breast cancer after left partial mastectomy and subaxillary lymph node dissection was treated with adjuvant chemoradiotherapy." | ( Ishiguro, A; Mitobe, S; Munakata, M; Okada, R; Sakata, Y; Shitara, K; Tomioka, R, 2006) |
| "We studied a cohort of 90 breast cancer patients who were treated with cyclophosphamide-methotrexate-5-fluorouracil after surgery and then monitored for up to 108 months." | ( Casado, FJ; Gloeckner-Hofmann, K; Guillén-Gómez, E; Pastor-Anglada, M; Porstmann, R; Rüschoff, J; Schmidtgen, C; Stoss, O; Ziegler, R, 2006) |
| "The decision for treating breast cancer patients with trastuzumab is based on HER-2 amplification and/or overexpression." | ( Lupu, R; Mehmi, I; Menendez, JA, 2006) |
| "Taken together, treatment of breast cancer cells that overexpress HER2 with the anti-HER2 antibody trastuzumab inhibits CDK2, Rb phosphorylation, E2F activity, NPAT, and histone H4 via PI3K signaling that are needed for both DNA and histone synthesis during progression from G(1) phase to S phase of the cell cycle." | ( Bast, RC; Bedrosian, I; Keyomarsi, K; Le, XF; Lee, MH; Lu, Z; Mao, W; Murray, M; Zhao, J, 2006) |
| "This analysis showed that risk of breast cancer associated with current use of estrogen and testosterone therapy was significantly greater compared with estrogen-only therapy (P for heterogeneity, ." | ( Chen, WY; Colditz, GA; Hankinson, SE; Rosner, B; Tamimi, RM, 2006) |
| "Our data suggest that pretreatment of breast cancer cells with trastuzumab induces turnover of the HER2/neu protein and enhanced killing by HER2/neu peptide-stimulated CTLs." | ( Mittendorf, EA; Peoples, GE; Ponniah, S; Shriver, CD; Storrer, CE, 2006) |
| "Women with breast cancer are not typically offered embryo or oocyte cryopreservation to preserve their fertility before chemotherapy because of the potential risks associated with high estrogen levels arising from ovarian stimulation." | ( Bang, H; Cil, A; Hourvitz, A; Oktay, K; Oktem, O; Safro, B; Sahin, G, 2006) |
| "Fifty-seven pregnant breast cancer patients were treated on a single-arm, multidisciplinary, institutional review board-approved protocol with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant (n = 32) or neoadjuvant (n = 25) setting." | ( Gordon, N; Hahn, KM; Hortobagyi, GN; Johnson, PH; Kuerer, H; Middleton, L; Perkins, G; Ramirez, M; Theriault, RL; Yang, W, 2006) |
| "Women with metastatic breast cancer were treated with docetaxel (30 mg/m(2)) given weekly for 3 of 4 weeks." | ( Berman, A; Cox, MC; Denduluri, N; Figg, WD; Lee, J; Low, J; Permenter, MG; Petros, WP; Price, DK; Sparreboom, A; Swain, SM; Walshe, J, 2006) |
| "A total of 118 patients with breast cancer were treated with either epirubicin 75 mg/m(2) and docetaxel 75 mg/m(2) or epirubicin 90 mg/m(2) and paclitaxel 200 mg/m(2) every 3 weeks; 88 received G-CSF support with daily filgrastim or lenograstim and 30 with pegfilgrastim once per cycle." | ( Bauernhofer, T; Dandachi, N; Holub, R; Samonigg, H; Schippinger, W, 2006) |
| "Lymph node status in the elderly breast cancer patient treated with hormonal therapy alone is a strong predictor of early distant recurrence." | ( Chagpar, AB; Edwards, MJ; Martin, RC; McMasters, KM; Nurko, JY; Thoene, C, 2006) |
| "Human MCF-7 breast cancer cells were treated with up to 100 microM zoledronic acid, were irradiated with up to 800 cGy or were exposed to combinations of both treatments to determine the antiproliferative effects of zoledronic acid and radiation." | ( Avcu, F; Candir, M; Guden, M; Ozcan, MA; Ural, AU, 2006) |
| "In time, breast cancer treatment will become truly individualised because physicians will be able to match patients with a variety of disease phenotypes to optimal combination therapies." | ( Dowsett, M; Leary, A, 2006) |
| "Thirty months after the right breast cancer treatment, Stage I left breast cancer was diagnosed." | ( Araki, N; Hiraoka, M; Kawamura, S; Kodama, H; Mise, K; Mitsumori, M; Nagata, Y; Narabayashi, M; Oya, N; Sakamoto, T; Tachiiri, S; Yamauchi, C, 2006) |
| "Twelve patients with metastatic breast cancer previously exposed to taxanes were treated on a Phase II trial with ixabepilone." | ( Berman, AW; Chow, CK; Cox, MC; Denduluri, N; Lee, JJ; Low, JA; Steinberg, SM; Swain, SM; Vatas, U; Walshe, J, 2007) |
| "Targeted therapy for breast carcinoma has achieved a major advance with the use of trastuzumab in Her2/neu-positive tumors." | ( Budman, DR; Calabro, A; Diasio, R; Soong, R; Tai, J, 2006) |
"Patients with EGFR-positive metastatic breast cancer treated with | ( Caravelli, J; D'Andrea, G; Hudis, C; Modi, S; Norton, L; Rosen, PP; Seidman, AD; Yao, TJ, 2006) | |
| "Nomograms were developed for breast cancer patients who received NACT to predict residual tumor size and whether the patient would thus become eligible for breast conservation therapy." | ( Berry, D; Delaloge, S; Garbay, JR; Hortobagyi, GN; Hunt, KK; Kuerer, HM; Pusztai, L; Rouzier, R, 2006) |
| "CAIX expression in breast cancer patients shows a negative predictive role of treatment efficacy in ER-positive patients on the adjuvant tamoxifen after primary chemo-endocrine therapy." | ( Aguggini, S; Allevi, G; Berruti, A; Bersiga, A; Bonardi, S; Bottini, A; Brizzi, MP; Bruzzi, P; Campo, L; Dogliotti, L; Fox, SB; Generali, D; Harris, AL; Milani, M; Wigfield, SM, 2006) |
| "The study comprised 158 female breast cancer patients before treatment and 50 healthy individuals as a reference group." | ( Fuksiewicz, M; Kaminska, J; Kotowicz, B; Kowalska, M; Pienkowski, T; Rubach, M, 2006) |
| "We report two cases of recurrent breast cancer with regional lymph node metastases that responded completely to treatment with trastuzumab and paclitaxel." | ( Inoue, K; Nagamoto, N; Nakahara, O; Ohsako, T; Yoshida, Y, 2006) |
| "Patients with measurable metastatic breast cancer were given oral paclitaxel 90 mg m-2 combined with CsA 10 mg kg-1 (30 min prior to each paclitaxel administration) twice on one day, each week." | ( Beijnen, JH; Helgason, HH; Huitema, AD; Kruijtzer, CM; Marcus, SG; Schellens, JH; Schornagel, JH; Schot, ME; ten Bokkel Huinink, WW, 2006) |
| "When treating breast cancer patients, oncologists should consider the same positive lifestyle changes that are proposed to lower the risk of cardiovascular disease in patients who do not have breast cancer." | ( Abramson, BL; Pritchard, KI, 2006) |
| "In this pilot study, breast cancer patients who started tamoxifen during radiotherapy and who had a moderate coffee and alcohol consumption demonstrated a significant improvement in their estrogen metabolite profile between the pre- and post-operative visits." | ( Bågeman, E; Ingvar, C; Jernström, H; Klug, TL; Rose, C, 2006) |
| "We surveyed patients with ER+ breast cancers who received adjuvant hormonal therapy to determine how these medications impacted their quality of life and whether side effects or cost influenced decisions to continue therapy." | ( Delamelena, T; Garreau, JR; Johnson, N; Karamlou, K; Walts, D, 2006) |
| "Estradiol is a potent growth factor of breast cancer cells and inhibition of its activity has been a basis for the treatment of this disease for a long time." | ( Giguère, V; Laganière, J, 2006) |
| "The treatment of human breast cancer cells with a nonsteroidal anti-inflammatory agent, indomethacin, reverted the high PC/low GPC pattern to a low PC/high GPC pattern indicative of a less malignant phenotype, supported by decreased invasion." | ( Bhujwalla, ZM; Glunde, K; Jie, C, 2006) |
| "In the orthotopic breast cancer model with MDA-MB-231, there were 3-fold more tumor-free mice in the fasudil-treated group versus saline control group (P < 0." | ( Alicke, B; Biroc, SL; Dinter, H; Kamata, Y; Li, WW; Ohashi, Y; Okada, T; Pagila, R; Xuan, JA; Ying, H, 2006) |
| "The present data suggest that 3RG3RG breast cancer patients are not good candidates for capecitabine therapy." | ( Ciccolini, J; Etienne-Grimaldi, MC; Ferrero, JM; Foa, C; Formento, JL; Francoual, M; Ginot, A; Lacarelle, B; Largillier, R; Milano, G; Namer, M; Nebbia, JF; Renée, N, 2006) |
| "In order to downstage locally advanced breast cancer, neoadjuvant chemotherapy consisting of intravenous vinorelbine 25 mg/m plus epirubicin 75 mg/m given on day 1 and oral vinorelbine 60 mg/m on day 8 was administered every 3 weeks for four courses." | ( Agresti, B; Biti, GP; Borghesi, S; De Luca Cardillo, C; Di Cosmo, D; Galardi, A; Gavilli, S; Livi, L; Nosi, F; Paiar, F; Santini, R, 2006) |
| "In patients with metastatic breast cancer who had received one prior chemotherapy regimen, 10-EDAM was well tolerated." | ( Beinart, GA; Booser, D; Broglio, K; Dhingra, K; Frye, D; Gonzalez-Angulo, AM; Gunale, S; Holmes, FA; Hortobagyi, GN; Rosenthal, J; Walters, R; Young, JA, 2007) |
| "Subjects treated for breast cancer with adjuvant chemotherapy remotely (5-10 years previously) were studied with neuropsychologic testing and positron emission tomography (PET), and were compared with control subjects who had never received chemotherapy." | ( Abraham, L; Castellon, SA; Dy, CJ; Ganz, PA; Lai, J; Petersen, L; Phelps, ME; Pio, BS; Silverman, DH; Waddell, K, 2007) |
| "Gene expression analysis in breast cancer patients undergoing neoadjuvant chemotherapy is an interesting tool for identification of gene signatures and new markers to predict tumor response." | ( Ahr, A; Gätje, R; Holtrich, U; Karn, T; Kaufmann, M; Kissler, S; Kourtis, K; Loibl, S; Munnes, M; Rody, A; Ruckhäberle, E; Solbach, C; von Minckwitz, G, 2007) |
| "To determine breast cancer prevalence in postmenopausal women with or without hormone replacement therapy (HRT)." | ( Chevallier, T; Daurès, JP; de Reilhac, P; Espié, M; Mares, P, 2006) |
| "A 44-year-old premenopausal woman with breast cancer treated with adjuvant tamoxifen presented with abdominal distension." | ( Atallah, D; Chahine, G; Checrallah, A; Ghossain, MA; Rouzier, R, 2006) |
| "A large proportion of breast cancer patients are treated with adjuvant chemotherapy after the primary operation, but some will recur in spite of this treatment." | ( Edén, P; Fernö, M; Johnsson, A; Niméus-Malmström, E; Ohlsson, M; Ostberg, G; Peterson, C; Ritz, C; Strand, C, 2006) |
| "A cohort of 32 breast cancer patients, pretreated with conservative surgery and adjuvant doxorubicin or taxane based chemotherapy, were treated with hypoARC." | ( Ambatzoglou, J; Koukourakis, MI; Manavis, J; Sismanidou, K, 2006) |
| "Thirteen breast cancer patients who would start tamoxifen following cytotoxic chemotherapy were enrolled in the study." | ( Babaoglu, MO; Boruban, MC; Bozkurt, A; Sencan, O; Yasar, U, 2006) |
| "Twenty sedentary females with breast carcinoma who were ages 35 to 65 years were randomized to aerobic exercise (AE) of walking for 20 to 45 minutes, 3 to 5 times per week, at 50% to 70% of measured maximum heart rates or to placebo stretching (PS) activities 3 to 5 days per week during 7 weeks of radiation treatment." | ( Beeler, J; Birk, TJ; Byrne, K; Drouin, JS; Hryniuk, LE; Hryniuk, WM; Young, TJ, 2006) |
| "In the treatment of recurrent breast cancer in patients previously treated with anthracycline drugs, taxane drugs are generally used." | ( Akamatsu, H; Imazu, Y; Koshida, Y; Motegi, K; Murayama, T; Ohyama, R; Toeda, H; Toriumi, F; Yoneyama, K, 2006) |
| "Antiestrogens used for breast cancer therapy can be categorized into two classes that differ in their effect on estrogen receptor (ER) alpha stability." | ( Aftab, SA; Chen, L; Fan, M; Nephew, KP; Rickert, EL; Weatherman, RV, 2007) |
| "Postmenopausal patients with advanced breast cancer who did not progress after 4 months of first line T therapy were randomised to continue T (40 mg daily) or to 2 monthly intermittent T or intermittent/alternated T and medroxyprogesterone acetate (MPA, 300 mg daily)." | ( Baila, L; Beex, L; Estape, J; Gorlia, T; Jassem, J; Lardenoije, S; Mouridsen, H; Nooij, M; Paridaens, R; Piccart, M; Rose, C, 2006) |
| "The treatment of MCF-7 breast cancer cells with 5-hydroxy-3,6,7,8,3',4'-hexamethoxyflavone (5-OH-HxMF) and 3'-hydroxy-5,6,7,4'-tetramethoxyflavone (3'-OH-TtMF) induced a sustained increase in concentration of intracellular Ca(2+) ([Ca(2+)](i)) resulting from both depletion of the endoplasmic reticulum Ca(2+) stores and Ca(2+) influx from the extracellular space." | ( Colby, J; Dushenkov, S; Ho, CT; Li, S; Sergeev, IN, 2006) |
| "We show that the combined treatment of breast cancer cells with TNFalpha and Adriamycin significantly increases cell death compared with the treatment with either agent alone." | ( Wu, GS; Xu, J; Zhou, JY, 2006) |
| "PGE2 levels may predict celecoxib breast cancer prevention and treatment efficacy." | ( Flynn, JT; Hewett, JE; Qin, W; Sauter, ER; Schlatter, L, 2006) |
| "The response of breast cancer patients to endocrine therapy is guided by the expression of two steroid hormone receptors (HR): estrogen receptor alpha (ERalpha) and/or progesterone receptors (PR)." | ( Calderwood, SK; Ciocca, DR; Fanelli, MA; Gago, FE, 2006) |
| "We report a case of metastatic breast cancer with pericardial effusion that was successfully treated with weekly paclitaxel." | ( Einama, T; Mochizuki, H; Sato, K; Tsuda, H, 2006) |
| "161 patients with breast cancer received preoperative chemotherapy consisted of epidoxorubicin 75 mg/m(2) and docetaxel 75 mg/m(2) administered in combination with granulocyte-colony stimulating factor (G-CSF) on days 3-10 (ED + G)." | ( Altorjai, G; Bartsch, R; Gnant, M; Haid, A; Hussian, D; Jakesz, R; Lang, A; Pluschnig, U; Steger, GG; Wenzel, C; Zielinski, CC, 2007) |
| "Early diagnosis of recurrent breast cancer is crucial to selection of the most appropriate therapy." | ( Bar-Shalom, R; Ben-Haim, S; Guralnik, L; Israel, O; Radan, L, 2006) |
| "The relative risks of invasive breast cancer in current users compared with never users of hormone therapy varied significantly according to tumour histology overall (p<0." | ( Beral, V; Bull, D; Gathani, T; Green, J; Reeves, GK, 2006) |
| "Two hundred and four patients with breast cancer were treated with neoadjuvant chemotherapy between 1996 and April 2005." | ( Chaturvedi, A; Drew, PJ; Fox, JN; Garimella, V; Long, ED; Qutob, O; Turnbull, LW, 2007) |
| "Benefit from chemotherapy treatment in breast cancer patients is determined by the molecular make-up of the tumour." | ( Bontenbal, M; de Vries, EG; Hannemann, J; Hupperets, P; Kristel, P; Nooij, MA; Rodenhuis, S; Smit, WM; van de Vijver, MJ; van der Wall, E; van Hoesel, QG; van Tinteren, H; Voest, EE, 2006) |
| "MCF-7 human breast cancer cells are relatively resistant to cisplatin treatment compared to other breast cancer cell lines." | ( Issinger, OG; Yde, CW, 2006) |
| "Despite significant progress in breast cancer treatment, mammary tumours still represent the second most frequent cause of cancer-related death in women in the US, with > 211,000 new cases in 2005; however, an expanding range of options for early diagnosis and more reliable risk assessment offers new alternatives for disease control by cancer prevention." | ( Brown, PH; Uray, IP, 2006) |
| "Only about 50% of metastatic breast cancer patients benefit from cytotoxic chemotherapy." | ( Brünner, N; Christensen, IJ; Foekens, JA; Holten-Andersen, MN; Look, MP; Meijer-van Gelder, ME; Mouridsen, HT; Schrohl, AS, 2006) |
| "Forty-two patients with invasive breast carcinoma received 4 cycles of anthracycline based neoadjuvant chemotherapy." | ( Arslan, M; Demiray, M; Ercan, I; Evrensel, T; Gokgoz, S; Manavoglu, O; Saraydaroglu, O; Ulukaya, EE, 2006) |
| "Paired breast cancer tissue samples were immunostained with commercially available antibodies against c-erbB2, estrogen receptor, and progesterone receptor with 1 tissue sample of each pair being pretreated with 98% formic acid." | ( Boesl, A; Burkhardt, M; Dahl, E; Dankof, A; Dietel, M; Fritzsche, FR; Kristiansen, G; Pahl, S, 2006) |
| "All underwent NA chemotherapy for breast cancer and thereafter surgery and/or radical radiotherapy." | ( Coombes, RC; Fayaz, A; Heller, W; Lowdell, C; Mazhar, D; Palmieri, C; Phillips, R; Shousha, S; Sinnett, HD; Ward, R, 2007) |
| "Neoadjuvant chemotherapy in breast cancer corresponds to the use of a systemic treatment applied before loco-regional treatment (surgery and/or radiotherapy)." | ( Abrial, C; Achard, JL; Chollet, P; Cure, H; Durando, X; Ferrière, JP; Gimbergues, P; Leheurteur, M; Mouret-Reynier, MA; Van Praagh, I, 2006) |
| "Of 268 advanced breast cancer patients treated: 71 were by paclitaxel alone, 32 by docetaxel alone, 110 by paclitaxel combined with anthracylines or gemcitabine or platins and 55 by docetaxel-based combinations." | ( Feng, SQ; Jiang, ZF; Liu, F; Song, ST; Sun, JZ; Zhang, SH, 2006) |
| "Fourty-four breast cancer patients who had failed in first-line chemotherapy were included in this trial." | ( Gao, YJ; Guan, XQ; Li, EX; Liu, JW; Nan, KJ; Sheng, LJ; Song, SP; Sun, Y; Wang, DL; Wang, XW; Wang, ZP; Wang, ZX; Yu, XJ; Zhang, MH; Zhang, XR, 2006) |
| "Adjuvant therapy for breast cancer can be associated with decreased bone mineral density (BMD) that may lead to skeletal morbidity." | ( Galid, A; Gnant, MF; Grampp, S; Hausmaninger, H; Jakesz, R; Kaessmann, H; Luschin-Ebengreuth, G; Menzel, C; Mittlboeck, M; Mlineritsch, B; Piswanger-Soelkner, JC; Schmid, M, 2007) |
| "The treatment of node-positive breast cancer has improved dramatically in the last 3 decades." | ( Chu, QD; Li, BD; McDonald, JC, 2006) |
| "During an initial 96-week period, breast cancer patients with bone metastases were randomised in double-blind fashion to placebo or ibandronic acid 6mg administered by intravenous infusion over 1-2 hours every 3-4 weeks as part of a previously reported phase III trial (MF 4265 study)." | ( Bergström, B; Body, JJ; Diel, I; Pecherstorfer, M; Rivkin, S, 2006) |
| "Treatment of breast cancer cells with different concentrations of a cell membrane permeable zinc chelator, N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) and the membrane impermeable zinc chelator, diethylenetriaminepentacetic acid, (DTPA) resulted in a significant increase of cell death." | ( Booy, EP; Eshraghi, M; Ghavami, S; Hashemi, M; Los, M, 2007) |
| "However, the role of PKC-alpha in human breast cancer cell proliferation and anticancer chemotherapy remains unclear." | ( Krebs, CE; Liu, DS; Liu, SJ, 2007) |
| "In the ER-negative human breast cancer lines, MDA-MB-231 and MDA-MB-435, treatment with LBH for 24 hours restored ER mRNA and protein expression without a concomitant demethylation of the CpG island at the ER promoter." | ( Atadja, P; Davidson, NE; Zhou, Q, 2007) |
| "Here we show that treatment of MCF-7 breast cancer cells with EGF activated Akt and ERK, induced morphological changes, and increased cell motility." | ( Franklin, RA; Garcia, R; McCubrey, JA, 2006) |
| "The MDA-MB-231 breast cancer cells were treated with or without GRN163L for 2-42 days." | ( Goldblatt, EM; Gomez-Millan, J; Gryaznov, SM; Herbert, BS; Mendonca, MS, 2007) |
| "ErbB2 overexpressing breast tumors have a poor prognosis and a high risk to develop chemoresistance to therapeutic treatment." | ( Bader, Y; Bernhaus, A; Fritzer-Szekeres, M; Gueorguieva, M; Krupitza, G; Leisser, C; Mader, RM; Madlener, S; Maier, S; Richter, S; Saiko, P; Schott, H; Strasser, S; Szekeres, T; Wesierska-Gadek, J, 2006) |
| "We describe a 56-year-old woman with breast cancer who received adjuvant chemotherapy after a breast-preserving surgical procedure." | ( Brouwer, RE; Uges, JW; Vollaard, AM; Wilms, EB, 2006) |
| "We show that the HCC1937 breast cancer cells have diminished ability to incise 8-OH-Gua and they accumulate higher levels of 8-OH-dG in the nuclear genome after H2O2 treatment despite a 30 min repair period when compared to the nonmalignant mammary cells." | ( Dizdaroglu, M; Evans, MK; Jaruga, P; Lohani, A; Nyaga, SG; Trzeciak, AR, 2006) |
| "Human MCF-7 breast cancer cells are relatively resistant to conventional chemotherapy due to the lack of caspase-3 activity." | ( Ranftler, C; Schmitz, ML; Wesierska-Gadek, J, 2007) |
| "Recent advances in breast cancer treatment include the advent of aromatase inhibitors (AIs) in the adjuvant setting with better efficacy and toxicity profiles than tamoxifen." | ( Gandhi, S; Verma, S, 2007) |
| "We report a case of advanced breast cancer with meningeal metastasis and orbital metastasis (T4bN3cM1, Stage IV) achieving a significant improvement in QOL by multi-disciplinary therapy." | ( Amano, S; Enomoto, K; Matsuo, S; Sakurai, K, 2006) |
| "In 32 evaluated breast cancer patients with endocrine-dependent distant metastases treated with a new immunotherapy schedule (cyclic administration of beta-interferon and interleukin-2), cellular immunity, cytokines and CRP were related to the clinical course." | ( Carpi, A; Nicolini, A; Rossi, G, 2007) |
| "Thirty-eight breast cancer-treated postmenopausal women with vasomotor symptoms were included in the study." | ( Hammar, M; Nedstrand, E; Wijma, K; Wyon, Y, 2006) |
| "MDA-MB-435 breast cancer cells were treated with 2ME2 (2 micromol/L) or vehicle alone." | ( Bhati, R; Borchers, CH; Dial, MJ; Fan, C; Gökmen-Polar, Y; Ketelsen, D; Klauber-DeMore, N; Nakshatri, H; Patterson, C; Sledge, GW, 2007) |
| "Gene expression profiling of the human breast cancer cell line MCF-7 treated with prodigiosin was analyzed by cDNA array technology." | ( Kelly, JA; Lambert, JR; Pérez-Tomás, R; Soto-Cerrato, V; Viñals, F, 2007) |
| "Eighty-two patients with untreated breast cancer received DSMM." | ( Bae, YT; Kim, DS; Kim, IJ; Kim, SJ; Kim, YK; Lee, JS, 2006) |
| "Mice implanted with human breast cancer (MX-1) were treated with cyclophosphamide and evaluated using diffusion MRI and growth kinetics." | ( Chenevert, TL; Ellingworth, S; Helvie, M; Juliar, R; Khan, AP; Layman, R; Lee, KC; Meyer, CR; Moffat, BA; Rehemtulla, A; Ross, BD; Schott, AF, 2007) |
| "The human breast carcinoma cell line MCF-7, the adriamycin-resistant MCF-7 (Adr/MCF-7) cell line, as well as normal human mammary epithelial (NME) cells were treated with DNA oligonucleotides homologous to the telomere 3' overhang (T-oligos)." | ( Cowan, KH; Eller, MS; Gilchrest, BA; Kubera, J; Panova, I; Wee, LH; Yaar, M, 2007) |
| "A total of 46 breast cancer cases and 80 unaffected controls matched to treatment allocation, years from randomization (+/-2 years) and age at randomization (+/-5 years), underwent genotyping for MTHFR C677T polymorphism using real time PCR." | ( Amadori, M; Bonanni, B; Botteri, E; Costa, A; D'Aiuto, G; Decensi, A; Gucciardo, G; Iodice, S; Johansson, H; Macis, D; Maisonneuve, P; Penco, S; Rosselli Del Turco, M; Santillo, B, 2007) |
| "In hormone-responsive breast cancer cells treatment with antiestrogens leads to the conversion of TGF-beta1 into a biologically active form." | ( Buck, MB; Knabbe, C, 2006) |
| "The response of bone-dominant (BD) breast cancer to therapy is difficult to assess by conventional imaging." | ( Dunnwald, LK; Ellis, GK; Gralow, JR; Kurland, BF; Linden, HM; Livingston, RB; Mankoff, DA; Schubert, EK; Specht, JM; Tam, SL, 2007) |
| "Of these, 28 demonstrated metastatic BD breast cancer, were undergoing treatment, had at least 2 serial PET scans, and had abnormal FDG uptake on the first scan." | ( Dunnwald, LK; Ellis, GK; Gralow, JR; Kurland, BF; Linden, HM; Livingston, RB; Mankoff, DA; Schubert, EK; Specht, JM; Tam, SL, 2007) |
| "After treatment of breast cancer MDA-MB-453 cell line with concanavalin A ( ConA, 20 microg/ml) for 24 h, MT1-MMP protein was detected in cancer cells by Western analysis and immunocytochemistry." | ( He, JH; Lin, P; Rong, TH; Song, LB; Yang, MT; Yao, GY; Zeng, MS; Zhang, X, 2006) |
| "The Danish Breast Cancer Cooperative Group recommends adjuvant hormonal therapy consisting of tamoxifen for 2." | ( Kamby, C; Lindberg, H; Nielsen, DL; Tuxen, MK, 2007) |
| "Records of 758 ER+ breast cancer patients who received adjuvant tamoxifen (TAM) for 3-5 years were reviewed to evaluate the predictive value of PgR for TAM treatment in ER+/PgR+ and ER+/PgR- groups." | ( Di, GH; Liu, GY; Lu, JS; Shao, ZM; Shen, KW; Shen, ZZ; Wu, J; Yu, KD, 2007) |
| "Patients with stage IIB or III breast cancer, including inflammatory disease, and HER2 overexpression (determined by fluorescent in situ hybridization) were treated with six cycles of docetaxel 60 mg/m2 and vinorelbine 45 mg/m2 administered every 14 days with granulocyte colony-stimulating factor and quinolone prophylaxis." | ( Brufsky, AM; Erban, JK; Jahanzeb, M; Lewis, D; Limentani, SA, 2007) |
| "Twelve advanced-stage primary breast cancer patients with neoadjuvant epirubicin+paclitaxel chemotherapy were studied." | ( Fuhr, U; Hempel, G; Hunz, M; Jaehde, U; Jetter, A; Kurbacher, C; Pantke, E; Tuscher, M; Untch, M; Warm, M, 2007) |
| "Treatment of human breast cancer cells MDA-MB-231 with SKI-606 caused a marked inhibition of cell proliferation, invasion, and migration by inhibiting mitogen-activated protein kinase and Akt phosphorylation." | ( Ali, S; Boschelli, F; Chen, G; Jallal, H; Rabbani, SA; Valentino, ML, 2007) |
| "The risk of ER-positive breast cancer was not statistically significantly lower in the tamoxifen arm than in the placebo arm during the 8-year treatment period (30 cancers in the tamoxifen arm and 39 in the placebo arm; HR = 0." | ( Ashley, S; Dowsett, M; Powles, TJ; Smith, IE; Tidy, A, 2007) |
| "The majority of invasive breast cancer patients present with hormone receptor-positive disease, and modulation of estrogen receptor (ER) activation is an essential component of systemic adjuvant therapy for these women." | ( Cianfrocca, M; Wolff, AC, 2007) |
| "We report a breast cancer patient who developed acute myeloid leukemia (AML) one year following her adjuvant chemotherapy consisting of cyclophosphamide, adriamycin and 5-fluorouracil." | ( Akçali, Z; Boğa, S; DemIrhan, B; Karakuş, S; Sahin, FI; Yilmaz, Z, 2006) |
| "A human breast cancer cell line, MDA-MB-231, was implanted in 30 female homozygotous athymic rats that were alternately assigned to either a drug treatment group that received celecoxib on a daily basis for 7 days or a control group that received saline." | ( Brasch, RC; Floyd, E; Fournier, LS; Fu, Y; Lucidi, V; Miller, T; Novikov, V; Shames, DM, 2007) |
| "[18F]FLT-PET can detect changes in breast cancer proliferation at 1 week after FEC chemotherapy." | ( Aboagye, EO; Al-Nahhas, A; Coombes, RC; Kenny, L; Shousha, S; Vigushin, DM, 2007) |
| "Invasive breast cancer cases were identified through biennial self-administered questionnaires completed from 1990 to 2002." | ( Berrino, F; Clavel-Chapelon, F; Fournier, A, 2008) |
| "The MCF-7 human breast cancer cell line currently in use in our laboratory did not respond to doxorubicin cell killing during a 24-h treatment period." | ( Dong, Y; Ip, C; Li, S; Wang, R; Zhang, H; Zhou, Y, 2007) |
| "In adjuvant breast cancer clinical trials with longer (> or =4 years) follow-up, hormonal therapy (tamoxifen or aromatase inhibitors) was prematurely discontinued by about 23-28% of the study participants." | ( Chlebowski, RT; Geller, ML, 2006) |
| "Adherence to prescribed breast cancer hormone therapy has not received concerted attention." | ( Chlebowski, RT; Geller, ML, 2006) |
| "In women with favorable early breast cancer treated by lumpectomy plus tamoxifen or anastrazole, it remains unclear whether whole breast radiotherapy is beneficial." | ( Draxler, W; Gnant, M; Haider, K; Hammer, J; Handl-Zeller, L; Hofbauer, F; Jakesz, R; Kapp, K; Kwasny, W; Luschin-Ebengreuth, G; Pakisch, B; Pöstlberger, S; Pötter, R; Reiner, G; Rottenfusser, A; Schmid, M; Sedlmayer, F; Stierer, M; Taucher, S; Tausch, C, 2007) |
| "Treatment of breast cancer cells with siRNAs targeting Plk1 improved the sensitivity toward paclitaxel and Herceptin in a synergistic manner." | ( Kaufmann, M; Kurunci-Csacsko, E; Spänkuch, B; Strebhardt, K, 2007) |
| "The enhanced sensitivity of OCM-treated breast cancer cells to imatinib would justify investigation on the efficacy of imatinib in bone breast cancer metastasis." | ( Arizzi, M; Basciani, S; Brama, M; Cherubini, S; Gnessi, L; Mariani, S; Migliaccio, S; Rosano, G; Spera, G, 2007) |
| "Two female breast cancer patients and one male colon cancer patient were treated with oxaliplatin monotherapy at 130 mg/m(2) given as a 3-h intravenous infusion." | ( Baur, M; Dittrich, C; Drescher, A; Gneist, M; Jaehde, U, 2008) |
| "Additionally, genetic profiling of breast cancer cells, grown and treated with low-dose indomethacin in cell culture using an RPMI-based medium, revealed the upregulation of several genes implicating cyclooxygenase-independent targets of indomethacin." | ( Ackerstaff, E; Artemov, D; Bhujwalla, ZM; Gimi, B, 2007) |
| "The clinical outcome for patients with breast cancer is influenced by the metastatic competence of the cancer and its sensitivity to endocrine therapy and chemotherapy." | ( Anderson, K; Andre, F; Hatzis, C; Hortobagyi, GN; Mazouni, C; Mejia, J; Pusztai, L; Sotiriou, C; Symmans, WF; Wang, B, 2007) |
| "Survival of patients with early-stage breast cancer is improved following treatment with single-modality tamoxifen, ovarian ablation or suppression, or chemotherapy." | ( , 2007) |
| "The Adjuvant Breast Cancer Chemotherapy Trial was a randomized phase III trial in which patients with early-stage breast cancer who were receiving prolonged (5 years) tamoxifen treatment, with or without ovarian ablation or suppression, were randomly assigned to standard chemotherapy versus none." | ( , 2007) |
| "Transcript profiles from the UCSF breast cancer cases revealed three NFkappaB and AP-1 upregulated genes--cyclin D1, uPA and VEGF--capable of dichotomizing node-negative ER-positive cases into early and late relapsing subsets despite adjuvant tamoxfien therapy and most prognostic for younger age cases." | ( Benz, CC; Chew, K; Dairkee, SH; Eppenberger, U; Eppenberger-Castori, S; Gray, JW; Moore, DH; Yau, C; Zhou, Y, 2007) |
| "An increase in the risk of breast cancer recurrence for women having had iCR treatment, compared to women not treated with iCR is unlikely." | ( Becher, H; Henneicke-von Zepelin, HH; Kostev, K; Meden, H; Schröder-Bernhardi, D; Stammwitz, U, 2007) |
| "Metastatic breast cancer patients who experienced disease progression after at least one (taxane or anthracycline based) chemotherapy regimen and an expected survival of at least 3 months and ECOG performance status 0-2 were eligible." | ( Creaven, P; Levine, E; O'connor, T; Rustum, Y, 2008) |
| "The International Breast Cancer Study Group (IBCSG) conducted two complementary randomized trials to assess whether a treatment-free gap during adjuvant chemotherapy influenced outcome." | ( Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Gelber, RD; Gelber, S; Goldhirsch, A; Pagani, O; Price, KN; Simoncini, E, 2007) |
| "Three ER,PR-negative breast cancer cell lines (HCC 1137, 1954, and 38), were treated with DHEAS." | ( Calhoun, K; Hardin, C; Jackson, T; Muller, P; Pommier, R; Pommier, S, 2007) |
| "A total of 31 metastatic breast cancer patients received DC regimen during each 3-week chemotherapy cycle." | ( Jiang, WQ; Shi, YX; Wang, XX; Yuan, ZY; Zhang, DS; Zhou, ZM, 2007) |
| "2005, 62 patients with stage II-III breast cancer were treated with 2 cycles of either GC regimen or FEC regimen before operation." | ( Cheng, B; Liu, K; Qiu, DB; Wang, GB, 2007) |
| "The endocrine therapy for breast cancer has made progress with the development of new endocrine drugs." | ( Lian, ZQ; Yang, MT, 2007) |
| "Treatment of breast cancer cells caused an increased translocation of Rac1, a positive regulatory protein of NOX, to the membrane fraction." | ( Alexandre, J; Hu, Y; Huang, P; Lu, W; Pelicano, H, 2007) |
| "Of 46 patients with metastatic breast cancer who were treated with trastuzumab, only one of nine patients (11." | ( Anido, J; Arribas, J; Baselga, J; Cortes, J; Di Cosimo, S; Guzman, M; Matias-Guiu, X; Ocaña, A; Ramon y Cajal, S; Rojo, F; Scaltriti, M, 2007) |
| "Data was obtained from the Bedford Breast Cancer Registry for all non-metastatic patients presenting between January 1990 and December 2004 who were initially treated non-operatively." | ( Atkin, GK; Callam, MJ; Scott, MA; Wiggins, JE, 2007) |
| "Among breast cancer patients, tamoxifen use is associated with reduced risk of disease relapse and death, but it is often difficult for women to sustain therapy during the 5 years required to obtain maximum benefit." | ( Adams, JL; Epstein, AM; Kahn, KL; Malin, JL; Schneider, EC, 2007) |
| "Treatment of T4-2 breast cancer cells in three-dimensional culture with cAMP analogs or a phosphatidylinositol 3-kinase inhibitor not only reverted their phenotype from nonpolar to polar acinar-like structures but also enhanced chromatin sensitivity to AluI." | ( Bissell, MJ; Folberg, R; Maniotis, AJ; Sandal, T; Spencer, VA; Valyi-Nagy, K, 2007) |
| "Women with breast cancer may experience treatment-induced menopausal symptoms or natural menopause." | ( Bordeleau, L; Goodwin, P; Loprinzi, C; Pritchard, K, 2007) |
| "The choice of endocrine therapy for breast cancer depends on the menopausal status and stage of disease." | ( Hanada, H; Kobayashi, N; Utsumi, T, 2007) |
| "As there is a risk for relapse in early breast cancer, especially at 1-3 years post surgery, the need for adjuvant therapy is clear." | ( Monnier, AM, 2007) |
| "ELP treatment of MDA-MB-453 breast cancer cells resulted in inhibition of the PI3K pathway whereas SF-ELP treatment inhibited both the PI3K and MAPK pathways, which contributed to the enhanced growth inhibitory effects of Her2/neu over-expressing breast cancer cells." | ( Cheema, SK; Gobin, AS; Lopez-Berestein, G; Mathur, AB; Newman, RA; Rhea, R, 2007) |
| "In a series of 109 patients with large breast tumors, a 4% or 10% charcoal suspension was injected at the time of the initial biopsy before preoperative chemotherapy." | ( Barreau-Pouhaer, L; Bonhomme-Faivre, L; Mathieu, MC; Rouzier, R; Seiller, M; Travagli, JP, 2007) |
| "Twenty-six patients with breast cancer (mean, 20 months postchemotherapy) and 10 healthy age-matched women were studied." | ( Courneya, KS; Haykowsky, M; Jones, LW; Joy, AA; Mackey, JR; Peddle, CJ; Pituskin, EN; Slamon, DJ; Tkachuk, LM, 2007) |
| "mRNA profiling in estradiol-treated breast cancer cell lines and tissues revealed that these genes are highly ERalpha responsive both in vitro and in vivo." | ( Bulun, SE; Huang, CC; Lin, Z; Reierstad, S, 2007) |
| "In patients with breast cancer who developed a subsequent endometrial cancer, tamoxifen-treated patients had higher proportions of aggressive endometrial cancer subtypes, but almost all cases were amenable to surgery, thus resulting in similar endometrial cancer control and survival when compared with nontamoxifen treated patients." | ( Berthelet, E; Kader, HA; McMurtrie, E; Olivotto, IA; Saadat, M; Speers, CH; Truong, PT, 2007) |
| "Treatment of human breast cancer cells with affinity purified, TAT-CARP-1 1-198, 197-454, and 896-1150 peptides caused inhibition of human breast cancer cell proliferation and elevated apoptosis." | ( Aboukameel, A; Adsay, V; Du, J; Hatfield, JS; Levi, E; Majumdar, AP; Majumder, P; Mohammad, R; Rishi, AK; Wali, A; Xu, H; Yu, Y; Zhang, L, 2007) |
| "Forty-year-old woman with breast cancer seeking fertility preservation before chemotherapy." | ( Chian, RC; Demirtas, E; Lostritto, K; Oktay, K; Son, WY; Tan, SL, 2008) |
| "Patients with stage II/III breast cancer were treated with docetaxel (65 mg/m(2)) followed by gemcitabine (2500 mg/m(2)) every 2 weeks for 6 cycles." | ( Calvo, I; Carrasco, E; Casado, V; Casillas, M; Díaz, M; Dómine, M; Estévez, LG; Jaén, A; León, A; Lobo, F; Miró, C; Rubio, G; San Antonio, B; Sánchez-Rovira, P, 2007) |
| "MTX cytotoxicity is decreased in MCF-7 breast cancer cells when the selective estrogen receptor modulator (SERM) Tam (10 microM) is administered 24 hours prior to 5-FU (10 microM) followed two hours later by MTX (early Tam) resulting in a growth rate of 57." | ( Bowen, D; Davis, JH; Desoto, JA; Fryar, EB; Southerland, WM, 2007) |
| "T47D human breast cancer cells were treated with RSVL and cell proliferation was measured by cell counting." | ( Alkhalaf, M, 2007) |
| "It is also a risk factor for breast cancer, and antiestrogen therapies have been shown to be effective in the treatment and prevention of breast cancers." | ( Cheng, SY; Gong, H; Guo, P; Jarzynka, MJ; Song, WC; Uppal, H; Xie, W; Zhai, Y; Zhou, J, 2007) |
| "Paclitaxel is an active agent used in breast cancer chemotherapy." | ( Davidson, NE; Fan, W; Huang, Y; Park, BH; Sui, M, 2007) |
| "Moreover, in MCF-7 human breast cancer cells, various p53-inducing agents (such as UV irradiation) or treatment with RITA (which inhibits the interaction of p53 with Mdm2) stabilized ERalpha and abolished its 17beta-estradiol-dependent turnover." | ( Bonnet, S; Boulle, N; Cavaillès, V; Chauvet, J; Daujat, S; Duong, V; Neel, H, 2007) |
| "The optimal treatment of metastatic breast cancer patients previously treated with anthracycline and taxane is unknown." | ( Clemons, M; Dranitsaris, G; Joy, A; Mackey, J; Trudeau, M; Verma, S; Wong, NS, 2007) |
| "Ischemic colitis in breast cancer patients being treated with taxane-based chemotherapy, which may lead to serious morbidities and even death, has recently been defined as a clinical entity." | ( David, CL; DuBrow, RA; Ibrahim, NK; Kaur, H; Loyer, EM; Sawaf, H, 2008) |
| "Primary therapies of breast carcinoma like surgery, chemotherapy, and radiotherapy for bony metastases can cause substantial pain relief." | ( Kumar, S; Saxena, AK, 2007) |
| "High-risk primary breast cancer patients treated with high-dose chemotherapy (HDC) and stem cell support (SCS) have shown prolonged disease-free survival (DFS) in many studies; however, only one trial has demonstrated an overall survival benefit (OS)." | ( Cohen, DJ; Donovan, D; Hesdorffer, CS; Lo, KS; Nichols, G; Savage, D; Tiersten, A; Troxel, A; Vahdat, LT; Zipin, D, 2007) |
| "Digestive cancer and breast cancer patients, who were administered cytotoxic agents, were the objects of this study." | ( Horiba, K; Ishikawa, N; Kanazawa, Y; Koizumi, M; Kudoh, H; Ohkawa, K; Seya, T; Shirakawa, T; Tajiri, T; Tanaka, N; Yamada, T; Yokoi, K; Yoshioka, M, 2007) |
| "66 women with stage I-III breast cancer beginning adjuvant chemotherapy." | ( Gallucci, B; Schwartz, AL; Winters-Stone, K, 2007) |
| "To evaluate, in breast cancer patients treated by neoadjuvant chemotherapy, the predictive value of reduction in FDG uptake with regard to complete pathological response (pCR)." | ( Arnould, L; Berriolo-Riedinger, A; Boichot, C; Brunotte, F; Cochet, A; Coudert, B; Fumoleau, P; Riedinger, JM; Toubeau, M; Touzery, C, 2007) |
| "Probabilities and costs of breast cancer recurrence and treatment-related adverse events and health-state utilities were based on published results of BIG 1-98 and other published studies." | ( Barghout, V; Delea, TE; Karnon, J; Papo, NL; Sofrygin, O; Thomas, SK, 2007) |
| "We monitored patients with breast cancer proven by biopsy who were undergoing neoadjuvant chemotherapy with ultrasound." | ( Fabel, K; Friedrich, K; Laniado, M; Petzold, A; Viehweg, P, 2007) |
| "Women with metastatic breast cancer previously untreated with taxanes have a meaningful durable response to single-agent ixabepilone therapy." | ( Berman, AW; Chow, CK; Denduluri, N; Lee, JJ; Low, JA; Steinberg, SM; Swain, SM; Vatas, U; Walshe, JM; Yang, SX, 2007) |
| "A major obstacle in the treatment of breast cancer is the lack of adequate methods for predicting patient response to a particular chemotherapy regime." | ( Györffy, B, 2007) |
| "In first-line metastatic breast cancer, both paclitaxel (P)-doxorubicin (A) and docetaxel (D)-doxorubicin (A) combinations have shown superiority over treatments without taxane." | ( Agostini, C; Bachelot, T; Cassier, PA; Chabaud, S; Cure, H; Guastalla, JP; Jacquin, JP; Martin, C; Orfeuvre, H; Peaud, PY; Pérol, D; Salles, B; Tigaud, JD; Trillet-Lenoir, V, 2008) |
| "We treated MDA-MB-453 human breast cancer cells with actein at 2 doses, 20 or 40 microg/mL, for 6 or 24 hr." | ( Einbond, LS; Friedman, R; Kronenberg, F; Ramirez, A; Su, T; Wang, X; Weinstein, IB; Wu, HA, 2007) |
| "In total, 79 patients (18 with breast cancer and 61 with prostate cancer) were treated (31 patients with 188Re-HEDP, 15 patients each with 186Re-HEDP and 153Sm-EDTMP, and 18 patients with 89Sr)." | ( Kotzerke, J; Liepe, K, 2007) |
| "The future for breast cancer therapy is promising, but it is important to be prepared for disappointment, as early success in animal models cannot guarantee a successful human therapy." | ( Hussain, SA; Palmer, DH; Rea, DW; Spooner, D, 2007) |
| "Our study provides new insights on breast cancer progression and endocrine therapy resistance, offering future strategies for delaying or reversing this process." | ( Cohen, I; Elkin, M; Maly, B; Meirovitz, A; Peretz, T; Pikarsky, E; Simon, I; Vlodavsky, I; Zcharia, E, 2007) |
| "Premenopausal breast cancer patients with stage II tumours (n = 564) were included and allocated to 2 years of adjuvant tamoxifen treatment versus no adjuvant treatment." | ( Bendahl, PO; Fernö, M; Landberg, G; Nordenskjöld, B; Rydén, L; Stål, O, 2008) |
| "HER2+ and ER+ breast cancer constituted a subgroup of tumours with poor prognosis in premenopausal breast cancer, whereas no treatment interaction was found between HER2 status and tamoxifen in ER+ tumours." | ( Bendahl, PO; Fernö, M; Landberg, G; Nordenskjöld, B; Rydén, L; Stål, O, 2008) |
| "Changes in breast cancer cell biology following hormonal treatment have been claimed as promising predictor markers of clinical benefit even outperforming clinical response." | ( Aguilar, H; Capellà, G; Dowsett, M; Germà-Lluch, JR; Martin, LA; Solé, X; Urruticoechea, A, 2008) |
| "Treatment of human breast cancer cells, MCF-7, with 40 microg/ml TSC resulted in a 2." | ( Iann, MC; Johnson, M; Martin, MB; Reiter, R; Richards, JK; Shah, MS; Singh, B; Stoica, A; Wang, A, 2007) |
| "Measurement of Ca2+ signaling in breast cancer cells showed that 4OHT treatment altered Ca2+ homeostasis and was cytotoxic for both an ERalpha+ and an ERalpha- cell line, MCF-7 and MDA-MB-231, respectively." | ( Bollig, A; Kuo, TH; Liao, JD; Thakur, A; Wu, J; Xu, L, 2007) |
| "Patients with HER2-positive breast cancer (defined as either immunohistochemical 3+ or fluorescence in situ hybridization-positive) that had received 24 weeks of neoadjuvant trastuzumab concurrently with taxane and anthracycline-based chemotherapy between 2004 and 2006 were included in the analysis." | ( Broglio, K; Buzdar, AU; Dawood, S; Gonzalez-Angulo, AM; Hortobagyi, GN; Islam, R; Kau, SW; Peintinger, F; Symmans, WF, 2007) |
| "Stage II and III HER2-positive breast cancer patients achieved a high rate of PCR with trastuzumab given concurrently with paclitaxel and FEC(75) chemotherapy." | ( Broglio, K; Buzdar, AU; Dawood, S; Gonzalez-Angulo, AM; Hortobagyi, GN; Islam, R; Kau, SW; Peintinger, F; Symmans, WF, 2007) |
| "Fifty patients with primary breast cancer were treated with 3 months of chemotherapy and 53 with 3 months of neoadjuvant letrozole." | ( Cameron, DA; Dixon, MJ; Green, RV; Julian, HS; Thomas, JS, 2007) |
| "In postmenopausal women with HR+ early breast cancer, initial adjuvant treatment with letrozole is cost-effective from the Canadian healthcare system perspective." | ( Delea, TE; El-Ouagari, K; Karnon, J; Sofrygin, O, 2008) |
| "In this study, human MCF-7 breast cancer cells, which express functional estrogen and progesterone receptors, were used to compare the efficacy of combined antiestrogen plus antiprogestin therapy to antiestrogen monotherapy." | ( Barrett, JT; Gaddy, VT; Ganapathy, V; Hou, M; Johnson, M; Kallab, A; Lewis, J; Samaddar, JS; Schoenlein, PV; Thangaraju, M, 2007) |
| "In patients with breast cancer and liver metastases who were treated with TACE, although changes in tumor size were small, significant early changes in the treated lesions occurred on contrast medium-enhanced and functional MR imaging." | ( Buijs, M; Georgiades, CS; Geschwind, JF; Hong, K; Kamel, IR; Vossen, JA, 2007) |
| "After taxane chemotherapy, women with breast cancer show significantly increased postural instability compared with matched controls." | ( Byl, NN; Hamel, K; Miaskowski, C; Rugo, HS; Topp, KS; Wampler, MA, 2007) |
| "Forty-five patients with primary breast cancer, proven by core needle biopsy, underwent 3 cycles of neoadjuvant chemotherapy." | ( Chen, JH; Li, D; Ling, R; Wang, J; Wang, L; Yao, Q, 2007) |
| "We identified 79 breast cancer patients who used the LNG IUS, and we selected a control group of 120 patients with no history of LNG IUS use and who were closely matched for age at diagnosis, tumor stage, tumor grade, and treatment modalities." | ( Buytaert, G; Makar, AP; Tjalma, WA; Trinh, XB; van Dam, PA; Weyler, J, 2008) |
| "The parental breast cancer cell line, MCF-7 and the derived adriamycin resistant cell line MCF-7(adm) were treated with concentration gradients of arsenic trioxide (ATO) and N-acetyl cysteine (NAC) for GSH modulation, followed by exposure to adriamycin." | ( Li, B; Lin, B; Liu, D; Liu, X; Wang, L; Ye, N; Zhong, R, 2007) |
| "The data of 114 breast cancer patients treated with adjuvant dose dense chemotherapy was retrospectively analyzed." | ( Guan, JH; Huan, HY; Mao, F; Sun, Q; Zhou, YD, 2007) |
| "Loss of ER-alpha in breast cancer is correlated with poor prognosis, increased recurrence after treatment, and an elevated incidence of metastasis." | ( Dhasarathy, A; Kajita, M; Wade, PA, 2007) |
| "In untreated metastatic breast cancer patients, the weekly administration of epirubicin and paclitaxel with granulocyte colony-stimulating factor support seems to be extremely tolerable and active, and deserves further investigation into a phase III trial." | ( Bria, E; Carpino, A; Cognetti, F; Cuppone, F; Fornier, M; Nisticò, C; Pace, A; Sperduti, I; Terzoli, E, 2007) |
| "Sixty two primary breast cancer patients were treated with docetaxel or paclitaxel as primary systemic treatment (PST)." | ( Akazawa, K; Arai, T; Kim, SJ; Maruyama, N; Miyoshi, Y; Noguchi, S; Taguchi, T; Tamaki, Y, 2008) |
| "Cotreatment with TAM and TRAIL in breast cancer cells decreased the levels of antiapoptotic proteins including FLIPs and Bcl-2, and enhanced the levels of proapoptotic proteins such as FADD, caspase 8, tBid, Bax and caspase 9." | ( Adriaenssens, E; Chopin, V; Hondermarck, H; Lagadec, C; Le Bourhis, X; Romon, R; Toillon, RA; Van Coppenolle, F, 2008) |
| "However, overexpression of Bcl-2 in breast cancer has been associated with better prognosis and response to hormonal therapy." | ( Archer, L; Bales, W; Osunkoya, A; Thor, AD; Tophkhane, C; Yang, S; Yang, X, 2007) |
| "New approaches to breast cancer treatment have enhanced clinical outcomes and patient care." | ( Boughey, JC; Brandt, KR; Degnim, AC; Dy, GK; Goetz, MP; Ingle, JN; Perez, EA; Pruthi, S; Reynolds, CA; Schomberg, PJ, 2007) |
| "We used stable breast cancer cell lines overexpressing Src (MCF-7-Src and BT474-Src) or overexpressing EGFR (BT474-EGFR), and control breast cancer cell lines for the treatment with different doses of TAE226 drug." | ( Cance, WG; Golubovskaya, VM; Virnig, C, 2008) |
| "Among breast cancer patients <35 years old at diagnosis, the use of PMRT after doxorubicin-based neoadjuvant chemotherapy and mastectomy led to a statistically greater rate of LRC and overall survival compared with patients without PMRT." | ( Buchholz, TA; Garg, AK; Hahn, K; Huang, E; Meric-Bernstam, F; Oh, JL; Oswald, MJ; Perkins, GH; Strom, EA; Tereffe, W; Woodward, WA; Yu, TK, 2007) |
| "Although an effective treatment for breast cancer, aromatase inhibitors indiscriminately abolish estrogen synthesis in all tissues, causing major side effects." | ( Brooks, C; Bulun, SE; Chen, D; Innes, J; Li, N; Lin, Z; Lu, M; Reierstad, S, 2007) |
| "Estrogen treatment of MCF-7 human breast cancer cells allows the reinitiation of synchronous cell cycle progression in antiestrogen-arrested cells." | ( Boonyaratanakornkit, V; Edwards, DP; Lehrbach, GM; McGowan, EM; Musgrove, EA; Russell, AJ; Saunders, DN; Sergio, CM; Sutherland, RL, 2007) |
| "For advanced breast cancer, there is no standard criteria regarding the time when to stop chemotherapy after obtaining a CR." | ( Imai, S; Ito, T; Kawamoto, K; Nagahisa, Y; Niwano, M; Ogasahara, K; Okabe, M; Park, T; Sano, K; Tsuruta, A; Yamaguchi, K; Yoshida, Y, 2007) |
| "In advanced breast cancers, TP53 mutation is highly predictive of complete response to high-dose epirubicin/cyclophosphamide chemotherapy." | ( Bertheau, P; Chapelin, D; de Roquancourt, A; de Thé, H; Espié, M; Feugeas, JP; Janin, A; Legrès, L; Misset, JL; Plassa, LF; Soliman, H; Turpin, E; Varna, M, 2007) |
| "Eighteen patients with metastatic breast cancer were treated with daily oral erlotinib at 150 mg." | ( Nguyen, D; Parr, AL; Steinberg, SM; Tan, AR; Yang, SX, 2008) |
| "The rarity of breast cancer in pregnancy and conflict between the optimal maternal therapy and fetal risks make its management challenging." | ( Biswas, N; Coleman, M; Eedarapalli, P, 2007) |
| "Women with early breast cancer are exposed to an ongoing risk of relapse, even after successful surgical resection of the primary tumor and, where given, radiotherapy." | ( Cufer, T, 2007) |
| "Patients aged 70 or older with early breast cancer were treated with tumour excision or simple mastectomy and adjuvant tamoxifen." | ( Apffelstaedt, JP; Odendaal, Jde V; Wasserman, LJ, 2007) |
| "Endocrine treatment for breast cancer was introduced more than a century ago." | ( Aebi, S; Castiglione-Gertsch, M; Rabaglio, M, 2007) |
| "Most breast cancer patients with bone metastases will receive bisphosphonate treatment." | ( Coleman, RE; Cook, RJ; Lipton, A; Major, P; Smith, MR, 2007) |
| "Among ERalpha-positive breast tumors from postmenopausal women treated with TAM, high KiSS1 combined with high GPR54 mRNA tumoral levels was unexpectedly associated with shorter relapse-free survival (RFS) relative to tumors expressing low tumoral mRNA levels of both genes." | ( Aumas, C; Bieche, I; Bouquet, C; de Roux, N; Esselin, S; Kuttenn, F; Lazennec, G; Lidereau, R; Marot, D; Perricaudet, M; Vacher, S, 2007) |
| "Metastatic breast cancer is an incurable disease, often characterized by poor response to standard chemotherapy, which is mainly based on anthracyclines and taxanes." | ( Gabano, E; Gariboldi, MB; Molteni, R; Monti, E; Osella, D; Ravizza, R, 2007) |
| "Treatments for metastatic breast cancer (MBC) are primarily palliative with variable efficacy and outcomes may be influenced by individual differences in drug metabolism." | ( Bewick, MA; Conlon, MS; Lafrenie, RM, 2008) |
| "Hormonal therapy for breast carcinoma lowers estrogen levels or blocks the growth-promoting effects of estrogens." | ( Schagen, SB; Schilder, CM, 2007) |
| "We report a case of elderly metastatic breast cancer with a complete response to the treatment with XC (X: capecitabine and C: cyclophosphamide)." | ( Furukawa, K; Iida, S; Iwasaki, R; Naito, Z; Noguchi, T; Sugisaki, Y; Tajiri, T; Tsuchiya, S; Yanagihara, K; Yokoyama, T, 2007) |
| "Hormonal breast cancer treatment increases menopausal symptoms in women." | ( Asmar, L; Blum, JL; Bordelon, JH; Brooks, R; Cantrell, J; Chittoor, S; Davis, JC; Hartung, NL; Holmes, FA; Ilegbodu, D; Jones, SE; Ketchel, SJ; Kochis, J; Negron, AG; O'Shaughnessy, J; Pippen, J; Richards, DA; Rivera, R; Vukelja, S; Whittaker, TL, 2007) |
| "After treatment of various breast cancer cell lines with the demethylating agent 5-aza-2'-deoxycytidine, reduction of mir-9-1 gene methylation and concomitant reactivation of expression could be observed." | ( Christgen, M; Hasemeier, B; Kreipe, H; Länger, F; Lehmann, U; Müller, M; Römermann, D, 2008) |
| "The ADM-resistant human breast cancer MCF-7/ADM cell lines and ADM-sensitive MCF-7/S cell lines were treated by thiol-depleting agent DEM for 3 h respectively." | ( Han, XQ; Jiang, YD; Li, ZH; Peng, KJ; Wang, LZ; Wang, SR; Zhang, JG, 2007) |
| "Forty-two breast carcinomas in 41 women were treated with HT and concurrent RT to the breast +/- lymph node bearing areas." | ( Antoni, G; Bollet, MA; Campana, F; Cottu, P; Dendale, R; Fourquet, A; Kirova, YM; Laki, F; Pierga, JY; Salmon, R; Sigal-Zafrani, B, 2007) |
| "Sixty-seven patients with early-stage breast cancer were treated in a Phase I/II clinical trial using a (103)Pd permanent breast seed implant as adjuvant radiotherapy after breast-conserving surgery." | ( Keller, BM; O'Brien, P; Pignol, JP; Rakovitch, E; Sankreacha, R, 2008) |
| "Complex examination of breast cancer patients (102, aged 35-63) receiving systemic polychemotherapy was carried out to make a case for a course of immunotherapy." | ( Chernetsova, LF; Matveeva, ON; Orlova, RV, 2007) |
| "The standard treatment of the axilla in breast cancer used to be an axillary lymph node dissection." | ( Elferink, MA; Hoekstra, CJ; Siesling, S; Spruit, PH; Vonk, EJ, 2007) |
| "Prognostic factors in locally advanced breast cancer treated with neoadjuvant chemotherapy differ from those of early breast cancer." | ( Bang, YJ; Chie, EK; Ha, SW; Han, W; Heo, DS; Im, SA; Keam, B; Kim, DW; Kim, HJ; Kim, JH; Kim, TY; Lee, SH; Moon, WK; Noh, DY; Oh, DY; Park, IA, 2007) |
| "A total of 145 stage II and III breast cancer patients received neoadjuvant docetaxel/doxorubicin chemotherapy were enrolled in this study." | ( Bang, YJ; Chie, EK; Ha, SW; Han, W; Heo, DS; Im, SA; Keam, B; Kim, DW; Kim, HJ; Kim, JH; Kim, TY; Lee, SH; Moon, WK; Noh, DY; Oh, DY; Park, IA, 2007) |
| "Treatment of MCF-7 breast cancer cells with these fractions inhibited growth and induced apoptosis associated with an increase in the basal level of intracellular Ca(2+)." | ( Colby, J; Dushenkov, S; Ho, CT; Li, S; Sergeev, IN, 2007) |
| "Many patients with a history of breast cancer (BC) will suffer from vasomotor symptoms, which can be induced or exacerbated by treatment with tamoxifen or aromatase inhibitors." | ( Beckmann, MW; Bundred, NJ; Egberts, J; Foidart, JM; Kenemans, P; Kubista, E; Planellas, J; Sismondi, P; van Os, S; Vassilopoulou-Sellin, R; von Schoultz, B; Yip, CH, 2007) |
| "To establish tailor-made therapy for breast cancer, we investigated the possibility of predicting chemotherapy sensitive cases based on pre-therapeutic histological features." | ( Akiyama, F; Horii, R; Ito, Y; Iwase, T; Matsuura, M; Miki, Y, 2007) |
| "A total of 87 breast cancer patients underwent neoadjuvant chemotherapy with a paclitaxel (80 mg/m(2)/q1w, 12 courses)or an epirubicin regimen (90 mg/m(2)/q3wks, 4 courses)." | ( Akiyama, F; Horii, R; Ito, Y; Iwase, T; Matsuura, M; Miki, Y, 2007) |
| "Subjects were 486 patients with primary breast cancer who underwent surgery and postoperative tamoxifen monotherapy in 1982-1993." | ( Akiyama, F; Horii, R; Ito, Y; Iwase, T, 2007) |
| "BRCA1 alters the response of breast cancer cells to antiestrogen therapy by directly modulating ER alpha expression." | ( Chung, WY; Couch, FJ; Daly, PA; Dervan, PA; Farragher, SM; Gorski, JJ; Harkin, DP; Hosey, AM; James, CR; Johnston, PG; Kay, E; McCann, A; Mullan, PB; Mulligan, JM; Murray, MM; Quinn, JE; Scott, AN; Stewart, GE, 2007) |
| "Treatment efficacy of breast cancer can be impaired by cell resistance." | ( Bertino, S; Boccuzzi, G; Bosco, O; Catalano, MG; Costantino, L; Fortunati, N; Vercellinatto, I, 2008) |
| "In MCF-7 breast cancer cells, metformin treatment led to a 30% decrease in global protein synthesis." | ( Dowling, RJ; Fantus, IG; Pollak, M; Sonenberg, N; Zakikhani, M, 2007) |
| "In a series of 283 breast cancers, in which ERalpha-positive tumours were treated with tamoxifen, the nuclear expression of ERbeta correlated significantly with ERalpha (p = 0." | ( Banham, AH; Bates, GJ; Fox, SB; Han, C; Harris, AL; Launchbury, R; Leek, RD, 2008) |
| "The majority of breast tumors is treated with the partial antiestrogen tamoxifen." | ( Emons, G; Girgert, R; Gründker, C; Hanf, V, 2008) |
| "Neoadjuvant chemotherapy for breast cancer has achieved a higher response rate with the combination of anthracycline and taxane." | ( Takada, M; Toi, M, 2007) |
| "Human breast cancer cells (MCF-7 and T47D) were treated with tamoxifen and tamoxifen metabolites and mRNA expression of TGFbeta2 and TbetaRII was analyzed by quantitative RT-PCR." | ( Buck, MB; Coller, JK; Eichelbaum, M; Knabbe, C; Mürdter, TE, 2008) |
| "HER2-positive cases of breast cancer tend to be more aggressive and more likely to become resistant to therapy than HER2-negative tumors." | ( Geyer, CE; Harkins, B, 2007) |
| "Estrogen receptor-negative breast cancers generally are highly malignant, resistant to chemotherapy and poorly prognostic." | ( Chang, YC; Fujiwara, I; Furukawa, C; Magae, J; Mizuta, M; Mizuta, N; Nakajima, H; Sakaguchi, K, 2007) |
| "Microarray analyses of human MDA-MB-435 breast cancer cells treated with vitamin E analog 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl) chroman-6-yloxy acetic acid (alpha-TEA) showed over 400 genes to be modulated." | ( Hu, Z; Iyer, VR; Jia, L; Kline, K; Sanders, BG; Wang, P; Yu, W, 2008) |
| "Here, we observed that in breast cancer cells resistant and insensitive to endocrine treatment, the growth factor EGF induced Ets-2 but not Ets-1 transcriptional regulation of the oncogene myc." | ( Al-azawi, D; Bane, FT; Cocchiglia, S; Hill, AD; Ilroy, MM; Kelly, G; Redmond, AM; Young, LS, 2008) |
| "Accelerated paclitaxel in breast cancer patients without prophylactic GCSF is safe, avoids side effects, reduces costs and is not associated with an increase risk of neutropenic sepsis or treatment delays." | ( Arnedos, M; Ashley, S; Smith, I; Sutherland, S, 2008) |
| "Human breast cancer cell line MDA-MB-435S was treated with 5 micromol/L 5-Aza-CdR, a specific demethylating agent for 0 to 8 days." | ( Chen, J; Huang, T; Liu, K; Wang, G; Zhang, B, 2007) |
| "Treatment of breast cancer is usually associated with significant psychological stress." | ( Bauer, ME; Braga Filho, AP; da Silva Hoffmann, F; Luz, C; Muller, MC; Nunes, DF; Rodriguez, AL, 2007) |
| "A large number of breast cancer patients receiving adjuvant chemotherapy is suffering from fatigue." | ( Abu-Saad, HH; Courtens, AM; de Jong, N; Kester, AD; Schouten, HC, 2007) |
| "The biology of metastatic breast cancer may demand palliation by oesophageal intubation or stenting combined with adjuvant chemo, radio or hormonal therapy in such instances." | ( Kotsis, L; Kovács, O; Krasznai, G, 2007) |
| "In selection of therapy for women with breast cancer, the focus has been almost exclusively on the characteristics of the tumor, eg, estrogen receptor (ER) and HER-2." | ( Ingle, JN, 2008) |
| "This review discusses male breast cancer and draws comparisons with female breast cancer and discusses current treatments available to treat this disease." | ( Dutta, U; Pant, K, 2008) |
| "Thirty-four patients with metastatic breast cancer, who had been previously treated with anthracyclines alone or with taxanes, were enrolled." | ( Jiang, WQ; Liu, DG; Teng, XY; Zhou, NN, 2007) |
| "Sixty-one patients with metastatic breast cancer were treated with intravenous vinorelbine 30 mg/m2 on days 1 and 8 of each 21-day cycle together with 5-FU 200 mg/m2/day by continuous infusion." | ( Bishop, JL; Joffe, JK; Johnston, SR; McIllmurray, MB; Neave, F; O'Reilly, SM; Price, CG; Stuart, NS; Whipp, EC, 2008) |
| "MCF-7 human breast cancer cells were treated with inhibitors for PLA2 (quinacrine), lipoxygenases (LOX-5 and LOX-12; baicalein, REV-5091, nordihydroguaiaretic acid), cyclooxygenases (COX-1, COX-2, indomethacin), and AROM (formestane)." | ( Crowley, J; Markaverich, BM; Rodriquez, M; Shoulars, K; Thompson, T, 2007) |
| "Adjuvant therapy for breast cancer with aromatase inhibitors improves survival compared with tamoxifen; however, whether they should be given upfront or sequentially after 2-3 years of tamoxifen in estrogen receptor-positive early breast cancer affecting postmenopausal women is unclear." | ( Bundred, NJ; Iddon, J, 2008) |
| "MDA-MB-468 human breast cancer cells were stably transfected to overexpress OPN (468-OPN) or a control vector (468-CON) and compared for functional differences in malignant/metastatic behavior in response to treatment with the thrombin-specific inhibitor Argatroban." | ( Al-Katib, W; Allan, AL; Chambers, AF; Goodale, D; Hedley, BD; Postenka, CO; Schulze, EB; Tuck, AB, 2008) |
| "In elderly patients with early breast cancer and a clinically clear axilla, axillary surgery, sentinel lymph node biopsy, and postoperative radiotherapy to the residual breast may not be necessary because of reduced life expectancy, effectiveness of hormone therapy in achieving long-term disease control, and generally favorable biologic behavior of breast cancer in elderly patients." | ( Coradini, D; Costa, A; Greco, M; Martelli, G; Miceli, R; Piromalli, D; Vetrella, G; Zurrida, S, 2008) |
| "Elderly patients with early breast cancer and no palpable axillary lymph nodes may be safely treated safety by conservative surgery without axillary dissection and without postoperative radiotherapy, provided that surgical margins are in tumor-free tissue and that hormone therapy is administered." | ( Coradini, D; Costa, A; Greco, M; Martelli, G; Miceli, R; Piromalli, D; Vetrella, G; Zurrida, S, 2008) |
| "Initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab prolongs progression-free survival, but not overall survival, as compared with paclitaxel alone." | ( Cella, D; Cobleigh, M; Davidson, NE; Dickler, M; Gralow, J; Miller, K; Perez, EA; Shenkier, T; Wang, M, 2007) |
| "Patients with lymph node-positive breast cancer (n = 2887) were randomly assigned to one of four treatments: 1) sequential control (four cycles of doxorubicin at 75 mg/m2, followed by three cycles of cyclophosphamide, methotrexate, and 5-fluorouracil [CMF]); 2) concurrent control (four cycles of doxorubicin at 60 mg/m2 plus cyclophosphamide at 600 mg/m2, followed by three cycles of CMF); 3) sequential docetaxel (three cycles of doxorubicin at 75 mg/m2, followed by three cycles of docetaxel at 100 mg/m2, followed by three cycles of CMF); 4) concurrent docetaxel (four cycles of doxorubicin at 50 mg/m2 plus docetaxel at 75 mg/m2, followed by three cycles of CMF)." | ( Andersson, M; Balil, A; Bendahmane, B; Buyse, M; Castiglione-Gertsch, M; Crown, J; Di Leo, A; Dolci, S; Francis, P; Gelber, RD; Goldhirsch, A; Gutiérrez, J; Jakesz, R; Jamin, S; Lang, I; Nordenskjöld, B; Piccart-Gebhart, M; van Hazel, G; Vorobiof, D, 2008) |
| "Patients with metastatic breast cancer received first-line treatment with both drugs on days 1-5." | ( Chatelut, E; Dalenc, F; Delord, JP; Lochon, I; Nguyen, L; Pinguet, F; Poublanc, M; Roche, H, 2007) |
| "595 high-risk breast cancer patients were treated with adjuvant anthracycline-based dose-dense sequential chemotherapy (E-CMF vs." | ( Alamani, M; Arapantoni-Dadioti, P; Aravantinos, G; Briasoulis, E; Dafni, U; Fountzilas, G; Gogas, H; Kalofonos, HP; Kastritis, E; Kostopoulos, I; Kyriakou, V; Kyroudi, A; Malamou-Mitsi, V; Papaspyrou, I; Pectasides, D; Skopa, C; Tzaida, O, 2007) |
| "A total of 1625 primary breast cancer patients who received post-surgery adjuvant chemotherapy in Tianjin Cancer Hospital, China, from July 2002 to November 2005 were included in the study." | ( Liu, Y; Zhang, J, 2008) |
| "Treatment of patients with metastatic breast cancer (MBC) exposed to anthracyclines and taxanes is challenging." | ( Alkis, N; Benekli, M; Buyukberber, S; Camci, C; Coskun, U; Er, O; Uner, A; Yamac, D; Yildiz, R, 2007) |
| "The treatment of human breast cancer cell lines with PPARgamma agonists is known to have antiproliferative effects but the role of PPARgamma activation in the process remains unclear." | ( Boisbrun, M; Chapleur, Y; Flament, S; Grillier-Vuissoz, I; Lecomte, J; Mazerbourg, S; Salamone, S, 2008) |
| "Forty-one female patients with advanced breast cancer before and after chemotherapy and 60 healthy females participated in the study." | ( Benítez-Bribiesca, L; Bravo, JL; Del Castillo, ER; Gallegos-Hernández, F; Ostrosky-Wegman, P; Peñarroja-Flores, R; Sánchez-Suárez, P; Toledo-García, J, 2008) |
| "We report a case of advanced breast cancer (T4b, N3c, M1) achieving a significant improvement on QOL by multi-disciplinary therapy and S-1 administration." | ( Amano, S; Enomoto, K; Kitajima, A; Sakurai, K; Tani, M, 2007) |
| "In Her2-postive metastatic breast carcinoma, first-line trastuzumab-based therapy is well established; many centres continue antibody treatment beyond disease progression." | ( Altorjai, G; Bartsch, R; Dubsky, P; Gampenrieder, SP; Gnant, M; Mader, RM; Pluschnig, U; Rottenfusser, A; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC, 2008) |
| "A 48-year-old woman with a diagnosis of breast carcinoma was treated with adjuvant chemotherapy through a central venous catheter with subcutaneous reservoir (Port-A-Cath)." | ( Andrade Santiago, J; Blanco Jarava, A; Chacón López-Muñiz, I; López Gómez, L; Martínez-Barbeito, MB; Pangua Méndez, C; Quintanar Verdúguez, T, 2008) |
| "International Breast Cancer Study Group (IBCSG) Trial 11-93 is the largest trial evaluating the role of the addition of chemotherapy to ovarian function suppression/ablation (OFS) and tamoxifen in premenopausal patients with endocrine-responsive early breast cancer." | ( Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Collins, J; Crivellari, D; Forbes, JF; Gelber, RD; Goldhirsch, A; Holmberg, SB; Price, KN; Thürlimann, B, 2009) |
| "However, whether the breast cancer cells with induced ER alpha restore response to endocrine therapy requires to be further researched." | ( Di, GH; Fan, J; Lu, JS; Shao, ZM; Shen, ZZ; Wang, L; Wu, FY; Wu, J; Yin, WJ, 2008) |
| "Using human breast cancer cell lines displaying different levels of alpha6beta4 and ErbB-3 receptors and a series of 232 breast cancer biopsies from patients submitted to adjuvant Tamoxifen monotherapy for five years, we evaluated the functional interaction between both receptors in relationship to Tamoxifen responsiveness." | ( Avetrani, P; Bon, G; Buglioni, S; Di Carlo, SE; Fabi, A; Falcioni, R; Folgiero, V; Melucci, E; Mottolese, M; Nisticò, C; Perracchio, L; Rosanò, L; Sacchi, A; Sperduti, I; Vici, P, 2008) |
| "Furthermore, we treated the breast cancer cells with ATP synthase inhibitors and examined the inhibitory efficiency." | ( Chang, HY; Chang, KJ; Hsu, CH; Huang, TC; Juan, HF; Kuo, WH, 2008) |
| "Patients treated surgically for early breast cancer show a peak recurrence 2 years following surgery." | ( Doughty, JC, 2008) |
| "Patient-level data were used from the Breast Cancer International Research Group (BCIRG) 001 trial for estimates of the effect of chemotherapy on toxicity and outcome, and an observational data set collected from a UK university hospital provided estimates of resource use and outcome for patients with relapsed disease." | ( Bagust, A; Cameron, DA; Tate, HC; Wolowacz, SE, 2008) |
| "We examined 22 patients with metastatic breast cancer administered ANA alone as first-line AI treatment, EXE alone as second-line (A--> E group), and 13 patients given EXE alone as first-line AI treatment (E --> A group) since December 2002 in our hospital." | ( Ikeda, M; Kurebayashi, J; Miyake, A; Nakashima, K; Nomura, T; Shiiki, S; Sonoo, H; Tanaka, K; Yamamoto, Y, 2008) |
| "In patients with advanced breast cancer or multiple myeloma, the incidence of SREs was similar in patients treated with zoledronic acid 4 mg or pamidronic acid 90 mg every 3-4 weeks for up to 25 months but, in breast cancer patients, zoledronic acid reduced the risk of SREs, including HCM, by an additional 20% compared with pamidronic acid." | ( McKeage, K; Plosker, GL, 2008) |
| "Treatment of breast cancer cells with the ErbB3 ligand heregulin (HRG) results in increased phosphorylation of Ebp1 and transcriptional repression." | ( Akinmade, D; Hamburger, AW; Kumar, R; Luo, WM; Talukder, AH; Zhang, Y, 2008) |
| "From 1998 to 2006, 370 primary breast cancer patients underwent curative surgical treatment after NAC containing both anthracycline and taxane at the National Cancer Center Hospital." | ( Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Hojo, T; Katsumata, N; Kinoshita, T; Kohno, T; Seki, K; Shibata, T; Shien, T; Shimizu, C, 2009) |
| "The patient responded well to breast cancer-targeted chemotherapy." | ( Davis, D; Dockery, KF; Puri, S; Qazi, R, 2008) |
| "The development of chemoresistant breast cancer is poorly understood and second treatment options are barely investigated." | ( Bader, Y; Erker, T; Fritzer-Szekeres, M; Gollinger, M; Handler, N; Huber, D; Jäger, W; Kopp, B; Krupitza, G; Madlener, S; Maier, S; Popescu, R; Saiko, P; Stark, N; Strasser, S; Szakmary, A; Szekeres, T; Tentes, I, 2008) |
| "In this study, we treated human breast cancer cell line MCF-7 and lung cancer cell line A549 as well as colon cancer cell line SW620 with sulindac to observe the effects of sulindac in other tissue sites." | ( Augenlicht, LH; Bi, X; Han, A; Hu, D; Song, Z; Tong, C; Yang, W, 2008) |
| "The clinical outcomes of breast cancer patients treated with tamoxifen may be influenced by the activity of cytochrome P450 2D6 (CYP2D6) enzyme because tamixifen is metabolized by CYP2D6 to its active forms of antiestrogenic metabolite, 4-hydroxytamoxifen and endoxifen." | ( Bando, Y; Hosono, N; Kiyotani, K; Kubo, M; Mushiroda, T; Nakamura, Y; Sasa, M; Sumitomo, I; Zembutsu, H, 2008) |
| "This adverse effect on breast cancer detection should be incorporated into risk-benefit discussions with women considering even short-term combined hormone therapy." | ( Anderson, G; Chen, C; Chlebowski, RT; Gillian, MA; Gilligan, MA; Lane, D; Langer, RD; McTiernan, A; Pettinger, M; Walsh, BW, 2008) |
| "MDA-MB-231 breast cancer cell cultures and xenografts were treated with apigenin, followed by measurement of reduced cellular viability/proliferation,proteasome inhibition, and apoptosis induction." | ( Chen, D; Chen, MS; Dou, QP; Landis-Piwowar, KR, 2007) |
| "Postmenopausal women with breast cancer were randomly assigned to receive alendronate or placebo for 1 year within 3 months after withdrawal of tamoxifen therapy." | ( Brown, IN; Cohen, A; Fleischer, JB; Hershman, DL; Joe, AK; Johnson, MK; McMahon, DJ; Silverberg, SJ, 2008) |
| "The International Breast Cancer Study Group initiated two concurrent trials in this population: in Premenopausal Endocrine Responsive Chemotherapy (PERCHE), chemotherapy use is determined by randomization and in Tamoxifen and Exemestane Trial (TEXT) by physician choice." | ( Castiglione-Gertsch, M; Coates, AS; Fleming, GF; Francis, P; Gelber, RD; Goldhirsch, A; Maibach, R; Pagani, O; Perez, EA; Price, KN; Regan, MM; Thürlimann, B; Torrisi, R; Walley, B, 2008) |
| "A 60-year old woman with medullary breast cancer stage IIIB underwent neoadjuvant chemotherapy with TAC (doxetaxele 100 mg/m2, doxorubicin 50 mg/m2 and cyclophosphamide 600 mg/m2)." | ( Fadjari, TH; Oehadian, A, 2008) |
| "Eligible breast cancer patients were chemotherapy-naive and treated with adjuvant AC chemotherapy (i." | ( Chan, SL; Ho, WM; Hui, EK; Koh, J; Kwan, WH; Lam, KC; Lau, W; Lee, KK; Mo, FK; Mok, TS; Poon, AN; Suen, JJ; Yeo, W; Yeung, WK; Zee, B, 2009) |
| "Substantial variation in adjuvant breast cancer chemotherapy dosing in obese women suggests that there is uncertainty about optimal practices." | ( Greenman, CG; Griggs, JJ; Jagielski, CH, 2008) |
| "We reported here a case of advanced breast cancer successfully treated with combination therapy including docetaxel, doxorubicin and cyclophosphamide (TAC) as salvage therapy." | ( Abe, S; Iyama, S; Kato, J; Murase, K; Niitsu, Y; Okamoto, K; Sagawa, T; Sato, T; Sato, Y; Takahashi, S; Takayama, T, 2008) |
| "International Breast Cancer Study Group Trial VIII compared cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy for 6 cycles followed by endocrine therapy with goserelin with either modality alone in pre- and perimenopausal patients." | ( Braye, S; Brown, RW; Castiglione-Gertsch, M; Coates, AS; Gelber, RD; Goldhirsch, A; Golouh, R; Grigolato, P; Gusterson, BA; Kovács, A; Maiorano, E; Mastropasqua, MG; Ohlschlegel, C; Perin, T; Pillay, K; Price, KN; Regan, MM; Rusca, T; Viale, G, 2008) |
| "Endocrine treatment of breast cancer is widely applied and effective." | ( Broertjes, M; de Jong, D; de Vries, I; Dorssers, LC; Sarwari, R; Smid, M; van Agthoven, T; van Agthoven, TL; Veldscholte, J; Vreede, L, 2009) |
| "From June 2005 to March 2007, 94 breast cancer patients who have been pathologically confirmed by core needle biopsy were treated with neoadjuvant chemotherapy before operation." | ( Chen, YQ; Jin, YC; Li, J; Li, R; Li, XR; Liu, HY; Ma, B; Wang, JD; Zhang, YJ; Zheng, YQ, 2008) |
| "Early stage breast cancer patients, who did not receive chemotherapy, self-selected into an 8-week MBSR program or into an assessment only, control group." | ( Albuquerque, K; Chroniak, C; Chroniak, KR; Durazo-Arvizu, R; Mathews, HL; Witek-Janusek, L, 2008) |
| "Thirty-four female patients with breast cancer treated with epirubicin up to 450 mg/m2 (study group), and a matched control group of 34 women diagnosed with breast tumours, who had not started chemotherapy, were assessed by echocardiography." | ( Duncea, C; Pripon, S; Radulescu, D; Radulescu, LI, 2008) |
| "Metronomic low-dose treatment of breast cancer indicated that RGD2-PTX is significantly more effective than PTX+RGD2 combination and solvent control." | ( Cao, Q; Chen, K; Chen, X; He, L; Li, ZB; Neamati, N; Wu, Z, 2008) |
| "Patients with T1-3, N0-1, M0 breast cancer were eligible after completion of surgery and chemotherapy and at least 4 months of tamoxifen (if prescribed)." | ( Albain, KS; Bearden, JD; Giguere, JK; Goodwin, JW; Green, SJ; Jiang, CS; Lippman, SM; Martino, S; Moinpour, CM, 2008) |
| "International Breast Cancer Study Group Trial VI accrued 1475 eligible pre- and perimenopausal women with node-positive breast cancer who were randomly assigned to receive three to nine courses of classical combination chemotherapy with cyclophosphamide, methotrexate, and fluorouracil." | ( Castiglione-Gertsch, M; Coates, AS; Cole, BF; Collins, J; Crivellari, D; Fey, MF; Gelber, RD; Goldhirsch, A; Golouh, R; Gruber, G; Gusterson, BA; Holmberg, SB; Lindtner, J; Price, KN; Simoncini, E; Thürlimann, B; Viale, G, 2008) |
| "Women with breast cancer without previous chemotherapy were eligible for this prospective study." | ( Bani, MR; Beckmann, MW; Engel, J; Fasching, PA; Kollmannsberger, B; Kreis, H; Lausen, B; Lux, MP; Niesler, B; Strick, R; Strissel, PL; Weihbrecht, S, 2008) |
| "Untreated breast cancer patients received two 3-week cycles of docetaxel at 75 mg/m(2), doxorubicin at 50 mg/m(2), and cyclophosphamide at 500 mg/m(2) (TAC)." | ( Costa, SD; Eidtmann, H; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Kaufmann, M; Kümmel, S; Loibl, S; Mehta, K; Vogel, P; von Minckwitz, G, 2008) |
| "Among breast cancer patients, nonresponse to initial neoadjuvant chemotherapy is associated with unfavorable outcome." | ( Costa, SD; Eidtmann, H; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Kaufmann, M; Kümmel, S; Loibl, S; Mehta, K; Vogel, P; von Minckwitz, G, 2008) |
| "Previously untreated breast cancer patients received two 3-week cycles of docetaxel at 75 mg/m(2), doxorubicin at 50 mg/m(2), and cyclophosphamide at 500 mg/m(2) per day (TAC)." | ( Costa, SD; Eidtmann, H; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Kaufmann, M; Kümmel, S; Loibl, S; Mehta, K; Vogel, P; von Minckwitz, G, 2008) |
| "Treatment of human breast cancer MCF-7 cells with adriamycin, a DNA topoisomerase II alpha inhibitor, caused apoptosis." | ( Cai, L; Chen, X; Sui, G; Wu, J; Yang, Y; Zhao, Y, 2008) |
| "Early breast cancer was chosen as a model as multiple samples can be collected during standard treatment and there is an intervening period in which experimental intervention can be applied." | ( Clack, G; Dixon, JM; Elvin, P; Fennell, M; Green, TP; Jacobs, V; Jones, RJ; Marshall, A; Renshaw, L; Womack, C; Young, O, 2009) |
| "The relative increased risk of breast cancer in MS women under IS treatment warrants further attention." | ( Berthier, F; Clavelou, P; Danzon, A; de Seze, J; Debouverie, M; Defer, G; Gout, O; Lebrun, C; Rumbach, L; Vermersch, P; Wiertlevski, S, 2008) |
| "Patients had HER-2-positive breast cancer, progressive brain metastases, prior trastuzumab treatment, and at least one measurable metastatic brain lesion." | ( Bullitt, E; Burstein, HJ; Carey, LA; Come, SE; Crawford, A; Ewend, M; Gelman, R; Harris, GJ; Henson, JW; Hochberg, F; Kasparian, E; Kirsch, DG; Li, X; Lin, NU; Liu, MC; Van den Abbeele, AD; Winer, EP; Younger, J, 2008) |
| "RSV treatment to breast cancer cells inhibited Bcl-2 and Bcl-X(L) expression and induced mitochondrial membrane depolarization." | ( Almaguel, F; De León, DD; De León, M; Moretta, D; Singh, SK, 2008) |
| "We report a patient with treated breast cancer, presenting with chest pain where FDG-PET to assess for recurrence was consistent with costochondritis and peri-implant inflammation." | ( El-Haddad, G; Lilien, DL; Mathew, AS; Takalkar, AM, 2008) |
| "Tumorigenic breast cancer cells that express high levels of CD44 and low or undetectable levels of CD24 (CD44(>)/CD24(>/low)) may be resistant to chemotherapy and therefore responsible for cancer relapse." | ( Chamness, GC; Chang, JC; Gutierrez, C; Hilsenbeck, SG; Huang, J; Lewis, MT; Li, X; Osborne, CK; Pavlick, A; Rosen, J; Wong, H; Wu, MF; Zhang, X, 2008) |
| "Paired breast cancer core biopsies were obtained from patients with primary breast cancer before and after 12 weeks of treatment with neoadjuvant chemotherapy (n = 31) or, for patients with HER2-positive tumors, before and after 6 weeks of treatment with the EGFR/HER2 inhibitor lapatinib (n = 21)." | ( Chamness, GC; Chang, JC; Gutierrez, C; Hilsenbeck, SG; Huang, J; Lewis, MT; Li, X; Osborne, CK; Pavlick, A; Rosen, J; Wong, H; Wu, MF; Zhang, X, 2008) |
| "In 17 early stage breast cancer patients receiving doxorubicin-cyclophosphamide chemotherapy every 14 days (ddAC) blood was collected on day 1 of each cycle." | ( Cole, DJ; Diaz-Montero, CM; Garrett-Mayer, E; Montero, AJ; Nishimura, MI; Salem, ML, 2009) |
| "Six other breast cancer survivors with menopausal symptoms were also treated with Nyoshinsan/TJ-67, and five of the six patients showed noticeable improvement without adverse effects." | ( Horiguchi, J; Ito, K; Ito, T; Kogure, T; Oku, Y; Sato, H; Takeyoshi, I; Tatsumi, T, 2008) |
| "Treatment of breast cancer cells with 10 nM 17beta-estradiol (E(2)) resulted in the upregulation of Aurora-A levels in an estrogen receptor-dependent manner." | ( Gopalan, G; Govindasamy, KM; Lee, HH; Zhu, Y, 2008) |
| "13 survivors of breast cancer (in remission) with severe hot flushes and night awakenings were treated with stellate-ganglion block at the anterolateral aspect of the C6 vertebra on the right side under fluoroscopy." | ( Joshi, JR; Lipov, EG; Lipov, S; Maganini, R; Sanders, S; Slavin, K; Wilcox, K; Xie, H, 2008) |
| "Most breast cancer patients with estrogen receptor-negative/progesterone receptor-positive (ER-/PgR+) tumors are premenopausal cases, with few alternatives of adjuvant endocrine therapy but tamoxifen (TAM)." | ( Di, GH; Liu, GY; Lu, JS; Shao, ZM; Shen, KW; Shen, ZZ; Wu, J; Yu, KD, 2008) |
| "Long-term follow-up of postmenopausal breast cancer patients who remained untreated following discontinuation of TAM therapy did not reveal any malignant endometrial pathology." | ( Aviram, R; Cohen, I; Fishman, A; Markovitch, O; Tepper, R, 2008) |
| "In 112 metastatic breast cancer patients treated with tamoxifen, one of the classifier components suggesting a cellular inflammatory mechanism was significantly predictive of response." | ( Berns, EM; Bontempi, G; Daidone, MG; Delorenzi, M; Desmedt, C; Ellis, P; Foekens, JA; Gillet, C; Haibe-Kains, B; Jansen, MP; Lallemand, F; Loi, S; Piccart, MJ; Pierotti, MA; Reid, JF; Ryder, K; Sotiriou, C; Tutt, AM; Wirapati, P, 2008) |
| "Patients with breast cancer on adjuvant chemotherapy can experience weight gain and concurrent losses in muscle mass." | ( Aziz, N; Blackwell, K; Case, LD; Demark-Wahnefried, W; Giguere, JK; Kraus, W; Marcom, PK; Shaw, E; Snyder, DC, 2008) |
| "Ninety premenopausal patients with breast cancer on adjuvant chemotherapy were randomized to a calcium-rich diet (CA) intervention (attention control) or to 2 experimental arms: a CA + exercise (EX) arm or a CA + EX and high fruit and vegetable, low-fat diet (FVLF) arm." | ( Aziz, N; Blackwell, K; Case, LD; Demark-Wahnefried, W; Giguere, JK; Kraus, W; Marcom, PK; Shaw, E; Snyder, DC, 2008) |
| "Patients with breast cancer treated with adjuvant CMF chemotherapy (n = 63) were examined with neuropsychological tests 1 year after treatment and compared with healthy women (n = 60; T1 portion of the study)." | ( Boogerd, W; Kreukels, BP; Ridderinkhof, KR; Schagen, SB; van Dam, FS, 2008) |
| "Case 3, a 44-year-old woman, having breast cancer treated with 5-fluorouracil, cyclophosphamide, and epirubicin developed an MPR after the second chemotherapy treatment." | ( Barbaud, A; Bursztejn, AC; Cuny, JF; Schmutz, JL; Tréchot, P, 2008) |
| "In the group of 72 postmenopausal breast cancer patients blood samples were taken before, during and after adjuvant chemotherapy and levels of estradiol, progesterone, LH, FSH, IGF-1 and IGFBP-3 were evaluated." | ( Kyr, M; Petruzelka, L; Pribylova, O; Springer, D; Svobodnik, A; Zima, T, 2008) |
| "After breast cancer surgery, women with lymph node-positive disease were randomly assigned to treatment with fluorouracil, epirubicin, and cyclophosphamide (FEC) or with FEC followed by weekly paclitaxel (FEC-P)." | ( Adrover, E; Alba, E; Almenar, S; Alvarez, I; Alvarez, JV; Antón, A; Aranda, E; Baena, JM; Calvo, L; Crespo, C; de Alava, E; García Puche, JL; Gonzalez, S; González-Palacios, JF; Gracia Marco, JM; Guitián, MD; Lluch, A; López García-Asenjo, JA; López-Vega, JM; Martín, M; Mayordomo, JI; Mel, JR; Modolell, A; Munárriz, B; Palacios, J; Pelegrí, A; Plazaola, A; Ramos, M; Rodríguez, CA; Rodríguez-Lescure, A; Ruiz, A; Ruiz-Borrego, M; Sánchez-Rovira, P; Seguí, MA; Vera, F, 2008) |
| "Among patients with operable breast cancer, FEC-P treatment statistically significantly reduced the risk of relapse compared with FEC as adjuvant therapy." | ( Adrover, E; Alba, E; Almenar, S; Alvarez, I; Alvarez, JV; Antón, A; Aranda, E; Baena, JM; Calvo, L; Crespo, C; de Alava, E; García Puche, JL; Gonzalez, S; González-Palacios, JF; Gracia Marco, JM; Guitián, MD; Lluch, A; López García-Asenjo, JA; López-Vega, JM; Martín, M; Mayordomo, JI; Mel, JR; Modolell, A; Munárriz, B; Palacios, J; Pelegrí, A; Plazaola, A; Ramos, M; Rodríguez, CA; Rodríguez-Lescure, A; Ruiz, A; Ruiz-Borrego, M; Sánchez-Rovira, P; Seguí, MA; Vera, F, 2008) |
| "Thirty women with breast cancer completed neuropsychological testing before the initiation of chemotherapy and after four cycles of doxorubicin and cyclophosphamide." | ( Dodd, MJ; Dowling, GA; Jansen, CE; Kramer, J; Miaskowski, CA, 2008) |
| "A total of 215 women with breast cancer were prospectively evaluated for fertility preservation before adjuvant chemotherapy." | ( Azim, AA; Costantini-Ferrando, M; Oktay, K, 2008) |
| "African Americans with metastatic breast cancer have an increased hazard of death compared with whites despite the receipt of similar per-protocol treatment, but experience no differences in TTF or overall response to therapy." | ( Bakri, K; Berry, DA; Cirrincione, C; Fleming, GF; Hudis, C; Lake, D; Marcom, K; Muss, H; Norton, L; Polite, BN; Schwartz, JH; Seidman, A; Shapiro, C; Winer, EP, 2008) |
| "AI is effective in treating breast cancer and may be safely used preoperatively." | ( Chow, LW; Lam, CK; Loo, WT; Toi, M; Yip, AY, 2008) |
| "Patients with metastatic breast cancer (MBC) are increasingly exposed to anthracyclines and taxanes either during treatment of primary breast cancer or during initial therapy of metastatic disease." | ( Fasching, PA; Heinemann, V; Kalischefski, B; Kolbl, H; Laessig, D; Maubach, P; Meerpohl, H; Melchert, F; Morack, G; Scharl, A; Stauch, M; Stemmler, HJ; Vehling-Kaiser, U; Weber, B, 2007) |
| "We used the breast cancer cell lines T47D and BT474, treated with steroid hormones or various pathway inhibitors." | ( Diamandis, EP; Paliouras, M, 2008) |
| "116 consecutive patients scheduled for breast cancer surgery were prospectively scored according to pain, PONV and sedation after being introduced to a combined evidence-based, empiric multimodal opioid-sparing prevention and treatment regime consisting of Paracetamol, Celecoxib, Dextromethorphan, Gabapetin, Dexamethason and Ondansetron." | ( Callesen, T; Gärtner, R; Kehlet, H; Kroman, N, 2008) |
| "Here, we provide further details about breast cancer incidence by tumor characteristics, duration of treatment, and subgroup." | ( Barrett-Connor, E; Cauley, JA; Collins, P; Geiger, MJ; Grady, D; Kornitzer, M; Mershon, J; Mosca, L; Song, J; Wenger, NK, 2008) |
| "Sexual dysfunction after breast cancer has been attributed to a variety of treatment associated and psychological factors." | ( Alder, J; Bitzer, J; Fink, N; Urech, C; Wight, E; Zanetti, R, 2008) |
| "Sexual dysfunction after breast cancer is common and women should be informed properly at an early stage of treatment." | ( Alder, J; Bitzer, J; Fink, N; Urech, C; Wight, E; Zanetti, R, 2008) |
| "Two had metastatic breast cancer and had been treated with zoledronic acid; one had also received pamidronate." | ( Kogan, R; Lehrer, S; Montazem, A; Pessin-Minsley, M; Pfail, J; Ramanathan, L; Stock, RG, 2008) |
| "Using MDA-MB-231 breast cancer cells, we found that (a) insulin stimulated leptin mRNA and protein expression, which was associated with increased activation of the leptin gene promoter; (b) insulin increased nuclear accumulation of transcription factors hypoxia inducible factor (HIF)-1alpha and Sp1 and their loading on the leptin promoter; (c) small interfering RNA (siRNA)-mediated knockdown of either HIF-1alpha or Sp1 significantly down-regulated insulin-induced leptin mRNA and protein expression; further inhibition of leptin expression was observed under the combined HIF-1alpha and Sp1 siRNA treatment; (d) inhibition of extracellular signal-regulated kinase (ERK)1/2 and phosphatidylinositol-3-OH kinase (PI-3K) pathways significantly, albeit partially, decreased insulin-dependent leptin mRNA and protein expression, which coincided with reduced association of HIF-1alpha and/or Sp1 with specific leptin promoter regions; and (e) inhibition of ERK1/2 reduced recruitment of both HIF-1alpha and Sp1 to the leptin promoter, whereas down-regulation of PI-3K influenced only HIF-1alpha binding." | ( Auriemma, A; Bartella, V; Cascio, S; Fiorio, E; Russo, A; Surmacz, E, 2008) |
| "The study will enroll 80 patients with breast cancer and indication to anthracycline chemotherapy, randomizing them in a 1:1 ratio to liposomal doxorubicin or standard epirubicin." | ( Abbate, A; Biondi-Zoccai, GG; Comerci, G; Di Persio, S; Lotrionte, M; Natali, R; Palazzoni, G, 2009) |
| "Twenty breast cancer patients who developed ONJ receiving BP treatment were included in group A, whereas group B consisted of 40 matched controls (breast cancer patients who did not progress to ONJ receiving BP treatment)." | ( Andreadis, C; Boukovinas, I; Koloutsos, G; Kyrgidis, A; Patrikidou, A; Teleioudis, Z; Triaridis, S; Vahtsevanos, K, 2008) |
| "20 women (aged 55 years or older) with breast cancer receiving hormonal treatment." | ( Held, J; Payne, JK; Shaw, H; Thorpe, J, 2008) |
| "A patient with breast cancer and SCD had a painful crisis after receiving paclitaxel as part of her chemotherapy regimen." | ( Espirito, JL; Pusztai, L; Valero, V; Wilson, NM, 2008) |
| "An increasing number of breast cancer patients seek to take supplements together with their standard treatment in the hope that these will either prevent recurrence or treat their menopausal symptoms." | ( Cantwell, MM; Keshtgar, MR; Leathem, AJ; Velentzis, LS; Woodside, JV, 2008) |
| "In the hormone receptor-positive breast cancer cell line T47-D expression of hCAR and its soluble isoforms was increased by treatment with estradiol and tamoxifen." | ( Auer, D; Daxenbichler, G; Fleischer, M; Marth, C; Müller-Holzner, E; Porto, V; Reimer, D; Roessler, J; Wiedemair, A; Zeimet, AG, 2009) |
| "The link between estrogen and breast cancer growth served as the incentive to develop long-term tamoxifen therapy and, subsequently, the aromatase inhibitors (AIs) as successful "anti-estrogenic" treatments." | ( Jordan, VC; Swaby, RF, 2008) |
| "Patients with locally advanced breast carcinoma (LABC) receive preoperative chemotherapy to provide early systemic treatment and assess in vivo tumor response." | ( Barlow, WE; Doot, RK; Dunnwald, LK; Ellis, GK; Gralow, JR; Kurland, BF; Lawton, TJ; Linden, HM; Livingston, RB; Mankoff, DA; Schubert, EK; Specht, JM, 2008) |
| "Our results suggest that breast cancer patients with metastatic bone disease may benefit from sequential treatment using doxorubicin and zoledronic acid." | ( Clezardin, P; Coleman, RE; Cross, S; Deux, B; Holen, I; Mönkkönen, H; Ottewell, PD, 2008) |
| "Furthermore, in primary breast cancer patients treated with adjuvant tamoxifen, SIAH2 predicted metastasis-free survival (MFS) (HR = 0." | ( Berns, EM; Dorssers, LC; Foekens, JA; Helleman, J; Jansen, MP; Klijn, JG; Look, MP; Meijer-van Gelder, ME; Ruigrok-Ritstier, K; Sieuwerts, AM; Sleijfer, S; van Staveren, IL, 2009) |
| "The treatment of breast cancer with selective estrogen receptor modulators such as tamoxifen and with aromatase inhibitors represents a major advance in cancer chemotherapy." | ( Weinshilboum, R, 2008) |
| "A 50-year-old woman with metastatic breast carcinoma was treated with oral capecitabine." | ( Bar-Sela, G; Haim, N, 2009) |
| "A case of metastatic infiltrating breast cancer in a young multiparous lady with 33 weeks pregnancy is presented who was treated with combination chemotherapy and hemostatic radiotherapy and had successful pregnancy outcome." | ( Kumar, S; Malhotra, N; Pushparaj, M; Raina, V; Roy, KK; Sharma, JB, 2009) |
| "Ten patients with breast cancer and a breast cancer susceptibility gene 1 (BRCA1) mutation, who presented with stages I to III breast cancer between December 2006 and 2007, were treated with four cycles of neoadjuvant cisplatin, followed by mastectomy and conventional chemotherapy." | ( Byrski, T; Cybulski, C; Dent, R; Gorski, B; Gronwald, J; Huzarski, T; Kladny, J; Lubinski, J; Narod, SA; Zuziak, D, 2009) |
| "MIF inhibits the growth of breast cancer by the mechanisms related to apoptosis promotion and inhibition of angiogenesis, so it can be used in breast cancer endocrine therapy." | ( Cong, MH; Sun, JZ; Tian, XS; Wu, GJ; Zhou, WH, 2008) |
| "Seventy-six patients with node-positive breast cancer received treatment with 4 cycles of docetaxel followed by 4 cycles of AC administered with pegfilgrastim at 2-week intervals." | ( Barton, JH; Burris, HA; Farley, CP; Greco, FA; Hainsworth, JD; Peacock, NW; Spigel, DR; Yardley, DA, 2008) |
| "Patients with primary breast cancer received clodronate 1600 mg/day for 2 years or no treatment along with standard adjuvant breast cancer treatment." | ( Bastert, G; Diel, IJ; Gollan, C; Jaschke, A; Schuetz, F; Sohn, C; Solomayer, EF, 2008) |
| "We included 199 patients with HER2+ breast cancer from three successive cohorts of neo-adjuvant chemotherapy on the basis of paclitaxel (Taxol) (P) administered weekly (w) or three weekly (3-w), followed by 5-fluorouracil (F), doxorubicin (A) or epirubicin (E), and cyclophosphamide (C)." | ( Buzdar, AU; Dawood, SS; Esteva, FJ; Gonzalez-Angulo, AM; Green, MC; Hatzis, C; Hortobagyi, GN; Kuerer, HM; Mejia, JA; Peintinger, F; Pusztai, L; Symmans, WF, 2008) |
| "Patients with HR+/HER2+ breast cancer obtained significant benefit from addition of trastuzumab to P/FEC chemotherapy; pathologic response rate was similar to that seen in HR-/HER2+ breast cancers." | ( Buzdar, AU; Dawood, SS; Esteva, FJ; Gonzalez-Angulo, AM; Green, MC; Hatzis, C; Hortobagyi, GN; Kuerer, HM; Mejia, JA; Peintinger, F; Pusztai, L; Symmans, WF, 2008) |
| "Archival materials of 442 invasive breast cancers from women treated with adjuvant tamoxifen monotherapy and with a long follow-up period (median, 11." | ( Akiyama, F; Honma, N; Horii, R; Ito, Y; Iwase, T; Matsuura, M; Saji, S; Sakamoto, G; Takubo, K; Younes, M, 2008) |
| "Greater than 40% of breast cancer patients treated with tamoxifen exhibit de novo or acquired tumor resistance." | ( Edgerton, SM; Jones, FE; Kumar, R; Naresh, A; Thor, AD; Torkko, KC, 2008) |
| "We examined the expression in breast cancer stem cells (BCSCs) of Globo H, a potential tumor-associated antigen for immunotherapy of epithelial cancers including breast cancer." | ( Chang, WW; Hsu, CW; Hung, JT; Lee, CH; Lee, P; Lin, J; Lin, JJ; Shao, LE; Wong, CH; Yu, AL; Yu, J; Yu, JC, 2008) |
| "In patients with breast cancer treated with the docetaxel-doxorubicin-cyclophosphamide regimen, low-dose filgrastim was associated with a higher frequency of febrile neutropenia, hospitalization due to febrile neutropenia, and cycles with febrile neutropenia compared with a historical control group treated with standard-dose filgrastim or lenograstim." | ( Chan, J; Ip, EJ; Lee-Ma, A; Troxell, LS, 2008) |
| "More importantly, breast cancer T47D cells in which Sp1 was knocked down or Sp1-knockout mouse embryonic stem cells were resistant to the combined treatments." | ( Philipsen, S; Wei, WZ; Wu, GS; Xu, J; Zhou, JY, 2008) |
| "Of 18 metastatic breast carcinoma patients experienced in our institution from November 2002 to July 2007, all patients had resisted the anthracycline or taxanes therapy before." | ( Harada, T; Iwamoto, M; Kimura, K; Nohara, T; Sumiyoshi, K; Takahashi, Y; Tanaka, S; Tanigawa, N, 2008) |
| "Adjuvant chemotherapy for breast cancer (BC) may be associated with increased rates of bone loss and decreased bone mineral density (BMD) and may lead to premature osteoporosis and increased fracture risk." | ( Brafman, L; Cremers, S; Crew, KD; Cucchiara, G; Hershman, DL; Irani, D; McMahon, DJ; Shane, E, 2008) |
| "NGF treatment of breast cancer cells activates NF-kappaB resulting in the inhibition of ceramide-induced apoptosis." | ( Hughes-Davies, L; Naderi, A, 2009) |
| "University of Colorado Cancer Center breast cancer patients treated with aromatase inhibitor therapy during July 2005 through July 2006 were studied." | ( Gibson, K; O'Bryant, CL, 2008) |
| "In 2005, the proportion of operable breast cancer patients treated with adjuvant endocrine therapy in the ages 40-59 was around 60 to 80%." | ( Jonsson, H; Kemetli, L; Lenner, P; Nyström, L; Rutqvist, LE; Törnberg, S, 2009) |
| "Thirty-two metastatic breast cancer patients were treated with epirubicin and docetaxel every 21 days." | ( Choi, IK; Kim, AR; Kim, JS; Kim, YH; Koo, BH; Lee, JB; Oh, SC; Park, KH; Seo, JH; Shin, SW; Sung, HJ, 2009) |
| "Four different breast cancer cell lines were treated with DENSPM." | ( Hegardt, C; Holst, CM; Jönsson, G; Oredsson, SM; Staaf, J, 2008) |
| "Patients with early breast cancer who receive anthracycline-containing chemotherapy experience improved relapse-free (RFS) and overall survival (OS) compared with those who receive non-anthracycline-containing chemotherapy." | ( Bartlett, JM; Cameron, DA; Munro, A; Prescott, R; Thomas, J; Twelves, CJ, 2008) |
| "ErbB2 (or Her2/Neu) overexpression in breast cancer signifies poorer prognosis, yet it has provided an avenue for targeted therapy as demonstrated by the success of the humanized monoclonal antibody Trastuzumab (Herceptin)." | ( Band, H; Band, V; Bhattacharyya, M; Cheng, H; Clubb, RJ; Dimri, M; Lakku-Reddi, A; Naramura, M; Ortega-Cava, C; Pan, W; Raja, SM, 2008) |
| "In the present study, breast cancer cells were injected into the back of the femoral bone of nude mice, and CX and MH were intraperitoneally administered every other day at doses of 30 and 40 mg/kg/day, respectively, for 30 days." | ( Cai, L; Liao, Z; Niu, G; Sun, L; Wei, R, 2008) |
| "Tamoxifen has efficacy as a breast cancer therapy and chemoprevention agent." | ( Carrier, L; Li, Z; Rowan, BG, 2008) |
| "Treatment of estrogen-dependent breast cancer cells with Protac-B induced the degradation of ERalpha in a proteasome-dependent manner." | ( Crews, CM; Cyrus, K; Deshaies, RJ; Kim, K; Rodriguez-Gonzalez, A; Sakamoto, KM; Salcius, M, 2008) |
| "Fragments of freshly harvested human breast tumors were embedded in fibrin-thrombin clots and treated with five drugs: adriamycin, taxol, 5-fluorouracil (5-FU), methotrexate, and vincristine." | ( Anthony, CT; Lyons, JM; Thomson, JL; Woltering, EA, 2008) |
| "Freshly harvested breast cancer specimens develop an angiogenic response in a fibrin-thrombin clot-based angiogenesis model and respond to treatment with antineoplastic/antiangiogenic drugs." | ( Anthony, CT; Lyons, JM; Thomson, JL; Woltering, EA, 2008) |
| "A patient with inflammatory breast carcinoma (IBC) diagnosed in the left breast responded to cisplatin and was treated with radical mastectomy and adjuvant therapy." | ( Amorós, A; Casinello, J; Heredia, M; Lázaro, A; López-Alfonso, A, 2008) |
| "We diagnosed advanced accessory breast cancer, and the patient was treated by combination chemotherapy with paclitaxel and trastuzumab." | ( Doi, K; Ishihara, A; Kudo, K; Maeda, T; Ogata, K; Ohchi, T; Suzuki, S, 2008) |
| "Early diagnosis and treatment of breast cancer may account for the current improvement in the mortality of breast cancer." | ( Lota, AS; Tan, PH, 2008) |
| "In 1999 breast cancer was diagnosed and surgically treated." | ( Höffken, O; Maier, C; Scherens, A; Tegenthoff, M, 2008) |
| "However, approximately 40% of breast cancer patients do not respond to tamoxifen treatment." | ( Kobayashi, D; Moriai, M; Moriai, R; Tsuji, N; Watanabe, N, 2009) |
| "Patients with HER2-overexpressing breast cancer were treated with trastuzumab 2 mg/kg/week and gefitinib 250 to 500 mg/day." | ( Arteaga, CL; Davidson, NE; Moulder, SL; O'Neill, A; Pins, M; Sledge, GW; Sparano, JA, 2008) |
| "In vitro, CsA treatment of breast cancer cells inhibited their growth, motility, invasion, and soft agar colony formation." | ( Clevenger, CV; Dutson, LV; Feeney, YB; Koblinski, JE; Zheng, J, 2008) |
| "Six anti-cancer treatments for breast cancer were included in the review: docetaxel, paclitaxel, trastuzumab, gemcitabine, lapatinib and bevacizumab." | ( Harris, P; Hartwell, D; Loveman, E; Takeda, A; Welch, K, 2008) |
| "A diagnosis of breast cancer and treatment are psychologically stressful events, particularly over the first year after diagnosis." | ( Antoni, MH; Blomberg, B; Carver, CS; Diaz, A; Holley, H; Lechner, S; McGregor, B; Phillips, K; Vargas, S, 2009) |
| "Patients with metastatic breast cancer were treated with 175 mg/m(2) paclitaxel per 3-week cycle." | ( Ahn, JB; Chang, H; Chung, HC; Im, CK; Jeung, HC; Kwon, WS; Rha, SY; Roh, JK; Yoo, NC, 2009) |
| "The time to diagnosis of ER-positive breast cancer was similar in both treatment arms." | ( Costantino, JP; Qin, J; Shen, Y, 2008) |
| "In this report, the Early Breast Cancer Trialists' Collaborative Group present their third 5-yearly systematic overview (meta-analysis) of treatment with tamoxifen." | ( Clarke, MJ, 2008) |
| "For premenopausal women with early breast cancer who are not known to be ER negative, the use of an LHRH agonist, with or without tamoxifen as adjuvant therapy is likely to lead to a reduction in the risk of recurrence and a delay in death." | ( Beith, J; Hamilton, A; Sharma, R, 2008) |
| "MCF-7 breast cancer xenograft was established in ovariectomized female athymic nude mice and treated with tamoxifen and/or MSC." | ( Belame, A; Burow, ME; Carrier, L; Li, Z; Rowan, BG; Salvo, VA; Thiyagarajah, A, 2009) |
| "However, significant proportions of breast cancers are either de novo resistant or develop tamoxifen resistance during the course of treatment through mechanisms which have been only partly characterized." | ( Aesoy, R; Lewensohn, R; Linderholm, B; Norum, JH; Sanchez, BC; Viktorsson, K, 2008) |
| "Thirty-seven patients with primary breast cancer, due to receive six cycles of neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy, were examined using DCE-MRI before neoadjuvant chemotherapy and after two cycles of treatment." | ( Ah-See, ML; Burcombe, RJ; Collins, DJ; d'Arcy, JA; Harrison, M; Makris, A; Padhani, AR; Pittam, MR; Ravichandran, D; Richman, PI; Stirling, JJ; Taylor, NJ, 2008) |
| "Estrogen receptor (ER) status in breast cancer is currently the most important predictive biomarker that determines breast cancer prognosis after treatment with endocrine therapy." | ( Badve, S; Baehner, F; Barry, TS; Cartun, RW; Dabbs, DJ; Eisen, RN; Floyd, AD; Goldstein, NS; Hammond, EH; Hewitt, SM; Hewlett, B; Hicks, DG; Martin, AW; Swanson, PE; Taylor, CR; Vyberg, M; Yaziji, H, 2008) |
| "Women undergoing treatment for breast cancer may experience hot flushes, which greatly impact on quality of life." | ( Ashley, S; Dyer, J; Shaw, C, 2008) |
| "To study the role of breast cancer molecular subtypes according to hormone receptors and HER2 status as a predictive factor for pathological complete response (pCR) to neoadjuvant chemotherapy." | ( de la Torre-Cabrera, C; Dueñas, B; Dueñas-García, R; Fernández-Navarro, M; García-Tapiador, AM; Jaén-Morago, A; Martín-Salvago, MD; Martínez-Ortega, E; Morales, F; Ortega-Granados, AL; Ramírez-Torosa, C; Rueda, AI; Sánchez-Muñoz, A; Sánchez-Rovira, P, 2008) |
| "In 54 patients with breast cancer, dynamic contrast-enhanced MRI was performed before chemotherapy and after two chemotherapy cycles." | ( Gilhuijs, KG; Hannemann, J; Loo, CE; Muller, SH; Peeters, MJ; Rodenhuis, S; Teertstra, HJ; van de Vijver, MJ, 2008) |
| "In HGF-treated breast cancer cells we studied (a) the chemoinvasion towards CXCL12 (ligand of the chemokine-receptor CXCR4) and (b) the mechanistic basis, that is, the transduction pathways that regulate CXCR4-mediated invasion, and the role played by histone deacetylases (HDACs) after blockade with trichostatin A (TSA)." | ( Desiderio, MA; Maroni, P; Matteucci, E; Ridolfi, E, 2008) |
| "Treatment of MCF-7 human breast cancer cells with glucose oxidase (GO, 0." | ( Murphy, LC; Ung, K; Weebadda, W; Weitsman, GE, 2009) |
| "For the medical treatment of early breast cancer, aromatase inhibitors (AIs) such as anastrozole, letrozole, and exemestane are more effective than selective estrogen-receptor modulators (SERMs) such as tamoxifen (TAM)." | ( Iwase, H; Yamamoto, Y, 2008) |
| "Patients with HER2-negative breast cancer received treatment with gemcitabine 1000 mg/m(2) intravenously (I." | ( Barton, JH; Burris, HA; Drosick, D; Greco, FA; Hainsworth, JD; Shipley, D; Simons, L; Spigel, DR; Yardley, DA, 2008) |
| "Patients with HER2-positive advanced breast cancer developing tumor progression during an initial trastuzumab-based regimen did not seem to benefit significantly from the continuation of trastuzumab in addition to chemotherapy." | ( Aglietta, M; Botti, G; Bottini, A; Clavarezza, M; Danese, S; dei Tos, AP; del Curto, B; Di Bonito, M; Di Palma, S; Donadio, M; Durando, A; Jacomuzzi, ME; Kulka, J; Montemurro, F; Redana, S; Sanna, G; Sapino, A; Valabrega, G; Viale, G, 2008) |
| "In the International Breast Cancer Study Group (IBCSG) Trials VII and 12-93, postmenopausal women with node-positive, estrogen receptor (ER)-positive or ER-negative, operable breast cancer were randomized to receive either chemotherapy or endocrine therapy or combined chemoendocrine treatment." | ( Castiglione-Gertsch, M; Coates, AS; Collins, J; Crivellari, D; Fey, MF; Forbes, JF; Gelber, RD; Gelber, S; Goldhirsch, A; Holmberg, SB; Lindtner, J; Murray, E; Pagani, O; Price, KN; Simoncini, E; Thürlimann, B, 2009) |
| "During endocrine treatment of breast cancer, the occurrence of symptoms related to oestrogen depletion or oestrogen blockade might thus be a predictor of treatment effectiveness." | ( Cella, D; Cuzick, J; Fallowfield, L; Sestak, I, 2008) |
| "Of particular interest in breast cancer chemotherapy, some coumarins and their active metabolite 7-hydroxycoumarin analogs have shown sulfatase and aromatase inhibitory activities." | ( Cooperwood, JS; Khan, MO; Musa, MA, 2008) |
| "A total of 103 breast cancer survivors: 35 using TMXg, 34 using letrozole group (LTZg) and 34 using no endocrine treatment group (NETg) were evaluated." | ( Dos Reis, FJ; Ferriani, RA; Filho, FM; Martins, WP; Nastri, CO, 2008) |
| "Measurement of residual breast cancer burden (RCB) has been proposed as a more practical alternative to predict survival after preoperative chemotherapy." | ( Glück, S; McKenna, EF; Royce, M, 2008) |
| "HER2 is a validated target in breast cancer therapy." | ( Blättler, WA; Chari, RV; Crocker, LM; Dugger, DL; Jacobson, FS; Kenkare-Mitra, SR; Koeppen, H; Lambert, JM; Lewis Phillips, GD; Li, G; Lutz, RJ; Mai, E; Parsons, KL; Schwall, RH; Sliwkowski, MX; Spencer, SD; Wong, WL, 2008) |
| "Interestingly, treatment of breast cancer cells in vitro with the PXR agonist rifampin induced OATP1A2 expression in a time-dependent and concentration-dependent manner." | ( Ho, RH; Kim, RB; Meyer zu Schwabedissen, HE; Tirona, RG; Yip, CS, 2008) |
| "Endocrine breast cancer treatment relies on estrogen receptor alpha (ERalpha) assessment, which does not predict response in all cases." | ( Amaral, S; Brauch, H; Fritz, P; Kugler, S; Schroth, W; Simon, W, 2009) |
| "Increased expression of HSP90A in breast cancer is correlated with increased cell survival and poor prognosis and HSP90alpha inhibitors are being tested in clinical trials as a breast cancer treatment." | ( Böcher, N; Bork, P; Groner, B; Liu, R; Parusel, CT; Perotti, C; Pfitzner, E; Schultz, J; Shemanko, CS, 2008) |
| "Postmenopausal metastatic breast cancer patients without previous adjuvant AI treatment received exemestane 25 mg/days plus either celecoxib 400 mg twice daily or placebo." | ( Bachelot, T; Crétin, J; Debled, M; Delozier, T; Falandry, C; Freyer, G; Mauriac, L; Mille, D; Pujade-Lauraine, E; Romestaing, P; You, B, 2009) |
| "Multidrug resistance (MDR) of breast cancer cells still represents an unmet medical need in chemotherapy." | ( Jeon, E; Onyüksel, H; Rubinstein, I, 2009) |
| "We discuss the characteristics of breast cancer that occurs after Hodgkin's lymphoma and also treatment options that could be implemented." | ( Alm El-Din, MA; El-Badawy, SA; Taghian, AG, 2008) |
| "Treatment of highly invasive MDA-MB-231 breast cancer cells with I3C shifted the stable accumulation of cyclin E protein from the hyperactive lower-molecular-mass 35-kDa form that is associated with cancer cell proliferation and poor clinical outcomes to the 50-kDa cyclin E form that typically is expressed in normal mammary tissue." | ( Aronchik, I; Bjeldanes, LF; Brar, GA; Firestone, GL; Nguyen, DH; Nguyen, HH, 2008) |
| "In total, 257 patients with metastatic breast cancer received platinum-containing chemotherapy at Samsung Medical Center from 1999 to 2006." | ( Ahn, JS; Cho, EY; Choi, YL; Im, YH; Jun, HJ; Kang, WK; Lee, SH; Lee, SJ; Park, K; Park, MJ; Park, YH; Uhm, JE; Yi, SY, 2009) |
| "Treatment of HER-2-negative metastatic breast cancer (MBC) patients after anthracycline exposure is controversial." | ( Bayo, J; Bernabé, R; Fernández, A; Fernández-Freire, A; Fuentes, J; Lomas, M; Moreno, A; Rodríguez, A; Ruiz, M; Salvador, J, 2008) |
| "Post-menopausal breast cancer patients scheduled to receive tamoxifen (n=31) or anastrozole (n=14) completed neuropsychological testing around the time of commencement of treatment (T1), and again 5-6 months later (T2)." | ( Bielajew, C; Collins, B; Mackenzie, J; Stewart, A; Verma, S, 2009) |
| "In hormone-receptor-positive breast cancer, meta-analysis data from older trials, and more specific recent trial data have made clearer the chronic natural history of this broad subtype of disease and the central role of hormonal therapy in its control." | ( Love, RR; Uy, GB, 2008) |
| "After local therapy, women with early breast cancer remain at risk of recurrence for an extended period." | ( Chlebowski, RT, 2008) |
| "Thirty-three women with breast cancer were recruited to examine the APOE polymorphism and fasting plasma lipid profiles before and after tamoxifen treatment for 6 months." | ( Chang, NW; Chen, DR; Chen, FN; Lin, CF; Wu, CT, 2009) |
| "To estimate the risk for breast cancer in Finnish women using postmenopausal estradiol (E2)-progestogen therapy." | ( Lyytinen, H; Pukkala, E; Ylikorkala, O, 2009) |
| "The risk for breast cancer in E2-progestogen therapy users was compared with that in the general population." | ( Lyytinen, H; Pukkala, E; Ylikorkala, O, 2009) |
| "The risk of lobular breast cancer increased sooner than that for ductal cancer and was detectable for E2-progestogen therapy use less than 3 years (1." | ( Lyytinen, H; Pukkala, E; Ylikorkala, O, 2009) |
| "In particular, the risk of breast cancer in women who used conjugated estrogen plus progestin for 4 or more years is approximately three times higher than in women who are not exposed to hormone therapy, so that the background incidence rate for women aged 50 to 64 years, which is around 3 per 1,000, would be increased to approximately 9 per 1,000 in women aged 50 to 64 years who have taken conjugated estrogen plus progestin for 48 months or more." | ( Hagberg, KW; Jick, H; Jick, SS; Kaye, JA, 2009) |
| "We report a case of advanced breast cancer with skin ulceration and bleeding (T4bN3bM0: Stage IIIC) achieving a significant improvement of QOL by toremifene and paclitaxel therapy." | ( Amano, S; Enomoto, K; Kitajima, A; Sakurai, K; Shiono, M; Tani, M, 2008) |
| "We here describe a case of advanced breast cancer (Stage IV) in which an oral S-1+TAM therapy following a primary systemic chemo-radiotherapy has been effective in maintaining the patient's QOL." | ( Enomoto, T; Hayashi, K; Iizuka, M; Kuranami, M; Nakakuma, T; Sengoku, N; Watanabe, M; Yoshimura, N, 2008) |
| "Taxol is widely used in breast cancer chemotherapy." | ( Besson, P; Gillet, L; Le Guennec, JY; Roger, S; Tran, TA; White, E, 2009) |
| "Mammograms from 148 women treated for breast cancer before and after surgery were reviewed: 68 were administered tamoxifen; 80 did not receive tamoxifen." | ( De Felice, C; Labi, L; Meggiorini, ML; Porfiri, LM; Savelli, S; Vestri, AR, 2008) |
| "Twenty-three human breast cancer cell lines were treated in monolayer culture with BMS-536924, and cell viability was measured." | ( Attar, RM; Carboni, JM; Fairchild, CR; Gottardis, MM; Kim, HJ; Kuiatse, I; Lee, AV; Litzenburger, BC, 2009) |
| "No overall increased risk for breast cancer was shown with infertility treatment." | ( Chia, KS; Conner, P; Czene, K; Dickman, PW; Hall, P; Holte, J; Nilsson, SJ; Orgéas, CC; Persson, I; Sanner, K; Sundfeldt, K; Wedren, S, 2009) |
| "Therapy decisions in advanced breast cancer (ABC) increasingly require assessment not only of treatment efficacy but also of cost-effectiveness." | ( Harbeck, N; Hartmann, M; Jackisch, C; Lux, MP; Oyee, J; Possinger, K; Raab, G; Schneeweiss, A, 2009) |
| "Thirty-three newly diagnosed breast cancer patients who received a total doxorubicin dosage of 240 mg/m2 over four treatment cycles as part of adjuvant chemotherapy after curative breast surgery were included in this study." | ( Akin, AM; Alan, S; Altintas, A; Cil, T; Isikdogan, A; Kaplan, AM, 2009) |
| "ONJ was recorded for all patients with breast cancer or gynecological malignancies treated with intravenous bisphosphonates at the Department of Gynecology and Obstetrics, University Hospital Tuebingen during April, 1999 and May, 2006." | ( Banys, M; Beck, V; Fehm, T; Hairass, M; Krimmel, M; Lipp, HP; Reinert, S; Solomayer, EF; Wallwiener, D, 2009) |
"Women with measurable metastatic breast cancer and | ( Chia, S; Dent, S; Eisenhauer, EA; Ellard, S; Ellis, PM; Gelmon, K; Powers, J; Seymour, L; Vandenberg, T; Walsh, W, 2009) | |
| "Fortunately, the mortality rate from breast cancer has decreased in recent years due to an increased emphasis on early detection and more effective treatments." | ( Izevbigie, E; Tchounwou, P; Yedjou, C, 2008) |
| "For treatment of recurrent breast carcinoma, S-1 is considered to be a useful and tolerable anticancer drug, and combination treatment of S-1 and ZOL is thought to be effective." | ( Arita, K; Hiranuma, S; Kuramochi, J; Kurokawa, T; Matsumoto, A; Sanada, K; Takiguchi, N; Tanaka, Y; Usui, S, 2009) |
| "Thirty-two consecutive women with breast cancer were injected in the arm ipsilateral to their breast cancers prior to radiation treatment with 0." | ( Alavi, A; Basu, S; Cheville, AL; Das, I; Schuerman, J; Solin, LJ; Srinivas, S; Velders, L, 2009) |
| "The patient was diagnosed with breast carcinoma 4 months after initial presentation and underwent resective surgery, radiotherapy, and hormonotherapy." | ( Abbott, RJ; Qaddoura, B; Rajabally, YA, 2008) |
| "Women diagnosed with breast cancer typically undergo a multimodal approach to treating their disease." | ( Reigle, BS; Wonders, KY, 2009) |
| "The care of patients with breast cancer has become increasingly complex with advancements in diagnostic modalities, surgical approaches, and adjuvant treatments." | ( Hansen, NM; Hulvat, MC; Jeruss, JS, 2009) |
| "Eighty-eight stage II and III breast cancer outpatients are randomly assigned to receive yoga (n = 44) or brief supportive therapy (n = 44) prior to radiotherapy treatment." | ( Ajaikumar, BS; Gopinath, KS; Kumar, V; Madhavi, YS; Nagarathna, R; Nagendra, HR; Nalini, R; Raghavendra, RM; Ramesh, BS; Rekha, M; Srinath, BS; Vadiraja, HS; Vanitha, N; Vishweshwara, MS, 2009) |
| "The failure of breast cancer treatment is largely due to the development of estrogen independence." | ( Cai, H; Cao, D; Chen, G; Diao, F; Jin, Y; Li, Y; Lu, J; Zhao, J, 2010) |
| "Patients with breast cancer often receive emetogenic anthracycline-based chemotherapy as part of their treatment." | ( Chan, A; Shih, V; Wan, HS, 2009) |
| "Clinical studies demonstrate that breast cancer patients treated with adjuvant tamoxifen who have decreased CYP2D6 due to genetic polymorphisms or drug interactions may have an increased risk of recurrence and reductions in disease-free survival." | ( Gaston, C; Kolesar, J, 2008) |
| "Subsequently, the incidence of breast cancer also dropped, suggesting a cause-and-effect relation between hormone treatment and breast cancer." | ( Anderson, G; Aragaki, AK; Chlebowski, RT; Gass, M; Hendrix, SL; Kuller, LH; Lane, DS; Manson, JE; Ockene, JK; Prentice, RL; Rajkovic, A; Ravdin, PM; Rohan, TE; Sarto, GE; Schenken, R; Stefanick, ML; Yasmeen, S, 2009) |
| "The increased risk of breast cancer associated with the use of estrogen plus progestin declined markedly soon after discontinuation of combined hormone therapy and was unrelated to changes in frequency of mammography." | ( Anderson, G; Aragaki, AK; Chlebowski, RT; Gass, M; Hendrix, SL; Kuller, LH; Lane, DS; Manson, JE; Ockene, JK; Prentice, RL; Rajkovic, A; Ravdin, PM; Rohan, TE; Sarto, GE; Schenken, R; Stefanick, ML; Yasmeen, S, 2009) |
| "Most patients with breast cancer need anthracycline-based chemotherapy regimens in the adjuvant setting, and an increasing number of them receive taxanes either in this setting or as first-line therapy for metastatic breast cancer (MBC)." | ( Hatake, K; Ito, Y; Iwase, T; Miura, H; Seto, Y; Sugihara, T; Takahashi, S; Tanabe, M; Tokudome, N, 2009) |
| "Estrogen receptor status in breast cancer is associated with response to hormonal therapy and clinical outcome." | ( Cheang, MC; Chia, SK; Leung, S; Liu, S; Mehl, E; Nielsen, TO; Rajput, A, 2010) |
| "33 patients (30 prostate carcinoma, 3 breast carcinoma) were treated with 150 MBq 89SrCl2 (9 patients), 1295 MBq 186Re-HEDP (12 patients) or 37 MBq/kg 153Sm-EDTMP (12 patients)." | ( de Klerk, JM; Hoekstra, A; Lam, MG; van Rijk, PP; Zonnenberg, BA, 2009) |
| "General treatments for breast cancer patients, such as surgery, chemotherapy, radiotherapy and lymphatic edema drainage, are performed at the Department of Breast Surgery in Kyushu Central Hospital." | ( Futagami, K; Higuchi, M; Kitamura, K; Matsuo, K; Nishino, H; Ogata, K; Ureshino, Y, 2009) |
| "Inflammatory breast cancer (IBC) is the most aggressive form of locally advanced breast cancer (LABC) characterized by rapid growth and aggressive invasion with no selective therapies developed to treat IBC." | ( Cristofanilli, M; Ghosh, S; Mazumdar, A; McMurray, JS; Robertson, FM; Shah, AH; Simeone, AM, 2008) |
| "It would be a tracking system form for breast cancer patients in Malaysia to help treatment outcomes." | ( Nor Aina, E, 2008) |
| "Eligible patients had HER2+ breast cancer, progressive brain metastases, prior trastuzumab, and cranial radiotherapy." | ( Blum, JL; Brufsky, A; Christodoulou, C; Ciruelos, E; Dharan, B; Diéras, V; Gori, S; Greil, R; Lin, NU; Liu, MC; Loibl, S; Lossignol, D; Oliva, C; Paoletti, P; Paul, D; Roché, H; Roychowdhury, D; Rubin, SD; Stemmler, HJ; Steplewski, K; Wardley, A; Winer, EP; Yardley, D; Zembryki, D, 2009) |
| "Among the breast cancer xenograft tumors, however, tumors with significantly increased CDK1 specific activity after paclitaxel treatment were sensitive to paclitaxel in vivo, whereas tumors without such an increase were resistant to paclitaxel in vivo." | ( Gohda, K; Hortobagyi, GN; Ishihara, H; Katayama, A; Kawasaki, Y; Matsushima, T; Nakayama, S; Noguchi, S; Sakai, T; Sudo, T; Takahashi, T; Torikoshi, Y; Ueno, NT; Yoshida, T, 2009) |
| "Studies of the natural history of breast cancer have shown that, while not reaching zero at any time point, the risk of recurrence is highest in the first 5 years following initial diagnosis and treatment." | ( Toi, M; Tsuji, W; Yamashiro, H, 2009) |
| "Using human MCF-7 breast cancer cells, we examined the effects of c9,t11 and t10,c12 CLA compared to oleic acid (OA), linoleic acid (LA), or untreated cells on cell membrane phospholipid composition, cell survival, and the insulin-like growth factor-I (IGF-I) and the downstream insulin receptor substrate-1 (IRS-1)." | ( Amarù, DL; Field, CJ, 2009) |
| "Female patients with locally advanced breast cancer being planned for the anthracycline-based neoadjuvant chemotherapy were included in this study." | ( Fatima, N; Hashmi, A; Hashmi, H; Nasir, Z; Raza, T; Zaman, MU, 2009) |
| "Patients with metastatic breast cancer who are pretreated with anthracyclines frequently receive taxane-based combinations." | ( Antón, A; Carrasco, E; Chan, S; Delozier, T; du Bois, A; Frimodt-Moller, B; Fumoleau, P; Harrison, M; Huober, J; Jones, A; Kreienberg, R; Llombart, A; Lluch, A; Mayordomo, JI; Romieu, G; Schneeweiss, A; Tubiana-Hulin, M; Vaury, AT, 2009) |
| "Sixty-five stage IV breast cancer patients, 13 pre-treated with hormones, 38 with chemotherapy and 15 with both, received, as a salvage therapy, TAM, beta-IFN and R." | ( Bisegna, R; Bratta, M; Candeloro, G; Necozione, S; Rea, S; Recchia, F; Sica, G, 2009) |
| "The ability of both normal-like and breast cancer cells to recover from DENSPM treatment was also studied." | ( Alm, K; Johansson, M; Myhre, L; Oredsson, SM, 2009) |
| "Patients with HER-2-positive breast cancer that progresses during treatment with trastuzumab were randomly assigned to receive capecitabine (2,500 mg/m(2) body-surface area on days 1 through 14 [1,250 mg/m(2) semi-daily]) alone or with continuation of trastuzumab (6 mg/kg body weight) in 3-week cycles." | ( Andersson, M; Bauer, W; Baumann, KH; Clemens, MR; Cufer, T; de Jongh, FE; du Bois, A; Duerr, R; Kaufmann, M; Loibl, S; Maartense, E; Maass, N; Nekljudova, V; Schmidt, M; Stein, RC; Uleer, C; von Minckwitz, G; Zielinski, C, 2009) |
| "MDA-MB-468 human breast cancer cells were treated overnight with (111)In-diethylenetriaminepentaacetic acid human epidermal growth factor ((111)In-DTPA-hEGF, 0-142 kBq/pmol) or exposed to gamma-radiation to induce DNA double strand breaks (DSB)." | ( Cai, Z; Reilly, RM; Vallis, KA, 2009) |
| "As more and more patients survive breast cancer, compliance with adjuvant therapy becomes increasingly important." | ( Hadji, P, 2010) |
| "Patients developing visceral breast cancer metastases generally receive chemotherapy rather than endocrine therapy." | ( Abreu, P; Cameron, DA; Campos, SM; Guastalla, JP; Subar, M; Winer, EP, 2009) |
| "When p53 is positive in triple-negative breast cancer, we could expect poor survival, prompting aggressive or alternative treatment." | ( Bae, JS; Chae, BJ; Jung, SS; Kim, JS; Lee, A; Park, WC; Seo, YJ; Song, BJ, 2009) |
| "Given the common hormonal dependence of breast cancer and the potential synergistic effect of these two treatment modalities, this strategy has been increasing in the adjuvant setting." | ( Azria, D; Belkacémi, Y; Gligorov, J; Jacot, W; Ozsahin, M; Romieu, G; Zaman, K, 2009) |
| "In MCF-7 human breast cancer cells, we previously reported that treatment with [Ca(2+)](o) for 24h leads to an over-expression of the Transient Receptor Potential Canonical 1 (TRPC1) cation channel and cell proliferation." | ( Ahidouch, A; El Hiani, Y; Lehen'kyi, V; Ouadid-Ahidouch, H, 2009) |
| "A total of 1,355 women with operable breast cancer were randomly assigned to one of three treatments: surgery followed by adjuvant doxorubicin (75 mg/m(2)) followed by cyclophosphamide, methotrexate, and fluorouracil (CMF; arm A); surgery followed by adjuvant paclitaxel (200 mg/m(2)) plus doxorubicin (60 mg/m(2)), followed by CMF (arm B); or paclitaxel (200 mg/m(2)) plus doxorubicin (60 mg/m(2)) followed by CMF followed by surgery (arm C)." | ( Baselga, J; Bonadonna, G; Bozhok, A; Byakhov, M; Cussac, AL; Eiermann, W; Gianni, L; Greco, M; Lluch, A; Lopez, JJ; Mansutti, M; Martinez-Agulló, A; Porta, VG; Raab, G; Sabadell, D; Semiglazov, V; Valagussa, P; Zambetti, M, 2009) |
| "However in the loco-regional breast cancer the treatment based on anthracycline was significantly better than that of the treatment based on CMF." | ( Afqir, S; Ahid, S; Arifi, S; Bazid, Z; Bekkouch, I; Benjaafar, N; El Gueddari, Bel K; El Mesbahi, O; Elmajjaoui, S; Erraki, A; Errihani, H; Ismaili, M; Ismaili, N; Masbah, O; Mellas, N; Tazi, MA, 2009) |
| "Fifty-five women with metastatic breast cancer resistant to anthracycline and/or taxane treatment were included." | ( Baracos, VE; Koski, S; Mackey, JR; McCargar, LJ; Mourtzakis, M; Pituskin, E; Prado, CM; Reiman, T; Sawyer, MB; Tonkin, K, 2009) |
| "NIS is expressed in >70% of breast cancers but at a level insufficient for radioiodine treatment." | ( Brent, GA; Kagechika, H; Kogai, T; Ohashi, E, 2009) |
| "Gene expression alterations of breast cancer were specific to doxorubicin and docetaxel treatment, and yielded mechanistic insights into resistance to either drug." | ( Goh, BC; Iau, P; Lee, SC; Lim, SE; Lim, YW; McLeod, H; Sukri, N; Tan, P; Tan, SH; Xu, X; Yap, HL; Yeo, WL, 2009) |
| "Adjuvant treatment of breast cancer with aromatase inhibitors has been associated with increased bone loss." | ( Hadji, P; Hasenburg, A; Kalder, M; Kieback, DG; Kuck, J; Menschik, T; Ziller, M, 2009) |
| "Early-stage breast cancer patients who were premenopausal at cancer diagnosis and treatment." | ( DeMichele, A; Gracia, CR; Green, J; Horn, M; Matro, J; Sammel, MD; Stankiewicz, C; Su, HI; Velders, L, 2010) |
| "A total of 127 breast cancer subjects who were premenopausal at cancer diagnosis and underwent cyclophosphamide-based chemotherapy were genotyped for nine single-nucleotide polymorphisms (SNPs) in enzymes involved in cyclophosphamide activation (CYP3A4, CYP2B6, CYP3A5) and detoxification (GSTA1, GSTM1, GSTP1, GSTT1)." | ( DeMichele, A; Gracia, CR; Green, J; Horn, M; Matro, J; Sammel, MD; Stankiewicz, C; Su, HI; Velders, L, 2010) |
| "However, only approximately 20% of breast cancer patients achieve a pathologic complete response, a fact that necessitates methods for monitoring therapeutic effectiveness early during therapy." | ( Avril, N; Roylance, R; Sassen, S, 2009) |
| "It is thought breast cancers respond to neoadjuvant chemotherapy of docetaxel alone regardless of HER2 status." | ( Aogi, K; Mimae, T; Nishimura, R; Ohsumi, S; Taira, N; Takabatake, D; Takashima, S, 2009) |
| "31 patients with breast cancer who had progressive metastatic bone disease despite treatment with early-generation BPs were switched to zoledronic acid." | ( Amir, E; Clemons, MJ; Dranitsaris, G; Simmons, CE; Trinkaus, M, 2009) |
| "Tumors from low-risk breast cancer patients randomized to adjuvant tamoxifen therapy or no adjuvant treatment were analyzed with immunohistochemistry to investigate protein expression of 17HSD1 and 17HSD2 in 912 cases." | ( Delander, L; Fornander, T; Gunnarsson, C; Jansson, A; Nordenskjöld, B; Skoog, L; Stål, O, 2009) |
| "These results indicated that breast cancer cell resistant to chemotherapy was associated with a group of microRNAs." | ( Chen, GQ; Liu, YJ; Yang, HJ; Zhao, ZW; Zhou, HY, 2010) |
| "When breast cancer cells were treated with NaPa in the presence of an MMP inhibitor (GM6001), apoptotic cell death decreased and the induction of autophagic vacuoles in MDA-MB-231 cells was inhibited." | ( Augustin, S; Berard, M; Crépin, M; Fauvel-Lafève, F; He, L; Kellaf, S; Legrand, C; Peyri, N, 2009) |
| "Of the 42,000 breast cancer patients who overexpress the HER2 growth factor receptor, <35% are responsive to treatment with the HER2-disabling antibody, called trastuzumab (Herceptin)." | ( Bamdad, C; Fessler, SP; Mahanta, SK; Wotkowicz, MT, 2009) |
| "cost effective and tailored breast cancer systemic treatment for low and middle income countries." | ( Elzawawy, A, 2009) |
| "Postmenopausal breast cancer risk associated with hormone therapy may be modified by genetically determined variations in phase I and II enzymes involved in steroid hormone metabolism." | ( , 2010) |
| "Five patients with advanced breast cancer and 1 patient with metastatic lung cancer responded to the chemotherapy." | ( Elson, P; Peereboom, D; Thomas Budd, G; Weiss, P; Wesolowski, R, 2010) |
| "Older women with breast cancer are underrepresented in clinical trials, and data on the effects of adjuvant chemotherapy in such patients are scant." | ( Becker, HP; Berry, DA; Burstein, HJ; Cirrincione, CT; Cohen, HJ; Dressler, LG; Gralow, JR; Grenier, D; Hart, RD; Hudis, CA; Kartcheske, PA; Kornblith, AB; Magrinat, G; Mahmood, AA; Mauer, AM; Muss, HB; Norton, L; Parker, BA; Partridge, AH; Perez, EA; Theodoulou, M; Wheeler, JD; Winer, EP; Wolff, AC, 2009) |
| "In the human breast cancer cell line MCF-7, I(2) treatment generates iodine-containing lipids similar to 6-iodo-5-hydroxy-eicosatrienoic acid and the 6-iodolactone (6-IL) derivative of arachidonic acid (AA), and it significantly decreases cellular proliferation and induces caspase-dependent apoptosis." | ( Aceves, C; Arroyo-Helguera, O; Cajero-Juárez, M; López-Bojorquez, L; Nuñez-Anita, RE, 2009) |
| "Node-positive breast cancer was treated with AC/ EC-weekly PAC, namely AC at 60/600 mg/m(2) or EC at 90/600 mg/m(2) x4 at three-week intervals, followed by weekly PAC (80 mg/m(2)) x 12, namely four cycles of single weekly administration for three weeks followed by a one-week rest (3 x 4 PAC) or single weekly administration for 12 consecutive weeks (12 PAC)." | ( Asaga, T; Chishima, T; Doi, T; Hamaguchi, Y; Ichikawa, Y; Inaba, M; Ishikawa, T; Kasahara, A; Katayama, K; Kito, A; Matsumoto, C; Momiyama, N; Morita, S; Narui, K; Ohta, I; Shimada, H; Shimizu, D; Shimizu, S; Suda, T; Tanabe, M; Yamaguchi, N; Yoshimoto, M, 2009) |
| "Treatment of breast cancer cells with PRL caused variable resistance to taxol, vinblastine, doxorubicin and cisplatin." | ( Afton, SE; Bahassi, el M; Ben-Jonathan, N; LaPensee, CR; LaPensee, EW; Schwemberger, SJ, 2009) |
| "However, for women, metastatic breast cancer still remains the number one cause of cancer death in Europe, and the detection and treatment of micrometastatic disease represent the most important challenge in breast cancer management." | ( Coleman, RE, 2009) |
| "The invasive breast cancer risk difference attributable to the hormone therapy was 0." | ( Cabral, H; Eaton, CB; Gramling, R; Lash, TL; Rothman, KJ; Silliman, RA, 2009) |
| "Twelve cases of invasive breast cancer occurred among 599 women breast cancer-free before treatment, giving an age adjusted IRR of 1." | ( Bell, RJ; Davis, SR; Farrugia, H; Ferdinand, A; Wolfe, R, 2009) |
| "Median survival from metastatic breast cancer is 12 months without treatment, but young people can survive up to 20 years with the disease, whereas in other metastatic cancers this would be considered unusual." | ( Slater, S; Slevin, M; Stebbing, J, 2007) |
| "Fourteen locally advanced breast cancers with clinical benefit on fulvestrant (250 mg/month) as first-line primary endocrine therapy had sequential serum bone-specific alkaline phosphatase (BAP), N-terminal propeptide of procollagen type 1 (PINP) and C-terminal telopeptide (CTX) at 0, 1, 6, 12, and 18 months." | ( Agrawal, A; Cheung, KL; Eastell, R; Hannon, RA; Robertson, JF, 2009) |
| "The incidence of breast cancer has increased steadily in the developed countries over the past few decades, but the mortality caused by breast cancer has decreased in recent years, partly because of improved screening techniques, surgical and radiotherapy interventions, understanding of the pathogenesis of the disease, and utilization of traditional chemotherapies in a more efficacious manner." | ( Fodor, J; Kásler, M; Polgár, C, 2009) |
| "Expression profiling of invasive breast carcinomas by DNA microarray techniques has identified five distinct subtypes of tumors (luminal A, luminal B, normal breast-like, HER2 overexpression, and basal-like) that are associated with different clinical outcomes and with different chemotherapy." | ( Ishihara, A; Kitagawa, K; Shiraishi, T; Tsuda, H; Yoneda, M, 2009) |
| "Study recruited 23 breast cancer patients and collected blood samples before (T0), at 1 (T1) and 24 hours (T24) after treatment administration." | ( Arredondo, F; Craft, N; DiGiulio, R; Il'yasova, D; Marcom, PK; Marks, J; Mixon, G; Spasojevich, I; Wang, F, 2009) |
| "Although some fear an increased risk of breast cancer with exogenous testosterone administration, recent studies support the idea that androgens can play a role in suppressing the proliferative effects of estrogen and progesterone." | ( Krapf, JM; Simon, JA, 2009) |
| "Diabetic patients with breast cancer receiving metformin and neoadjuvant chemotherapy have a higher pCR rate than do diabetics not receiving metformin." | ( Barnett, CM; Giordano, SH; Gonzalez-Angulo, AM; Hortobagyi, GN; Hsu, L; Hung, MC; Jiralerspong, S; Liedtke, C; Meric-Bernstam, F; Palla, SL, 2009) |
| "160 patients with stage II/III breast cancer, all females, aged 47 (22-66), were treated with docetaxel plus epirubicin or pirarubicin with 3 weeks as a cycle." | ( Chen, YQ; Jin, YC; Kong, QL; Li, J; Li, R; Li, XR; Ma, B; Wang, JD; Zhang, YJ; Zheng, YQ, 2009) |
| "About two-thirds of all breast cancer patients are treated with adjuvant hormonal therapy." | ( Albrich, S; Boehm, DU; Eckhardt, T; Kandelhardt, E; Koelbl, H; Lebrecht, A; Schmidt, M; Siggelkow, W, 2009) |
| "Five years previously breast cancer had been diagnosed and had been successfully treated with subtotal mastectomy and postoperative radiotherapy, as well as aromatase inhibitor until shortly before the present admission." | ( Adorf, D; Gehbauer, G; Guggemos, W; Hecht, A; Seilmaier, M, 2009) |
| "The aim of this study on primary breast cancer patients undergoing adjuvant tamoxifen treatment was to determine how their perceptions of the treatment and their experience of side-effects contributed to their adherence to the treatment." | ( Julian-Reynier, C; Lacour, AC; Largillier, R; Pellegrini, I; Sarradon-Eck, A; Soussan, PB; Tallet, A; Tarpin, C, 2010) |
| "A consecutive series of primary breast cancer patients eligible for tamoxifen therapy were studied qualitatively by conducting semi-structured in-depth interviews at two French cancer centres." | ( Julian-Reynier, C; Lacour, AC; Largillier, R; Pellegrini, I; Sarradon-Eck, A; Soussan, PB; Tallet, A; Tarpin, C, 2010) |
| "Primary breast cancer patients (n = 108) treated with neoadjuvant chemotherapy consisting of sequential paclitaxel and epirubicin-based chemotherapy were included in the study." | ( Kim, SJ; Morimoto, K; Noguchi, S; Shimazu, K; Taguchi, T; Tamaki, Y; Tanei, T; Tanji, Y, 2009) |
| "Our findings suggest that breast cancer stem cells identified as ALDH1-positive, but not CD44(+)/CD24(-), play a significant role in resistance to chemotherapy." | ( Kim, SJ; Morimoto, K; Noguchi, S; Shimazu, K; Taguchi, T; Tamaki, Y; Tanei, T; Tanji, Y, 2009) |
| "Indeed, treatment of breast cancer cells with lapatinib reduced FoxM1 expression at protein, mRNA and gene promoter levels." | ( Coombes, RC; Filipovic, A; Francis, RE; Gojis, O; Guest, SK; Hartman, J; Krol, J; Lam, EW; McGovern, UB; Myatt, SS; Palmieri, C; Peck, B; Peston, D; Shousha, S; Sicinski, P; Wang, J; Yu, Q, 2009) |
| "A total of 116 breast cancer patients were divided into 3 groups: Thirty-eight patients in group A were given epirubicin (Epi) of 120-340 mg/m(2), 42 patients in group B received epirubicin of > or = 360 mg/m(2), and 36 patients after surging without chemotherapy served as the control group C." | ( Bi, X; Deng, Y; Li, C; Wu, Y; Zeng, F; Zhao, C; Zhu, Y, 2009) |
| "A 35-year-old woman with a history of breast cancer, treated 3 years ago with surgery, radiation, and chemotherapy presented with a rapid onset of severe Raynaud's phenomenon." | ( Allen, D; Mittoo, S; Robinson, D, 2010) |
| "The expressions of NFkappaB in breast cancer cells treated with curcumin were studied by immunochemistry and western blot." | ( Liu, Q; Loo, WT; Sze, SC; Tong, Y, 2009) |
| "The study included 656 postmenopausal breast cancer patients receiving ANA as postoperative adjuvant therapy in our hospital." | ( Ando, M; Baba, S; Dokiya, F; Douchi, T; Kosha, S; Matsuyama, Y; Ohi, Y; Rai, Y; Sagara, Y; Tamada, S, 2010) |
| "Extended adjuvant endocrine therapy for breast cancer with aromatase inhibitors may potentially alter the lipid profile of postmenopausal patients and thus increase the risk of developing cardiovascular disease." | ( Antonopoulou, Z; Dafni, U; Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Papadiamantis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2009) |
| "Locally advanced breast carcinoma represents a disease, where the combination of treatment--chemotherapy with antracycline and radiotherapy--is generally accepted as standard therapy." | ( Bustová, I, 2009) |
| "Every 21 days, sequential surgery of breast carcinoma, adjuvant chemotherapy FAC and irradiation." | ( Bustová, I, 2009) |
| "Women with breast cancer were treated for 12 months with 400 mg pentoxifylline t." | ( Höglund, P; Johansson, K; Jönsson, C; Killander, F; Kjellén, E; Magnusson, M; Malmström, P; Weddig, A, 2009) |
| "We tested 23 archival breast tumors as well as 136 archival head and neck cancers from ENHANCE, a Phase III trial of 351 patients randomized to Epo versus placebo concomitant with radiotherapy following complete resection, partial resection, or no resection of tumor." | ( Blau, CA; Henke, M; Kaiser, JF; Lowe, KA; Mattern, D; Miller, CP; Urban, N; Valliant-Saunders, K, 2009) |
| "Treatment choices are dependent on breast cancer biology (receptor status) as well as patient factors (ovarian function and desire for future fertility)." | ( Griggs, JJ; Henry, NL, 2009) |
| "A total of 17 breast cancer patients underwent RFA using a single needle featuring an internally cooled electrode; this was followed by whole-breast irradiation and adjuvant systemic therapy." | ( Fujimoto, H; Kazama, T; Miyazaki, M; Nagashima, T; Sakakibara, M; Sangai, T, 2009) |
| "Triple-negative breast cancer (TNBC) is an aggressive disease, nevertheless exhibiting a high response rate to chemotherapy." | ( Brighenti, E; Ceccarelli, C; Derenzini, M; Donati, G; Montanaro, L; Santini, D; Taffurelli, M; Treré, D, 2009) |
| "In women with lobular breast cancer under adjuvant anastrozole therapy, who present with vaginal bleeding, uterine metastasis of lobular carcinoma should be considered in the differential diagnosis." | ( Barisik, NO; Bilici, A; Gumus, M; Salepci, T; Salman, T; Seker, M; Ustaalioglu, BB; Yaylaci, M, 2009) |
| "Tamoxifen treatment for breast cancer does not appear to increase the risk of ovarian cancer in BRCA1 mutation carriers." | ( Domchek, S; Isaacs, C; Kauff, ND; Lubinski, J; Lynch, HT; Narod, SA; Rosen, B; Sun, P; Tung, N; Vicus, D, 2009) |
| "In the clinical treatment of breast cancer, antimitotic cytotoxic agents are one of the most commonly employed chemotherapies, owing largely to their antiproliferative effects on the growth and survival of adherent cells in studies that model primary tumor growth." | ( Balzer, EM; Cho, EH; Martin, SS; Matrone, MA; Whipple, RA, 2010) |
| "Nineteen breast cancer patients, all female, who failed to achieve complete remission (CR) or partial remission (PR) to the combination of anthracyclines and taxanes as neoadjuvant regimen were treated with 2 cycles of NP regimen (vinorelbine 25 mg/m(2), on days 1 and 8 and cisplatin 70 mg/m(2), on days 1 and 3, both by intravenous infusion, as a cycle)." | ( Duan, XN; Liu, YH; Xu, L; Ye, JM; Zhao, JX, 2009) |
| "All patients were diagnosed as invasive breast cancer by 14G core needle biopsy and treated with three cycles of VE regimen before the operation." | ( Chen, CM; Di, GH; Hou, YF; Hu, Z; Huang, O; Liu, GY; Lu, JS; Shao, ZM; Shen, KW; Shen, ZZ; Wu, J; Wu, JY; Zhang, JX, 2009) |
| "The survival rates of breast cancer patients have steadily improved over recent years; thus, research into symptoms that persist after treatment is important." | ( Buzdar, A; Morrow, PK; Reyes-Gibby, CC; Shete, S, 2009) |
| "The study was completed for 38 primary breast cancer patients (M0) who received pre-operative epirubicin and paclitaxel chemotherapy." | ( Fischer, T; Harbeck, N; Kates, R; Thomas, A; Warm, M, 2009) |
| "There is no standard treatment for breast cancer patients whose tumors have been exposed both to anthracyclines and taxanes." | ( Giannopoulos, A; Gogas, H; Markopoulos, C; Papadopoulos, O; Polyzos, A; Polyzos, K; Tsavaris, N, 2009) |
| "Inhibition of cyclin E expression in breast cancer cells can block their cell cycle at G(1) phase, reduce their cell growth, differentiation and proliferation, and increase their sensitivity to chemotherapy." | ( He, WS; Huang, T; Ren, JH, 2009) |
| "Primary breast cancer with an unmethylated BRCA1 gene is prone to achieve a pathological complete response to anthracycline-based neoadjuvant chemotherapy than those with a methylated BRCA1 gene." | ( Fan, T; Fan, ZQ; Li, JF; Lin, BY; Ouyang, T; Wang, TF; Xie, YT; Xu, Y; Yuan, P, 2009) |
| "From April 1998 to April 2004, 112 breast cancer patients were treated with neoadjuvant chemotherapy." | ( Fu, JF; Hong, ZW; Wang, B, 2009) |
| "We show here that treatment of human breast cancer cells with 17DMAG facilitates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis." | ( López-Pérez, AI; López-Rivas, A; Palacios, C, 2010) |
| "A decrease in breast cancer cell growth was observed in SK-BR-3 cells at 12 and 24 h post treatment with 100 microM of amentoflavone, followed by a dramatic suppression after 48 h." | ( Lee, JS; Lee, MS; Oh, WK; Sul, JY, 2009) |
| "To investigate the role of ENO-1 in breast cancer diagnosis and therapy, the mRNA levels of ENO-1 in 244 tumor and normal paired tissue samples and 20 laser capture-microdissected cell clusters were examined by quantitative real-time PCR analysis." | ( Chang, CC; Chen, CS; Chen, LC; Cheng, TC; Chu, JS; Ho, YS; Huang, CS; Lee, CH; Leu, SJ; Lin, HW; Shih, NY; Tam, KW; Tu, SH; Wang, YJ; Wu, CH, 2010) |
| "At the 6th European Breast Cancer Conference, the European School of Oncology Metastatic Breast Cancer Task Force convened an open debate on the relative benefits of combination vs sequential therapy." | ( Albain, KS; Bedard, PL; Cardoso, F; Costa, A; Cufer, T; Fallowfield, LJ; Kyriakides, S; Pagani, O; Senkus-Konefka, E; Winer, EP, 2009) |
| "Total RNA was extracted from MCF-7 breast cancer cells treated with 1,25-(OH)2D3 or WY1112 and was used for microarray analysis." | ( Beullens, I; Bouillon, R; De Clercq, P; De Moor, B; Eelen, G; Engelen, K; Marcelis, S; Marchal, K; Vanoirbeek, E; Verlinden, L; Verstuyf, A, 2009) |
| "Survival time for metastatic breast cancer (MBC) can be substantially improved by combination chemotherapy in the adjuvant setting." | ( Alexopoulos, A; Ardavanis, A; Ioannidis, G; Kandylis, C; Malliou, S; Orphanos, G; Rigatos, G; Stavrakakis, J, 2010) |
| "Eight pre/peri-menopausal women with breast cancer had middle ear analysis (tympanometry) and pure tone audiometry conducted prior to and 6 months following Fluorouracil, Epirubicin, Cyclophosphamide (FEC) or FEC plus taxotere chemotherapy treatments." | ( Jenkins, V; Low, R; Mitra, S, 2009) |
| "Patients with recurrent or advanced breast cancer who had measurable or evaluable lesions, and were diagnosed as having progressive disease during AI treatment and subsequently given TOR at 120 mg/day (TOR120) as endocrine therapy were selected and analyzed retrospectively in relation to their medical history." | ( Hozumi, Y; Ishikawa, T; Iwase, H; Kasahara, Y; Kimijima, I; Masuda, N; Ohtake, T; Saji, S; Sawaki, M; Yamamoto, Y; Yamashita, H, 2010) |
| "Adjuvant systemic treatment for breast cancer has evolved resulting in improved outcomes." | ( Gelmon, K; Kennecke, H; Knowling, M; Speers, C; Woods, R; Yerushalmi, R, 2010) |
| "Patients with metastatic breast cancer (MBC) are usually exposed to both anthracyclines and taxanes during neoadjuvant or adjuvant treatment of primary breast cancer or during initial therapy of MBC." | ( Chan, D; Chuah, B; Goh, BC; Lee, SC; Lim, SE; Soo, R; Tan, SH; Tiemsim Cordero, M; Wong, CI; Yeo, WL, 2010) |
| "Tissue microarrays containing 500 breast tumors from premenopausal women randomized to tamoxifen or no adjuvant treatment were evaluated for EPOR expression by immunohistochemistry." | ( Fredlund, E; Jirström, K; Landberg, G; Larsson, AM; Nilsson, S; Påhlman, S; Rydén, L, 2009) |
| "Treatment of breast cancer is becoming more individualized with the recognition of tumor subgroups that respond differently to available therapies." | ( Cornelissen-Steijger, P; Drost, R; Evers, B; Jonkers, J; Joosse, SA; Liu, X; Nederlof, P; Pietersen, AM; Puppe, J; van Lohuizen, M; Yu, Q, 2009) |
| "RF ablation was used to treat 87 breast cancer liver metastases (mean diameter, 2." | ( Andreano, A; Laeseke, PF; Lee, FT; Livraghi, T; Meloni, MF; Sironi, S, 2009) |
| "This can be attributed to lack of breast cancer awareness leading to late presentation and refusal of treatment, coupled with insufficient health service funding." | ( Chuah, JA; Kumar, VM; Leong, BD; Rohamini, S; Siti, ZS; Yip, CH, 2009) |
| "Brain metastases of breast cancer seem to be increasingin incidence as systemic therapy improves." | ( Aldape, K; Bronder, JL; Davis, G; Davis, S; Fitzgerald, D; Hua, E; Kurek, R; Mehdorn, HM; Meltzer, PS; Merino, MJ; Palmieri, D; Shreeve, SM; Stark, AM; Steeg, PS; Steinberg, SM; Weil, RJ, 2009) |
| "Chemotherapy is often used for breast cancer treatment, but individual outcome varies widely." | ( Chang, HR; Chung, DU; Faull, KF; He, J; Saxton, RE; Shen, D; Whitelegge, JP, 2009) |
| "Advances in breast cancer detection and treatment have contributed to improve the rate of survival, although mortality rates remains significantly high." | ( Bertollo, CM; Correa, CR; Goes, AM, 2009) |
| "After adaptation of the Dutch national breast cancer treatment guidelines, patients received prolonged and increased doses of anthracyclines." | ( Hokken, JW; Schep, G; van der Cruijsen-Raaijmakers, M; Vreugdenhil, G, 2009) |
| "We report our experience with advanced breast cancer patients who received combination therapy with trastuzumab+paclitaxel." | ( Ishii, M; Kimijima, I; Suzuki, M, 2009) |
| "In human breast cancer cells, we observed that treatment with SK inhibits tumor cell growth in estrogen receptor alpha (ERalpha)-positive, but not ERalpha-negative breast cancer cells." | ( Yao, Y; Zhou, Q, 2010) |
| "Triptolide treatment of MCF-7 breast cancer cells expressing ectopic ADAM10 or dominant negative ADAM10 (DN ADAM10) resulted in a decreased expression of ADAM10 with a concomitant increase in ADAM10 cleaved products." | ( Marignani, PA; Robertson, GS; Sayat, R; Soundararajan, R, 2009) |
| "We found that when the breast cancer cells were treated with alpha-ESA in the presence of the antioxidant alpha-tocotrienol (20 micromol/L), the growth inhibition and apoptosis effects of alpha-ESA were lost." | ( Cleary, MP; Dammen, ML; Grossmann, ME; Mizuno, NK; Ray, A; Schuster, T, 2009) |
| "The p53-overexpressing patients with breast cancer between 35 and 50 years of age who received tamoxifen following chemotherapy had the greatest adverse effect on outcome." | ( Ahn, SH; Kim, HJ; Kim, HS; Kim, JH; Lee, JW; Park, YL; Sohn, JH; Yom, CK, 2010) |
| "Among women with breast cancer treated with tamoxifen, there was an association between CYP2D6 variation and clinical outcomes, such that the presence of 2 functional CYP2D6 alleles was associated with better clinical outcomes and the presence of nonfunctional or reduced-function alleles with worse outcomes." | ( Ames, MM; Beckmann, MW; Boländer, J; Brauch, H; Eichelbaum, M; Fasching, PA; Fritz, P; Goetz, MP; Hamann, U; Ingle, JN; Koelbl, H; Kuffel, MJ; Safgren, SL; Schmidt, M; Schroth, W; Schwab, M; Simon, W; Strick, R; Suman, VJ; Ulmer, HU; Weinshilboum, RM; Winter, S, 2009) |
| "Using a set of 47 breast cancer patients, we obtained paired prechemotherapy and postchemotherapy tumor biopsies and developed gene panels of baseline tumor (T1), postchemotherapy tumor (T2), and chemotherapy-induced relative change signatures (TDelta) to predict pathological response and progression-free survival (PFS)." | ( Buhari, SA; Chng, WJ; Chuah, B; Goh, BC; Guo, J; Iau, P; Lee, SC; Lim, SE; Lim, YW; McLeod, HL; Sukri, N; Tan, P; Watson, M; Wong, CI; Xu, X; Yap, HL, 2009) |
| "Estrogen receptor (ER)-negative breast cancer is an aggressive form that currently requires more drug treatment options." | ( Chandramouli, A; Larsen, L; Nelson, MA; Rosengren, RJ; Somers-Edgar, TJ; Taurin, S, 2011) |
| "Women diagnosed with advanced breast cancer were randomly allocated to receive 3-weekly docetaxel (group D) or 3-weekly docetaxel alternating with 3-weekly gemcitabine (group D/G) until treatment failure as first-line chemotherapy." | ( Alanko, T; Asola, R; Bono, P; Hahka-Kemppinen, M; Huuhtanen, R; Joensuu, H; Kellokumpu-Lehtinen, P; Kokko, R; Leinonen, M; Pyrhönen, S; Sailas, L; Sunela, K; Turpeenniemi-Hujanen, T; Utriainen, M; Wigren, T, 2010) |
| "An intractable problem impeding breast cancer treatment by the most frequently prescribed endocrine therapy tamoxifen is the inevitable development of resistance, and the molecular mechanisms underlying this loss of responsiveness by breast cancers have been under intense investigation but are not yet fully elucidated." | ( Faller, DV; Wang, S; Zhang, B, 2009) |
| "We report the case of a woman with breast cancer and meningeal carcinomatosis who developed severe progressive myelopathy after four cycles of intrathecal MTX administration." | ( Ackermann, R; Fornoff, F; Hattingen, E; Linnebank, M; Maurer, GD; Semmler, A; Steinbach, JP, 2010) |
| "Its in vivo ability to bind to breast tumors responding to therapy was determined by treating nude mice, xenografted with various tumor cell lines, with sunitinib and using near IR imaging to assess the ability of the peptide conjugated to Alexafluor-750 to bind tumors." | ( Diaz, R; Hallahan, DE; Passarella, RJ; Phillips, JG; Wu, H; Zhou, L, 2009) |
| "Five patients with bleeding from breast cancer under various circumstances were treated with this technique in 2008." | ( Kakimoto, M; Okamura, T; Tokita, H; Yoshino, K, 2010) |
| "Tamoxifen is widely used in the breast cancer treatment." | ( Dupré, PF; Homer, L; Lucas, B; Muller, M; Pradier, O, 2009) |
| "Approximately 80% of breast cancers express the estrogen receptor-alpha (ERalpha) and are treated with anti-estrogens." | ( Cheung, LW; Hao, L; Miele, L; Osborne, BA; Osipo, C; Pannuti, A; Rizzo, P; Sonenshein, G; Wyatt, D, 2010) |
| "Patients with locally advanced breast cancer or MBC were treated with the aromatase inhibitor (AI) letrozole (2." | ( Caravelli, JF; Dang, C; Dickler, MN; Flombaum, CD; Fornier, M; Geneus, S; Grothusen, J; Hudis, CA; Lake, D; Melisko, ME; Norton, L; Park, JW; Patil, S; Paulson, M; Robson, M; Rugo, HS; Seidman, AD; Theodoulou, M; Traina, TA; Yeh, B, 2010) |
| "HER2-positive metastatic breast cancer (MBC) relapsing after trastuzumab-based therapy may require continued HER2 receptor inhibition to control the disease and preserve the patients' quality-of-life." | ( Allen, KE; Aogi, K; Arai, T; Ellis, CE; Fujiwara, Y; Gagnon, RC; Ito, Y; Iwata, H; Katsura, K; Nakamura, S; Rai, Y; Sasaki, Y; Taguchi, T; Takashima, S; Toi, M; Tokuda, Y; Wakamatsu, T; Watanabe, J, 2009) |
| "A serious complication associated with breast cancer treatment is the increased risk for development of therapy-related myeloid neoplasms (t-MN)." | ( Albain, KS; Bedell, V; Ellis, GK; Hortobagyi, GN; Lew, D; Livingston, RB; Martino, S; Perez, EA; Sher, D; Slovak, ML; Stock, W, 2010) |
| "Anthracyclines are a component of breast cancer chemotherapy regimens in both adjuvant and metastatic settings." | ( Clemons, MJ; Goel, R; Latreille, J; Panasci, L; Pouliot, JF; Provencher, L; Rahim, Y; Rayson, D; Trudeau, ME; Vandenberg, T; Yelle, L; Zibdawi, L, 2009) |
| "The UPR is activated in the majority of breast cancers and confers resistance to chemotherapy." | ( Balasubramanian, S; Coulson, S; Cross, S; Haines, R; Scriven, P; Wyld, L, 2009) |
| "Prognostic factors of breast cancer have been used for the prediction of clinical outcome or selection of patients for complementary treatment." | ( Chang, YW; Choi, DL; Kim, Y; Kwon, KH; Lee, DW; Lee, HK; Lee, MH; Seo, DY; Yang, SB, 2009) |
| "Forty-seven human breast cancer and immortalized cell lines representing the known molecular subgroups of breast cancer were treated with PD 0332991 to determine IC50 values." | ( Atefi, M; Chen, I; Cohen, DJ; Conklin, D; Dering, J; Desai, AJ; Finn, RS; Fowst, C; Ginther, C; Kalous, O; Los, G; Slamon, DJ, 2009) |
| "In spite of national guidelines, breast cancer treatment on specific issues widely varied between the various Dutch regions." | ( Beex, LV; de Jong, RS; Maartense, E; Meershoek-Klein Kranenbarg, WM; Nortier, JW; Putter, H; Roumen, RM; Seynaeve, C; van de Velde, CJ; van Nes, JG, 2010) |
| "As the majority of these breast cancer patients completed the initial chemotherapy plan, this study indicates that breast cancer patients with HCV can be treated with cytotoxic therapy." | ( Broglio, KR; Hahn, KM; Hortobagyi, GN; Kau, SC; Morrow, PKH; Tarrand, JJ; Taylor, SH; Theriault, RL, 2010) |
| "Human breast cancer cell lines (estrogen receptor-positive and -negative) were treated with tanshinone IIA and tamoxifen." | ( Chen, J; Lu, Q; Zhang, P; Zhang, X, 2009) |
| "Patients with advanced breast cancer pretreated with or ineligible for anthracycline-containing therapy were treated with capecitabine." | ( Gohler, T; Hesse, T; Nusch, A; Siedentopf, F; Sulberg, H, 2009) |
| "Over 60% of surgically treated breast cancer patients received either CMF (cyclophosphamide, methotrexate, fluorouracil) or CEF (cyclophosphamide, epirubicin, fluorouracil)." | ( Pan, IW; Shih, YC; Tsai, YW, 2009) |
| "While we studied breast cancer cells, the fluorine emulsions could be applied for treatment of other cancer cells overexpressing HER-2." | ( Bartusik, D; Tomanek, B, 2010) |
| "Patients with HER2-positive breast cancer were treated on two trials: ddAC followed by P and trastuzumab (T) and ddAC followed by PT and lapatinib." | ( Chen, C; Come, S; Dang, CT; Dickler, M; Godfrey, L; Hudis, CA; Lin, N; McArthur, HL; Morris, PG; Moy, B; Norton, L; Nulsen, B; Rugo, H; Steingart, R; Sugarman, S; Traina, T; Winer, E, 2009) |
| "Endocrine therapies of breast cancer are effective but ultimately fail because of the development of treatment resistance." | ( Brinkman, A; den Dekker, AT; Dorssers, LC; Foekens, JA; Leroy, IM; Meijer-van Gelder, ME; Sieuwerts, AM; Sleijfer, S; Smid, M; van Agthoven, T; van Ijcken, WF; Veldscholte, J, 2009) |
| "The results indicate that, in some breast cancer patients with ordinary menopause, E2 rebounds following AI therapy." | ( Hirose, T; Honda, J; Kira, M; Nagao, T; Nakamura, Y; Sasa, M; Takahashi, M; Tangoku, A; Zembutsu, H, 2009) |
| "Tamoxifen, an effective treatment of breast cancer, has been shown to cause ocular toxic effects." | ( Berezovsky, A; Gebrim, LH; Motono, M; Pereira, JM; Sacai, PY; Sallum, JM; Salomão, SR; Watanabe, SE, 2010) |
| "Treatment decisions for breast cancer patients are currently based on a small number of crude predictive markers, despite the known complexity and heterogeneity of the disease." | ( Hertz, DL; Hoskins, JM; McLeod, HL, 2009) |
| "Gallen early breast cancer conference: an update on the monotherapy arms of the BIG 1-98 study, and results from the sequential treatment arms." | ( Joerger, M; Thürlimann, B, 2009) |
| "Cumulative incidence analysis of breast cancer recurrence favors the initiation of adjuvant endocrine treatment with letrozole instead of tamoxifen, especially in patients at higher risk for early recurrence." | ( Joerger, M; Thürlimann, B, 2009) |
| "The MCF-7 breast cancer cell-line and nontumorigenic MCF-10A human mammary epithelial cells were treated with alpha-ESA and compared with negative control (without treatment) and positive control groups (treated with rosiglitazone), and changes of apoptosis-related molecules, PPARgamma and pERK1/2 were examined." | ( Cho, CS; Choi, YJ; Eom, JM; Guo, DD; Jo, K; Kang, JS; Lee, HG; Moon, HS; Yun, CH, 2010) |
| "In late reproductive-aged breast cancer survivors, there is a need for real-time biomarkers of postchemotherapy ovarian function." | ( DeMichele, A; Freeman, EW; Gracia, CR; Green, J; Matro, J; Sammel, MD; Stankiewicz, C; Su, HI; Velders, L, 2010) |
| "This cooperation may be targeted in breast cancer treatment by a combination of mTOR and MAPK inhibitors." | ( Holz, MK; Yamnik, RL, 2010) |
| "Parity also reduces mammary cancer risk in carcinogen-exposed rats, and administering pregnancy hormones to these animals is similarly effective." | ( Agarwal, A; Andersen, TT; Bennett, JA; Jacobson, HI; Lemanski, N; Narendran, A; Turner, KE, 2010) |
| "CYP2C8/9 polymorphisms may influence breast cancer-free survival after diagnosis due to their role in the metabolism of tamoxifen, paclitaxel, and other chemotherapy." | ( Bågeman, E; Ingvar, C; Jernström, H; Jönsson, PE; Rose, C, 2009) |
| "Seventy-six anthracycline-pretreated breast cancer patients were evaluated and were stratified according to previous treatment of advanced disease (group-1: not previously treated and group-2: previously treated)." | ( Andrés, R; Baselga, J; Bermejo, B; Ciruelos, EM; Cortés, J; Cortés-Funes, H; García, E; Gómez, P; Lluch, A; Manso, L; Mayordomo, JI; Mendiola, C; Muñoz, M; Ojeda, B; Rodríguez, CA; Saura, C, 2010) |
| "The median interval between breast cancer diagnosis and MBC was 52 months (range 0-479); 76% had received endocrine therapy for MBC, 58% had visceral involvement and 30% had 3 or more metastatic sites." | ( Brouste, V; Debled, M; Donamaria, C; Durand, M; Floquet, A; Madranges, N; Mauriac, L; Trainaud, A, 2009) |
| "Furthermore, breast cancer cells (MCF-7 (wild type p53) and MDA-MB-231 (mutant p53)) were treated with curcumin and the effect on expression of maspin gene at transcription and translation levels was analyzed by RT-PCR, immunofluorescence and Western blotting." | ( Bhatnagar, D; Mathur, S; Prasad, CP; Ralhan, R; Rath, G, 2010) |
| "Patients with early breast cancer surgically treated and eligible to adjuvant chemotherapy were enrolled." | ( Albrile, F; Biggi, A; Bobbio, M; Feola, M; Francini, A; Garrone, O; Merlano, M; Occelli, M; Visconti, G, 2011) |
| "Treatment of breast cancer cells with a combination of the EGFR-tyrosine kinase inhibitor (EGFR-TKI) gefitinib and the anti-ErbB-2 monoclonal antibody trastuzumab results in a synergistic antitumor effect." | ( D'Alessio, A; De Luca, A; Gallo, M; Lamura, L; Maiello, MR; Napolitano, M; Normanno, N; Rachiglio, AM, 2010) |
| "Women with early-stage breast cancers that express estrogen and/or progesterone receptors benefit from adjuvant hormonal therapy with antiestrogen drugs." | ( Ward, JH, 2010) |
| "Patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy or chemoradiotherapy were recruited to this study (n = 10)." | ( Czarnota, GJ; Soliman, H; Yaffe, MJ, 2009) |
| "Although endocrine treatment of breast cancer is effective and common practice, in advanced disease the development of resistance is nearly inevitable." | ( Dorssers, LC; Foekens, JA; Meijer, D; Meijer-van Gelder, ME; Sarwari, R; Sieuwerts, AM; Sleijfer, S; van Agthoven, T; van Agthoven, TL, 2010) |
| "The treatment of breast cancer cells with omega-3 PUFAs, but not omega-6 PUFAs, led to downregulation of EZH2." | ( Bommi, PV; Dimri, GP; Dimri, M; Khandekar, JD; Sahasrabuddhe, AA, 2010) |
| "For node-positive breast cancer, we investigated whether the recurrence score was prognostic in women treated with tamoxifen alone and whether it identified those who might not benefit from anthracycline-based chemotherapy, despite higher risks of recurrence." | ( Albain, KS; Allred, DC; Baehner, FL; Barlow, WE; Bugarini, R; Davidson, NE; Gralow, JR; Hayes, DF; Hortobagyi, GN; Hudis, C; Ingle, JN; Livingston, RB; Osborne, CK; Perez, EA; Pritchard, KI; Ravdin, P; Shak, S; Shepherd, L; Sledge, GW; Winer, EP; Yeh, IT; Yoshizawa, C, 2010) |
| "MDA-MB-436, MDA-MB-231 and MCF-7 breast cancer cells and MCF-10A non-malignant breast epithelial cells were treated with zoledronic acid in vitro, and the effect on Cenp-F localization was analysed by immunoflourescence microscopy." | ( Brown, HK; Coleman, RE; Holen, I; Ottewell, PD, 2011) |
| "A patient suffering from metastatic breast cancer and another one with metastatic nonsmall cell lung cancer were recently referred to our department because of severe dyspnea occurring during chemotherapy treatment." | ( Antonelli, G; Colina, P; Ferraù, F; Giamo, V; Parisi, A; Rotondo, S; Sessa, E; Vitale, FV, 2011) |
| "In the phase III study in breast cancer patients, the administration of Zarzio was efficacious and safe, triggering no immunogenicity." | ( Balser, S; Einmahl, S; Fuhr, U; Gascon, P; Kinzig-Schippers, M; Makhson, A; Muenzberg, M; Sörgel, F, 2010) |
| "We report a case of advanced breast cancer with skin ulceration and bleeding (T4bN3bM0, Stage IIIC) achieving a significant improvement of QOL by paclitaxel (PTX) and toremifene (TOR) therapy." | ( Amano, S; Enomoto, K; Fujisaki, S; Kitajima, A; Matsuo, S; Ogura, M; Sakurai, K; Shiono, M; Tani, M, 2009) |
| "In this study, MCF-7 breast cancer cells were treated with iejimalide A or B and analyzed for changes in cell-cycle dynamics, apoptosis, lysosomal pH, cytoplasmic pH, mitochondrial membrane potential, and generation of reactive oxygen species." | ( Davisson, VJ; Devitt, E; Helquist, P; Kluesner, N; McHenry, P; McKee, E; Schweitzer, D; Tenniswood, M; Wang, WL, 2010) |
| "This phase II study in breast cancer patients assessed the utility of a single 6 mg subcutaneous dose of pegfilgrastim administered on day 9 of an intravenous (IV) "split" CMF (cyclophosphamide 600 mg/m(2), methotrexate 40 mg/m(2) and 5-fluorouracil 600 mg/m(2)) chemotherapy regimen administered on days 1 and 8 and repeated every 28 days for 6 cycles." | ( Bacon, P; Casas, A; Castellanos, J; Duque, A; Falcone, A; Gridelli, C; Lawrinson, S; Mansutti, M; Mattioli, R; Skacel, T, 2009) |
| "Eligible patients had metastatic breast cancer and were treated with PLD according to the dose and schedule determined by their physician as part of routine practice." | ( Fett, W; Gerhardt, S; Goehler, T; Huober, J; Lück, HJ; Neise, M; Nusch, A; Rost, A; Schmidt, M; Wischnik, A, 2010) |
| "Recent evidence suggests that breast cancer and other solid tumors possess a rare population of cells capable of extensive self-renewal that contribute to metastasis and treatment resistance." | ( Birnbaum, D; Brown, M; Cabaud, O; Charafe-Jauffret, E; Diebel, ME; Dontu, G; Ginestier, C; Guan, JL; Korkaya, H; Liu, S; Luo, M; Wicha, MS; Wicinski, J, 2010) |
| "The increased survival of patients with breast cancer has given rise to other problems associated with the complications of chemotherapy." | ( Choi, D; Im, YH; Koo, YA; Park, HJ; Yoon, BK, 2010) |
| "Patients with high-risk, operable breast cancer were treated with three cycles of paclitaxel followed by concurrent paclitaxel/radiation." | ( Ayers, GD; Bauer, JA; Caprioli, RM; Chakravarthy, AB; De Matos Granja-Ingram, N; Formenti, SC; Johnson, KN; Kelley, MC; Mayer, IA; Means-Powell, JA; Meszoely, IM; Mi, D; Olivares, MG; Pietenpol, JA; Rosenbluth, JM; Sanders, ME; Schneider, RJ; Seeley, EH; Tsai, CJ, 2010) |
| "In women with early breast cancer receiving adjuvant chemotherapy, the most powerful predictor of benefit from anthracyclines is Ch17CEP duplication." | ( Bartlett, JM; Caldas, C; Cameron, DA; Campbell, FM; Dunn, JA; Earl, H; Hiller, L; Jordan, S; McConkey, C; Munro, AF; Pharoah, P; Poole, CJ; Provenzano, E; Rea, DW; Thomas, J; Twelves, CJ, 2010) |
| "In patients with breast cancer, large clinical trials of UFT-based postoperative chemotherapy conducted in Japan have shown that UFT is useful for the treatment of intermediate-risk patients with no lymph node metastasis." | ( Nakayama, T; Noguchi, S, 2010) |
| "Twenty-six breast cancer women (56+/-13 years, all post-menopausal) were prospectively evaluated during their first and third course of chemotherapy (4-week interval)." | ( Benlakehal, M; Cottu, P; Gay-Bellile, C; Guillon, H; Houzé, P; Le Bricon, T, 2010) |
| "Ninety-one patients with metastatic breast cancer who had been previously treated with anthracyclines and/or taxanes were treated with UFT and leucovorin, given orally, for the first 28 days of a 35-day cycle." | ( Booser, DJ; Heim, W; Hortobagyi, GN; Hutchins, L; Kirshner, J; Mason, B; Rivera, E, 2010) |
| "Given the importance of estrogens in breast cancer growth, aromatase inhibitors are used to treat breast cancer in different settings." | ( Colleoni, M; Dellapasqua, S, 2010) |
| "Further, bortezomib-treated breast cancer cells showed induction of the unfolded protein response, with upregulation of CH OP and GRP78." | ( Barrett, JR; Bhalla, KN; Erickson, B; Ganapathy, V; Gopal, E; Hill, WD; Jackson, WH; Periyasamy-Thandavan, S; Raney, L; Samaddar, JS; Schoenlein, PV, 2010) |
| "Patterns of breast cancer care continue to be amended because of the more frequent use of anthracyclines and taxanes in earlier lines of therapy (particularly in the adjuvant setting) and the emergence of multidrug resistance." | ( Stein, A, 2010) |
| "In pre-menopausal breast cancer PM or IM patients, an increase in dosage of tamoxifen or a treatment with LH-RH analogues with aromatase inhibitors (AI) may be beneficial instead of the actual recommendations of a 5-year tamoxifen therapy." | ( Barrière, J; Ferrero, JM; Formento, JL; Milano, G, 2010) |
| "An analysis of mRNA expression in T47D breast cancer cells treated with the synthetic progestin R5020 revealed a subset of progesterone receptor (PR) target genes that are enriched for E2F binding sites." | ( Brown, M; Eaton, ML; Geistlinger, TR; Jansen, MS; Kobayashi, S; Lobenhofer, EK; Lupien, M; McDonnell, DP; Nevins, JR; Otteson, DC; Wade, HE; Zhu, W, 2010) |
| "Thirty-eight patients with invasive breast cancer of >3 cm and/or lymph node metastasis underwent FDG PET/CT before neoadjuvant chemotherapy." | ( Aukema, TS; Gilhuijs, KG; Olmos, RA; Peeters, MJ; Rutgers, EJ; Schot, ME; Straver, ME; Vogel, WV, 2010) |
| "The treatment of inflammatory breast cancer (IBC) has been hampered by the diagnostic rarity of the disease and its consequent inclusion in clinical trials of preoperative treatment for the more indolent locally advanced breast cancer (LABC)." | ( Overmoyer, BA, 2010) |
| "Patients with metastatic breast cancer receiving intravenous bisphosphonate (IVBP) therapy who had > or =3 osseous lesions on nuclear bone scan were eligible." | ( Divgi, C; Grewal, RK; Hudis, CA; Larson, S; Mak, AF; Modi, S; Morris, PG; Patil, S; Poznak, CV, 2010) |
| "Triple-negative breast cancer (TNB) has poor prognosis and moreover patients with TNB do not benefit from established targeted drugs with endocrine therapy or trastuzumab." | ( Fernö, M; Haglund, M; Jirström, K; Rydén, L; Stål, O, 2010) |
| "PR expression in breast cancer decreases after neoadjuvant chemotherapy, while ER and Her-2 expressions remain stable." | ( Li, T; Liu, YH; Qin, XQ; Wang, YH; Ye, JM; Yin, HF; Zhang, H, 2009) |
| "Patients suffering from breast cancers have a poor prognosis because of the lack of effective agents and treatment strategies." | ( Dash, R; Fisher, PB; Mandal, M; Mazumdar, A; Sarkar, D; Sarkar, S, 2010) |
| "Risk of death from breast cancer after completion of tamoxifen treatment, as a function of the proportion of time on tamoxifen during which each SSRI had been co-prescribed." | ( Austin, PC; Duong-Hua, M; Gomes, T; Juurlink, DN; Kelly, CM; Paszat, LF; Pritchard, KI, 2010) |
| "Lastly, breast cancer patients whose tumors overexpress LMW-E were not responsive to AI treatment." | ( Akli, S; Biernacka, A; Bui, T; Hunt, KK; Keyomarsi, K; Moulder, S; Tucker, SL; Wingate, H, 2010) |
| "A cohort of women with breast cancer, a tumour commonly treated with oestrogen antagonists, was examined to identify the subsequent risk of developing OAC." | ( Cooper, SC; Croft, S; Day, R; Thomson, CS; Trudgill, NJ, 2010) |
| "Patients with invasive ductal breast cancer where polychemotherapy was indicated were monitored in the period from 2005-2007." | ( Bacić, I; Druzijanić, N; Jagić, S; Karlo, R; Skifić, I, 2010) |
| "In the clinically relevant group of breast cancer patients, (18)F-FDG uptake in BAT can be reduced by a single oral administration of diazepam combined with controlled room temperature in resting rooms." | ( Aukema, TS; Hoefnagel, CA; Valdés Olmos, RA; Vogel, WV, 2010) |
| "Aromatase-expressing breast cancer cells were treated with letrozole and ZA either simultaneously or in sequence, and the resulting apoptosis was assessed by staining with Hoechst 33342 and propidium iodide and examined using a fluorescent inverted Leica DMIRB microscope and a UV filter." | ( Coleman, RE; Holen, I; Neville-Webbe, HL, 2010) |
| "Chemotherapy for breast cancer is given on the basis of empirical information from clinical trials, an approach which falls to take into account the known heterogeneity of chemosensitivity between patients." | ( Min, HY; Ning, YL; Qi, CJ; Qian, KQ; Ye, H; Zhu, YL, 2009) |
| "Nine patients with breast cancer who were scheduled to receive neoadjuvant chemotherapy were recruited." | ( Fukuma, E; Oyama, Y; Tozaki, M, 2010) |
| "Accordingly, treatment of the breast cancer cells with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine reverses the methylation of the PDLIM2 promoter, restored PDLIM2 expression, and suppressed tumorigenicities of human breast cancer cells both in vitro and in vivo." | ( Cheng, SY; Fu, J; Hu, J; Qu, Z; Xiao, G; Yan, P, 2010) |
| "The Danish Breast Cancer Cooperative Group (DBCG) 77B trial examined the relative efficacy of levamisole, single-agent oral cyclophosphamide, and the classic combination of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) against no adjuvant systemic therapy in high-risk breast cancer patients." | ( Andersen, J; Andersson, M; Ejlertsen, B; Jensen, MB; Kamby, C; Knoop, AS; Mouridsen, HT, 2010) |
| "Trastuzumab plays an important role in breast cancer therapy." | ( Barok, M; Hemmilä, P; Ilvesaro, J; Isola, J; Köninki, K; Pitkänen, J; Staff, S; Tanner, M, 2010) |
| "In the Stockholm trial, breast cancer survivors were randomized to HT (estradiol and progestogen) or to a control group (no treatment)." | ( Brandberg, Y; Carlström, K; Fahlén, M; Svensson, G; von Schoultz, E; Wallberg, B; Wilking, N, 2011) |
| "Adjuvant treatment of early breast cancer has changed considerably in recent years, and the majority of patients are currently treated with the most active single agents in this setting." | ( Conti, F; Di Lauro, L; Foggi, P; Lopez, M; Vici, P; Viola, G, 2009) |
| "Human SK-BR3 and MCF-7 breast carcinoma cell growth and capacity of anchorage transfected with siRNA-Egr-1 or treated with cpt was slower than that of the control group." | ( Ferreira, J; Parra, E, 2010) |
| "Various agents used in breast cancer chemotherapy provoke DNA double-strand breaks (DSBs)." | ( Asakawa, H; Fukuda, M; Iwase, H; Koike, A; Koizumi, H; Ohta, T; Takahashi, M; Wu, W, 2010) |
| "The role of angiogenesis inhibition in breast cancer treatment should continue to be defined using more efficacious and specific inhibitors." | ( Barton, JH; Burris, HA; Greco, FA; Hainsworth, JD; Jones, SF; Meluch, AA; Shipley, D; Yardley, DA, 2010) |
| "Patients with primary breast cancer treated with adjuvant tamoxifen for 2 years were included." | ( Bendahl, PO; Falck, AK; Fernö, M; Rydén, L, 2010) |
| "Ninety-four patients with metastatic breast cancer who had been previously treated with anthracyclines and/or taxanes were treated with UFT and leucovorin, given orally, for the first 28 days of a 35-day cycle." | ( Gore, I; Hermann, R; Hortobagyi, GN; Ibrahim, NK; Karwal, M; Murray, JL; Watkins, SP; Young, RR, 2010) |
| "In patients with metastatic breast cancer whose pretreatment status ranged from no prior therapy to progression on several classes of agents, overall response rates (ORR) in the phase II ixabepilone monotherapy trials ranged from 6 to 55%, comparable to rates seen in patients with non-triple-negative tumors." | ( Moreno-Aspitia, A; Patel, T; Perez, EA, 2010) |
| "PURPOSE Although most breast cancer patients who receive neoadjuvant chemotherapy (NCT) have a tumor response, a small proportion experience progressive disease (PD)." | ( Caudle, AS; Gonzalez-Angulo, AM; Hortobagyi, GN; Hunt, KK; Kuerer, HM; Liu, P; Meric-Bernstam, F; Mittendorf, EA; Pusztai, L; Symmans, WF, 2010) |
| "Given the important role of the breast cancer resistance protein (ABCG2/BCRP) in the efflux of conjugated forms, the present study investigates the bioavailability and tissue distribution of trans-resveratrol and its metabolites after the oral administration of 60 mg/kg in Bcrp1(-/-) mice." | ( Alfaras, I; Alvarez, AI; Juan, ME; Merino, G; Pérez, M; Planas, JM; Prieto, JG, 2010) |
| "Eligible women with advanced breast cancer treated with taxanes in the adjuvant or metastatic setting received pemetrexed 500 mg/m2 on day 1 followed by gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle." | ( Elias, AD; Gralow, J; Muscato, J; Neubauer, M; O'Shaughnessy, JA; Orlando, M; Pippen, J; Shonukan, O; Stokoe, C; Vaughn, LG; Wang, Y, 2010) |
| "We recruited 9 newly diagnosed breast cancer patients scheduled for induction chemotherapy." | ( Bahrani-Mougeot, FK; Brennan, MT; Coleman, S; Frenette, G; Kent, ML; Lockhart, PB; Mougeot, JL; Napeñas, JJ; Noll, J; Nussbaum, ML; Paster, BJ, 2010) |
| "In this study, we report that, in MCF-7 breast cancer cell, expressing both ERalpha and ERbeta, PTRF treatment increases ERbeta nuclear translocation, as demonstrated by immunofluorescence experiments and significantly inhibits ERalpha expression (-458." | ( Ambra, R; Canali, R; Comitato, R; Leoni, G; Nesaretnam, K; Virgili, F, 2010) |
| "Fifty-four patients with breast cancer (mean age, 47 years; age range, 30-74 years) treated with NAC protocol and enrolled in a breast MR imaging research study were studied." | ( Bahri, S; Chen, JH; Hsu, CC; Hsu, FT; Lin, M; Nalcioglu, O; Nie, K; Shih, HN; Su, MY, 2010) |
| "An increased risk of breast cancer with extended use is another reason short-term treatment is advised." | ( Schiff, I; Shifren, JL, 2010) |
| "This patient with advanced breast cancer accompanied by distant metastasis responded to trastuzumab/docetaxel combination therapy." | ( Kanzaki, M; Maeda, M; Matsumoto, K; Miyoshi, S; Takano, Y; Teshima, S; Wakita, T; Yoshinouchi, S, 2010) |
| "A 35-year-old woman with recurrent breast cancer with liver metastasis was treated with classical CMF because they had been resistant to anthracycline, taxane and vinorelbine." | ( Chishima, T; Hasegawa, S; Ichikawa, Y; Ishikawa, T; Shimizu, D, 2010) |
| "Of 1020 new breast cancer patients, 918 (90%) were oestrogen receptor (OR) positive and were started on gT as part of their treatment." | ( Blencowe, NS; Gahir, J; Paterson, I; Reichl, C, 2010) |
| "Most older women with early-stage breast cancer were adherent to short-term oral chemotherapy in a randomized clinical trial." | ( Archer, L; Berry, D; Gralow, J; Grenier, D; Hudis, C; Kastrissios, H; Kornblith, AB; Muss, H; Partridge, AH; Perez, E; Wang, X; Winer, E; Wolff, AC, 2010) |
| "In subcutaneous MDA-MB-435 human breast cancer xenograft models, RRV-mediated yCD and TK suicide gene therapy significantly suppressed tumor growth after prodrug administration." | ( Lu, YC; Luo, YP; Tai, CK; Wang, YW, 2010) |
| "Osteoporosis is of concern in breast cancer patients who are undergoing chemotherapy." | ( Cheung, MN; Chow, LW; Jin, LJ; Loo, WT; Wang, M, 2010) |
| "Human ER-negative MDA-MB231 breast cancer cells were treated with different doses of Tam and Ral." | ( Kaufmann, Y; Klimberg, VS; Luo, S; Todorova, VK, 2011) |
| "Tamoxifen, commonly used in breast cancer treatment, may interfere with the protective effects of estrogen and increase risk of PD." | ( Destefano, AL; Dybdahl, M; Lash, TL; Latourelle, JC; Myers, RH, 2010) |
| "In this substudy, breast cancer patients taking adjuvant letrozole during the fifth year of treatment had better cognitive function than those taking tamoxifen, suggesting aromatase inhibitors do not adversely impact cognition compared with tamoxifen." | ( Bernhard, J; Cardoso, F; Coates, AS; Gelber, RD; Goldhirsch, A; Harvey, V; Pagani, O; Phillips, KA; Price, KN; Ribi, K; Stephens, A; Sun, Z; Thompson, A; Thürlimann, B, 2010) |
| "Patients with breast cancer treated with adjuvant tamoxifen between 1994 and 2006 were included." | ( Casparie, MK; Dezentjé, VO; Egberts, AC; Gelderblom, H; Guchelaar, HJ; Nortier, JW; Putter, H; van Blijderveen, NJ; van Herk-Sukel, MP, 2010) |
| "Successful treatment of breast cancer relies on a better understanding of the molecular mechanisms involved in breast cancer initiation and progression." | ( Beland, FA; Chekhun, VF; Kovalchuk, O; Pogribny, IP; Shpyleva, SI; Starlard-Davenport, A; Tryndyak, VP, 2011) |
| "In a group of women with early breast cancer (EBC) and baseline Vitamin D deficiency (<30 ng/ml) who are treated with AI, we aim to describe: serum levels of Vitamin D, bone mineral density (BMD), calcium intake, and the increase of serum 25(OH)D accomplished in 3 months of treatment with Vitamin D supplements." | ( Albanell, J; Diez-Perez, A; Mellibovsky, L; Nadal, R; Nogues, X; Peña, MJ; Prieto-Alhambra, D; Servitja, S; Tusquets, I, 2010) |
| "Patients with metastatic breast cancer have a five-year survival rate of 27% compared to 98% for localized cancer, and the presence of even a few cancer cells in lymph nodes, known as isolated tumor cells or nanometastases, significantly increases the risk of relapse in the absence of aggressive treatment." | ( Bagby, TR; Cai, S; Cohen, MS; Davies, NM; Diab, HM; Forrest, ML; Thati, S, 2010) |
| "Metastatic breast cancer patients who had received no chemotherapy for recurrent disease received capecitabine 825 mg/m(2) twice daily, on days 1-21 of a 28-day cycle until disease progression or unacceptable toxicity." | ( Abe, C; Akagi, K; Masuda, N; Nakayama, T; Nishida, Y; Noguchi, S; Ogino, N; Sakamoto, J; Taguchi, T; Yoshidome, K; Yoshikawa, Y, 2010) |
| "The patient had a medical history of breast cancer with bone metastasis that was treated by chemotherapy with 45 mg pamidronate in 2 weekly courses for 16 months." | ( Inokuchi, S; Koga, C; Koga, M; Kusukawa, J; Tanaka, Y; Yokomizo, Y, 2010) |
| "Treatment of breast cancer cell lines with a combination of DSF-Cu and LY294002, a pan-PI3K inhibitor, resulted in the significant inhibition of cell growth when compared with either drug alone." | ( Chen, D; Chen, W; Cui, QC; Dou, QP; Ethier, SP; Ringler, J; Wu, G; Zhang, H, 2010) |
| "We retrospectively analyzed 103 breast cancer patients who were treated with neoadjuvant chemotherapy including epirubicin-based chemotherapy followed by docetaxel." | ( Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K, 2010) |
| "Neutropenia occurring in early breast cancer patients during the initial neoadjuvant treatment is strongly associated with a better prognosis." | ( Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K, 2010) |
| "In a follow-up a 74-year-old woman with breast cancer (clinical stage T4N1M0 at onset, treatment by surgical resection and tamoxifen) presented a combination of two distinct diseases in the lung: breast cancer metastasis and tuberculosis." | ( Cartei, G; Endri, M; Fassina, A; Serino, FS; Zustovich, F, 2010) |
| "OVX mice with established ER+ human breast tumors (MCF-7) were treated for 8 wk with basal diet (BD, control) or BD supplemented with SDG (1 g/kg), FO (38." | ( Chen, J; Corey, P; Saggar, JK; Thompson, LU, 2010) |
| "Taxanes are agents for the treatment of breast cancer." | ( Barni, S; Borgonovo, K; Petrelli, F, 2010) |
| "A 47 years-old female with breast cancer was performed total mastectomy six years ago and received six cures of chemotherapy after surgery." | ( Aydemir, S; Bacakoğlu, F; Taşbakan, MS; Yamazhan, T, 2010) |
| "Basal-like/EGFR+ SUM149 breast cancer tumors were completely resistant to treatment with lapatinib alone but highly growth impaired with lapatinib plus radiotherapy, exhibiting an enhancement ratio average of 2." | ( Camp, JT; Kimple, RJ; Livasy, CA; Peters, E; Sambade, MJ; Sartor, CI; Shields, JM, 2010) |
| "Patients with primary breast cancer who have extensive axillary lymph node involvement have a poor prognosis after conventional adjuvant therapy." | ( du Bois, A; Harbeck, N; Hinke, A; Huober, J; Jackisch, C; Konecny, GE; Kreienberg, R; Kuhn, W; Kurbacher, C; Lueck, HJ; Moebus, V; Nitz, U; Runnebaum, IB; Schneeweiss, A; Thomssen, C; Untch, M; von Minckwitz, G, 2010) |
| "Patients with hormone-resistant breast cancer are assigned to either TS-1 (40-60 mg twice daily for 28 consecutive days, followed by a 14-day rest period) or standard chemotherapy (docetaxel 60-75 mg/m(2) at 3- or 4-week intervals, paclitaxel 175 mg/m(2) at 3- or 4-week intervals or paclitaxel 80-100 mg/m(2) weekly, followed by a 1-week rest period)." | ( Hozumi, Y; Masuda, N; Mitsuyama, S; Mukai, H; Murakami, S; Ohashi, Y; Ohmura, T; Takashima, T; Watanabe, T; Yajima, T, 2010) |
| "Less ER-positive secondary breast cancers occurred in the TAM treated patients than in follow-up patients (1 vs 10, p = 0." | ( Bidoli, E; Crivellari, D; Lombardi, D; Magri, MD; Miolo, G; Scalone, S; Veronesi, A, 2010) |
| "To examine this approach in breast cancer, a Phase I trial was conducted in which zoledronate, a Vgamma9Vdelta2 T cell agonist, plus low-dose interleukin (IL)-2 were administered to 10 therapeutically terminal, advanced metastatic breast cancer patients." | ( Buccheri, S; Caccamo, N; Cicero, G; D'Asaro, M; Dieli, F; Eberl, M; Guggino, G; Hayday, AC; La Mendola, C; Meraviglia, S; Orlando, V; Roberts, A; Scarpa, F; Stassi, G; Todaro, M; Vermijlen, D, 2010) |
| "We experienced 3 cases of recurrent breast cancer treated with S-1 therapy, delaying tumor progression and improving their quality of life (QOL)." | ( Kaisaki, S; Kato, M; Kitayama, J; Nagawa, H; Sanuki, J; Yamaguchi, H, 2010) |
| "Most breast cancers elaborate oestrogen receptors (ER) and in such cases endocrine therapies such as tamoxifen and aromatase-inhibitors (AIs) are effective adjuvant treatments." | ( Eden, JA, 2011) |
| "Treatments for inflammatory breast cancer (IBC) have changed over the last 15 to 20 years." | ( Ashley, S; Johnston, SR; Smith, IE; Sutherland, S; Walsh, G, 2010) |
| "The paradigm of early breast cancer treated by epirubicin according to a branch of an actual clinical trial (the Trial of Principle, TOP trial) has been addressed." | ( Desmedt, C; Dionysiou, DD; Georgiadi, ECh; Kolokotroni, EA; Stamatakos, GS, 2010) |
| "A significant proportion of breast cancer patients face failure of endocrine therapy due to the acquisition of endocrine resistance." | ( Arnoni, MV; Lanari, C; Novaro, V; Polo, ML; Riggio, M; Wargon, V, 2010) |
| "The occurrence of uterine cancer in breast cancer patients who received tamoxifen treatment, is well described." | ( Khunamornpong, S; Suprasert, P, 2010) |
| "Forty-four patients with primary breast cancer clinically classified as cT2, cT3 or cT4(a-c) cN0-N2 or cN3 M0 and with a baseline FDG PET scan positive both in the site of primary tumour and axillary lymph nodes underwent neoadjuvant therapy and then a second FDG PET scan." | ( Bagnardi, V; Cardillo, A; Colleoni, M; De Cicco, C; Dellapasqua, S; Galimberti, V; Gilardi, L; Montagna, E; Paganelli, G, 2010) |
| "A recurrent breast cancer patient received high-dose chemotherapy, a transplant of multidrug resistance 1 (MDR1)-transduced cells and four different protocols of post-transplantation chemotherapy." | ( Aiba, K; Hatake, K; Hosoyama, H; Ito, Y; Katayama, K; Mitsuhashi, J; Noguchi, K; Sugimoto, Y; Takahashi, S; Tsukahara, S, 2010) |
| "The increasing incidence of breast cancer in Asia and the limitations of existing treatments pose additional challenges." | ( Chan, A; Gril, B; Kim, SB; Kurebayashi, J; Liu, L; Lu, YS; Moon, H; Vogel, C, 2010) |
| "A total of 2074 patients diagnosed with breast cancer between 1994 and 2008 who were treated with neoadjuvant anthracycline- and taxane-based chemotherapy were included." | ( Bondy, ML; Chavez-Macgregor, M; Chen, H; Giordano, SH; Gonzalez-Angulo, AM; Hortobagyi, GN; Hudis, CA; Litton, J; Valero, V; Wolff, AC, 2010) |
| "We then studied 167 breast cancer patients who received tamoxifen-combined therapy to evaluate the effects of concomitant treatment on the association analysis and observed no significant association between CYP2D6 genotype and recurrence-free survival (P=0." | ( Aki, F; Hirata, K; Hosono, N; Kiyotani, K; Kubo, M; Mushiroda, T; Nakamura, Y; Ohsumi, S; Okazaki, M; Okazaki, Y; Sasa, M; Takatsuka, Y; Tsunoda, T; Yamakawa, T; Zembutsu, H, 2010) |
| "Patient-derived breast cancer cells were injected into mouse abdominal or thoracic mammary glands +/- estrogen and/or etoposide pretreatment." | ( Fleming, JM; Ginsburg, E; Meyer, MJ; Miller, TC; Vonderhaar, BK, 2010) |
| "A 60-yr-old woman with breast cancer underwent breast-conserving surgery followed by 6 cycles of adjuvant chemotherapy (cyclophosphamide, epirubicin, and fluorouracil) and radiation therapy (dose, 5,040 cGy to the left breast and a 1,000 cGy boost to the tumor bed)." | ( Cho, J; Hur, M; Lee, CH; Lee, HG; Moon, HW; Yun, YM, 2010) |
| "Patients with breast cancer were enrolled in a trial of adjuvant AI therapy." | ( A'Hern, R; Charles, P; Flockhart, DA; Hayes, DF; Henry, NL; Li, L; Nguyen, AT; Pchejetski, D; Stearns, V; Stebbing, J; Storniolo, AM; Waxman, J, 2010) |
| "Patients with early-stage breast cancer, treated with endocrine therapy, have approximately 90% 5-year disease-free survival." | ( Bartlett, JM; Beck, RA; Cameron, DA; Campbell, FM; Chetty, U; Jack, W; Johnstone, L; Kerr, GR; Kunkler, IH; Munro, A; Pedersen, HC; Ring, BZ; Ross, DT; Seitz, RS; Thomas, J, 2010) |
| "Lung, prostate, and breast cancer cells were treated with IR (2-8 Gy) after incubation with either ATM or AMPK inhibitors or the AMPK activator metformin." | ( Bristow, RG; Cutz, JC; Harding, S; Liu, C; Rashid, A; Sanli, T; Singh, G; Tsakiridis, T; Wright, J, 2010) |
| "Treatment of MCF-7 breast cancer cells with shikonin inhibits estrogen-induced 8-hydroxy-2-deoxyguanosine (8-OHdG), a marker of DNA damage." | ( Brodie, AM; Davidson, NE; Kensler, TW; Yao, Y; Zhou, Q, 2010) |
| "To compare quality of life (QOL) in breast cancer patients from a developing country after breast conservation surgery (BCS) or mastectomy and adjuvant radiotherapy (RT)." | ( Badwe, R; Budrukkar, A; Dutta, D; Gupta, S; Jalali, R; Kakkar, S; Munshi, A; Parmar, V; Sarin, R, 2010) |
| "We studied 95 patients affected by breast cancer and under treatment with taxanes as adjuvant, metastatic or neo-adjuvant therapy." | ( Baricordi, OR; Ferlini, A; Indelli, M; Lelli, G; Rimessi, P; Rizzo, R; Spaggiari, F, 2010) |
| "MCF-7 breast cancer cells were injected intra-tibially into vitamin D deficient and vitamin D sufficient mice co-treated with and without osteoprotegerin (OPG)." | ( Conigrave, AD; Dunstan, CR; Ooi, LL; Seibel, MJ; Trivedi, T; Zheng, Y; Zhou, H, 2010) |
| "MDA-MB-231 cells, a human breast cancer cell line, were treated with various concentrations of LA (0, 250, 500, or 1000 mumol/L) to measure metastasis, MMP activity, and mRNA expression." | ( Kim, WK; Lee, HS; Na, MH, 2010) |
| "The use of endocrine therapy in breast cancer represents one of the earliest molecular targeting strategies used in cancer treatment." | ( Aapro, MS, 2010) |
| "MCF-7 breast cancer cells were treated with sodium butyrate, vitamin E succinate or 12-O-tetradecanoylphorbol-13-acetate to induce differentiation as measured by Nile Red staining of lipid droplets and β-casein expression." | ( Drabsch, Y; Gonda, TJ; Robert, RG, 2010) |
| "Patients with breast cancer (BC) experience bone loss as a result of either cancer treatment or metastatic disease to the bone." | ( Brufsky, AM, 2010) |
| "Thirteen patients with breast cancer-related acute DIC were treated with various kinds of chemotherapy, one with tamoxifen, and two with supportive care only." | ( Chang, DY; Cheng, AL; Huang, CS; Lin, CH; Lin, PH; Lu, YS; Yeh, KH, 2010) |
| "Basal-like breast cancer poses serious clinical challenges as there are currently no targeted therapies available to treat it." | ( Cheong, SK; Choo, HL; Chua, CH; Chung, C; Fow, C; Kong, WY; Lee, CY; Leong, CO; Lim, JY; Quah, SI; Rosli, R; So, I; Tan, BS; Tiong, KH; Wong, SW; Yue, YC, 2011) |
| "Endocrine therapy in the setting of breast cancer has undoubtedly advanced clinical outcomes in this disease, but treatment with endocrine therapy is accompanied by a wide spectrum of side effects." | ( Agrawal, K; Mortimer, JE; Onami, S; Pal, SK, 2010) |
| "Postmenopausal women with advanced breast cancer received 6 cycles of intravenous chemotherapy (5-fluorouracil [5-FU], epirubicin, and cyclophosphamide) and exemestane 25 mg/day that was continued after chemotherapy was completed." | ( Aguilar, EA; Baena Cañada, JM; Conejo, EA; de la Haba-Rodriguez, J; Mancha, RG; Manga, GP; Rovira, PS, 2010) |
| "Patients with HER2-overexpressing breast cancers who were to undergo planned trastuzumab therapy first received unlabeled trastuzumab (4-8 mg/kg IV), followed 4 hours later by 5 mCi (111)In-MxDTPA-trastuzumab (10 mg antibody)." | ( Colcher, D; Raubitschek, A; Shively, JE; Somlo, G; Williams, LE; Wong, JY; Wu, AM; Yamauchi, D; Yazaki, P, 2010) |
| "The results compared vitamin C-treated breast cancer patients with normal individuals and showed that co-administration of vitamin C is more beneficial in breast cancer patients treated with tamoxifen." | ( Amanullah, S; Basha, MI; Boopalan, S; Muralikrishnan, G; Shakeel, F; Vijayakumar, S, 2010) |
| "As adjuvant chemotherapy for breast cancer, the addition of taxane to regimens containing anthracycline has been shown to be effective." | ( Abe, H; Cho, H; Kawai, Y; Kubota, Y; Kurumi, Y; Mekata, E; Mori, T; Tanaka, M; Tani, T; Umeda, T, 2010) |
| "Patients with invasive breast cancer of >3 cm and/or proven axillary lymph node metastasis were included for before neo-adjuvant chemotherapy." | ( Aukema, TS; Gilhuijs, KG; Olmos, RA; Peeters, MJ; Russell, NS; Rutgers, EJ; Straver, ME; Vogel, WV, 2010) |
| "Plasma samples of 310 breast cancer patients undergoing anti-estrogen therapy were analyzed." | ( Beer, B; Hubalek, M; Meraner, V; Oberacher, H; Oberguggenberger, A; Schubert, B, 2010) |
| "There were 312 deaths from breast cancer, in the tamoxifen treated patients, with over 18000 years of cumulative follow-up." | ( Abraham, JE; Baynes, C; Caldas, C; Driver, KE; Dunning, AM; Earl, HM; Greenberg, D; Ingle, S; Kalmyrzaev, B; Luccarini, C; Maranian, MJ; Pharoah, PD; Platte, R; Shah, M, 2010) |
| "Basal-like breast cancers are triple-negative (estrogen receptor negative, progesterone receptor negative, erythroblastic leukemia viral oncogene homolog 2 (ERBB2) negative) tumors with an aggressive clinical behavior that lacks effective molecular targets for therapy." | ( Inoue, J; Ishida, T; Ito, T; Semba, K; Shimizu, T; Watanabe, S; Yamaguchi, N; Yamamoto, M, 2010) |
| "208 women with breast cancer who were to receive whole breast radiation therapy." | ( Gosselin, TK; Plambeck, MA; Rowe, K; Schneider, SM, 2010) |
| "The heterogeneity of breast cancer is now understood on a molecular level, and different targeted therapeutic strategies have been approved in an attempt to tailor treatment strategies." | ( Awada, A; Azim, HA; Metzger Filho, O; Saini, KS, 2012) |
| "Brain metastases of breast cancer appear to be increasing in incidence, confer significant morbidity, and threaten to compromise gains made in systemic chemotherapy." | ( Adkins, CE; Bohn, KA; Gaasch, JA; Gril, B; Huang, S; Lockman, PR; Mittapalli, RK; Palmieri, D; Roberts, A; Rudraraju, V; Smith, QR; Steeg, PS; Taskar, KS; Thorsheim, HR, 2010) |
| "Moreover, GI-101A breast cancer xenografts were effectively treated by the combination therapy." | ( Chen, N; Donat, U; Gentschev, I; Hess, M; Krewer, B; Seubert, CM; Stritzker, J; Sturm, JB; Szalay, AA; Tietze, LF; von Hof, JM, 2011) |
| "Subsequently, MDA-MB-436 breast cancer cells, which produce high levels of both TF and VEGF (western blot analysis), were established in vivo, following which tumours were treated three times per week for 3 weeks with intra-tumoural injections of either anti-VEGF siRNA, anti-TF shRNA, the two treatments combined, or relevant controls." | ( Amarzguioui, M; Bluff, JE; Brown, NJ; Reed, MW; Slattery, J; Staton, CA, 2011) |
| "Patients with breast cancer exposed to chemotherapy (n = 60; mean age, 51." | ( Ahles, TA; Furstenberg, CT; Hanscom, BS; Kaufman, PA; Li, Y; McDonald, BC; Mulrooney, TJ; Saykin, AJ; Schwartz, GN, 2010) |
| "We report on a 34-year-old woman with breast cancer who developed gross hematuria after initiation of carboplatin-based chemotherapy." | ( Mohamed, I; Shafiq, Q; Taj, A; Vijendra, D, 2011) |
| "Patients with early breast cancer who presented asthenia >3 on the Visual Analogue Scale (VAS) after the first cycle of docetaxel-based chemotherapy were included." | ( Anido, U; Areses, C; Bernárdez, B; Calvo, M; Candamio, S; Cueva, JF; Curiel, T; Gallardo, E; García, J; Gayoso, L; Javier Barón, F; Jesús Lamas, M; León, L; López, R; Vázquez, F; Vidal, Y, 2012) |
| "Determination of HER2 status in breast cancer has become important to identify potential candidates for anti-HER2 therapy." | ( Baraskar, N; Basak, R; Chacko, R; Chinoy, R; Desai, S; Epari, S; Gupta, S; Gursale, S; Hawaldar, R; Karpate, A; Panjwani, P; Rajsekharan, P; Shet, T; Shirsat, H, 2010) |
| "Treatment of breast cancer cells with CDK inhibitors (flavopiridol; roscovitine) enhanced the lethality of the ERBB1 inhibitor lapatinib in a synergistic fashion." | ( Bareford, MD; Dent, P; Eulitt, P; Hossein, H; Martin, AP; Mitchell, C; Nephew, KP; Yacoub, A; Yang, C, 2010) |
| "Two hundred and forty-two breast cancer patients initiating chemotherapy were randomized to usual care (n = 82), resistance exercise (RET, n = 82), or AET (n = 78) groups for the duration of their chemotherapy (median, 17 weeks)." | ( Courneya, KS; Dolan, LB; Gelmon, K; Lane, K; Mackey, JR; McKenzie, DC; Reid, RD; Segal, RJ, 2010) |
| "Nude rats bearing breast cancer bone metastases were treated with sorafenib tosylate (7 mg/kg, n=11), paclitaxel (5mg/kg, n=11) or the combination of both (n=10) and were compared to untreated controls (n=11)." | ( Bäuerle, T; Komljenovic, D; Merz, M; Semmler, W; Zwick, S, 2011) |
| "Women with operable stage 2 or 3 breast cancer who received preoperative systemic therapy were studied using dynamic contrast-enhanced magnetic resonance imaging, magnetic resonance spectroscopy, and ²³Na magnetic resonance." | ( Argani, P; Barker, PB; Bhujwalla, ZM; Bluemke, DA; Davidson, NE; Jacobs, MA; Khouri, N; Macura, K; Ouwerkerk, R; Stearns, V; Tsangaris, T; Wolff, AC, 2010) |
| "Plasma samples of 25 breast cancer patients obtained before and 24 h after initiation of epirubicin/docetaxel-based neoadjuvant chemotherapy were analysed using two-dimensional differential gel electrophoresis (2D-DIGE)." | ( Allmaier, G; Bachleitner-Hofmann, T; Bartsch, R; Baumann, S; Bergmann, M; Burghuber, C; Gnant, M; Graf, A; Greil, R; Marchetti-Deschmann, M; Michlmayr, A; Oehler, R; Pluschnig, U; Rech-Weichselbraun, I; Steger, G, 2010) |
| "In patients with breast cancer, taxane as well as anthracycline play central roles in systemic chemotherapy." | ( Akiyama, F; Hatake, K; Horii, R; Ito, Y; Iwase, T; Makita, M; Matsuura, M; Miki, Y; Nagasaki, K; Noda, T; Takahashi, S; Tokudome, N; Ushijima, M; Yoshimoto, M, 2011) |
| "In MCF-7 breast cancer cells, we demonstrated that ERRγ mRNA was up-regulated dose-dependently by estrogen, and that this up-regulation of ERRγ mRNA by estrogen was abolished by ICI 182,780 treatment." | ( Fujimura, T; Horie-Inoue, K; Ijichi, N; Ikeda, K; Inoue, S; Osaki, A; Saeki, T; Shigekawa, T; Tsuda, H, 2011) |
| "Metastatic breast cancers are hard to treat and almost always fatal." | ( Deng, XQ; Jiang, PD; Li, ZG; Mao, YQ; Shi, W; Tang, QQ; Wei, YQ; Yang, SY; Zhao, YL; Zheng, YZ, 2010) |
| "Estrogen receptor α (ERα) expression in breast cancer is predictive of response to endocrine therapy; however, resistance is common in ERα-positive tumors that overexpress the growth factor receptor ERBB2." | ( Bailey, ST; Brown, M; Carroll, JS; Cook, J; Eeckhoute, J; Liu, XS; Lupien, M; Meyer, CA; Rhodes, DR; Westerling, T; Zhang, X, 2010) |
| "MCF-7 breast cancer cells expressing the α(v)β(3) [alpha(v)beta(3)] integrin receptor are considered as appropriate candidates for such a targeted therapy." | ( Bäuerle, T; Braun, K; Ehemann, V; Fleischhacker, H; Lorenz, P; Müller, G; Pipkorn, R; Waldeck, W; Wiessler, M, 2010) |
| "This prospective study includes 209 breast cancer patients treated by external beam radiotherapy from December 2007 until August 2008." | ( Carvalho, ACP; Franca, CAS; Nogueira, CR; Penna, ABRC; Ramalho, A; Vieira, SL, 2011) |
| "MCF-7 breast cancer, MCF-10A non-transformed breast, and LNCaP prostate cancer cell lines supplemented with PHS were treated with high and low physiological concentrations of six hormones (17β-estradiol, dehydroepiandosterone (DHEA), dihydrotestosterone (DHT), testosterone, insulin, and glucagon)." | ( Archer, MC; Bashyam, B; Esfahani, A; Jenkins, DJ; Kendall, CW, 2010) |
| "Human breast cancer MCF-7 and T47 D cells were treated with or without tamoxifen, siRNA against claudin-1, or tamoxifen and claudin-1 siRNA." | ( Akasaka, H; Hakamada, K; Kijima, H; Kondo, J; Liu, Y; Morohashi, S; Odagiri, H; Sato, F; Wu, Y, 2010) |
| "Adverse outcomes in breast cancer patients treated with recombinant human erythropoietin (rhEpo) have been linked to the expression of Epo-receptors (EpoR) in cancer cells, although limited data on the clinical significance of these observations are available." | ( Ciresa-König, A; Kurz, K; Marth, C; Theurl, I; Volgger, B; Weiss, G; Zöschg, K, 2010) |
| "Forty-one patients with early breast cancer and 4 or more positive lymph nodes were treated with 3 cycles of EoP (oral etoposide plus cisplatin) in addition to 3 cycles of AC (doxorubicin plus cyclophosphamide) and 3 cycles of T (docetaxel) (Group 1)." | ( Akbulut, H; Demirkazık, A; Icli, F; Onur, H; Senler, FÇ; Yalcin, B, 2011) |
| "Treatment of the mammary cancer cell lines MCF-7 and T47D with PhIP induces cells to digest and migrate through a reconstituted basement membrane." | ( Gooderham, NJ; Lauber, SN, 2011) |
| "Patients with node-positive primary breast cancer receiving epirubicin-paclitaxel-cyclophosphamide chemotherapy were randomized to receive P2 versus P4." | ( Conrad, B; Forstbauer, H; Koehne, CH; Kremers, S; Linder, M; Loibl, S; Moebus, V; Mueller, V; Nekljudova, V; von Minckwitz, G, 2011) |
| "A 39-year-old patient with breast cancer underwent neoadjuvant chemotherapy, radical mastectomy, and radiation therapy." | ( Hutchins, LF; Kortebein, PM; Krishna, K; Yacoub, A, 2011) |
| "Fifty (50) participants with early breast cancer completed eight TA treatments." | ( de Valois, BA; Maher, EJ; McCourt, C; Robinson, N; Young, TE, 2010) |
| "The promise of personalized therapy for breast cancer is that therapeutic efficacy will be increased while toxic effects are reduced to a minimum." | ( Ashworth, A; Lord, CJ; Rehman, FL, 2010) |
| "Seven human breast cancer cell lines were treated with dasatinib and/or seven chemotherapeutic agents." | ( Kanomata, N; Kozuka, Y; Kurebayashi, J; Moriya, T; Sonoo, H; Watanabe, M, 2010) |
| "Many breast cancer patients with HER2 overexpression do not respond to initial therapy with trastuzumab (Herceptin(®)), and a vast majority of these develop resistance to this monoclonal antibody within one year." | ( Brunner, C; Hubalek, M; Marth, C; Matthä, K, 2010) |
| "Patients with invasive breast cancer receiving adjuvant or palliative chemotherapy between 2005 and 2006 and who were scheduled for at least two further cycles of this specific chemotherapy were included in this pilot study." | ( Petru, C; Petru, E; Stranz, B, 2010) |
| "These findings suggest that breast cancer patients with the TYMS 3'-UTR +6 bp/+6 bp polymorphism whose tumours show a 6 bp deletion within TYMS 3'-UTR represent a group that may derive the most benefit from 5-FU chemotherapy." | ( Azumi, T; Fujishima, M; Hashimoto, Y; Hojo, T; Inui, H; Kato, H; Matsunami, N; Shiozaki, H; Watatani, M; Yamamoto, N; Yamato, M, 2010) |
| "In the treatment of breast cancer, although a wide of choice of drugs and treatment modalities are available, drug resistance or drug toxicity poses a considerable challenge." | ( Ace, O; Jothy, S; Prud'homme, GJ; Subramaniam, V, 2011) |
| "The adjuvant setting of early breast cancer treatment is an evolving field where different modalities must be combined to improve outcomes; moreover, quality of life of breast cancer survivors emerges as a new important parameter to consider, thus implying a better understanding of toxicities of these modalities." | ( Belkacemi, Y; Bese, N; Boussen, H; Gligorov, J; Koukourakis, MI; Kuten, A; Tsoutsou, PG, 2010) |
| "Endocrine therapy for breast cancer may affect cognition." | ( Aldridge, J; Bernhard, J; Cardoso, F; Coates, AS; Gelber, RD; Goldhirsch, A; Harvey, V; Pagani, O; Phillips, KA; Price, KN; Ribi, K; Sun, Z; Thompson, A; Thürlimann, B, 2011) |
| "Two estrogen receptor-positive breast cancer cell lines, MCF7 and ZR-751, were pretreated with graduated doses of pterostilbene for 24 hours, followed by 5 μmol/L tamoxifen." | ( Mannal, P; McDonald, D; McFadden, D, 2010) |
| "51 women with stage I or II breast cancer who were receiving an adjuvant chemotherapy protocol that included doxorubicin." | ( Musgrave, CF; Prigozin, A; Uziely, B, 2010) |
| "The success of breast cancer treatment relies on the ability to detect the disease and correct molecular abnormalities at an early stage of disease development." | ( Pogribny, IP, 2010) |
| "Tamoxifen treatment of MDA-435 breast cancer cells enhanced the CD44(+) /CD176(+) phenotype." | ( Cao, Y; Cheng, RC; Goletz, S; Karsten, U; Lin, WM, 2011) |
| "The discovery of breast cancer carcinoma sensitivity to estradiol (E) suppression is the starting point of hormonal treatment." | ( Delozier, T, 2010) |
| "MCF-7 breast cancer cells were treated with colloidal silver (ranged from 1." | ( Alcocer-González, JM; Castillo-Tello, P; Franco-Molina, MA; Gómez-Flores, RA; Mendoza-Gamboa, E; Miranda-Hernández, DF; Rodríguez-Padilla, C; Sierra-Rivera, CA; Tamez-Guerra, RS; Zapata-Benavides, P, 2010) |
| "Since 2004, metastatic breast cancer patients pretreated with anthracyclines, taxanes, and capecitabine have been treated in our institution with a combination of mitomycin C, methotrexate, and VP-16 (VMM)." | ( Aldabbagh, K; Fabbro, M; Jacot, W; Pouderoux, S; Poujol, S; Roca, L; Romieu, G, 2012) |
| "A retrospective study of breast cancer patients treated with Doxorubicin as part of their neoadjuvant protocol." | ( Barsuk, D; Berkenstadt, H; Papa, MZ; Segev, L; Shapiro, R; Shimon-Paluch, S; Zippel, DB, 2011) |
| "Treatment of metastatic breast cancer (MBC) remains one of the major challenges in cancer care." | ( Gradishar, WJ, 2011) |
| "A series of 30 breast cancer patients who underwent standardised chemotherapy were prospectively evaluated before chemotherapeutic treatment as well as four weeks after chemotherapy and two years after chemotherapy for the serological expression of inhibin A." | ( Burkhardt, N; Friese, K; Janni, W; Jückstock, J; Kuhn, C; Mylonas, I; Rack, B; Schindlbeck, C; Sommer, H, 2010) |
| "Metastatic breast cancer (MBC) is currently an incurable condition that is primarily treated with palliative measures." | ( Abd Hamid, UM; Cristofanilli, M; Reuben, JM; Rudd, PM; Saldova, R, 2011) |
| "Patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes often have decreased performance status secondary to extensive tumor involvement." | ( Conte, P; Hortobagyi, GN; Jassem, J; Kelleher, T; Peck, R; Perez, EA; Roché, H; Sparano, JA; Xu, B, 2011) |
| "Twenty-eight women with breast cancer, as evidenced by pathology, underwent MR imaging prior to and after chemotherapy." | ( Fan, B; Jiang, XX; Wang, XY; Wu, CX; Yang, XD; Zhong, H, 2011) |
| "In women undergoing NAC for breast cancer treatment, R2* and ΔR2*% appear to provide predictive information of tumor response which is probably associated with changes in tumor angiogenesis and tissue oxygenation." | ( Fan, B; Jiang, XX; Wang, XY; Wu, CX; Yang, XD; Zhong, H, 2011) |
| "Stomach, colon, and breast cancer cells were treated with berry extract and with HCl and ascorbic acid solutions of the same pH." | ( God, J; Larcom, LL; Tate, PL, 2010) |
| "Patients with histologically confirmed breast cancer after mastectomy who received postoperative chemotherapy in Jiangsu Cancer Hospital and Research Institute were recruited in this study." | ( Cui, L; Huang, XE; Jiang, Y; Tang, JH; Xiang, J; Yan, PW, 2010) |
| "However, older breast cancer patients can present with wide variations in health status, and treatment in older patients should therefore include a careful evaluation of comorbidities, physical function, polypharmacy, and other issues that could potentially impact a patient's ability to undergo chemotherapy without excessive risk." | ( Muss, HB, 2010) |
| "The National Surgical Adjuvant Study of Breast Cancer (N-SAS-BC06) New primary Endocrine-therapy Origination Study (NEOS) is a randomized phase III trial conducted in Japanese centers." | ( Iwata, H, 2011) |
| "Treatment of breast cancer (BC) has changed over the last decade with the advent of targeted therapies." | ( Catalano, O; De Giuli, L; Della Porta, MG; Eleuteri, E; Riccardi, A; Tondini, C; Zambelli, A, 2011) |
| "Posttreated patients with breast cancer were matched with healthy women based on age, physical fitness level, and menopausal status." | ( Battaglini, CL; Evans, ES; Groff, D; Hackney, AC; Tosti, KP, 2011) |
| "In untreated breast cancer cohorts, the 23 gene signature-based ER status provided significantly improved prognostic power compared to IHC-based ER status (P = 0." | ( Eklund, AC; Haibe-Kains, B; Juul, N; Li, Q; Richardson, AL; Swanton, C; Szallasi, Z; Workman, CT, 2010) |
| "We report a 69-year-old woman with breast cancer who was effectively treated with letrozole as a second-line therapy after becoming resistant to anastrozole." | ( Fujimoto, A; Goto, K; Ichinose, Y; Kobayashi, T; Sasaoki, T; Uchida, S, 2010) |
| "HER2-overexpressing breast cancer cell lines were treated with genistein alone and in combination with trastuzumab." | ( Goerse, R; Lattrich, C; Lubig, J; Ortmann, O; Springwald, A; Treeck, O, 2011) |
| "Records from 140 breast cancer patients treated on five prospective trials with mastectomy and doxorubicin-based chemotherapy, with or without radiation, who developed a LRR were reviewed." | ( Buchholz, TA; Levy, L; Oh, JL; Perkins, GH; Reddy, JP; Strom, EA; Woodward, WA, 2011) |
| "Human breast cancer MCF-7 and ZR-75-1 cells were treated with glycerol guaiacolate and the therapeutic efficacy and biological activity of this drug was investigated on breast cancer cell growth." | ( Baker, CH; Colon, J; Isley, B; Konduri, SD; Madero-Visbal, R; Smith, JS, 2010) |
| "Patients with metastatic breast cancer usually accept several lines of chemotherapy." | ( Chen, SM; Chen, YY; Huang, CH; Li, SH; Rau, KM; Tang, Y; Wu, SC, 2011) |
| "It has been suggested that breast cancer stem cells (CSCs), which characterized by CD44(+)CD24(-/low), may result in treatment failure in patients with breast cancer." | ( Di, L; Jia, J; Lu, Z; Ma, B; Ren, J; Song, G; Wang, X; Yu, J; Yuan, Y; Zhou, X; Zhu, Y, 2011) |
| "Estrogen receptor β expression in breast cancer is associated with favorable outcome in women treated with adjuvant tamoxifen, even in tumors negative for estrogen receptor α." | ( Honma, N; Younes, M, 2011) |
| "Triple-negative breast cancers have inherent defects in DNA repair, making this cancer a rational target for therapy based on poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition." | ( Bradley, C; Koo, IC; O'Shaughnessy, J; Osborne, C; Patt, D; Pippen, JE; Rocha, C; Sherman, BM; Yoffe, M, 2011) |
| "Moreover, in the breast cancer cell, LPA treatment resulted in remarkable production of reactive oxygen species (ROS), while LPA-induced ROS generation, PI3K/PAK1/ERK activation and cell migration could be inhibited by N-acetyl-L-Cysteine, a scavenger of ROS." | ( Du, J; Gu, L; Hu, Z; Lu, X; Sun, C; Yang, Y; Zheng, D; Zhu, Y, 2010) |
| "3,971 breast cancer patients whose treatment modalities as well as ER level were known, were included in this retrospective analysis." | ( Kreienberg, R; Kurzeder, C; Novopashenny, I; Possinger, K; Regierer, AC; Wischnewsky, MB; Wöckel, A; Wolters, R, 2011) |
| "Total of 37 postmenopausal breast cancer patients receiving 20-40 mg/day of tamoxifen treatment for at least 6 months were included in the study." | ( Chiyabutra, T; Sinawat, S, 2004) |
| "Patients with inflammatory breast cancer (IBC) or locally advanced breast cancer (LABC) were randomly assigned to 21-day doxorubicin and cyclophosphamide administered for five cycles (standard arm) versus weekly doxorubicin and daily oral cyclophosphamide administered with granulocyte colony-stimulating factor support for 15 weeks (continuous arm)." | ( Barlow, WE; Ellis, GK; Gralow, JR; Hortobagyi, GN; Lew, D; Livingston, RB; Perez, EA; Royce, ME; Russell, CA, 2011) |
| "The antihormonal therapy of breast cancer patients with the antiestrogen tamoxifen often induces or aggravates menopausal complaints." | ( Bartsch, HH; Fischer, J; Mumm, A; Rostock, M; Saller, R; Stammwitz, U, 2011) |
| "Many young breast cancer survivors experience menopausal symptoms and feel concerned about infertility due to oncologic treatment." | ( Abusief, ME; Gelber, S; Ginsburg, ES; Meyer, ME; Partridge, AH; Ruddy, KJ; Schapira, L, 2011) |
| "We surveyed breast cancer survivors with regular menses after adjuvant chemotherapy and compared them with age-matched, gravidity-matched controls as part of a study to evaluate the effects of chemotherapy on ovarian reserve." | ( Abusief, ME; Gelber, S; Ginsburg, ES; Meyer, ME; Partridge, AH; Ruddy, KJ; Schapira, L, 2011) |
| "T47D and MDA-MB231 human breast cancer cells were treated with ferulic acid and examined cell proliferation by means of MTT assay." | ( Hao, Q; Niu, J; Wang, J; Xue, X; Yu, J; Zhao, P, 2010) |
| "In anthracycline-pretreated metastatic breast cancer (MBC) patients, it is unknown whether weekly single-agent docetaxel is preferable to 3-weekly docetaxel regarding its toxicity and efficacy profile." | ( Creemers, GJ; de Graaf, H; de Munck, L; Erjavec, Z; Schröder, CP; Smit, WM; Stouthard, JM; Vader, W; van Bochove, A; van Deijk, G; Westermann, AM; Willemse, PH, 2011) |
| "Results from breast cancer treatment trials suggest that aromatase inhibitors may be even more effective in preventing breast cancer than SERMs." | ( Brown, PH; Uray, IP, 2011) |
| "Patients with primary breast cancer underwent MRI before neoadjuvant chemotherapy and were identified as ER-/PR-/HER2- or ER+/PR+/HER2- from core biopsy specimens." | ( Ah-See, ML; Beresford, MJ; Collins, DJ; d'Arcy, JA; Li, SP; Makris, A; Padhani, AR; Stirling, JJ; Taylor, NJ, 2011) |
| "Metastatic breast cancers (MBC) previously treated with anthracyclines (A) and taxanes (T) have a complicated management." | ( Brito, LG; de Andrade, JM; Lins-Almeida, T; Marana, HR; Peria, FM; Pinheiro, MN; Tiezzi, DG; Zola, FE, 2012) |
| "Here we show that treating MCF7 breast cancer cells with rapamycin (an mTOR inhibitor) results in significant suppression of homologous recombination (HR) and nonhomologous end joining (NHEJ), two major mechanisms required for repairing ionizing radiation-induced DNA DSBs." | ( Chen, H; Feng, Z; Gonzalez-Suarez, I; Gonzalo, S; Ma, Z; Roti Roti, JL; Vanderwaal, RP; Wang, S; Zhang, J, 2011) |
| "Two hundred and ninety-two breast cancer patients who had undergone breast-conserving surgery and been treated with Tam or Ana, with or without RT, were retrospectively analyzed." | ( Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K; Nakahara, S, 2011) |
| "Although breast cancer risk is greater in users of estrogen-progestin than estrogen-only formulations of menopausal hormonal therapy, reports on their effects have been somewhat inconsistent." | ( Beral, V; Bull, D; Green, J; Reeves, G, 2011) |
| "The relative risks for breast cancer in current users were greater if hormonal therapy was begun before or soon after menopause than after a longer gap (P(heterogeneity) < ." | ( Beral, V; Bull, D; Green, J; Reeves, G, 2011) |
| "There was substantial heterogeneity in breast cancer risk among current users of hormonal therapy." | ( Beral, V; Bull, D; Green, J; Reeves, G, 2011) |
| "The mortality rate due to breast cancer has declined over the preceding decades to a great extent, secondary to the development and use of effective adjuvant therapy." | ( Dizon, DS; Sakr, BJ, 2011) |
| "Similarly, breast cancer-free interval (BCFI) was identical in the ER-positive cohort but significantly improved by chemotherapy in the ER-negative cohort (13-year BCFI 80% versus 63%, P = 0." | ( Aebi, S; Braun, D; Castiglione-Gertsch, M; Coates, AS; Crivellari, D; Gelber, RD; Goldhirsch, A; Gusterson, BA; Karlsson, P; Lindtner, J; Price, KN; Rabaglio, M; Regan, MM; Simoncini, E; Snyder, R; Sun, Z; Viale, G, 2011) |
| "From the database, 1912 breast cancer patients who had received anthracycline-based adjuvant chemotherapy were identified." | ( Ahn, JS; Choi, MS; Gwak, GY; Im, YH; Kang, ES; Kim, KH; Lee, JE; Nam, SJ; Park, YH; Yang, JH; Yun, J, 2011) |
| "Using the initial ADC values of breast cancer tumors and the early changes in ADC values after NCT, we may be able to predict tumor response to chemotherapy." | ( Cheng, LQ; Li, J; Li, XR; Liu, L; Liu, M; Song, X; Wang, JD; Zhang, AL; Zhang, YJ; Zheng, YQ, 2012) |
| "Current hormonal adjuvant therapies for breast cancer including tamoxifen treatment and estrogen depletion are overall tumoristatic and are severely limited by the frequent recurrence of the tumors." | ( Iman, M; Kisovic, I; Patki, M; Ratnam, M; Salazar, MD; Trumbly, R, 2011) |
| "In estrogen-sensitive breast cancer cells the effects of hormone depletion and treatment with estrogen, tamoxifen, all-trans retinoic acid (ATRA), fulvestrant, estrogen receptor α (ER) siRNA or retinoic acid receptor α (RARα) siRNA were studied by examining cell growth and cycling, apoptosis, various mRNA and protein expression levels, mRNA profiles and known chromatin associations of RAR." | ( Iman, M; Kisovic, I; Patki, M; Ratnam, M; Salazar, MD; Trumbly, R, 2011) |
| "The majority of breast cancer patients are resistant to chemotherapy or radiotherapy due to the down-regulation or lack of caspase-3 expression." | ( Chang, HC; Chen, DR; Chen, ST; Chien, SY; Kuo, SJ; Tsai, HT, 2011) |
| "Premenopausal women with breast cancer receiving adjuvant chemotherapy are at risk for amenorrhea." | ( Atkins, JN; Cecchini, RS; Costantino, JP; Erban, JK; Fehrenbacher, L; Ganz, PA; Geyer, CE; Land, SR; Livingston, RB; Mamounas, EP; Pajon, ER; Perez, EA; Polikoff, JA; Swain, SM; Vogel, VG; Wolmark, N, 2011) |
| "From March 1994 to March 1998, breast cancer patients (an estimated relapse risk with 70% or more within five years with standard therapy) were randomised to treatment with tailored fluorouracil, epirubicin, and cyclophosphamide (FEC) therapy or FEC followed by marrow-supported high dose therapy in the Scandinavian Breast Group 9401 study." | ( Bergh, J; Brandberg, Y; Iiristo, M; Wiklund, T; Wilking, N, 2011) |
| "The International Breast Cancer Study Group Trial VIII compared long-term efficacy of endocrine therapy (goserelin), chemotherapy [cyclophosphamide, methotrexate and fluorouracil (CMF)], and chemoendocrine therapy (CMF followed by goserelin) for pre/perimenopausal women with lymph-node-negative breast cancer." | ( Braun, D; Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Collins, J; Crivellari, D; Gelber, RD; Goldhirsch, A; Gusterson, BA; Karlsson, P; Murray, E; Price, KN; Rabaglio, M; Regan, MM; Sun, Z; Viale, G; Zaman, K, 2011) |
| "Women with breast cancer pretreated in adjuvant/neoadjuvant setting with anthracyclines received bi-weekly G (1,250 mg/m² days 1, 15) and D (50 mg/m² days 1, 15) every 28 days with restaging after 3 and 6 cycles." | ( Ballestrero, A; Bergaglio, M; Bertolotti, F; Brema, F; Canobbio, L; Cinzia, N; Folco, U; Mencoboni, M; Murialdo, R; Parodi, M; Pastorino, G; Simoni, C; Vaira, F, 2011) |
| "In ER-positive, operable breast cancer, PR negativity may provide additional information on poor prognosis or tamoxifen resistance during adjuvant tamoxifen therapy within 5 years postsurgery." | ( Chung, HC; Kang, DR; Koo, JS; Moon, YW; Park, BW; Park, HS; Park, S; Sohn, JH, 2011) |
| "The prostate and breast cancer cell lines were investigated: MCF-7, a human breast cancer responsive to androgen therapy; MDA-MB231, a more aggressive human breast cancer non-responsive to androgen therapy; LNCaP, a lymphonodal metastasis of prostate carcinoma responsive to androgen therapy; DU-145, a human prostate cancer non-responsive to androgen therapy." | ( Małecki, M; Nowak-Stępniowska, A; Padzik-Graczyk, A; Romiszewska, A; Wiktorska, K, 2011) |
| "In normal luminal breast cells and in breast cancer cells, P4 and MPA combined with E2 treatment have opposing mitogenic effects due to GR." | ( Chaouat, M; Cimino, D; Communal, L; Courtin, A; de Bortoli, M; Faussat, AM; Forgez, P; Gompel, A; Mourra, N; Taverna, D; Vilasco, M, 2012) |
| "Most patients with metastatic breast cancer (MBC) progress after chemotherapy." | ( Awada, A; Besse, T; Campone, M; Dubin, F; Machiels, JP; Magherini, E; Pivot, X; Semiond, D; Villanueva, C, 2011) |
| "Following surgery for early breast cancer, the standard of care for postmenopausal women is adjuvant therapy with any combination of radiation therapy, endocrine therapy, chemotherapy and/or targeted therapy." | ( Jackisch, C; Verma, S, 2011) |
| "Using data from the Swedish Breast Cancer Group adjuvant trial of 5 vs 2 years of tamoxifen treatment, we now report both short-term and long-term effects on morbidity as well as mortality because of cerebrovascular disease." | ( Bengtsson, NO; Carstensen, J; Fornander, T; Hatschek, T; Lindman, H; Malmström, PO; Nordenskjöld, B; Rosell, J; Stål, O; Wallgren, A, 2011) |
| "Treatment of the breast cancer cell lines MDA-MB-231 and MCF-7 with MPA resulted in differentiation of adipose tissue that was characterized by accumulation of intracellular lipids, enlargement of cell volume, and permanent withdrawal from the cell cycle at the G1/G0 stage." | ( He, XB; Jiang, Q; Liu, C; Lu, XH; Shui, XX; Si, SY; Yang, Y; Zhang, H; Zhao, BH; Zheng, ZH, 2011) |
| "Patients with early breast cancer with highly proliferative (S-phase fraction >4%) operable tumors of >3 cm received 4 cycles of intensified neoadjuvant chemotherapy with high-dose cyclophosphamide (doxorubicin 70 mg/m d1, cyclophosphamide 700 mg/m d1/d8, and 5 FU 700 mg/m d1-d5) every 3 weeks." | ( Alran, S; Beuzeboc, P; Dettwiler, S; Diéras, V; Fréneaux, P; Laurence, V; Le Tourneau, C; Pierga, JY; Sigal-Zafrani, B; Vincent-Salomon, A, 2012) |
| "Two hundred and forty breast cancer patients undergoing elective operations were assigned to six groups according to treatment received before their operation and the use of intravenous anesthetics during anesthesia; non-adjuvant chemotherapy + propofol group (group NP, n = 40), Taxol + propofol group (group TP, n = 40), adriamycin + cyclophosphamide + 5-Fu + propofol group (group CP, n = 40), non-adjuvant chemotherapy + etomidate group (group NE, n = 40), taxol + etomidate group (group TE, n = 40), adriamycin + cyclophosphamide + 5-Fu + etomidate group (group CE, n = 40)." | ( Fan, ZY; He, ZJ; Hu, YH, 2011) |
| "Triple negative breast cancer (TNBC) has a poorer survival, despite a higher response rate to neoadjuvant chemotherapy." | ( Bang, YJ; Han, SW; Han, W; Heo, DS; Im, SA; Keam, B; Kim, DW; Kim, JH; Kim, TY; Lee, KH; Lee, SH; Noh, DY; Oh, DY; Park, IA, 2011) |
| "Here, model systems of ER-positive breast cancers with differential susceptibility to endocrine therapy were employed to define common nodes for new therapeutic interventions." | ( Aldaz, CM; Clarke, R; Dean, JL; Ertel, A; Knudsen, ES; Knudsen, KE; Thangavel, C; Witkiewicz, AK, 2011) |
| "A 78-year-old woman diagnosed with left breast cancer (T2N1M0, Stage II B) was given breast-conserving therapy with axillary dissection." | ( Horiguchi, J; Ikeda, F; Ito, H; Kurozumi, S; Takeo, T; Takeyoshi, I, 2011) |
| "Hormone- and trastuzumab-insensitive breast cancer has limited and ineffective clinical treatment options." | ( Chiu, GN; Wong, MY, 2011) |
| "Forty-three patients diagnosed with breast cancer who received anthracyclines and trastuzumab therapy underwent echocardiography and blood sampling at 3 time points (baseline and 3 and 6 months during the course of chemotherapy)." | ( Carver, JR; Cohen, V; Gerszten, RE; Gosavi, S; Halpern, EF; Januzzi, JL; Kuter, I; Ky, B; Martin, RP; Passeri, J; Picard, MH; Plana, JC; Sawaya, H; Scherrer-Crosbie, M; Sebag, IA; Wiegers, SE, 2011) |
| "Women with operable early-stage breast cancer were enrolled in a multicenter study of neoadjuvant therapy for four 21-day cycles with capecitabine 825 mg/m(2) plus docetaxel 75 mg/m(2) if human epidermal growth factor receptor 2 (HER2)-negative, and additionally, a standard trastuzumab dose if HER2-positive." | ( Avisar, E; Glück, S; McKenna, EF; Perou, CM; Ross, JS; Royce, M; Wu, L, 2012) |
| "For those diagnosed with metastatic breast cancer, the 5-year survival rates are low as, ultimately, patients develop tumors that become refractory to treatment." | ( Cortes, J; Lorca, R, 2011) |
| "Participants were 12 women with breast cancer who had undergone mastectomy or breast-conserving treatment and adjuvant chemotherapy; they attended 8 weekly music therapy sessions, each lasting 2 hours." | ( Chuang, CY; Han, WR; Li, PC; Song, MY; Young, ST, 2011) |
| "Twenty-one postmenopausal breast cancer patients on AIs with symptoms of vaginal atrophy were treated with testosterone cream applied to the vaginal epithelium daily for 28 days." | ( Demers, L; Johnson, J; Littenberg, B; Maclean, CD; Mount, S; Muss, H; Witherby, S; Wood, M, 2011) |
| "Although I-IBTR increased the risk for breast cancer-related death, radiation therapy and tamoxifen reduced I-IBTR, and long-term prognosis remained excellent after breast-conserving surgery for DCIS." | ( Anderson, SJ; Costantino, JP; Dignam, JJ; Fisher, B; Julian, TB; Land, SR; Mamounas, EP; Margolese, RG; Swain, SM; Wapnir, IL; Wolmark, N, 2011) |
| "Tamoxifen does not reduce breast cancer-specific or overall mortality when added to loco-regional therapy for DCIS of the breast (surgery plus or minus RT)." | ( Barni, S; Petrelli, F, 2011) |
| "Lymphedema of hand after breast cancer treatment causes significant loss of hand function." | ( Boland, RA; Czerniec, S; Kilbreath, SL; Lee, MJ, 2011) |
| "In addition, approximately 25% of breast cancers do not express the estrogen receptor (ERα) and consequently, are innately resistant to endocrine therapy." | ( Brodie, AM; Chumsri, S; Howes, T; Sabnis, GJ, 2011) |
| "Hormone-dependent breast cancer can be successfully treated by either blocking the estrogen receptor, as with tamoxifen, or reducing the production of estrogens, as with aromatase inhibitors." | ( Lintermans, A; Neven, P; Paridaens, R, 2011) |
| "Tamoxifen used in the treatment of breast cancer is reported to cause hepatic steatosis." | ( Akhondi-Meybodi, M; Hashemian, Z; Moaiedi, M; Mortazavy-Zadah, MR, 2011) |
| "However, treatment with MNBA on breast cancer cells can inhibit EGF-induced migration and chemotaxis in vitro." | ( Blake, DJ; Chen, P; Guo, H; Hao, X; Kong, X; Li, M; Niu, R; Zhang, N, 2011) |
| "Our subjects comprised 257 breast cancer patients who received 3 cycles of anthracycline/taxane-based neoadjuvant chemotherapy." | ( Kim, SI; Koo, JS; Park, BW; Park, HS; Park, SH; Sohn, J, 2010) |
| "Because breast cancer is the most common malignancy and the second most common cause of cancer death among women, many nuclear medicine imaging techniques are essential in the evaluation and therapy of patients with this disease." | ( Moadel, RM, 2011) |
| "Clinically, ~30% of breast cancer patients diagnosed with early-stage disease undergo metastatic progression, an event that (a) severely limits treatment options, (b) typically results in chemoresistance and low response rates, and (c) greatly contributes to aggressive relapses and dismal survival rates." | ( Parvani, JG; Schiemann, WP; Taylor, MA, 2011) |
| "Patients with a stage II or III breast cancer receiving PST were selected and underwent positron emission tomography (PET), magnetic resonance imaging (MRI), and breast biopsies at baseline and after the first cycle of PST (days 7-8) during the full course of treatment." | ( Bluemke, DA; Gabrielson, E; Jacobs, MA; Jeter, S; Ouwerkerk, R; Stearns, V; Wahl, R; Warzecha, H; Wolff, AC, 2011) |
| "N-glycan-defective breast cancer cells (MA782 cells) were prepared by swainsonine (SW) treatment and the cytotoxicity of SW to MA782 cells was evaluated using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay." | ( Cai, H; Chen, H; Chen, L; Li, D; Wu, X, 2011) |
| "A 52-year-old woman, with a metastatic breast cancer, presented with a nasal septum perforation while receiving a treatment combining paclitaxel and bevacizumab." | ( Afchain, P; Bengrine-Lefevre, L; Chibaudel, B; De Gramont, A; Gervais, H; Louvet, C; Tournigand, C, 2011) |
| "The basal-like breast cancer (BLBC) molecular subtype is associated with poorer outcomes, but is more responsive to taxane-based chemotherapy." | ( Bebek, G; Budd, GT; De, S; Downs-Kelly, E; Eng, C; Orloff, MS; Stark, GR; Tan, MH; Wesolowski, R, 2012) |
| "Patients with relapsed breast cancer not previously treated with adjuvant anthracyclines were randomly assigned to epirubicin/vinorelbine (arm A: EPI/VNB, EPI 90 mg/m2 on day 1, VNB 25 mg/m2 on days 1,5 plus G-CSF subcutaneously on days 7-12, with cycles repeated every 21 days), or to pegylated liposomal doxorubicin/VNB (arm B: PLD/VNB, PLD 40 mg/m2 on day 1, VNB 30 mg/m2 on days 1, 15, with cycles repeated every 4 weeks)." | ( Botti, C; Carpino, A; Colucci, G; Di Lauro, L; Filippelli, G; Giannarelli, D; Giotta, F; Latorre, A; Lopez, M; Perri, P; Pizzuti, L; Sergi, D; Vici, P; Vizza, E, 2011) |
| "Seventeen patients with stage IV breast cancer received dose-escalated vandetanib in combination with low-dose oral chemotherapy." | ( Beckman, JA; Burstein, HJ; Dallabrida, SM; Hannagan, K; Ismail, NS; Mayer, EL; Redline, WM; Rupnick, MA, 2011) |
| "With breast cancer plaguing the United States as the second leading cause of cancer related deaths amongst women, as well as the adverse effects of current treatment options there is a need to develop safer and noninvasive treatments." | ( Halaby, R; Messina, ME, 2011) |
| "Patients with histologically confirmed breast cancer, measurable disease, no more than one prior chemotherapy regimen for metastatic disease, an Eastern Cooperative Oncology Group (ECOG) performance status ≤2, and adequate bone marrow, renal and liver function were eligible." | ( Antón, A; Barnadas, A; Florián, J; Gayo, J; González-Quintás, A; Lao, J; Lomas, M; Margelí, M; Paules, AB; Ramos, M; Ribelles, N, 2011) |
| "The use of neoadjuvant chemotherapy for breast cancer is effective as postoperative adjuvant therapy, permits more lumpectomies, and can be used to study breast cancer biology." | ( Kadowaki, M; Kazama, T; Miyazaki, M; Miyoshi, T; Nagashima, T; Nakatani, Y; Ohki, Y; Sakakibara, M; Suzuki, TH; Yokomizo, J, 2011) |
| "Patients with T3-4, N2 M0 breast cancer diagnosed between January 2005 and December 2008 and who received at least one cycle of neoadjuvant chemotherapy were eligible for this study." | ( Aslan, NM; Azrif, M; Fong, KV; Ibrahim, J; Ismail, F, 2011) |
| "Of the cultured breast cancer tumor specimens treated with sunitinib, ChemoFx classified 7." | ( Brower, SL; Ervin, PR; Hancher, LM; Suchy, SL; Wang, D, 2011) |
| "Data on 39 elderly HER-2 overexpressing breast cancer patients treated with both curative surgery and adjuvant trastuzumab were retrospectively collected from a Japanese multicenter study." | ( Horio, A; Mizuno, T; Mukai, H; Nakayama, T; Ohashi, Y; Sawaki, M; Taira, N; Tokudome, N; Uemura, Y; Watanabe, T; Yamamoto, Y, 2012) |
| "Patients with metaplastic breast cancer (MBC) exhibit reduced response to chemotherapy and have poor prognosis." | ( Ishiguro, H; Kanao, S; Mikami, Y; Sugie, T; Takada, M; Takuwa, H; Toi, M; Ueno, T, 2014) |
| "A total of 153 breast cancer patients, who were treated with postoperative 5-fluorouracil-based chemotherapies, were randomly selected." | ( Harada, S; Ishihara, H; Kanomata, N; Kawasaki, Y; Kikukawa, N; Kozuka, Y; Kurebayashi, J; Moriya, T; Nakayama, S; Noguchi, S; Sonoo, H; Tamura, S, 2011) |
| "Patients suffering from triple-negative breast cancer (TNBC) have poor prognosis mainly because no standard treatment is currently available." | ( Jiang, X; Lin, G; Liu, D; Peng, J; Peng, R; Qin, T; Shi, Y; Teng, X; Wang, S; Wang, X; Yuan, Z, 2012) |
| "Locally advanced breast cancer (LABC) remains a clinical challenge as the majority of patients with this diagnosis develop distant metastases despite appropriate therapy." | ( Bhatnagar, D; Chakraborty, A; Chintamani, C; Devi, TR; Kapur, S; Mishra, AK; Saxena, S; Singh, LC; Sugandhi, N, 2012) |
| "Human breast cancer tissues, as well as normal tissues from the same patients, were treated with clotrimazole (CTZ) and have their capacities for glucose consumption and lactate production evaluated." | ( Calaça, Ide C; Celestrini, Dde M; Coelho, RG; Correia, AH; Costa, MA; Sola-Penna, M, 2011) |
| "The effect of progestogens on breast cancer tumorigenesis may depend on the specific progestogen used for hormone therapy or oral contraception." | ( Cahill, MA; Fehm, T; Mueck, AO; Neubauer, H; Ruan, X; Seeger, H; Tong, X; Yang, Y, 2011) |
| "Because the majority of breast carcinomas express the estrogen receptor ERα, endocrine therapy that impedes estrogen-ER signaling reduces breast cancer mortality and has become a mainstay of breast cancer treatment." | ( Ao, A; López, JA; Lu, J; Morrison, BJ; Reynolds, BA; Wang, H, 2011) |
| "Tissue samples of recurrent breast cancer are sometimes hard to obtain just before treatment because the tumor is often difficult to access." | ( Amano, S; Enomoto, K; Matsuo, S; Sakurai, K; Shiono, M, 2011) |
| "Premenopausal patients with breast cancer receiving goserelin simultaneously with modern neoadjuvant chemotherapy did not experience statistically significantly less amenorrhea 6 months after end of chemotherapy compared with those receiving chemotherapy alone." | ( Conrad, B; Fehm, T; Felberbaum, R; Fischer, D; Gerber, B; Loibl, S; Maass, N; Mehta, K; Ortmann, O; Reimer, T; Rezai, M; Sommer, HL; Stehle, H; von Minckwitz, G, 2011) |
| "Many breast tumors respond to chemotherapy, but cells that survive this initial response gain resistance to subsequent treatments." | ( Grizzle, WE; Johnson, EL; Johnson-Holiday, C; Lillard, JW; Singh, R; Singh, S, 2011) |
| "Patients with ER-positive metastatic breast cancer progressing on endocrine therapy were treated with 400 mg of vorinostat daily for 3 of 4 weeks and 20 mg tamoxifen daily, continuously." | ( Ismail-Khan, R; Lacevic, M; Melisko, M; Miller, A; Minton, SE; Moasser, M; Munster, PN; Raha, P; Rugo, H; Thomas, S; Thurn, KT, 2011) |
| "A continuous risk model (Breast Cancer Index (BCI)) was developed with the tamoxifen-treated group and the prognostic performance tested in the untreated group was 53% of patients categorised as low risk with an 8." | ( Erlander, MG; Fornander, T; Holmlund, B; Jerevall, PL; Kesty, NC; Li, H; Ma, XJ; Nordenskjöld, B; Salunga, R; Sgroi, DC; Skoog, L; Stål, O, 2011) |
| "Two lines of human breast cancer cells characterized by different expression of ER and EGFR receptors were treated with AA, EPA or DHA." | ( Berra, B; Corsetto, PA; Cremona, A; Jovenitti, IE; Montorfano, G; Rizzo, AM; Zava, S, 2011) |
| "Patients with HER2(-) advanced breast cancer who were disease free for ≥ 12 months after adjuvant taxane treatment were randomized (1:1; planned enrollment 740 patients) to receive intravenous (I." | ( Brufsky, AM; Copur, MS; Davis, J; Generali, D; Gernhardt, D; Giguere, JK; Gressot, L; Huang, X; Kern, KA; Liau, KF; Minton, SE; Paul, D; Richards, PD; Robert, NJ; Saleh, MN; Smith, JW, 2011) |
| "Because chemotherapy for metastatic breast cancer (MBC) is associated with relevant toxicity, sequential monotherapy trastuzumab followed by cytotoxic therapy at disease progression might be an attractive approach." | ( Bontenbal, M; Bos, MM; Braun, HJ; Creemers, GJ; Erdkamp, FL; Hamberg, P; Klijn, JG; Loosveld, OJ; Muller, EW; Portielje, JE; Pruijt, JF; Schmitz, PI; Seynaeve, C; Smit, WM; Stouthard, JM; van Deijk, GA; van der Stelt-Frissen, IN, 2011) |
| "Case 1: a 72-year-old woman with breast carcinoma relapsing after surgery, chemotherapy, hormone therapy, and without treatment for 6 months, was admitted for an acute erythematous slightly squamous and photo-distributed eruption." | ( Bagot, M; Cosnes, A; Duong, TA; Gantzer, A; Ortonne, N; Regnier, S; Wolkenstein, P, 2011) |
| "Patients with advanced breast cancer and without prior palliative chemotherapy were scheduled for 6 cycles." | ( Blijham, GH; Erdkamp, FL; Knibbeler-van Rossum, CT; Lalisang, RI; Loosveld, OJ; Nortier, JW; Rodenburg, CJ; Schouten, HC; Slee, PH; Smals, AE; Tjan-Heijnen, VC; van Bochove, A; Voest, EE; Wals, J; Wils, JA, 2011) |
| "In HER2-overexpressing breast cancer, this crosstalk results in increased cancer cell proliferation, survival and invasion, accelerated metastasis in animal models, and resistance to chemotherapy and HER2-targeted therapy." | ( Arteaga, CL; Chow, A; Wang, SE, 2011) |
| "Skp2 can play an important role in breast cancer progression and may also be a novel molecular target for the treatment of breast cancer, especially estrogen receptor (ER)/human epidermal growth factor 2 (HER2) negative breast cancers." | ( Huang, HC; Lin, CL; Lin, JK, 2011) |
| "GPR30 expression in breast cancer independently predicts a poor RFS in patients treated with tamoxifen." | ( Bischoff, J; Costa, SD; Eggemann, H; Ignatov, A; Ignatov, T; Kalinski, T; Roessner, A; Semczuk, A; Weissenborn, C, 2011) |
| "ER-positive MCF-7 (human breast cancer) cells were treated with different concentrations of calycosin." | ( Chen, J; Chen, X; Hou, R; Liu, L; Shao, Z; Wu, Y; Zhou, L, 2011) |
| "Systemic treatment of breast cancer is effective at the beginning of therapy." | ( Bachmeier, B; Efferth, T; Fichtner, I; Killian, PH; Kronski, E; Pfeffer, U, 2011) |
| "Patients with left-sided breast cancer show higher values of NT-pro BNP after RT when compared with non–RT-treated matched patients, increasing in correlation with high doses in small volumes of heart and ventricle." | ( Andreassi, MG; D'Errico, MP; Gianicolo, EA; Grimaldi, L; Monetti, A; Petruzzelli, MF; Picano, E; Pili, G; Placella, R; Portaluri, M; Sicari, R; Tramacere, F, 2012) |
| "Taxol is widely used to treat breast cancer, but resistance occurs in 25-69% of patients and it is vital to understand how Taxol resistance develops to improve chemotherapy." | ( Bekele, RT; Brindley, DN; Goping, IS; Samadi, N; Schang, LM, 2011) |
| "In cases of triple-negative breast cancer involving clear intratumoral necrosis with an irregular mass shape, it is predicted that the effects of neoadjuvant chemotherapy will likely be poor, and therefore, the presence of such image findings may be useful for determining the optimal application of neoadjuvant chemotherapy." | ( Furukawa, H; Inokuchi, M; Kawashima, H; Kitamura, S, 2011) |
| "Metformin may reduce the incidence of breast cancer and enhance response to neoadjuvant chemotherapy in diabetic women." | ( Baker, L; Bray, S; Deharo, S; Dewar, JA; Hadad, S; Hardie, DG; Iwamoto, T; Jellema, G; Jordan, L; Moulder-Thompson, S; Purdie, C; Pusztai, L; Thompson, AM, 2011) |
| "After successful treatment of early breast cancer, many women still report pain symptoms, and attribute them to the previous illness or its treatment." | ( Bardwell, WA; Dimsdale, JE; Flatt, SW; Natarajan, L; Pierce, JP; Rief, W, 2011) |
| "Stage IV breast cancer patients diagnosed from 1995-2005, treated with chemotherapy, ≥66 years old, with full coverage of Medicare A and B were included." | ( Chavez-MacGregor, M; Fang, S; Giordano, SH; Hortobagyi, GN; Srokowski, TP; Zhao, H, 2011) |
| "Aromatase inhibitors (AI) that inhibit breast cancer cell growth by blocking estrogen synthesis have become the treatment of choice for post-menopausal women with estrogen receptor positive (ER+) breast cancer." | ( Abrhale, T; Brodie, A; Macedo, L; Sabnis, G; Serrero, G; Tian, C; Yue, B, 2011) |
| "Many estrogen receptor (ER)-positive breast cancers respond well initially to endocrine therapies, but often develop resistance during treatment with selective ER modulators (SERMs) such as tamoxifen." | ( Bergamaschi, A; Katzenellenbogen, BS, 2012) |
| "In women with node-negative breast cancer, replacing fluorouracil with docetaxel in the adjuvant chemotherapy protocol did not improve efficacy but in one trial led to a 5-fold increase in serious adverse effects." | ( , 2011) |
| "Management of arm lymphedema following breast cancer treatment is challenging, and emphasis should be put on early diagnosis and prevention of secondary lymphedema." | ( Doi, K; Iida, T; Koshima, I; Mihara, M; Narushima, M; Ogata, F; Oshima, A; Todokoro, T; Yamamoto, N; Yamamoto, T; Yoshimatsu, H, 2011) |
| "Apoptosis is induced in MCF-7 breast cancer cells following treatment with salicylic acid (20 mM), either in the presence or absence of a heat shock (42°C for 30 min)." | ( Cronjé, MJ; Ferreira, E, 2012) |
| "In highly metastatic MCF-7, human breast cancer cell line T3 treatment repressed SMP30 expression leading to enhanced apoptosis." | ( Das Mohapatra, A; Mishra, SK; Peter, R; Rath, B; Sar, P, 2011) |
| "Triple negative breast cancer (TNBC) has increased recurrence and poor survival, despite a high response rate to neoadjuvant chemotherapy." | ( Bandyopadhyay, S; Reddy, KB; Sethi, S; Xu, L; Yin, S, 2011) |
| "Older women with breast cancer derive similar efficacy from treatment with paclitaxel as younger women." | ( Cirrincione, CT; Cohen, HJ; Hudis, C; Hurria, A; Lichtman, SM; Muss, HB; Seidman, AD; Winer, E, 2012) |
| "It is unclear which patients with breast cancer benefit from anthracycline-based neoadjuvant chemotherapy and whether taxanes increase survival." | ( Collie-Duguid, ES; Heys, SD; Miller, ID; Smyth, E; Stewart, KN; Sweeney, K, 2012) |
| "Patients with progressive metastatic breast cancer to the central nervous system (CNS) have limited treatment options." | ( Bullitt, E; Eisenberg, E; Freedman, RA; Gelman, R; Harris, G; Krop, IE; Ligibel, JA; Lin, NU; Partridge, AH; Sun, L; Winer, EP, 2011) |
| "Member institutions of the Japan Breast Cancer Research Group were invited to complete a questionnaire on the occurrence of grade 2 or higher HFS and FE among patients treated between April 2007 and March 2008 with docetaxel as an adjuvant or neoadjuvant chemotherapeutic treatment for breast cancer." | ( Aogi, K; Ishiguro, H; Iwata, H; Kawaguchi, K; Kuroi, K; Masuda, N; Morita, S; Nakamura, S; Ohno, S; Toi, M, 2011) |
| "Primary breast cancer patients (n = 216) treated with adjuvant FEC (60, 75 or 100 mg/m(2)) were included in this study." | ( Kim, SJ; Maruyama, N; Nakayama, T; Noguchi, S; Okishiro, M; Shimazu, K; Shimomura, A; Tamaki, Y; Tsunashima, R, 2012) |
| "Patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and cranial radiotherapy were included." | ( Campone, M; Eierman, W; Greil, R; Kaufman, B; Lane, SR; Lin, NU; Rubin, SD; Steplewski, K; Winer, EP; Zembryki, D, 2011) |
| "Adjuvant tamoxifen therapy of breast cancer patients with estrogen receptor-positive tumors reduces the rate of breast cancer recurrence by approximately a half." | ( Cronin-Fenton, DP; Lash, TL, 2011) |
| "A total of 370 stage II or III breast cancer patients who received neoadjuvant docetaxel/doxorubicin chemotherapy were enrolled in this study." | ( Bang, YJ; Han, SW; Han, W; Heo, DS; Im, SA; Keam, B; Kim, DW; Kim, JH; Kim, TY; Lee, SH; Nam, BH; Noh, DY; Oh, DY; Park, IA; Park, S, 2011) |
| "Triple-negative breast cancer [TNBC, which is negative for the estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2] is a high-risk form of the disease without a specific therapy." | ( Abe, E; Arima, Y; Hayashi, H; Hayashi, N; Kai, K; Mikami, S; Nakamura, S; Sasaki, M; Saya, H; Sugihara, E; Yoshida, A, 2012) |
| "Liver metastases from breast cancer are generally treated with systemic therapy such as chemotherapy or hormonotherapy." | ( Danno, K; Imaoka, S; Inatome, J; Kagara, N; Kagawa, K; Kanoh, T; Kim, C; Kimura, Y; Monden, T; Nakamura, H; Nakano, Y; Ohnishi, T; Taniguchi, H; Tono, T; Watanabe, A, 2014) |
| "Individualized chemotherapy for breast cancer improves the outcome." | ( Brodowicz, T; Csörgo, E; Kahán, Z; Kaizer, L; Lázár, G; Nikolényi, A; Ormándi, K; Sükösd, F; Thurzó, L; Uhercsák, G; Vörös, A, 2011) |
| "Forty-three patients with 45 breast cancers were treated with neoadjuvant docetaxel-epirubicin with/without capecitabine chemotherapy." | ( Brodowicz, T; Csörgo, E; Kahán, Z; Kaizer, L; Lázár, G; Nikolényi, A; Ormándi, K; Sükösd, F; Thurzó, L; Uhercsák, G; Vörös, A, 2011) |
| "Patients with HER2-positive, advanced breast cancer who progressed during treatment with trastuzumab with or without 1st-line metastatic chemotherapy were prospectively randomised to X (2500mg/m(2) on days 1-14, q3w) or XH (6 (8)mg/kg, q3w)." | ( Andersson, M; Barinoff, J; Baumann, KH; Bischoff, J; Cufer, T; de Jongh, FE; Harbeck, N; Loibl, S; Lück, HJ; Maartense, E; Maass, N; Mundhenke, C; Nekljudova, V; Schmidt, M; Schwedler, K; Stein, RC; von Minckwitz, G; Zielinski, C, 2011) |
| "Treatment with Rp1 inhibited breast cancer cell proliferation and inhibited both anchorage-dependent and -independent breast cancer cell colony formation." | ( Choi, C; Kang, JH; Oh, SH; Park, MH; Rhee, MH; Song, KH; Woo, JK, 2011) |
| "We used the Danish Breast Cancer Cooperative Group registry to identify 541 cases of recurrent breast cancer among women with estrogen receptor-positive tumors treated with tamoxifen for at least 1 year (ER(+)/TAM(+)), and 300 cases of recurrent breast cancer among women with estrogen receptor-negative tumors who were not treated with tamoxifen (ER(-)/TAM(-))." | ( Ahern, TP; Christensen, M; Cronin-Fenton, DP; Garne, JP; Gjerde, J; Hamilton-Dutoit, S; Lash, TL; Lunetta, KL; Rosenberg, CL; Silliman, RA; Søiland, H; Sørensen, HT, 2011) |
| "In HER2-overexpressing breast cancer, accumulating preclinical evidences suggest that some chemotherapies, like trastuzumab, but also taxanes, are able to trigger a T helper 1 (Th1) anticancer immune response that contribute to treatment success." | ( Apetoh, L; Arnould, L; Coudert, B; Fumoleau, P; Ghiringhelli, F; Ladoire, S; Martin, F; Mignot, G; Rébé, C, 2011) |
| "Consequently, treatment of ER-positive breast cancer cells in vitro with α-methyl-DL-tryptophan (α-MT), a selective blocker of SLC6A14, induces amino acid deprivation, inhibits mTOR, and activates autophagy." | ( Babu, E; Coothankandaswamy, V; Elangovan, S; Ganapathy, V; Gnanaprakasam, JP; Gurav, A; Karunakaran, S; Periyasamy-Thandavan, S; Prasad, PD; Ramachandran, S; Schoenlein, PV; Singh, N; Thangaraju, M, 2011) |
| "Premenopausal patients with breast cancer are at high risk of premature ovarian failure induced by systemic treatments, but no standard strategies for preventing this adverse effect are yet available." | ( Bighin, C; Boni, L; Cresti, N; Del Mastro, L; Gamucci, T; Garrone, O; Giordano, M; Giraudi, S; Gori, S; Levaggi, A; Magnolfi, E; Michelotti, A; Olmeo, N; Pronzato, P; Scotto, T; Vecchio, C; Venturini, M, 2011) |
| "Bone metastases in advanced breast cancer patients remains a significant treatment challenge." | ( Abele, JT; El-Mabhouh, AA; McEwan, AJ; Mercer, JR; Nation, PN; Postema, E; Riauka, T, 2011) |
| "More than 80% of patients with breast cancer undergoing postsurgical radiotherapy (RT) will develop radiodermatitis and approximately 10% of these patients show grade 3 lesions." | ( Becker-Schiebe, M; Bulitta, M; Hoffmann, W; Mengs, U; Schaefer, M, 2011) |
| "BT474 and SK-BR-3 breast cancer cell lines were treated with Trastuzumab, Pertuzumab, and Lapatinib alone using different combinations and concentrations." | ( Breindl, S; Brockhoff, G; Buchholz, S; Diermeier-Daucher, S; Ortmann, O, 2011) |
| "ErbB2-positive breast cancer is tend to be more aggressive than other types of breast cancer and therefore further investigation on the signaling pathways of erbB2 is needed for the therapeutic target for breast cancer treatment." | ( Adachi, R; Hasegawa, T; Horiuchi, S; Sakamaki, T; Sakurazawa, Y; Sato, K, 2011) |
| "Endocrine therapy in patients with breast cancer can be limited by the problem of resistance." | ( Beyer, A; Cai, WY; Elledge, R; Fuqua, S; Hilsenbeck, S; Huang, J; Massarweh, S; Rimawi, M; Sexton, K; Tham, YL; Tsimelzon, A; Weiss, H, 2011) |
| "The results showed that advanced breast cancer diseased (AD) patients without previous chemotherapy presented anemia and high oxidative stress status characterized by elevated levels of lipid peroxidation and nitric oxide, and reduced catalase activity when compared with controls." | ( Campos, FC; Cecchini, AL; Cecchini, R; Colado Simão, AN; De Rossi, T; Freitas, LF; Herrera, AC; Panis, C; Victorino, VJ, 2012) |
| "The increased risk of breast cancer recently observed with some specific estro-progestin associations has raised concerns about the harmful effects of menopausal hormone replacement therapy (HRT)." | ( de Cremoux, P; Jacquot, Y; Leclercq, G; This, P, 2011) |
| "To improve the treatment of breast cancer, there has been a need for alternative aromatase inhibitors (AIs) that bring about adequate aromatase inhibition, while limiting side effects." | ( Cushman, M; Flockhart, DA; Lu, WJ; Mayhoub, AS; Pei, Z; Xu, C, 2012) |
| "The majority of breast cancer deaths are because of ineffective treatment of metastatic disease." | ( Allan, AL; Croker, AK, 2012) |
| "ppGCSF should be strongly considered in breast cancer patients receiving adjuvant TC chemotherapy." | ( Advani, PP; Kossoff, EB; Levine, EG; Ngamphaiboon, N; O'Connor, TL, 2012) |
| "Primary breast carcinomas expressing both estrogen and progesterone receptors are most likely to respond to tamoxifen therapy, especially in patients with early-stage lesions." | ( Kerr, DA; Wittliff, JL, 2011) |
| "To date, only one breast cancer case has been reported in the literature in a FtM transsexual after 10 years of testosterone therapy." | ( Grossbard, ML; Klein, P; Shao, T, 2011) |
| "Thrombosis is a common complication for breast cancer patients receiving chemotherapy." | ( Liaw, PC; Mukherjee, S; Swystun, LL, 2011) |
| "The samples used were from 21 primary breast cancer patients who underwent neoadjuvant chemotherapy and 17 cases with sentinel lymph nodes that had lymph node micrometastasis." | ( Kai, M; Katano, M; Kubo, M; Onishi, H; Souzaki, M; Tanaka, H; Tanaka, M, 2011) |
| "Human breast cancer T47D cells were treated with ethanol at various concentrations." | ( Hong, J; Nunez, NP; Paulson, QX; Poh, K; Schrader, E; Stubbins, RE; Wong, AW, 2011) |
| "Adjuvant hormonal therapy (HT) for breast cancer improves survival, yet studies have shown that early discontinuation and suboptimal adherence are common." | ( Li, L; Nekhlyudov, L; Ross-Degnan, D; Wagner, AK, 2011) |
| "Current breast cancer treatments are often associated with severe side effects." | ( Beqa, L; Fan, Z; Ray, PC; Senapati, D; Singh, AK, 2011) |
| "Thirty-four women with 34 invasive breast cancers underwent DWI and PET/CT before and after chemotherapy and before surgery." | ( Chang, JM; Cho, N; Han, W; Im, SA; Kang, KW; Moon, WK; Noh, DY; Park, IA; Park, SH, 2012) |
| "All 3 breast cancer patients showed retention of (18)F-fluoropaclitaxel and ultimately demonstrated a complete pathologic response (no invasive cancer in the breast or axillary nodes) to chemotherapy that included a taxane (either paclitaxel or docetaxel) at surgical resection." | ( Adler, S; Bear, HD; Choyke, PL; Hirsch, JI; Kalen, JD; Kurdziel, KA; Logan, J; McCumisky, J; Moorman-Sykes, K; Wilson, JD, 2011) |
| "Therapy of cancer, including basallike breast tumors, that targets the epidermal growth factor receptor (EGFR) would greatly benefit from noninvasive methods that can quantitatively monitor receptor status and treatment response." | ( Choe, YS; Jung, KH; Lee, KH; Paik, JY, 2011) |
| "However, a major problem during breast cancer treatment is the sudden onset of menopause and many women seek for alternative medicines, such as the soy isoflavone genistein." | ( de Jong, PC; de Morree, ES; Nijmeijer, SM; van den Berg, M; van Duursen, MB, 2011) |
| "Chest wall breast cancer recurrence after mastectomy is a disease difficult to treat." | ( Cemazar, M; Cufer, T; Paulin, SM; Sersa, G; Snoj, M, 2012) |
| "ERα is a well-established target for breast cancer therapy, but strategies to target its function remain of interest to address therapeutic resistance and further improve treatment." | ( Begus-Nahrmann, Y; Beissbarth, T; Eick, D; Gorsler, T; Hennion, M; Hintermair, C; Hsu, C; Johnsen, SA; Kramer, F; Kremmer, E; Prenzel, T; Simons, M, 2011) |
| "In ER-positive clinical breast cancers treated with preoperative chemotherapy, significantly more number of specimens that showed increased or positive YB-1 expression after chemotherapy was positive for HER2 expression." | ( Amano, J; Ito, K; Ito, T; Izumi, H; Kamijo, S; Kohno, K, 2012) |
| "In advanced breast cancer, multiple sequential lines of treatments are frequently applied." | ( Bartsch, R; Fiegl, M; Hubalek, M; Mlineritsch, B; Pluschnig, U; Steger, GG, 2011) |
| "129 consecutive patients with advanced breast cancer, of whom the majority had been massively pretreated, received PLD as monotherapy within licensed approval, for which efficacy and toxicities were documented." | ( Bartsch, R; Fiegl, M; Hubalek, M; Mlineritsch, B; Pluschnig, U; Steger, GG, 2011) |
| "It has long been known that breast tumors expressing ERα protein (ERα+) behave in a fundamentally different fashion than ERα-negative (ERα-) tumors with regard to their responses to hormonal therapy." | ( Fan, W; Sui, M; Zhang, H, 2011) |
| "Elucidating the response of breast cancer cells to chemotherapeutic and hormonal based drugs and radiation is clearly important as these are common treatment approaches." | ( Abrams, SL; Chappell, WH; Cocco, L; Drobot, LB; Franklin, RA; Libra, M; Martelli, AM; McCubrey, JA; Navolanic, P; Nicoletti, F; Steelman, LS; Stivala, F; Wong, EW, 2011) |
| "The treatment of metastatic breast cancer (MBC) is essentially palliative and should be based on hormone therapy or optimized chemotherapy designed to delay disease progression and maximize survival with good quality of life." | ( Cortes, J; Roché, H, 2012) |
| "Women who developed breast cancer (both noninvasive and invasive) while on 5 years of selective estrogen receptor modulators therapy (cases) were matched to controls free of breast cancer." | ( Ames, MM; Batzler, A; Carlson, EE; Costantino, JP; Flockhart, DA; Goetz, MP; Ingle, JN; Kubo, M; Mushiroda, T; Nakamura, Y; Paik, S; Safgren, S; Schaid, DJ; Vogel, VG; Weinshilboum, RM; Wickerham, DL; Wolmark, N, 2011) |
| "Memory deficits were observed in breast cancer patients who receive either chemotherapy or tamoxifen alone compared to age-adjusted norms." | ( Cwikel, J; Faran, Y; Geffen, DB; Prokasheva, S, 2011) |
| "The use of in vivo MRS in breast cancer diagnosis and treatment monitoring should bring supplementary information to the standard MR imaging protocol." | ( Bathen, TF; Bofin, A; Gribbestad, IS; Heldahl, MG; Lundgren, S; Sitter, B; Vettukattil, R, 2011) |
| "When treating advanced and metastatic breast cancer patients with chemotherapy, it is mandatory to maintain the patients quality of life while keeping an acceptable level of antitumor activity." | ( Akizuki, M; Fujii, K; Fukutomi, T; Kobayashi, K; Kosaka, J; Mouri, Y; Nakano, S; Yorozuya, K; Yoshida, M, 2011) |
| "Women with node-positive primary breast cancer were randomly assigned to receive tamoxifen (20 mg/d for 5 years) during (concurrent arm) or after (sequential arm) adjuvant chemotherapy." | ( Bedognetti, D; Boccardo, F; Bruzzi, P; Del Mastro, L; Gardin, G; Monzeglio, C; Pastorino, S; Pronzato, P; Queirolo, P; Sertoli, MR; Siffredi, G; Taveggia, P; Venturini, M; Wang, E; Zanardi, E, 2011) |
| "She had been diagnosed with metastatic breast cancer and bisphosphonate therapy along with zoledronic acid." | ( Ishiguro, N; Iwase, T; Kishimoto, Y; Koyama, A; Masui, T; Matsuo, H; Yoshida, G, 2011) |
| "In postmenopausal breast cancer patients treated with tamoxifen, TVS alone is not sufficient for the detection of endometrial pathologies." | ( Feng, LM; Gao, WL; Zhang, LP, 2011) |
| "Cultured breast cancer cells were treated with DM102 [(2R,3Z)-N-(1-hydroxyoctadec-3-en-2-yl)pivalamide, C6-cer, or the combination." | ( Abad, JL; Cabot, MC; Casas, J; Delgado, A; Fabriás, G; Flowers, M, 2012) |
| "There is increasing evidence linking breast cancer and diabetes; however, few studies have explored the association between cancer treatments and risk of diabetes." | ( Anderson, GM; Austin, P; Fischer, HD; Gruneir, A; Lipscombe, LL; Paszat, L; Rochon, PA; Yun, L, 2012) |
| "212 female breast cancer patients ≤35 years old were treated during 1997-2007." | ( Leidenius, M; Liukkonen, S; Saarto, T; Sjöström-Mattson, J, 2011) |
| "Metastatic breast cancer (MBC) patients with rapid disease relapse after neo/adjuvant chemotherapy including anthracyclines and taxanes have limited treatment options and their efficacy is marginal." | ( Campone, M; Fein, L; Jassem, J; Karwal, M; Peck, R; Poulart, V; Vahdat, L, 2012) |
| "Patients with breast cancer with early relapse following neo/adjuvant treatment with anthracyclines and taxanes may benefit from ixabepilone plus capecitabine." | ( Campone, M; Fein, L; Jassem, J; Karwal, M; Peck, R; Poulart, V; Vahdat, L, 2012) |
| "All patients with breast cancer who were initially treated with PHT between January 2002 and December 2008 were identified from a single consultant's prospectively maintained database." | ( Champ, C; Gower-Thomas, K; Jones, M; Osborn, G; Vaughan-Williams, E, 2011) |
| "Postmenopausal breast cancer risk associated with combined therapy may be modified by genetic variation in SRD5A1." | ( Abbas, S; Chang-Claude, J; Flesch-Janys, D; Hein, R; Salazar, R; Seibold, P, 2012) |
| "Expression of miR-128 in breast cancer tissues was examined by in situ hybridization and correlated with breast tumor response to neoadjuvant chemotherapy and patient survival." | ( Chen, J; Feng, J; Gong, C; Jiao, Y; Song, E; Su, F; Tang, W; Yao, H; Yu, F; Zhang, Y; Zhu, Y, 2011) |
| "HER2-positive breast cancers exhibit high rates of innate and acquired resistance to trastuzumab (TZ), a HER2-directed antibody used as a first line treatment for this disease." | ( Baker, JH; Bally, MB; Dragowska, WH; Franssen, Y; Gelmon, KA; Kapanen, AI; Kierkels, GJ; Masin, D; Minchinton, AI; Qadir, MA; Weppler, SA; Wong, LY, 2011) |
| "During paclitaxel therapy, breast cancer patients were administered meloxicam (10 mg per day) daily, when experiencing symptoms of grade 2 neuropathy (motor or sensory)." | ( Iwase, S; Kitamura, K; Kuroda, Y; Nagumo, Y; Odagiri, H; Yamamoto, C; Yamamoto, D; Yoshida, H, 2011) |
| "At necropsy, breast tumors were detected in 44% of rats co-treated with tamoxifen+E2." | ( Bhat, HK; Bhat, NK; Singh, B, 2011) |
| "Put-analysis in 40 patients with breast cancer, to chanalicular infiltrated, eligible were treated in a prospective study, to double blind person, using per os: letrozol, 2." | ( Amador, DD; Font López, KC; Novoa Vargas, A, 2011) |
| "Thirty-seven consecutive breast cancer patients scheduled to surgery following neoadjuvant therapy preoperatively underwent a Tc-99m-tetrofosmin SPECT/CT study, using a dual head gamma camera integrated with a x-ray tube for low-dose CT, including both breasts and axillary regions in the field of view." | ( Chessa, F; Farris, A; Madeddu, G; Nuvoli, S; Sanna, D; Spanu, A, 2011) |
| "Triple negative breast cancers (TNBC) are clinically heterogeneous and prognostic markers and biology-based therapies are needed to better treat this disease." | ( Ahr, A; Gaetje, R; Hanker, L; Holtrich, U; Karn, T; Kaufmann, M; Liedtke, C; Metzler, D; Müller, V; Pusztai, L; Rody, A; Ruckhaeberle, E; Schmidt, M; Solbach, C, 2011) |
| "Postmenopausal breast cancer (BC) patients receiving adjuvant aromatase inhibitor therapy are at risk of progressive bone loss and fractures." | ( Argonza-Aviles, E; Beck, JT; Bosserman, L; Brufsky, AM; Ericson, SG; Harker, WG; Hohneker, J; Jin, L; Perez, EA; Seidler, C; Vogel, C; Warsi, G, 2012) |
| "One hundred and fourteen cases of breast cancer with NA therapy were analyzed and clinical data were collected from March 2007 to December 2010." | ( Farkas, R; Horváth, OP; Kálmán, E; Kovács, G; Kövér, E; Pavlovics, G; Szalai, G; Tizedes, G; Zapf, I, 2011) |
| "In women with breast tumors expressing medium or high ER levels (n = 1,438), the interaction between Ki67 and adjuvant endocrine treatment was significant for RFS (P = 0." | ( Bago-Horvath, Z; Böhm, G; Dubsky, P; Filipits, M; Gnant, M; Greil, R; Gruber, C; Haid, A; Jakesz, R; Jasarevic, Z; Jelen, A; Kemmerling, R; Pöstlberger, S; Rudas, M; Singer, CF, 2011) |
| "Fifteen patients with metastatic breast cancer were treated with docetaxel (doses of 40-75 mg/m(2) intravenously on day 1 of a 21-day cycle) in combination with everolimus (doses ranging from 20 to 50 mg orally on days 1 and 8 of a 21-day cycle) in a phase 1 trial using the continuous reassessment method to determine maximum tolerated dose." | ( Booser, D; Brewster, A; Cristofanilli, M; Ensor, J; Giordano, SH; Gladish, G; Gonzalez-Angulo, AM; Hortobagyi, GN; Moore, J; Moulder, S; Murray, JL; Rivera, E; Tran, HT, 2012) |
| "Thirty-six stage II/III breast cancers (34 patients) were measured in vivo with DOSI prior to, in the middle of and after the completion of pre-surgical neoadjuvant chemotherapy." | ( Butler, J; Cerussi, AE; Hsiang, D; Mehta, RS; Tanamai, VW; Tromberg, BJ, 2011) |
| "Patients with high-risk node-positive breast cancer were treated with three cycles of fluorouracil 500 mg m(-2), epirubicin 100 mg m(-2), cyclophosphamide 500 mg m(-2) (FEC 100) followed by three cycles of docetaxel 100 mg m(-2) delivered at 2-weekly intervals supported by primary prophylaxis with filgrastim." | ( Asselain, B; Bonnetain, F; Brain, E; Delva, R; Fumoleau, P; Gauthier, M; Jimenez, M; Levy, C; Martin, AL; Mauriac, L; Rios, M; Roché, H; Serin, D; Spielmann, M; Veyret, C, 2011) |
| "Seventy-eight stage II or III breast cancer patients who received neoadjuvant docetaxel/doxorubicin chemotherapy were enrolled in this study." | ( Bang, YJ; Cho, N; Chung, JK; Han, SW; Han, W; Im, SA; Kang, KW; Keam, B; Kim, JH; Kim, TY; Koh, Y; Moon, WK; Noh, DY; Oh, DY; Park, IA, 2011) |
| "To eradicate both breast cancer cells and breast cancer stem cells which can not be eliminated by the conventional chemotherapy, octreotide (Oct)-modified paclitaxel (PTX)-loaded PEG-b-PCL polymeric micelles (Oct-M-PTX) and salinomycin (SAL)-loaded PEG-b-PCL polymeric micelles (M-SAL) were developed and investigated in combination." | ( Wang, J; Wang, X; Zhang, H; Zhang, Q; Zhang, X; Zhang, Y, 2012) |
| "Multi-drug resistance of breast cancer is a major obstacle in chemotherapy of cancer treatments." | ( Berkovitch-Luria, G; Feuerstein, T; Malik, Z; Nudelman, A; Rephaeli, A, 2011) |
| "In total, 157 metastatic breast cancer patients received 35 mg/m2 docetaxel weekly as a recommended treatment." | ( Aravantinos, G; Bafaloukos, D; Bournakis, E; Dimopoulos, AM; Fountzilas, G; Fountzilas, H; Kalofonos, HP; Kalogeras, KT; Korantzis, I; Kosmidis, P; Kotoula, V; Koutras, A; Papakostas, P; Papaxoinis, G; Pectasides, D; Skarlos, D; Varthalitis, I, 2012) |
| "Human breast cancer cell lines pretreated with TGFβ small molecule inhibitor were radiosensitized, irrespective of sensitivity to TGFβ growth inhibition." | ( Akhurst, RJ; Babb, JS; Barcellos-Hoff, MH; Bouquet, F; Demaria, S; DeWyngaert, JK; Formenti, SC; Hann, B; Lonning, SM; Pal, A; Pilones, KA, 2011) |
| "There were 59 breast cancer events in the 569 patients with invasive cancers and no preoperative treatment." | ( Henningson, M; Hietala, M; Ingvar, C; Jernström, H; Lundin, KB; Rose, C, 2011) |
| "Ninety-one breast cancer patients treated with weekly PCb NCT were retrospectively analyzed." | ( Chen, X; Huang, O; Lu, H; Shen, K; Wu, J, 2012) |
| "Neoadjuvant therapy in breast cancer has emerged as an important setting for the development of targeted drugs." | ( de Azambuja, E; Metzger-Filho, O, 2011) |
| "Five hundred and ninety-five high-risk breast cancer patients were treated in a two-arm trial evaluating postoperative, dose-dense sequential chemotherapy with epirubicin followed by CMF (cyclophosphamide, methotrexate and 5-fluorouracil) with or without paclitaxel (Taxol)." | ( Aravantinos, G; Batistatou, A; Bournakis, E; Christodoulou, C; Economopoulos, T; Fountzilas, G; Gogas, H; Kalogeras, KT; Kronenwett, R; Linardou, H; Makatsoris, T; Pavlidis, N; Pectasides, D; Psyrri, A; Timotheadou, E; Wirtz, RM, 2012) |
| "Neutrophil counts from 140 breast cancer patients with observed grade IV neutropenia during the first course of docetaxel treatment were included." | ( Friberg, LE; Hansson, EK, 2012) |
| "Four women with newly diagnosed breast cancer who were about to undergo primary medical therapy gave informed and voluntary consent to take part in the study." | ( Cantanhede, G; Douek, M; Enfield, LC; Gibson, AP; Hebden, JC; Purushotham, AD; Westbroek, D, 2011) |
| "As to breast cancer therapy, lengthy hormonal therapy is very important for the treatment and prevention of recurrence." | ( Chino, A; Hirasaki, Y; Namiki, T; Ogawa, K; Okamoto, H; Ueda, K, 2011) |
| "MDA-MB-231 and T-47D breast cancer cell lines were used to assess the effect of paclitaxel treatment on apoptosis and cell cycle, the possible mechanisms of paclitaxel resistance as well as the enhancement of paclitaxel-induced apoptosis based on its combination with phenylethyl isothiocyanate (PEITC)." | ( Ávila, R; Castilla, C; Flores, ML; Japón, MA; Ruiz-Borrego, M; Sáez, C, 2012) |
| "HER-2-positive breast cancers frequently sustain elevated AKT/mTOR signaling, which has been associated with resistance to doxorubicin treatment." | ( Brentani, H; Brentani, MM; de Araujo Lima, L; Katayama, ML; Ravacci, GR; Roela, RA; Trapé, AP, 2012) |
| "For patients with metastatic breast cancer, we previously described that increased EZH2 expression levels were associated with an adverse outcome to tamoxifen therapy." | ( Berns, EM; Foekens, JA; Heine, AA; Jansen, MP; Look, MP; Martens, JW; Reijm, EA; Rodríguez-González, FG; Ruigrok-Ritstier, K; Sieuwerts, AM; Sleijfer, S, 2012) |
| "Patients with advanced breast cancer were randomized to first-line chemotherapy with a combination of epirubicin (Farmorubicin(®)) and paclitaxel (Taxol(®)) alone (ET) or in combination with capecitabine (Xeloda(®), TEX)." | ( Aström, G; Bergh, J; Brandberg, Y; Carlsson, L; Carstensen, J; Einbeigi, Z; Fernö, M; Hatschek, T; Hellström, M; Lidbrink, E; Linderholm, B; Lindh, B; Loman, N; Malmberg, M; Rotstein, S; Söderberg, M; Sundquist, M; Svensson, H; Walz, TM, 2012) |
| "Patients (n = 98) with breast cancer (98 lesions) underwent MRS (point-resolved spectroscopy sequence [PRESS]; TR/TE, 2000/100 msec; voxel size, 15 × 15 × 15 mm) before the administration of GBCA." | ( Ishigaki, S; Kawai, H; Maruyama, K; Mori, M; Naganawa, S; Sakurai, Y; Satake, H, 2012) |
| "A group of breast cancer survivors who did not receive chemotherapy was scanned for comparison (n = 15)." | ( Boogerd, W; Boven, E; Caan, M; de Ruiter, MB; Douaud, G; Lavini, C; Linn, SC; Reneman, L; Schagen, SB; van Dam, FS; Veltman, DJ, 2012) |
| "The dual roles of G3 in modulating breast cancer cell resistance to chemotherapeutic agents may in part explain a potential mechanism for breast cancer cell resistance to chemotherapy and EGFR therapy." | ( Deng, Z; Du, WW; Fang, L; Jeyapalan, Z; Seth, A; Shan, SW; Yang, BB; Yang, BL; Yee, AJ; Zhang, Y, 2011) |
| "Because TGFβ favors progression of breast cancer metastasis to bone, we hypothesized that treatment using anti-TGFβ antibody may reduce tumor burden and rescue tumor-associated bone loss in metastatic breast cancer." | ( Alvarez, J; Ayres, A; Biswas, S; Chakrabarti, A; Edwards, J; Johnson, R; Lonning, S; Matrisian, LM; Mundy, GR; Nyman, JS; Perrien, DS; Rana, T; Shyr, Y; Sterling, J, 2011) |
| "The effect of zoledronic acid in breast cancer adjuvant therapy concerning improvement of patient survival has yet to be confirmed." | ( Du, Y; Jiang, Y; Lu, J; Shao, Z; Yan, T; Yin, W; Zhou, L; Zhou, Q, 2012) |
| "Compared with the control arm, adjuvant breast cancer treatment with zoledronic acid did not significantly improve overall survival, disease free survival, bone metastasis free survival, distant and locoregional recurrence free survival." | ( Du, Y; Jiang, Y; Lu, J; Shao, Z; Yan, T; Yin, W; Zhou, L; Zhou, Q, 2012) |
| "Three breast cancer cell lines (MCF-7, MDA-MB-231, and Hs-578T) were treated with Gemcitabine and small molecule receptor tyrosine kinase inhibitor cis-3-[3-(4-methyl-piperazin-l-yl)-cyclobutyl]1-(2-phenyl-quinolin-7-yl)-imidazo [1,5-a]pyrazin-8-ylamine (PQIP) as single agents and then in combination in the forward (Gemcitabine followed by PQIP) and reverse (PQIP followed by Gemcitabine) sequences." | ( Brundage, RC; Hull, JM; Khatri, A; Kirstein, MN; Williams, BW; Yee, D, 2012) |
| "We identified 219 breast cancer patients who received paclitaxel as adjuvant chemotherapy between 2002 and 2009." | ( Ando, M; Fujiwara, Y; Harano, K; Hashimoto, K; Hirakawa, A; Katsumata, N; Kinoshita, T; Shimizu, C; Tamura, K; Tanabe, Y; Yonemori, K; Yunokawa, M, 2013) |
| "We studied whether lenalidomide treated breast cancer cells would acquire sensitivity to 1,25-D3 with resulting growth inhibition." | ( Brosseau, C; Colston, K; Dalgleish, AG; Galustian, C, 2012) |
| "The overall survival, breast cancer-specific death rate, age, race, nuclear grade, stage, menopausal status, estrogen and progesterone receptor status, body mass index and classes of antidiabetic pharmacotherapy were analyzed." | ( Ensor, J; Esteva, FJ; He, X; Hortobagyi, GN; Lee, MH; Yeung, SC, 2012) |
| "Purposive sampling of 19 breast cancer patients presenting with delayed treatment and/ or advanced cancer diagnosed within two years at the University Malaya Medical Centre, Kuala Lumpur were carried out." | ( Low, WY; Taib, NA; Yip, CH, 2011) |
| "A total of 655 breast cancer patients were treated postoperatively in Jiangsu Cancer Hospital and Research Institute from 1995-2005, 292 were treated with FPC (5-Fu 500 mg/m2 i." | ( Huang, XE; Li, CG; Li, Y; Tang, JH, 2011) |
| "Treatment of breast cancer is complex and challenging due to the heterogeneity of the disease." | ( Baxter, RC; Christopherson, RI; Leong, S; McKay, MJ, 2012) |
| "Hormonal dependence of breast cancer has been known for a long time, yet about half of breast cancers with estrogen receptor will not respond to antihormonal therapy." | ( Bachelot, T; Guastalla, JP; Heudel, PÉ; Ray-Coquard, I; Tredan, O; Treilleux, I, 2011) |
| "We now map CTCF binding genome wide in breast cancer cells and find that CTCF binding is unchanged in response to estrogen or tamoxifen treatment." | ( Brown, GD; Carroll, JS; Ross-Innes, CS, 2011) |
| "Radiotherapy in breast cancer may be an independent predictive factor for the development of new diffuse thyroidal uptake in PET-CT associated with thyroid dysfunction during follow-up." | ( Bae, YT; Kim, BH; Kim, IJ; Kim, SJ; Kim, SS; Kim, YK; Lee, JY, 2012) |
| "MCF7/Rx2(dox) breast cancer cells were treated with estradiol and/or doxycycline to induce Runx2, and global gene expression was profiled to define genes regulated by estradiol, Runx2, or both." | ( Baniwal, SK; Berman, BP; Chimge, NO; Coetzee, S; Ellis, MJ; Frenkel, B; Khalid, O; Luo, J; Tripathy, D, 2012) |
| "Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian target of rapamycin (mTOR) intracellular signaling pathway." | ( Bachelot, T; Baselga, J; Beck, JT; Burris, HA; Campone, M; Deleu, I; Gnant, M; Hortobagyi, GN; Ito, Y; Lebrun, F; Lebwohl, D; Mukhopadhyay, P; Noguchi, S; Perez, A; Piccart, M; Pritchard, KI; Rugo, HS; Sahmoud, T; Vittori, L; Xu, Z; Yardley, D, 2012) |
| "The sexual consequences of breast cancer and its treatments are well known and previously reviewed." | ( Katz, A; Krychman, ML, 2012) |
| "MCF-7 breast cancer cells were treated for 3 h (pulse treatment) and 72 h (permanent treatment) with ZA, and apoptosis rates and cell viability, defined as ATP content, were determined after 72 h." | ( Benad, P; Ebert, R; Hofbauer, LC; Jakob, F; Klein-Hitpass, L; Klotz, B; Meissner-Weigl, J; Rachner, TD; Rudert, M; Zeck, S, 2012) |
| "Blood samples from 95 breast cancer patients treated with tamoxifen were collected and genotyped for CYP2D6 and ABCB1 variants using allele-specific PCR method." | ( Din, J; Henry, G; Hla U, KT; Mohamed, NI; Muniandy, SP; Ngow, HA; Rajoo, TS; Rohaizak, M; Roslan, H; Saladina, JJ; Salleh, MZ; Shahrun, NS; Shia, JK; Sood, S; Teh, LK, 2012) |
| "A 61-year-old woman with metastatic breast cancer who was undergoing treatment with capecitabine developed erythema, fissuring, and erosions over both hands and feet, consistent with HFS." | ( Baker, SG; Cotliar, JA; Gunawardane, ND; Hoesly, FJ, 2011) |
| "Secondary breast cancer represents 6 to 9% of secondary neoplasia after treatments for Hodgkin Disease (HD)." | ( Guillaume, A; Mathelin, C; Morin, B, 2012) |
| "60 non-SSM) with Stage III breast cancer received anthracycline- and/or taxane-based neoadjuvant chemotherapy, mastectomy, and adjuvant XRT." | ( Carlson, G; Fasola, C; Gabram, S; Godette, K; Losken, A; O'Regan, R; Prabhu, R; Torres, M; Zelnak, A, 2012) |
| "In a series of 352 breast carcinoma tissues from patients that had been post-operatively treated with epirubicin-CMF with or without paclitaxel, we assessed HER2 and TOP2A gene status (chromogenic in situ hybridization), mRNA expression (quantitative reverse transcription PCR), as well as HER2 and TopoIIa protein expression (immunohistochemistry)." | ( Arapantoni, P; Aravantinos, G; Batistatou, A; Bobos, M; Christodoulou, C; Eleftheraki, AG; Fountzilas, G; Gogas, H; Kalogeras, KT; Kotoula, V; Koutras, A; Kronenwett, R; Pectasides, D; Pentheroudakis, G; Polychronidou, G; Soupos, N; Timotheadou, E; Tzaida, O; Valavanis, C; Vlachodimitropoulos, D; Wirtz, RM, 2012) |
| "Using a model of triple-negative breast cancer stem cells, we show that BCSCs are markedly resistant to traditional hyperthermia and become enriched in the surviving cell population following treatment." | ( Ajayan, PM; Burke, AR; Carroll, DL; D'Agostino, RB; Singh, RN; Torti, FM; Torti, SV; Wood, JC, 2012) |
| "The special case of 29 breast cancer patients treated with permanent (103)Pd seed implant is considered here." | ( Afsharpour, H; Beaulieu, L; Keller, BM; Landry, G; Pignol, JP; Reniers, B; Verhaegen, F, 2012) |
| "Furthermore, analysis of leptin-treated breast tumors shows increased expression of Wnt1, pGSK3β, and vimentin along with higher nuclear accumulation of β-catenin and reduced E-cadherin expression providing in vivo evidence for a previously unrecognized cross-talk between leptin and MTA1/Wnt signaling in epithelial-mesenchymal transition of breast cancer cells." | ( Avtanski, D; Saxena, NK; Sharma, D; Yan, D, 2012) |
| "Patients with untreated HER2-negative breast cancer were eligible if they had large tumors, hormone-receptor-negative disease, or hormone-receptor-positive disease with palpable nodes or positive findings on sentinel-node biopsy, and no increased cardiovascular or bleeding risk." | ( Blohmer, JU; Denkert, C; Eggemann, H; Eidtmann, H; Fasching, PA; Fehm, T; Gerber, B; Hanusch, C; Hauschild, M; Huober, J; Jackisch, C; Kittel, K; Kreienberg, R; Kunz, G; Loibl, S; Müller, BM; Nekljudova, V; Rezai, M; Schrader, I; Solbach, C; Tesch, H; Untch, M; von Minckwitz, G, 2012) |
| "Tamoxifen, a prodrug used for adjuvant breast cancer therapy, requires conversion to the active metabolite endoxifen through CYP 2D6." | ( Burstein, HJ; Desantis, SD; Gerona, R; Ji, W; Lorizio, W; Lynch, K; Ruan, W; Ruddy, KJ; Tchu, S; Wu, AH; Ziv, E, 2012) |
| "In this study of women with breast cancer undergoing chemotherapy, we explored the longitudinal relationship between fatigue and sleep measured both subjectively and objectively." | ( Ancoli-Israel, S; Dimsdale, JE; Fiorentino, L; Liu, L; Mills, PJ; Natarajan, L; Parker, BA; Rissling, M; Sadler, GR, 2012) |
| "In locally advanced breast cancer patients, the rates of pCR seem to differ among the 3 chemotherapy regimens with 6." | ( Jin, F; Li, B; Li, Y; Lv, M; Mao, X; Yao, F, 2011) |
| "Seventy-seven stage II or III breast cancer patients who received 3 cycles of neoadjuvant docetaxel/doxorubicin chemotherapy were enrolled in this prospective study." | ( Bang, YJ; Cho, N; Chung, JK; Han, SW; Han, W; Im, SA; Kang, KW; Keam, B; Kim, JH; Kim, TY; Koh, Y; Moon, WK; Noh, DY; Oh, DY; Park, IA, 2013) |
| "Metastatic breast cancer and stage IIIb/IV lung cancer patients who had received chemotherapy were eligible." | ( Antoine, EC; Cals, L; Morère, JF; Ray-Coquard, I; Scotté, F, 2012) |
| "A total of 123 primary breast cancer patients treated with neoadjuvant chemotherapy (P-FEC) were included in this study." | ( Kim, SJ; Maruyama, N; Nakamura, Y; Nakayama, T; Naoi, Y; Noguchi, S; Oshima, K; Shimazu, K; Shimomura, A; Tamaki, Y, 2012) |
| "ERα is critical in many breast tumors and is inhibited by antiestrogens such as tamoxifen in cancer therapy." | ( de Leeuw, R; Houtman, R; Martens, JW; Melchers, D; Michalides, R; Neefjes, J; Rondaij, M; Ruijtenbeek, R; Verwoerd, D, 2012) |
| "In this study, primary breast cancer patients (n = 123, stage II-III) treated with neoadjuvant P-FEC were analyzed." | ( Kim, SJ; Maruyama, N; Miyake, T; Nakayama, T; Naoi, Y; Noguchi, S; Otani, Y; Shimazu, K; Shimomura, A; Tamaki, Y; Yamamoto, N, 2012) |
| "Failure of chemotherapy in breast cancer presents a major problem and is often due to elevated expression of ATP binding cassette (ABC)-type transporters, such as MDR1 protein." | ( Balint, E; Boros, IM; Toth, M, 2012) |
| "Patients with breast cancer were treated postoperatively with paclitaxel 40 mg/m2 intravenously on days 1, 8 and 15, cisplatin 25 mg/ m2 also intravenously on days 1,8 and 15, repeated every 21-28 days as a cycle." | ( Huang, XE; Li, CG; Li, Y; Lu, YY; Tang, JH; Xiang, J, 2011) |
| "MCF-7, human breast cancer cells, were cultured in phenol red-free DMEM and treated with 1 nM 2-OH-E2 or 4-OH-E2." | ( Gregoraszczuk, EL; Kwiecinska, P; Ptak, A; Wrobel, A, 2012) |
| "Women with early-stage breast cancer initiating AI therapy were enrolled onto a multicenter, prospective, open-label randomized trial of exemestane versus letrozole." | ( Azzouz, F; Desta, Z; Flockhart, DA; Hayden, J; Hayes, DF; Henry, NL; Lemler, S; Li, L; Nguyen, AT; Stearns, V; Storniolo, AM; Tarpinian, K; Yakim, E, 2012) |
| "Adjuvant/neoadjuvant chemotherapy in breast cancer patients may be associated with amenorrhea and a marked reduction in ovarian reserve." | ( Ben-Aharon, I; Ben-Haroush, A; Farhi, J; Fisch, B; Pinkas, H; Sapir, O, 2011) |
| "Twenty-four breast cancer patients were treated with recombinant FSH (150-450 U/day) and letrozole (5 mg/day) in a long GnRH-agonist (n=7) or GnRH-antagonist (n=17) protocol." | ( Ben-Aharon, I; Ben-Haroush, A; Farhi, J; Fisch, B; Pinkas, H; Sapir, O, 2011) |
| "In early-stage breast cancer, adjuvant chemotherapy is associated with significant systemic toxicity with only a modest survival benefit." | ( Bentley, RC; Betof, AS; Blackwell, KL; Broadwater, G; Dewhirst, MW; Hardee, ME; Harris, LN; Horton, JK; Kim, SJ; Oosterwijk, E; Rabbani, ZN; Snyder, SA; Vujaskovic, Z, 2012) |
| "A major challenge in breast cancer therapy is the lack of an effective therapeutic option for a particularly aggressive subtype of breast cancer, triple-negative breast cancer." | ( Dong, Y; Fu, X; Hill, SM; Qi, Y; Rowan, BG; Xiong, Z; Zhang, H, 2012) |
| "Recent studies suggest that intrinsic breast cancer subtypes may differ in their responsiveness to specific chemotherapy regimens." | ( Bernard, PS; Cheang, MC; Chia, SK; Davies, S; Davis, C; Ebbert, MT; Ellis, MJ; Jiang, S; Leung, S; Levine, MN; Nielsen, TO; Parker, JS; Perou, CM; Pritchard, KI; Shepherd, LE; Stijleman, IJ; Tu, D; Voduc, KD, 2012) |
| "The data of 504 patients with breast cancer patients with MSCC were retrospectively analyzed with respect to posttreatment motor function, local control of MSCC, and survival." | ( Bajrovic, A; Douglas, S; Rades, D; Rudat, V; Schild, SE; Stalpers, LJ; Veninga, T, 2012) |
| "MDA-231 breast cancer cells were treated with thrombin in presence or absence of argatroban, and TF activity was measured in the form of activated factor X." | ( Akita, N; Asanuma, K; Asanuma, Y; Hayashi, T; Matsumine, A; Okamoto, T; Sudo, A; Uchida, A; Wakabayashi, H; Yoshikawa, T, 2013) |
| "Adjuvant chemotherapy for breast cancer can have adverse effects on cognition shortly after administration." | ( Boogerd, W; Breteler, MM; Gundy, C; Koppelmans, V; Schagen, SB; Seynaeve, C, 2012) |
| "Survivors of breast cancer treated with adjuvant CMF chemotherapy more than 20 years ago perform worse, on average, than random population controls on neuropsychological tests." | ( Boogerd, W; Breteler, MM; Gundy, C; Koppelmans, V; Schagen, SB; Seynaeve, C, 2012) |
| "Should chemotherapy for breast cancer be indicated in pregnancy from the second trimester onwards only, contraindications would be other risks for pre-eclampsia and intrauterine growth restriction, such as smoking and gestational diabetes." | ( Loibl, S; Massey Skatulla, L; Müller, T; Schauf, B, 2012) |
| "Therefore, when systemic therapy for breast cancer is recommended, early counseling and referral to a reproductive endocrinologist is warranted to provide optimal fertility preservation options." | ( Litton, JK, 2012) |
| "Forty-eight breast cancer patients who completed active cancer treatment were randomly assigned to receive either 8 weekly body-mind-spirit (BMS) group therapy sessions or 1 educational (EDU) session." | ( Chan, CL; Chang, KJ; Chen, YT; Ho, RT; Hsiao, FH; Jow, GM; Kuo, WH; Lai, YM; Liu, YF; Ng, SM, 2012) |
| "Claudin-low breast cancer (CLBC) is associated with early metastasis and resistance to chemotherapy, while gene profiling indicates it is characterized by the expression of markers of epithelial-mesenchymal transition (EMT) - a phenotypic conversion linked with metastasis." | ( Dong, C; Evers, BM; Rychahou, PG; Wang, Y; Wu, Y; Yao, J; Yu, Y; Zhou, BP, 2012) |
| "Human breast cancer (MCF-7 and MDA-MB-231) and normal breast cells (MCF-10A) were treated with drugs alone/in combination/sequentially." | ( Atmaca, H; Cakar, B; Karabulut, B; Karaca, B; Kisim, A; Sezgin, C; Uslu, R; Uzunoglu, S, 2012) |
| "Moreover, pretreatment of breast cancer cells with AT-101 and then with TRAIL caused enhancement of the expression levels of DR4 and DR5 in both cancer cell lines, suggesting that these cells were under strong apoptotic stimuli." | ( Atmaca, H; Cakar, B; Karabulut, B; Karaca, B; Kisim, A; Sezgin, C; Uslu, R; Uzunoglu, S, 2012) |
| "The goals of treatment for metastatic breast cancer (MBC) are to prolong overall survival (OS) while maximizing quality of life, palliating symptoms, and delaying tumor progression." | ( Dalivoust, P; Debled, M; Harbeck, N; Kaufmann, M; O'Shaughnessy, JA; Robert, NJ; Siedentopf, F, 2012) |
| "From June 2007 to July 2008, 61 breast cancer patients eligible for this study received anthracycline-based chemotherapy(FEC100: 5-FU 500mg/m / / 2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2)at National Kyushu Cancer Center and Iwate Medical University Hospital." | ( Fukazawa, M; Kashiwaba, K; Kawaguchi, H; Koga, C; Mori, E; Nakamura, Y; Nishimura, S; Ohno, S; Satou, S; Sawamura, K; Shigematsu, H, 2012) |
| "MCF-7 human breast cancer cells were infected with adenoviral constructs encoding the cDNA of PKGII (pAd-PKGII) to increase the expression of PKGII and treated with 8-pCPT-cGMP to activate the enzyme." | ( Chen, Y; Jiang, L; Lan, T; Sang, J; Tao, Y; Wang, Y; Wu, Y, 2012) |
| "Concerns regarding hormone therapy and breast cancer were initially based on case reports and retrospective case-control studies." | ( Anderson, GL; Chlebowski, RT, 2012) |
| "In a xenograft model of human breast cancer, combined treatment of Mito-CP and 2-DG led to significant tumor regression in the absence of significant morphologic changes in kidney, liver, or heart." | ( Cheng, G; Dranka, BP; Joseph, J; Kalyanaraman, B; Mackinnon, AC; McAllister, D; Zielonka, J, 2012) |
| "The docetaxel chemotherapy of breast carcinomas induced a similar sequential effect, with vessel enlargement after two cycles of docetaxel treatment and an antiangiogenic effect after six cycles." | ( Bleuzen, A; Bougnoux, P; Chevalier, S; Goupille, C; Mahéo, K; Richard, S; Serrière, S; Tranquart, F; Vibet, S, 2012) |
| "Among the low and intermediate grade breast cancers, the FGFR1 negative tumors were resistant to chemoradiotherapy." | ( Belin, L; Cohen-Jonathan-Moyal, E; Fourquet, A; Hall, J; Kirova, YM; Massabeau, C; Mégnin-Chanet, F; Richardson, M; Savignoni, A; Sigal-Zafrani, B, 2012) |
| "In metastatic breast cancer (MBC) patients, randomised controlled trials evaluated Bevacizumab as first-line treatment showed improvements in tumour response rate and progression-free survival (PFS) when added to chemotherapy." | ( Boulaamane, L; Boutayeb, S; Errihani, H, 2012) |
| "Many patients with relapsed metastatic breast cancer are pre-treated with taxanes and anthracyclines, which are usually given in the neoadjuvant/adjuvant setting or as first-line treatment for metastatic disease." | ( Abdullah, M; Al Khodary, A; Barsoum, M; El Nowieam, S; El Zawahry, H; Gaafar, R; Gouda, Y; Halim, IA; Hamada, E; Hamid, TA; Kohail, H; Mansour, O; Meshref, M; Shehata, S; Taleb, FA; Wareth, AA, 2012) |
| "The BITC-treated breast cancer cells (MDA-MB-231, MCF-7, MDA-MB-468, BT-474, and BRI-JM04) and MDA-MB-231 xenografts from BITC-treated mice exhibited several features characteristic of autophagy, including appearance of double-membrane vacuoles (transmission electron microscopy) and acidic vesicular organelles (acridine orange staining), cleavage of microtubule-associated protein 1 light chain 3 (LC3), and/or suppression of p62 (p62/SQSTM1 or sequestosome 1) expression." | ( Bommareddy, A; Hahm, ER; Kim, SH; Sehrawat, A; Singh, SV; Xiao, D, 2012) |
| "Premenopausal patients with metastatic breast cancer eligible for endocrine treatment received fulvestrant 250 mg and goserelin 3." | ( Bago-Horvath, Z; Bartsch, R; Berghoff, A; DeVries, C; Dubsky, P; Fitzal, F; Gnant, M; Mader, RM; Pluschnig, U; Rottenfusser, A; Rudas, M; Steger, GG; Zielinski, CC, 2012) |
| "HER2 gene amplification occurs in breast cancers and has implications for treatment and prognosis." | ( Chang, H; Jeong, H; Kim, A; Kim, Y; Lee, Y; Ryu, Y, 2012) |
| "Treatment option for metastatic breast cancer (MBC) patients pre-treated with chemotherapy is limited." | ( Fan, Y; Li, Q; Ma, F; Wang, JY; Xu, BH; Yuan, P; Zhang, P, 2012) |
| "Currently, the chemotherapy for breast cancer is underdeveloped." | ( Chen, Y; He, L; Liu, C; Smith, WW; Wang, N; Zhan, Y; Zhang, J; Zhang, Y; Zheng, L, 2012) |
| "Classical chemotherapeutic agents for breast cancer have dominated treatment regimens even in the era of targeted therapy." | ( Butler, SK; McBride, A, 2012) |
| "Docetaxel is a major drug in metastatic breast cancer (MBC) treatment." | ( Bonnefoi, H; Brouste, V; Debled, M; Donamaria, C; Durand, M; MacGrogan, G; Madranges, N; Mauriac, L; Toulmonde, M, 2012) |
| "Resistance of breast cancer cells to the available chemotherapeutics is a major obstacle to successful treatment." | ( Al-Akhras, MA; Albiss, B; Aldaher, AN; Aledealat, K; Aljarrah, K; Alsheyab, FM; Mhaidat, NM, 2012) |
| "The majority of patients with breast cancer receiving chemotherapy report multiple symptoms." | ( Golan-Vered, Y; Pud, D, 2013) |
| "However, 3% to 20% of breast cancer patients develop chronic cardiomyopathic changes and congestive heart failure because of doxorubicin therapy." | ( Greenlee, H; Lau, YI; Maurer, M; Naini, A; Shaw, J, 2012) |
| "In tamoxifen-resistant breast cancer cells, BG alone or in combination with antiestrogen (tamoxifen [TAM]/ICI 182,780 [fulvestrant, Faslodex]) therapy enhances p53 upregulated modulator of apoptosis (PUMA) expression, cytochrome C release and poly (ADP-ribose) polymerase (PARP) cleavage, all indicative of apoptosis." | ( Baidas, S; Baker, CH; Bobustuc, GC; Caparas, ML; Constantino, SM; Isley, B; Jeudy, S; Konduri, SD; Limaye, A; Maddipatla, S; Shah, N; Smith, JS; Srivenugopal, KS, 2012) |
| "Treatment with JKA97 arrested breast cancer cells in G1 phase and induced apoptosis." | ( Buolamwini, JK; Qin, JJ; Sharma, H; Wang, H; Wang, MH; Wang, W; Yang, X; Zhang, R, 2012) |
| "Patients with locally advanced breast cancer treated with neoadjuvant chemotherapy are at risk of cancer treatment-induced bone loss and consequently of increased skeletal morbidity." | ( Bleuse, JP; Chapelle, A; Jacot, W; Lamy, PJ; Pouderoux, S; Romieu, G; Thezenas, S, 2012) |
| "A 43-year-old woman with breast cancer received radiotherapy following a mastectomy and partial axillary lymph node dissection, shortly after which she developed a hot, tender, erythematous and indurated plaque at the mastectomy site." | ( Marshman, G; Newland, K, 2012) |
| "Women treated for breast cancer by a sequential adjuvant FEC and docetaxel regimen who developed permanent alopecia diagnosed between 2007 and 2011 were identified from the Department of Dermatology (Saint-Eloi Hospital, Montpellier, France) and the Department of Medical Oncology (CRLC Val d'Aurelle, Montpellier, France)." | ( Bessis, D; Dereure, O; Frouin, E; Guillot, B; Jacot, W; Kluger, N; Poujol, S; Rigau, V; Romieu, G, 2012) |
| "The ability of a breast cancer cell to evade apoptosis has a key role in tumor progression and sensitivity to treatment." | ( McCormack, D; McDonald, D; McFadden, D; Moon, D, 2013) |
| "Our model strongly suggests that breast cancer prevention with anti-estrogens or aromatase inhibitors represents early treatment not prevention." | ( Heitjan, DF; Santen, RJ; Yue, W, 2012) |
| "Nude mice and primary human breast cancer cells were treated with phosphate buffered saline (PBS), ulinastatin, docetaxel, or ulinastatin plus docetaxel, respectively." | ( Shen, H; Sun, X; Sun, Z; Wang, H; Zhang, Y; Zhong, B, 2012) |
| "Cytotoxic assays were evaluated in breast carcinoma (MCF-7) cells treated by the sulforhodamine B colorimetric method." | ( Aránega, A; Boulaiz, H; Ortega-Vinuesa, JL; Peula-García, JM; Sánchez-Moreno, P, 2012) |
| "High PDGFRβ in primary ER+ breast cancer of 81 patients prior to neoadjuvant treatment with an AI was associated with poorer antiproliferative response." | ( Dowsett, M; Dunbier, A; Ghazoui, Z; Martin, LA; Pancholi, S; Weigel, MT, 2012) |
| "Tamoxifen is used in the treatment of breast cancer to prevent recurrences." | ( Adithan, C; Damodaran, SE; Kadambari, D; Pradhan, SC; Reddy, KS; Umamaheswaran, G, 2012) |
| "Tamoxifen is commonly used for breast cancer therapy." | ( Bouchez, LC; Cho, CY; Dubrovska, A; Hartung, A; Reddy, VA; Schultz, PG; Walker, JR, 2012) |
| "Pharmacological targeting of breast cancer stem cells (CSCs) is highly promising for the treatment of breast cancer, as the small population of CSCs appears responsible for tumor initiation and progression and also for resistance to conventional treatment." | ( Cheng, KW; Constantinides, P; Huang, L; Ouyang, N; Rigas, B; Sun, Y; Zhu, C, 2012) |
| "Treatment of human breast cancer cells with L-ascorbate differentially induced cell death, dependent on the SVCT-2 protein level." | ( Cho, BJ; Cho, IJ; Hong, SW; Hwang, JJ; Hwang, YI; Jeong, YJ; Jin, DH; Jung, DJ; Kang, JS; Kim, DE; Kim, DJ; Kim, HS; Kim, JE; Kim, TW; Ko, E; Lee, JS; Lee, SH; Lee, WJ; Moon, JH; Noh, DY; Shin, JS, 2013) |
| "Taxanes used in adjuvant therapy for breast cancer are neurotoxic, and thereby being a potential risk factor for persistent pain after breast cancer treatment (PPBCT) and sensory disturbances." | ( Andersen, KG; Eckhoff, L; Gärtner, R; Jensen, MB; Kehlet, H; Kroman, N, 2012) |
| "Docetaxcel as adjuvant treatment for breast cancer does not increase the risk of PPBCT, sensory disturbances in the surgical area or functional impairment, but increase risk for peripheral sensory disturbances." | ( Andersen, KG; Eckhoff, L; Gärtner, R; Jensen, MB; Kehlet, H; Kroman, N, 2012) |
| "Tamoxifen is an effective treatment for breast cancer but an undesirable side-effect is an increased risk of endometrial cancer, particularly rare tumor types associated with poor prognosis." | ( Bernstein, L; Hollema, H; Hoogendoorn, WE; Jones, ME; Mourits, MJ; Press, MF; Swerdlow, AJ; van Boven, H; van Leeuwen, FE, 2012) |
| "Patients with endometrial cancer after breast cancer who received tamoxifen treatment for five years for breast cancer have greater endometrial cancer mortality risk than those who did not receive tamoxifen." | ( Bernstein, L; Hollema, H; Hoogendoorn, WE; Jones, ME; Mourits, MJ; Press, MF; Swerdlow, AJ; van Boven, H; van Leeuwen, FE, 2012) |
| "Studies on the role of TP53 mutation in breast cancer response to chemotherapy are conflicting." | ( Chang, LL; El-Naggar, AK; Garza, D; Jackson, JG; Li, Q; Li, Y; Lozano, G; Manshouri, T; Pant, V; Quintás-Cardama, A; Tavana, O; Yang, P, 2012) |
| "Patients with triple-negative breast cancers (TNBCs) typically have a poor prognosis because such cancers have no effective therapeutic targets, such as estrogen receptors for endocrine therapy or human epidermal growth factor receptor 2 (HER2) receptors for anti-HER2 therapy." | ( Ando, M; Fujiwara, Y; Katanasaka, Y; Kitamura, Y; Kodaira, M; Koizumi, F; Masutomi, K; Okamoto, N; Shimizu, C; Tamura, K; Yonemori, K; Yoshida, T; Yunokawa, M, 2012) |
| "In Japan, few cases of primary breast cancer treated preoperatively using carboplatin-containing regimens have been described." | ( Aruga, T; Honda, Y; Horiguchi, K; Kitagawa, D; Kuroi, K; Nako, Y; Shigekawa, T; Yamashita, T, 2012) |
| "The lack of pathologic breast cancer response to neoadjuvant chemotherapy (NCT), a negative prognostic factor, has prompted the addition of chemotherapy to adjuvant radiotherapy." | ( Angelergues, A; Bollet, MA; Campana, F; Dendale, R; Fourquet, A; Gobaux, V; Hajage, D; Kirova, YM; Marchand, V; Pierga, JY; Reyal, F, 2013) |
| "Two groups of patients treated for breast cancer between 1997 and 2002 by NCT, surgery, and radiotherapy with or without concurrent chemotherapy, were matched on age, body mass index (BMI), treatment period, treated side, and surgery type." | ( Angelergues, A; Bollet, MA; Campana, F; Dendale, R; Fourquet, A; Gobaux, V; Hajage, D; Kirova, YM; Marchand, V; Pierga, JY; Reyal, F, 2013) |
| "Women with metastatic breast cancer who had been previously treated with a taxane in the adjuvant or metastatic setting were eligible." | ( Au, JL; Berger, M; Brenner, L; Chen, L; Grever, M; Jensen, RR; Lustberg, MB; Mrozek, E; Pant, S; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shen, T; Shiels, D; Wei, Y; Wientjes, MG, 2012) |
| "In xenograft model of human breast cancer in nude mice, both systemic and local administration of vinpocetine significantly suppressed the tumor growth without observed toxicity." | ( Guan, YY; Huang, EW; Tang, YB; Xue, SJ; Zhang, Z; Zhou, JG, 2012) |
| "She had a history of surgery for breast cancer after which she had been treated with oral tamoxifen citrate for 2 years before presentation." | ( Das, D; Gandhi, RA; Goyal, A; Nair, AG, 2012) |
| "A case of solitary bone metastasis from breast cancer, where MRI assessment of treatment response was inaccurate and whole-body fluorodeoxyglucose ((18)FDG) positron emission tomography with computed tomography (PET-CT) proved more reliable and objective, is presented." | ( Correa, PD; Han, S; Rizwanullah, M; Shrimali, RK, 2010) |
| "Women at high risk of breast cancer should be considered for treatment with raloxifene." | ( Birkhäuser, M; Buchard, PA; De Geyter, C; Imthurn, B; Lamy, O; Lippuner, K; Litschgi, M; Luzuy, F; Schiessl, K; Stute, P, 2012) |
| "In patients with breast cancer treated with anthracyclines, taxanes, and trastuzumab, systolic longitudinal myocardial strain and ultrasensitive troponin I measured at the completion of anthracyclines therapy are useful in the prediction of subsequent cardiotoxicity and may help guide treatment to avoid cardiac side-effects." | ( Banchs, J; Carver, JR; Cohen, V; Gerszten, RE; Halpern, EF; Januzzi, JL; Kuter, I; Ky, B; Martin, RP; Passeri, J; Picard, MH; Plana, JC; Sawaya, H; Scherrer-Crosbie, M; Sebag, IA; Tan, TC; Wiegers, SE, 2012) |
| "In early-stage (stages I, II, and III) breast cancer, treatment with the bisphosphonate zoledronic acid has shown improvements in disease-free and overall survival." | ( Clezardin, P; Coleman, R; Gnant, M; Morgan, G, 2012) |
| "Patients with breast cancer treated with trastuzumab after an anthracycline-based regimen exhibited a significantly higher QTd than non-treated patients (0." | ( Barutca, S; Meydan, N; Tanriverdi, O, 2012) |
| "Forty-seven human breast cancer and immortalized breast epithelial lines representing the known molecular subgroups of breast cancer were treated with dacomitinib to determine IC(50) values." | ( Anderson, L; Britten, CD; Christensen, JG; Cohen, DJ; Conklin, D; Desai, AJ; Finn, RS; Ginther, C; Kalous, O; O'Brien, NA; Slamon, DJ; Taylor, I, 2012) |
| "Lipid profiles in women with early breast cancer receiving anastrozole with or without risedronate were examined within an international Phase III/IV study to assess for possible treatment related changes." | ( Barlow, DH; Clack, G; Eastell, R; Makris, A; Van Poznak, C, 2012) |
| "HER-2-positive breast cancer is a breast cancer subtype with an increasing body of knowledge regarding potential targeted drug combinations that are significantly improving outcomes through a biologically tailored therapy approach; neratinib emerges as a promising tool in this context." | ( Jerez, Y; López-Tarruella, S; Márquez-Rodas, I; Martín, M, 2012) |
| "Postmenopausal women with breast cancer and MR imaging findings of the contralateral unaffected breast, before and during 6-12 months of AI treatment (anastrozole, letrozole, or exemestane), between August 1999 and June 2010 were retrospectively identified (n = 149)." | ( Brooks, JD; Dickler, MN; Goldfarb, SB; Jozefara, JE; King, V; Morris, EA; Nulsen, BF; Pike, MC; Sung, JS, 2012) |
| "Stage II-IIIC HER2-positive breast cancer patients, including inflammatory disease, were treated with weekly-trastuzumab for 24 weeks administered concurrently with all primary chemotherapy containing paclitaxel (80 mg/m(2)) for 12 weeks and 4 cycles of FEC-75 (fluorouracil 500 mg/m(2), epirubicine 75 mg/m(2), and cyclophosphamide 500 mg/m(2)) followed by surgery." | ( Climent, F; de Olza, MO; Falo, C; Fernandez-Otega, A; García-Tejedor, A; Germà, JR; Gil-Gil, M; Gumà, A; López-Ojeda, A; Mesia, C; Pérez-Martin, FJ; Pernas, S; Petit, A; Pla, MJ; Urruticoechea, A, 2012) |
| "Systemic chemotherapy administered in breast cancer induce reduction of lysozyme activity in tears, that may cause higher morbidity of ocular surface infections caused by Gram-positive bacteria." | ( Jurowski, P; Rózalska, B; Wieckowska-Szakiel, M; Wojciechowska, K, 2012) |
| "Growth profiles of breast cancer cell lines were evaluated in co-cultures with differentiated adipocytes or their precursor cells and upon treatment with adipocyte conditioned media." | ( Beguinot, F; Canta, L; D'Esposito, V; Formisano, P; Hammarstedt, A; Liguoro, D; Miele, C; Molea, G; Passaretti, F; Smith, U; Terracciano, D, 2012) |
| "In early stage breast cancer, treatment with zoledronic acid has shown improvements in disease-free and overall survival, notably in women with established menopause at diagnosis and in premenopausal women with endocrine-responsive disease, treated with goserelin to suppress ovarian function." | ( Coleman, RE, 2012) |
| "The authors identified patients with breast carcinoma who received chemotherapy in a teaching hospital in Taipei in 2008 through a chart review process." | ( Chen, CS; Chien, LY; Chiou, JF; Huang, SM; Tai, CJ, 2013) |
| "Two groups of breast cancer patients (53±2 years) in clinical remission receiving no specific therapy were examined: group 1, with BRCA1 gene mutations (N=11) and group 2, without mutations of this kind (N=11)." | ( Berstein, LM; Boyarkina, MP; Imyanitov, EN; Kovalenko, IG; Poroshina, TE; Semiglazov, VF; Vasilyev, DA, 2012) |
| "It is now being used to treat operable breast cancer to facilitate breast-conserving surgery, but the accuracy of sentinel lymph node biopsy (SLNB) in breast cancer patients receiving NAC remains open to considerable debate." | ( Asakura, K; Hayashida, T; Jinno, H; Kitagawa, Y; Sakata, M; Takahashi, M, 2012) |
| "Treatment of ER-positive xenograft-based breast tumors with PELP1-siRNA-DOPC or pargyline reduced tumor volume by 58." | ( Cortez, V; Lopez-Berestein, G; Mann, M; Miyata, N; Rodriguez-Aguayo, C; Sood, AK; Suzuki, T; Tekmal, S; Vadlamudi, RK, 2012) |
| "A 42 year-old woman with breast cancer and major depression resistant to medical treatment received a 90 minute intravenous infusion of 0." | ( Alférez-García, I; Alonso-Menoyo, MB; Carricondo-Martínez, MA; Cortiñas-Saenz, M; Errando-Oyonarte, CL, 2013) |
| "Treatment of human breast cancer cells with cordycepin caused either apoptosis or persistent cell cycle arrest that was associated with reduced clonal growth of cordycepin-treated breast cancer cells." | ( Brüning, A; Burger, P; Friese, K; Lee, HJ; Vogel, M, 2012) |
| "For women with resected primary breast cancer and zero to three positive nodes, we found no evidence that extending chemotherapy regimens of AC or single-agent T from four to six cycles improves clinical outcome." | ( Atkins, JN; Becker, HP; Berry, DA; Cirrincione, CT; Hudis, C; Kimmick, G; Martino, S; Mayer, E; Muss, H; Norton, L; O'Regan, R; Perez, EA; Schneider, CJ; Shulman, LN; Winer, EP, 2012) |
| "Chemotherapy in breast cancer fails due to resistance to chemotherapeutic drugs." | ( Biswas, J; Mukherjee, S; Royt, M; Sarkar, R, 2011) |
| "To do this, we treated human breast cancer cells with rosemary/carnosic acid and assessed effects on cell proliferation, cell cycle distribution, gene expression patterns, activity of the purified Na/K ATPase and combinations with curcumin." | ( Einbond, LS; Goldsberry, S; He, K; Kashiwazaki, R; Roller, M; Su, T; Wang, X; Wu, HA, 2012) |
| "Antineoplastic treatment for breast cancer is frequently associated with alopecia." | ( Blume-Peytavi, U; Garcia Bartels, N; Hillmann, K; Lademann, J; Lindner, J; Lux, A; Schneider, A; Stroux, A, 2012) |
| "Metabolomic fingerprint of breast cancer cells treated with the antidiabetic drug metformin revealed a significant accumulation of 5-formimino-tetrahydrofolate, one of the tetrahydrofolate forms carrying activated one-carbon units that are essential for the de novo synthesis of purines and pyrimidines." | ( Corominas-Faja, B; Cufí, S; Joven, J; Martin-Castillo, B; Menendez, JA; Micol, V; Oliveras-Ferraros, C; Quirantes-Piné, R; Segura-Carretero, A; Vazquez-Martin, A, 2012) |
| "As treatment of breast cancer evolves, both tamoxifen and the AIs are being increasingly used in the adjuvant setting." | ( Aapro, M; Bischoff, J; Brain, E; Cardoso, F; Lück, HJ; Tanner, M; Tjan-Heijnen, VC; Zotano, ÁG, 2013) |
| "Patients with pre-treated metastatic breast cancer received weekly carboplatin at AUC2 and daily oral everolimus at different dose-levels (level I: 2." | ( Eucker, J; Habbel, P; Liu, H; Martus, P; Neumann, C; Possinger, K; Regierer, AC; Schefe, JH; Scholz, CW; Schulz, CO; Schwarzlose-Schwarck, S; Zang, C, 2012) |
| "Fifty-three breast cancer patients with localized disease were enrolled and randomized to treatment with oral PTX 400 mg 3 times daily and oral vitamin E 400 IU daily for 6 months after radiation (n=26), or standard follow up (n=27)." | ( Bhatia, S; Bodeker, K; Buatti, J; Button, AM; Jacobson, G; Smith, BJ, 2013) |
| "This study of postirradiation breast cancer patients treated with PTX/vitamin E or standard follow-up indicated a significant difference in radiation-induced fibrosis as measured by TCM." | ( Bhatia, S; Bodeker, K; Buatti, J; Button, AM; Jacobson, G; Smith, BJ, 2013) |
| "309 early and local advanced breast cancer patients were treated with anthracycline-based neoadjuvant chemotherapies in intense dose dense (IDD) (CE, Cyclophosphamide + Epirubicin) or conventional (TE, Paclitaxel + Epirubicin) regimens." | ( Fan, Y; Li, Q; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P, 2012) |
| "Successful treatment of breast cancer is frequently limited by the resistance of tumors to chemotherapy." | ( Abu-Ghanem, S; Ariad, S; Karp, G; Livneh, E; Mermershtain, W; Novack, V; Sion-Vardy, N, 2012) |
| "Resistance to endocrine therapy in breast cancer is common." | ( Blighe, K; Chow, LW; Coombes, RC; Filipovic, A; Giamas, G; Grothey, A; Lit, LC; Miki, Y; Sasano, H; Shaw, JA; Stebbing, J; Xu, Y, 2013) |
| "Regarding patients being treated for breast cancer and on oral capecitabine, the main side effect is the hand-foot syndrome (HFS), or Palmar-Plantar Erythrodysesthesia (PPE)." | ( Carrié, S; Cottu, P; De Rycke, Y; Falcou, MC; Llambrich, C; Medjbari, M, 2012) |
| "Tamoxifen-treated breast cancer patients were included in this prospective study between February 2009 and June 2010." | ( Baloglu, A; Bezircioglu, I; Oziz, E; Tarhan, MO; Yigit, S, 2012) |
| "Similar results were obtained for breast cancer cells treated with the estrogen in combination with MMP-9." | ( Aronica, SM; Fatunmbi, M; Shelton, J, 2012) |
| "The intensified treatment of breast cancer improves survival but has a price in terms of side-effects." | ( de Bock, GH; Lammerink, EA; Mourits, MJ; Schröder, CP, 2012) |
| "To determine how many breast cancer patients who initiated adjuvant endocrine therapy discontinued early and to evaluate adherence in patients who persisted with therapy." | ( Chambers, CR; Danilak, M, 2013) |
| "Primary tumour FDG uptake in breast cancer patients scheduled for neoadjuvant chemotherapy is significantly higher in tumours with prognostically unfavourable characteristics." | ( Aukema, TS; Gilhuijs, KG; Koolen, BB; Lips, EH; Rodenhuis, S; Rutgers, EJ; Valdés Olmos, RA; van Werkhoven, E; Vogel, WV; Vrancken Peeters, MJ; Wesseling, J, 2012) |
| "A total of 136 women with breast cancer who had completed their therapy were recruited at one university-based cancer center in Korea." | ( Cho, YU; Kim, JH; Kim, SH; Kim, SJ; Lee, JE, 2013) |
| "Neoadjuvant chemotherapy for advanced breast cancer may improve the radicality for a subset of patients, but others may suffer from severe adverse drug reactions without any benefit." | ( Chen, CM; Chen, YZ; Liu, F; Liu, GY; Meng, X; Shao, ZM; Shen, ZZ; Wu, F; Wu, J; Xu, QH; Xue, JY; Yang, BL; Ye, X, 2012) |
| "Women with estrogen-positive breast cancers receive endocrine treatment such as tamoxifen and aromatase inhibitors (AI) for 5-10 years." | ( Azoulay, L; Bonnetain, F; Dell'Aniello, S; Le Ray, I; Suissa, S, 2012) |
| "Cardiotoxicity associated with breast cancer treatment is an important concern in the oncology clinic." | ( Castellano, L; Pellegrino, L; Roca-Alonso, L; Stebbing, J, 2012) |
| "Using an in vivo model of human breast cancer, limonin in combination with cyclophosphamide was not found to inhibit the cyclophosphamide-induced tumor regression through a reduced mitotic index of tumor xenograft cells when compared to treatment with cyclophosphamide alone." | ( Jayaprakasha, GK; Patil, B; Pearce, K; Price, J; Shuck, R; Somasundaram, S, 2012) |
| "Simultaneous treatment of breast cancer cell lines with LBH589 and 5azaC did not show significant synergy in killing cells." | ( Atadja, P; Feng, X; Ganapathy, A; Kumar Mishra, M; Morris, D; Qiao Shi, Z; Riabowol, K; Thakur, S, 2012) |
| "Reversine treatment in human breast cancer cells reduced cell viability in a dose-dependent manner." | ( Chang, YP; Chen, PT; Chen, SH; Kuo, CH; Lee, YR; Lu, YC; Shi, CS; Tseng, YS; Wu, FL, 2014) |
| "Preclinical data suggest that current breast cancer treatment strategies lead to CSC enrichment, contributing to chemotherapy and radiotherapy resistance, although a strong correlation with clinical parameters and prognosis is yet to be established." | ( Economopoulou, P; Kaklamani, VG; Siziopikou, K, 2012) |
| "Diet is modestly associated with breast cancer risk; associations appear more pronounced for postmenopausal disease, and healthy choices after diagnosis and treatment likely support longevity more so than reduced risk for recurrent disease." | ( Thomson, CA, 2012) |
| "Because of the clinical relevance of breast cancer forms having the triple negative and/or chemoresistant phenotype, our results showing comparable effects of GF even on aggressively growing cells encourage further studies to verify the potential of this compound in improving the chemotherapy of breast cancer." | ( Di Stefano, G; Farabegoli, F; Fiume, L; Manerba, M; Roberti, M; Vettraino, M, 2012) |
| "Two highly aggressive breast cancer cell lines, SUM159 and MDA-231, were sorted based on aldehyde dehydrogenase (ALDH) activity and subsequently ALDH-negative and ALDH-positive cells were treated with one of two known HDAC inhibitors, VA or suberoylanilide hydroxamic acid." | ( Atkinson, R; Buchholz, TA; Debeb, BG; Krishnamurthy, S; Lacerda, L; Larson, R; Reuben, JM; Solley, T; Sulman, EP; Ueno, NT; Woodward, WA; Xu, W, 2012) |
| "Despite the fact that most breast cancer patients have estrogen receptor (ER) α-positive tumors, up to 50% of the patients are or soon develop resistance to endocrine therapy." | ( Cui, J; Germer, K; Luo, J; Wang, J; Wang, Q; Wang, SC; Wu, T; Zhang, X, 2012) |
| "Women with breast cancer and diabetes, however, had an increased all-cause mortality risk highlighting the potential importance of maintaining adequate glycemic control alongside anti-cancer treatments and subsequent follow-up." | ( Ben-Shlomo, Y; Jeffreys, M; Martin, RM; May, MT; Redaniel, MT, 2012) |
| "Eighteen women with non-metastatic breast cancer who have been exposed to chemotherapy were evaluated with a battery of neuropsychological and psychological tests before (time 1) and 1 month after chemotherapy (time 2)." | ( Ando-Tanabe, N; Iwamitsu, Y; Kuranami, M; Miyaoka, H; Nakatani, Y; Okazaki, S; Watanabe, M; Yamamoto, K; Yasuda, H, 2014) |
| "Neoadjuvant chemotherapy in breast cancer patients aims at preoperative reduction of tumor volume for better resection results and prognosis." | ( Braun, M; Feller, AM; Fersching, DM; Gabka, CJ; Hamann, U; Heinemann, V; Holdenrieder, S; Nagel, D; Salat, C; Siegele, B; Steinkohl, O; Stoetzer, OJ, 2013) |
| "For this purpose, 29 Caucasian women, breast cancer patients under CMF or CEF adjuvant chemotherapy were included in the study." | ( Comendador, MA; Fra, J; Lacave, AJ; Martínez-Camblor, P; Sierra, LM; Sierra, M; Uriol, E, 2013) |
| "Neoadjuvant treatment of breast cancer has become established as the safe and often effective therapeutic approach of choice for larger primary and for locally advanced breast cancer." | ( Moulder-Thompson, SL; Thompson, AM, 2012) |
| "The triple negative human breast cancer cell lines MDA-MB231 and its sub-progenies SCP2 and SCP25, SUM159PT, SUM149PT, SUM229PE and SUM1315MO2 were treated with 5 ng/ml TGFβ and the protein expression levels were measured by Western blot." | ( Al-Odaini, AA; Ali, S; Arakelian, A; Dai, M; Lebrun, JJ; Rabbani, SA, 2012) |
| "Eligible patients had metastatic breast cancer with 0-4 prior chemotherapy regimens." | ( Burstein, HJ; Chen, WY; Downing, SR; Gelman, R; Hannagan, K; Isakoff, SJ; Klement, G; Mayer, EL; Winer, EP, 2012) |
| "Patients with metastatic breast cancer (MBC) with disease progression after anthracycline-and/or taxane-containing therapy need an effective drug regimen with low toxicity." | ( Blohmer, JU; du Bois, A; Lück, HJ; Schippert, C; Warm, M, 2012) |
| "The ability to monitor breast cancer initiation and progression on the molecular level would provide an effective tool for early diagnosis and therapy." | ( Gendler, SJ; Ghosh, SK; Gong, J; Medarova, Z; Moore, A; Ross, AW; Uchida, M; Yoo, B, 2013) |
| "Neoadjuvant chemotherapy (NCT) of breast cancer enabled improved outcomes especially in patients with advanced and inflammatory diseases." | ( Fuksa, L; Grim, J; Hornychova, H; Micuda, S; Ryska, A, 2012) |
| "Interest in breast cancer prevention is growing, and more clinical evidence is needed regarding the effects of preventive therapy, alone or in combination." | ( Chen, PC; Guo, YL; Ho, WC; Lee, CH; Lee, HH; Lin, MH; Tsan, YT; Tseng, CD; Wang, JD, 2012) |
| "Tissue microarrays of two breast cancer cohorts including in total 743 invasive breast cancer samples were analyzed for ERK phosphorylation (pERK) and smooth muscle actin-alpha expression (SMAα) in cancer-associated fibroblasts (CAFs) and links to clinico-pathological data and treatment-predictive values were delineated." | ( Busch, S; Jirström, K; Landberg, G; Rydén, L; Stål, O, 2012) |
| "Primary systemic therapy (PST) in early breast cancer is utilized in locally advanced breast tumors and when breast-conserving surgery is desirable." | ( Bell, R; Khasraw, M, 2012) |
| "The modalities of recognition of breast tumors by Vγ9Vδ2 T cells in N-BP-treated animals were also examined." | ( Benzaïd, I; Bonnelye, E; Clézardin, P; Mönkkönen, H; Mönkkönen, J, 2012) |
| "In first-line treatment of metastatic breast cancer, the best use of the available therapeutic agents is unclear." | ( Arrowsmith, E; Beck, T; Borson, R; Bromund, J; Hager, S; Harker, G; Harrer, G; Horvath, W; Jones, M; Kornberg, LJ; Kudrik, FJ; Malamud, SC; Obasaju, C; Orlando, M; Reeves, J; Tai, DF; Tillinghast, G; Yardley, DA; Zeigler, H, 2012) |
| "Subjects were 420 breast cancer patients who had completed all chemotherapy cycles." | ( Amos, E; Heckler, C; Jacobs, A; Kirshner, JJ; Lavigne, JE; Lord, R; Mathews, JL; Morrow, GR; Mustian, K; Palesh, O, 2012) |
| "The incidence of contralateral breast cancer and the absolute benefit of endocrine therapy among patients with unilateral minimum-risk breast cancer in Japan, where the incidence of breast cancer is low, are unknown." | ( Aihara, T; Egawa, C; Hozumi, Y; Ishitobi, M; Iwata, H; Sagara, Y; Takei, H; Tanaka, S; Yamaguchi, H, 2014) |
| "In total, 157 patients with metastatic breast cancer received docetaxel at 35 mg/m(2) on a weekly basis as first-line treatment." | ( Christodoulou, C; Dionysopoulos, D; Fountzilas, G; Kalogeras, KT; Korantzis, I; Kotoula, V; Koutras, A; Linardou, H; Papakostas, P; Papaxoinis, G; Pectasides, D; Samantas, E; Soupos, N, 2012) |
| "Therefore, RQC treatment inhibits breast cancer progression and may potentiate anti-EGFR therapy by inhibition of Akt/mTOR signaling." | ( Castillo-Pichardo, L; Dharmawardhane, SF, 2012) |
| "The study included 31 breast cancer patients who were treated with NAC between August 2010 and October 2011." | ( Cao, X; Xue, J; Zhao, B, 2012) |
| "Administration of this DDS to breast cancer cells (MCF-7 and MDA-MB-231) shows significant inhibition of breast cancer cell proliferation compared to pristine doxorubicin." | ( Barui, AK; Bhadra, MP; Mukherjee, S; Patra, CR; Patra, S; Sreedhar, B; Sushma, V, 2012) |
| "If this also proves to be true for breast cancer, these natural treatments will be promising agents against breast cancer that can serve as potentially effective and nontoxic alternatives or adjuncts to the use of conventional selective estrogen receptor modulators for breast cancer prevention and treatment." | ( Martins-Green, M; Penichet, M; Rocha, A; Wang, L, 2012) |
| "Outpatients with early breast cancer treated with anastrozole completed the multi-method assessment of adherence." | ( Beer, B; Gamper, E; Giesinger, J; Holzner, B; Hubalek, M; Kemmler, G; Marth, C; Meraner, V; Oberacher, H; Oberguggenberger, AS; Schubert, B; Sperner-Unterweger, B; Sztankay, M, 2012) |
| "The NF-κB DNA-binding activity of breast cancer cells treated with parthenolide was analyzed using electrophoretic mobility assays." | ( Guo, S; Li, C; Shi, T, 2013) |
| "In early-stage breast cancer, radiotherapy delivered after conservative surgery leads to a reduction in the risk of local recurrences by approximately two thirds." | ( Bollet, MA; Fourchotte, V; Jacob, J; Kirova, YM; Pierga, JY, 2012) |
| "The basaloid triple-negative breast cancer (B-TNBC) is one of the most aggressive, therapy-resistant, and metastatic tumors." | ( Hall, KL; Rajput, S; Ran, S; Volk-Draper, LD; Wilber, A, 2012) |
| "Concerns about increased breast cancer risk with estrogen and progestin therapy have led to an increased interest in progestin alternatives." | ( Appt, SE; Clarkson, TB; Cline, JM; Ethun, KF; Register, TC; Wood, CE, 2012) |
| "Treatment of HER2-positive breast cancer with the monoclonal antibody trastuzumab (Herceptin) has improved patient survival, but the development of trastuzumab resistance is a major medical problem." | ( Bose, R; Boyer, AP; Collier, TS; Vidavsky, I, 2013) |
| "One hundred and forty-nine breast cancer patients eligible for neoadjuvant chemotherapy were included in the study between February 2004 and January 2009 at three centers." | ( Blot, E; Bonneterre, J; Desauw, C; Fournier, C; Hornez, L; Kramar, A; Peyrat, JP; Révillion, F, 2013) |
| "Lack of eradication of disseminated breast cancer by chemotherapy is a central clinical problem." | ( Jonkers, J; Rottenberg, S, 2012) |
| "Treatment of breast cancer cells with a demethylating agent and histone deacetylase inhibitors reduced methylation of the CR-1 promoter and reactivated CR-1 mRNA and protein expression in these cells, promoting migration and invasion of breast cancer cells." | ( Baraty, C; Bianco, C; Castro, NP; Gonzales, M; Held, N; Karasawa, H; Rangel, MC; Rollman, K; Salomon, DS; Strizzi, L, 2013) |
| "Cell death of human breast cancer cell line MCF-7/pDsRed2-Mito, caused by independent- or multi-administration of three anticancer drugs, cyclophosphamide [CPA], doxorubicin [DXR], and 5-fluorouracil [5-FU], was studied using fluorescence and electron microscopy." | ( Dalkhuren, SO; Kugawa, F; Ueno, A; Yamashita, K, 2012) |
| "Treatment of breast cancer patients with Zol alone decreased the number of Vγ2Vδ2 T cells and reduced their ex vivo responsiveness." | ( Iwasaki, M; Li, W; Minato, N; Morita, CT; Murata-Hirai, K; Okamura, H; Sugie, T; Tanaka, Y; Toi, M, 2013) |
| "This case suggests that when the breast cancer is human epidermal growth factor receptor-2-positive, trastuzumab should be administered as adjuvant therapy." | ( Akashi, M; Fujii, T; Inoue, Y; Momosaki, S; Nakayama, Y; Nishida, R; Saitsu, H; Shirouzu, K; Takahashi, H; Takahashi, R; Takami, Y; Takayoshi, K; Uchino, K, 2012) |
| "ERα can be re-expressed in ERα-negative breast cancer MDA-MB-435s cells after treated with As2O3 by inhibiting the DNMT1 activity." | ( Fan, QX; Wang, F; Wang, LX; Wang, R; Wu, XA; Xu, DF; Zhang, WJ, 2012) |
| "Radiosensitization of breast cancer to X-radiation with AuNPs was successfully achieved with an optimized therapeutic strategy of molecular targeting of HER-2 and intratumoral administration." | ( Cai, Z; Chattopadhyay, N; Kwon, YL; Lechtman, E; Pignol, JP; Reilly, RM, 2013) |
| "Despite recent advances in therapy, breast cancer remains the second most common cause of death from malignancy in women." | ( Alvarez, R; Aribi, A; Chan, KT; Doan, NB; Gery, S; Ho, Q; Koeffler, HP; Lee, DH; Lee, K; Said, JW; Thoennissen, GB; Thoennissen, NH; Toh, M, 2013) |
| "Of a total 1,023 of breast cancer and 814 lung cancer patients identified, 292 had hypercalcemia at first hospitalization or during cancer treatment (174 breast and 118 lung cancer patients)." | ( Hassali, MA; Hassan, BA; Othman, SB; Weiderpass, E; Yusoff, ZB, 2012) |
| "Treatment of breast cancer cells with oleuropein could help in prevention of cancer metastasis by increasing the TIMPs and suppressing the MMPs gene expressions." | ( Al-Olayan, EM; Daghestani, MH; Elamin, MH; Elobeid, MA; Hassan, ZK; Mohammed, OB; Omer, SA; Virk, P, 2012) |
| "In the estrogen receptor-negative breast cancer cell lines MDA-MB-468 and Hs578T, which express IGFBP-3 highly, nuclear localization of EGFR and IGFBP-3 was enhanced by treatment with cytotoxic drugs etoposide or doxorubicin and reduced by the EGFR kinase inhibitor gefitinib." | ( Baxter, RC; Lin, MZ; Martin, JL; Marzec, KA, 2014) |
| "These data support that in PR(+) breast cancers, progestins induce a subpopulation of CK5(+)ER(-)PR(-) cells with enhanced progenitor properties and have implications for treatment resistance and recurrence in luminal breast cancer." | ( Axlund, SD; Kabos, P; Labarbera, DV; Rosen, RB; Sartorius, CA; Schaack, J; Yoo, BH, 2013) |
| "Here, 42 breast cancer cell lines were evaluated by chemoresponse tests after treatment with either TFAC or FEC, two widely used standard combination chemotherapies for breast cancer." | ( Gabrin, MJ; Kim, Y; Lee, JK; Pusztai, L; Rice, SD; Shen, K; Song, N; Symmans, WF; Tian, C, 2012) |
| "In overall and in tamoxifen-treated breast cancer patients, leptin expression (IRS≥1) correlated with poor prognosis, (log-rank test, P=0." | ( Chen, W; Chen, X; Li, J; Qiu, J; Røe, OD; Wang, Z; Yin, Y; Zha, X; Zhu, T, 2013) |
| "HER2-positive breast cancer initially responds to trastuzumab treatment, but over time, resistance develops and rapid cancer progression occurs, for which various explanations have been proposed." | ( Chiu, K; DeLaney, A; Kumandan, S; Mahadevan, NR; Zanetti, M, 2013) |
| "Patients with stage II/III breast cancer received 4 cycles of XT (capecitabine and docetaxel) followed by 4 cycles of FEC (fluorouracil, epirubicin, and cyclophosphamide) as preoperative chemotherapy." | ( Hayashida, T; Hirose, S; Ikeda, T; Jinno, H; Kitagawa, Y; Matsuda, S; Takahashi, M, 2012) |
| "Doxorubicin is frequently used in breast cancer therapy either as single-agent or in combination with other drugs like docetaxel and cyclophosphamide." | ( Kopp, F; Oak, PS; Roidl, A; Wagner, E, 2012) |
| "In 11 breast cancer cell lines, the relative expression of phospho-p90RSK was inversely correlated with cell survival after doxorubicin treatment (p = 0." | ( Ahn, S; Han, W; Ju, JH; Kim, HS; Lee, HY; Lee, KM; Moon, HG; Noh, DY; Shin, HC; Shin, I; Yi, JK; Yi, M, 2012) |
| "Although breast cancer patients with localized disease exhibit an excellent long-term prognosis, up to 40% of patients treated with local resection alone may harbor occult nodal metastatic disease leading to increased locoregional recurrence and decreased survival." | ( Catalano, PJ; Colson, YL; Gilmore, DM; Grinstaff, MW; Liu, R; Padera, RF; Xu, X; Zubris, KA, 2013) |
| "Pin1 was adducted in MDA-MB-231 breast cancer cells treated with 8-alkynyl-HNE as judged by click chemistry conjugation with biotin followed by streptavidin-based pulldown and Western blotting with anti-Pin1 antibody." | ( Aluise, CD; Boiani, M; Manna, JD; Marnett, LJ; Porter, NA; Reyzer, ML; Rose, K; Tallman, K, 2013) |
| "Treatment delays in breast cancer are generally thought to affect prognosis but the impact on survival remains unclear." | ( Dahlui, M; Mujar, M; Taib, NA; Yip, CH, 2013) |
| "A total of 648 breast cancer patients treated in the University Malaya Medical Center (UMMC), Malaysia between 2004 and 2005 were included in the study." | ( Dahlui, M; Mujar, M; Taib, NA; Yip, CH, 2013) |
| "Due to the recognition and diagnosis of breast cancer in increasingly early stages, quality of life becomes an important part of treatment beyond the efficacy indicators." | ( Horváth, Z, 2012) |
| "Treatment of a mouse model of breast cancer with LDN193189 caused reduced expression of markers associated with epithelial-to-mesenchymal transition (EMT)." | ( Balboni, AL; Cherukuri, P; DeCastro, AJ; DiRenzo, J; Hutchinson, JA; Liby, K; Schwartz, GN; Sempere, LF; Sporn, MB; Wells, WA; Yu, PB, 2013) |
| "In MDA-MB-231 and MCF-7 breast cancer cells, treatment with submolar concentrations of ciglitazone and GW1929 elevated the expression of leptin and VEGF mRNA and protein, and increased cell viability and migration." | ( Amodeo, V; Bazan, V; Caruso, S; Cicero, G; Contaldo, C; Corsini, LR; Fanale, D; Fiorio, E; Insalaco, L; Lo Re, G; Mercanti, A; Russo, A; Surmacz, E; Terrasi, M, 2013) |
| "We recently showed that irradiating breast cancer COH-BR1 cells after treating with 5-aminolevulinic acid (ALA, a pro-sensitizer) resulted in rapid upregulation of inducible nitric oxide (NO) synthase (iNOS)." | ( Bhowmick, R; Girotti, AW, 2013) |
| "The CD8+/Treg ratio in breast cancer tissue can be a potential surrogate marker in surgical pathology specimens for predicting responses to neoadjuvant endocrine therapy, not only incorporating features of carcinoma cells as in Ki-67 LI but also those of adjacent stromal cells in the tumor microenvironment, especially in the early stage of treatment prior to any detectable clinical and/or histopathological changes." | ( Chan, MS; Chow, LW; Felizola, SJ; Loo, W; Sasano, H; Suzuki, T; Toi, M; Ueno, T; Wang, L, 2012) |
| "The higher incidence of breast cancer in developed countries has been tempered by reductions in mortality, largely attributable to mammographic screening programmes and advances in adjuvant therapy." | ( Dowsett, M; Martin, LA; Patani, N, 2013) |
| "However, within the breast cancer survivors, time since treatment was inversely associated with lower global and focal white matter integrity." | ( Boogerd, W; Breteler, MM; de Groot, M; de Ruiter, MB; Koppelmans, V; Niessen, WJ; Schagen, SB; Seynaeve, C; Vernooij, MW, 2014) |
| "Development of new, targeted antibreast cancer drug which can treat both the hormone receptor (positive and negative) breast cancers is a very challenging task." | ( Avula, SR; Bathula, SR; Palnati, GR; Sashidhara, KV; Sharma, K, 2013) |
| "In hormone-dependent breast cancer, GnRH analogs are used for therapy in premenopausal women." | ( Chatzaki, E; Chemonidou, C; Constantinidis, TC; Galaktidou, G; Kakolyris, S; Kaprara, A; Kiziridou, A; Koffa, M; Kolios, G; Kortsaris, A; Koureta, M; Lambropoulou, M; Pazaitou-Panayiotou, K; Poupi, A, 2013) |
| "61 women with ER+ breast cancer receiving tamoxifen monotherapy were investigated in order to assess the relationships between CYP2D6 UM phenotype and side effects." | ( Agostino, FD; Alabiso, O; Bellomo, G; Borra, G; Fanello, MR; Forti, L; Meola, S; Nicolotti, C; Pollarolo, P; Rolla, R; Rossi, V; Saggia, C; Stratica, F; Vidali, M, 2012) |
| "Syndecan-1 is a prognostic factor in breast cancer, and has a predicitive value for neodadjuvant chemotherapy." | ( Götte, M; Greve, B; Hassan, H; Ibrahim, SA; Kiesel, L; Pavao, MS, 2013) |
| "The basal-like breast cancer subtype represents one of the most aggressive and lethal types of breast cancer, and due to poor mechanistic understanding, it lacks targeted therapy." | ( Hopkins, BD; Parsons, RE; Pires, MM; Saal, LH, 2013) |
| "Background In women with node-positive breast cancer, the Breast International Group (BIG) 02-98 tested the incorporation of docetaxel (Taxotere) into doxorubicin (Adriamycin)-based chemotherapy, and compared sequential and concurrent docetaxel." | ( Andersson, M; Buyse, M; Crown, J; De Azambuja, E; Dell'orto, P; Di Leo, A; Francis, PA; Gelber, RD; Gutiérrez, J; Harvey, V; Jakesz, R; Larsimont, D; Margeli Vila, M; Nordenskjöld, B; Oakman, C; Piccart-Gebhart, M; Punzalan, L; Quinaux, E; Steinberg, I; Thürlimann, B; Viale, G, 2013) |
| "Advances in chemotherapy for breast cancer (BC) have prolonged overall survival, especially for patients with human epidermal growth factor receptor-2 (HER2) positive cancer." | ( Cho, N; Hayashi, M; Yomo, S, 2013) |
| "Neoadjuvant treatment of breast cancer involving capecitabine did not significantly improve pCR, tnpCR, BCS or ORR." | ( Jiang, Y; Li, Q; Liu, J; Wei, W; Yang, H, 2013) |
| "In metastatic breast cancer (MBC), capecitabine is an effective and well-tolerated therapeutic option both in monotherapy and in combination with chemotherapeutic or molecular-targeted agents." | ( D'Alessio, A; Daniele, G; De Luca, A; Del Giudice, A; Gallo, M; Giordano, P; La Porta, ML; Normanno, N; Perrone, F; Piccirillo, MC, 2013) |
| "In HER2-positive metastatic breast cancer with brain metastases not previously treated with whole brain radiotherapy, capecitabine and lapatinib combination obtains a volumetric reponse in two thirds of patients (LANDSCAPE study)." | ( Bachelot, T; Bonneterre, J; Gilabert, M; Gonçalves, A; Heudel, P; Labidi-Gally, I; Le Rhun, E; Pierga, JY, 2013) |
| "HER2-targeted therapy for HER2-positive breast cancer is one of the success stories in medical oncology." | ( Noguchi, E; Shimizu, C, 2013) |
| "The growth of many breast cancer cells is dependent on hyperactive ErbB receptor networks and one of the most successful approaches in antineoplastic therapy during the last decade was the development of ErbB-targeted therapies." | ( Ammer, H; Koutnik, S; Weingaertner, IR, 2013) |
| "Randomised phase 3 trials in metastatic breast cancer have shown that combining bevacizumab with either paclitaxel or capecitabine significantly improves progression-free survival and response rate compared with chemotherapy alone but the relative efficacy of bevacizumab plus paclitaxel versus bevacizumab plus capecitabine has not been investigated." | ( Beslija, S; Brodowicz, T; Greil, R; Kahan, Z; Kaufman, B; Lang, I; Melichar, B; Messinger, D; Pienkowski, T; Ryvo, L; Sirbu, D; Steger, GG; Stemmer, SM; Zielinski, C; Zvirbule, Z, 2013) |
| "We applied ketamine to breast cancer cell line MDA-MB-231 to detect the effect of treatment and molecular mechanisms involved." | ( Cao, S; Chen, J; Gong, B; He, H; Hu, HY; Xie, WP; Yang, LQ, 2013) |
| "A total of 127 breast cancer patients were treated with neoadjuvant chemotherapy every 2 weeks as part of 2 studies." | ( Alba-Conejo, E; de la Torre-Cabrera, C; Fernández, M; Fernández-Navarro, M; Jaén-Morago, A; Llácer, C; Lomas-Garrido, M; Navarro-Perez, V; Plata-Fernández, YM; Ramirez-Tortosa, C; Sánchez-Muñoz, A; Sánchez-Rovira, P, 2013) |
| "Two cohorts of 33 and 73 breast cancer patients receiving neoadjuvant chemotherapy were recruited for whole-genome expression analysis and validation assay, respectively." | ( Lorente, JA; Quiles, JL; Ramirez-Tortosa, CL; Ramirez-Tortosa, M; Sanchez-Rovira, P; Vera-Ramirez, L, 2013) |
| "Triple-negative breast cancers (TNBC) are among the most aggressive and therapy resistant to breast tumors." | ( Pandeswara, S; Saikumar, P; Singha, PK; Venkatachalam, MA, 2013) |
| "Of 405 metastatic breast cancer patients with brain metastases at referral centers in Turkey, 46 were treated with lapatinib plus capecitabine only after the development of brain metastasis." | ( Akman, T; Alici, S; Arslan, UY; Boruban, C; Coskun, U; Dayan, A; Demir, L; Durnalı, AG; Elkiran, ET; Geredeli, C; Gumusay, O; Inal, A; Inanc, M; Isikdogan, A; Kaplan, MA; Koca, D; Kocer, M; Kucukoner, M; Oksuzoglu, B; Ozdemir, NY; Sener, N; Suner, A; Tarhan, MO; Urakci, Z; Yildiz, R, 2014) |
| "The majority of breast cancers undergo progression from an initially endocrine responsive phenotype to an endocrine therapy-resistant phenotype, and acquired resistance to tamoxifen (Tam) is a major clinical problem." | ( Bai, E; Han, SX; Jing, GH; Li, M; Wang, LJ; Yang, AG; Zhao, J; Zhou, X; Zhu, Q, 2013) |
| "In recent trends, patients with breast cancer seek integrative medical treatment when receiving either hormonal (tamoxifen [Tam]) or target (trastuzumab) therapy." | ( Chang, WC; Chen, JL; Chen, WS; Chiu, JH; King, KL; Lin, YH; Shyr, YM; Tsai, YF; Tseng, LM; Wang, JY, 2013) |
| "Using 4T1 or 67NR models of basal-like breast cancer, tumor growth was measured in mice treated with an FGFR inhibitor (dovitinib/TKI258), a PI3K/mTOR inhibitor (NVP-BEZ235) or a pan-ErbB inhibitor (AEE788) individually or in combination." | ( Dey, JH; Gill, JW; Heideman, MR; Hynes, NE; Issa, A; Sahin, O; Wiemann, S, 2013) |
| "Considering that sub-classes of human breast tumors co-express ErbB receptors and FGFRs, these results have implications for targeted therapy." | ( Dey, JH; Gill, JW; Heideman, MR; Hynes, NE; Issa, A; Sahin, O; Wiemann, S, 2013) |
| "The HER2-positive breast cancer cells were also exposed to the targeted therapy trastuzumab and dual exposure to trastuzumab and paclitaxel." | ( Gabrielson, M; Tina, E, 2013) |
| "Sixty-four breast cancer patients treated with doxorubicin plus cyclophosphamide were evaluated for their responses to antiemetic therapy." | ( Daimon, T; Hayashi, H; Inoue, K; Itoh, K; Iwabe, Y; Kim, YI; Nakamichi, H; Suwa, K; Tsuji, D; Yoshida, M, 2013) |
| "Pretreatment of breast cancer cells with adiponectin protects against leptin-induced activation of ERK and Akt." | ( Knight, BB; Nagalingam, A; Oberlick, E; Saxena, NK; Sharma, D; Taliaferro-Smith, L, 2013) |
| "Information on known or suggested breast cancer risk factors was obtained by a self-administered questionnaire." | ( Kashiki, Y; Nagao, Y; Nagata, C; Nakamura, K; Tamai, Y; Tsuji, M; Wada, K; Yamamoto, S, 2013) |
| "A major challenge in modern breast cancer treatment is to unravel the effect of drug activity through the systematic rewiring of cellular networks over time." | ( Bezerianos, A; Dimitrakopoulos, G; Dimitrakopoulou, K; Maraziotis, IA; Sgarbas, K; Zacharaki, EI, 2012) |
| "A subset of breast cancer patients with high HER-2/neu levels eventually experience metastatic disease progression when treated with Herceptin as a single agent." | ( Ahmad, A; Ahmed, A; Ali, AS; Ali, S; Rahman, KM; Raz, A; Sakr, WA, 2013) |
| "The subjects were 10 patients with breast cancer who were undergoing antiestrogen therapy with tamoxifen or anastrozole and who were suffering from hot flashes." | ( Bong, JG; Jeong, YJ; Kwon, HJ; Park, SH; Park, YS; Shin, IH, 2013) |
| "Metastatic breast cancer (MBC) remains an incurable disease despite advances in treatment modalities." | ( Choi, M; Gaber, G; Gradishar, W; Kiel, K; Mehta, M; Refaat, T; Small, W, 2014) |
| "Estrogens also have been used to treat breast cancer which seems puzzling, since there is convincing evidence to support a link between high lifetime estrogen exposure and increased breast cancer risk." | ( de Assis, S; Hilakivi-Clarke, L; Warri, A, 2013) |
| "A panel of 16 human gastric and 45 breast cancer cell lines, including 16 HER2-amplified (3 and 13, respectively) cells, was treated with AUY922 over various concentrations." | ( Akimov, M; Anghel, A; Ayala, R; Conklin, D; Desai, AJ; Finn, RS; Kalous, O; O'Brien, NA; Quadt, C; Rogers, AM; Slamon, DJ; Wainberg, ZA, 2013) |
| "For second breast cancer, no raised relative risk was observed during the period ≥10 or more years after radiotherapy." | ( Aleknavicius, E; Atkocius, V; Kuzmickiene, I; Liukpetryte, S; Ostapenko, V; Valuckas, KP, 2013) |
| "Invasive breast cancer can be accurately identified using hospital-derived diagnosis alone or in combination with surgeries and breast radiotherapy." | ( Bulsara, M; Holman, CD; Kemp, A; Preen, DB; Rogers, K; Roughead, EE; Saunders, C, 2013) |
| "PubMed database, ASCO and San Antonio Breast Cancer Symposium Meeting abstracts were searched up to September 2012 by using the terms 'trastuzumab emtansine (T-DM1) and anti-HER2 treatment'; papers which were considered relevant for the aim of this review were selected by the authors." | ( Aksoy, S; Altundag, K; Babacan, T; Boyraz, B; Kizilarslanoglu, MC; Petekkaya, I; Roach, EC; Sendur, MA, 2013) |
| "Zoledronic acid as adjuvant therapy in breast cancer patients appears to not only reduce the fracture risk but also offer a survival benefit over placebo or no treatment." | ( Aft, R; Brufsky, AM; Coleman, RE; Eidtmann, H; Gnant, M; Lind, P; Mauri, D; Polyzos, NP; Swenson, K; Tevaarwerk, AJ; Valachis, A, 2013) |
| "The response of breast cancer patients to neoadjuvant chemotherapy (NCT) is highly heterogeneous, and reliable predictive instruments remain to be defined." | ( Arnold, T; Bachleitner-Hofmann, T; Bartsch, R; Baumann, S; Bergmann, M; Burghuber, C; Gnant, M; Michlmayr, A; Oehler, R; Pluschnig, U; Steger, G, 2013) |
| "Women with Stage I-III breast cancer were enrolled into an open label study and treated with CLA (1:1 mix of 9c,11t- and 10t,12c-CLA isomers, 7." | ( Barth, RJ; Beaulieu, BB; Eastman, A; Eisenberg, BL; Froehlich, HM; Kinlaw, WB; Kuemmerle, NB; Lewis, LD; Li, Z; McGowan, MM; Rosenkrantz, KM; Schwartz, GN; Tosteson, TD; Wells, WA, 2013) |
| "New strategies are needed for breast cancer treatment and one initial step is to test new chemotherapeutic drugs in breast cancer cell lines, to choose candidates for further studies towards clinical use." | ( Andersson, S; Marques, MP; Oredsson, S; Persson, L; Silva, TM; Sukumaran, SK, 2013) |
| "Triple negative breast cancer (TNBC) acquires an unfavorable prognosis, emerging as a major challenge for the treatment of breast cancer." | ( Deng, JY; Liu, AW; Liu, Q; Wang, J; Wu, JB; Wu, X; Xu, J; Yang, SB; Yuan, ZY; Yue, CF; Zhou, WH, 2013) |
| "HYL-6d-treated human breast cancer MCF-7 cells exhibited an increased population arrested at the sub-G1 and S phases, as well as an increase of p53 and decrease of cyclin D1, A and CDK2." | ( Chan, HC; Chuang, YC; Huang, LJ; Huang, YL; Lee, TH; Lin, C; Liu, CH; Tsai, KJ, 2013) |
| "Triple-negative breast cancer (TNBC) studies have shown that neoadjuvant chemotherapy before surgery was effective in the minority of women, whereas the majority who had residual tumor had a relatively poor outcome." | ( Banerjee, S; Bonfil, RD; Reddy, KB; Sarkar, FH; Sethi, S; Xu, L; Yin, S, 2013) |
| "More than a third of breast cancer patients undergoing aromatase inhibitor (AI) treatment report joint pain." | ( Cleeland, CS; Giordano, SH; Lu, H; Malveaux, D; Saleeba, AK; Shi, Q, 2013) |
| "There is no optimal treatment for breast cancers lacking estrogen (ER) and progesterone (PgR) receptors in elderly women with co-morbidities that prevent use of "standard chemotherapy regimens" such as AC or CMF." | ( Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Crivellari, D; Dellapasqua, S; Gelber, RD; Gianni, L; Goldhirsch, A; Gray, KP; Láng, I; Lüthi, JM; Maibach, R; Pinotti, G; Price, KN; Puglisi, F; Rabaglio, M; Regan, MM; Ribi, K; Spazzapan, S, 2013) |
| "Our camp did diagnose recurrence of breast cancer in two previously treated breast cancer patients, who were promptly referred to a regional cancer hospital." | ( Bevers, T; Ninan, T; Reddy, N; Tabar, L, 2012) |
| "Although some women with early breast cancer (BC) may be cured with loco-regional treatment alone, up to 20% of patients with early-stage BC will ultimately experience treatment failure and recurrence." | ( Gonzalez-Angulo, AM; Hernandez-Aya, LF, 2013) |
| "A positive response to breast cancer treatment is largely dependent on the successful combination of anticancer treatment modalities, such as chemotherapy and radiation therapy." | ( Chekhun, VF; Golubov, A; Ilnytskyy, S; Kovalchuk, O; Luzhna, L, 2013) |
| "Treatment of breast cancer cells with BMS-777607 at therapeutic doses inhibited cancerous clonogenic growth but had only minimal effect on cell apoptosis." | ( Hu, X; Sharma, S; Wang, MH; Yao, HP; Zeng, JY; Zhang, R; Zhou, YQ; Zhuang, CM, 2013) |
| "Sixty nude mice bearing with MCF-7 breast cancer were administrated with either adriamycin or sterile saline." | ( Cao, LH; Chen, Y; Li, AH; Liu, JB; Luo, RZ; Wang, JW; Zheng, W; Zhou, JH, 2013) |
| "Thirty-two patients with invasive breast cancer (26 ductal, 4 lobular, 2 other), prior to and/or during neoadjuvant chemotherapy, underwent both conventional PET/CT and MAMMI PET in prone position with hanging breasts." | ( Aukema, TS; Benlloch Baviera, JM; Caballero Ontanaya, L; González Martínez, AJ; Koolen, BB; Rutgers, EJ; Valdés Olmos, RA; Vogel, WV; Vrancken Peeters, MJ; Vroonland, CJ, 2013) |
| "Human primary breast cancer cells and breast cancer cell line MDA-MB-231 cells were treated with UTI with or without TXT, and invasion and metastasis ability of these cells were evaluated, respectively, by a transwell assay." | ( Gao, F; Luo, J; Sun, X; Sun, Z; Wang, H; Zhang, Y; Zhao, X; Zhong, B, 2013) |
| "We aimed to identify in clinical breast cancer those genes and pathways most associated with resistance to aromatase inhibitors by examining the global transcriptional effects of AI treatment." | ( A'hern, R; Anderson, H; Dowsett, M; Dunbier, AK; Ghazoui, Z; Miller, WR; Nerurkar, A; Osin, P; Salter, J; Smith, IE, 2013) |
| "We used 4 different breast cancer gene expression datasets including two cohorts of patients who received no systemic adjuvant therapy (Mainz: n = 206, TRANSBIG: n = 134) and two other cohorts that received adjuvant tamoxifen (JBI: n = 227, MDACC/SET: n = 192)." | ( Iwamoto, T; Kulka, J; Matsuoka, J; Pusztai, L; Qi, Y; Swanton, C; Symmans, WF; Szasz, AM; Szekely, B; Tokes, AM, 2013) |
| "The randomized, controlled BOLERO-2 (Breast Cancer Trials of Oral Everolimus) trial demonstrated significantly improved progression-free survival with the use of everolimus plus exemestane (EVE + EXE) versus placebo plus exemestane (PBO + EXE) in patients with advanced breast cancer who developed disease progression after treatment with nonsteroidal aromatase inhibitors." | ( Baselga, J; Bauly, H; Beck, JT; Bennett, L; Burris, HA; Chouinard, E; Gnant, M; Hortobagyi, GN; Komorowski, A; Lebrun, F; Neven, P; Noguchi, S; Petrakova, K; Piccart, M; Pritchard, KI; Ricci, JF; Rugo, HS; Sahmoud, T; Taran, T; Young, R, 2013) |
| "In patients with advanced breast cancer who develop disease progression after treatment with nonsteroidal aromatase inhibitors, EVE + EXE was associated with a longer TDD in global HRQOL versus PBO + EXE." | ( Baselga, J; Bauly, H; Beck, JT; Bennett, L; Burris, HA; Chouinard, E; Gnant, M; Hortobagyi, GN; Komorowski, A; Lebrun, F; Neven, P; Noguchi, S; Petrakova, K; Piccart, M; Pritchard, KI; Ricci, JF; Rugo, HS; Sahmoud, T; Taran, T; Young, R, 2013) |
| "Sixty-one women with breast carcinoma had FDG-PET/CT imaging at baseline and then after the second course of neoadjuvant chemotherapy." | ( Colletti, PM; Delord, M; Groheux, D; Hindié, E; Nguyen, ML; Rubello, D, 2013) |
| "To initiate breast tumors, we inoculated the mammary carcinoma Mvt-1 cell line into the inguinal mammary fat pad of the hyperinsulinemic MKR female mice, and to study the role of IR, we treated the mice bearing tumors with the recently reported high-affinity IR antagonist-S961, in addition to the well-documented IGF-IR inhibitor picropodophyllin (PPP)." | ( Bitton-Worms, K; Caspi, A; LeRoith, D; Rostoker, R; Shen-Orr, Z, 2013) |
| "Patients with primary invasive breast cancer <2 cm diameter, grade 1 or good prognosis special type, and node negative, treated by wide local excision (WLE) with clear margins were randomised into a 2 × 2 clinical trial of factorial design with or without radiotherapy and with or without tamoxifen." | ( Bates, T; Blamey, RW; Chetty, U; Duffy, SW; Ellis, IO; George, D; Macmillan, RD; Mallon, E; Mitchell, MJ; Monypenny, I; Morgan, DA; Patnick, J; Pinder, SE, 2013) |
| "Factor 1 comprised the effects of breast cancer treatment on the emotion and thought, while Factor 2 informed attempts to limit exposure of the body to self or others." | ( Bustam, AZ; Guan, NC; Sabki, ZA; Shuib, N; Zainal, NZ, 2013) |
| "Women with breast cancer were all treated with chemotherapy." | ( Kesler, SR; Koovakkattu, D; Lee, C; Mahaffey, ML; O'Hara, R; Watson, C; Wefel, JS, 2013) |
| "Survival after breast cancer, measured from diagnosis, was similar in combined hormone therapy users and nonusers (HR = 1." | ( Anderson, GL; Aragaki, AK; Cauley, JA; Chen, C; Chlebowski, RT; Johnson, KC; Lane, DS; Manson, JE; Newcomb, PA; Prentice, RL; Qi, L; Stefanick, ML; Wactawski-Wende, J; Yasmeen, S, 2013) |
| "Women with advanced breast cancer, with ≥1 measurable lesion per RECIST, were stratified by line of treatment (1st, 2nd), visceral disease (yes/no), ECOG PS (0-1 vs." | ( Amadori, D; Bauknecht, T; Carrasco, E; Desaiah, D; Labianca, R; Martin, M; Moreau, V; Roesel, S; Soldatenkova, V; Uziely, B, 2013) |
| "However, most breast tumors are eventually resistant to TAM therapy." | ( Wang, ZY; Zhang, X, 2013) |
| "Chemotherapy-naive patients with breast cancer were given HEC in an adjuvant or neoadjuvant setting." | ( Cardillo, FD; Cognetti, F; Evangelista, S; Fabi, A; Fattoruso, SI; Pacetti, U; Veltri, E, 2013) |
| "From January 1999 to December 2008, 152 breast cancer patients treated with TAM (20 mg/day), symptomatic (with bleeding) or asymptomatic, pre-and postmenopausal, were included consecutively in a prospective and observational follow-up study." | ( Bartt, O; Bazán, G; Dalbert, DB; Figueredo, A; Mural, J; Rodríguez de la Peña, MM; Rossi, C; Subiela, R, 2013) |
| "Nine women with locally advanced breast cancer were imaged with both HR-DWI and STD-DWI before and after 3 weeks (early treatment) of neoadjuvant taxane-based treatment." | ( Banerjee, S; Hylton, NM; Joe, BN; Jones, EF; Kornak, J; McLaughlin, RL; Newitt, DC; Proctor, E; Saritas, EU; Shankaranarayanan, A; Singer, L; Sinha, SP; Wilmes, LJ; Wisner, DJ, 2013) |
| "In human breast cancer cells, paclitaxel treatment resulted in MCL-1 degradation which was prevented by a proteasome inhibitor, MG132." | ( Harada, H; Hicks, MA; Miller, AV; Nakajima, W; Richardson, AC; Windle, JJ, 2013) |
| "They both had a history of breast cancer Stage IIB previously treated with modified radical mastectomy, at 51 and 78 months, respectively." | ( Androutsopoulos, G; Arnogiannaki, N; Grigoriadis, C; Terzakis, E; Zygouris, D, 2013) |
| "Triple-negative breast cancers (TNBC) are notoriously difficult to treat because they lack hormone receptors and have limited targeted therapies." | ( Cheema, AS; Cherkasov, A; Couto, N; Dunn, SE; Hassell, JA; Islam, S; Jones, SJ; Jung, K; Law, JH; Li, H; Li, Y; Reipas, KM, 2013) |
| "Of examined 37 breast cancer patients (average age 42,3 +/- 1,2 years) 25 had not had any specific therapy by the date of investigation and the rest 12 had received in average 5,3 +/- 0,6 cycles of neoadjuvant chemotherapy mainly TAC and FAC." | ( Bershteĭn, LM; Boriakina, MP; Bozhok, AA; Poroshina, TE; Tsyrlina, EV, 2012) |
| "Patients with HER2-positive metastatic breast cancer who had not received previous chemotherapy or biological treatment for their metastatic disease were randomly assigned to receive either pertuzumab, trastuzumab, and docetaxel (n=402) or the same regimen with a matching placebo replacing pertuzumab (n=406)." | ( Baselga, J; Benyunes, MC; Campone, M; Ciruelos, E; Clark, E; Cortés, J; Ferrero, JM; Kim, SB; Knott, A; Ro, J; Ross, G; Schneeweiss, A; Semiglazov, V; Swain, SM, 2013) |
| "Delay in seeking treatment for breast cancer is a barrier to the early diagnosis and management of the disease, resulting in a poorer prognosis." | ( Cheong, KC; Ghazali, SM; Hock, LK; Kamaluddin, MA; Mustafa, AN; Othman, Z; Wan Mahiyuddin, WR; Yusoff, AF, 2013) |
| "In 237 T₁₋₂N₀M₀ breast cancers without systemic adjuvant treatment, formalized MAI assessment and strictly standardized, fully automated quantitative immunohistochemistry (IHC) for Ki67, PPH3, estrogen (ER) and progesterone receptor (PR), HER2, cytokeratins-5/6 and -14, and automated digital image analysis (DIA) for measuring PPH3 and Ki67 were performed." | ( Baak, JP; Feng, W; Gudlaugsson, E; Janssen, EA; Klos, J; Malpica, A; Shao, Z; Skaland, I; Smaaland, R, 2013) |
| "The study revealed that breast cancer patients treated with FAC, there was an inverse association between creatinine clearance and occurrence of neutropenia." | ( Amparo, JR; Catedral, MM; Cristal-Luna, GR; Lava, AL; Luna, HG; Montoya, JE; Morelos, AB, 2013) |
| "A woman with bilateral breast cancer treated with bilateral mastectomies, implant reconstructions, chemotherapy, and hormonal therapy underwent FDG PET/CT imaging." | ( Cody, HS; D'Andrea, G; Ulaner, GA, 2013) |
| "In 53 men and women with breast cancer, leukemia, or lymphoma, we assessed left ventricular volumes, LVEF, circumferential strain, aortic pulse wave velocity, late gadolinium enhancement, serum B-type natriuretic peptide, troponin I, and the impact of treatment on QOL before and 1, 3, and 6 months after receipt of Anth-bC." | ( Avis, N; D'Agostino, R; Drafts, BC; Ellis, LR; Hamilton, CA; Hundley, WG; Jordan, J; Lawrence, J; Little, WC; Melin, SA; Thohan, V; Torti, FM; Twomley, KM, 2013) |
| "Thirty patients with breast cancer treated with epirubicin chemotherapy and 30 normal controls were included in the study." | ( Jiang, Y; Peng, Q; Tang, Z; Zhou, Q, 2013) |
| "Women with Stage I to III breast cancer treated with anthracycline and taxane-based neoadjuvant chemotherapy (four cycles of docetaxel every 3 weeks followed by four cycles of FEC every 3 weeks) between 2006 and 2011 were retrospectively analyzed." | ( Hatanaka, KC; Hatanaka, Y; Hosoda, M; Matsuno, Y; Taguchi, K; Takakuwa, E; Yamamoto, M; Yamashita, H; Yoshioka, T, 2015) |
| "UCD38B treatment of human breast cancer cells promotes autophagy reflected in LC3 conversion, and induces the dramatic swelling of the endoplasmic reticulum, however these events do not appear to be the cause of cell death." | ( Carraway, KL; Gorin, F; Leon, LJ; Pasupuleti, N, 2013) |
| "Primary breast cancer patients on neoadjuvant chemotherapy and non-responsive to anthracyclines plus taxanes received the NP regimen." | ( Duan, XN; Liu, YH; Wang, J; Xu, L; Ye, JM; Zhao, JX, 2013) |
| "Nine patients with advanced breast cancer ulcer finished the treatment." | ( Ding, LJ; Jiang, ZF; Meng, XY; Song, ST; Sun, B; Wu, SK; Zhao, X, 2013) |
| "Consecutive patients with early breast cancer recommended for docetaxel-based chemotherapy with no prior ocular symptoms were included." | ( Chan, A; de Boer, RH; Gajdatsy, A; Su, C, 2013) |
| "Before surgery, breast cancer patients underwent a PET/CT scan of the breasts and axillary regions 4 d after intravenous administration of 37 MBq of (89)Zr-bevacizumab per 5 mg." | ( Bart, J; Brouwers, AH; de Jong, JR; de Vries, EG; de Vries, J; Gaykema, SB; Jansen, L; Lub-de Hooge, MN; Pleijhuis, RG; Pot, L; Schröder, CP; Timmer-Bosscha, H; van Dam, GM; van der Meulen, SB, 2013) |
| "Peripheral blood was collected from 12 breast cancer patients showing no early skin reactions after radiotherapy (RTOG grade 0) and from 14 breast cancer patients who developed acute severe skin reactions (RTOG grade 3-4)." | ( Andersson, A; Brehwens, K; Haghdoost, S; Harms-Ringdahl, M; Lidbrink, E; Naslund, I; Skiöld, S; Wersall, P; Wojcik, A, 2013) |
| "In HER2-positive breast cancer cells treated with the HER2 tyrosine kinase inhibitor lapatinib, MDM2 was degraded and HUWE1 was stabilized." | ( Dewhirst, MW; Geradts, J; Henao, R; Kim, J; Kim, WJ; Kornbluth, S; Kurokawa, M; Liu, L; Lucas, JE; Matsuura, K; Ran, X; Ribar, TJ; Spector, NL; Wang, S; Xia, W, 2013) |
| "Chemotherapy regimens for breast cancer containing anthracycline and cyclophosphamide are classified as highly emetogenic." | ( Hatake, K; Ito, Y; Nakayama, Y; Takahashi, S; Tanabe, M, 2015) |
| "Metastatic breast cancer is currently incurable and the goals of therapy focus on prolonging survival and maintaining quality of life by controlling symptoms and minimizing toxicity." | ( Saji, S, 2013) |
| "The accruing cases of breast cancer were matched to controls by age at diagnosis, baseline age, and hormone replacement therapy (HRT)." | ( Loft, S; Møller, P; Olsen, A; Poulsen, HE; Tjønneland, A, 2013) |
| "Patients with metastatic breast cancer and HER2 non-amplified primary tumors with EGFR-positive CTCs were recruited and lapatinib 1500 mg daily was administered, in a standard two step phase 2 trial." | ( Avery, M; Coombes, RC; Di Leo, A; Frampton, AE; Krell, J; Payne, R; Pestrin, M; Reise, J; Stebbing, J; Woodley, L, 2013) |
| "In patients with ER-positive breast cancer expressing low tumour levels of AIB1 (<75%), we found no significant difference in recurrence-free survival (RFS) or breast cancer-specific survival (BCS) between tamoxifen treated and untreated patients." | ( Fornander, T; Nordenskjöld, B; Sgroi, DC; Skoog, L; Stål, O; Weiner, M, 2013) |
| "Eligible patients had breast cancer with impaired liver function secondary to hepatic metastases and were candidates for docetaxel therapy." | ( Booser, DJ; Eckmann, K; Esparza-Guerra, L; Green, MC; Hortobagyi, GN; Kawedia, J; Madden, TL; Michaud, LB; Rivera, E; Valero, V, 2014) |
| "Tau expression in breast cancer may be important for chemotherapy optimization." | ( Cui, WQ; Gong, Y; Hou, YF; Li, ZH; Qiu, W; Tu, JH; Wei, WS; Xiong, QY; Zhang, HQ, 2013) |
| "We enrolled patients with breast cancer who had one or more bone metastases and had completed 12-15 months of monthly treatment with zoledronic acid." | ( Aglietta, M; Alessi, B; Amadori, D; Bertoldo, F; Bogani, P; Farina, G; Gaion, F; Gianni, L; Ibrahim, T; Ripamonti, CI; Rondena, R; Santini, D, 2013) |
| "Thirty-nine postoperative breast cancer patients were randomized into three groups for intraindividual comparison (skin to be irradiated was divided into 2 parts): (1) 3M No Sting Barrier Film versus no treatment; (2) corticosteroid versus no treatment; and (3) corticosteroid versus 3M No Sting Barrier Film." | ( Lang, CH; Lui, LT; Nien, HH; Shaw, SZ; Su, JF; Wu, CJ, 2015) |
| "Operable stage I-III breast cancer patients who received ≥ 1 dose of docetaxel monotherapy at 75-100 mg/m(2) q3w were included in this study." | ( Berger, M; Layman, R; Lustberg, M; Mrozek, E; Olson, E; Poi, MJ; Ramaswamy, B; Shapiro, CL; Wesolowski, R, 2013) |
| "Here we report that in breast cancer cells, the unliganded progesterone receptor (PR) binds genomic sites and targets a repressive complex containing HP1γ (heterochromatin protein 1γ), LSD1 (lysine-specific demethylase 1), HDAC1/2, CoREST (corepressor for REST [RE1 {neuronal repressor element 1} silencing transcription factor]), KDM5B, and the RNA SRA (steroid receptor RNA activator) to 20% of hormone-inducible genes, keeping these genes silenced prior to hormone treatment." | ( Beato, M; Font-Mateu, J; Le Dily, F; Nacht, AS; Reyes, D; Soronellas, D; Vicent, GP; Zaurin, R, 2013) |
| "Treatment of breast cancer cell lines with lapatinib and OSU-03012 (a small molecule derivative of the Cox-2 inhibitor celecoxib) induced synergistic cytotoxic/cytostatic effects." | ( Chalfant, CE; Garcia-Vargas, A; Park, MA; West, NW, 2013) |
| "To evaluate whether breast cancer (BC) patients with CYP2D6 gene variation have different clinical tamoxifen (TAM) treatment outcomes to those with normal function of CYP2D6." | ( Chen, Z; Li, R; Li, S; Liu, Y; Liu, Z; Peng, Q; Qin, X; Wang, J; Xie, L; You, J; Zeng, Z, 2013) |
| "A total of 122 breast cancer patients after operation were randomly divided into two groups: The experimental group of 61 cases treated with EPI plus DEX (DEX:EPI = 10:1) as adjuvant chemotherapy regimen, and the control group of 61 cases treated with EPI but without DEX." | ( Hao, XM; Li, WJ; Wang, P; Zhang, J; Zhang, S; Zhang, XB, 2013) |
| "Skeletal metastasis of breast carcinoma is refractory to intensive chemo-radiation therapy and therefore is assumed impossible to cure." | ( Kuranishi, F; Ohno, T, 2013) |
| "Metastatic breast cancer chemotherapy in the elderly is considered effective in carefully selected patients, but there is little data regarding its effect in vulnerable patients." | ( Abadie-Lacourtoisie, S; Bonnefoy, M; Brain, E; Cretin, J; El Kouri, C; Falandry, C; Freyer, G; Guillem, O; Jacquin, JP; Jovenin, N; Mefti, F; Paraiso, D; Rigal, O; Uwer, L, 2013) |
| "The BOLERO-2 (Breast cancer trial of OraLEveROlimus-2) trial showed that combination treatment with EVE and exemestane (EXE) versus placebo (PBO)+EXE prolonged progression-free survival (PFS) by both investigator (7." | ( Arena, F; Bachelot, T; Baselga, J; Burris, HA; Campone, M; Deleu, I; El-Hashimyt, M; Gnant, M; Hart, L; Héniquez, A; Hortobagyi, GN; Melichar, B; Noguchi, S; Panneerselvam, A; Piccart, M; Pistilli, B; Pritchard, KI; Provencher, L; Rugo, HS; Sahmoud, T; Shtivelband, M; Taran, T, 2013) |
| "In conclusion, breast cancer patients carrying at least one CYP2C19 2 allele have an adverse prognosis in the absence of adjuvant systemic treatment, which can be substantially improved by adjuvant tamoxifen treatment." | ( Beelen, K; Berns, EM; Hauptmann, M; Koornstra, RH; Linn, SC; Opdam, M; Severson, TM; van Diest, PJ; van Schaik, RH; Vermorken, JB; Vincent, AD, 2013) |
| "Certain somatic alterations in breast cancer can define prognosis and response to therapy." | ( Bono, P; Claes, B; Fumagalli, D; Joensuu, H; Kataja, V; Kellokumpu-Lehtinen, PL; Lambrechts, D; Loi, S; Michiels, S; Piccart, MJ; Sotiriou, C, 2013) |
| "Patients with recurrent triple-negative breast cancer (TNBC) currently have no established treatment option other than chemotherapy." | ( Bing, S; Lijuan, D; Santai, S; Shaohua, Z; Shikai, W; Tao, W; Xiangying, M; Xin, Z; Yan, M; Yue, W; Zefei, J, 2013) |
| "The prolactin-responsive human T47D breast cancer cell line was xenotransplanted into nude mice and global transcript profiling was carried out following treatment with or without human PRL for 48 h." | ( Ertel, A; Lin, J; Liu, C; Neilson, LM; Peck, AR; Rui, H; Sato, T; Tran, TH, 2013) |
| "Twenty-three MCF-7 breast cancer bearing nude mice treated by either adriamycin (n = 11) or sterile saline (n = 12) were imaged before and after treatment with an ultrasound scanner after bolus injection of SonoVue." | ( Cao, LH; Chen, Y; Han, F; Li, AH; Wang, JW; Zheng, W; Zhou, JH, 2013) |
| "The OR for differences in breast cancer risk during SERM therapy for subjects homozygous for both protective or both risk alleles for ZNF423 and CTSO was 5." | ( Ames, MM; Batzler, A; Carlson, EE; Costantino, JP; Flockhart, DA; Goetz, MP; Ingle, JN; Jenkins, GD; Kubo, M; Liu, M; Mushiroda, T; Nakamura, Y; Paik, S; Schaid, DJ; Vogel, VG; Wang, L; Weinshilboum, RM; Wickerham, DL; Wolmark, N, 2013) |
| "Early-stage breast cancer (ESBC) is commonly treated with myelosuppressive chemotherapy, and maintaining full-dose chemotherapy on the planned schedule is associated with improved patient outcome." | ( Crawford, J; Dale, DC; Lyman, GH; Tomita, D; Whittaker, S, 2013) |
| "Estrogen receptor-positive breast cancer tumors depend on estrogen signaling for their growth and replication and can be treated by anti-estrogen therapy with tamoxifen." | ( Bandres, F; Blancas, I; de Dueñas, EM; de Haro, T; Farez-Vidal, E; Gomez-Capilla, JA; Gomez-Llorente, C; Ochoa-Aranda, E; Zafra-Ceres, M, 2013) |
| "In early breast cancer treated by chemotherapy, only baseline hemoglobin and hepcidin levels are independent predictive factors of anemic syndrome occurrence." | ( Durigova, A; Gutowski, M; Jacot, W; Lamy, PJ; Montels, F; Pouderoux, S; Romieu, G; Thezenas, S, 2013) |
| "Like breast cancer cell lines, a wild-type murine embryonic fibroblast (MEF) cell line exhibited enhanced cytotoxicity and maximally up-regulated Chop after combined treatment with SAHA, CAM, and BZ; however, a Chop knockout MEF cell line almost completely canceled this enhanced effect." | ( Che, XF; Kohno, N; Komatsu, S; Miyazawa, K; Moriya, S; Yokoyama, T, 2013) |
| "Twenty-four MCF-7 breast cancer bearing nude mice were treated with adriamycin or sterile saline administered by intraperitoneal injection." | ( Cao, LH; Chen, Y; Feng, ZZ; Li, AH; Lin, CY; Wang, JW; Zheng, W; Zhou, JH, 2013) |
| "Treatments of cells from breast cancer cell-lines MDA-MB-231, T47D, or SKBR-3 with GnRH-p53 in combination with 5-FU significantly enhanced p53-activated apoptosis signals, including PUMA expression, BAX translocation to mitochondria, and activated caspase-3." | ( Chen, L; Deng, W; Li, LY; Lin, X; Lotze, M; Lu, Y; Wang, Z; Yan, Z; Zhang, Z, 2013) |
| "Hormone receptor-positive breast cancer is treated with estrogen inhibitors." | ( Alencar, VM; Audeh, MW; Brown, K; Chan, A; de Oliveira, C; Hyams, DM; Klein, P; Lombard, J; Mookerjee, B; Snyder, R; Vinholes, J; Xu, J, 2013) |
| "The triple negative breast cancer (TNBC) was most sensitive to chemotherapy with 19% achieving clinical-complete-response (cCR) followed by HER2 enriched (2/22 (9%) cCR), luminal B (1/6 (7%) cCR) and luminal A (0/10 (0%) cCR)." | ( Khokher, S; Mahmood, S; Nagi, AH; Qureshi, MU, 2013) |
| "A panel of breast cancer cell lines was treated with these agents, trastuzumab, gefitinib and cytotoxic therapies and the expression pattern of a specific panel of genes using RT-PCR was investigated as a potential marker of early drug response to HER2-targeting therapies." | ( Aherne, ST; Clynes, M; Crown, J; Doolan, P; Madden, SF; O'Connor, R; O'Neill, F, 2013) |
| "After the exposure of breast cancer cells to (-)-xanthatin or etoposide, a prolonged and marked up-regulation in the expression of c-fos, a proapoptotic molecule, was detected together with GADD45γ; and the expression of these molecules was stabilized by ROS and abrogated by the pretreatment with N-acetyl-L-cysteine (NAC), a potent ROS scavenger." | ( Amamoto, T; Aramaki, H; Koyachi, K; Matsumoto, K; Nishimura, H; Okamoto, Y; Shindo, M; Takeda, S; Yoshida, K, 2013) |
| "Oral administration of nitazoxanide in breast cancer xenograft mouse models significantly suppressed tumor growth by inhibition of c-Myc and induction of apoptosis." | ( Bodapati, S; Fan, A; Fan-Minogue, H; Felsher, DW; Gambhir, SS; Massoud, TF; Paulmurugan, R; Solow-Cordero, D, 2013) |
| "Because metastatic breast cancer (MBC) is incurable in most cases, the goals of treatment are improvement in quality of life, management of symptoms, and prolonged survival." | ( Gradishar, WJ, 2013) |
| "Most breast cancers expressing the estrogen receptor α (ERα) are treated successfully with the receptor antagonist tamoxifen (TAM), but many of these tumors recur." | ( Chang, HY; Cho, S; Cimino-Mathews, A; Cope, L; Cruz, LA; Goswami, CP; Gupta, R; Jin, K; Nakshatri, H; Park, S; Sadik, H; Shah, N; Sukumar, S; Umbricht, C; Zhang, Z, 2013) |
| "Patients with breast cancer face substantial challenges to bone health from bone metastases, as well as from chemotherapy and endocrine therapies that generally elicit disease control at the cost of increased bone turnover." | ( Coleman, R; Gnant, M; Hadji, P, 2013) |
| "A significant proportion of elderly breast cancer patients in the UK have no surgical treatment recorded and appear to be treated with primary endocrine therapy (PET) only." | ( Ravichandran, D; Wylie, S, 2013) |
| "Hormonal therapy for breast cancer is the first targeted therapy used in any type of cancer." | ( Pritchard, KI, 2013) |
| "Women with newly diagnosed breast cancer were randomly assigned to neoadjuvant chemotherapy of four cycles of doxorubicin and cyclophosphamide followed by four cycles of docetaxel (AC 60/600 - T 100 mg/m(2)) or six cycles of TAC (75/50/500 mg/m(2)) every 3 weeks." | ( Aarts, MJ; Borm, GF; de Boer, M; de Vries, B; Smilde, TJ; Tjan-Heijnen, VC; van Gastel, SM; van Spronsen, DJ; van Warmerdam, LJ; Vriens, BE; Wals, J, 2013) |
| "One hundred and four breast cancer patients undergoing chemotherapy were enrolled in the study." | ( Fukuma, E; Higaki, K; Masuda, N; Mizutani, M; Ohno, S; Osaki, A; Saeki, T; Sagara, Y; Sato, K; Suzuki, M; Takano, T; Tokuda, Y, 2013) |
| "FSK0808 was safe and well tolerated in breast cancer patients undergoing chemotherapy and effectively stimulated neutrophil recovery." | ( Fukuma, E; Higaki, K; Masuda, N; Mizutani, M; Ohno, S; Osaki, A; Saeki, T; Sagara, Y; Sato, K; Suzuki, M; Takano, T; Tokuda, Y, 2013) |
| "Tissue samples of 118 women treated for breast cancer were obtained." | ( Cadore, S; Derchain, SF; Febraio, S; Heinrich, JK; Rodrigues-Peres, RM; Sarian, LO; Serra, KP; Vassallo, J, 2013) |
| "Treatment for breast cancer patients aimed at fertility preservation, includes ovarian hyperstimulation, the harvest of oocytes, and subsequent cryopreservation of oocytes or embryos." | ( Child, T; Fatum, M; McVeigh, E, 2013) |
| "Pain from bone metastases of breast cancer origin is treated with localized radiation." | ( Brenner, B; Fenig, E; Kaufman, B; Kundel, Y; Nasser, NJ; Pfeffer, RM; Purim, O; Rizel, S; Stemmer, SM; Sulkes, A; Symon, Z; Yerushalmi, R, 2013) |
| "Basal-like and luminal-like breast cancer xenografts were treated with the dual PI3K/mTOR inhibitor BEZ235, and the impact of treatment on the concentration of phosphocholine, glycerophosphocholine, phosphoethanolamine and glycerophosphoethanolamine was evaluated." | ( Bathen, TF; Engebråten, O; Esmaeili, M; Gribbestad, IS; Moestue, SA; Mælandsmo, GM, 2014) |
| "Patients with a diagnosis of invasive breast cancer from January 2005 through December 2009 who underwent both DCE MR imaging and FDG PET/CT before treatment initiation were retrospectively identified." | ( Banfield, KS; Behr, SC; Bolouri, MS; Elias, SG; Hawkins, RA; Hylton, NM; Joe, BN; Suzuki, SA; Wisner, DJ, 2013) |
| "Women with breast cancer treated with aromatase inhibitors (AIs) may experience musculoskeletal symptoms that lead to discontinuation of effective therapy." | ( Liu, H; Liu, L; Lu, K; Ma, W; Pan, B; Song, Y; Sun, W; Tang, D; Wang, J; Wang, Y; Xie, L; Xuan, Q; Zhang, Q; Zhao, H; Zhao, S, 2013) |
| "We treated MCF-7 and T-47D breast cancer cells with the ERβ agonists ERB-041 and WAY-200070 and measured the effects on cell growth." | ( Häring, J; Lattrich, C; Ortmann, O; Schüler, S; Skrzypczak, M; Treeck, O, 2014) |
| "Patients (n = 120) with breast cancer (T1-4N0-3M0) treated by 2-4 cycles of NAC (CAX, FAC, and taxane regimes) and 4 cycles of adjuvant chemotherapy (FAC) were included." | ( Cherdyntseva, NV; Denisov, EV; Garbukov, EIu; Khristenko, KIu; Litviakov, NV; Slonimskaia, EM; Tsyganov, MM; Vtorushin, SV; Zav'ialova, MV, 2013) |
| "Patients with HER2-positive breast cancer often exhibit intrinsic or acquired resistance to trastuzumab treatment." | ( Baselga, J; Jin, C; Kharbanda, A; Kharbanda, S; Kufe, D; Panchamoorthy, G; Raina, D; Rajabi, H; Scaltriti, M; Uchida, Y, 2014) |
| "Hormone-receptor (HR)-positive breast cancer is associated with a poor response to adjuvant chemotherapy." | ( Du, Y; Liu, Y; Lu, J; Shao, Z; Yan, T; Yin, W, 2013) |
| "Using spontaneous breast cancer metastasis mouse model (syngeneic) of GFP-4T1-BrM5 mammary tumor cells administered into mammary fat pads of Balb/c mice, SP inhibitor spantide III inhibited in vivo changes in permeability of the BBB and BMEC-TJs ZO-1 and claudin-5 structures as well as decreased tumor cell colonization in brain." | ( Avraham, HK; Avraham, S; Fu, Y; Jiang, S; Rodriguez, PL, 2014) |
| "MDA-MB-231 breast cancer cells were treated with various concentrations of AgNPs (5 to 25 μg/mL) for 24 h." | ( Eppakayala, V; Gurunathan, S; Han, JW; Jeyaraj, M; Kim, JH, 2013) |
| "Prognosis and selection of therapy in breast cancer depends upon various factors including clinical parameters, histopathological subtype and molecular characteristics of primary tumour." | ( Bandyopadhyay, A; Barui, G; Chakrabarti, S; Karmakar, R; Maity, PK; Roy, A, 2012) |
| "A 54-year-old metastatic breast cancer patient who had undergone chemotherapy and radiotherapy was transferred to our hospital for further treatment." | ( Sun, Y; Xue, J; Yang, Z; Yao, Z; Zhang, Y, 2013) |
| "A total of 112 breast cancer specimens from a prospective neoadjuvant chemotherapy trial (GeparDuo) were studied." | ( Ataseven, B; Becker, S; Darb-Esfahani, S; Denkert, C; Holtrich, U; Karn, T; Loibl, S; Nekljudova, V; Reimer, T; Rody, A; Ruckhäberle, E; von Minckwitz, G, 2013) |
| "In premenopausal women treated for breast cancer, loss of bone mineral density (BMD) follows from menopause induced by chemotherapy or loss of ovarian function biochemically or by surgical oophorectomy." | ( Bisquera, OC; De La Peña, AS; Dofitas, RB; Jarjoura, D; Laudico, AV; Linh, ND; Love, RR; Mirasol-Lumague, MR; Navarro, NS; Quang, le H; Salvador, JD; Siguan, SS; Uy, GB; Van Dinh, N; Young, GS, 2013) |
| "For anthracycline-naive metastatic breast cancer (AN-MBC), early anthracycline treatment is a common practice." | ( Chang, DY; Chen, WW; Cheng, AL; Hsu, C; Huang, CS; Huang, SM; Lin, CH; Lin, MH; Lu, YS, 2013) |
| "In induced rat models of breast cancer, PEG-GoldMag-pod nanoparticles combined with lymphatic vessels were significantly detectable at MRI 60 min after nanoparticle administration, the signal intensity was negatively correlated with the lymphatic vessel density of breast cancer (r = -0." | ( Diao, XW; Gong, MF; Qi, YY; Yang, H; Zhang, D; Zhang, S; Zhou, SW; Zou, LG, 2013) |
| "The impact of the Oncotype Dx (ODX) breast cancer assay on adjuvant chemotherapy (ACT) treatment decisions has been evaluated in many previous studies." | ( Carlson, JJ; Roth, JA, 2013) |
| "Patients with node-positive early breast cancer were randomly assigned 1:1 to two different dose-dense chemotherapy regimens and 2:1 to ibandronate 50 mg per day orally for 2 years or observation." | ( Barinoff, J; Bauerfeind, I; Belau, A; Clemens, M; Conrad, B; Diel, IJ; Elling, D; Forstbauer, H; Harbeck, N; Huober, J; Jackisch, C; Kreienberg, R; Loibl, S; Lück, HJ; Möbus, V; Müller, V; Nekljudova, V; Noeding, S; Schmidt, M; Schneeweiss, A; Thomssen, C; Untch, M; von Minckwitz, G, 2013) |
| "Endocrinotherapy is the most common breast cancer therapy and acquired tamoxifen (TAM) resistance is the main reason for endocrinotherapy failure during such therapy." | ( Cui, SD; Fan, QX; Guo, XH; He, YN; Liu, H; Sun, XF; Zhang, HW, 2013) |
| "Targeting breast cancer stem cells (BCSCs) offers a promising strategy for breast cancer treatment." | ( Banarji, A; Chauhan, PS; Chikati, R; Kumar, CS; Pandrangi, SL; Saxena, S, 2014) |
| "Our studies suggest that breast cancer patients with BCRP-mediated MDR may be successfully treated with PROG." | ( Gao, P; Hu, J; Li, L; Li, W; Su, P; Sun, L; Wang, X; Wu, X; Zhang, H; Zhang, X; Zhou, G, 2013) |
| "However, patients with breast cancer who are treated by the drugs often develop resistance to them and some other drugs." | ( Chen, Z; Li, W; Xu, J; Zhao, J; Zhong, S, 2013) |
| "Identifying breast cancer patients at high risk of developing cardiotoxicity after anthracycline therapy would be of value in guiding the use of these agents." | ( Feola, M; Garrone, O; Lo Nigro, C; Merlano, M; Monteverde, M; Vivenza, D, 2013) |
| "Data of 50 ER+ breast cancer patients undergoing COH to cryopreserve oocytes before gonadotoxic chemotherapy with a letrozole plus gonadotropins (Le+Gn) protocol were compared with those of 25 young women with ER- breast cancer, submitted to COH using a protocol with gonadotropins alone (Gn-only)." | ( Anserini, P; Delle Piane, L; Levi Setti, PE; Merlo, DF; Porcu, E; Revelli, A, 2013) |
| "Therefore we assessed the proportion of breast cancer patients treated with NAC in which pre-chemotherapy 18F-FDG PET/CT detected ≥4 axillary nodes or occult N3-disease, upstaging nodal status and changing risk estimation for locoregional recurrence (LRR)." | ( Elkhuizen, PH; Koolen, BB; Rodenhuis, S; Rutgers, EJ; Valdés Olmos, RA; Vogel, WV; Vrancken Peeters, MJ, 2013) |
| "We found that breast cancer stem-like cells (BCSC) isolated from patient tumors express the EPO receptor and respond to EPO treatment with increased proliferation and self-renewal." | ( Bartucci, M; Biffoni, M; Dattilo, R; De Maria, R; Federici, G; Iovino, F; Stassi, G; Todaro, M; Turdo, A; Zeuner, A, 2013) |
| "Weight gain in breast cancer patients during treatment is prevalent; the metabolic implications of this weight gain are poorly understood." | ( Bahl, M; Bell, KE; Califaretti, N; Campbell, C; Di Sebastiano, KM; Dubin, JA; Hanning, R; Mitchell, A; Mourtzakis, M; Quadrilatero, J; Russell, C; Vance, V, 2014) |
| "Stage I-II breast cancer patients (n = 8) were evaluated near the initiation of chemotherapy and compared with a group of age- and body mass index-matched, as well as a group of young healthy, non-malignant females." | ( Bahl, M; Bell, KE; Califaretti, N; Campbell, C; Di Sebastiano, KM; Dubin, JA; Hanning, R; Mitchell, A; Mourtzakis, M; Quadrilatero, J; Russell, C; Vance, V, 2014) |
| "Women treated for breast cancer have an increased risk for developing metachronous contralateral breast cancer (CBC)." | ( Lizarraga, IM; Scott-Conner, CE; Sugg, SL; Weigel, RJ, 2013) |
| "Forty-five postmenopausal women with breast cancer (ER and/or PgR positive) undergoing tamoxifen therapy for six to 48 months, were selected from the files of the 2nd Department of Obstetrics and Gynecology, University of Athens Aretaieion Hospital, among a total of 120 patients treated from 2004-2009." | ( Anastasopoulos, C; Botsis, D; Boutas, I; Kalampokas, E; Kalampokas, T; Kondi-Pafiti, A; Melloy, S; Salakos, N; Sofoudis, C, 2013) |
| "The growth of two breast cancer cell lines was markedly decreased following treatment with ZOL." | ( Chang, CL; Chi, CW; Hsu, CC; Lan, YC; Lee, HC; Sung, MT; Tseng, LM; Wang, KC; Yin, PH, 2013) |
| "In vivo, pre-treatment of AR breast tumors in the brain with valproate restored the chemo-sensitivity of the tumors and prolonged animal survival." | ( Booth, L; Cruickshanks, N; Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Sajithlal, GB; Syed, J; Tavallai, S, 2013) |
| "The malignant biological behavior of breast cancer remains obscure on diagnostic images, although understanding the grade of such malignancy is important for selecting appropriate treatment." | ( Aogi, K; Kadoya, T; Kiyoto, S; Masumoto, N; Okada, M; Sugawara, Y, 2013) |
| "Treatment of breast cancer cells (MCF-7, T47D, and MDA-231) with ACCA resulted in dose- and time-dependent decrease of cell proliferation, viability in colony formation assay, and programmed cell death (apoptosis) with minimal effects on non-tumoral cells." | ( Al Muataz, Y; Arrar, Z; Boukerche, H; Hamdan, L; Mulengi, JK; Négrier, C; Suleiman, L, 2013) |
| "Statistically significant elevations in breast cancer risk were seen with greater pretreatment levels of total estradiol (P trend = ." | ( Anderson, G; Cauley, JA; Chlebowski, RT; Cummings, SR; Farhat, GN; Grady, D; Huang, AJ; Jackson, R; Lacroix, AZ; Lane, DS; Lee, JS; Manson, JE; Parimi, N; Phillips, L; Simon, MS; Vittinghoff, E, 2013) |
| "Treatment of breast cancer meningeal carcinomatosis (MC) relies on intrathecal chemotherapy." | ( Bidard, FC; Comte, A; Cottu, PH; Dieras, V; Dorval, T; Guilhaume, MN; Jdid, W; Kriegel, I; Mignot, L; Pierga, JY; Piperno-Neumann, S, 2013) |
| "Moreover, treating breast cancer cells with siRNA targeting integrin β1 inhibited cell invasion and migration." | ( Chen, WD; Deng, R; Feng, GK; Gao, YH; Ji, J; Jiao, L; Qin, J; Tang, J; Zhu, XF, 2013) |
| "Despite advances in breast cancer treatment, mortality from breast cancer is still high." | ( Yiannakopoulou, ECh, 2014) |
| "In summary, treatments of breast cancer cells with DCA and allopurinol result in larger changes in metabolites found in extracellular medium than intracellular pools." | ( Brown, A; Culf, AS; Cuperlovic-Culf, M; Lefort, N; Lloyd, V; Ouellette, R; Touaibia, M, 2014) |
| "Here we summarize, in the context of breast cancer, another approach, namely, the development of postsurgical models of either macroscopic or microscopic metastatic disease to mimic metastatic or adjuvant therapy." | ( Ebos, JM; Francia, G; Guerin, E; Kerbel, RS; Lee, CR; Man, S; Xu, P, 2013) |
| "Despite remarkable improvements in breast cancer survival in the last decades, a proportion of patients still relapse after treatment for early disease." | ( Andre, F; Arnedos, M; Delaloge, S; Dieci, MV, 2013) |
| "About 9% of node positive T0-2 breast cancer will have residual positive node in level III region after neoadjuvant chemotherapy." | ( Fan, T; Fan, Z; Li, J; Lin, B; Ouyang, T; Wang, T; Xie, Y, 2013) |
| "Women with breast cancer who are treated with aromatase inhibitors often experience vaginal atrophy symptoms and sexual dysfunction." | ( Baumgart, J; Göransson, E; Kallak, TK; Nilsson, K; Poromaa, IS; Stavreus-Evers, A, 2014) |
| "Women with aromatase inhibitor-treated breast cancer exhibit reduced proliferation and altered steroid hormone receptor staining intensity in the vagina, which are related to clinical signs of vaginal atrophy." | ( Baumgart, J; Göransson, E; Kallak, TK; Nilsson, K; Poromaa, IS; Stavreus-Evers, A, 2014) |
| "Postmenopausal women with breast cancer who were initiating adjuvant AI therapy were enrolled onto a multicentre, randomised clinical trial of exemestane vs letrozole, designed to identify associations between AI-induced change in MPD and single-nucleotide polymorphisms in candidate genes." | ( Chan, HP; Dantzer, J; Desta, Z; Flockhart, DA; Goswami, CP; Hadjiiski, L; Hayes, DF; Helvie, MA; Henry, NL; Khouri, N; Li, L; Nguyen, AT; Oesterreich, S; Philips, S; Pinsky, R; Rae, JM; Robarge, J; Skaar, TC; Stearns, V; Storniolo, AM; Zhou, C, 2013) |
| "A total of 127 breast cancer patients were treated with DDNC in two prospective studies." | ( Alba, E; de la Torre-Cabrera, C; Fernández, M; Fernández-Navarro, M; Jaén-Morago, A; Pascual, J; Plata-Fernández, Y; Ramirez-Tortosa, C; Sánchez-Muñoz, A; Sánchez-Rovira, P, 2014) |
| "Not all breast cancer patients respond to tamoxifen treatment, possibly due to genetic predisposition." | ( Brauch, H; Czene, K; Hall, P; Humphreys, K; Li, J; Li, Y; Saladores, P; Schroth, W, 2013) |
| "Treatment of breast cancer cells with 5-Aza/TSA derepressed miR-205 and reduced HMGB3 mRNA while knockdown of the transcriptional repressor NRSF/REST, reduced miR-205 and increased HMGB3." | ( Azevedo-Pouly, AC; Elgamal, OA; Gusev, Y; Jiang, J; Park, JK; Roopra, A; Schmittgen, TD, 2013) |
| "Tamoxifen is used for breast cancer treatment and has been reported to be beneficial for the cardiovascular system, but it is unclear whether tamoxifen exhibits a favorable cardiovascular effect in Asian patients." | ( Chan, WL; Chen, JW; Chiang, CH; Chung, CM; Huang, CC; Huang, PH; Leu, HB; Lin, SJ; Wu, TC; Yang, TL, 2014) |
| "The treatment of breast cancer is one of the best examples to underline the outstanding effectiveness of the individualized approach." | ( Dank, M; Tõkés, T, 2013) |
| "In human breast carcinoma cells, treatment with LDL-cholesterol or overexpressing LDLR elevates nuclear beta-catenin activity and facilitates tumor cell proliferation." | ( Chen, J; Lam, KS; Liu, J; Shepherd, PR; Wang, Y; Wong, NS; Xu, A, 2013) |
| "Attributable burden of breast cancer due to high body mass index (BMI), use of hormone replacement therapy (HRT), alcohol consumption and inadequate physical activity." | ( Dunn, NA; Page, AN; Pandeya, N; Protani, MM; Taylor, RJ; Wilson, LF, 2013) |
| "Neoadjuvant chemotherapy (NAC) in breast cancer is currently used not only for locally advanced tumors, but also for large operable tumors when breast preservation is considered." | ( Andrade, WP; Baiocchi, G; Bitencourt, AG; Damascena, AS; do Socorro Maciel, M; Fanelli, MF; Lima, EN; Osório, CA; Soares, FA, 2013) |
| "Molecular subtyping of breast cancer is necessary for therapy selection and mandatory for all breast cancer patients." | ( Barupal, DK; Brockmöller, SF; Budczies, J; Denkert, C; Dietel, M; Fiehn, O; Griffin, JL; Kleine-Tebbe, A; Müller, BM; Orešič, M; Richter-Ehrenstein, C, 2013) |
| "With the recent advance in breast cancer therapy, the survival rate of breast cancer patients has improved greatly." | ( Chen, LW; Chen, SC; Chen, TC; Chiang, KC; Hsu, JT; Juang, HH; Kittaka, A; Kuo, SF; Liu, YY; Pang, JH; Shen, SC; Sun, CC; Takano, M; Yeh, CN, 2014) |
| "Patients with primary breast cancer and DTC-positive bone marrow were randomized to treatment with ZOL plus adjuvant systemic therapy (n = 40) or adjuvant systemic therapy alone (n = 46) between 03/2002 and 12/2004." | ( Banys, M; Becker, S; Fehm, T; Gebauer, G; Hirnle, P; Huober, J; Janni, W; Kraemer, B; Krawczyk, N; Lueck, HJ; Solomayer, EF; Wackwitz, B; Wallwiener, D, 2013) |
| "Advances in breast cancer (BC) treatments have resulted in significantly improved survival rates." | ( Hosseini, SM; Kesler, SR, 2014) |
| "Obesity is a recognized risk factor for breast cancer development and poorer response to therapy." | ( Surmacz, E, 2013) |
| "A 57-year-old woman with invasive breast cancer was referred for adjuvant chemotherapy after undergoing breast conservative therapy and axillary dissection." | ( Schoenegg, W; Vasconcelos, I, 2013) |
| "Two MCF-7 and MDA-MB-231 human breast cancer cell lines were treated with tamoxifen and/or tranilast." | ( Darakhshan, S; Ghanbari, A, 2013) |
| "PVP was performed in 43 patients with breast cancer and painful osteolytic spinal metastases; 126 vertebrae were treated." | ( Han, K; Hu, H; Shen, Z; Sun, Y; Tang, L; Wang, Y; Wu, C; Yao, Y; Zhang, J, 2013) |
| "Treatment of prostate cancer, breast cancer and glioblastoma tumor cell lines with Y27632 following MV infection resulted in increased cytopathic effect, as assessed by trypan blue exclusion assays." | ( Allen, C; Galanis, E; Iankov, I; Msaouel, P; Opyrchal, M, 2013) |
| "Twenty-six patients with metastatic breast cancer (median = 7 prior systemic therapies) (all with prior trastuzumab; 23 with prior lapatinib; one with prior bevacizumab) received treatment on a range of dose levels." | ( Bastida, CC; Falchook, GS; Jiang, Y; Kurzrock, R; Moulder, SL; Wheler, JJ, 2013) |
| "Cultured breast cancer Hs578T cells were treated with various concentrations of pp2 (0,1,2,4,8,16,32 μmol/L) for 24h." | ( Dong, SY; Han, X; Jiang, GJ; Tong, XH; Zheng, C, 2013) |
| "Women with newly diagnosed metastatic breast cancer (MBC) from an ER-positive primary tumor were imaged before starting endocrine therapy." | ( Eary, JF; Gadi, VK; Kurland, BF; Linden, HM; Link, JM; Mankoff, DA; Peterson, LM; Porter, P; Schubert, EK; Shankar, LK; Specht, JM, 2014) |
| "In addition, breast cancer cells were treated with dimethyloxalylglycine (DMOG), a cell-permeable inhibitor of both proline and asparaginyl hydroxylases able to induce HIF-1 α stabilization in normoxia, providing results comparable to those previously described." | ( Bazan, V; Bronte, G; Caruso, S; Castiglia, M; Cicero, G; Fanale, D; Rolfo, C; Russo, A, 2013) |
| "The zebrafish-embryonic breast cancer xenograft model is applicable for the mechanistic understanding, screening and development of anti-TGF-β drugs for the treatment of metastatic breast cancer in a timely and cost-effective manner." | ( Drabsch, Y; He, S; Snaar-Jagalska, BE; ten Dijke, P; Zhang, L, 2013) |
| "Medical history was remarkable for breast cancer with breast-preserving surgery and chemoradiotherapy." | ( Kahl, S; Mörike, K; Müssig, K; Roden, M, 2013) |
| "Primary breast carcinomas were obtained from 112 women who received AI therapy after failing adjuvant tamoxifen therapy and developing recurrent breast cancer." | ( Bulun, SE; Khan, SA; Lin, Z; Moy, I; Rademaker, AW; Reierstad, S, 2013) |
| "Blood samples were collected from 152 breast cancer patients before and after each cycle of doxorubicin chemotherapy to measure the serum levels of ischemia-modified albumin, cardiac troponin T and creatine kinase-MB." | ( Bao, Y; Jiao, F; Kang, W; Ma, Y, 2013) |
| "Roughly two-thirds of all breast cancers are ERα-positive and can be treated with the antiestrogen, Tamoxifen, however resistance occurs in 33% of women who take the drug for more than 5 y." | ( Anderton, DL; Arcaro, KF; Lee, MP; Pentecost, BT; Williams, KE, 2014) |
| "However, about 50% of ER-expressing breast cancer is intrinsically refractory to the antihormone therapy and strategies to improve the therapeutic response are urgently needed." | ( Chen, G; Ma, S; Migliaccio, A; Suresh, PS, 2014) |
| "She underwent surgery to treat breast cancer in 1992." | ( Hattori, M; Iwata, H; Kaise, H; Kawaguchi Ushio, A; Kohno, N, 2013) |
| "Accordingly, in a series of 52 human breast carcinomas, we detected high maspin expression in tumors that progressed under doxorubicin (DXR)-based chemotherapy." | ( Aiello, P; Balsari, A; Carcangiu, ML; Casalini, P; Cominetti, D; Di Modica, M; Ghirelli, C; Moliterni, A; Ratti, M; Regondi, V; Tagliabue, E; Tortoreto, M; Triulzi, T, 2014) |
| "Many patients with metastatic breast cancer (MBC) have been treated previously with taxanes and/or anthracyclines, which renders reinduction of anthracyclines in the palliative setting impossible because of the high cardiotoxicity of these drugs." | ( Bechstein, S; Domschke, C; Golatta, M; Heil, J; Marme, F; Mayer, C; Rom, J; Schneeweiss, A; Schuetz, F; Smetanay, K; Sohn, C; Thum, J; Wallwiener, M; Windemuth-Kieselbach, C, 2014) |
| "In tamoxifen-treated breast cancer patients the occurrence of hot flashes may be associated with effective estrogen receptor antagonism dependent on genetic variations of metabolic enzymes and the estrogen receptor." | ( Berns, EM; Dezentjé, VO; Gelderblom, H; Guchelaar, HJ; Kranenbarg, EM; Nortier, JW; Putter, H; Seynaeve, C; Van de Velde, CJ; Van der Straaten, T; Van Schaik, RH; Vletter-Bogaartz, JM; Wessels, JA, 2014) |
| "Treatment of MDA-MB-231 breast cancer cells with various concentrations of AgNPs (1-10 μg/mL) for 24 hours revealed that AgNPs could inhibit cell viability and induce membrane leakage in a dose-dependent manner." | ( Abd Malek, SN; Gurunathan, S; John, PA; Raman, J; Vikineswary, S, 2013) |
| "Patients with metastatic breast cancer who were not currently receiving cytotoxic chemotherapy were eligible." | ( Eby, CS; Johnson, F; Lammers, PE; Naughton, MJ; Pluard, TJ; Roop, RP; Schneider, JG; Van Poznak, C; Weilbaecher, KN, 2013) |
| "Forty women with breast cancer (mean age, 51 ± 8 years), scheduled to be treated with epirubicin-based chemotherapy, were prospectively enrolled." | ( Enescu, OA; Florescu, M; Jinga, D; Magda, LS; Vinereanu, D, 2014) |
| "Postmenopausal women with advanced breast cancer recurring/progressing on or after initial (adjuvant or first-line) endocrine therapy may be treated multiple times with one of several endocrine or combinatorial targeted treatment options before initiating chemotherapy." | ( Bachelot, T; Duffy, S; Fleetwood, K; Glanville, J; Jerusalem, G; McCool, R; Varley, D; Zhang, J, 2014) |
| "Patients with breast cancer completed a neuropsychological battery, self-reported memory questionnaire, and geriatric assessment before initiation of AI therapy and again 6 months later." | ( Chuang, C; Feng, T; Geist, CL; Hansen, K; Hurria, A; Katheria, V; Luu, T; Mortimer, J; Patel, SK; Ramani, R; Silverman, DH; Somlo, G, 2014) |
| "A total of 23 metastatic breast cancer patients with skin metastasis who were treated with eribulin were analyzed." | ( Addamo, G; Barbieri, E; Borgonovo, K; Botta, M; Ciccarese, M; Cretella, E; Dazzani, MC; Di Maio, M; Farina, G; Gamucci, T; Girelli, S; La Verde, N; Mentuccia, L; Moretti, A; Pavese, I; Pellegrino, A; Piva, S; Rispoli, AI; Saladino, T; Salesi, N; Traverso, ES; Varese, P; Zuradelli, M, 2013) |
| "In Notch-addicted breast cancer cells, BafA1 treatment reduces growth in cells expressing membrane tethered forms of Notch, while sparing cells expressing cytoplasmic forms." | ( Deflorian, G; Duchi, S; Kobia, F; Vaccari, T, 2014) |
| "After breast cancer treatments, lymph obstruction at the axilla leads to abnormal lymph circulation, resulting in lymph pump dysfunction." | ( Iida, T; Kikuchi, K; Koshima, I; Narushima, M; Todokoro, T; Yamamoto, N; Yamamoto, T; Yoshimatsu, H, 2014) |
| "In patients with breast cancer treated with anthracycline plus cyclophosphamide chemotherapy and receiving the same antiemetic prophylaxis for acute emesis, dexamethasone was not superior to aprepitant but instead had similar efficacy and toxicity in preventing delayed emesis." | ( Ballatori, E; Del Favero, A; Roila, F; Ruggeri, B; Tonato, M, 2014) |
| "Obese patients treated for early breast cancer more frequently required a reduction in docetaxel RDI." | ( Chaker, M; Clatot, F; Gouérant, S; Lauridant, G; Leheurteur, M; Modzelewski, R; Rigal, O; Veyret, C, 2013) |
| "Eugenol exhibits anti-breast cancer properties both in vitro and in vivo, indicating that it could be used to consolidate the adjuvant treatment of breast cancer through targeting the E2F1/survivin pathway, especially for the less responsive triple-negative subtype of the disease." | ( Aboussekhra, A; Al-Sharif, I; Remmal, A, 2013) |
| "Interestingly, silencing of PTEN in breast cancer cells reversed the phenomenon of Wnt/TCF signaling cascade inhibition after BNFA-D treatment." | ( Choudhuri, T; Das, D; Kundu, CN; Mohapatra, P; Preet, R; Satapathy, SR; Siddharth, S, 2013) |
| "Short-term memory (STM) decline in breast cancer patients resulting from chemotherapy was evaluated by means of blood biomarkers, a questionnaire, and a computerized STM test." | ( Chen, J; Chow, LW; Liu, Q; Loo, WT; Ng, EL; Wang, M; Yip, MC, 2013) |
| "We used breast cancer cell lines expressing wild-type and mutant PRs, cells sensitive and resistant to endocrine therapy, a variety of molecular and cellular biology approaches, in vitro proliferation studies and preclinical models to explore PR regulation of cyclin D1 expression, tumor growth, and response to endocrine therapy." | ( Béguelin, W; Charreau, EH; Díaz Flaqué, MC; Elizalde, PV; Galigniana, NM; Guzmán, P; Maronna, E; Mercogliano, M; Muñoz, S; Pineda, V; Proietti, CJ; Rivas, MA; Roa, JC; Russo, R; Schillaci, R; Tkach, M; Vicario, R; Yankilevich, P, 2013) |
| "Our studies in a cohort of human breast tumors identified PR and AP-1 nuclear interaction as a marker of good prognosis and better OS in patients treated with tamoxifen (Tam), an anti-estrogen receptor therapy." | ( Béguelin, W; Charreau, EH; Díaz Flaqué, MC; Elizalde, PV; Galigniana, NM; Guzmán, P; Maronna, E; Mercogliano, M; Muñoz, S; Pineda, V; Proietti, CJ; Rivas, MA; Roa, JC; Russo, R; Schillaci, R; Tkach, M; Vicario, R; Yankilevich, P, 2013) |
| "Endocrine therapy for breast cancer has been the cornerstone of treatment for over a century since the discovery of the regressive effect of oophorectomy on 'cancer of the mamma' in 1896 by Beatson." | ( Harris, LN; Williams, N, 2014) |
| "Similarly, breast cancer patients had increased levels of plasma MUC-1(+) TMPs following chemotherapy." | ( Aharon, A; Alishekevitz, D; Brenner, B; Bril, R; Fremder, E; Gingis-Velitski, S; Loven, D; Miller, V; Munster, M; Scherer, SJ; Shaked, Y; Voloshin, T, 2014) |
| "Low estrogen receptor (ER) levels in breast tumors are associated with poorer response to antiestrogen therapy." | ( Miller, TW, 2014) |
| "Here, we used ten breast cancer cell lines to compare NVP-BEZ235 sensitivity and in the context of androgen receptor (AR) activation during NVP-BEZ235 treatment." | ( Altemus, J; Eng, C; He, X; Romigh, T; Wang, Y; Yu, Q, 2014) |
| "Human breast cancer MCF-7, T47D, and MDA-MB-435 and colorectal cancer HCT116 cells were treated with tamoxifen." | ( Bae, YS; Kang, BS; Lee, YH, 2014) |
| "Sixty breast cancer patients were treated with DOC." | ( Abe, H; Kawai, Y; Kubota, Y; Mori, T; Tani, T; Tomida, K; Umeda, T, 2013) |
| "Human breast cancer cell lines, MCF-7 and MDA-MB-231, were treated with tamoxifen and/or tranilast alone or in combination and percentage cell survival and proliferative activity were evaluated using LDH leakage and MTT assays." | ( Bidmeshkipour, A; Darakhshan, S; Ghanbari, A; Khazaei, M; Rabzia, A, 2013) |
| "Administration of plumbagin to breast cancer bearing mice delayed the tumor growth by 2-3 weeks and reduced the tumor volume by 44%-74%." | ( Du, L; Fan, QM; Li, HW; Tang, TT; Wang, TY; Xu, JK; Yan, W; Zhai, ZJ, 2014) |
| "Nurses can inform women with breast cancer about the expected changes in body weight after chemotherapy to reduce their uncertainty." | ( Chen, ML; Jeng, C; Lin, YC; Liu, LN; Miaskowski, C; Wang, JS; Wen, FH, 2014) |
| "Female patients with operable breast cancer that was clinically T2 (≥3 cm) or T3-4, N0-1, M0 were enrolled to receive 24 weeks of neoadjuvant chemotherapy using epirubicin and cyclophosphamide followed by docetaxel and gemcitabine, plus trastuzumab if HER2-positive." | ( Abdi, E; Badger, HD; Boyle, F; Bull, J; Chirgwin, J; Forbes, JF; Francis, PA; Gebski, V; Kannourakis, G; Leong, E; Lindsay, DF; McCarthy, N; Reaby, L; Simpson, A; Veillard, AS; Wilcken, N; Zannino, D; Zdenkowski, N, 2014) |
| "We report a case of primary advanced breast cancer that was locally controlled by treatment with Mohs paste." | ( Bizen, A; Inada, H; Jin, M; Kobayashi, I; Kurita, A; Mineta, S; Miyauchi, K; Mizutani, T; Nakakuma, T; Oshima, H; Ueno, S; Yamamoto, K, 2013) |
| "Choice of therapy for breast cancer relies on human epidermal growth factor receptor-2 (HER2) and estrogen receptor α (ER) status." | ( Andrighetto, S; Chen, B; Dell'orto, P; Dueck, AC; Gelber, RD; Jackisch, C; Jenkins, RB; McCullough, AE; Perez, EA; Piccart-Gebhart, MJ; Reinholz, MM; Russo, L; Untch, M; Viale, G, 2014) |
| "In a new independent cohort of 191 breast cancer patients treated with adjuvant 5-fluorouracil, epirubicin, and cyclophosphamide, a positive assay result predicted 5-year relapse-free survival with a hazard ratio of 0." | ( Boyle, D; Bylesjo, M; Couch, FJ; Davison, TS; Deharo, S; Hill, LA; Irwin, G; James, CR; James, J; Johnston, PG; Keating, KE; Kennedy, RD; Kerr, P; Lindor, NM; McDyer, FA; Mullan, PB; Mulligan, JM; O'Brien, E; Paul Harkin, D; Proutski, V; Quinn, JE; Raji, OY; Salto-Tellez, M; Walker, SM, 2014) |
| "In patients with triple-negative breast cancer, pathologic complete response may be prognostic and the appropriate use of neoadjuvant chemotherapy is crucial to achieve improved survival." | ( Dent, R; Dent, S; Sulpher, J, 2014) |
| "106 patients treated for breast cancer at Southampton University Hospital with PHT without surgery were identified (Mean age 84." | ( Cutress, RI; Layfield, DM; Mohamud, M; Odofin, O; Royle, GT; Walsh, C, 2015) |
| "Forty patients who were breast cancer survivors and were suffering from hot flushes to the degree that they seeked for treatment were included in the study and randomly divided into two groups: group I: (N = 20) stellate ganglion block was done for the patients of this group; and group II: (N = 20) in this group, the patients received 75 mg pregabalin twice daily." | ( Othman, AH; Zaky, AH, 2014) |
| "In the Western world, over 80% of breast cancers are hormone-receptor positive for which endocrine therapy is administered." | ( Lintermans, A; Neven, P; Paridaens, R; Van Asten, K; Wildiers, H, 2014) |
| "Although an improved understanding of breast cancer pathogenesis and the role of HER2 signaling has resulted in significant survival improvements in the past 20 years, resistance to HER2-targeted therapy remains a concern." | ( Eroglu, Z; Somlo, G; Tagawa, T, 2014) |
| "In metastatic breast cancer patients with previous exposure to endocrine therapy, the addition of a mammalian target of rapamycine (mTOR) inhibitor has been shown to be beneficial." | ( Beelen, K; Berns, EM; Koornstra, RH; Linn, SC; Muris, JJ; Opdam, M; Severson, TM; van Diest, PJ; Vermorken, JB; Vincent, AD; Wesseling, J, 2014) |
| "In systemically untreated breast cancer patients, p-p70S6K was associated with a decreased risk for recurrence." | ( Beelen, K; Berns, EM; Koornstra, RH; Linn, SC; Muris, JJ; Opdam, M; Severson, TM; van Diest, PJ; Vermorken, JB; Vincent, AD; Wesseling, J, 2014) |
| "Doxorubicin (Dox) is widely used for breast cancer treatment but causes serious side effects including cardiotoxicity that may adversely impact patient lifespan even if treatment is successful." | ( Gmeiner, WH; Horita, DA; Lively, MO; Salsbury, FR; Stuart, CH; Thomas, MJ, 2014) |
| "AR to ER ratio may influence breast cancer response to traditional endocrine therapy." | ( Alfaro, IE; Bernales, S; Cittelly, DM; Cochrane, DR; D'Amato, NC; Edgerton, SM; Elias, AD; Gómez, F; Guerrero, J; Howe, EN; Jacobsen, BM; Jean, A; Jedlicka, P; McCullagh, E; Medicherla, S; Protter, AA; Richer, JK; Spoelstra, NS; Thor, AD; Torkko, KC, 2014) |
| "Patients with a confirmed breast cancer diagnosis who started therapy (tamoxifen or aromatase inhibitors) between January 2001 and December 2011 were selected from the representative IMS Disease Analyzer database and analyzed with regard to their compliance." | ( Hadji, P; Jockwig, A; Jockwig, B; Kostev, K; Waehlert, L, 2014) |
| "The human breast cancer cell lines MCF-7 (p53 wildtype) and MDA-MB-231 (p53 mutant) were treated with DCQ under normoxia or hypoxia." | ( El-Sabban, M; El-Sitt, S; Gali-Muhtasib, H; Ghattass, K; Haddadin, MJ; Rayes, S; Zibara, K, 2014) |
| "Circulating CD14(+)CD16(+) of breast cancer patients and induced CD14(+)CD16(+) DCs were identified as tDCs by treating CD14(+) monocytes with galectin-1 and cancer cell-derived medium combined with IL-4 and GM-CSF." | ( Cheng, DE; Hou, MF; Hsu, YL; Huang, MS; Hung, JY; Kuo, PL; Lu, CY; Tsai, EM, 2014) |
| "For the breast cancer patients with a high galectin-1 expression, blebbistatin and genistein show potential in immune modulation and cancer immunotherapy." | ( Cheng, DE; Hou, MF; Hsu, YL; Huang, MS; Hung, JY; Kuo, PL; Lu, CY; Tsai, EM, 2014) |
| "Further, combination treatment of breast cancer cells with both onapristone and IGF1R tyrosine kinase inhibitor AEW541 was more effective than either agent alone." | ( D'Assoro, AB; Daniel, AR; Gaviglio, AL; Knutson, TP; Lange, CA; Ostrander, JH; Peng, Y; Raj, GV; Ravindranathan, P; Yee, D, 2015) |
| "For patients with progressive breast cancer brain metastasis (BCBM) after whole brain radiotherapy (WBRT), few options exist." | ( Ahluwalia, MS; Baar, J; Conlin, A; Eichler, A; Elson, P; Murphy, C; Peereboom, DM; Seidman, AD; Van Poznak, C, 2014) |
| "For patients with breast cancer, obtaining tissue samples from liver lesion becomes more and more important for both differential diagnosis and subsequent treatment." | ( Fan, M; Hu, S; Hu, X; Li, T; Shui, R; Zhang, Y, 2014) |
| "Treatment of MCF-7 and MDA-MB-231 breast cancer cells with 20 µM EGCG and 10 µg/mL GTP for 72 h significantly induces TIMP-3 mRNA and protein levels." | ( Deb, G; Gupta, S; Limaye, AM; Thakur, VS, 2015) |
| "(a) ERα(+) breast cancer cells dysfunctional for TP53 which proliferate irrespective of low estrogen and chemical MEK inhibition are likely to increase metabolic consumption becoming increasingly susceptible to 3-BrPA; (b) targeting the pyruvate pathway may improve response to endocrine therapy in ERα(+) breast cancer with p53 dysfunction." | ( Rieber, M; Strasberg-Rieber, M, 2014) |
| "HER2(+) breast cancer is currently treated with chemotherapy plus anti-HER2 inhibitors." | ( Al-Awar, R; Aman, A; Chung, PE; Deng, T; Egan, SE; Jiang, Z; Joseph, B; Ketela, T; Liu, JC; Moffat, J; Rottapel, R; Schachter, NF; Uehling, D; Zacksenhaus, E, 2014) |
| "Up to 55% of patients with HER2+ breast cancer will develop brain metastases requiring some form of radiation therapy." | ( Borges, VF; Carlson, JA; Diamond, JR; Elias, A; Kabos, P; Kavanagh, B; Nooruddin, Z; Rusthoven, C, 2014) |
| "As a result, more premenopausal breast cancer patients will be continuing adjuvant endocrine therapy through the menopause transition." | ( Chlebowski, RT; Pan, K, 2014) |
| "The advancement of breast cancer therapy is limited by the biologic behaviors of cancer cells, such as metastasis and recurrence." | ( Chen, X; Kang, F; Li, L; Ma, W; Ma, X; Shao, Y; Wang, J; Yang, W, 2014) |
| "Seventy-two patients with breast cancer who failed chemotherapy were treated at the Tumor Hospital of Harbin Medical University from January 2001 to January 2012." | ( Guo, RT; Li, XL; Li, Y; Luan, JW; Nie, D; Wu, J; You, QS; Zhang, LP, 2013) |
| "The treatment of patients with invasive breast cancer remains a major issue because of the acquisition of drug resistance to conventional chemotherapy." | ( Borges, S; Döppler, HR; Storz, P, 2014) |
| "Some cases of breast cancer are composed of clones of hormonal-independent growing cells, which do not respond to therapy." | ( Azzam, N; Fares, B; Fares, F; Larsen, S; Lindkaer-Jensen, S, 2014) |
| "Since more than 75% of breast cancers overexpress estrogen receptors (ER), endocrine therapy targeting ER has significantly improved the survival rate." | ( Ahn, G; Amagai, Y; Ishizaka, S; Jang, H; Jensen-Jarolim, E; Jung, K; Matsuda, A; Matsuda, H; Nishikawa, S; Oida, K; Tanaka, A; Xia, Y, 2014) |
| "We treated MCF-7 and MDA-MB-231 human breast cancer cells with genistein in vitro." | ( Bai, Q; Chang, H; Mi, MT; Xie, Q; Yi, L; Zhang, QY; Zhou, Y; Zhu, JD; Zou, LY, 2014) |
| "Multidrug-resistant breast cancers have limited and ineffective clinical treatment options." | ( Chen, Y; Fang, DL; Lei, Y; Li, HL; Ren, K; Song, XR; Xu, B; Yang, Y; Zhang, JK; Zheng, XL, 2014) |
| "Approximately 70% of breast cancers are estrogen receptor (ER) positive, and interfering with estrogen action with tamoxifen has been the treatment of choice for ER-positive breast cancer patients." | ( Ghaderian, SM; Mirfakhraie, R; Rezvani, H; Tabarestani, S, 2014) |
| "Most breast cancers are estrogen receptor-positive and treated with antiestrogens, but aberrant signaling networks can induce drug resistance." | ( Pasquale, EB; Riedl, SJ; Wallez, Y, 2014) |
| "Tamoxifen therapy reduces the risk of breast cancer but increases the risk of serious adverse events including endometrial cancer and thromboembolic events." | ( Allman, R; Dinh, TA; Green, LE; Hinds, DA; Walser, BL, 2014) |
| "Triple-negative breast cancer (TNBC) accounts for 20% of breast cancer in women and lacks an effective targeted therapy." | ( Feigin, ME; Hammell, MC; Muthuswamy, SK; Xue, B, 2014) |
| "Eligible patients had metastatic breast cancer treated with a NSAI with at least 6-month progression-free survival (PFS), or relapse after ≥1 year on adjuvant NSAI." | ( Bines, J; Branco, LGP; Camacho, PG; Castro, TM; Costa, MEF; Dienstmann, R; Obadia, RM; Quintella, DC; Soares, FA, 2014) |
| "Previously, we demonstrated in breast cancer cells that a 3-day treatment with 10 μM 8-Cl-Ado causes a 90% loss of clonogenic survival." | ( Le, XF; Mao, W; Shentu, S; Stellrecht, CM; Vangapandu, HV, 2014) |
| "Treatment of breast cancer with aromatase inhibitors is associated with damage to bones." | ( Badovinac-Crnjevic, T; Chalchal, H; Chapman, JA; Cheung, AM; Elliott, CR; Goss, PE; Hershman, DL; Ingle, JN; Khosla, S; Linden, HM; Muss, HB; Pritchard, KI; Rowland, K; Scher, J; Shepherd, LE; St Louis, J; Stearns, V, 2014) |
| "However, eIF-5A2 overexpression in breast cancer and its effect on chemotherapy are unknown." | ( Chen, W; Du, F; Fu, P; Liu, Y; Lv, K; Yao, M, 2015) |
| "In women with breast cancer, chemotherapy-induced alopecia is a highly feared but common side-effect of antineoplastic treatment." | ( Bangemann, N; Blume-Peytavi, U; Garcia Bartels, N; Hillmann, K; Kanti, V; Kleine-Tebbe, A; Lindner, J; Nuwayhid, R; Stroux, A, 2014) |
| "Female patients with breast cancer were included (n = 34), who were receiving chemotherapy (group C, n = 17) or tamoxifen (group T, n = 17) after surgery." | ( Bangemann, N; Blume-Peytavi, U; Garcia Bartels, N; Hillmann, K; Kanti, V; Kleine-Tebbe, A; Lindner, J; Nuwayhid, R; Stroux, A, 2014) |
| "We exposed MCF-7 breast cancer cells pretreated with doxorubicin for 10 days to mangiferin (10, 25 or 50 μM) for 96 hours." | ( Louisa, M; Soediro, TM; Suyatna, FD, 2014) |
| "Human breast cancer cells were treated with different concentrations of D-pinitol and cytotoxicity was measured by MTT and LDH assays." | ( Balasubramanian, MP; Haribabu, L; Nandakumar, N; Nishigaki, I; Rajendran, P; Rengarajan, T, 2014) |
| "In MDA-231 breast cancer cells that stably over express RKIP, IL-6 treatment blocked STAT3 phosphorylation and transcriptional activation." | ( Al-Mulla, F; Bonavida, B; Brilliant, K; Chatterjee, D; Chin, E; Cross-Knorr, S; Duan, M; LaValle, T; Moen, EL; Yeung, KC; Yousuf, S, 2014) |
| "Treatment of MCF7 breast cancer cells with tamoxifen increased MKP-2, but not MKP-1, protein levels." | ( Haagenson, KK; Shekhar, MP; Wu, GS; Xu, Z; Zhang, JW, 2014) |
| "In a series of ER+, tamoxifen-treated breast cancer patients, we show a highly significant (P=0." | ( Ahmad, AS; Chelala, C; Gillett, C; Hurst, HC; Jones, JL; Speirs, V; Wong, PP; Yeoh, CC, 2014) |
| "The role of estrogens in breast cancer (BC) development is widely accepted, leading to the development of selective estrogen receptor modulators and aromatase inhibitors for BC treatment and prevention." | ( Bauer, BA; Cha, SS; Hoskin, TL; Loehrer, LL; Olson, JE; Wahner-Roedler, DL, 2014) |
| "Following CEE treatment, breast cancer risk was associated with higher concentrations of baseline serum estrogens, and with lower concentrations of sex hormone binding globulin." | ( Anderson, GL; Beresford, SA; Chlebowski, RT; Gass, M; Kuller, LH; Lane, DS; Lavasani, S; Manson, JE; Patterson, R; Prentice, RL; Rohan, TE; Rossouw, JE; Zhao, S, 2014) |
| "We evaluated fatal breast cancer risk in relation to recency and duration of use of CHT and unopposed estrogen hormone therapy (EHT)." | ( Barlow, WE; Cook, LS; Li, CI; Newcomb, PA; Pocobelli, G; Weiss, NS, 2014) |
| "Approximately 30% of breast tumors do not express the estrogen receptor (ER) α, which is necessary for endocrine therapy approaches." | ( Avila, E; Barrera, D; Camacho, J; Díaz, L; Esparza-López, J; García-Becerra, R; García-Quiroz, J; Halhali, A; Ibarra-Sánchez, MJ; Larrea, F; Medina-Franco, H; Ordaz-Rosado, D; Santos-Martínez, N, 2014) |
| "Cultured cells derived from ERα-negative breast tumors and an ERα-negative breast cancer cell line (SUM-229PE) were treated with calcitriol and ERα expression was assessed by real time PCR and western blots." | ( Avila, E; Barrera, D; Camacho, J; Díaz, L; Esparza-López, J; García-Becerra, R; García-Quiroz, J; Halhali, A; Ibarra-Sánchez, MJ; Larrea, F; Medina-Franco, H; Ordaz-Rosado, D; Santos-Martínez, N, 2014) |
| "Trastuzumab is a standard treatment in breast cancer overexpressing Her2 oncogene." | ( Chargari, C; Libert, N; Magne, N; Meillan, N; Tanz, R; Vedrine, L, 2014) |
| "Clinical trials in early breast cancer have suggested that benefits of adjuvant bone-targeted treatments are restricted to women with established menopause." | ( Brown, HK; Croucher, PI; Eaton, CL; Fowles, CA; Holen, I; Ottewell, PD; Reeves, KJ; Wang, N, 2014) |
| "The therapeutic resistance of breast cancer has motivated the development of new agents for prevention and treatment." | ( Cheng, TL; Ho, WY; Huang, PJ; Hung, JH; Lee, KH; Wang, CC; Wu, SJ, 2014) |
| "The potential causes of breast cancer are genetic predisposition, long -term hormonal replacement therapy, alcohol, environmental pollution, and possibly modern lifestyle." | ( Gajos, G; Konduracka, E; Krzemieniecki, K, 2014) |
| "In YC-1-treated breast cancer cells and tumour specimens from YC-1-treated MDA-MB-468 xenografts, EZH2 expression was analysed by Western blotting." | ( Chang, LC; Chou, RH; Hsieh, MT; Huang, LJ; Hung, HY; Kuo, SC; Lee, FY; Lin, HY; Teng, CM; Tsai, MT; Yu, YL, 2014) |
| "We investigated the effect of breast cancer adjuvant treatment on vitamin D status, as measured by serum hydroxyvitamin D (25OHD)." | ( Ahn, SH; Kim, HJ; Kim, SB; Koh, BS; Lee, JW; Son, BH; Yu, JH, 2014) |
| "A total of 111 patients with metastatic breast cancer treated with weekly docetaxel or ixabepilone without bevacizumab (cohort A) and 100 treated with weekly paclitaxel and bevacizumab (cohort B) were studied." | ( Charalambous, E; Dimopoulos, MA; Dionysopoulos, D; Fountzilas, G; Kotoula, V; Koutras, A; Kouvatseas, G; Papandreou, CN; Papazisis, K; Pectasides, D; Pentheroudakis, G; Samantas, E; Zagouri, F, 2014) |
| "In patients with invasive breast carcinoma, estrogen receptor α (ERα) and progesterone receptor (PR) expressions need to be assessed in core-needle biopsies (CNBs) before the start of neoadjuvant systemic treatment." | ( Barentsz, MW; Kalkman, S; van der Wall, E; van Diest, PJ; Verkooijen, HM; Witkamp, AJ, 2014) |
| "Treatment of breast cancer T47D cells with AZD8055 induced activation of AKT and phosphatidylinositol 3-kinase (PI3K), which was accompanied with increase in expression of multiple upstream proteins including EGFR, HER2, HER3 and IRS-1." | ( Chen, SM; Chen, Y; Ding, J; Guo, CL; Meng, LH; Shen, YY; Shi, JJ; Su, Y; Xu, YC, 2014) |
| "The overall survival (OS), breast cancer-specific survival (BCSS), and relapse-free survival (RFS), assessed by using Kaplan-Meier survival analysis and multivariate Cox regression analysis, were evaluated according to the adjuvant treatments and the rs4880 and rs13181 genotypes." | ( Hirvonen, A; Kataja, V; Kosma, VM; Mannermaa, A; Soini, Y; Tengström, M, 2014) |
| "Most patients with advanced breast cancer experience resistance to endocrine treatment and eventual disease progression." | ( Fan, Y; Gong, DD; Man, CF; Xu, J, 2014) |
| "Sleep disturbances are common among breast cancer survivors, even after completion of active cancer treatment." | ( Chen, WY; Gantman, K; Giobbie-Hurder, A; Parker, LM; Savoie, J; Scheib, R; Schernhammer, ES, 2014) |
| "Seven patients with invasive breast cancer were imaged with HR-DWI before and early during treatment." | ( Hylton, NM; Joe, BN; Jones, EF; Kornak, J; McLaughlin, RL; Newitt, DC; Proctor, E; Wilmes, LJ; Wisner, DJ, 2014) |
| "After the breast cancer cell line with a low expression of LAMP2A was treated with three different concentrations of paclitaxel (1, 10, 100 nmol/L), MTT assay was performed to observe the difference in the proliferation ability between the control group and the low LAMP2A expression groups." | ( Chen, A; Chen, S; Han, Q; Hu, C; Li, S; Yang, M; Zhang, Z, 2014) |
| "However, in breast cancer data from microarray analysis indicated a predictive value of high mRNA expression levels of STAT1 and STAT1 target genes belonging to the interferon-related signature for a poor response to therapy." | ( Charoentong, P; Doppler, W; Fiegl, H; Hackl, H; Müller-Holzner, E; Obrist, P; Peyrat, JP; Revillion, F; Spilka, R; Trajanoski, Z; Tymoszuk, P, 2014) |
| "Twenty-three advanced breast cancer patients with progressive bone-dominant disease, and no longer candidates for further endocrine therapy, were to receive radium-223 (50 kBq/kg IV) every 4 weeks for 4 cycles." | ( Aksnes, AK; Coleman, R; Flamen, P; Garcia, C; Jerusalem, G; Naume, B; Piccart, M; Thuresson, M; Vobecky, N, 2014) |
| "A total of 85 women treated for breast cancer 3 to 18 months previously were randomly allocated to a 6-month exercise and hypocaloric healthy eating program plus usual care or usual care alone (control group)." | ( Coleman, RE; Crank, H; Daley, AJ; Mutrie, N; Powers, HJ; Saxton, JM; Scott, EJ; Woodroofe, M, 2014) |
| "Twenty-nine breast cancer patients with bone lesions (42 lesions in total) underwent [18F]FDG PET-CT studies after surgical resection of breast cancer primitives, and before (PET-II) chemotherapy and hormone treatment." | ( Gallivanone, F; Gastiglioni, I; Gilardi, MC; Messa, C; Stefano, A, 2014) |
| "Nude mice implanted with MDA-MB-231 breast cancer cells were studied after chronic treatment with doxorubicin, doxorubicin/GGA, GGA, or saline." | ( Bartock, R; Bedja, D; Gabrielson, KL; Guo, X; Hsieh, A; Moens, A; Orita, H; Pin, S; Raman, V; Sysa-Shah, P; Tsao, A; Wolin, MS; Xu, Y, 2014) |
| "Patients with breast cancer who received 4 or more cycles of DTX with or without trastuzumab or DTX and cyclophosphamide(TC)with or without trastuzumab as pre- or post-operative chemotherapy in our hospital between January 2010 and May 2012 were analyzed in this retrospective study." | ( Hirohata, K; Kato, A; Komori, K; Makihara, K; Masuda, N; Mizutani, M; Ueno, H; Yamamura, J; Yamauchi, K; Yasojima, H, 2014) |
| "We report the cases of 2 breast cancer patients who received capecitabine(CAP)and concomitant anticonvulsant therapy with either phenytoin(PHT)or valproate(VPA)for brain metastasis." | ( Ibayashi, Y; Jotoku, H; Takahashi, M; Takasaki, M; Tanaka, H; Watanabe, K, 2014) |
| "Current treatments for breast cancer, a common malignancy in human females, are less than satisfactory because of high rates of metastasis." | ( Jiang, F; Li, Y; Li, Z; Mu, J; Ning, S; Si, L; Wang, X; Ye, X, 2014) |
| "A case of a 50 years-old breast cancer patient treated with weekly paclitaxel and BIBF 1120 is reported herein." | ( Burbujo, J; Calderón-Komaromy, A; Córdoba, S; de Pablo, NP; Freites-Martínez, A; Martinez-Sánchez, D, 2014) |
| "Women with locally advanced breast cancer were randomly assigned to receive four cycles of anthracycline-based chemotherapy, followed by four cycles of taxane therapy (Arm A), or the same regimen in reverse order (Arm B)." | ( Alamgeer, M; Fox, J; Ganju, V; Harris, M; Hart, S; Kumar, B; Prodanovic, Z; Schneider-Kolsky, ME; Stuckey, J; Watkins, DN; White, M, 2014) |
| "91 women with early-stage breast cancer who received endocrine therapy." | ( Bender, CM; Brufsky, AM; Casillo, FE; Cohen, SM; Dailey, MM; Donovan, HS; Dunbar-Jacob, J; Gentry, AL; Jankowitz, RC; Rosenzweig, MQ; Sereika, SM; Sherwood, PR, 2014) |
| "Women with breast cancer may be at risk for nonadherence to prescribed endocrine therapy if they experience depression or anxiety and symptoms prior to initiating therapy." | ( Bender, CM; Brufsky, AM; Casillo, FE; Cohen, SM; Dailey, MM; Donovan, HS; Dunbar-Jacob, J; Gentry, AL; Jankowitz, RC; Rosenzweig, MQ; Sereika, SM; Sherwood, PR, 2014) |
| "She was previously diagnosed with left breast cancer 2 months ago and completed a course of chemotherapy 1 week prior to presentation." | ( Al-Ani, A; Bolln, C; Hodnett, R; Ramsingh, J, 2014) |
| "Here, treatment of human breast cancer cells with proton pump inhibitor (PPI) lansoprazole (LPZ) induces cell apoptosis in a dose-dependent manner." | ( Li, SJ; Wang, Y; Zhang, S, 2014) |
| "Symptom clusters in breast cancer survivors that are present before the initiation of adjuvant AI therapy may have a negative impact on a patient's persistence with therapy." | ( Carpenter, J; Clauw, DJ; Flockhart, DA; Harte, SE; Hayes, DF; Henry, NL; Kidwell, KM; Stearns, V; Storniolo, AM; Williams, DA, 2014) |
| "184 patients with early breast cancer treated between Jan 2008 and Dec 2010 were recruited to complete a questionnaire." | ( Jamaris, S; Ng, CH; See, MH; Shaari, NE; Taib, NA; Tan, GH; Teh, YC; Yip, CH, 2014) |
| "Whether metformin therapy affects breast cancer risk in Asian patients with type 2 diabetes mellitus (T2DM) has not been investigated." | ( Tseng, CH, 2014) |
| "Postmenopausal early breast cancer patients scheduled to start AI or tamoxifen therapy were recruited." | ( Christiaens, MR; Laenen, A; Leunen, K; Lintermans, A; Neven, P; Paridaens, R; Smeets, A; Van Asten, K; Van Limbergen, E; Vanderschueren, D; Verhaeghe, J; Weltens, C; Wildiers, H, 2014) |
| "We showed recently that mammary cancer development in a transgenic mouse model (mouse mammary tumor virus-neu; MMTV-neu) was inhibited significantly upon treatment with withaferin A (WA), a steroidal lactone derived from a medicinal plant." | ( Kim, SH; Singh, SV, 2014) |
| "The existing EGFR treatments in breast cancer have shown limited benefit." | ( Eroles, P; Lluch, A; Perez-Fidalgo, JA, 2014) |
| "Twenty women with primary breast cancer had a baseline FLT-PET-CT scan that was repeated before the second cycle of chemotherapy." | ( Ah-See, ML; Amin, V; Beresford, M; Detre, S; Dowsett, M; Li, SP; Makris, A; Miles, D; Sanghera, B; Sonoda, L; Wong, WL; Woolf, DK, 2014) |
| "Although the development of fatigue in breast cancer patients seems largely impacted by cancer therapy, for the long-term persistence of fatigue, preexisting medical or psychological conditions related to depression or pain and lifestyle factors appear to be more relevant." | ( Chang-Claude, J; Flesch-Janys, D; Heinz, J; Schmidt, ME; Seibold, P; Steindorf, K; Vrieling, A, 2015) |
| "Eighty female, chemotherapy-naïve breast cancer patients (median age 49, range 24-67 years) scheduled for four or five courses of adjuvant 3 weekly doxorubicin plus cyclophosphamide (AC) chemotherapy, were randomly assigned to receive 80 mg PC-SOD (human recombinant SOD bound to lecithin) or placebo, administered intravenously (i." | ( Bax, JJ; Broeyer, FJ; Bruning, T; Burggraaf, J; Cohen, AF; de Jongh, F; de Kam, ML; Mituzhima, Y; Osanto, S; Ritsema van Eck, HJ; Suzuki, J; Tanis, BC; van Slooten, H, 2014) |
| "Thirty-seven breast cancer patients following completion of chemotherapy (median 16 months) and 14 controls were studied." | ( Crowgey, T; Herndon, JE; Hornsby, WE; Jones, LW; Lane, A; McSherry, F; Peters, KB; West, MJ; Williams, CL, 2014) |
| "Using a Tam-R breast cancer xenograft mouse model, we demonstrated in vivo anti-breast cancer activity by JQ1 and a strong long-lasting effect of combination therapy with JQ1 and the ER degrader fulvestrant." | ( Bradner, J; Coarfa, C; Creighton, CJ; Feng, Q; Fu, X; He, B; Hilsenbeck, SG; Lanz, R; Mitsiades, CS; Mitsiades, N; Nardone, A; O'Malley, BW; Osborne, CK; Schiff, R; Shea, MJ; Song, Y; Wang, L; Zhang, Z, 2014) |
| "Basal-like breast cancer (BLBC) remains a great challenge because of its clinically aggressive nature and lack of effective targeted therapy." | ( Amici, A; Andreani, C; Bartolacci, C; Belletti, B; Gambini, V; Garulli, C; Giangrossi, M; Iezzi, M; Kalogris, C; Lucci, C; Marchini, C; Pietrella, L; Pucciarelli, S; Tilio, M; Zabaleta, ME, 2014) |
| "Eighty-six patients diagnosed with breast cancer N+ and treated with axillary lymphadenectomy received a TachoSil patch in the axillary wound." | ( Álvarez-Benito, M; Bascuñana-Estudillo, G; Briceño-Delgado, J; Ciria-Bru, R; Díaz-Jiménez, N; Gómez-Luque, I; Navarro-Rodríguez, E; Rioja-Torres, P; Rufián-Peña, S; Ruiz-Rabelo, JF, 2014) |
| "She also had advanced breast cancer when the combination therapy was initiated." | ( Furukawa, Y; Ikeda, T; Ishida, C; Kato-Motozaki, Y; Komai, K; Nozaki, I; Tagami, A; Takahashi, K, 2014) |
| "The molecular determinants of breast cancer resistance to first-line anthracycline-containing chemotherapy are unknown." | ( Altieri, DC; Bosari, S; Faversani, A; Lopergolo, A; Moro, GP; Rivadeneira, D; Schultz, DC; Tosi, D; Vaira, V, 2014) |
| "These data suggest that in breast tumors where there is intact estrogen regulated signaling, mTOR is regulated by estrogen and therefore associated with an increased likelihood of responsiveness to endocrine therapy." | ( Bader, T; Bruce, M; Jaksic, D; Murphy, L; Nugent, Z; Penner, C; Seekallu, S; Shrivastav, A; Watson, P, 2014) |
| "To explore the expression of breast cancer resistance protein (ABCG2), p-glycoprotein (P-gp) in residual breast cancer tissue after chemotherapy and their correlation with epithelial mesenchymal transition (EMT)." | ( Duan, L; Fang, L; Long, X; Qu, H, 2014) |
| "Compared with breast cancer tissue before chemotherapy, ABCG2, P-gp and vimentin protein were highly expressed in residual breast cancer tissue after chemotherapy." | ( Duan, L; Fang, L; Long, X; Qu, H, 2014) |
| "Screening for germline mutations in breast cancer-associated genes BRCA1 and BRCA2 is indicated for patients with breast cancer from high-risk breast cancer families and influences both treatment options and clinical management." | ( Benítez, J; Gómez-López, G; Marquez-Rodas, I; Martinez-Delgado, B; Osorio, A; Pisano, DG; Rodriguez-Pinilla, MS; Tanic, M; Yanowski, K, 2015) |
| "Different breast cancer cell lines were treated with butein and then subjected to cell viability and apoptosis assays." | ( Cho, SG; Ko, SG; Woo, SM, 2014) |
| "Among the breast cancer-related miRNAs, miR-222 expression was elevated in samples treated with celecoxib." | ( Chan, FL; Chen, S; Leung, LK; Li, F; Lin, SM; Wong, TY, 2014) |
| "Treatment of HER2-positive metastatic breast cancer with ado-trastuzumab emtansine (T-DM1), a novel antibody-drug conjugate, has resulted in both improved progression-free and overall survival." | ( Busam, KJ; Delord, JP; Lacouture, ME; Modi, S; Niec, RE; Roché, H; Schindler, K; Sibaud, V, 2014) |
| "Two groups of breast cancer patients: premenopausal patients treated with adjuvant tamoxifen; and patients undergoing in vitro fertilization (IVF) for fertility preservation." | ( Biderman, H; Brengauz, M; Catane, R; Cohen, Y; Dor, J; Hourvitz, A; Kaufman, B; Kuchuk, I; Levron, J; Maman, E; Manela, D; Meirow, D; Mozer-Mendel, M; Orvieto, R; Paluch-Shimon, S; Raanani, H; Shapira, M, 2014) |
| "Angiogenic cytokine profiles of breast cancer cell lines, before and after treatment with trabectedin, were investigated using an angiogenesis antibody array." | ( Atmaca, H; Uzunoglu, S, 2014) |
| "A total of 428 breast cancer patients who received neoadjuvant/adjuvant chemotherapy without any prophylactic use of colony-stimulating factor were included." | ( Chen, K; Deng, H; Deng, X; Jia, W; Su, F; Zhang, X; Zhu, L, 2014) |
| "Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging." | ( Beißbarth, T; Bender, C; Henjes, F; Korf, U; Sonntag, J; von der Heyde, S, 2014) |
| "In premenopausal women with breast cancer, standard adjuvant endocrine therapy has been 5 years of tamoxifen." | ( Barry, W; Block, CC; Borges, V; DeSantis, SD; Guo, H; Partridge, AH; Ruddy, KJ; Winer, EP, 2014) |
| "with DID-labelled MDA-MB-231-NW1-luc2 breast cancer cells 5days after zoledronic acid treatment, followed by assessment of tumour cell homing to bone and soft tissues by multiphoton microscopy, flow cytometry and ex vivo cultures." | ( Brown, HK; Dear, TN; Haider, MT; Holen, I; Hunter, K, 2014) |
| "Previously, her breast carcinoma was treated with right lumpectomy, adjuvant chemotherapy and breast radiotherapy." | ( Bongiovanni, M; Conti-Beltraminelli, M; Di Lascio, S; Espeli, V; Pagani, O; Pittoni, P; Richetti, A; Valli, MC, 2014) |
| "To investigate the influence of breast cancer subtypes on survival duration of patients with breast cancer spinal metastases, and to aid spine surgeons in selecting treatments on a more precise basis." | ( Bünger, CE; Dahl, B; Jensen, AB; Li, H; Morgen, SS; Sun, M; Wang, M; Wu, CS, 2014) |
| "Treating cyclin D overexpressing breast cancer cells with combination therapy also resulted in the greatest increase in apoptosis, resulted in decreased expression of anti-apoptotic proteins survivin and XIAP, and impacted subcellular localization of pro-apoptotic Smac/DIABLO." | ( Dokic, D; Hamdan, R; Hardy, A; Jeruss, JS; Nunez, O; Straehla, J; Tarasewicz, E; Zelivianski, S, 2014) |
| "In the model estrogen-independent breast cancer, lunasin and aspirin administration inhibits cell proliferation, arrest cell cycle in S-phase as well as a decreases expression of cancer genes." | ( Kuźmicz, I; Markowska, A; Wołosik, K, 2014) |
| "Premenopausal women with breast cancer treated with chemotherapy who did not receive tamoxifen." | ( Fung, C; Han, Y; Hoeger, K; Messing, S; Shayne, M; Vitek, WS, 2014) |
| "Eighteen women with breast cancer who received radiotherapy and developed moist desquamation were enrolled." | ( Feng, L; Liang, L; Shuchun, L; Xia, W; Xiaoshan, W; Yuyi, W; Zhixi, L, 2014) |
| "Acute treatment of PFOA inhibited breast cancer cell viability in a dose-dependent manner." | ( Akl, MR; Ebrahim, HY; El Sayed, KA; Elsayed, HE; Haggag, EG; Kamal, AM, 2014) |
| "Among female breast cancer patients who had undergone tamoxifen therapy, CHP consumption decreased the risk of subsequent endometrial cancer." | ( Lai, JN; Tsai, YT; Wu, CT, 2014) |
| "Treatment of human BT-474 breast cancer cells with RO reduced levels of estrogen-induced PR protein, confirming that RO blocks ERα activity in tumor cells." | ( Hyder, SM; Liang, Y; Mafuvadze, B, 2014) |
| "Most adjuvant breast cancer treatment regimens include the combination of an anthracycline (epirubicin or doxorubicin) and the alkylating agent cyclophosphamide." | ( Boddy, AV; Cresti, N; Griffin, M; Jackson, R; Jamieson, D; Lee, J; Sludden, J; Verrill, M, 2014) |
| "Fourteen breast cancer patients were divided into a 3S group (n=7) and a control group (n=7), and were treated with 260 mg/m(2) of nab-PTX once every three weeks." | ( De Kerckhove, C; De Kerckhove, M; Haraguchi, M; Inoue, K; Irie, J; Izumida, R; Kitajima, M; Kosaka, M; Matsuda, S; Mine, T; Ohno, T; Shinichiro, I; Tanaka, T; Tokai, H; Yoshioka, H, 2014) |
| "Patients with breast cancer receiving postoperative chemotherapy were retrospectively collected, and divided into four groups: group A with cantharidin sodium injection combined with chemotherapy; group B with Shenmai injection combined with chemotherapy; group C with both cantharidin sodium and Shenmai injection combined with chemotherapy; while group D (control group) received chemotherapy alone." | ( Cao, J; Huang, XE; Wang, L, 2014) |
| "Existing treatments for metastatic breast cancer (mBC) are often effective but can cause adverse events (AEs)." | ( Brammer, M; Guardino, E; Guerin, A; Hurvitz, S; Lalla, D; Latremouille Viau, D; Wu, EQ; Zhou, ZY, 2014) |
| "Fifteen women having breast cancer and bone metastases underwent MRI before and after radiotherapy (3 weeks [time 1], 2 months [time 2], and 4 months [time 3]), consisting of DW, perfusion-sensitive (IVIM), and DCE acquisitions." | ( Amato, E; Benedetto, C; Blandino, A; D'Angelo, T; Gaeta, M; Mazziotti, S; Minutoli, F; Mormina, E; Pergolizzi, S; Racchiusa, S, 2014) |
| "However, most common types of breast cancers, such as Luminal A, are low-P-gp expressing, at least during the initial phases of treatment." | ( Chen, M; Cui, Z; Gao, W; Lin, Z; Yang, X; Yuan, L; Zhang, Q; Zhang, X, 2014) |
| "Hazard ratio for incident breast cancer in the bisphosphonate treatment group compared to the placebo group." | ( Barrett-Connor, E; Bauer, DC; Black, DM; Cauley, JA; Cummings, SR; Ensrud, KE; Hue, TF, 2014) |
| "Twenty breast cancer patients who received OTX chemotherapy at our outpatient facility were included." | ( Abe, H; Kawai, Y; Kubota, Y; Mori, T; Tani, T; Umeda, T; Yamazaki, K, 2014) |
| "One hundred and seven women with breast cancer and a BRCA1 mutation, who were diagnosed with stage I to III breast cancer between December 2006 and June 2014, were treated with cisplatin 75 mg/m(2) every 3 weeks for four cycles, followed by mastectomy and conventional chemotherapy." | ( Byrski, T; Cybulski, C; Dent, R; Godlewski, D; Gronwald, J; Huzarski, T; Jakubowicz, J; Jasiowka, M; Lubinski, J; Marczyk, E; Narod, SA; Wisniowski, R, 2014) |
| "A large number of breast cancer patients receive various neuroactive drugs to combat complications of systemic anti-tumor therapies and to treat concomitant diseases." | ( Amico-Ruvio, SA; Brown, EB; Dickerson, IM; Kelly, EA; Majewska, AK; Shapovalov, Y; Sipe, GO; Spielman, SC; Zettel, M, 2014) |
| "The luminal A subtype of breast cancer has a good prognosis and is sensitive to endocrine therapy but is less sensitive to chemotherapy." | ( Cai, R; Li, Q; Liu, M; Luo, Y; Ma, F; Wang, L; Xu, B; Xu, N, 2014) |
| "Sixty-eight breast cancer patients received neoadjuvant chemotherapy with epirubicin plus paclitaxel." | ( Cai, R; Li, Q; Liu, M; Luo, Y; Ma, F; Wang, L; Xu, B; Xu, N, 2014) |
| "Unresectable chest wall recurrences of breast cancer (CWR) in heavily pretreated patients are especially difficult to treat." | ( Blackwell, KL; Boico, A; Borys, N; Boss, MK; Craciunescu, O; Dewhirst, MW; Diederich, C; Formenti, S; Hsu, IC; Maccarini, P; Muggia, F; Myerson, R; Needham, D; O'Connor, B; Rugo, H; Stauffer, P; Straube, W; Vujaskovic, Z; Zagar, TM, 2014) |
| "The majority of human breast cancers express estrogen receptor alpha (ER), which is important for therapy with anti-estrogens." | ( Birchmeier, W; Bleckmann, A; Brembeck, FH; Bunzendahl, J; Perske, C; Wiese, M; Zatula, N, 2014) |
| "We selected early breast cancer patients treated between 2000 and 2010 with 4-6 cycles of (neo-)adjuvant 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) or 3 cycles FEC followed by 3 cycles docetaxel." | ( Dieudonné, AS; Hatse, S; Lambrechts, D; Neven, P; Paridaens, R; Peeters, M; Pettengell, R; Pfeil, AM; Schwenkglenks, M; Szucs, TD; van Dam, P; Vulsteke, C; Wildiers, H, 2014) |
| "Tamoxifen‑resistant breast cancer is a major clinical problem and new treatment strategies are highly warranted." | ( Lykkesfeldt, AE; Pedersen, AM; Thrane, S; Yde, CW, 2014) |
| "Human metastatic breast cancer cells (MT-1) were cultured in vitro and treated with zol (10μM) for 24h, followed by PDT treatment." | ( Akens, MK; Schwock, J; Whyne, CM; Wilson, BC; Wise-Milestone, L; Won, E; Yee, AJ, 2014) |
| "Using the 4T1 murine model of breast cancer, cationic liposomes containing monophosphoryl lipid A (MPL) and interleukin (IL)-12 were administered by intratumoral injection." | ( Gu, J; Li, J; Meraz, IM; Rhudy, J; Savage, DJ; Segura-Ibarra, V; Serda, RE, 2014) |
| "Metastatic breast cancer (MBC) is a highly heterogeneous disease with great differences in outcome to both chemo- and endocrine therapy." | ( Berns, PMJJ; Foekens, JA; Jansen, MPHM; Look, MP; Martens, JWM; Meijer-van Gelder, ME; Reijm, EA; Sleijfer, S; Stobbe, CK; Timmermans, AM; van Deurzen, CHM, 2014) |
| "HER2-positive breast carcinomas with a PIK3CA mutation are less likely to achieve a pCR after neoadjuvant anthracycline-taxane-based chemotherapy plus anti-HER2 treatment, even if a dual anti-HER2 treatment is given." | ( Andre, F; Denkert, C; Dohnal, K; Dykgers, A; Eidtmann, H; Fasching, PA; Gade, S; Guo, S; Heinrichs, C; Huober, J; Khandan, F; Lehmann, A; Lindner, JL; Loi, S; Loibl, S; Nekljudova, V; Paepke, S; Pfitzner, B; Rezai, M; Schneeweiss, A; Sinn, P; Sotiriou, C; Untch, M; von Minckwitz, G; Zahm, DM, 2014) |
| "However, most breast tumors develop tamoxifen resistance and are eventually refractory to tamoxifen therapy." | ( Bian, XW; Guo, YM; Wang, ZY; Yin, L; Zhang, XT, 2014) |
| "4,626 patients with a diagnosis of breast cancer with current or terminated treatment with TAM or AIs between January 2003 and March 2012 in Germany were included." | ( Albert, US; Hadji, P; Jockwig, A; Kostev, K; Kyvernitakis, I; Schmidt, N, 2014) |
| "A total of 47 patients with T4 breast cancer undergoing treatment with a platinum-based regimen were collected and followed up (median 159 months; range, 42-239 months)." | ( Atzori, F; Budroni, M; Cossu, A; Frau, B; Ionta, M; Massidda, B; Notari, F; Ombra, M; Palmieri, G; Palomba, G; Pusceddu, V; Sini, M, 2014) |
| "These findings are relevant to design breast cancer prevention and treatment trials with metformin." | ( Aristarco, V; Bassi, F; Bonanni, B; Cazzaniga, M; DeCensi, A; Gandini, S; Guerrieri-Gonzaga, A; Hofmann, U; Johansson, HA; Lazzeroni, M; Luini, A; Macis, D; Mora, S; Pollak, MN; Pruneri, G; Puntoni, M; Schwab, M; Serrano, D, 2014) |
| "Analysis of data from ERα(+) breast cancers demonstrates elevated expression of a UPR gene signature that is a powerful new prognostic marker tightly correlated with subsequent resistance to tamoxifen therapy, reduced time to recurrence and poor survival." | ( Andruska, N; Helferich, WG; Shapiro, DJ; Yang, X; Zheng, X, 2015) |
| "Recurrence of breast cancer after chemotherapy is thought to arise from resistant breast cancer stem cells which are eventually able to repopulate the tumor." | ( Arnold, KM; Davis, J; Flynn, D; Opdenaker, LM; Sims-Mourtada, J, 2015) |
| "Estrogen receptor positive breast cancers have high recurrence rates despite tamoxifen therapy." | ( Hansen, JE; Muller, PJ; Naik, AM; O'Neill, S; Pommier, RF; Pommier, SJ; Schillace, RV; Skinner, AM, 2014) |
| "Accurate initial staging in breast carcinoma is important for treatment planning and for establishing the likely prognosis." | ( Goel, R; Jena, A; Kaul, S; Sarin, R; Taneja, S, 2014) |
| "Co-treatment of MCF7 breast cancer cells stably overexpressing miR-155 with RAD001 and E2 restored E2-induced PgR gene expression." | ( Burow, ME; Collins-Burow, BM; Elliott, S; Flemington, EK; Krebs, AE; Martin, EC; Nephew, KP; Rhodes, LV, 2014) |
| "Our data suggest that breast cancer patients under hormonal therapy with stable disease on FDG-PET have a longer PFS when compared to non-responders." | ( Borms, M; Cocquyt, V; Kruse, V; Maes, A; Pottel, H; VAN Belle, S; VAN DE Wiele, C, 2017) |
| "Postmenopausal women with an early breast cancer scheduled to start adjuvant endocrine therapy with an AI or tamoxifen were recruited." | ( Billen, J; Christiaens, MR; Jans, I; Laenen, A; Lintermans, A; Neven, P; Paridaens, R; Pauwels, S; Van Asten, K; Van Herck, E; Vanderschueren, D; Verhaeghe, J; Vermeersch, P; Wildiers, H, 2014) |
| "Mice inoculated with 4T1 or EO771 breast cancer cells orthotopically were treated with Emodin after the primary tumors reached 200 mm3 in size." | ( Fan, D; Hu, J; Iwanowycz, S; Jia, X; Saaoud, F; Wang, J; Wang, Q; Wang, Y; Yu, F, 2014) |
| "Main indications for BP treatment were breast cancer (36%), multiple myeloma (24%), prostate cancer (16%) and kidney cancer (4%)." | ( Felsenberg, D; Gabbert, TI; Hoffmeister, B, 2015) |
| "Importantly, breast cancer risk elevations appear to be higher among women who initiate treatment at the menopause, or soon thereafter, compared with women having a longer gap time." | ( Prentice, RL, 2014) |
| "Recently, a cohort of breast cancer patients was left with tungsten in their breasts following testing of a tungsten-based shield during intraoperative radiotherapy." | ( Bolt, AM; Lemaire, M; Mann, KK; Molina, MF; Negro Silva, LF; Plourde, D; Police, AM; Sabourin, V; Ursini-Siegel, J, 2015) |
| "If a breast cancer patient expresses ER or PR, a chemotherapy with estrogen inhibitors such as tamoxifen is supposed to be effective." | ( Ahn, S; Jung, D; Kim, S; Lee, D; Lee, H; Park, KH; Park, S; Wang, HY, 2014) |
| "About 70% of all breast cancers are estrogen receptor alpha positive (ER+) and are treated with antiestrogens." | ( Clarke, R; Cook, KL; Demas, DM; Eltayeb, AE; Facey, CO; Hilakivi-Clarke, LA; Schwartz-Roberts, JL; Shajahan-Haq, AN; Warri, AM, 2014) |
| "Newly diagnosed breast cancer patients who had received a dual-phased FDG positron emission tomography/computed tomography scan for pretreatment staging were enrolled retrospectively." | ( Chang, CC; Chen, YW; Hou, MF; Lin, CY; Tu, HP, 2014) |
| "Treatment of MCF7 breast carcinoma cells with a heteroleptic phosphorescent cyclometalated iridium(III) complex C2 followed by confocal imaging indicates that the complex selectively localizes and exhibits high fluorescence in the endoplasmic reticulum." | ( Ghosh, R; Gupta, P; Mandal, S; Poria, DK; Ray, PS, 2014) |
| "Patients with invasive breast cancer who received doxorubicin-containing chemotherapy at University Hospitals Case Medical Center from 1998 to 2006 were included." | ( Qin, A; Silverman, P; Thompson, CL, 2015) |
| "Cultured MDA-MB-231 human breast cancer cells were treated with different concentrations of a cocktail of 4 fluorochrome-conjugated monoclonal antibodies." | ( Akudugu, JM; Domogauer, JD; Howell, RW; Khullar, A; Pasternack, JB, 2014) |
| "From this group 37 breast cancer patients had DM type 2 or hyperglycemia and were pretreated with metformin alone or sometimes in combination with other antidiabetic drugs." | ( Abu Rabi, Z; Antić-Stanković, J; Damjanović, A; Damjanović, S; Džodić, R; Juranić, Z; Kanjer, K; Matić, IZ; Milovanović, Z; Nikolić, S; Roki, K; Ðorđić, M; Ðurović, MN, 2015) |
| "Treatment of human breast cancer cells (MCF-7 and MDA-MB-231 cells) with berberine induced inhibition of cell viability in concentration- and time-dependent manner irrespective of their estrogen receptor (ER) expression." | ( Chen, Y; Fu, J; Huang, X; Wang, L; Xi, M; Xie, J; Xu, Y, 2015) |
| "We genotyped 306 patients with early breast cancer, who were randomised to receive post-operative radiotherapy or CMF chemotherapy, for the RAD51 135G>C polymorphism." | ( Asklid, A; Fornander, T; Söderlund Leifler, K; Stenmark Askmalm, M, 2015) |
| "Patients with early breast cancer who had completed six cycles of adjuvant fluorouracil, epirubicin, and cyclophosphamide (FEC) chemotherapy underwent BM aspiration 2 to 3 months (BM1) and 8 to 9 months (BM2) after FEC." | ( Bendigtsen Schirmer, C; Borgen, E; Falk, RS; Kersten, C; Mjaaland, I; Naume, B; Risberg, T; Rypdal, MC; Sommer, HH; Synnestvedt, M; Sætersdal, AB; Vindi, L; Weyde, K; Wiedswang, G; Wist, EA, 2014) |
| "Eighty-eight distressed breast cancer survivors with a diagnosis of stage I to III cancer (using the American Joint Committee on Cancer (AJCC) TNM staging system) who had completed treatment at least 3 months prior participated." | ( Beattie, TL; Carlson, LE; Degelman, ES; Faris, P; Fick, LJ; Giese-Davis, J; Speca, M; Tamagawa, R, 2015) |
| "The rising trend of breast cancer both in developed and developing countries is a real threat challenging all efforts to screening, prevention and treatment aspects to reduce its impact." | ( Biswas, J; Das, I; Datta, K; Ghosh, D; Guha, S; Nanda, D; Roy, A; Sikdar, S, 2014) |
| "Despite advancements in breast cancer treatment, chemotherapeutic outcomes remain far from satisfactory, prompting a search for effective natural agents with few side‑effects." | ( Dai, K; Fan, Q; Li, H; Liu, G; Liu, X; Ouyang, Z; Qin, A; Qu, X; Tang, T; Yan, W; Zhai, Z, 2015) |
| "Using two human breast cancer cell lines MCF-7 (with wild-type p53) and MDA-MB-231 (with mutant p53), we quantitated the expression levels of kinesin super-family protein 4A (Kif4A) and poly (ADP-ribose) Polymerase-1 (PARP-1) by Western blot after doxorubicin treatment and examined the apoptosis by flow cytometry after treatment with doxorubicin and PARP-1 inhibitor, 3-Aminobenzamide (3-ABA)." | ( Chen, T; Jiang, J; Li, Q; Lu, C; Tan, Y; Wang, H; Wu, C; Xie, J, 2014) |
| "In the present study 92 Turkish breast cancer patients with early-stage hormone receptor-positive tumors treated with adjuvant tamoxifen (20 mg) were evaluated for CYP2D6 genotype and metabolic profiles." | ( Afşar, CU; Erçolak, V; Erkisi, M; Gulec, UK; Günaldı, M; Kara, IO; Paydas, S; Sahin, B; Secilmis, A, 2014) |
| "Patients with breast cancer and central nervous system (CNS) metastases received whole-brain radiotherapy concurrently with capecitabine (1,000 mg/m(2) per day for 14 consecutive days), followed by concomitant capecitabine (2,000 mg/m(2) per day for 2 weeks followed by a 1-week break) and sunitinib (37." | ( Elledge, R; Foreman, C; Hilsenbeck, SG; Niravath, P; Rimawi, M; Rodriguez, A; Tham, YL; Wang, T, 2015) |
| "In premenopausal women with breast cancer treatment-induced bone loss, 24 months of intravenous ZOL treatment significantly increased the lumbar spine BMD and the TBS." | ( Albert, US; Baier-Ebert, M; Hadji, P; Kalder, M; Kyvernitakis, I, 2015) |
| "Neoadjuvant treatment of breast cancer refers to the use of different treatment modalities prior to surgical excision of the tumor." | ( Piccart, M; Zardavas, D, 2015) |
| "Estrogen receptor-positive (ER(+)) breast cancers adapt to hormone deprivation and become resistant to antiestrogen therapy." | ( Abramson, V; Arteaga, CL; Balko, JM; Estrada, MV; Fox, EM; Garrett, JT; González-Angulo, AM; Kelley, MC; Kuba, MG; Mayer, IA; Meszoely, IM; Mills, GB; Red-Brewer, M; Rizzo, M; Schwarz, LJ, 2014) |
| "The MCF-7 breast cancer cells were treated with different concentrations of CdCl2 and cell viability was assessed using the MTT assay." | ( Aghaei, M; Gharagozloo, M; Khojastehfar, A; Panjehpour, M, 2015) |
| "She developed breast cancer and ultimately agreed to begin estrogen deprivation therapy with tamoxifen; this treatment regimen resulted in an increased seizure threshold, necessitating an increase in stimulus power settings." | ( Kahn, DA; Stewart, JT, 2014) |
| "Stage II/III breast cancer patients were treated with three cycles of neoadjuvant, after which the patients received curative surgery and adjuvant chemotherapy." | ( Ham, HS; Han, W; Im, SA; Jang, IJ; Keam, B; Kim, HJ; Kim, JH; Kim, TY; Kim, YJ; Lee, KH; Noh, DY; Oh, DY; Park, IA, 2015) |
| "Eligible patients had non-metastatic breast cancer and were to receive adjuvant or neo-adjuvant chemotherapy with prophylaxis for febrile neutropenia." | ( Florendo, J; Higgins, B; Jones, G; Kano, J; Leung, M; Marr-Del Monte, T; Menon, T; Myers, R, 2015) |
| "We retrospectively examined breast cancer patients with luminal human epidermal growth factor receptor 2 (HER2)-negative tumours, as defined by immunohistochemistry, who received neo-adjuvant chemotherapy (NAC) and investigated the relationship between treatment effects and FOXA1 expression." | ( Arakawa, A; Harada-Shoji, N; Himuro, T; Hino, O; Horimoto, Y; Igari, F; Mamat, O; Saito, M; Sonoue, H; Tanabe, M; Tokuda, E; Yoshida, Y, 2015) |
| "A total of 145 female breast cancer patients admitted to the American University of Beirut Medical Center for breast cancer-related therapy were included." | ( Al-Shaar, L; Bazarbachi, A; Cascorbi, I; El-Saghir, N; Habib, RH; Haroun, F; Salem, Z; Shamseddine, A; Taher, A; Tfayli, A; Zgheib, NK, 2015) |
| "Moreover, many of the ER(+) breast cancer patients receiving anti-estrogen drugs relapsed within a couple of years and become resistant to antiestrogen therapy." | ( Chaudhry, N; Mittal, R; Mukherjee, TK; Pathania, S, 2014) |
| "In women with breast cancer who were treated with either continuous tamoxifen alone or sequential tamoxifen followed by megestrol acetate (MA), we demonstrated significant positive associations between the breast tumor estrogen receptor (ER) and an increase in serum sex hormone-binding globulin (SHBG) during tamoxifen treatment." | ( Carlström, K; Fahlén, M; Löfgren, L; Naessén, S; Söderqvist, G; von Schoultz, E, 2013) |
| "Treatment of HER2+ breast cancers has been greatly improved in recent years, but the accompanying upregulation of HER3 induced by HER2 blockade has subdued the therapeutic effect." | ( Cao, PR; Huang, W; Kong, YL; Wu, QD; Xu, JH; Ye, M; Zhang, M; Zheng, W, 2015) |
| "Compared to the breast cancer tissues from chemotherapy responders, 10 miRNAs were identified to be dysregulated in the chemoresistant breast cancer tissues." | ( Chen, F; Fu, Z; Gao, S; Lv, J; Ma, J; Sun, E; Wang, F; Xia, K; Xie, H; Xu, P; Zhang, M; Zhou, P; Zhou, Q, 2014) |
| "In patients with HER2-positive breast cancer, tri-weekly Trastuzumab was administered with TRI-ABC." | ( Emi, A; Kadoya, T; Kajitani, K; Masumoto, N; Ohara, M; Okada, M; Sasada, T; Shigematsu, H, 2015) |
| "In patients with HER2-positive breast cancer, early PET assessment can help to identify non-responders to neoadjuvant docetaxel plus trastuzumab therapy." | ( Arnould, L; Bachelot, T; Berriolo-Riedinger, A; Bougnoux, P; Coeffic, D; Coudert, B; Coudert, M; Dupré, PF; Ferrero, JM; Gabelle, P; Giard, S; Hernandez, J; Kerbrat, P; Kerrou, K; Mouret-Reynier, MA; Paintaud, G; Petit, T; Pierga, JY; Prevost, JB; Thibault, G, 2014) |
| "Research on breast cancer EMT/MET aims at delivering biomolecules that can be used diagnostically in cancer pathology and possibly provide ideas for how to improve breast cancer therapy." | ( Moustakas, A; Olsson, AK; Tan, EJ, 2015) |
| "Among 31,938 tamoxifen-treated breast cancer survivors, 157 cases of subsequent endometrial cancer were identified." | ( Lai, JN; Tsai, YT; Wu, CT, 2014) |
| "Dang-qui consumption is common among breast cancer survivors aged 20-79 years and seems decrease the risk of subsequent endometrial cancer after less than a cumulative dose of 7,500 mg of tamoxifen treatment." | ( Lai, JN; Tsai, YT; Wu, CT, 2014) |
| "Linked data from the Waikato Breast Cancer Registry and National Pharmaceutical Database were examined to identify differences by ethnicity in adherence to adjuvant endocrine therapy and the effect of sub-optimal adherence on cancer recurrence and mortality." | ( Campbell, I; Kim, B; Kuper-Hommel, M; Lawrenson, R; Pillai, A; Scott, N; Seneviratne, S, 2015) |
| "Estrogen receptor-positive (ER+) breast cancer cells were treated ±P7170." | ( Agarwal, VR; Barth, RJ; Bean, JR; Chen, VS; Dillon, LM; Hosford, SR; Marotti, JD; Miller, TW; Muller, KE; Owens, P; Rosenkranz, KM; Schwartz, GN; Shee, K; Symonds, LK; Yang, W, 2015) |
| "MDA-MB-231, T47D and MCF-7 breast cancer cells were treated with BP (zoledronic acid, risedronate, ibandronate, alendronate) and the pyrophosphate channel inhibitors probenecid and novobiocin." | ( Auriola, S; Coimbra de Sousa, S; Ebert, R; Graser, S; Hofbauer, LC; Jakob, F; Määttä, J; Meissner-Weigl, J; Mentrup, B; Rachner, TD; Zeck, S, 2014) |
| "However, in a cohort of metastatic breast cancer patients who received tamoxifen treatment, high BCAR3 mRNA levels were associated with favorable progression-free survival outcome." | ( Ali, S; Canaff, L; Dai, M; Fils-Aimé, N; Guo, J; Korah, J; Lebrun, JJ; Park, M; Rajadurai, CV; Tian, J; Villatoro, M, 2014) |
| "MCF‑7 breast cancer cells were treated with different concentrations of SBHA and tested for cell viability, apoptosis and gene expression changes." | ( Hu, X; Shi, Z; Yang, X; Yang, Z; Zhang, N, 2015) |
| "Animals implanted with resistant breast cancer cells into the mammary fat pad and treated with a combination of drozitumab and doxorubicin showed inhibition of tumor growth and a substantial delay in tumor progression compared to untreated controls and mice treated with each agent alone." | ( Atkins, GJ; Denichilo, M; Evdokiou, A; Findlay, DM; Hay, S; Ingman, W; Labrinidis, A; Liapis, V; Panagopoulos, V; Ponomarev, V; Zannettino, AC; Zinonos, I, 2014) |
| "Despite advances in breast cancer treatment, mortality from breast cancer is still high." | ( Ch Yiannakopoulou, E, 2015) |
| "Fifty cases of breast cancer receiving neoadjuvant therapy were collected." | ( Mu, K; Shi, R; Wang, Y; Yang, Q; Yun, H; Zhang, X; Zhou, X, 2014) |
| "Blocking breast cancer cell A3 adenosine receptors resulted in higher extravasation rates of cancer cells into the myoblast-containing matrices compared with untreated cells, suggesting a role for adenosine in reducing extravasation." | ( Bersini, S; Charest, JL; Dubini, G; Gilardi, M; Jeon, JS; Kamm, RD; Moretti, M, 2015) |
| "One class of hormonal therapy for breast cancer drugs -non steroidal aromatase inhibitors- are triazole analogues." | ( Ardestani, SK; Asadipour, A; Dadgar, A; Firoozpour, L; Foroumadi, A; Moshafi, MH; Pordeli, M; Rodaki, A; Safavi, M; Vosooghi, M, 2014) |
| "Overall, 15% of breast cancer survivors treated with docetaxel report PN 1-3years after treatment with a significant negative impact on HRQOL." | ( Eckhoff, L; Ewertz, M; Jensen, MB; Knoop, A, 2015) |
| "Patients with HER2-negative stage III breast cancer were treated with doxorubicin 60 mg/m(2) and cyclophosphamide 600 mg/m(2) for four cycles every 3 weeks followed by weekly paclitaxel 80 mg/m(2) on days 1, 8, and 15 every 28 days for four cycles concurrently with pazopanib 800 mg orally daily prior to surgery." | ( Bhatt, K; Bury, MJ; Fehrenbacher, L; Flynn, PJ; Geyer, CE; Goel, R; Jacobs, SA; Johannes, H; Julian, TB; Mamounas, EP; Provencher, L; Rastogi, P; Robidoux, A; Stella, PJ; Swain, SM; Tan, AR; Thirlwell, MP; Wolmark, N, 2015) |
| "Lack of effective treatment to breast cancer brain metastases (BCBMs) is probably due to inability of the current therapeutic agents to cross the blood-brain barrier." | ( Bai, Y; Cheng, Z; Li, S; Lv, J; Xie, L; Yan, Y; Zhang, J; Zhang, L; Zhang, X; Zhong, W, 2015) |
| "in treating breast cancer have been reviewed." | ( Barua, CC; Gaikwad, AB; Jamdade, VS; Kadakol, A; Kumar, P; Mundhe, NA; Shasthrula, PK, 2015) |
| "Most primary breast cancers express estrogen receptor α and can be treated via endocrine therapy using anti-estrogens such as tamoxifen; however, acquired endocrine resistance is a critical issue." | ( Horie-Inoue, K; Ikeda, K; Inoue, S; Okamoto, K; Osaki, A; Saeki, T; Sato, W; Shigekawa, T; Suzuki, T; Takeda, S; Ujihira, T; Yamaga, R, 2015) |
| "In the neoadjuvant setting of breast cancer, the metabolic response can predict the final complete pathologic response after the first cycles of chemotherapy." | ( Berriolo-Riedinger, A; Brunotte, F; Cochet, A; Coudert, B; Fumoleau, P; Humbert, O; Kanoun, S, 2015) |
| "In vitro studies with MDA-MB-231-LM2 breast cancer cell line showed significant cell killing upon treatment of cell-liposome suspensions with the laser." | ( Blumenthal, R; Charron, H; Joshi, A; Puri, A; Schiff, R; Sine, J; Tata, DB; Thayer, D; Urban, C; Valim, N, 2015) |
| "Premenopausal women with stage I/II breast cancers receiving adjuvant chemotherapy were evaluated at chemotherapy initiation, 6 and 12 months." | ( Lustberg, MB; Oostra, DR; Pan, X; Reinbolt, RE; Shapiro, CL; Wesolowski, R, 2015) |
| "Patients with primary HER2-positive breast cancer treated with trastuzumab-based NST were categorised according to adjuvant trastuzumab administration and pCR status." | ( Chavez-MacGregor, M; Gonzalez-Angulo, AM; Hortobagyi, GN; Hunt, KK; Lei, X; Mittendorf, EA; Parinyanitikul, N; Valero, V; Zhang, H, 2015) |
| "The participants were 62 breast cancer women who were aged 40 years and below, and had completed active breast cancer treatment." | ( Chang, KJ; Hsiao, FH; Huang, CS; Jow, GM; Kuo, WH; Lai, YM; Lam, HB; Lee, JJ; Liu, YF; Yang, PS, 2015) |
| "In particular, in the metastatic breast cancer model, the lung metastasis was notably reduced by SN treatment, and the VCAM-1 expression in lung tissues was significantly inhibited." | ( Cao, H; Chen, L; Gu, W; He, X; Li, Y; Yin, Q; Yu, H; Zhang, Z; Zhao, S, 2015) |
| "ERα-positive breast cancer cells (T47D, MCF-7) were treated with biochanin A." | ( Chen, J; Ge, B; Huang, Z; Wang, Y; Ye, Y; Zeng, S, 2015) |
| "The prognosis of HER2-positive breast cancer has been improved by trastuzumab therapy, which features high specificity and limited side effects." | ( Fujiwara, T; Hashimoto, Y; Ishida, M; Kagawa, S; Kobayashi, H; Matsuoka, J; Noma, K; Shimoyama, K; Takehara, K; Tanabe, S; Tazawa, H; Watanabe, S, 2015) |
| "Pretreatment of breast cancer cells with melatonin 1 wk before radiation led to a significantly greater decrease of MCF-7 cell proliferation compared with radiation alone." | ( Alonso-González, C; Cos, S; Gómez-Arozamena, J; González, A; Martínez-Campa, C, 2015) |
| "It includes 40 breast cancer patients suffering from chemotherapy-induced peripheral neuropathy." | ( Delage, N; Dubray, C; Joly, D; Martin, E; Morel, V; Pereira, B; Pickering, G; Villatte, C, 2015) |
| "In comparison to breast cancer cells without treatment, nemorosone induced discrete cell cycle arrest in the G1 phase and significant depletion in the G2 phase." | ( Camargo, MS; Cuesta-Rubio, O; Espanha, LG; Nogueira, CH; Oliveira, MT; Oliveira-Höhne, AP; Resende, FA; Santoni, MM; Varanda, EA; Vilegas, W, 2015) |
| "In 11 patients with breast cancer following quadrantectomy (n = 8) or modified radical mastectomy (n = 3), any grade 3 (G3) or higher nonhematologic toxicity (excluding alopecia, nausea or vomiting, and bone pain, which might be a consequence of the administration of filgrastim) and adherence to the scheduled dose-dense treatment (deliverability) were monitored with the purpose of enrolling an additional 27 patients in the case of a satisfying toxicity profile and deliverability of the planned treatment (at least 7 patients completing the treatment)." | ( Amadori, D; Andreis, D; De Giorgi, U; Fabbri, F; Kopf, B; Menna, C; Pietri, E; Rocca, A; Schirone, A, 2015) |
| "Endocrine treatment regimens for breast cancer that target the estrogen receptor-α (ERα) are effective, but acquired resistance remains a limiting drawback." | ( Anzeneder, T; Benes, V; Burwinkel, B; Büttner, R; Deuschle, U; Heck, S; Lichter, P; Nicholson, RI; Sauter, G; Schlotter, M; Schneeweiss, A; Schroeter, P; Simon, R; Sinn, HP; Thewes, V; Zapatka, M, 2015) |
| "Estrogen receptor (ER)-positive breast cancer patients may turn ER-negative and develop acquired drug resistance, which compromises the efficacy of endocrine therapy." | ( Dong, W; Fang, S; Li, C; Li, M; Liu, J; Song, B; Tang, B; Wang, Z; Zhang, B; Zhang, X; Zhang, Y, 2015) |
| "One hundred consecutive cases with breast cancers treated by NAC were enrolled in this study." | ( Endo, I; Ichikawa, Y; Ishikawa, T; Kida, K; Sasaki, T; Shimizu, D; Tanabe, M; Yamada, A, 2015) |
| "Some of HER-2 positive breast cancer patients failed to trastuzumab treatment." | ( Hu, BQ; Ji, YR; Liang, B; Liang, JW; Liu, YL; Lu, Q; Shang, FF; Wang, J; Wang, Q; Xia, Y; Zhang, W, 2015) |
| "However, the effect of ANQ on breast cancer treatment is unknown." | ( Chen, KC; Chen, YC; Cheng, CH; Lee, TH; Lee, WT; Lin, CW, 2015) |
| "Chemoresistance of breast cancer is a growing problem and still a major clinical obstacle to successful treatment in clinical patients." | ( Dai, L; Fu, Z; Ji, C; Lv, J; Lv, M; Pan, B; Shi, M; Xia, K; Xie, H; Xu, P, 2015) |
| "The treatment methods used for treating breast cancer had no effect on the response to treatment of lymphedema." | ( Caramat, I; Cinar, E; Eyigör, S; Unlu, BK, 2015) |
| "Human breast cancer cell lines (MCF-7, MDA-MB 231) and non-tumorigenic MCF-10A breast epithelial cells were treated with either 5-aza 2' dC, EGCG, or their combination for 7 days." | ( Mahalingaiah, PK; Singh, KP; Treas, JN; Tyagi, T, 2015) |
| "A prior analysis of postmenopausal breast cancer patients linked a decline in mammographic density (MD) following the initiation of tamoxifen treatment with improved survival, but excluded premenopausal women, for whom tamoxifen is the primary anti-endocrine therapy." | ( Aiello Bowles, EJ; Berrington de Gonzalez, A; Brinton, LA; Gierach, GL; Glass, A; Hoover, RN; Nyante, SJ; Pfeiffer, RM; Sherman, ME, 2015) |
| "MCF-7 human breast cancer cells were treated with various concentrations of genistein, and cell proliferation was evaluated by the MTT assay." | ( Chen, J; Duan, Y; Ge, B; Ye, Y; Zhang, X, 2015) |
| "• PET/CT may be relevant in staging breast cancer patients at higher risk for metastases • PET/CT may modify the N and M stage in multiple patients • PET/CT may impact treatment planning in breast cancer patients." | ( Brade, J; Buesing, KA; Kaiser, CG; Krammer, J; Schnitzer, A; Schoenberg, SO; Sperk, E; Suetterlin, M; Sutton, EJ; Wasgindt, S; Wasser, K, 2015) |
| "In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel." | ( Baselga, J; Benyunes, MC; Campone, M; Ciruelos, E; Clark, E; Cortés, J; Ferrero, JM; Heeson, S; Kim, SB; Ro, J; Ross, G; Schneeweiss, A; Semiglazov, V; Swain, SM, 2015) |
| "A markedly higher risk of breast cancer was also observed for alcohol combined with hormone therapy use compared with abstinent nonusers (P for interaction = 0." | ( Andersen, I; Bojesen, SE; Diderichsen, F; Grønbæk, M; Hansen, ÅM; Hvidtfeldt, UA; Keiding, N; Lange, T; Prescott, E; Rod, NH; Sørensen, TI; Tjønneland, A, 2015) |
| "Orthotopic murine breast tumors (4T1 and E0771 with high and low MMP14 expression, respectively; n = 5-10 per group) were treated with an anti-MMP14 inhibitory antibody (DX-2400), IgG control, fractionated radiation therapy, or their combination." | ( Ager, EI; Askoxylakis, V; Boucher, Y; Devy, L; Dransfield, DT; Finkelstein, DM; Fukumura, D; Goel, S; Huang, Y; Jain, RK; Kirkpatrick, ND; Kodack, DP; Kozin, SV; Muzikansky, A; Seano, G; Snuderl, M, 2015) |
| "The premise that breast cancer (BC) has a tendency toward early systemic dissemination, together with empirical findings showing that drugs given after breast tumor surgery improve outcome, led to the development of systemic adjuvant therapy." | ( Piccart, M; Sonnenblick, A, 2015) |
| "Here, we report that breast cancer nodules in mice can be effectively treated by preconditioning the tumors with 1α, 25-dihydroxyvitamin D3 (calcitriol; Vit D) prior to administering 5-aminolevulinate (ALA)-based PDT." | ( Anand, S; Maytin, EV; Rollakanti, KR, 2015) |
| "In tamoxifen-treated patients, breast cancer recurrence differs according to CYP2D6 genotype and endoxifen steady-state concentrations (Endx Css)." | ( Ames, MM; Black, JL; Buhrow, SA; Gilbert, JA; Goetz, MP; Ingle, JN; Kosel, ML; Modak, AS; Northfelt, DW; Reid, JM; Rosen, D; Safgren, SL; Suman, VJ, 2015) |
| "We validated PREDICT, a free online breast cancer prognostication and treatment benefit tool, in a resource-limited setting." | ( Alias, Z; Bhoo-Pathy, N; Hartman, M; Ho, GF; Ng, CH; Subramaniam, S; Taib, NA; Verkooijen, HM; Wong, HS; Yip, CH, 2015) |
| "Eighty female patients with breast cancer with DM2 were randomly assigned to receive chemotherapy only or chemotherapy plus DEX." | ( Geng, C; Li, X; Qi, X; Sun, F, 2015) |
| "The treatment of breast cancer cells with ω-3FFA attenuated tamoxifen-induced cell apoptosis." | ( Chen, YQ; Guo, Y; He, Z; Wu, S; Wu, Y; Zhu, S, 2015) |
| "In patients with node-positive early breast cancer, dose-dense adjuvant chemotherapy improved disease-free survival compared with standard interval chemotherapy." | ( Ardizzoni, A; Barni, S; Bighin, C; Bisagni, G; Boni, C; Bruzzi, P; Cavazzini, G; Cognetti, F; Colantuoni, G; De Laurentiis, M; De Placido, S; Del Mastro, L; Durando, A; Forestieri, V; Gamucci, T; Garrone, O; Giuliano, M; Gravina, A; Montemurro, F; Nisticò, C; Papaldo, P; Puglisi, F; Turletti, A; Valle, E, 2015) |
| "Heterogeneity of breast cancer (BC) subtypes makes BC treatment difficult." | ( Mason, JK; Thompson, LU; Wiggins, AK, 2015) |
| "Adjuvant chemotherapy for breast cancer has been associated with deterioration of fine motor skill." | ( Boogerd, W; Breteler, MM; Hoogendam, YY; Ikram, MA; Koppelmans, V; Schagen, SB; Seidler, RD; Seynaeve, C; Van der Geest, JN, 2015) |
| "The group of chemotherapy-exposed breast cancer survivors was slower in drawing an Archimedes spiral than the reference group." | ( Boogerd, W; Breteler, MM; Hoogendam, YY; Ikram, MA; Koppelmans, V; Schagen, SB; Seidler, RD; Seynaeve, C; Van der Geest, JN, 2015) |
| "Tau expression levels in early breast cancer were correlated with the responsiveness of taxane-containing chemotherapy." | ( Chen, G; Han, G; He, W; Li, H; Luo, R; Qian, S; Tan, X; Zhang, Q; Zhou, J, 2015) |
| "In detail, many miRNAs associated with breast cancer tamoxifen resistance have been identified, which offer new targets for breast cancer therapy." | ( Guan, X; Shi, Y; Sun, Q; Xu, J; Zhang, Q; Zhang, W, 2015) |
| "Human breast cancer cells expressing wild-type (MCF-7) or mutant p53 (T47D) were treated with a concentration range and time course of each phytochemical under conditions of cell cycle arrest as detected by flow cytometry to examine the potential connection between miR-34a expression and their anti-proliferative responses." | ( Firestone, GL; Hargraves, KG; He, L, 2016) |
| "Hormone-dependent breast cancer is the first example of cancer treated by targeted therapy for more than 30 years." | ( Bachelot, T; Cohen, P; Heudel, PE; Maudelonde, T; Tredan, O; Treilleux, I; Vilquin, P, 2015) |
| "Fifty-two women with HER2(+) breast cancer treated with trastuzumab were included in this study." | ( Akbulut, H; Demirkazık, A; İçli, F; Onur, H; Oztuna, DG; Şenler, FC; Ürun, Y; Utkan, G; Yalcin, B, 2015) |
| "Primary breast cancer patients (stage II-III) preoperatively treated with sequential paclitaxel (12 cycles) and fluorouracil, epirubicin, and cyclophosphamide (4 cycles), followed by surgery were retrospectively enrolled, and 229 patients were eligible." | ( Kagara, N; Kim, SJ; Maruyama, N; Michishita, S; Naoi, Y; Noguchi, S; Shimazu, K; Shimoda, M; Shimomura, A; Sota, Y, 2015) |
| "Here, we report a case of stage IV breast cancer with multiple liver, lung, and bone metastases maintaining a long-term partial response (PR) with tri-weekly paclitaxel plus bevacizumab administration." | ( Fujita, Y; Nakatsukasa, K; Okamoto, A; Sakaguchi, K; Sugimoto, R; Taguchi, T, 2015) |
| "Up to 50% of breast cancer survivors on aromatase inhibitor therapy report musculoskeletal symptoms such as joint and muscle pain, significantly impacting treatment adherence and discontinuation rates." | ( Esparaz, BT; Gaur, R; Gewandter, JS; Janelsins, MC; Kamen, C; Kirshner, JJ; Mohile, SG; Mustian, KM; Peppone, LJ; Ruzich, J; Sprod, LK, 2015) |
| "The development of breast cancer is linked to the loss of estrogen receptor (ER) during the course of tumor progression, resulting in loss of responsiveness to hormonal treatment." | ( Hedges, RA; Kadlubar, SA; Kieber-Emmons, T; Monzavi-Karbassi, B; Rogers, LJ; Yao-Borengasser, A, 2015) |
| "Women with untreated breast cancer who did not have diabetes were given 500 mg of metformin three times daily for ≥2 weeks after diagnostic biopsy until surgery." | ( Chang, MC; Done, SJ; Dowling, RJ; Ennis, M; Escallon, JM; Goodwin, PJ; Leong, WL; McCready, DR; Niraula, S; Reedijk, M; Stambolic, V, 2015) |
| "This identifies ER(-) breast cancers as ideal for treatment with the PKD inhibitor CRT0066101." | ( Borges, S; Geiger, XJ; Perez, EA; Radisky, DC; Storz, P; Thompson, EA, 2015) |
| "We queried our institutional breast cancer database for the following patients: age > 65 years, stage T1-T2N0, HR(+), and treatment with breast-conserving surgery, including adjuvant RT." | ( Anderson, PR; Bleicher, RJ; Eastwick, G; Hayes, SB; Johnson, ME; Li, T; Murphy, CT; Obeid, EI; Wang, LS; Weiss, SE, 2015) |
| "T47D human breast cancer cell line was treated with different concentrations of IM and/or CLT for 48 h." | ( Fahim, SA; Motawi, TM; Sadik, NA; Shouman, SA, 2015) |
| "The heterogeneity of breast cancer, confounded by comorbidity of disease in the elderly population, makes it difficult to determine the actual benefits of metformin therapy." | ( Hatoum, D; McGowan, EM, 2015) |
| "Radiotherapy is a critical component of breast cancer treatment." | ( Cenk, U; Eda, K; Murat, T; Uzer, K, 2016) |
| "Mesenchymal/metaplastic breast cancers (MpBCs) are often triple-negative (TNBC), and chemo-refractory, and can harbor phosphoinositide 3-kinase (PI3kinase) alterations; thus, therapy with mTor inhibitors may demonstrate activity." | ( Albarracin, C; Atkins, J; Booser, D; Gilcrease, M; Helgason, T; Janku, F; Koenig, K; Kurzrock, R; Moroney, J; Morrow, PK; Moulder, S; Wheler, J, 2015) |
| "After initial treatment of breast cancer (BC), monitoring locoregional recurrence and distant metastases is a great clinical challenge." | ( Amer, S; Dong, Y; Hou, H; Li, J; Tian, M; Wang, C; Yao, Q, 2015) |
| "Since breast cancer is highly resistant to chemotherapy, alternative anticancer strategies have been developed." | ( Arra, C; Barbieri, A; Bimonte, S; D'Aiuto, M; Izzo, F; Luciano, A; Palma, G; Rea, D, 2015) |
| "Furthermore, treating ER+ breast cancer cells with a combination of ACT1 and tamoxifen or HER2+ breast cancer cells with ACT1 and lapatinib augments the activity of these targeted inhibitors." | ( Abt, MA; Bruce, JS; Ghatnekar, GS; Grek, CL; Rhett, JM; Yeh, ES, 2015) |
| "MCF-7 breast cancer bearing mice were treated with different dose of cisplatin in group B (1 mg/kg) and group C (3 mg/kg)." | ( Cao, LH; Chen, Y; Guo, ZX; Han, F; Li, AH; Li, C; Li, Q; Wang, JW; Zheng, W; Zhou, JH, 2015) |
| "The percentage of Japanese breast cancer patients completing the 18-course treatment and the cumulative percentage of administration for 365 days using S-1 after standard primary systemic chemotherapy were similar with the results of another study of adjuvant chemotherapy for the Japanese gastric cancer patients with no severe adverse effects." | ( Hirokawa, E; Kanbayashi, C; Nakamiya, N; Osaki, A; Saeki, T; Sano, H; Sato, N; Sekine, H; Shigekawa, T; Shimada, H; Sugitani, I; Sugiyama, M; Takahashi, T; Takeuchi, H; Ueda, S, 2015) |
| "The efficacy of current breast cancer treatments is limited, and they have numerous side effects and permit high recurrence." | ( Chang, FW; Chen, SP; Chen, YH; Fu, CL; Ho, JY; Hsu, RJ; Hsu, YC; Liu, JM; Yu, CP; Yu, JC, 2015) |
| "Luminal B breast cancers are associated with early relapse following endocrine therapy and often exhibit a poor prognosis that is similar to that of the aggressive basal-like breast cancers." | ( Maggi, LB; Weber, JD, 2015) |
| "Successful treatment of two breast cancer patients who developed LC after whole brain irradiation treatment for the brain metastases is reported here." | ( Chen, IC; Cheng, AL; Jan, IS; Lin, CH; Lu, YS, 2016) |
| "Between 1990 and 2004, 1104 HR-positive breast cancer patients who had received tamoxifen treatment at our institution and had been disease free for at least 6 years were included in this analysis." | ( Chang, HK; Chen, SC; Hsueh, S; Lin, YC; Lo, YF; Wu, CE, 2016) |
| "Our findings suggest that HR-positive breast cancer women either aged < 40 years or with positive lymph node status were justified in continuing with tamoxifen therapy for > 5 years." | ( Chang, HK; Chen, SC; Hsueh, S; Lin, YC; Lo, YF; Wu, CE, 2016) |
| "Women with breast cancer had poorer executive functioning from the period before therapy through the entire first 18 months of therapy." | ( Ahrendt, GM; Bender, CM; Berga, SL; Brufsky, AM; Casillo, FE; Dailey, MM; Erickson, KI; Gentry, AL; Kratofil, FM; McAuliffe, PF; Merriman, JD; Rosenzweig, MQ; Ryan, CM; Sereika, SM, 2015) |
| "The study included 100 breast cancer patients treated with an NCT regimen of epirubicin and docetaxel (ET) who were divided into groups based on cancer subtype (luminal, HER2 over-expression, and basal-like subtype)." | ( Dai, XL; Feng, YZ; Han, ZB; Liu, YF; Qiu, J; Yang, YT, 2015) |
| "Therefore, the MDR of breast cancers could be obviously overcome by enhanced chemotherapy and NIR-triggered inorganic PDT of FA-NPs-DOX nanocomposites under the excitation of a 980 nm laser." | ( Lu, G; Pan, Y; Ren, W; Tian, Y; Wang, S; Wang, X; Wu, A; Zeng, L, 2015) |
| "ISL administration suppressed in vivo breast cancer initiation and progression, accompanied by reduced CSC-like populations." | ( Chen, J; Guan, X; Peng, C; Peng, F; Shen, J; Tang, H; Wang, N; Wang, Y; Wang, Z; Xie, X; You, J, 2015) |
| "T47D human breast cancer cells were treated with 2-deoxy- D-glucose (2DG), L-buthionine sulfoximine (BSO), or doxorubicin (DOX), individually or in combination, and changes in intracellular total glutathione and malondialdehyde (MDA) levels were measured." | ( Abdalla, MY; Ahmad, IM; Al-Hudhud, MY; Elkarmi, AZ; Mahmoud, HT; Mustafa, EH; Tahtamouni, LH; Yasin, SR, 2015) |
| "Estrogen receptor-α (ER)-positive breast cancer cells undergo hormone-independent proliferation after deprivation of oestrogen, leading to endocrine therapy resistance." | ( Abdalla, MOA; Fujiwara, S; Iwase, H; Maehara, K; Matsumori, H; Nakao, M; Ohkawa, Y; Saitoh, N; Tomita, S, 2015) |
| "MDA-MB-231 cells and HS 578t breast cancer cells were treated with different concentrations of DATS." | ( Cao, Y; Chen, W; Liu, Y; Liu, Z; Lu, Y; Ruan, J; Shan, Y; Sheng, X; Sun, L; Tao, L; Wang, A; Wang, S; Wang, Y; Wei, Z; Zhu, P; Zhu, Z, 2015) |
| "In luminal B type NAC-treated breast cancer patients, it is possible to use PET/CT as an early surrogate marker for predicting pCR and it is significantly more predictable for pCR than MRI." | ( Choe, JG; Kim, S; Pahk, K, 2015) |
| "Many breast cancer survivors on endocrine therapy (ET) experience a range of side effects while taking ET." | ( Partridge, AH; Petrie, KJ; Rosenberg, SM; Stanton, AL, 2015) |
| "Among the 26,656 tamoxifen-treated breast cancer survivors, we evaluated the usage, frequency of service, and prescription of Chinese herbal products containing coumestrol, genistein, or daidzein." | ( Hu, YC; Lai, JN; Tsai, YT; Wu, CT, 2015) |
| "Among those tamoxifen-treated female breast cancer survivors in Taiwan, consumption of Chinese herbal products containing coumestrol, genistein, or daidzein is negatively correlated with subsequent endometrial cancer risk." | ( Hu, YC; Lai, JN; Tsai, YT; Wu, CT, 2015) |
| "Human oral cancer cells, breast cancer cells, and colon cancer cells were treated with ZA at a wide range of concentrations in different Ca(2+) concentration environments." | ( Arai, N; Hattori, Y; Inoue, S; Noguchi, M; Takashina, M; Tomihara, K, 2015) |
| "As most node-positive patients with HR+ breast cancer currently receive adjuvant chemotherapy improved methods for characterization of individuals' metastasis risk are needed to reduce overtreatment." | ( Balic, M; Cowens, JW; Cuzick, J; Dowsett, M; Dubsky, P; Ferree, S; Fesl, C; Filipits, M; Gnant, M; Greil, R; Jakesz, R; Lopez-Knowles, E; Nielsen, T; Rudas, M; Schaper, C; Sestak, I; Stoeger, H, 2015) |
| "We treated MCF-7 breast cancer cells with 100 ng/mL leptin for 10 days and analyzed cell growth, ROS production and oxidative damage, as well as, some of the main antioxidant systems." | ( Nadal-Serrano, M; Oliver, J; Roca, P; Sastre-Serra, J; Valle, A, 2015) |
| "Screening TNBC/basal-like breast cancer for EGFR mutations may prove useful for directing therapy but, as in non-small cell lung cancer, accompanying mutations in PIK3CA may confer gefitinib resistance." | ( Al-Ejeh, F; Bessette, DC; Chenevix-Trench, G; Cocciardi, S; Grimmond, SM; Khanna, KK; Lakhani, SR; McCart-Reed, A; Quinn, MC; Saunus, JM; Seidens, T; Shi, W; Simpson, PT; Tilch, E; Waddell, N; Wiegmans, AP, 2015) |
| "The histologic subtype of breast cancer affects the appearance of untreated osseous metastases on FDG PET/CT." | ( Corben, AD; Dashevsky, BZ; Goldman, DA; Gönen, M; Hudis, CA; Jochelson, MS; Morrow, M; Parsons, M; Ulaner, GA, 2015) |
| "Of 55 breast cancer patients biomarkers were assessed and echocardiography was performed one year after treatment with anthracyclines." | ( Bellersen, L; Bulten, BF; de Geus-Oei, LF; Joosten, LA; Kapusta, L; Mandigers, CM; Mavinkurve-Groothuis, AM; van Boxtel, W; van Laarhoven, HW, 2015) |
| "For HER2 positive metastatic breast cancer (MBC), continuing anti-HER2 therapy beyond progression is associated with improved outcome." | ( Arpaci, E; Arslan, UY; Artac, M; Bayoglu, IV; Demirci, U; Dogan, M; Guler, T; Isikdogan, A; Koca, D; Kucukoner, M; Kucukzeybek, Y; Oguz, A; Turker, I; Uncu, D; Zengin, N, 2015) |
| "We investigated 141 patients with breast cancer treated with doxorubicin and cyclophosphamide (AC) chemotherapy." | ( Daimon, T; Hatori, M; Hayashi, H; Ikeda, M; Inoue, K; Itoh, K; Iwabe, Y; Kim, YI; Makuta, R; Nakamichi, H; Shiokawa, M; Tsuji, D; Yamamoto, K, 2015) |
| "There were 50257 and 25231 women with breast cancer who did and did not receive tamoxifen treatment, respectively." | ( Chen, HT; Hsu, HC; Hwang, WL; Muo, CH; Tsai, CH; Tzeng, HE, 2015) |
| "For the in vivo study, human breast cancer was induced in athymic mice and treated with 300 mg/kg/day of curcumin administered intraperitoneally." | ( Ali, MM; Arbab, AS; Borin, TF; Ferreira, LC; Iskander, AS; Jardim-Perassi, BV; Shankar, A; Varma, NR; Zuccari, DA, 2015) |
| "However, its role in response to breast cancer therapy is unknown." | ( Arias, E; Castelao, E; Eiró, N; Garcia-Caballero, T; Lopez-Lopez, R; Macia, M; Maestro, M; Martinez-Ordoñez, A; Mouriño, A; Perez-Fernandez, R; Sendon-Lago, J; Seoane, S; Sigueiro, R; Vizoso, F, 2015) |
| "A total of 318 breast cancer patients were demonstrated with lymph node metastasis by needle biopsy and given neoadjuvant chemotherapy." | ( Chen, J; Han, Z; Lv, Y; Wang, B; Wang, H; Wang, L; Wang, T; Yao, Q; Zhang, J, 2015) |
| "Radiotherapy for left-sided breast cancer was associated with cardiac failure (OR 3." | ( Dieudonné, AS; Hatse, S; Lambrechts, D; Maggen, C; Neven, P; Paridaens, R; Pettengell, R; Pfeil, AM; Schwenkglenks, M; Szucs, TD; Vulsteke, C; Wildiers, H, 2015) |
| "Generalized strategies to improve breast cancer treatment remain of interest to develop." | ( Kubisch-Dohmen, R; Lehr, T; Liebl, J; Menche, D; Schneider, LS; Trauner, D; Ulrich, M; Vollmar, AM; von Schwarzenberg, K, 2015) |
| "Thirty-two patients with breast cancer were treated on study and 5 (16 %) achieved a partial or complete response." | ( Atkins, JT; Janku, F; Kurzrock, R; Moulder, SL; Stephens, PJ; Wheler, JJ; Yelensky, R, 2015) |
| "Treatment for metaplastic breast carcinoma is relatively unknown because of the rarity of the disease, but studies suggest that removal of the tumor and adjuvant radiation therapy has the greatest benefit." | ( McKinnon, E; Xiao, P, 2015) |
| "In a mouse model of breast cancer, systemic administration of AS1411-GNS could completely inhibit tumor growth with no signs of toxicity." | ( Bardi, GT; Bates, PJ; Casson, LK; Kang, KA; Malik, MT; Ng, CK; O'Toole, MG; Reyes-Reyes, EM; Thomas, SD, 2015) |
| "As a result breast cancer develops during long-term hormone replacement therapy (HRT)." | ( Abderrahman, B; Curpan, RF; Fan, P; Jordan, VC; Maximov, PY, 2015) |
| "Increased risk of breast cancer is a critical side effect associated with the use of a menopausal hormone therapy (MHT)." | ( Arnal, JF; Communal, L; Foidart, JM; Gérard, C; Gompel, A; Lenfant, F; Mestdagt, M; Noel, A; Péqueux, C; Silva, E; Tskitishvili, E, 2015) |
| "Non-adherence and non-persistence in breast cancer patients taking antihormonal therapy (AHT) is common." | ( De Baere, S; Decoene, E; Van Hecke, A; Vandendorpe, B; Verbrugghe, M; Verhaeghe, S, 2017) |
| "Although approximately 70% of breast cancer patients demonstrate a clinical response on neoadjuvant systemic therapy on physical examination or on anatomic radiographic imaging, only 3%-40% achieve a pathologic complete response (pCR)." | ( Semiglazov, V, 2015) |
| "For estrogen-receptor positive breast cancer cases, tamoxifen has been the most important adjuvant hormonal therapy for the purpose of reducing recurrence rates and prolonging disease free survival." | ( Chang, HT; Lee, CH; Pan, HJ, 2016) |
| "In this retrospective study, 241 breast cancer patients who received neoadjuvant chemotherapy were included." | ( Abdel-Aziz, NM; Abozeed, WN; Alsaleh, K; Alzahrani, A; Elbiomy, MA; Elsamany, S; Farooq, MU; Rasmy, A; Rawah, E, 2015) |
| "In particular, the triple-negative breast cancer subtype of breast cancer has no targeted therapy available so it is essential to continue to work on any potential therapies." | ( Hodgins, SJ; Kiely, M; Kiely, PA; Merrigan, BA; O'Connor, EM; Tormey, S, 2015) |
| "A total of 48 local advanced breast cancer patients that received taxane-containing neoadjuvant chemotherapy were studied." | ( Guo, G; Hu, X; Pan, Y; Xiang, Y; Yang, Y; Zhang, H; Zhang, X, 2016) |
| "In a mouse model of ductal breast carcinoma we identify a tumor regressive stromal reaction that is induced by neoadjuvant endocrine therapy." | ( Boughey, J; Frost, M; Goetz, M; Kaen, D; Lanari, C; May, M; Novaro, V; Perrone, MC; Polo, ML; Radisky, D; Riggio, M; Rodríguez, MJ; Stallings-Mann, M, 2015) |
| "In all, 131 women with stage ≤ 3 breast cancer underwent ovarian stimulation and received concurrent letrozole 5 mg per day before receiving adjuvant chemotherapy and cryopreserving embryos." | ( Bedoschi, G; Moy, F; Oktay, K; Pacheco, FS; Turan, V, 2015) |
| "Epirubicin, which is widely used for breast cancer chemotherapy, is an anthracycline that has less cardiac toxicity than doxorubicin." | ( Arai, M; Horiguchi, J; Koitabashi, N; Kurabayashi, M; Ohyama, Y; Rokutanda, N; Tateno, R, 2015) |
| "Among 29 patients with advanced breast cancer, 4 patients chose pemetrexed based regimens as second-line treatment,1 of them was PR,the other 3 got SD." | ( Huang, XE; Qian, T, 2015) |
| "Patients with early-stage breast cancer who had received anthracycline-cyclophosphamide-based chemotherapy were surveyed." | ( Clemons, M; Dranitsaris, G; Hernandez Torres, C; Hutton, B; Jacobs, C; Mazzarello, S; Munro, A; Ng, T; Smith, S, 2015) |
| "Although greater than 40% of breast cancers occur in patients aged ≥65 years, these individuals are frequently undertreated." | ( Alfer, J; Burchardi, N; Conrad, B; Decker, T; Denkert, C; Eidtmann, H; Eiermann, W; Hackmann, J; Huober, J; Jackisch, C; Loibl, S; Marmé, F; Möbus, V; Nekljudova, V; Potenberg, J; Reimer, T; Simon, E; Stickeler, E; Thomssen, C; von Minckwitz, G, 2015) |
| "Four females with confirmed breast carcinoma diagnosis and breast image reporting and data system Category 5 on mammography underwent whole-body and thorax single-photon emission CT/CT imaging 1 and 3 h after (99m)Tc-doxorubicin administration." | ( Araujo, FI; Ferreira, CG; Fonseca, LM; Gutfilen, B; Moreira, RD; Proença, FP; Rosado de Castro, PH; Souza, SA; Ventilari, SC, 2015) |
| "Locally advanced HER2-overexpressing breast cancer (BC) patients achieve a high rate of pathological complete responses (pCR) after neoadjuvant chemotherapy (NC)." | ( Comaro, E; Crivellari, D; Dolcetti, R; Lombardi, D; Martorelli, D; Massarut, S; Militello, L; Miolo, G; Muraro, E; Perin, T; Scalone, S; Spazzapan, S; Talamini, R; Turchet, E, 2015) |
| "Luminal type breast cancers expressing hormone estrogen receptor (ER) or progesterone (PR) and without HER2 overexpression are generally sensitive to endocrine therapy, but raise the issue of the occurrence of resistance to treatment, particularly at metastatic stage." | ( Bachelot, T; Bally, O; Heudel, P; Kassem, L; Tredan, O; Vanacker, H, 2015) |
| "Patients with GI tumors or breast cancer treated with capecitabine were included in this randomized phase III study." | ( Al-Batran, SE; Bolz, G; Gencer, D; Hegewisch-Becker, S; Hofheinz, RD; Kronawitter, U; Loeffler, LM; Potenberg, J; Schneeweiss, A; Schulz, H; Stahl, M; Tauchert, F, 2015) |
| "The therapy of gefitinib towards breast cancer through reversing breast cancer biomarker arginine was demonstrated." | ( Geng, D; Sun, D; Zhang, L; Zhang, W, 2015) |
| "The enrolled breast cancer patients were randomly divided into two groups: treatment and observation." | ( Cheng, C; Hou, DX; Li, C; Li, JH; Lv, Y; Yan, T; Zhang, E, 2015) |
| "Locally advanced breast cancer (LABC) is a good setting in which to monitor response to neoadjuvant chemotherapy, to downsize the tumor (which facilitates breast-conserving surgery), and to test newer agents in untreated patients." | ( Abraham, J; Alcorn, H; Buyse, ME; Jacobs, SA; Limentani, S; Robidoux, A; Shalaby, I; Sturtz, K; Tan, AR; Wolmark, N, 2015) |
| "Some breast cancer survivors report cognitive difficulties greater than 1 year after chemotherapy." | ( Balcueva, EP; Case, LD; Griffin, L; Groteluschen, DL; Lawrence, JA; Lesser, GJ; Naughton, MJ; Rapp, SR; Samuel, TA; Shaw, EG, 2016) |
| "A total of 52 outpatients with breast cancer with mild to moderate depression, who suffered from pain and needed analgesics, participated in the trial and underwent 6 weeks of treatment with either celecoxib (200 mg twice daily) or diclofenac (50 mg twice daily)." | ( Akhondzadeh, S; Arya, P; Emami, SA; Esfandbod, M; Kashani, L; Kaviani, A; Mohammadinejad, P; Najafi, M; Zeinoddini, A, 2015) |
| "We present evidence that NMI sensitizes breast cancer cells to cisplatin treatment through DRAM1 dependent autophagy." | ( Chen, D; Metge, BJ; Mitra, A; Samant, RS; Shevde, LA, 2015) |
| "In luminal breast cancers, ErbB3 upregulation following treatment with the antiestrogen fulvestrant enhances PI3K/mTOR-mediated cell survival." | ( Aurisicchio, L; Ciliberto, G; Cook, RS; Hicks, D; Lim, J; McKernan, C; Morrison, MM; Simion, C; Sweeney, C; Vaught, DB; Williams, MM, 2016) |
| "Although metastatic breast cancer remains incurable, it is definitely treatable; especially in this era of emerging novel therapeutics." | ( Dawood, S; Dent, R; Eng, LG, 2015) |
| "Finally, triple negative breast cancer has an enlarging range of therapeutic options including immunotherapy, antiangiogenesis therapy, and targeted therapies including agents that interfere with androgen receptor signaling." | ( Dawood, S; Dent, R; Eng, LG, 2015) |
| "We recruited 235 women with breast cancer who were prescribed AI therapy." | ( Brier, MJ; Chambless, D; DeMichele, A; Gross, R; Mao, JJ; Su, HI, 2015) |
| "However, multidrug resistance of breast cancer interferes with the chemotherapy." | ( Choi, HS; Hong, SH; Kim, SR; Ko, SG; Ku, JM; Seo, HS; Shin, YC, 2015) |
| "In patients with locally advanced breast cancer treated with AT neoadjuvant chemotherapy." | ( Karpińska, A; Kładny, J; Safranow, K; Sulżyc-Bielicka, V, 2015) |
| "In women with breast cancer undergoing chemotherapy, assessment of cardiac sympathetic activity with 123I-mIBG appears to be an early marker of cardiotoxicity." | ( Andrade, LR; Brandão, SC; Guimarães, SL; Maia, RJ; Markman Filho, B, 2015) |
| "Thus costunolide effectively induced breast cancer cell apoptosis targeting cell cycle regulation, and the compound can be used as an effective herbal therapeutic molecule to treat breast cancer with further explorations." | ( Manikkam, R; Roy, A, 2015) |
| "Particularly, in breast cancer, anti-Her2/EGFR molecules represent the standard therapy for Her2-positive malignancies." | ( Budani, MC; Capone, E; D'Agostino, D; De Cola, A; De Laurenzi, V; Di Ilio, C; Ferracin, M; Lattanzio, R; Negrini, M; Piantelli, M; Sala, G; Stassi, G; Todaro, M; Turdo, A; Veronese, A; Volpe, S, 2015) |
| "Estrogen receptor negative (ER(-)) breast cancer is aggressive, responds poorly to current treatments and has a poor prognosis." | ( Chattopadhyay, M; Kashfi, K; Kodela, R; Nath, N; Nazarenko, A; Rodes, DB, 2015) |
| "A total of 377 patients with breast cancer who received preoperative chemotherapy were included in this retrospective study." | ( Bago-Horvath, Z; Bartsch, R; Bergen, E; Dubsky, P; Exner, R; Gnant, M; Jakesz, R; Mittlböck, M; Ott, J; Panhofer, P; Promberger, R; Rudas, M; Seemann, R; Singer, C; Steger, G, 2015) |
| "We report a case of Stage IV breast cancer in a 62-year-old woman who responded well to alternate-day S-1/letrozole combination therapy." | ( Fujita, Y; Muranishi, Y; Nakayama, I, 2015) |
| "We studied 38 patients with breast cancer who underwent TC treatment in our department between August 2008 and November 2009, and discussed the development of side effects in the patients." | ( Imanishi, S; Koyama, H; Matsui, C, 2015) |
| "A 61-year-old postmenopausal woman with breast cancer and carcinomatous pleurisy was successfully treated with bevacizumab and paclitaxel." | ( Hase, K; Hasegawa, S; Moriya, T; Sakaguchi, N; Tsuda, H; Yamagishi, Y; Yamamoto, J; Yamazaki, T, 2015) |
| "BCSCs (breast cancer stem cells) have been shown to be resistant to chemotherapy." | ( Chen, J; Cui, Z; Fu, L; Fu, Y; He, M; Jiang, Q; Jin, F; Mi, X; Wang, E; Wei, M; Wu, H; Xiao, Q; Yan, Y; Yao, W; Yu, Z; Zhao, H; Zhao, L, 2015) |
| "CD24 is overexpressed in breast cancer, and patients with high CD24 expression was resistant to tamoxifen treatment." | ( Chen, YP; Ma, ZL; Song, JL; Wang, YQ, 2015) |
| "In a multicenter cohort of 78 breast cancer patients undergoing doxorubicin and trastuzumab therapy, 8 biomarkers were evaluated at baseline and every 3 months over a maximum follow-up of 15 months." | ( Banchs, J; Carver, JR; Cohen, V; Gerszten, RE; Hahn, VS; Halpern, EF; Januzzi, JL; Kuter, I; Ky, B; Martin, RP; Passeri, J; Picard, MH; Plana, JC; Putt, M; Sawaya, H; Scherrer-Crosbie, M; Sebag, IA, 2015) |
| "For treating breast cancer, numerous natural products have been considered as chemotherapeutic drugs." | ( Kim, JY; Kim, KH; Kwak, JH; Pyo, S, 2015) |
| "Eighty-nine patients with breast cancer underwent breast DCE-MRI; 38 patients (39 lesions) were treated with NAC and examined for residual disease following therapy." | ( Li, G; Qiao, P; Sheng, F; Xing, X; Zhang, H; Zhou, J, 2016) |
| "We report the case of a HER2(+) breast cancer patient, with early relapse, refractory to HER2-targeted therapy and treated with eribulin mesylate." | ( Casanova, C; Dazzi, C; Mazza, V; Verlicchi, A, 2015) |
| "Human breast cancer MDA-MB-231SArfp cells were treated with ZA, PL or a combination of ZA and PL." | ( Fan, QM; Han, XG; Qiao, H; Qin, A; Tang, TT; Wang, TY; Wang, YG; Yan, W, 2015) |
| "In HER2-positive breast cancer patients the addition of trastuzumab to neoadjuvant chemotherapy improved the overall and pathological complete response." | ( Bozhok, AA; Dashyan, GA; Komyakhov, AV; Lalak, IA; Manikhas, AG; Paltuev, RM; Petrenko, OL; Semiglazov, VF; Semiglazov, VV; Semiglazova, TY, 2015) |
| "Overall, 121 breast cancer patients positive for human epidermal growth factor 2 (HER2) were randomly assigned to neoadjuvant chemotherapy plus trastuzumab, lapatinib, or both trastuzumab and lapatinib." | ( Bettelli, S; Bicciato, S; Bisagni, G; Cagossi, K; Conte, P; Crescenzo, R; Dieci, MV; Ellis, C; Ficarra, G; Frassoldati, A; Generali, DG; Guarneri, V; Maiorana, A; Musolino, A; Sarti, S; Tagliafico, E, 2015) |
| "However, breast cancer patients often experience disease progression after prolonged Herceptin treatment." | ( Fang, J; Huang, C; Jiang, J; Li, D; Li, H; Li, Z; Lou, L; Wang, X; Xie, K; Xu, Q; Yao, X, 2015) |
| "The International Breast Cancer Study Group (IBCSG)-led adjuvant endocrine therapy trials BIG 1-98, for postmenopausal women, and SOFT and TEXT, for premenopausal women, can shed light on the role for risk of recurrence in identifying who should receive which type of adjuvant endocrine therapy and for how long." | ( Regan, MM, 2015) |
| "A majority of breast cancer, however, will often fail to respond to endocrine therapy." | ( Berezikov, E; Horie-Inoue, K; Ikeda, K; Inoue, S; Mano, H; Osaki, A; Saeki, T; Sato, W; Shigekawa, T; Suzuki, T; Ueno, T, 2015) |
| "Thirty-two patients with metastatic breast cancer, receiving hormonal or trastuzumab therapy, took 5 mg of melatonin at bedtime for 2 months." | ( Bjarnason, GA; Clemons, M; Eisen, A; Innominato, PF; Kiss, A; Lim, AS; Palesh, O; Pritchard, KI; Trudeau, M; Wang, C, 2016) |
| "In the syngeneic 4T1 metastatic breast cancer model, DPP4 overexpression increased tumour development, whereas treatment with sitagliptin and/or juglone suppressed it." | ( Choi, HJ; Choi, HS; Kim, G; Kim, JY; Lim, SC; Yun, HJ, 2015) |
| "The endocrine therapy for breast cancer could be traced back to the excision of the metastatic breast cancer by oophorectomy in a premenopausal women performed by Beatson in 1896." | ( Liu, Y; Zhang, Y, 2015) |
| "Estrogen Receptor alpha (ERα)-positive breast cancer patients receive endocrine therapy, often in the form of tamoxifen." | ( Alexi, X; Beelen, K; Bentin Toaldo, C; Berns, E; Hauptmann, M; Jansen, M; Kok, M; Linn, S; Michalides, R; Neefjes, J; Zwart, W, 2015) |
| "Postmenopausal women with ER positive breast cancers benefit from adjuvant endocrine therapy." | ( Burstein, HJ; Mayer, EL, 2015) |
| "Approximately 30% of breast cancer does not express the estrogen receptor (ER), which is necessary for endocrine-based therapy approaches." | ( Du, F; Fu, P; Hong, Y; Liu, R; Liu, Y; Yao, M; Zhang, X; Zheng, S, 2015) |
| "Between 2001 and 2009, 110 breast cancer patients with IMN or SCN involvement were treated with primary systemic treatment followed by surgery and RT." | ( Choi, DH; Huh, SJ; Keum, KC; Kim, KH; Kim, YB; Noh, JM; Park, W; Suh, CO, 2015) |
| "Tumor biopsies from breast cancer patients enrolled in two preoperative clinical trials were obtained at baseline and after one dose of bevacizumab (HER2-negative), trastuzumab (HER2-positive) or nab-paclitaxel, followed by treatment with combination chemo-biologic therapy." | ( Abu-Khalaf, M; Banerjee, N; Basavanhalli, A; Bossuyt, V; Dimitrova, N; Gilmore, H; Harris, LN; Janevski, A; Kamalakaran, S; Lannin, DR; Lezon-Geyda, K; Madabhushi, A; Miskimen, KL; Sikov, W; Varadan, V; Williams, N, 2016) |
| "The heterogeneity of the disease makes breast cancer exceptionally difficult to treat, particularly for those patients with triple-negative disease." | ( McCabe, CJ; Poole, VL, 2015) |
| "Metastatic and nonmetastatic breast cancer cell lines were treated with melatonin as well as with specific ROCK-1 inhibitor (Y27632)." | ( Arbab, AS; Borin, TF; Coimbra, VB; de Oliveira, JG; Fabri, VA; Ferreira, LC; Gelaleti, GB; Iskander, AS; Jardim-Perassi, BV; Moschetta, MG; Shankar, A; Varma, NR; Zuccari, DA, 2016) |
| "Recurrence of invasive breast cancer could arise from the residual cancer cells after comprehensive treatment." | ( Ju, RJ; Li, XT; Li, XY; Lu, WL; Mu, LM; Shi, JF; Sun, MG; Yan, Y; Zeng, F; Zhao, Y, 2015) |
| "The four intrinsic subtypes of breast cancer, defined by differential expression of 50 genes (PAM50), have been shown to be predictive of risk of recurrence and benefit of hormonal therapy and chemotherapy." | ( Bernard, PS; Davies, SR; Dowidar, N; Ellis, MJ; Ferree, S; Geiss, G; Gnant, M; Leung, S; Liu, S; Mardis, ER; Nielsen, T; Parker, JS; Perou, CM; Schaper, C; Sestak, I; Snider, J; Storhoff, J; Vickery, T; Wallden, B, 2015) |
| "Adjuvant tamoxifen reduces breast cancer recurrence risk and mortality; however, initiation and treatment persistence are poor for younger patients." | ( Estevez, SL; Jeruss, JS; Llarena, NC; Tucker, SL, 2015) |
| "The molecular subtypes of breast cancer have individual patterns of behaviour, prognosis and sensitivity to treatment, with subsequent implications for the choice of, or indeed role for adjuvant therapy." | ( Biganzoli, L; Di Leo, A; Hart, CD; Sanna, G; Siclari, O, 2015) |
| "She was diagnosed with breast cancer recurrence and was administered combination chemotherapy consisting of gemcitabine and paclitaxel." | ( Dai, Y; Ishibashi, O; Kondo, T; Maeda, M; Ohkohchi, N; Watanabe, M, 2015) |
| "We treated 81 locally advanced breast cancer patients with four cycles of neoadjuvant chemotherapy (NAC)." | ( Bao, X; Cheng, J; Geng, D; Liu, G; Mo, M; Wang, Y; Zhang, J; Zhang, Y, 2015) |
| "Data from 520 consecutive breast cancer patients, treated between 1999 and 2004, were evaluated." | ( Gerger, A; Kapp, KS; Krenn-Pilko, S; Langsenlehner, T; Langsenlehner, U; Pichler, M; Stojakovic, T, 2015) |
| "IGFBP-3 downregulation in some breast cancer cell lines in response to DNA-damaging chemotherapy may have clinical implications because suppression of IGFBP-3 may modulate the apoptotic response." | ( Baxter, RC; Lin, MZ; Martin, JL; Marzec, KA, 2015) |
| "After human breast cancer MCF-7 cells were treated with different-concentration cyclopamine for different periods, MTT assay was used to detect the inhibitory effect of cyclopamine on MCF-7 cell proliferation, flow cytometry was used to determine the distribution of MCF-7 cell cycle and the effect of cyclopamine on MCF-7 apoptosis, and Western blot was used to measure the protein levels of cyclins D1 and p21 in MCF-7 cells." | ( Li, JC; Tao, W; Xue, WL; Zhu, DM, 2015) |
| "Five hundred and eighty eight breast cancer patients treated with anthracycline with/without taxane-based NAC were retrospectively analyzed, and the ypTNM stage, residual cancer burden (RCB), residual disease in breast and nodes (RDBN), tumor response ratio, Sataloff's classification, and Miller-Payne grading system were evaluated." | ( Ahn, JH; Ahn, SH; Gong, G; Jung, KH; Kim, HH; Kim, SB; Lee, HJ; Park, IA; Song, IH, 2015) |
| "About 50-70% of breast cancers are estrogen receptor α (ERα) positive and most of them are sensitive to endocrine therapy including tamoxifen." | ( Chu, J; Gong, C; Hu, P; Liu, B; Liu, Q; Liu, Y; Lv, X; Song, E; Su, F; Sun, L; Wu, Y; Zhu, Y, 2015) |
| "In women with advanced breast cancer receiving neoadjuvant chemo-therapy, prevalence of IMN adenopathy was 16%, equally detected by breast MRI and PET/CT." | ( Dershaw, DD; Jacobs, SS; Jochelson, MS; Lebron, L; Morris, EA; Moskowitz, CS; Powell, SN; Sacchini, V; Ulaner, GA; Zheng, J, 2015) |
| "The age at which breast cancer was diagnosed, and relationship to hormone therapy were analysed based on medical documentation." | ( Habánová, M; Predná, L; Sláviková, E; Wyka, J, 2015) |
| "In women who took hormonal treatment, breast cancer was diagnosed at the mean age of 50." | ( Habánová, M; Predná, L; Sláviková, E; Wyka, J, 2015) |
| "Nowadays, the breast cancer treatment, especially at early stages, is successful, however, the malignant breast neoplasm remains the most common oncological disease causing the death amongst women." | ( Habánová, M; Predná, L; Sláviková, E; Wyka, J, 2015) |
| "Treatment of breast cancer cells for 6 and 9 h with α-santalol (20, and 40 μM) resulted in statistically significant concentration-dependent down-regulation of survivin." | ( Bommareddy, A; Brozena, S; Crisamore, K; Dwivedi, C; Fillman, S; Landis, T; Steigerwalt, J; Vanwert, AL, 2015) |
| "For patients with HER2-positive breast cancer who initially respond to therapy, the majority develop resistance within one year of treatment." | ( Christenson, JL; Denny, EC; Kane, SE, 2015) |
| "Diabetic patients with breast cancer receiving metformin and neoadjuvant chemotherapy have a higher pathologic complete response rate than do diabetic patients not receiving metformin, but findings on salvage treatment have been inconsistent." | ( Chen, K; Dai, Y; Jia, X; Li, D; Mao, Y; Tao, M; Tian, Y; Xie, J; Xu, H, 2015) |
| "Diabetic patients with breast cancer receiving metformin and neoadjuvant chemotherapy have a higher pathologic complete response rate than diabetic patients not receiving metformin, but findings on salvage treatment have been inconsistent." | ( Chen, K; Dai, Y; Jia, X; Li, D; Mao, Y; Tao, M; Tian, Y; Xie, J; Xu, H, 2015) |
| "A prospective study on 100 breast cancer patients with mean age of 66 years in adjuvant treatment with anthracyclines, taxanes, and trastuzumab was performed." | ( Cardelli, P; De Biase, L; De Iuliis, F; Lanza, R; Salerno, G; Scarpa, S; Taglieri, L, 2016) |
| "Fatigue is a major burden for breast cancer patients undergoing adjuvant therapy." | ( Habermann, N; Schmidt, ME; Semik, J; Steindorf, K; Ulrich, CM; Wiskemann, J, 2016) |
| "From January 2012 to December 2014, breast cancer patients managed by radical mastectomy previously and receiving tamoxifen treatment for at least 12 months were enrolled." | ( Cao, X; Fang, J; Zhang, B; Zhang, Y, 2015) |
| "The treatment efficacy of advanced breast cancer is still not promising." | ( Chen, Y; Han, C; Jiao, S; Li, J; Linghu, R; Si, W; Yang, B; Yang, J; You, J; Zhang, X; Zhu, Y, 2015) |
| "In human ovarian and breast cancer samples, expression of EphB4 rather than the canonical EpoR correlated with decreased disease-specific survival in rhEpo-treated patients." | ( Alpay, SN; Armaiz-Peña, GN; Brock, S; Cho, MS; Coleman, RL; Dalton, HJ; Danes, C; Gharpure, K; Goodman, B; Haghpeykar, S; Han, HD; Hansen, JM; Hu, W; Huang, J; Hung, MC; Jackson, DB; Jaladurgam, P; Kruger, C; Ladbury, JE; Li, C; Liu, J; Lopez-Berestein, G; Mangala, LS; Matsuo, K; Mora, EM; Nagaraja, AS; Nick, AM; Nishimura, M; Noh, K; Ozpolat, B; Pecot, CV; Pradeep, S; Previs, RA; Rodriguez-Aguayo, C; Rupaimoole, R; Schneider, A; Sood, AK; Stagg, LJ; Stein, MA; Stone, RL; Urbauer, D; Vivas-Mejia, P; Wen, Y; Wu, SY; Xiong, C; Zand, B, 2015) |
| "Estrogen pretreatment of breast cancer cells increases PR steady state levels, resulting in an unequivocal progesterone response that upregulates key members of growth factor pathways." | ( Buchanan, G; Gill, PG; Giorgio, L; Graham, JD; Ingman, WV; Leach, DA; Need, EF; O'Loughlin, MA; Selth, LA; Smith, E; Trotta, AP, 2015) |
| "Docetaxel (DTX) is favoured option for breast cancer treatment; however its marketed formulation (Taxotere) generates therapeutic response at the cost of undue toxicity." | ( Bora, HK; Chaurasia, M; Chourasia, MK; Gupta, A; Gupta, S; Meher, JG; Pawar, VK; Sharma, K; Singh, P; Singh, Y, 2015) |
| "Analyses of data from the Breast Cancer Trials of Oral Everolimus 2 trial have shown that, despite a greater frequency of AEs in the everolimus plus exemestane treatment arm, the AEs were effectively managed with temporary dose reductions or interruptions." | ( Rugo, HS, 2016) |
| "Knowledge about breast cancer, its symptoms, risk factors, diagnostic modalities, and treatment was similarly poor in both rural and urban women." | ( Gangane, N; Ng, N; Sebastian, MS, 2015) |
| "The case of a 58-year-old female with breast cancer who developed multiple and ultimately fatal metastases despite 3 years of treatment with chemotherapeutic drugs and intravenous bisphosphonates, is presented herein." | ( Bagan, JV; Bagan, L; Poveda, R; Scully, C, 2016) |
| "The benefits of breast cancer adjuvant systemic treatments are generally assumed to be proportional (or constant) over time, but limited data suggest that some treatment effects may vary with time." | ( Anderson, WF; Bandos, H; Jatoi, I; Jeong, JH; Mamounas, EP; Romond, EH; Wolmark, N, 2016) |
| "The NSABP breast cancer trials were tested for the proportionality of hazard rates between randomized treatment groups for five endpoints: overall survival, disease-free survival and recurrence, local-regional recurrence, or distant recurrence as first events." | ( Anderson, WF; Bandos, H; Jatoi, I; Jeong, JH; Mamounas, EP; Romond, EH; Wolmark, N, 2016) |
| "We treated the breast cancer cell line MCF7 with 24-methylenecycloartanyl ferulate (24-MCF), a γ-oryzanol compound." | ( Choe, JS; Cui, X; Jang, HH; Kang, DR; Kim, HR; Kim, HW; Kim, JB; Lee, SH; Lim, EJ; Park, JH; Yang, YM, 2015) |
| "Triple-negative breast cancer (TNBC), which does not show hormone sensitivity, is a poor prognosis disease without an established targeted treatment, so that establishing a therapeutic target for each subtype is desired." | ( Furuya, K; Oguchi, K; Oyamada, H; Sasaki, A; Tsuchiya, H; Tsuji, M; Tsunoda, Y; Udaka, Y, 2016) |
| "Twenty-eight women with breast cancer were monitored before chemotherapy and after the second and fourth cycles of therapy with cyclophosphamide and doxorubicin." | ( Carvalho, Sda C; Cavalcante, AA; da Silva, LI; de Freitas, RM; Ferreira, PM; Gomes Júnior, AL; Machado, Kda C; Paz, MF; Satyal, P; Sobral, AL, 2015) |
| "In stage II/III breast cancer, neoadjuvant chemotherapy (NAC) is a standard treatment." | ( Cho, S; Ham, HS; Han, SW; Han, W; Im, SA; Keam, B; Kim, H; Kim, TY; Lee, KH; Min, A; Noh, DY; Oh, DY; Park, IA; Ryu, HS; Yang, Y; Youk, J, 2016) |
| "MCF-7 and SK-BR-3 breast cancer cells were cultured in 1% oxygen or treated with cobalt chloride (CoCl2 ) to mimic hypoxia." | ( Cui, XY; Dahm, AE; Iversen, N; Jin, Y; Kanse, S; Sahlberg, KK; Sandset, PM; Seidl, S; Skretting, G; Stavik, B; Tinholt, M, 2016) |
| "Four hundred and two patients with breast cancer and treated with bevacizumab were included." | ( Beuzeboc, P; Daniel, C; Deray, G; Dorent, R; Gligorov, J; Goldwasser, F; Janus, N; Jouannaud, C; Launay-Vacher, V; Ludwig, L; Mir, O; Morere, JF; Oudard, S; Ray-Coquard, I; Rey, JB; Scotté, F; Selle, F; Spano, JP; Thery, JC, 2015) |
| "Patients with breast cancer who received radiotherapy to the chest wall after mastectomy were enrolled." | ( Chen, G; Jia, L; Kong, L; Li, X; Meng, X; Sun, X; Xing, L; Yu, J; Zhao, H; Zhao, X; Zhu, W, 2016) |
| "The odds ratio for ER+ breast cancer associated with combination use, relative to never use of either estrogen alone or combination therapy, was 1." | ( Ambrosone, CB; Bandera, EV; Bethea, TN; Haiman, CA; Hong, CC; Kolonel, LN; Olshan, AF; Palmer, JR; Rosenberg, L; Troester, MA; Viscidi, E, 2016) |
| "Fifty adult female breast carcinoma patients were randomized after modified radical mastectomy and chemotherapy to receive prophylactic placebo cream (n = 27) or 1% hydrocortisone cream (n = 23) during radiation therapy." | ( Arcillas, JG; Co, HS; Cupino, NA; Maaño, CC; Meghrajani, CF, 2016) |
| "Thus, magnetic 5-FU-IP is promising for breast cancer therapy with high efficacy." | ( Hashemi-Moghaddam, H; Jamili, M; Kazemi-Bagsangani, S; Zavareh, S, 2016) |
| "Inflammatory and invasive breast cancers are aggressive and require better understanding for the development of new treatments and more accurate prognosis." | ( Chandran, K; Goswami, S; Sharma-Walia, N, 2016) |
| "We examined 16 887 breast cancer survivors (TNM stages 0-II) diagnosed between 1996 and 2007 and treated with tamoxifen in two California health plans." | ( Ahmed, SA; Avila, C; Cheetham, TC; Chung, J; Fletcher, SW; Habel, LA; Haque, R; Kleinman, K; Kwan, ML; Schottinger, JE; Shi, J, 2016) |
| "In patients with early node-negative breast cancer who were endocrine-only treated, 38% were GG1 with a 10-year DRFI of 99% (95% CI, 97%-100%), and 18% were histological grade 1 with a 10-year DRFI of 100% (95% CI, 100%-100%)." | ( Azim, HA; Dell'Orto, P; Desmedt, C; Ditzel, HJ; Giobbie-Hurder, A; Ignatiadis, M; Kammler, R; Laïos, I; Larsimont, D; Leyland-Jones, B; Lyng, MB; Michiels, S; Piccart, M; Regan, MM; Rothé, F; Salgado, R; Sotiriou, C; Veys, I; Viale, G, 2016) |
| "Nearly 60% of all breast cancer premenopausal women are diagnosed with a hormone receptor positive tumor and, therefore, are candidates for adjuvant hormonal therapy." | ( De Laurentiis, M; Del Mastro, L; Montemurro, F; Puglisi, F, 2016) |
| "Premenopausal patients with breast cancer and more than 10 positive axillary nodes (BC>10) have a poor prognosis: In these patients the best adjuvant therapy (CT) has not yet been established." | ( Bratta, M; Candeloro, G; D'Orazi, V; Fumagalli, LA; Pasta, V; Rea, S; Recchia, F; Rosselli, M, 2015) |
| "MCF-7 estrogen receptor-positive (ER+) breast cancer cells were treated with raloxifene to upregulate the TGF-β pathway and PX-866 to down-regulate the PI3K/Akt pathway." | ( Peek, GW; Tollefsbol, TO, 2016) |
| "The limitation of current breast cancer treatments was elucidated by the presence of cancer stem cells (CSCs) that play essential role in cancer initiation, progression, resistance, recurrence and metastasis." | ( Al Faraj, A; Al Jammaz, I; Al Sayed, B; Halwani, R; Shaik, AS, 2016) |
| "To test this hypothesis, we treated breast cancer MDA-MB-231 cells with tamoxifen (TMX), which induces autophagy through an estrogen receptor-independent pathway." | ( Ann, DK; Chen, YR; Hu, S; Liu, X; Ma, H; Tsou, B; Yen, Y, 2016) |
| "In metastatic breast cancer, sequential administration of different non-cross resistant drugs offers a chance to delay cytotoxic chemotherapy." | ( Bartsch, R; Gnant, M; Steger, GG, 2016) |
| "The primary outcome was breast cancer-free interval, defined as time from randomisation to any breast cancer event (local, regional, or distant recurrence, or contralateral breast cancer, invasive disease, or ductal carcinoma in situ), analysed by intention to treat." | ( Albain, KS; Brufsky, AM; Cecchini, RS; Cianfrocca, ME; Costantino, JP; Fehrenbacher, L; Ganz, PA; Gross, HM; Hopkins, JO; Julian, TB; Mamounas, EP; Margolese, RG; Seay, TE; Soori, GS; Sturtz, K; Vallow, LA; Whitworth, PW; Wolmark, N; Wozniak, TF, 2016) |
| "Oestrogen receptor-negative (ER-) breast cancer is intrinsically sensitive to chemotherapy." | ( Beurdeley, A; Bièche, I; Cairo, S; Château-Joubert, S; Déas, O; Decaudin, D; Depil, S; Fontaine, JJ; Gaston, J; Judde, JG; Lassalle, M; Legrier, ME; Marangoni, E; Poupon, MF; Roman-Roman, S; Servely, JL; Thuleau, A; Tucker, GC; Vacher, S; Yvonnet, V, 2016) |
| "Treating mice that carry breast tumors with T-DM1 improves survival, but the tumors suppress the infiltrating lymphocytes." | ( , 2016) |
| "Letrozole-resistant breast cancer cells (LTLT-Ca) were treated with a novel phytoalexin, glyceollin I, and exhibited morphological characteristics synonymous with an epithelial phenotype and decreased proliferation." | ( Boué, SM; Burks, H; Burow, ME; Carriere, PP; Collins-Burow, B; Davenport, IR; Davidson, AM; Hilliard, A; Llopis, SD; Naiki, AC; Nguyen, G; Nguyen, MM; Nguyen, TA; Parker-Lemieux, K; Payton-Stewart, F; Phan, T; Pratt, J; Preyan, LC; Tilghman, SL; Williams, CC; Yearby, L, 2015) |
| "Human breast cancer MDA-MB-231 cells were treated with salinomycin at different concentrations and at various time points." | ( Hou, Z; Li, L; Li, Q; Lu, Y; Ma, W; Mao, J; Yu, X; Zhang, C, 2015) |
| "The sensitization of breast cancer stem cells (BrCSCs) to the inhibitive effects of radiotherapy through adjuvant therapy which targets oncogenic pathways represents a prospective strategy for improving the effect of radiation in patients with triple-negative breast cancer (TNBC)." | ( He, S; Lai, Y; Lin, X; Yu, X, 2016) |
| "Obesity is associated with a worse breast cancer prognosis, while greater breast tumor estrogen receptor beta (ERβ) expression is correlated with improved therapy response and survival." | ( Bowers, LW; Brenner, AJ; deGraffenried, LA; Hursting, SD; Rossi, EL; Tekmal, RR; Wiese, M, 2015) |
| "Women with early stage breast cancer receiving adjuvant taxane chemotherapy were assessed with the FACT-Ntx score and serum was collected before and after the taxane treatment." | ( Awad, D; Chen, EI; Crew, KD; Hershman, DL; Kalinsky, K; Kim Kim, J; Koller, A; Maurer, M; Patel, P; Trivedi, M, 2015) |
| "The patients who have HER-2-positive breast cancer recurrence and metastasis after treated by anthracyclines and taxanes were enrolled in this study." | ( Bian, L; Jiang, Z; Li, W; Song, S; Wang, T; Zhang, H; Zhang, S; Zhou, J, 2015) |
| "As an approach to improve treatment of breast cancer metastasis to the brain, we employed genetically engineered stem cells (GESTECs, HB1." | ( Choi, KC; Kim, SU; Yi, BR, 2016) |
| "In the present study, MCF-7, human breast cancer cells were treated with ATRA in combination with a VEGFP-TK/CD gene suicide system developed by our group." | ( Huang, Z; Kong, H; Liu, X; Qi, K; Wang, H; Yang, L; Zhang, H; Zhang, J, 2016) |
| "Herein two breast cancer cell lines, SKBr3 and BT474, overexpressing human epithelial receptor 2 (HER2), the target of the humanised antibody trastuzumab, were treated with a range of concentrations (20-2000 nM) of doxorubicin with and without trastuzumab in the presence of clinically relevant doses of the ACE inhibitor enalapril, the beta-blocker carvedilol, metformin or dexrazoxane, and cell survival determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay." | ( Akabuogu, EU; Phyu, SM; Smith, TA, 2016) |
| "Data from 177 breast cancer patients receiving anthracycline and cyclophosphamide-based chemotherapy was used to calculate CINV control rates using the 15 most commonly reported CINV endpoints." | ( Clemons, M; Dranitsaris, G; Hutton, B; Mazzarello, S; Ng, T; Smith, S; Vandermeer, L; Wang, Z, 2016) |
| "Radioembolization for breast cancer liver metastases shows encouraging local response rates with low incidence of serious adverse events, especially in those patients with sequential lobar treatment or without prior angiosuppressive therapy." | ( Bartenstein, P; Fendler, WP; Haug, AR; Jakobs, TF; Lechner, H; Lehner, S; Michl, M; Paprottka, KJ; Paprottka, PM; Todica, A, 2016) |
| "All women with breast cancer treated at SJMC between 2008 and 2012 were enrolled for this observational cohort study." | ( Abdullah, MM; Chua, CT; Foo, YC; Hoo, L; Lee, CM; Lim, TO; Mohamed, AK; Wu, CH; Yen, SW, 2015) |
| "A panel of human breast cancer cell lines were treated with evofosfamide under hypoxia and assessed for cell viability." | ( Atkins, GJ; DeNichilo, M; Evdokiou, A; Findlay, DM; Hay, S; Ingman, W; Labrinidis, A; Liapis, V; Panagopoulos, V; Ponomarev, V; Zannettino, AC; Zinonos, I; Zysk, A, 2016) |
| "Incidence of invasive ER-positive breast cancer was reduced by SERMs treatment, especially for those women with high risk of developing breast cancer." | ( Dou, J; Li, F; Li, S; Liu, J; Wei, L, 2016) |
| "Based above, tamoxifen was approved for breast cancer prevention by the US Food and Drug Administration in 1998." | ( Dou, J; Li, F; Li, S; Liu, J; Wei, L, 2016) |
| "The patients with breast cancer received two chemotherapy cycles, and the NSCLC patients received 1-2 cycles of chemotherapy according to their condition." | ( Bi, J; Cao, B; Chen, L; Dai, H; Deng, Y; Hu, J; Jia, L; Jiang, H; Li, W; Meng, C; Nan, K; Shen, K; Shen, P; Shi, J; Song, Y; Sun, Q; Sun, Y; Tang, L; Tian, F; Tong, Z; Wang, S; Wu, G; Wu, Q; Wu, Y; Xie, X; Xu, B; Yu, J; Yuan, Z; Yue, S; Zhang, B; Zhang, Q; Zhang, Y; Zhuang, W, 2016) |
| "In patients with breast cancer and non-small cell lung cancer (NSCLC) undergoing TAC/TA chemotherapy, a single 100 μg/kg injection or a single fixed 6 mg dose of PEG-rhG-CSF at 48 hours after chemotherapy show definite therapeutic effect with a low incidence of adverse events and mild adverse reactions." | ( Bi, J; Cao, B; Chen, L; Dai, H; Deng, Y; Hu, J; Jia, L; Jiang, H; Li, W; Meng, C; Nan, K; Shen, K; Shen, P; Shi, J; Song, Y; Sun, Q; Sun, Y; Tang, L; Tian, F; Tong, Z; Wang, S; Wu, G; Wu, Q; Wu, Y; Xie, X; Xu, B; Yu, J; Yuan, Z; Yue, S; Zhang, B; Zhang, Q; Zhang, Y; Zhuang, W, 2016) |
| "254 early breast cancer patients starting AI (n = 159) or tamoxifen therapy (n = 95) were included in this genetic biomarker study." | ( Jongen, L; Laenen, A; Lambrechts, D; Lintermans, A; Neven, P; Van Asten, K; Van Brussel, T; Vanderschueren, D; Verhaeghe, J, 2016) |
| "We studied plasma lipid levels in 12 breast cancer patients throughout their chemotherapy." | ( Black, K; Jones, LM; McCormick, SP; McLaren, B; Sharma, M; Tuaine, J; Waters, DL, 2016) |
| "Targeting breast cancer and more specifically cancer stem cell (CSC) subpopulation, responsible for tumor growth, resistance and self-renewal, using combination of therapeutic drugs selectively delivered via biocompatible nanocarriers, provides a novel approach for effective therapy." | ( Al Faraj, A; Halwani, R; Ratemi, E; Shaik, AS, 2016) |
| "Thus, NFV overcomes MDR in breast cancer cells and should be tested as an adjunct to chemotherapy." | ( Abdel-Mageed, AB; Chakravarty, G; Datta, A; Gerlach, S; Mallade, P; Mathur, A; Mondal, D; Srivastav, S; Willis, J, 2016) |
| "Drug resistance in breast cancer is the major obstacle to effective treatment with chemotherapy." | ( Bartlett, JM; Boutros, PC; Braunstein, M; Kalatskaya, I; Krzyzanowski, PM; Liao, L; Lobo, N; Lyttle, N; Marcellus, R; Spears, M; Stein, LD; Taylor, KJ; Twelves, CJ; Yao, CQ, 2016) |
| "The primary outcome was invasive breast cancer events (new invasive primary, local, regional or distant recurrence, or contralateral breast cancer), analysed by intention to treat." | ( Bayliss, E; Boyle, FM; Campbell, I; Coates, AS; Cuzick, J; Davies, L; Della-Fiorentina, S; Forbes, JF; Gebski, V; Gill, PG; Green, M; Kannourakis, G; Kling, N; Mann, GB; Reaby, L; Saunders, C; Thornton, R; Zdenkowski, N, 2016) |
| "The treatment of breast cancer-induced osteolysis remains a challenge in clinical settings." | ( Fan, QM; Han, XG; Liu, XQ; Qiao, H; Qin, A; Tang, TT; Wang, TY; Wang, YG; Yu, ZF, 2016) |
| "These data confirmed the dependency of breast cancer progression on EZH2 activity and the usefulness of ZLD1039 as a promising treatment for breast cancer." | ( Feng, Q; Gao, T; Lei, Q; Shi, Y; Song, X; Wang, N; Wei, Y; Xia, Y; Xiong, M; Yang, F; Ye, T; You, X; Yu, L; Zhang, L; Zhu, Y, 2016) |
| "These advances in breast cancer research indicate that LXR may be a new therapeutic target to treat the refractory or drug-resistant subtypes of breast cancer." | ( Cao, HX; Chen, D; Feng, JF; Hu, Y; Liu, Y; Wu, Y; Yan, DL; Yu, DD; Yu, SR; Zhang, HD, 2016) |
| "To improve breast cancer treatment it is vital to understand the mechanisms that result in tamoxifen resistance." | ( Bekele, RT; Benesch, MG; Brindley, DN; Curtis, JM; Godbout, R; Liu, RZ; Mackey, JR; McMullen, TP; Mi, S; Tang, X; Venkatraman, G, 2016) |
| "However, most breast tumors are eventually resistant to tamoxifen therapy." | ( Wang, ZY; Yin, L, 2016) |
| "Women with stage II or III breast cancers who would ordinarily be advised to receive adjuvant chemotherapy should receive ovarian suppression with endocrine therapy." | ( Anderson, H; Buchholz, TA; Burstein, HJ; Davidson, NE; Gelmon, KE; Giordano, SH; Griggs, JJ; Hudis, CA; Lacchetti, C; Solky, AJ; Stearns, V; Winer, EP, 2016) |
| "We selected 139 women with breast cancer who underwent neoadjuvant chemotherapy (docetaxel plus epirubicin), and detected the expression of IGF1R and estrogen receptor in the samples taken before chemotherapy by Immunohistochemistry." | ( Li, X; Liu, L; Zhang, J, 2015) |
| "A total of 117 patients out of 133 breast cancer patients recruited by universal sampling were interviewed using a structured questionnaire consisted of three parts: participants' socio-demographic and disease characteristics, Supportive Care Needs Survey-Short Form Questionnaire (SCNS-SF34) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30)." | ( Al-Dubai, SA; Binti Abdullah, N; Edib, Z; Kumarasamy, V; Rizal, AM, 2016) |
| "In patients treated for early breast cancer with adjuvant anthracycline-containing regimens with or without trastuzumab and radiation, concomitant treatment with candesartan provides protection against early decline in global left ventricular function." | ( Bratland, Å; Fagerland, MW; Geisler, J; Gravdehaug, B; Gulati, G; Hagve, TA; Heck, SL; Hoffmann, P; Omland, T; Ree, AH; Røsjø, H; Schulz-Menger, J; Steine, K; Storås, TH; von Knobelsdorff-Brenkenhoff, F, 2016) |
| "JIMT-1 breast cancer cells were treated with three C20-O-acylated analogs, the C1-methyl ester of salinomycin, and salinomycin." | ( Borgström, B; Hegardt, C; Huang, X; Kempengren, S; Oredsson, S; Persson, L; Strand, D, 2016) |
| "In the example of an early breast cancer trial for which a new treatment significantly delayed disease recurrence, our Bayesian analysis showed that with very reasonable assumptions on the effects of treatment after recurrence, there is a high probability that the new treatment improves overall survival." | ( Finkelstein, DM; Schoenfeld, DA, 2016) |
| "Nanoparticle treatment of breast cancer transplants on chick embryo chorioallantoic membranes efficiently reduced the cancer stem cell population of the tumor." | ( Beck, M; Desai, D; Gronroos, T; Kronqvist, P; Landor, S; Linden, M; Mamaeva, V; McCormack, E; Niemi, R; Özliseli, E; Pettersen, IK; Rosenholm, JM; Sahlgren, C, 2016) |
| "MCF7 cells, a model of breast cancer cells, were resistant to the individual application of AICAR or MTX, however combined treatment of AICAR and MTX reduced cell proliferation." | ( Abdul-Rahman, O; Bai, P; Dér, Á; Fodor, T; Kiss, B; Nagy, L; Szántó, M, 2016) |
| "Zj6413 treated breast cancers (BCs) showed an elevated level of DNA damage evidenced by the accumulation of γ-H2AX foci and DNA damaged related proteins." | ( Chen, J; Chen, X; Ji, M; Jin, J; Xu, B; Xue, N; Zhou, J; Zhou, Q, 2016) |
| "We treated MDA-MB-231 breast cancer cells with TGF-β and TGF-β inhibitor SB431542, and then detect the level of PMEPA1 using Western blotting." | ( Jia, L; Wang, L; Wang, S; Wang, T; Yang, A; Zhang, Y; Zou, Y, 2016) |
| "Endocrine receptor-positive breast cancers can be categorized molecularly into luminal A and B subtypes, of which the latter is an aggressive form that is less responsive to endocrine therapy with inferior prognosis." | ( Gius, D; O'Brien, J; Santa-Maria, CA; Zhu, Y; Zou, X, 2016) |
| "The mechanism of how luminal B breast cancer develops resistance to endocrine therapy remains unclear." | ( Gius, D; O'Brien, J; Santa-Maria, CA; Zhu, Y; Zou, X, 2016) |
| "Human breast cancer MDA‑MB‑231 cells and MCF‑7 cells were treated with different concentrations of triptolide, with or without 10 ng/ml TNF‑α, for different durations, followed by measurement of cell proliferation using a 3‑[4,5‑dimethyltiazol‑2‑yl]‑2." | ( Cheng, X; Liang, P; Lu, L; Shi, W; Wang, G; Zhang, D; Zhao, C, 2016) |
| "Patients with previously untreated breast cancer (stages Ic-III) were treated with four cycles of paclitaxel (175 mg/m(2), intravenous drip, D1) and carboplatin (area under the curve of 5, D1)." | ( Li, XR; Liao, N; Liu, CL; Liu, YH; Wang, K; Xu, FP; Zhang, GC; Zhang, YF; Zhu, T; Zu, J, 2016) |
| "The optimal regimen for adjuvant breast cancer chemotherapy is undefined." | ( Bensfia, S; Buyse, M; Chan, A; Crown, J; Drevot, P; Eiermann, W; Hitier, S; Houé, V; Lindsay, M; Mackey, JR; Martin, M; Pieńkowski, T; Press, MF; Provencher, L; Sadeghi, S; Saleh, M; Sauter, G; Sehdev, S; Semiglazov, V, 2016) |
| "WSG AM 01 randomized high-risk breast cancer patients to induction (2× epirubicin-cyclophosphamide) followed by tandem HD chemotherapy with epirubicin, cyclophosphamide and thiotepa versus dose dense chemotherapy (4× epirubicin-cyclophospamide followed by 3× cyclophosphamide-methotrexate-5-fluorouracil)." | ( Diallo-Danebrock, R; Frick, M; Gluz, O; Harbeck, N; Kates, R; Kerkhoven, RM; Kruizinga, J; Liedtke, C; Linn, SC; Marme, F; Mohrmann, S; Nieuwland, M; Nitz, U; Pelz, E; Schouten, PC; Velds, A, 2016) |
| "Forty-five patients with breast cancer who experienced >Grade 1 nausea or any vomiting after the first cycle of chemotherapy using both epirubicin and cyclophosphamide were included." | ( Ishida, K; Kashiwaba, M; Komatsu, H; Kudo, K; Nihei, S; Sato, J, 2016) |
| "p53 wild-type and p53 mutant breast cancer cells were treated with metformin, and expression of TTP and c-Myc was analyzed by semi-quantitative RT-PCR, Western blots, and promoter activity assay." | ( Chen, Y; Chung, HT; Joe, Y; Kim, HJ; Pandiri, I; Park, J; Park, JW, 2016) |
| "MDA-MB-468, BT474 and SKBr3 breast cancer cell lines were treated with metformin and [3H-methyl]choline and [14C(U)]glucose incorporation and lipid accumulation determined in the presence and absence of lipase inhibitors." | ( Phyu, SM; Smith, TA, 2016) |
| "Approximately 5-23% of breast cancer tumors are known to respond to CPT-based chemotherapy." | ( Agarwal, D; Aleskandarany, MA; Arora, A; Ball, G; Bohr, VA; Croteau, DL; Ellis, IO; Lu, H; Madhusudan, S; Pommier, Y; Shamanna, RA, 2016) |
| "Individualized physiological testing in breast cancer survivors can identify important contributors to exercise intolerance which can be targeted for treatment." | ( Dudgeon, DJ; Elbehairy, AF; Langer, D; Neder, JA; O'Donnell, DE; Webb, KA, 2016) |
| "The incidence of AF in female breast cancer patients in Taiwan is associated with morphine, but prevented by tamoxifen treatment." | ( Kao, CH; Lee, CW; Liang, JA; Lin, MC; Muo, CH, 2016) |
| "Human breast cancer cells MDA-MB-231 and MCF-7 were treated with radiation alone, Glut1 inhibitor alone or the combination of both to evaluate cell glucose metabolism and apoptosis." | ( Fan, L; Ming, J; Zhao, F; Zhou, Y, 2016) |
| "In E2-treated breast cancer cell lines, NRF2 protein level was found to be decreased." | ( Liu, Q; Teng, Y; Wang, B, 2016) |
| "Triple negative breast cancer (TNBC) is the hardest breast cancer subtype to treat due to lacking therapeutic target and treatment options." | ( Ding, F; Dong, T; Geng, C; Li, J; Sun, Y; Tian, X; Wu, G; Yang, Q; Zhang, Z, 2016) |
| "Women with stage I-III breast cancer scheduled to receive taxane therapy were randomized to receive a standardized protocol of 12 true or sham EA (SEA) weekly treatments concurrent with taxane treatment." | ( Awad, D; Buono, D; Capodice, J; Crew, KD; Greenlee, H; Hershman, DL; Jeffres, A; Kalinsky, K; Shi, Z; Trivedi, MS; Whitman, W; Wyse, S, 2016) |
| "The heterogeneous nature of breast cancer makes it one of the most challenging cancers to treat." | ( Akbari, ME; Bashash, D; Nooshinfar, E; Safaroghli-Azar, A, 2017) |
| "We describe a breast cancer patient with HER-2 positive leptomeningeal disease in the spinal cord successfully treated with intrathecal trastuzumab and methotrexate, alongside systemic anti-HER-2 therapy and radiotherapy." | ( Kordbacheh, T; Law, WY; Smith, IE, 2016) |
| "Major advances in breast cancer treatment have almost always been linked to the actions of estrogen." | ( Guestini, F; Kikuchi, K; McNamara, KM; Sakurai, M; Sasano, H, 2016) |
| "To analyze expression of miRNA in human breast cancer cells, sensitive and resistant to cisplatin and doxorubicin, and to explore possible modification of drug sensitivity via treatment of cells with 5-azacytidine (5-aza), a demethylating agent." | ( Borikun, TV; Chekhun, VF; Lukianova, NY, 2016) |
| "Targeting the TGF-β1 pathway for breast cancer metastasis therapy has become an attractive strategy." | ( Dong, W; Liang, W; Qiu, Y; Wang, L; Yin, X; Zeng, W; Zhang, C; Zhang, F; Zhang, L, 2016) |
| "HCC1937 and MCF-7 breast cancer cells were treated with the RAPTA-EA1 complex." | ( Dyson, PJ; Hongthong, K; Nhukeaw, T; Ratanaphan, A, 2017) |
| "For this study, 52 breast cancer patients with bone metastases treated with zoledronic acid (n = 36) or denosumab (n = 22) were enrolled (6 patients were treated sequentially with both agents)." | ( Higuchi, T; Imamura, M; Miyagawa, Y; Miyoshi, Y; Murase, K; Nishimukai, A; Ozawa, H; Takatsuka, Y; Yanai, A, 2017) |
| "Furthermore, in breast cancer patients with ER-positive primary tumors who received adjuvant tamoxifen treatment, FOXC1 expression is associated with decreased or undetectable ER expression in recurrent tumors." | ( Bose, S; Cheng, L; Cui, X; Deng, N; Gao, B; Giuliano, AE; Han, B; Jin, Y; Johnson, J; Liu, Z; Qu, Y; Sun, Z; Tanaka, H; Watanabe, T; Yu-Rice, Y, 2016) |
| "Although both E2 and TOT treatment of breast cancer cells results in recruitment of the estrogen receptor (ER) to common and distinct genomic sites, the mechanisms and proteins underlying TOT preferential recruitment of the ER remains poorly defined." | ( Bhatt, S; Joshi, S; Katzenellenbogen, BS; Stender, JD; Wu, G, 2016) |
| "We report a case of breast cancer with multiple liver metastases successfully treated with capecitabine monotherapy after failure of combination therapy comprising bevacizumab (Bev) and paclitaxel (PTX)." | ( Ooe, A; Suganuma, Y, 2016) |
| "Patients with breast cancer undergoing radiotherapy to the breast or chest wall were randomized." | ( Anders, JC; Atherton, PJ; Bearden, JD; Birckhead, BJ; Griffin, PC; Haselow, RE; Loprinzi, CL; Martenson, JA; Miller, RC; Morton, RF; Mowat, RB; Schwartz, DJ; Seisler, DK; Sio, TT; Sloan, JA; Stoffel, TJ; Wittich, MA, 2016) |
| "Diagnosis and treatment of breast cancer at an early stage cannot improve the rate of tumor-free survival." | ( Suba, Z, 2016) |
| "Pregnancy outcomes for breast cancer patients undergoing frozen-thawed 2-PN embryo transfers (FETs) after oncologic treatment were also noted." | ( Cordeiro, CN; Hancock, K; Lekovich, JP; Pereira, N; Rosenwaks, Z; Schattman, GL, 2016) |
| "Apoptosis markers in breast cancer include circulating soluble FasL, granzyme B, and cytochrome c that increase following chemotherapy." | ( Abhang, SA; Kadam, CY, 2016) |
| "Estrogen receptor alpha (ERα)-positive breast cancers are frequently treated with tamoxifen, but resistance is common." | ( Beumer, I; Droog, M; Glas, AM; Kim, Y; Koornstra, R; Krijgsman, O; Kuilman, T; Linn, SC; Nevedomskaya, E; Peeper, D; Peeters, J; Severson, TM; Simon, IM; van Rossum, A; Wesseling, J; Wessels, L; Zwart, W, 2016) |
| "The risk of breast cancer recurrence in patients who received methotrexate, thiopurine, or anti-TNF therapy was not statistically significantly increased, although we cannot rule out a 2-fold or greater increased risk in those treated with thiopurines." | ( Boursi, B; Brensinger, CM; Chen, L; Clark, AS; Curtis, JR; Lewis, JD; Mamtani, R; Osterman, MT; Scott, FI; Xie, F; Yun, H, 2016) |
| "Chemotherapy, a prominent treatment for breast cancer (BC), can have detrimental side effects on the patient's cognitive functions including the executive function." | ( Bian, Y; He, X; Hu, S; Li, J; Miao, H; Partridge, SC; Qiu, B; Ren, J; Yu, Y, 2016) |
| "In this study, twenty-three breast cancer patients were treated with chemotherapy and twenty-six healthy subjects were recruited as the healthy control (HC) group." | ( Bian, Y; He, X; Hu, S; Li, J; Miao, H; Partridge, SC; Qiu, B; Ren, J; Yu, Y, 2016) |
| "Premenopausal patients with primary breast cancer (N = 564) were randomly assigned to 2 years of tamoxifen (n = 276) or no systemic treatment (n = 288)." | ( Bendahl, PO; Ekholm, M; Fernö, M; Nordenskjöld, B; Rydén, L; Stål, O, 2016) |
| "Metastasis, which frequently occurs in breast cancer, is the major cause of mortality; therefore, new treatment strategies are urgently needed." | ( Jiang, R; Li, H; Lin, D; Wan, J; Zhang, X, 2016) |
| "Furthermore, the potential risk of breast cancer recurrence with vaginal estrogen therapy represents a long-term safety concern for the patients with HR + BC." | ( Bhat, R; Han, T; Niravath, P; Sulaica, E; Trivedi, MV; Wang, W, 2016) |
| "Human breast cancer MCF-7 cells were treated with oxymatrine at concentrations of 0 (control), 25, 50 and 100 µg/mL." | ( Li, D; Lin, B; Zhang, L, 2016) |
| "Applying STEPP to data from a breast cancer treatment trial with multiple markers, we found that none of the three benefit functions identified a promising subgroup for further study." | ( Baker, SG; Bonetti, M, 2016) |
| "In 2008, the Korean Breast Cancer Society Study Group initiated the ASTRRA randomized phase III trial to evaluate the efficacy of OFS in addition to standard tamoxifen treatment in hormone receptor-positive breast cancer patients who remain or regain premenopausal status after chemotherapy." | ( Ahn, SH; Cho, SH; Choi, SY; Choi, YJ; Gwak, GH; Han, SH; Han, W; Hur, MH; Im, SA; Jeong, J; Jung, SH; Jung, SS; Jung, YS; Kang, SH; Kang, YJ; Kim, D; Kim, HA; Kim, HJ; Kim, J; Kim, JG; Kim, LS; Kim, SJ; Kim, SY; Kim, TH; Lee, ES; Lee, KJ; Lee, MH; Lee, SJ; Lim, CW; Moon, BI; Nam, SJ; Noh, WC; Park, C; Park, H; Park, S; Ro, J; Shin, HJ; Song, YJ; Yoo, Y; Yoon, JH, 2016) |
| "The biological subtype of breast cancer influences the selection of systemic therapy." | ( Auvinen, P; Eidt, S; Heikkilä, P; Isola, J; Joensuu, H; Jyrkkiö, S; Kellokumpu-Lehtinen, PL; Laible, M; Lakis, S; Sahin, U; Schlombs, K; Sihto, H; Turpeenniemi-Hujanen, T; Weber, S; Wirtz, RM, 2016) |
| "Nine breast cancer patients with a high risk of preoperative or postoperative recurrence received EC therapy(epirubicin 90 mg/m(2) and cyclo- phosphamide 600 mg/m(2))for 4 cycles every 2 weeks in combination with a subcutaneous injection of pegfilgrastim (3." | ( Hagio, K; Ikarashi, M; Sato, M; Takahashi, Y; Takahasi, M; Tamaki, S; Tomioka, N; Watanabe, K; Yamamoto, M, 2016) |
| "A total of 270 patients with breast cancer, who were treated in First Affilitated Hospital of Henan University of Science and Technology from January 2013 to March 2015, were chosen and given sentinel lymph node biopsy (SLN) with nano-carbon, and the influencial factors were examined by logistic analysis." | ( Hou, Y; Liu, J; Wang, M; Wang, N; Wang, X, 2016) |
| "The natural history of HER2-positive breast cancer has progressively improved since the introduction of the first anti-HER2 directed therapy (trastuzumab)." | ( López-Tarruella, S; Martin, M, 2016) |
| "Ibrutinib treatment impacts HER2(+) breast cancer cell viability at lower concentrations than the established breast cancer therapeutic lapatinib." | ( Conklin, DS; Khan, F; Kokabee, L; Sevinsky, CJ; Sun, Y; Wang, X; Wong, J, 2016) |
| "Paclitaxel is a commonly used agent for breast cancer therapy, which comes across the obstacle "drug resistance", resulting in shortened overall survival of patients." | ( Cao, Z; Ge, X; Gu, Y; Han, M; Li, J; Lyu, P; Wang, F; Xia, W; Yu, Z, 2016) |
| "Resistance to taxane-based therapy in breast cancer patients is a major clinical problem that may be addressed through insight of the genomic alterations leading to taxane resistance in breast cancer cells." | ( Bolund, L; Brünner, N; Ditzel, HJ; Ehlers, NS; Gupta, R; Hansen, SN; Hou, Y; Liu, D; Moreira, J; Nielsen, RL; Schrohl, AS; Stenvang, J; Thomsen, MB; Wang, G; Wang, J; Xu, X; Yang, H; Zhang, X; Zhu, S, 2016) |
| "Pretreated metastatic breast cancer (MBC) remains a formidable challenge with unmet needs both in terms of prolonged survival and quality-of-life-related issues." | ( Aroldi, F; Bertocchi, P; Fraccon, AP; Mutti, S; Prochilo, T; Rizzi, A; Savelli, G; Zaniboni, A, 2017) |
| "Drug resistance in breast cancer remains a major obstacle of clinical therapy." | ( Kim, KP; Ko, JJ; Park, JH; Park, KS, 2016) |
| "A 61-year old woman with recurrent breast cancer received combined treatment with paclitaxel (PTX) and bevacizumab (BV) as the third-line chemotherapy." | ( Ishiguro, M; Iwamoto, A; Nishidoi, H; Shibata, S; Tada, Y; Takaya, S; Yamaguchi, Y; Yamashiro, Y, 2016) |
| "In vivo experiments in breast cancer model of nude mice further demonstrate that the GNR@HPMOs-PTX@MSCs significantly inhibit tumor growth, suggesting their great potential for synergistic therapy of cancer." | ( Li, Y; Liu, Y; Lu, G; Pan, J; Su, X; Su, Y; Tang, Y; Teng, Z; Tian, J; Tian, Y; Wang, C; Wang, S; Wu, J; Zhu, H, 2016) |
| "Moreover, CBR1 overexpression enabled breast cancer cells to obtain chemotherapeutic resistance to DOX treatment." | ( Akter, S; Cho, H; Choi, TG; Ha, J; Jo, A; Jo, YH; Jyothi, KR; Kang, I; Kim, JH; Kim, SS; Kim, W; Lee, J; Lee, KH; Lee, S; Lim, S; Nguyen, MN; Shahid, M; Shokat, KM; Yoon, KS, 2017) |
| "Karyotypes of both ER+ and ER& breast cancer cells increased in complexity after treatments with E2 and TAM leading to specific chromosomal abnormalities, some of which were consistent throughout the treatment duration." | ( Annaratone, L; Castellano, I; Di Cantogno, LV; Manetta, T; Marchiò, C; Rangel, N; Rondón-Lagos, M; Russo, R; Sapino, A, 2016) |
| "Triple-negative breast cancer (TNBC) is one of the most difficult breast cancers to treat because there is no targeted treatment, and conventional cytotoxic chemotherapy followed by adjuvant radiation therapy is the standard of care for patients with TNBC." | ( Chen, H; Ding, D; Gao, Y; Wang, J; Yin, L; Zhang, J; Zhang, X; Zhang, Y, 2016) |
| "Treating breast cancer brain metastases (BCBMs) is challenging." | ( Carrasco, N; De, A; Do, J; Foster, D; Jeffrey, SS; Renier, C; Reyna-Neyra, A; Tse, V; Vogel, H; Wapnir, I, 2016) |
| "Patients with HER2- positive breast cancer will develop brain metastases with greater incidence than patients with non-HER2 cancers, and many of them will undergo stereotactic radiosurgery (SRS) or other CNS radiotherapy." | ( Harada, H; Hayashi, N; Ito, I; Mitsuya, K; Nakasu, Y; Watanabe, J, 2016) |
| "Treatment of MCF-7 and MDA-MB-231 breast cancer cell lines with SB743921 results in decreased ability of colony formation in culture." | ( Fang, M; Sheng, Y; Sun, H; Wang, H; Wang, L; Xiao, F; Yang, Y; Yu, Y; Zhu, L, 2016) |
| "The medical records of 157 metastatic breast cancer patients treated with eribulin between July 2011 and November 2013 at Cancer Institute Hospital were retrospectively analyzed." | ( Fukada, I; Ito, Y; Iwase, T; Kobayashi, T; Ohno, S; Shibayama, T; Takahashi, S; Teruya, N; Tomomatsu, J, 2016) |
| "Treatment of HER-2-overexpressing breast cancer cells with AE reduced tumor initiation, cell migration, and cell invasion." | ( Ho, CT; Hung, CM; Kao, JY; Lin, YC; Ma, JW; Way, TD, 2016) |
| "Expression of the HER2 oncogene in breast cancer is associated with resistance to treatment, and Her2 may regulate bioenergetics." | ( Alizadeh Pesdar, E; Bezawork-Geleta, A; Blecha, J; Cerny, J; Dong, LF; Endaya, B; Goodwin, J; Hozak, P; Jezek, P; Neuzil, J; Nguyen, MN; Rohlena, J; Rohlenova, K; Sachaphibulkij, K; Sobol, M; Spacek, T; Stursa, J; Truksa, J; Vondrusova, M; Werner, L; Yan, B; Zobalova, R, 2017) |
| "Luminal A breast cancer is the most common breast cancer subtype which is usually treated with selective estrogen receptor modulators (SERMS) like tamoxifen." | ( Bräuchle, C; Hermawan, A; Knyazev, P; Ljepoja, B; Mickler, FM; Roidl, A; Sommer, AK; Ullrich, A; Wagner, E, 2016) |
| "Taxanes are frequently used in breast cancer treatments, but the acquisition of resistance makes these treatments ineffective." | ( Flores, ML; Gasca, J; Giráldez, S; Japón, MA; Romero, F; Ruiz-Borrego, M; Sáez, C; Tortolero, M, 2016) |
| "Of these, 1008 had breast cancer with hormone therapy only and the other 15,120 controls did not have breast cancer or hormone therapy." | ( Cheng, CL; de Groat, WC; Li, JR; Lin, CH, 2016) |
| "Thirty-three breast cancer patients (BC) after receiving chemotherapy and 31 matched healthy controls (HC) were enrolled in this study." | ( Lin, H; Tao, L; Wang, L; Xu, X; Yan, Y; Yu, Y; Zhang, J, 2017) |
| "Patients with cancers that harbor breast cancer 1 (BRCA1) mutations initially respond well to platinum and poly(ADP-ribose) polymerase inhibitor (PARPi) therapy; however, resistance invariably arises in these patients and is a major clinical problem." | ( Bernhardy, AJ; Cai, KQ; George, E; Harrell, MI; Johnson, N; Kim, HH; Krais, JJ; Nicolas, E; Simpkins, F; Swisher, EM; Wang, Y, 2016) |
| "However, breast cancer patients have failed to benefit from proteasome inhibitor treatment partially due to proteasome heterogeneity, which is poorly understood in malignant breast neoplasm." | ( Che, J; Huang, L; Song, H; Xi, QS; Xiong, H; Xiong, HH; Zhang, P, 2016) |
| "We analyzed nationwide Finnish data on breast cancer mortality risk in women using HT consisting of estradiol-only therapy (ET) or estrogen-progestogen therapy (EPT)." | ( Gissler, M; Hoti, F; Mikkola, TS; Savolainen-Peltonen, H; Tuomikoski, P; Vattulainen, P; Ylikorkala, O, 2016) |
| "To evaluate the effects of plumbagin on breast cancer cell types, we employed a variety of techniques comprising cell viability, cell cycle assay, comet assay, western blotting, immunocytochemistry, measurement of telomerase activity, telomere restriction fragment length, quantitative fluorescence in situ hybridisation, along with gene expression analysis of untreated cells." | ( Hande, MP; Sameni, S, 2016) |
| "PLR was evaluated in 177 breast cancer patients treated with the NAC 5-fluorouracil, epirubicin and cyclophosphamide, followed by weekly paclitaxel and subsequent curative surgery." | ( Asano, Y; Hirakawa, K; Kashiwagi, S; Kawajiri, H; Kitagawa, S; Noda, S; Ohsawa, M; Onoda, N; Takashima, T, 2016) |
| "For patients with breast cancer treated with NAC, a low PLR indicated high chemotherapy sensitivity, suggesting that PLR could serve as a predictive marker of the therapeutic effect of NAC." | ( Asano, Y; Hirakawa, K; Kashiwagi, S; Kawajiri, H; Kitagawa, S; Noda, S; Ohsawa, M; Onoda, N; Takashima, T, 2016) |
| "Notably, pre-treatment of breast cancer cells with 20μM histamine prevented the mesenchymal changes induced by ionizing radiation and also reduced the migratory behavior of irradiated cells decreasing phospho-Src levels." | ( Bergoc, RM; Crescenti, EJ; Cricco, GP; Galarza, TE; Martín, GA; Mohamad, NA; Táquez Delgado, MA; Vedoya, GM, 2016) |
| "To evaluate toxicity in breast cancer patients treated with anthracycline and taxane based chemotherapy and whole breast hypofractionated radiotherapy, and to identify the risk factors for toxicity." | ( Agresti, R; Baili, P; Bianchi, G; Bonfantini, F; De Santis, MC; Di Cosimo, S; Di Salvo, F; Dispinzieri, M; Lozza, L; Maggi, C; Mantero, E; Pignoli, E; Sant, M; Soncini, F; Valdagni, R, 2016) |
| "537 early breast cancer patients receiving hypofractionated radiotherapy after conservative surgery were enrolled from April 2009 to December 2014, in an Italian cancer institute." | ( Agresti, R; Baili, P; Bianchi, G; Bonfantini, F; De Santis, MC; Di Cosimo, S; Di Salvo, F; Dispinzieri, M; Lozza, L; Maggi, C; Mantero, E; Pignoli, E; Sant, M; Soncini, F; Valdagni, R, 2016) |
| "Hitherto, it is not known if ERα+/ERβ+ breast cancers would benefit from a treatment strategy combining tamoxifen and fulvestrant or if fulvestrant exert any therapeutic effects in ERα-/ERβ+ breast cancer." | ( Abrahamsson, A; Dabrosin, C; Mishra, AK, 2016) |
| "Overexpression of miR-145 sensitized breast cancer cells to doxorubicin in vitro and enhanced to doxorubicin chemotherapy in vivo through inducing intracellular doxorubicin accumulation via inhibiting MRP1." | ( Gao, M; Li, C; Liu, M; Miao, L; Qi, X; Ren, J; Wang, Y; Yan, H; Yin, Y; Yu, C, 2016) |
| "Prolonged treatment of breast cancer with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) often results in acquired resistance and a narrow therapeutic index." | ( Chen, T; Gao, N; Hu, Y; Huang, X; Jia, T; Jin, G; Jin, Z; Liu, B; Peng, B; Wang, Z; Zhang, N, 2016) |
| "PBC gene expression of 33 breast cancer patients was conducted before and after the first cycle of DOX-based chemotherapy." | ( Beggs, ML; Carter, W; Klimberg, VS; Makhoul, I; Owen, A; Siegel, ER; Stone, A; Todorova, VK; Wei, J, 2016) |
| "MCF-7 human breast cancer cell line was treated with vanillin (1 and 2mM), DOX (100μM) or their combination." | ( Elseweidy, MM; Elsherbiny, NM; Shaheen, MA; Younis, NN, 2016) |
| "In HER2+ and triple-negative breast cancers, neoadjuvant chemotherapy is associated with a high probability of pathological complete response, which strongly predicts survival outcome." | ( Gonçalves, A, 2016) |
| "Using a 4T1 breast cancer model, we show that in vivo administration of PX-478, an inhibitor of oxygen-sensitive HIF-1α, led to reduced expression of Foxp3 and VEGF transcript and/or protein, molecules that are directly controlled by HIF-1." | ( Ajami, M; Arab, S; Ashourpour, M; Hadjati, J; Jadidi-Niaragh, F; Kheshtchin, N; Khosravianfar, N; Mirzaei, R; Mousavi, N; Namdar, A; Noorbakhsh, F, 2016) |
| "We used the EMT6, 4 T1 and E0771 murine breast cancer models to evaluate in vitro and in vivo the effects of co-treatment with MG1 and Paclitaxel." | ( Aitken, AS; Arulanandam, R; Bell, JC; Bourgeois-Daigneault, MC; Diallo, JS; Falls, T; Garcia, V; Pelin, A; Roy, DG; St-Germain, LE, 2016) |
| "Multidrug resistance (MDR) of breast cancer is a major obstacle in chemotherapy of cancer treatments." | ( Li, L; Liu, Q; Wang, H; Wang, P; Wang, X; Zhang, K, 2016) |
| "The treatment of metastatic breast cancer (MBC) remains a great clinical challenge as drug resistance frequently develops." | ( Di, L; Li, W; Liu, W; Qiu, R; Tang, L; Tian, F; Tong, Z; Wang, Y; Xu, B; Yang, J; Zhang, P, 2016) |
| "The goal of chemotherapy for metastatic breast cancer (MBC) is to prolong survival and maintain health-related quality of life." | ( Akabane, H; Doihara, H; Fukuda, T; Hagiwara, Y; Kashiwaba, M; Mouri, M; Mukai, H; Ohashi, Y; Shimozuma, K; Shiroiwa, T; Watanabe, T, 2017) |
| "The effect of metformin treatment on breast cancer cell viability and miR-26a, BCL-2, PTEN, MCL-1, EZH2, and MTDH modulation were evaluated." | ( Cabello, P; Eroles, P; Lluch, A; Pineda, B; Tormo, E, 2016) |
| "Triple-negative breast cancer (TNBC) lacks specific therapeutic target and limits to chemotherapy and is essential to develop novel therapeutic regimens." | ( Cha, TL; Chang, SY; Kao, CC; Kuo, SC; Sun, GH; Way, TD; Wu, ST, 2016) |
| "Considering that breast cancer is a very heterogeneous disease and patients respond differently to treatment, the molecular analysis of TAM's biological activity could provide the necessary framework to understand the complex effects of this drug in target cells." | ( Rangel, N; Rondón-Lagos, M; Sánchez, MC; Villegas, VE; Zaphiropoulos, PG, 2016) |
| "Occasionally, breast cancer relapses more than 5 years after initial treatment, sometimes with highly aggressive disease in such late-recurring patients." | ( Ithimakin, S; Wangchinda, P, 2016) |
| "Thus we studied MDA-MB-231 and SK-BR-3 breast cancer cell lines treated with epirubicin (EPI) to assess autophagy and apoptosis." | ( Guo, W; Wang, Y; Wang, YP; Wang, Z; Zheng, H, 2016) |
| "In phase Ib, treatment-naïve breast cancer patients received four cycles of pre-operative doxorubicin/cyclophosphamide, with sunitinib before each cycle." | ( Buhari, SA; Chan, CW; Goh, BC; Hartman, M; Ho, J; Huang, Y; Iau, P; Jeyasekharan, AD; Lee, SC; Mogro, J; Ng, TC; Ow, SG; Pang, AS; Soh, TI; Sundar, R; Tan, CS; Tan, SH; Thng, CH; Wang, L; Wang, TT; Wong, AL; Zhang, B, 2016) |
| "Approximately 70% of breast cancers express the estrogen receptor (ER)α and are treated with the ERα antagonist, tamoxifen." | ( Basik, M; Légaré, S, 2016) |
| "Metastatic breast cancer to the sternum, if detected early and treated aggressively, holds the possibility of such a cure." | ( Anzalone, AA; Cajozzo, M; Fatica, F; Geraci, G; Modica, G, 2016) |
| "Patients ≥65 years of age with breast cancer (pT1-2/pN0-2) treated with breast conserving surgery and postoperative radiation therapy at the Netherlands Cancer Institute (NKI) between 1980 and 2008 were identified." | ( Bartelink, H; Bosma, S; Elkhuizen, PHM; Linn, SC; Rutgers, EJ; Scholten, A; van de Vijver, MJ; van der Leij, F; van Werkhoven, E, 2016) |
| "However, whether it could treat breast cancer and its underlying mechanism remained largely unknown." | ( Li, Z; Mao, J; Qi, X; Qin, B; Wu, D, 2016) |
| "Treatment of metastatic breast cancer cell lines (e." | ( Abe, A; Hiramoto, M; Hirasawa, K; Hirota, A; Ishikawa, T; Kazama, H; Kokuba, H; Komatsu, S; Miyahara, K; Miyazawa, K; Moriya, S; Takemura, J, 2016) |
| "In the breast cancer mice models, ultrasound-mediated therapy with doxorubicin-loaded PFH nanodroplets showed excellent anti-cancer effects characterized by tumor regression." | ( Baghbani, F; Mohandesi, JA; Mokhtari-Dizaji, M; Moztarzadeh, F; Yazdian, F, 2016) |
| "TP53 mutations are frequent in breast cancer, however their clinical relevance in terms of response to chemotherapy is controversial." | ( Blohmer, JU; Darb-Esfahani, S; Denkert, C; Dietel, M; Endris, V; Jackisch, C; Klare, P; Kümmel, S; Loi, S; Loibl, S; Möbs, M; Nekljudova, V; Reimer, T; Salat, C; Schem, C; Schmitt, W; Sinn, B; Sinn, P; Stenzinger, A; Tesch, H; Untch, M; von Minckwitz, G; Weichert, W, 2016) |
| "This is a key tool in the treatment of breast cancer, and the combination with vit C seems to be of particular interest due to the fact that it can potentiate anti-proliferative effect of DOX." | ( Adamek, M; Alexovic, M; Andrasina, I; Benckova, M; Bober, P; Ciccocioppo, R; Kruzliak, P; Petrovic, D; Sabo, J; Talian, I; Tomkova, Z; Viscorova, Z, 2017) |
| "Furthermore, treating breast cancer cells with pioglitazone that stabilizes the 3Cys-1His cluster of NAF-1 results in a similar effect on mitochondrial iron and reactive oxygen species accumulation." | ( Bai, F; Darash-Yahana, M; Geiger, T; Jennings, PA; Karmi, O; Lu, M; Mittler, R; Nechushtai, R; Onuchic, JN; Pikarsky, E; Pozniak, Y; Sohn, YS; Song, L; Tamir, S, 2016) |
| "We report a case of a patient with breast cancer who had fatal acute interstitial lung disease after auxiliary chemotherapy with docetaxel." | ( Afqir, S; Brahmi, SA; Youssef, S; Ziani, FZ, 2016) |
| "Hormone receptor positive breast cancer (HR-positive BC) is the most frequent BC subtype (∼70%), with endocrine treatment constituting its therapeutic cornerstone; despite its efficacy, endocrine resistance can develop, clinically as a relapse or a progression of the early or advanced disease respectively, hence necessitating alternative treatments." | ( Katzenellenbogen, BS; Piccart, M; Tryfonidis, K; Zardavas, D, 2016) |
| "Forty amenorrheic breast cancer patients scheduled for AI treatment but requiring hormonological confirmation of their menopausal status were studied." | ( Honda, J; Imoto, I; Morimoto, M; Sasa, M; Takahashi, M; Tangoku, A; Toba, H; Yoshida, M; Yoshida, T, 2016) |
| "Chemotherapy outcome for breast cancer is hampered due to poor response and irreversible dose-dependent cardiotoxicity which is determined by genetic variations in drug metabolizing enzymes and transporters." | ( Kaliyanasundaram, M; MaryHelen, KG; Munirajan, AK; Revathidevi, S; Sudesh, R; Sukanya, G; Vaishnavi, V, 2016) |
| "In the adjuvant treatment of breast cancer, anthracycline and taxane based regimens can be used concomitantly or sequentially." | ( Dagher, NM; Yaghan, RJ, 2016) |
| "Elderly patients with metastatic breast cancer are expected to derive similar benefits from chemotherapy as younger patients, but are more likely to experience therapy-related toxicity." | ( Bidoli, P; Capici, S; Cazzaniga, ME; Cicchiello, F; Cortinovis, D; Digiacomo, N; Porcu, L; Riva, F; Torri, V, 2017) |
| "Endocrine therapy for breast cancer can exacerbate menopausal symptoms." | ( Anders, CK; Bensen, JT; Doll, KM; Hendrix, L; Landi, SN; Nichols, HB; Wu, JM, 2016) |
| "Among the 548 women with a breast cancer diagnosis, 49 % received endocrine therapy." | ( Anders, CK; Bensen, JT; Doll, KM; Hendrix, L; Landi, SN; Nichols, HB; Wu, JM, 2016) |
| "In these breast cancer patients treated with HBOT for LRITT, the patient-reported outcomes were positive and improvements were observed." | ( Bol Raap, R; Huang, Y; Koole, A; Koppert, LB; Struikmans, H; Teguh, DN; van Hulst, RA; Verhoef, C, 2016) |
| "Adults with HER2-positive breast cancer being treated with trastuzumab, pertuzumab, and docetaxel or paclitaxel (THP) or trastuzumab, pertuzumab, docetaxel, and carboplatin (TCHP) will be randomized to receive crofelemer or no medication for diarrhea prophylaxis." | ( Gao, JJ; Pohlmann, PR; Swain, SM; Tan, M, 2017) |
| "However, metastatic HER2-positive breast cancer patients eventually develop resistance to this treatment regimen eventually." | ( Chen, WW; Kuo, HH, 2016) |
| "Patients with restrictions due to breast cancer-related surgery and pretreated with chemotherapy might benefit the most." | ( Debus, J; Klassen, O; Potthoff, K; Schmidt, ME; Steindorf, K; Ulrich, CM; Wiskemann, J, 2017) |
| "BLBC is an aggressive subtype of breast cancer associated with liver and lung metastases and poorer prognosis than other subtypes and for which chemotherapy is the only systemic therapy." | ( Amersi, F; Bagaria, S; Choi, M; Cui, X; Dadmanesh, F; Giuliano, AE; Han, B; Johnson, J; Qu, Y; Taylor, C; Yu-Rice, Y; Zhang, X, 2016) |
| "As a gene delivery method in breast cancer therapy, knocking down the undesired genes in the cancerous cells would be promising." | ( Arami, S; Fathi, M; Hejazi, MS; Mahdavi, M; Rashidi, MR; Samadi, N, 2016) |
| "We enrolled breast cancer patients receiving AC who experienced moderate to severe nausea or vomiting during the first chemotherapy cycle." | ( Akewanlop, C; Chantharasamee, J; Danchaivijitr, P; Ithimakin, S; Korphaisarn, K; Soparattanapaisarn, N; Srimuninnimit, V; Techawathanawanna, S; Thamlikitkul, L, 2017) |
| "In this study, we show that breast cancer cells (MCF-7 and MDA-MB-231) overexpressing HPIP were more sensitive to paclitaxel treatment as evaluated by MTT assay, exhibiting a significant reduction in IC50 of paclitaxel compared with the control." | ( Feng, R; Tian, X; Yu, B; Zhang, L, 2016) |
| "We recruited 10 recurrent or metastatic breast cancer patients who were administered eribulin." | ( Adachi, K; Enomoto, K; Hara, Y; Hirano, T; Masuo, Y; Nagashima, S; Sakurai, K; Suzuki, S, 2016) |
| "Four breast cancer cell lines (T-47D, MCF7, MDA-MB-231 and HBCx-19 established from the eponymous PDX) were treated in vitro with mafosfamide, a DNA damage inducer." | ( Cairo, S; Cheradame, L; Deas, O; Gaston, J; Goffin, V; Judde, JG; Poupon, MF; Yvonnet, V, 2016) |
| "Older patients with breast cancer represent a vulnerable population at higher risk of experiencing distress and pain, as well as medication-related adverse events from pharmacological treatment of these symptoms." | ( Chang, SL; Mayo, NE; Meguerditchian, AN; Syrowatka, A; Tamblyn, R, 2016) |
| "In MDA-MB-231 breast cancer xenografts and MMTV-Wnt1 transgenic mice, administration of prodigiosin slowed tumor progression and reduced the expression of phosphorylated LRP6, phosphorylated and unphosphorylated DVL2, Ser9 phosphorylated GSK3β, active β-catenin, and cyclin D1." | ( Carson, DA; Jiang, W; Li, B; Lu, D; Sha, O; Song, J; Su, Z; Sun, Q; Wang, X; Wang, Z; Wei, L; Willert, K; Yu, S; Zhou, L, 2016) |
| "Cisplatin is an effective breast cancer drug but resistance often develops over prolonged chemotherapy." | ( Chen, W; Chisholm, CL; Deng, CX; Vazquez-Ortiz, G; Wang, H; Wong, AH; Xu, X, 2016) |
| "Estrogen-dependent breast cancer is often treated with the aromatase inhibitors or estrogen receptor (ER) antagonists." | ( He, J; Kou, X; Nie, P; Song, Z; Wang, S; Wu, B; Zhu, J; Zou, Z, 2016) |
| "Therefore, new avenues of treatment for breast cancer are needed." | ( Chu, P; Fang, D; Luo, R; Tang, Z; Wu, H; Zhang, Z, 2016) |
| "In patients with breast cancer after anthracycline therapy: Left intra-atrial, inter-atrial electromechanical intervals were prolonged." | ( Gokoz-Dogu, G; Saricopur, A; Senol, H; Yaylali, YT; Yurtdas, M, 2016) |
| "Among women with high-risk early breast cancer, the use of tailored dose-dense chemotherapy compared with standard adjuvant chemotherapy did not result in a statistically significant improvement in breast cancer recurrence-free survival." | ( Anderson, H; Bengtsson, NO; Bergh, J; Brandberg, Y; Carlsson, L; Egle, D; Fornander, T; Foukakis, T; Gnant, M; Greil, R; Hellström, M; Johansson, H; Karlsson, E; Loibl, S; Malmström, P; Mlineritsch, B; Möbus, V; Schmatloch, S; Singer, CF; Steger, G; Untch, M; von Minckwitz, G; Wallberg, B, 2016) |
| "The heterogeneity of breast cancer makes it a challenging solid tumor to diagnose and treat." | ( Hu, Y; Liu, Y; Wang, J; Yuan, C; Zhou, J, 2017) |
| "In HER2+ early breast cancer, a dual HER2-targeted combination of pertuzumab and trastuzumab, together with taxane-epirubicin-cyclophosphamide neoadjuvant chemotherapy, achieved high rates of pCR." | ( Aktas, B; Blohmer, JU; Clemens, M; Dan Costa, S; Denkert, C; Engels, K; Gerber, B; Hackmann, J; Hanusch, C; Jackisch, C; Just, M; Kümmel, S; Loibl, S; Nekljudova, V; Paepke, S; Schmatloch, S; Schneeweiss, A; Untch, M; von Minckwitz, G; Warm, M; Wiebringhaus, H, 2017) |
| "The early diagnosis of breast cancer is crucial for the successful treatment and recovery phases of the patients suffering from the disease." | ( Andrade, CAS; Frías, IAM; Oliveira, MDL; Pitta, MGR; Rêgo, MJBM; Sacilloti, M; Zanghelini, F, 2017) |
| "Additional PET/CT staging allows breast cancer patients to be treated according to the true stage, still stage II/III breast cancer patients upstaged to N2/3 by PET/CT have worse short-term outcome, despite adjustment of treatment, than patients staged high-risk with conventional imaging." | ( Elkhuizen, PH; Koolen, BB; Rodenhuis, S; Rutgers, EJ; Stokkel, MP; Teixeira, SC; Valdés Olmos, RA; van der Noort, V; Vrancken Peeters, MT, 2017) |
| "Twenty-four breast cancer patients, under zolendronic acid treatment for bone metastasis, were included." | ( Andreadis, C; Antoniades, K; Kouvelas, D; Kyrgidis, A; Lagoudaki, R; Yavropoulou, MP, 2017) |
| "A total of 110 early stage breast cancer patients with type 2 diabetes were divided randomly into 2 even groups: chemotherapy alone (Chemo) and chemotherapy + DRZ (Chemo + DRZ)." | ( Geng, C; Shi, J; Sun, F, 2016) |
| "As women with breast cancer have to undergo various treatment modalities, continued care by a pivot nurse is thought to enhance treatment adherence." | ( Binu, VS; Chakrabarty, J; Chillakunnel Hussain Rawther, S; Devi, ES; Fernandes, DJ; George, A; Mathew, S; Nayak, BS; Pai, MS, 2017) |
| "Patients with lymph node-positive breast cancer were prospectively randomized for either sequential anthracycline-taxane or epirubicin/fluorouracil/cyclophosphamid chemotherapy (FEC) therapy." | ( Augustin, D; Eichler, M; Ettl, J; Fink, V; Harbeck, N; Janni, W; Kiechle, M; Leinert, E; Rack, B; Schwentner, L; Singer, S; Weissenbacher, T; Wischnik, A, 2017) |
| "After chemotherapy for breast cancer, poor soft tissue wound healing is a major problem." | ( Alexeev, E; Benites, J; Brockunier, R; Brown, SA; Carpenter, JP; Chang, S; Harris, WM; Kappy, N; Ortiz, T; Plastini, M; Zhang, P, 2017) |
| "We investigated muscle strength in breast cancer patients in different adjuvant treatment settings and also compared it with data from healthy individuals." | ( Klassen, O; Potthoff, K; Schmidt, ME; Schneeweiss, A; Steindorf, K; Ulrich, CM; Wiskemann, J, 2017) |
| "CTCs in 2 (10%) of 20 breast carcinomas, more than 1 CTC was detected before adjuvant therapy, and both cases showed a decrease to 0 after chemotherapy." | ( Kinoshita, S; Shimada, T; Takeyama, H; Uchida, K, 2017) |
| "This study included 561 breast cancer patients undergoing radiotherapy between 2013 and 2015." | ( de Jong, PA; de Vos, BD; Gernaat, SA; Grobbee, DE; Išgum, I; Leiner, T; Pignol, JP; Rijnberg, N; Takx, RA; van den Bongard, DH; van der Graaf, Y; Verkooijen, HM; Young-Afat, DA, 2016) |
| "One in four breast cancer patients planned for radiotherapy have elevated CAC score." | ( de Jong, PA; de Vos, BD; Gernaat, SA; Grobbee, DE; Išgum, I; Leiner, T; Pignol, JP; Rijnberg, N; Takx, RA; van den Bongard, DH; van der Graaf, Y; Verkooijen, HM; Young-Afat, DA, 2016) |
| "Anti-HER2 treatment for HER2-positive breast cancer has changed the natural biology of this disease." | ( Gianni, L; Loibl, S, 2017) |
| "In patients with advanced HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab or placebo, higher TIL values are significantly associated with improved overall survival, suggesting that the effect of antitumour immunity extends to the advanced setting." | ( Baselga, J; Clark, E; Eng-Wong, J; Fox, S; Kiermaier, A; Loi, S; Luen, SJ; Michiels, S; Salgado, R; Savas, P; Swain, SM, 2017) |
| "Estrogen receptor positive breast cancer is the most common type of breast cancer and in most cases, hormone therapy is considered complementary to surgery." | ( Canseven, AG; Coskun, A; Esmekaya, MA; Kayhan, H; Yagci, M, 2017) |
| "Patients with stage II/III breast cancer who received adjuvant chemotherapy were evaluated for lymphedema on the basis of arm circumference measurements." | ( Chen, W; Gu, H; Li, D; Li, X; Ren, J; Shu, Y; Wang, D; Zhu, W, 2017) |
| "This study included 915 breast cancer patients who underwent neoadjuvant chemotherapy at five public hospitals in Singapore and Malaysia." | ( Bhoo-Pathy, N; Chan, P; Hartman, M; Lee, JA; Lee, SC; Lim, GH; Lim, JS; Lim, LY; Lim, SH; Miao, H; Ong, KW; Taib, NA; Tan, EY; Tan, PH; Tan, YS; Wong, FY; Wong, M; Woo, E; Yap, YS; Yip, CH, 2017) |
| "Enhanced apoptosis in breast cancer cells was detected in SST-DNL treated groups as monitored by cell cycle analysis and changes in expression level of apoptotic/anti-apoptotic proteins Bcl-2, Bax, cleaved Caspase 3 and PARP." | ( Banerjee, I; Bharti, R; Das, CK; Das, SK; Dey, G; Dey, KK; Emdad, L; Fisher, PB; Kumar, BN; Mandal, M; Misra, M; Mukherjee, M; Pal, I; Parida, S; Pradhan, AK, 2017) |
| "Among patients treated for breast cancer, those who received radiotherapy was associated with an excess risk of sarcoma as compared to those have not had (RR 5." | ( Asselain, B; Bazire, L; De Rycke, Y; Fourquet, A; Kirova, YM, 2017) |
| "Women treated for breast cancer had a significantly increased risk of several kinds of second malignancies compared to the general population." | ( Asselain, B; Bazire, L; De Rycke, Y; Fourquet, A; Kirova, YM, 2017) |
| "Chemotherapeutic treatment of breast cancer is based on maximum tolerated dose (MTD) approach." | ( Bellini, M; Corsi, F; Fiandra, L; Longhi, E; Mazzucchelli, S; Nebuloni, M; Prosperi, D; Rizzuto, MA; Sorrentino, L; Truffi, M, 2017) |
| "Incidence, multiplicity, and burden of breast cancer in rats were decreased by WA administration." | ( Beumer, JH; Christner, SM; Davidson, NE; Hahm, ER; Kim, SH; Pore, SK; Roy, R; Samanta, SK; Sehrawat, A; Shuai, Y; Singh, KB; Singh, SV, 2017) |
| "Among 1,147 patients with N1 breast cancer who received post-lumpectomy radiotherapy and AT-based chemotherapy in 12 hospitals, 542 were selected after propensity score matching." | ( Ahn, SJ; Cha, J; Choi, DH; Chun, M; Huh, SJ; Kang, HS; Kim, H; Kim, JH; Kim, JS; Kim, K; Kim, YB; Kim, YJ; Lee, ES; Lee, HS; Lee, JH; Lee, KS; Park, IH; Park, KR; Park, W; Shin, KH; Wee, CW; Yu, JI, 2017) |
| "Patients with breast cancer receiving chemotherapy (CTX) experience multiple concurrent symptoms, but little is known about how symptoms change during and after treatment." | ( Albusoul, RM; Berger, AM; Gay, CL; Janson, SL; Lee, KA, 2017) |
| "Patients with bilateral breast cancer (BBC) are usually excluded from participating in clinical trials and little is known about the response and outcome of BBC to neoadjuvant chemotherapy compared to unilateral BC (UBC)." | ( Blohmer, JU; Denkert, C; Hanusch, C; Huober, J; Jackisch, C; Kümmel, S; Lederer, B; Loibl, S; Nekljudova V, V; Reinisch, M; Rhiem, K; Schneeweiss, A; Untch, M; von Minckwitz, G, 2017) |
| "In early breast cancer patients, the effects of hormonal therapy (tamoxifen and aromatase inhibitors) on plasma fibroblast growth factor 21 (FGF-21), lipid levels and body composition have not yet been investigated." | ( Akyol, M; Alacacioglu, A; Bayoglu, V; Demir, L; Gumus, Z; Kara, M; Kucukzeybek, Y; Oflazoglu, U; Salman, T; Tarhan, MO; Taskaynatan, H; Varol, U; Yildiz, Y, 2017) |
| "The main risk factors for developing breast cancer are family history, increased density of breast tissue, atypical hyperplasia of the breast and previous radiotherapy to the chest area." | ( Weinberger, V; Zikán, M, 2016) |
| "In early breast cancer chemotherapy, it is important to maintain the relative dose intensity(RDI)." | ( Fujimori, T; Ishii, N; Kasagawa, T; Udagawa, I, 2016) |
| "A diagnosis ofbreast cancer with stage II A(T1N1M0)was made, and we started neoadjuvant chemotherapy." | ( Aomatsu, N; Haraoka, G; Hirakawa, T; Iwauchi, T; Morimoto, J; Nagashima, D; Nakazawa, K; Nishii, T; Nonomura, A; Takeuchi, K; Tei, S; Tsujio, G; Uchima, Y; Wang, E; Yamakoshi, Y, 2016) |
| "We report a case of advanced breast cancer with pathological complete response (pCR)obtained by eribulin chemotherapy." | ( Asano, Y; Goto, W; Hirakawa, K; Kashiwagi, S; Morisaki, T; Noda, S; Ohira, M; Ohsawa, M; Onoda, N; Takada, K; Takashima, T, 2016) |
| "We used human breast cancer cell lines to investigate the effects of Interleukin-1beta treatment on osteoprotegerin secretion as measured by ELISA." | ( Chung, ST; Connelly, L; Geerts, D; Renaud, A; Roseman, K, 2017) |
| "Co-culture of breast cancer cells with Interleukin-1beta-secreting macrophages resulted in a similar increase in osteoprotegerin secretion in breast cancer cells as Interleukin-1beta treatment." | ( Chung, ST; Connelly, L; Geerts, D; Renaud, A; Roseman, K, 2017) |
| "In HER2-positive early breast cancer, neoadjuvant treatment with a combination of sequential chemotherapy and HER2-targeted therapy is currently the standard of care." | ( Harbeck, N; Wuerstlein, R, 2017) |
| "Data on patient demographics, stage of breast cancer, pathology reports, surgical data, and information on systemic therapy were collected." | ( Argolo, D; Barrio, A; Baselga, J; Boafo, C; Dang, C; Hudis, CA; Jones, LW; Mamtani, A; Modi, S; Morrow, M; Norton, L; Patil, S; Schweber, S; Singh, JC; Smyth, LM; Sugarman, S; Yu, AF, 2017) |
| "Chemotherapy has been widely used in breast cancer patients to reduce tumor size." | ( Kiani, MF; Soroush, F; Tang, Y; Tong, Z; Wang, B, 2017) |
| "There is evidence that breast cancer patients treated with tamoxifen exhibit cognitive dysfunction." | ( Chen, X; He, X; Li, J; Qiu, B; Tao, L; Wang, K; Wu, J; Yu, F; Yu, Y; Zhang, J; Zhang, L; Zhu, C, 2017) |
| "We report a case of metastatic breast cancer with parathyroid hormone-related protein associated with hypercalcemia of malignancy that was treated with transarterial embolization of the hepatic metastatic lesions." | ( Apuri, S; Kis, B; Loftus, L; Nanjappa, S; Pla-Fernandez, CA, 2017) |
| "Locally advanced breast cancers have shown good response with taxane based sequential chemotherapy." | ( Sharma, D; Singh, G, 2016) |
| "Among women with stage I to II breast cancer receiving chemotherapy with a taxane, anthracycline, or both, those who underwent scalp cooling were significantly more likely to have less than 50% hair loss after the fourth chemotherapy cycle compared with those who received no scalp cooling." | ( Abraham, J; Courtright, J; Hilsenbeck, S; Holmes, F; Lacouture, M; Nangia, J; Niravath, P; Osborne, C; Osborne, CK; Otte, K; Papish, S; Paxman, R; Rimawi, M; Rude, M; Wang, T, 2017) |
| "BD sensitized ER-positive human breast cancer cells to 4-OHT/TAM treatment in vitro and in vivo." | ( Alvarado, M; Castillo, V; Cheng, S; Eliaz, I; Sandusky, GE; Sliva, D; Temm, CJ; Welty, M, 2017) |
| "A treatment concept of blocking breast cancer cell migration from interaction with SDF- 1α by using LFC131-NPs and then attacking breast cancer cells with doxorubicin might increase the efficacy of current breast cancer treatment." | ( Chittasupho, C; Kewsuwan, P; Murakami, T, 2017) |
| "Exposure of breast cancer cells to chemotherapy leads to an enrichment of BCSCs." | ( Chen, I; Lu, H; Park, Y; Semenza, GL; Shimoda, LA; Tran, L; Zhang, C; Zhang, H, 2017) |
| "In 10 patients with breast cancer, skeletal tumour burden in pretreatment and post-treatment F-NaF PET/CT was compared with tumour marker and clinical evolution." | ( Costa, G; Iagaru, A; Lapa, P; Marques, M; Pedroso de Lima, J, 2017) |
| "Four decades of erroneous breast cancer therapy with antiestrogens yielded the chaotic mixture of manifestations of artificial ER-inhibition and compensatory activating ER-mutations together with unreckonable tumor responses." | ( Suba, Z, 2017) |
| "However, treatment of breast cancer patients with EPO has been associated with poor prognosis and decrease of survival." | ( Cortes-Reynosa, P; Ordoñez-Moreno, A; Perez Salazar, E; Perez-Carreon, JI; Rodriguez-Monterrosas, C, 2017) |
| "Liver resection in patients with breast cancer liver metastasis proved to be cost-effective when compared with systemic therapy alone, particularly in estrogen receptor-positive tumors or when newer agents were used." | ( Bagante, F; Connolly, R; Pawlik, TM; Spolverato, G; Vitale, A, 2017) |
| "Patients with locally advanced breast cancer were randomized to receive 4-6 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracil-epirubicin-cyclophosphamide (FEC) regimen or weekly paclitaxel-epirubicin (PE) regimen." | ( Chen, J; He, P; Luo, T; Lv, Q; Tan, QW; Tian, TL; Zeng, HL; Zheng, H, 2017) |
| "Chemotherapy failure of breast cancer is mainly associated with multidrug resistance of cancer cells." | ( Cheng, L; Li, XT; Liu, S; Song, XL; Wang, X; Wang, XM; Wang, YH; Xiao, Y, 2017) |
| "A convenience sample of 118 Malaysian breast cancer patients voluntarily participated in the study and responded to a set of questionnaires including: socio-demographic questionnaire, the short form of Locus of Control Scale, the Functional Assessment of Cancer Therapy-Breast (FACT-B), the Hospital Anxiety and Depression Scale (HADS), and the Short-Form Mishel Uncertainty in Illness Scale (SF-MUIS)." | ( Pahlevan Sharif, S, 2017) |
| "SKBR3 and MCF-7 breast cancer cells were treated with 500 μM 2DG and/or MLN4924 (30, 100, 200 and 300 nM), and in combination in the presence and absence of 1, 1." | ( Asghari Jafar Abadi, M; Baradaran, B; Farajollahi, A; Mohammadi, M; Oladghaffari, M; Pirayesh Islamian, J; Shabestani Monfared, A; Shanehbandi, D, 2017) |
| "Treatment of stage IV metastatic breast cancer patients is limited to palliative options and represents an unmet clinical need." | ( Dudley, M; Kavishwar, A; Medarova, Z; Moore, A; Pantazopoulos, P; Ross, A; Wang, P; Yoo, B, 2017) |
| "HER2-overexpressing breast cancer cells treated with TGF-β have a reduced response to trastuzumab and exhibited EMT-like phenotype." | ( Clayton, S; Dwabe, S; Farias-Eisner, R; Kim, J; Nava, M; Pietras, R; Sarkissyan, M; Tran, T; Vadgama, JV; Wu, Y, 2017) |
| "Among women with recurrent breast cancer, a longer DFI between a patient's initial breast cancer diagnosis and their recurrence was associated with a longer TTF on F500 therapy." | ( Anan, K; Aogi, K; Fujisawa, T; Hasegawa, Y; Hattori, M; Ito, Y; Kawaguchi, H; Masuda, N; Morita, S; Nakamura, S; Nakayama, T; Ohno, S; Ohtani, S; Saji, S; Sato, N; Toi, M; Tokunaga, E; Yamaguchi, M; Yamamoto, Y; Yamashita, T, 2017) |
| "SKBR3 and T47D breast cancer cells were treated with superparamagnetic mesoporous hydroxyapatite nanocomposites (SPmHANs)conjugated with 1 μM doxorubicin and 0." | ( Asghari Jafarabadi, M; Aval, NA; Hatamian, M; Mesbahi, A; Mohammadzadeh, M; Pirayesh Islamian, J; Rashidi, MR, 2017) |
| "We studied 1347 women with ER-positive breast cancer who were treated at Women's College Hospital between 1987 and 2000." | ( Narod, SA; Sopik, V; Sun, P, 2017) |
| "Nearly 75% of breast tumors express estrogen receptor (ER), and will be treated with endocrine therapy, such as selective estrogen receptor modulator (SERM), tamoxifen, or aromatase inhibitors." | ( Brovkovych, SD; Frasor, J; Kastrati, I; Siklos, MI; Thatcher, GRJ, 2017) |
| "Moreover, endocrine resistant breast cancer patients with elevated S100β may benefit from combined endocrine and tyrosine-kinase inhibitor treatment." | ( Bane, FT; Byrne, C; Charmsaz, S; Cocchiglia, S; Dwyer, RM; Hennessy, BT; Hill, AD; Hughes, É; Kerin, MJ; McBryan, J; McIlroy, M; Tibbitts, P; Young, LS, 2017) |
| "We measure tissue blood flow markers in breast tumors during neoadjuvant chemotherapy and investigate their correlation to pathologic complete response in a pilot longitudinal patient study (n = 4)." | ( Baker, WB; Busch, DR; Chung, SH; Cochran, JM; DeMichele, AM; Leproux, A; Tchou, J; Tromberg, BJ; Yodh, AG, 2017) |
| "We enrolled 309 breast cancer patients who received two types of regimens: cyclophosphamide + epirubicin dose-dense neoadjuvant chemotherapy followed by sequential postoperative paclitaxel single-drug medication, and paclitaxel + epirubicin standard neoadjuvant chemotherapy followed by two cycles of the same chemotherapy after surgery." | ( Cai, R; Chen, S; Fan, Y; Li, Q; Luo, Y; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P, 2017) |
| "A sample of 177 patients with primary breast cancer (stage I-III) and who received neoadjuvant therapy were included." | ( Espinosa Fematt, J; Gallegos-Arreola, MP; Méndez-Hernández, A; Moreno-Macías, H; Pérez-Morales, R, 2017) |
| "Anemia is common in breast cancer patients and can be treated with blood transfusions or with recombinant erythropoietin (EPO) to stimulate red blood cell production." | ( Chan, KK; Coulter, JA; Davidson, MA; El-Tanani, M; Hengst, L; Irwin, GW; Jaekel, H; Lappin, TR; Matchett, KB; Maxwell, P; McCrudden, CM; Mills, KI; Platt-Higgins, A; Rudland, PS; Rülicke, T; Schober, S; Yuen, HF; Zhang, SD, 2017) |
| "Over half of breast cancer patients discontinue their adjuvant hormone therapy, permanently or temporarily." | ( Czene, K; Fang, F; Hall, P; He, W; Margolin, S; Olsson, H; Smedby, KE, 2017) |
| "We followed women diagnosed with breast cancer (Stockholm, Sweden, 2005-2008) from their first prescription of tamoxifen or aromatase inhibitors through January 31, 2015, and categorized them as continuers (n = 1 607), restarters (n = 953), and nonrestarters (n = 511) of adjuvant hormone therapy." | ( Czene, K; Fang, F; Hall, P; He, W; Margolin, S; Olsson, H; Smedby, KE, 2017) |
| "This method was applied to MDA-MB-231 breast cancer cells treated with the antidiabetic drug metformin, which is being repurposed for treatment of triple-negative breast cancer." | ( Athreya, AP; Cairns, J; Gaglio, AJ; Iyer, RK; Kalari, KR; Niu, N; Wang, L; Weinshilboum, R; Wills, QF, 2017) |
| "We prospectively observed breast cancer patients treated with anthracycline or trastuzumab at Tonan Hospital." | ( Hirayama, M; Kawada, M; Kitayama, H; Kondo, T; Kurimoto, K; Nishino, Y; Sugiyama, J; Tsuji, Y, 2017) |
| "Patients with metastatic breast cancer were to receive either 100 or 150 or 200 mg oral ART daily as add-on to their guideline-based oncological therapy for a study period of four weeks with frequent clinical and laboratory monitoring until 4-8 weeks thereafter." | ( Edler, L; Efferth, T; Elsässer, M; Goeckenjan, M; Munzinger, J; Osburg, J; Remppis, BA; Schneeweiss, A; Sertel, S; Storch-Hagenlocher, B; Strowitzki, T; von Hagens, C; Walter-Sack, I, 2017) |
| "Plasma of 20 patients treated for breast cancer with DOX-chemotherapy was analyzed using quantitative RT-PCR." | ( Klimberg, VS; Makhoul, I; Todorova, VK; Wei, J, 2017) |
| "Since the incidence of breast cancer increases dramatically all over the world, the search for effective treatment is an urgent need." | ( Abo Mansour, HE; El-Ashmawy, NE; El-Bahrawy, HA; Khedr, NF, 2017) |
| "Sixty-five patients with metastatic breast cancer treated with first- or second-line systemic therapy in prospective clinical trials were included." | ( Baltzer, P; Dickler, M; Gönen, M; Jochelson, MS; McArthur, HL; Ong, LT; Pinker, K; Riedl, CC; Ulaner, GA; Weber, WA, 2017) |
| "Women of reproductive age with breast cancer generally receive gonadotoxic chemotherapy." | ( Bachelot, T; Barriere, P; Bendavid, C; Campone, M; Debled, M; Delozier, T; Dezellus, A; Freour, T; Gallais-Umbert, A; Jouannaud, C; Lemanski, C; Levy, C; Loustalot, C; Masson, D; Mignot, L; Mouret-Reynier, MA; Vanlemmens, L, 2017) |
| "Therefore, new approaches for breast cancer treatments are necessary." | ( Antonow, MB; Asbahr, ACC; Beckenkamp, A; Buffon, A; Guterres, SS; Pohlmann, AR; Raddatz, P, 2017) |
| "Triple negative breast cancer cells (MBA-MB-231) and hASCs (institutional review board-approved clinical isolates) were treated with a standard therapeutic dose of paclitaxel (1." | ( Bird, D; Brown, SA; Carpenter, JP; Chang, S; Fromer, MW; Gaughan, JP; Hagaman, AL; Koko, KR; Matthews, M; Nolan, RS; Zhang, P, 2017) |
| "A high proportion of patients with breast cancer develop bone metastases, yet data on routine treatment with bone-targeted agents (BTA) are rare." | ( Fietz, T; Fleitz, A; Jänicke, M; Köhler, A; Marschner, N; Petersen, V; Schröder, J; Spring, L; Tesch, H, 2017) |
| "In an orthotopic metastatic breast cancer model, intravenously administered PCMs could be efficiently delivered to the tumor sites, resulting in a 71." | ( Cao, HQ; He, B; Hu, HY; Li, YP; Tan, T; Zhang, ZW; Zhong, T, 2017) |
| "Viability of SKBR-3 and MDA-MB-231 breast cancer cells treated with SF was determined by SRB and clonogenic assays." | ( Felczykowska, A; Hać, A; Herman-Antosiewicz, A; Pawlik, A; Wała, M, 2017) |
| "Kinomics and transcriptomics of MCF-7 breast cancer cells treated with the secretome of CAAT revealed activation of Akt-, ERK- and JNK-pathways and differential expression of activator protein 1 (AP-1) and cAMP responsive element-binding protein (CREB) target genes." | ( Bracke, M; Braems, G; Cocquyt, V; De Wever, O; Denys, H; Hendrix, A; Lapeire, L; Lecoutere, E; Maynard, D; Müller, C; Van Bockstal, M; Van Den Broecke, R; Vandesompele, J, 2017) |
| "In HER2-positive breast cancer, high baseline TIL are associated with increased pCR probability irrespective of neoadjuvant anti-HER2 agent(s) and chemotherapy regimens used." | ( Buisseret, L; Ceppi, M; de Azambuja, E; Fumagalli, D; Garaud, S; Ignatiadis, M; Lambertini, M; Salgado, R; Scartozzi, M; Solinas, C; Sotiriou, C; Willard-Gallo, K, 2017) |
| "DKK-1 serum levels were reduced in breast cancer patients receiving an adjuvant therapy with tamoxifen, possibly contributing to its bone-protective properties." | ( Browne, AJ; Göbel, A; Hofbauer, LC; Kuhlmann, JD; Link, T; Rachner, TD; Rauner, M; Wimberger, P, 2017) |
| "PTP1B and SHP2 are overexpressed in breast cancer cells, thus inhibition of their activity can be potentially effective in breast cancer therapy." | ( Gorska-Ponikowska, M; Kuban-Jankowska, A; Wozniak, M, 2017) |
| "A total of 827 patients with breast cancer treated with taxane-based adjuvant chemotherapy were included in the study." | ( Aravantinos, G; Chrisafi, S; Fountzilas, G; Gavressea, T; Gogas, H; Kalofonos, HP; Kalogeras, KT; Karanikiotis, C; Koliou, GA; Koufopoulos, N; Koutras, A; Lazaridis, G; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pavlakis, K; Pazarli, E; Pectasides, D; Petraki, K; Tsigaridas, K; Zagouri, F, 2017) |
| "One hundred and twenty Malaysian breast cancer patients receiving docetaxel as single agent chemotherapy were investigated for AAG plasma level using enzyme-linked immunosorbent assay technique." | ( Annuar, MABA; Ho, GF; Jabir, RS; Stanslas, J, 2018) |
| "Many women with breast cancer experience depressive symptoms that interfere with their treatment, recovery, and quality of life." | ( Asher, A; Bower, JE; Crespi, CM; Ganz, PA; Irwin, MR; Kuhlman, KR; Petersen, L, 2017) |
| "To this end, breast cancer cells were incubated with leptin in the absence or presence of inhibitor pretreatment, and changes in aromatase and cyclooxygenase-2 (COX-2) expression were evaluated at the mRNA and protein levels." | ( Chung, YC; Hwang, YJ; Jeong, HG; Jeong, TC; Jin, SW; Khanal, T; Kim, HG; Kim, SJ; Kim, YA; Lee, GH; Rhee, SD, 2017) |
| "While higher breast cancer risk with hormone replacement therapy is particularly evident among lean women, in postmenopausal women who are not taking exogenous hormones, general obesity is a significant predictor for breast cancer." | ( Engin, A, 2017) |
| "Chemotherapy and radiotherapy for breast cancer may lead to cardiac dysfunction, but the prevalence of long-term echocardiographic evidence of cardiac dysfunction is unknown among survivors." | ( Berendsen, AJ; Berger, MY; Boerman, LM; de Bock, GH; Gietema, JA; Hummel, YM; Maass, SWMC; Maduro, JH; van der Meer, P, 2017) |
| "We treated the MCF‑7 breast cancer cell line with the HMOX‑1 inducer hemin and observed that hemin induced HMOX‑1 expression and inhibited migration, invasion and ROS generation in transforming growth factor‑β (TGF‑β)‑treated MCF‑7 cells using quantitative RT‑qPCR, western blotting, wound‑healing and cell invasion assays as well as fluorescent probe DCFDA." | ( Cheng, X; Huang, S; Kong, F; Ma, J; Sun, S; Zeng, F; Zeng, L; Zhu, X, 2017) |
| "In conclusion, ER + breast cancer patients may benefit from addition of Viscum album to low-dose Dox chemotherapy due to suppression of cancer cell senescence and induction of apoptosis." | ( Cavic, M; Galun, D; Jevric, M; Kanjer, K; Kardum, N; Konic-Ristic, A; Santibañez, JF; Srdic-Rajic, T; Tisma-Miletic, N; Zoranovic, T, 2017) |
| "We identified 541 recurrent breast cancer cases with estrogen receptor-positive disease treated with tamoxifen for at least 1 year (ER+/TAM+) and 300 cases with estrogen receptor-negative disease never treated with tamoxifen (ER-/TAM-)." | ( Cronin-Fenton, D; Hamilton-Dutoit, S; Hellberg, Y; Kjærsgaard, A; Lash, TL; Mortensen, K; Sørensen, HT; Thistle, JE, 2017) |
| "Aggressive breast cancer tumors classified as Triple Negative do not respond to hormonal treatment because they lack three crucial receptors, one of which is the estrogen receptor alpha (ERα)." | ( Ayala-Sumuano, JT; Domínguez-Robles, MC; Jiménez-Garduño, AM; Mendoza-Rodríguez, MG; Meza, I; Pérez-Yépez, EA; Urrutia-Cabrera, D, 2017) |
| "Pre-operative progesterone treatment of breast cancer has been shown to confer survival benefits to patients independent of their progesterone receptor (PR) status." | ( Badwe, R; Dutt, A; Godbole, M; Gupta, S; Tiwary, K, 2017) |
| "Here, we presented that breast cancer MCF-7 and SKBR3 cells under treatment with 4-hydroxytamoxifen displayed decreased level of pyruvate kinase M2." | ( Chen, T; Guo, B; Huang, L; Huang, Y; Ji, F; Jiang, Y; Jin, Q; Liu, Y; Su, M; Wang, N; Wei, L; Yang, J; Zhang, Z; Zhong, C, 2017) |
| "Germline DNA from 467 breast cancer patients in Sarawak General Hospital, Malaysia, where 93% of the breast cancer patients in Sarawak are treated, was sequenced for the entire coding region of BRCA1; BRCA2; PALB2; Exons 6, 7, and 8 of TP53; and Exons 7 and 8 of PTEN." | ( Best, A; Dean, M; Devi, BCR; Garland, L; Guida, J; Hicks, B; Hu, N; Jones, K; Luo, W; Moitra, K; Mucaki, EJ; Rodriguez-Herrera, M; Rogan, PK; Sung, H; Tang, TS; Wang, C; Xiao, Y; Xie, Y; Yang, XR, 2017) |
| "Half of estrogen receptor-positive breast cancers contain a subpopulation of cytokeratin 5 (CK5)-expressing cells that are therapy resistant and exhibit increased cancer stem cell (CSC) properties." | ( Fettig, LM; Finlay-Schultz, J; LaBarbera, DV; McGinn, O; Nordeen, SK; Sartorius, CA, 2017) |
| "Chemotherapy for breast cancer may have a negative impact on reproductive function due to gonadotoxicity." | ( Balkenende, EME; Beerendonk, CCM; Bos, AME; Cantineau, AEP; Dahhan, T; de Bruin, JP; Fleischer, K; Goddijn, M; Kopeika, Y; Lambalk, CB; Linn, SC; Louwé, LA; Reddy, N; Schats, R; Schipper, I; Smeenk, JMJ; Stoop, D; van der Veen, F; van Golde, RJT; van Wely, M, 2017) |
| "A group of breast cancer patients who applied the hydroactive gel from start to end of post-lumpectomy radiotherapy (Preventive Hydrogel group) were compared with two groups of matched historical controls: a group applying a dexpanthenol cream throughout their therapy and a group applying first the dexpanthenol cream then, after 11-14 fractions of radiotherapy, the hydroactive gel (Curative Hydrogel group)." | ( Braekers, R; Bulens, P; Censabella, S; Claes, S; Orlandini, M, 2017) |
| "Metastatic breast cancer (MBC) progressing after endocrine therapy frequently activates PI3K/AKT/mTOR pathway." | ( Álvarez, C; Apellániz-Ruiz, M; Ciruelos, E; Cueto-Felgueroso, C; Inglada-Pérez, L; Manso, L; Pascual, T; Pernaut, C; Robledo, M; Rodríguez-Antona, C; Villalba, P, 2017) |
| "Information at initial breast cancer diagnosis were retrieved from patients' medical records and include age at diagnosis, tumor characteristics, anti-cancer treatments, blood pressure and body weight and height." | ( Koh, J; Liem, GS; Loong, HHF; Mo, FKF; Ng, RYW; Pang, E; Suen, JJS; Tang, NLS; Yeo, W; Yip, CCH; Yip, CHW, 2017) |
| "Among young premenopausal Chinese breast cancer patients who had received adjuvant chemotherapy, the current study has revealed that although there was only a median weight gain of 1." | ( Koh, J; Liem, GS; Loong, HHF; Mo, FKF; Ng, RYW; Pang, E; Suen, JJS; Tang, NLS; Yeo, W; Yip, CCH; Yip, CHW, 2017) |
| "For triple negative breast cancer, chemotherapy remains the mainstay of standard treatment." | ( Chen, DR; Tsai, CF; Yeh, WL, 2017) |
| "Metastasis causes high mortality of breast cancer, and the inability of drug delivery to metastatic sites remains a crucial challenge for antimetastasis therapy." | ( Cao, H; He, X; Li, Y; Tan, T; Wang, H; Yin, Q; Yu, H; Zhang, P; Zhang, Z, 2017) |
| "Furthermore, the cell cycle of breast cancer cells treated with oxymatrine was arrested at the S-phase of the cell cycle." | ( Cai, Y; Li, H; Li, M; Tan, Z; Wu, J; Zhang, Y, 2017) |
| "Patients with ER-positive breast cancer, regardless of high or low 70-gene risk classification, receive significant survival benefit lasting over 10 years from adjuvant tamoxifen therapy, even when given for a relatively short duration." | ( Benz, CC; Esserman, LJ; Fornander, T; Lindström, LS; Nordenskjöld, B; Stål, O; van 't Veer, LJ; Yau, C; Yu, NY, 2017) |
| "Patients with primary breast cancer received a total of 4 cycles of dose-dense EC treatment every 2 weeks, together with a subcutaneous injection of 3." | ( Adachi, Y; Ando, Y; Hayashi, H; Inaishi, T; Kikumori, T; Maeda, O; Matsuoka, A; Mizutani, T; Morita, S; Nakanishi, K; Ota, A; Shibata, M; Shimokata, T; Takeuchi, D; Tsunoda, N, 2018) |
| "Cognitive functioning difficultiesin breast cancer patients receiving chemotherapy are common, but not all women experience these impairments." | ( Janelsins, M; Jo, B; Kamen, C; Palesh, O; Scheiber, C; Shen, H, 2017) |
| "MCF-7 breast cancer cells were cultured and treated with visfatin." | ( Alaee, M; Behrouzfar, K; Gholinejad, Z; Golestani, A; Nourbakhsh, M, 2017) |
| "Moreover, the invasive activity of breast cancer cell lines after radiation treatment was significantly inhibited in the presence of RGD/P-AuNPs." | ( Giaccia, AJ; Hashimoto, T; Ichikawa, Y; Nam, JM; Onodera, Y; Qian, W; Rankin, EB; Shirato, H; Watanabe, Y; Wu, PH, 2017) |
| "Treatment of metastatic breast cancer cells with targeted nanomicelles significantly increased the necrosis rate to 65%, compared to 33% in non-targeted nanomicelles and 8% in control group." | ( Abdolghaffari, AH; Amini, M; Atyabi, F; Bahadorikhalili, S; Daman, Z; Dinarvand, R; Esfandyari-Manesh, M; Ghahremani, MH; Lavasanifar, A; Mahdaviani, P; Navaei-Nigjeh, M; Vafaei, SY, 2017) |
| "ER-positive/PgR-negative breast carcinomas are associated with higher response but also worse long-term outcome after neoadjuvant therapy." | ( Blohmer, JU; Denkert, C; Fasching, PA; Hanusch, C; Huober, J; Jackisch, C; Karn, T; Kümmel, S; Loibl, S; Marmé, F; Müller, V; Nekljudova, V; Schem, C; Schneeweiss, A; Stickeler, E; Untch, M; van Mackelenbergh, MT; von Minckwitz, G; Weber, KE, 2018) |
| "We performed small RNA sequencing of breast cancer cells for identification of microRNAs targeting PR in response to progesterone treatment." | ( Badwe, R; Chandrani, P; Dhamne, H; Dutt, A; Gardi, N; Godbole, M; Gupta, S; Patel, K; Yadav, N, 2017) |
| "Using breast cancer as model, we show a synergistic interaction between heat (photoconversion at 530 nm) and cytotoxic action by doxorubicin with clear advantages to those of the individual therapy approaches." | ( Baptista, PV; Fernandes, AR; Lima, JC; Mendes, R; Pedrosa, P, 2017) |
| "Of 168 patients with metastatic breast cancer who were treated with paclitaxel, EPN was documented in 101 patients (60." | ( Akiyama, F; Fukada, I; Horii, R; Ito, Y; Iwase, T; Kobayashi, K; Ohno, S; Shibayama, T; Takahashi, S, 2017) |
| "In the present study, wild-type breast carcinoma cells (MCF-7/W) were treated chronically with 10 nM doxorubicin (DOX) to establish a low-dose DOX-resistant mammary cancer model (MCF-7/D)." | ( Aceves, C; Bontempo, A; Delgado-González, E; Rodríguez, ÁL; Ugalde-Villanueva, B, 2017) |
| "In spite of advances in breast cancer treatment and early diagnosis, drug toxicity, cancer relapse, multidrug resistance and metastasis are the major impediment to the developments of efficient drugs." | ( Gunasekaran, VP; Mathan, G; Nishi, K; Sivakumar, D; Sivaraman, T, 2018) |
| "Treatment of MDA-MB-231 human breast cancer cells with TUB-A or PdNPs showed a dose-dependent effect on cell viability." | ( Gurunathan, S; Peng, QL; Yuan, YG, 2017) |
| "Two female breast cancer patients developed epiphora after administration of cyclophosphamide and/or anthracyclines based 2-day chemotherapy regimen." | ( Chavada, B; Kalra, R; Madhani, NR; Purohit, B; Tripathi, CB, 2018) |
| "MCF-7 breast cancer cells showed similar motility behaviour as salinomycin-treated JIMT-1 cells." | ( Alm, K; Janicke, B; Kamlund, S; Oredsson, S; Strand, D, 2017) |
| "Doxorubicin (DOX) resistance in breast cancer largely results from the breast cancer stem cell like cells (BCSCs) which could be targetted to improve the efficacy of chemotherapy." | ( Fan, H; Guo, L; Wang, H; Xu, W; Zheng, P; Zhou, W, 2017) |
| "Adjuvant endocrine therapy in breast cancer has increased survival rates; however, it is not without musculoskeletal side effects." | ( Burtin, C; Slot, DE; van der Weijden, GA; Van der Weijden-Van Doornik, EM, 2017) |
| "Neoadjuvant treatment (NAT) of breast cancer (BCa) is an option for patients with the locally advanced disease." | ( Martel, AL; Nofech-Mozes, S; Peikari, M; Salama, S, 2017) |
| "In MCF-7 human breast carcinoma cells, α5β1 integrin hyperexpression, which was accomplished by transduction of a full-length α5 integrin cDNA, increased by about 50-70% the number of cells, survived during 48-72 h cell treatment with doxorubicin." | ( Berman, AE; Kozlova, NI; Lupatov, AY; Morozevich, GE; Susova, OY, 2017) |
| "Chemotherapy is the main method of breast cancer treatment but there are side effects." | ( Astuti, M; Mubarika Haryana, S; Murdiati, A; Zuhrotun Nisa, F, 2017) |
| "Acid ceramidase is highly upregulated in breast tumors and treatment with an acid ceramidase inhibitor, ceranib-2, significantly induced apoptosis in human breast cancer cell lines." | ( Jayaprakasam, M; Murali, S; Padmanaban, VP; Sekar, AK; Sesurajan, BP; Vethakanraj, HS, 2018) |
| "As the first-line drug for breast cancer chemotherapy, doxorubicin (Dox) has strong cardiotoxicity." | ( Lai, H; Li, K, 2017) |
| "Recommendations Patients with breast cancer who have evidence of bone metastases should be treated with BMAs." | ( Barlow, WE; Biermann, JS; Bosserman, LD; Clemons, MJ; Dhesy-Thind, SK; Dillmon, MS; Eisen, A; Frank, ES; Jagsi, R; Jimenez, R; Moy, B; Somerfield, MR; Theriault, RL; Van Poznak, C; Vandenberg, TA; Yee, GC, 2017) |
| "However, ER-positive (ER+) breast cancers receiving anti-hormone and/or chemotherapy sometimes lose their ER expression, which leads to the evolution of the disease to higher aggressiveness and drug resistance." | ( Gu, XT; He, DX; Liu, DQ; Lu, CX; Ma, X; Wu, XL; Zhang, GY, 2017) |
| "For patients with early-stage breast cancer who received PLD-based adjuvant chemotherapy, 5-year DFS was comparable and toxicity was acceptable, yet different from those of patients who received epirubicin-based regimens." | ( Chang, KJ; Chen, DR; Hou, MF; Hsieh, CM; Hsu, NC; Lu, YC; Moi, SH; Tu, CW; Wang, HC; Yang, FO, 2018) |
| "Treatment of breast cancer cells and tumor-bearing mice with these curcumin-loaded nanoparticles gave rise to reduced phosphoinositide 3-kinase signaling, decreased cancer cell viability, attenuated drug clearance from the circulation, and suppressed tumor burden compared with free curcumin or non-EGFR targeting nanoparticles." | ( Cai, J; Evans, CE; Jiang, J; Jin, H; Li, T; Pi, J; Yang, P; Zeng, X; Zhao, Y, 2017) |
| "Enophthalmos in the setting of breast cancer metastatic to the orbit results primarily from the disease pathogenesis, or secondary to treatment effects." | ( Alameddine, RM; Kikkawa, DO; Ko, AC; Korn, BS; Lin, JH; Mimura, M; Parker, BA, 2018) |
| "In mice bearing breast cancer xenografts, administration of Sali-NP-HER2 exhibited superior efficacy in inhibiting tumor growth." | ( Chen, H; Han, J; Li, J; Song, H; Wang, B; Xu, W; Yuan, X, 2017) |
| "In a murine breast cancer model, sphingosine kinase 1, S1P receptor 1, interleukin 6, and STAT3 were overexpressed in the doxorubicin-treated group, whereas all of them were significantly suppressed with addition of FTY720." | ( Hait, NC; Katsuta, E; Lyon, DE; Nagahashi, M; Rashid, OM; Raza, A; Sturgill, JL; Takabe, K; Yan, L, 2017) |
| "CONCLUSIONS Scutellarin-treated breast carcinoma MCF-7 cells had significantly inhibited growth and induced apoptosis, which is associated with induction of autophagy through regulation of the HIPPO-YAP signaling pathway, providing support to the clinical use of Scutellarin-based medication to achieve optimized outcome in patients with breast carcinoma." | ( Chen, L; Fang, L; Hou, L, 2017) |
| "Triple negative breast cancer (TNBC) is a complex and intrinsically aggressive tumour with poor prognosis, and the discovery of targeted small-molecule drugs for TNBC treatment still remains in its infancy." | ( Chen, L; Jiang, Y; Ouyang, L; Sun, D; Yu, Y; Zhao, Y; Zhu, L, 2018) |
| "The majority of breast cancers express estrogen receptor (ER)α, and endocrine therapy is the primary therapeutic approach to treat ER positive breast cancers." | ( Krishnegowda, N; Ramasamy, K; Samayoa, C; Tekmal, RR, 2017) |
| "Twenty-four women with early stage breast cancer were randomly assigned to perform a 30-min, vigorous-intensity treadmill bout 24 h prior to each of four doxorubicin-containing chemotherapy treatments or to usual care." | ( Bland, KA; Bovard, J; Campbell, KL; Eves, ND; Gelmon, KA; Kirkham, AA; McKenzie, DC; Shave, RE; Stöhr, EJ; Virani, SA; Waburton, DER, 2018) |
| "Anastrozole reduces breast cancer risk in women at high risk, but implementing preventive therapy in clinical practice is difficult." | ( Cuzick, J; Forbes, JF; Howell, A; Sestak, I; Smith, SG, 2018) |
| "Finally, publicly available breast cancer patient datasets indicate that MTA1 levels correlate with poor prognosis and development of recurrence in patients with breast cancer treated with tamoxifen." | ( Hong, S; Ka, NL; Kim, HJ; Kim, S; Koh, D; Lee, MH; Lee, MO; Na, H; Seong, JK; Shin, YK, 2018) |
| "MDA-MB-231 breast cancer cells were implanted into medullary canals of ovariectomized female athymic nude mice femurs (N = 8 mice/treatment)." | ( Boyan, BD; Cohen, DJ; Patel, V; Schwartz, Z; Verma, A, 2019) |
| "We report a rare case of breast carcinoma metastatic to the left mandibular condyle in a 55-year-old Japanese woman, who visited our department for a dental check-up prior to chemotherapy." | ( Dodo, M; Hirakawa, H; Kato, Y; Koseki, T; Kumagai, M, 2017) |
| "We presented a case of breast cancer with severe fatty liver as a consequence of the administration of CAP that was not involved in DPD deficiency or CAP-associated hypertriglyceridemia; these potential adverse effects of therapy with CAP should be intensely investigated." | ( He, Q; Jiang, Y; Li, S; Shi, C; Yang, X, 2017) |
| "Twelve patients with breast cancer were treated: five had estrogen receptor positive disease and five were HER2 amplified." | ( Brenin, CM; Brenin, DR; Chianese-Bullock, KA; Dillon, PM; Fanous, IS; Hall, EH; Nail, CJ; Olson, WC; Petroni, GR; Slingluff, CL; Smith, KT; Smolkin, ME, 2017) |
| "Hormone receptor (HR)-positive breast cancer (BC) shows a poor response to neoadjuvant chemotherapy (NACT)." | ( Darb-Esfahani, S; Denkert, C; Engels, K; Furlanetto, J; Huober, J; Kümmel, S; Lederer, B; Loibl, S; Marmé, F; Mehta, K; Müller, V; Pfitzner, BM; Schem, C; Villegas, SL; von Minckwitz, G; Weber, K, 2018) |
| "Multidrug resistance (MDR) in breast cancer therapy occurs frequently." | ( Jiang, QC; Wang, SR; Zhang, ZL, 2018) |
| "To identify patients with breast cancer at risk for cardiotoxicity, we evaluated homoarginine (HA) behavior during adjuvant treatment." | ( Aula, H; Hämäläinen, M; Kellokumpu-Lehtinen, PL; Luukkaala, T; Moilanen, E; Raatikainen, P; Skyttä, T; Tuohinen, S; Virtanen, V, 2017) |
| "The value of androgen receptor (AR) in breast cancer has gained renewed interest as a prognostic and treatment predictive biomarker." | ( Folkesson, E; Hartman, L; Klintman, M; Niméus, E; Nodin, B, 2017) |
| "In human breast cancer LM-MCF-7 and MDA-MB-231 cells, treatment with LPI (2." | ( Guo, X; Song, YP; Zhou, XL; Zhu, CY; Zou, W, 2018) |
| "For both studies, we recruited early breast cancer patients who had an increase in their fatigue scores after their first cycle of adjuvant chemotherapy." | ( Cruz, FM; Cubero, DIG; Del Giglio, A; Fonseca, F; Peppone, LJ; Pianowski, LF; Ribas de Alcântara, BB; Schoueri, JHM; Sette, CVM, 2018) |
| "The Danish Breast Cancer Group (DBCG) clinical database provides high-quality prospectively collected data on breast cancer diagnosis, treatment, and routine follow-up for breast cancer recurrence." | ( Ahern, TP; Christiansen, P; Cronin-Fenton, D; Damkier, P; Ejlertsen, B; Lash, TL; Sørensen, HT, 2018) |
| "There is substantial use of CAM among breast cancer patients in UMMC prior to seeking hospital treatment, and the most popular CAM modality is dietary supplements." | ( Abdul Majid, H; Al-Sadat, N; Bhoo-Pathy, N; Dahlui, M; Hussain, S; Islam, T; Mohd Taib, NA; Zulkipli, AF, 2018) |
| "Chemotherapy for early breast cancer is associated with a small risk of developing myelodysplastic syndrome (MDS) and/or acute myeloid leukemia (AML)." | ( Chavez-MacGregor, M; Giordano, SH; Niu, J; Rosenstock, AS; Wolff, AC; Zhao, H, 2018) |
| "Human breast cancer cells MCF-7 and T47D were treated with, or without, different doses (0, 6." | ( Feng, C; Li, S; Tian, J; Wang, Y; Wu, G; Ye, Y, 2017) |
| "Using the Curtis dataset of breast cancer (n=1980) within the cBioPortal database, we examined a correlation of SIPL1 expression with ER+ BC and resistance to hormone therapy." | ( Bane, A; Ojo, D; Tang, D; Wu, Y, 2018) |
| "However, many patients with ER+ breast cancer have experienced resistance and other adverse side effects following treatment with tamoxifen." | ( Guo, Z; Lv, Q; Zhou, H, 2018) |
| "Histological subtype, (invasive ductal breast cancer (IDBC)/invasive lobular breast cancer (ILBC)), might be a marker for differential response to endocrine therapy in breast cancer." | ( Chen, BE; Goss, PE; Liedke, PER; O'Shaughnessy, J; Parulekar, WR; Ramjeesingh, R; Shepherd, LE; Strasser-Weippl, K; Sudan, G, 2018) |
| "Conventional treatment strategies for breast cancer consist of chemotherapy, radiation, surgery, chemoradiation, hormone therapy, and targeted therapies." | ( Du, J; Yu, Y; Zhan, J; Zhang, H, 2017) |
| "In estrogen receptor-positive (ER+) breast cancer models, activation of Aurora A kinase (AURKA) is associated with downregulation of ERα expression and resistance to endocrine therapy." | ( D'Assoro, A; Goetz, MP; Haddad, TC; Ingle, JN; Liu, MC; Opyrchal, M; Peethambaram, P; Suman, V, 2018) |
| "MDA-MB-231 breast cancer cells were treated with sinomenine and/or cyclopamine a proven SHh inhibitor." | ( Dai, Z; He, J; Kang, H; Liu, D; Song, L; Wang, X; Xue, X; Zan, Y; Zhang, S; Zhao, Y, 2018) |
| "Advanced breast cancer is resistant to chemotherapy and its underlying mechanisms are not fully explored." | ( Chai, F; Li, Z; Liu, L; Qu, M; Sun, Y; Wan, H; Zhang, P, 2018) |
| "Early-stage breast cancer patients receiving anthracycline- or taxane-based chemotherapy were recruited." | ( Beh, SY; Chae, JW; Chan, A; Chay, WY; Chua, PS; Dent, R; Dorajoo, S; Foo, KM; Gan, YX; Ho, HK; Koo, SL; Lee, GE; Lim, EH; Loh, KW; Ng, R; Ng, T; Shwe, M; Tan, TJY; Yap, YS; Yeo, AHL, 2018) |
| "MDA-MB-231 breast cancer cells were engineered such that NAT1 expression was elevated or suppressed, or treated with a small molecule inhibitor of NAT1." | ( Carlisle, SM; Doll, MA; Hein, DW; States, JC; Stepp, MW, 2018) |
| "In patients with HER2-positive advanced breast cancer who have been heavily pretreated with anti-HER2 agents and cytotoxic chemotherapy, T-DM1 is well tolerated and provided a meaningful progression-free survival of 6 months and an overall survival that has not been reached." | ( Chan, K; Leung, C; Luk, MY; Mo, FK; Ng, TY; Ngan, RK; Soong, IS; Suen, JJ; Tsang, J; Wong, SY; Yeo, W; Yuen, TY, 2018) |
| "Role of activated hedgehog pathway in breast cancer metastasis provides a novel target for cancer therapy against aggressive cancer subtypes." | ( Jiang, WG; Khan, JS; Malik, MFA; Riaz, SK; Shah, STA; Wang, F; Ye, L, 2018) |
| "MATERIAL AND METHODS Breast cancer cells were treated with PTX, MG132, or PTX plus MG132, and the therapeutic effects were evaluated phenotypically." | ( Li, X; Yang, B; Zhai, Z; Zhang, L; Zhang, Y; Zhao, J, 2018) |
| "After treatment with lutein, breast cancer cell proliferation was significantly decreased in a dose-dependent manner." | ( Chang, J; Guo, Y; Li, Y; Lu, K; Qi, Q; Shen, Y; Wang, M; Zhang, S; Zhang, Y, 2018) |
| "Treatment of breast cancer cell lines with a next-generation hypomethylating agent, guadecitabine, upregulates MHC-I expression in response to interferon-γ." | ( Balko, JM; Gonzalez-Ericsson, PI; Li, H; Liu, F; Luo, N; Manning, HC; Nickels, ML; Nixon, MJ; Opalenik, SR; Sanchez, V; Sanders, ME; Tantawy, MN; Zahnow, CA, 2018) |
| "The outcome of breast cancer treatment largely depends on the timing of detection." | ( Agide, FD; Garmaroudi, G; Sadeghi, R; Tigabu, BM, 2018) |
| "Moreover, we found that co-treatment of breast cancer cell lines with GroA and the ErbB2 kinase-inhibitor tyrphostin AG-825 enhances the anti-cancer effects exerted by GroA alone in terms of cell viability, mortality, migration, and invasiveness." | ( Goldshmit, Y; Pinkas-Kramarski, R; Schmukler, E; Solomon, S; Wolfson, E, 2018) |
| "MATERIAL AND METHODS We evaluated breast cancer stem cell proliferation, clone generation, and mammosphere formation to determine the effect of quercetin treatment on breast cancer stem cells." | ( Cai, Q; Li, S; Li, X; Liu, Q; Tan, J; Wang, R; Yang, L; Ye, D; Zhao, Z, 2018) |
| "Women with pre-treatment breast cancer had non-significantly elevated oestrogen levels; controls' (but not cases') oestrogens were directly correlated with their IgA-negative microbiota alpha diversity (P=0." | ( Bielecka, A; Feigelson, HS; Fujiwara, M; Goedert, JJ; Hua, X; Jones, GS; Milne, GL; Okayasu, I; Palm, NW; Ravel, J; Shi, J; Sinha, R; Wan, Y; Xu, X, 2018) |
| "For the treatment of locally advanced breast cancer, chemotherapy involving anthracycline and/or taxane-containg regimens is generally performed." | ( Adachi, K; Enomoto, K; Fujiwara, A; Hara, Y; Izu, A; Koshinaga, T; Kubota, H; Makishima, M; Sakurai, K; Sugitani, M; Suzuki, S, 2018) |
| "Chemotherapy for breast cancer is significantly restricted by the tumor's physio-pathological complexity." | ( Chen, L; Huang, Y; Peng, J; Qian, Z; Tan, L; Wang, Y; Zhao, H, 2016) |
| "Accurate and early detection of breast cancer is of high importance, as it is directly associated with the patients' overall well-being during treatment and their chances of survival." | ( Ghanbarzadeh Dagheyan, A; Martinez Lorenzo, JA; Martinez, A; Molaei, A; Obermeier, R; Westwood, A, 2018) |
| "CINV was poorly controlled in breast cancer patients receiving AC chemotherapy, in which age younger than 55-year-old was a significant risk for both nausea and vomiting." | ( Futamura, M; Hirose, C; Itoh, Y; Kobayashi, R; Matsuoka, R; Mori, R; Nawa-Nishigaki, M; Sugiyama, T; Suzuki, A; Yoshida, K, 2018) |
| "Respondents in this study were 344 breast cancer patients who received treatment at 4 referral hospitals between 2015 and 2016." | ( Aljunid, SM; Mahmud, A, 2018) |
| "In a large cohort study of breast cancer patients who underwent surgery followed by tamoxifen treatment, we demonstrate that ERα36, a variant of ERα66, correlates with poor prognosis." | ( Bian, XW; Bu, H; Chen, F; Cui, YH; He, ZC; Hu, B; Jiang, J; Meng, K; Ping, YF; Qi, X; Song, E; Tai, Y; Wang, B; Wang, JM; Wang, Q; Wang, Y; Wang, YX; Wang, Z; Xie, XQ; Xu, S; Xu, W; Yan, ZX; Yao, XH; Ying, G; Zhang, X, 2018) |
| "In the present study, MCF‑7 human breast cancer cells were cultured in vitro and treated with various concentrations of liraglutide." | ( Gu, W; Liu, J; Sun, B; Zhang, H; Zhang, X; Zhao, W; Zhou, Z, 2018) |
| "Patients with metastatic breast cancer (MBC) can derive clinical benefit from several subsequent lines of chemotherapy." | ( Genta, S; Ghisoni, E; Giannone, G; Milani, A; Mittica, G; Montemurro, F; Valabrega, G, 2018) |
| "Subsequently, spheroids of MDA-MB-231 breast cancer cells were developed and treated with citral at different concentrations." | ( Kamalideghan, B; Ky, H; Nigjeh, SE; Nordin, N; Rosli, R; Yeap, SK, 2018) |
| "Therefore, breast cancer patients on L-thyroxine treatment may need special monitoring of their thyroid levels and of fatigue during chemotherapy and should be encouraged to exercise." | ( Habermann, N; Johnson, T; Schmidt, ME; Schneeweiss, A; Steindorf, K; Wiskemann, J, 2018) |
| "The tumor volume of nude mice bearing breast cancer MCF-7 treated with hUC-MSCs-Tf-inspired-NPs, was remarkably reduced compared to those treated with free drug or Tf-inspired-NPs." | ( Alahdal, M; Cao, S; Gao, H; Guo, J; He, Y; Hu, W; Jiang, H; Jin, L; Qin, L; Tang, S; Yang, Z; Zhao, Y, 2018) |
| "Estrogen receptor-α positive (ERα⁺) breast cancers represent 75% of all invasive breast cancer cases, while de novo or acquired resistance to ER-directed therapy is also on the rise." | ( Cherkasov, A; Dalal, K; Lallous, N; Munuganti, RSN; Rennie, PS; Sharma, A; Singh, K; Yamazaki, T; Yoon, JS, 2018) |
| "We report a case of primary advanced breast cancer that was locally controlled by treatment with bevacizumab." | ( Adachi, K; Enomoto, K; Fujiwara, A; Hara, Y; Hirano, T; Ono, Y; Sakurai, K; Waga, E, 2018) |
| "We analyzed a series of 156 breast cancer samples from patients of the COX2 inhibitor-treated arm included in the REMAGUS-02 randomized phase II trial." | ( Asselain, B; Bertheau, P; Bièche, I; Brain, E; DE Cremoux, P; Giacchetti, S; Guinebretière, JM; Hamy, AS; Lehmann-Che, J; Marty, M; Mathieu, MC; Pierga, JY; Scott, V; Sigal, B; Spyratos, F, 2018) |
| "Although early breast cancer (BC) is highly curable, advanced or metastatic disease poses numerous challenges in terms of medical management and treatment decisions and is associated with significantly worse prognosis." | ( Corona, SP; Generali, D, 2018) |
| "Results of studies in a rat orthotopic breast cancer model indicated that SFN enhanced the efficacy of DOX in regression of tumor growth, and that the DOX dosage required to treat the tumor could be reduced when SFN was administered concomitantly." | ( Awasthi, S; Beneš, H; Boerma, M; Bose, C; Hauer-Jensen, M; Sharma, R; Singh, SP, 2018) |
| "Use of pharmaceutical agent for breast cancer chemotherapy is an interesting method that induces cells death by different way, such as apoptosis." | ( Enferadi, ST; Jafari, N; Nazeri, S, 2018) |
| "Treatment of breast cancer cells with TA-III resulted in inhibition of oncogenic phenotypes such as proliferation, migration and invasion, and induction of cellular senescence." | ( Dimri, GP; Dimri, M; Dorsey, AE; Gergely, JE, 2018) |
| "The risk of OFR during AI treatment in breast cancer patients with chemotherapy-induced ovarian function failure is relevant, even beyond 45 years." | ( de Boer, M; de Graaf, H; de Roos, WK; Erdkamp, FLG; Honkoop, AH; Imholz, ALT; Kitzen, JJEM; Kroep, JR; Linn, SC; Peer, PGM; Seynaeve, CM; Smorenburg, CH; Swinkels, ACP; Tjan-Heijnen, VCG; van den Berkmortel, FWPJ; van der Sangen, MJC; van Hellemond, IEG; Vriens, IJH, 2017) |
| "Treatment of ERα positive breast cancer has long relied on endocrine therapies such as selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor degraders (SERDs)." | ( Abrams, T; Baird, J; Burks, HE; Firestone, B; Gaither, LA; Hamann, LG; He, G; Kim, S; Kirby, CA; Lombardo, F; Macchi, KJ; McDonnell, DP; Mishina, Y; Norris, JD; Nunez, J; Peukert, S; Springer, C; Sun, Y; Thomsen, NM; Tiong-Yip, CL; Tria, GS; Wang, C; Wang, J; Yu, B, 2018) |
| "MCF-7 and MDA-MB-231 breast cancer cells treated with increasing concentrations of the iron chelator deferoxamine were assessed for intracellular iron status, the expression of key proteins involved in iron metabolism, cell viability, growth potential, and apoptosis at different time points following treatment." | ( Bajbouj, K; Hamad, M; Shafarin, J, 2018) |
| "Perfusion of breast cancer tissue limits oxygen availability and metabolism but angiogenesis inhibitors have hitherto been unsuccessful for breast cancer therapy." | ( Boedtkjer, E; Froelunde, AS; Hansen, KB; Jessen, N; Kim, S; Ohlenbusch, M, 2018) |
| "She was diagnosed as having inoperable breast cancer T2 N1 M1 (pleura, peritoneum), Stage IV, and received chemotherapy by paclitaxel." | ( Fujii, Y; Hirahara, N; Hyakudomi, R; Kaji, S; Tajima, Y; Taniura, T; Yamamoto, T, 2018) |
| "Axillary surgery in breast cancer patients has shifted from more extensive to minimalist approaches with re-evaluation of the risks versus benefits of available treatment options which are increasingly tailored to individual patient characteristics." | ( Benson, JR; Catanuto, G; Dumitru, D; Khan, A; Nava, MB; Rocco, N, 2018) |
| "Triple-Negative Breast Cancer (TNBC) has a poor prognosis due to lack of targeted therapy." | ( Basson, MD; Chaturvedi, LS; Deshpande, KS; Lopez-Hisijos, N; Shah, P; Vyas, A; Vyas, D, 2017) |
| "Currently, breast cancer diagnosis and treatment considers only the α isoform of ER; however, there is a second ER, ERβ." | ( Britt, KL; Byrne, D; Dall, GV; Gustafsson, JA; Hawthorne, S; Murphy, L; Risbridger, GP; Seyed-Razavi, Y; Vieusseux, J; Wu, W, 2018) |
| "Adjuvant chemotherapy is used for human breast cancer patients, even after curative surgery of primary tumor, to prevent tumor recurrence primarily as a form of metastasis." | ( Baba, T; Matsugo, S; Mukaida, N; Muranaka, H; Sasaki, S; Takahashi, C; Tanabe, Y, 2018) |
| "Sixty breast cancer patients were randomly assigned to use CLX (400 mg per day) or placebo capsules during radiotherapy." | ( Danesh, B; Ghasemi, A; Hosseinimehr, SJ; Yazdani-Charati, J, 2018) |
| "Chemotherapy for breast cancer induces alopecia, representing a major source of patient distress." | ( Schoenegg, W; Vasconcelos, I; Wiesske, A, 2018) |
| "It is now increasingly common for breast cancer patients to receive adjuvant tamoxifen therapy for a period of up to 10 years." | ( Alip, A; Khang, TF; Lim, IL; Loo, AVP; See, MH; Subrayan, V; Taib, NAM, 2018) |
| "Patients with breast cancer who have a pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) have improved survival." | ( Bashour, SI; Hess, K; Ibrahim, NK; Thompson, AM; Weiss, A, 2018) |
| "Purpose Breast cancer treatments have been associated with an increased risk of multiple health-related adverse outcomes, but the relationship with diabetes remains unclear." | ( Hamood, H; Hamood, R; Keinan-Boker, L; Merhasin, I, 2018) |
| "A total of 145 early-stage breast cancer patients were recruited and assessed before chemotherapy (T1), during chemotherapy (T2), and at the end of chemotherapy (T3)." | ( Chan, A; Gan, YX; Ho, HK; Ng, R; Ng, T; Phey, XY; Shwe, M; Yeo, HL, 2018) |
| "One of the major problems in breast cancer treatment is pharmacoresistance." | ( Eucker, J; Habbel, JP; Liu, H; Ma, Y; Possinger, K; Reinhardt, A; Zang, C; Zhou, Y, 2018) |
| "Twenty-three consecutive patients with breast cancer were followed prospectively during ACT chemotherapy and were analyzed according to their QT measurements." | ( Darrieux, FCDC; Hachul, DT; Hajjar, LA; Sacilotto, L; Scanavacca, MI; Veronese, C; Veronese, P; Wu, TC, 2018) |
| "Basal-like breast cancer (BLBC) is associated with a poor clinical outcome as a result of the few treatment options and poor therapeutic response." | ( Cao, Q; Chen, X; Dong, C; Huang, J; Huang, P; Liao, R; Ren, G; Tan, Y; Wang, L; Wu, X, 2018) |
| "Assessing therapy response of breast cancer bone metastases is challenging." | ( Gadi, VK; Gralow, J; Jenkins, I; Kinahan, P; Lee, JH; Linden, HM; Mankoff, D; Montgomery, S; Muzi, M; Novakova-Jiresova, A; O'Sullivan, J; Peterson, LM; Shields, A; Specht, JM; Wu, QV, 2018) |
| "The results of breast cancer oxygen state study under chemotherapy action obtained by diffuse optical spectroscopy (DOS) in combination with Doppler ultrasonic imaging are presented." | ( Golubyatnikov, GY; Ilyinskaya, OY; Kalganova, TI; Lyubimtseva, YS; Maslennikova, AV; Orlova, AG; Pavlov, MV; Plekhanov, VI; Safonov, DV; Shakhova, NM; Subochev, PV, 2018) |
| "Treatment of metastatic breast cancer experienced significant improvement in the past decades by introduction of highly effective therapies, but survival still remains poor." | ( Altgassen, C; Friedrich, M; Terjung, A, 2017) |
| "(2) Tissue microarray (TMA) of 74 HR-breast carcinomas treated with adjuvant therapy (77." | ( Ács, B; Báthori, Á; Bende, KC; Kahán, Z; Kulka, J; Lotz, G; Molnár, BÁ; Papp, O; Rusz, O; Szállási, Z; Székely, T; Szundi, C; Tőkés, AM; Vízkeleti, L, 2018) |
| "Thus CGNCs may be suitable for breast cancer treatment due to delivering the drug at the site of action for a prolonged period of time." | ( Gautam, N; Kathle, PK; Kesavan, K, 2018) |
| "However, patients with breast cancer often fail to respond for tamoxifen therapy due to the development of a drug-resistant phenotype." | ( Das, SK; Emdad, L; Fisher, PB; Kumar, BNP; Kundu, SC; Mahto, MK; Mandal, M; Pathak, A; Puvvada, N; Rajput, S; Reis, RL; Sarkar, S; Yallapu, MM, 2018) |
| "Despite the recent advances in breast cancer early detection and awareness, a significant portion of patients present with an advanced-stage disease and more patients will progress to stage IV despite adequate treatment of their initial early-stage disease." | ( Abdel-Razeq, H, 2019) |
| "Individual mice with 4T1 breast cancer were treated with either nanoparticle-delivered or free doxorubicin, with results demonstrating improved cancer kill efficacy of doxorubicin loaded nanoparticles in comparison to free doxorubicin." | ( Brinker, CJ; Brocato, TA; Coker, EN; Cristini, V; Durfee, PN; Lin, YS; Townson, J; Wang, Z; Wyckoff, EF, 2018) |
| "Overall, the drug treatment may benefit breast cancer patients through reducing systemic inflammation and pro-metastatic/pro-growth biomarkers in the excised tumor and PBMCs." | ( Allweis, T; Barshack, I; Ben-Eliyahu, S; Birnbaum, Y; Cole, S; Haldar, R; Lavon, H; Lyons, YA; Shaashua, L; Sharon, E; Sood, AK; Zmora, O, 2018) |
| "After 18 months of follow-up, her breast cancer has been successfully treated and a substantial decrease of the rate of bullous mucous lesions and improvement of time to lesion healing and resolution was observed." | ( Baldovino, S; Radin, M; Roccatello, D; Sciascia, S, 2018) |
| "The prevalence of nonhematologic AEs in breast cancer patients treated with docetaxel has been relatively high." | ( Annuar, MABA; Ho, GF; Jabir, RS; Stanslas, J, 2018) |
| "Female breast cancer patients who needed a course of radiation therapy in our institution were enrolled and randomized into 2 groups 1 with Mebo ointment and 1 with Biafine cream." | ( Andraos, T; Chehab, C; Eid, T; Geara, FB; Ramia, P; Thebian, R; Youssef, B; Zeidan, YH; Zouain, N, 2018) |
| "Eligible adults with advanced breast cancer were administered cipatinib 200 mg/day (n = 3) as an initial dose, with escalating dosages of 400 mg (n = 4), 800 mg (n = 2), 1200 mg (n = 3), 1400 mg (n = 3), 1600 mg (n = 3), and 1800 mg (n = 2) in 21 day cycles." | ( Cai, R; Chen, S; Fan, Y; Han, Y; Li, Q; Luo, Y; Ma, F; Shi, X; Wang, J; Xu, B; Yuan, P; Zhang, P, 2018) |
| "Patients with early-breast cancer were randomized 3 : 1 to oral palbociclib 125 mg daily for 14 days until the day before the surgery versus no treatment." | ( Adam, J; Andre, F; Arnedos, M; Balleyguier, C; Bayar, MA; Bieche, I; Bouakka, I; Cheaib, B; Delaloge, S; Gentien, D; Lacroix-Triki, M; Leroux-Kozal, V; Marty, V; Mazouni, C; Michiels, S; Rapinat, A; Sarfati, B; Scott, V; Valent, A, 2018) |
| "Basal like breast cancer (BLBC) is a very aggressive subtype of breast cancer giving few chances of survival, against which cisplatin based therapy is a compromise among the anticancer activity, the resistance development and the severe side effects." | ( Amici, A; Andreani, C; Bartolacci, C; Dou, QP; Ferraro, S; Galassi, R; Gambini, V; Iezzi, M; Maina, EW; Marchini, C; Pucciarelli, S; Ramadori, AT; Simon, OC; Tilio, M; Wang, J; Wu, G, 2018) |
| "Basal-like breast cancer (BLBC) is resistant to endocrinotherapy and targeted therapy and new molecular therapies are needed for BLBC." | ( Chen, C; Cheng, S; Dong, X; Li, L; Liang, X; Liu, S; Liu, T; Sun, H; Wang, Y; Yang, Z; Yao, N; Zhao, X, 2018) |
| "Finding a cure for breast cancer currently remains a medical challenge in due to the failure of common treatment methods to inhibit invasion and metastasis of cancer cells, which eventually leads to recurrence of breast cancer." | ( Chang, X; Cui, PF; He, YJ; Jiang, HL; Jin, QR; Qiao, JB; Xiao, Y; Xing, L; Yu, RY; Zhou, TJ, 2018) |
| "A total of 185 breast cancer patients treated with NAC were recruited." | ( Bun, A; Fujimoto, Y; Higuchi, T; Imamura, M; Kira, A; Miyagawa, Y; Miyoshi, Y; Nishimukai, A; Ozawa, H, 2018) |
| "Approximately 25% of breast cancer patients experience treatment delays or discontinuation due to paclitaxel-induced peripheral neuropathy (PN)." | ( Hayes, DF; Henry, NL; Hertz, DL; Kim, JH; Smith, EML; Stringer, KA; Sun, Y; Vangipuram, K; Yeomans, L, 2018) |
| "Most breast cancer deaths are caused by metastasis and treatment options beyond radiation and cytotoxic drugs, which have severe side effects, and hormonal treatments, which are or become ineffective for many patients, are urgently needed." | ( Dadurian, C; Hoshino, A; Kim, HS; Lyden, D; Seybold, MP; Wittkowski, KM, 2018) |
| "In vivo, the 4T1 mouse model of breast carcinoma was used to examine the efficacy of combinatorial therapy with docetaxel and anti-VEGFR3 on lymph node metastasis and tumor growth." | ( Harris, AR; Munson, JM; Perez, MJ, 2018) |
| "On the other hand, HER2-negative breast cancer cell lines showed a significantly decreased expression of tumor-suppressor miRNAs, a putative mechanism of resisting the therapy." | ( Asghari, F; Baradaran, B; Haghnavaz, N; Kazemi, T; Khaze, V; Shanehbandi, D, 2018) |
| "Quality of life (QOL) in breast cancer survivors is affected by various long term sequelae of breast cancer treatment." | ( Gupta, A; Jain, A; Kaur, N; Sharma, AK, 2018) |
| "Endocrine treatment of breast cancer may interfere with bone turnover and influence fracture risk." | ( Hadji, P; Kostev, K; Kyvernitakis, I, 2018) |
| "The irradiation of breast cancer cells treated with AuNPs has shown no significant variation in cell cycle distribution as opposed to X-ray radiation alone." | ( Bibić, J; Dražić, G; Gotić, M; Hanžić, N; Horvat, A; Jurkin, T; Marijanović, I; Slade, N; Unfried, K, 2018) |
| "Nude mice breast cancer models were randomly divided into control, MWA, doxorubicin, and combined treatment groups." | ( Chen, L; Ding, Q; Ge, H; Kong, P; Li, L; Ma, G; Pan, H; Shi, X; Wang, S; Yu, M; Zhou, W; Zhu, J, 2018) |
| "PARP3 inhibitors sensitize breast cancer cells to vinorelbine, a vinca alkaloid used in the treatment of metastatic breast cancer." | ( Aloyz, R; Amrein, L; Panasci, L; Sharif-Askari, B, 2018) |
| "In this case, a patient with recurrent breast cancer responded to the sequential administration of bevacizumab plus paclitaxel combination therapy followed by eribulin monotherapy." | ( Higashi, T; Mase, K; Mizutani, M; Moriya, T; Onodera, Y; Ozawa, K; Takagi, S; Takeshita, A; Usuba, O; Yokoyama, M, 2018) |
| "MHA due to breast cancer is rare and is associated with poor prognosis; however, rapid initiation of chemotherapy may be effective." | ( Aoki, R; Asai, H; Kamei, Y; Komatsu, S; Kusakabe, E; Mizuno, Y; Murakami, A; Nishiyama, K; Sugimori, W; Taguchi, K; Takada, Y; Yamasawa, H; Yamashita, M, 2018) |
| "The biomedical imaging of metastatic breast cancer, especially in lymphatic and lung metastasis, is highly significant in cancer staging as it helps assess disease prognosis and treatment." | ( Gong, X; Lin, X; Liu, C; Sheng, Z; Song, L; Sun, M; Zhang, R; Zheng, H, 2018) |
| "Obesity increases breast cancer mortality by promoting resistance to therapy." | ( Anderson, SM; Brechbuhl, HM; Dannenberg, AJ; Edgerton, SM; El-Hely, O; Elias, A; Falcone, DJ; Gillen, AE; Iyengar, NM; Jacobsen, BM; Johnson, SJ; Kabos, P; MacLean, PS; Morrow, M; Rudolph, MC; Sartorius, CA; Thor, AD; Wellberg, EA; Zhou, XK, 2018) |
| "Because incidence of breast cancer and comorbidities increase with age, it is important to determine treatment benefit in elderly patients." | ( Bartlett, CH; Finn, RS; Harbeck, N; Huang, X; Im, SA; Iyer, S; Johnston, S; Joy, AA; Kim, S; Masuda, N; Rugo, HS; Schnell, P; Sun, W; Turner, NC; Verma, S, 2018) |
| "Neoadjuvant treatments for primary breast cancer are becoming more common; however, little is known about how these impact on response to subsequent adjuvant therapies." | ( Baxter, DE; Hanby, AM; Hughes, TA; Kim, B; Sims, AH; Verghese, ET, 2018) |
| "A total of 109 patients with metastatic breast cancer and liver dysfunction were treated; time-to-progression, overall survival and trends in liver function were evaluated." | ( Biagioni, C; Biganzoli, L; DI Leo, A; Malorni, L; McCartney, A; Moretti, E; Pestrin, M; Risi, E; Rossi, L; Sanna, G, 2018) |
| "After chemotherapy for breast cancer, most women will recover some ovarian function, but the timing and extent of this recovery are poorly understood." | ( Cedars, MI; Harris, E; Imbar, T; Letourneau, JM; Li, B; Mok-Lin, E; Rosen, MP; Sinha, N; Wald, K; Xiong, P, 2018) |
| "Reproductive age breast cancer patients who were seen prior to chemotherapy for fertility preservation consult were consented for follow-up ovarian function assessment (every 3-6 months after chemotherapy) with antral follicle count (AFC) in this prospective cohort study." | ( Cedars, MI; Harris, E; Imbar, T; Letourneau, JM; Li, B; Mok-Lin, E; Rosen, MP; Sinha, N; Wald, K; Xiong, P, 2018) |
| "Up to 82% of breast cancer patients receive a chemotherapy‑containing treatment regimen." | ( Arnold, GJ; Fröhlich, T; Hermawan, A; Ljepoja, B; Roidl, A; Sommer, AK; Wagner, E, 2018) |
| "Therefore, breast cancer treatment may benefit from the use of a combination of drugs in chemotherapy." | ( Calaf, GM; Carrión, F; Ponce-Cusi, R, 2018) |
| "Patients with breast cancer who receive weekly paclitaxel therapy may experience deleterious effects associated with prophylactic dexamethasone use for 12 consecutive weeks." | ( Castro, SN; de Castro Baccarin, AL; de Iracema Gomes Cubero, D; Del Giglio, A; Irene, MN; Luz, AS; Móz, LES; Sordi, R, 2019) |
| "Menopausal symptoms following breast cancer can occur at an earlier age, be more severe and significantly influence a woman's overall wellbeing, in particular, sexual function, quality of life and adherence to treatment." | ( Baber, R; Phua, C, 2018) |
| "A significant challenge in treating breast cancer is the limited array of therapeutic options and the rapid development of resistance to existing agents." | ( Harrelson, J; Heers, H; Lee, MW; Stanislaw, J, 2018) |
| "More than 40% of patients with luminal breast cancer treated with endocrine therapy agent tamoxifen demonstrate resistance." | ( Adeoye, O; Brantley, EJ; Campbell, PS; Cavalli, F; Davis, MB; Denham, LJ; Guevara, A; Jenkins, BD; Khan, S; Loaiza-Pérez, AI; Mavingire, N; Nagaraj, G; Opoku-Agyeman, A; Rowland, LK; Schiff, R; Soto, U; Wooten, JV, 2018) |
| "We enrolled 126 female breast cancer patients initiated on letrozole therapy and prospectively collected blood samples at baseline and two follow-up time points to determine letrozole plasma concentrations and CYP2A6 genotype." | ( Borrie, AE; Choi, YH; Dinniwell, R; Hahn, K; Kim, RB; Lenehan, J; Lock, M; Logan, D; Perera, FE; Potvin, K; Read, N; Rose, RV; Sexton, T; Teft, WA; Tyndale, RF; Vandenberg, TA; Welch, S; Yaremko, B; Younus, J; Yu, E, 2018) |
| "Early-stage breast cancer patients receiving TC chemotherapy were randomised to either ciprofloxacin or G-CSF." | ( Clemons, M; Fergusson, D; Hilton, J; Hutton, B; Ibrahim, MF; Joy, A; Kehoe, A; Mallick, R; Mazzarello, S; Price-Hiller, J; Sienkiewicz, M; Stober, C; Vandermeer, L; Verma, S; Zhu, X, 2019) |
| "GNB4 is important for growth of breast cancer cells and a potential target for treatment." | ( Carpenter, E; Farfus, A; Filkowski, J; Kovalchuk, O; Li, D; Lykkesfeldt, AE; Malach, M; Rodriguez-Juarez, R; Storozynsky, Q; Wang, B, 2018) |
| "Herein, we present a breast cancer patient who received trastuzumab and pertuzumab treatment during the first 20 weeks of pregnancy." | ( Bahceci, A; Yildirim, N, 2018) |
| "Among patients with advanced breast cancer and a germline BRCA1/2 mutation, single-agent talazoparib provided a significant benefit over standard chemotherapy with respect to progression-free survival." | ( Blum, JL; Eiermann, W; Ettl, J; Fehrenbacher, L; Gonçalves, A; Hannah, AL; Hurvitz, SA; Im, YH; Lee, KH; Litton, JK; Markova, D; Martin, M; Mina, LA; Quek, RGW; Roché, H; Rugo, HS; Tudor, IC; Yerushalmi, R, 2018) |
| "Three breast cancer cell lines and immunocompetent and immunodeficient mice were used to evaluate the therapeutic effects of Rp plus ω-3 PUFA treatment." | ( Chen, W; Chen, YQ; Feng, N; He, Z; Jiang, X; Lin, G; Tong, Y; Wang, S; Yang, Q; Zhu, S, 2018) |
| "Doctors and patients fear the risk of breast cancer when using hormone replacement therapy (HRT)." | ( Mueck, AO; Ruan, X, 2018) |
| "Treatment for breast cancer involves the surgical removal of cancer tissue, followed by chemotherapy." | ( Boechat, FCS; Branco, JR; Chipoline, IC; da Silva, FC; de Souza, MCBV; Esteves, AM; Ferreira, VF; Lima, MFO; Oliveira, VG; Sola-Penna, M; Zancan, P, 2018) |
| "Multidrug resistance (MDR) of breast cancer is the major challenge to successful chemotherapy while mitochondria-targeting therapy was a promising strategy to overcome MDR." | ( Chen, D; Hu, H; Li, J; Li, X; Pan, S; Qiao, M; Shi, M; Yang, C; Zhang, J; Zhao, X, 2018) |
| "Previous studies showed that women with breast cancer treated in anthroposophic clinic versus conventional care had increased quality of life (QoL) parameters, fighting spirit, and anxiety coping." | ( Ernerudh, J; Hamrin, E; Rosén, A, 2018) |
| "Overall, women with breast cancer in anthroposophic or conventional therapy did not differ in their immune profiles over time, with exception of decreased cytotoxic T cells in the anthroposophic group." | ( Ernerudh, J; Hamrin, E; Rosén, A, 2018) |
| "We used Ki-67 response in breast cancer tissues after preoperative short-term tamoxifen therapy as a surrogate marker for response to tamoxifen." | ( Akashi-Tanaka, S; Baba, S; Chan, CW; Endo, I; Hartman, M; Hasegawa, Y; Ishikawa, T; Kubo, M; Kutomi, G; Kuwayama, T; Lee, SC; Low, SK; Matsukata, A; Matsumoto, H; Miyahara, K; Momozawa, Y; Nakamura, S; Okazaki, M; Onishi, H; Onomura, M; Sagara, Y; Satomi, F; Shima, H; Shimada, K; Shimizu, D; Shimo, A; Takamaru, T; Takei, H; Tsugawa, K; Udagawa, C; Watanabe, C; Yamada, A; Zaha, H; Zembutsu, H, 2018) |
| "Most breast cancers (BCs) express estrogen receptor α (ERα) and are treated with the endocrine therapy (ET) drugs 4OH-tamoxifen (Tam) and fulvestrant (ICI 182,780; ICI)." | ( Acconcia, F; Bianchi, F; Busonero, C; Leone, S, 2018) |
| "Related microarray data set of breast cancer was obtained from Gene Expression Omnibus database, and differential-expressed genes (DEGs) between two control samples and two treated samples were analysed using statistical software R." | ( Guo, L; Hu, Y; Ji, D; Luo, X; Shang, D; Zhang, L, 2018) |
| "For the breast cancer, the patient underwentneoadjuvant chemotherapy and anti-HER2 monoclonal antibody, after which she was submitted to surgery." | ( Barroso, S; Borges Faria, D; Francisco, E; Pereira de Oliveira, J; Sampaio Vieira, T; Souto Moura, C, 2018) |
| "Forty-two patients with breast cancer and prior radiation for HL were identified, 15 of which received chemotherapy for breast cancer." | ( Baxstrom, K; Blaes, A; Lee, C; Peterson, B; Turcotte, L; Vogel, R; Watson, AP, 2018) |
| "Treatment of breast cancer is strongly influenced by prior treatment of HL." | ( Baxstrom, K; Blaes, A; Lee, C; Peterson, B; Turcotte, L; Vogel, R; Watson, AP, 2018) |
| "Traditional chemotherapy for breast cancer has serious side effects for patients, such as the first-line drug docetaxel." | ( Fan, D; Liu, Y, 2018) |
| "Concerns about breast cancer had become the most dangerous cancer to women over the world, more and more anti-cancer agents are developed to treat this malignancy." | ( Kong, Y; Pei, L; Shao, C; Wang, Z; Yue, X; Zhang, N, 2018) |
| "4T1 cells-induced breast cancer mouse model was used for treatment with the complex to confirm their action in tumour regression." | ( Chowdhury, EH; Tiash, S, 2019) |
| "A total of 202 patients with stage ≤IIA breast cancer who underwent breast conservative therapy with separate incision from January 2004 to February 2017 were reviewed." | ( Koyanagi, A; Takemoto, N; Yamamoto, H; Yasuda, M, 2018) |
| "We will enroll 80 breast cancer patients who are newly diagnosed with CIPN after chemotherapy." | ( Bae, K; Jang, CE; Jung, MS; Kim, JR; Kim, M; Lee, JS; Sohn, EH; Yoo, HS, 2018) |
| "Most of estrogen receptor positive breast cancer patients respond well initially to endocrine therapies, but often develop resistance during treatment with selective estrogen receptor modulators (SERMs) such as tamoxifen." | ( Jin, J; Jin, S; Li, J; Lu, M; Lu, X; Xu, T, 2018) |
| "Prospective longitudinal study in 24 breast cancer patients undergoing treatment with doxorubicin and cyclophosphamide." | ( Alves, B; Borges, KBG; Drummond-Lage, AP; Malachias, MVB; Oliveira, AN; Rezende, BA; Simões, R; Souza, CA; Zogeib, JB, 2018) |
| "Different biological subtype breast cancers respond differently to neoadjuvant chemotherapy, but it is unknown whether neoadjuvant or adjuvant chemotherapy leads to different long-term survival in each specific subtype although equal outcomes have been reported in general population." | ( Cao, Y; Cheng, L; Guo, J; Liu, H; Liu, M; Liu, P; Peng, Y; Tong, F; Wang, S; Xie, F; Yang, H; Zhou, B; Zhou, L, 2018) |
| "Eligible patients with node positive breast cancer undergoing chemotherapy with paclitaxel were assessed." | ( Asghari Jafarabadi, M; Esfahani, A; Fathifar, Z; Ghoreishi, Z; Goodman, KA; Keshavarz, S, 2018) |
| "Seventy breast cancer patients were randomly assigned to use topical ATV 1% or placebo gels during radiotherapy twice daily." | ( Akbari, J; Ghasemi, A; Ghashghai, Z; Hosseinimehr, SJ; Salehifar, E; Yazdani-Charati, J, 2019) |
| "Oxygen consumption of T-47D breast cancer cells was measured during therapy with protoporphyrin IX." | ( Aravindalochanan, K; Flamm, H; Kieninger, J; Marzioch, J; Peng, Q; Pettersen, EO; Sandvik, JA; Urban, GA; Weltin, A, 2018) |
| "Following HGF treatment, the breast cancer cells displayed a significant increase in migration, matrix adhesion, vessel/tubule formation, invasion and c-Met activation." | ( Ali, AY; Parr, C, 2018) |
| "Although ERα -positive breast cancer can be effectively treated by endocrine therapy, endocrine resistance is an urgent clinical problem." | ( Hou, Y; Li, Q; Li, X; Mu, K; Niu, G; Wang, H; Wu, G; Xu, J; Xue, M; Yang, H; Zhu, J; Zhuang, T; Zhuo, S, 2018) |
| "For patients with HER2-positive early breast cancer, having a pregnancy after treatment completion appears to be safe without compromising fetal outcome or maternal prognosis." | ( Azim, HA; Baselga, J; Campbell, C; de Azambuja, E; Di Cosimo, S; Gelber, RD; Guillaume, S; Hilbers, FS; Huober, J; Ignatiadis, M; Korde, L; Lambertini, M; Martel, S; Moreno-Aspitia, A; Piccart-Gebhart, M; Schuehly, U; Tenglin, RC, 2019) |
| "HER2-negative metastatic breast cancer (MBC) is a common setting in which chemotherapy could be effective even in later lines of treatment." | ( Cabel, L; Carton, M; Cheaib, B; Dalenc, F; Debled, M; Desmoulins, I; Eymard, JC; Ferrero, JM; Gonçalves, A; Jacot, W; Lefeuvre, C; Leheurteur, M; Lerebours, F; Levy, C; Mailliez, A; Mouret-Reynier, MA; Pérol, D; Perrocheau, G; Petit, T; Pierga, JY; Piot, I; Simon, G; Uwer, L, 2019) |
| "In locally advanced breast cancer (LABC) treatment starts with neoadjuvant chemotherapy (CTx) with the standard regimens CMF, FAC, АС." | ( Adekenov, S; Arystan, L; Madiyarov, A; Rakhimov, K; Sirota, V; Zhumakayeva, A, 2018) |
| "Metastatic or advanced breast cancer (mBC/ABC) remains incurable despite many different systemic treatment options." | ( Cardoso, F; Ribnikar, D; Volovat, SR, 2019) |
| "AGE treatment of ER+ breast cancer cells altered ERα phosphorylation and promoted resistance to tamoxifen therapy." | ( Abbott, AM; Ambs, S; Armeson, KE; Chan, K; Clair, MJ; Findlay, VJ; Ford, ME; Garrett-Mayer, E; Gregoski, MJ; Hilton, EJ; Knight, KD; Kramer, RM; Krisanits, BA; La Rue, AC; Lilly, MB; Magwood, G; Nogueira, LM; Peterson, LL; Phan, V; Singh, S; Spruill, L; Taylor, MH; Turner, DP; Turner, TF; Uribarri, J; Varner, H; Walter, KR, 2019) |
| "Along with the increased breast cancer incidence in Korea, the frequencies of breast cancer treatments have increased." | ( Chung, IY; Hong, JH; Hur, H; Lee, J; Lee, JW; Park, S; Youn, HJ, 2018) |
| "Of the 40 patients with breast cancer who were prescribed rose geranium nasal spray, 100% were receiving cancer-directed therapy: 58 % were receiving taxane chemotherapy; others received a variety of cytotoxic and targeted therapy treatments." | ( Cathcart-Rake, EJ; Loprinzi, CL; Smith, D; Zahrieh, D, 2020) |
| "Eleven primary breast cancer patients were examined after eribulin was administered; PD was confirmed eventually, and administration was discontinued." | ( Adachi, K; Enomoto, K; Fujisaki, S; Hara, Y; Hirano, T; Kubota, H; Sakurai, K; Suzuki, S; Tomita, R, 2018) |
| "Women with breast cancer were subsequently subdivided into recently diagnosed/treatment-naive (n = 112) and chemotherapy-treated (n = 33)." | ( Mantzoros, CS; Panagiotou, G; Papakonstantinou, E; Polyzos, SA; Vagionas, A, 2019) |
| "Basal-like breast cancer (BLBC) is a poor prognosis subgroup of triple-negative carcinomas that still lack specific target therapies and accurate biomarkers for treatment selection." | ( Almeida, J; Carvalho, FA; Fonseca, M; Mendes, N; Monteiro, J; Nobre, AR; Paredes, J; Polónia, A; Ribeiro, AS; Sanches, JM; Santos, NC; Seruca, R; Sousa, B; Vieira, AF, 2018) |
| "The treatment of MCF-7 and T47D human breast cancer cell lines with amygdalin was able to reduce the growth of both cells, in concentration and time-dependent manners." | ( Abboud, MM; Abu-Ayyad, AN; Al Awaida, W; Alkhateeb, HH, 2019) |
| "In metastatic breast cancer patients treated with EM in 'real-world' setting, the clinician-registered outcomes were comparable to those reported in pivotal trials." | ( Barni, S; Cinieri, S; Del Mastro, L; Fontanella, C; Livraghi, L; Michelotti, A; Morritti, M; Porcu, L; Puglisi, F; Vici, P, 2019) |
| "MCF7 and T47D luminal A breast cancer cell lines were either treated with miR-27a mimics, or ER-signaling was modulated ectopically." | ( García-Roman, J; Ljepoja, B; Roidl, A; Sommer, AK; Wagner, E, 2019) |
| "MiR-27a sensitizes luminal A breast cancer cells to SERM treatments based on a positive feedback loop with ERα." | ( García-Roman, J; Ljepoja, B; Roidl, A; Sommer, AK; Wagner, E, 2019) |
| "Identifying markers for breast cancer is important for both diagnosis and the design of treatment strategies." | ( Bi, C; Huang, J; Li, X; Luo, X; Peng, W; Ren, G; Xiang, T; Yang, D; Yin, X, 2018) |
| "Approximately 30% of metastatic breast cancers harbor estrogen receptor α (ERα) mutations associated with resistance to endocrine therapy and reduced survival." | ( Duraki, D; Helferich, WG; Huang, R; Kim, JE; Mao, C; Nelson, ER; Park, BH; Shapiro, DJ; Wang, L; Yu, L, 2019) |
| "Left-sided breast cancer patients treated with radiotherapy (RT) are at risk for late radiation-induced cardiovascular complications." | ( Andreassi, MG; Petruzzelli, MF; Portaluri, M; Tramacere, F, 2019) |
| "An index case of metastatic breast cancer progressing on HER2-targeted therapy was found to have the NCOA4-RET fusion." | ( Ali, SM; Chung, JH; DiClemente, F; Dolfi, SC; Ganesan, S; Gay, LM; Hirshfield, KM; Kulkarni, A; Lee, E; Leyland-Jones, B; Lin, S; Liu, C; Paratala, BS; Petrosky, W; Pham, K; Rodriguez-Rodriguez, L; Ross, JS; Schrock, AB; Williams, CB; Williams, K; Yao, M; Yilmazel, B, 2018) |
| "As adjuvant treatment of HER2-negative breast cancer, sequential A+T regimen was associated with increased risk of toxicities and no clear survival benefit as compared to 6 cycles of TC." | ( Bruzzone, M; Caparica, R; Ceppi, M; de Azambuja, E; Lambertini, M; Poggio, F, 2019) |
| "The growth and viability of human HER2+ breast cancer (HCC1954) and ovarian cancer (SKOV3) cell lines were significantly impaired upon treatment with the marine macrolide mycalolide B (Myc B) at doses above 100 nanomolar." | ( Allingham, JS; Craig, AW; Evans, PA; Nersesian, S; Newsted, D; Shah, K; Williams, R; Young, S, 2018) |
| "USP37 is required for the regulation of breast cancer progression, as well as a critical target for clinical treatment of breast cancer." | ( Fan, S; Feng, X; Li, B; Li, L; Li, M; Liu, D; Liu, L; Lu, Y; Mao, J; Qin, T; Song, B; Yang, J; Yu, X; Zhang, J; Zhang, Q, 2018) |
| "In endocrine therapy resistant breast cancer cells Fulvestrant is ineffective in decreasing ERα levels." | ( Basak, P; Bhat, V; Chatterjee, S; Hu, P; Jin, H; Lee-Wing, V; Liu, Q; Murphy, LC; Raouf, A; Su, A, 2018) |
| "Importantly, many women with metastatic breast cancer do well for a long time with endocrine therapy alone and CDK inhibitors do not have a predictive marker." | ( Niraula, S, 2019) |
| "Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)-targeted therapy have a worse prognosis than those who have no residual cancer." | ( Arce-Salinas, C; Conlin, AK; Crown, JP; DiGiovanna, MP; Douthwaite, H; Fasching, PA; Fischer, HH; Geyer, CE; Huang, CS; Jackisch, C; Jacot, W; Lam, LH; Loibl, S; Mamounas, EP; Mano, MS; Rastogi, P; Redondo, A; Rota Caremoli, E; Schneeweiss, A; Shao, Z; Singel, SM; Smitt, M; Tesarowski, D; Untch, M; von Minckwitz, G; Wapnir, IL; Wolmark, N; Wu, H; Wülfing, P, 2019) |
| "Among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer or death was 50% lower with adjuvant T-DM1 than with trastuzumab alone." | ( Arce-Salinas, C; Conlin, AK; Crown, JP; DiGiovanna, MP; Douthwaite, H; Fasching, PA; Fischer, HH; Geyer, CE; Huang, CS; Jackisch, C; Jacot, W; Lam, LH; Loibl, S; Mamounas, EP; Mano, MS; Rastogi, P; Redondo, A; Rota Caremoli, E; Schneeweiss, A; Shao, Z; Singel, SM; Smitt, M; Tesarowski, D; Untch, M; von Minckwitz, G; Wapnir, IL; Wolmark, N; Wu, H; Wülfing, P, 2019) |
| "Metastatic breast cancer may be resistant to chemo-immunotherapy due to the existence of cancer stem cells (CSC)." | ( Lang, T; Li, Y; Liu, Y; Ran, W; Yin, Q; Zhai, Y; Zhang, P; Zheng, Z, 2019) |
| "Uptake of breast cancer preventive therapy was low." | ( Horne, R; Side, L; Smith, SG; Thorneloe, RJ; Wolf, MS, 2019) |
| "Using data from a large breast cancer cohort treated in South Africa's public healthcare system, the authors looked at determinants of neoadjuvant chemotherapy use and time to initiate treatment." | ( Buccimazza, I; Čačala, S; Crew, KD; Cubasch, H; Jacobson, JS; Joffe, M; Neugut, AI; Nietz, S; O'Neil, DS; Ruff, P; Singh, U; Stopforth, LW, 2019) |
| "She had distant history of metastatic breast cancer treated with chemotherapy, surgical resection and tamoxifen." | ( Diamond, T; Kumar, S, 2019) |
| "Seventy percent of breast cancers express the estrogen receptor (ER), and agents that target the ER are the mainstay of treatment." | ( Cohen, O; Cuoco, MS; Freeman, S; Helvie, K; Kapstad, C; Lin, NU; Ma, CX; Marini, L; Nayar, U; Oliver, N; Painter, C; Persky, NS; Regev, A; Rozenblatt-Rosen, O; Wagle, N; Waks, AG; Wander, SA; Winer, EP, 2019) |
| "A total of 70% of breast cancers express the estrogen receptor (ER)α; therefore, targeting the ER may be an effective endocrine therapy with which to inhibit breast cancer growth." | ( Ding, Q; Li, XX; Qian, JY; Shi, L; Sun, X; Wei, JF; Wu, J; Xia, TS; Zhou, WB; Zhou, XJ; Zhu, L, 2019) |
| "Many breast cancer patients suffer from obvious side effects induced by chemotherapy." | ( Guo, Y; Ren, Q; Wang, Y; Xin, M, 2019) |
| "Postmenopausal breast cancer patients on endocrine therapy were recruited at three hospitals in Malaysia." | ( Abdullah, N; Ahmad, HZ; Bustamam, RSA; Choo, SB; Fadzil, ML; Redzuan, AM; Saifulbahri, A; Shah, NM; Zullkifli, SN, 2019) |
| "Furthermore, the in-vivo (DMBA induced breast cancer rats) studies were carried out and treatment with PTX- loaded GO-g-MA/FA nanocarrier attenuates the levels of mitochondrial citric acids enzymes to near normal." | ( Elumalai, N; Rajan, M; Rajendran, NK; Ramu, A; Vinothini, K, 2019) |
| "We present a rare case of breast cancer in female-to-male transsexual patient after long-term hormonal therapy." | ( Bursa, V; Hes, O; Treskova, I, 2018) |
| "Estrogen/ERα signaling is critical for breast cancer progression and therapeutic treatments." | ( Ayyanathan, K; Chen, N; Hou, Z; Jia, H; Li, Q; Meng, Q; Ni, P; Qian, W; Wang, J; Xu, B; Zhu, C, 2019) |
| "Sox9 is elevated in breast cancer patients after endocrine therapy failure." | ( Aurrekoetxea-Rodríguez, I; Comaills, V; Domenici, G; Howard, BA; Kypta, RM; Lee, SY; López-Ruiz, JA; Millán, JS; Oliemuller, E; Rábano, M; Simões, BM; Vivanco, MD; Zabalza, I, 2019) |
| "Many breast cancer patients suffer from chemotherapy-induced hair loss." | ( Hasegawa, Y; Imai, H; Nozawa, K; Ohashi, Y; Okada, H; Saito, M; Sangai, T; Shimozuma, K; Takayama, T; Tamai, N; Watanabe, T; Yagata, H; Yajima, T; Yamaguchi, T; Yoshida, Y; Yoshimura, A, 2019) |
| "Tamoxifen is the gold standard for breast cancer endocrinotherapy." | ( Li, H; Li, S; Li, Z; Lv, Y; Yu, D, 2019) |
| "Advanced breast cancer patients treated with exemestane plus everolimus in 2012-2014 were included from the SONABRE registry." | ( Croes, S; de Boer, M; de Fallois, AOJ; Dercksen, MW; Geurts, SME; Ibragimova, KIE; Knapen, LM; Lobbezoo, DJA; Pepels, MJAE; Tjan-Heijnen, VCG; van de Wouw, AJ; van den Berkmortel, FWPJ; Vriens, BEPJ, 2019) |
| "In human breast cancer, high LIPG expression was observed in a limited subset of tumours and was significantly associated with shorter metastasis-free survival in node-negative, untreated patients." | ( Adawy, A; Cadenas, C; Claus, M; Edlund, K; Franckenstein, D; Frank, S; Gianmoena, K; Glotzbach, A; Grgas, K; Hayen, H; Hellwig, B; Hengstler, JG; Käfferlein, HU; Lesjak, MS; Madjar, K; Marchan, R; Mardinoglu, A; Micke, P; Pontén, F; Rahnenführer, J; Schmidt, M; Schriewer, A; Stewart, JD; Thaler, S; Vosbeck, S; Watzl, C; Zhang, C, 2019) |
| "Patients with hormone-receptor-positive breast cancer usually receive adjuvant endocrine therapy for 5 years or longer." | ( Barac, A; Chlebowski, RT; Haque, R; Shi, J; Xu, X, 2019) |
| "Treat of HER2 positive breast cancers has been greatly promoted in last few years, but the accompany HER2 blockade has hindered the therapeutic effect." | ( Chen, M; Deng, W; Hong, R; Kaping, L; Lu, Q; Qin, G; Shi, Y; Wang, S; Xia, W; Xu, F; Yuan, Z; Zhai, Q; Zhang, K; Zheng, Q, 2019) |
| "We report 2 cases of unresectable breast cancer for which pertuzumab, trastuzumab, and docetaxel therapy was effective." | ( Kato, H; Kawai, Y; Kitamura, M; Mori, T; Sakai, S; Shimada, K; Shimizu, T; Tani, M; Tatsumi, M; Tomida, K; Umeda, T, 2018) |
| "Patients with luminal early breast cancer are at risk of relapse, even after five years of adjuvant endocrine therapy." | ( Biganzoli, L; De Santo, I; Di Leo, A; Malorni, L; McCartney, A; Moretti, E; Risi, E; Rossi, L, 2019) |
| "CAIX is overexpressed in breast cancer and is associated with the poor survival of patients after radiotherapy." | ( Bache, M; Güttler, A; Kessler, J; Riemann, A; Theuerkorn, K; Thews, O; Vordermark, D; Wichmann, H, 2019) |
| "Patients with breast cancer positive for human epidermal growth factor receptor 2 (HER2) remain at high risk of intracranial relapse following treatment and experience increased rates of intracranial failure after stereotactic radiosurgery (SRS)." | ( Abraham, J; Ahluwalia, MS; Angelov, L; Barnett, GH; Budd, GT; Chao, ST; Kim, JM; Kotecha, R; Miller, JA; Mohammadi, AM; Moore, H; Murphy, ES; Peereboom, DM; Suh, JH; Vogelbaum, MA, 2019) |
| "women with breast cancer under treatment with oral HT." | ( de Medeiros, LM; de Souza, CM; Ferracini, AC; Juliato, CRT; Mazzola, PG; Stahlschmidt, R, 2019) |
| "A low percentage of women with breast cancer were highly adherent to HT treatment." | ( de Medeiros, LM; de Souza, CM; Ferracini, AC; Juliato, CRT; Mazzola, PG; Stahlschmidt, R, 2019) |
| "Women under breast cancer management receiving tamoxifen and showing symptoms of vaginal atrophy were randomized triple-blind to an 8-week trial on vaginal suppository vitamin E or vitamin D or placebo administered every night before bedtime." | ( Alipour, S; Janghorban, R; Jokar, A; Keshavarzi, Z; Tahmasebi, S, 2019) |
| "Serum uric acid (SUA) in patients with breast cancer or with breast benign tumor was assayed when the diagnosis was made, and SUA in patients with breast cancer was also assayed just after chemotherapy." | ( Dong, X; Duan, W; Hu, X; Liu, D; Yang, D; Yin, H; Yun, Y; Zhang, L; Zhang, N, 2019) |
| "However, ~30% of tamoxifen‑treated breast cancers do not initially respond to tamoxifen, and neither do they eventually develop tamoxifen resistance." | ( Cui, F; Du, Y; Feng, X; Liu, H; Lu, S; Ma, Y, 2019) |
| "Bone health in women with HR+ breast cancer enrolled on the prospective randomized Exemestane and Letrozole Pharmacogenetics (ELPh) trial was determined by measuring bone turnover markers (BTM) and bone mineral density (BMD) pre-treatment and after 3 BTM and 24 BMD months of treatment with either the steroidal AI exemestane or the nonsteroidal AI letrozole." | ( Clark, BL; Gersch, CL; Gregory, BJ; Hayes, DF; Henry, NL; Hertz, DL; Kamdem, LK; Kidwell, KM; Rae, JM; Stearns, V; Storniolo, AM; Xi, J, 2019) |
| "3 year) in postmenopausal women with breast cancer previously treated with 2-3 years of tamoxifen." | ( de Boer, M; de Graaf, H; de Roos, WK; Erdkamp, FLG; Honkoop, AH; Imholz, ALT; Kroep, JR; Linn, SC; Peer, PGM; Seynaeve, CM; Smorenburg, CH; Swinkels, ACP; Tjan-Heijnen, VCG; van den Berkmortel, FWPJ; van der Sangen, MJC; van Hellemond, IEG, 2019) |
| "Premenopausal patients with primary breast cancer were randomised to 2 years of tamoxifen (n = 277) or no systemic treatment (n = 287), irrespective of ER status." | ( Bendahl, PO; Ekholm, M; Fernö, M; Nordenskjöld, B; Rydén, L; Stål, O, 2019) |
| "Women with breast cancer were randomized into two groups of paclitaxel chemotherapy with gabapentin 300 mg/three times a day orally or placebo for 2 weeks started at day 1 of each paclitaxel cycle." | ( Aghili, M; Akrami, S; Esmati, E; Ghalehtaki, R; Kalaghchi, B; Mousavi, N; Sotoudeh, S; Zare, M, 2019) |
| "In this study, we enrolled 247 breast cancer patients receiving anthracycline-taxane-based NAC treatment." | ( Bao, L; Bu, H; Chen, G; Chui, M; Hu, P; Jia, Y; Li, W; Li, X; Liu, J; Liu, Y; Ouyang, N; Shi, Y; Wang, Z; Xia, P; Yang, L; Ye, F; Ye, J; Zhang, Z; Zhou, X, 2019) |
| "Women with HER2-positive early-stage breast cancer with prior standard primary therapy and trastuzumab-based (neo)adjuvant therapy were randomized to neratinib 240 mg/day or placebo for 12 months." | ( Di Palma, J; Jahanzeb, M; Mortimer, J; Schmid, K; Ye, Y, 2019) |
| "Investigating the relevance to breast cancer management, we found that the levels of PRNP transcript in pre-treatment tumor biopsies stratified relapse-free survival after neoadjuvant treatment with anthracyclines, particularly amongst doxorubicin-treated patients with residual disease at surgery (p=2." | ( Al-Ejeh, F; Atkinson, C; Collins, SJ; Dalley, AJ; Ferguson, K; Foliaki, ST; Ham, S; Johnstone, CN; Kutasovic, JR; Lakhani, SR; Lewis, V; Lobb, R; Miranda, M; Möller, A; Niland, C; Saunus, JM; Wiegmans, AP, 2019) |
| "Patients with metastatic breast cancer receiving palbociclib in any line of therapy were identified from a cohort of 845 patients at a large academic institution." | ( Clifton, K; Karuturi, M; Kimmel, J; Litton, J; Min, Y; Tripathy, D, 2019) |
| "Brain metastatic breast cancer is challenging to treat due to the presence of the blood-brain barrier (BBB) and a lack of ability to target precisely." | ( Chaudhary, P; Kumar, P; Ranjan, AP; Treuren, TV; Vishwanatha, JK, 2019) |
| "Symptoms were measured by the Breast Cancer Prevention Trial Symptom Checklist and the Functional Assessment of Cancer Therapy-Endocrine Subscale." | ( Jeon, S; Park, SH; Tish Knobf, M, 2019) |
| "Eighty-one patients with early-stage breast cancer (stages I-III) who had no prior exposure to chemotherapy and/or radiotherapy and were scheduled to receive anthracycline-based or taxane-based chemotherapy treatment with curative intent." | ( Bansal, S; Chan, A; Lau, AJ; Shariq Mujtaba, J; Shwe, M; Toh, YL; Yeo, A, 2019) |
| "Chemoresistance is the leading cause of breast cancer therapy failure, and studies of the mechanisms underlying chemoresistance and the treatment of drug-resistant tumors remain challenging." | ( Duan, Z; Kan, Q; Li, D; Wang, X; Yang, M, 2019) |
| "To test this, we primed orthotopic 4T1 breast tumors with a paclitaxel (PTX)-loaded iron-oxide-decorated poly(lactic- co-glycolic acid) nanoparticle (NP) composite (PTX@PINC), which can be quickly concentrated in target tissues with the aid of an external magnet, and monitored its effect on the delivery of subsequently administered NPs." | ( Castanares, MA; Collins, DS; Park, J; Yeo, Y, 2019) |
| "Patients with postmenopausal breast cancer (n = 20) treated with aromatase inhibitors and 20 age-matched control subjects." | ( Andrew, R; Clarke, C; Dixon, JM; Faqehi, AMM; Gibb, FW; Homer, NZ; Walker, BR, 2019) |
| "To induce a safe death to MCF-7 human breast cancer cell line through gene therapy based on iC9 suicide gene." | ( Akbari-Birgani, S; Kaboudin, B; Madadi, Z; Mohseni-Dargah, M; Saghatchi, F, 2019) |
| "In early stage, ERα-positive breast cancer, concurrent use of endocrine therapy and chemotherapy has not been shown to be superior to sequential use." | ( Ingle, JN; Liu, M; Qin, S; Shen, K; Wang, G; Wang, L; Weinshilboum, RM; Zayas, J, 2019) |
| "The effect(s) of rhFSH on human breast cancer cells treated with DOX or CPA was measured in terms of (1) cell viability, (2) cytotoxicity, (3) multidrug resistance (MDR) genes and proteins expression and activities, and (4) hypoxia-inducible factor 1-alpha (HIF-1α) activation." | ( Benedetto, C; Bergandi, L; Canosa, S; Doublier, S; Gennarelli, G; Pittatore, G; Revelli, A; Silvagno, F, 2019) |
| "The results demonstrated that 4 T1 breast cancer cells in allotransplanted mice treated with AF2240 showed a noticeable inhibition of tumour growth and induce apoptotic-related cytokines." | ( Ahmad, U; Eshak, Z; Ideris, A; Othman, F; Raihan, J; Yong, YK, 2019) |
| "Concurrent chemo-radiotherapy in breast cancer (BC) may yield better local control with minimal toxicity in node positive patients." | ( Ali Hassan, A; Ibrahim, NY; Jassen, MAR, 2019) |
| "Optimising breast cancer treatment remains a challenge." | ( Alqudah, A; Annett, S; Clarke, RB; Furlong, F; McCarthy, HO; McClements, L; McIntosh, SA; Moustafa, N; O'Rourke, M; Robson, T; Short, A; Simões, BM; Valentine, A; Yakkundi, A, 2019) |
| "The longevity of women with ER-positive breast cancer treated with adjuvant endocrine therapy emphasises the need to mitigate the adverse skeletal effects of these therapies in order to maximise benefit." | ( Cheung, YM; Grossmann, M; Ramchand, SK; Yeo, B, 2019) |
| "Past studies indicate that >90% of breast cancer survivors taking adjuvant endocrine therapy (AET) experience menopausal symptoms including sexual problems (eg, vaginal dryness, dyspareunia); however, research examining the impact of these problems on quality-of-life is limited." | ( Arthur, SS; Corbett, C; Dorfman, CS; Edmond, SN; Kimmick, GG; Marcom, PK; Shelby, RA; Westbrook, KW, 2019) |
| "Postmenopausal breast cancer survivors taking AET completed measures of sexual problems (Menopause-Specific Quality-of-Life [MENQOL] sexual subscale], sexual self-efficacy, psychosocial quality-of-life (MENQOL psychosocial subscale), and sexual satisfaction (Functional Assessment of Cancer Therapy-General item)." | ( Arthur, SS; Corbett, C; Dorfman, CS; Edmond, SN; Kimmick, GG; Marcom, PK; Shelby, RA; Westbrook, KW, 2019) |
| "Women with HER2-positive breast cancer treated prior to effective anti-HER2 therapy have higher rates of local-regional recurrence (LRR) than those with HER2-negative disease." | ( Albain, KS; Barry, WT; Bellon, JR; Burstein, HJ; Carey, LA; Dang, CT; Ellis, M; Guo, H; Hudis, CA; Krop, I; Marcom, PK; Moy, B; Overmoyer, BA; Partridge, AH; Rugo, HS; Tolaney, SM; Winer, EP; Wolff, AC; Yardley, DA, 2019) |
| "Nearly 75% of breast cancers are hormone receptor-positive (HR+) and human epidermal growth factor receptor type 2-negative (HER2-), making endocrine therapy the mainstay of treatment for HR+ and HER2- combination." | ( Li, J; Shao, Z; Wang, Z, 2019) |
| "To assess how women in Sweden with breast cancer (BC), endometrial cancer (EC), and/or pulmonary embolism (PE) were dispensed menopausal hormone therapy (HT)." | ( Fredrikson, M; Hammar, M; Hoffmann, M; Lindh-Åstrand, L; Spetz Holm, AC, 2019) |
| "Identification of HER2-positive breast cancers with high anti-HER2 sensitivity could help de-escalate chemotherapy." | ( Adamo, B; Bermejo, B; Brasó-Maristany, F; Conte, P; Cortés, J; De Angelis, C; Dieci, MV; Fasani, R; Forero, A; Galván, P; Griguolo, G; Guarneri, V; Gutierrez, C; Hilsenbeck, SG; Izquierdo, M; Krop, I; Llombart-Cussac, A; Morales, S; Nuciforo, P; Oliveira, M; Osborne, CK; Paré, L; Parker, JS; Pascual, T; Pavlick, AC; Prat, A; Reis-Filho, JS; Rexer, B; Rimawi, MF; Rodrik-Outmezguine, V; Schiff, R; Veeraraghavan, J; Vidal, M; Wang, T; Wolff, AC, 2020) |
| "Mammographic screening for breast cancer has led to increased detection of ductal carcinoma in situ (DCIS) and a reappraisal of the necessity of aggressive treatment with their attendant toxicities for a preneoplastic lesion." | ( Chen, C; Korangath, P; Li, S; Merino, VF; Nie, G; Pai, P; Stearns, V; Sukumar, S; Sun, S; Wang, G; Yuan, J, 2019) |
| "The increasing incidence of breast cancer brain metastases is a major clinical problem with its associated poor prognosis and limited treatment options." | ( Anders, CK; Cortés, J; Dieras, V; Hannah, AL; Ibrahim, N; Müller, V; Rugo, HS; Seidman, AD; Tagliaferri, M; Tolaney, SM; Tripathy, D; Twelves, C, 2019) |
| "Patients with HR-positive breast cancer who were treated with everolimus at the Cancer Hospital, Chinese Academy of Medical Sciences from February 2014 to March 2017 were enrolled in the present study." | ( Guan, X; Li, C; Li, L; Liu, B; Ma, F; Qian, H; Xu, B; Yi, Z, 2019) |
| "In total, 120 patients with metastatic breast cancer who were treated with everolimus were enrolled in the present study." | ( Guan, X; Li, C; Li, L; Liu, B; Ma, F; Qian, H; Xu, B; Yi, Z, 2019) |
| "Within the realm of breast cancer, significant advances in therapy have led to improved survival outcomes, yet there is room for improvement." | ( Clamon, G; Phadke, S, 2019) |
| "Sixteen consecutive metastatic breast cancer patients with 24 radiotherapy treatments were studied." | ( D'Angelillo, RM; Dell'Aquila, E; Fiore, M; Greco, C; Ippolito, E; Petrianni, GM; Ramella, S; Silipigni, S; Tonini, G, 2019) |
| "Moreover, cotreatment of breast cancer cells with p38 MAPK and JNK inhibitors significantly counteracted the caudatin-induced expression of DR5." | ( Du, X; Fei, HR; Li, ZJ; Wang, FZ; Wang, GL; Yuan, C; Zhao, Y, 2019) |
| "The analysis of breast cancer residual tumors after neoadjuvant chemotherapy (nCT) may be useful for identifying new biomarkers." | ( Ayala de la Peña, F; Chaves-Benito, A; Conesa-Zamora, P; García-Garre, E; García-Martínez, E; González-Billalabeitia, E; Luengo-Gil, G; Martínez-Carrasco, A; Navarro-Manzano, E; Vicente, V, 2019) |
| "Thirty-two women with breast cancer undertaking adjuvant chemotherapy participated in the study (trained group n=20 and control group n=12)." | ( Ahmaidi, S; Al-Haddabi, B; Doutrellot, PL; Gmada, N; Hiraoui, M; Mezlini, A, 2019) |
| "Female Asian HER2+ breast cancer patients (n=154) who were candidates for lapatinib-based treatment following metastasis and having an available primary tumor biopsy specimen were included." | ( Chiu, J; Choi, YJ; Cornelio, G; Do, IG; Gong, G; Kim, SB; Kim, TY; Lee, EM; Lee, M; Lee, S; Nathaniel, C; Ng, TY; Oh, HS; Paik, S; Park, KH; Park, S; Ro, J; Sohn, J; Tsang, J; Yap, YS, 2019) |
| "Metastatic breast cancer models were constructed to compare microvessel density (MVD), vascular maturity and function, lung metastasis and chemosensitivity in metformin-treated or untreated mice." | ( Feng, J; Han, SX; Jiang, YN; Li, GY; Liu, JL; Liu, PJ; Lu, SY; Shen, YW; Sun, X; Wang, B; Wang, JC; Wang, MD; Zhou, C, 2019) |
| "Cancer recurrence, second breast or non-breast cancer and death were considered events for the intention-to-treat disease-free survival (DFS) analysis." | ( Arenare, L; Barni, S; Cinieri, S; Daniele, G; De Laurentiis, M; De Maio, E; de Matteis, A; De Placido, S; Del Mastro, L; Di Rella, F; Fabbri, A; Forestieri, V; Gallo, C; Gori, S; Gravina, A; Ibrahim, T; Iodice, G; Landi, G; Lauria, R; Mosconi, AM; Normanno, N; Nuzzo, F; Orditura, M; Pacilio, C; Perrone, F; Piccirillo, MC; Putzu, C; Ribecco, AS; Riccardi, F; Rossi, E; Simeon, V; Tinessa, V, 2019) |
| "In patients with HER2-positive breast cancer treated with trastuzumab, both lisinopril and carvedilol prevented cardiotoxicity in patients receiving anthracyclines." | ( Bello-Matricaria, L; Fink, A; Guglin, M; Krischer, J; McCaskill-Stevens, W; Munster, PN; Tamura, R, 2019) |
| "A woman with a right breast cancer underwent a mastectomy, then adjuvant chemotherapy, radiation therapy and hormonotherapy." | ( Bachelot, T; Racadot, S; Visy, A, 2019) |
| "Treatment options in metastatic breast cancer are limited." | ( Balslev, E; Brünner, N; Ejlertsen, B; Jakobsen, EH; Kümler, I; Nielsen, DL; Stenvang, J, 2019) |
| "Moreover, patients with breast cancer exhibited higher ISR after chemotherapy, and the elevated mRNA levels of HMOX1, SHMT2 and EIF2A were correlated with poor prognosis." | ( Chen, L; Ding, N; Duan, Y; He, J; Li, W; Sun, LQ; Xiao, Z; Zhou, J, 2019) |
| "Half of hormone receptor-positive (HR+) breast cancer patients will develop joint pain, termed aromatase inhibitor-induced arthralgia (AIA), while taking aromatase inhibitor therapy." | ( Ademuyiwa, F; Ellis, M; Frith, A; Hilsenbeck, SG; Jiralerspong, S; Kent Osborne, C; Ma, C; Nangia, J; Niravath, P; Park, H; Pavlick, A; Rigden, C; Rimawi, MF; Suresh, R; Wang, T, 2019) |
| "Direct treatment of ER (+) breast cancer with Formestane diminishes the tumor within weeks." | ( Bao, Z; Deng, H; Gao, L; Li, J; Li, X; Liu, L; Nie, D; Rong, Z; Teichmann, AT; Wang, G; Wieland, FH; Yang, Y, 2019) |
| "In chemoresistant breast cancer patients, chemotherapy increased the expression of TM9SF4 proteins in breast tumor samples." | ( Chan, FL; Chi, K; Hu, X; Leung, LK; Liu, C; Meng, Z; Xie, M; Yao, X; Zhu, Y, 2019) |
| "Eight patients with symptomatic breast cancer-related MPE were treated at the Gunma Prefectural Cancer Center, between July 2010 and March 2016." | ( Fujisawa, T; Imai, H; Kaira, K; Kotake, M; Minato, K; Yanagita, Y, 2019) |
| "Triple-negative breast cancer (TNBC) is highly proliferative and metastatic, and because it lacks three major molecular targets for chemotherapy (estrogen receptor, progesterone receptor, and human epidermal receptor 2), it is extremely refractory." | ( Iizumi, K; Kikuchi, H; Kubohara, Y; Makioka, Y; Oshima, Y; Takahashi, K; Totsuka, K, 2019) |
| "In metastatic breast cancer (MBC), expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) guides treatment selection." | ( Angus, L; Bensch, F; Boon, E; de Vries, EGE; Gerritse, S; Jager, A; Menke-van der Houven van Oordt, CW; Oosting, SF; Overbosch, J; Schröder, CP; van der Vegt, B; van Es, SC; van Helden, EJ; van Herpen, CML; Verheul, HM, 2019) |
| "Curcumin treatment suppressed breast cancer cells viabilities and the activation of TLR4-mediated TRIF signaling pathway by the downregulation of TLR4 and IRF3 expression levels and the inhibition of type I IFN (IFN-α/β) levels induced by LPS." | ( Bilir, C; Deveci Özkan, A; Güney Eskiler, G; Kaleli, S, 2019) |
| "Patients with breast cancer receiving antiestrogen therapy, specifically aromatase inhibitors, often suffer from vaginal dryness, itching, irritation, dyspareunia, and dysuria, collectively known as genitourinary syndrome of menopause (GSM)." | ( Abraham, J; Kruse, ML; Sussman, TA; Thacker, HL, 2019) |
| "Among a cohort of postmenopausal breast cancer survivors, we aimed to compare the risk of dementia associated with aromatase inhibitor (AI) therapy versus tamoxifen." | ( Bhaskaran, K; Bromley, SE; Matthews, A; Smeeth, L; Stanway, S, 2019) |
| "The proliferation rate of breast cancer cells on zoledronate-treated bone was significantly lower compared to cells on control bone." | ( Bava, U; Cornish, J; Lin, JM; Naot, D; Park, YE; Reid, IR, 2019) |
| "Using Japanese Breast Cancer Society registry data, we compared disease-free survival (DFS) of patients with ER-positive, HER2-negative breast cancer, excluding those receiving neoadjuvant chemotherapy, between those who received an anthracycline-based regimen followed by a taxane-based regimen (A + T) and those who received only an anthracycline-based regimen (A w/o T), stratified by lymph node status." | ( Anan, K; Aogi, K; Hojo, T; Iwamoto, T; Kinoshita, T; Kojima, Y; Kumamaru, H; Masuda, N; Masuoka, H; Miyata, H; Nakamura, S; Niikura, N; Ohnishi, T; Sagara, Y; Sakatani, T; Tsuda, H; Yamauchi, C; Yoshida, M, 2020) |
| "Hormone receptor-positive breast cancer accounts for nearly two-thirds of breast cancer cases; it ultimately acquires resistance during endocrine treatment and becomes more aggressive." | ( Chae, YS; Jeong, JH; Jung, JH; Kang, SH; Kim, EA; Kim, WW; Lee, J; Lee, SJ; Park, HY; Park, JH; Park, JY, 2019) |
| "Blood samples of 40 HR+/HER2- advanced breast cancer patients were collected before (T0) the administration of palbociclib plus hormonal therapy and after 3 months (T1)." | ( Bertolini, I; Cavallero, D; Crucitta, S; Danesi, R; De Angelis, C; Del Re, M; Diodati, L; Falcone, A; Fogli, S; Fontana, A; Fontanelli, L; Ghilli, M; Gianfilippo, G; Morganti, R; Naccarato, AG; Rofi, E; Roncella, M; Salvadori, B; Scatena, C, 2019) |
| "Trimodality breast cancer treatment factors interact to promote lymphedema." | ( Arsene-Henry, A; Byun, HK; Chang, JS; Cho, YU; Choi, SH; Im, SH; Keum, KC; Kim, GM; Kim, JW; Kim, JY; Kim, YB; Kirova, YM; Lee, IJ; Park, HS; Sohn, JH; Suh, CO, 2021) |
| "Estrogen receptor-positive (ER+) breast carcinoma therapy faces the challenges of estrogen receptors heterogeneity and endocrine therapy resistance." | ( Jiang, Z; Wang, C; Wang, Z; Xiong, H; Yao, J; Zhou, J, 2019) |
| "When breast cancer patients start to exhibit resistance to hormonal therapy or chemotherapy, the mTOR inhibitor everolimus can be considered as an alternative therapeutic agent." | ( Chen, CL; Hsu, WF; Huang, GS; Kuo, CT; Li, CC; Lin, CH; Lu, YS; Ma, WY; Wo, AM, 2019) |
| "All cases of breast cancer with chemotherapy are collected in our hospital from January 2016 to October 2018, and 354 eligible patients were included in analysis." | ( Huang, L; Meng, L; Xu, Y; Zhang, W, 2020) |
| "Triple-negative breast cancer (TNBC) has a high recurrence rate and poor prognosis given its resistance to chemotherapy." | ( Feng, X; Gao, C; He, Y; Hou, S; Shan, M; Yang, Y; Zhang, G; Zhang, L; Zhang, R, 2019) |
| "Its safety for breast cancer is the same as for only estrogen therapy and better than for estrogen-gestagen therapy." | ( Fait, T, 2019) |
| "In women with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines, and/or trastuzumab, pyrotinib plus capecitabine yielded statistically significant better overall response rate and progression-free survival than lapatinib plus capecitabine in this randomized phase II trial." | ( Feng, J; Hu, X; Jiang, Z; Li, H; Li, W; Liu, Y; Ma, F; Ouyang, Q; Tong, Z; Wang, S; Xu, B; Yu, S; Zhu, X; Zou, J, 2019) |
| "61 women with left breast cancer without severe cardiovascular pathology were examined at the stage of doxorubicin therapy and 3D conformal radiation therapy." | ( Vologdina, IV; Zhabina, RM, 2019) |
| "Elderly patients with breast cancer and with multiple co-morbidities are often prevented from having a standard treatment as they are considered unfit for general anaesthesia." | ( Nadeem, M; Sahu, A, 2020) |
| "Furthermore, propranolol treatment of breast cancer cells increased p53 levels, enhanced caspase cleavage, and induced apoptosis." | ( Aguilera, R; Bryan, B; Dickerson, E; Montoya, A; Nahleh, Z; Pasquier, E; Torabi, A; Varela-Ramirez, A, 2019) |
| "Women with breast cancer often experience multiple concurrent symptoms during AI therapy." | ( Bender, CM; Conley, YP; Li, H; Marsland, AL; Sereika, SM, 2019) |
| "One hundred thirteen breast cancer patients who underwent pre-treatment F18 [FDG] PET-computed tomography with biopsy-proven axillary lymph node status were included in the current study." | ( Çermik, TF; Dağ, S; Ergul, N; Yilmaz, B, 2019) |
| "Published findings on breast cancer risk associated with different types of menopausal hormone therapy (MHT) are inconsistent, with limited information on long-term effects." | ( , 2019) |
| "In early-stage HER2-positive breast cancer, the neoadjuvant treatment with T-DM1, lapatinib, and nab-paclitaxel was more effective than the standard treatment, particularly in the ER-positive cohort." | ( Belcheva, A; Boone, T; Chang, JC; Creamer, SL; Darcourt, JG; Ensor, JE; Kaklamani, VG; Kuhn, JG; Li, X; Meisel, JL; Niravath, PA; Patel, TA; Qian, W; Rodriguez, AA; Rosato, RR; Schwartz, MR; Zhao, J, 2019) |
| "Our findings show that breast cancer diagnosed during mid-pregnancy is often treated with chemotherapy." | ( Anazodo, A; Dickinson, JE; Li, Z; Lui, K; Safi, N; Sullivan, EA; Wang, AY, 2019) |
| "Women with breast cancer who were prescribed taxane-based chemotherapy were randomly assigned to a supervised aerobic and resistance exercise program after a chemotherapy-periodized exercise prescription (n = 12) or to usual care during chemotherapy (n = 15)." | ( Bland, KA; Bovard, J; Campbell, KL; Davis, MK; Gelmon, KA; Kirkham, AA; McKenzie, DC; Shenkier, T; Zucker, DS, 2020) |
| "Human breast cancer cells Bcap37 and MDA-MB-453 were treated with VC at low dose (0." | ( Chen, S; Wang, Q; Wei, A; Xu, Q; Zeng, L; Zhang, C, 2019) |
| "Human breast cancer cells Bcap37 and MDA-MB-453 were treated with VC at low dose (0." | ( Chen, S; Wang, Q; Wei, A; Xu, Q; Zeng, L; Zhang, C, 2019) |
| "Eighty-three breast cancer patients who underwent six cycles of EC chemotherapy regimen (epirubicin + cyclophosphamide) without symptoms and signs of heart disease were enrolled in the study." | ( Chen, J; Sun, G; Wang, L; Wu, FF, 2019) |
| "In ER+HER2- metastatic breast cancer patients, capecitabine monochemotherapy in second line may be associated with a particularly satisfactory PFS and no impact in terms of QoL." | ( Barba, M; Barchiesi, G; Ciliberto, G; Giulia, MD; Krasniqi, E; Massimiani, G; Pizzuti, L; Vici, P, 2019) |
| "She underwent right mastectomy for breast cancer and had received aromatase inhibitor and denosumab therapy for 5 years." | ( Kushima, C; Nakazato, M; Uchida, T; Yamaguchi, H; Yonekawa, T, 2020) |
| "HER2-positive breast tumors are found in 25-30% of patients with breast cancer and are characterized by aggressive course and reduced sensitivity to both chemotherapy and hormone therapy." | ( Alexandrov, VA; Baranenko, DA; Bespalov, VG; Filatova, LV; Osipov, MA; Panchenko, AV; Semenov, AL; Semiglazova, TY; Stukov, AN; Tyndyk, ML; Yurova, MN, 2019) |
| "The luminal-A-like and luminal-B-like breast cancer groups have distinct biological features that lead to differences in the treatment response and clinical outcome." | ( Babyshkina, N; Cherdyntseva, N; Choynzonov, E; Dronova, T; Kzhyshkowska, J; Patalyak, S; Slonimskaya, E; Vtorushin, S, 2019) |
| "Twenty-four breast cancer patients underwent PET/MRI (following 18F-fluorodeoxyglucose (18F-FDG) injection) at baseline and during neoadjuvant treatment, yielding 53 data sets (24 untreated, 29 treated)." | ( Andreassen, MMS; Bathen, TF; Deng, C; Eikesdal, HP; Goa, PE; Hedayati, R; Jerome, NP; Lundgren, S; Sjøbakk, TE; Østlie, A, 2020) |
| "A high 21-gene recurrence score (RS) by breast cancer assay is prognostic for distant recurrence of early breast cancer after local therapy and endocrine therapy alone, and for chemotherapy benefit." | ( Abrams, J; Albain, KS; Badve, SS; Berenberg, JL; Brufsky, AM; Dees, EC; Desbiens, C; Ellis, MJ; Geyer, CE; Goetz, MP; Goggins, TF; Gomez, HL; Gray, RJ; Hayes, DF; Kaklamani, VG; Keane, MM; Lively, T; Mahalcioiu, C; Makower, DF; Mayer, IA; Olson, JA; Paik, S; Reddy, PS; Saphner, TJ; Sledge, GW; Sparano, JA; Toppmeyer, DL; Wagner, LI; Wood, WC, 2020) |
| "Estrogen receptor-positive breast cancers are treated with tamoxifen, a drug that competitively inhibits the binding of estrogen to its receptor." | ( Gun, M; Hong, XY; Wang, Q, 2019) |
| "This cross-sectional study examined breast cancer patients who received docetaxel-based chemotherapy from the general surgery outpatient department and oncology outpatient department of a medical center in northern Taiwan." | ( Chen, SC; Hsu, YH; Lin, YF; Shen, WC; Wang, CH, 2019) |
| "Despite the many advances in breast cancer treatment, there is still a need to improve drug efficacy and reduce non-specific effects." | ( Constantinou, AI; Gregoriou, G; Mesaritis, A; Neophytou, CM, 2019) |
| "Women diagnosed with breast cancer between 2006 and 2015 and treated with tamoxifen or aromatase inhibitors (n = 36,472) were stratified according to low (without osteoporosis diagnosis nor bisphosphonates exposure) or high (with osteoporosis and/or treated with bisphosphonates) fracture risk." | ( Diez-Perez, A; Garcia-Giralt, N; Nogués, X; Pineda-Moncusí, M; Prieto-Alhambra, D; Servitja, S; Tusquets, I, 2020) |
| "To effectively inhibit the growth of breast cancer cells (MDA-MB-231 cells) by the combination method of chemotherapy and magnetic hyperthermia, we fabricated a biomimetic drug delivery (CSiFePNs) system composed of mesoporous silica nanoparticles (MSNs) containing superparamagnetic ferroferric oxide and Paclitaxel (PTX) coated with MDA-MB-231 cell membranes (CMs)." | ( Cai, D; Han, C; Liu, L; Ma, X; Qian, J; Zhou, J; Zhu, W, 2019) |
| "We included 3,177 patients with HER2+ breast cancer treated with adjuvant chemotherapy alone or with trastuzumab from the North Central Cancer Treatment Group N9831 (ClinicalTrials." | ( Chumsri, S; Colon-Otero, G; Gavin, PG; Li, Z; Mashadi-Hossein, A; Moreno-Aspitia, A; Paik, S; Perez, EA; Pogue-Geile, KL; Serie, DJ; Song, N; Thompson, EA, 2019) |
| "Cytotoxicity studies using 4T1 breast cancer cells showed lower inhibitory concentration 50% (IC50) value for LCFL-PTX/DXR treatment (0." | ( Andrade, MS; de Barros, ALB; Franco, MS; Leite, EA; Oliveira, MC; Roque, MC; Vilela, JMC, 2019) |
| "Treatment of breast cancer by paclitaxel (PAX) often encounters therapeutic failure most likely caused by innate/acquired resistance." | ( Adel, A; Al-Toukhy, GM; Ammar, RA; Attia, YM; El-Kersh, DM; Elmazar, MM; Eskander, K; Hamdy, M; Khalil, A; Mansour, MT; Mohsen, NE; Reda, N; Walid, H, 2020) |
| "The most common molecular type of breast cancer is the luminal subtype, which expresses estrogen and progesterone receptors and is typically treated with surgery and adjuvant endocrine therapy (ET)." | ( Huizing, MT; Najim, O; Papadimitriou, K; Seghers, S; Sergoynne, L; Tjalma, W; Trinh, XB; Van Gaver, H; Wouters, K, 2019) |
| "The adhesion and TEM measured between breast cancer cells and inflamed or Tβ4-treated endothelium were inhibited by P4D." | ( Babinska, A; Bednarek, R; Karolczak, K; Popielarski, M; Salifu, MO; Selmi, A; Stasiak, M; Swiatkowska, M; Wojkowska, D, 2020) |
| "It could be a promising agent for breast cancer therapy." | ( Chen, Y; Lou, C; Xu, X; Zhao, H, 2019) |
| "The effectiveness of chemotherapy in breast cancer treatment can be increased using a combinatorial agent." | ( Hermawan, A; Putri, H; Utomo, RY, 2020) |
| "Assessment of AR-signal in breast cancer tissue maybe useful for treatment selections." | ( Hanamura, T; Hokibara, S; Ito, KI; Kaizuka, M; Koyama, H; Murasawa, H; Nakamura, T; Ohno, K; Sawano, S; Watanabe, H, 2019) |
| "With TGFA pretreatment, ER+ breast cancer cells were resistant to 4-hydroxytamoxifen (4-OHT)." | ( Bae, SY; Choi, HJ; Jeong, Y; Jung, SP; Kim, I; Kim, S; Kim, SW; Lee, JE; Lee, SK; Nam, SJ; You, D; Yu, J, 2019) |
| "Potent drugs for breast cancer treatment are Tamoxifen, Trastuzumab, Paclitaxel, etc." | ( Acharya, R; Bose, P; Chacko, S; Lapenna, A; Pattanayak, SP, 2019) |
| "When breast cancer cells were simultaneously treated with doxorubicin and miR-154 mimic, cell viability was considerably reduced compared to treatment with doxorubicin alone in both cell lines." | ( Abdolvahabi, Z; Bolandghamat Pour, Z; Ezzati Mobasser, S; Ghorbanhosseini, SS; Hesari, Z; Madjd, Z; Mousavizadeh, K; Nourbakhsh, M, 2019) |
| "MCF-7 and MDA-MB-231 breast cancer cell lines were treated with 30 mM and 20 mM concentrations of lithium chloride (LiCl), respectively." | ( Omidi, M; Ramshini, S; Rouhani, M, 2019) |
| "A general therapeutic strategy to treat breast cancer is attractive as different subtypes of breast cancers often exhibit distinct response to existing cancer therapeutics." | ( Chao, Y; Chen, M; Chen, MC; Dong, Z; Dong, ZL; Feng, L; Feng, LZ; Hao, Y; Liu, Z, 2020) |
| "nipponicus may be useful for breast cancer prevention and treatment in the future." | ( Buranrat, B; Sangdee, A; Sangdee, K, 2019) |
| "Twenty seven postmenopausal breast cancer patients receiving AI therapy were recruited for this study." | ( Baum, T; Dieckmeyer, M; Einspieler, I; Karampinos, DC; Kirschke, JS; Metz, S; Rohrmeier, A; Rummeny, EJ; Ruschke, S; Schmidmayr, M; Seifert-Klauss, V; Syväri, J; Zimmer, C, 2019) |
| "Triple-Negative Breast Cancers (TNBC) are among the most aggressive and therapyresistant breast tumors." | ( El-Shafey, ES; Elsherbiny, ES, 2019) |
| "We found that treatment of breast cancer cells with WZ35 exerts stronger anti-tumor activities than curcumin both in vitro and in vivo." | ( Chen, H; Chen, T; Cui, R; He, Y; Huang, X; Liang, G; Tao, Z; Wang, C; Wang, L; Wu, W; Yang, L; Yu, Y; Zhao, L; Zheng, B; Zhu, Z, 2019) |
| "MCF-7 mammary cancer cell proliferation was significantly decreased within 24 h after treatment with 4HC at 50 μM, while no effect was observed on the viability of MCF-10a non-cancerous mammary cells." | ( Bachari, K; Berry, A; Caldefie-Chézet, F; Decombat, C; Delort, L; Ramdani, LH; Silva, A; Talhi, O; Vasson, MP; Vermerie, M, 2019) |
| "Triple-negative breast cancer (TNBC) is very aggressive with high metastatic and mortality rates and unfortunately, except for chemotherapy, there are few therapeutic options." | ( Singh, SK; Spiegel, S, 2020) |
| "Metastatic breast cancer remains incurable, and the presence of triple-negative phenotypes makes targeted treatment impossible." | ( Baker, JR; McCluskey, A; Sakoff, JA, 2020) |
| "In the GIM2 trial, node-positive early breast cancer patients were randomized to receive four cycles of (fluorouracil)epirubicin/cyclophosphamide followed by four cycles of paclitaxel administered every 2 (dose-dense) or 3 (standard-interval) weeks." | ( Bighin, C; Bisagni, G; Bruzzone, M; Ceppi, M; Cognetti, F; Conte, B; de Azambuja, E; De Laurentiis, M; Del Mastro, L; Durando, A; Fabi, A; Garrone, O; Giuliano, M; Lambertini, M; Montemurro, F; Poggio, F; Puglisi, F; Turletti, A; Urracci, Y, 2020) |
| "We conducted a clinical trial in breast cancer patients who received paclitaxel treatment to assess the effectiveness of cooling for CIPN prevention." | ( Hanai, A, 2019) |
| "Triple negative breast cancer (TNBC), a subtype lacking the known breast cancer receptors used for targeted therapy, is reliant on chemotherapy as the standard of care." | ( Keffler, K; McClintock, S; Milac, L; Prosperi, JR; Stefanski, CD, 2019) |
| "Women with early-stage breast cancer may still have a future child wish, while chemotherapy may impair fertility." | ( de Die-Smulders, CEC; Derhaag, JGJ; Leter, EME; Smidt, MM; Ter Welle-Butalid, MEE; Tjan-Heijnen, VCGV; van Golde, RJTR; Vriens, IJHI, 2019) |
| "Thus, strategies for the treatment of breast cancer need to be continuously refined to achieve a better patient outcome." | ( Avan, A; Cho, WC; Hasanian, SM; Khazaei, M; Soleimanpour, S; Yaghoubi, A, 2019) |
| "Triple-negative breast cancers (TNBC) are often associated with high relapse rates, despite treatment with chemotherapy agents such as doxorubicin." | ( Bassett, JJ; Bong, AHL; Monteith, GR; Roberts-Thomson, SJ, 2020) |
| "Here, IL-6 untreated/pretreated human breast cancer cells were cultured with single or combination of NVP-BEZ235 and/or SIRT1 activator (SRT1720)/inhibitor (EX-527) under radiotherapy condition." | ( Ghatrehsamani, M; Masoumi, H; Soltani, A, 2020) |
| "This indicates that breast tumors belonging to the TNBC subtype, may benefit from treatment with CPT derivatives." | ( Algreen, L; Andersen, AB; Andersen, MB; Gromov, P; Gromova, I; Hansen, NY; Jakobsen, AK; Knudsen, BR; Kristoffersen, EL; Petersen, KW; Simonsen, AK; Stougaard, M; Tesauro, C, 2019) |
| "The fifth case was a breast cancer patient with distant metastases in CR, while receiving beta-interferon and interleukin-2 in addition to conventional hormone therapy." | ( Carpi, A; Ferrari, P; Morganti, R; Nicolini, A, 2019) |
| "As not all breast cancer types respond to the anti-hormonal therapy, the development of new antineoplastic drugs is necessary." | ( Alves, RJ; Gomes, ER; Oliveira, MC; Ottoni, FM; Pádua, RM; Silva, IT, 2020) |
| "Bone metastasis caused by breast cancer leads to significant complications in treatment, and the resulting osteolysis considerably affects patients' overall survival and quality of life." | ( Feng, W; Huang, X; Li, J; Luan, Z; Ma, S; Song, F; Wei, L; Wu, Z; Yang, Z; Yao, J; Zhang, X, 2020) |
| "The procedures used for breast cancer treatment are able to increase the level of oxidative stress and cause depletion of antioxidants." | ( Carvalho, A; Franca, C; Lanes Vieira, S; Lessa, S; Nogueira, C; Penna, A; Ramalho, A; Rosa, C, 2019) |
| "Chemoresistance of triple negative breast cancer against paclitaxel (PAX) is one of the major issues for the patients under chemotherapy." | ( Du, WW; Fang, L; Hibberd, S; Ma, J; Wu, N; Yang, BB; Yang, Q, 2019) |
| "We compared the response of breast cancer to the oral administration of A." | ( Azevedo, ÍM; Macedo, R; Medeiros, AC; Oliveira, CN; Rocha, KBF, 2019) |
| "Among women with early-stage breast cancer who received at least one cycle of paclitaxel, 119 were included in the 2016 cohort who received cryotherapy when they developed symptoms of CIPN, and 96 patients in the 2017 cohort who received prophylactic cryotherapy." | ( Ewertz, M; Hjelmborg, JVB; Holm, HS; Jensen, JD; Rosenbaek, F, 2020) |
| "Eligible breast cancer patients who will start chemotherapy will be randomly divided into group A (YH0618 granule) and group B (placebo)." | ( Cao, YL; Chen, JP; Guo, L; Guo, Z; Huang, M; Lin, MD; Liu, HL; Qu, WL; Shi, XL; Sun, YZ; Xu, Q; You, JS, 2019) |
| "Consecutive early breast cancer patients admitted to Istituto Oncologico Veneto who were recommended to receive neoadjuvant or adjuvant CT, were eligible to undergo scalp cooling during the CT administration within this study." | ( Di Liso, E; Dieci, MV; Faggioni, G; Falci, C; Frezzini, S; Giarratano, T; Giorgi, CA; Griguolo, G; Grosso, D; Guarneri, V; Mantiero, M; Menichetti, A; Miglietta, F; Mioranza, E; Tasca, G; Vernaci, G; Zanocco, M, 2020) |
| "In triple-negative early breast cancer patients presenting invasive residual disease after neoadjuvant chemotherapy, the CREATE-X trial demonstrated the benefit of post-neoadjuvant capecitabine." | ( Brandão, M; Caparica, R; Piccart, M, 2019) |
| "Invasive oestrogen receptor-positive breast cancer was reduced by 54% (HR 0·46, 95% CI 0·33-0·65, p<0·0001), with a continued significant effect in the period after treatment." | ( Bonanni, B; Cawthorn, S; Cuzick, J; Dowsett, M; Evans, DG; Forbes, JF; Howell, A; Loibl, S; Mansel, RE; Sestak, I, 2020) |
| "Most thromboembolic complication after breast cancer chemotherapy was venous thrombosis after multiagent chemotherapy." | ( Choi, YJ; Jang, LC, 2019) |
| "TAM-treated breast cancer patients (n = 40) previously believed to have CYP3A activity within the normal range based on oral midazolam and phenotyped as CYP2D6 normal metabolizers using oral metoprolol were divided into two groups according to premenopausal (n = 20; aged 35-50 years) or postmenopausal (n = 20; aged 60-79 years) status." | ( Coelho, EB; de Andrade, JM; Lanchote, VL; Marques, MP; Suarez-Kurtz, G; Ximenez, JPB, 2019) |
| "Patients with breast cancer randomly assigned to an intergroup metronomic trial of cyclophosphamide, doxorubicin, and paclitaxel were queried on their use of supplements at registration and during treatment (n =1,134)." | ( Albain, KS; Ambrosone, CB; Barlow, WE; Budd, GT; Cannioto, R; Gralow, JR; Hershman, DL; Hobday, TJ; Hortobagyi, GN; Hutson, AD; Isaacs, C; Kelly, KM; McCann, SE; McCann, WE; Moore, HCF; Salim, M; Stewart, JA; Sucheston-Campbell, LE; Unger, JM; Zirpoli, GR, 2020) |
| "Cytotoxic therapy for breast cancer inhibits the growth of primary tumors, but promotes metastasis to the sentinel lymph nodes through the lymphatic system." | ( Alves, M; Chollet, C; Fougeray, T; Franchet, C; Garmy-Susini, B; Gomez-Brouchet, A; Guillermet-Guibert, J; Lacazette, E; Martinez, LO; Najib, S; Prats, AC; Tatin, F; Therville, N; Vaysse, C; Zamora, A, 2019) |
| "Women with breast cancer receiving A or T chemotherapy receiving SC were significantly more likely to have less than 50% hair loss after CT, superior hair regrowth and improvement in patient reported outcomes, with acceptable tolerance." | ( Bajpai, J; Banavali, SD; Chandrasekharan, A; Dandekar, S; Ghosh, J; Gupta, S; Kagwade, S; Kanan, S; Kembhavi, Y, 2020) |
| "Of 269 breast cancer patients, median (Inter Quartile Range) overall delay was 203 (110-401) days, presentation delay was 35 (10-112) days and treatment delay was 130 (75-258) days." | ( Bhagabaty, SM; Kumar, A; Purkayastha, J; Selvaraj, K; Singh, R; Tripathy, JP, 2019) |
| "The treatment of metastatic breast cancer remained a challenge despite the recent breakthrough in the immunotherapy regimens." | ( Alföldi, R; Balog, JÁ; Hackler, L; Kovács, AK; Nagy, LI; Neuperger, P; Puskás, LG; Szebeni, GJ, 2019) |
| "In the collected tumor tissues of breast cancer in the present study, high expression of CYTOR was detected in tissues from patients with no response to tamoxifen compared with those from patients who were not treated with tamoxifen." | ( Li, M; Liu, Y; Piao, H; Yu, H, 2020) |
| "In this case report, we present a breast cancer patient who was commenced on Tamoxifen treatment presenting with formation of both atypical stromal cells in an endometrial polyp and osteoclastic like giant cells in the leiomyoma of the uterus." | ( Çay, T; Karacan, T; Kasımogullar, EV; Öztürk, Ç; Tetikkurt, S, 2019) |
| "We enrolled 50 women with breast cancer treated with taxanes (docetaxel or paclitaxel) in a 3-month prospective study." | ( Cantello, R; Clemente, N; Comi, C; Luigi Foglio Bonda, P; Pizzamiglio, C; Prandi, P; Ripellino, P; Rossi, V; Saggia, C; Strigaro, G, 2020) |
| "Doxorubicin is widely used in breast cancer chemotherapy." | ( Auboeuf, D; Benoit-Pilven, C; Bièche, I; Chakraborty, A; Delattre, O; Dutertre, M; Labiod, D; Lam, EWF; Pouzoulet, F; Saulnier, O; Tanaka, I; Vacher, S; Vagner, S, 2020) |
| "Patients with breast cancer (BC) show strong interest in complementary and alternative medicine (CAM), particularly for adverse effects of adjuvant endocrine treatment - e." | ( Almstedt, K; Baake, G; Bayer, CM; Beckmann, MW; Brodkorb, T; Brucker, C; Brucker, SY; Fasching, PA; Fehm, T; Fischer, G; Fridman, A; Gass, P; Graf, H; Häberle, L; Hack, CC; Harbeck, N; Hartkopf, AD; Hein, A; Heindl, F; Hoffmann, O; Janni, W; Kohls, A; Kolberg, HC; Krabisch, P; Kuemmel, S; Lindner, C; Loehberg, CR; Lux, MP; Maass, N; Malter, W; Martin, B; Nabieva, N; Pelzer, V; Rack, B; Rauh, C; Rody, A; Schulz, V; Steinfeld-Birg, D; Thomssen, C; Volz, B; Walter, CB; Weigel, M; Willer, L; Wolf, C; Wuerstlein, R, 2020) |
| "Estrogen receptor-expressing breast cancer exhibits better prognosis due to responsiveness to antiestrogen treatment." | ( Bal, A; Chhabra, A; Kumar, R; Laroiya, I; Mittal, BR; Shukla, J; Singh, G; Vatsa, R, 2020) |
| "The treatment for breast cancer may involve surgery, hormonal therapy (Tamoxifen, an aromatase inhibitor, etc." | ( Ananth, AH; Bhattacharjee, A; Elancheran, R; Kabilan, S; Lakshmithendral, K; Manikandan, N; Rajan, RK; Ramanathan, M, 2020) |
| "We employed breast cancer cell lines to assess the potential synergistic effect of a combined treatment of AEs/paclitaxel (PTX) or AEs/adriamycin (ADR) and to determine the underlying mechanisms correlated to this potential therapeutic approach." | ( Di Venere, D; Mardente, S; Miccadei, S; Mileo, AM, 2020) |
| "Despite proven survival benefits after breast cancer, long-trem compliance with adjuvant hormone therapy remains a major issue, partly due to the side effects of treatment." | ( Lesur, A; Saghatchian, M, 2019) |
| "We describe in a patient with breast cancer the change in c-MET expression during everolimus treatment, opening a better understanding of the resistance to everolimus and a role for cabozantinib." | ( Augusto, D; Grisay, G; Honoré, N; Jadot, G; Laes, JF; Petit, B; Pierrard, J; Sauvage, S; Seront, E; Van den Bossche, V, 2020) |
| "Using a CIN model of Kras-driven breast cancer, we demonstrate that aneuploid tumours acquire genetic modifications that facilitate the development of resistance to targeted therapy faster than euploid tumours." | ( Buccitelli, C; Kandala, S; Korbel, JO; Rowald, K; Salgueiro, L; Somogyi, K; Sotillo, R, 2020) |
| "Multidrug resistance (MDR) in breast cancer treatment is the major cause leading to the failure of chemotherapy." | ( Dong, GH; Gao, ZF; Li, G; Li, HL; Li, X; Wang, AL; Wu, Y; Yin, DL; Zhang, YH, 2020) |
| "HER2-positive (HER2+) breast cancer has become an effectively treatable disease in the era of targeted therapies, and outcomes have improved such that prognosis of this subtype is demonstrated to be superior to HER2-negative disease." | ( Brufsky, A; Nasrazadani, A, 2020) |
| "Women with residual invasive breast cancer at the primary site or axillary lymph nodes following neoadjuvant chemotherapy have a high risk of recurrence." | ( Anz, B; Daniel, B; DeBusk, LM; Hainsworth, JD; Jankov, A; Molthrop, DC; Pasek, J; Peacock, N; Shastry, M; Shroff, SK; Vander Woude, A; Yardley, DA; Young, R, 2020) |
| "Women with localized breast cancer who had residual invasive cancer following ≥ 4 cycles of standard anthracycline and/or taxane-containing neoadjuvant chemotherapy received adjuvant eribulin treatment." | ( Anz, B; Daniel, B; DeBusk, LM; Hainsworth, JD; Jankov, A; Molthrop, DC; Pasek, J; Peacock, N; Shastry, M; Shroff, SK; Vander Woude, A; Yardley, DA; Young, R, 2020) |
| "Using a xenograft breast cancer mouse model, we have found that Intralipid pre-treatment significantly increases the amount of paclitaxel reaching the tumor and promotes tumor apoptosis." | ( Chen, CP; Chen, CT; Chen, YJ; Cheng, YM; Chiu, TY; Chou, LH; Ho, C; Liu, L; Liu, TW; Nieh, SW; Tsai, CY; Wang, MH; Yeh, TK, 2020) |
| "Adjuvant treatment for breast cancer in postmenopausal women is a risk factor for bone loss." | ( Ahn, SH; Choi, SW; Chung, IY; Kim, H; Kim, HJ; Kim, J; Kim, M; Ko, BS; Lee, JW; Lee, SB; Sohn, G; Son, BH; Tabatabaie, V, 2020) |
| "Triple negative breast cancer (TNBC) is characterized by highly aggressive phenotype, limited treatment options and a poor prognosis." | ( Fujiwara-Tani, R; Goto, K; Kawahara, I; Kishi, S; Kondoh, M; Kuniyasu, H; Luo, Y; Mori, S; Mori, T; Nishiguchi, Y; Ohmori, H; Sasaki, T, 2020) |
| "The majority of breast cancers are oestrogen-receptor-positive (ER+) and are subject to endocrine therapy; however, an unpredictable subgroup of patients will develop resistance to endocrine therapy." | ( Alfarsi, LH; Craze, ML; El-Ansari, R; Ellis, IO; Green, AR; Masisi, BK; Mohammed, OJ; Rakha, EA, 2020) |
| "In spite of attempts to classifying breast cancer according to its histological and molecular properties, it is almost considered as a dilemma in treatment." | ( Ezzati, M; Safa, A; Velaei, K; Yousefi, B, 2020) |
| "However, most breast tumors are immuno-suppressive and only modestly respond to immunotherapy." | ( Fernando, V; Furuta, S; Letson, J; Sharma, V; Walia, Y; Zheng, X, 2020) |
| "Management of patients with breast cancer undergoing chemotherapy is complicated by a very high rate of adverse drug reactions which is even more challenging in developing countries like Ethiopia where the toxicity profile of chemotherapy is lacking." | ( Assefa, M; Gadisa, DA; Wang, SH; Yimer, G, 2020) |
| "Disease-free breast cancer survivors (n = 422) who completed chemotherapy and/or radiotherapy 12-60 months previously and report significant fatigue will be randomized 1:1 to receive bupropion (300 mg/day) or placebo." | ( Babilonia, MB; Bower, J; Cole, S; Culakova, E; Desta, Z; Han, HS; Heckler, C; Hoogland, AI; Janelsins, M; Jim, HSL; Morrow, G; Peppone, L; Williams, GC, 2020) |
| "This review begins with an outline of breast cancer, the current treatment options and a history of how TAM has been used as a combatant of BC." | ( Day, CM; Garg, S; Hickey, SM; Plush, SE; Song, Y, 2020) |
| "In treatment-naïve breast tumors, DCK was higher in TNBCs, and DCK levels were sustained or increased post chemotherapy treatment." | ( Coyle, KM; Cruickshank, BM; Dahn, ML; Dean, C; Giacomantonio, CA; Goralski, KB; Hall, SR; Holloway, RW; Jackson, AJ; Maillet, H; Marcato, P; Waisman, DM; Weaver, ICG, 2020) |
| "In the treatment of advanced breast cancer, onlya few drugs confer overall survival(OS)benefit." | ( Asano, Y; Goto, W; Hirakawa, K; Ishihara, S; Kashiwagi, S; Kouhashi, R; Morisaki, T; Noda, S; Ohira, M; Onoda, N; Takada, K; Takashima, T; Tauchi, Y, 2019) |
| "To examine the risk of incident breast cancer in women with rheumatoid arthritis (RA), and the risk of RA in women with a history of breast cancer, taking antihormonal treatment for breast cancer into account." | ( Askling, J; Pettersson, A; Smedby, KE; Wadström, H, 2020) |
| "Chemo-naive women with primary breast cancer were randomly administered either palonosetron 0." | ( Aogi, K; Baba, M; Chiba, Y; Fujiwara, K; Hirano, G; Imamura, CK; Imoto, S; Matsumoto, K; Matsuura, K; Miyazaki, C; Naito, Y; Osaki, A; Saeki, T; Sato, K; Takahashi, M; Takano, T; Tamura, K; Tokunaga, S; Yanagihara, K, 2020) |
| "The resistance of breast cancer cells to drugs is a major obstacle to effective cancer chemotherapy." | ( Huang, T; Wang, F; Xiang, Z; Zhang, M; Zhou, WB, 2020) |
| "Treatment of ADG-2e against metastatic breast cancer cells (MDA-MB-231) suppressed tumor cell migration by multi-directional lamellipodium formation, indicating their anti-metastatic potential." | ( Bang, JK; Chirumarry, S; Gunasekaran, P; Han, J; Kim, EY; Lee, YH; Ryu, EK; Shin, SY; Soung, NK, 2020) |
| "Patients receiving HMT for breast cancer treatment were identified." | ( Branigan, GL; Brinton, RD; Neumayer, L; Rodgers, K; Soto, M, 2020) |
| "Subsequent trends in breast cancer incidence have been described, but most reports have not focused on the postmenopausal age group or fully engaged the potential influence of reduced hormone therapy on breast cancer incidence trends by race/ethnicity." | ( Anderson, GL; Aragaki, AK; Chlebowski, RT; Prentice, RL, 2020) |
| "We retrospectively analyzed data from breast cancer patients who began treatment with regimens of lapatinib plus capecitabine (LC or LX) or trastuzumab beyond progression (TBP) at eight hospitals between May 2010 and October 2017." | ( Fu, P; Fu, Z; Huang, X; Jiang, Z; Jin, F; Li, J; Li, W; Li, Y; Sun, C; Wang, B; Wang, H; Wang, J; Wu, H; Yan, M; Yang, F; Yang, M; Yin, Y; Zeng, T; Zhang, J, 2020) |
| "Obesity represents a risk factor for breast cancer development and therapy resistance, but the molecular players underling these links are unclear." | ( Andò, S; Barone, I; Bonofiglio, D; Camera, G; Campana, A; Catalano, S; Fuqua, S; Gelsomino, L; Giordano, C; Grande, F; Leggio, A; Marsico, S; Rinaldi, A; Sisci, D; Tarallo, R, 2020) |
| "Nearly 70% of breast cancer (BC) is hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and endocrine therapy is the mainstay of treatment for this subtype." | ( Huang, J; Jin, XY; Shen, LS; Tou, LZ; Wang, XM, 2020) |
| "MCF7 breast cancer cells expressing luciferase and Y537S or D538G ER were injected into NOD-SCID-gamma female mice, and animals were treated orally with the antiestrogen K-07 or control vehicle." | ( Dey, P; Katzenellenbogen, BS; Katzenellenbogen, JA; Kim, SH; Laws, MJ; Nelson, ER; Nettles, KW; Park, BH; Shahoei, SH; Yasuda, M; Ziegler, Y, 2020) |
| "These breast cancer cells established metastases in liver and lung, and K-07 treatment reduced the metastatic burden." | ( Dey, P; Katzenellenbogen, BS; Katzenellenbogen, JA; Kim, SH; Laws, MJ; Nelson, ER; Nettles, KW; Park, BH; Shahoei, SH; Yasuda, M; Ziegler, Y, 2020) |
| "This is a case report of a HER2+ breast cancer woman with diffuse brain metastases that experienced long survival and clinical benefit from multiple radiotherapy treatments and combined systemic therapy, without increased toxicity." | ( Gangemi, E; Greco, C; Ippolito, E; La Cesa, A; Matteucci, P; Ramella, S; Santini, D; Santo, B; Silipigni, S, 2020) |
| "Surgically treated breast cancer patients in 2015 (aOR = 0." | ( Baillargeon, JG; Chou, LN; Gibson, DC; Kuo, YF; Raji, MA, 2020) |
| "Surgically treated breast cancer patients are less likely to receive short- and long-term opioid prescriptions following the implementation of hydrocodone rescheduling." | ( Baillargeon, JG; Chou, LN; Gibson, DC; Kuo, YF; Raji, MA, 2020) |
| "EM treatment of older patients with breast cancer is feasible and reflects the outcomes for the general population." | ( Amoroso, V; Ardine, M; Barni, S; Berruti, A; Borgonovo, K; Cabiddu, M; di Mauro, P; Ghidini, A; Ghilardi, M; Monteverdi, S; Parati, MC; Pedersini, R; Petrelli, F; Simoncini, EL; Turla, A; Vassalli, L; Volta, AD, 2020) |
| "Dual-targeted therapy in HER2-positive breast cancer cells with the combination of carbon dots/HER3 siRNA and trastuzumab resulted in enhanced antitumor activity, which overcomes the resistance to trastuzumab monotherapy." | ( Gao, F; He, G; Hu, N; Shu, M; Su, Y; Wu, Y; Xu, L; Yang, Z; Yu, C; Zeng, M; Zhou, Z, 2020) |
| "TILs in breast cancer (BC) play a role in tumor response to therapy in the adjuvant and neoadjuvant settings, especially in triple-negative cancers." | ( Agarwal, C; Chauhan, V; Jain, H; Pujani, M; Singh, K; Singh, M, 2020) |
| "Patients with hormone receptor-positive breast tumors receive hormonal therapy with either selective estrogen receptor modulators (SERMs) (eg, tamoxifen) or aromatase inhibitors (AIs) (eg, anastrozole) for 5 to 10 years." | ( Cook, JA; Dolejs, S; Fisher, C; Hassanein, AH; Lester, ME; Spera, LJ, 2020) |
| "Thirty-six patients with metastatic breast cancer treated with sirolimus plus endocrine therapy were included." | ( Guan, X; Li, C; Li, H; Li, L; Liu, B; Ma, F; Qian, H; Rong, G; Sun, X; Wang, W; Xu, B; Yi, Z; Zhai, J, 2020) |
| "There were no differences in overall or breast cancer-specific survival between patients who received adjuvant radiotherapy and those who did not." | ( Ahlgren, J; Arnesson, LG; Emdin, S; Ingvar, C; Lofgren, L; Niméus, E; Nordander, M, 2020) |
| "By using breast cancer as an example, at a minimum, key tumor prognostic information required before the initiation of treatment includes subtype, tumor grade, tumor size, lymph node status when possible, and biomarker expression determined by immunohistochemistry for estrogen receptor." | ( Anglade, F; Brock, JE; Milner, DA, 2020) |
| "Patients with HER2-positive breast cancer who have received two or more previous therapies for advanced disease have few effective treatment options." | ( André, F; Catron, K; Chan, A; Chapman, SC; Gainford, MC; Goel, S; Hilton, JF; Im, SA; Johnston, SR; Kim, SB; Price, GL; Ricci, F; Tolaney, SM; Troso-Sandoval, TA; Wardley, AM; Yang, Z; Zambelli, S, 2020) |
| "Targeting the mTOR pathway in breast cancer treatment may be a treatment option." | ( Ekizceli, G; Inan, S; Uluer, ET, 2020) |
| "We used a large human breast cancer gene expression panel to select candidate prognostic biomarkers for pCR among women treated with trastuzumab in NSABP B-41." | ( Bandos, H; Brauer, HA; Geyer, CE; Goerlitz, DS; Harris, BT; Lucas, PC; Mamounas, EP; Rastogi, P; Ren, Y; Robidoux, A; Swain, SM; Tang, G; Wolmark, N, 2020) |
| "Capecitabine is important in breast cancer treatment but causes diarrhea and hand-foot syndrome (HFS), affecting adherence and quality of life." | ( Abramson, VG; Chang, JC; Cox, N; Dees, EC; Dolan, ME; Fleming, GF; Forero, A; Hahn, OM; Hall, JP; Hoffman, PC; Huang, RS; Huo, D; Ingle, JN; Liu, MC; Merkel, DE; Morrow, PK; Nanda, R; Nath, A; Nurhussein-Patterson, A; O'Donnell, PH; Olopade, OI; Peppercorn, JM; Ratain, MJ; Rosner, GL; Rugo, HS; Storniolo, AM; Trubetskoy, V; Van Poznak, C; Wolff, AC, 2020) |
| "Female Japanese breast cancer patients who planned to receive (neo)adjuvant chemotherapy participated in this prospective study on the efficacy of scalp cooling using the Paxman Scalp Cooling System for alopecia prevention." | ( Aogi, K; Doi, M; Hara, F; Kiyoto, S; Matsuda, M; Ohsumi, S; Takahashi, M; Takashima, S; Yamamura, N, 2021) |
| "A 32-year-old woman was treated for breast carcinoma." | ( Giladi, MR; Hod, N; Kazap, DE; Lantsberg, S; Levin, D, 2020) |
| "After neoadjuvant chemotherapy of breast cancer pathologic complete response (pCR) indicates a favorable prognosis." | ( Tribukait, B, 2020) |
| "Precision medicine in breast cancer demands markers sensitive to early treatment response." | ( Cheung, SM; He, J; Heys, SD; Husain, E; Masannat, Y; Miller, ID; Wahle, K, 2020) |
| "Women who present with locally advanced breast cancer that would require a mastectomy are often recommended to undergo chemotherapy prior to surgery in hopes of down-staging the tumor and allowing for breast-conserving surgery." | ( Barlev, C; Friedman, NS; Shaham, L; Sharon, N, 2020) |
| "In an orthotopic breast cancer xenograft model (HCC1954), the growth of the tumour cells resumes after having achieved a complete response to T-DM1 treatment." | ( Baldari, S; Bernassola, F; D'Amico, S; de Braud, F; Di Giacinto, F; Gambacurta, A; Krasnowska, EK; Lucibello, M; Manni, I; Piaggio, G; Ranalli, M; Toietta, G; Vernieri, C, 2020) |
| "MCF-7 ER-positive breast cancer cell line was used, and the cytotoxic effect of TAM treatment, alone and in combination with HCA was evaluated." | ( Doghish, AS; E M Elsadek, B; Ismail, A; Mariee, AD; Salama, SA, 2020) |
| "Proliferation of MCF-7, a breast cancer cell line, was investigated after treatment with Lactobacillus Brevis supernatant (LBS) solely, and in combination with Tamoxifen." | ( Akbari, N; Mirfazli, SS; Montazeri, H; Nasiri, Z; Tarighi, P, 2021) |
| "TP53 wild-type breast tumors rarely undergo a complete pathological response after chemotherapy treatment." | ( Anderson, AY; Frey, WD; Jackson, JG; Olayiwola, JO; Rao, SG; Shahbandi, A; Ungerleider, NA, 2020) |
| "We recruited women with primary breast cancer following primary treatment with seven or more HFNS/week (including 4/10 or above on the HFNS problem rating scale), from six UK hospitals to an open, randomised, phase 3 effectiveness trial." | ( Day, L; Ellis, M; Fenlon, D; Fields, J; Griffiths, G; Hunter, MS; Maishman, T; May, C; Nuttall, J; Raftery, J; Turner, L, 2020) |
| "Steroidal drugs have been suggested for breast cancer treatment as aromatase enzymes inhibitors ." | ( Jamal, QMS, 2020) |
| "Treatment of hormone sensitive breast cancer tumors with endocrine therapy such as antiestrogens or aromatase inhibitors has improved the outcome significantly." | ( Goloubeva, O; Kazi, A; Sabnis, GJ; Schech, A; Yu, S, 2020) |
| "Estrogen-receptor-negative breast cancer (BCER-) is mainly treated with chemotherapeutics." | ( Gonzalez-Perez, RR; Gottesman, MM; Harbuzariu, A; Huff, LM; Lipsey, CC; Robey, RW, 2020) |
| "Estrogen receptor (ER) positive breast cancer is frequently sensitive to endocrine therapy." | ( Alferez, D; Andò, S; Chiodo, C; Clarke, RB; Conole, D; Eyre, R; Howell, SJ; Kohler, B; Lanzino, M; Lovell, S; Marangoni, E; Moreira, T; Morisset, L; Santiago-Gómez, A; Sarmiento-Castro, A; Simões, BM; Sims, AH; Spence, K; Tate, EW, 2020) |
| "As endocrine therapies for breast cancer progressed through the twentieth century from oophorectomy to antiestrogens, it was recognized in the 1970s that the presence of estrogen receptors (ER) alone could not efficiently predict treatment responses." | ( Horwitz, KB; Sartorius, CA, 2020) |
| "A total of 261 patients with breast cancer underwent complete resection after neoadjuvant chemotherapy." | ( Arihiro, K; Emi, A; Kadoya, T; Kimura, Y; Masumoto, N; Okada, M; Sasada, S, 2020) |
| "A total of 709 patients with breast cancer underwent dbPET before treatment." | ( Emi, A; Kadoya, T; Kimura, Y; Masumoto, N; Okada, M; Sasada, S, 2020) |
| "A total of 64 breast cancer post-operation patients who received pirarubicin chemotherapy were randomly divided into two groups: the experimental group (with dexrazoxane added) and the control group (without dexrazoxane)." | ( Li, H; Liu, K; Lu, C; Wang, Y; Yu, M; Zhang, P, 2020) |
| "Mice bearing 4T1 breast tumors were treated with AZD3965 100 mg/kg i." | ( Guan, X; Morris, ME, 2020) |
| "Functional follow-up of breast cancer genome-wide association studies has led to the discovery of genes that regulate endocrine therapy response in a SNP- and drug-dependent manner." | ( Ingle, JN; Qin, S; Wang, L; Yu, J; Zayas, J, 2020) |
| "Early detection of breast cancer is important in diagnosis and treatment, and so in enhancing patient survival and reducing death rates." | ( Belal, A; Darwish, H; Omran, M; Rashed, R; Zahran, F, 2020) |
| "Her2-dependent breast cancer is treated with pharmacological drugs (eg, Herceptin, lapatinib) that target Her2 signaling." | ( Crawford, DR; Ilic, Z; Saxena, AR; Sripada, V, 2020) |
| "Study participants included nine breast cancer patients who were treated with tamoxifen at Kosin University Hospital and Saegyero Hospital in Busan Metropolitan City, Korea." | ( Choi, JH; Han, JW; Lee, KC; Park, JS, 2020) |
| "Recent developments in breast cancer therapy have significantly improved patient survival rate; however, recurrence remains a major problem." | ( Li, M; Shi, L; Shi, Y; Wang, H; Wang, M; Wang, P; Yu, J; Zhang, Q; Zhang, T; Zhao, H, 2020) |
| "MCF-7 breast cancer cell line was prepared and treated with various concentrations of DOX and NVP-AUY922 in single-drug treatments." | ( Feizollahzadeh, S; Karimi Douna, B; Mahmoudi, R; Mohammadian, M; Rezapour-Firouzi, S; Toofani Milani, A, 2020) |
| "The MCF7 breast cancer stem cells were treated with NPs and the viability and differentiation were evaluated by Western blotting and sphere formation assay." | ( Atyabi, F; Dara, T; Ghahremani, MH; Javaheri Kachousangi, M; Ostad, SN; Sepand, MR; Shamsian, A, 2020) |
| "Female patients with breast cancer frequently develop arthralgia when treated with aromatase inhibitors (AI)." | ( Borrie, AE; Choi, YH; Hahn, K; Kim, RB; Lenehan, J; Lock, M; Logan, D; Perera, FE; Potvin, K; Read, N; Rose, FA; Sexton, T; Teft, WA; Vandenberg, TA; Welch, S; Yaremko, B; Younus, J; Yu, E, 2020) |
| "treatment of breast cancer as one of the most common cancers in the world remains an important area of drug development based on nanoparticulate systems." | ( Mohammadi, Z; Rahmani, S; Samadi, FY, 2020) |
| "Concordantly, we found that breast cancer patients with a low-TRAF4 expression benefited most from chemotherapy, who had higher tumor volume reduction rate and better pathological response, while, the high-TRAF4 expression group had lower tumor volume reduction rate and poor pathological response." | ( Huang, H; Kou, J; Li, H; Li, W; Liu, Y; Meng, Z; Mi, X; Ren, H; Sun, M; Wei, N; Yang, J; Zhang, H; Zhao, P; Zhao, X, 2020) |
| "Compound 1 was cytotoxic for both breast cancer cell lines and the majority of cells died by treatment-induced apoptosis." | ( Čulić, VČ; Marijan, S; Markotić, A; Mastelić, A; Pilkington, LI; Reynisson, J; Režić-Mužinić, N, 2020) |
| "Estrogen receptor (ER) positive breast cancer is often effectively treated with drugs that inhibit ER signaling, i." | ( Borgoni, S; Moerland, PD; Sofyalı, E; Soleimani Dodaran, M; van Kampen, AHC; Verschure, PJ; Wiemann, S, 2020) |
| "The human breast cancer cell line MCF-7 was treated with different levels of crude extracts at different time intervals in order to show their effects on the cell proliferation using a cell viability colorimetric assay (MTT)." | ( Abdelmigid, H; Albogami, S; Alnefaie, A; Alotaibi, S; Nour El-Deen, A; Yahia Darwish, H, 2020) |
| "Treatment of human breast cancer MBA-MD-231 and T47D cells with CB resulted in a dose- and time-dependent inhibition of cell viability and G0/G1-phase cell cycle arrest." | ( Gupta, S; Kumar, S; Kushwaha, PP; Prajapati, KS; Shuaib, M; Singh, AK; Vardhan, PS, 2020) |
| "In total, 118 Swedish premenopausal breast cancer patients diagnosed 2006-2014, with on-going postoperative tamoxifen treatment January 2017, were included." | ( Ackehed, G; Bergh, J; Eliasson, E; Hall, P; Kringen, MK; Lindh, JD; Margolin, S; Molden, E; Thorén, L, 2021) |
| "Although metastatic breast cancer can be fatal, a series of randomized double-blind placebo-controlled phase 3 trials (MONALEESA studies) have shown that ribociclib is an effective anticancer drug for the treatment of advanced breast cancer with bones, liver, lungs, and brain as major metastatic sites." | ( Guarino, S; Massaioli, C; Stocchi, L, 2020) |
| "We recruited 10 patients with advanced breast cancer with ECOG (Eastern Cooperative Oncology Group) performance status score of zero to two, who needed chemotherapy in the first or second-line setting to receive two-weekly docetaxel for 8 cycles." | ( Ismail, F; Kang, IH; Lee, DW, 2020) |
| "More than a third of primary breast cancer patients are treated with cytotoxic chemotherapy, typically without guidance from predictive markers." | ( Al Amri, WS; Baxter, DE; Hanby, AM; Hughes, TA; Stead, LF; Thorne, JL; Verghese, ET, 2020) |
| "While patients suffering an advanced breast cancer are dependent on mono drugs, yet the build out of resistance leading to treatment fails has become inevitable." | ( Adhikary, A; Basu, A; Bhattacharjee, M; Das, S; Ghosh, A; Ghosh, S; Sarker, S; Upadhyay, P, 2020) |
| "Following neoadjuvant chemotherapy for breast cancer, postoperative systemic therapy, also called post-neoadjuvant treatment, has been established in defined risk settings." | ( Baumann, R; Budach, W; Duma, MN; Dunst, J; Feyer, P; Fietkau, R; Haase, W; Harms, W; Hehr, T; Krug, D; Piroth, MD; Sauer, R; Sedlmayer, F; Souchon, R; Strnad, V, 2021) |
| "The targeted elimination of breast cancer stem cells by a telomerase inhibitor in cancer treatment may limit the mobility and stemness of cancer cells interrupting the EMT mechanism, thus may prevent metastasis." | ( Biray Avci, C; Goker Bagca, B; Gunduz, C; Kusoglu, A; Ozates Ay, NP, 2020) |
| "Notch signaling components from breast cancer cells treated in culture with Resveratrol was investigated." | ( Cheng, R; Dong, J; Han, J; Li, L; Yang, W, 2020) |
| "The existing treatment options for breast cancer are largely associated with severe toxicities, and lower efficacies." | ( Ashfaq Khan, M; Badran, A; Baydoun, E; Choudhary, MI; Imad, R; Mohammad, N; Tul-Wahab, A; Zafar, H, 2020) |
| "HER2-positive breast cancer is an aggressive subtype that typically responds poorly to standard chemotherapy." | ( Brabec, V; Kasparkova, J; Kostrhunova, H; Markova, L; Zajac, J, 2020) |
| "Metastatic luminal breast cancer progressed under standard endocrine therapy and chemotherapy." | ( Barba, M; Barchiesi, G; Krasniqi, E; Mazzotta, M; Pizzuti, L; Vici, P; Villa, A, 2020) |
| "More important, breast cancer cells expressing ectopic or endogenous ESR1-CCDC170 are highly sensitive to treatment regimens combining endocrine agents with the HER2 inhibitor lapatinib and/or the SRC inhibitor dasatinib." | ( Hu, Y; Lee, S; Li, L; Lin, L; Schiff, R; Tan, Y; Veeraraghavan, J; Wang, X; Wang, XS, 2020) |
| "ESR1-CCDC170 may endow breast cancer cell survival under endocrine therapy via maintaining/activating HER2/HER3/SRC/AKT signaling which implies a potential therapeutic strategy for managing these fusion positive tumors." | ( Hu, Y; Lee, S; Li, L; Lin, L; Schiff, R; Tan, Y; Veeraraghavan, J; Wang, X; Wang, XS, 2020) |
| "Indepth research on breast cancer (BC) pathogenesis and prevention and treatment methods are gradually receiving attention." | ( Feng, X; Han, H; Sun, T; Xu, J; Zhou, W, 2021) |
| "The survival rates of women with breast cancer have improved significantly over the last four decades due to advances in breast cancer early diagnosis and therapy." | ( Alam, AS; Dyck, JRB; El-Kadi, AOS; Ferdaoussi, M; Maayah, ZH; Mackey, JR; Paterson, DI; Pituskin, E; Sutendra, G; Takahara, S, 2020) |
| "As a model to study the resistance of breast cancer cells to hormone treatment, we previously established clones of long-term estrogen depletion-resistant MCF-7 (LTED) cells." | ( Akaza, M; Fujii, T; Harada, N; Hayashi, T; Hikichi, M; Hisatomi, Y; Nishio, E; Shimono, Y; Utsumi, T, 2020) |
| "In the case of breast cancer treatment, these nanomedicines contain paclitaxel; and, for ovarian cancer, nanoformulations containing paclitaxel or camptothecin analogs are being evaluated." | ( Fraguas-Sánchez, AI; Martín-Sabroso, C; Raposo-González, R; Torres-Suárez, AI, 2021) |
| "In the case of breast cancer, rescue of the breast cancer patient's life is the top priority, but after completion of the effective treatment , the question about the ability to accomplish a pregnancy arises." | ( Dinas, KD, 2020) |
| "In patients with HER2-positive breast cancer relapsing after prior (neo)adjuvant trastuzumab, first-line treatment with trastuzumab or lapatinib was not associated with a significant difference in the clinical outcomes." | ( Bighin, C; Blondeaux, E; Cardinali, B; Del Mastro, L; Ferreira, AR; Fontana, A; Fregatti, P; Lai, A; Lambertini, M; Minuti, G; Montemurro, F; Mura, S; Poggio, F; Poletto, E; Puglisi, F; Sini, V; Sottotetti, F, 2020) |
| "Triple negative breast cancer (TNBC) is a deadly form of breast cancer due to the development of resistance to chemotherapy affecting over 30% of patients." | ( Arrowsmith, CH; Ba-Alawi, W; Cameron, S; Cescon, DW; Chen, W; Cruickshank, J; Deblois, G; Dirks, PB; Dogan-Artun, N; Done, SJ; Duan, S; Fortier, AM; Haibe-Kains, B; Haight, J; Kuasne, H; Kushida, M; Lima-Fernandes, E; Lupien, M; Mahmoud, H; McKee, TD; Nie, Y; Park, M; Prinos, P; Tonekaboni, SAM; Vellanki, RN; Wouters, BG; Wu, Q; Zhang, LX; Zhou, S, 2020) |
| "The use of nanoparticles for breast cancer targeting and treatment has become a reality." | ( Ceña, V; Sorolla, A; Sorolla, MA; Wang, E, 2020) |
| "The specific characteristics of breast cancer have allowed for the development of targeted therapy towards each breast cancer subtype." | ( Heo, KS; Huynh, DTN; Jeon, H; Jin, Y; Nguyen, TLL, 2020) |
| "We showed that MDA-MB-231 and MCF-7 breast cancer cells underwent reversible senescence/polyploidization upon pulse treatment with doxorubicin (dox)." | ( Bojko, A; Czarnecka-Herok, J; Dudkowska, M; Salmina, K; Sikora, E; Śliwińska, MA; Staniak, K; Sunderland, P, 2020) |
| "In spite of advancements in breast cancer therapy, this disease is still one of the significant causes of women fatalities globally." | ( Amini-Farsani, Z; Asgharzade, S; Ghasempour, E; Heidari, R; Jazaeri, A; Mohammadi, M; Rahmati, S; Sheikhshabani, SH, 2020) |
| "Elderly breast cancer patients with early-stage hormone-receptor-positive disease receiving primary surgical intervention plus endocrine therapy may have significantly improved survival than those receiving primary endocrine therapy alone." | ( Gallagher, KK; Iles, K; Jadi, J; Jameison, D; McGuire, KP; Nayyar, A; Strassle, PD, 2020) |
| "Participants of this study were 30 breast cancer patients who had received doxorubicin in their therapy regimen." | ( Ardiningsih, P; Corintias Winarti, A; Harahap, Y; Purwanto, DJ, 2020) |
| "Wider breast cancer (BC) treatment options, short consultation time with physicians, lack of knowledge, and poor coping skills at the time of diagnosis may affect patients' decisions causing treatment delays and non-adherence." | ( Abd Rahman, Z; Abdullah Din, N; Cheng, ML; Filza, J; Harun, F; Ho, GF; Hoong, SM; Islam, T; Jamaris, S; Kaur, R; Mohamed, KN; Musthaffa, S; Taib, NA, 2021) |
| "About 30% of breast cancers metastasize to the brain; those widely disseminated are fatal typically in 3-4 months, even with the best available treatments, including surgery, drugs, and radiotherapy." | ( Hainfeld, JF; Ridwan, SM; Smilowitz, HM; Stanishevskiy, FY, 2020) |
| "Approximately 70% of breast cancers are estrogen receptor (ER)-positive and treated with endocrine therapy." | ( Cho, Y; Jeong, DS; Kim, CY; Kim, KH; Kim, MH; Lee, JY; Nam, KT; Oh, JH, 2020) |
| "The persistence of breast cancer as the leading cause of mortality among women, coupled with drug resistance to tamoxifen, the standard endocrine therapy for the disease, exacts continuous attention." | ( Awolade, P; Cele, N; Ebenezer, O; Gu, L; Gummidi, L; Kaur, M; Kerru, N; Palma, G; Singh, P, 2021) |
| "If a five-fraction regimen of breast cancer is proven to be non-inferior, this will result in a significant improvement in the access to radiotherapy, as well as reduced costs of treatment." | ( Chakraborty, S; Chatterjee, S, 2020) |
| "Despite advances in treatment, breast cancer remains the widest spread disease among females with a high mortality rate." | ( Aborehab, NM; Elnagar, MR; Waly, NE, 2021) |
| "MicroRNAs in the circulation of breast cancer (BC) patients have great potential for the early diagnosis, treatment and monitoring of breast cancer." | ( Bobrovska, M; Brany, D; Dankova, Z; Dvorska, D; Grendar, M; Holubekova, V; Jagelkova, M; Kalman, M; Kolkova, Z; Kudela, E; Laucekova, Z; Liskova, A; Samec, M; Stastny, I; Zelinova, K; Zubor, P, 2020) |
| "The CIPN was assessed after breast cancer diagnosed and before chemotherapy (T1), before cycle 1 to 4 taxane infusion (T2 to T5), and after chemotherapy completion (T6 to T8)." | ( Chan, YN; Jheng, YW; Lin, MW; Liu, LC; Tsai, YF; Tseng, LM; Wang, YJ; Wu, CJ, 2021) |
| "ERα-positive breast cancers are successfully treated with tamoxifen; however, a significant number of patients develop tamoxifen-resistant disease." | ( Barkovskaya, A; Itkonen, HM; Mills, IG; Moestue, SA; Prasmickaite, L; Seip, K, 2020) |
| "We also demonstrated that breast cancer patients treated with paclitaxel chemotherapy exhibited increased CD44-expressing TMPs." | ( Avraham, S; Geiger, T; Harel, M; Loven, D; Mukherjee, A; Orian-Rousseau, V; Prinz, E; Sagredo, LM; Shaked, Y; Shechter, D; Wolfenson, H, 2020) |
| "Treatment of breast cancer cells with DEX inhibited cell adhesion, migration, and invasion in a dose-dependent manner." | ( Huang, YC; Kao, MC; Lin, KT; Pan, YR; Pang, JM; Shen, CY; Sun, SP; Wang, LH; Wang, RH, 2020) |
| "Treatment of the breast cancer cells with TDZ (1-50 μmol/L) caused more stressful environment and induced a significant increase in active caspase-positive cells." | ( Ahmed, EA; Ammar, RB; Ibrahim, HM; Ismail, MB, 2021) |
| "Human primary breast cancer cells were either cultured alone or co-cultured with autologous MOs before treatment with MET." | ( Addou-Klouche, L; Aribi, M; Benaissti, MI; Chahinez Djebri, N; Dahmani, Z; Dahou, S; Fernandez, A; Gizard, F; Lamb, NJ; Lefranc, G; Messaoud, A; Miliani, M; Mostefaoui, M; Nouari, W; Terbeche, H, 2020) |
| "To assess the risks of breast cancer associated with different types and durations of hormone replacement therapy (HRT)." | ( Coupland, C; Hippisley-Cox, J; Vinogradova, Y, 2020) |
| "Tamoxifen is the most common breast cancer treatment option in ER+ patients, which acts as an adjuvant endocrinotherapy with X-ray and surgery." | ( Barreto, GE; González, J; Keikha, M; Sahebkar, A, 2021) |
| "Despite this, the current breast cancer therapy is characterized by significant side effects and high risk of recurrence." | ( Alla, PK; Avram, S; Coricovac, D; Cretu, OM; Dehelean, C; Farcas, CG; Ghiulai, R; Loghin, F; Mioc, M; Moaca, EA; Pavel, I; Pinzaru, IA; Socoliuc, V; Soica, C, 2020) |
| "The incidence of pregnancy-associated breast cancer (PABC) is increasing nowadays, and its diagnosis and treatment remain complicated due to the consideration of the fetus." | ( Liu, Y; Ma, L; Tang, T; Yang, C, 2020) |
| "Altogether 117 breast cancer patients who had axillary lymphadenectomy were randomized into two analgesic study groups and the analgesic treatment lasted 4 weeks." | ( Besic, N; Smrekar, J; Strazisar, B, 2020) |
| "A second option was to treat stage IV breast cancer." | ( Jordan, VC, 2021) |
| "In early-stage HER2-positive breast cancer, escalation or de-escalation of systemic therapy is a controversial topic." | ( Adamo, B; Alarcón, J; Bisagni, G; Brandes, AA; Brasó-Maristany, F; Carey, LA; Cejalvo, JM; Chic, N; Ciruelos, E; Conte, B; Conte, P; Cortés, J; D'Amico, R; Dieci, MV; Frassoldati, A; González-Farré, B; Griguolo, G; Guarneri, V; Llombart-Cussac, A; López, R; Manso, L; Miglietta, F; Muñoz, M; Musolino, A; Oliveira, M; Paré, L; Parker, JS; Pascual, T; Pernas, S; Perou, CM; Piacentini, F; Prat, A; Sanfeliu, E; Saura, C; Schettini, F; Tagliafico, E; Urso, L; Vidal, M; Villagrasa, P, 2020) |
| "We pretreated the BEAS-2B and breast cancer (MDA-MB-231) cells with TDZ and deliberated alteration in a cell viability, mammosphere, migration, NF-кB signalling, PI3K/AKT signalling and matrix metalloproteinase (MMP) expression and analysed the EMT induction by TGF-β/TNF-α-stimulated BEAS-2B cells." | ( Al-Ramadan, SY; Al-Saeedi, FJ; Ben Ammar, R; Elsayed Mohamed, M; Islam, M; Rajendran, P, 2020) |
| "Biochemical analysis of untreated breast cancer group revealed marked changes in liver and kidney functions manifested by raised activity levels of alanine transaminase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN) and creatinine." | ( Alnamlah, RA; Awad, MA; El-Nagar, DM; Hendi, AA; Merghani, NM; Ortashi, KM, 2020) |
| "One-hundred and fourteen patients with breast cancer undergoing neoadjuvant chemotherapy were included in the study." | ( Barry, J; Brady, C; Corrigan, MA; Duddy, L; Livingstone, V; Murphy, LC; Quinn, EM; Razzaq, Z; Redmond, HP, 2020) |
| "Further, in 2 patients with metastatic breast cancer, intracranial response was observed in association with avatrombopag-enabled niraparib therapy." | ( Gabrail, N; Smith, C, 2020) |
| "Notably, in an orthotopic model of breast cancer, administration of sDNPs induced a durable inhibition of primary tumors and reduced the metastatic tumor burden, significantly surpassing the effects of the free DAS inhibitor after oral delivery." | ( Chen, X; Hu, Z; Wan, J; Wang, H; Zhang, F; Zhou, L, 2021) |
| "Human breast cancer cells cultured in normal physiological and high glucose were treated with IGF-I (0-500 ng/mL)." | ( Holly, JMP; Koobotse, MO; Perks, CM; Schmidt, D, 2020) |
| "For the majority of breast cancer patients, treatment plans involve 5-10 yrs of endocrine therapy, but hair loss/thinning is a common side effect." | ( Dell'Acqua, G; Richards, A; Thornton, MJ, 2020) |
| "The majority of deaths resulting from breast cancer are attributable to metastatic growth; in addition, chemoresistance is a major concern in the treatment of patients with breast cancer." | ( Ahn, KS; Kim, M; Kim, S; Lee, C; Oh, SR; Park, J; Ryu, HW, 2020) |
| "Therapeutic regimens of breast cancer treatment are increasingly inclined to adopt combination strategy based on the broad spectrum antitumor effect of doxorubicin (Dox)." | ( Fu, C; Gao, F; Leung, GP; Li, J; Li, R; Mak, WWS; Shi, J; Wu, X; Zhang, J; Zou, L, 2021) |
| "In 3D spheroid models of breast cancer cell lines, YARS overexpression significantly improved chemotherapy response via phosphorylation of the necrosome complex." | ( Choi, J; Han, D; Hwang, EH; Im, SA; Kang, SE; Kim, K; Lee, H; Lee, KH; Lee, KM; Moon, WK; Oh, HJ; Ryu, HS, 2020) |
| "Additionally, various breast cancer cell lines growing in adherent, two-dimensional cell culture express HSATII RNA at different levels, and levels are markedly increased when cells are infected with HCMV or treated with zeocin." | ( Nogalski, MT; Shenk, T, 2020) |
| "A 59-year-old woman with Stage ⅢB left breast cancer had undergone total mastectomy with axillary lymph node dissection after receiving neoadjuvant therapy." | ( Fujimoto, A; Ichinose, Y; Matsuura, K; Nukui, A; Osaki, A; Saeki, T, 2020) |
| "Most of the breast cancers which develop resistance to therapy are ER+ and are typically treated with tamoxifen and fulvestrant." | ( Kar, S; Konar, D; Kumar, K; Maru, S, 2022) |
| "Cell viability in both breast cancer cell lines demonstrated a dose-dependent decrease in response to treatment with free TQ or TQ-loaded cubosomes, with enhanced antitumor activity upon treating with the latter formulation." | ( Alwattar, JK; Chouaib, R; Gali-Muhtasib, H; Mehanna, MM; Sarieddine, R, 2020) |
| "Localized breast cancer treatments involve taxanes which are often responsible for acute peripheral neuropathy." | ( Fischbach, C; Kalish, M; Pabst, L; Petit, T; Pflumio, C; Pivot, X; Velten, M, 2020) |
| "Once HR positive breast cancer patients relapse on ET, targeted therapy agents such as cyclin dependent kinase inhibitors are frequently implemented, though secondary resistance remains a threat." | ( Aja, J; Brantley, E; Campbell, P; Davis, MB; Loaiza-Perez, A; Mavingire, N; Wooten, J, 2021) |
| "The discovery of high-risk breast cancer susceptibility genes, such as Breast cancer associated gene 1 (BRCA1) and Breast cancer associated gene 2 (BRCA2) has led to accurate identification of individuals for risk management and targeted therapy." | ( Biswas, K; Chong, CE; Das, R; Easton, DF; Fadzli, F; Hartman, M; Hassan, T; Li, J; Lim, J; North, SL; Ravichandran, A; Reid, S; Sharan, SK; Southon, E; Stauffer, S; Sullivan, T; Taib, NAM; Teo, SH; Thirthagiri, E; van Dam, RM; Wijaya, E; Yip, CH, 2021) |
| "In many cases, breast cancer has shown resistance to chemotherapy, radiotherapy and hormonal therapy." | ( Alhumaydhi, FA; Ali, I; Bourguet-Kondracki, ML; Hussain, A; Hussain, F; Hussain, H; Hussain, J; Hussain, R; Ibrahim, M; Khalid, M; Khalil, AA; Khan, M; Rauf, A; Rengasamy, KRR, 2022) |
| "MCF-7 breast cancer cells were assigned to four groups: Control (cells in normal condition); myricetin (cells treated with the IC50 dosage of myricetin) in three different incubation times (24, 48, and 72 h)." | ( Homayoun, M; Mohammadi, F; Sajedi, N; Soleimani, M, 2020) |
| "T47D breast cancer cells were assigned into five groups: control (cells in normal condition), myricetin (cells treated with myricetin IC50 concentration) in two different incubation times (24, 48 and 72 hours)." | ( Sajedi, N; Soleimani, M, 2020) |
| "The treatment of breast cancer is often ineffective due to the protection of the tumor microenvironment and the low immunogenicity of tumor cells, leading to a poor therapeutic effect." | ( Dong, Q; Du, C; Du, J; Li, F; Wan, C; Xu, L; Yang, H; Zheng, D, 2020) |
| "Trastuzumab treatment used in breast cancer therapy require a visualization to validate their delivery and response." | ( Aebisher, D; Bartusik-Aebisher, D; Bober, Z; Chrzanowski, G, 2021) |
| "In contrast, ER+/PR+ breast cancer cells, where PAI-1 expression is absent or low, do not adequately respond to treatment." | ( Geromichalos, G; Lavrentiadou, SN; Pantazaki, AA; Papaspyropoulos, A; Tsantarliotou, MP; Tzekaki, EE, 2021) |
| "Treatment of breast cancer underwent extensive progress in recent years with molecularly targeted therapies." | ( Anayiotos, A; Andreou, C; Constantinou, AI; Dietis, N; Gregoriou, G; Gregoriou, Y; Kapnisis, K; Prokopi, M; Strati, K; Yilmaz, V, 2021) |
| "Intravenous (IV) taxanes for metastatic breast cancer (mBC) are associated with toxicities, such as chemotherapy-induced peripheral neuropathy (CIPN), which can detrimentally impact outcomes." | ( Brady, BL; Chebili, CL; Cooper, C; Dokubo, I; Fox, KM; Lucci, M; Varker, H; Wilson, K; Wojtynek, J, 2021) |
| "About 80% of breast cancer (BC) cases express estrogen receptor (ER), which has been correlated with good prognosis and response to estrogen deprivation Aim: To characterize ER positive advanced BC (ABC) patients treated at our institution assessing the impact of clinical pre-sentation (stage IV, de novo disease at diagnosis versus systemic recurrence) and BC subtype on survival rates." | ( Acevedo, F; Briones, J; Camus, M; Domínguez, F; Galindo, H; Medina, L; Merino, T; Navarro, ME; Oddo, D; Peña, J; Razmilic, D; Sánchez, C; Villarroel, A, 2020) |
| "Retrospective cohort study of 118 breast cancer patients undergoing fertility preservation treatment between 2008 and 2018." | ( Almog, B; Azem, F; Cohen, Y; Fouks, Y; Kalma, Y; Shulman, Y, 2021) |
| "Of 242 breast cancer patients enrolled between December 2015 and November 2019, 76 in control group and 73 in goserelin group were able to be assessed at 1 year after chemotherapy." | ( Hu, T; Jia, M; Pei, L; Wang, S, 2021) |
| "One of the most used regimens to treat breast cancer is the dose-dense ACT protocol, a combination of anthracycline doxorubicin (DOX) with cyclophosphamide and paclitaxel (PCTX)." | ( Busatto, FF; Saffi, J; Schaefer, BT; Viero, VP, 2021) |
| "Diagnosis and treatment of breast cancer in pregnancy can result in morbidity and mortality for the mother and fetus." | ( Ahmed, MS; Al-Enazy, S; Albekairi, NA; Ali, S; Nanovskaya, TN; Patrikeeva, S; Rytting, E; Shah, M, 2021) |
| "Hormone-receptor-positive breast cancer (HR + BC) is the most common pathological type of breast cancer, of which the main treatment method is endocrine therapy." | ( Gu, Y; Ji, H; Li, J; Niu, X; Wang, J; Wang, Y; Yang, Y; Yin, L; Zhang, H; Zhang, Q; Zhou, X, 2021) |
| "How to target breast cancer stem cells is the key to improving the efficacy of breast cancer radiotherapy." | ( Guo, T; Hu, C; Li, M; Li, Y; Liao, Z; Lin, J; Wu, Y; Yang, K, 2020) |
| "Pretreatment diagnosis was right breast cancer, cT4bN1M0, Stage ⅢB, Luminal HER." | ( Asano, Y; Hirakawa, K; Ishihara, S; Kashiwagi, S; Kawano, Y; Kouhashi, R; Morisaki, T; Noda, S; Ohira, M; Onoda, N; Takashima, T; Tauchi, Y; Yabumoto, A, 2020) |
| "After diagnosis of right breast cancer with multiple bone metastasis, CMF therapy was performed, and then 40 cycles of docetaxel and bevacizumab therapy were performed." | ( Maruo, K; Nishimori, T; Sakurai, Y; Takemura, S, 2020) |
| "Meta-analyses of large breast cancer microarray cohorts were used to evaluate the association of CHRNA5 expression with estrogen (E2) treatment, estrogen receptor (ER) status and patient prognosis." | ( Acikgöz, AA; Biyik-Sit, R; Cagnan, I; Cingir-Koker, S; Gunes, D; Jahja, E; Keskus, AG; Konu, O; Olmezer, G; Ozdemir, SE; Shehwana, H; Sucularli, C, 2021) |
| "In metastatic breast cancer (MBC) population treated with capecitabine monotherapy, we investigated clinical-pathological features as possible biomarkers for the oncological outcome." | ( Berteloot, P; Beuselinck, B; Clement, P; Floris, G; Han, S; Janssen, H; Laenen, A; Menten, J; Nevelsteen, I; Neven, P; Punie, K; Remmerie, C; Smeets, A; Thijssen, S; Van Gorp, T; Van Nieuwenhuysen, E; Vergote, I; Weltens, C; Wildiers, H, 2021) |
| "Several treatments for patients with breast cancer are associated with long-term or latent adverse events." | ( Bananis, E; Colleoni, M; Cristofanilli, M; Diéras, V; Finn, RS; Gauthier, E; Gelmon, KA; Loi, S; Lu, DR; Mori, A; Rugo, HS; Schnell, P; Theall, KP; Turner, NC, 2021) |
| "Hormonal receptor positive (HR+) breast cancer is the most commonly diagnosed molecular subtype of breast cancer; which showed good response to doxorubicin (DOX)-based chemotherapy." | ( Fouad, MA; Hafez, HF; Huwait, EA; Osman, AM; Sayed-Ahmed, MM, 2021) |
| "We have focused on breast cancer as a model cancer that is well amenable to prevention, early detection and stage appropriate treatment." | ( Basu, P; Mehrotra, R; Ray, K; Srivastava, A; Tripathi, R, 2021) |
| "Estrogen receptor (ER) testing of breast cancer imperfectly predicts response to endocrine therapy (ET)." | ( Dehdashti, F; Katzenellenbogen, JA; Ma, CX; Naughton, MJ; Siegel, BA; Wu, N, 2021) |
| "Sixty-four patients with breast cancer treated with DOXO were included." | ( Alves, MT; de Oliveira, AN; Gomes, KB; Oliveira, HHM; Pestana, RMC; Sabino, AP; Silva, LM; Simões, R; Soares, CE, 2022) |
| "A case of de novo metastatic breast cancer harboring both HER2 amplification and the L755S mutation in an untreated breast primary tumor displayed clinical resistance to standard trastuzumab- or lapatinib-based therapies but good responses to ado-trastuzumab emtansine (T-DM1) and fam-trastuzumab deruxtecan (T-DXd)." | ( Fukasawa, Y; Funasaka, C; Harano, K; Hosono, A; Kondoh, C; Kusuhara, S; Kuwata, T; Matsubara, N; Mimaki, S; Mukohara, T; Naito, Y; Nakao, T; Nakayama, A; Tsuchihara, K, 2021) |
| "We enrolled 119 women with breast cancer who had undergone breast-conserving surgery or mastectomy followed by TMXF treatment for postmenopausal women (TMXF group, n = 63, 52." | ( Jeon, YK; Kang, T; Kim, EH; Kim, IJ; Kim, K; Kim, KE; Kim, SJ; Pak, K, 2021) |
| "Recurrent breast cancer presents significant challenges with aggressive phenotypes and treatment resistance." | ( Alvarez, JV; Chen, PH; Chi, JT; Ding, CC; Lin, CC; Lin, YT; Qu, DC; Tang, X; Yang, WH, 2021) |
| "Goals of endocrine therapy for advanced breast cancer (ABC) include prolonging survival rates, maintaining the quality of life, and delaying the initiation of chemotherapy." | ( Baena-Cañada, JM; Bayo, JL; Blancas, I; Carabantes, F; Conde, V; Cruz, J; Herrero, C; Olier, C; Ruiz-Borrego, M; Zarcos-Pedrinaci, I, 2021) |
| "That could enhance the effect of breast cancer treatment." | ( Chiang, MH; Huang, SW; Lee, WS; Lee, YT; Lin, FH; Su, YS; Sun, JS; Sun, MT; Tzeng, SC; Wang, YC; Wu, TY; Yang, YS, 2022) |
| "Appropriate combined therapy in breast cancer is recommended to improve outcomes." | ( Chiang, MH; Huang, SW; Lee, WS; Lee, YT; Lin, FH; Su, YS; Sun, JS; Sun, MT; Tzeng, SC; Wang, YC; Wu, TY; Yang, YS, 2022) |
| "Human breast cancer cells MCF-7 were found to be sensitive to Daidzein treatment, with an IC50 value of 50µM." | ( Chauhan, SS; Kumar, V, 2021) |
| "We analyzed 66 patients with low-risk breast cancer (≥60 years; cT1-2pN0) treated within the Preoperative Accelerated Partial Breast Irradiation (PAPBI) trial." | ( Bartelink, H; Bosma, SCJ; Elkhuizen, PHM; Loo, CE; van de Vijver, MJ; van der Leij, F; Vogel, WV; Vreeswijk, S, 2021) |
| "Treatment landscape for HER2+ breast cancer is rapidly changing, and CDK4/6 and PI3K inhibitors represent a new promising strategy to improve patients' outcomes." | ( Agostinetto, E; de Azambuja, E; Debien, V; Lambertini, M; Marta, GN; Piccart-Gebhart, M, 2021) |
| "Locally advanced breast cancer (LABC) is an aggressive disease characterized by late clinical presentation, large tumor size, treatment resistance and low survival rate." | ( Ahmed, S; Diab, AA; El Mahdy, MM; El-Husseiny, N; El-Sherif, AA; El-Shinawi, M; Mohamed, HT; Mohamed, MM; Safwat, G, 2021) |
| "Bone metastases frequently occur in breast cancer patients and lack appropriate treatment options." | ( Baranowsky, A; Clezardin, P; Hinz, N; Horn, M; Jücker, M; Kriegs, M; Lange, T; Schinke, T; Sibbertsen, F; Smit, DJ, 2021) |
| "In a prospective study of breast cancer patients switching to letrozole treatment after previous tamoxifen, plasma estrogen levels were measured at baseline and after 3- and 12-months using LC-MS/MS." | ( Blomqvist, C; Faltinová, M; Haanpää, M; Hämäläinen, E; Lyytinen, H; Mattson, J; Tiitinen, A; Vehmanen, L, 2021) |
| "The new therapeutic solutions for breast cancer treatment are needed, for example, combined therapy consisted of several drugs that characterize different mechanisms of action and modern drug delivery systems." | ( Jelonek, K; Kaps, A; Kasperczyk, J; Musiał-Kulik, M; Wilczok, A; Zajdel, A, 2021) |
| "Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with no effective standard therapy." | ( Anand, V; Andreeff, M; Battula, VL; Cai, S; Cai, Y; El-Dana, F; Ly, S; Nguyen, K; Piwnica-Worms, H; Sahin, AA; Tripathy, D, 2021) |
| "Although many treatments for breast cancer are available, poor tumour targeting limits the effectiveness of most approaches." | ( Chen, D; Ding, Y; He, D; Liu, Y; Shen, Y; Tu, J; Wang, R; Xu, P; Yang, W; Ye, Z, 2021) |
| "A total of 227 female operable breast cancer patients who were diagnosed between January 2009 and December 2017 and completed neoadjuvant PLD-based chemotherapy were retrospectively included." | ( Hung, CC; Tsai, IC, 2021) |
| "More than half of patients with breast cancer benefit from treatment with adjuvant paclitaxel chemotherapy following the early postoperative period." | ( Chen, C; Dong, Z; Li, Y; Wang, W; Xu, H; Yan, L; Yang, Q; Zhang, L, 2021) |
| "Patients with HER2-positive metastatic breast cancer had similar survival with first-line treatment of taxane or vinorelbine combined with trastuzumab and pertuzumab." | ( Goldvaser, H; Gottfried, M; Hendler, D; Kuchuk, I; Neiman, V; Nisenbaum, B; Olitzky, O; Prus, J; Reinhorn, D; Rotem, O; Sarfaty, M; Shochat, T; Sulkes, A; Tsoref, D; Yerushalmi, R; Yust-Katz, S, 2021) |
| "A total of 138 non-metastatic breast cancer patients who were accrued in this study at TMC before imposing of lockdown, and their treatment was impacted because of the COVID-19 outbreak, were interviewed." | ( Gupta, S; Kannan, S; Mohanty, SK; Parmar, V; Rane, P; Sarin, R; Sen, S; Wadasadawala, T; Watekar, R, 2021) |
| "Results in HER2-positive breast cancer cell lines recapitulate the clinical observations, with increased RANK expression observed after short-term treatment with the HER2 inhibitor lapatinib or dual anti-HER2 therapy and in lapatinib-resistant cells." | ( Alsaleem, M; Arribas, J; Benítez, S; Ciscar, M; Galván, P; Gomez-Miragaya, J; Gonzalez-Suarez, E; Green, AR; Jimenez, M; Lemeer, S; Morancho, B; Mulder, C; Palomeras, S; Pascual, T; Pedersen, K; Pernas, S; Petit, A; Prat, A; Puig, T; Rakha, EA; Santamaria, PG; Sanz-Moreno, A; Soler-Monsó, MT; Viñas, G, 2021) |
| "Whether HER2-positive breast cancer patients with tumoral RANK expression might benefit from dual HER2 and RANK inhibition therapy remains to be elucidated." | ( Alsaleem, M; Arribas, J; Benítez, S; Ciscar, M; Galván, P; Gomez-Miragaya, J; Gonzalez-Suarez, E; Green, AR; Jimenez, M; Lemeer, S; Morancho, B; Mulder, C; Palomeras, S; Pascual, T; Pedersen, K; Pernas, S; Petit, A; Prat, A; Puig, T; Rakha, EA; Santamaria, PG; Sanz-Moreno, A; Soler-Monsó, MT; Viñas, G, 2021) |
| "Moreover, treatment of an aggressive breast cancer model with intratumoral PNP-R848 delays tumor growth and inhibits lung metastasis." | ( Bahmani, B; Bui, JD; DeTeresa, E; Fang, RH; Gao, W; Gong, H; Haushalter, KJ; Luk, BT; Previti, M; Zhang, J; Zhang, L; Zhou, J, 2021) |
| "In MCF-7 breast cancer cells, administration of MOR in concentrations of 0." | ( El-Sheikh, AAK; Khired, Z, 2021) |
| "Treatment options for metastatic breast cancer (MBC) refractory to anthracyclines and taxanes are limited." | ( Chalasani, P; Farr, K; Gadi, VK; Jenkins, I; Linden, H; Liu, A; Parker, S; Specht, J; Wu, V, 2021) |
| "Although the prognosis of metastatic breast cancer (BC) has improved, some patients still develop high burden metastases or visceral crisis (VC) and polychemotherapy is commonly used in these cases." | ( Awada, A; de Azambuja, E; Eiger, D; Ferreira, SC; Franzoi, MA; Saúde-Conde, R, 2021) |
| "For certain women at high risk for breast cancer, endocrine therapy (ET) can greatly decrease the risk." | ( Gilman, EA; Hofstatter, EW; Mussallem, DM; Pruthi, S, 2021) |
| "Luminal breast cancer is resistant to chemotherapy and is more likely to not respond to chemotherapy before surgery." | ( Choi, JH; Jeon, CW; Jung, M; Jung, SU, 2021) |
| "Multivariate sub-analyses of breast cancer survivors showed that 57 years of age or older and endocrine therapy before paclitaxel treatment were significantly associated with severe PIPN (grades 2-4)." | ( Fujitani, M; Fukuyama, H; Hatanaka, S; Hiramoto, S; Kanto, A; Kawabata, A; Koizumi, Y; Miyamoto, T; Sekiguchi, F; Tsubota, M, 2021) |
| "In ER+ breast cancer cells, combined treatment with TAM and CSNK1G2 knockdown further enhanced the TAM-mediated decrease in phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR)/ribosomal protein S6 kinase (S6K) signaling but not extracellular signal-regulated kinase (ERK) signaling." | ( Hoe, KL; Lee, SJ; Nguyen Hoang, AT, 2021) |
| "Estrogen receptor alpha (ER)-positive breast cancer is commonly treated with endocrine therapies, including antiestrogens that bind and inhibit ER activity, and aromatase inhibitors that suppress estrogen biosynthesis to inhibit estrogen-dependent ER activity." | ( Brauer, BL; Demidenko, E; Hosford, SR; Jiang, A; Marotti, JD; Miller, TW; Traphagen, NA, 2021) |
| "The majority of breast cancers are estrogen receptor (ERα) positive making endocrine therapy a mainstay for these patients." | ( Alers, V; Balinda, HU; Brenner, AJ; deGraffenried, L; Garcia, M; Gruslova, A; Huang, T; McClellan, B; Sareddy, GR; Vadlamudi, RK; Viswanadhapalli, S, 2021) |
| "Visceral crisis in metastatic breast cancer (MBC) is defined as severe organ dysfunction requiring rapidly efficacious therapy." | ( Fukasawa, Y; Funasaka, C; Harano, K; Hosono, A; Kawasaki, T; Kogawa, T; Komuro, A; Kondoh, C; Kusuhara, S; Mamishin, K; Matsubara, N; Mukohara, T; Naito, Y; Nakao, T; Okunaka, M, 2021) |
| "Blood was co-cultured with breast cancer cell lines (MCF7 and T47D) pre-treated with anastrozole and/or antiplatelet drugs for 24 h." | ( Augustine, TN; Xulu, KR, 2021) |
| "Hormone-specific anticancer drugs for breast cancer treatment can cause serious side effects." | ( Bae, SW; Jang, KJ; Kang, DY; Lee, JM; Sp, N, 2021) |
| "The regression of positive nodes in breast cancer after neoadjuvant chemotherapy (NAC) remains unknown." | ( Cao, Y; Chen, B; Jia, S; Kong, L; Li, J; Liu, Y; Wang, Y; Zhang, Y, 2022) |
| "Metastatic breast cancer remains a serious health concern and numerous investigations recommended medicinal plants as a complementary therapy." | ( Abedini, MR; Arzi, L; Chamani, E; Farahi, A; Farhoudi, R; Hoshyar, R; Javdani, H; Talebloo, N, 2021) |
| "This result provides new insight into breast cancer mechanisms and hormone therapy using Klebsiella found in the microbiome." | ( An, J; Kim, HO; Kim, JB; Kim, YK; Kwon, H; Lee, WH; Lim, W; Moon, BI; Paik, NS; Yang, EY; Yang, J, 2021) |
| "CDK4/6 inhibitor-treated breast cancer cells recruit T cells via metabolic stress-induced chemokines." | ( Pillai, A; Rafie, C, 2021) |
| "Adjuvant breast cancer therapy containing anthracyclines with or without anti-human epidermal growth factor receptor-2 antibodies and radiotherapy is associated with cancer treatment-related cardiac dysfunction." | ( Fagerland, MW; Geisler, J; Gravdehaug, B; Gulati, G; Heck, SL; Hoffmann, P; Mecinaj, A; Omland, T; Ree, AH; Røsjø, H; Schulz-Menger, J; Steine, K, 2021) |
| "Among breast cancer patients without a CV risk treated with doxorubicin-containing chemotherapy, subclinical cardiotoxicity is prevalent and concomitant administration of low-dose candesartan might be effective to prevent an early decrease in LVEF." | ( Chung, WB; Lee, JE; Lee, M; Park, CS; Park, WC; Song, BJ; Youn, HJ, 2021) |
| "Direct costs of advanced breast cancer treatment were based on Canadian-specific values from published sources." | ( Chandiwana, D; Delea, TE; Park, J; Stellato, D; Thabane, ME, 2021) |
| "For 250 patients with triple-negative breast cancer OS was significantly worse in patients who received chemotherapy ≥31 versus <31 days (HR = 2." | ( Angelis, V; Asare, B; Coakley, M; Irfan, T; Johnston, SRD; Kipps, E; Mohammed, K; Okines, AFC; Parton, M; Ring, A; Smith, IE; Turner, NC; Walsh, G, 2021) |
| "Formalin fixed, paraffin-embedded breast cancer tissues from SBG0102 phase 3 trial patients randomly assigned to treatment with GD or docetaxel were used." | ( Asleh, K; Balslev, E; Gao, D; Jensen, MB; Leung, S; Lænkholm, AV; Nielsen, D; Nielsen, LB; Nielsen, TO; Riaz, N; Stovgaard, ES, 2021) |
| "HER2-positive (HER2 +) breast cancer patients that do not respond to targeted treatment have a poor prognosis." | ( Aure, MR; Haugen, MH; Hongisto, V; Kristensen, VN; Leivonen, SK; Mælandsmo, GM; Normann, LS; Sahlberg, KK, 2021) |
| "Thirty breast cancer patients who underwent chemotherapy using the TAC regimen were included in this study." | ( Djabir, YY; Hapidah, H; Prihantono, P, 2021) |
| "mRNA expression was also quantified in breast cancer cell lines treated with estrogen and progesterone in vitro." | ( Bernhardt, SM; Dasari, P; Glynn, DJ; Ingman, WV; Price, TJ; Townsend, AR, 2021) |
| "However, the involvement of IL-32θ in breast cancer cell proliferation is not yet fully understood; therefore, the current study aimed to determine how IL-32θ affects cancer cell growth and evaluated the responses of IL-32θ-expressing cells to other cancer therapy." | ( Hong, JT; Kim, J; Park, HM; Pham, TH; Yoon, DY, 2021) |
| "In HER2-positive breast cancer (HER2+ BC), neoadjuvant chemotherapy (NACT) with dual HER2-targeted therapy achieves high pathologic complete response (pCR) rates." | ( Bian, JJ; Cutitar, M; Dizon, DS; Edmondson, DA; Emmick, CM; Fenton, M; Gass, JS; Graves, TA; Legare, RD; Lopresti, ML; Olszewski, AJ; Pandya, SV; Sakr, BJ; Sikov, WM; Strenger, RS; Stuckey, AR; Witherby, SM, 2021) |
| "Treatment of breast cancer cells with IL-1β+ E2 decreased the sensitivity to 4-OH tamoxifen compared to both E2-treated and untreated cells." | ( Alamolhodaei, NS; Behravan, J; Gharaee, ME; Mosaffa, F; Rashidpoor, H; Valinezhad Sani, F, 2021) |
| "Standard therapy for HER2+ breast cancers includes HER2 inhibition." | ( Austin, E; Kalomeris, T; Larimer, B; Mahmood, U; Nesti, S; Sinevici, N; Wehrenberg-Klee, E, 2021) |
| "In a panel of HER2+ breast cancer cell lines treated with the HER2 inhibitor lapatinib, we evaluate changes in HER3 expression and viability." | ( Austin, E; Kalomeris, T; Larimer, B; Mahmood, U; Nesti, S; Sinevici, N; Wehrenberg-Klee, E, 2021) |
| "Lapatinib treatment of a panel of HER2+ breast cancer cell lines increased HER3 expression in the lapatinib-resistant cell line MDA-MB 453 but not the lapatinib-resistant cell-line HCC-1569." | ( Austin, E; Kalomeris, T; Larimer, B; Mahmood, U; Nesti, S; Sinevici, N; Wehrenberg-Klee, E, 2021) |
| "The management of breast cancer during pregnancy is a challenge for physicians due to mother´s desire to carry the pregnancy to term despite the need for chemotherapy." | ( Andrianandrasana, NO; Rafaramino, F; Rakotomalala, HM; Ramahandrisoa, AVN; Razakanaivo, M, 2021) |
| "The human breast cancer cell lines MDA-MB-231 (triple negative) and MCF-7 (luminal A) were treated with scaling doses of doxorubicin in monolayer cultures, 3D collagen scaffolds, or orthotopically transplanted murine models." | ( Amadori, D; Bongiovanni, A; Cocchi, C; De Lucia, A; De Vita, A; Fabbri, F; Ibrahim, T; La Manna, F; Liverani, C; Martinelli, G; Mercatali, L; Miserocchi, G; Spadazzi, C; Tasciotti, E; Tebaldi, M, 2022) |
| "Despite great success as a targeted breast cancer therapy, trastuzumab use may be complicated by heart failure and loss of left ventricular contractile function." | ( Bishopric, NH; Dabas, N; Dempsey, N; Kropotova, Y; Lippman, M; Rosenthal, A, 2021) |
| "Paclitaxel (PTX) is used to treat breast cancer both as a monotherapy and in combination with other anticancer drugs." | ( Nycz, J; Wilczok, A; Zajdel, A, 2021) |
| "Although the breast cancer mortality has slowed down from 2008 to 2017, breast cancer incidence rate continues to rise and thus, new and/or improved treatments are highly needed." | ( Kuo, YT; Lin, LT; Liu, CH; Pan, YC; Wong, SH, 2021) |
| "Patients with metastatic HER2+ breast cancer progressing on at least 2 lines of HER2-directed therapy were eligible." | ( Accordino, M; Andreopoulou, E; Califano, A; Chi, DC; Cigler, T; Franks, L; Goel, A; Hershman, DL; Kalinsky, K; Kearney, M; Klein, P; Lee, S; Makower, DF; Mundi, P; Silva, J; Sparano, J; Tiersten, A; Trivedi, M, 2021) |
| "Patients with triple-negative breast cancer (TNBC) who do not achieve pathological complete response (pCR) following neoadjuvant chemotherapy have a high risk of recurrence and death." | ( Ademuyiwa, FO; Akintola-Ogunremi, O; Anurag, M; Bagegni, N; Basu, A; Bose, R; Chen, I; Church, SE; Clifton, K; Davis, J; Ellis, MJ; Ferrando-Martinez, S; Fisk, B; Frith, A; Gao, F; Gillanders, W; Griffith, M; Griffith, OL; Hagemann, IS; Hernandez-Aya, LF; Jeffers, G; Lee, BH; Luo, J; Ma, CX; Opyrchal, M; Peterson, LL; Rearden, TP; Richters, M; Rigden, CE; Rimawi, MF; Roshal, A; Skidmore, ZL; Suresh, R; Weilbaecher, K, 2021) |
| "Moreover, metastatic tumors such as breast cancer are much more resistant to treatment, and current treatments have not been very successful in treating them and remain a challenge." | ( Abbasi, A; Hassan, ZM; Pakravan, N, 2021) |
| "The existence of multiple breast cancer subtypes often leads to chemotherapy failure or the development of drug resistance." | ( Jiang, Q; Sun, Q; Xuan, Z; Yang, Y; Yin, D; Zhang, M, 2021) |
| "ER-positive breast cancer patients commonly undergo endocrine therapy with drugs such as tamoxifen." | ( Kim, CY; Kim, MH; Kim, YC; Oh, JH, 2021) |
| "Patients diagnosed with advanced breast cancer were included, and were administered SAOLP or placebo 4 mg qd for two cycles." | ( Cao, B; Ma, X; Ma, Y; Ma, Z; Shang, K; Wang, J; Wu, S, 2021) |
| "Patients with breast cancer remain at risk of relapse after adjuvant therapy." | ( Bartlett, J; Bliss, JM; Borley, A; Coleman, R; Coombes, RC; Denkert, C; Dibble, T; Evans, A; Grieve, R; Hicks, J; Kilburn, L; Kunze, CA; Loibl, S; Lu, XL; Makris, A; Mansi, J; Mehta, K; Mousa, K; Murray, E; Palmieri, C; Rautenberg, B; Rhein, U; Schmidt, M; Tovey, H; von Minckwitz, G, 2021) |
| "Key Words: Breast cancer, FDG PET/CT, Neoadjuvant therapy." | ( Atag, E; Coban, E; Gungor, S; Gurleyik, G; Sari, M; Simsek, ET, 2021) |
| "Residual breast cancer after neo-adjuvant chemotherapy (NACT) predicts disease outcome and is a surrogate for survival in aggressive breast cancer (BC) subtypes." | ( Buisseret, L; Craciun, L; De Caluwé, A; Eiger, D; Ignatiadis, M; Isabelle, V; Larsimont, D; Paesmans, M; Piccart, M; Poortmans, P; Reyal, F; Romano, E; Salgado, R; Sotiriou, C; Stylianos, D; Van Gestel, D; Vandekerckhove, C, 2021) |
| "Patients with breast cancer who received neoadjuvant/adjuvant anthracycline-based chemotherapy in the medical oncology polyclinic between 2017 and 2020 were included in the study." | ( Bozdag Kaplan, N; Kaplan, O, 2021) |
| "Studies have shown that breast cancer is a heterogeneous tumor with varying response to treatments." | ( Aburmaileh, B; Ahram, M; Al-Ameer, HJ; Kebsa, W; Lahouel, M; Mansour Al Shhab, MA; Mustafa, E; Rouibah, H; Zihlif, M, 2021) |
| "Canine inflammatory mammary cancer (IMC) is highly malignant, invasive and a therapeutic challenge, because effective medical treatment is still unavailable." | ( Alonso-Diez, Á; Alonso-Miguel, D; Clares, I; García-San José, P; Peña, L; Pérez-Alenza, MD; Portero, M; Valdivia, G, 2022) |
| "Patients with metastatic breast cancer treated with nab-paclitaxel (Abraxane®) between March 2016 and March 2020 were enrolled." | ( Han, SW; Im, SA; Kim, JH; Kim, JS; Kim, M; Kim, SH; Kim, TY; Lee, DW; Lee, KH; Park, IA; Park, SY; Ryu, HS; Suh, KJ; Woo, GU, 2022) |
| "The current methods of chemotherapy for breast cancer generally have strong adverse reactions and drug resistance." | ( Liu, X; Xiao, C; Yao, X; Zeng, W; Zheng, F; Zhu, Y, 2022) |
| "A total of 222 newly diagnosed breast cancer patients making treatment decisions were sampled conveniently from three breast clinics between August 2015 and February 2016." | ( Aishah Mohd Taib, N; Chinna, K; Ng, CJ; Shunnmugam, B, 2021) |
| "A retrospective analysis of 82 breast cancer patients' data treated with anthracycline-cyclophosphamide-paclitaxel (AC-T) NAC in three oncology institutions in south Croatia from 2013 to 2020 was carried out." | ( Ban, M; Belac Lovasić, I; Boraska Jelavić, T; Curić, Z; Podrug, M; Vrdoljak, E, 2022) |
| "We retrospectively examined 91 breast cancer patients; all were previously treated with chemotherapy and fulvestrant (84% and 59%, respectively)." | ( Abdel-Razeq, H; Abdel-Razeq, N; Abdulelah, H; Bater, R; Inserat, B; Salam, M; Sharaf, B, 2022) |
| "Mice challenged with breast cancer xenografts were then treated with 60 mg/kg HCQ via intraperitoneal dosing, and subsequent PK and PD responses were assessed." | ( Gustafson, DL; Van Eaton, KM, 2021) |
| "HER2-positive breast cancer cell lines, SK-BR-3 as trastuzumab-sensitive cells, and JIMT-1 as Tz-resistant cells were treated with Tz and sodium selenite (selenite)." | ( Cho, T; Kim, JB; Kwon, H; Lim, W; Moon, BI; Woo, J; Yoo, EH, 2021) |
| "Doxorubicin (Dox) is routinely used for breast cancer treatment but toxicity and drug resistance limit its use." | ( Patel, P; Shah, J, 2021) |
| "In postmenopausal patients with breast cancer who received 2-3 years of tamoxifen, extended treatment with 5 years of letrozole resulted in a significant improvement in disease-free survival compared with the standard 2-3 years of letrozole." | ( Amaducci, L; Arpino, G; Ballestrero, A; Barone, C; Bighin, C; Bisagni, G; Bruzzi, P; Campadelli, E; Cognetti, F; De Placido, S; Del Mastro, L; Durando, A; Fabi, A; Frassoldati, A; Garrone, O; Gori, S; Lambertini, M; Mansutti, M; Michelotti, A; Montemurro, F; Moretti, G; Mura, S; Poggio, F; Ponzone, R; Puglisi, F; Sanna, G; Tamberi, S; Urracci, Y, 2021) |
| "Swedish breast cancer patients (n = 699) operated 2006-2014, genotyped for CYP2D6, having at least three months postoperative tamoxifen treatment, a baseline, and at least one follow-up digital mammogram were included in the study." | ( Bergh, J; Czene, K; Eliasson, E; Eriksson, M; Hall, P; Lindh, JD; Margolin, S; Thorén, L, 2021) |
| "Radiotherapy is commonly used to treat breast cancer, reducing the risk of recurrence after surgery." | ( Aversa, I; Bond, HM; Chiarella, E; Fernandes Guerreiro, J; Garcia-Calderón, D; Genard, G; Hanley, R; Marafioti, MG; Mesuraca, M; Nisticò, C; Pagliari, F; Seco, JC; Spadea, MF; Tirinato, L, 2021) |
| "HER2+ breast cancer is highly aggressive and proliferative even after multiple chemotherapy regimens." | ( Gan, N; Li, H; Peng, X; Sun, Q; Suo, Z; Zhang, S; Zhao, G; Zhao, L, 2021) |
| "Oestrogen receptor-positive (ER+) breast cancer is commonly treated using endocrine therapies such as aromatase inhibitors which block synthesis of oestradiol, but the influence of this therapy on the immune composition of breast tumours has not been fully explored." | ( Aiderus, A; Dunbier, AK; Hazlett, J; Kemp, R; Niemi, V; Powell, K; Wise, L, 2021) |
| "Many breast cancer patients harbor high estrogen receptor (ER) expression in tumors that can be treated with endocrine therapy, which includes aromatase inhibitors (AI); unfortunately, resistance often occurs." | ( Chang, YL; Chen, S; Lee, HC; Tseng, LM; Tzeng, YD; Wang, SF; Wang, YZ; Wu, CL, 2021) |
| "Almost half of patients with breast cancer use cannabis, most commonly during active treatment to manage common symptoms and side effects: pain, anxiety, insomnia, and nausea." | ( Aliano-Ruiz, KE; Bollmann-Jenkins, M; Buckley, ME; Chlebowski, RT; Danese, SR; Gilman, PB; Green, NL; Hibbs, JE; Kaklamani, VG; Larson, SL; Le, EH; Leitenberger, A; Martinez, DM; McHugh, TW; Meske, SW; Weiss, MC, 2022) |
| "Quer potentiates the sensitivity of breast cancer to 5-FU so that this combination may be proposed as a treatment for breast cancer." | ( Khedri, A; Mawalizadeh, F; Mohammadzadeh, G; Rashidi, M, 2021) |
| "A group of breast cancer patients treated with chemotherapy, who relapsed within 12 months from treatment initiation, were compared to a sub-cohort of chemo-treated patients who did not recur within 12 months of follow-up." | ( Baccarani, U; Bertozzi, S; Bulfoni, M; Cedolini, C; Cesselli, D; Corradetti, B; Londero, AP; Mariuzzi, L; Marzinotto, S; Orsaria, M; Viola, L, 2021) |
| "Fourteen female breast cancer patients receiving paclitaxel or docetaxel were evaluated using the McGill Pain Questionnaire (MPQ), National Cancer Institute Common Toxicity Criteria (NCI-CTC) grading, clinical total neuropathy score (TNSc), quantitative sensory testing (QST) of pressure pain threshold (PPT), and numeric rating scale (NRS) scores and stocking and glove distribution testing (SGDT), at the start (T0), midst (T1), and end (T2) of their treatment and after 3 months (T3)." | ( Ligtenberg, M; Steegers, M; van den Heuvel, S; van Haren, F; Vissers, K, 2022) |
| "The first-line treatment of metastatic breast cancer in premenopausal women relies on tamoxifen." | ( Albustanji, S; Alhusban, AA; Hamadneh, LA; Shallan, AI, 2022) |
| "Incidence of a secondary primary breast cancer Two studies of 451 women on exemestane, tamoxifen, or unknown endocrine therapy reported risk ratio point estimates of ~0." | ( Atakpa, EC; Brentnall, AR; Cuzick, J; Thorat, MA, 2021) |
| "The majority of breast cancers are hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2‒), and endocrine therapy is an effective therapy for this type of breast cancer." | ( Iwata, H; Kosaka, N; Masuda, N; Toi, M, 2021) |
| "World Health Organization categorized breast cancer as one of the leading cancer types in females worldwide, and its treatment remains challenging." | ( Gandhi, K; Maheshwari, R; Mtewa, AG; Patel, A; Patel, M; Patel, S; Shah, U, 2022) |
| "Precise staging of breast cancer-related lymphedema (BCRL) is important to guide treatment-decision making." | ( Christensen, S; Hermann, AP; Jørgensen, MG; Madsen, AR; Sørensen, JA, 2021) |
| "We identified 541 cases of breast cancer recurrence among women with estrogen receptor (ER)-positive disease who were treated with tamoxifen for at least 1 year (ER+ TAM+)." | ( Ahern, TP; Christensen, KB; Christiansen, PM; Collin, LJ; Cronin-Fenton, DP; Damkier, P; Hamilton-Dutoit, S; Lash, TL; Maliniak, ML; Sørensen, HT; Ulrichsen, SP; Yacoub, R, 2021) |
| "It was found that breast cancer cell lines were more sensitive to X-ray irradiation, whilst cervical and lung cancer cell lines were more sensitive to EGFR and PI3K/mTOR inhibitor therapy." | ( Akudugu, JM; Hamid, MB; Serafin, AM, 2021) |
| "This paper explores the consequences of breast cancer and its treatment on the sexuality and sexual health of women with breast cancer using a qualitative design and a phenomenological methodology." | ( Ab Hadi, I; Che Ya, SN; Hassan, II; Ishak, A; Liamputtong, P; Low, WY; Mohd Zain, N; Muhamad, R; Zakaria, R, 2022) |
| "We report two cases with stage IV breast cancer, aged 66 and 71 years, who developed sclerodermic skin lesions in their extremities after starting treatment with placlitaxel and nabplaclitaxel respectively." | ( Cury-Martins, J; Giesen, L; González, S; Molgo, M; Sanches, JA, 2021) |
| "Migration patterns of various breast cancer cells after staurosporine treatment were investigated using Western blot, cell toxicity assays, single and collective cell migration assays, and video time-lapse." | ( Glassmann, A; Kraus, D; Meyer, FAH; Probstmeier, R; Veit, N; Winter, J, 2021) |
| "Ginsenoside Rg1 (10 µM) treated breast cancer cells were exposed to 8 nM of doxorubicin, and the chemosensitizing potential was measured by cell-based assays." | ( Gao, F; Huang, J; Liu, S; Yin, Z; Zhang, R, 2022) |
| "Inhibition of HER2 in HER2-amplified breast cancer has been remarkably successful clinically, as demonstrated by the efficacy of HER-kinase inhibitors and HER2-antibody treatments." | ( Arribas, J; Chandarlapaty, S; de Stanchina, E; Ferraro, E; Kulick, A; Lahuerta, EJA; Li, Q; Morales, CB; Razavi, P; Reis-Filho, J; Rosen, N; Ross, D; Safonov, A; Smith, AE; Solit, DB, 2021) |
| "Circulating estrogens in breast cancer patients and survivors are often extremely low due to menopause and estrogen-reducing cancer treatments." | ( Grant, CV; Pyter, LM; Russart, KLG, 2022) |
| "Women with hormone receptor positive breast cancer may receive 5 years of treatment with aromatase inhibitors but the magnitude of benefit was relatively small." | ( Goss, PE; Ingle, JN; Li, Y; Parulekar, WR; Qin, G; Tu, D; Zheng, X, 2022) |
| "We have investigated motility in breast cancer cell lines in association with the expression of Transglutaminase type 2 (TG2) as well as upon the administration of Doxorubicin (Dox), an active cytotoxic agent that is employed in chemotherapy." | ( Aguiari, G; Bergamini, CM; Bertagnolo, V; Bianchi, N; Bourgeois, K; Brugnoli, F; Grassilli, S; Keillor, JW; Volinia, S, 2021) |
| "The patients followed up at our breast cancer clinic (BCC) and their demographic, clinical, pathological radiological and treatment details noted." | ( Dhar, A; Hari, S; Kataria, K; Khadka, S; Lohani, KR; Mathur, S; Puri, G; Ranjan, P; Srivastava, A, 2021) |
| "Despite significant advancements in breast cancer therapy, novel drugs with lower side effects are still being demanded." | ( Amin, B; Daneshforouz, A; Gholami, O; Kafami, M; Nazemi, S, 2021) |
| "Postsurgical localized chemotherapy for breast cancer recurrence (BCR) still faces many problems which dampen researchers' enthusiasm and discounted prognosis." | ( Chen, X; Cui, Z; Gu, S; Huang, X; Liu, X; Mei, H; Nie, G; Teng, W; Wang, K; Xu, J; Zhang, Y, 2022) |
| "Clinical data of invasive breast cancer patients who received neoadjuvant or adjuvant chemotherapy with PLD or epirubicin were retrospectively collected." | ( Bao, G; Jiang, H; Wang, H; Wang, X; Zhang, G; Zhang, J, 2021) |
| "Chemotherapy, as the main treatment for breast cancer, inevitably damages normal tissues due to the lack of targeting." | ( Guo, L; Li, R; Nie, R; Peng, Y; Pu, Y; Wu, Y; Zhao, Y, 2022) |
| "The question of whether treatment of breast cancer during pregnancy (PrBC) should be similar to non-pregnant young patients with breast cancer is controversial." | ( Cheng, J; Du, J; Gu, M; Jin, F; Li, Y; Liu, X; Mueck, AO; Ruan, X; Wang, H, 2021) |
| "In addition, DTX, a model drug for breast cancer treatment, was loaded (76." | ( Ji, J; Kong, X; Liu, D; Qiu, N; Xi, Y; Yang, X; Ye, L; Zhai, G; Zhang, J; Zhang, Y, 2021) |
| "The human breast cancer cell lines, T47D and MDA-MB-231, and non-tumorigenic cell line MCF 10A were treated and compared to astaxanthin, melatonin, and co-administration of these two compounds." | ( Abdolmaleki, A; Asadi, A; Bahadori, MH; Ghorbani-Anarkooli, M; Hajizadeh Moghadam, A; Karimian, A; Mir Mohammadrezaei, F, 2022) |
| "Specifically, in breast cancer, we show the co-existence of hybrid E/M phenotypes, enhanced resistance to anti-estrogen therapy and increased PD-L1 levels." | ( Hari, K; Jolly, MK; Kishore, A; Levine, H; Mandal, S; Nayak, SP; Purkait, P; Sahoo, S, 2021) |
| "The median treatment line for advanced breast cancer was 6 (range, 1-14), the median progression-free survival was 6." | ( Aoyama, Y; Fukada, I; Hara, F; Hosonaga, M; Inagaki, L; Kawai, S; Kobayashi, K; Kobayashi, T; Kurata, M; Maeda, T; Masuda, J; Miyake, S; Ohno, S; Ozaki, Y; Saeki, S; Shibayama, T; Takano, T; Ueno, T; Yoshida, K, 2022) |
| "Most hormone-dependent human breast cancers develop resistance to anti-hormone therapy over time." | ( Besch-Williford, C; Hyder, SM; Liang, Y, 2022) |
| "Two thirds of breast cancer patients have hormone-dependent tumors, which is very likely be treated with hormonal therapy." | ( Acar Çevik, U; Ahmad, I; Celik, I; Işık, A; Kaplancıklı, ZA; Özkay, Y; Patel, H, 2023) |
| "Approximately 30% of breast cancer patients develop endocrine resistance after tamoxifen therapy." | ( Chen, H; Lin, X; Wang, X; Yan, Y; Zeng, Q, 2022) |
| "The transcriptome profiles of human breast cancer cell line MCF-7 treated with tamoxifen at different time scales were collected from LINCS, SRA and GEO databases." | ( Chen, H; Lin, X; Wang, X; Yan, Y; Zeng, Q, 2022) |
| "Eleven patients with HER2 positive breast cancer who had completed neoadjuvant chemotherapy and undergone surgery included in this study." | ( Asahi, S; Hasegawa, S, 2021) |
| "In 1,076 patients with breast cancer who underwent dbPET, 276 findings were incidentally diagnosed before treatment." | ( Emi, A; Kadoya, T; Masumoto, N; Okada, M; Sasada, S, 2022) |
| "Methods MDA-MB-231 breast cancer cells were randomly divided into control group and (50, 100, 200, 400) ng/mL leptin treated groups." | ( Liu, J; Liu, Q; Liu, W; Luo, N; Wei, R; Yang, S; Zhou, X, 2022) |
| "Consecutive patients with stage I-III breast cancer (BC) who were planned for neoadjuvant treatment (NAT)." | ( Aker, F; Atag, E; Coban, E; Gungor, S; Sari, M; Simsek, ET, 2022) |
| "Key Words: PET scan, Breast cancer, Positron emission tomography, Neoadjuvant treatment, Cancer staging, Staging system, TNM." | ( Aker, F; Atag, E; Coban, E; Gungor, S; Sari, M; Simsek, ET, 2022) |
| "A patient, diagnosed with metastatic breast cancer and positive for human epidermal growth factor receptor 2 (HER2) with high Ki67, presented with bilateral severe marginal corneal infiltration upon undergoing first cycle of triple chemotherapy: trastuzumab, pertuzumab, and docetaxel." | ( Al-Husban, A; Asir, N; Hegab, M; Horani, M; Kafa, G; Musa, F, 2023) |
| "HER2-positive primary breast cancer patients treated using NAC containing trastuzumab were enrolled between September 2006 and July 2018 at Osaka Breast Clinic." | ( Aono, T; Enomoto, Y; Fujita, K; Fujita, N; Iguchi, C; Inakami, K; Kasugai, T; Kim, SJ; Miyagawa, Y; Nomura, T; Shiba, E; Tomoike, R; Yanagisawa, T, 2022) |
| "Patients suffering from certain breast cancers, such as triple-negative breast cancer (TNBC), lack effective treatments." | ( Díez, P; García-Fernández, A; Llopis-Lorente, A; Martínez-Máñez, R; Morellá-Aucejo, Á; Orzáez, M; Vivo-Llorca, G, 2022) |
| "The dosage and the phenotype of the breast cancer should be considered as important factors for the rational administration of antidiabetic drugs, especially that of liraglutide in breast cancer patients." | ( Duan, XX; Han, X; Hu, X; Lan, L; Liu, BW; Liu, ZZ; Qin, JF; Wang, Y; Yu, J; Yuan, MC, 2022) |
| "We encourage breast cancer oncologists to re-consider concurrent endocrine chemotherapy as a possible treatment strategy enabling early start of potentially curative endocrine treatment." | ( Jacobs, CF; Soesan, M; Sonke, GS, 2022) |
| "The threat that women may develop breast cancer is the major reason why both physicians and women are afraid to use menopausal hormone therapy (MHT)." | ( Dayu, ARB; Tan, DA, 2022) |
| "Thus, ferroptosis activation in breast cancer with high Fascin level may serve as a potential treatment." | ( Chen, C; Chen, L; Chen, Y; Ju, S; Li, Z; Mao, M; Wang, L; Xie, B; Xu, L; Yang, J; Zhang, X; Zhou, J; Zhou, Y; Zhuo, W, 2022) |
| "Human breast cancer BT474 and MDA-MB-436 cells were treated with different concentrations of PPⅠ, and then the effect of PPⅠ on cell proliferation was detected by MTT assay, trypan blue dye exclusion assay, real-time cell analysis, and clone forming assay, respectively." | ( Liu, Y; Lu, JF; Wen, J; Xiong, YL; Zhang, L; Zhang, T, 2022) |
| "Finally, using breast cancer tissue microarrays, we found that ATP-HIF-1α signaling is associated with cancer progression, poor prognosis, and resistance to chemotherapy." | ( Fang, WG; Geng, YH; Tian, XX; Wang, P; Yang, H; Zhang, HQ, 2022) |
| "Triple-negative breast cancer is highly dependent on glycolysis and is typically treated with a combination of surgery, radiation therapy, and chemotherapy." | ( De la Mora-De la Mora, I; de Vos, P; Enríquez-Flores, S; Fernández-Lainez, C; Flores-López, LA; García-Torres, I; Gracia-Mora, I; Gutiérrez-Castrellón, P; López-Velázquez, G; Martínez-Pérez, Y; Olaya-Vargas, A, 2022) |
| "Most patients with ER+ metastatic breast cancer (MBC) undergo treatment with the estrogen receptor antagonist fulvestrant as standard of care." | ( Aranda, E; Chien, C; Drnevich, J; Imir, OB; Katzenellenbogen, BS; Kulkoyluoglu-Cotul, E; Liu, YJ; Madak Erdogan, Z; Mogol, AN; O'Neill, JD; Park, BH; Park, NH; Raghavendra, AS; Santaliz Casiano, A; Shapiro, DJ; Tripathy, D; Ziegler, Y; Zuo, Q, 2022) |
| "While estrogen receptor (ER) positive breast tumors generally respond well to endocrine therapy (ET), up to 40% of patients will experience relapse, either while on endocrine therapy or after ET is completed." | ( Alarid, ET; Frasor, J; Greene, GL; Huggins, RJ; Kansara, NS; Pal, P; Semina, SE, 2022) |
| "To target breast cancer (BC), epigenetic modulation could be a promising therapy strategy due to its role in the genesis, growth, and metastases of BC." | ( Bakalara, N; Correa-Basurto, J; Estrada-Pérez, AR; Fromager, B; García-Vázquez, JB; Rosales-Hernández, MC, 2022) |
| "Because the 5-year survival rate of breast cancer greatly increases when treated in its initial stage, the importance of early detection has been increasing." | ( Haam, S; Huh, YM; Ki, J; Kim, E; Kim, J; Park, J; Rho, HW; Son, HY, 2022) |
| "Between 1982 and 1990 the Danish Breast Cancer Cooperative Group (DBCG) conducted a randomized trial in high-risk pre- and postmenopausal (<70 years) breast cancer patients comparing mastectomy plus adjuvant systemic therapy alone versus the same treatment plus postoperative irradiation." | ( Alsner, J; Grantzau, TL; Højris, I; Nielsen, HM; Offersen, BV; Overgaard, J; Overgaard, M; Tramm, T, 2022) |
| "This study was conducted in breast cancer patients to evaluate the safety of pegfilgrastim administered subcutaneously via the OBI." | ( Aruga, T; Doihara, H; Hara, Y; Ishida, T; Kaneko, K; Ohtake, T; Saji, S; Taira, T; Takeshita, T; Tsurutani, J; Tsuyuki, S; Uehara, K; Yamaguchi, Y; Yamashita, T; Yanagita, Y, 2022) |
| "Regardless of the breast cancer subtype the efficiency of AEB071 treatment was significantly lower in the presence of N1 fibroblast cells." | ( Albert, V; Brockhoff, G; Gaumann, A; Hummel, M; Jagla, W; Lammert, H; Ortmann, O; Piendl, G; Wege, AK; Yousseff, D, 2022) |
| "Studies in women with breast cancer treated with tamoxifen or non-steroidal aromatase inhibitors point to their adverse effects on NAFLD development, although a more pronounced effect of tamoxifen is reported." | ( Armeni, E; Goulis, DG; Lambrinoudaki, I; Pafili, K; Paschou, SA; Polyzos, SA, 2022) |
| "After treatment of MCF-7 breast cancer cells with IMP, cells were exposed to 4 Gy X-rays or HT (42 °C for 1 hour)." | ( Aliasgharzadeh, A; Amini, P; Aryafar, T; Ashrafizadeh, M; Farhood, B; Musa, AE; Najafi, M; Nodooshan, SJ; Taeb, S; Tavakoli, S; Vakili, Z, 2022) |
| "In this study, triple-negative breast cancer (TNBC) patients were treated preoperatively with docetaxel and cyclophosphamide alternating with epirubicin and cisplatin every 2 weeks." | ( Andrews, AG; Chacko, RT; Georgy, JT; Joel, A; John, AO; Premkumar, PS; Sharma, P; Singh, A, 2022) |
| "Two postmenopausal women with breast cancer developed acute confusion and seizures, less than 24 hours after the first cycle of neoadjuvant chemotherapy with fluorouracil, epirubicin and low-dose cyclophosphamide." | ( AbdelGadir, H; Parikh, S; Pettit, L, 2022) |
| "Monitoring cardiotoxicity in breast cancer treatment in pregnant patients is essential to avoid two complications: for the pregnant woman and the fetus." | ( Castilho, SR; Gomes, MCB; Martins, WA; Valente, PMS, 2022) |
| "Antiestrogen therapy of breast cancer has been a "gold standard" of treatment of estrogen receptor (ER)-positive breast cancer for decades." | ( Abderrahman, B; Curpan, R; Fan, P; Jordan, VC; Maximov, PY, 2022) |
| "Patients with advanced ER+/HER2- breast cancer were treated with lenvatinib plus letrozole in a phase Ib/II trial." | ( Ang, YLE; Chan, GHJ; Chee, CE; Chong, WQ; Choo, JRE; Goh, BC; Jain, S; Lee, M; Lee, SC; Lim, JSJ; Lim, SE; Lim, YW; Ngoi, NYL; Ow, SGW; Soo, RA; Sundar, R; Tai, BC; Tan, DSP; Tan, HL; Wang, L; Wong, ALA; Yadav, K; Yong, WP, 2022) |
| "Adjuvant and neoadjuvant breast cancer treatments can reduce breast cancer mortality but may increase mortality from other causes." | ( Darby, SC; Dodwell, D; Duane, F; Holt, F; Kerr, AJ; Mannu, G; McGale, P; Taylor, CW, 2022) |
| "Most treatment comparisons reduced breast cancer mortality or recurrence by 10-25%, with no increase in non-breast-cancer death." | ( Darby, SC; Dodwell, D; Duane, F; Holt, F; Kerr, AJ; Mannu, G; McGale, P; Taylor, CW, 2022) |
| "Approximately 70% of breast cancer patients express estrogen receptor (ER), and intervention therapy for ER has been the primary treatment strategy to prevent the development and metastasis of breast cancer." | ( Chen, J; Hu, S; Nie, L; Qin, J; Wang, Y; Yin, F, 2022) |
| "BRCA-Mutated Advanced Breast Cancer (BROCADE3) is a phase 3 study, evaluating veliparib in combination with carboplatin/paclitaxel with continuation as monotherapy if carboplatin/paclitaxel is discontinued in patients with germline BRCA1/2 mutation-associated, advanced human epidermal growth factor receptor 2-negative breast cancer." | ( Eckert, D; Joshi, R; Menon, R; Mensing, S; Nuthalapati, S; Ratajczak, CK; Stodtmann, S; Xiong, H, 2022) |
| "In xenograft models of HER2+ breast cancer that also express estrogen receptor (ER; HER2+/ER+), tucatinib showed combined efficacy with inhibitors of CDK4/6 and ER, indicating potential novel therapeutic strategies for difficult-to-treat subtypes of HER2+ breast cancer." | ( Ayala, R; Gong, KW; Huang, HKT; Issakhanian, S; Lu, M; Luo, T; Madrid, AM; McDermott, MSJ; O'Brien, NA; Slamon, DJ; Zhang, J, 2022) |
| "However, about a third of treated breast cancer patients are known to suffer from disease recurrences and progression to metastasis." | ( Bay, BH; Chen, XY; Tan, PH; Yung, LL, 2022) |
| "In clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy (NST), nodal metastases can be initially marked and then removed during surgical axillary staging." | ( de Boniface, J; Dembrower, K; Frisell, J; Gerber, B; Hartmann, S; Kühn, T; Nyman, P; Reimer, T; Wiklander-Bråkenhielm, I; Zouzos, A, 2022) |
| "Metastatic breast cancer (MBC) patients were enrolled between 03/2010 and 09/2016 at the beginning of a new systemic therapy." | ( Burwinkel, B; Golatta, M; Hartkopf, A; Nees, J; Schafferer, S; Scheffler, M; Schneeweiß, A; Tang, Q; Wallwiener, M; Yuan, B, 2022) |
| "However, the role of autophagy in breast cancer cells cotreated with doxorubicin and ixazomib remains unclear." | ( Foo, JB; Loh, JS; Rahim, NA; Tor, YS, 2022) |
| "Treating breast cancer, especially in the invasive state, is one of the challenges in treating cancer." | ( Behroozi, J; Chavoshi, H; Hajezimian, S; Isazadeh, A; Kazemzadeh, H; Maroufi, NF; Mir, A; Nejabati, HR; Nouri, M; Poormolaie, N; Vahedian, V, 2022) |
| "We treated two breast cancer mouse models with Nano-PI in combination with α-PD1, which remodeled the tumor microenvironment in both lymph nodes and tumors." | ( Bugada, L; Gao, W; Hu, H; Li, C; Li, R; Rajanayake, KK; Song, Y; Sun, D; Truchan, NA; Wen, F; Yuan, H; Zhang, L, 2022) |
| "VTE in patients with breast cancer was strongly associated with patient-, tumor-, and non-tumor-related risk factors, such as age, disease stage, central catheter placement, and chemotherapy and tamoxifen use, especially within 2 years of breast cancer diagnosis." | ( Ali, NT; Escalante, CP; Nguyen, VQ; Razouki, ZA, 2022) |
| "MDA-MB-231 and SK-BR-3 human breast cancer cell lines were transfected with a miR-302/367 expressing vector and treated with aspirin." | ( Ardekani, AM; Eghtedari, A; Javeri, A; Rezania, MA; Taha, MF, 2022) |
| "Subtype reassessment in advanced breast cancer allows for optimal treatment." | ( Bardia, A; Brufsky, A; Cortés, J; Hamilton, E; Henry, S; Hurvitz, SA; Kalinsky, K; Leon-Ferre, R; Loirat, D; Mayer, I; O'Shaughnessy, J; Phan, S; Punie, K; Rugo, HS; Sardesai, S; Tolaney, SM; Traina, T; Zhu, Y, 2022) |
| "32 patients with breast cancer T1-4N0-3M0 received six cycles of polychemotherapy according to the AT scheme (paclitaxel, doxorubicin) or ET scheme (paclitaxel, epirubicin)." | ( Holotiuk, IS; Holotiuk, SI; Holotiuk, VV; Kryzhanivska, AY; Maliborska, SV, 2022) |
| "Patients with breast cancer and brain metastases (BM) have a poor prognosis and high clinical need for novel treatments; however, historically, studies have often excluded these patients." | ( Anders, CK; Cortés, J; Currie, SL; Diéras, V; Du, Y; Hannah, AL; Hoch, U; Ibrahim, N; Müller, V; Rugo, HS; Seidman, AD; Tagliaferri, M; Tolaney, SM; Tripathy, D; Twelves, C, 2022) |
| "Despite the widespread use of PTX for breast cancer, and the initiative to repurpose this drug for gliomas, there are no predictive biomarkers to inform which patients will likely benefit from this therapy." | ( Ahmed, AU; Amidei, C; Arrieta, VA; Castro, B; Chang, CL; Chen, L; Cordero, A; Dmello, C; Gould, A; Győrffy, B; Horbinski, C; Hsu, P; Kang, SJ; Kanojia, D; Lesniak, MS; Sonabend, A; Sonabend, AM; Stupp, R; Winter, J; Zhang, DY; Zhang, J, 2022) |
| "Thirty-four patients with stage I-III breast cancer were enrolled before trastuzumab-containing and/or anthracycline-containing chemotherapy." | ( Grenier, JG; Haykowsky, MJ; Ian Paterson, D; Kirkham, AA; Mackey, JR; Pituskin, E; Thompson, RB, 2022) |
| "Further verification in cultured breast cancer cells indicated that phosphoenolpyruvate carboxykinase 2 (PCK2) was significantly inhibited after therapy treatment." | ( Gao, Y; Gong, W; Huna, A; Liu, J; Liu, W; Ma, X; Wang, X; Xu, L, 2022) |
| "Among patients with high-risk operable breast cancer without diabetes, the addition of metformin vs placebo to standard breast cancer treatment did not significantly improve invasive disease-free survival." | ( Abramson, VG; Bliss, JM; Chen, BE; Ennis, M; Gelmon, KA; Goodwin, PJ; Hershman, DL; Hobday, TJ; Lemieux, J; Ligibel, JA; Mackey, JR; Mayer, IA; Mukherjee, SD; Oja, C; Parulekar, WR; Rabaglio-Poretti, M; Rastogi, P; Rea, DW; Shepherd, LE; Stambolic, V; Stos, PM; Thompson, AM; Wesolowski, R; Whelan, TJ, 2022) |
| "Up to 60% of breast cancer patients treated with chemotherapy is confronted with cognitive problems, which can have a significant impact on daily activities and quality of life (QoL)." | ( Bos, MEMM; de Ruiter, MB; Geerlings, MI; Göker, E; Jobsen, JJ; Koevoets, EW; May, AM; Menke-Pluijmers, MBE; Monninkhof, EM; Schagen, SB; Sonke, GS; Stuiver, MM; Tick, LW; van der Palen, J; van der Pol, CC; van der Wall, E; van Holsteijn, NA; Velthuis, MJ; Witlox, L, 2022) |
| "Chemotherapy-exposed breast cancer patients, with both self-reported cognitive problems and lower than expected performance on neuropsychological tests, were randomized to an exercise or control group." | ( Bos, MEMM; de Ruiter, MB; Geerlings, MI; Göker, E; Jobsen, JJ; Koevoets, EW; May, AM; Menke-Pluijmers, MBE; Monninkhof, EM; Schagen, SB; Sonke, GS; Stuiver, MM; Tick, LW; van der Palen, J; van der Pol, CC; van der Wall, E; van Holsteijn, NA; Velthuis, MJ; Witlox, L, 2022) |
| "Patients with incurable breast cancer may be treated with chemotherapy to improve cancer-related symptoms, quality of life and survival." | ( Bright, CJ; Chen, C; Dodwell, D; Dunlop, C; Hanbury, G; Kipps, E; McPhail, S; Peake, M; Pritchard-Jones, K; Smittenaar, R, 2022) |
| "The treatment of metastatic breast cancer (mBC) has evolved significantly in the past several years with the approval of new targeted agents." | ( Armitage, M; Bardia, A; Harnden, K; Mauro, L; Pennisi, A; Soliman, H, 2022) |
| "The endocrine therapy resistance of breast cancer is the difficulty and challenge to be urgently solved in the current treatment." | ( Fang, SQ; Hu, H; Li, LW; Li, XY; Liu, H; Liu, YW; Lu, ZX; Wang, H; Wu, TW; Xiang, Y; Zhan, Y; Zong, QB, 2022) |
| "Although luminal B breast tumors may respond to chemotherapy and endocrine therapy, this subtype is associated with poor prognosis, inadequate response and/or acquired drug resistance." | ( Avila, E; Díaz, L; García-Quiroz, J; Larrea, F; Méndez-Pérez, EA; Morales-Guadarrama, G, 2022) |
| "T-47D breast cancer cells were treated with different concentrations of metformin (MET) and artemisinin (ART) co-loaded in PLGA-PEG NPs and free form." | ( Dadashpour, M; Hassani, N; Jafari-Gharabaghlou, D; Zarghami, N, 2022) |
| "The majority of breast cancer expresses estrogen receptor (ER) and endocrine therapy is a standard treatment of ER-positive breast cancer." | ( Horie, K; Iino, K; Ikeda, K; Inoue, S; Kawabata, H; Mitobe, Y; Sato, W; Suzuki, T; Takeiwa, T, 2022) |
| "For women with a high-risk of breast cancer, their risk can be reduced by two main therapeutic approaches: 1) preventive treatments such as hormonal therapies (i." | ( Alagoz, O; Ergun, MA; Hajjar, A; Rampurwala, M, 2022) |
| "In absence of contraindication, breast cancer patients of reproductive age can undergo fertility preservation with controlled ovarian stimulation for oocyte/embryo cryopreservation before the administration of potentially gonadotoxic treatments." | ( Cedrin-Durnerin, I; Comtet, M; Grynberg, M; Krief, F; Labrosse, J; Lalami, I; Peigne, M; Sifer, C; Vinolas, C, 2022) |
| "Taxanes form the mainstay of breast cancer therapy in the curative setting." | ( Mellerick, A; Nicolae, R; Siderov, J; Uccellini, A; Wong, V; Yeo, B, 2023) |
| "TIPN is common in breast cancer patients undergoing weekly paclitaxel therapy." | ( Mellerick, A; Nicolae, R; Siderov, J; Uccellini, A; Wong, V; Yeo, B, 2023) |
| "In individuals with early-stage breast cancer, preoperative MRI characteristics of breast edema could be a promising predictor for pALN burden, which may aid in treatment planning." | ( Chen, M; Cui, Y; Deng, X; Ding, Y; Han, C; Li, P; Liang, C; Lin, H; Liu, C; Liu, Z; Pan, X; Shi, Z; Wang, H; Xie, Y; Xu, Z; Zhao, K, 2022) |
| "Also, treating mice with established breast tumors (4T1) using NPs loaded with siRNA molecules in combination with DC vaccine pulsed with tumor lysate significantly inhibited tumor growth and increased survival in mice." | ( Afsharimanesh, N; Barshidi, A; Ebrahimi, F; Hassannia, H; Hojjat-Farsangi, M; Jadidi-Niaragh, F; Jafari, R; Jalali, P; Karpisheh, V; Kiaie, SH; Kiani, FK; Mahmoodpoor, A; Mohammadi, M; Nami, S; Navashenaq, JG; Noukabadi, FK; Zolbanin, NM, 2022) |
| "For patients with breast cancer who receive docetaxel chemotherapy, taxane-associated acute pain syndrome (T-APS), considered a form of neural pathology, is a significant clinical problem." | ( Chen, Y; Cheng, M; Gao, HF; Ji, F; Li, J; Shen, B; Wang, K; Yang, C; Yang, M; Zhang, J; Zhang, L; Zhang, T; Zhu, T, 2022) |
| "In the course of chemotherapy for breast cancer, doxorubicin (DOX) is one of the most commonly prescribed agents." | ( Bai, D; Chen, Q; Han, X; Li, K; Shao, L; Zhang, Y, 2022) |
| "MCF-7 and MDA-MB-231 human breast cancer cells were treated with different concentrations of linalool (100, 200, 400, 600, 800, 1000 µM) at 24 h and 48 h." | ( Baygar, T; Cavusoglu, T; Elbe, H; Ozturk, F; Yigitturk, G, 2022) |
| "In this article, we review breast cancer positron emission tomography (PET) imaging biomarkers for providing early response assessment and predicting treatment outcomes." | ( Edmonds, CE; Mankoff, DA; O'Brien, SR; Pantel, AR, 2022) |
| "A 65-year-old breast cancer patient who had multiple bone metastases and had been previously treated with letrozole and ribociclib, started alpelisib and fulvestrant combination upon the development of liver metastases." | ( Basaran, G; Cuhadaroglu, C; Gumusay, O; Isiklar, A; Kocagoz, AS; Sepin, B, 2023) |
| "Thus, successful breast cancer therapy would need to target these BCSCs, as well the tumor bulk cells." | ( Nguyen, M; Osipo, C, 2022) |
| "Multi-drug resistance (MDR) in breast cancer poses a great threat to chemotherapy." | ( Gu, M; Liu, Y; Ma, L; Mu, C; Qian, K; Shi, J; Tan, H; Xiong, Y; Xu, L; Xu, S; Yu, J; Zhang, H; Zhao, Y, 2022) |
| "Locally advanced breast cancer is a heterogeneous disease with respect to response to neoadjuvant chemotherapy (NACT) and survival." | ( Bathen, TF; Cao, MD; Eikesdal, HP; Fleischer, T; Giskeødegård, GF; Knappskog, S; Kristensen, VN; Lønning, PE; Pedersen, CA; Rye, MB; Tessem, MB; Tost, J, 2022) |
| "Our findings indicate that treatment of breast cancer cells with melatonin increased the inhibitory effect of melatonin on cell growth through both apoptosis and autophagy in vitro." | ( Önder, GÖ; Özdamar, S; Sezer, G; Yay, A, 2022) |
| "Up to 80% of breast cancers (BCa) are estrogen receptor positive and current treatments target the estrogen receptor (endocrine therapies) and/or CDK4/6 (CDK4/6 inhibitors)." | ( Becker, TM; de Souza, P; Jeffreys, SA; Khan, S; Neubauer, H; Powter, B; Soon, P, 2022) |
| "Doxorubicin is a common treatment for breast cancer." | ( Ballester, PJ; Ghislat, G; Gonçalves, A; Ogunleye, AZ; Piyawajanusorn, C, 2022) |
| "In patients with T1-3, N0-2, M0 breast cancer, 4 cycles of 260 mg/m2 nab-PTX were administered every 3 weeks after 4 cycles of EC therapy(100 mg/m2 of epirubicin and 600 mg/m2 of cyclophosphamide)as NAC." | ( Fukuma, Y; Jo, A; Kawano, S; Kishino, E; Koike, Y; Kurebayashi, J; Mikami, T; Nomura, T; Ogata, R; Saito, W; Soda, M; Tanaka, K; Yamamoto, Y, 2022) |
| "The current treatment protocols for breast cancer have shifted from single agent therapies to combinatorial approaches that offer synergistic efficacies and reduced side effects." | ( Abdelmoneem, MA; Atallah, MA; Bekhit, AA; Elkhodairy, KA; Elzoghby, AO; Khafaga, AF; Khattab, SN; Noreldin, AE; Sallam, MA; Teleb, M, 2022) |
| "For this purpose, 100 women treated for breast cancer from April 2018 to July 2019 were enrolled as research objects." | ( Cui, W; Ji, X; Liu, X; Shan, S; Wang, L; Zhang, B, 2022) |
| "Women treated for breast cancer (BC) often suffer genitourinary syndrome of menopause." | ( Christiansen, P; Cold, F; Cold, S; Cronin-Fenton, D; Ejlertsen, B; Jensen, MB, 2022) |
| "We evaluated breast cancer patients with (n = 511) or without (n = 600) adjuvant radiotherapy (RT) between 2005 and 2013." | ( Byun, HK; Chang, JS; Cho, I; Chung, SY; Kim, K; Kim, KH; Oh, C; Oh, J; Yoon, HI, 2022) |
| "Most of endocrine therapy-resistant breast cancers continue to depend on ERα signaling for growth and survival." | ( Li, X; Li, Z; Lin, X; Lu, X; Luo, G; Xiang, H, 2022) |
| "Post-menopausal breast cancer (BC) patients who receive adjuvant aromatase inhibitor (AI) therapy may be at increased risk of bone loss, osteoporosis, and bone fracture." | ( Akagi, Y; Matushima, S; Ogata, N; Ogata, S; Sudou, T; Sugihara, R; Takao, Y; Toh, U; Watanabe, H, 2022) |
| "Tamoxifen is a widely used drug for breast cancer therapy; however, concerns and controversies regarding its efficiency arise as it induces various side effects, including endometrial cancer." | ( Dela Cruz, JMD; Dones, SAA; Labrador, AM; Santiago-Bautista, MR; Villanueva, RC, 2022) |
| "Triple-negative breast cancer (TNBC) is persistently refractory to therapy, and methods to improve targeting and evaluation of responses to therapy in this disease are needed." | ( Adrada, BE; Boge, M; Candelaria, RP; Elshafeey, N; Huo, L; Jarrett, AM; Litton, JK; Ma, J; Mohamed, RMM; Rauch, GM; Son, JB; Tripathy, D; Valero, V; White, JB; Wu, C; Yam, C; Yankeelov, TE; Zhou, Z, 2022) |
| "61 patients with breast cancer who started FEC therapy for the first time as preoperative or postoperative chemotherapy were studied." | ( Matsubara, H; Nakamura, T, 2022) |
| "Although many patients with metastatic breast cancer require palliative radiotherapy (RT), there are limited data on the safety of combining a CDK4/6 inhibitor with palliative RT." | ( Kim, KN; LaRiviere, MJ; Matro, J; Salerno, M; Shah, PD, 2023) |
| "Eighty women with breast cancer and indication for DOXO treatment were selected." | ( Alves, MT; de Oliveira, AN; Gomes, KB; Oliveira, HHM; Pestana, RMC; Sabino, AP; Silva, LM; Simões, R; Soares, CE, 2023) |
| "Theophylline-treated breast cancer cells showed increased expression of death receptor, TNFR1, along with elevated levels of active caspase-8, -9 and -3." | ( Dutta, S; Ghosal, N; Pal, A; Pal, R; Tapadar, P, 2022) |
| "Subclonal evolution during primary breast cancer treatment is largely unexplored." | ( Aas, T; Aase, HS; Deng, W; Eikesdal, HP; Engebrethsen, C; Geisler, J; Geisler, S; Hovig, E; Iversen, GT; Knappskog, S; Lønning, PE; Meza-Zepeda, LA; Myklebost, O; Nakken, S; Seyedzadeh, M; Steinskog, ES; Venizelos, A; Vodak, D, 2022) |
| "Most breast cancer patients receive chemotherapy; consequently, patients frequently experience adverse effects of chemotherapy-induced peripheral neuropathy." | ( Chen, CY; Pai, HC; Yang, TT, 2023) |
| "Among patients with breast cancer who were recommended to extend adjuvant hormone therapy by the national guidelines, the proportion of women who extended therapy increased 5 folds during the past 10 years, reaching 80." | ( Bergqvist, J; Czene, K; He, W; Sjölander, A; Zeng, E, 2022) |
| "The proportion of patients with breast cancer extending adjuvant hormone therapy beyond 5 years has increased dramatically in recent years, which is associated with improved patient outcomes." | ( Bergqvist, J; Czene, K; He, W; Sjölander, A; Zeng, E, 2022) |
| "HR+/HER2(-) breast cancer patients in urban mainland China were prescribed chemotherapy regimens more frequently than CDK4/6 inhibitors." | ( Clark, O; Davis, C; Durbin, L; Hawthorne, S; Kanas, G; Li, S; Murali, B; Vijaykumar, S; Yang, L; Zhao, L, 2022) |
| "Results showed that Breast cancer cells treated with SFN showed reduced cell proliferation, decreased cell activity, increased apoptosis ratio, and inhibited gene expression and protein phosphorylation of MMP-9 as well as gene expression of NF-κB (P < 0." | ( Tong, C; Zhou, M; Zhou, T; Zhuo, M, 2022) |
| "As patients with breast cancer have been reported to have higher serum TNF levels, we aimed at developing a novel treatment for breast cancer by evaluating the effect of Trigonella foenum-graecum extract (TFG)-reduced AgNPs on the MCF-7 cell line, which serves as a model of human breast cancer." | ( Abdellatif, AAH; Al Rugaie, O; Alqasoumi, A; Alsharidah, M; Bouazzaoui, A; Faris, TM; Mousa, AM; Osman, SK, 2022) |
| "The majority of breast cancer patients is treated with breast-conserving surgery (BCS) combined with adjuvant radiation therapy." | ( Basilion, JP; Bijlstra, OD; Burggraaf, J; Fallert, LC; Hilling, DE; Kuppen, PJK; Linders, DGJ; March, TL; Pool, M; Straight, B; Vahrmeijer, AL; Valentijn, ARPM; Walker, E, 2023) |
| "Lung metastatic breast cancer (LMBC) leads to a large number of deaths in women with breast cancer, and radiotherapy has been considered the common assay for tumour therapy except for surgery." | ( Jiao, J; Liu, Y; Miao, S; Wang, L; Wang, Q; Xi, Y; Xue, S; Zhang, Q; Zhang, Y, 2022) |
| "The standard breast cancer therapy still faces major challenges due to non-specific tumor distribution and occurrence of dose-limiting adverse side-effects." | ( Granja, A; Nunes, C; Reis, S; Sousa, CT, 2022) |
| "Female sex, breast cancer diagnosis, capecitabine monotherapy, and severe HFS were found to be associated with dose reductions (p-values < 0." | ( Barton, DL; Chittiprolu, A; Cho, Y; Gong, Y; Harden, K; Harris, MR; Jiang, Y; Mason, M; Zhang, X, 2022) |
| "Patients with breast cancer clinical tumor categories 1 through 4 (cT1-4; tumor diameter <2 cm and up to >5 cm or extension to the chest wall or skin) and pathologically proven positive axillary lymph nodes (ie, clinical node categories cN1, metastases to movable ipsilateral level I and/or level II axillary nodes; cN2, metastases to fixed or matted ipsilateral level I and/or level II axillary nodes; cN3b, metastases to ipsilateral level I and/or level II axillary nodes with metastases to internal mammary nodes) who were treated with NAC were eligible for inclusion." | ( Boskamp, M; Contant, CME; de Boer, M; Heijmans, HJ; Jager, A; Kam, BLR; Kelder, W; Koppert, LB; Lobbes, MBI; Luiten, EJT; Menke-Pluijmers, MBE; Sars, PRA; Simons, JM; Smidt, ML; Smit, LHM; van der Pol, CC; van Diest, PJ; van Haaren, ERM; van Klaveren, D; van Nijnatten, TJA; Verhoef, C; Vles, WJ, 2022) |
| "Advanced breast cancer patients who were treated with 1st-line palbociclib plus endocrine therapy were enrolled." | ( Im, SA; Kim, JH; Kim, M; Kim, SH; Kim, TY; Lee, DW; Lee, KH; Park, IA; Park, SY; Ryu, HS; Suh, KJ, 2022) |
| "On murine 4T1 breast cancer models, we isolated immune cells from peripheral blood after treatment with propofol and sevoflurane during tumor resection." | ( Ma, X; Song, T; Tian, J; Wang, W; Yan, R, 2023) |
| "Eligible patients had primary breast cancer without nodal involvement (cN0), or had clinically positive lymph nodes (cN1) that were downstaged to cN0 after neoadjuvant chemotherapy." | ( Chen, Y; Cheng, M; Gao, H; Ji, F; Li, J; Lin, Y; Shen, B; Wang, K; Yang, C; Yang, M; Zhang, J; Zhang, L; Zhu, T, 2022) |
| "Patients with HER2+ breast cancer with activating PIK3CA mutations had lower pCR rates and shorter PFS with palliative HER2-targeted therapy than those with wild-type PIK3CA." | ( Cho, KR; Jung, SP; Kim, CY; Kim, JW; Lee, JH; Lee, NK; Lim, AR; Park, KH; Song, SE; You, JY, 2023) |
| "In biopsy-proven node-positive breast cancer treated with NAC, using a flowchart to optimize patient selection reduces the FNR of single-tracer (methylene-blue-dye) guided SLNB." | ( Chen, L; Chen, M; Fu, F; Guo, J; Guo, W; Huang, M; Huang, X; Jacobs, L; Li, S; Lin, Y; Wang, C, 2022) |
| "The cytotoxic study against the breast cancer cell line demonstrated that ExoSpHL-DOX treatment significantly reduced the cancer cell viability." | ( Barbosa, TC; Calado, HDR; Carvalho, AT; Ferreira, LL; Gomes, ER; Oliveira, MC; Sabino, AP, 2022) |
| "However, these breast cancer patients still suffer from tumor relapse and severe side effects because various therapeutic agents have inherent different biodistributions, resulting in insufficient treatment effects and unfavorable normal organ uptake of these therapeutic agents." | ( Chen, M; Ge, X; Liu, J; Ma, Q; Tang, Y; Wen, Q; Zhang, L; Zhao, M; Zhu, L, 2022) |
| "HER2-positive breast cancers have high mortality rate hence detection at an early stage is vital for successful treatment, improved cancer care and survival rate." | ( Das, T; Mukherjee, A; Sarma, HD; Satpati, D; Sharma, AK; Sharma, R; Vats, K, 2022) |
| "Prescribing exercise in early-stage breast cancer during chemotherapy: a simple periodized approach to align with the cyclic phases of chemotherapy." | ( Beaudry, RI; Bigaran, A; Foulkes, S; Fraser, SF; Haykowsky, MJ; Howden, EJ; Janssens, K; La Gerche, A; Selig, SE, 2022) |
| "Even though breast cancer is the most diagnosed cancer among women, treatments are not always successful in preventing its progression." | ( Danen, EHJ; Dekker, Y; Le Dévédec, SE; Liu, Q, 2022) |
| "Based on a large breast cancer cohort at West China Hospital, we aimed to compare the risk of dyslipidemia between premenopausal and postmenopausal women based on the endocrine therapy used." | ( Hu, Y; Jiang, J; Luo, T; Qiu, J; Wang, J; Yin, J; Zheng, H; Zhong, X; Zhu, K, 2022) |
| "A total of 1,883 early-stage breast cancer (EBC) patients who received endocrine monotherapy [selective estrogen receptor modulator (SERM) and aromatase inhibitor (AI), with or without ovarian function suppression] with normal blood lipid levels at baseline were retrospectively included between October 2008 and April 2017." | ( Hu, Y; Jiang, J; Luo, T; Qiu, J; Wang, J; Yin, J; Zheng, H; Zhong, X; Zhu, K, 2022) |
| "At the end of the treatment, many young breast cancer (BC) survivors face difficulties related to fertility and sexuality, mainly due to the side effects of treatment." | ( Assogba, ELF; Coutant, C; Dabakuyo-Yonli, TS; Desmoulins, I; Dumas, A; Ladoire, S; Mollévi, C; Woronoff, AS, 2022) |
| "Women with hereditary breast cancer factors are more likely to be infertile and tend to receive fertility treatments." | ( Liu, X; Pervaiz, R; Wang, L; Yue, J; Zhang, H, 2022) |
| "Mortality from breast cancer is almost exclusively a result of tumor metastasis and resistance to therapy and therefore understanding the underlying mechanisms is an urgent challenge." | ( Avivi, C; Barshack, I; Ben-Yosef, S; Doron, H; Erez, N; Ershaid, N; Monteran, L; Scharff, Y; Sonnenblick, A; Zait, Y, 2022) |
| "Established risk factors for breast cancer include genetic disposition, reproductive factors, hormone therapy, and lifestyle-related factors such as alcohol consumption, physical inactivity, smoking, and obesity." | ( Andersen, ZJ; Bellander, T; Boutron-Ruault, MC; Brandt, J; Brunekreef, B; Brynedal, B; Chen, J; de Hoogh, K; Fecht, D; Forastiere, F; Gulliver, J; Hertel, O; Hoek, G; Hoffmann, BH; Hvidtfeldt, UA; Katsouyanni, K; Ketzel, M; Leander, K; Ljungman, PLS; Magnusson, PKE; Nagel, G; Pershagen, G; Raaschou-Nielsen, O; Rizzuto, D; Rodopoulou, S; Samoli, E; So, R; Stafoggia, M; Strak, M; Tjønneland, A; Vermeulen, R; Verschuren, WMM; Weinmayr, G; Wolf, K; Zhang, J; Zitt, E, 2023) |
| "After human breast cancer cells (MCF-7) treated with CeONPs alone or together with PAC for 24, 48, and 72 h, the effects of CeONPs on cell viability, apoptosis, migration, and adhesion were investigated." | ( Atlı Şekeroğlu, Z; Aydın, B; Kontaş Yedier, S; Şekeroğlu, V, 2023) |
| "The molecular classification of breast cancer (BC) dictates pharmacological treatment." | ( Acconcia, F, 2022) |
| "Due to the heterogeneity of breast cancer, current available treatment options are moderately effective at best." | ( Agarwal, S; Baig, NF; Chilamakuri, R; Gupta, V; Kulkarni, NS; Parvathaneni, V, 2022) |
| "In this paper, breast cancer patients were monitored throughout their chemotherapy treatments (CHT), with blood serum sample Raman spectroscopy and multivariate analysis, approximately for a year." | ( Aguilar-Lemarroy, A; González-Solís, JL; Jave-Suárez, LF; Martínez-Zérega, BE; Oseguera-Galindo, DO; Torre-Gutiérrez, LG; Torres-González, LA, 2022) |
| "Most breast cancer is estrogen receptor (ER) positive but responds less to neoadjuvant or adjuvant chemotherapy than ER-negative breast cancer." | ( Fan, Z; Jin, C; Jin, Y; Li, L; Li, S; Liu, C; Miao, QR; Zhang, X; Zhao, B, 2023) |
| "Conclusions In breast cancer survivors in Korea, endocrine therapy is associated with a higher risk of cardiovascular diseases and type 2 diabetes." | ( Choi, J; Choi, JY; Han, W; Kang, D; Kim, JE; Park, J, 2022) |
| "HER2-enriched breast cancer with high levels of hormone receptor expression, known as "triple positive" breast cancer, may represent a new entity with a relatively favourable prognosis against which the combination of chemotherapy, HER-2 inhibition, and endocrine treatment may be considered overtreatment." | ( Al-Hroub, HM; Almehdi, A; El-Awady, R; Giddey, AD; Menon, V; Mousa, M; Okendo, J; Semreen, MH; Sharaf, BM; Soares, NC, 2022) |
| "In a model of local bone metastasis of breast cancer, haematogenous administration of AO reduced tumour size and more so when combined with ZOL." | ( Abe, K; Harata, S; Hongo, M; Igarashi, S; Kasama, F; Kasukawa, Y; Kudo, D; Miyakoshi, N; Nagasawa, H; Nozaka, K; Saito, H; Shoji, R; Tsuchie, H, 2022) |
| "Oligometastatic patients from breast cancer were treated with SBRT for up to five lung and/or liver lesions." | ( Comito, T; Di Cristina, L; Di Gallo, A; Dominici, L; Franceschini, D; Franzese, C; Lo Faro, L; Marini, B; Marzo, MA; Scorsetti, M; Spoto, R; Stefanini, S; Vernier, V, 2022) |
| "Metastatic breast cancer (MBC) is an incurable disease and its treatment focuses on prolonging patients' (pts) overall survival (OS) and improving their quality of life." | ( Bertolini, AS; Bramati, A; Cassano, A; Cavanna, L; Ciccarese, M; Collovà, E; Cretella, E; Damia, G; Fabi, A; Farina, G; Ferraris, E; Garrone, O; Generali, DG; Guffanti, F; La Verde, N; Legramandi, L; Meattini, I; Moretti, A; Nunzi, M; Poletto, E; Romagnoli, E; Rulli, E; Santini, D; Scandurra, G; Torri, V; Vici, P, 2022) |
| "20-25% of breast cancer patients with ErbB2-overexpressing develop resistance to treatment." | ( Chen, J; Huang, B; Luo, Y; Lv, S; Song, J; Zhang, Y; Zhao, Y, 2022) |
| "Endocrine therapy resistance in breast cancer is an enduring clinical problem mediated in part by aberrant receptor tyrosine kinase (RTK) signaling." | ( Calhoun, SJ; Duan, L; Gattuso, P; Macias, V; Maki, CG; Mir, F; Perez, RE, 2022) |
| "The serious problems of conventional breast cancer therapy strategies such as drug resistance, severe side effects, and lack of selectivity prompted the development of various cold atmospheric plasma (CAP) devices." | ( Ansari, MJ; Chupradit, S; Ghazi Esfahani, B; Kuznetsova, M; Radhi Majeed, B; Suksatan, W; Turki Jalil, A; Widjaja, G, 2023) |
| "Forty-three breast cancer patients who received surgical treatment at Yijishan Hospital of Wannan Medical College were selected." | ( Chen, B; Dong, B; Fang, R; Jiao, W; Wang, Y; Wang, Z; Yin, Z; Zhao, K; Zhao, W; Zhou, Y, 2022) |
| "Most women with HER2-positive breast cancer receive neoadjuvant chemotherapy plus HER2-targeted therapies." | ( Lo, HW; Manore, SG; Najjar, MK; Regua, AT, 2022) |
| "Tamoxifen is an antiestrogen for breast cancer therapy known for adverse drug reactions (ADRs)." | ( Keller, DN; Kim, RB; Medwid, SJ; Ross, CD; Wigle, TJ, 2023) |
| "Download TCGA breast cancer mRNA-seq data and analyze the relationship between LSP1 expression and breast cancer chemotherapy sensitivity." | ( Chen, J; Li, X; Li, Y; Liu, R; Liu, Z; Long, X; Xiao, Q; Xiong, H, 2022) |
| "Download TCGA breast cancer mRNA-seq data and analyze the relationship between LSP1 expression and breast cancer chemotherapy sensitivity." | ( Chen, J; Li, X; Li, Y; Liu, R; Liu, Z; Long, X; Xiao, Q; Xiong, H, 2022) |
| "Download TCGA breast cancer mRNA-seq data and analyze the relationship between LSP1 expression and breast cancer chemotherapy sensitivity." | ( Chen, J; Li, X; Li, Y; Liu, R; Liu, Z; Long, X; Xiao, Q; Xiong, H, 2022) |
| "Inflammatory breast cancer (IBC) is a difficult-to-treat disease with poor clinical outcomes due to high risk of metastasis and resistance to treatment." | ( Alečković, M; Almendro, V; Clement, K; Egri, SB; Fassl, A; Frank, DA; Geck, RC; Harper, NW; Jaffe, JD; Jovanović, B; Kingston, NL; Li, Z; Long, HW; Meissner, A; Michor, F; Overmoyer, BA; Papanastasiou, M; Park, SY; Peluffo, G; Polyak, K; Pyke, AL; Qiu, X; Salas, J; Seehawer, M; Shu, S; Sicinski, P; Stevens, LE; Temko, D; Toker, A; Trinh, A; Walker, S; Wilde, CM; Zhou, N, 2023) |
| "Chemotherapy resistance in inflammatory breast cancer is driven by the JAK2/STAT3 pathway, in part via cAMP/PKA signaling and a cell state switch, which can be overcome using paclitaxel combined with JAK2 inhibitors." | ( Alečković, M; Almendro, V; Clement, K; Egri, SB; Fassl, A; Frank, DA; Geck, RC; Harper, NW; Jaffe, JD; Jovanović, B; Kingston, NL; Li, Z; Long, HW; Meissner, A; Michor, F; Overmoyer, BA; Papanastasiou, M; Park, SY; Peluffo, G; Polyak, K; Pyke, AL; Qiu, X; Salas, J; Seehawer, M; Shu, S; Sicinski, P; Stevens, LE; Temko, D; Toker, A; Trinh, A; Walker, S; Wilde, CM; Zhou, N, 2023) |
| "Inflammatory breast cancer (IBC) is a difficult-to-treat disease with poor clinical outcomes due to high risk of metastasis and resistance to treatment." | ( Alečković, M; Almendro, V; Clement, K; Egri, SB; Fassl, A; Frank, DA; Geck, RC; Harper, NW; Jaffe, JD; Jovanović, B; Kingston, NL; Li, Z; Long, HW; Meissner, A; Michor, F; Overmoyer, BA; Papanastasiou, M; Park, SY; Peluffo, G; Polyak, K; Pyke, AL; Qiu, X; Salas, J; Seehawer, M; Shu, S; Sicinski, P; Stevens, LE; Temko, D; Toker, A; Trinh, A; Walker, S; Wilde, CM; Zhou, N, 2023) |
| "Chemotherapy resistance in inflammatory breast cancer is driven by the JAK2/STAT3 pathway, in part via cAMP/PKA signaling and a cell state switch, which can be overcome using paclitaxel combined with JAK2 inhibitors." | ( Alečković, M; Almendro, V; Clement, K; Egri, SB; Fassl, A; Frank, DA; Geck, RC; Harper, NW; Jaffe, JD; Jovanović, B; Kingston, NL; Li, Z; Long, HW; Meissner, A; Michor, F; Overmoyer, BA; Papanastasiou, M; Park, SY; Peluffo, G; Polyak, K; Pyke, AL; Qiu, X; Salas, J; Seehawer, M; Shu, S; Sicinski, P; Stevens, LE; Temko, D; Toker, A; Trinh, A; Walker, S; Wilde, CM; Zhou, N, 2023) |
| "Inflammatory breast cancer (IBC) is a difficult-to-treat disease with poor clinical outcomes due to high risk of metastasis and resistance to treatment." | ( Alečković, M; Almendro, V; Clement, K; Egri, SB; Fassl, A; Frank, DA; Geck, RC; Harper, NW; Jaffe, JD; Jovanović, B; Kingston, NL; Li, Z; Long, HW; Meissner, A; Michor, F; Overmoyer, BA; Papanastasiou, M; Park, SY; Peluffo, G; Polyak, K; Pyke, AL; Qiu, X; Salas, J; Seehawer, M; Shu, S; Sicinski, P; Stevens, LE; Temko, D; Toker, A; Trinh, A; Walker, S; Wilde, CM; Zhou, N, 2023) |
| "Chemotherapy resistance in inflammatory breast cancer is driven by the JAK2/STAT3 pathway, in part via cAMP/PKA signaling and a cell state switch, which can be overcome using paclitaxel combined with JAK2 inhibitors." | ( Alečković, M; Almendro, V; Clement, K; Egri, SB; Fassl, A; Frank, DA; Geck, RC; Harper, NW; Jaffe, JD; Jovanović, B; Kingston, NL; Li, Z; Long, HW; Meissner, A; Michor, F; Overmoyer, BA; Papanastasiou, M; Park, SY; Peluffo, G; Polyak, K; Pyke, AL; Qiu, X; Salas, J; Seehawer, M; Shu, S; Sicinski, P; Stevens, LE; Temko, D; Toker, A; Trinh, A; Walker, S; Wilde, CM; Zhou, N, 2023) |
| "Patients with advanced or metastatic breast cancer underwent a combined treatment of PTX and bevacizumab with(n=20; patients wore 2 SGs for 120 min)or without(n=15) compression therapy." | ( Hamada-Nishimoto, M; Kang, Y; Katayama, T; Tsuyuki, S, 2022) |
| "Patients with advanced or metastatic breast cancer underwent a combined treatment of PTX and bevacizumab with(n=20; patients wore 2 SGs for 120 min)or without(n=15) compression therapy." | ( Hamada-Nishimoto, M; Kang, Y; Katayama, T; Tsuyuki, S, 2022) |
| "Patients with advanced or metastatic breast cancer underwent a combined treatment of PTX and bevacizumab with(n=20; patients wore 2 SGs for 120 min)or without(n=15) compression therapy." | ( Hamada-Nishimoto, M; Kang, Y; Katayama, T; Tsuyuki, S, 2022) |
| "An early on time detection of breast cancer significantly affects the treatment process and outcome." | ( Aydın, EB; Aydın, M; Sezgintürk, MK, 2023) |
| "An early on time detection of breast cancer significantly affects the treatment process and outcome." | ( Aydın, EB; Aydın, M; Sezgintürk, MK, 2023) |
| "An early on time detection of breast cancer significantly affects the treatment process and outcome." | ( Aydın, EB; Aydın, M; Sezgintürk, MK, 2023) |
| "Approximately 15%~30% of breast cancers have gene amplification or overexpression of the human epidermal growth factor receptor 2 (HER2), resulting in the chemotherapy resistance, a more-aggressive phenotype and poor prognosis." | ( Chen, LC; Chen, M; Cheng, WJ; Chuang, KH; Ho, HO; Hsieh, CM; Lin, SY; Sheu, MT, 2022) |
| "Approximately 15%~30% of breast cancers have gene amplification or overexpression of the human epidermal growth factor receptor 2 (HER2), resulting in the chemotherapy resistance, a more-aggressive phenotype and poor prognosis." | ( Chen, LC; Chen, M; Cheng, WJ; Chuang, KH; Ho, HO; Hsieh, CM; Lin, SY; Sheu, MT, 2022) |
| "Approximately 15%~30% of breast cancers have gene amplification or overexpression of the human epidermal growth factor receptor 2 (HER2), resulting in the chemotherapy resistance, a more-aggressive phenotype and poor prognosis." | ( Chen, LC; Chen, M; Cheng, WJ; Chuang, KH; Ho, HO; Hsieh, CM; Lin, SY; Sheu, MT, 2022) |
| "In total, 30 patients with breast cancer were recruited prior to initiating treatment and randomized into HIIT (n = 15) or control (n = 15)." | ( Christopher, CN; Dieli-Conwright, CM; Gonzalo-Encabo, P; Lee, K; Normann, AJ; Norris, MK; Wang, E; Yunker, AG, 2023) |
| "In total, 30 patients with breast cancer were recruited prior to initiating treatment and randomized into HIIT (n = 15) or control (n = 15)." | ( Christopher, CN; Dieli-Conwright, CM; Gonzalo-Encabo, P; Lee, K; Normann, AJ; Norris, MK; Wang, E; Yunker, AG, 2023) |
| "In total, 30 patients with breast cancer were recruited prior to initiating treatment and randomized into HIIT (n = 15) or control (n = 15)." | ( Christopher, CN; Dieli-Conwright, CM; Gonzalo-Encabo, P; Lee, K; Normann, AJ; Norris, MK; Wang, E; Yunker, AG, 2023) |
| "Using mouse models of mammary cancer that elicit robust MDSC responses, we demonstrated that the DHODH inhibitor brequinar (a) suppressed MDSC production from early-stage myeloid progenitors, which was accompanied by enhanced myeloid maturation; (b) augmented the antitumor and antimetastatic activities of programmed cell death 1-based (PD-1-based) ICI therapy in ICI-resistant mammary cancer models; and (c) acted in concert with PD-1 blockade through modulation of MDSC and CD8+ T cell responses." | ( Abrams, SI; Amitrano, AM; Barbi, J; Colligan, SH; Kramer, ED; Morreale, B; Nemeth, MJ; Opyrchal, M; Peresie, J; Singh, PK; Sykes, DB; Wang, J; Yu, H; Zollo, RA, 2022) |
| "Using mouse models of mammary cancer that elicit robust MDSC responses, we demonstrated that the DHODH inhibitor brequinar (a) suppressed MDSC production from early-stage myeloid progenitors, which was accompanied by enhanced myeloid maturation; (b) augmented the antitumor and antimetastatic activities of programmed cell death 1-based (PD-1-based) ICI therapy in ICI-resistant mammary cancer models; and (c) acted in concert with PD-1 blockade through modulation of MDSC and CD8+ T cell responses." | ( Abrams, SI; Amitrano, AM; Barbi, J; Colligan, SH; Kramer, ED; Morreale, B; Nemeth, MJ; Opyrchal, M; Peresie, J; Singh, PK; Sykes, DB; Wang, J; Yu, H; Zollo, RA, 2022) |
| "Older women with high-risk early breast cancer (EBC) benefit from adjuvant chemotherapy, but their treatment is frequently complicated by toxic side effects, resulting in dose reductions and delays." | ( Chapman, AE; Chow, S; Cohen, HJ; Dale, W; Dotan, E; Fenton, MA; Freedman, RA; Gross, CP; Ji, J; Katheria, V; Klepin, HD; Kuderer, NM; Lyman, GH; Magnuson, A; Moy, B; Muss, HB; O'Connor, T; Sedrak, MS; Sun, CL; Tew, WP; Wildes, TM, 2023) |
| "Older women with high-risk early breast cancer (EBC) benefit from adjuvant chemotherapy, but their treatment is frequently complicated by toxic side effects, resulting in dose reductions and delays." | ( Chapman, AE; Chow, S; Cohen, HJ; Dale, W; Dotan, E; Fenton, MA; Freedman, RA; Gross, CP; Ji, J; Katheria, V; Klepin, HD; Kuderer, NM; Lyman, GH; Magnuson, A; Moy, B; Muss, HB; O'Connor, T; Sedrak, MS; Sun, CL; Tew, WP; Wildes, TM, 2023) |
| "In this work, luminal A breast cancer cells were treated with AVP, and then Dynasore (DYN) was employed to inhibit Dyn2 to explore the combined effect of AVP and Dyn2 inhibition on the survival of breast cancer cells." | ( Alkafaas, SS; Diab, T; Hessien, M; Loutfy, SA, 2022) |
| "In this work, luminal A breast cancer cells were treated with AVP, and then Dynasore (DYN) was employed to inhibit Dyn2 to explore the combined effect of AVP and Dyn2 inhibition on the survival of breast cancer cells." | ( Alkafaas, SS; Diab, T; Hessien, M; Loutfy, SA, 2022) |
| "By selecting four breast cancer cell lines that represent the main breast tumor subtypes, we investigated their ability to accumulate the fluorescent protoporphyrin IX upon treatment with the marketed 5-aminolevulinic acid hexyl ester (ALA-Hex) or our new and more stable derivative PSI-ALA-Hex." | ( Kiening, M; Lange, N, 2022) |
| "By selecting four breast cancer cell lines that represent the main breast tumor subtypes, we investigated their ability to accumulate the fluorescent protoporphyrin IX upon treatment with the marketed 5-aminolevulinic acid hexyl ester (ALA-Hex) or our new and more stable derivative PSI-ALA-Hex." | ( Kiening, M; Lange, N, 2022) |
| "This article is about a treatment for breast cancer that is a type of drug-induced menopause." | ( S Mano, M, 2022) |
| "This article is about a treatment for breast cancer that is a type of drug-induced menopause." | ( S Mano, M, 2022) |
| "Docetaxel(DTX)is a key drug for breast cancer treatment; however, its formulation contains alcohol, which can cause several problems." | ( Eto, T; Hara, M; Ijichi, H; Koga, C; Misumi, N; Nakamura, Y; Okamoto, M; Tajiri, W; Tokunaga, E, 2022) |
| "The treatment of MCF7 breast cancer cells with ursolic acid elevates lysosomal pH, alters the cellular lipid profile, and causes lysosomal membrane permeabilization and leakage of lysosomal enzymes into the cytosol." | ( Balnytė, K; Corcelle-Termeau, E; Dinant, C; Fogde, DL; Holland, LKK; Jäättelä, M; Maeda, K; Pereira-Wilson, C; Stahl-Meyer, K; Xavier, CPR, 2022) |
| "To treat some types of breast cancer, CDK4/6 inhibitors, such as palbociclib, have been developed that target the phosphorylation of the retinoblastoma tumor suppressor gene." | ( Cheng, K; DiSalvo, KH; Krasniqi, D; Kravtsov, R; Krucher, NA; Petrella, CP; Velez, BC, 2023) |
| "The sequencing of cfDNA of Metastatic Breast Cancer (MBC) patients allows assessment of therapy response and noninvasive treatment." | ( Devi, MSS; Doss C, GP; K, SS; Kumar S, U; Naayanan, PJ; R, G; R, HC; Sathiyarajeswaren, P, 2023) |
| "High-expressed IFT20 in breast cancer cells increases resistance to cell death upon paclitaxel treatment; in contrast, IFT20 knockdown enhances apoptosis in breast cancer cells in response to paclitaxel." | ( Ao, X; Cui, L; He, ZM; Jiang, M; Jin, H; Li, HS; Liang, HL; Qiu, N; Xia, HM; Zhan, YT; Zhou, J, 2023) |
| "Obesity is a major health concern for breast cancer survivors, being associated with high recurrence and reduced efficacy during cancer treatment." | ( Bellerba, F; Bonanni, B; Chatziioannou, AC; Gandini, S; Hartman, SJ; Jasbi, P; Johansson, H; Keski-Rahkonen, P; Robinot, N; Scalbert, A; Sears, DD; Trolat, A; Vozar, B, 2022) |
| "Our results in overweight breast cancer survivors identify new metabolic effects of metformin treatment that may mechanistically contribute to reduced risk of recurrence in this population and reduced obesity-related cancer risk reported in observational studies." | ( Bellerba, F; Bonanni, B; Chatziioannou, AC; Gandini, S; Hartman, SJ; Jasbi, P; Johansson, H; Keski-Rahkonen, P; Robinot, N; Scalbert, A; Sears, DD; Trolat, A; Vozar, B, 2022) |
| "The findings suggest that breast cancer patients with a higher cumulative chemotherapy dose, lower pretreatment sodium ions, and higher pretreatment chloride ions receiving taxanes should receive closer monitoring to mitigate the development of short-term and long-term TIPN." | ( Cao, M; Li, H; Lv, Z; Ma, F; Mo, H; Pan, B; Sun, X; Xu, B; Zhai, J; Zhao, F; Zhao, J, 2023) |
| "Seventy-nine subjects scheduled for breast cancer surgery with SLN excision completed this IRB-approved study, out of which 18 (23%) underwent neoadjuvant chemotherapy before surgery." | ( Berger, A; Brill, K; Forsberg, F; Lazar, M; Liu, JB; Machado, P; Nazarian, S; Needleman, L; Willis, AI, 2023) |
| "Lung metastatic breast cancer (LMBC) is mainly diagnosed through CT imaging and radiotherapy could be the most common method in the clinic to inhibit tumor proliferation." | ( Chen, D; Liu, C; Liu, J; Liu, Y; Miao, S; Shen, Y; Wang, Q; Wen, J; Xue, S; Zhang, Q, 2023) |
| "CK0403 is reported in breast cancer treatment and is more potent than CK0402 against estrogen receptor-negative HER2." | ( Aparna, B; Byran, G; Emran, TB; Gonçalves Lima, CM; Nafady, MH; Rajagopal, K; Raman, K; Rashid, S; Varakumar, P; Wybraniec, S, 2022) |
| "ER-positive human breast cancer cells MCF-7 were treated with 17β-estradiol (E2) in the presence or absence of selected Keap1-Nrf2 PPI inhibitors." | ( Ali, AR; Furmanski, P; Hu, L; Joyce, R; Le, Y; Suh, N; Winz, C; Xie, T; Yang, G; Zahid, H; Zhou, R, 2023) |
| "The chemotherapy of triple-negative breast cancer based on doxorubicin (DOX) regimens suffers from great challenges on toxicity and autophagy raised off-target." | ( Cao, Z; Hua, Z; Li, Y; Liu, R; Liu, Y; Lu, A; Lu, C; Luo, X; Wang, X; Xue, Z; Zhang, Z, 2023) |
| "Tamoxifen prevents recurrence of breast cancer and is suggested for preventive risk-reducing therapy." | ( Bäcklund, M; Bergqvist, J; Borgquist, S; Czene, K; Gabrielson, M; Hall, P; Hammarström, M; Hellgren, R; Lång, K; Rosendahl, AH, 2023) |
| "Dual anti-HER2-targeted therapy in breast cancer (BC) significantly increased the rate of pathological complete response (pCR) compared to single blockade when added to chemotherapy." | ( Aspitia, AM; Bliss, J; Cameron, D; Coccia-Portugal, MA; Colleoni, M; de Azambuja, E; Di Cosimo, S; El-Abed, S; Ferro, A; Fielding, S; Gelber, R; Gkolfi, P; Gombos, A; Gomez, H; Huober, J; Kroep, J; Kunz, G; Lerzo, G; Moebus, V; Nuciforo, P; Piccart, MJ; Saura, C; Semiglazov, V; Sohn, J; Townend, J; Tseng, LM; Werutsky, G, 2023) |
| "Patients with stage I-III breast cancer, scheduled for neo/adjuvant chemotherapy, completed a cognitive battery prior to and 4 weeks after completing chemotherapy." | ( Abdou, Y; Ahles, TA; Carey, LA; Copeland, A; Deal, AM; Dees, EC; Heiling, HM; Jolly, TA; Joseph, R; Lopez, YE; McNamara, MA; Muss, HB; Nakamura, ZM; Nyrop, KA; O'Hare Kelly, E; Olajide, OA; Park, EM; Quillen, LJ; Rauch, JK; Ray, EM; Reeder-Hayes, KE; Stanton, KE, 2023) |
| "Eribulin treatment of HR-positive breast cancer may resensitize cells to hormone blockade." | ( Asano, Y; Goto, W; Iimori, N; Kashiwagi, S; Kouhashi, R; Maeda, K; Morisaki, T; Ogisawa, K; Shibutani, M; Takada, K; Tanaka, H; Tauchi, Y; Yabumoto, A, 2023) |
| "Eligible patients had HER2+ breast cancer with brain metastases and were within 12 weeks of whole brain radiation therapy (WBRT), stereotactic radiosurgery, and/or surgery." | ( Anders, CK; Arisa, O; Armstrong, TS; Brastianos, P; Burton, E; Carter, S; Connolly, RM; Figg, WD; Gilbert, MR; Houston, N; Jenkins, S; Khan, I; Lipkowitz, S; Mendoza, TR; Mozarsky, B; Nousome, D; Peer, CJ; Shah, R; Smart, DD; Smith, KL; Steeg, PS; Steinberg, SM; Tweed, C; Vera, E; Wu, X; Zhang, W; Zimmer, AS, 2023) |
| "It has proven clear advantages in breast cancer therapy over conventional thermal ablation because of its easily-tuned features of irradiation light with inside hyperthermia ability." | ( Aziz, AA; Braim, FS; Dheyab, MA; Jameel, MS; Khaniabadi, PM; Mehrdel, B; Oladzadabbasabadi, N; Rahman, AA, 2023) |
| "She was diagnosed with left breast cancer cT2N1M0, Stage ⅡB, Luminal B-like, and was desided dose-dense AC therapy(ddAC)plus dose-dense paclitaxel therapy(ddPTX)as preoperative chemotherapy." | ( Hata, T; Hiraki, M; Hori, A; Ikeshima, R; Katsuyama, S; Kikumori, K; Masuzawa, T; Mitsuyoshi, A; Murata, K; Ohmura, Y; Oshima, K; Shinke, G; Sugimura, K; Takeda, Y; Yanagawa, T, 2022) |
| "Among 6 patients with luminal B breast cancer, 5 converted to luminal A after one cycle of therapy." | ( Acosta, EP; Elkhanany, AM; Forero-Torres, A; Grizzle, WE; Li, Y; Ryan, KJ; Stringer-Reasor, EM; Theuer, CP; Vaklavas, C; Wei, S; Yang, ES, 2023) |
| "Survivors of breast cancer using aromatase inhibitors were assessed for eligibility, and eligible patients were randomized into the 2 treatment groups." | ( Alonso, I; Anglès-Acedo, S; Castelo-Branco, C; Castrejón, N; Farré, R; Gómez, S; Matas, I; Mension, E; Ordi, J; Otero, J; Rakislova, N; Ribera, L; Ros, C; Saco, A; Tortajada, M; Vega, N; Villarino, Á, 2023) |
| "When breast cancer cells were incubated with DOPA-rGO@TMgel and exposed to NIR light (photothermal therapy), their viability was reduced to about 59 %." | ( Alves, CG; Correia, IJ; Costa, FJP; de Melo-Diogo, D; Lima-Sousa, R; Melo, BL; Nave, M, 2023) |
| "Taxanes are major drugs for metastatic breast cancer (MBC) treatment, and are generally well tolerated, making them attractive for therapeutic reintroduction (rechallenge) during metastatic course." | ( Bertaut, A; Coudert, B; Desmoulins, I; Fouquier, A; Hennequin, A; Ilie, S; Kaderbhai, C; Ladoire, S; Mayeur, D; Réda, M, 2023) |
| "The Oncotype DX Breast Cancer Recurrence Score program(Oncotype DX)is a test that can be used to limit overtreatment in hormone receptor-positive, HER2-negative, low-risk early breast cancer." | ( Habiro, T; Hayashi, K; Inukai, M; Ishii, K; Kojima, K; Oshida, S; Waraya, M, 2023) |
| "A total of 373 breast cancer patients treated with AET filled out a specific questionnaire during their follow up visits at the Breast Unit of our Centre." | ( Actis, S; Biglia, N; Bounous, VE; Cipullo, I; D'Alonzo, M; Rosso, R; Salerno, E, 2023) |
| "Although breast cancer (BC) treatment has entered the era of precision therapy, the prognosis is good in the case of comprehensive multimodal treatment such as neoadjuvant, endocrine, and targeted therapy." | ( Chen, H; Dai, Y; Kang, Y; Pei, S; Xia, Y; Xie, H; Yang, L; Zhang, P; Zhao, S; Zheng, M, 2023) |
| "Multidrug resistance in breast cancer and the associated side-effects of anticancer therapies are significant hurdles in chemotherapy-based treatment." | ( Gandhi, S; Kavisri, M; Maddiboyina, B; Moovendhan, M; Nakkala, RK; Roy, H, 2023) |
| "Therefore ER-/PR+ breast cancer has a poor clinical outcome, and novel drug therapy for ER-/PR+ breast cancer could benefit these patients." | ( Jung, D; Kang, PS; Kendi, AT; Lee, S; Lowe, VJ; Shim, JY; Song, C, 2023) |
| "The main challenge in treating breast cancer patients is developing resistance to chemotherapeutics, so it is urgent to find potential strategies that can improve the chemotherapy effect of patients." | ( Fang, P; Gong, W; Leng, M; Shi, Y, 2023) |
| "Patients with stage I-III breast cancer who underwent neoadjuvant therapy followed by surgery between January 2018 and December 2019 were retrospectively reviewed." | ( Hung, CC; Hung, CS; Kuo, YL; Li, CL; Lin, CY; Tsai, JH; Yeh, DC, 2023) |
| "Endocrine treatment for breast cancer acts largely by inhibiting tumor cell proliferation." | ( Bhaskaran, R; Louis, DM; Nair, LM; Narmadha, MP; Vallonthaiel, AG; Vijaykumar, DK; Yesodharan, J, 2023) |
| "In the present study, breast cancer cells (MCF-7) and MDA-MB-231 along with human amniotic cells (WISH) were treated with two concentrations (50, and 100 µM) of erlotinib (ERL) and vorinostat (as known as SAHA) for 24 h." | ( Abdel-Ghany, S; Alqosaibi, AI, 2023) |
| "Thirty-nine breast cancer patients who underwent anthracycline- and/or taxane-based chemotherapy were assigned to the scalp cooling group(27 patients)and the hair loss observation group(12 patients)." | ( Fukuma, E; Kato, M; Nomizu, T; Ueo, H, 2023) |
| "The study included 113 breast cancer patients after breast cancer surgery with axillary lymphadenectomy treated with either 75/650 mg or 37." | ( Besic, N; Dolzan, V; Goricar, K; Strazisar, B; Vidic, Z, 2023) |
| "Many breast cancer survivors (BCS) suffer the consequences of antineoplastic treatments that induce a hypoestrogenic state, leading to chronic climacteric symptoms such as genitourinary syndrome of menopause (GSM), arousing significant alteration in their quality of life." | ( Anglès-Acedo, S; Castelo-Branco, C; Cebrecos, I; Mension, E; Torras, I, 2023) |
| "In cohort of patients with breast cancer, the effect of platinum therapy on the transcriptome of TAMs was validated, and differential expression of regulators of endocytosis was identified." | ( Bezgodova, N; Cherdyntseva, N; Denisov, E; Iamshchikov, P; Ibragimova, M; Kazakova, E; Kiselev, A; Koshkin, P; Kzhyshkowska, J; Larionova, I; Litviakov, N; Liu, Q; Liu, T; Mossel, DM; Patysheva, M; Pyankov, D; Rakina, M; Riabov, V; Sergushichev, A; Tsyganov, M; Vtorushin, S, 2023) |
| "Thus, TIPE2 may be a new target for breast cancer chemotherapy." | ( Du, J; Hu, W; Li, J; Tian, Z; Zhao, P; Zhao, Y; Zheng, W, 2023) |
| "The treatment of breast cancer patients includes surgery, radiation, hormone therapy, chemotherapy, targeted drug therapy and immunotherapy." | ( Chen, X; Lian, B; Shen, K, 2023) |
| "More than two thirds of women with breast cancer show expression for hormone receptors, and in these cases, hormone therapy with tamoxifen is indicated, which may represent a risk factor for the development of endometrial cancer (four-fold greater relative risk)." | ( Castelo Filho, A; Lopes, GM; Nicolau, SM; Vizzotto, AO, 2023) |
| "a total of 364 breast cancer patients were evaluated, 286 who used tamoxifen and 78 who did not use this hormone therapy." | ( Castelo Filho, A; Lopes, GM; Nicolau, SM; Vizzotto, AO, 2023) |
| "We enrolled 220 patients diagnosed with breast cancer who were treated with tamoxifen." | ( Blancas, I; Garrido, JM; Herrero-Vicent, C; Linares-Rodríguez, M; Martínez de Dueñas, E; Molero-Mir, MD; Rodríguez-Serrano, F, 2023) |
| "Here, immune-cell activity of breast cancer tumors was inferred by expression-based analysis to determine if it is prognostic and/or predictive of response to neoadjuvant paclitaxel-based therapy in the GeparSepto (G7) trial (NCT01583426)." | ( Benz, S; Budczies, J; Denkert, C; Fasching, PA; Heinmöller, E; Jackisch, C; Karn, T; Loibl, S; Marmé, F; Mueller, V; Nekljudova, V; Rabizadeh, S; Schem, C; Schmatloch, S; Schneeweiss, A; Sinn, HP; Soon-Shiong, P; Spilman, P; Stickeler, E; Szeto, C; Untch, M; van Mackelenbergh, M; Warm, M; Weber, K, 2023) |
| "Women with incident breast cancers from Calgary, Alberta, Canada enrolled in the Breast to Bone (B2B) study between 2010 to 2016 and provided blood samples prior to any treatment initiation." | ( Harper, A; Joubert, D; Khan, M; Kopciuk, K; Payen, L; Prieur, A; Vire, B, 2023) |
| "Women with early breast cancer planned for upfront surgery without prior neoadjuvant treatment were randomly assigned to receive peritumoral injection of 0." | ( Badwe, RA; Balasubramanian, S; Borthakur, BB; Chitale, PV; Dewade, A; Gaikwad, V; Gupta, S; Harris, C; Hawaldar, R; Joshi, S; Kadayaprath, G; Nair, N; Neve, R; Pandya, S; Parmar, V; Pawar, S; Rao Thammineedi, S; Siddique, S; Srivastava, A; Vanmali, VJ, 2023) |
| "In women with ERBB2-positive breast cancer receiving sequential anthracycline and trastuzumab therapy, CMR tissue biomarkers suggest inflammation and edema peaking early during therapy and were associated with ventricular remodeling and BNP elevation." | ( Abdel-Qadir, H; Amir, E; Brezden-Masley, C; Fan, CS; Hanneman, K; Houbois, C; Koch, CA; Malowany, JM; McIntosh, C; Power, C; Shalmon, T; Somerset, E; Spiller, N; Sussman, MS; Thavendiranathan, P; Thevakumaran, Y; Urzua-Fresno, C; Wintersperger, BJ; Yan, AT; Yip, P, 2023) |
| "Since this a case of advanced breast cancer, we initiated treatment with bevacizumab plus paclitaxel." | ( Kamo, N; Konishi, J; Nozaki, Y; Tanaka, N; Yamamuro, M, 2023) |
| "Three breast cancer cell lines were treated with a combination of 1 μM TAM and 10 μM of a cholesterol depleting agent (Acetyl Plumbagin: AP) following transfection with a miR-128 inhibitor or a miR-223 mimic." | ( Kaur, M; Palma, GBH, 2023) |
| "Case-B (breast cancer): After 11 days on treatment, she developed skin rash and alpelisib was interrupted." | ( de Wit, GF; Geurts, BS; Kok, M; Opdam, FL; Schutte, T; Zeverijn, LJ, 2023) |
| "Low dose embelin treated breast cancer cell lines in combination with IL-1β induced TRAIL-expressing hUCMSCs may become a potential anti-tumor therapy." | ( Chiu, YH; Hung, E; Liang, YH; Teng, JW; Tyan, YS; Wang, HS; Wu, JM, 2023) |
| "We invited women with breast cancer treated with surgery, axillary dissection and radiotherapy, who had participated in a randomized controlled trial and who presented with LE 1 year after surgery." | ( Ammitzbøll, G; Dalton, SO; Forchhammer, M; Hyldegaard, O; Jensen, LT; Johansen, C; Kroman, N; Lanng, C; Rottensten, H; Zerahn, B, 2023) |
| "Among patients with breast cancer and patients with head and neck cancer (N = 77), none of the 39 patients treated with BD and 9 of the 38 patients (23." | ( Daily, JP; Deutsch, A; Hosgood, HD; Kabarriti, R; Kost, Y; Lin, J; McLellan, BN; Mieczkowska, K; Muskat, A; Nazarian, R; Ohri, N; Shinoda, K, 2023) |
| "Human breast cancer cells were used to detect cell viability and epigenetic-related gene expression after treatment with EGCG and/or SFN." | ( Chen, M; Li, S; Tollefsbol, TO; Wu, H, 2023) |
| "Two-hundred patients diagnosed with breast cancer who were treated with AIs as adjuvant treatment were included." | ( Coskun, HS; Goksu, SS; Ilhan, RG; Ilhan, Y; Tatli, AM, 2023) |
| "The cell death of MCF-7 breast cancer cells treated with 13." | ( Banaei, A; Hashemi, B; Mehdi Mahdavi, SR; Mohammadi, A; Solimani, M, 2023) |
| "A 73-year-old female patient with breast cancer with axillary lymph node, adrenal gland and bone metastases was started on ribociclib letrozole and denosumab treatment." | ( Aktürk Esen, S; Bayram, D; Köş, FT; Uçar, G, 2023) |
| "Approximately 70% of human breast cancers express estrogen receptor-α (ERα), providing a potential target for endocrine therapy." | ( Erdogan, ZM; Imir, OB; Kaminsky, AZ; Landesman, Y; Mogol, AN; Walker, CJ; Yoo, JY; Zuo, Q, 2023) |
| "Many women with early-stage breast cancer are predicted to be at sufficiently low risk for recurrence that they may forego chemotherapy." | ( Lim, D; Narod, SA; Sopik, V; Sun, P, 2023) |
| "When DILD occurs during breast cancer treatment, choosing the right drug for subsequent treatment is often difficult." | ( Hayash, M; Hirata, A; Kimura, K; Morita, S; Takashima, Y; Terasawa, R, 2023) |
| "Neoadjuvant treatment of breast cancer is applied to an increasing extent, but treatment response varies and side effects pose a challenge." | ( Andersen, RF; Bechmann, T; Jakobsen, A; Jakobsen, EH; Kahns, S; Kjær, IM; Madsen, JS; Tabor, TP; Timm, S, 2023) |
| "The luminal subtype of breast cancer shows less NAC response than the basal subtype, with an inefficient NAC treatment effect." | ( Fang, Z; Ma, Y; Shen, H; Tang, JH; Wang, Y; Wo, G; Xu, J; Yang, K; Yu, Q; Zhu, Z, 2023) |
| "Treatment of 5 mutant p53 breast cancer cell lines with COTI-2 resulted in dose-dependent MYC degradation." | ( Crown, J; Duffy, MJ; Tang, M, 2023) |
| "HER2-negative breast cancer patients with brain metastases (BCBM) face an extremely poor prognosis, and a lack of effective treatment options." | ( Bai, X; Chen, L; Chen, X; Du, C; Guo, J; Huang, J; Lan, X; Song, L; Xie, X; Zhang, Q, 2023) |
| "Patients with breast cancer undergoing tamoxifen therapy may be screened prior to tamoxifen therapy and followed during treatment by SD-OCT." | ( Açıkgöz, V; Erbahçeci Timur, İE; Hızal, M; Kara, H; Şendur, MAN; Uğurlu, N; Yalçın, B, 2023) |
| "Here, we present a metastatic breast cancer patient who had digital necrosis due to arterial occlusion with gemcitabine monotherapy." | ( Doğan, M; Kurtuluş, A; Özdemir, M; Türkel, A, 2023) |
| "Analysis of the subset of breast cancer patients enrolled in the EMERALD study who had previously received a fulvestrant-containing regimen indicates that they had better progression-free survival with elacestrant than with standard-of-care endocrine therapy, a finding that was independent estrogen receptor (ESR1) gene mutations." | ( Aftimos, P; Arlt, H; Bardia, A; Bidard, FC; Bihani, T; Binaschi, M; Burr, R; Chirn, B; Cortés, J; Dubash, TD; Fiascarelli, A; Habboubi, N; Haber, DA; Iafrate, AJ; Kaklamani, VG; LiCausi, JA; Maheswaran, S; Patel, H; Rai, S; Reeves, BA; Scartoni, S; Toner, M; Wittner, BS, 2023) |
| "As a first-line drug for breast cancer chemotherapy, the effectiveness of doxorubicin (DOX) is challenged by high doses and high toxicity." | ( Dai, F; Li, J; Lu, M; Ma, L; Qiu, T; Song, F; Tong, M; Zhang, X, 2023) |
| "Associations between 27-HC and breast cancer prognosis varied by circulating estradiol levels and endocrine therapy." | ( Behrens, S; Chang-Claude, J; Decker, NS; Fortner, RT; Johnson, T; Kaaks, R; Obi, N, 2023) |
| "Drug therapy for breast cancer is currently selected based on the subtype classification; however, many anticancer drugs are highly cytotoxic." | ( Kizawa, M; Koda, D; Komura, Y; Kurita, T; Nakajima, T; Niwa, N; Takahashi, M; Takizawa, Y, 2023) |
| "Patients with breast cancer (BC) harbouring a germinal BRCA pathogenic variant (gBRCA-PV) may have an enhanced sensitivity to platinum-based chemotherapy (PBC) and PARP inhibitors (PARPi)." | ( Berardi, R; Boscolo Bielo, L; Cortesi, L; Curigliano, G; Del Mastro, L; Favero, D; Gandini, S; Giarratano, T; Guarneri, V; Lambertini, M; Marra, A; Moscetti, L; Pistelli, M; Sposetti, C; Trapani, D; Valenza, C; Vernieri, C; Zambelli, A, 2023) |
| "Twenty-nine (29) breast cancer women, scheduled for adjuvant chemotherapy were included in this pilot study after obtaining written informed consent and approval of the study by the WKMU ethics committee." | ( Abdelazim, IA; Aitmagambetova, M; Amanzholkyzy, A; Donayeva, A; Gubasheva, G; Imanbaev, N; Kandygulova, G; Kereyeva, N; Khamidullina, Z; Koishybaev, A; Sakhanova, S; Saparbayev, S; Smagulova, G; Tulyaeva, A; Zholmukhamedova, D, 2023) |
| "For patients with early-stage breast cancers, neoadjuvant treatment is recommended for non-luminal tumors instead of luminal tumors." | ( Guo, R; Hu, Y; Hu, Z; Huang, W; Huang, Y; Li, L; Luo, R; Mao, R; Tang, X; Wang, Y; Yang, L; Yao, Z; Yu, J; Zhou, J, 2023) |
| "Metastatic breast cancer (MBC) is usually incurable; treatment aims to maximize patients' function and quality of life (QOL)." | ( Ito, Y; Kawaguchi, H; Kobayashi, K; Masuda, N; Miura, K; Mizuno, T; Ohtani, S; Saeki, T; Takeuchi, M; Toi, M; Tokuda, Y; Yoshinami, T, 2023) |
| "Here, we report a case of breast cancer in which the primary lesion degenerated into squamous cell carcinoma(triple negative)after drug treatment for invasive ductal carcinoma(Luminal type)." | ( Araya, J; Hirano, S; Konishi, K; Nagabuchi, M; Ogino, J; Sakamoto, T, 2023) |
| "Therapy for patients of metastatic breast cancer based on palbociclib, a cyclin-dependent kinase 4/6 inhibitor, has been approved in Japan." | ( Kuwahara, S; Maeda, H; Mino, K; Takada, S; Tomioka, N; Umehara, K; Watanabe, K; Yamamoto, M, 2023) |
| "Sev was applied to treat breast cancer cells." | ( Chen, T; Lin, Q; Lin, W; Wang, L; Zeng, X; Zheng, Q, 2023) |
| "To assess the risk of recurrence of breast cancer associated with vaginal estrogen therapy in women diagnosed with genitourinary syndrome of menopause with a history of breast cancer using a large U." | ( Able, C; Agrawal, P; Clifton, M; Dumas, K; Kohn, J; Kohn, TP; Singh, SM, 2023) |
| "The effective treatment of breast cancer remains a profound clinical challenge, especially due to drug resistance and metastasis which unfortunately arise in many patients." | ( Chang, CH; Hsieh, HC; Hu, MC; Kuo, YH; Lai, TC; Yang, FM, 2023) |
| "Totally 200 patients with stage III breast cancer were evenly randomized into control group (albumin-bound paclitaxel for chemotherapy) and observation group (Xihuang Capsules for adjuvant therapy based on the treatment of the control group)." | ( Jin, L; Kang, X; Li, H; Sun, D; Wang, Z; Wu, F; Zhang, H; Zhang, X, 2023) |
| "Female patients with breast cancer underwent SPECT MPI before commencing radiotherapy and 12 months later were enrolled from January 2014 to December 2018." | ( Hsu, CX; Lin, KH; Shueng, PW; Tsai, WT; Wang, SY; Wu, TH; Wu, YW; Yang, SY; Yu, CW, 2023) |
| "Shorter breast cancer (BC) survival outcomes persist by neighborhood disadvantage independent of patient, tumor, and treatment characteristics." | ( Antoni, MH; Blomberg, BB; Clarke, ES; Cole, S; Goel, N; Hernandez, AE; Ream, M, 2023) |
| "Up to 20% of breast cancer overexpress HER2 protein, making it a reliable target for antibody-based treatments." | ( Agostinetto, E; Azambuja, E; Barchiesi, G; Botticelli, A; De Giorgi, U; Debien, V; Duhoux, FP; Jacobs, F; Lambertini, M; Marta, GN; Molinelli, C; Moreau, M; Paesmans, M; Piccart, M; Santoro, A; Sirico, M; Speranza, I; Taylor, D; Wildiers, H, 2023) |
| "We aim to highlight the importance of breast cancer treatment and surgical reconstruction in this group and whether they should be considered for early breast cancer screening." | ( Banerjee, D; Boutsikos, G; Ertansel, BN; Lodhia, S; Rajagopal, S, 2023) |
| "Interplay between breast cancer (BC) cells and the tumor microenvironment (TME) influences the outcome of cancer treatment." | ( Cai, L; Chen, H; Guo, Z; Tan, Y; Wang, X; Wang, Y; Yang, T; Zhang, S, 2023) |
| "ER+/HER2- advanced breast cancer (ABC) with visceral crisis (VC) or impending VC (IVC) is commonly treated with chemotherapy instead of CDK4/6 inhibitors (CDK4/6i)." | ( Armstrong, AC; Behrouzi, R; Howell, SJ, 2023) |
| "Approximately 70% of breast cancers are estrogen receptor(ER)positive, an indication for endocrine therapy." | ( Hayashi, M; Hirata, A; Kimura, K; Morita, S; Takashima, Y; Terasawa, R, 2023) |
| "The human breast cancer cell line MDA-MB-231 was transfected with miR-138-5p mimics and treated with PTX, in a combined or separate manner." | ( Banan-Khojasteh, SM; Baradaran, B; Hosseinpour Feizi, MA; Lotfinejad, P; Rasoolnezhad, M; Roshani Asl, E; Safaralizadeh, R, 2023) |
| "Astragaloside IV (AS‑IV) was used for breast cancer (BC) treatment in China from ancient times; however, the mechanism of the prevention effect of AS-IV on BC remains not entirely clear." | ( Hao, J; Liu, H; Qiao, S; Shi, J; Wang, L; Wu, J; Xie, C; Yu, Y; Zheng, X, 2023) |
| "About 40 to 50 percent of breast cancer women who undergo chemotherapy are experiencing premature menopause symptoms, including hot flashes." | ( Esfandbod, M; Etesam, F; Taleghani, SY, 2023) |
| "Compared with patients without breast cancer, those with breast cancer and those who received any endocrine therapy had elevated risk of incident T2D (EE = 1." | ( Borgquist, S; Cronin-Fenton, D; Jordt, N; Kjærgaard, KA; Thomsen, RW, 2023) |
| "We included 531 breast cancer patients who were treated with BCS and adjuvant radiotherapy." | ( Ahn, SG; Bae, SJ; Chang, JS; Cho, Y; Hwang, J; Jeong, J; Ji, JH; Kim, D; Kim, JY; Lee, HS; Lee, J; Yoon, CI, 2023) |
| "Despite many efforts, breast cancer remains one of the deadliest cancers and its treatment faces challenges related to cancer drug side effects and metastasis." | ( Abolhassani, H; Bashiri, Z; Farmani, AR; Hossein-Khannazer, N; Moeinabadi-Bidgoli, K; Moeinzadeh, A; Moradbeygi, F; Nabipoorashrafi, SA; Rostami, N; Seyedi, SA; Tavakkoli Yaraki, M; Zaer, M, 2023) |
| "Patients with breast cancer scheduled for epirubicin and cyclophosphamide (EC) or docetaxel and cyclophosphamide (TC) therapy were selected and allocated in a 1:1 ratio to the intervention and control groups." | ( Eguchi, S; Hatachi, T; Kanetaka, K; Kawashita, Y; Kuba, S; Maeda, S; Matsumoto, M; Morita, M; Nagayasu, T; Otsubo, R; Sato, S; Shibata, K; Soutome, S; Tanaka, A; Taniguchi, H; Umeda, M; Yamanouchi, K; Yano, H, 2023) |
| "Tamoxifen is a drug used for treating breast cancer (BC), especially for individuals diagnosed with estrogen receptor-positive (ER+) BC." | ( Fu, Z; Gao, S; Jiang, Z; Ma, J; Wang, M; Zhang, M, 2023) |
| "We recruited 693 Korean female breast cancer survivors at two university-affiliated hospitals and collected study data through a self-administered questionnaire and a review of medical records." | ( Cho, B; Kim, S; Shin, DW; Shin, J; Song, YM; Yeo, Y, 2023) |
| "Left-sided breast cancer patients receiving adjuvant radiotherapy are at risk for coronary artery disease, and/or radiation mediated effects on the microvasculature." | ( Biernaski, H; Butler, J; Chau, OW; deKemp, R; El-Sherif, O; Gaede, S; Mouawad, M; Prato, FS; Renaud, J; Sykes, JM; Wisenberg, G, 2023) |
| "Gene expression (GEX) signatures in breast cancer provide prognostic information, but little is known about their predictive value for tamoxifen treatment." | ( Bendahl, PO; Church, SE; Ekholm, M; Fernö, M; Forsare, C; Lundgren, C; Nordenskjöld, B; Rydén, L; Stål, O; Tutzauer, J, 2023) |
| "Prolonged treatment of HER2+ breast cancer with lapatinib (LAP) causes cellular senescence and acquired drug resistance, which often associating with poor prognosis for patients." | ( Chang, L; Chen, X; Gao, X; Li, Q; Li, Y; Luo, H; Wei, X; Westover, KD; Zhang, Y; Zhou, Z; Zhu, J, 2023) |
| "Chemotherapy resistance of breast cancer cells is one of the major factors affecting patient survival rate." | ( Bi, X; Cheng, L; Huang, C; Luo, L; Yan, X; Yin, Z; Zhang, M; Zhou, J, 2023) |
| "Two human breast cancer cell lines (MCF-7 and AMJ-13) and a normal epithelial cell line (HBL-100) were used and treated with NDV and/or GNPs." | ( Al-Dulimi, AG; Al-Shammari, AM; Albukhaty, S; Ali, ZO; Elgorban, AM; Eswaramoorthy, R; Hamzah, SS; Jabir, MS; Jawad, SF; Najm, MAA; Sulaiman, GM; Syed, A; Zaghloul, NSS, 2023) |
| "Triple-negative breast cancer is a subtype of breast cancer with a poor response to chemotherapy." | ( Hatami, M; Kheirollah, A; Khorsandi, L; Kouchak, M; Rashidi, M, 2023) |
| "Radiotherapy (RT) is dominantly used in breast cancer therapy but is facing fierce side effects because of the limited difference between tumor and normal tissues in response to ionizing radiation." | ( Chen, J; Chen, M; Chen, X; Chen, Y; Huang, N; Meng, W; Peng, J; Zhang, L; Zhang, W, 2023) |
| "The treatment of breast cancer relies heavily on chemotherapy, but chemotherapy is limited by the disadvantages of poor targeting, susceptibility to extracellular matrix (ECM) interference and a short duration of action in tumor cells." | ( Bai, J; Li, A; Ma, J; Meng, F; Peng, F; Tang, S; Zhai, X; Zhou, B; Zou, X, 2023) |
| "Colony formation of breast cancer cell lines was mitigated with a combinatorial regimen of bursatol and oxaliplatin than the individual treatment regimen." | ( A U, C; Bannimath, G; Bannimath, N; Beeraka, NM; Fan, R; Liu, J; Manogaran, P; Shivaprakash, P; Sinelnikov, MY; Vikram Pr, H; Zhang, J; Zhao, D, 2023) |
| "Luminal-B type human breast cancer cell line (BT-474) to assess the synergistic effects of ozone applied after chemotherapeutic treatment with various dosages of doxorubicin, and compare the results with the effects on L929 fibroblast cell line." | ( Karagülle, OO; Yurttaş, AG, 2023) |
| "Although many methods for treating breast cancer have been improved, there is still a need to discover and develop new methods for breast cancer treatment." | ( Ahn, KS; Basappa, B; Basappa, S; Lobie, PE; Mohan, AK; Pandey, V; Ravish, A; Sethi, G; Yang, MH, 2023) |
| "Eight breast cancer patients already diagnosed with MRONJ and treated with cyclin inhibitors and ARDs were in the control group." | ( Baima, G; Bosso, I; Erovigni, F; Mussano, F; Pavone, L; Pedraza, R; Roato, I, 2023) |
| "Furthermore, patients with breast cancer who developed TamR during chemotherapy had significantly lower expression of ELOVL2-AS1 compared to those who responded to Tam." | ( Baek, M; Jang, S; Jung, S; Kim, HW; Kim, SJ; Kwak, BS; Lee, H; Yang, SH, 2023) |
| "Estrogen receptor-positive/negative, breast cancer cells were cultured to understand the synergetic effects of piperine with radiotherapy." | ( Ali, HS; Lakshmanan-M, D; Prabhu, BS; Shaheer, K, 2024) |
| "Treatments of the breast cancer cells by Apa, Dox, and Apa-Dox significantly increase apoptosis percentage." | ( Aghaei, E; Heiat, M; Kohan, L; Soltanzadeh, H, 2023) |
| "Triple-positive breast cancer (TPBC) is highly invasive and lacks well-established treatment strategies, especially in patients with advanced stage disease." | ( Fan, Y; Jiang, H; Li, Q; Ma, F; Tan, Y; Tian, X; Wang, J; Xu, B; Zhang, P; Zhao, W, 2023) |
| "Forty women with early breast cancer were randomly assigned to EHW (n = 20) or observation (n = 20) during neo(adjuvant) chemotherapy." | ( Almeida, P; Bomfim, VHV; Costa E Silva, M; da Silva, CF; de Castro, ALR; de Cerqueira Mathias, CM; de Oliveira Dantas Viana, P; Dienstmann, R; Dos Santos, APT; Freitas Muniz Teixeira, A; Jamile Santiago Costa, M; Landeiro, LCG; Lopes Paim Miranda, D; Mathias Machado, R; Teixeira Machado, B; Viviane Carvalho Rodrigues Gonçalves, M, 2023) |
| "Nine breast cancer patient-derived xenografts (PDXs) with various FGFR1-4 alterations and expression levels were treated with futibatinib." | ( Akcakanat, A; Chen, H; Damodaran, S; DiPeri, TP; Evans, KW; Ha, MJ; Kirby, BP; Meric-Bernstam, F; Mills, GB; Ng, PKS; Rodon Ahnert, J; Saridogan, T; Scott, S; Yuca, E; Zhao, M; Zheng, X, 2023) |
| "CAFs were isolated from breast cancer tissues, treated with Curcumin, and co-cultured with patients' PBMCs to evaluate gene expression and cytokine production alterations." | ( Abolhasani-Zadeh, F; Afgar, A; Jalilian, E; Langroudi, L; Samoudi, A; Zeinalynezhad, H, 2023) |
| "The viability and migration of MCF-7 breast cancer cells elevated when treated with a combination of fructose and glucose, and glucose alone, compared to fructose alone." | ( Aswad, H; Aziz, I; Hafiyani, L; Hardjo, M; Margawati, H; Natsir, R; Yustisia, I, 2023) |
| "All studies include breast cancer survivors in adjuvant endocrine therapy, and are conducted at the Department of Obstetrics and Gynecology, Randers Regional Hospital, Denmark." | ( Bor, P; Forman, A; Glavind-Kristensen, M; Jacobsen, S; Jensen, AB, 2023) |
| "We present the case of a breast cancer patient with multiple metastases who achieved a good response and tolerance to the combination treatment of utidelone plus capecitabine." | ( Feng, X; Gao, S; Gao, X; Ge, TT; Pan, XJ; Shi, XG; Sun, P; Wang, TS; Wang, YK; Zuo, XM, 2023) |
| "Fighting breast tumors mandates finding different agents devoid of chemotherapy side effects." | ( Dewidar, SA; El Gayar, AM; El-Mesery, M; Hamdy, O; Soliman, MM, 2023) |
| "One hundred six eligible breast cancer patients were randomly distributed into a low-level light therapy group and a control group, after receiving chemotherapy." | ( Chang, ZY; Cheng, HY; Lee, CH; Li, CH; Shiao, YH; Wu, CX; Wu, TH; Yeh, YC, 2023) |